<SEC-DOCUMENT>0001628280-25-048785.txt : 20251104
<SEC-HEADER>0001628280-25-048785.hdr.sgml : 20251104
<ACCEPTANCE-DATETIME>20251104160257
ACCESSION NUMBER:		0001628280-25-048785
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		99
CONFORMED PERIOD OF REPORT:	20250930
FILED AS OF DATE:		20251104
DATE AS OF CHANGE:		20251104

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOCRYST PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000882796
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				621413174
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23186
		FILM NUMBER:		251448845

	BUSINESS ADDRESS:	
		STREET 1:		4505 EMPEROR BOULEVARD
		STREET 2:		SUITE 200
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27703
		BUSINESS PHONE:		919-859-1302

	MAIL ADDRESS:	
		STREET 1:		4505 EMPEROR BOULEVARD
		STREET 2:		SUITE 200
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>bcrx-20250930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:9a36bdce-1161-4cfc-8f27-e0c5ed23a9d7,g:923a909e-42f3-4f9e-a634-f93d4ee01684,d:d1b8c440ead54d70904211d3c0a5ea1f-->
<html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bcrx="http://www.biocryst.com/20250930" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>bcrx-20250930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-25">0000882796</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" id="f-26">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-27">2025</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-28">Q3</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-29">false</ix:nonNumeric><ix:nonNumeric contextRef="c-3" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList" id="f-584">http://fasb.org/us-gaap/2025#ShortTermInvestments</ix:nonNumeric><ix:nonNumeric contextRef="c-4" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList" id="f-595">http://fasb.org/us-gaap/2025#ShortTermInvestments</ix:nonNumeric><ix:nonNumeric contextRef="c-205" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="f-764">P3Y0M0D</ix:nonNumeric><ix:nonNumeric contextRef="c-3" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="f-793">http://www.biocryst.com/20250930#RightOfUseAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-4" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="f-794">http://www.biocryst.com/20250930#RightOfUseAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-3" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="f-803">http://www.biocryst.com/20250930#RightOfUseAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-4" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="f-804">http://www.biocryst.com/20250930#RightOfUseAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-304" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-1156">139</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="bcrx-20250930.xsd"/></ix:references><ix:resources><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>bcrx:segment</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="security"><xbrli:measure>bcrx:security</xbrli:measure></xbrli:unit><xbrli:unit id="plan"><xbrli:measure>bcrx:plan</xbrli:measure></xbrli:unit><xbrli:unit id="dose"><xbrli:measure>bcrx:dose</xbrli:measure></xbrli:unit><xbrli:unit id="period"><xbrli:measure>bcrx:period</xbrli:measure></xbrli:unit><xbrli:unit id="payment"><xbrli:measure>bcrx:payment</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">bcrx:CollateralForCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">bcrx:CollateralForCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bcrx:LaboratoryEquipmentOfficeEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bcrx:BioCrystIrelandMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bcrx:BioCrystIrelandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionDomesticMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionDomesticMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionDomesticMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionDomesticMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:OtherIncomeFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:OtherIncomeFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:OtherIncomeFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:OtherIncomeFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:PeramivirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:PeramivirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:RoyaltyReceivablesFromPartnersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:RoyaltyReceivablesFromPartnersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcrx:FutureRoyaltiesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesUnder350000Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesBetween350000And550000Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesOver550000Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesUnder150000Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesBetween150000And230000Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesOver230000Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2021And2020IntermediateFinanceTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcrx:FutureRoyaltiesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:The2021RPIRoyaltyPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesUnder350000Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:The2021RPIRoyaltyPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesBetween350000And550000Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:The2021RPIRoyaltyPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesOver550000Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:The2021RPIRoyaltyPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesUnder150000Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:The2021RPIRoyaltyPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesBetween150000And230000Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesUnder350000Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesBetween350000And550000Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesOver550000Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesUnder350000Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesBetween350000And550000Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesOver550000Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesUnder150000Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesBetween150000And230000Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesOver230000Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyRPIRoyaltyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyOneRPIRoyaltyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSRoyaltyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyRPIRoyaltyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyOneRPIRoyaltyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSRoyaltyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyRPIRoyaltyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyOneRPIRoyaltyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSRoyaltyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyRPIRoyaltyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyOneRPIRoyaltyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSRoyaltyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyRPIRoyaltyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyOneRPIRoyaltyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSRoyaltyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyRPIRoyaltyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyOneRPIRoyaltyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSRoyaltyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyRPIRoyaltyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyOneRPIRoyaltyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSRoyaltyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:LoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:PharmakonAdvisorsLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:PharmakonAdvisorsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:TermLoanTrancheAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bcrx:SeniorCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-17</xbrli:startDate><xbrli:endDate>2023-04-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:LoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:PharmakonAdvisorsLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-17</xbrli:startDate><xbrli:endDate>2023-04-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:PharmakonAdvisorsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:TermLoanTrancheCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:PharmakonAdvisorsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:TermLoanTrancheDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:PharmakonAdvisorsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:TermLoanTrancheBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:PharmakonAdvisorsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:TermLoanTrancheAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-17</xbrli:startDate><xbrli:endDate>2023-04-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:PharmakonAdvisorsLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-17</xbrli:startDate><xbrli:endDate>2023-04-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:PharmakonAdvisorsLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bcrx:DebtCovenantTermsAxis">bcrx:PikInterestPaymentIsMadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:PharmakonAdvisorsLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-17</xbrli:startDate><xbrli:endDate>2023-04-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:PharmakonAdvisorsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:TermLoanTrancheAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:PharmakonAdvisorsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:TermLoanTrancheAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:PharmakonAdvisorsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:PharmakonAdvisorsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bcrx:DebtCovenantTermsAxis">bcrx:BetweenTheSecondAndThirdAnniversariesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:PharmakonAdvisorsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bcrx:DebtCovenantTermsAxis">bcrx:AfterThirdAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:PharmakonAdvisorsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bcrx:DebtCovenantTermsAxis">bcrx:AfterFourthAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:PharmakonAdvisorsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-18</xbrli:startDate><xbrli:endDate>2025-04-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:PharmakonAdvisorsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-24</xbrli:startDate><xbrli:endDate>2025-07-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:PharmakonAdvisorsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:PharmakonAdvisorsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:TermLoanTrancheAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:PharmakonAdvisorsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:TermLoanTrancheAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:PharmakonAdvisorsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:TermLoanTrancheAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:PharmakonAdvisorsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bcrx:DebtCovenantTermsAxis">bcrx:PikInterestPaymentIsMadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:TermLoanTrancheAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:PharmakonAdvisorsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bcrx:DebtCovenantTermsAxis">bcrx:PikInterestPaymentIsMadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:TermLoanTrancheAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:PharmakonAdvisorsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:TermLoanTrancheAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-05</xbrli:startDate><xbrli:endDate>2019-11-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:HHSOfficeOfTheAdministrationForStrategicPreparednessAndResponseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:HHSOfficeOfTheAdministrationForStrategicPreparednessAndResponseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:RAPIVABMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:HHSOfficeOfTheAdministrationForStrategicPreparednessAndResponseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:RAPIVABMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:HHSOfficeOfTheAdministrationForStrategicPreparednessAndResponseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:RAPIVABMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:HHSOfficeOfTheAdministrationForStrategicPreparednessAndResponseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:RAPIVABMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:HHSOfficeOfTheAdministrationForStrategicPreparednessAndResponseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:RAPIVABMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ClearsideBiomedicalIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-03</xbrli:startDate><xbrli:endDate>2023-11-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ClearsideBiomedicalIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-03</xbrli:startDate><xbrli:endDate>2023-11-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ClearsideBiomedicalIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesOf2MillionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-03</xbrli:startDate><xbrli:endDate>2023-11-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ClearsideBiomedicalIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesGreaterThan15MillionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-03</xbrli:startDate><xbrli:endDate>2023-11-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:BerotralstatMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:BerotralstatMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:BerotralstatMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:BerotralstatMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:BCX17725Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:BCX17725Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:BCX17725Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:BCX17725Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:AvoralstatMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:AvoralstatMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:AvoralstatMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:AvoralstatMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:FactorDProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:FactorDProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:FactorDProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:FactorDProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-279"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ResearchDiscoveryAndPreclinicalProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-280"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ResearchDiscoveryAndPreclinicalProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-281"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ResearchDiscoveryAndPreclinicalProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ResearchDiscoveryAndPreclinicalProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CompensationAndRelatedPersonnelCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CompensationAndRelatedPersonnelCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CompensationAndRelatedPersonnelCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-286"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CompensationAndRelatedPersonnelCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-287"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:StockBasedCompensationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-288"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:StockBasedCompensationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:StockBasedCompensationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:StockBasedCompensationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-291"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:OtherExpenses1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:OtherExpenses1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-293"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:OtherExpenses1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-294"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:OtherExpenses1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-295"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-298"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-299"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:PharmakonAdvisorsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-08</xbrli:startDate><xbrli:endDate>2025-10-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-300"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bcrx:AstriaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:BlackstoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:BlackstoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-14</xbrli:startDate><xbrli:endDate>2025-10-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:BlackstoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">bcrx:A.MachelleSandersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">bcrx:A.MachelleSandersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="id1b8c440ead54d70904211d3c0a5ea1f_1"></div><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="f-2">x</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">September 30, 2025</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">or</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-4">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the transition period from ______________________ to ______________________</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">000-23186</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">BIOCRYST PHARMACEUTICALS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">62-1413174</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(State or other jurisdiction of</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(I.R.S. Employer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Identification No.)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">4505 Emperor Blvd., Suite 200</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-10">Durham</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-11">North Carolina</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-12">27703</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(Zip Code)</span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">+1-<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-13">919</ix:nonNumeric>-<ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-14">859-1302</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.932%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-15">Common Stock, par value $0.01</ix:nonNumeric></span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-16">BCRX</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-17">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-18">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-19">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.680%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-20">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="f-21">o</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-22">o</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-23">x</ix:nonNumeric></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of October&#160;31, 2025, the registrant had <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-24">210,543,224</ix:nonFraction> shares of common stock outstanding. </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="id1b8c440ead54d70904211d3c0a5ea1f_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">BIOCRYST PHARMACEUTICALS, INC.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:90.869%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.931%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Page No.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_10">Cautionary Note Regarding Forward-Looking Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_10">i</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_13">Risk Factor Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_13">ii</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_16">Part I. Financial Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_16">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_19">Item 1. Financial Statements (Unaudited):</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_19">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_22">Condensed Consolidated Balance Sheets as of </a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_22">September</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_22"> 30, 2025 and December 31, 2024</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_22">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_25">Condensed Consolidated Statements of Comprehensive Income (Loss) for the Three and </a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_25">Nine</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_25"> Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_25">September</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_25"> 30, 2025 and 2024</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_25">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_28">Condensed Consolidated Statements of Cash Flows for the </a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_28">Nine</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_28"> Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_28">Sep</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_28">tember</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_28"> 30, 2025 and 2024</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_28">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_31">Condensed Consolidated Statements of Stockholders&#8217; Deficit for the Three and </a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_31">Nine</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_31"> Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_31">September</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_31"> 30, 2025 and 2024</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_31">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_34">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_34">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_88">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_88">35</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_112">Item 3. Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_112">49</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_115">Item 4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_115">50</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_118">Part II. Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_118">51</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_121">Item 1. Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_121">51</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_124">Item 1A. Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_124">51</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_127">Item 5. Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_127">82</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_133">Item 6. Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_133">83</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_136">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_136">85</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="id1b8c440ead54d70904211d3c0a5ea1f_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">When used in this report, unless otherwise indicated, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">we,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">our,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">us,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> the </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Company,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BioCryst</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> refer to BioCryst Pharmaceuticals, Inc. and, where appropriate, its subsidiaries. </span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Cautionary Note Regarding Forward-Looking Statements </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q (this &#8220;report&#8221;) includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), which are subject to the &#8220;safe harbor&#8221; created in Section 21E. In particular, statements about our expectations, beliefs, plans, objectives or assumptions of future events or performance are contained or incorporated by reference in this report. All statements other than statements of historical facts contained herein are forward-looking statements. These forward-looking statements can generally be identified by the use of words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; the negative of these words or similar expressions. Statements that describe our future plans, strategies, intentions, expectations, objectives, goals or prospects are also forward-looking statements. Discussions containing these forward-looking statements are principally contained in the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; sections of this report, as well as any amendments we make to those sections in filings with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;). These forward-looking statements include, but are not limited to, statements about:</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the preclinical development, clinical development, commercialization, or post-marketing studies of our products and product candidates, including ORLADEYO&#174; (berotralstat), BCX17725, avoralstat, and early-stage discovery programs, and our plans and anticipated timing regarding the same;</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our discovery and commercialization of best-in-class and first-in-class medicines;</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and success of our commercialization of ORLADEYO in the United States and elsewhere and expectations regarding the commercial market for ORLADEYO;</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additional regulatory approvals, or milestones, royalties or profit from sales of our products by us or our partners;</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the implementation of our business model, strategic plans for our business, products, product candidates and technology;</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain collaborations or out-license rights to our products and product candidates;</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">plans, programs, progress and potential success of our collaborations, including with Torii Pharmaceutical Co., Ltd. (&#8220;Torii&#8221;) for ORLADEYO in Japan and Shionogi &amp; Co., Ltd. (&#8220;Shionogi&#8221;) and Green Cross Corporation (&#8220;Green Cross&#8221;) for peramivir in their territories;</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our and any subsidiary guarantors&#8217; ability to satisfy obligations under and to comply with the covenants set forth in any future definitive documentation entered into pursuant to the Commitment Letter (as defined below) with certain affiliates of Blackstone, Inc.; </span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of protection we are able to establish and maintain for intellectual property rights covering our products, product candidates, and technology;</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to operate our business without infringing the intellectual property rights of others;</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">estimates of our revenues, expenses, capital requirements, annual cash utilization, and our needs for additional capital or financing;</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing or likelihood of regulatory filings or regulatory agreements, deferrals, approvals, and other decisions (including with respect to the ORLADEYO pediatric program);</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to manage our liquidity needs to fund our operations or repay potential recourse debt obligations;</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our financial performance;</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">statements and projections regarding financial goals, including timing for achieving sustained profitability or positive cash flow; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">i</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competitive companies, technologies, and our industry; and</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the proposed Merger (as defined below) including, but not limited to, our expectations regarding the timing, closing, cost, and benefits of the proposed Merger and the transactions contemplated by the Merger Agreement.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have based any forward-looking statements on our current expectations about future events or performance. While we believe these expectations are reasonable, forward-looking statements are inherently subject to known and unknown risks and uncertainties, many of which are beyond our control. Actual results may differ materially from those suggested or implied by these forward-looking statements for various reasons, including those discussed in this report under the heading &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; in Part II, Item 1A, some of which are summarized in the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factor Summary</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; below. Any forward-looking statement is subject to these and other risks, uncertainties, and assumptions relating to our operations, results of operations, industry, and future growth. Given these risks and uncertainties, you are cautioned not to place undue reliance on our forward-looking statements. The forward-looking statements included in this report are made only as of the date hereof. We do not undertake, and specifically decline, any obligation to update, revise or correct any of these statements or to publicly announce the results of any such revisions to any forward-looking statements to reflect future events or developments, except as may be required by U.S. federal securities laws.</span></div><div id="id1b8c440ead54d70904211d3c0a5ea1f_13"></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Risk Factor Summary </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">An investment in the Company involves risks. You should carefully read this entire report and consider the uncertainties and risks discussed in the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; section in Part II, Item 1A of this report, which may adversely affect our business, financial condition, or results of operations, along with the other information included in our other filings with the SEC, before making an investment decision in the Company. A summary of the principal factors that make an investment in the Company speculative or risky is set forth below.</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not achieve sustained profitability, and we may need to raise additional capital in the future. If we are unable to raise capital if and when needed, we may need to adjust our operations.</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face risks relating to the proposed Merger and our ability to consummate the Merger, including that failure to complete the Merger could negatively impact us, the pending Merger may disrupt our ongoing business operations, and we may fail to realize the anticipated benefits of the Merger.</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our success depends in part upon our ability to manage our product candidate pipeline, advance our product candidates through the various stages of development, especially through the clinical trial process, and to receive and maintain regulatory approvals for the commercial sale of our product candidates. The development process and related regulatory processes are complex and uncertain, may be lengthy and expensive, and require, among other things, an indication that our products and product candidates are safe and effective. For example, applicable regulatory agencies could refuse to approve, or impose restrictions or warnings on, our product candidates, require us to conduct additional studies or adopt study designs that differ from our planned development strategies, suspend or terminate our clinical trials, withdraw approval for our products, or take other actions that could materially impact the cost, timing, and success of our planned development and commercialization strategies.</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely heavily upon third parties, including development partners, contractors, contract research organizations, and third-party suppliers, manufacturers, and distributors, for many important stages of our product candidate development and in the commercialization of certain of our products and product candidates. Our failure to establish and maintain these relationships, the failure of any such third party to perform its obligations under agreements with us, or the failure of such a relationship to meet our expectations could have a material adverse impact on our business, financial condition, and results of operations.</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we fail to obtain additional financing or acceptable partnership arrangements if and when needed, we may be unable to complete the development and commercialization of our products and product candidates or continue operations.</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If the U.S. Food and Drug Administration or comparable foreign regulatory authorities approve generic versions of any of our products that receive marketing approval, the sales of our products could be adversely affected.</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The commercial viability of any approved product could be compromised if the product is less effective than expected, causes undesirable side effects that either were not previously identified or were worse than expected, or fails to achieve market acceptance by physicians, patients, third-party payors, health authorities, and others.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">ii</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">There can be no assurance that our or our partners&#8217; commercialization efforts, methods, and strategies for our products or technologies will succeed, and our future revenue generation is uncertain.</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face intense competition, and if we are unable to compete effectively, the demand for our products may be reduced. In addition, developments by others may render our products, product candidates, or technologies obsolete or noncompetitive.</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are subject to various laws and regulations related to our products and product candidates, and if we or our employees, consultants, or partners do not comply with these laws and regulations, we could face substantial penalties, and our reputation could be harmed. In addition, we and our partners may be subject to new legislation, regulatory proposals, and healthcare payor initiatives that may increase our costs of compliance and adversely affect our or our partners&#8217; ability to market our products or develop our product candidates.</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we fail to adequately protect or enforce our intellectual property rights, the value of those rights would diminish. Legal proceedings to protect or enforce our patents, the patents of our partners, or our other intellectual property rights could be expensive, time-consuming, and unsuccessful. If we fail to secure the rights to patents of others, this could adversely affect our business.</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face an inherent risk of liability in the event that the use or misuse of our products or product candidates results in personal injury or death, and our product liability insurance coverage may be insufficient.</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we fail to reach milestones or to make annual minimum payments or otherwise breach our obligations under our license agreements, our licensors may terminate our agreements with them and/or seek additional remedies.</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We anticipate incurring significant indebtedness in connection with the Commitment Letter (as defined below), and the definitive documentation for such indebtedness may contain conditions and restrictions that limit our flexibility in operating our business.</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">International expansion of our business exposes us to business, legal, regulatory, political, operational, financial, and economic risks. For example, our actual or perceived failure to comply with non-U.S. governmental laws and regulations and other obligations related to privacy, data protection, and information security could harm our business.</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If our facilities, or the facilities of our third-party vendors, incur damage or power is lost for a significant length of time, our operations will be disrupted, which will adversely affect our business.</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cyber incidents and related disruptions in our or our third-party vendors&#8217; information technology systems, as well as challenges with properly managing artificial intelligence, could adversely affect our business.</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business, operations, clinical development or commercialization plans and timelines, and access to capital could be adversely affected by unpredictable and unstable market and economic conditions.</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we fail to retain our existing key personnel, or fail to attract and retain additional key personnel, the development of our product candidates, the commercialization of our products, and the related expansion of our business may be delayed or stopped. </span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Future acquisitions, strategic investments, partnerships, alliances, or divestitures could fail to meet our expectations and/or adversely affect our operating results and financial condition.</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our existing principal stockholders hold a substantial amount of our common stock and may be able to influence significant corporate decisions, which may conflict with the interests of other stockholders.</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our stock price has been, and is likely to continue to be, highly volatile, which could cause the value of an investment in our common stock to decline significantly.</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we fail to maintain effective internal control over financial reporting, we may not be able to produce accurate and timely financial statements, which may adversely affect investor confidence in us and our financial reporting, adversely affect our business and operating results and negatively impact the trading price of our common stock.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">iii</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Natural disasters, epidemic or pandemic disease outbreaks, trade wars, armed conflicts, political unrest, or other events could disrupt our business or operations, or those of our development partners, manufacturers, regulators, or third parties with whom we conduct business now or in the future.</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are subject to legal proceedings, which could harm our reputation or result in other losses or unexpected expenditure of time and resources.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">iv</span></div></div></div><div id="id1b8c440ead54d70904211d3c0a5ea1f_16"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div id="id1b8c440ead54d70904211d3c0a5ea1f_19"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.&#160;&#160;&#160;&#160;Financial Statements</span></div><div id="id1b8c440ead54d70904211d3c0a5ea1f_22"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">BIOCRYST PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except par value amounts, Unaudited)</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-30">84,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-31">104,713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="f-32">579</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="f-33">210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-34">128,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-35">216,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Trade receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-36">91,325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-37">79,069</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Inventory, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-38">5,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-39">8,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-40">16,502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-41">13,752</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Current assets held for sale</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" format="ixt:num-dot-decimal" scale="3" id="f-42">29,173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" format="ixt:fixed-zero" scale="3" id="f-43">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-44">355,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-45">421,968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Long-term inventory, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-46">23,390</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-47">23,187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-48">8,396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-49">7,777</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-50">39,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-51">20,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Right of use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="bcrx:RightOfUseAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-52">10,840</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="bcrx:RightOfUseAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-53">12,008</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-54">4,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-55">5,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Non-current assets held for sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-56">4,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" format="ixt:fixed-zero" scale="3" id="f-57">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-58">446,424</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-59">490,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Deficit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-60">5,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-61">11,644</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-62">118,778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-63">113,292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-64">348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-65">937</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-66">1,435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-67">1,835</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Royalty financing obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="bcrx:RoyaltyFinancingLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-68">37,686</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="bcrx:RoyaltyFinancingLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-69">32,676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities held for sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" format="ixt:num-dot-decimal" scale="3" id="f-70">26,423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" format="ixt:fixed-zero" scale="3" id="f-71">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-72">190,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-73">160,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-74">8,425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-75">7,924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-76">1,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-77">2,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Royalty financing obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="bcrx:RoyaltyFinancingLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-78">439,107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="bcrx:RoyaltyFinancingLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-79">481,053</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Secured term loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-80">194,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-81">314,869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Non-current liabilities held for sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" scale="3" id="f-82">436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" format="ixt:fixed-zero" scale="3" id="f-83">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-84">834,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-85">966,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Stockholders&#8217; deficit:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-86"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-87">0.01</ix:nonFraction></ix:nonFraction> par value; shares authorized - <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-88"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-89">5,000</ix:nonFraction></ix:nonFraction>; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-90"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-91"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-92"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-93">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at September&#160;30, 2025 and December&#160;31, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-94">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-95">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-96"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-97">0.01</ix:nonFraction></ix:nonFraction> par value; shares authorized - <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-98"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-99">450,000</ix:nonFraction></ix:nonFraction>; shares issued and outstanding &#8211; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-100"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-101">210,522</ix:nonFraction></ix:nonFraction> at September&#160;30, 2025 and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-102"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-103">208,543</ix:nonFraction></ix:nonFraction> at December&#160;31, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="3" id="f-104">2,105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="3" id="f-105">2,085</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-106">1,360,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-107">1,291,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-108">1,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-109">921</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-110">1,752,024</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-111">1,770,040</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total stockholders&#8217; deficit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-112">387,889</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-113">475,934</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; deficit</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-114">446,424</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-115">490,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">1</span></div></div></div><div id="id1b8c440ead54d70904211d3c0a5ea1f_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">BIOCRYST PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share amounts, Unaudited)</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Revenues</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-116">159,395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-117">117,085</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-118">468,282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-119">319,178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-120">2,187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-121">3,211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-122">9,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-123">6,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-124">44,603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-125">41,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-126">125,259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-127">125,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-128">83,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-129">65,101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-130">252,866</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-131">185,841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-132">129,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-133">109,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-134">387,678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-135">317,213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-136">29,591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-137">7,692</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-138">80,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-139">1,965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InterestAndOtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-140">2,238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:InterestAndOtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-141">3,591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestAndOtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-142">7,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:InterestAndOtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-143">11,176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-144">19,661</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-145">24,828</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-146">64,737</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-147">74,067</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency gains (losses), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="3" id="f-148">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="3" id="f-149">98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="3" id="f-150">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="3" id="f-151">37</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-152">2,740</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="f-153">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-154">6,911</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="f-155">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-156">2,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OtherIncome" format="ixt:fixed-zero" scale="3" id="f-157">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-158">2,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:OtherIncome" format="ixt:fixed-zero" scale="3" id="f-159">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total other expense, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-160">17,461</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-161">21,139</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-162">61,230</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-163">62,928</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-164">12,130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-165">13,447</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-166">19,374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-167">60,963</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-168">769</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-169">586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-170">1,358</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-171">1,123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-172">12,899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-173">14,033</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-174">18,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-175">62,086</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-176">523</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-177">563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-178">545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-179">170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on available for sale investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-180">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-181">1,173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-182">326</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-183">786</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="f-184">506</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-185">1,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="f-186">219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="f-187">956</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net comprehensive income (loss)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-188">12,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-189">12,297</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-190">18,235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-191">61,130</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per common share: basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-192">0.06</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-8" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-193">0.07</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-194">0.09</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-9" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-195">0.30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding: basic</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-196">210,176</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-197">206,905</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-198">209,531</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-199">206,466</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per common share: diluted</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-200">0.06</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-8" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-201">0.07</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-202">0.08</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-9" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-203">0.30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding: diluted</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-204">219,885</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-205">206,905</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-206">218,349</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-207">206,466</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">2</span></div></div></div><div id="id1b8c440ead54d70904211d3c0a5ea1f_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">BIOCRYST PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, Unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-208">18,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-209">62,086</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="f-210">995</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="f-211">937</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Inventory obsolescence</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="3" id="f-212">1,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="3" id="f-213">1,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-214">61,273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-215">44,074</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Payment of Pharmakon PIK Interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="bcrx:PaymentsForPaidInKindInterest" format="ixt:num-dot-decimal" scale="3" id="f-216">9,153</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="bcrx:PaymentsForPaidInKindInterest" format="ixt:fixed-zero" scale="3" id="f-217">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash interest expense on royalty financing obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="bcrx:NonCashInterestExpenseOnRoyaltyFinancingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-218">39,839</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="bcrx:NonCashInterestExpenseOnRoyaltyFinancingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-219">42,469</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash interest expense on secured term loan and amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="bcrx:NonCashInterestExpenseOnSecuredTermLoanAndSecuredTermLoanAndAmortizationOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-220">1,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="bcrx:NonCashInterestExpenseOnSecuredTermLoanAndSecuredTermLoanAndAmortizationOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-221">11,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of discount on investments, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="bcrx:AmortizationOfPremiumDiscountOnInvestments" format="ixt:num-dot-decimal" scale="3" id="f-222">3,240</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="bcrx:AmortizationOfPremiumDiscountOnInvestments" format="ixt:num-dot-decimal" scale="3" id="f-223">8,713</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-224">6,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="f-225">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Gain on sale of non-financial asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GainLossOnSaleOfOtherAssets" scale="3" id="f-226">550</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:GainLossOnSaleOfOtherAssets" format="ixt:fixed-zero" scale="3" id="f-227">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Increase in receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInReceivables" format="ixt:num-dot-decimal" scale="3" id="f-228">21,312</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:IncreaseDecreaseInReceivables" format="ixt:num-dot-decimal" scale="3" id="f-229">15,402</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Increase in inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-230">1,124</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-231">2,001</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(Increase) decrease in prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-232">5,890</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-233">1,385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Decrease in royalty financing obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="bcrx:IncreaseDecreaseInRoyaltyFinancingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-234">55,240</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="bcrx:IncreaseDecreaseInRoyaltyFinancingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-235">54,308</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Increase (decrease) in accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-236">22,441</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-237">5,625</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Net cash provided by (used in) operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-238">55,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-239">46,807</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Acquisitions of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireProductiveAssets" format="ixt:num-dot-decimal" scale="3" id="f-240">1,666</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="3" id="f-241">449</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="f-242">136,737</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="f-243">227,235</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Sales and maturities of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-244">207,647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-245">262,480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Sale of non-financial asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleOfOtherAssetsInvestingActivities" scale="3" id="f-246">550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:ProceedsFromSaleOfOtherAssetsInvestingActivities" format="ixt:fixed-zero" scale="3" id="f-247">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-248">69,794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-249">34,796</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net proceeds from common stock issued under stock-based compensation plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="f-250">8,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="f-251">4,030</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Common stock issued to directors in lieu of cash retainer</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="bcrx:ProceedsFromIssuanceOfCommonStockIssuedForServices" scale="3" id="f-252">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="bcrx:ProceedsFromIssuanceOfCommonStockIssuedForServices" scale="3" id="f-253">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Repayment of Pharmakon term loan principal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-254">115,847</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="f-255">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Prepayment premium and fees on Pharmakon term loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" format="ixt:num-dot-decimal" scale="3" id="f-256">3,802</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" format="ixt:fixed-zero" scale="3" id="f-257">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Principal payments on royalty financing obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="bcrx:RepaymentOfRoyaltyFinancingLiabilitiesPrincipal" format="ixt:num-dot-decimal" scale="3" id="f-258">16,406</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="bcrx:RepaymentOfRoyaltyFinancingLiabilitiesPrincipal" format="ixt:fixed-zero" scale="3" id="f-259">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Withholding taxes paid on stock-based awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-260">2,845</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-261">4,451</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Principal payments on finance lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:num-dot-decimal" scale="3" id="f-262">1,565</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:num-dot-decimal" scale="3" id="f-263">1,348</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-264">131,971</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-265">1,740</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Effect of exchange rates on cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-266">1,342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-267">368</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Decrease in cash, cash equivalents and restricted cash, including cash classified within current assets held for sale </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="f-268">5,426</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="f-269">13,383</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Less: cash and cash equivalents classified within current assets held for sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="bcrx:CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperationsLessAssetsHeldForSale" format="ixt:num-dot-decimal" scale="3" id="f-270">14,840</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="bcrx:CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperationsLessAssetsHeldForSale" format="ixt:fixed-zero" scale="3" id="f-271">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Net decrease in cash, and cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="bcrx:CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperationsExcludingAssetsHeldForSale" format="ixt:num-dot-decimal" scale="3" id="f-272">20,266</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="bcrx:CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperationsExcludingAssetsHeldForSale" format="ixt:num-dot-decimal" scale="3" id="f-273">13,383</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Cash, cash equivalents and restricted cash:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-274">106,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-275">112,447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">End of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="bcrx:CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentContinuingOperationExcludingAssetsHeldForSale" format="ixt:num-dot-decimal" scale="3" id="f-276">86,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="bcrx:CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentContinuingOperationExcludingAssetsHeldForSale" format="ixt:num-dot-decimal" scale="3" id="f-277">99,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Reconciliation of cash, cash equivalents and restricted cash:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-278">84,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-279">96,841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="f-280">579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="f-281">813</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash in other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="bcrx:RestrictedCashAndCashEquivalentsIncludedInOtherAssetsNonCurrent" format="ixt:num-dot-decimal" scale="3" id="f-282">1,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="bcrx:RestrictedCashAndCashEquivalentsIncludedInOtherAssetsNonCurrent" format="ixt:num-dot-decimal" scale="3" id="f-283">1,410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="bcrx:CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentContinuingOperationExcludingAssetsHeldForSale" format="ixt:num-dot-decimal" scale="3" id="f-284">86,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="bcrx:CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentContinuingOperationExcludingAssetsHeldForSale" format="ixt:num-dot-decimal" scale="3" id="f-285">99,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental cash flow disclosure:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-286">22,789</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-287">20,242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="3" id="f-288">2,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="3" id="f-289">1,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Taxes withheld on stock-based awards included in accrued expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="bcrx:WithholdingTaxesAccrued" scale="3" id="f-290">151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="bcrx:WithholdingTaxesAccrued" scale="3" id="f-291">245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">4</span></div></div></div><div id="id1b8c440ead54d70904211d3c0a5ea1f_31"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">BIOCRYST PHARMACEUTICALS, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> DEFICIT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, Unaudited)</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.573%"/><td style="width:0.1%"/></tr><tr style="height:30pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Deficit</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-292">208,543</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-293">2,085</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-294">1,291,100</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-295">921</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-296">1,770,040</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-297">475,934</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:NetIncomeLoss" scale="3" id="f-298">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:NetIncomeLoss" scale="3" id="f-299">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="f-300">211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="f-301">211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-19" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-302">286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-303">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-304">1,226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-305">1,229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Vesting of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-19" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="3" id="f-306">184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="f-307">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="f-308">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" format="ixt:fixed-zero" scale="3" id="f-309">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Shares withheld for taxes for vesting of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-19" decimals="-3" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="3" id="f-310">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-311">56</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-312">56</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Employee stock purchase plan sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-19" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="f-313">202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-314">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="f-315">1,215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="f-316">1,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Issuance of shares to directors in lieu of cash retainer</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-19" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="3" id="f-317">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="f-318">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="f-319">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-320">21,368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-321">21,368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2025</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-322">209,208</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-323">2,092</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-324">1,314,857</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-325">1,132</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-326">1,770,008</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-327">451,927</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-328">5,085</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-329">5,085</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="f-330">514</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="f-331">514</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-29" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-332">560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-333">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-334">3,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-335">3,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Vesting of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-29" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="3" id="f-336">136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="f-337">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="f-338">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" format="ixt:fixed-zero" scale="3" id="f-339">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Issuance of shares to directors in lieu of cash retainer</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-29" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="3" id="f-340">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="f-341">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="f-342">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-343">21,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-344">21,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June 30, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-31" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-345">209,905</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-346">2,099</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-347">1,339,584</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-348">1,646</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-349">1,764,923</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-350">421,594</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-351">12,899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-352">12,899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="f-353">506</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="f-354">506</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Exercise of stock options, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-38" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-355">300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-356">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-357">1,563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-358">1,566</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Vesting of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-38" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="3" id="f-359">147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="f-360">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="f-361">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" format="ixt:fixed-zero" scale="3" id="f-362">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Employee stock purchase plan sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-38" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="f-363">167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-364">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="f-365">1,079</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="f-366">1,081</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Issuance of shares to directors in lieu of cash retainer</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-38" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="3" id="f-367">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="f-368">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="f-369">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-370">18,644</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-371">18,644</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Balance at September 30, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-40" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-372">210,522</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-373">2,105</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-374">1,360,890</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-375">1,140</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-376">1,752,024</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-377">387,889</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="margin-top:10pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">BIOCRYST PHARMACEUTICALS, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> DEFICIT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, Unaudited)</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.573%"/><td style="width:0.1%"/></tr><tr style="height:30pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Deficit</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-44" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-378">205,771</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-379">2,058</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-380">1,222,236</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-381">1,337</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-382">1,681,159</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-383">455,528</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-384">35,379</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-385">35,379</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="f-386">566</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="f-387">566</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-51" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-388">176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-389">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-390">550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-391">552</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Vesting of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-51" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="3" id="f-392">155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="f-393">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="f-394">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" format="ixt:fixed-zero" scale="3" id="f-395">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Shares withheld for taxes for vesting of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-51" decimals="-3" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="3" id="f-396">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-397">38</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-398">38</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Employee stock purchase plan sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-51" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="f-399">251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-400">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="f-401">1,127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="f-402">1,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Issuance of shares to directors in lieu of cash retainer</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-51" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="3" id="f-403">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="f-404">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="f-405">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-406">13,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-407">13,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-53" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-408">206,347</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-409">2,063</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-410">1,237,537</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-411">771</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-412">1,716,538</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-413">476,167</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-414">12,674</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-415">12,674</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="f-416">214</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="f-417">214</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-61" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-418">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-419">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-420">263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-421">264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Vesting of restricted stock units</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-61" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="3" id="f-422">200</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="f-423">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="f-424">2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" format="ixt:fixed-zero" scale="3" id="f-425">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Issuance of shares to directors in lieu of cash retainer</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-61" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="3" id="f-426">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="f-427">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="f-428">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Stock-based compensation expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-429">13,173</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-430">13,173</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June 30, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-63" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-431">206,629</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-432">2,066</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-433">1,250,983</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-434">557</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-435">1,729,212</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-436">475,606</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-437">14,033</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-438">14,033</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-439">1,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-440">1,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-70" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-441">262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-442">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-443">1,359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-444">1,362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Vesting of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-70" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="3" id="f-445">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="f-446">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="f-447">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" format="ixt:fixed-zero" scale="3" id="f-448">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Employee stock purchase plan sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-70" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="f-449">161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-450">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-451">722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-452">723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Issuance of shares to directors in lieu of cash retainer</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-70" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="3" id="f-453">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="f-454">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="f-455">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-456">17,249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-457">17,249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Balance at September 30, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-72" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-458">207,119</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-459">2,071</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-460">1,270,318</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-461">2,293</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-462">1,743,245</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-463">468,563</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">6</span></div></div></div><div id="id1b8c440ead54d70904211d3c0a5ea1f_34"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div id="id1b8c440ead54d70904211d3c0a5ea1f_37"></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">BIOCRYST PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Note 1 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-464" continuedAt="f-464-1" escape="true">Significant Accounting Policies and Concentrations of Risk</ix:nonNumeric></span></div><ix:continuation id="f-464-1" continuedAt="f-464-2"><ix:nonNumeric contextRef="c-1" name="bcrx:DescriptionOfCompanyPolicyTextBlock" id="f-465" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Company</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">BioCryst Pharmaceuticals, Inc. (the &#8220;Company&#8221;) is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (&#8220;HAE&#8221;) and other rare diseases, driven by the Company&#8217;s deep commitment to improving the lives of people living with these conditions. The Company has built a robust commercial infrastructure to support the launch and continued success of ORLADEYO&#174;, an oral, once-daily therapy discovered and developed internally for the prevention of HAE attacks. The Company&#8217;s business strategy includes leveraging this established commercial platform to successfully commercialize a pipeline of potential first-in-class or best-in-class oral small-molecule and injectable protein therapeutics targeting a range of rare diseases. These programs are being pursued through both internal discovery efforts and strategic business development. By utilizing its existing commercial capabilities and focusing on rare disease markets, the Company believes that it can more effectively optimize its costs and strategically allocate resources to support long-term, sustainable growth. The Company was founded in 1986 and incorporated in Delaware in 1991, and its headquarters is located in Durham, North Carolina.  </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s marketed products include oral, once-daily ORLADEYO&#174; for the prevention of HAE attacks and RAPIVAB&#174; (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. ORLADEYO has received regulatory approval in the United States and other global markets. The Company is commercializing ORLADEYO in each of these territories directly or through other parties. In addition to its approval in the United States, peramivir injection has received regulatory approvals in Canada (RAPIVAB), Australia (RAPIVAB), Japan (RAPIACTA), Taiwan (RAPIACTA) and Korea (PERAMIFLU). </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Based on the Company&#8217;s expectations for revenue and operating expenses, the Company believes its financial resources available at September&#160;30, 2025 will be sufficient to fund its operations for at least the next 12 months. The Company may, in the future, issue securities, including common stock, preferred stock, depositary shares, purchase contracts, warrants, debt securities and units, through private placement transactions or registered public offerings. The Company&#8217;s future liquidity needs, and ability to address those needs, will largely be determined by the success of its products and product candidates; the timing, scope and magnitude of its research and development and commercial expenses; and key developments and regulatory events and its decisions in the future.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-466" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany transactions and balances among the consolidated entities have been eliminated from the condensed consolidated financial statements. The Company operates and manages its business as <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-467"><ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-468">one</ix:nonFraction></ix:nonFraction> reportable and operating segment (see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 13&#8212;Segment Information</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) for interim financial reporting and the instructions to Form 10-Q and do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Such financial statements reflect all adjustments that are, in management&#8217;s opinion, necessary to present fairly, in all material respects, the Company&#8217;s condensed consolidated financial position, results of operations, and cash flows. There were no adjustments other than normal recurring adjustments. Certain prior year amounts have been reclassified to conform to the current year presentation. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements should be read in conjunction with the financial statements for the fiscal year ended December&#160;31, 2024 and the notes thereto included in the Company&#8217;s 2024 Annual Report on Form 10-K as filed with the SEC on February 25, 2025. Interim operating results are not necessarily indicative of operating results for the full fiscal year. The condensed consolidated balance sheet as of December&#160;31, 2024 was derived from the audited consolidated financial statements included in the Company&#8217;s most recent Annual Report on Form 10-K.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><ix:continuation id="f-464-2" continuedAt="f-464-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-469" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. Significant estimates in the Company&#8217;s condensed consolidated financial statements have been made relative to the calculation of net product sales, royalty financing obligations, inventory reserves, certain accruals, primarily related to the Company&#8217;s research and development expenses, the valuation of stock options and the valuation allowance for deferred tax assets resulting from net operating losses. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="bcrx:AssetsHeldForSalePolicyTextBlock" id="f-470" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets Held for Sale</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies its long-lived assets to be sold as held for sale when the six criteria in ASC 360, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, Plant and Equipment</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> are met. This generally occurs when an agreement to sell exists, or when management has committed to a plan to sell the assets within one year. Assets and liabilities to be disposed of together as a group in a single transaction (&#8220;disposal groups&#8221;) are classified as held for sale if their carrying amounts are principally expected to be recovered through a sale transaction rather than through continuing use.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The long-lived assets included in a disposal group are reported at the lower of their carrying value or fair value less cost to sell, beginning in the period the held for sale criteria are met. Prior to disposal, losses are recognized for any initial or subsequent write-down to fair value less cost to sell. Any gains or losses not previously recognized that result from the sale of a disposal group shall be recognized at the date of sale. Upon designation as an asset held for sale, the Company stops recording depreciation and amortization expense on long-lived assets. The Company assesses the fair value of a long-lived asset less any costs to sell at each reporting period and until the asset is no longer classified as held for sale.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="f-471" continuedAt="f-471-1" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="f-472" continuedAt="f-472-1" escape="true"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded the following revenues for the three and nine months ended September&#160;30, 2025 and 2024 (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-473">157,735</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-474">116,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-475">463,952</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-476">313,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Collaborative and other revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-477">1,660</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-478">1,019</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-479">4,330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-480">5,853</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-481">159,395</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-482">117,085</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-483">468,282</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-484">319,178</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, the Company recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, Topic 606 includes provisions within a five-step model that includes (i) identifying the contract with a customer, (ii) identifying the performance obligations in the contract, (iii) determining the transaction price, (iv) allocating the transaction price to the performance obligations, and (v) recognizing revenue when, or as, an entity satisfies a performance obligation.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, the Company identifies the goods or services promised within each contract, assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Sales, Net</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s principal sources of product sales are sales of ORLADEYO, which the Company began shipping to patients in December 2020, and sales of peramivir (RAPIVAB/RAPIACTA/PERAMIFLU) to the Company&#8217;s licensing partners and to the U.S. Department of Health and Human Services (&#8220;HHS&#8221;). In the United States, the Company generally ships ORLADEYO directly to patients through a single specialty pharmacy, which is considered its customer. Outside the United States, the Company sells ORLADEYO to specialty distributors and to hospitals and pharmacies, which collectively are considered its customers.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><ix:continuation id="f-471-1" continuedAt="f-471-2"><ix:continuation id="f-464-3" continuedAt="f-464-4"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue for sales when the customer obtains control of the product, which generally occurs upon delivery. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue from sales of ORLADEYO is recorded at net selling price (transaction price), which includes reserves for variable consideration such as (i) estimated government rebates, such as Medicaid and Medicare Part D reimbursements, and estimated managed care rebates, (ii) estimated chargebacks, (iii) estimated costs of co-payment assistance programs and (iv) product returns. These reserves, representing the Company&#8217;s best estimates of the amount of consideration to which it is entitled based on the terms of the applicable contracts and statutory requirements, are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable if no payments are required of the Company or a current liability if a payment is required of the Company. Actual amounts of consideration may differ from the Company&#8217;s estimates. If actual results vary from estimates, these estimates are adjusted, which would affect net product revenue and earnings in the period such variances become known.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government and Managed Care Rebates</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The Company contracts with government agencies and managed care organizations or, collectively, third-party payors, so that ORLADEYO will be eligible for purchase by, or partial or full reimbursement from, such third-party payors. The Company estimates the rebates it will provide to third-party payors and deducts these estimated amounts from total gross product revenues at the time the revenues are recognized, resulting in a reduction of product revenue and the establishment of a current liability. The Company estimates the rebates that it will provide to third-party payors based upon (i) the Company&#8217;s contracts with these third-party payors, (ii) the government mandated discounts applicable to government-funded programs, and (iii) product distribution information obtained from the Company&#8217;s specialty pharmacy regarding payor mix.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chargebacks</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Chargebacks are discounts that occur when certain contracted customers, pharmacy benefit managers, insurance companies, and government programs purchase directly from the Company&#8217;s specialty pharmacy. These customers purchase the Company&#8217;s product under contracts negotiated between them and the Company&#8217;s specialty pharmacy. The specialty pharmacy, in turn, charges back to the Company the difference between the price that the specialty pharmacy paid and the negotiated price paid by the contracted customers, which may be higher or lower than the specialty pharmacy&#8217;s purchase price with the Company. The Company estimates chargebacks and adjusts gross product revenues and establishes a current liability at the time revenues are recognized.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Co-payment assistance and patient assistance programs</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. Based upon the terms of the program and co-payment assistance utilization reports received from the specialty pharmacy, the Company estimates the co-payment assistance amounts, which are recorded in the same period in which the related revenue is recognized, resulting in a reduction of product revenue and establishment of a current liability. The Company also offers a patient assistance program that provides free drug product, for a limited period of time, to allow a patient&#8217;s insurance coverage to be established. Based on patient assistance program utilization reports provided by the specialty pharmacy, the Company records gross revenue of the product provided and a full reduction of the revenue amount for the free drug discount.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product returns</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The Company does not provide contractual return rights to its customers, except in instances where the product is damaged or defective. Non-acceptance by the patient of shipped drug product by the specialty pharmacy is reflected as a reversal of sales in the period in which the sales were originally recorded. Reserves for estimated non-acceptances by patients are recorded as a reduction of revenue in the period that the related revenue is recognized, as well as a reduction to accounts receivable. Estimates of non-acceptance are based on quantitative information provided by the specialty pharmacy.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Revenues</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has collaboration and license agreements with a number of third parties. The Company&#8217;s primary sources of revenue from these collaborative and other research and development arrangements are license, service and royalty revenues.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from license fees, royalty payments, milestone payments, and research and development fees are recognized as revenue when the earnings process is complete and the Company has no further continuing performance obligations or the Company has completed the performance obligations under the terms of the agreement.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Arrangements that involve the delivery of more than one performance obligation are initially evaluated as to whether the intellectual property licenses granted by the Company represent distinct performance obligations. If they are determined to be distinct, the value of the intellectual property licenses would be recognized up front while the research and development service fees would be recognized as the performance obligations are satisfied. For performance obligations </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><ix:continuation id="f-464-4" continuedAt="f-464-5"><ix:continuation id="f-471-2"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">based on services performed, the Company measures progress using an input method based on the effort it expends or costs it incurs toward the satisfaction of the performance obligation in relation to the total estimated effort or costs. Variable consideration is assessed at each reporting period as to whether it is not subject to significant future reversal and, therefore, should be included in the transaction price at the inception of the contract. If a contract includes a fixed or minimum amount of research and development support, this also would be included in the transaction price. Changes to collaborations, such as the extensions of the research term or increasing the number of targets or technology covered under an existing agreement, are assessed for whether they represent a modification or should be accounted for as a new contract. For contracts with multiple performance obligations, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the products or services. If a standalone selling price is not directly observable, then the Company estimates the standalone selling price using either an adjusted market assessment approach or an expected cost plus margin approach, representing the amount that the Company believes the market is willing to pay for the product or service. Analyzing the arrangement to identify performance obligations requires the use of judgment, and each may be an obligation to deliver services, a right or license to use an asset, or another performance obligation. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under certain of the Company&#8217;s license agreements, the Company receives royalty payments based upon its licensees&#8217; net sales of covered products. Royalties are recognized at the later of when (i) the subsequent sale or usage occurs, or (ii) the performance obligation to which some or all of the sales-based or usage-based royalty has been satisfied.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-485" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally considers cash equivalents to be all cash held in commercial checking accounts, money market accounts, or investments in debt instruments and certificates of deposit with maturities of three months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="f-486" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Total restricted cash was $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-487">1,979</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-488">1,610</ix:nonFraction> as of September&#160;30, 2025 and December&#160;31, 2024, respectively, and primarily consisted of $<ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-489"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-490">1,400</ix:nonFraction></ix:nonFraction> as of September&#160;30, 2025 and December&#160;31, 2024, for a letter of credit the Company is required to maintain associated with its Birmingham lease. The letter of credit associated with the Birmingham lease of $<ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-491"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-492">1,400</ix:nonFraction></ix:nonFraction> is reflected within other assets on the Condensed Consolidated Balance Sheets as of September&#160;30, 2025 and December&#160;31, 2024.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentPolicyTextBlock" id="f-493" continuedAt="f-493-1" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests in high credit quality investments in accordance with its investment policy. The objectives of the Company&#8217;s investment policy are to eliminate or greatly minimize the probability of a loss of principal value, maintain sufficient liquidity to meet cash flow requirements, and earn a competitive level of return. The Company places its excess cash with high credit quality financial institutions to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that may consist of U.S. Treasury obligations, U.S government agency securities, money market funds, certificates of deposits and corporate notes and bonds. The Company&#8217;s investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of <ix:nonNumeric contextRef="c-86" name="bcrx:MaturityPeriodOfHighQualityMarketableSecurities" format="ixt-sec:durwordsen" id="f-494">two years</ix:nonNumeric> and requires an average portfolio maturity of no more than <ix:nonNumeric contextRef="c-86" name="bcrx:AverageMaturityPeriodOfHighQualityMarketableSecurities" format="ixt-sec:durmonth" id="f-495">12</ix:nonNumeric> months. Some of the securities in which the Company invests may have market risk. This means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, the Company does not believe it has a material exposure to interest rate risk arising from its investments. The Company has not realized any significant losses from its investments.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies all of its investments as available-for-sale. Available-for-sale investments are reported at fair value at each balance sheet date, and include any unrealized holding gains and losses in accumulated other comprehensive income, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company reviews its investments for other than temporary declines in fair value below cost basis at the end of each reporting period and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Factors considered to determine whether an unrealized loss is temporary include whether a decline in fair value below the amortized cost basis is due to credit-related factors or non-credit-related factors, the financial condition and near-term prospects of the Company, and the Company&#8217;s intent and ability to hold the investment to allow for an anticipated recovery in fair value. A credit-related impairment is recognized as an allowance on the balance sheet with a corresponding adjustment to earnings. Any impairment that is not credit-related is recognized in </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><ix:continuation id="f-464-5" continuedAt="f-464-6"><ix:continuation id="f-493-1"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">other comprehensive income, net of applicable taxes unless deemed other than temporary. Realized gains and losses are reflected in interest and other income in the Condensed Consolidated Statements of Comprehensive Income (Loss) and are determined using the specific identification method with transactions recorded on a settlement date basis. Investments with original maturities at date of purchase beyond three months and which mature at or less than <ix:nonNumeric contextRef="c-86" name="bcrx:MaturityPeriodOfShortTermInvestment" format="ixt-sec:durmonth" id="f-496">12</ix:nonNumeric> months from the balance sheet date are classified as current. Investments with a maturity beyond <ix:nonNumeric contextRef="c-1" name="bcrx:LongTermInvestmentMaturityMinimum" format="ixt-sec:durmonth" id="f-497">12</ix:nonNumeric> months from the balance sheet date are classified as long-term.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="f-498" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities recorded at fair value on a recurring basis on the Condensed Consolidated Balance Sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Assets measured at fair value on a recurring basis include investments (See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 4&#8212;Investments</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). There were no liabilities measured at fair value on a recurring basis as of September&#160;30, 2025 and December&#160;31, 2024. The carrying amounts reflected in the Condensed Consolidated Balance Sheets for cash and cash equivalents, trade receivables, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ReceivablesPolicyTextBlock" id="f-499" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trade Receivables</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company&#8217;s trade receivables arise from product sales and primarily represent amounts due from its specialty pharmacy customer in the United States and other third-party distributors, hospitals and pharmacies globally and have standard payment terms that generally require payment within 30 to 90 days.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Receivables from collaborations are recorded for amounts due to the Company related to royalty receivables from the Company&#8217;s partners, including Shionogi &amp; Co., Ltd., Green Cross, and Torii (See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 12&#8212;Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides reserves against trade receivables for estimated losses that may result from a customer&#8217;s inability to pay. Receivables are evaluated to determine if any reserve or allowance should be recorded based on consideration of the current economic environment, expectations of future economic conditions, specific circumstances and the Company&#8217;s own historical collection experience. Amounts determined to be uncollectible are charged or written-off against the reserve.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryPolicyTextBlock" id="f-500" continuedAt="f-500-1" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s inventory primarily relates to ORLADEYO and also includes peramivir.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company values its inventory at the lower of cost or estimated net realizable value. The Company determines the cost of its inventory on a first-in, first-out (FIFO) basis. Raw materials and work-in-process include all inventory costs prior to packaging and labeling, including raw material, active product ingredient, and the drug product. Finished goods include packaged and labeled products. The Company classifies inventory as long-term when consumption or sale of the inventory is not expected to occur within 12 months from the balance sheet date.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s inventory is subject to expiration dating. At each reporting date, the Company evaluates the carrying value of its inventory and provides valuation reserves for any estimated excess, obsolete, short-dated or unmarketable inventory. In addition, the Company may experience spoilage of its raw materials and supplies. The Company&#8217;s determination that a valuation reserve might be required, in addition to the quantification of such reserve, requires it to utilize significant judgment. Additionally, the Company&#8217;s inventory is subject to strict quality control and monitoring that is performed throughout the manufacturing process, including release of work-in-process to finished goods. In the event that certain batches or units of product do not meet quality specifications, the Company will record a write-down of any potential unmarketable inventory to its estimated net realizable value and record the expense as cost of product in the Condensed Consolidated Statements of Comprehensive Income (Loss).</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prior to obtaining initial regulatory approval for an investigational product candidate, the Company expenses costs relating to production of pre-launch inventory as research and development expense in its Condensed Consolidated </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><ix:continuation id="f-464-6" continuedAt="f-464-7"><ix:continuation id="f-500-1"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Statements of Comprehensive Income (Loss) in the period incurred. After regulatory approval has been received, the Company capitalizes inventory costs.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-501" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Computer equipment and office equipment are depreciated over a life of <ix:nonNumeric contextRef="c-87" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="f-502">three years</ix:nonNumeric>. Laboratory equipment, software, and furniture and fixtures are depreciated over a life of <ix:nonNumeric contextRef="c-88" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="f-503"><ix:nonNumeric contextRef="c-89" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="f-504">five years</ix:nonNumeric></ix:nonNumeric>. Leasehold improvements are amortized over their estimated useful lives or the expected lease term, whichever is less. Construction in progress reflects amounts incurred for construction or improvements of property and equipment that have not been placed in service.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically reviews its property and equipment for impairment when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values. Property and equipment to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="bcrx:AccruedExpensesPolicyTextBlock" id="f-505" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into contractual agreements with third-party vendors who provide research and development, manufacturing, distribution, and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing, and services are completed over an extended period of time. The Company records liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel to identify services that have been performed on its behalf and estimating the actual work completed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of actual cost. The majority of service providers invoice the Company monthly in arrears for services performed. The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances, which can include assumptions such as expected patient enrollment, site activation and estimated project duration. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued expenses include (i) fees paid to clinical research organizations (&#8220;CROs&#8221;) in connection with preclinical and toxicology studies and clinical trials; (ii) fees paid to investigative sites in connection with clinical trials; (iii) fees paid to contract manufacturers in connection with the production of the Company&#8217;s raw materials, drug substance, drug products, and product candidates; and (iv) professional fees.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company bases its expenses related to clinical trials on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on the Company&#8217;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. The Company accrues costs for clinical trial activities based upon estimates of the actual work completed in accordance with agreements established with third-party vendors. If the Company underestimates or overestimates the level of these costs, actual expenses could differ from such estimates. As of September&#160;30, 2025 and December&#160;31, 2024, the carrying value of accrued expenses approximates their fair value due to their short-term settlement.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CostOfSalesPolicyTextBlock" id="f-506" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Product Sales</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product sales includes the cost of producing inventory that is related to product revenue during the respective period, including freight. Cost of product sales may also include costs related to excess or obsolete inventory adjustment charges.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-507" continuedAt="f-507-1" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of costs associated with research activities as well as those with the Company&#8217;s product development efforts, conducting preclinical trials, clinical trials and manufacturing activities. Research and development expenses are expensed as incurred. Most of the Company&#8217;s clinical and preclinical studies are performed by third-party CROs. Costs for studies performed by CROs are accrued based upon estimates of the actual work completed in accordance with the third-party agreements. Advance payments for goods or services that will be used or rendered for </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><ix:continuation id="f-464-7" continuedAt="f-464-8"><ix:continuation id="f-507-1"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of costs associated with research activities as well as those associated with product development efforts, conducting pre-clinical trials, clinical trials and manufacturing activities. Direct expenses consist of compensation for research and development personnel and costs of outside parties to conduct laboratory studies, develop manufacturing processes and manufacture the product candidate, conduct and manage clinical trials, as well as other costs related to the Company&#8217;s clinical and preclinical studies. Additionally, direct expenses consist of those costs necessary to discontinue and close out a development program, including termination fees and other commitments. Indirect expenses consist of lab supplies and services, facility expenses, depreciation of development equipment and an allocation of its general and administrative overhead costs that support the Company&#8217;s research and development efforts.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" id="f-508" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses are comprised of compensation and benefits and related costs associated with sales and marketing, finance, human resources, legal, information technology, quality, safety and regulatory activities related to marketed products, and other general and administrative personnel. Additionally, selling, general and administrative expenses are comprised of market research, marketing, advertising and legal expenses, including patent costs, licenses and other administrative costs.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All patent related costs are expensed to selling, general and administrative expenses when incurred as recoverability of such expenditures is uncertain.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-509" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases certain assets under operating and finance leases, which consist of real estate leases, laboratory equipment leases and office equipment leases as of September&#160;30, 2025. The Company determines whether a contract is, or contains, a lease at inception. The Company accounts for lease obligations in accordance with ASU 2016-02: </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases (Topic 842)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, which requires a lessee to recognize a right-of-use asset and a lease liability on its balance sheet for most leases. The Company elected the practical expedient that exempts leases with an initial lease term of twelve months or less, as well as the practical expedient that allows companies to select, by class of underlying asset, not to separate lease and non-lease components. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s operating leases provide for renewal options, which can vary by lease. The right-of-use asset and lease liabilities on the Company&#8217;s Condensed Consolidated Balance Sheets represent payments over the lease term, which include renewal options for certain real estate leases that the Company is likely to exercise. Certain operating leases include rent escalation provisions, which the Company recognizes as expense on a straight-line basis. Lease expense for leases with an initial term of twelve months or less was not material.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The discount rate used to determine the Company&#8217;s right-of-use asset and lease liability is the Company&#8217;s incremental borrowing rate on a collateralized basis over a similar term and amount in a similar economic environment, as generally an implicit rate in the lease is not readily determinable. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not made any residual value guarantees related to its leases; therefore, the Company has no corresponding liability recorded on its Condensed Consolidated Balance Sheets.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-510" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in the Company&#8217;s Condensed Consolidated Statements of Comprehensive Income (Loss) based on their fair values. Stock-based compensation cost is estimated at the grant date based on the fair value of the award and is recognized as expense on a straight-line basis over the requisite service period of the award. Determining the appropriate fair value model and the related assumptions for the model requires judgment, including estimating the stock price volatility and the expected term. The Company utilizes the Black-Scholes option-pricing model to value its stock option awards and recognize compensation expense on a straight-line basis over the requisite service period. The Company reduces stock-based compensation expense for estimated forfeitures. The estimation of share-based payment awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from the Company&#8217;s current estimates, such amounts will be recorded as a cumulative adjustment in the period estimates are revised. Actual results, and future changes in estimates, may differ substantially from the Company&#8217;s current estimates.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><ix:continuation id="f-464-8" continuedAt="f-464-9"><ix:nonNumeric contextRef="c-1" name="bcrx:InterestExpenseDeferredFinancingCostsAndRoyaltyFinancingLiabilitiesPolicyTextBlock" id="f-511" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense, Deferred Financing Costs and Royalty Financing Obligations</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense primarily relates to the royalty financing obligations (see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7&#8212;Royalty Financing Obligations</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and the term loan borrowings under the Pharmakon Loan Agreement (see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8&#8212;Deb</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">t&#8221;) during the nine months ended September&#160;30, 2025 and 2024. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Costs directly associated with the borrowings were capitalized and netted against the corresponding debt liabilities on the Condensed Consolidated Balance Sheets. These costs are amortized to interest expense over the terms of the corresponding borrowings using the effective interest rate method. When utilizing the effective interest method, in periods in which payment-in-kind (&#8220;PIK&#8221;) interest was designated and added to the outstanding principal balance of the borrowing, the amortization of the deferred debt fees and issuance costs was accretive.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The royalty financing obligations are eligible to be repaid based on royalties from net sales of ORLADEYO. Interest expense is accrued using the effective interest rate method over the estimated period each of the related liabilities will be paid. This requires the Company to estimate the total amount of future royalty payments to be generated from product sales over the life of the agreement. The Company imputes interest on the carrying value of each of the royalty financing obligations and records interest expense using an imputed effective interest rate. The Company reassesses the expected royalty payments each reporting period and accounts for any changes through an adjustment to the effective interest rate on a prospective basis. The assumptions used in determining the expected repayment term of the debt and amortization period of the issuance costs require that the Company make estimates that could impact the carrying value of each of the liabilities, as well as the periods over which associated issuance costs will be amortized. A significant increase or decrease in forecasted net sales could materially impact each of the liability balances, interest expense and the time periods for repayment.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-512" continuedAt="f-512-1" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The liability method is used in the Company&#8217;s accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Significant management judgment is required in determining the Company&#8217;s provision for income taxes, deferred tax assets and liabilities and any valuation allowance recorded against net deferred tax assets. The Company has recorded a valuation allowance against substantially all potential tax assets, due to uncertainties in its ability to utilize deferred tax assets, primarily consisting of certain net operating losses carried forward, before they expire. The valuation allowance is based on estimates of future earnings in each of the jurisdictions in which the Company operates and the period over which its deferred tax assets will be recoverable.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertain tax positions in accordance with U.S. GAAP. Uncertain tax positions are recorded based upon certain recognition and measurement criteria. The Company re-evaluates uncertain tax positions and considers various factors, including, but not limited to, changes in tax law and the measurement of tax positions taken or expected to be taken in tax returns. The Company adjusts the amount of the liability to reflect any subsequent changes in the relevant facts and circumstances surrounding the uncertain tax positions. The Company recognizes interest and penalties related to income tax matters in income tax expense.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in fiscal year 2021, the Company began accruing for U.S. state taxes and foreign income taxes as a result of increased nexus in both U.S. state and foreign jurisdictions where historically the Company had no presence and where no net operating losses had historically been established.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, starting in 2022, amendments to Section 174 of the Internal Revenue Code of 1986, as amended (&#8220;IRC&#8221;), no longer permit an immediate deduction for research and development expenditures conducted on foreign soil in the tax year that such costs are incurred. Instead, these IRC Section 174 development costs must now be capitalized and amortized over a 15-year period. The new amortization period begins with the midpoint of any taxable year that IRC Section 174 costs are first incurred, regardless of whether the expenditures were made prior to or after July 1, and runs until the midpoint of year sixteen.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Certain countries in which the Company has operations have adopted legislation influenced by the Organization for Economic Cooperation and Development (&#8220;OECD&#8221;) Pillar Two rules, including a minimum tax rate of 15%. It is uncertain whether the U.S. will enact legislation to adopt the Pillar Two framework. While the Company is currently not within the scope of the rules, it is continuing to review and evaluate additional guidance released by the OECD, along with the pending legislative adoption by additional individual countries where the Company operates. </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="text-indent:27pt"><span><br/></span></div><ix:continuation id="f-464-9" continuedAt="f-464-10"><ix:continuation id="f-512-1"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">On July 4, 2025, the One Big Beautiful Bill Act (&#8220;OBBBA&#8221;) was signed into law, making permanent certain provisions of the Tax Cuts and Jobs Act, including permanent 100% bonus depreciation, expensing of domestic research costs, and amendments to the business interest expense limitation. In accordance with ASC Topic 740, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Income Taxes,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> the Company has recognized the effects of the new tax law in the period of enactment. As the Company maintains a full valuation allowance on its U.S. federal deferred tax assets, the legislation does not have a material impact on its condensed consolidated financial statements for the three months ended September 30, 2025.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="f-513" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency of each of the Company&#8217;s foreign subsidiaries is primarily the local currency of the country in which the subsidiary operates. The Company&#8217;s asset and liability accounts are translated at the current exchange rate as of the balance sheet date. Revenue and expense accounts are translated at the average exchange rate over the period. Adjustments resulting from the translation of the financial statements of the Company&#8217;s foreign subsidiaries into U.S. dollars are accumulated as a separate component of stockholders&#8217; equity within accumulated other comprehensive income. Gains or losses resulting from transactions denominated in foreign currencies are included in foreign currency losses, net, within the Condensed Consolidated Statement of Comprehensive Income (Loss).</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-514" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Income (Loss) Per Share</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income (loss) per share is based upon the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share is based upon the weighted average number of common shares outstanding and potentially dilutive common shares during the period as determined by using the treasury stock method. Potential common equivalent shares are excluded if their effect is anti-dilutive.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="f-515" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive income is comprised of cumulative foreign currency translation adjustments and unrealized gains and losses on available-for-sale investments and is disclosed as a separate component of stockholders&#8217; equity. Realized gain and loss amounts on available-for-sale investments are reclassified from accumulated other comprehensive income and recorded as interest and other income on the Condensed Consolidated Statements of Comprehensive Income (Loss). There were <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" format="ixt:fixed-zero" scale="3" id="f-516"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" format="ixt:fixed-zero" scale="3" id="f-517">no</ix:nonFraction></ix:nonFraction> realized gains or losses reclassified out of accumulated other comprehensive income for the three and nine months ended September&#160;30, 2025 and 2024.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="bcrx:ConcentrationOfMarketRiskPolicyTextBlock" id="f-518" continuedAt="f-518-1" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Customers and Other Risks</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Significant Customers</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s primary sources of revenue and cash flow are the sales of ORLADEYO in the United States.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ORLADEYO is generally distributed through an arrangement with a single specialty pharmacy in the United States. The specialty pharmacy subsequently sells ORLADEYO to its customers (pharmacy benefit managers, insurance companies, government programs and group purchasing organizations) and dispenses product to patients. RAPIVAB is also generally distributed through the same specialty pharmacy in the United States. The specialty pharmacy&#8217;s inability or unwillingness to continue these distribution activities could adversely impact the Company&#8217;s business, results of operations and financial condition. Revenue where the specialty pharmacy is considered the customer was approximately <ix:nonFraction unitRef="number" contextRef="c-90" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-519">88</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-91" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-520">86</ix:nonFraction>% of total net revenues for the three and nine months ended September&#160;30, 2025, respectively. Revenue where the specialty pharmacy is considered the customer was approximately <ix:nonFraction unitRef="number" contextRef="c-92" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-521"><ix:nonFraction unitRef="number" contextRef="c-93" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-522">88</ix:nonFraction></ix:nonFraction>% of total net revenues for both the three and nine months ended September&#160;30, 2024.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is distributing ORLADEYO in other global markets directly or through other parties.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks from Third-Party Manufacturing and Distribution Concentration</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company relies on a single source manufacturer for active pharmaceutical ingredient and finished drug product manufacturing of product candidates in development and on a single specialty pharmacy for distribution of approved drug product in the United States. Delays or disruption in the manufacture or distribution of any product could adversely impact the future procurement stockpiling of the Company&#8217;s commercial product, commercial revenue and product candidates.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><ix:continuation id="f-464-10"><ix:continuation id="f-518-1" continuedAt="f-518-2"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Further, the Company&#8217;s drug development activities are performed by a limited group of third-party vendors. If any of these vendors were unable to perform its services, this could significantly impact the Company&#8217;s ability to complete its drug development activities.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Risk</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents and investments are financial instruments that potentially subject the Company to concentration of risk to the extent recorded on the Condensed Consolidated Balance Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances may exceed the amount of insurance provided on such deposits. The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio of investments with an average maturity of approximately 12 months or less.</span></div></ix:continuation><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-518-2">The Company&#8217;s receivables from sales of ORLADEYO are primarily due from one customer, resulting in a concentration of credit risk.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-523" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There have been no new accounting pronouncements adopted by the Company during the nine months ended September 30, 2025.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company expects adoption of this ASU will result in additional disclosures but does not expect it will have a material effect on the Company&#8217;s consolidated balance sheet, statement of comprehensive income (loss), or statement of cash flows.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which requires public entities, on an annual and interim basis, to provide disaggregated disclosure of certain income statement expenses into specified categories within the footnotes to the financial statements. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The Company is evaluating the impact of adopting ASU 2024-03.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In September 2025, the FASB issued ASU 2025-06, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software, which clarifies and modernizes the accounting for costs related to internal-use software, eliminating references to project stages and clarifying the threshold entities apply to begin capitalizing costs. ASU 2025-06 is effective for fiscal years beginning after December 15, 2027, and interim periods within those annual reporting periods, with early adoption permitted. The Company is evaluating the impact of adopting ASU 2025-06 but does not expect it will have a material effect on its consolidated balance sheet, statement of comprehensive income (loss), or statement of cash flows.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not expect any other recently issued accounting standards to have a material impact to its financial statements or disclosures.</span></div></ix:nonNumeric></ix:continuation><div id="id1b8c440ead54d70904211d3c0a5ea1f_40"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Note 2</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> &#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"> <ix:nonNumeric contextRef="c-1" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="f-524" continuedAt="f-524-1" escape="true">Assets and Liabilities Held for Sale</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-524-1" continuedAt="f-524-2"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On June 27, 2025, the Company entered into a definitive agreement (the &#8220;Stock Purchase Agreement&#8221;) with BioCryst Ireland Limited (&#8220;BioCryst Ireland&#8221;), a wholly owned subsidiary that operates the European ORLADEYO business, and Neopharmed Gentili S.p.A. (&#8220;Neopharmed&#8221;). On October 1, 2025 (the &#8220;Closing&#8221;), under the terms of the Stock Purchase Agreement, the Company sold to Neopharmed all of its equity interests in BioCryst Ireland, which, together with its subsidiaries, holds certain assets, rights, and employees related to our European ORLADEYO business (the &#8220;European ORLADEYO Business&#8221;). At the Closing, the Company received cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" format="ixt:num-dot-decimal" scale="3" id="f-525">250,000</ix:nonFraction>, plus customary purchase price adjustments as set forth in the Stock Purchase Agreement. In addition, Neopharmed has agreed to pay the Company up to $<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="bcrx:DisposalGroupIncludingDiscontinuedOperationContingentConsideration" format="ixt:num-dot-decimal" scale="3" id="f-526">14,000</ix:nonFraction> if certain revenue milestones are achieved prior to December 31, 2032. Concurrent with the Closing, Neopharmed also paid a $<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="bcrx:DisposalGroupIncludingDiscontinuedOperationConsiderationRoyaltyReleaseFee" format="ixt:num-dot-decimal" scale="3" id="f-527">15,000</ix:nonFraction> royalty release fee to RPI 2019 Intermediate Finance Trust.  In connection </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><ix:continuation id="f-524-2"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">with the sale, the Company entered into several agreements with Neopharmed, including an Amended and Restated IP Licence Agreement, a Supply Agreement, a Global Brand and Support Agreement, a Transition Services Agreement, and a Trademark License Agreement (each as defined in</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Note 16&#8212;Subsequent Events&#8221;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On October 8, 2025, the Company used a portion of the proceeds from the sale of the European ORLADEYO business to pay off in full the outstanding principal balance and terminate the Pharmakon Loan Agreement (as defined in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8&#8212;Debt&#8221;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">). See </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Note 16&#8212;Subsequent Events&#8221;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2025, the Company concluded that the criteria under ASC 360-10-45-9 for classification as held for sale were met for BioCryst Ireland. Accordingly, the assets and liabilities of BioCryst Ireland are classified as a disposal group held for sale in the Company&#8217;s Condensed Consolidated Balance Sheet. The disposal group is not considered a discontinued operation under ASC 205-20, as it does not represent a strategic shift that will have a major effect on the Company&#8217;s operations or financial results. Therefore, the results of operations for BioCryst Ireland are included in income from continuing operations for all periods presented.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">No impairment loss was recognized in connection with the classification of the disposal group as held for sale, as the estimated fair value less costs to sell exceeded its carrying value.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" id="f-528" escape="true"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the assets and liabilities of BioCryst Ireland that are classified as held for sale on the unaudited Condensed Consolidated Balance Sheet as of September&#160;30, 2025 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-529">14,840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" format="ixt:num-dot-decimal" scale="3" id="f-530">10,285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Inventory, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" format="ixt:num-dot-decimal" scale="3" id="f-531">2,146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-532">1,902</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Current assets held for sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" format="ixt:num-dot-decimal" scale="3" id="f-533">29,173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Non-current assets held for sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-534">4,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total assets held for sale</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation" format="ixt:num-dot-decimal" scale="3" id="f-535">33,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-536">1,714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-537">24,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" scale="3" id="f-538">338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities held for sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" format="ixt:num-dot-decimal" scale="3" id="f-539">26,423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Non-current liabilities held for sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" scale="3" id="f-540">436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities held for sale</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" format="ixt:num-dot-decimal" scale="3" id="f-541">26,859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">17</span></div></div></div><div id="id1b8c440ead54d70904211d3c0a5ea1f_43"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Note 3</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="f-542" continuedAt="f-542-1" escape="true">Revenue</ix:nonNumeric></span></div><ix:continuation id="f-542-1"><ix:continuation id="f-472-1"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded the following revenues for the three and nine months ended September&#160;30, 2025 and 2024 (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">ORLADEYO:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-543">141,557</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-544">103,112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-545">402,054</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-546">278,987</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outside of U.S.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-547">17,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-548">13,207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-549">48,103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-550">34,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total ORLADEYO</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-551">159,077</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-552">116,319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-553">450,157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-554">313,474</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="f-555">318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="f-556">766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-557">18,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-558">5,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-559">159,395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-560">117,085</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-561">468,282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-562">319,178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ORLADEYO revenues represent total revenues from product sales, collaborative revenues, and royalties. Other revenues primarily relate to the Company&#8217;s product sales and royalties for peramivir.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">No individual country outside of the U.S. exceeded 10% of total revenues for the three and nine months ended September&#160;30, 2025 and 2024.</span></div></ix:continuation><div id="id1b8c440ead54d70904211d3c0a5ea1f_46"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock" id="f-563" continuedAt="f-563-1" escape="true">Investments</ix:nonNumeric></span></div><ix:continuation id="f-563-1" continuedAt="f-563-2"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. Fair value is determined based on observable and unobservable inputs. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect certain market assumptions. As a basis for considering such assumptions, U.S. GAAP establishes a three-tier value hierarchy, which prioritizes the inputs used to develop the assumptions and for measuring fair value as follows: (Level 1) observable inputs such as quoted prices in active markets for identical assets; (Level 2) inputs other than the quoted prices in active markets that are observable either directly or indirectly; and (Level 3) unobservable inputs for which there is little or no market data, which requires the Company to develop its own assumptions. This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments that are measured at fair value on a recurring basis consist of fixed income investments. These valuations are based on observable direct and indirect inputs, primarily quoted prices of similar, but not identical, instruments in active markets or quoted prices for identical or similar instruments in markets that are not active. These fair values are obtained from independent pricing services. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-564" continuedAt="f-564-1" escape="true"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Assets measured at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.475%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Price in Active Markets (Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable Inputs (Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable Inputs&#160;(Level&#160;3)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Obligations of U.S. Government and its agencies</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-565">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-566">168,464</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-567">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-568">168,464</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-569">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-570">168,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-571">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-572">168,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><ix:continuation id="f-563-2"><ix:continuation id="f-564-1"><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.475%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Price in Active Markets (Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable Inputs (Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable Inputs&#160;(Level&#160;3)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Obligations of U.S. Government and its agencies</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-573">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-574">236,460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-575">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-576">236,460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-577">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-578">236,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-579">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-580">236,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2025, the Company had <ix:nonFraction unitRef="security" contextRef="c-3" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" format="ixt-sec:numwordsen" scale="0" id="f-581">seven</ix:nonFraction> securities with a total estimated fair value of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="f-582">69,245</ix:nonFraction> in an unrealized loss position. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. The Company does not have an intent to sell these investments, and it is more likely than not that the investments will be held until recovery of their amortized cost basis. As such, no allowance was recognized.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="f-583" escape="true"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the fair value of the Company&#8217;s investments by type (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:f-584">Accrued<br/>Interest</span></span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Obligations of U.S. Government and its agencies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-585">167,149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-586">1,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-587">138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-588">26</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-589">168,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-590">167,149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-591">1,203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-592">138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-593">26</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-594">168,464</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:f-595">Accrued<br/>Interest</span></span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Obligations of U.S. Government and its agencies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-596">234,902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-597">1,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-598">451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-599">14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-600">236,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-601">234,902</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-602">1,121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-603">451</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-604">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-605">236,460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:HeldToMaturitySecuritiesTextBlock" id="f-606" escape="true"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the scheduled maturity for the Company&#8217;s investments at September&#160;30, 2025 and December&#160;31, 2024 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="f-607">128,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="f-608">216,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through two years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="bcrx:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterOneYearAndBeforeTwoYears" format="ixt:num-dot-decimal" scale="3" id="f-609">39,669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="bcrx:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterOneYearAndBeforeTwoYears" format="ixt:num-dot-decimal" scale="3" id="f-610">20,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-611">168,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-612">236,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="id1b8c440ead54d70904211d3c0a5ea1f_49"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Note 5</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="bcrx:TradeReceivablesTextBlock" id="f-613" continuedAt="f-613-1" escape="true">Trade Receivables</ix:nonNumeric></span></div><ix:continuation id="f-613-1" continuedAt="f-613-2"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Receivables from product sales are recorded for amounts due to the Company related to sales of ORLADEYO and peramivir. At September&#160;30, 2025 and December&#160;31, 2024, receivables, net of reserves, related to sales of ORLADEYO were $<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:AccountsReceivableNet" format="ixt:num-dot-decimal" scale="3" id="f-614">88,034</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-3" name="us-gaap:AccountsReceivableNet" format="ixt:num-dot-decimal" scale="3" id="f-615">76,282</ix:nonFraction>, respectively. At September&#160;30, 2025 and December&#160;31, 2024, receivables related to sales of peramivir were $<ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-3" name="us-gaap:AccountsReceivableNet" scale="3" id="f-616">153</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="us-gaap:AccountsReceivableNet" scale="3" id="f-617">564</ix:nonFraction>, respectively. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2025, there was $<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" format="ixt:num-dot-decimal" scale="3" id="f-618">10,285</ix:nonFraction> of accounts receivable, net of reserves, included in current assets held for sale. See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2&#8212;Assets and Liabilities Held for Sale</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; for further details. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><ix:continuation id="f-613-2"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaborative and Other Revenue</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> At September&#160;30, 2025 and December&#160;31, 2024 receivables from the Company&#8217;s royalty partners were $<ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-619">3,138</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-3" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-620">2,223</ix:nonFraction>, respectively.</span></div></ix:continuation><div id="id1b8c440ead54d70904211d3c0a5ea1f_52"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Note 6 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryDisclosureTextBlock" id="f-621" continuedAt="f-621-1" escape="true">Inventory</ix:nonNumeric></span></div><ix:continuation id="f-621-1" continuedAt="f-621-2"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2025 and December&#160;31, 2024, the Company&#8217;s inventory primarily related to ORLADEYO. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="f-622" continuedAt="f-622-1" escape="true">The Company&#8217;s inventories consisted of the following (in thousands):  </ix:nonNumeric></span><ix:continuation id="f-622-1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InventoryRawMaterials" format="ixt:num-dot-decimal" scale="3" id="f-623">9,324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryRawMaterials" format="ixt:num-dot-decimal" scale="3" id="f-624">10,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="3" id="f-625">14,982</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="3" id="f-626">16,152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="f-627">5,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="f-628">7,765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="f-629">30,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="f-630">33,923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Reserves</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InventoryValuationReserves" format="ixt:num-dot-decimal" scale="3" id="f-631">1,661</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryValuationReserves" format="ixt:num-dot-decimal" scale="3" id="f-632">2,649</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="bcrx:InventoryIncludingNoncurrentPortion" format="ixt:num-dot-decimal" scale="3" id="f-633">28,622</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="bcrx:InventoryIncludingNoncurrentPortion" format="ixt:num-dot-decimal" scale="3" id="f-634">31,274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></ix:continuation></div></ix:continuation><div style="margin-top:10pt;text-indent:27pt"><ix:continuation id="f-621-2" continuedAt="f-621-3"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2025, there was $<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" format="ixt:num-dot-decimal" scale="3" id="f-635">2,146</ix:nonFraction> of inventory, net in current assets held for sale and $<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryNoncurrent" scale="3" id="f-636">705</ix:nonFraction> of inventory, net in non-current assets held for sale. See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2&#8212;Assets and Liabilities Held for Sale</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-621-3">&#8221; for further details.</ix:continuation> </span></div><div id="id1b8c440ead54d70904211d3c0a5ea1f_55"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Note 7 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="bcrx:RoyaltyFinancingLiabilitiesTextBlock" id="f-637" continuedAt="f-637-1" escape="true">Royalty Financing Obligations</ix:nonNumeric></span></div><ix:continuation id="f-637-1" continuedAt="f-637-2"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;7, 2020, the Company and RPI 2019 Intermediate Finance Trust (&#8220;RPI&#8221;) entered into a Purchase and Sale Agreement (the &#8220;2020 RPI Royalty Purchase Agreement&#8221;), pursuant to which the Company sold to RPI the right to receive certain royalty payments from the Company for a purchase price of $<ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-638">125,000</ix:nonFraction> in cash (the &#8220;2020 RPI Royalty Sale&#8221;). Under the 2020 RPI Royalty Purchase Agreement, RPI is entitled to receive tiered, sales-based royalties on net product sales of ORLADEYO in the United States and certain key European markets (collectively, the &#8220;Key Territories&#8221;), and other markets where the Company sells ORLADEYO directly or through distributors (collectively, the &#8220;Direct Sales&#8221;) in an amount equal to: (i) <ix:nonFraction unitRef="number" contextRef="c-133" decimals="4" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories" scale="-2" id="f-639">8.75</ix:nonFraction>% of aggregate annual net sales of ORLADEYO for annual net sales up to $350,000 and (ii) <ix:nonFraction unitRef="number" contextRef="c-134" decimals="4" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories" scale="-2" id="f-640">2.75</ix:nonFraction>% of annual net sales for annual net sales between $350,000 and $550,000. <ix:nonFraction unitRef="number" contextRef="c-135" decimals="INF" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories" format="ixt:fixed-zero" scale="-2" id="f-641">No</ix:nonFraction> royalty payments are payable on annual Direct Sales over $550,000.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2020 RPI Royalty Purchase Agreement, RPI is also entitled to receive a tiered revenue share on ORLADEYO sublicense revenue or net sales by licensees outside of the Key Territories (the &#8220;Other Markets&#8221;) equal to: (i) <ix:nonFraction unitRef="number" contextRef="c-136" decimals="2" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets" scale="-2" id="f-642">20</ix:nonFraction>% of the proceeds received by the Company for upfront license fees and development milestones for ORLADEYO in the Other Markets, (ii) <ix:nonFraction unitRef="number" contextRef="c-137" decimals="1" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets" scale="-2" id="f-643">20</ix:nonFraction>% of proceeds received on annual net sales of up to $150,000 in the Other Markets, and (iii) <ix:nonFraction unitRef="number" contextRef="c-138" decimals="2" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets" scale="-2" id="f-644">10</ix:nonFraction>% of proceeds received by the Company on annual net sales between $150,000 and $230,000 in the Other Markets. <ix:nonFraction unitRef="number" contextRef="c-139" decimals="INF" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets" format="ixt:fixed-zero" scale="-2" id="f-645">No</ix:nonFraction> royalty payments are payable on annual net sales above $230,000 in the Other Markets.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;19, 2021, the Company and RPI entered into (i) a Purchase and Sale Agreement (the &#8220;2021 RPI Royalty Purchase Agreement&#8221; and together with the 2020 RPI Royalty Purchase Agreement, the &#8220;RPI Royalty Purchase Agreements&#8221;), pursuant to which the Company sold to RPI the right to receive certain royalty payments from the Company for a purchase price of $<ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-646">150,000</ix:nonFraction> in cash, and (ii) a Purchase and Sale Agreement with OCM IP Healthcare Holdings Limited, an affiliate of OMERS Capital Markets (&#8220;OMERS&#8221;) (the &#8220;OMERS Royalty Purchase Agreement&#8221; and collectively with the RPI Royalty Purchase Agreements, the &#8220;Royalty Purchase Agreements&#8221;), pursuant to which the Company sold to OMERS the right to receive certain royalty payments from the Company for a purchase price of an additional $<ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount" format="ixt:num-dot-decimal" scale="3" id="f-647">150,000</ix:nonFraction> in cash.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2021 RPI Royalty Purchase Agreement, RPI is entitled to receive tiered, sales-based royalties on Direct Sales in an amount equal to: (i) <ix:nonFraction unitRef="number" contextRef="c-142" decimals="4" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories" scale="-2" id="f-648">0.75</ix:nonFraction>% of aggregate annual net sales of ORLADEYO for annual net sales up to $350,000 and (ii) <ix:nonFraction unitRef="number" contextRef="c-143" decimals="4" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories" scale="-2" id="f-649">1.75</ix:nonFraction>% of annual net sales of ORLADEYO for annual net sales between $350,000 and $550,000. <ix:nonFraction unitRef="number" contextRef="c-144" decimals="INF" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets" format="ixt:fixed-zero" scale="-2" id="f-650">No</ix:nonFraction> royalty payments are payable on Direct Sales over $550,000. RPI is also entitled to receive a tiered revenue share on ORLADEYO sublicense revenue or net sales by licensees in the Other Markets in an amount equal to (i) <ix:nonFraction unitRef="number" contextRef="c-145" decimals="2" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets" scale="-2" id="f-651">3.0</ix:nonFraction>% of proceeds received by the Company on annual net sales of up to $150,000 in the Other Markets and (ii) <ix:nonFraction unitRef="number" contextRef="c-146" decimals="2" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets" scale="-2" id="f-652">2.0</ix:nonFraction>% of proceeds received by the Company on annual net sales between $150,000 and $230,000 in the Other Markets. No royalty payments are payable on annual net sales above $230,000 in the Other Markets.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><ix:continuation id="f-637-2" continuedAt="f-637-3"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> The royalties payable under the 2021 RPI Royalty Purchase Agreement are in addition to the royalties payable to RPI under the 2020 RPI Royalty Purchase Agreement.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the OMERS Royalty Purchase Agreement, for the calendar quarter beginning October 1, 2023, OMERS was entitled to receive tiered, sales-based royalties on Direct Sales in an amount equal to: (i) <ix:nonFraction unitRef="number" contextRef="c-147" decimals="3" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales" scale="-2" id="f-653">7.5</ix:nonFraction>% of aggregate annual net sales of ORLADEYO for annual net sales up to $350,000 and (ii) <ix:nonFraction unitRef="number" contextRef="c-148" decimals="2" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales" scale="-2" id="f-654">6.0</ix:nonFraction>% of annual net sales of ORLADEYO for annual net sales between $350,000 and $550,000 (with <ix:nonFraction unitRef="number" contextRef="c-149" decimals="INF" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales" format="ixt:fixed-zero" scale="-2" id="f-655">no</ix:nonFraction> royalty payments payable on annual Direct Sales over $550,000). Commencing with the calendar quarter beginning January 1, 2024, OMERS is entitled to receive tiered, sales-based royalties on Direct Sales in an amount equal to: (i) <ix:nonFraction unitRef="number" contextRef="c-150" decimals="3" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales" scale="-2" id="f-656">10.0</ix:nonFraction>% of aggregate annual net sales of ORLADEYO for annual net sales up to $350,000 and (ii) <ix:nonFraction unitRef="number" contextRef="c-151" decimals="2" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales" scale="-2" id="f-657">3.0</ix:nonFraction>% of annual net sales of ORLADEYO for annual net sales between $350,000 and $550,000 (with <ix:nonFraction unitRef="number" contextRef="c-152" decimals="INF" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales" format="ixt:fixed-zero" scale="-2" id="f-658">no</ix:nonFraction> royalty payments payable on annual Direct Sales over $550,000).</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the OMERS Royalty Purchase Agreement, OMERS is also entitled to receive a tiered revenue share on ORLADEYO sublicense revenue or net sales by licensees in the Other Markets in an amount equal to: (i) <ix:nonFraction unitRef="number" contextRef="c-153" decimals="1" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets" scale="-2" id="f-659">20.0</ix:nonFraction>% of the proceeds received by the Company for upfront license fees and development milestones for ORLADEYO in the Other Markets, (ii) <ix:nonFraction unitRef="number" contextRef="c-154" decimals="1" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets" scale="-2" id="f-660">20.0</ix:nonFraction>% of proceeds received by the Company on annual net sales of up to $150,000 in the Other Markets, and (iii) <ix:nonFraction unitRef="number" contextRef="c-155" decimals="1" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets" scale="-2" id="f-661">10.0</ix:nonFraction>% of proceeds received by the Company on annual net sales between $150,000 and $230,000 in the Other Markets. <ix:nonFraction unitRef="number" contextRef="c-156" decimals="INF" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets" format="ixt:fixed-zero" scale="-2" id="f-662">No</ix:nonFraction> royalty payments are payable on annual net sales above $230,000 in the Other Markets. OMERS is also entitled to receive profit share amounts of up to <ix:nonFraction unitRef="number" contextRef="c-153" decimals="1" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets" scale="-2" id="f-663">10</ix:nonFraction>% from certain other permitted sales in certain other markets.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2020 RPI Royalty Purchase Agreement, the Company is required to make royalty payments of amounts owed to RPI each calendar quarter following the first commercial sale of ORLADEYO in any country. Under the 2021 RPI Royalty Purchase Agreement, the Company is required to make payments to RPI in respect of net sales or sublicense revenue in each calendar quarter from and after October 1, 2021. Under the OMERS Royalty Purchase Agreement, the Company is required to make payments to OMERS in respect of net sales or sublicense revenue in each calendar quarter from and after October 1, 2023. OMERS will no longer be entitled to receive any payments on the date in which aggregate payments actually received by OMERS equals <ix:nonFraction unitRef="number" contextRef="c-153" decimals="3" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice" scale="-2" id="f-664">155.0</ix:nonFraction>% of the $<ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount" format="ixt:num-dot-decimal" scale="3" id="f-665">150,000</ix:nonFraction> purchase price.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The transactions contemplated by each of the Royalty Purchase Agreements are referred to herein as the &#8220;Royalty Sales&#8221;.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the Royalty Purchase Agreements, the Company has agreed to specified affirmative and negative covenants, including covenants regarding periodic reporting of information by the Company to RPI and OMERS, third-party audits of royalties paid under the Royalty Purchase Agreements, and restrictions on the ability of the Company or any of its subsidiaries to incur indebtedness other than certain royalty sales and as was permitted to be incurred under the terms of the Athyrium Credit Agreement (as defined in Note 8 herein) through its payoff and termination on April 17, 2023 or, subsequent to that date, the Pharmakon Loan Agreement (as defined in Note 8 herein), as applicable. See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8&#8212;Debt</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; for further details on the Athyrium Credit Agreement and the Pharmakon Loan Agreement. The restrictions under the Royalty Purchase Agreements on the ability of the Company or any of its subsidiaries to incur indebtedness are eliminated after the achievement of certain specified milestones in the Royalty Purchase Agreements. In addition, in connection with the Stock Purchase Agreement (as defined in </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2&#8212;Assets and Liabilities Held for Sale&#8221;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">), RPI and OMERS provided their written consent of the consummation of the sale of the Company&#8217;s European ORLADEYO Business. See </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Note 16&#8212;Subsequent Events&#8221;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information on the sale of the Company&#8217;s European ORLADEYO Business.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The cash consideration obtained pursuant to the Royalty Purchase Agreements is recorded in &#8220;Royalty financing obligations&#8221; on the Company&#8217;s Condensed Consolidated Balance Sheets. The fair value for the royalty financing obligations at the time of the transactions was based on the Company&#8217;s estimates of future royalties expected to be paid to the counterparty over the life of the arrangement. The Company subsequently records the obligations at their carrying value using the effective interest method. As of September&#160;30, 2025 and December&#160;31, 2024, the carrying value of the royalty financing obligations under the Royalty Purchase Agreements approximated fair value and was measured based on the Company&#8217;s current estimates of future payments to RPI and OMERS over the lives of the agreements, which are considered Level 3 inputs. The Company utilizes the prospective method to account for subsequent changes in the estimated future royalties to be paid by the Company to the counterparty over the life of the arrangement. Under the prospective method, a new effective interest rate is determined based on the revised estimate of remaining cash flows. The new rate is the discount rate that equates the present value of the revised estimate of remaining cash flows with the carrying amount of the debt, and it will be used to recognize interest expense for the remaining periods. The Company periodically assesses the amount and timing of expected royalty payments using internal projections of future net product sales, which are based on key assumptions, including paid patients and price. To the extent such payments are greater or less than the Company&#8217;s initial estimates or the timing of such payments is materially different than its original estimates, the Company </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><ix:continuation id="f-637-3"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">will prospectively adjust the amortization of the royalty financing obligations and the effective interest rate. On a quarterly basis, the Company assesses the projected royalty payments relative to the projected interest accretion for the next twelve months to determine if the royalty liability balance is reduced relative to the current outstanding liability. In such case of excess payments relative to interest accretion for the next twelve months, the excess payments are considered to be a short-term liability and classified within current liabilities on the Company&#8217;s Condensed Consolidated Balance Sheets.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2025, there were no significant changes to the amount and timing of expected royalties under the Royalty Purchase Agreements based on the Company&#8217;s latest forecasts related to ORLADEYO sales. </span></div><ix:nonNumeric contextRef="c-1" name="bcrx:RoyaltyFinancingLiabilitiesTableTextBlock" id="f-666" escape="true"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the royalty financing obligations activity for the three and nine months ended September&#160;30, 2025 (in thousands) as well as the effective interest rate as of September&#160;30, 2025: </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2020 RPI<br/>Royalty<br/>Agreement</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2021 RPI<br/>Royalty<br/>Agreement</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">OMERS<br/>Royalty<br/>Agreement</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-3" name="bcrx:RoyaltyFinancingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-667">180,413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-3" name="bcrx:RoyaltyFinancingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-668">181,140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-3" name="bcrx:RoyaltyFinancingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-669">152,176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="bcrx:RoyaltyFinancingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-670">513,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense on royalty financing obligations</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-3" name="bcrx:NonCashInterestExpenseOnRoyaltyFinancingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-671">9,756</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-3" name="bcrx:NonCashInterestExpenseOnRoyaltyFinancingLiabilities" format="ixt:fixed-zero" scale="3" id="f-672">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-3" name="bcrx:NonCashInterestExpenseOnRoyaltyFinancingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-673">3,758</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="bcrx:NonCashInterestExpenseOnRoyaltyFinancingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-674">13,514</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenues payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-3" sign="-" name="bcrx:RoyaltyRevenuesPayable" format="ixt:num-dot-decimal" scale="3" id="f-675">11,818</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-3" sign="-" name="bcrx:RoyaltyRevenuesPayable" format="ixt:num-dot-decimal" scale="3" id="f-676">1,021</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-3" sign="-" name="bcrx:RoyaltyRevenuesPayable" format="ixt:num-dot-decimal" scale="3" id="f-677">13,486</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="bcrx:RoyaltyRevenuesPayable" format="ixt:num-dot-decimal" scale="3" id="f-678">26,325</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of March 31, 2025</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-3" name="bcrx:RoyaltyFinancingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-679">178,351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-3" name="bcrx:RoyaltyFinancingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-680">180,119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-3" name="bcrx:RoyaltyFinancingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-681">142,448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="bcrx:RoyaltyFinancingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-682">500,918</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense on royalty financing obligations</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="bcrx:NonCashInterestExpenseOnRoyaltyFinancingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-683">9,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-3" name="bcrx:NonCashInterestExpenseOnRoyaltyFinancingLiabilities" format="ixt:fixed-zero" scale="3" id="f-684">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-3" name="bcrx:NonCashInterestExpenseOnRoyaltyFinancingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-685">3,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="bcrx:NonCashInterestExpenseOnRoyaltyFinancingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-686">13,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenues payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" sign="-" name="bcrx:RoyaltyRevenuesPayable" format="ixt:num-dot-decimal" scale="3" id="f-687">13,798</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-3" sign="-" name="bcrx:RoyaltyRevenuesPayable" format="ixt:num-dot-decimal" scale="3" id="f-688">1,193</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-3" sign="-" name="bcrx:RoyaltyRevenuesPayable" format="ixt:num-dot-decimal" scale="3" id="f-689">15,746</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="bcrx:RoyaltyRevenuesPayable" format="ixt:num-dot-decimal" scale="3" id="f-690">30,737</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2025</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-3" name="bcrx:RoyaltyFinancingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-691">174,357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-3" name="bcrx:RoyaltyFinancingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-692">178,926</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-3" name="bcrx:RoyaltyFinancingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-693">130,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="bcrx:RoyaltyFinancingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-694">483,583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense on royalty financing obligations</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-3" name="bcrx:NonCashInterestExpenseOnRoyaltyFinancingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-695">9,610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-3" name="bcrx:NonCashInterestExpenseOnRoyaltyFinancingLiabilities" format="ixt:fixed-zero" scale="3" id="f-696">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-3" name="bcrx:NonCashInterestExpenseOnRoyaltyFinancingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-697">3,313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="bcrx:NonCashInterestExpenseOnRoyaltyFinancingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-698">12,923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenues payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-3" sign="-" name="bcrx:RoyaltyRevenuesPayable" format="ixt:num-dot-decimal" scale="3" id="f-699">8,258</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-3" sign="-" name="bcrx:RoyaltyRevenuesPayable" format="ixt:num-dot-decimal" scale="3" id="f-700">2,195</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-3" sign="-" name="bcrx:RoyaltyRevenuesPayable" format="ixt:num-dot-decimal" scale="3" id="f-701">9,260</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="bcrx:RoyaltyRevenuesPayable" format="ixt:num-dot-decimal" scale="3" id="f-702">19,713</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of September 30, 2025</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-3" name="bcrx:RoyaltyFinancingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-703">175,709</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-3" name="bcrx:RoyaltyFinancingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-704">176,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-3" name="bcrx:RoyaltyFinancingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-705">124,353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="bcrx:RoyaltyFinancingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-706">476,793</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Effective interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-175" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-707">21.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-176" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" format="ixt:fixed-zero" scale="-2" id="f-708">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-177" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-709">10.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for interest on the royalty financing obligations was $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="bcrx:InterestPaidRoyaltyFinancingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-710">18,319</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="bcrx:InterestPaidRoyaltyFinancingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-711">55,240</ix:nonFraction> for the three and nine months ended September&#160;30, 2025, respectively. Cash paid for interest on the royalty financing obligations was $<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="bcrx:InterestPaidRoyaltyFinancingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-712">21,239</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="bcrx:InterestPaidRoyaltyFinancingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-713">54,308</ix:nonFraction> for the three and nine months ended September&#160;30, 2024, respectively.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Concurrent with entering into the 2021 RPI Royalty Purchase Agreement, the Company and RPI entered into a Common Stock Purchase Agreement pursuant to which the Company sold common stock to RPI for a premium of $<ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-3" name="bcrx:SharesIssuedCommonStockPremium" format="ixt:num-dot-decimal" scale="3" id="f-714">4,269</ix:nonFraction>. This premium has been deferred and is being amortized through interest expense using the effective interest method over the term of the applicable arrangement.</span></div></ix:continuation><div id="id1b8c440ead54d70904211d3c0a5ea1f_58"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Note 8 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-715" continuedAt="f-715-1" escape="true">Debt</ix:nonNumeric></span></div><ix:continuation id="f-715-1" continuedAt="f-715-2"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pharmakon Loan Agreement</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On April 17, 2023, the Company entered into a $<ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="f-716">450,000</ix:nonFraction> Loan Agreement (the &#8220;Pharmakon Loan Agreement&#8221;) with BioPharma Credit Investments V (Master) LP and BPCR Limited Partnership, as lenders, and BioPharma Credit PLC, as collateral agent for the lenders. Certain of the Company&#8217;s wholly-owned subsidiaries were guarantors to the Pharmakon Loan Agreement. The Pharmakon Loan Agreement provided for an initial term loan in the principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-717">300,000</ix:nonFraction> (the &#8220;Tranche A Loan&#8221;) funded on April 17, 2023 (the &#8220;Tranche A Closing Date&#8221;). The Company used a portion of the proceeds from the Tranche A Loan to repay the $<ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-3" name="us-gaap:RepaymentsOfLinesOfCredit" format="ixt:num-dot-decimal" scale="3" id="f-718">241,787</ix:nonFraction> of outstanding indebtedness (principal and interest due as of April 17, 2023) under the then-existing credit facility with Athyrium Opportunities III Co-Invest 1 LP (the &#8220;Athyrium Credit Agreement&#8221;) and to pay associated transaction costs and fees, and used the remaining net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-719">25,805</ix:nonFraction> for other general corporate purposes.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmakon Loan Agreement also provided for three additional term loan tranches, at the Company&#8217;s option, in principal amounts of $<ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="f-720"><ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="f-721"><ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="f-722">50,000</ix:nonFraction></ix:nonFraction></ix:nonFraction> each (each a &#8220;Subsequent Tranche Loan&#8221; and, collectively with the Tranche A Loan, the </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><ix:continuation id="f-715-2" continuedAt="f-715-3"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Pharmakon Term Loans&#8221; and each, a &#8220;Pharmakon Term Loan&#8221;), which could have been requested on or prior to September 30, 2024. The Company chose not to request any Subsequent Tranche Loans and the options have since expired. The maturity date of the Pharmakon Loan Agreement was April 17, 2028 (the &#8220;Maturity Date&#8221;), the fifth anniversary of the Tranche A Closing Date.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmakon Loan Agreement provided for quarterly interest-only payments until the Maturity Date, with the unpaid principal amount of the outstanding Pharmakon Term Loans due and payable on the Maturity Date. During the first <ix:nonNumeric contextRef="c-186" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durmonth" id="f-723">18</ix:nonNumeric> months following the Tranche A Closing Date, the Company had the option to make a portion of the applicable interest payment on the Tranche A Loan in-kind (a &#8220;Pharmakon PIK Interest Payment&#8221;) by capitalizing as principal up to <ix:nonFraction unitRef="number" contextRef="c-187" decimals="2" name="bcrx:DebtInstrumentCapitalizedInterestRate" scale="-2" id="f-724">50</ix:nonFraction>% of the amount of interest accrued on the Tranche A Loan during the applicable interest period. The Pharmakon Term Loans bore interest at a rate equal to the three-month Secured Overnight Financing Rate (&#8220;SOFR&#8221;), which could be no less than <ix:nonFraction unitRef="number" contextRef="c-188" decimals="4" name="bcrx:DebtInstrumentVariableRateFloor" scale="-2" id="f-725">1.75</ix:nonFraction>%, plus <ix:nonFraction unitRef="number" contextRef="c-187" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-726">7.00</ix:nonFraction>%, per annum or, for each interest period in which a Pharmakon PIK Interest Payment was made, with respect to the Tranche A Loan, SOFR plus <ix:nonFraction unitRef="number" contextRef="c-189" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-727">7.25</ix:nonFraction>%, per annum.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Tranche A Loan accrued interest at an effective interest rate of <ix:nonFraction unitRef="number" contextRef="c-190" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-728">12.28</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-191" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-729">13.34</ix:nonFraction>% for the three months ended September&#160;30, 2025 and 2024, respectively.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company was required to make a mandatory prepayment of the Pharmakon Term Loans (i) upon the occurrence of a change of control and (ii) prior to any repayment of any convertible debt that the Company may have issued in the future, subject to certain exceptions. The Company could make voluntary prepayments in whole or in part, in minimum $<ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="us-gaap:DebtInstrumentPeriodicPayment" format="ixt:num-dot-decimal" scale="3" id="f-730">25,000</ix:nonFraction> increments. Prepayments were subject to a prepayment premium equal to, (i) with respect to any prepayment made prior to the second anniversary of the applicable Pharmakon Term Loan borrowing date, the sum of (1) <ix:nonFraction unitRef="number" contextRef="c-192" decimals="4" name="bcrx:DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments" scale="-2" id="f-731">3.00</ix:nonFraction>% of the principal amount of the Pharmakon Term Loan being prepaid plus (2) the aggregate amount of all interest that would have accrued on the principal amount of the Pharmakon Term Loan being prepaid from the date of prepayment through and including the second anniversary of the date of the borrowing of such Pharmakon Term Loan; (ii) with respect to any prepayment made on or after the second anniversary and prior to the third anniversary of the applicable Pharmakon Term Loan borrowing date, <ix:nonFraction unitRef="number" contextRef="c-193" decimals="4" name="bcrx:DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments" scale="-2" id="f-732">3.00</ix:nonFraction>% of the principal amount of the Pharmakon Term Loan being prepaid; (iii) with respect to any prepayment made on or after the third anniversary and prior to the fourth anniversary of the applicable Pharmakon Term Loan, <ix:nonFraction unitRef="number" contextRef="c-194" decimals="4" name="bcrx:DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments" scale="-2" id="f-733">2.00</ix:nonFraction>% of the principal amount of the Pharmakon Term Loan being prepaid; and (iv) with respect to any prepayment made on or after the fourth anniversary of the applicable Pharmakon Term Loan borrowing date and before the Maturity Date, <ix:nonFraction unitRef="number" contextRef="c-195" decimals="4" name="bcrx:DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments" scale="-2" id="f-734">1.00</ix:nonFraction>% of the principal amount of the Pharmakon Term Loan being prepaid. In addition, if the Company had requested any Subsequent Tranche Loans, certain funding fees would have been required to be paid.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmakon Loan Agreement also contained representations and warranties and affirmative and negative covenants customary for financings of this type, as well as customary events of default. Certain of the customary negative covenants limited the ability of the Company and certain of its subsidiaries to, among other things, dispose of assets, engage in mergers, acquisitions, and similar transactions, incur additional indebtedness, grant liens, make investments, pay dividends or make distributions or certain other restricted payments in respect of equity, prepay other indebtedness, enter into restrictive agreements, undertake fundamental changes or amend certain material contracts, among other customary covenants, in each case subject to certain exceptions.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A failure to comply with the covenants in the Pharmakon Loan Agreement, or an occurrence of any other event of default, could have permitted the lenders under the Pharmakon Loan Agreement to declare the borrowings thereunder, together with accrued interest and fees, and any applicable prepayment premium, to be immediately due and payable.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s obligations under the Pharmakon Loan Agreement were secured by a security interest in, subject to certain exceptions, substantially all of the Company&#8217;s assets.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On April 18, 2025, as allowable under the Pharmakon Loan Agreement, the Company made a $<ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-3" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" format="ixt:num-dot-decimal" scale="3" id="f-735">75,000</ix:nonFraction> partial prepayment on the outstanding principal amount under the Pharmakon Term Loan. In conjunction with the partial prepayment, the Company incurred a $<ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-3" name="bcrx:DebtInstrumentPrepaymentPremium" format="ixt:num-dot-decimal" scale="3" id="f-736">2,250</ix:nonFraction> prepayment premium and paid $<ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-3" name="us-gaap:InterestExpenseLongTermDebt" scale="3" id="f-737">424</ix:nonFraction> of interest accrued through the payment date. Additionally, unamortized deferred financing costs of $<ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-3" name="bcrx:UnamortizedDeferredFinancingCosts" format="ixt:num-dot-decimal" scale="3" id="f-738">1,921</ix:nonFraction> associated with the Pharmakon Term Loan were written-off at the time of repayment. Collectively, the prepayment and unamortized deferred financing costs totaled $<ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-739">4,171</ix:nonFraction> and are reflected as a one-time loss on extinguishment of debt on the Condensed Consolidated Statements of Comprehensive Income (Loss) for the nine months ended September 30, 2025.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On July 24, 2025, as allowable under the Pharmakon Loan Agreement, the Company made a $<ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-3" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" format="ixt:num-dot-decimal" scale="3" id="f-740">50,000</ix:nonFraction> partial prepayment on the outstanding principal amount under the Pharmakon Term Loan. In conjunction with the partial prepayment, the Company incurred a $<ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-3" name="bcrx:DebtInstrumentPrepaymentPremium" format="ixt:num-dot-decimal" scale="3" id="f-741">1,500</ix:nonFraction> prepayment premium and fees of $<ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-3" name="us-gaap:DebtInstrumentFeeAmount" scale="3" id="f-742">52</ix:nonFraction> and paid $<ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-3" name="us-gaap:InterestExpenseLongTermDebt" scale="3" id="f-743">376</ix:nonFraction> of interest accrued through the payment date. Additionally, unamortized deferred financing costs of $<ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-3" name="bcrx:UnamortizedDeferredFinancingCosts" format="ixt:num-dot-decimal" scale="3" id="f-744">1,188</ix:nonFraction> associated with the Pharmakon </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><ix:continuation id="f-715-3"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Term Loan were written-off at the time of repayment. Collectively, the prepayment and unamortized deferred financing costs totaled $<ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-3" name="bcrx:DeferredDebtPrepaymentAndDebtIssuanceCostsWriteoff" format="ixt:num-dot-decimal" scale="3" id="f-745">2,740</ix:nonFraction> and are reflected as a one-time loss on extinguishment of debt on the Condensed Consolidated Statements of Comprehensive Income (Loss) for the three and nine months ended September 30, 2025.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2025, borrowings, including Pharmakon PIK Interest Payments, totaled $<ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="3" id="f-746">198,704</ix:nonFraction> under the Pharmakon Loan Agreement. Interest expense on the Tranche A Loan for the three and nine months ended September&#160;30, 2025 was $<ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-747">6,110</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-748">22,789</ix:nonFraction>, respectively, all of which was paid at the end of the quarterly period. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2024, borrowings, including the Pharmakon PIK Interest Payments, totaled $<ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="3" id="f-749">323,704</ix:nonFraction> under the Pharmakon Loan Agreement. Interest expense on the Tranche A Loan for the three and nine months ended September&#160;30, 2024 was $<ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-750">10,201</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-751">30,283</ix:nonFraction>, respectively. As allowable under the Pharmakon Loan Agreement, the Company designated and accounted for <ix:nonFraction unitRef="number" contextRef="c-202" decimals="2" name="bcrx:PercentOfInterestPayment" scale="-2" id="f-752"><ix:nonFraction unitRef="number" contextRef="c-203" decimals="2" name="bcrx:PercentOfInterestPayment" scale="-2" id="f-753">50</ix:nonFraction></ix:nonFraction>% of the quarterly interest payments for each of the three months ended March&#160;31, 2024 and June&#160;30, 2024 as a Pharmakon PIK Interest Payment and the total amount of $<ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-3" name="us-gaap:DebtInstrumentPeriodicPaymentInterest" format="ixt:num-dot-decimal" scale="3" id="f-754">10,041</ix:nonFraction> was added to the outstanding principal balance of the borrowing. The remaining <ix:nonFraction unitRef="number" contextRef="c-203" decimals="2" name="bcrx:PercentOfInterestPayment" scale="-2" id="f-755"><ix:nonFraction unitRef="number" contextRef="c-202" decimals="2" name="bcrx:PercentOfInterestPayment" scale="-2" id="f-756">50</ix:nonFraction></ix:nonFraction>% of the total quarterly interest payments for the three months ended March&#160;31, 2024 and June&#160;30, 2024 and the full quarterly interest payment for the three months ended September 30, 2024 totaling $<ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-3" name="us-gaap:DebtInstrumentPeriodicPaymentInterest" format="ixt:num-dot-decimal" scale="3" id="f-757">20,242</ix:nonFraction> was paid at the end of each quarterly period. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the debt approximated its carrying value based on prevailing interest rates as of the balance sheet date and was considered as Level 2 in the fair value hierarchy.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Debt fees and issuance costs incurred with the Tranche A Loan under the Pharmakon Loan Agreement totaled $<ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="f-758">11,147</ix:nonFraction> and were deferred and amortized as interest expense on an effective interest rate method over the term of the Tranche A Loan. Deferred financing amortization of $<ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="f-759">384</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="3" id="f-760">1,387</ix:nonFraction> was recognized for the three and nine months ended September&#160;30, 2025, respectively. Deferred financing amortization of $<ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="f-761">511</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="3" id="f-762">1,061</ix:nonFraction> was recognized for the three and nine months ended September&#160;30, 2024, respectively.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> In connection with the Stock Purchase Agreement (as defined in </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2&#8212;Assets and Liabilities Held for Sale&#8221;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">), Pharmakon provided its written consent of the consummation of the sale of the Company&#8217;s European ORLADEYO Business. On October 8, 2025, the Company used a portion of the proceeds from the sale of the European ORLADEYO Business to pay off in full the outstanding principal balance and terminate the Pharmakon Loan Agreement. See </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Note 16&#8212;Subsequent Events&#8221;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information.</span></div></ix:continuation><div id="id1b8c440ead54d70904211d3c0a5ea1f_61"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Note 9 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-763" continuedAt="f-763-1" escape="true">Lease Obligations </ix:nonNumeric></span></div><ix:continuation id="f-763-1" continuedAt="f-763-2"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases certain assets under operating leases, which primarily consist of real estate leases, and finance leases, which generally consist of laboratory equipment leases and office equipment leases, as of September&#160;30, 2025. The Company&#8217;s real estate agreements expire at various times between 2026 through 2033 and include renewal options that range from <span style="-sec-ix-hidden:f-764">three</span> to <ix:nonNumeric contextRef="c-206" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="f-765">five years</ix:nonNumeric> in length.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LeaseCostTableTextBlock" id="f-766" continuedAt="f-766-1" escape="true"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Lease expense under operating and finance leases was as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseExpense" scale="3" id="f-767">526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OperatingLeaseExpense" scale="3" id="f-768">569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="f-769">1,596</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="f-770">1,741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Finance lease expense:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Amortization of right-of-use assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="f-771">547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="f-772">455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:num-dot-decimal" scale="3" id="f-773">1,639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:num-dot-decimal" scale="3" id="f-774">1,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="f-775">84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="f-776">81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="f-777">268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="f-778">231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total finance lease expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="bcrx:FinancingLeaseExpense" scale="3" id="f-779">631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="bcrx:FinancingLeaseExpense" scale="3" id="f-780">536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="bcrx:FinancingLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="f-781">1,907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="bcrx:FinancingLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="f-782">1,509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><ix:continuation id="f-763-2" continuedAt="f-763-3"><ix:nonNumeric contextRef="c-1" name="bcrx:OtherSupplementalInformationRelatedToLeasesTableTextBlock" id="f-783" escape="true"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other supplemental information related to leases was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-3" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-784">9.7</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-4" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-785">9.0</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-3" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-786">2.5</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-4" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-787">2.6</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-3" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-788">10.71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-4" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-789">10.91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-3" decimals="4" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-790">9.63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-4" decimals="4" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-791">8.66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="bcrx:LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock" id="f-792" escape="true"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the presentation in the Condensed Consolidated Balance Sheets of the Company&#8217;s operating leases (in thousands): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Balance Sheet Location</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-793"><span style="-sec-ix-hidden:f-794">Right of use assets</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-795">7,725</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-796">8,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Operating lease liabilities &#8211; current liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-797">348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-798">937</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Operating lease liabilities &#8211; long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-799">8,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-800">7,924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-801">8,773</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-802">8,861</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the presentation in the Condensed Consolidated Balance Sheets of the Company&#8217;s finance leases (in thousands): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Balance Sheet Location</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-803"><span style="-sec-ix-hidden:f-804">Right of use assets</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-805">3,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-806">3,947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Current finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Finance lease liabilities &#8211; current liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-807">1,435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-808">1,835</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Non-current finance lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Finance lease liabilities &#8211; long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-809">1,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-810">2,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FinanceLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-811">3,177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-812">3,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease assets are recorded net of accumulated amortization of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="bcrx:OperatingLeaseRightOfUseAssetAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-813">2,314</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="bcrx:OperatingLeaseRightOfUseAssetAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-814">6,065</ix:nonFraction> as of September&#160;30, 2025 and December&#160;31, 2024, respectively. Finance lease assets are recorded net of accumulated amortization of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-815">4,519</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-816">4,059</ix:nonFraction> as of September&#160;30, 2025 and December&#160;31, 2024, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><ix:continuation id="f-763-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-817" escape="true"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of September&#160;30, 2025 are as follows (in thousands): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Finance Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2025 (remaining)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="f-818">119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="f-819">496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-820">1,153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-821">1,520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-822">1,462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-823">1,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="f-824">1,506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" scale="3" id="f-825">486</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="f-826">1,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" scale="3" id="f-827">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="bcrx:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="f-828">9,024</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="bcrx:FinanceLeaseLiabilityToBePaidAfterYearFour" format="ixt:fixed-zero" scale="3" id="f-829">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-830">14,802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-831">3,578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="f-832">6,029</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="3" id="f-833">401</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-834">8,773</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FinanceLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-835">3,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:continuation id="f-766-1"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases was as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows for finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="f-836">268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="f-837">231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows for operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-838">1,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-839">1,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets obtained in exchange for operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="f-840">366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="f-841">261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease assets obtained in exchange for finance lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" id="f-842">870</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" id="f-843">828</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash increase to operating lease assets due to remeasurement of operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="bcrx:NonCashIncreaseInOperatingLeaseAssetsDueToRemeasurementOfOperatingLeaseLiabilities" scale="3" id="f-844">786</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="bcrx:NonCashIncreaseInOperatingLeaseAssetsDueToRemeasurementOfOperatingLeaseLiabilities" scale="3" id="f-845">365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div id="id1b8c440ead54d70904211d3c0a5ea1f_67"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Note 10 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-846" continuedAt="f-846-1" escape="true">Stockholders</ix:nonNumeric></span><ix:continuation id="f-846-1" continuedAt="f-846-2"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> Equity</span></ix:continuation></div><ix:continuation id="f-846-2"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shares Reserved for Future Issuance of Common Stock</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfStockByClassTextBlock" id="f-847" escape="true"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company had reserved shares of common stock for issuance as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Shares reserved for exercises of outstanding stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-207" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="f-848">41,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-208" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="f-849">44,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Shares reserved for vesting of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-209" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="f-850">9,744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-210" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="f-851">10,112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Shares reserved for future issuance under the Stock Incentive Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-211" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="f-852">13,721</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-212" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="f-853">1,065</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Shares reserved for future issuance under the Inducement Equity Incentive Plan </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-213" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="f-854">1,508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-214" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="f-855">1,699</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Shares reserved for future issuance under the Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-215" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="f-856">4,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-216" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="f-857">5,042</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total shares reserved for future issuance</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="f-858">71,169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="f-859">62,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="id1b8c440ead54d70904211d3c0a5ea1f_70"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Note 11 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-860" continuedAt="f-860-1" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="f-860-1" continuedAt="f-860-2"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2025, the Company had <ix:nonFraction unitRef="plan" contextRef="c-3" decimals="INF" name="bcrx:ShareBasedPaymentArrangementNumberOfPlans" format="ixt-sec:numwordsen" scale="0" id="f-861">three</ix:nonFraction> stock-based employee compensation plans: the Amended and Restated Stock Incentive Plan (&#8220;Incentive Plan&#8221;), the Amended and Restated Inducement Equity Incentive Plan (&#8220;Inducement Plan&#8221;) and the Amended and Restated Employee Stock Purchase Plan (&#8220;ESPP&#8221;). The Incentive Plan was most recently amended and restated on April 21, 2025 and approved by the Company&#8217;s stockholders on June 12, 2025. The Inducement Plan was most recently amended and restated by the Company&#8217;s Board of Directors on October 26, 2023. The ESPP was most recently amended and restated by the Company&#8217;s Board of Directors on July 7, 2023.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" id="f-862" continuedAt="f-862-1" escape="true"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded the following stock-based compensation expense (in thousands):</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><ix:continuation id="f-860-2" continuedAt="f-860-3"><ix:continuation id="f-862-1" continuedAt="f-862-2"><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Incentive Plan</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" format="ixt:num-dot-decimal" scale="3" id="f-863">16,232</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" format="ixt:num-dot-decimal" scale="3" id="f-864">14,794</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" format="ixt:num-dot-decimal" scale="3" id="f-865">54,841</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" format="ixt:num-dot-decimal" scale="3" id="f-866">37,294</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Inducement Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" format="ixt:num-dot-decimal" scale="3" id="f-867">2,179</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" format="ixt:num-dot-decimal" scale="3" id="f-868">2,234</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" format="ixt:num-dot-decimal" scale="3" id="f-869">5,852</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" format="ixt:num-dot-decimal" scale="3" id="f-870">6,241</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" scale="3" id="f-871">233</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" scale="3" id="f-872">221</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" scale="3" id="f-873">623</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" scale="3" id="f-874">539</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation costs</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" format="ixt:num-dot-decimal" scale="3" id="f-875">18,644</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" format="ixt:num-dot-decimal" scale="3" id="f-876">17,249</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" format="ixt:num-dot-decimal" scale="3" id="f-877">61,316</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" format="ixt:num-dot-decimal" scale="3" id="f-878">44,074</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized stock-based compensation costs</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="3" id="f-879">43</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:fixed-zero" scale="3" id="f-880">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="3" id="f-881">43</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:fixed-zero" scale="3" id="f-882">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation costs included in operating expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-883">18,601</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-884">17,249</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-885">61,273</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-886">44,074</ix:nonFraction></span></td></tr></table></div></ix:continuation><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Incentive Plan</span></div><ix:continuation id="f-862-2" continuedAt="f-862-3"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity under the Incentive Plan:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Shares<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-229" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="f-887">39,082</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-229" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-888">7.96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-230" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" id="f-889">538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-230" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-890">9.31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-230" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-891">897</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-230" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-892">5.36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-893">3,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled or Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-230" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="3" id="f-894">1,924</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-230" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-895">9.99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="f-896">36,799</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-897">7.94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-230" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-898">6.10</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-899">28,966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2025</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="f-900">23,314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-901">7.92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-230" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-902">4.74</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="f-903">23,388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="f-904" continuedAt="f-904-1" escape="true"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restricted stock unit activity under the Incentive Plan:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Shares <br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-232" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="f-905">9,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-232" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-906">7.73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-233" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="f-907">393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-233" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-908">9.17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-233" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="f-909">270</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-233" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-910">8.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-233" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="f-911">667</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-233" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-912">7.64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at September 30, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-234" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="f-913">8,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-234" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-914">7.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For restricted stock unit awards granted under the Incentive Plan, the fair value of the awards is determined based on the market value of the Company&#8217;s shares on the grant date. The weighted average grant date fair value of these awards granted during the first nine months of 2025 and 2024 was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-233" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-915">9.17</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-235" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-916">5.80</ix:nonFraction>, respectively. The fair value of the restricted stock unit awards is amortized to expense over the vesting periods using a straight-line expense attribution method.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><ix:continuation id="f-860-3" continuedAt="f-860-4"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inducement Equity Incentive Plan</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><ix:continuation id="f-862-3"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity under the Inducement Plan:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Shares<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-236" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="f-917">5,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-236" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-918">8.44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-237" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" id="f-919">96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-237" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-920">8.07</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-237" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-921">252</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-237" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-922">5.65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="f-923">994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled or Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-237" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="3" id="f-924">279</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-237" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-925">11.31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-238" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="f-926">4,723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-238" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-927">8.41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-237" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-928">6.20</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-929">6,940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2025</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-238" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="f-930">3,519</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-238" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-931">8.18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-237" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-932">5.60</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="f-933">6,324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><ix:continuation id="f-904-1"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restricted stock unit activity under the Inducement Plan:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Shares<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-239" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="f-934">823</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-239" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-935">8.53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-240" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="f-936">472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-240" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-937">8.47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-240" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="f-938">197</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-240" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-939">9.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-240" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="f-940">99</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-240" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-941">8.33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at September 30, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-241" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="f-942">999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-241" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-943">8.39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For restricted stock unit awards granted under the Inducement Plan, the fair value of the awards is determined based on the market value of the Company&#8217;s shares on the grant date. The weighted average grant date fair value of these awards granted during the first nine months of 2025 and 2024 was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-240" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-944">8.47</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-242" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-945">6.25</ix:nonFraction>, respectively. The fair value of the restricted stock unit awards is amortized to expense over the vesting periods using a straight-line expense attribution method.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors under the Incentive and Inducement Plans</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For stock option awards granted under the Incentive Plan and the Inducement Plan, the fair value is estimated on the date of grant using a Black-Scholes option pricing model and the assumptions noted below. The fair value of the stock option awards is amortized to expense over the vesting periods using a straight-line expense attribution method. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-946" continuedAt="f-946-1" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Incentive Plan</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the key assumptions used by the Company to value the stock option awards granted under the Incentive Plan during the nine months ended September 30, 2025 and 2024. </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Expected Life in Years</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-219" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-947">6.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-220" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-948">5.8</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Expected Volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-219" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-949">79.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-220" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-950">83.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Expected Dividend Yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-219" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-951">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-220" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-952">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Risk-Free Interest Rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-219" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-953">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-220" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-954">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Weighted average grant date fair value per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-219" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-955">6.64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-220" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-956">4.56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><ix:continuation id="f-946-1"><ix:continuation id="f-860-4"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inducement Equity Incentive Plan</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the key assumptions used by the Company to value the stock option awards granted under the Inducement Plan during the nine months ended September 30, 2025 and 2024.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Expected Life in Years</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-223" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-957">6.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-224" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-958">5.8</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Expected Volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-223" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-959">80.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-224" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-960">83.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Expected Dividend Yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-223" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-961">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-224" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-962">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Risk-Free Interest Rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-223" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-963">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-224" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-964">4.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Weighted average grant date fair value per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-223" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-965">5.89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-224" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-966">4.43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div id="id1b8c440ead54d70904211d3c0a5ea1f_73"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Note 12</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="f-967" continuedAt="f-967-1" escape="true">Collaborative and Other Relationships</ix:nonNumeric></span></div><ix:continuation id="f-967-1" continuedAt="f-967-2"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ORLADEYO</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Torii Pharmaceutical Co., Ltd</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(&#8220;Torii&#8221;)</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;5, 2019, the Company entered into a Commercialization and License Agreement with Torii (the &#8220;Original Torii Agreement&#8221;), granting Torii the exclusive right to commercialize ORLADEYO for the prevention of HAE attacks in Japan. Under the Original Torii Agreement, the Company received an upfront, non-refundable payment of $<ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-968">22,000</ix:nonFraction>. The Company received an additional milestone payment of $<ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-6" name="bcrx:PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeMilestone" format="ixt:num-dot-decimal" scale="3" id="f-969">15,000</ix:nonFraction> in the second quarter of 2021 upon receipt from the Japanese National Health Insurance System of a reimbursement price approval for ORLADEYO. In addition, the Company was entitled to receive tiered royalty payments, ranging from <ix:nonFraction unitRef="number" contextRef="c-245" decimals="2" name="bcrx:RoyaltyRateIfMaintainsSakigakeDesignation" scale="-2" id="f-970">20</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-246" decimals="2" name="bcrx:RoyaltyRateIfMaintainsSakigakeDesignation" scale="-2" id="f-971">40</ix:nonFraction>% of annual net sales of ORLADEYO in Japan during each calendar year. Torii&#8217;s royalty payment obligations were subject to customary reductions in certain circumstances, but could not be reduced by more than <ix:nonFraction unitRef="number" contextRef="c-244" decimals="2" name="bcrx:MaximumCustomaryReductionOnRoyaltyRate" scale="-2" id="f-972">50</ix:nonFraction>% of the amount that otherwise would have been payable to the Company in the applicable calendar quarter. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company identified performance obligations under the Original Torii Agreement related to (i) the license to develop and commercialize ORLADEYO, (ii) regulatory approval support, and (iii) reimbursement pricing approval support. These were each determined to be distinct from the other performance obligations. The Company allocated the $<ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-973">22,000</ix:nonFraction> upfront consideration to the identified performance obligations using estimation approaches to determine the standalone selling prices under ASC Topic 606. Specifically, in determining the value related to the license, a valuation approach utilizing risk adjusted discounted cash flow projections was used, and an expected cost plus margin approach was utilized for the other performance obligations. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;30, 2023, the Company entered into an Amended and Restated Commercialization and License Agreement with Torii (as amended, the &#8220;Torii Agreement&#8221;). Under the Torii Agreement, the Company is entitled to receive tiered royalty payments, ranging from <ix:nonFraction unitRef="number" contextRef="c-247" decimals="2" name="bcrx:RoyaltyRate" scale="-2" id="f-974">20</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-248" decimals="2" name="bcrx:RoyaltyRate" scale="-2" id="f-975">80</ix:nonFraction>% of annual net sales of ORLADEYO in Japan during each calendar year. The Company is now responsible for all commercial promotion activities to support ORLADEYO sales in Japan, and Torii is responsible for HAE disease awareness activities in Japan. The Company will receive a <ix:nonFraction unitRef="number" contextRef="c-247" decimals="2" name="bcrx:RoyaltyRate" scale="-2" id="f-976">20</ix:nonFraction>% royalty on annual Japanese sales below a prespecified threshold and an <ix:nonFraction unitRef="number" contextRef="c-248" decimals="2" name="bcrx:RoyaltyRate" scale="-2" id="f-977">80</ix:nonFraction>% royalty on annual Japanese sales above the prespecified threshold.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Torii&#8217;s updated royalty payment obligations commenced on November&#160;30, 2023 and expire upon the later of (i) the tenth anniversary of the date of first commercial sale of ORLADEYO in Japan, (ii) the expiration of the Company&#8217;s patents covering ORLADEYO, and (iii) the expiration of regulatory exclusivity for ORLADEYO in Japan. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the Torii Agreement represented a contract modification to be accounted for as if it were part of the Original Torii Agreement under ASC Topic 606. As the performance obligations under the Original Torii Agreement had been fully satisfied, the Company was not required to adjust revenue previously recognized. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Peramivir Injection (RAPIVAB, RAPIACTA, PERAMIFLU)</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Department of Health and Human Services (&#8220;HHS&#8221;)</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><ix:continuation id="f-967-2"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In September 2024, the HHS awarded the Company up to a $<ix:nonFraction unitRef="usd" contextRef="c-249" decimals="-3" name="bcrx:CollaborativeAgreementContractValue" format="ixt:num-dot-decimal" scale="3" id="f-978">69,388</ix:nonFraction> contract for the procurement of up to <ix:nonFraction unitRef="dose" contextRef="c-250" decimals="-2" name="bcrx:MaximumNumberOfProductsPermittedToBeObtainedDoses" format="ixt:num-dot-decimal" scale="3" id="f-979">95.6</ix:nonFraction> thousand doses over a <ix:nonNumeric contextRef="c-249" name="bcrx:ContractTerm" format="ixt-sec:durwordsen" id="f-980">five-year</ix:nonNumeric> period of RAPIVAB (peramivir injection) for the treatment of influenza. The contract, awarded by the HHS Office of the Administration for Strategic Preparedness and Response (&#8220;ASPR&#8221;), supplied the Center for the Strategic National Stockpile, the nation&#8217;s largest supply of life-saving pharmaceuticals and medical supplies for use in a public health emergency. The contract was structured with a <ix:nonNumeric contextRef="c-250" name="bcrx:ContractTerm" format="ixt-sec:durwordsen" id="f-981">12-month</ix:nonNumeric> base ordering period and <ix:nonFraction unitRef="period" contextRef="c-250" decimals="INF" name="bcrx:NumberOfOptionalOrderingPeriods" format="ixt-sec:numwordsen" scale="0" id="f-982">four</ix:nonFraction> optional <ix:nonNumeric contextRef="c-250" name="bcrx:ContractTerm" format="ixt-sec:durwordsen" id="f-983">12-month</ix:nonNumeric> ordering periods, which the government could exercise on an annual basis. ASPR executed the first ordering period for $<ix:nonFraction unitRef="usd" contextRef="c-250" decimals="-3" name="us-gaap:ProceedsFromCollaborators" format="ixt:num-dot-decimal" scale="3" id="f-984">13,878</ix:nonFraction>. The Company delivered <ix:nonFraction unitRef="dose" contextRef="c-251" decimals="INF" name="bcrx:NumberOfProductDeliveredDoses" format="ixt:fixed-zero" scale="0" id="f-985">no</ix:nonFraction> doses of peramivir under this contract and recorded <ix:nonFraction unitRef="dose" contextRef="c-251" decimals="INF" name="bcrx:NumberOfProductDeliveredDoses" format="ixt:fixed-zero" scale="0" id="f-986">no</ix:nonFraction> revenue for the three months ended September 30, 2025. The Company delivered <ix:nonFraction unitRef="dose" contextRef="c-252" decimals="INF" name="bcrx:NumberOfProductDeliveredDoses" format="ixt:num-dot-decimal" scale="3" id="f-987">16.8</ix:nonFraction> thousand doses of peramivir under this contract and recorded revenue of $<ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-988">12,206</ix:nonFraction> for the nine months ended September 30, 2025. There were <ix:nonFraction unitRef="dose" contextRef="c-253" decimals="INF" name="bcrx:NumberOfProductDeliveredDoses" format="ixt:fixed-zero" scale="0" id="f-989"><ix:nonFraction unitRef="dose" contextRef="c-254" decimals="INF" name="bcrx:NumberOfProductDeliveredDoses" format="ixt:fixed-zero" scale="0" id="f-990">no</ix:nonFraction></ix:nonFraction> doses delivered and <ix:nonFraction unitRef="dose" contextRef="c-253" decimals="INF" name="bcrx:NumberOfProductDeliveredDoses" format="ixt:fixed-zero" scale="0" id="f-991"><ix:nonFraction unitRef="dose" contextRef="c-254" decimals="INF" name="bcrx:NumberOfProductDeliveredDoses" format="ixt:fixed-zero" scale="0" id="f-992">no</ix:nonFraction></ix:nonFraction> revenue recorded for the three and nine months ended September 30, 2024.  On May 15, 2025, ASPR notified the Company of its intent to not exercise any additional optional ordering periods available under the agreement.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shionogi &amp; Co., Ltd. (&#8220;Shionogi&#8221;)</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In February 2007, the Company entered into an exclusive license agreement with Shionogi to develop and commercialize peramivir in Japan for the treatment of seasonal and potentially life-threatening human influenza. Under the terms of the agreement, Shionogi obtained rights to injectable formulations of peramivir in Japan. In October 2008, the Company and Shionogi amended the license agreement to expand the territory covered by the agreement to include Taiwan. Shionogi has commercially launched peramivir under the commercial name RAPIACTA in Japan and Taiwan. The Company developed peramivir under a license from UAB and owes sublicense payments to UAB on any future milestone payments and/or royalties received by the Company from Shionogi. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Green Cross Corporation</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(&#8220;Green Cross&#8221;)</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In June 2006, the Company entered into an agreement with Green Cross to develop and commercialize peramivir in Korea. Under the terms of the agreement, Green Cross is responsible for all development, regulatory, and commercialization costs in Korea and the Company is entitled to share in profits resulting from the sale of peramivir in Korea, including the sale of peramivir to the Korean government for stockpiling purposes. Furthermore, Green Cross will pay the Company a premium over its cost to supply peramivir for development and any future marketing of peramivir products in Korea.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Collaborations and Relationships</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clearside Biomedical, Inc. (&#8220;Clearside&#8221;)</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;3, 2023, the Company announced that it entered into a license agreement (the &#8220;Clearside Agreement&#8221;) with Clearside, enabling the Company to develop its investigational plasma kallikrein inhibitor, avoralstat, with Clearside&#8217;s SCS Microinjector&#174; to deliver avoralstat to the back of the eye through the suprachoroidal space to treat patients with diabetic macular edema. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the Clearside Agreement, Clearside received a $<ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-3" name="bcrx:LicenseAgreementUpfrontPayment" format="ixt:num-dot-decimal" scale="3" id="f-993">5,000</ix:nonFraction> upfront license fee from the Company, which was recognized in research and development expenses during the year ended December 31, 2023. Clearside is eligible to receive up to an additional $<ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="bcrx:PotentialMilestonePaymentsPayable" format="ixt:num-dot-decimal" scale="3" id="f-994">30,000</ix:nonFraction> in clinical and regulatory milestone payments, and up to a total of $<ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="bcrx:PotentialMilestonePaymentsPayableIfRegulatoryApprovalBeforeMilestone" format="ixt:num-dot-decimal" scale="3" id="f-995">47,500</ix:nonFraction> in <ix:nonFraction unitRef="payment" contextRef="c-255" decimals="0" name="bcrx:LicenseAgreementNumberOfMilestonePayments" format="ixt-sec:numwordsen" scale="0" id="f-996">three</ix:nonFraction> post-approval sales-based milestone payments as annual global net sales progress to $<ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-6" name="bcrx:LicenseAgreementAnnualGlobalNetSales" format="ixt:num-dot-decimal" scale="3" id="f-997">2,000,000</ix:nonFraction>. The Company will pay Clearside tiered mid-single digit royalties on annual global net product sales, at <ix:nonFraction unitRef="payment" contextRef="c-255" decimals="0" name="bcrx:LicenseAgreementRoyaltyPaymentNumberOfTiers" format="ixt-sec:numwordsen" scale="0" id="f-998">three</ix:nonFraction> tiers, including a top tier of &gt;$<ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-6" name="bcrx:LicenseAgreementAnnualGlobalNetSales" format="ixt:num-dot-decimal" scale="3" id="f-999">1,500,000</ix:nonFraction>.</span></div></ix:continuation><div id="id1b8c440ead54d70904211d3c0a5ea1f_76"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Note 13 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"> <ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-1000" continuedAt="f-1000-1" escape="true">Segment Information</ix:nonNumeric></span></div><ix:continuation id="f-1000-1" continuedAt="f-1000-2"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-1001"><ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-1002">one</ix:nonFraction></ix:nonFraction> reportable and operating segment, centered around its commercialized product, ORLADEYO, and its pipeline with the goal of developing first-in-class or best-in-class oral small-molecule and injectable protein therapeutics to target difficult-to-treat rare diseases. The determination of a single segment is consistent with the consolidated financial information regularly provided to the Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;). The Chief Executive Officer, as the CODM, uses consolidated, single-segment financial information for purposes of evaluating performance, making operating decisions, allocating resources, and planning and forecasting for future periods.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> The CODM assesses performance and decides how to allocate resources based on consolidated net income (loss). This measure is used to monitor budget versus actual results to evaluate the performance of the segment. The CODM uses consolidated cash, cash equivalents and investments as the measure of segment assets. As of September&#160;30, 2025 the Company&#8217;s cash, cash equivalents, and investments were $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="bcrx:CashCashEquivalentsShortAndLongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-1003">267,382</ix:nonFraction>, of which $<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-1004">14,840</ix:nonFraction> was considered held for sale (see </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><ix:continuation id="f-1000-2" continuedAt="f-1000-3"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2 - Assets Held for Sale&#8221;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">). As of December&#160;31, 2024 the Company&#8217;s cash, cash equivalents, and investments were $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="bcrx:CashCashEquivalentsShortAndLongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-1005">341,173</ix:nonFraction>.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="f-1006" continuedAt="f-1006-1" escape="true"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table illustrates information about segment revenues, significant segment expenses, and segment net income (loss) for the three and nine months ended September 30, 2025 and 2024 (in thousands):</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt"><ix:continuation id="f-1000-3" continuedAt="f-1000-4"><ix:continuation id="f-1006-1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1007">159,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1008">117,085</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1009">468,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1010">319,178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Less</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-1011">2,187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-1012">3,211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-1013">9,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-1014">6,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Berotralstat</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-263" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1015">2,575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-264" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1016">2,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1017">9,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1018">10,504</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">BCX17725</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1019">7,574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-268" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1020">1,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1021">13,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1022">6,591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Avoralstat</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-271" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1023">1,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-272" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1024">2,104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-273" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1025">7,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-274" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1026">4,960</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Factor D Program</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-275" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="f-1027">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-276" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1028">1,193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="f-1029">454</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1030">7,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Research, discovery and preclinical programs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1031">5,457</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1032">3,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1033">11,641</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1034">8,325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and related personnel costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-283" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1035">13,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 25pt 0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-284" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1036">14,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1037">38,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1038">42,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-287" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1039">6,520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 25pt 0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1040">8,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1041">24,374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1042">20,923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other non-program specific and indirect costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1043">7,329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 25pt 0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1044">7,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1045">20,621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1046">23,965</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1047">83,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1048">65,101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1049">252,866</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1050">185,841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-3" name="us-gaap:InterestIncomeOperating" format="ixt:num-dot-decimal" scale="3" id="f-1051">2,238</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-3" name="us-gaap:InterestIncomeOperating" format="ixt:num-dot-decimal" scale="3" id="f-1052">3,591</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-3" name="us-gaap:InterestIncomeOperating" format="ixt:num-dot-decimal" scale="3" id="f-1053">7,778</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-3" name="us-gaap:InterestIncomeOperating" format="ixt:num-dot-decimal" scale="3" id="f-1054">11,176</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-1055">19,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-1056">24,828</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-1057">64,737</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-1058">74,067</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency (gains) losses, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-3" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" id="f-1059">35</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-3" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" id="f-1060">98</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" id="f-1061">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" id="f-1062">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-1063">2,740</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="f-1064">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-1065">6,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="f-1066">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-1067">2,667</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-3" name="us-gaap:OtherIncome" format="ixt:fixed-zero" scale="3" id="f-1068">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-1069">2,667</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-3" name="us-gaap:OtherIncome" format="ixt:fixed-zero" scale="3" id="f-1070">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-1071">769</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-1072">586</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1073">1,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1074">1,123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Segment net income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1075">12,899</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1076">14,033</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1077">18,016</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1078">62,086</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Reconciliation of segment profit or loss:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments and reconciling items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-3" name="bcrx:SegmentReportingAdjustmentsAndReconcilingItemsAmount" format="ixt:fixed-zero" scale="3" id="f-1079">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-3" name="bcrx:SegmentReportingAdjustmentsAndReconcilingItemsAmount" format="ixt:fixed-zero" scale="3" id="f-1080">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-3" name="bcrx:SegmentReportingAdjustmentsAndReconcilingItemsAmount" format="ixt:fixed-zero" scale="3" id="f-1081">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-3" name="bcrx:SegmentReportingAdjustmentsAndReconcilingItemsAmount" format="ixt:fixed-zero" scale="3" id="f-1082">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated net income (loss)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1083">12,899</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1084">14,033</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1085">18,016</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1086">62,086</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">1 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">The significant expense categories and amounts align with the segment-level information that is regularly provided to the CODM.</span></div></td></tr></table></ix:continuation><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">All material long-lived assets of the Company reside in the U.S. For geographic information about the Company&#8217;s product revenues, see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Note 3&#8212;Revenue</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-1000-4">&#8221;.</ix:continuation> </span></div><div id="id1b8c440ead54d70904211d3c0a5ea1f_79"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Note 14</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-1087" continuedAt="f-1087-1" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="f-1087-1" continuedAt="f-1087-2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Abbreviated New Drug Application</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In January 2025, the Company received a Paragraph IV notice of certification (the &#8220;Notice Letter&#8221;) from Annora Pharma Private Limited (&#8220;Annora&#8221;) advising that Annora has submitted an Abbreviated New Drug Application (&#8220;ANDA&#8221;) to the FDA seeking approval to manufacture, use or sell a generic version of ORLADEYO in the United States prior to the expiration of three patents listed in the FDA&#8217;s Orange Book: U.S. Patent Nos. 10,662,160; 11,117,867; and 11,618,733 (the &#8220;Challenged Patents&#8221;). The Notice Letter alleges that the Challenged Patents, which expire in 2039, are invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of the generic product described in </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><ix:continuation id="f-1087-2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Annora&#8217;s ANDA. The Notice Letter does not challenge the following six ORLADEYO Orange Book patents that expire in 2035:  U.S. Patent Nos. 10,125,102; 10,329,260; 10,689,346; 11,230,530; 11,708,333; and 12,116,346. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On March 10, 2025, the Company &#64257;led a patent infringement lawsuit in the United States District Court for the District of Delaware against Annora, Hetero Labs Limited, Hetero USA, Inc., and Camber Pharmaceuticals, Inc. (collectively, the &#8220;Defendants&#8221;), asserting infringement of the Challenged Patents arising from Annora&#8217;s ANDA filing with the FDA. The Company is seeking, among other remedies, equitable relief enjoining the Defendants from infringing the Challenged Patents, as well as an order that the e&#64256;ective date of any FDA approval of the ANDA would be a date no earlier than the expiration of the Challenged Patents (including any regulatory extensions). While the Company intends to vigorously defend its intellectual property rights protecting ORLADEYO, this matter is in the early stages of litigation and no assessment can be made as to the likely outcome of this matter or whether it will be material to the Company. Accordingly, an estimate of the potential loss, or range of loss, if any, to the Company relating to this matter is not possible at this time.</span></div></ix:continuation><div id="id1b8c440ead54d70904211d3c0a5ea1f_82"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Note 15</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-1088" continuedAt="f-1088-1" escape="true">Net Income (Loss) Per Share</ix:nonNumeric></span></div><ix:continuation id="f-1088-1" continuedAt="f-1088-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" id="f-1089" escape="true"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net income (loss) per share for the three and nine months ended September&#160;30, 2025 and 2024 were calculated as follows (in thousands, except per share amounts):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1090">12,899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1091">14,033</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1092">18,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1093">62,086</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding: basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-1094">210,176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-1095">206,905</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-1096">209,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-1097">206,466</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per common share: basic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1098">0.06</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-8" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1099">0.07</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1100">0.09</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-9" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1101">0.30</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stock options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="f-1102">5,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="f-1103">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="f-1104">5,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="f-1105">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock unit awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements" format="ixt:num-dot-decimal" scale="3" id="f-1106">4,663</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements" format="ixt:fixed-zero" scale="3" id="f-1107">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements" format="ixt:num-dot-decimal" scale="3" id="f-1108">3,532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements" format="ixt:fixed-zero" scale="3" id="f-1109">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable under the employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="bcrx:IncrementalCommonSharesAttributableToDilutiveEffectOfSharePurchasePlans" scale="3" id="f-1110">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="-3" name="bcrx:IncrementalCommonSharesAttributableToDilutiveEffectOfSharePurchasePlans" format="ixt:fixed-zero" scale="3" id="f-1111">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="bcrx:IncrementalCommonSharesAttributableToDilutiveEffectOfSharePurchasePlans" scale="3" id="f-1112">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="-3" name="bcrx:IncrementalCommonSharesAttributableToDilutiveEffectOfSharePurchasePlans" format="ixt:fixed-zero" scale="3" id="f-1113">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive potential common shares</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="3" id="f-1114">9,709</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="-3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:fixed-zero" scale="3" id="f-1115">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="3" id="f-1116">8,818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="-3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:fixed-zero" scale="3" id="f-1117">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding: diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-1118">219,885</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-1119">206,905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-1120">218,349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-1121">206,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per common share: diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1122">0.06</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-8" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1123">0.07</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1124">0.08</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-9" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1125">0.30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s potentially dilutive securities include outstanding stock options, unvested restricted stock units and shares issuable under the employee stock purchase plan for the three and nine months ended September&#160;30, 2025 and 2024. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2025, the dilutive effect of outstanding stock options, restricted stock unit awards, and shares issuable under the employee stock purchase plan was calculated using the treasury method, whereby all such awards are assumed to be exercised at the beginning of the period. The hypothetical proceeds from such exercises, including the average unrecognized stock compensation expense for outstanding stock options, restricted stock units and shares issuable under the employee stock purchase plan, were assumed to be used to purchase outstanding common stock at the average price during the period. The net share impact of dilutive securities was added to the weighted average basic common shares outstanding to calculate weighted average diluted shares outstanding.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2024, during which the Company recorded a net loss, all potentially dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share, and thus they are considered &#8220;anti-dilutive.&#8221;  For this period, the weighted average number </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><ix:continuation id="f-1088-2"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of shares of common stock outstanding used to calculate both basic and diluted net loss per share of common stock is the same.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-1126" escape="true"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes potential shares of common stock that were excluded from the computation of diluted net income (loss) per share attributable to common stockholders as they were anti-dilutive:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.869%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.113%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-295" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-1127">21,818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-296" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-1128">38,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock unit awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-297" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="f-1129">373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-298" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-1130">5,882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-1131">22,191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-1132">44,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="id1b8c440ead54d70904211d3c0a5ea1f_85"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Note 16</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="us-gaap:SubsequentEventsTextBlock" id="f-1133" continuedAt="f-1133-1" escape="true">Subsequent Events</ix:nonNumeric></span></div><ix:continuation id="f-1133-1" continuedAt="f-1133-2"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Neopharmed Gentili S.p.A. Stock Purchase Agreement</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On October 1, 2025, under the terms of the Stock Purchase Agreement, the Company sold to Neopharmed all of its equity interests in BioCryst Ireland, which, together with its subsidiaries, holds certain assets, rights, and employees related to the Company&#8217;s European ORLADEYO Business. At the Closing, the Company received cash proceeds of </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" format="ixt:num-dot-decimal" scale="3" id="f-1134">250,000</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, plus customary purchase price adjustments as set forth in the Stock Purchase Agreement. In addition, Neopharmed has agreed to pay the Company up to </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="bcrx:DisposalGroupIncludingDiscontinuedOperationContingentConsideration" format="ixt:num-dot-decimal" scale="3" id="f-1135">14,000</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> if certain revenue milestones are achieved prior to December 31, 2032. In connection with the Closing, Neopharmed also paid a </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="bcrx:DisposalGroupIncludingDiscontinuedOperationConsiderationRoyaltyReleaseFee" format="ixt:num-dot-decimal" scale="3" id="f-1136">15,000</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> royalty release fee to RPI 2019 Intermediate Finance Trust.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Concurrent with the Closing of the transactions contemplated by the Stock Purchase Agreement, on October 1, 2025, the Company and BioCryst Ireland amended and restated their existing intellectual property licence agreement pursuant to which the Company will continue to grant to BioCryst Ireland certain rights with respect to ORLADEYO in the territory (the &#8220;Amended and Restated IP Licence Agreement&#8221;). The terms of the Amended and Restated IP Licence Agreement may also extend to the pediatric line extension of ORLADEYO, subject to certain regulatory approvals. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Closing, on October 1, 2025, the Company entered into a supply agreement with BioCryst Ireland, pursuant to which the Company will be the exclusive supplier of ORLADEYO products to BioCryst Ireland for commercialization in the territory (the &#8220;Supply Agreement&#8221;). Additionally, in connection with the Closing, on October 1, 2025, the Company entered into a global brand and support agreement with BioCryst Ireland, which provides for coordination of brand and regulatory activities between the Company and BioCryst Ireland regarding ORLADEYO products (the &#8220;Global Brand and Support Agreement&#8221;). In connection with the Closing, on October 1, 2025, the Company entered into a mutual transition services agreement with BioCryst Ireland, pursuant to which the Company and BioCryst Ireland will provide each other with certain transition services for the periods of time and for the compensation set forth under the agreement, on customary commercial terms (the &#8220;Transition Services Agreement&#8221;).</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Lastly, in connection with the Closing, on October 1, 2025, the Company entered into a trademark license agreement with BioCryst Ireland, pursuant to which the Company granted to BioCryst Ireland a non-exclusive transitionary license to use the &#8220;BioCryst&#8221; name, solely to develop, manufacture and commercialize ORLADEYO products in the territory for a limited period of time, and an exclusive license to use the ORLADEYO product name to commercialize ORLADEYO products for such uses for the term of the Amended and Restated IP Licence Agreement, in each case subject to the terms and conditions set forth therein (the &#8220;Trademark License Agreement&#8221;).</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pharmakon Loan Agreement</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On October 8, 2025, the Company used a portion of the proceeds from the sale of the European ORLADEYO Business to pay off in full the outstanding principal balance of $<ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-3" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" format="ixt:num-dot-decimal" scale="3" id="f-1137">198,704</ix:nonFraction> and terminate the Pharmakon Loan Agreement. In conjunction with the repayment the Company incurred a $<ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-3" name="bcrx:DebtInstrumentPrepaymentPremium" format="ixt:num-dot-decimal" scale="3" id="f-1138">5,961</ix:nonFraction> prepayment premium and paid $<ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-3" name="us-gaap:InterestExpenseLongTermDebt" scale="3" id="f-1139">485</ix:nonFraction> of interest accrued through the payment date.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Astria Therapeutics, Inc. Agreement and Plan of Merger</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On October 14, 2025, the Company, Axel Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (&#8220;Merger Sub&#8221;), and Astria Therapeutics, Inc., a Delaware corporation (&#8220;Astria&#8221;), entered into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;).  Pursuant to the Merger Agreement, and subject to the </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><ix:continuation id="f-1133-2"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">satisfaction or waiver of the conditions specified therein, at the Effective Time (as defined below), Merger Sub will merge with and into Astria, with Astria surviving as a wholly owned subsidiary of the Company (the &#8220;Merger&#8221;). </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms and conditions of the Merger Agreement, at the effective time of the Merger (the &#8220;Effective Time&#8221;), each share of Astria common stock, par value $0.001 per share, issued and outstanding immediately prior to the Effective Time will be, subject to certain exceptions, converted into the right to receive (i) <ix:nonFraction unitRef="number" contextRef="c-300" decimals="4" name="bcrx:CommonStockConversionRatio" scale="0" id="f-1140">0.59</ix:nonFraction> of a share of the Company&#8217;s common stock (and, if applicable, cash in lieu of fractional shares), and (ii) $<ix:nonFraction unitRef="usdPerShare" contextRef="c-300" decimals="2" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="f-1141">8.55</ix:nonFraction> in cash, without interest, subject to certain adjustments and applicable withholding taxes. Holders of Astria&#8217;s Series X Convertible Preferred Stock, warrants, and certain options will also be entitled to certain consideration, as further set forth in the Merger Agreement. The Merger is subject to the approval of Astria&#8217;s stockholders, as well as customary regulatory approvals. In connection with entering into the Merger Agreement, certain stockholders of Astria entered into voting and support agreements with the Company, pursuant to which each such stockholder has agreed, among other things, to vote its, his or her shares of Astria common stock in favor of the adoption of the Merger Agreement and approval of the transactions contemplated thereby and, subject to certain exceptions, not to transfer such shares of Astria common stock prior to the earlier of the Effective Time and the termination of the Merger Agreement, without the prior written consent of the Company.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Commitments</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the transactions contemplated by the Merger Agreement, on October 14, 2025, the Company entered into a debt commitment letter (the &#8220;Commitment Letter&#8221;) with certain affiliates of Blackstone, Inc. (&#8220;Blackstone&#8221;), pursuant to which Blackstone agreed to provide a $<ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="0" id="f-1142">550,000</ix:nonFraction> senior secured credit facility consisting of (i) a committed initial term loan in an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="0" id="f-1143">350,000</ix:nonFraction> (the &#8220;Initial Term Loan&#8221;), (ii) a committed delayed draw term loan facility in an aggregate principal amount not exceeding $<ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="0" id="f-1144">50,000</ix:nonFraction> (the loans thereunder, the &#8220;Committed Delayed Draw Term Loans&#8221;), and (iii) an uncommitted delayed draw term loan facility in an aggregate principal amount not exceeding $<ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="0" id="f-1145">150,000</ix:nonFraction>. The Initial Term Loan and any Committed Delayed Draw Term Loans funded on the closing date of the Merger will be used for the purpose of, among other things, funding the consideration for the transactions contemplated by the Merger Agreement and paying for related fees and expenses. The commitments with respect to the Initial Term Loan and any Committed Delayed Draw Term Loans funded on the closing date of the Merger are subject to customary conditions for acquisition financings, including the execution and delivery of definitive documentation with respect to the senior secured credit facility in accordance with the terms set forth in the Commitment Letter and the consummation of the Merger.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">34</span></div></div></div><div id="id1b8c440ead54d70904211d3c0a5ea1f_88"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.&#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following Management</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">s Discussion and Analysis (</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MD&amp;A</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">) is intended to help the reader understand our results of operations and financial condition. This MD&amp;A is provided as a supplement to, and should be read in conjunction with, our unaudited condensed consolidated financial statements and the accompanying notes to the financial statements and other disclosures included in this report (including the </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cautionary Note Regarding Forward-Looking Statements</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> at the beginning of this report and the </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> section in Part II, Item 1A of this report).</span></div><div id="id1b8c440ead54d70904211d3c0a5ea1f_91"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (&#8220;HAE&#8221;) and other rare diseases, driven by our deep commitment to improving the lives of people living with these conditions. We have built a robust commercial infrastructure to support the launch and continued success of ORLADEYO, an oral, once-daily therapy discovered and developed internally for the prevention of HAE attacks. Our business strategy includes leveraging this established commercial platform to successfully commercialize a pipeline of potential first-in-class or best-in-class oral small-molecule and injectable protein therapeutics targeting a range of rare diseases. These programs are being pursued through both internal discovery efforts and strategic business development. By utilizing our existing commercial capabilities and focusing on rare disease markets, we believe that we can more effectively optimize our costs and strategically allocate resources to support long-term, sustainable growth.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Products and Product Candidates</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">  </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ORLADEYO</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> (berotralstat)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ORLADEYO is an oral capsule, once-daily therapy discovered and developed by us for the prevention of HAE attacks. ORLADEYO is approved in the United States and other global markets for the prevention of HAE attacks in adults and pediatric patients 12 years and older. In addition, the ongoing APeX-P clinical trial, which is complete through the primary endpoint, is continuing to assess an oral granule formulation of ORLADEYO in pediatric patients who are 2 to 11 years of age at enrollment. The Prescription Drug User Fee Act goal date for our new drug application for ORLADEYO granules in children with HAE aged 2 to 11 is December 12, 2025. ORLADEYO would be the first targeted oral prophylactic therapy for children with HAE.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Based on proprietary analyses of HAE prevalence and market research studies with HAE patients, physicians, and payors in the United States and Europe, and nearly five years of commercialization experience with ORLADEYO, we anticipate that the global commercial market for ORLADEYO has the potential to reach a global peak of $1 billion in annual net ORLADEYO revenues. These expectations are subject to numerous risks and uncertainties that may cause our actual results, performance, or achievements to be materially different. There can be no assurance that our commercialization methods and strategies will succeed, or that the market for ORLADEYO will develop in line with our current expectations. See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors&#8212;Risks Relating to Our Business&#8212;Risks Relating to Drug Development and Commercialization&#8212;There can be no assurance that our or our partners&#8217; commercialization efforts, methods, and strategies for our products or technologies will succeed, and our future revenue generation is uncertain</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; in Part II, Item 1A of this report for further discussion of these risks.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from sales of ORLADEYO for the three and nine months ended September&#160;30, 2025 is discussed under &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; in this MD&amp;A. Revenue from sales of ORLADEYO in future periods is subject to uncertainties and will depend on several factors, including, but not limited to, the success of our and our partners&#8217; commercialization efforts in the United States and elsewhere, the number of new patients switching to ORLADEYO, patient retention and demand, the number of physicians prescribing ORLADEYO, the rate of monthly prescriptions, reimbursement from third-party and government pa</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">yors, the number of patients receiv</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ing free product, our pricing strategy, and market trends. We monitor and analyze this data on an ongoing basis as we continue to commercialize ORLADEYO and adjust our forecasts accordingly.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BCX17725 (Netherton syndrome)</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">BCX17725 is a potent and selective investigational protein therapeutic KLK5 inhibitor designed to provide best-in-class, potentially disease-modifying, treatment for people with Netherton syndrome. Netherton syndrome is a serious, rare, lifelong genetic disorder causing disruption of the skin barrier with premature separation of the skin layers, chronic inflammation and vulnerability to serious infections, caused by lack of normal function of a natural inhibitor of KLK5. People with Netherton syndrome often have itchy, red, scaly, inflamed skin, fragile hair, and are more likely to develop severe food allergies, asthma and eczema. Netherton syndrome can be life-threatening, especially during infancy when </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">patients are vulnerable to dehydration and recurrent infections. Currently, there are no approved treatments that target the underlying cause of Netherton syndrome. BCX17725 is designed to replace missing functions of the natural KLK5 inhibitor, which could restore the normal skin barrier and result in improved skin function, including protection from severe inflammatory and infectious complications of the disease.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Avoralstat</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Avoralstat, an investigational plasma kallikrein inhibitor, is designed to treat patients with diabetic macular edema (&#8220;DME&#8221;) through delivery of avoralstat to the back of the eye through the suprachoroidal space.  DME is an important cause of vision loss in diabetes and is due to leakage of fluid from the blood vessels in the retina. While current treatments focus on vascular endothelial growth factor (&#8220;VEGF&#8221;) inhibition, DME can develop from other mechanisms, such as the kallikrein-bradykinin pathway. This is supported by observations that many DME patients have an incomplete response to intravitreal anti-VEGF therapies that are administered every four to eight weeks. Avoralstat targets the kallikrein-bradykinin system on the retinal vascular endothelial cells and may result in less vascular leakage and less edema. Avoralstat, delivered to the suprachoroidal space, is designed to provide long-lasting exposure to the retinal vessels, which could result in less frequent injections and a reduced burden on patients and the healthcare system.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RAPIVAB</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">/RAPIACTA</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">/PERAMIFLU</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> (peramivir injection)</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older. Since the 2009 H1N1 pandemic, RAPIVAB has been an important component of the U.S. Government&#8217;s influenza preparedness efforts. Peramivir injection is also approved in Canada (RAPIVAB), Australia (RAPIVAB), Japan (RAPIACTA), Taiwan (RAPIACTA), and Korea (PERAMIFLU).</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues and Expenses</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues are difficult to predict and depend on several factors, including those discussed in the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; section in Part II, Item 1A of this report. For example, our revenues depend, in part, on regulatory approval decisions for our products and product candidates, the effectiveness of our and our collaborative partners&#8217; commercialization efforts, market acceptance of our products, particularly ORLADEYO, and the resources dedicated to our products and product candidates by us and our collaborative partners, as well as entering into or modifying licensing agreements for our product candidates. Furthermore, revenues related to our collaborative development activities are dependent upon the progress toward, and the achievement of, developmental milestones by us or our collaborative partners. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our operating expenses are also difficult to predict and depend primarily on research and development activities, including drug manufacturing, clinical research activities, and the ongoing requirements of our development programs, as well as the costs of commercialization, direction from regulatory agencies and the factors discussed in the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; section in Part II, Item 1A of this report. Management may be able to control the timing and level of research and development and selling, general and administrative expenses, but many of these expenditures will occur irrespective of our actions due to contractually committed activities and/or payments.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As a result of these factors, we believe that period-to-period comparisons are not necessarily meaningful, and you should not rely on them as an indication of future performance. Due to the foregoing factors, it is possible that our operating results will be below the expectations of market analysts and investors. In such event, the prevailing market price of our common stock could be materially adversely affected.</span></div><div id="id1b8c440ead54d70904211d3c0a5ea1f_94"></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Developments </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ORLADEYO (berotralstat)</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On August 4, 2025, we announced that new real-world data from over 350 patients with HAE with normal C1 inhibitor showed substantial reductions in attack rates with ORLADEYO, which we believe reinforces its value for a historically underserved patient segment and provides strong evidence to close gaps in both treatment and reimbursement.</span></div><div style="text-indent:27pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BCX17725 (Netherton syndrome)</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On July 30, 2025</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, we were notified that the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) granted Fast Track designation for BCX17725 for the treatment of Netherton syndrome. On November 3, 2025, we announced that we expect initial data from Netherton syndrome patients participating in our phase 1 trial of BCX17725 by the end of the first quarter of 2026.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="text-indent:27pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Avoralstat</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On August 4, 2025, we announced that we were enrolling patients in the first clinical trial with suprachoroidal delivery of avoralstat in Australia. On November 3, 2025, we reaffirmed that we expect initial data from the avoralstat program by the end of the year and announced that we plan to seek a strategic partner for development beyond phase 1.</span></div><div style="text-indent:27pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Neopharmed Gentili S.p.A. Transaction</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, on June 27, 2025, we entered into a stock purchase agreement (the &#8220;Stock Purchase Agreement&#8221;) with BioCryst Ireland Limited (&#8220;BioCryst Ireland&#8221;), a private limited company incorporated under the laws of Ireland and a wholly owned subsidiary of the Company, and Neopharmed Gentili S.p.A., a corporation organized under the laws of Italy (&#8220;Neopharmed&#8221;). On October 1, 2025 (the &#8220;Closing&#8221;), under the terms of the Stock Purchase Agreement, we sold to Neopharmed all of our equity interests in BioCryst Ireland, which, together with its subsidiaries, holds certain assets, rights, and employees related to our European ORLADEYO business (the &#8220;European ORLADEYO Business&#8221;). At the Closing, we received cash proceeds of </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$250.0 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, plus customary purchase price adjustments as set forth in the Stock Purchase Agreement. In addition, Neopharmed has agreed to pay us up to </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$14.0 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> if certain revenue milestones are achieved prior to December 31, 2032</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. In connection with the Closing, Neopharmed also paid a $15.0 million royalty release fee to RPI 2019 Intermediate Finance Trust. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Concurrent with the Closing of the transactions contemplated by the Stock Purchase Agreement, on October 1, 2025, we and BioCryst Ireland amended and restated our existing intellectual property licence agreement pursuant to which we will continue to grant to BioCryst Ireland certain rights with respect to ORLADEYO in the territory (the &#8220;Amended and Restated IP Licence Agreement&#8221;). The terms of the Amended and Restated IP Licence Agreement may also extend to the pediatric line extension of ORLADEYO, subject to certain regulatory approvals. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Closing, on October 1, 2025, we entered into a supply agreement with BioCryst Ireland, pursuant to which we will be the exclusive supplier of ORLADEYO products to BioCryst Ireland for commercialization in the territory. Additionally, in connection with the Closing, on October 1, 2025, we entered into a global brand and support agreement with BioCryst Ireland, which provides for coordination of brand and regulatory activities between us and BioCryst Ireland regarding ORLADEYO products. In connection with the Closing, on October 1, 2025, we also entered into a mutual transition services agreement with BioCryst Ireland, pursuant to which we and BioCryst Ireland will provide each other with certain transition services for the periods of time and for the compensation set forth under the agreement, on customary commercial terms.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Lastly, in connection with the Closing, on October 1, 2025, we entered into a trademark license agreement with BioCryst Ireland, pursuant to which we granted to BioCryst Ireland a non-exclusive transitionary license to use the &#8220;BioCryst&#8221; name, solely to develop, manufacture and commercialize ORLADEYO products in the territory for a limited period of time, and an exclusive license to use the ORLADEYO product name to commercialize ORLADEYO products for such uses for the term of the Amended and Restated IP Licence Agreement, in each case subject to the terms and conditions set forth therein.</span></div><div style="text-indent:27pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pharmakon Loan Agreement</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> on July 24, 2025, we made a partial prepayment of </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$50.0 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> of the outstanding principal amount under the Pharmakon Loan Agreement. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On October 8, 2025, we used a portion of the proceeds from the sale of the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">European ORLADEYO Business</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> to pay off in full the outstanding principal balance of $198.7 million and terminate the Pharmakon Loan Agreement.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:27pt"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Astria Therapeutics, Inc. Agreement and Plan of Merger</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On October 14, 2025, we entered into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;) with Axel Merger Sub, Inc., a Delaware corporation and our wholly owned subsidiary (&#8220;Merger Sub&#8221;), and Astria Therapeutics, Inc., a Delaware corporation (&#8220;Astria&#8221;). Pursuant to the Merger Agreement, and subject to the satisfaction or waiver of the conditions specified therein, at the Effective Time (as defined below), Merger Sub will merge with and into Astria, with Astria surviving as our wholly owned subsidiary (the &#8220;Merger&#8221;). </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms and conditions of the Merger Agreement, at the effective time of the Merger (the &#8220;Effective Time&#8221;), each share of Astria common stock, par value $0.001 per share, issued and outstanding immediately prior to the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Effective Time will be, subject to certain exceptions, converted into the right to receive (i) 0.59 of a share of our common stock (and, if applicable, cash in lieu of fractional shares), and (ii) $8.55 in cash, without interest, subject to certain adjustments and applicable withholding taxes. Holders of Astria&#8217;s Series X Convertible Preferred Stock, warrants, and certain options will also be entitled to certain consideration, as further set forth in the Merger Agreement. The Merger is subject to the approval of Astria&#8217;s stockholders, as well as customary regulatory approvals. In connection with entering into the Merger Agreement, certain stockholders of Astria entered into voting and support agreements with us, pursuant to which each such stockholder has agreed, among other things, to vote its, his or her shares of Astria common stock in favor of the adoption of the Merger Agreement and approval of the transactions contemplated thereby and, subject to certain exceptions, not to transfer such shares of Astria common stock prior to the earlier of the Effective Time and the termination of the Merger Agreement, without our prior written consent.</span></div><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Commitments</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On October 14, 2025, in connection with the transactions contemplated by the Merger Agreement, we entered into a debt commitment letter (the &#8220;Commitment Letter&#8221;) with certain affiliates of Blackstone, Inc. (&#8220;Blackstone&#8221;) pursuant to which Blackstone agreed to provide a $550.0 million senior secured credit facility consisting of (i) a committed initial term loan in an aggregate principal amount of $350.0 million (the &#8220;Initial Term Loan&#8221;), (ii) a committed delayed draw term loan facility in an aggregate principal amount not exceeding $50.0 million (the loans thereunder, the &#8220;Committed Delayed Draw Term Loans&#8221;) and (iii) an uncommitted delayed draw term loan facility in an aggregate principal amount not exceeding $150.0 million. The Initial Term Loan and any Committed Delayed Draw Term Loans funded on the closing date of the Merger will be used for the purpose of, among other things, funding the consideration for the transactions contemplated by the Merger Agreement and paying fees and expenses related to the Merger. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The commitments with respect to the Initial Term Loan and any Committed Delayed Draw Term Loans funded on the closing date of the Merger are subject to customary conditions for acquisition financings, including the execution and delivery of definitive documentation with respect to the senior secured credit facility in accordance with the terms set forth in the Commitment Letter and the consummation of the Merger.</span></div><div id="id1b8c440ead54d70904211d3c0a5ea1f_97"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations (three months ended September 30, 2025 compared to the three months ended September 30, 2024)</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September 30, 2025, total revenues were $159.4 million compared to $117.1 million for the three months ended September 30, 2024. The increase in total revenues was due to a $42.8 million increase in ORLADEYO net revenue, including royalties, primarily due to an increase in volume of direct sales of ORLADEYO, which was driven by strong patient demand, an increase in price, and an increase in the rate of paid shipments.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product sales for the three months ended September 30, 2025 and 2024 was $2.2 million and $3.2 million, respectively. The decrease in cost of product sales was primarily due to a decrease in inventory reserves recorded during the three months ended September 30, 2025 compared to the three months ended September 30, 2024.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our research and development expenses, including program specific costs and shared or indirect operating costs recognized as research and development expenses for the periods indicated (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Berotralstat</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,575&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,954&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">BCX17725</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,574&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Avoralstat</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Factor D Program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Research, discovery and preclinical programs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,457&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and related personnel costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13,313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8,530&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other non-program specific and indirect costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Total research and development expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">44,603</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">41,081</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> We do not maintain or evaluate internal research and development costs on a program-by-program basis. As a result, a significant portion of our research and development expenses are not tracked on a program-by-program basis, as the costs may benefit multiple programs. Beginning the quarter ended September&#160;30, 2025, we no longer allocate non-program specific external costs or internal costs to programs. These costs are separately presented on the respective line items listed above. Research and development expenses have been reclassified for the three months ended September 30, 2024 for comparability. There is no impact on total research and development expenses.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased to $44.6 million for the three months ended September 30, 2025 from $41.1 million for the three months ended September 30, 2024. The increase was primarily driven by the following:</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$6.4 million increase in BCX17725 primarily due to an increase in manufacturing and clinical operations as we enroll our phase 1 trial in healthy volunteers and patients;</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$2.1 million increase in research, discovery and preclinical programs primarily due to investigational new drug application-enabling activities related to our early-phase pipeline programs; partially offset by:</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$2.0 million decrease in stock-based compensation expense primarily due to the acceleration of stock-based compensation expense upon adoption of the retirement policy in July 2024, partially offset by an increase in restricted stock unit awards granted;</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$1.2 million decrease in Factor D Program due to the discontinuation and close-out of the program in 2024; and</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$0.9 million decrease in compensation and related personnel costs primarily attributed to a decrease in research and development related headcount.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include all direct and indirect expenses relating to research and development activities. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Direct expenses consist of compensation for research and development personnel and costs of outside parties to conduct laboratory studies, develop manufacturing processes and manufacture the product candidates, and conduct and manage clinical trials, as well as other costs related to our clinical and preclinical studies. Additionally, direct expenses consist of those costs necessary to discontinue and close out a development program, including termination fees and other commitments. Indirect expenses consist of lab supplies and services, facility expenses, depreciation of development equipment and other overhead of our research and development efforts. Research and development expenses vary according to the number of programs in clinical development and the stage of development of our clinical programs. Later stage clinical programs tend to cost more than earlier stage programs due to the longer length of time of the clinical trials and the higher number of patients enrolled in these clinical trials.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses for the three months ended September 30, 2025 were $83.0 million compared to $65.1 million for the three months ended September 30, 2024. This increase was driven by an increase in ORLADEYO related regulatory, safety and quality activities as efforts shifted from development to supporting commercial products, reflecting the program&#8217;s commercial progression, as well as increases in variable costs driven by the increase in ORLADEYO sales and an increase in headcount primarily associated with European growth. This increase was also driven by $3.5 million of transaction-related costs and a $3.4 million increase in stock-based compensation expense as a result of an increase in restricted stock units granted and adjustments for estimated forfeitures. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the three months ended September 30, 2025 was $19.7 million compared to $24.8 million for the three months ended September 30, 2024. Interest expense is primarily comprised of non-cash interest expense due to the amortization of interest associated with the royalty financing obligations and interest expense associated with the borrowings under the Pharmakon Loan Agreement (as defined below), including the amortization of the deferred financing costs, associated with the borrowings under the Pharmakon Loan. The decrease in interest expense was primarily the result of the $75.0 million and $50.0 million partial prepayments on the outstanding principal amount under the Pharmakon Term Loan in April 2025 and July 2025, respectively, and a decrease in the effective interest rate related to the Pharmakon Loan Agreement.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September 30, 2025, interest income was $2.2 million compared to $3.6 million for the three months ended September 30, 2024. The decrease in interest income was primarily the result of an overall decrease in our investment portfolio and a decrease in interest rates. Net foreign currency gains were less than $0.1 million for the three months ended September 30, 2025 and $0.1 million for the three months ended September 30, 2024. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In July 2025, the Company made a $50.0 million partial prepayment on the outstanding principal amount under the Pharmakon Term Loan resulting in a one-time loss on extinguishment of debt of $2.7 million for the three months ended September 30, 2025.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September 30, 2025, other income was $2.7 million, which was primarily comprised of  pre-close transaction services BioCryst performed on behalf of Neopharmed related to the sale of BioCryst Ireland. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September 30, 2025, income tax benefit was $0.8 million compared to income tax expense of $0.6 million for the three months ended September 30, 2024. The increase was primarily driven by the impact of the One Big Beautiful Bill Act (&#8220;OBBBA&#8221;) which was signed into law on July 4, 2025.</span></div><div id="id1b8c440ead54d70904211d3c0a5ea1f_100"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations (nine months ended September 30, 2025 compared to the nine months ended September 30, 2024)</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2025, total revenues were $468.3 million compared to $319.2 million for the</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2024. The increase in total revenues was due to a $136.7 million increase in ORLADEYO net revenue, including royalties, primarily due to an increase in volume of direct sales of ORLADEYO, which was driven by strong patient demand, an increase in price, and an increase in the rate of paid shipments. The increase in total revenues was also due to an increase in other revenues of $12.4 million, primarily due to an increase in direct sales of peramivir.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product sales for the nine months ended September 30, 2025 and 2024 was $9.6 million and $6.2 million, respectively. The increase in cost of product sales was primarily due to the increase in peramivir sales.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our research and development expenses, including program specific costs and shared or indirect operating costs recognized as research and development expenses for the periods indicated (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Berotralstat</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9,214&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10,504&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">BCX17725</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13,346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Avoralstat</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,960&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Factor D Program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,299&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Research, discovery and preclinical programs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11,641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8,325&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and related personnel costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">38,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">42,630&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">24,374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">20,923&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other non-program specific and indirect costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">20,621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">23,965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Total research and development expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">125,259</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">125,197</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We do not maintain or evaluate internal research and development costs on a program-by-program basis. As a result, a significant portion of our research and development expenses are not tracked on a program-by-program basis, as the costs may benefit multiple programs. Beginning with the quarter ended September&#160;30, 2025, we no longer allocate non-program specific external costs or internal costs to programs. These costs are separately presented on the respective line items listed above. Research and development expenses have been reclassified for the nine months ended September 30, 2024 for comparability. There is no impact on total research and development expenses.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased to $125.3 million for the nine months ended September 30, 2025 from $125.2 million for the nine months ended September 30, 2024. The increase was primarily driven by the following:</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$6.8 million increase in BCX17725 primarily due to an increase in manufacturing and clinical operations as we enroll our phase 1 trial in healthy volunteers and patients;</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$3.5 million increase in stock-based compensation expense primarily due an increase in restricted stock unit awards granted and the retirement policy adopted in July 2024; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$3.3 million increase in research, discovery and preclinical programs due to investigational new drug application-enabling activities related to our early-phase pipeline programs; and</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$2.6 million increase in avoralstat due to an increase in manufacturing and clinical startup activities; partially offset by:</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$6.8 million decrease in Factor D Program due to the discontinuation and close-out of the program in 2024;</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$4.6 million decrease in compensation and related personnel costs primarily attributed to a decrease in research and development related headcount;</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$3.3 million decrease in other non-program specific and indirect costs primarily attributed to a decrease in the general and administrative expense allocation due to our commercial progression; and</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$1.3 million decrease in berotralstat primarily attributed to a decrease in costs associated with the APeX-P clinical trial, which is complete through the primary endpoint.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include all direct and indirect expenses relating to research and development activities. Direct expenses consist of compensation for research and development personnel and costs of outside parties to conduct laboratory studies, develop manufacturing processes and manufacture the product candidates, and conduct and manage clinical trials, as well as other costs related to our clinical and preclinical studies. Additionally, direct expenses consist of those costs n</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ecessary to discontinue and close out a development program, including termination fees and other commitments. Indirect expenses consist of lab supplies and services, facility expenses, depreciation of development equipment and other overhead of our research and development efforts. Research and development expenses vary according to the number of programs in clinical development and the stage of development of our clinical programs. Later stage clinical programs tend to cost more than earlier stage programs due to the longer length of time of the clinical trials and the higher number of patients enrolled in these clinical trials.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses for the nine months ended September 30, 2025 were $252.9 million compared to $185.8 million for the nine months ended September 30, 2024. The increase was driven by an increase in ORLADEYO related regulatory, safety and quality activities as efforts shifted from development to supporting commercial products, reflecting the program&#8217;s commercial progression, as well as increases in variable costs driven by the increase in ORLADEYO sales, an increase from a change in general and administrative expense allocations, and an increase in headcount primarily associated with European growth. The increase was also driven by $9.9 million of transaction-related costs and a $13.7 million increase in stock-based compensation expense as a result of the retirement policy adopted in July 2024 and an increase in restricted stock unit awards granted.  </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the nine months ended September 30, 2025 was $64.7 million compared to $74.1 million for the nine months ended September 30, 2024. Interest expense is primarily comprised of non-cash interest expense due to the amortization of interest associated with the royalty financing obligations and interest expense associated with the borrowings under the Pharmakon Loan Agreement, including the amortization of the deferred financing costs, associated with the borrowings under the Pharmakon Loan. The decrease in interest expense was primarily the result of the $75.0 million and $50.0 million partial prepayments on the outstanding principal amount under the Pharmakon Term Loan in April 2025 and July 2025, respectively, the decrease in the effective interest rate related to the Pharmakon Loan Agreement, and a decrease in non-cash interest expense associated with our royalty financing obligations as a result of a lower outstanding balance.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2025, interest income was $7.8 million compared to $11.2 million for the nine months ended September 30, 2024. The decrease in interest income was primarily the result of an overall decrease in our investment portfolio and a decrease in interest rates. Net foreign currency losses were less than $0.1 million for the nine months ended September 30, 2025 and 2024.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In April 2025 and July 2025, the Company made $75.0 million and $50.0 million partial prepayments on the outstanding principal amount under the Pharmakon Term Loan, respectively, resulting in a one-time loss on extinguishment of debt of $6.9 million for the nine months ended September 30, 2025.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2025, other income was $2.7 million, which was primarily comprised of pre-close transaction services BioCryst performed on behalf of Neopharmed related to the sale of BioCryst Ireland. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2025, income tax expense was $1.4 million compared to $1.1 million for the nine months ended September 30, 2024. The increase in income tax expense was primarily driven by the increase in foreign and US taxable income for the nine months ended September 30, 2025 compared to the nine months ended September 30, 2024. </span></div><div id="id1b8c440ead54d70904211d3c0a5ea1f_103"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources of Liquidity</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our operations have principally been funded through public offerings and private placements of equity securities; our credit facilities; revenues from ORLADEYO; royalty financing transactions; and cash from collaborative and other research and development agreements, including U.S. Government contracts. In addition to the above, we have received funding from other sources, including government grants, research grants, and interest income on our investments.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On October 14, 2025, in connection with the Merger Agreement, we entered into the Commitment Letter with Blackstone, pursuant to which Blackstone agreed to provide a $550.0 million senior secured credit facility consisting of (i) the Initial Term Loan in an aggregate principal amount of $350.0 million, (ii) the Committed Delayed Draw Term Loans in an aggregate principal amount not exceeding $50.0 million, and (iii) an uncommitted delayed draw term loan facility in an aggregate principal amount not exceeding $150.0 million. The Initial Term Loan and any Committed Delayed Draw Term Loans funded on the closing date of the Merger will be used for the purpose of, among other things, funding the consideration for the transactions contemplated by the Merger Agreement and paying for related fees and expenses. The commitments with respect to the Initial Term Loan and any Committed Delayed Draw Term Loans funded on the closing date of the Merger are subject to customary conditions for acquisition financings, including the execution and delivery of definitive documentation with respect to the senior secured credit facility in accordance with the terms set forth in the Commitment Letter and the consummation of the Merger. See </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Note 16&#8212;Subsequent Events&#8221;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> in the Notes to Condensed Consolidated Financial Statements in Part I, Item 1 of this report for additional information about the Merger.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On April 17, 2023, we entered into a $450.0 million Loan Agreement (the &#8220;Pharmakon Loan Agre</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ement&#8221;) with BioPharma Credit Investments V (Master) LP and BPCR Limited Partnership, as lenders, and BioPharma Credit PLC, as collateral agent for the lenders. The Pharmakon Loan Agreement provided for an initial term loan in the principal amount of $300.0 million (the &#8220;Tranche A Loan&#8221;), which was funded on April 17, 2023. We utilized a portion of the proceeds from the Tranche A Loan to repay the approximate $241.8 million of outstanding indebtedness under the then-existing credit facility with Athyrium Opportunities III Co-Invest 1 LP (the &#8220;Athyrium Credit Agreement&#8221;) and to pay transaction costs and fees, and we used the remaining net proceeds of approximately $25.8 million for other general corporate purposes. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmakon Loan Agreement also provided for three additional term loan tranches in principal amounts of $50.0 million each, which we could have requested, at our option, on or prior to September 30, 2024. We chose not to request any of the additional term loan tranches. The maturity date of the Pharmakon Loan Agreement was April 17, 2028. On April 18, 2025, we made a partial prepayment of $75.0 million of the outstanding principal amount under the Pharmakon Loan Agreement, and o</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">n July 24, 2025, we made an additional partial prepayment of </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$50.0 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> of the outstanding principal amount under the Pharmakon Loan Agreement. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On October 8, 2025, we used a portion of the proceeds from the sale of the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">European ORLADEYO Business</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> to pay off in full the outstanding principal balance of $198.7 million and terminate the Pharmakon Loan Agreement. Together, these payoffs of the Pharmakon Loan are expected to save approximately $90.0 million of interest, as of September 30, 2025. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In 2020 and 2021, we entered into the Royalty Purchase Agreements (as defined in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7&#8212;Royalty Financing Obligations</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; in the Notes to Condensed Consolidated Financial Statements in Part I, Item 1 of this report) with RPI 2019 Intermediate Finance Trust (&#8220;RPI&#8221;) and OCM IP Healthcare Holdings Limited, an affiliate of OMERS Capital Markets (&#8220;OMERS&#8221;). Under the Royalty Purchase Agreements, RPI and OMERS are entitled to receive tiered, sales-based royalties on net product sales of ORLADEYO in the United State</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">s and certain key European markets (collectively, the &#8220;Key </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Territories&#8221;), and other markets where we sell ORLADEYO directly or through distributors. In addition, RPI and OMERS are entitled to receive a tiered revenue share on amounts generally received by us on account of ORLADEYO sublicense revenue or net sales by licensees outside of the Key Territories. Our required payments to OMERS commenced with the calendar quarter beginning October 1, 2023. See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7&#8212;Royalty Financing Obligations</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; in the Notes to Condensed Consolidated Financial Statements in Part I, Item 1 of this report for additional information about these financing transactions.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our principal sources of liquidity at September&#160;30, 2025 were approximately $267.4 million in cash and cash equivalents and available-for-sale investments, of which $14.8 million was considered held for sale as of September&#160;30, 2025.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for each period presented (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">55,409&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(46,807)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">69,794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">34,796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(131,971)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(1,740)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Effect of exchange rates on cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,342&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Decrease in cash, cash equivalents and restricted cash, including cash classified within current assets held for sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(5,426)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(13,383)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Less: net increase in cash and cash equivalents classified within current assets held for sale</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(14,840)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Net decrease in cash, and cash equivalents, and restricted cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(20,266)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(13,383)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2025, net cash provided by operating activities of $55.4&#160;million consisted primarily of net income of $18.0 million and $107.7&#160;million of non-cash items. Non-cash items included $61.3&#160;million of stock-based compensation expense, $39.8 million of non-cash interest expense on royalty financing obligations, and a loss on extinguishment of debt of $6.9 million. Net income and non-cash items were partially offset by $61.1&#160;million of changes in operating assets and liabilities, primarily due to a decrease in royalty financing obligations and increases in receivables and accounts payable and accrued expenses, and $9.2 million in payments of Pharmakon PIK interest. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2024, net cash used in operating activities of $46.8&#160;million consisted primarily of a net loss of $62.1&#160;million and $76.0&#160;million of changes in operating assets and liabilities, primarily due to a decrease in royalty financing obligations, a decrease in accounts payable and accrued expenses, and an increase in accounts receivable, partially offset by $91.2&#160;million of non-cash items, including $44.1&#160;million of stock-based compensation expense, $42.5 million in non-cash interest expense on royalty financing obligations, and $11.1 million of non-cash interest expense on secured term loan and amortization of debt issuance costs.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2025, net cash provided by investing activities of $69.8&#160;million primarily related to sales and maturities of investment securities, partially offset by purchases of investment securities.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2024, net cash provided by investing activities of $34.8&#160;million primarily related to maturities of investment securities, partially offset by purchases of investment securities.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2025, net cash used in financing activities of $132.0&#160;million primarily consisted of repayment of Pharmakon term loan principal and related prepayment premium and fees totaling $119.6 million, and $16.4 million in principal payments on royalty financing obligations, partially offset by net proceeds from common stock issued under stock-based compensation plans.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2024, net cash used in financing activities of $1.7&#160;million primarily consisted of withholding taxes paid on stock-based awards and principal payments on finance lease liabilities, partially offset by net proceeds from common stock issued under stock-based compensation plans.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Plan of Operation and Future Funding Requirements</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We intend to contain costs and cash flow requirements by closely managing our third-party costs and headcount, leasing scientific equipment and facilities, and contracting with other parties to conduct certain research and development projects. We may incur additional expenses, potentially resulting in significant losses, as we continue to pursue our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">research and development activities, commercialize ORLADEYO, and engage in strategic business development. We may incur additional expenses related to the filing, prosecution, maintenance, defense, and enforcement of patent and other intellectual property claims and additional regulatory costs as our clinical programs advance through later stages of development or as regulatory exclusivity for our products expires. The objective of our investment policy is to ensure the safety and preservation of invested funds, as well as to maintain liquidity sufficient to meet cash flow requirements. We place our excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of our credit exposure. We have not realized any significant losses on our investments.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the future, we may finance our needs principally from the following: </span></div><div style="margin-top:10pt;padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our existing capital resources and interest earned on that capital;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">revenues from product sales; </span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">payments under current or future collaborative and licensing agreements with corporate partners; </span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lease, royalty, or loan financing; and</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">public or private equity and/or debt financing.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our current and planned clinical trials, plus the related development, manufacturing, regulatory approval process requirements, and additional resources required for the continuing development of our product candidates and the commercialization of our products will consume significant capital resources and could increase our expenses. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our expenses, revenues and cash utilization rate could vary significantly depending on many factors, including the progress and results of our current and proposed clinical trials for our most advanced product candidates; the progress made in the manufacturing of our lead product candidates; the success of our commercialization efforts for, and market acceptance of, our products; the overall progression of our other programs; our business development activities; the amount of funding or assistance, if any, we receive from new partnerships with third parties for the development and/or commercialization of our products and product candidates; the development progress of any collaborative agreements for our product candidates; and the amount and timing of funding we receive, if any, from U.S. Government contracts. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Based on our expectations for revenue and operating expenses, we believe our financial resources will be sufficient to fund our operations for at least the next 12 months. We did not draw down the additional debt available to us under the Pharmakon Loan Agreement, and, on October 8, 2025, we prepaid the remaining outstanding principal amount on the Pharmakon Loan Agreement.  In connection with the Merger Agreement, we entered into the Commitment Letter </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">with Blackstone, pursuant to which Blackstone agreed to provide a $550.0 million senior secured credit facility, subject to customary conditions for acquisition financings, including the execution and delivery of definitive documentation with respect to the senior secured credit facility in accordance with the terms set forth in the Commitment Letter and the consummation of the Merger.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our liquidity needs will be largely determined by the success of operations in regard to the successful commercialization of our products and the future progression of our product candidates. From time to time, we evaluate other opportunities to fund future operations, including: (1) out-licensing rights to certain of our products or product candidates, pursuant to which we would receive cash milestone payments; (2) royalty or other monetization transactions; (3) obtaining additional product candidate regulatory approvals, which would generate revenue, milestone payments and cash flow; (4) reducing spending on one or more research and development programs, including by discontinuing development; (5) restructuring operations to change our overhead structure; and/or (6) securing U.S. Government funding of our programs, including obtaining procurement contracts. We may, in the future, issue securities, including common stock, preferred stock, depositary shares, purchase contracts, warrants, debt securities, and units, through private placement transactions or registered public offerings. Our future liquidity needs, and our ability to address those needs, will largely be determined by the success of our products and product candidates; the timing, scope, and magnitude of our research and development and commercial expenses; and key developments and regulatory events and our decisions in the future.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our long-term capital requirements and the adequacy of our available funds will depend upon many factors, including:</span></div><div style="margin-top:10pt;padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sustained market acceptance of approved products and successful commercialization of such products by either us or our partners;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to perform under any government contracts and to receive reimbursement and stockpiling procurement contracts;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress and magnitude of our research, drug discovery and development programs;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in existing collaborative relationships;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish additional collaborative relationships with academic institutions, biotechnology or pharmaceutical companies, and governmental agencies or other third parties;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which our partners will share in the costs associated with the development of our programs or run the development programs themselves;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to negotiate favorable development and marketing strategic alliances for certain products and product candidates;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any decision to build or expand internal development and commercial capabilities;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope and results of preclinical studies and clinical trials to identify and develop product candidates;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to engage sites and enroll subjects in our clinical trials;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of manufacturing of our products to support our commercial operations and of our product candidates to support our preclinical research and clinical trials;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increases in personnel and related costs to support the development and commercialization of our products and product candidates;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of manufacturing of our drug substance and product candidates required for future new drug application (&#8220;NDA&#8221;) filings;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competitive and technological advances;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the time and costs involved in obtaining regulatory approvals;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">post-approval commitments for any products that receive regulatory approval; </span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our business development activities; and</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs involved in all aspects of intellectual property strategy and protection, including the costs involved in preparing, filing, prosecuting, maintaining, defending, and enforcing patent claims.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We may, in the future, be required to raise additional capital to complete the development and commercialization of our products and product candidates, and we may seek to raise capital in the future, including to take advantage of favorable opportunities in the capital markets. Additional funding may not be available when needed or in the form or on terms acceptable to us. Our future working capital requirements, including the need for additional working capital, will largely be determined by the advancement of our portfolio of product candidates and the commercialization of ORLADEYO. More specifically, our working capital requirements will be dependent on the number, magnitude, scope and timing of our development programs; regulatory approval of our product candidates; the cost, timing and outcome of regulatory reviews, regulatory investigations, and changes in regulatory requirements; the costs of obtaining patent protection for our product candidates; the timing and terms of business development activities; the rate of technological advances relevant to our operations; the efficiency of manufacturing processes developed on our behalf by third parties; the timing, scope and magnitude of commercial spending; and the level of required administrative support for our daily operations. See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors&#8212;Risks Relating to Our Business&#8212;Financial and Liquidity Risks</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors&#8212;Risks Relating to Our Business&#8212;Risks Relating to Drug Development and Commercialization&#8212;If we fail to obtain additional financing or acceptable partnership arrangements if and when needed, we may be unable to complete the development and commercialization of our products and product candidates or continue operations</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; in Part II, Item 1A of this report for further discussion of the risks related to obtaining additional capital. </span></div><div id="id1b8c440ead54d70904211d3c0a5ea1f_106"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have established various accounting policies that govern the application of U.S. GAAP, which were utilized in the preparation of our condensed consolidated financial statements. Certain accounting policies involve significant judgments and assumptions by management that have or are reasonably likely to have a material impact on the carrying value of certain assets and liabilities. Management considers such accounting policies to be critical accounting policies. The judgments and assumptions used by management are based on historical experience and other factors, which are believed to be reasonable under the circumstances. Because of the nature of the judgments and assumptions made by management, actual results could differ from these judgments and estimates, which could have a material impact on the carrying values of assets and liabilities and the results of operations.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">While our significant accounting policies are more fully described in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1&#8212;Significant Accounting Policies and Concentrations of Risk</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; in the Notes to Condensed Consolidated Financial Statements in Part I, Item 1 of this report, we believe that the following accounting policies are the most critical to aid you in fully understanding and evaluating our reported financial results and affect the more significant judgments and estimates that we use in the preparation of our financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, we recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, Topic 606 includes provisions within a five-step model that includes (i) identifying the contract with a customer, (ii) identifying the performance obligations in the contract, (iii) determining the transaction price, (iv) allocating the transaction price to the performance obligations, and (v) recognizing revenue when, or as, an entity satisfies a performance obligation.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, we identify the goods or services promised within each contract, assess whether each promised good or service is distinct, and determine those that are performance obligations. We recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Sales, Net</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our principal sources of product sales are sales of ORLADEYO, which we began shipping to patients in December 2020, and sales of peramivir. In the United States, we generally ship ORLADEYO directly to patients through a single specialty pharmacy, which is considered our customer. Outside the United States, we sell ORLADEYO to specialty distributors and to hospitals and pharmacies, which collectively are considered our customers.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue for sales when the customer obtains control of the product, which generally occurs upon delivery. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue from sales of ORLADEYO is recorded at net selling price (transaction price), which includes reserves for variable consideration such as (i) estimated government rebates, such as Medicaid and Medicare Part D reimbursements, and estimated managed care rebates, (ii) estimated chargebacks, (iii) estimated costs of co-payment assistance programs, and (iv) product returns. These reserves, representing our best estimates of the amount of consideration to which we are entitled based on the terms of the applicable contracts and statutory requirements, are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable if no payments are required of us or a current liability if a payment is required of us. Actual amounts of consideration may differ from our estimates. If actual results vary from estimates, these estimates are adjusted, which would affect net product revenue and earnings in the period such variances become known.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government and Managed Care Rebates</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. We contract with government agencies and managed care organizations or, collectively, third-party payors, so that ORLADEYO will be eligible for purchase by, or partial or full reimbursement from, such third-party payors. We estimate the rebates we will provide to third-party payors and deduct these estimated amounts from total gross product revenues at the time the revenues are recognized, resulting in a reduction of product revenue and the establishment of a current liability. We estimate the rebates that we will provide to third-party payors based upon (i) our contracts with these third-party payors, (ii) the government mandated discounts applicable to government-funded programs, and (iii) product distribution information obtained from our specialty pharmacy regarding payor mix.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chargebacks</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Chargebacks are discounts that occur when certain contracted customers, pharmacy benefit managers, insurance companies, and government programs purchase directly from our specialty pharmacy. These customers purchase our product under contracts negotiated between them and our specialty pharmacy. The specialty pharmacy, in turn, charges back to us the difference between the price that the specialty pharmacy paid and the negotiated price paid by the contracted customers, which may be higher or lower than the specialty pharmacy&#8217;s purchase price with us. We estimate chargebacks and adjust gross product revenues and establish a current liability at the time revenues are recognized.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Co-payment assistance and patient assistance programs</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. Based upon the terms of the program and co-payment assistance utilization reports received from the specialty pharmacy, we estimate the co-payment assistance amounts, which are recorded in the same period in which the related revenue is recognized, resulting in a reduction of product revenue and establishment of a current liability. We also offer a patient assistance program that provides free drug product, for a limited period of time, to allow a patient&#8217;s insurance coverage to be established. Based on patient assistance program utilization reports provided by the specialty pharmacy, we record gross revenue of the product provided and a full reduction of the revenue amount for the free drug discount.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product returns</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. We do not provide contractual return rights to our customers, except in instances where the product is damaged or defective. Non-acceptance by the patient of shipped drug product by the specialty pharmacy is reflected as a reversal of sales in the period in which the sales were originally recorded. Reserves for estimated non-acceptances by patients are recorded as a reduction of revenue in the period that the related revenue is recognized, as well as a reduction to accounts receivable. Estimates of non-acceptance are based on quantitative information provided by the specialty pharmacy.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Revenues</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have collaboration and license agreements with a number of third parties. Our primary sources of revenue from these collaborative and other research and development arrangements are license, service and royalty revenues.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from license fees, royalty payments, milestone payments, and research and development fees are recognized as revenue when the earnings process is complete and we have no further continuing performance obligations or we have completed the performance obligations under the terms of the agreement.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Arrangements that involve the delivery of more than one performance obligation are initially evaluated as to whether the intellectual property licenses granted by us represent distinct performance obligations. If they are determined to be distinct, the value of the intellectual property licenses would be recognized up front while the research and development service fees would be recognized as the performance obligations are satisfied. For performance obligations based on services performed, we measure progress using an input method based on the effort we expend or costs we incur toward the satisfaction of the performance obligation in relation to the total estimated effort or costs. Variable consideration is assessed at each reporting period as to whether it is not subject to significant future reversal and, therefore, should be included in the transaction price at the inception of the contract. If a contract includes a fixed or minimum amount of research and development support, this also would be included in the transaction price. Changes to collaborations, such as the extensions of the research term or increasing the number of targets or technology covered under an existing agreement, are assessed for whether they represent a modification or should be accounted for as a new contract. For contracts with multiple performance obligations, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which we separately sell the products or services. If a standalone selling price is not directly observable, then we estimate the standalone selling price using either an adjusted market assessment approach or an expected cost plus margin approach, representing the amount that we believe the market is willing to pay for the product or service. Analyzing the arrangement to identify performance obligations requires the use of judgment, and each may be an obligation to deliver services, a right or license to use an asset, or another performance obligation. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under certain of our license agreements, we receive royalty payments based upon our licensees&#8217; net sales of covered products. Royalties are recognized at the later of when (i) the subsequent sale or usage occurs, or (ii) the performance obligation to which some or all of the sales-based or usage-based royalty has been satisfied.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our inventory primarily relates to ORLADEYO. Our inventory also includes peramivir.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We value our inventory at the lower of cost or estimated net realizable value. We determine the cost of our inventory on a first-in, first-out (FIFO) basis. Raw materials and work-in-process include all inventory costs prior to packaging and labeling, including raw material, active product ingredient, and the drug product. Finished goods include packaged and labeled products. We classify inventory as long-term when consumption or sale of the inventory is not expected to occur within 12 months from the balance sheet date.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our inventory is subject to expiration dating. At each reporting date, we evaluate the carrying value of our inventory and provide valuation reserves for any estimated excess, obsolete, short-dated or unmarketable inventory. In addition, we may experience spoilage of our raw materials and supplies. Our determination that a valuation reserve might be required, in addition to the quantification of such reserve, requires us to utilize significant judgment. Additionally, our inventory is subject to strict quality control and monitoring that is performed throughout the manufacturing process, including release of work-in-process to finished goods. In the event that certain batches or units of product do not meet quality specifications, we will record a write-down of any potential unmarketable inventory to its estimated net realizable value and record the expense as cost of product in the Condensed Consolidated Statements of Comprehensive Income (Loss).</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prior to obtaining initial regulatory approval for an investigational product candidate, we expense costs relating to production of pre-launch inventory as research and development expense in our Condensed Consolidated Statements of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive Income (Loss) in the period incurred. After regulatory approval has been received, we capitalize inventory costs.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses and Related Accruals</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by clinical research organizations (&#8220;CROs&#8221;), materials and supplies, and overhead allocations consisting of various administrative and facilities related costs, as well as termination fees and other commitments associated with discontinued programs. Most of our manufacturing and clinical and preclinical studies are performed by third-party CROs. Our research and development costs are charged to expense when incurred. Research and development expenses include all direct and indirect development costs related to the development of our portfolio of product candidates. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of costs associated with research activities as well as those associated with our product development efforts, conducting pre-clinical trials, clinical trials and manufacturing activities. Direct expenses consist of compensation for research and development personnel and costs of outside parties to conduct laboratory studies, develop manufacturing processes and manufacture the product candidate, conduct and manage clinical trials, as well as other costs related to our clinical and preclinical studies. Additionally, direct expenses consist of those costs necessary to discontinue and close out a development program, including termination fees and other commitments. Indirect expenses consist of lab supplies and services, facility expenses, depreciation of development equipment and other overhead of our research and development efforts. These costs apply to our discovery research efforts.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued research and development expenses. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel to identify services that have been performed on its behalf and estimating the actual work completed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of actual cost. The majority of our service providers invoice us monthly in arrears for services performed. We periodically confirm the accuracy of our estimates with the service providers and make adjustments if necessary. When evaluating the adequacy of accrued expenses, we consider facts and circumstances known to us at the time, which can include assumptions such as expected patient enrollment, site activation and estimated project duration. Examples of estimated accrued research and development expenses include (i) fees paid to CROs in connection with preclinical and toxicology studies and clinical trials, (ii) fees paid to investigative sites in connection with clinical trials, (iii) fees paid to contract manufacturers in connection with the production of our raw materials, drug substance, drug products, and product candidates, and (iv) professional fees. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The financial terms of our agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of milestones. We record liabilities under these contractual commitments when we determine an obligation has been incurred, regardless of the timing of the invoice. In expensing service fees, we estimate the time period over which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we will adjust the accrual accordingly. If we do not identify costs that we have begun to incur or if we underestimate or overestimate the level of these costs, our actual expenses could differ from our estimates. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in our Condensed Consolidated Statements of Comprehensive Income (Loss) based on their fair values. Stock-based compensation cost is estimated at the grant date based on the fair value of the award and is recognized as expense on a straight-line basis over the requisite service period of the award. Determining the appropriate fair value model and the related assumptions for the model requires judgment, including estimating the stock price volatility, and the expected term. We utilize the Black-Scholes option-pricing model to value our stock option awards and recognize compensation expense on a straight-line basis over the requisite service period. We reduce stock-based compensation expense for estimated forfeitures. The estimation of share-based payment awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from our current estimates, such amounts will be recorded as a cumulative adjustment in the period estimates are revised. Actual results, and future changes in estimates, may differ substantially from our current estimates.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense and Royalty Financing Obligations</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The royalty financing obligations are eligible to be repaid based on royalties from net sales of ORLADEYO. Interest expense is accrued using the effective interest rate method over the estimated period each of the related liabilities will be paid. This requires us to estimate the total amount of future royalty payments to be generated from product sales over the life of the agreement. We impute interest on the carrying value of each of the royalty financing obligations and record interest expense using an imputed effective interest rate. We reassess the expected royalty payments each reporting period and account for any changes through an adjustment to the effective interest rate on a prospective basis. The assumptions used in determining the expected repayment term of the debt and amortization period of the issuance costs requires that we make estimates that could impact the carrying value of each of the liabilities, as well as the periods over which associated issuance costs will be amortized. A significant increase or decrease in forecasted net sales could materially impact each of the liability balances, interest expense and the time periods for repayment.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The liability method is used in our accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Significant management judgment is required in determining our provision for income taxes, deferred tax assets and liabilities and any valuation allowance recorded against net deferred tax assets. We have recorded a valuation allowance against substantially all potential tax assets, due to uncertainties in our ability to utilize deferred tax assets, primarily consisting of certain net operating losses carried forward, before they expire. The valuation allowance is based on estimates of future earnings in each of the jurisdictions in which we operate and the period over which our deferred tax assets will be recoverable.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We account for uncertain tax positions in accordance with U.S. GAAP. Uncertain tax positions are recorded based upon certain recognition and measurement criteria. We re-evaluate uncertain tax positions and consider various factors, including, but not limited to, changes in tax law and the measurement of tax positions taken or expected to be taken in tax returns. We adjust the amount of the liability to reflect any subsequent changes in the relevant facts and circumstances surrounding the uncertain tax positions. We recognize interest and penalties related to income tax matters in income tax expense.</span></div><div id="id1b8c440ead54d70904211d3c0a5ea1f_109"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1&#8212;Significant Accounting Policies and Concentrations of Risk</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; in the Notes to Condensed Consolidated Financial Statements included in Part I, Item 1 of this report discusses accounting pronouncements recently issued or proposed but not yet required to be adopted.</span></div><div id="id1b8c440ead54d70904211d3c0a5ea1f_112"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to interest rate risk on our investment portfolio. We invest in marketable securities in accordance with our investment policy. The primary objectives of our investment policy are to preserve capital, maintain proper liquidity to meet operating needs and earn a competitive level of return. Our investment policy specifies credit quality standards for our investments and limits the amount of credit exposure to any single issue, issuer or type of investment. We place our excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of credit exposure. Some of the securities we invest in may have market risk. This means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our investment exposure to market risk for changes in interest rates relates to the increase or decrease in the amount of interest income we can earn on our portfolio, changes in the market value due to changes in interest rates and other market factors, as well as the increase or decrease in any realized gains and losses. Our investment portfolio includes only marketable securities and instruments with active secondary or resale markets to help ensure portfolio liquidity. A hypothetical 100 basis point increase or decrease in interest rates along the entire interest rate yield curve would not significantly affect the fair value of our interest sensitive financial instruments, including our borrowings, but may affect our future earnings and cash flows. We generally have the ability to hold our fixed-income investments to maturity and, therefore, do not expect that our operating results, financial position or cash flows will be materially impacted due to a sudden change in interest rates. However, our future investment income may fall short of expectations due to changes in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">interest rates, or we may suffer losses in principal if forced to sell securities which have declined in market value due to changes in interest rates or other factors, such as changes in credit risk related to the securities&#8217; issuers. To minimize this risk, we schedule our investments to have maturities that coincide with our expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, we do not believe that we have material exposure to interest rate risk arising from our investments. Generally, our investments are not collateralized. We have not realized any significant losses from our investments.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We do not use interest rate derivative instruments to manage exposure to interest rate changes. We ensure the safety and preservation of invested principal funds by limiting default risk, market risk and reinvestment risk. We reduce default risk by investing exclusively in investment grade securities.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Risk</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Most of our revenues and expenses are denominated in U.S. dollars. Our royalties from Torii are in Japanese Yen. We also had other transactions denominated in foreign currencies during the nine months ended September 30, 2025, primarily related to operations in Europe, contract manufacturing and ex-U.S. clinical trial activities, and we expect to continue to do so. Our limited foreign currency exposure relative to our operations is to fluctuations in the Euro, British Pound, and Canadian Dollar.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We do not anticipate that foreign currency transaction gains or losses will be significant at our current level of operations. We have not engaged in foreign currency hedging during the nine months ended September 30, 2025; however, we may do so in the future. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inflation Risk</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inflation generally impacts us by potentially increasing our operating expenses, including cost of product sales, clinical trial costs and selling activities. We do not believe that inflation has had a material impact on our business or results of operations during the periods for which the condensed consolidated financial statements are presented in this report. Significant adverse changes in inflation could negatively impact our future results of operations.</span></div><div id="id1b8c440ead54d70904211d3c0a5ea1f_115"></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.&#160;&#160;&#160;&#160;Controls and Procedures</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a set of disclosure controls and procedures that are designed to ensure that information relating to the Company required to be disclosed in our periodic filings under the Exchange Act is recorded, processed, summarized and reported in a timely manner under the Exchange Act. We carried out an evaluation, under the supervision and with the participation of management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that, as of September&#160;30, 2025, the Company&#8217;s disclosure controls and procedures are effective to ensure that information required to be disclosed by the Company in the reports filed or submitted by it under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and include controls and procedures designed to ensure that information required to be disclosed by the Company in such reports is accumulated and communicated to the Company&#8217;s management, including the Chief Executive Officer and Chief Financial Officer of the Company, as appropriate to allow timely decisions regarding required disclosure.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in our internal control over financial reporting that occurred during the three months ended September 30, 2025 that have materially affected, or are reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">50</span></div></div></div><div id="id1b8c440ead54d70904211d3c0a5ea1f_118"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="id1b8c440ead54d70904211d3c0a5ea1f_121"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, in January 2025, we received a Paragraph IV notice of certification (the &#8220;Notice Letter&#8221;) from Annora Pharma Private Limited (&#8220;Annora&#8221;) advising that Annora has submitted an Abbreviated New Drug Application (&#8220;ANDA&#8221;) to the FDA seeking approval to manufacture, use or sell a generic version of ORLADEYO in the United States prior to the expiration of three patents listed in the FDA&#8217;s Orange Book: U.S. Patent Nos. 10,662,160; 11,117,867; and 11,618,733 (the &#8220;Challenged Patents&#8221;). The Notice Letter alleges that the Challenged Patents, which expire in 2039, are invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of the generic product described in Annora&#8217;s ANDA. The Notice Letter does not challenge the following six ORLADEYO Orange Book patents that expire in 2035: U.S. Patent Nos. 10,125,102; 10,329,260; 10,689,346; 11,230,530; 11,708,333; and 12,116,346.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On March 10, 2025, we &#64257;led a patent infringement lawsuit in the United States District Court for the District of Delaware against Annora, Hetero Labs Limited, Hetero USA, Inc., and Camber Pharmaceuticals, Inc. (collectively, the &#8220;Defendants&#8221;), asserting infringement of the Challenged Patents arising from Annora&#8217;s ANDA filing with the FDA. We are seeking, among other remedies, equitable relief enjoining the Defendants from infringing the Challenged Patents, as well as an order that the e&#64256;ective date of any FDA approval of the ANDA would be a date no earlier than the expiration of the Challenged Patents (including any regulatory extensions). We intend to vigorously defend our intellectual property rights protecting ORLADEYO.</span></div><div id="id1b8c440ead54d70904211d3c0a5ea1f_124"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">An investment in our stock involves risks. You should carefully read this entire report and consider the following uncertainties and risks, which may adversely affect our business, financial condition or results of operations, along with all of the other information included in our other filings with the SEC, before making an investment decision regarding our common stock. Additionally, while some of the factors, events and contingencies described herein may have occurred in the past, the disclosures herein are not representations as to whether or not they have occurred and are instead provided because future occurrences thereof could adversely affect the Company.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to Our Business</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Financial and Liquidity Risks</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not achieve sustained profitability.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have not achieved sustained profitability. Our expectations as to the sustainability of our profitability may change based upon our ability to execute our commercialization goals and operational initiatives and whether or not the assumptions underlying our projected revenues and expenses are correct. Our beliefs and projections regarding the attainment of our financial goals may differ from actual results based on market factors like competition, patient and physician acceptance of our products, reimbursement levels, or on our ability to execute our operational and budget plans, including management&#8217;s ability to properly forecast our capital allocation needs. To achieve sustained profitability, we, or our collaborative partners, must successfully manufacture and develop or acquire products and product candidates, receive regulatory approvals, and successfully commercialize our products and/or enter into profitable commercialization arrangements with other parties. Even if we are able to successfully commercialize our existing products, or to develop or otherwise acquire new commercially viable products, certain obligations we have to third parties, including, without limitation, our obligation to pay RPI and OMERS, as applicable, royalties on certain revenues from ORLADEYO under the Royalty Purchase Agreements (as defined in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7&#8212; Royalty Financing Obligations</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; in the Notes to Condensed Consolidated Financial Statements in Part I, Item 1 of this report), may reduce the profitability of such products.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with developing or acquiring product candidates, launching new products, and their potential for commercialization, we are unable to predict the extent of any future losses. Even though we have achieved profitability in a given reporting period, we may not be able to sustain or increase profitability on a quarterly or annual basis. If we are unable to achieve sustained profitability on our anticipated timeline, or at all, the market value of our common stock will likely decline.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need to raise additional capital in the future. If we are unable to raise capital if and when needed, we may need to adjust our operations.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have sustained operating losses for the majority of our corporate history. Even if we achieve sustained profitability, in order to continue future operations, progress our drug discovery and development programs, engage in strategic business development activities, and commercialize our products and product candidates, we may be required to raise additional capital in the future. In addition to seeking strategic partnerships and transactions, we may access the equity or debt markets, incur additional borrowings, pursue royalty or other monetization transactions, or seek other sources of funding to meet liquidity needs at any time, including to take advantage of attractive opportunities in the capital markets. Additional funding, whether through additional sales of securities, additional borrowings, royalty or other monetization transactions, collaborative arrangements with partners, or from other sources, may not be available if or when needed or in a form or on terms acceptable to us. The issuance of preferred or common stock or convertible securities, with terms and prices significantly more favorable than those of our currently outstanding common stock, could have the effect of diluting or adversely affecting the holdings or rights of our existing stockholders. Additional borrowings may subject us to more restrictive covenants than were applicable to us under the Pharmakon Loan Agreement. In addition, collaborative arrangements may require us to transfer certain material rights to our corporate partners. Insufficient funds or lack of an acceptable partnership have in the past, and may again in the future, require us to delay, scale-back or eliminate certain of our research and development programs. See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Relating to Our Business&#8212;Risks Relating to Drug Development and Commercialization&#8212;If we fail to obtain additional financing or acceptable partnership arrangements if and when needed, we may be unable to complete the development and commercialization of our products and product candidates or continue operations</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; in this section for further discussion of the capital requirements for our development and commercialization efforts.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our liquidity needs will largely be determined by the success of operations in regard to the commercialization of our products, particularly ORLADEYO, the progression of our product candidates in the future, and our ability to execute our budget plans. Our current plans for managing our liquidity needs primarily include controlling the timing and spending on our research and development programs and commercializing our approved products. See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Liquidity and Capital Resources</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; in Part I, Item 2 of this report for additional information about our liquidity needs, capital requirements, potential funding alternatives, and adequacy of available funds.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that any of our plans will be successful or that additional capital will be available to us on reasonable terms, or at all, if needed. If we are unable to obtain sufficient additional capital if and when needed, we may be forced to adjust or curtail our operations; delay, reduce, or stop ongoing clinical trials or commercialization efforts; cease operations altogether; or file for bankruptcy.</span></div><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Risks Relating to the Proposed Merger</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to complete the Merger could negatively impact us.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Merger Agreement is subject to a number of conditions which must be fulfilled in order to complete the Merger. If the Merger is not completed for any reason, there may be various adverse consequences and we may experience negative reactions from the financial markets and from our counterparties and employees. For example, if the Merger is not completed we will not realize any of the anticipated benefits of the Merger, and our business may be impacted adversely by the failure to pursue other beneficial opportunities due to the focus of our management on the Merger. Additionally, if the Merger Agreement is terminated, the market price of our common stock could decline to the extent that current market prices reflect a market assumption that the Merger will be beneficial and will be completed. We also could be subject to litigation related to any failure to complete the Merger or to proceedings commenced against us to perform our obligations under the Merger Agreement.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we have incurred and will incur substantial expenses relating to negotiation and completion of the transactions contemplated by the Merger Agreement. If the Merger is not completed, we would have to recognize these expenses without realizing the expected benefits of the Merger.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will be subject to business uncertainties, disruptions and contractual restrictions while the Merger is pending.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Uncertainty about the effect of the Merger on employees, suppliers, vendors and other counterparties may have an adverse effect on our business, financial condition and results of operations. These uncertainties may impair our ability to attract, retain and motivate key personnel and counterparties pending the completion of the Merger, as such personnel and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">counterparties may experience uncertainty about their future roles and relationships following the completion of the Merger. Additionally, these uncertainties could cause suppliers, vendors and other counterparties to seek to change existing business relationships with us or fail to extend an existing relationship with us, as applicable. In addition, competitors may target our existing personnel and counterparties by highlighting potential uncertainties and integration difficulties that may result from the Merger.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The pursuit of the Merger and the preparation for the integration may place a burden on our management and internal resources. Any significant diversion of management attention away from ongoing business concerns and any difficulties encountered in the transition and integration process could have an adverse effect on our business, financial condition and results of operations.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Merger Agreement restricts us from taking certain actions without Astria&#8217;s consent while the Merger is pending. These restrictions could prevent us from pursuing attractive business opportunities that may arise prior to completion of the Merger.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the benefits of the Merger do not meet the expectations of investors or securities analysts, the market price of our common stock may decline.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock may decline as a result of the Merger if we do not achieve the perceived benefits of the Merger as rapidly or to the extent anticipated by financial analysts or the effect of the Merger on our financial results is not consistent with the expectations of financial analysts. Accordingly, holders of our common stock following the consummation of the Merger may experience a loss as a result of a decline in the market price of such common stock. In addition, a decline in the market price of our common stock following the consummation of the Merger could adversely affect our ability to issue additional securities if needed and to obtain additional financing in the future.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Combining Astria with our business may be more difficult, costly or time consuming than expected and the combined company following completion of the Merger (the &#8220;combined company&#8221;) may fail to realize the anticipated benefits and cost savings of the Merger.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The success of the Merger will depend, in part, on the ability to realize the anticipated benefits and cost savings from combining our business and Astria&#8217;s business. To realize the anticipated benefits and cost savings from the Merger, we and Astria must successfully integrate and combine our businesses in a manner that permits those benefits and costs savings to be realized. If we and Astria are not able to successfully achieve these objectives, the anticipated benefits of the Merger may not be realized fully or at all or may take longer to realize than expected. In addition, the actual cost savings and anticipated benefits of the Merger could be less than anticipated, and integration may result in additional unforeseen expenses.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">An inability to realize the full extent of the anticipated benefits of the Merger and the other transactions contemplated by the Merger Agreement, as well as any delays encountered in the integration process, could have an adverse effect on the revenues, levels of expenses and operating results of the combined company following the completion of the Merger, which may adversely affect the value of the common stock of the combined company following the completion of the Merger.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We and Astria have operated and, until the completion of the Merger, must continue to operate, independently. It is possible that the integration process could result in the loss of key employees, the disruption of each company&#8217;s ongoing business or inconsistencies in standards, controls, procedures and policies that adversely affect each company&#8217;s ability to maintain relationships with employees and counterparties or to achieve the anticipated benefits and cost savings of the Merger. Integration efforts may also divert management attention during this transition period and for an undetermined period after completion of the Merger, which may have an adverse effect on the combined company.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The combined company will likely incur substantial expenses related to the Merger.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We expect that the combined company will incur substantial expenses in connection with completion of the Merger and combining the business, operations, networks, systems, technologies, policies and procedures of the two companies. Although we and Astria have assumed that a certain level of transaction and combination expenses will be incurred, there are a number of factors beyond our control that could affect the total amount or the timing of our combination expenses. Many of the expenses that will be incurred are, by their nature, difficult to estimate accurately at the present time. We expect to incur these expenses before and after the completion of the Merger. The charges taken in connection with the Merger are expected to be significant, although the aggregate amount and timing of such charges are uncertain at present. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that the anticipated benefits related to the integration of Astria with our business will be realized to offset these transaction and integration expenses over time.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issuance of shares of our common stock in connection with the Merger may adversely affect the market price of our common stock.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the payment of the merger consideration as contemplated by the Merger Agreement, we may issue up to 19.9% of the shares of our common stock issued and outstanding immediately prior to the effective time of the Merger. Based on 210,543,224 shares outstanding as of October 31, 2025, that maximum number is 41,898,101 shares. The issuance of these new shares of our common stock may result in fluctuations in the market price of our common stock, including a stock price decrease. In addition, following the closing of the Merger, former Astria stockholders or holders of other Astria securities may decide not to hold the shares of our common stock that they receive in or in connection with the Merger, and our stockholders may decide to reduce their investment in us as a result of the changes to our investment profile as a result of the Merger, which may result in further fluctuations in the market price of our common stock, including a stock price decrease.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Risks Relating to Drug Development and Commercialization</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success depends in part upon our ability to manage our product candidate pipeline, advance our product candidates through the various stages of development, especially through the clinical trial process, and to receive regulatory approvals for the commercial sale of our product candidates.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The success of our business depends in part upon our ability to manage our product candidate pipeline, including through expanding the pipeline, as appropriate, through our internal identification and discovery of product candidates or otherwise in-licensing or acquiring products or product candidates and integrating them into our business effectively and efficiently; advancing our product candidates through the various stages of development; and receiving regulatory approvals for the commercial sale of our product candidates. Identifying, selecting, and in-licensing or acquiring products or product candidates requires substantial expense and technical and financial expertise, and if we are unable to effectively manage our pipeline or integrate viable products or product candidates into our business on acceptable terms, or at all, our business and drug development efforts could suffer.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">To receive the regulatory approvals necessary for the commercial sale of our product candidates, we or our partners must demonstrate through preclinical studies and clinical trials that each product candidate is safe and effective. The development process and related regulatory process are complex and uncertain. The preclinical and clinical development of our product candidates is susceptible to the risk of failure inherent at any stage of drug development, including failure to demonstrate efficacy and safety, failure to demonstrate adequate benefit-risk balance, failure to achieve a commercially attractive and competitive product label, failure to achieve approval in commercially attractive indications, the occurrence of adverse events that are severe or medically or commercially unacceptable, our or our partners&#8217; failure to comply with trial protocols, applicable regulatory requirements, or industry standards, or a determination by the FDA or any comparable foreign regulatory authority that a product candidate may not continue development or be approved in accordance with our development plans or at all. The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. For example, any successful results of our preclinical and early clinical work for avoralstat, BCX17725 and our early-stage discovery programs do not guarantee the success of later clinical trials. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and for some product candidates, there may not be an ideal model for preclinical testing. We also cannot guarantee that any preclinical studies and clinical trials will be conducted as planned or completed on schedule, if at all, or that the results of such trials will be sufficient to support regulatory approval for our product candidates.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Progression of our product candidates through the clinical development process is dependent upon our trials indicating that our product candidates have adequate safety and efficacy in the patients being treated by achieving predetermined safety and efficacy endpoints according to the clinical trial protocols, as well as an adequate benefit-risk profile. Failure to achieve any of these endpoints or to show adequate benefit-risk profile in any of our programs has in the past, and could again in the future, result in delays in, modifications to, or discontinuations of our trials or require the performance of additional unplanned trials. If any of our product candidates is associated with adverse events or undesirable side effects or has properties that are unexpected, we may need to abandon development or limit development of that product candidate to certain uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a benefit-risk perspective. Product candidates that initially show promise in clinical or preclinical testing could later be found to be associated with or to cause undesirable or unexpected </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">side effects that could result in substantial modifications or delays in the development plans for our product candidates, significant unexpected costs, or the termination of programs. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the development plans for our product candidates, including our clinical trials, may not be adequately designed or executed, which could negatively affect the outcome and analysis of study results. Because of the cost and duration of clinical trials, we have decided in the past, and may in the future decide, to discontinue development of product candidates for various reasons, including, but not limited to, that such candidates are unlikely to show favorable results in clinical trials, unlikely to help advance a product to the point of a meaningful collaboration, or unlikely to have reasonable commercial potential.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Undesirable or inconclusive data in our preclinical studies and clinical trials or side effects in humans could result in the FDA or foreign regulatory authorities (including, e.g., the European Medicines Agency (&#8220;EMA&#8221;), the Ministry of Health, Labor and Welfare (&#8220;MHLW&#8221;) in Japan, or the United Kingdom&#8217;s Medicines and Healthcare products Regulatory Agency (&#8220;MHRA&#8221;)) refusing to approve a product candidate for any targeted indications or imposing restrictions or warnings that could impact development or the ultimate commercial viability of a product candidate. In addition, the FDA or foreign regulatory authorities may determine that study data from our product candidates necessitates additional studies or study designs which differ from our planned development strategy, and such regulatory authorities may also require patient monitoring and testing or may implement restrictions or other conditions on our development activities, any of which could materially impact the cost and timing of our planned development strategy. We, our partners, the FDA, or foreign regulatory authorities have previously, and may again in the future, pause enrollment in, suspend, or terminate clinical trials at any time if we or they believe the trial participants face unacceptable health risks.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to complete the clinical development process successfully is dependent upon many factors, including, but not limited to:</span></div><div style="margin-top:10pt;padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our or our partners&#8217; ability to secure suitable clinical sites and investigators and to enroll and maintain an adequate number of patients on a timely basis or at all;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patients that enroll in a clinical trial may not comply with the clinical trial protocols or maintain contact with investigators to provide complete data during and after treatment;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our product candidates may not prove to be either safe or effective for our targeted indications, or at all, or may produce unfavorable or inconclusive results;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our partners may decide, or be required by regulatory authorities, to pause enrollment in, suspend, or terminate clinical research for various reasons, including a finding that the participants are being exposed to unacceptable health risks, undesirable side effects or other unexpected characteristics of the product candidate, noncompliance with regulatory requirements or their standards of conduct or evolving guidance, or findings of undesirable effects caused by a chemically or mechanistically similar product or product candidate;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may disagree with our or our partners&#8217; clinical trial protocols or our or their interpretation of data from preclinical studies and clinical trials;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical protocols or study procedures may not be adequately designed or followed by the investigators;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">formulation improvements may not work as expected, which could negatively impact commercial demand for our product candidates;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may fail to approve or subsequently find fault with the manufacturing processes or facilities of third-party manufacturers with which we or our partners enter into agreements for clinical and commercial supplies;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the supply or quantity of raw materials or manufactured product candidates or other materials necessary to conduct development activities may be insufficient, inadequate, or unavailable at an acceptable cost, and we or our partners may experience interruptions in supply;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our or our partners&#8217; development plans may be delayed or changed as a result of changes in development strategy, the impact of new or different regulations, requirements, and guidelines, or other unexpected events or conditions;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of preclinical studies and clinical trials may be greater than we anticipate;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our third-party contractors, including those manufacturing our product candidates or components or ingredients thereof, or conducting clinical trials or laboratory testing on our or our partners&#8217; behalf, may fail to comply with regulatory requirements and industry standards or meet contractual obligations in a timely manner or at all; and</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of any global health epidemic or pandemic, such as COVID-19, on one or more of the foregoing factors.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials are lengthy and expensive. Many of the factors listed above could result in increased clinical development costs or longer clinical development times for any of our programs. We and our partners incur substantial expense for, and devote significant time to, preclinical testing and clinical trials, yet we cannot be certain that the tests and trials will ever result in the commercial sale of a product. Even if we or our partners successfully complete clinical trials for our product candidates, we or our partners might not file the required regulatory submissions in a timely manner or may not receive regulatory approval for the product candidates, which in either case would adversely impact or preclude our ability to generate any revenues from product sales or licensing arrangements. In addition, any product candidate, if approved, may be subject to restrictions on labeling, marketing, distribution, prescribing, and use, which could adversely impact the sales of such product.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our development collaborations with third parties, such as our development partners, contractors and contract research organizations, fail, the development of our product candidates will be delayed or stopped.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We rely heavily upon third parties for many important stages of our product candidate development, including, but not limited to:</span></div><div style="margin-top:10pt;padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">discovery of natural proteins that cause or enable biological reactions necessary for the progression of the disease or disorder;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">execution of certain pharmacology preclinical studies and late-stage development for our compounds and product candidates;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">management of our phase 1, 2 and 3 clinical trials, including medical monitoring, laboratory testing, and data management;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">execution of toxicology studies that may be required to obtain approval for our product candidates;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">formulation improvement strategies and methods;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing the starting materials and drug substance required to formulate our products and the product candidates to be used in our clinical trials, toxicology studies and any potential commercial product; and</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">management of certain regulatory interactions outside of the United States.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our failure to engage in successful collaborations at any one of these stages would greatly impact our business. If we do not license protein targets or inhibitors from academic institutions or from other biotechnology companies on acceptable terms, or at all, our drug development efforts could suffer. Similarly, if the contract research organizations or third-party contractors that conduct our initial or late-stage clinical trials, conduct our toxicology or other studies, manufacture our starting materials, drug substance and product candidates, provide laboratory testing or other services (including clinical operation services) in connection with our clinical trials, provide medical writing services, or assist with our regulatory function breach their obligations to us, perform their services inconsistent with industry standards, or fail to comply with regulatory requirements, this would delay or prevent both the development of our product candidates and the availability of any potential commercial product.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If we lose our relationship with any one or more of these parties, we could experience a significant delay in both identifying another comparable provider and then contracting for its services. We may be unable to retain an alternative provider on reasonable terms, if at all. Even if we locate an alternative provider, it is likely that this provider may need additional time to respond to our needs and may not provide the same type or level of service as the original provider. In addition, any provider that we retain will be subject to applicable FDA current Good Laboratory Practices, current Good Manufacturing Practices (&#8220;cGMP&#8221;), and current Good Clinical Practices, and comparable foreign standards. We do not have control over compliance with these regulations by these providers. Consequently, if these practices and standards are not adhered to by these providers, the development and commercialization of our product candidates could be delayed. If any of the foregoing risks is realized, our business, financial condition and results of operations could be materially adversely affected.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to obtain additional financing or acceptable partnership arrangements if and when needed, we may be unable to complete the development and commercialization of our products and product candidates or continue operations.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As our programs advance, our costs could increase. Our current and planned discovery, development, approval, and commercialization efforts may require significant capital. Our expenses, revenues and cash utilization rate could vary significantly depending on many factors, including: our ability to effectively manage our product candidate pipeline; our ability to obtain regulatory approvals for our product candidates; our ability to maintain regulatory approvals for, successfully commercialize, and achieve sustained market acceptance of our products, including ORLADEYO; our ability to successfully consummate the proposed Merger, as contemplated under the Merger Agreement; our future business development activities; our ability to raise additional capital if needed; our ability to secure partnerships with third parties </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">for our product candidates when deemed advisable; the amount of funding we receive from partnerships with third parties for the development and commercialization of our products and product candidates; the commercial success of our products achieved by our partners; the progress and results of our current and proposed clinical trials for our product candidates; and the progress made in the manufacture of our lead products and the progression of our other programs.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In order to continue future operations, progress our drug discovery and development programs, expand our pipeline, and commercialize our products and product candidates, we may be required to raise additional capital. Our ability to raise additional capital if and when needed may be limited and may greatly depend u</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">pon ou</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">r sustained success in commercializing and maintaining market acceptance of ORLADEYO and the success of our current and future drug development programs, including the progress, timeline and ultimate outcome of such development programs (including, but not limited to, formulation progress, long-term human safety studies, clinical trial investigations, and carcinogenicity, drug-drug interaction, toxicity, or other required studies), as well as any post-approval studies for our products. In addition, constriction and volatility in the equity and debt markets, including as a result of the impacts of inflation, increased interest rates, disruption or instability in the banking industry, geopolitical instability, or public health emergencies such as the COVID-19 pandemic, may restrict our future flexibility to raise capital if and when such needs arise. See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Relating to Our Business&#8212;Financial and Liquidity Risks&#8212;We may need to raise additional capital in the future. If we are unable to raise capital if and when needed, we may need to adjust our operations</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; in this section and &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Liquidity and Capital Resources</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; in Part I, Item 2 of this report for additional information about our liquidity risks and capital requirements.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, we have exposure to many different industries, financing partners and counterparties, including commercial banks, investment banks and partners (which include investors, licensing partners, distribution partners, and others), which may be unstable or may become unstable in the current economic and political environment, including as a result of the impacts of inflation, increased interest rates, disruption or instability in the banking industry, U.S. Government shutdowns, changes in presidential administration in the United States, geopolitical instability, actual or threatened public health emergencies, outbreaks of disease, epidemics or pandemics (such as the COVID-19 pandemic). Any such instability may impact these parties&#8217; ability to fulfill contractual obligations to us, or it might limit or place burdensome conditions upon future transactions with us. Also, it is possible that suppliers may be negatively impacted as a result of economic and political instability. Any such unfavorable outcomes in our current programs or unfavorable economic conditions have in the past and could again place severe downward pressure on the price of our common stock and may decrease opportunities to raise capital in the capital or credit markets, and further could reduce the return available on invested corporate cash, which, if severe and sustained, could have a material and adverse impact on our results of operations and cash flows and limit our ability to continue development and commercialization of our products and product candidates.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our partners do not obtain regulatory approvals for our product candidates or maintain regulatory approvals for our products, we or our partners will not be able to commercialize and sell these products and potential products, which would significantly harm our business because we will receive no revenue.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We or our partners must obtain regulatory approvals before marketing or selling our products. If the FDA or a comparable foreign regulatory authority delays or denies regulatory approval of one of our product candidates, or revokes approval of a previously approved product, we would be unable to market or sell the product in the applicable jurisdiction and would not receive revenue from sales or licensing arrangements related thereto, which could have a material and adverse impact on our business.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The process of preparing for and obtaining regulatory approval in any jurisdiction may be lengthy and expensive, and approval is never certain. Because of the risks and uncertainties inherent to the development process, our product candidates could take a significantly longer time to gain regulatory approval than we expect or may never gain approval. As discussed under &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors&#8212;Risks Relating to Our Business&#8212;Risks Relating to Drug Development and Commercialization&#8212;Our success depends in part upon our ability to manage our product candidate pipeline, advance our product candidates through the various stages of development, especially through the clinical trial process, and to receive regulatory approvals for the commercial sale of our product candidates</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; we and our partners have experienced, and may again in the future</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">experience, any number of unfavorable outcomes during or as a result of preclinical studies and clinical trials that could delay or prevent regulatory approval of our product candidates, or negatively impact our management&#8217;s credibility, our value and our operating results.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Even if the FDA or foreign regulatory authorities approve a product candidate, the approval may limit the indicated uses for a product candidate, impose other restrictions on the product candidate, and/or may require post-approval studies that could impair the commercial viability of a product candidate. Even upon any approval to market our potential products, whether in the United States or internationally, we will continue to be subject to extensive regulatory </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">requirements, as discussed under &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors&#8212;Risks Relating to Our Business&#8212;Legal and Regulatory Risks&#8212;We are subject to various laws and regulations related to our products and product candidates, and if we or our partners do not comply with these laws and regulations, we could face substantial penalties</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221;</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our failure to comply with existing or future regulatory requirements for regulatory approval, or our loss of, or changes to, previously obtained approvals, could impair our ability to generate any revenues from product sales or licensing arrangements, which could have a material adverse effect on our business, financial condition, and results of operations.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We focus primarily on rare diseases, which may create additional risks and challenges, including that the target patient populations of our products and product candidates may be small.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Because we focus primarily on developing drugs as treatments for rare diseases, we may seek orphan drug, breakthrough therapy or fast track designations for our product candidates in the United States or the equivalent designations elsewhere in the world. Often, regulatory authorities have broad discretion in determining whether or not to grant such designations. We cannot guarantee that our product candidates will receive orphan drug status from the FDA or equivalent designations from other regulatory authorities. Even with an orphan drug designation for our current and potential future product candidates, we may not be the first to obtain marketing approval for any particular orphan indication due to the uncertainties associated with developing pharmaceutical products. Further, even if we obtain orphan drug exclusivity for an existing or future product candidate, that exclusivity may not effectively protect the product from competition. See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business&#8212;Government Regulation&#8212;FDA Regulation&#8212;Orphan Drugs</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; in Part I, Item 1 of our most recent Annual Report on Form 10-K.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We also cannot guarantee that we will receive breakthrough therapy, fast track, or equivalent designations, which provide certain potential benefits such as more frequent meetings with the applicable regulatory authorities to discuss development plans, intensive guidance on efficient drug development programs, and potential eligibility for rolling review or priority review. Even if we are successful in obtaining any such designations for our product candidates, such designations may not lead to faster development or regulatory review or approval and do not increase the likelihood that our product candidates will receive marketing approval. We may not be able to obtain or maintain these designations for our product candidates that receive them, and our competitors may obtain these designations for their product candidates, which could impact our ability to develop and commercialize our products and product candidates or compete with such competitors, which may adversely impact our business, financial condition or results of operations.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Given the small number of patients who have the diseases that we are targeting, it is important to our ability to grow and become profitable that we continue to successfully identify patients with these rare diseases. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with our products and product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including the scientific literature, surveys of clinics, patient foundations, or market research, and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these diseases. The number of patients may turn out to be lower than expected. Additionally, the potentially addressable patient population for each of our products and product candidates may be limited or may not be amenable to treatment with our products and product candidates, and new patients may become increasingly difficult to identify or access. Further, even if we obtain significant market share for our products and product candidates, because the potential target populations are small, we may never become or remain profitable nor generate sufficient revenue growth to sustain our business.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the FDA or comparable foreign regulatory authorities approve generic versions of any of our products that receive marketing approval, or such authorities do not grant our products appropriate periods of data or market exclusivity before approving generic versions of our products, the sales of our products could be adversely affected.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Once an NDA is approved, the drug covered thereby becomes a &#8220;reference-listed drug&#8221; in the FDA&#8217;s publication, &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations.&#8221; Manufacturers may seek marketing approval of generic versions of reference-listed drugs through submission of abbreviated new drug applications, or ANDAs, in the United States, as described in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business&#8212;Government Regulation&#8212;FDA Regulation&#8212;Abbreviated New Drug Applications for Generic Drugs</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; in Part I, Item 1 of our most recent Annual Report on Form 10-K. Generic drugs may be significantly less costly to bring to market than the reference-listed drug and companies that produce generic drugs are generally able to offer them at lower prices. Thus, following the introduction of a generic drug, a significant percentage of the sales of any branded product or reference-listed drug is typically lost to the generic drug.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may not approve an ANDA for a generic drug until any applicable period of non-patent exclusivity for the reference-listed drug has expired, as described in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business&#8212;Government Regulation&#8212;FDA Regulation&#8212;Abbreviated New Drug Applications for Generic Drugs</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; in Part I, Item 1 of our most recent Annual Report on Form 10-K, but such exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the nonclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness. Manufacturers may seek to launch generic drugs following the expiration of the marketing exclusivity period, even if we still have patent protection for such drugs. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Competition that our products or product candidates may face from generic drugs could materially and adversely impact our future revenue, profitability and cash flows and substantially limit our ability to obtain a return on the investments we have made in those product candidates. Our future revenues, profitability and cash flows could also be materially and adversely affected and our ability to obtain a return on the investments we have made in those product candidates may be substantially limited if our products or, if and when approved, product candidates, are not afforded the appropriate periods of non-patent exclusivity.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The commercial viability of any approved product could be compromised if the product is less effective than expected, causes undesirable side effects that either were not previously identified or were worse than expected, or fails to achieve market acceptance within the medical community.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If, after obtaining regulatory approval of a product, we or others discover that the product is less effective than previously believed or causes undesirable side effects that either were not previously identified or were worse than expected, any of the following adverse events could occur:</span></div><div style="margin-top:10pt;padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may withdraw their approval of, or impose marketing or manufacturing restrictions on, the product, or require us or our partners to create a medication guide outlining the risks of unidentified side effects for distribution to patients;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our partners may be required to recall the product, change the way the product is administered, conduct additional clinical trials, or be subject to civil or criminal penalties; and</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the product may become less competitive and our reputation may suffer.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Even after receiving regulatory approval, any product could fail to gain sufficient, or any, market acceptance by physicians, patients, third-party payors, health authorities and others in the medical community. For example, physicians are often reluctant to switch their patients from existing therapies even when new and potentially more effective or convenient treatments enter the market. Further, patients often acclimate to the therapy that they are currently taking and do not want to switch unless their physicians recommend switching products or they are required to switch therapies due to lack of reimbursement for existing therapies. If an approved product does not achieve an adequate level of market acceptance, it may not generate significant revenues. The occurrence of any of the foregoing could have a material and adverse impact on our business.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to successfully commercialize or establish collaborative relationships to commercialize or develop certain of our products and product candidates, or if any partner terminates or fails to perform its obligations under agreements with us, potential revenues from commercialization of our products and product candidates could be reduced, delayed or eliminated.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our business strategy includes increasing the asset value of our product and product candidate portfolio. We believe this is best achieved by retaining full product rights or through collaborative arrangements with third parties as appropriate. As needed, potential third-party relationships could relate to preclinical development, clinical development, regulatory approval, marketing, sales, and distribution of our products and product candidates.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Currently, we have established collaborative relationships with, among others, third-party distributors for ORLADEYO in certain markets, with Torii for ORLADEYO in Japan, with each of Shionogi and Green Cross for the development and commercialization of peramivir, and with Clearside for the development of avoralstat with Clearside&#8217;s SCS Microinjector&#174;. The process of establishing and implementing collaborative relationships is difficult, time-consuming and involves significant uncertainty, including:</span></div><div style="margin-top:10pt;padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our partners may seek to renegotiate or terminate our relationships due to unsatisfactory commercial, regulatory or clinical results, including post-approval clinical commitments, a change in business strategy, a change of control or other reasons;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our contracts for collaborative arrangements may expire;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the possibility that expiration or termination of collaborative relationships, such as those with certain of our distribution partners, may trigger repurchase obligations of the Company for unsold product held by our partners;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our partners may choose to pursue alternative technologies, including those of our competitors;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we have had in the past, and in the future may have, disputes with a partner that could lead to litigation or arbitration, which could result in substantial costs and divert the attention of our management;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we do not have day-to-day control over the activities of our partners and have limited control over their decisions;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to generate future event payments and royalties from our partners depends upon their abilities to establish the safety and efficacy of our product candidates, obtain regulatory approvals and achieve market acceptance of products developed from our product candidates;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our partners may fail to properly initiate, maintain or defend our intellectual property rights, where applicable, or a party may utilize our proprietary information in such a way as to invite litigation that could jeopardize or potentially invalidate our proprietary information or expose us to potential liability;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our partners may not devote sufficient capital or resources toward our products and product candidates; and</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our partners may not comply with applicable government regulatory requirements.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If we or our partners fail to fulfill our responsibilities in a timely manner, or at all, our development and commercialization efforts related to that collaboration could be reduced, delayed or terminated, or it may be necessary for us to assume responsibility for activities that would otherwise have been the responsibility of our partner. If we are unable to establish and maintain collaborative relationships on acceptable terms, we may have to delay or discontinue further development or commercialization of one or more of our products or product candidates, undertake commercialization activities at our own expense or find alternative sources of funding. Any delay in the development or commercialization of our products and product candidates would severely affect our business, because if our product candidates do not progress through the development process or reach the market in a timely manner, or at all, or if our products do not achieve market success, we may not receive any revenues from product sales or licensing arrangements.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The results of our partnership with Torii may not meet our current expectations.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have a partnership agreement with Torii for ORLADEYO in Japan. Under our agreement with Torii,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> we are responsible for all field promotional activities with respect to ORLADEYO in Japan, which we conduct through our Japanese subsidiary, BioCryst Japan K.K. Furthermore, we remain responsible for regulatory activities with respect to ORLADEYO in Japan, and we use third parties to satisfy those regulatory responsibilities and certain other obligations in Japan. If any party fails to meet its obligations, the commercial success of ORLADEYO in Japan and the economic benefit expected could be negatively impacted.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">There can be no assurance that our or our partners&#8217; commercialization efforts, methods, and strategies for our products or technologies will succeed, and our future revenue generation is uncertain.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that our or our partners&#8217; commercialization efforts, methods and strategies will succeed. We may be unable to establish or sufficiently increase our sales, marketing and distribution capabilities for products we currently, or plan to, commercialize. Our ability to receive revenue from products we or our partners commercialize is subject to several risks, including:</span></div><div style="margin-top:10pt;padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our partners may fail to complete clinical trials successfully, or satisfy post-marketing commitments, sufficient to obtain and maintain regulatory agency marketing approval;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">many competitors are more experienced and have significantly more resources, and their products could reach the market faster, be more cost effective or have a better efficacy or tolerability profile than our products and product candidates;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may fail to employ a comprehensive and effective intellectual property strategy, which could result in decreased commercial value of our Company, our products and product candidates, or royalties associated with such products (e.g., the loss of the peramivir patent in Korea, which may result in a reduced royalty from Green Cross);</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may fail to employ a comprehensive and effective regulatory strategy, which could result in a delay or failure in commercialization of our products;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our and our partners&#8217; ability to successfully commercialize our products is affected by the competitive landscape, which cannot be fully known at this time;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">revenue from product sales depends on our ability to obtain and maintain favorable pricing;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reimbursement is constantly changing, which could greatly affect usage of our products;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">future revenue from product sales will depend on our ability to successfully complete clinical studies, obtain regulatory approvals, and manufacture, market, distribute and commercialize our approved drugs; and</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">the impact of public health emergencies or the outbreak of disease, such as the COVID-19 pandemic, on us or our partners.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, future revenue from sales of ORLADEYO is subject to uncertainties and will depend on several factors, including the success of our and our partners&#8217; commercialization efforts in the United States and elsewhere, the number of new patients switching to ORLADEYO, patient retention and demand, the number of physicians prescribing ORLADEYO, the rate of monthly prescriptions, reimbursement from third-party and government payors, the number of patients receiving free product, the conversion of patients from our clinical trials and early access programs to commercial customers, our pricing strategy, and market trends</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are able to successfully commercialize our existing products, or to develop new commercially viable products, certain obligations we have to third parties, including, without limitation, our obligations to pay royalties on certain revenues from ORLADEYO under the Royalty Purchase Agreements, may reduce the profitability of such products.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have expanded our development and regulatory capabilities and implemented sales, marketing and distribution capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced significant growth in the number of our employees and the scope of our operations in the United States and internationally, particularly in the areas of drug development, regulatory affairs, sales, marketing, and distribution. To manage our growth, we must continue to implement and improve our managerial, operational and financial systems and processes, and continue to recruit and train qualified personnel as needed. Due to our limited financial resources and the limited experience of our management team in managing a company with such growth, we may not be able to effectively manage such expansion of our operations, implement appropriate systems and processes in a timely manner or at all, or recruit, train, and retain qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. In addition, if a commercial launch for any product or product candidate for which we recruit a commercial team and establish marketing capabilities in any region is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on third-party vendors in the manufacture and distribution of our products, product candidates and the materials for our products and product candidates. If we cannot rely on existing third-party vendors, we will be required to incur significant costs and potential delays in finding new third-party vendors, which could adversely impact the development and commercialization timeframes for our products and product candidates.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We depend on third-party vendors, including third-party manufacturers, distributors, and specialty pharmacies, in the manufacture and distribution of our products, product candidates, and the materials for our products and product candidates. Often, especially in the early development and commercialization process, we have only one or limited sources for a particular product or service, such as manufacturing and/or distribution. We depend on these third-party vendors to perform their obligations in a timely manner and in accordance with applicable governmental regulations. Our third-party vendors, particularly our third-party manufacturers and distributors, each of which may be the only vendor we have engaged for a particular product, product candidate, or service or in a particular region, may encounter difficulties with meeting our requirements, including, but not limited to, problems involving, as applicable:</span></div><div style="margin-top:10pt;padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">insufficient resources being devoted in the manner necessary to satisfy our requirements within expected timeframes;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inconsistent production yields;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product liability claims or recalls of commercial product;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties in scaling production to commercial and validation sizes;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption of the delivery of materials required for the manufacturing process;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to distribute commercial supplies of our products to commercial vendors or end users in a timely manner;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">scheduling of plant time with other vendors or unexpected equipment failure;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential catastrophes that could strike their facilities or have an effect on infrastructure;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential impurities in our drug substance or products that could affect availability of product for our clinical trials or future commercialization;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">poor quality control and assurance or inadequate process controls;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to provide us with accurate or timely information regarding inventory, the number of patients who are using our products, or serious adverse events and/or product complaints regarding our products;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability of third parties to satisfy their financial obligations to us or to others;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential breach of the manufacturing or distribution agreement by the third party;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">possible termination or non-renewal of a material agreement by the third party at a time that is costly or inconvenient to us; and</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack of compliance or cooperation with regulations and specifications or requests set forth by the FDA or other foreign regulatory agencies or local customs.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Many additional factors could cause production or distribution interruptions with the manufacture and distribution of any of our products and product candidates, including human error, natural disasters, pandemics, labor disputes or shortages, acts of terrorism or war, equipment malfunctions, raw material shortages or supply chain issues. If our commercial distribution partners are not able to satisfy our requirements within the expected timeframe, or are unable to provide us with accurate or timely information and data, including with respect to inventory and sales, serious adverse events, and/or product complaints, our business, including our commercialization efforts for and sales of ORLADEYO, may be at risk. In addition, if specialty pharmacy services, including our third-party call center services, which provide patient support and financial services, prescription intake and distribution, reimbursement adjudication, and ongoing compliance support, are not effectively managed, the continuance of our commercialization efforts for and sales of ORLADEYO may be delayed or compromised.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our contract manufacturers may not be able to manufacture the materials required for our products or product candidates at a cost or in quantities necessary to make them commercially viable. Our raw materials, drug substances, products, and product candidates are manufactured by a limited group of suppliers, including some at a single facility. If any of these suppliers were unable to produce these items, this could significantly impact our supply of products and product candidate material for further preclinical testing and clinical trials. Our third-party manufacturers also may not meet our manufacturing requirements. Furthermore, changes in the manufacturing process or procedures, including a change in the location where the drug is manufactured or a change of a third-party manufacturer, may require prior review and approval in accordance with the FDA&#8217;s cGMP and comparable foreign requirements. This review may be costly and time-consuming and could delay or prevent the launch of a product. The FDA or foreign regulatory authorities may at any time implement new standards, or change their interpretation and enforcement of existing standards, for manufacture, packaging or testing of products. If we or our contract manufacturers are unable to comply, we or they may be subject to regulatory action, civil actions or penalties, any of which could be costly to us and could result in a delay or shortage of product.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We currently contract with a foreign CMO in China for the manufacturing of one of our product candidates. Foreign CMOs may be subject to U.S. legislation, including the proposed BIOSECURE Act, sanctions, trade restrictions and other foreign regulatory requirements, which could increase the cost or reduce the supply of material available to us or delay the procurement or supply of such material.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to maintain current third-party relationships, or enter into new agreements with additional third parties on commercially reasonable terms, or at all, or if there is poor manufacturing or distribution performance or failure to comply with any regulatory agency on the part of any of our third-party vendors, we may not be able to complete development of, obtain timely approval of, or commercialize our products and product candidates.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commercialization of our products by us and our partners is subject to the potential commercialization risks described herein and numerous additional risks.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any potential revenue benefits to us, including in the form of milestone payments, royalties or other consideration, are highly speculative.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Commercial success of our products is uncertain and is subject to all the risks and uncertainties disclosed in our other risk factors relating to drug development and commercialization. In addition, commercialization of our products is subject to further risks and may be negatively impacted by a number of factors, including, but not limited to, the following:</span></div><div style="margin-top:10pt;padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our products may not prove to be adequately safe and effective for market approval in markets other than the markets in which they are currently approved;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">necessary funding for post-marketing commitments and further development of our products may not be available timely, at all, or in sufficient amounts;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advances in competing products could substantially replace potential demand for our products;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">government and third-party payors may not provide sufficient coverage or reimbursement, which would negatively impact the demand for our products;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be able to supply commercial material to our partners and our partners may not be able to maintain or establish sufficient and acceptable commercial manufacturing, either directly or through third-party manufacturers;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the commercial demand for and acceptance of our products by healthcare providers and by patients may not be sufficient to result in substantial product revenues to us or to our partners and may result in little to no revenue, milestone payments, or royalties to us;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">effectiveness of marketing and commercialization efforts for our products by us or our partners;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market satisfaction with existing alternative therapies;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">perceived efficacy relative to other available therapies;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disease prevalence;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cost of treatment;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our pricing and reimbursement strategy may not be effective;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">new legislative or regulatory proposals may influence our pricing and reimbursement strategy, which could impact product revenues;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pricing and availability of imports or alternative products;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">marketing and sales activities of competitors;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">shifts in the medical community to new treatment paradigms or standards of care; and</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">relative convenience and ease of administration.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Risks Relating to Competing in Our Industry</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face intense competition, and if we are unable to compete effectively, the demand for our products may be reduced.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industries are highly competitive and subject to rapid and substantial technological change. There are many companies seeking to develop products for the same indications that we currently target. Our competitors in the United States and elsewhere are numerous and include, among others, major multinational pharmaceutical and chemical companies and specialized biotechnology firms. Most of these competitors have greater resources than we do, including greater financial resources, larger research and development staffs and more experienced manufacturing, marketing, and sales organizations. In addition, most of our competitors have greater experience than we do in conducting clinical trials and obtaining FDA and other regulatory approvals. Accordingly, our competitors may succeed in obtaining FDA or other regulatory approvals of product candidates more rapidly than we do for products that compete with our products. Companies that complete clinical trials, obtain required regulatory approvals, and commence commercial sale of their drugs before we do may achieve a significant competitive advantage, including patent and FDA exclusivity rights that would delay our ability to market products. We face, and will continue to face, competition in the commercialization of our products, licensing of potential product candidates for desirable disease targets, licensing of desirable product candidates, and development and marketing of our product candidates from academic institutions, government agencies, research institutions and biotechnology and pharmaceutical companies. Competition may also arise from, among other things:</span></div><div style="margin-top:10pt;padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other drug development technologies;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">methods of preventing or reducing the incidence of disease, including vaccines; and</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">new small molecule or other classes of therapeutic agents.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Developments by others may render our products, product candidates, or technologies obsolete or noncompetitive.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We received FDA approval of ORLADEYO, an oral, once-daily therapy for the prevention of HAE attacks in adults and pediatric patients aged 12 years and older, in December 2020, and subsequently received regulatory approvals for ORLADEYO in other global markets. In addition, the ongoing APeX-P clinical trial, which is complete through the primary endpoint, is continuing to assess an oral granule formulation of ORLADEYO in pediatric patients who are 2 to 11 years of age at enrollment. We are also performing research on or developing products for the treatment of several other rare diseases, and we expect to encounter significant competition for our pharmaceutical products and product candidates. Companies that complete clinical trials, obtain required funding or government support, obtain required regulatory approvals and commence commercial sales or stockpiling orders of their products before their competitors may achieve a significant competitive advantage. In addition, various government entities throughout the world may offer incentives, grants and contracts to encourage additional investment into certain preventative and therapeutic agents, which may have the effect of further increasing the number of our competitors and/or providing advantages to certain competitors. See </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business&#8212;Competition</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; in Part I, Item 1 of our most recent Annual Report on Form 10-K for further discussion of our competitors, competitive products or programs, and the competitive conditions in these and other therapeutic areas.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If one or more of our competitors&#8217; products or programs, including potential competitors not currently identified, are successful, the market for our products may be reduced or eliminated.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Compared to us, many of our competitors and potential competitors have substantially greater:</span></div><div style="margin-top:10pt;padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">capital resources;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">research and development resources, including personnel and technology;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory experience;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preclinical study and clinical testing experience;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing, marketing, and sales experience; and</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">production facilities.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Any of these competitive factors could impede our funding efforts, render our products, product candidates, or technologies noncompetitive or eliminate or reduce demand for our products and product candidates.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Legal and Regulatory Risks</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to various laws and regulations related to our products and product candidates, and if we or our partners do not comply with these laws and regulations, we could face substantial penalties.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our and our partners&#8217; activities related to approved products or, following their regulatory approval (if applicable), any of our product candidates under development, are subject to regulatory and law enforcement authorities in the United States (including the FDA, the Federal Trade Commission, the Department of Justice (&#8220;DOJ&#8221;), and state and local governments) and their foreign equivalents.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are responsible for reporting adverse drug experiences, have responsibility for certain post-approval studies, and may have responsibilities and costs related to a recall or withdrawal of our products from sale in the jurisdictions in which they are approved. We may also incur liability associated with product manufacturing contracted by us or in support of any of our partners. We are required to maintain records and provide data and reports to regulatory agencies related to our products (e.g., risk evaluation and mitigation strategies, track and trace requirements, and adverse events), and we may incur certain promotional regulatory and government pricing risks, all of which could have a material adverse impact on our operations and financial condition. Similar responsibilities would apply upon regulatory approval of any of our other product candidates currently under development.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are subject to the federal Physician Payment Sunshine Act and certain similar physician payment and drug pricing transparency legislation in various states. We are also subject to various federal and state laws pertaining to healthcare &#8220;fraud and abuse,&#8221; including both federal and state anti-kickback and false claims laws. Outside of the United States, we may be subject to analogous foreign laws and regulations in the various jurisdictions in which we operate. These laws and regulations apply to our and our partners&#8217; operations, sales and marketing practices, price reporting, and relationships with physicians and other customers and third-party payors. Although we seek to comply with these statutes, it is possible that our practices, or those of our partners, might be challenged under healthcare fraud and abuse, anti-kickback, false claims or similar laws. Violations of the federal Physician Payment Sunshine Act and similar legislation or the fraud and abuse laws may be punishable by civil or criminal sanctions, including fines and civil monetary penalties, and future exclusion from participation in government healthcare programs.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to certain regulatory authorities, including the FDA and comparable foreign regulatory authorities. Consequently, the FDA or other regulatory authority may conclude that a financial relationship between us and a principal investigator creates a conflict of interest or otherwise affects interpretation of the study. In the event of a conflict of interest with respect to a study, the integrity of the data generated at the applicable clinical trial site may be questioned or the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or other regulatory authority, as the case may be, and may ultimately lead to the denial of marketing approval of one or more of our product candidates.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and foreign regulatory authorities may also impose post-approval commitments on us for approved products, which we may not complete successfully or on time for any number of reasons, including, but not limited to, lack </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of funds to complete the studies and insufficient interest by appropriate sites, investigators or study subjects. We are currently subject to certain post-approval commitments and evolving FDA guidance. If we fail to comply with any post-approval legal and regulatory requirements, we could be subject to penalties, and our products could be subject to continual recordkeeping and reporting requirements, review and periodic inspections by the FDA and other regulatory bodies. Regulatory approval of a product may be subject to limitations on the indicated uses for which the product may be marketed or to other restrictive conditions of approval that limit our ability to promote, sell or distribute a product. Furthermore, the approval of our products and any other future product candidates may be subject to requirements for costly post-approval testing and surveillance to monitor their safety or efficacy or certain post-approval labeling, packaging and storage requirements.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Advertising and promotion are subject to stringent oversight from the FDA and foreign regulators, and as an NDA holder, we may be held responsible for any advertising and promotion that is not in compliance with applicable rules and regulations. Applicable regulatory authorities, competitors, and other third parties may take the position that we are not in compliance with such regulations. In addition to medical education efforts, we may offer patient support services to assist patients receiving treatment with our commercially approved products, and these support services have increasingly become the focus of government investigation.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Adverse event information concerning approved products must be reviewed, and as an NDA holder, we are required to make expedited and periodic adverse event reports to the FDA and other regulatory authorities. In addition, the research, manufacturing, distribution, sale and promotion of products are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;), other divisions of HHS, the DOJ and individual U.S. Attorney offices within the DOJ, state and local governments, and foreign equivalents of the foregoing. All of these activities are also potentially subject to healthcare false claims and fraud and abuse laws, as well as consumer protection and unfair competition laws.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If our operations with respect to our products that are subject to healthcare laws and regulations are found to be in violation of any of the healthcare fraud and abuse laws described above or in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business&#8212;Government Regulation</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; in Part I, Item 1 of our most recent Annual Report on Form 10-K or any other governmental regulations that apply to us, we may be subject to liability and penalties, including civil and criminal penalties, damages, fines, debarment or exclusion from participating in government-funded healthcare programs such as Medicare or Medicaid, and the curtailment or restructuring of our operations. Any penalties, damages, fines, debarment, exclusion, curtailment or restructuring of our operations could adversely affect our ability to operate our business and our financial results. Although compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, the risks cannot be entirely eliminated. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. Moreover, achieving and sustaining compliance with all applicable fraud and abuse laws may be costly.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We cannot predict the likelihood, nature or extent of government regulation or other measures that may arise from future legislation or administrative or executive action, either in the United States or abroad.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The policies of the FDA and other regulatory authorities may change, including as a result of changes in presidential administration of the United States, and additional government regulations or executive orders may be enacted that could prevent, limit or delay regulatory approval of our product candidates, change our continuing compliance obligations, or otherwise adversely affect our business. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability. In addition, significant tariffs or other restrictions imposed and related countermeasures taken by impacted foreign countries could adversely affect our operations and financial results.</span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">We cannot predict the likelihood, nature or extent of government regulation or other measures that may arise from future legislation or administrative or executive action, either in the United States or abroad.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, consultants and partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements, which could cause significant liability for us and harm our reputation.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the risk of fraud or other misconduct by our employees, consultants and partners, including intentional or unintentional failures to comply with FDA regulations or similar regulations of comparable other regulatory authorities, provide accurate information to the FDA or comparable other regulatory authorities, comply with manufacturing standards we have established, comply with federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable other regulatory authorities, report financial information or data accurately or disclose unauthorized activities to us. Employee and consultant misconduct </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter employee and consultant misconduct, whether intentional, reckless, negligent, or unintentional, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws, standards or regulations. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant fines or other sanctions.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our partners may be subject to new legislation, regulatory proposals and healthcare payor initiatives that may increase our costs of compliance and adversely affect our or our partners</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8217; </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ability to market our products or develop our product candidates.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to new legislation, regulatory, and healthcare payor initiatives, including the Patient Protection and Affordable Care Act (&#8220;PPACA&#8221;), which made extensive changes to the delivery of healthcare in the United States, as discussed in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business&#8212;Government Regulation</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; in Part I, Item 1 of our most recent Annual Report on Form 10-K. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare could result in decreased net revenues from our pharmaceutical products and decrease potential returns from our development efforts. In addition, pharmaceutical and device manufacturers are also required to report and disclose certain payments and transfers of value to, and investment interests held by, physicians and their immediate family members during the preceding calendar year. Failure to submit required information may result in civil monetary penalties for payments, transfers of value, or ownership or investment interests not reported in an annual submission. Compliance with the PPACA and state laws with similar provisions is difficult and time-consuming, and companies that do not comply with these state laws face civil penalties. Because of the breadth of these laws and the narrowness of the applicable safe harbors, it is possible that some of our business activities could be subject to challenge under one or more of such laws. Such a challenge could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there have been a number of other legislative and regulatory proposals aimed at changing the pharmaceutical industry. For example, legislation has been enacted in certain states and at a federal level that requires development of an electronic pedigree to track and trace each prescription drug at the saleable unit level through the distribution system. Compliance with these electronic pedigree requirements may increase our operational expenses and impose significant administrative burdens. In addition, our compliance may be deemed insufficient and we could face a material adverse effect on our business, financial condition, results of operations and growth prospects. As a result of these and other new proposals, we may determine to change our current manner of operation, provide additional benefits or change our contract arrangements, any of which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Adequate coverage and reimbursement in the United States and other markets is essential to the commercial success of our approved products. Recently in the United States, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products. For example, the Inflation Reduction Act of 2022 (&#8220;IRA&#8221;) implements a number of drug pricing measures intended to lower the cost of prescription drugs and related healthcare reforms, including limits on price increases and subjecting an escalating number of drugs to annual price negotiations with CMS. The IRA includes several provisions that will impact our business to varying degrees, including provisions that reduced the out-of-pocket spending&#8239;cap for Medicare Part D beneficiaries to $2,000 in 2025; impose new manufacturer financial liability on all drugs in Medicare Part D; allow the U.S. Government to negotiate Medicare Part B and Part D pricing for certain high-cost drugs and biologics without generic or biosimilar competition; require companies to pay rebates to Medicare for drug prices that increase faster than inflation; and delay the rebate rule that would require pass through of pharmacy benefit manager rebates to beneficiaries. Further, under the IRA, orphan drugs are exempted from the Medicare drug price negotiation program, but only if they have one orphan designation and for which the only approved indication or indications are for that disease or condition.&#8239;If a product receives multiple rare disease designations or has multiple approved indications for more than one disease or condition, it may not qualify for the orphan drug exemption. On July 4, 2025, the One Big Beautiful Bill Act (&#8220;OBBBA&#8221;) was signed into law in the United States. Although we are still evaluating the impact of the OBBBA on the provisions of the IRA and on our business, the OBBBA contains a variety of provisions that could impact our business and results of operations.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We cannot be sure whether additional legislation or rule-making related to the IRA will be issued or enacted, how insurance pharmacy benefit managers and other insurance providers that manage benefits for Medicare recipients will react to the IRA, or what impact, if any, such additional changes will have on the insurance coverage and profitability of our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">products or any of our product candidates, if approved for commercial use, in the future. The full effect of the IRA on our business and the healthcare industry in general is not yet known. The IRA or other government efforts to reduce the price of prescription drugs or to limit the amount that governments pay for healthcare products and services could result in additional pricing pressure and have a significant impact on our business.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. Third-party payors are increasingly challenging the prices charged for medical products and services and, in some cases, imposing restrictions on the coverage of particular drugs. Many third-party payors negotiate the price of medical services and products and develop formularies which establish pricing and reimbursement levels. Exclusion of a product from a formulary can lead to its sharply reduced usage in the third-party payor&#8217;s patient population. The process for obtaining coverage can be lengthy and costly, and we expect that it could take several months before a particular payor initially reviews a product and makes a decision with respect to coverage. For example, third-party payors may require cost-benefit analysis data from us in order to demonstrate the cost-effectiveness of our products or any other product we might bring to market. For any individual third-party payor, we may not be able to provide data sufficient to gain reimbursement on a similar or preferred basis to competitive products, or at all, which may have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to data privacy and security risks, and our actual or perceived failure to comply with regulations and other legal obligations related to privacy and data protection could harm our business.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We may be subject to legal obligations at the federal, state, and local level related to privacy and data protection, as described in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business&#8212;Government Regulation&#8212;Data Privacy and Security Laws</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; in Part I, Item 1 of our most recent Annual Report on Form 10-K. Compliance with stringent and evolving U.S. data protection laws and regulations could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use, and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. For example, we may be subject to the California Consumer Privacy Act (&#8220;CCPA&#8221;), which gives California residents expanded rights to access and require deletion of their personal data, opt out of certain personal data sharing, and receive detailed information about how their personal data is used. The CCPA provides for civil penalties of up to $7,500 per violation and allows private litigants affected by certain data breaches to recover significant statutory damages. Although the CCPA exempts some data processed in the context of clinical trials, the CCPA may increase compliance costs and potential liability with respect to other personal data we may maintain about California residents.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We also may be subject to the General Data Protection Regulation (&#8220;GDPR&#8221;) in the European Economic Area (&#8220;EEA&#8221;) and similar legislation in the United Kingdom and Switzerland. See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business&#8212;Government Regulation&#8212;Data Privacy and Security Laws</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; in Part I, Item 1 of our most recent Annual Report on Form 10-K and &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Relating to Our Business&#8212;Risks Relating to International Operations&#8212;Our actual or perceived failure to comply with European governmental laws and regulations and other legal obligations related to privacy, data protection and information security could harm our business</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; in this section for additional discussion of privacy laws and regulations. Failure to comply with these laws and regulations could result in government enforcement actions, private litigation, or harm to our reputation and our business.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Despite our efforts, our personnel or third parties on whom we rely may fail to comply with such data privacy and security obligations, which could negatively impact our business operations. If we or the third parties on which we rely fail, or are perceived to have failed, to address or comply with applicable data privacy and security obligations, we could face significant consequences, including, but not limited to, regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse business consequences.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If, because of our use of hazardous materials, we violate any environmental controls or regulations that apply to such materials, we may incur substantial costs and expenses in our remediation efforts.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development involves the controlled use of hazardous materials, chemicals and various radioactive compounds. We are subject to federal, state and local laws and regulations governing the use, storage, handling and disposal of these materials and some waste products. Accidental contamination or injury from these materials could occur. In the event of an accident, we could be liable for any damages that result, and any liabilities could exceed our resources. Compliance with environmental laws and regulations or a violation of such environmental laws and regulations could require us to incur substantial unexpected costs, which would materially and adversely affect our results of operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Intellectual Property Risks</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to adequately protect or enforce our intellectual property rights, the value of those rights would diminish, and if we fail to secure the rights to patents of others, it could adversely affect our business.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our success will depend in part on our ability and the abilities of our partners to obtain, protect and enforce viable intellectual property rights including, but not limited to, trade name, trademark and patent protection for our Company and its products, methods, processes and other technologies we may license or develop, to preserve our trade secrets, and to operate without infringing the proprietary rights of third parties both domestically and abroad. The patent position of biotechnology and pharmaceutical companies is generally highly uncertain, involves complex legal and factual questions and has recently been the subject of much litigation. Neither the United States Patent and Trademark Office (&#8220;USPTO&#8221;), the Patent Cooperation Treaty offices, nor the courts of the United States and other jurisdictions have consistent policies nor predictable rulings regarding the breadth of claims allowed or the degree of protection afforded under many biotechnology and pharmaceutical patents. Further, we may not have worldwide patent protection for all of our product candidates and our intellectual property rights may not be legally protected or enforceable in all countries throughout the world. In some jurisdictions, some of our product candidates in certain programs, including our HAE program, may have short or no composition of matter patent life and we may therefore rely on orphan drug exclusivity or data exclusivity. There can be no assurance that we will obtain orphan drug exclusivity or data exclusivity in every jurisdiction. Further, in some jurisdictions, we may rely on formulation patents or method of use patents. Both the ability to achieve issuance and the enforcement of formulation and method of use patents can be highly uncertain and can vary from jurisdiction to jurisdiction, and such patents may therefore not adequately prevent competitors and potential infringers in some jurisdictions. The validity, scope, enforceability, and commercial value of the rights protected by such patents, therefore, is highly uncertain.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We also rely on trade secrets to protect technology in cases when we believe patent protection is not appropriate or obtainable. However, trade secrets are difficult to protect. In addition, increasing restrictions on non-compete agreements could increase the difficulty of protecting certain proprietary information. If we cannot maintain the confidentiality of our technology and other confidential information in connection with our collaborators and advisors, our ability to receive patent protection or protect our proprietary information may be imperiled.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be involved in legal proceedings to protect or enforce our patents, the patents of our partners or our other intellectual property rights, which could be expensive, time-consuming and unsuccessful.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may infringe or otherwise violate our patents, the patents of our licensors or our other intellectual property rights, or may design around our patent claims to produce competitive products that fall outside the scope of our patents. For example, a third party may develop a competitive drug that is similar to one or more of our products or product candidates but that has a different composition that falls outside the scope of our patent protection. To counter infringement or unauthorized use, we may be required to file legal claims, which can be expensive, time-consuming, and unsuccessful. An adverse result in any legal proceeding could put one or more of our patents at risk. Our success depends in part on avoiding the infringement of other parties&#8217; patents and other intellectual property rights as well as avoiding the breach of any licenses relating to our technologies and products. In the United States, patent applications filed in recent years are confidential for 18 months after the earliest effective filing date, while older applications are not published until the patent issues. As a result, avoiding patent infringement may be difficult and we may inadvertently infringe third-party patents or proprietary rights. These third parties could bring claims against us, our partners or our licensors that even if resolved in our favor, could cause us to incur substantial expenses and, if resolved against us, could additionally cause us to pay substantial damages. Further, if a patent infringement suit were brought against us, our partners or our licensors, we or they could be forced to stop or delay research, development, manufacturing or sales of any infringing product in the country or countries covered by the patent we infringe, unless we can obtain a license from the patent holder. Such a license may not be available on acceptable terms, or at all, particularly if the third party is developing or marketing a product competitive with the infringing product. Even if we, our partners or our licensors were able to obtain a license, the rights may be nonexclusive, which would give our competitors access to the same intellectual property.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as described under &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business&#8212;Government Regulation&#8212;FDA Regulation&#8212;Abbreviated New Drug Applications for Generic Drugs</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; in Part I, Item 1 of our most recent Annual Report on Form 10-K, third parties may not file an ANDA for a generic drug with the FDA until the expiration of five years following the original product approval unless the submission is accompanied by a Paragraph IV certification, in which case third parties may submit an ANDA four years following the original product approval (referred to as the &#8220;NCE-1 date&#8221;). As the NCE-1 date for ORLADEYO was in December 2024, we anticipate that third parties will challenge our applicable patents, which may result in our initiation of patent infringement litigation in response to such challenge. For example, in January 2025, we received a </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Paragraph IV notice of certification from Annora advising that Annora has submitted an ANDA to the FDA seeking approval to manufacture, use or sell a generic version of ORLADEYO in the United States prior to the expiration of three patents listed in the FDA&#8217;s Orange Book, which expire in 2039</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. On March 10, 2025, we &#64257;led a patent infringement lawsuit in the United States District Court for the District of Delaware against the Defendants (as defined above) asserting infringement of the challenged patents arising from Annora&#8217;s ANDA filing with the FDA. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For further information, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">see the section titled &#8220;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; included in Part II, Item 1 of this report </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 14&#8212;Commitments and Contingencies&#8221;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> in the Notes to Condensed Consolidated Financial Statements in Part I, Item 1 of this report. We intend to vigorously defend our intellectual property rights protecting ORLADEYO. We cannot predict how any additional third party would address our listed patents, whether we would sue on any such patents, or the outcome of any such suit. However, litigation to enforce or defend intellectual property rights is complex, costly, and involves significant commitments of management&#8217;s time.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If we or our partners are unable or fail to adequately initiate, protect, defend or enforce our intellectual property rights in any area of commercial interest or in any part of the world where we wish to seek regulatory approval for our products, methods, processes and other technologies, the value of our products and product candidates to produce revenue would diminish. Additionally, if our products, methods, processes, and other technologies or our commercial use of such products, processes, and other technologies, including, but not limited to, any trade name, trademark or commercial strategy infringe the proprietary rights of other parties, we could incur substantial costs. The USPTO and the patent offices of other jurisdictions have issued to us a number of patents for our various inventions, and we have in-licensed several patents from various institutions. We have filed additional patent applications and provisional patent applications with the USPTO. We have filed a number of corresponding foreign patent applications and intend to file additional foreign and U.S. patent applications, as appropriate. We have also filed certain trademark and trade name applications worldwide. We cannot assure you as to:</span></div><div style="margin-top:10pt;padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the degree and range of protection any patents will afford against competitors with similar products;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if and when patents will issue;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if patents do issue, we cannot be sure that we will be able to adequately defend such patents and whether or not we will be able to adequately enforce such patents; or</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether or not others will obtain patents claiming aspects similar to those covered by our patent applications.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If the USPTO or other foreign patent office upholds patents issued to others or if the USPTO grants patent applications filed by others, we may have to:</span></div><div style="margin-top:10pt;padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain licenses or redesign our products or processes to avoid infringement;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">stop using the subject matter claimed in those patents; or</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pay damages.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We may initiate, or others may bring against us, litigation or administrative proceedings related to intellectual property rights, including proceedings before the USPTO or other foreign patent office. Any judgment adverse to us in any litigation or other proceeding arising in connection with a patent or patent application could materially and adversely affect our business, financial condition and results of operations. In addition, the costs of any litigation or administrative proceeding may be substantial whether or not we are successful.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our success is also dependent upon the skills, knowledge and experience, none of which is patentable, of our scientific and technical personnel. To help protect our rights, we require all employees, consultants, advisors and partners to enter into confidentiality agreements that prohibit the disclosure of confidential information to anyone outside of our Company and require disclosure and assignment to us of their ideas, developments, discoveries and inventions. These agreements may not provide adequate protection for our trade secrets, know-how or other proprietary information in the event of any unauthorized use or disclosure or the lawful development by others of such information, and if any of our proprietary information is disclosed, our business will suffer because our revenues depend upon our ability to license or commercialize our products and product candidates and any such events would significantly impair the value of such products and product candidates.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have diversified our pipeline to include the development of protein therapeutics, which may create additional risks and challenges. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have diversified our pipeline beyond small-molecule medicines to develop protein therapeutics. The development of protein therapeutics may create additional risks and challenges, including, among others:</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patent protection for protein therapeutics may be narrower in scope than for our small-molecule medicines, and our patents and patent applications may not adequately protect our intellectual property, provide exclusivity for our protein therapeutic candidates or prevent others from designing around our claims;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">formulation issues with our protein therapeutic candidates may require redevelopment of the formulation, which may be time-consuming or unsuccessful;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patent applications that we own or in-license may fail to result in issued patents with claims that cover our protein therapeutic candidates in the United States or in other countries;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitors may be able to more easily develop and seek patent protection on similar protein therapeutic candidates; and</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">orally-administered drugs are often less expensive and present a reduced treatment burden as compared to protein therapeutics and therefore would have competitive advantages if they were developed and shown to be safe and effective for the indication that our protein therapeutic product candidates are targeting.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As is the case with other biotechnology and pharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biotechnology and pharmaceutical industries involves both technological and legal complexity. Therefore, obtaining and enforcing such patents is costly, time-consuming, and inherently uncertain. In addition, the United States has recently enacted and is currently implementing wide-ranging patent reform legislation. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. Additionally, there have been recent proposals for additional changes to the patent laws of the United States and other countries that, if adopted, could impact our ability to obtain patent protection for our proprietary technology or our ability to enforce our proprietary technology. Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and the relevant law-making bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We employ certain individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Our efforts to vet our employees, consultants, and independent contractors and prevent their use of the proprietary information or know-how of others in their work for us may not be successful, and we may in the future be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely impact our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and distract management and other employees.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Product Liability Risks</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face an inherent risk of liability in the event that the use or misuse of our products or product candidates results in personal injury or death, and our product liability insurance coverage may be insufficient.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If the use or misuse of any products we sell, or a partner sells, harms people, we may be subject to costly and damaging product liability claims brought against us by consumers, healthcare providers, pharmaceutical companies, third-party payors or others. The use of our product candidates in clinical trials, including post-marketing clinical studies, could also expose us to product liability claims. We cannot predict all of the possible harms or side effects that may result from the use of our products or the testing of product candidates, and therefore, the amount of insurance coverage we currently have may not be adequate to cover all liabilities or defense costs we might incur. A product liability claim or series of claims brought against us could give rise to a substantial liability that could exceed our resources. Even if claims are not successful, the costs of defending such claims and potential adverse publicity could be harmful to our business.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and face even greater risks upon commercialization by us of our products or product candidates. We have product liability insurance covering our clinical trials. Clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to obtain sufficient insurance or increase our existing coverage at a reasonable </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">cost to protect us against losses that could have a material adverse effect on our business. An individual may bring a product liability claim against us if one of our products or product candidates causes, or is claimed to have caused, an injury or is found to be unsuitable for consumer use. Any product liability claim brought against us, with or without merit, could result in:</span></div><div style="margin-top:10pt;padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">liabilities that substantially exceed our product liability insurance, which we would then be required to pay from other sources, if available;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase of our product liability insurance rates or the inability to maintain insurance coverage in the future on acceptable terms, or at all;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the withdrawal of clinical trial volunteers or patients;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">damage to our reputation and the reputation of our products, resulting in lower sales;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory investigations that could require costly recalls or product modifications;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">litigation costs; and</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the diversion of management&#8217;s attention from managing our business.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Risks Relating to Contractual Arrangements</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face risks related to our U.S. Government contracts, which may create a disadvantage and additional risks to us.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In September 2024, we entered into a contract with ASPR for the procurement of up to 95,625 doses over a five-year period of RAPIVAB for the treatment of influenza. The contract was structured with a 12-month base ordering period and four optional 12-month ordering periods, which the U.S. Government could exercise on an annual basis. While ASPR executed the first ordering period, on May 15, 2025, ASPR notified the Company of its intent to not exercise any additional optional ordering periods available under the agreement. We have delivered all doses under the base ordering period, effectively completing the contract with ASPR.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We had contracts with the Biomedical Advanced Research and Development Authority within the U.S. Department of Health and Human Services (&#8220;BARDA/HHS&#8221;) and the National Institute of Allergy and Infectious Diseases within HHS (&#8220;NIAID/HHS&#8221;) for the development of galidesivir as a treatment for diseases caused by RNA pathogens, including Marburg virus disease, Yellow Fever and Ebola virus disease. In contracting with U.S. Government agencies, we became subject to various U.S. Government contract requirements, including general clauses for a cost-reimbursement research and development contract, which may limit our reimbursement. While all U.S. Government funding for galidesivir expired in 2022, we may still face risks related to these U.S. Government contracts pending final close out of these contracts.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Government contracts typically contain a number of extraordinary provisions that would not typically be found in commercial contracts, and which may create a disadvantage and additional risks to us as compared to competitors that do not have U.S. Government contracts. If we enter into any new U.S. Government contracts, we may be subject to an increased risk of investigations, criminal prosecution, civil fraud, whistleblower lawsuits and other legal actions and liabilities as compared to private sector commercial companies, and we could suffer serious harm to our reputation if allegations of impropriety were made against us. We could be subject to severe penalties, including legal actions and liabilities, in the event that we are unable to comply with delivery requirements or any other provision of a future U.S. Government contract.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to reach milestones or to make annual minimum payments or otherwise breach our obligations under our license agreements, our licensors may terminate our agreements with them and/or seek additional remedies.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable or fail to meet payment obligations, performance milestones relating to the timing of regulatory filings, product supply obligations, post-approval commitments, or development and commercial diligence obligations; are unable or fail to make milestone payments or material data use payments in accordance with applicable provisions; or fail to pay the minimum annual payments under any of our in-licenses relating to our products or product candidates, our licensors may terminate the applicable license and/or seek other available remedies. As a result, our development of the respective product candidate or commercialization of the product would cease.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because continuing events of default exist under the PhaRMA Notes, the holders of the PhaRMA Notes may be able to foreclose on the collateral securing the PhaRMA Notes and our equity interest in Royalty Sub. As a result, we may not realize the benefit of future royalty payments, if any, that might otherwise accrue to us following repayment of the PhaRMA Notes and we could otherwise be adversely affected.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In March 2011, JPR Royalty Sub LLC, our wholly-owned subsidiary (&#8220;Royalty Sub&#8221;), issued $30.0 million in aggregate principal amount of PhaRMA Senior Secured 14.0% Notes due on December 1, 2020 (the &#8220;PhaRMA Notes&#8221;). </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The PhaRMA Notes are secured principally by (i) certain royalty and milestone payments under our agreement with Shionogi, pursuant to which Shionogi licensed from us the rights to market peramivir in Japan and Taiwan and (ii) the pledge by us of our equity interest in Royalty Sub. Since September 1, 2014, payments from Shionogi have been insufficient for Royalty Sub to service its obligations under the PhaRMA Notes, resulting in a continuing event of default with respect to the PhaRMA Notes since that time. In addition, the PhaRMA Notes had a final legal maturity date of December 1, 2020, at which time the outstanding principal amount of the PhaRMA Notes of $30.0 million, together with accrued and unpaid interest of $20.6 million, was due in full. The failure by Royalty Sub to repay these amounts at the maturity date constituted an additional event of default under the PhaRMA Notes. As Royalty Sub has been unable to service its obligations under the PhaRMA Notes and continuing events of default exist under the PhaRMA Notes, the holders of the PhaRMA Notes may be able to foreclose on the collateral securing the PhaRMA Notes and our equity interest in Royalty Sub and may exercise other remedies available to them under the indenture or other documents related to the PhaRMA Notes. In such event, we may not realize the benefit of future royalty payments, if any, that might otherwise accrue to us following repayment of the PhaRMA Notes, we may incur legal costs, and we might otherwise be adversely affected.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict whether holders of PhaRMA Notes will seek to pursue any remedies as a result of the continuing events of default with respect to the PhaRMA Notes. The PhaRMA Notes are the obligation of Royalty Sub. Due to the non-recourse nature of the PhaRMA Notes, in the event of any potential foreclosure, we believe the primary impact to us would be the loss of future royalty payments, if any, from Shionogi and the legal costs associated with retiring the PhaRMA Notes. As a result, we do not currently expect the continuing events of default on the PhaRMA Notes to have a significant impact on our future results of operations or cash flows. However, we cannot assure you that this will be the case or that we will not otherwise be adversely affected as a result of the continuing events of default under the PhaRMA Notes or the failure by Royalty Sub to repay the PhaRMA Notes at maturity.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">While Royalty Sub continues to pay the holders of the PhaRMA Notes any royalty payments received from Shionogi, which are immaterial, we wrote off the balance due under the PhaRMA Notes to other income as a debt extinguishment as of December 31, 2021.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We anticipate incurring significant indebtedness in connection with the previously announced financing commitments provided by certain affiliates of Blackstone, Inc., which could adversely affect our business. We anticipate that the definitive documentation in connection with such financing (the &#8220;Expected Loan Agreement&#8221;) will contain conditions and restrictions that limit our flexibility in operating our business. Under the Expected Loan Agreement, we may be required to make a prepayment or repay our outstanding indebtedness earlier than we expect if a prepayment event or an event of default occurs, including a material adverse change with respect to us, which could have a material adverse effect on our business.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On October 14, 2025, we entered into a debt commitment letter with certain affiliates of Blackstone, Inc. (&#8220;Blackstone&#8221;) pursuant to which Blackstone agreed to provide a $550.0 million senior secured credit facility consisting of (i) a committed initial term loan in an aggregate principal amount of $350.0 million, (ii) a committed delayed draw term loan facility in an aggregate principal amount not exceeding $50.0 million and (iii) an uncommitted delayed draw term loan facility in an aggregate principal amount not exceeding $150.0 million. Under the Expected Loan Agreement, we will be required to pay to the lenders a prepayment premium or a make-whole premium, as applicable, plus certain fees or expenses to be set forth in the Expected Loan Agreement in the event that we prepay, or are required to prepay, voluntarily or pursuant to a mandatory prepayment obligation under the Expected Loan Agreement (e.g., upon a change of control of the Company and specified other events, subject to certain exceptions), all or part of the then-outstanding term loans under the Expected Loan Agreement, in each case, subject to certain exceptions to be set forth in the Expected Loan Agreement.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our future indebtedness could have important consequences to our stockholders. For example, we expect that such Expected Loan Agreement will:</span></div><div><span><br/></span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increase our vulnerability to adverse general economic or industry conditions;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit our flexibility in planning for, or reacting to, changes in our business or the industry in which we operate;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">makes us more vulnerable to increases in interest rates, as borrowings under the Expected Loan Agreement will accrue interest at variable, uncapped rates, such that increases in interest rates will increase the associated interest payments that we are required to make on outstanding borrowings;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require us to dedicate a portion of our cash flow from operations to interest payments, limiting the availability of cash for other purposes;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit our ability to obtain additional financing or refinancing in the future for working capital or other purposes; and</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">place us at a competitive disadvantage compared to our competitors that have less indebtedness.</span></div><div><span><br/></span></div><div style="text-indent:27.35pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, we anticipate that the Expected Loan Agreement will contain various covenants that limit our ability to engage in specified types of transactions. Subject to certain exceptio</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ns, these covenants are expected to limit our ability to, among other things, dispose of assets; engage in certain mergers, acquisitions, and similar</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> transactions; incur additional indebtedness; grant liens; make investments; pay dividends or make distributions or certain other restricted payments in respect of equity; prepay other indebtedness; enter into restrictive agreements; undertake fundamental changes; or amend certain material contracts.</span></div><div><span><br/></span></div><div style="text-indent:27.35pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The covenants that will be contained in the Expected Loan Agreement could cause us to be unable to pursue business opportunities that we or our stockholders may consider beneficial without the lenders&#8217; permission or without repaying all outstanding obligations under the Expected Loan Agreement.</span></div><div><span><br/></span></div><div style="text-indent:27.35pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A breach of any of these covenants could result in an event of default under the Expected Loan Agreement. An event of default would also occur if, among other things, we fail to pay amounts due under the Expected Loan Agreement, we fail to repay certain other indebtedness having an aggregate principal amount in excess of a threshold amount, an insolvency event occurs with respect to us, judgments for the payment of money in excess of a threshold amount are entered into against us, or a material impairment of our ability to perform our obligations under the Expected Loan Agreement occurs or certain negative regulatory events occur. In the case of a continuing event of default under the Expected Loan Agreement, the lenders under the Expected Loan Agreement will be able to elect to declare all amounts outstanding to be immediately due and payable, proceed against the collateral in which we anticipate granting to the lenders a security interest, or otherwise exercise the rights of a secured creditor. Amounts outstanding under the Expected Loan Agreement are expected to be secured by a security interest in, subject to certain exceptions, substantially all of our assets. Because substantially all of our assets are anticipated to be pledged to secure the Expected Loan Agreement obligations, our ability to incur additional secured indebtedness or to sell or dispose of assets to raise capital may be impaired, which could have an adverse effect on our financial flexibility.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Risks Relating to International Operations</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">International expansion of our business exposes us to business, legal, regulatory, political, operational, financial, and economic risks.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We currently conduct clinical studies and regulatory activities and have hired employees outside of the United States. Doing business internationally involves a number of risks, including, but not limited to:</span></div><div style="margin-top:10pt;padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">multiple, conflicting, and changing laws and regulations such as privacy and data regulations, transparency regulations, tax laws, export and import restrictions, employment laws, regulatory requirements, and other governmental approvals, permits, and licenses;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">introduction of new health authority requirements and/or changes in health authority expectations;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure by us or our partners to obtain and maintain regulatory approvals for the use of our products in various countries;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">complexities and difficulties in obtaining and maintaining protection for, and enforcing, our intellectual property;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties in staffing and managing foreign operations;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">complexities associated with managing multiple payor reimbursement regimes, government payors, or patient self-pay systems;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limits on our ability to penetrate international markets;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for our products, and exposure to foreign currency exchange rate fluctuations, which have been increasingly prevalent alongside a fluctuating U.S. dollar;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">natural disasters and political and economic instability, including wars, terrorism, political unrest, results of certain elections and votes, actual or threatened public health emergencies and outbreak of disease, epidemics or pandemics (e.g., the COVID-19 pandemic), boycotts, adoption or expansion of government trade restrictions, and other business restrictions;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">certain expenses including, among others, expenses for travel, translation, and insurance;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory and compliance risks that relate to maintaining accurate information and control over commercial operations and activities that may fall within the purview of the U.S. Foreign Corrupt Practices </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="padding-left:63pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Act, including its books and records provisions or anti-bribery provisions, and foreign laws and regulations; and</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory and compliance risks relating to doing business with any entity that is subject to sanctions administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Any of these factors could significantly harm our international expansion of operations and adversely affect our business and results of operations. Additionally, in some countries, such as Japan, the pricing of prescription pharmaceuticals is subject to governmental control and access. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we or our partners may be required to conduct a clinical trial that compares the cost-effectiveness of our product to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be materially harmed.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign currency exchange rate fluctuations could have an adverse impact on our results of operations, financial position, and cash flows.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We conduct operations in countries outside of the United States involving transactions in a variety of currencies other than the U.S. dollar. These transactions include, without limitation, commercial sales, contract manufacturing, and clinical trial activities. Although most of our revenues and expenses are denominated in U.S. dollars, we have foreign currency exposure to fluctuations in other foreign currencies, such as the Euro, British Pound, Japanese Yen and Canadian Dollar. Changes in the value of these currencies relative to the U.S. dollar may impact our condensed consolidated operating results, including our revenues and expenses, causing fluctuations in our operating results from period to period and/or resulting in foreign currency transaction losses that adversely impact our results of operations, financial position, and cash flows.  See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Quantitative and Qualitative Disclosures about Market Risk&#8212;Foreign Currency Risk</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; in Part I, Item 3 of this report for additional information about our foreign currency risk.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our actual or perceived failure to comply with European governmental laws and regulations and other legal obligations related to privacy, data protection and information security could harm our business.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States, an increasing number of laws and regulations may govern data privacy and security. EU member states, the United Kingdom, Switzerland and other countries have adopted data protection laws and regulations, which impose significant compliance obligations. These laws include the GDPR and similar national legislation within the EEA, the United Kingdom GDPR, Switzerland&#8217;s Federal Data Protection Act, the EU Clinical Trials Regulation, and the e-Privacy Directive (2002/58/EC), and are discussed in more detail in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business&#8212;Government Regulation&#8212;Data Privacy and Security Laws</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; in Part I, Item 1 of our most recent Annual Report on Form 10-K. Failure to comply with the requirements of these laws may result in significant fines. For example, noncompliance with the GDPR or related national data protection laws, which may deviate from the GDPR, may result in significant fines of up to 4.0% of global revenues, or &#8364;20.0 million, whichever is greater.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition to such fines, failure to comply with the requirements of the GDPR or similar national legislation may result in temporary or definitive bans on data processing and other corrective actions and subject us to litigation and/or adverse publicity, which could have material adverse effects on our reputation and business. As a result of the implementation of the GDPR, we are required to put in place additional mechanisms to ensure compliance with the data protection rules. For example, the GDPR requires us to make more detailed disclosures to data subjects, requires disclosure of the legal basis on which we can process personal data, makes it harder for us to obtain valid consent for processing, requires the appointment of a data protection officer where sensitive personal data (i.e., health data) is processed on a large scale, introduces mandatory data breach notification throughout the European Union, imposes additional obligations on us when we are contracting with service providers and requires us to adopt appropriate privacy governance including policies, procedures, training and data audits. We depend on a number of third parties in relation to the provision of our services, a number of which process personal data of EU individuals on our behalf. With each such provider, we are required to enter into contractual arrangements under which they are contractually obligated to only process personal data according to our instructions, and conduct diligence to ensure that they have sufficient technical and organizational security measures in place. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Compliance with evolving laws regarding the transfer of personal data to the United States and other countries also requires increased resources and may result in increased exposure to regulatory actions, fines and penalties, the inability to transfer data and work with partners, vendors and other third parties, and injunctions against our processing or transferring of personal data necessary to operate our business. We are also subject to evolving European privacy laws on electronic marketing and cookies.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Compliance with the requirements imposed by the GDPR and other such laws can be time-consuming, expensive and difficult, and may increase our cost of doing business or require us to change our business practices, and despite our efforts we may not be successful in achieving compliance if our personnel, collaborators, partners or vendors do not comply with applicable data protection obligations. Despite our efforts, our personnel or third parties on whom we rely may fail to comply with such obligations, which could negatively impact our business operations. If we or the third parties on which we rely fail, or are perceived to have failed, to address or comply with applicable data privacy and security obligations, we could face significant consequences, including but not limited to: regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse business consequences.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Risks Relating to Technology</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our facilities, or the facilities of our third-party vendors, incur damage or power is lost for a significant length of time, our business will suffer.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We and our third-party vendors store commercial product, clinical and stability samples, and manufacturing data at our facilities that could be damaged if the facilities incur physical damage or in the event of an extended power failure. We have backup power systems in addition to backup generators to maintain power to all critical functions, but any loss of these products or samples could result in significant delays in our commercialization or drug development process.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we store most of our preclinical and clinical data at our facilities. While duplicate copies of most clinical data are secured off-site, and a significant portion of our data is included in regular backups of our systems, we could lose important data if our facilities incur damage, or if our vendor data systems fail, suffer damage or are destroyed. Any significant degradation or failure of our computer systems could cause us to inaccurately calculate or lose our data. Loss of data could result in significant delays in our drug development process, and any system failure could harm our business and operations.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cyber incidents and related disruptions in our or our third-party vendors&#8217; information technology systems could adversely affect our business.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are increasingly dependent on information technology systems to operate our business. In addition, the FDA and comparable foreign regulatory authorities regulate, among other things, the record keeping and storage of data pertaining to potential pharmaceutical products. Like other companies in our industry, our information technology systems and infrastructure (as well as those of our third-party providers) and our lab equipment and operations technology may be vulnerable to cyber incidents, intrusions, and other similar activities that threaten the confidentiality, integrity, and availability of our information. These threats come from a variety of sources, including by computer hackers, foreign governments, foreign companies, or competitors, or may be breached by employee error, malfeasance or other disruption. These threats are prevalent, continue to rise, and are becoming increasingly difficult to detect. Recently, there have been reports of disruptions in billing and data systems in healthcare (e.g., the cybersecurity incident affecting Change Healthcare in February 2024). Such cybersecurity events which materially disrupt the healthcare system upon which our business relies could adversely affect our business if such disruption is widespread and continues for an extended period of time.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cyber incidents could also include the use of artificial intelligence (&#8220;AI&#8221;) and machine learning to launch more automated, targeted and coordinated attacks on targets. Cyber incidents may lead to operational outages, loss of intellectual property due to industrial espionage, malware, and financial or data attacks via social engineering. These risks have increased as we have experienced significant growth in the number of our employees and the scope of our operations and as virtual and remote working have become more widely used, and sensitive data is accessed by employees working in less secure, home-based environments. A breakdown, invasion, corruption, destruction, or interruption of information technology systems could negatively impact operations. If our systems are damaged, fail to function properly or otherwise become unavailable, we may incur substantial costs to repair or replace them, and we may experience loss of critical data and interruptions or delays in our ability to perform critical functions, which could adversely affect our business, financial condition or results of operations. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we rely on third-party service providers and technologies to operate significant information technology systems and business infrastructure, and we currently use these providers to perform business critical information technology and business services. Supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties&#8217; infrastructure in our supply chain or our third-party partners&#8217; supply chains have not been or will not be compromised.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced cybersecurity threats and incidents, which to date have not had a material impact on our reputation, business, financial condition, or operations; however; there is no assurance that such impacts will not be material in the future.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Any compromise of our data security could also result in a violation of applicable privacy and other laws, significant legal, regulatory, and financial exposure, damage to our reputation, loss or misuse of the information and a loss of confidence in our data security measures, which could harm our business. Loss or misuse of our intellectual property, clinical trial data, or commercially sensitive data could adversely impact our business. While we have implemented security measures designed to protect against security incidents and a significant portion of our data is included in regular backups of our systems, there can be no assurance that our efforts to protect our data and information technology systems will prevent breakdowns or breaches in our systems, or those of third parties with which we do business, and any such events could adversely affect our business.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">From time to time, we use artificial intelligence in our business, and challenges with properly managing its use could adversely affect our business.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The increasing use of AI and machine learning technology in the biopharmaceutical industry, combined with an uncertain regulatory environment, presents new risks and challenges. From time to time, we adopt and integrate AI solutions into our systems for specific use cases reviewed by legal and information security, and applications of AI may become important in our operations over time. Our vendors may incorporate AI tools into their offerings without disclosing this use to us, and the providers of these tools may not meet existing or rapidly evolving regulatory or industry standards with respect to privacy and data protection. Moreover, the use of AI-based software may lead to the inadvertent release of confidential or proprietary information, which may adversely impact our ability to realize the benefit of our intellectual property, cause us to incur liabilities as the result of any breaches of confidentiality or impact our ability to comply with data security and privacy laws. Further, as the regulatory framework for these technologies evolves, it is possible that new laws and regulations will be adopted, or that existing laws and regulations may be interpreted in ways that would affect our business, including as a result of the cost to comply with such laws or regulations. Our competitors or other third parties may also incorporate AI into their businesses more efficiently than us, which could impair our ability to compete effectively and adversely affect our results of operations. The rapid innovation and developments surrounding AI, including potential government regulation of AI, may require significant resources to develop, test and maintain our implementations of AI.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Operational Risks</span></div><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to realize the anticipated benefits of the sale of our European ORLADEYO Business.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to realize the anticipated benefits from the sale of our European ORLADEYO Business </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(as defined in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2&#8212;Assets and Liabilities Held for Sale</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; in the Notes to Condensed Consolidated Financial Statements in Part I, Item 1 of this report)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Our ability to realize the anticipated benefits of the sale and the success of the remaining company is subject to various risks and uncertainties, including the possibility that we may not be able to successfully sustain being a higher margin business or that we may not increase profitability through sustainable ORLADEYO growth, our pipeline, and potential external opportunities.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Further, upon closing of the sale of the European ORLADEYO Business, we entered into a transition services agreement, which will provide for certain transition services to be provided to BioCryst Ireland Limited by us, for the periods of time and compensation set forth therein, in order to facilitate the transition of the European ORLADEYO Business to Neopharmed. Performance of our ongoing obligations under the transition services agreement is subject to additional risks, including that we may incur significant financial costs, we may not be able to successfully perform such obligations, and the focus and attention of our management and employee resources may be diverted, which could have a negative impact on our future revenues and/or results of operations.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the amount of the milestone payments we may receive following the sale of our European ORLADEYO Business is subject to various risks and uncertainties. The milestone payments will be based on the achievement of specified net sales targets for the sale of ORLADEYO in Central and Eastern Europe. It is not possible to determine with precision as of the date of this Quarterly Report on Form 10-Q the amount or timing of sales of ORLADEYO in Central and Eastern Europe in the future and, therefore, it is possible that the milestone payments will not be earned or will be limited by lower net sales than anticipated. The specified net sales targets for ORLADEYO in Central and Eastern Europe were based on certain assumptions about the future financial performance of ORLADEYO in Central and Eastern Europe, and there can be no assurance that such projections will be achieved or that the milestone payments will become payable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Health epidemics or pandemics could materially adversely affect our business, operations, clinical development or commercialization plans and timelines, or that of third parties with whom we conduct business, including, without limitation, our development partners, manufacturers, CROs, and others, as well as the regulatory and government agencies with whom we work.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A health epidemic or pandemic, such as the COVID-19 pandemic, and related government orders or responsive business policies and procedures, could cause disruptions to our business, operations, and clinical development or commercialization plans and timelines, as well as the business and operations of third parties with whom we conduct business.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If our operations or those of third parties with whom we conduct business, such as development partners, manufacturers, CROs and others, are impaired or curtailed as a result of such events, the development and commercialization of our products and product candidates could be stopped or delayed, or the costs of such development and commercialization activities could increase, any of which could have a material adverse impact on our business. For example, our suppliers or other vendors may be unable to meet their obligations to us or perform their services as expected. In such circumstances, we may not be able to enter into arrangements with alternative suppliers or vendors or do so on commercially reasonable terms or in a timely manner. Such delays could adversely impact our ability to meet our desired clinical development and any commercialization timelines.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our clinical trials were affected by the COVID-19 pandemic and we may experience similar delays or interruptions due to health epidemics or pandemics in the future, which could adversely impact our clinical trial operations. Health epidemics or pandemics could also affect the operations of regulators and other health and governmental authorities, which could result in delays of reviews and approvals, inspections, or other regulatory activities, including as we continue to expand internationally and bring ORLADEYO to additional global markets.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The global impact of a health epidemic or pandemic, such as the COVID-19 pandemic, could also materially affect global economies and financial markets, which could reduce our ability to access the equity or debt capital markets or obtain other sources of capital if needed, which could negatively affect our liquidity. In addition, a recession or market correction could materially affect our business and the value of our common stock. Health epidemics or pandemics could also have the effect of heightening many of the other risks described in this report.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business, operations, clinical development or commercialization plans and timelines, and access to capital could be adversely affected by unpredictable and unstable market and economic conditions.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our business, operations, clinical development or commercialization plans and timelines, and access to capital could be adversely affected by unpredictable and unstable market and economic conditions, including as a result of inflation, increased interest rates, disruption or instability in the banking industry, foreign exchange rate fluctuations, U.S. Government shutdowns, instability in connection with changes in the presidential administration in the United States, geopolitical instability, actual or threatened public health emergencies, or outbreaks of disease, epidemics or pandemics (such as the COVID-19 pandemic). The magnitude, duration and long-term effect of each of these factors, as well as the effects of actions taken by governments to address them, are unknown at this time, but they could result in further significant disruption of the global economy and financial markets. Our business may be adversely affected by any related economic downturn, volatile geopolitical and business environment, or continued market instability.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Unstable market and economic conditions could materially affect our ability to access the equity or debt capital markets or obtain other sources of capital if needed in the future, which could negatively affect our liquidity. In addition, a recession or market correction could materially affect our business and the value of our common stock.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Market and economic conditions continue to evolve, with the ultimate impacts being uncertain and subject to change. These effects could be material, and we will continue to monitor the economic climate closely. We do not yet know the full extent and magnitude of the impacts that these developments will have on our business, on the healthcare system, or on the global economy. In addition, unstable market conditions could have the effect of heightening many of the other risks described in this report.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Insurance coverage is increasingly more costly and difficult to obtain or maintain.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">While we currently have insurance for our business, property, directors and officers, and our products, insurance is increasingly more costly and narrower in scope, and we may be required to assume more risk in the future. If we are subject to claims or suffer a loss or damage in excess of our insurance coverage, we will be required to bear any loss in excess of our insurance limits. If we are subject to claims or suffer a loss or damage that is outside of our insurance </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">coverage, we may incur significant uninsured costs associated with loss or damage that could have an adverse effect on our operations and financial position. Furthermore, any claims made on our insurance policies may impact our ability to obtain or maintain insurance coverage at reasonable costs or at all.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to retain our existing key personnel or fail to attract and retain additional key personnel, the development of our product candidates, the commercialization of our products, and the related expansion of our business may be delayed or stopped.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent upon our senior management and scientific team, the unexpected loss of whose services might impede the achievement of our development and commercial objectives. Competition for key personnel with the experience that we require is intense and is expected to continue to increase. Our inability to attract and retain the required number of skilled and experienced management, commercial, operational and scientific personnel may harm our business because we rely upon these personnel for many important functions of our business.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our risk management committee and other compliance methods are not effective, our business, financial condition and operating results may be adversely affected.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to identify, manage and respond to the various risks related to our business is largely dependent on our established and maintained compliance, risk, audit and reporting systems and procedures. The Board of Directors has ultimate responsibility for risk oversight of the Company and carries out this duty through its committees. The Board of Directors may delegate oversight authority with respect to certain issues in a committee&#8217;s applicable areas of expertise. At the Company level, our senior management team similarly monitors risk through the risk management committee and other sub-committees focused on specific areas of risk (e.g., cybersecurity, quality assurance). Membership of the risk management committee consists primarily of key department heads who are asked to bring to such committee relevant items for discussion that they or their teams have identified at the numerous sub-committees these individuals chair or attend. The risk management committee, along with the other sub-committees in the Company, identifies key risks and mitigation strategies which are reported directly to our senior management, the Audit Committee and to the full Board of Directors on a regular basis.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If our policies, procedures, and compliance systems, including our risk management committee, are not effective, or if we are not successful in monitoring or evaluating the risks to which we are or may be exposed, our business, reputation, financial condition and operating results could be materially adversely affected. We cannot provide assurance that our policies and procedures will always be effective, or that our management or the risk management committee would be able to identify any such ineffectiveness. If our compliance and risk management strategies are not effective, our business, financial condition and operating results may be adversely affected.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future acquisitions, strategic investments, partnerships, alliances, or divestitures could be difficult to identify and integrate, divert the attention of management, disrupt our business, dilute stockholder value, materially change the risk profile of the Company and could fail to meet our expectations, any of which could adversely affect our operating results and financial condition.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that we will seek to acquire or invest in businesses, products or technologies that we believe could complement or expand our portfolio or otherwise offer growth opportunities. The pursuit of potential acquisitions may divert the attention of management and cause us to incur various expenses in identifying, investigating and pursuing businesses or products. In addition, we may not be able to find and identify desirable acquisition targets or be successful in entering into an agreement with any particular target or consummating any such agreement. Even if we do consummate an acquisition, in connection therewith we may be required to issue equity (thereby diluting our current stockholders) or debt, we may not be able to integrate successfully the acquired personnel, operations and technologies, or effectively manage the combined business following the acquisition, or the acquired business could otherwise fail to meet our expectations, which, in each case, could have a material adverse effect on our business projections, financial condition, results of operations and prospects. See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Relating to the Proposed Merger</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; in this section for further discussion of the potential business disruptions, financial uncertainties, and operational risks that we face while the Merger is pending.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may divest or license all or a portion of certain business or product categories, which could cause a decline in revenue or profitability and may make our financial results more volatile. We may be unable to complete any such divestiture or license on terms favorable to us, within the expected timeframes, or at all. We may have continued financial exposure to divested or licensed businesses following the completion of any such transaction, including increased costs due to potential litigation, contingent liabilities and indemnification of the buyer or licensee related to, among other things, lawsuits, regulatory matters or tax liabilities. Such divestitures or licenses may also divert management&#8217;s attention from our core businesses and lead to potential issues with employees, customers or suppliers. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business and operations could be negatively affected if we become subject to stockholder activism or hostile bids, which could cause us to incur significant expense, hinder execution of our business strategy and impact our stock price.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stockholder activism, which takes many forms and arises in a variety of situations, has been increasingly prevalent. Stock price declines may also increase our vulnerability to unsolicited approaches. If we become the subject of certain forms of stockholder activism, such as proxy contests or hostile bids, the attention of our management and our Board of Directors may be diverted from execution of our strategy. Such stockholder activism could give rise to perceived uncertainties as to our future strategy, adversely affect our relationships with business partners and make it more difficult to attract and retain qualified personnel. Also, we may incur substantial costs, including significant legal fees and other expenses, related to activist stockholder matters. Our stock price could be subject to significant fluctuation or otherwise be adversely affected by the events, risks and uncertainties of any stockholder activism.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to Investing in Our Common Stock</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our existing principal stockholders hold a substantial amount of our common stock and may be able to influence significant corporate decisions, which may conflict with the interest of other stockholders.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Some of our stockholders own greater than 5% of our outstanding common stock. Our top ten stockholders own approximately</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> 42% </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of our common stock and can individually, and as a group, influence our operations based upon their concentrated ownership and may also be able to influence the outcome of matters requiring approval of the stockholders, including the election of our directors and other corporate actions.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our stock price has been, and is likely to continue to be, highly volatile, which could cause the value of an investment in our common stock to decline significantly.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The market prices for securities of biotechnology companies in general have been highly volatile and may continue to be highly volatile in the future. Moreover, our stock price has fluctuated frequently, and these fluctuations are often not related to our financial results. For the twelve months ended September&#160;30, 2025, the 52-week range of the market price of our stock was from $6.02 to $11.31 per share. The following factors, in addition to other risk factors described in this section, may have, and in some cases have had, a significant impact on the market price of our common stock:</span></div><div style="margin-top:10pt;padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of technological innovations or new products by us or our competitors;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments or disputes concerning patents or proprietary rights;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additional dilution through sales of our common stock or other derivative securities;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">status of new or existing licensing or collaborative agreements and government contracts;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements relating to the status of our programs;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">us or our partners achieving or failing to achieve development milestones;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">publicity regarding actual or potential medical results relating to products under development by us or our competitors;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">publicity regarding certain public health concerns for which we are or may be developing treatments;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments in both the United States and foreign countries;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">public concern as to the safety of pharmaceutical products;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actual or anticipated fluctuations in our operating results;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in financial estimates or recommendations by securities analysts and the comparison of such estimates to our actual results;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">online automated financial platforms&#8217; treatment or classification of our financial information;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in our public guidance;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of healthcare payment systems, including developments in price control legislation;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">announcements by us or our competitors of significant acquisitions (such as the proposed Merger), strategic partnerships, divestitures (such as the transaction with Neopharmed), joint ventures, capital commitments or other monetization transactions;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions or departures of key personnel or members of our Board of Directors;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">purchases or sales of substantial amounts of our stock by existing stockholders, including officers or directors;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic and other external factors or other disasters or crises; and</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">period-to-period fluctuations in our financial results.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">This volatility could cause the value of an investment in our common stock to decline significantly. In addition, companies that have experienced volatility in the market price of their stock in the past have been subject to securities class action litigation. Securities litigation, and any other type of litigation, brought against us could result in substantial costs </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and divert our management&#8217;s attention from other business concerns, which could seriously harm our business and adversely affect our results of operations.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to maintain effective internal control over financial reporting, we may not be able to produce accurate and timely financial statements, which may adversely affect investor confidence in us and our financial reporting, adversely affect our business and operating results and negatively impact the trading price of our common stock. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we are required to maintain effective internal control over financial reporting (as described in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Controls and Procedures</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; in Part I, Item 4 of this report), and effective disclosure controls and procedures. If we identify one or more material weaknesses in our internal control over financial reporting, we will not be able to assert that our internal controls and procedures are effective. A material weakness, as defined in Rule 12b-2 under the Exchange Act, is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of annual or interim financial statements will not be prevented or detected on a timely basis. In 2023, we identified and timely reported two material weaknesses in our internal control over financial reporting, which management determined to be subsequently remediated as of December 31, 2023 and September 30, 2024, respectively.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Although we believe the financial statements included in this report fairly present, in all material respects, our financial condition, results of operations and cash flows for the periods presented in conformity with U.S. GAAP, any failure to maintain effective internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If our internal control over financial reporting is not effective, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future sales and issuances of securities may dilute the ownership interests of our current stockholders and cause our stock price to decline.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Future sales of our common stock by us or our current stockholders into the public market could cause the market price of our stock to fall. As of September&#160;30, 2025, there were 210,521,833 shares of our common stock outstanding. We may from time to time issue securities in relation to a license arrangement, collaboration, merger or acquisition. See, for example, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors&#8212;Risks Relating to Our Business&#8212;Risks Relating to the Proposed Merger&#8212;Issuance of shares of our common stock in connection with the Merger may adversely affect the market price of our common stock.&#8221;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> We may also sell, for our own account, shares of common stock or other equity securities, from time to time at prices and on terms to be determined at the time of sale.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2025, there were 45,543,939 stock options and restricted stock units outstanding and 13,721,069 shares available for issuance under our Amended and Restated Stock Incentive Plan, 5,722,015 stock options and restricted stock units outstanding and 1,507,933 shares avai</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">lable for issuance under our Amended and Restated Inducement Equity Incentive Plan, and </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,674,237 shares a</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">vailable for issuance under our Amended and Restated Employee Stock Purchase Plan. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we could also make equity grants outside of our Amended and Restated Stock Incentive Plan or Amended and Restated Inducement Equity Incentive Plan. The shares underlying existing stock options, restricted stock units and possible future stock options, stock appreciation rights, restricted stock units and stock awards have been, or will be, registered pursuant to registration statements on Form S-8.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If some or all of such shares are sold or otherwise issued into the public market over a short period of time, our current stockholders&#8217; ownership interests may be diluted and the value of all publicly traded shares is likely to decline, as the market may not be able to absorb those shares at then-current market prices. Additionally, such sales and issuances may make it more difficult for us to sell equity securities or equity-related securities in the future at a time and price that our management deems acceptable, or at all.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have anti-takeover provisions in our corporate charter documents that may result in outcomes with which you do not agree.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors has the authority to issue up to 5,000,000 shares of undesignated preferred stock and to determine the rights, preferences, privileges and restrictions of those shares without further vote or action by our stockholders. The rights of the holders of any preferred stock that may be issued in the future may adversely affect the rights of the holders of common stock. The issuance of preferred stock could make it more difficult for third parties to acquire a majority of our outstanding voting stock.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our Certificate of Incorporation provides for staggered terms for the members of the Board of Directors and supermajority approval of the removal of any member of the Board of Directors and prevents our stockholders from acting by written consent. Our Certificate of Incorporation also requires supermajority approval of any amendment of these provisions. These provisions and other provisions of our Amended and Restated By-Laws and of Delaware law applicable to us could delay or make more difficult a merger, tender offer or proxy contest involving us.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have never paid dividends on our common stock and do not anticipate doing so in the foreseeable future.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have never paid cash dividends on our stock. We currently intend to retain all future earnings, if any, for use in the operation of our business. Accordingly, we do not anticipate paying cash dividends on our common stock in the foreseeable future.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Amended and Restated By-Laws provide that the Court of Chancery of the State of Delaware will be the sole and exclusive forum for certain litigation that may be initiated by our stockholders, which may limit a stockholder</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">s ability to obtain a favorable judicial forum for such disputes with us or our directors, officers or employees.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our Amended and Restated By-Laws provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, stockholders, employees or agents to us or our stockholders, (iii) any action asserting a claim against us or any of our directors, officers, stockholders, employees or agents arising out of or relating to any provision of the General Corporation Law of Delaware or our Certificate of Incorporation or Amended and Restated By-Laws, or (iv) any action against us or any of our directors, officers, stockholders, employees or agents governed by the internal affairs doctrine of the State of Delaware. This exclusive forum provision does not apply to establish the Delaware Court of Chancery as the forum for actions or proceedings brought to enforce a duty or liability created by the Securities Act of 1933, as amended, or the Exchange Act, or any other claim for which the federal courts have exclusive jurisdiction.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">This exclusive forum provision may limit a stockholder&#8217;s ability to choose its preferred judicial forum for disputes with us or our directors, officers, employees or agents, which may discourage the filing of lawsuits with respect to such claims. If a court were to find this exclusive forum provision to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in another jurisdiction, which could adversely affect our business and financial condition.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Natural disasters, epidemic or pandemic disease outbreaks, trade wars, armed conflicts, political unrest or other events could disrupt our business or operations or those of our development partners, manufacturers, regulators or other third parties with whom we conduct business now or in the future.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A wide variety of events beyond our control, such as natural disasters (including as a result of climate change), epidemic or pandemic disease outbreaks (such as the COVID-19 pandemic), trade wars, armed conflict, political unrest, government shutdowns, instability in connection with changes in the presidential administration in the United States, or other events could disrupt our business or operations or those of our development partners, manufacturers, regulatory authorities, or other third parties with whom we conduct business. These events may cause businesses and government agencies to be shut down, supply chains or trade to be interrupted, slowed, or rendered inoperable, and individuals to become ill, quarantined, or otherwise unable to work and/or travel due to health reasons or governmental restrictions. If our operations or those of third parties with whom we conduct business are impaired or curtailed as a result of these events, the development and commercialization of our products and product candidates could be impaired or halted, which could have a material adverse impact on our business. See, for example, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors&#8212;Risks Relating to Our Business&#8212;Other Operational Risks&#8212;Our business, operations, clinical development or commercialization plans and timelines, and access to capital could be adversely affected by unpredictable and unstable market and economic conditions</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221; In addition, other events, such as the Ukraine-Russia and Middle East conflicts, or rising tensions between China and Taiwan, could adversely impact our business. For example, the conflicts could lead to sanctions, embargoes, supply shortages, regional instability, geopolitical shifts, cyber-attacks, other retaliatory actions, and adverse effects on macroeconomic conditions, currency exchange rates, and financial markets, which could adversely impact our operations and financial results, as well as those of third parties with whom we conduct business.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to legal proceedings, which could harm our reputation or result in other losses or unexpected expenditure of time and resources.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may be involved in disputes, including, without limitation, disputes with our employees, collaborative partners, and third-party vendors. We may be called upon to initiate legal proceedings or to defend ourselves in such legal proceedings relating to our relationships with these parties, our decisions and actions or omissions with respect thereto, and our business. In addition, if our stock price is volatile, we may become involved in securities class action lawsuits in the future. Due to the inherent uncertainties in legal proceedings, we cannot accurately predict the ultimate outcome of any such proceeding. An unfavorable outcome in any such proceeding could have an adverse impact on our business, financial condition and results of operations. Any current or future dispute resolution or legal proceeding, regardless of the merits of any such proceeding, could harm our reputation and result in substantial costs and a diversion of management&#8217;s attention and resources that are needed to successfully run our business.</span></div><div id="id1b8c440ead54d70904211d3c0a5ea1f_127"></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Item 5. Other Information</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Director and Officer Trading Arrangements</span></div><ix:nonNumeric contextRef="c-7" name="ecd:MtrlTermsOfTrdArrTextBlock" id="f-1146" escape="true"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2025, two of the directors and officers of the Company <ix:nonNumeric contextRef="c-7" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-1147">adopted</ix:nonNumeric>, modified or <ix:nonNumeric contextRef="c-7" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-1148"><ix:nonNumeric contextRef="c-7" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-1149">terminated</ix:nonNumeric></ix:nonNumeric> the &#8220;Rule 10b5-1 trading arrangements&#8221; (as such term is defined in Item 408(a) of Regulation S-K) as set forth in the table below.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.242%"><tr><td style="width:1.0%"/><td style="width:28.212%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.410%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.167%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.410%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.167%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.410%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.289%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.410%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.225%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Name (Title)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Action</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Date of Action</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Duration of Trading Arrangement</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Number of Securities</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Alane P. Barnes,</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chief Legal Officer and Secretary</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Modification</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">August 13, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Until December 20, 2027, or such earlier date upon which all transactions are completed or the plan is terminated</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-304" name="ecd:TrdArrIndName" id="f-1150">A. Machelle Sanders</ix:nonNumeric>, </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-304" name="ecd:TrdArrIndTitle" id="f-1151">Member of the Board of Directors</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-304" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-1152">Adoption</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-304" name="ecd:TrdArrAdoptionDate" id="f-1153">August 14, 2025</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Until <ix:nonNumeric contextRef="c-304" name="ecd:TrdArrExpirationDate" id="f-1154">December&#160;31, 2025</ix:nonNumeric>, or such earlier date upon which all transactions are completed or the plan is terminated</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></div></td></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1) This trading plan was originally adopted on December 1, 2022 (the &#8220;2022 Barnes Plan&#8221;) and provided for the sale of up to (i) 24,710 shares of common stock and (ii) 137,897 shares of common stock underlying stock options through December 29, 2025. The 2022 Barnes Plan was amended on May 15, 2024 to cancel all open orders under the 2022 Barnes Plan and to provide for the sale of up to 119,897 shares of common stock underlying stock options expiring in 2024 and 2025 (the &#8220;2024 Barnes Plan&#8221;). The 2024 Barnes Plan was amended on August 13, 2025 (the &#8220;2025 Barnes Plan&#8221;) to cancel all open orders under the 2024 Barnes Plan and to provide for the sale of up to (i) 123,100 shares of common stock underlying restricted stock units, net of shares withheld to cover taxes, (ii) 19,770 shares of common stock, and (iii) 347,501 shares of common stock underlying stock options expiring in 2025 through 2027, pursuant to the terms of the 2025 Barnes Plan.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2) This trading plan (the &#8220;Sanders Plan&#8221;) provides for the sale of up to <ix:nonFraction unitRef="shares" contextRef="c-305" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-1155">9,600</ix:nonFraction> shares of common stock, pursuant to the terms of the Sanders Plan.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">82</span></div></div></div><div id="id1b8c440ead54d70904211d3c0a5ea1f_133"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 6.&#160;&#160;&#160;&#160;Exhibits</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:495.00pt"><tr><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:433.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:39pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">2.1***</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/882796/000114036125024089/ef20051351_ex2-1.htm">Stock Purchase Agreement, dated as of June 27, 2025, by and among BioCryst Pharmaceuticals, Inc., BioCryst Ireland Limited and Neopharmed Gentili S.p.A. Incorporated by reference to Exhibit 2.1 to the Company&#8217;s Form 8-K filed June 30, 2025.</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:39pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">2.2***</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/882796/000114036125038031/ef20057029_ex2-1.htm">Agreement and Plan of Merger, dated as of October 14, 2025, by and among BioCryst Pharmaceuticals, Inc., Axel Merger Sub, Inc., and Astria Therapeutics, Inc. Incorporated by reference to Exhibit 2.1 to the Company&#8217;s Form 8-K filed October 14, 2025.</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:27pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">3.1</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/882796/000103570406000836/d42297exv3w1.htm">Third Restated Certificate of Incorporation of Registrant. Incorporated by reference to Exhibit 3.1 to the Company&#8217;s Form 8-K filed December 22, 2006.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:27pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">3.2</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/882796/000136231007001386/c70813exv3w1.htm">Certificate of Amendment to the Third Restated Certificate of Incorporation of Registrant. Incorporated by reference to Exhibit 3.1 to the&#160;Company&#8217;s Form 8-K filed July 24, 2007.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:27pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">3.3</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/882796/000119312514186707/d722313dex31.htm">Certificate of Amendment to the Third Restated Certificate of Incorporation of Registrant. Incorporated by reference to Exhibit 3.1 to the&#160;Company&#8217;s Form 8-K filed May 7, 2014.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:27pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">3.4</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/882796/000117184320003680/exh_31.htm">Certificate of Elimination of the Series B Junior Participating Preferred Stock. Incorporated by reference to Exhibit 3.1 to the Company&#8217;s Form 8-K filed May 13, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882796/000117184320003680/exh_32.htm">0.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:27pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">3.5</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/882796/000117184320003680/exh_32.htm">Certificate of Amendment to the Third Restated Certificate of Incorporation of Registrant. Incorporated by reference to Exhibit 3.2 to the Company&#8217;s Form 8-K filed May 13, 2020.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:27pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">3.6</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/882796/000117184324000297/exh_31.htm">Amended and Restated By-Laws of BioCryst Pharmaceuticals, Inc., effective January 16, 2024. Incorporated by reference to Exhibit 3.1 to the Company&#8217;s Form 8-K filed January 18, 2024.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:39pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.1*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/882796/000162828025037795/bcrx-20250630x10xqxex103.htm">Amended and Restated Employment Agreement, effective July 23, 2025, by and between BioCryst Pharmaceuticals, Inc. and Babar Ghias. Incorporated by reference to Exhibit 10.3 to the Company&#8217;s Form 10-Q filed August 5, 2025.</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:39pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.2*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/882796/000162828025037795/bcrx-20250630x10xqxex104.htm">Amendment No. 2 to the Employment Agreement, effective August 1, 2025, by and between BioCryst Pharmaceuticals, Inc. and Charles Gayer. Incorporated by reference to Exhibit 10.4 to the Company&#8217;s Form 10-Q filed August 5, 2025.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:27pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(10.3)*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="thackray-biocrystseparat.htm">Separation Agreement, effective September 1, 2025, by and between BioCryst Pharmaceuticals, Inc. and Helen Thackray.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:27pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(10.4)*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="bcrx-20250930x10xqxex104.htm">Consulting Agreement, effective September 1, 2025, by and between BioCryst Pharmaceuticals, Inc. and Helen Thackray.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:39pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.5***</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/882796/000114036125036875/ef20056247_ex10-1.htm">Amended and Restated IP Licence Agreement, effective October 1, 2025, by and between BioCryst Pharmaceuticals, Inc. and BioCryst Ireland Limited. Incorporated by reference to Exhibit 10.1 to the Company</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/882796/000114036125036875/ef20056247_ex10-1.htm">&#8217;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/882796/000114036125036875/ef20056247_ex10-1.htm">s Form 8-K filed October 1, 2025.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:39pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.6***</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/882796/000114036125036875/ef20056247_ex10-2.htm">Supply Agreement, effective October 1, 2025, by and between BioCryst Pharmaceuticals, Inc. and BioCryst Ireland Limited. Incorporated by reference to Exhibit 10.2 to the Company</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/882796/000114036125036875/ef20056247_ex10-2.htm">&#8217;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/882796/000114036125036875/ef20056247_ex10-2.htm">s Form 8-K filed October 1, 2025.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:495.00pt"><tr><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:433.00pt"/><td style="width:1.0pt"/></tr><tr style="height:39pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.7***</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/882796/000114036125036875/ef20056247_ex10-3.htm">Global Brand and Support Agreement, effective October 1, 2025, by and between BioCryst Pharmaceuticals, Inc. and BioCryst Ireland Limited. Incorporated by reference to Exhibit 10.3 to the Company</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/882796/000114036125036875/ef20056247_ex10-3.htm">&#8217;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/882796/000114036125036875/ef20056247_ex10-3.htm">s Form 8-K filed October 1, 2025.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:39pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.8***</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/882796/000114036125036875/ef20056247_ex10-4.htm">Transition Services Agreement, effective October 1, 2025, by and between BioCryst Pharmaceuticals, Inc. and BioCryst Ireland Limited. Incorporated by reference to Exhibit 10.4 to the Company</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/882796/000114036125036875/ef20056247_ex10-4.htm">&#8217;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/882796/000114036125036875/ef20056247_ex10-4.htm">s Form 8-K filed October 1, 2025.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:39pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.9***</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/882796/000114036125036875/ef20056247_ex10-5.htm">Trademark License Agreement, effective October 1, 2025, by and between BioCryst Pharmaceuticals, Inc. and BioCryst Ireland Limited. Incorporated by reference to Exhibit 10.5 to the Company</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/882796/000114036125036875/ef20056247_ex10-5.htm">&#8217;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/882796/000114036125036875/ef20056247_ex10-5.htm">s Form 8-K filed October 1, 2025.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:27pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.10</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/882796/000114036125038031/ef20057029_ex99-1.htm">Form of Voting and Support Agreement. Incorporated by reference to Exhibit 99.1 to the Company</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/882796/000114036125038031/ef20057029_ex99-1.htm">&#8217;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/882796/000114036125038031/ef20057029_ex99-1.htm">s Form 8-K filed October 14, 2025.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:39pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(31.1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="bcrx-20250930x10xqxex311.htm">Certification of the Principal Executive Officer Pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as Amended, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:39pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(31.2)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="bcrx-20250930x10xqxex312.htm">Certification of the Principal Financial Officer Pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as Amended, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:27pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(32.1)**</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="bcrx-20250930x10xqxex321.htm">Certification of the Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:27pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(32.2)**</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="bcrx-20250930x10xqxex322.htm">Certification of the Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:75pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Financial statements from the Quarterly Report on Form 10-Q of BioCryst Pharmaceuticals, Inc. for the three and nine months ended September 30, 2025, formatted in Inline XBRL: (i) Condensed Consolidated Balance Sheets, (ii) Condensed Consolidated Statements of Comprehensive Income (Loss), (iii) Condensed Consolidated Statements of Cash Flows, (iv) Condensed Consolidated Statements of Stockholders&#8217; Deficit, and (v) Notes to Condensed Consolidated Financial Statements, tagged as blocks of text and including detailed tags.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(104)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">( )</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Filed herewith.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Management contract.</span></div></td></tr><tr style="height:42pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">**</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The certification is being furnished solely to accompany this Quarterly Report on Form 10-Q pursuant to 18 U.S.C. Section 1350, and will not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act, except to the extent that the Company specifically incorporates it by reference.</span></div></td></tr><tr style="height:39pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">***</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish supplementally a copy of such schedules and exhibits, or any section thereof, to the SEC upon request.</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">84</span></div></div></div><div id="id1b8c440ead54d70904211d3c0a5ea1f_136"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id1b8c440ead54d70904211d3c0a5ea1f_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 4th day of November, 2025.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.627%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:61.173%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">BIOCRYST PHARMACEUTICALS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;By:</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Jon P. Stonehouse</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Jon P. Stonehouse</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">Chief Executive Officer</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">(Principal Executive Officer)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;By:</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Babar Ghias</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Babar Ghias</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">Chief Financial Officer</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">(Principal Financial Officer and Principal Accounting Officer)</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">85</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>2
<FILENAME>thackray-biocrystseparat.htm
<DESCRIPTION>EX-10.3
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>thackray-biocrystseparat</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- thackray-biocrystseparat001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="thackray-biocrystseparat001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- thackray-biocrystseparat002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="thackray-biocrystseparat002.jpg" title="slide2" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">SEPARATION AGREEMENT   PAGE 2 OF 11 EMPLOYEE&#8217;S INITIALS HT  of responsibilities and duties.  If your employment is terminated for Cause during  the Transition Period, you will not receive the Severance and other benefits  described in Section 3 below. For purposes of this Agreement, &#8220;Cause&#8221; means a  breach of this Agreement, or an act of misconduct, such as a violation of law, a  wilful violation of Company policy or an act that risks or causes material harm to a  co-worker, a Company relationship, or any Company assets.    2) Employment Compensation and Benefits.      a) The Company will pay you on the regular payroll dates for your wages earned for the pay  periods between now and the Separation Date, as well as, where applicable state laws  require, any accrued but unused vacation time.    b) Your health, dental, and vision coverage under the Company&#8217;s benefits plans ends on  September 30, 2025. The Company will provide you the necessary forms to request  continuation of applicable coverage.    3) Severance and Other Separation Benefits.     a) The Company will provide you the Severance, as defined below in subsection 3(b)(i), and  other benefits, as defined below in subsection 3(b)(ii-v) (sections 3(b)(i) &#8211; (v), collectively  referred to as &#8220;Severance Benefits&#8221;), subject to the following conditions:     i) You must sign and return this Agreement signed by you, to Steph Angelini &#8211; Chief  People Officer (sangelini@biocryst.com) on or before the Due Date shown on the  signature page below and comply fully with the terms of this Agreement;     i) Your employment with the Company must not be terminated by the Company for  &#8220;Cause&#8221; as defined in Section 1 of this Agreement; and    ii) You must comply in all respects with your obligations under any and all agreements  between you and any member of the Company Group, which includes the Company  and its Affiliates (defined below), and each of their successors and assigns  (collectively, the &#8220;Company Group&#8221;).  For purposes of this Agreement, the  Company&#8217;s &#8220;Affiliates&#8221; means those entities that directly or indirectly control, are  controlled by, or are under common control with, the Company.    b) The Severance Benefits to be provided to you subject to the conditions set forth in  Section 3(a) are as follows:    i) Severance in the total amount of $635,388 (the &#8220;Severance&#8221;), representing the amount  of your base salary for the twelve (12) month period immediately following the  Separation Date (&#8220;Severance Period&#8221;), minus applicable taxes and other withholdings  as provided by law; provided that if you revoke your release of ADEA claims as  provided in Section 11(b) below, the Severance will be reduced to $1,000.  The  Severance will be paid in approximately equal installments in accordance with the  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- thackray-biocrystseparat003.jpg -->
<DIV style="padding-top:2em;">
<IMG src="thackray-biocrystseparat003.jpg" title="slide3" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">SEPARATION AGREEMENT   PAGE 3 OF 11 EMPLOYEE&#8217;S INITIALS HT  Company&#8217;s regular payroll schedule and procedures, beginning on the first regular  payroll date that is at least five (5) business days after the expiration of the seven-day  revocation period described in Section 11(b), provided that the first such installment  shall include installments for any payroll dates falling between the Separation Date and  the first installment payment hereunder, and in the event that the installment schedule  will not result in the full Severance being paid on or before March 15th of the year  following the year in which your employment terminated, then a final installment  payment in an amount equal to the remaining unpaid Severance due hereunder will be  made at that time.    ii) A payment, the amount of which to be determined in or around December 2025 by the  Company&#8217;s Compensation Committee of the Board of Directors, representing the  equivalent of the actual annual Incentive Compensation for the 2025 fiscal year, to be  paid in one lump sum payment, minus applicable taxes and other withholdings as  provided by law. Such Incentive Compensation payment detailed in Section 3(b)(ii)  herein shall be subject to the same terms and conditions imposed upon all eligible  employees or personnel of BioCryst notwithstanding that you will cease to remain an  employee of BioCryst, and shall be paid to you at or around the same time as all of the  Company&#8217;s eligible employees or personnel (provided, however, that continued  employment shall not be required in order to receive such bonus payment and any such  bonus payment will be fully vested immediately upon grant).     iii) A payment the equivalent of one times (1x) your target annual Incentive Compensation  in effect for the fiscal year in which the Separation Date occurred, i.e., in the total  amount of $444,771.60, to be paid in one lump sum payment on December 31, 2025,  minus applicable taxes and other withholdings as provided by law.    iv) If you timely elect COBRA continuation of any COBRA-eligible insurance coverage  in which you are participating under the Company&#8217;s benefits plans as of your  Separation Date (including employee, dependent or family coverage as applicable), the  Company will directly pay to the COBRA plan administrator the full cost of monthly  premiums for COBRA continuation of such coverage,  for the twelve (12) month period  immediately following the Separation Date (through September, 2026) or until the date  upon which Employee commences employment with an entity other than the Company.  Employee will notify the Company in writing within five (5) days of Employee&#8217;s  receipt of an offer of employment with any entity other than the Company and will  accordingly identify the date upon which Employee will commence employment in  such writing. Any coverage beyond the stated period will be at your own expense.  In  the event that you inadvertently receive reimbursement from the Company for a  COBRA premium that you did not actually pay, you shall immediately return to the  Company the full amount reimbursed for such premium.    v) Outplacement assistance package providing up to six (6) months of outplacement  services that you may use at any time during the twelve (12) month period following  the Separation Date; such services to be administered by a third party&#8212;the provider  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- thackray-biocrystseparat004.jpg -->
<DIV style="padding-top:2em;">
<IMG src="thackray-biocrystseparat004.jpg" title="slide4" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">SEPARATION AGREEMENT   PAGE 4 OF 11 EMPLOYEE&#8217;S INITIALS HT  and services to be chosen, and paid directly to the provider, by the Company.   Outplacement services not used within twelve (12) months following the Separation  Date shall be forfeited.    vi) Notwithstanding the applicable provisions of the Company&#8217;s Stock Incentive Plan or  Inducement Equity Incentive Plan relating to termination of service and the Separation  Date set forth herein, the Company hereby acknowledges and agrees that any portion  of the unvested stock options and unvested restricted stock units you hold as of the  Separation Date that would have vested in calendar year 2025 or calendar year 2026 if  you remained in service with the Company through the applicable vesting date shall  vest on December 31, 2025.    c) All amounts paid or provided hereunder are subject to taxes and other withholdings as  provided by law.  The Company agrees that it will remit all withheld amounts to the proper  taxing authorities and agrees to indemnify, defend, and hold you harmless for all taxes and  all related fees, assessments or penalties that you may incur as a result of the Company&#8217;s  failure to remit such amounts to the proper taxing authorities.  Similarly, you agree that  you are responsible for any and all additional taxes (over and above the amounts that are  withheld by the Company) that may be assessed as a result of any payments and benefits  paid or provided to you hereunder, and you hereby agree to indemnify, defend and hold  harmless all members of the Company Group with respect to any such additional taxes and  all related fees, assessments or penalties, that result directly from your failure to timely pay  such amounts to the proper taxing authorities.  Any amounts that you owe to any member  of the Company Group at or after the Separation Date will be deducted from the Severance.      2) Release of all Claims.  In consideration of the Severance Benefits to be provided to you  pursuant to this Agreement, by signing below you hereby agree on your own behalf and on  behalf of your heirs, executors, successors and assigns, that you hereby release in full and  forever discharge the Company, every other member of the Company Group, and each and all  of their respective past, present and future officers, directors, trustees, shareholders, members,  owners, employees, employee benefit plans, agents, general and limited partners, investors,  members, managers, joint venturers, representatives, successors and assigns, and all others  connected with any of them, both individually and in their official capacities (collectively the  &#8220;Released Parties&#8221;), from any and all causes of action, rights or claims (&#8220;claims&#8221;) of any type  or description, known or unknown, which you have or had through and including the date of  your signature below, including without limitation all claims in any way related to your  employment by the Company or any member of the Company Group and the termination of  such employment, including but not limited to any claim arising under any federal, state or  local law, regulation or other requirement (including without limitation Title VII of the Civil  Rights Act of 1964, the Age Discrimination in Employment Act, as amended by the Older  Workers Benefit Protection Act, the Employee Retirement Income Security Act, the  Americans with Disabilities Act, and the fair employment practices laws of the state or states  in which you were employed by the Employer or otherwise had a relationship with the  Employer or any of its subsidiaries or other affiliates, each as amended from time to time),  (collectively, &#8220;Released Claims&#8221;), and you hereby agree that you will not assert any claim  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- thackray-biocrystseparat005.jpg -->
<DIV style="padding-top:2em;">
<IMG src="thackray-biocrystseparat005.jpg" title="slide5" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">SEPARATION AGREEMENT   PAGE 5 OF 11 EMPLOYEE&#8217;S INITIALS HT  against any of the Released Parties with respect to any of the Released Claims and will not  accept any benefit based on any of the Released Claims; provided that notwithstanding the  foregoing, you are not releasing (i) vested benefits pursuant to any benefit plan, subject to and  in accordance with the terms of such plan(s), (ii) claims that arise after you sign this  Agreement, (iii) claims which cannot by law be released, (iv) the right to pursue unemployment  compensation, (v) any rights you may have pursuant to the Company&#8217;s Stock Incentive Plan,  or (vi) the right to make a report or complaint to a law enforcement agency or to participate in  a law enforcement agency proceeding, but you do waive any right to receive equitable or  monetary relief related to any of the Released Claims as a result of any such proceeding.    By signing this Agreement, you confirm and adopt the following statement:    I expressly waive all rights afforded by any statute which limits the effect  of a release with respect to unknown claims.  I understand the significance  of my release of unknown claims and my waiver of statutory protection.  3) Employee Covenants.  You acknowledge and agree that because of your association with the  Company and any other member of the Company Group, you have acquired a considerable  amount of knowledge and goodwill with respect to the business of the Company and the  Company Group, as well as the Company&#8217;s and Company Group&#8217;s customers, personnel and  other business relationships, which knowledge and good will are extremely valuable to the  Company and the Company Group and could be used to compete with them.  It is therefore  understood and agreed that the following Covenants are necessary to afford fair protection to  the Company and the Company Group from unfair competition by you. Consequently, as  material inducement for the Severance Benefits provided to you pursuant to this Agreement,  you agree to the following &#8220;Covenants&#8221;:     a) Pursuant to obligations set forth by the Securities and Exchange Commission (SEC), this  Agreement shall be filed publicly with the SEC. Notwithstanding such obligations, the  Parties represent, warrant, and confirm that they have not and will not disclose or discuss,  orally or in writing, the circumstances relating to the negotiations and discussions leading  to this Agreement other than (i) by Employee to or with Employee&#8217;s immediate family  members, attorneys, accountants or professional tax advisors, each on the condition that  such persons maintain the confidentiality of such information, or as provided in Section  5(i); or (ii) by the Company to or with to the Company&#8217;s employees on a limited, business  need-to-know basis.  If Employee is required by law or pursuant to a subpoena to disclose  such information, Employee agrees to promptly provide written notice to Alane Barnes at  abarnes@biocryst.com.    b) You agree that for the duration of the Severance Period, you will fully cooperate with  the Company in winding up and transferring your Company Group work and related  records to the individuals designated by the Company and assist the Company with the  transition of all accounts that you created or used for Company Group business (including  without limitation, banking, purchasing, online access, data storage and processing, email,  messaging and social media accounts), including providing all information that may be  necessary to ensure that the Company is able to access and control such accounts.    </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- thackray-biocrystseparat006.jpg -->
<DIV style="padding-top:2em;">
<IMG src="thackray-biocrystseparat006.jpg" title="slide6" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">SEPARATION AGREEMENT   PAGE 6 OF 11 EMPLOYEE&#8217;S INITIALS HT  c) You confirm and agree that you have already or you will, by close of business on  September 19, 2025, update all social media that you control to remove any implication  of ongoing employment with any member of the Company group.  Dates of employment  and positions held may remain.    d) You confirm and agree that you have already or you will, by close of business on  September 19, 2025 (&#8220;Return Date&#8221;), return to the Company, or fully disclose and  cooperate with the Company for the disposition of, all property that you were issued or  otherwise acquired as a result of your employment with any member of the Company  Group (&#8220;Company Group Property&#8221;), within your possession or under your control,  including but not limited to the following types of items, regardless of the form, location,  device or media in which such items are stored:  company car; mobile phone, laptop,  external drives, hand-held devices, and all other equipment and computer hardware and  software; keys, credit card; air card; logon information and passwords to all accounts you  have created or accessed on behalf of any member of the Company Group; all information,  Proprietary Information (as defined in your Employee&#8217;s Proprietary Information and  Inventions Agreement referenced in Section 5(f) below), and other business records, files,  documents, books and manuals; and all contact information, business communications and  other documents and information related in any way to customers, employees, contractors  and referral sources.  You agree that all Company Group Property belongs to the Company  Group, and that you will not assert any rights to ownership, use or control of any Company  Group Property. You agree that if any Company Group Property exists in electronic form  on a non-Company Group device, you will provide not later than the Return Date a detailed  summary of such items and follow the Company&#8217;s instructions with respect to the  disposition of such items, including if requested by the Company, submission of devices  and accounts to a third party vendor designated by the Company, for inspection and  removal of any Company Group Property.  You agree that you will not retain any copies,  excerpts or summaries of Company Group Property, and if you later discover any such  items in your possession or under your control you will immediately notify the Company  and follow the Company&#8217;s instructions with respect to the disposition of such items. You  represent and agree you have not deleted and will not delete any emails, files or other  information from any Company Group computer or device prior to returning it as provided  herein. You agree that failure to return any such Company Group Property detailed in this  subsection shall result in the deduction of the cost of such property from the Severance.    e) You acknowledge that certain Company Group matters in which you have been involved  may need your cooperation in the future.  Accordingly, you agree that to the extent  reasonably requested by the Company you will make yourself reasonably available to  respond to queries regarding matters arising out of or related to your service to any member  of the Company Group.    f) You represent that you have fully complied with the terms of and acknowledge and agree  that you remain bound by the terms of the Employee&#8217;s Proprietary Information and  Inventions Agreement dated March 2, 2021, and the Non-Competition and Non-Solicitation  Agreement dated March 2, 2021, and you agree to comply with them in all respects, except  for disclosure expressly permitted by Section 5(i) below.  You represent that as of the date  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- thackray-biocrystseparat007.jpg -->
<DIV style="padding-top:2em;">
<IMG src="thackray-biocrystseparat007.jpg" title="slide7" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">SEPARATION AGREEMENT   PAGE 7 OF 11 EMPLOYEE&#8217;S INITIALS HT  of your signature to this Agreement, you have disclosed and assigned to the Company, and  hereby assign to the Company, all Proprietary Information (as defined in your Employee&#8217;s  Proprietary Information and Inventions Agreement).     g) You warrant, represent and agree that after the Separation Date, except for the benefit of  the Company Group and with the express written permission of an authorized officer of a  member of the Company Group, you will not and will not aid any other party to, access or  attempt to access any Company Group computer systems, networks, accounts or any  resources or data that resides thereon, nor access, use, update, or modify any social media  and other online accounts and profiles you created or used on behalf of any member of the  Company Group, including without limitation accounts and profiles featuring or displaying  the  name and trademarks of any member of the Company Group. This Covenant shall not  apply to any social media accounts or profiles that you created or used exclusively for your  own personal use.    h) You warrant, represent and agree that since receipt of this Agreement you have not, and  for a period of five (5) years following the Effective Date of this Agreement you will not,  disparage or otherwise make negative statements about any of the Released Parties  (including without limitation their products and/or services, policies and practices) in any  manner likely to be harmful to any of them or their business, business relationships,  business reputation or personal reputation; provided however, this covenant does not  prohibit statements expressly permitted by Section 5(i) below so long as such statements  are not maliciously untrue.     i) Nothing in this Agreement or the agreements referred to in Section 5(f) is intended to, or  will be interpreted to, prevent you from (i) disclosing your own personal compensation and  benefits information, or other personal information; (ii) disclosing information pertaining  to sexual harassment or sexual assault in violation of federal, tribal, or state law, other  sexual misconduct, or disputes regarding such matters; (iii) disclosing information to a law  enforcement agency such as the EEOC, Department of Labor or NLRB, for the purposes  of reporting or participating in the investigation of a suspected violation of applicable law;  (iv) disclosing information that you are required to disclose pursuant to applicable law or  legal process, provided that you notify the Company in writing of such required disclosure  as much in advance as is practicable in the circumstances and cooperate with the Company  or any other member of the Company Group to limit the scope of such required disclosure;  or (v) if you are or were as of your last day of employment a non-supervisory employee,  engaging in &#8220;concerted activity&#8221; with other employees or former employees of your  employer to improve the terms and conditions of employment with such employer, as such  activity is defined by the National Labor Relations Act and its implementing rules and  regulations, including disclosing information relevant to such activity.  Further, you will  not be held criminally or civilly liable under any federal or state trade secret law if you  discloses a trade secret (iv) to federal, state, or local government officials, to your attorneys,  or in a sealed court document, for the purpose of reporting or investigating a suspected  violation of the law; or (v) to your attorneys or in a sealed court document in connection  with a lawsuit for retaliation by an employer for reporting a suspected violation of the law.      </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- thackray-biocrystseparat008.jpg -->
<DIV style="padding-top:2em;">
<IMG src="thackray-biocrystseparat008.jpg" title="slide8" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">SEPARATION AGREEMENT   PAGE 8 OF 11 EMPLOYEE&#8217;S INITIALS HT  j) You agree that a breach or threatened breach of any of the Covenants in this Agreement  may result in immediate and irreparable injury to the Company, and in the event that you  breach any of these Covenants the Company shall be entitled, without limitation of remedy  or the requirement to post a bond, to (i) seek temporary and permanent injunctive and other  equitable relief restraining activities constituting a breach or threatened breach of this  Agreement to the fullest extent allowed by law, without the requirement for posting a bond;  and (ii) all such other remedies available at law or in equity, including, without limitation,  the recovery of damages.  No waiver of any breach of this Agreement shall be construed  as a waiver of any succeeding breach of this Agreement.    4) Notwithstanding anything in this Agreement to the contrary, you agree that in the event a court  of competent jurisdiction determines that you materially breach any of the terms of this  Agreement, all Severance Benefits described in Section 3 above shall cease and in the event of  a final, binding, non-appealable judgement including such a determination, you shall refund to  the Company any amounts paid hereunder by the Company in excess of $1,000; you will not  be entitled to any payment or benefits under this Agreement in excess thereof, in addition to  any other damages available for such breach in law or in equity; you will indemnify the  Company Group for all expenses incurred by any member thereof in seeking to enforce the  Agreement or as a result of your failure to abide by this Agreement, including reasonable  attorneys&#8217; fees and costs; and, you will remain subject to the terms of this Agreement.    5) Every provision of this Agreement is severable from every other provision. If any provision of  this Agreement is declared illegal or unenforceable in whole or in part by any court of  competent jurisdiction, such declaration shall only be applicable in the jurisdiction that it is  rendered, the remainder of the Agreement shall remain in full force and effect, and the parties  agree that such court shall modify the offending provision(s) with as narrow a modification as  possible to make it/them enforceable, and the Parties hereby consent to such modification.      6) This Agreement, together with the agreements referred to in Section 5(f), supersedes any and  all other understandings and agreements between the Parties, either oral or in writing, related  in any way to your employment or the termination thereof (or other matters addressed in this  Agreement), constitutes the sole and only agreement between you and the Company related to  such matters, and may only be amended by a written instrument signed by both Parties,  provided that this Agreement does not supersede any obligations that you owe to any member  of the Company Group related to confidential or proprietary information, intellectual property,  non-competition, non-solicitation, and/or arbitration, which shall continue in full effect in  accordance with their terms. The rights, duties and obligations of the Parties under this  Agreement shall inure to the benefit of and shall be binding upon their respective  representatives, successors, and permitted assigns (and in your case, heirs). Your rights and  obligations hereunder may not be assigned to any person or entity. The Company may assign  its rights and obligations hereunder to any of its affiliates or any successor in interest.  It is  expressly agreed that this Agreement is not, and is not to be used as, an admission of  wrongdoing on the part of either of the Parties.    7) This Agreement will be governed by Maryland law, without giving effect to any choice or  conflicts of law principles of any jurisdiction. Each party (i) consents to the personal  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- thackray-biocrystseparat009.jpg -->
<DIV style="padding-top:2em;">
<IMG src="thackray-biocrystseparat009.jpg" title="slide9" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">SEPARATION AGREEMENT   PAGE 9 OF 11 EMPLOYEE&#8217;S INITIALS HT  jurisdiction of any state or federal court located in Montgomery County, Maryland (and any  corresponding appellate court) in any proceeding for interlocutory or equitable relief arising  out of or relating to this Agreement, and (ii) waives any venue or inconvenient forum defense  to any such proceeding maintained in such courts.  Except as provided herein below, each Party  agrees not to bring any proceeding arising out of or relating to this Agreement or your prior  employment by the Company in any other court. Process in any such proceeding may be served  on either party anywhere in the world.  All other claims and disputes arising out of or relating  to this Agreement or your employment by the Company or termination thereof shall be  adjudicated by binding arbitration in Montgomery County, Maryland, in accordance with the  provisions herein.  Notice of arbitration shall be provided to the non-complaining party in  accordance with the notice provisions of this Agreement within ninety (90) days after the  circumstances giving rise to the claim shall become known or knowable to the complaining  party through reasonable diligence. Within ten (10) business days after delivery of such notice,  the parties shall each select one arbitrator willing to serve and provide notice to the other party;  and, within ten (10) business days after notice is provided of the first two arbitrators, those two  arbitrators shall select a third arbitrator who shall serve as the lead arbitrator, and notify the  parties. The parties shall exchange reasonable discovery requests within thirty (30) days  following selection of the three arbitrators, with responses due thirty (30) days thereafter, and  each party may conduct one (1) deposition within thirty (30) days after receipt of discovery  responses. The arbitration shall occur at a mutually agreeable time and location within sixty  (60) days after responses to discovery and depositions are due. The arbitrators may limit or  allow discovery and shorten or extend deadlines in their discretion, may conduct hearings in  advance of arbitration, and may award preliminary and/or permanent relief.  The arbitrators  will allow but not require briefs or memoranda. The arbitrators shall be authorized to make  any decision or award allowed by law, including but not limited to any remedy provided by  law or equity, and the decisions of the arbitrators shall be final and binding on all parties  without right of appeal. Unless awarded by the arbitrators, the cost of arbitration shall be born  equally by the parties, except that each party shall pay the arbitrator that party selected.    8) SECTION 409A.  This Agreement is intended to comply with Section 409A of the Internal  Revenue Code of 1986, as amended (Section 409A), including the exceptions thereto, and shall  be construed and administered in accordance with such intent. Notwithstanding any other  provision of this Agreement, payments provided under this Agreement may only be made upon  an event and in a manner that complies with Section 409A or an applicable exemption. Any  payments under this Agreement that may be excluded from Section 409A either as separation  pay due to an involuntary separation from service, as a short-term deferral, or as a settlement  payment pursuant to a bona fide legal dispute shall be excluded from Section 409A to the  maximum extent possible. For purposes of Section 409A, any installment payments provided  under this Agreement shall each be treated as a separate payment. To the extent required under  Section 409A, any payments to be made under this Agreement in connection with a termination  of employment shall only be made if such termination constitutes a &quot;separation from service&quot;  under Section 409A. Notwithstanding the foregoing, the Company makes no representations  that the payments and benefits provided under this Agreement comply with Section 409A and  in no event shall the Company be liable for all or any portion of any taxes, penalties, interest,  or other expenses that may be incurred by you on account of non-compliance with Section  409A.  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- thackray-biocrystseparat010.jpg -->
<DIV style="padding-top:2em;">
<IMG src="thackray-biocrystseparat010.jpg" title="slide10" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">SEPARATION AGREEMENT   PAGE 10 OF 11 EMPLOYEE&#8217;S INITIALS HT    9) You hereby represent, warrant and agree as follows:    a) You acknowledge your understanding that you are allowed at least twenty-one (21) days  to consider the terms of this Agreement before signing it, that the Delivery Date listed  above accurately reflects the date that you received it, and that to the extent you signed  sooner than required, you did so without any pressure from the Released Parties. You also  acknowledge that you are advised by the Company to seek the advice of an attorney prior  to signing this Agreement; that you have had sufficient time to do so if you wished to; and  that you have carefully read and are signing this Agreement voluntarily and with a full  understanding of its terms.    b) You are advised and understand that at any time within seven (7) calendar days following  the date of your signature to this Agreement, you may revoke your release of claims arising  under the Age Discrimination in Employment Act (&#8220;ADEA&#8221;) (and only your release of  those claims) by providing written notice to Steph Angelini &#8211; Chief People Officer  (sangelini@biocryst.com), in which case the total amount of Severance to be paid to you  hereunder will be reduced to $1,000. If you do not revoke your release of ADEA claims as  provided herein, your release of those claims will become effective and irrevocable on the  8th day after you sign this Agreement. Your release as to all other claims (and your  agreement to all other terms of this Agreement) shall become effective and irrevocable  when you sign and return this Agreement on or before the Due Date.        c) As of the date of your signature below, you have been paid all compensation and benefits  due you as a result of your work for the Company, and you retain no rights to receive nor  will you take any action to pursue any additional compensation, payments, or benefits from  the Company, other than the compensation and benefits described in this Agreement.    d) You have not filed, caused or permitted to be filed on your behalf any charge, complaint  or action before any federal, state or local administrative agency or court against the  Company, or submitted any grievance against the Company.      e) You have not relied on any promises or representations express or implied, that are not set  forth expressly in this Agreement.     f) YOU HAVE CAREFULLY READ THIS DOCUMENT, FULLY UNDERSTAND EACH  AND EVERY TERM, AND VOLUNTARILY ENTER INTO IT.  Please keep the Company apprised of any address changes you have between now and the  expiration of all payment obligations noted herein.  Unless notified otherwise, the Company will  send applicable notices and payments to your address noted at the top of this letter.  [THE NEXT PAGE IS THE SIGNATURE PAGE]   </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- thackray-biocrystseparat011.jpg -->
<DIV style="padding-top:2em;">
<IMG src="thackray-biocrystseparat011.jpg" title="slide11" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">SEPARATION AGREEMENT   PAGE 11 OF 11 EMPLOYEE&#8217;S INITIALS HT  If you agree to the above terms, please initial each page, sign this Agreement, and return it to Steph  Angelini &#8211; Chief People Officer (sangelini@biocryst.com) not later than the Due Date shown at  the top of your signature block below, whereupon it will become a binding agreement between  you and the Company.   Be sure to keep a copy of these documents for your records, so that we both have an agreed  guideline to follow with respect to your transition and separation from the Company.    Sincerely,  BioCryst Pharmaceuticals, Inc.  By: /s/ Stephanie Angelini    Name: Stephanie Angelini      Title: Chief People Officer   EMPLOYEE SIGNATURE DUE DATE:  21 days from your Delivery Date.     By signing below, I agree to the terms set forth above and intend this Agreement to  be legally binding.  I acknowledge receipt of this letter on the Delivery Date noted at the top  of this letter.  I understand that if I sign this Agreement before my last day of employment,  I may be required to sign another copy of this Agreement, in order to receive the Severance  Benefits provided in Section 3 of this Agreement.         /s/ Helen_Thackray                29 August 2025   EMPLOYEE: Helen Thackray   DATE        FOR COMPANY USE ONLY:  Received and accepted this 29 day of August, 2025:  BioCryst Pharmaceuticals, Inc.   By: /s/ Alane Barnes   Name: Alane Barnes    Title: Chief Legal Officer         </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>3
<FILENAME>bcrx-20250930x10xqxex104.htm
<DESCRIPTION>EX-10.4
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i216afe4f455f4cffa2d222419fd12f4e_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.4</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">CONSULTING AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;This </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">CONSULTING AGREEMENT</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> (the &#8220;Agreement&#8221;) is hereby entered into by and between Helen Thackray (&#8220;Consultant&#8221;) and BioCryst Pharmaceuticals, Inc. (together with its Affiliates, &#8220;BioCryst&#8221;) a Delaware corporation, with offices at 4505 Emperor Boulevard, Suite 200, Durham, North Carolina 27703 and shall be effective as of September 1, 2025 (the &#8220;Effective Date&#8221;). With respect to either party, &#8220;Affiliate&#8221; means any entity or organization controlling, controlled by or under common control with such party.  For the purposes of this definition &#8220;control&#8221; means the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of an organization or entity, whether the ownership of voting securities, by contract or otherwise.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">W I T N E S S E T H&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In consideration of the services rendered by Consultant to BioCryst, the compensation to be paid to Consultant by BioCryst, and the mutual promises and agreements hereinafter set forth, the parties hereto agree as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9pt;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement will commence on the Effective Date and continue in effect up to and through December 31, 2025, unless earlier terminated pursuant to Section 12 of this Agreement (the &#8220;Term&#8221;).  </font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9pt;text-decoration:underline">Services</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.  During the Term, Consultant agrees to make herself reasonably available to respond to inquiries from senior executives of BioCryst regarding the transition of her services and other matters about which Consultant has knowledge (collectively, the &#8220;Services&#8221;).  Consultant shall report directly to BioCryst and shall provide the Services in accordance with reasonable instructions given to her by BioCryst.  Consultant shall not utilize any third party in the performance of the Services without the prior written consent of BioCryst.</font></div><div style="padding-left:18pt;padding-right:13.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Services rendered under this Agreement constitute services in accordance with the terms BioCryst Stock Incentive Plan (the &#8220;Incentive Plan&#8221;) and the BioCryst Inducement Equity Incentive Plan (the &#8220;Inducement Plan&#8221; and together with the Incentive Plan, the &#8220;Plans&#8221;&#59; and capitalized terms used but not defined in this Agreement shall have the meanings set forth in the Plans), and therefore, Consultant&#8217;s equity awards received while in the employment of BioCryst (the &#8220;Equity Awards&#8221;) will continue to vest during the Term in accordance with the provisions of the applicable Plans and any related award agreements. Without limiting the foregoing, the parties agree that there has not been and will not be any lapse of &#8220;Services&#8221; rendered to BioCryst with respect to the transition of Consultant from an Employee of BioCryst immediately prior to the effectiveness of this Agreement, and the existing outstanding Equity Awards heretofore granted Consultant shall remain in full force and effect, notwithstanding the transition of Consultant from Employee status to Consultant or independent contractor status.</font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, upon expiration or termination of the Term, the Services will terminate and, therefore, the period for exercising any applicable vested stock options shall be a 180-day period commencing with the expiration or termination of the Term, but in no event shall this stock option be exercisable at any time after the Expiration Date. Upon the expiration of such 180-day period or (if earlier) upon the Expiration Date, vested stock options shall terminate and cease to be outstanding.  Further, upon expiration or termination of the Term, Consultant&#8217;s then-unvested stock options and then-unvested restricted stock units shall be forfeited immediately and automatically to the Company and shall cease to be exercisable by Consultant.  </font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9pt;text-decoration:underline">Payment and Expenses</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.  BioCryst shall pay to Consultant a flat retainer fee of $12,500&#47;month for Services provided hereunder.  No amounts will be withheld from this payment, but all such amounts will be reported on a form 1099 in the ordinary course.  In addition, BioCryst shall reimburse Consultant for actual and reasonable out-of-pocket expenses that have been approved by BioCryst in advance, and incurred in the performance of the Services.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The continued vesting of the Equity Awards and the monthly retainer are Consultant&#8217;s sole compensation for rendering Services to BioCryst.  Consultant shall provide BioCryst with monthly statements detailing any expense reimbursements that Consultant believes are due under this Agreement, and shall itemize and provide receipts for all expenses.  BioCryst agrees to pay approved invoices within thirty (30) days of receipt. Consultant will not be reimbursed for individual expenses exceeding $25.00 without a corresponding receipt.  BioCryst shall not be responsible for reimbursing expenses which are not billed within three (3) months of the date such expenses are incurred. </font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9pt;text-decoration:underline">Proprietary Information</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:28.37pt;text-decoration:underline">Definition of &#8220;Proprietary Information&#8221;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Consultant understands that BioCryst possesses and will possess Proprietary Information that is important to its business.  In addition, BioCryst frequently receives information from third parties that is confidential in nature, and which BioCryst is obligated to keep confidential.  For purposes of this Agreement, &#8220;Proprietary Information&#8221; is all information, whether or not in writing or other tangible form, that was or will be developed, created, or discovered by or on behalf of BioCryst, or which became or will become known by, or was or is conveyed to BioCryst (including, without limitation, &#8220;Results&#8221; as defined above), which has commercial value to BioCryst or which BioCryst is obligated to keep confidential.  &#8220;Proprietary Information&#8221; includes, but is not limited to, business, financial, marketing and customer information, product development plans, forecasts, inventions (whether patentable or not) technology, know-how, processes, data, ideas, techniques, inventions, trade secrets, chemical materials, biological materials, genetic sequences, data, technical information, information about software programs and subroutines, source and object code, databases, database criteria, processes, designs, methodologies, internal documentation, works of authorship, the salaries and terms of compensation of other individuals, client and supplier lists, contacts at or knowledge of clients or prospective clients of BioCryst, and other information concerning the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">actual or anticipated products or services, business, research or development, or any information which is received in confidence by or for BioCryst from any other person</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27.75pt;text-decoration:underline">Definition of &#8220;BioCryst Materials</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Consultant understands that BioCryst possesses or will possess &#8220;BioCryst Materials&#8221; which are important to its business.  For purposes of this Agreement, &#8220;BioCryst Materials&#8221; are documents or other media or tangible items that contain or embody Proprietary Information or any other information concerning the business, operations or plans of BioCryst or clients, whether such documents have been prepared by Consultant or by others.  &#8220;BioCryst Materials&#8221; include, but are not limited to, blueprints, drawings, photographs, charts, graphs, notebooks, customer lists, computer disks, tapes or printouts, sound and video recordings and other printed, typewritten or handwritten documents, sample products, prototypes and models.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:28.37pt;text-decoration:underline">Ownership of Proprietary Information&#59; Assignment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">All Proprietary Information and all title, patents, patent rights, copyrights, trade secret rights, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">sui generis</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> database rights and other intellectual or industrial property rights of any sort anywhere in the world (collectively &#8220;Rights&#8221;) in connection therewith shall be the sole property of BioCryst.  Consultant hereby assigns to BioCryst any Rights Consultant may have or acquire in such Proprietary Information.  At all times, both during the term of this Agreement and after its termination, Consultant will keep in confidence and trust and will not use or disclose any Proprietary Information or anything related to it without the prior written consent of an officer of BioCryst.  Consultant acknowledges that any disclosure or unauthorized use of Proprietary Information will constitute a material breach of this Agreement and cause substantial harm to BioCryst for which monetary damages would not be a fully adequate remedy and, therefore, in the event of any such breach, in addition to other available remedies, BioCryst shall have the right to injunctive relief.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27.75pt;text-decoration:underline">Ownership of BioCryst Materials</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">All BioCryst Materials shall be the sole property of BioCryst.  Consultant agrees that during the term of this Agreement, Consultant will not remove any BioCryst Materials from the business premises of BioCryst or deliver any BioCryst Materials to any person or entity outside BioCryst, except as required to do in connection with performance of the Services under this Agreement.  Consultant further agrees that, immediately upon BioCryst&#8217;s request and in any event upon completion of the Services or termination of this Agreement, Consultant shall deliver within fifteen (15) days to BioCryst all BioCryst Materials, any document or media which contains Results, apparatus, equipment and other physical property or any reproduction of such property, excepting only Consultant&#8217;s copy of this Agreement.  </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9pt;text-decoration:underline">Developments</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:28.37pt;text-decoration:underline">Disclosure of Developments to BioCryst</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Consultant will promptly disclose in writing to</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">BioCryst, or to any persons designated by BioCryst from time to time, all &#8220;Developments&#8221; (which term includes, without limitation, inventions, data, chemical materials, biological materials, works of authorship, discoveries, improvements, designs, source and software code, trade secrets, technology, algorithms, computer programs, audio, video or other files or other content, ideas, processes, techniques, know-how and data, whether or not patentable), made, conceived, reduced to practice or developed by Consultant, either alone or jointly with others, during the term of this Agreement in connection with the Services.  Consultant shall also disclose to BioCryst all Developments conceived, reduced to practice or developed by Consultant within fifteen (15) days of the termination of this Agreement that relate to any Proprietary Information of BioCryst.  Such disclosures shall be received by BioCryst in confidence (to the extent that they are not assigned under Section 5(b) below) and do not extend the assignment made in Section 5(b) below.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27.75pt;text-decoration:underline">Assignment of Developments</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">  Consultant agrees that all Developments which Consultant makes, conceives, reduces to practice or develops (in whole or in part, either alone or jointly with others) during the term of this Agreement in connection with the Services or which relate to any Proprietary Information shall be the sole property of BioCryst.  Consultant agrees to assign and hereby assigns to BioCryst all Rights to all Developments.  BioCryst shall be the sole owner of all Rights in connection such Developments.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:28.37pt;text-decoration:underline">License</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">If any Rights or Developments assigned hereunder or any Results are based on, or incorporate, or are improvements or derivatives of, or cannot be reasonably made, used, reproduced and distributed without using or violating technology or Rights owned or licensed by Consultant and not assigned hereunder, Consultant hereby grants BioCryst a perpetual, worldwide, royalty-free, non-exclusive, sublicensable right and license to exploit and exercise all such technology and Rights in support of BioCryst&#8217;s exercise or exploitation of any Results or assigned Rights or Developments (including any modifications, improvements and derivatives thereof).</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9pt;text-decoration:underline">Right to Inspect</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.  At all times before or after completion of the Services, Consultant agrees to permit authorized representatives of BioCryst, upon reasonable advance notice and during regular business hours, to examine and inspect (and where applicable make copies of) (i) the Developments and any materials relating thereto&#59; (ii) Consultants facilities used to conduct services, (iii) raw study data, (iv) and any other relevant information necessary to confirm compliance with this Agreement and industry guidelines.  Consultant agrees to take any steps necessary to cure deficiencies in the defined services at Consultant&#8217;s expense.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9pt;text-decoration:underline">Assistance by Consultant</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.  Consultant agrees to perform, during and after the term of this Agreement, all acts deemed necessary or desirable by BioCryst to permit and assist it </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">in evidencing, perfecting, obtaining, maintaining, defending and enforcing Rights and&#47;or Consultant&#8217;s assignment with respect to the Results and the Developments in any and all countries.  Such acts may include, but are not limited to, execution of documents and assistance or cooperation in legal proceedings.  Consultant hereby irrevocably designates and appoints BioCryst and its duly authorized officers and agents, as Consultant&#8217;s agents and attorneys-in-fact to act for and on behalf of and instead of Consultant, to execute and file any documents and to do all other lawfully permitted acts to further the above purposes with the same legal force and effect as if executed by Consultant.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9pt;text-decoration:underline">Non-Solicitation and Non-competition</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.  Consultant represents that Consultant has fully complied with the terms of and acknowledge and agrees that Consultant remains bound by the terms of the </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Employee&#8217;s Proprietary Information and Inventions Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> dated March 2, 2021, and the </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Non-Competition and Non-Solicitation Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> dated March 2, 2021, and Consultant agrees to comply with those agreements in all respects.  Consultant represents that as of the date of Consultant&#8217;s signature to this Agreement, Consultant has disclosed and assigned to the Company, and hereby assigns to the Company, all Proprietary Information (as defined in Consultant&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Employee&#8217;s Proprietary Information and Inventions Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">) in Consultant&#8217;s possession or control, regardless of how or where such items are stored (e.g., including in any personal or family member devices). </font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9pt;text-decoration:underline">Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.  Consultant represents and warrants that&#58;</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:28.37pt;text-decoration:underline">Non-disclosure of Third-party&#8217;s Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">  The performance of all the terms of this Agreement will not breach any agreement to keep in confidence proprietary information acquired by Consultant in confidence or in trust prior to the execution of this Agreement, and Consultant has not entered into, and Consultant agrees not to enter into, any agreement, either written or oral, that conflicts or might conflict with Consultant&#8217;s performance of the Services and other obligations under this Agreement.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27.75pt;text-decoration:underline">Debarment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">  Consultant shall comply with all applicable laws and regulations related to the performance of the Services&#59; Consultant has not been, and shall not be debarred by the FDA under 21 USC 335a and&#47;or disqualified under 21 CFR 312.70&#59; Consultant has not and shall not utilize any individual or facility that has been so disqualified or debarred in the performance of the Services&#59; and Consultant shall immediately notify BioCryst upon its learning of any person or entity providing services in any capacity in connection with this agreement that is or becomes so debarred or disqualified or receives notice of an action of or for disbarment or disqualification.  </font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:28.37pt;text-decoration:underline">Compliance with Law</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. Consultant will comply with all applicable federal, state and local laws, regulations, professional standards, and industry codes, ordinances and orders, as amended from time to time, including but not limited to (i) the Foreign Corrupt Practices Act of 1977 and the UK Bribery Act, (ii) the federal anti-kickback statute (42 U.S.C. &#167;1320a-7b(b)), and state anti-kickback and other </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">laws restricting gifts to, relationships with and information from prescribers, (iii) the federal Food and Drug Administration laws, regulations and guidance, including the federal Food, Drug and Cosmetic Act and the Prescription Drug Marketing Act, (iv) those governing the purchase and sale of securities while in possession of material, non-public information about a company, and (v) Good Laboratory Practices (&#8220;GLP&#8221;) and Good Clinical Practices (&#8220;GCP&#8221;).  During the Term, Consultant shall promptly notify BioCryst in writing of any known or expected violations of this Section 9(c). In addition, Consultant will materially comply with all reasonable and applicable BioCryst policies and procedures as provided in writing to Consultant.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27.75pt;text-decoration:underline">Originality of Developments</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">.  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Any and all Developments that it has created or will create under this Agreement will be original and shall not infringe the rights of any third party.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:3pt;text-decoration:underline">Limitation of Liability</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.  BIOCRYST SHALL NOT BE LIABLE WITH RESPECT TO ANY SUBJECT MATTER OF THIS AGREEMENT UNDER ANY CONTRACT, NEGLIGENCE, STRICT LIABILITY OR OTHER THEORY FOR ANY INDIRECT, INCIDENTAL, SPECIAL, EXEMPLARY OR CONSEQUENTIAL DAMAGES, INCLUDING WITHOUT LIMITATION, ANY LOSS OR REVENUES OR PROFITS.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:3pt;text-decoration:underline">Termination</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement may only be terminated by BioCryst if (i) Consultant has materially breached a material term of this Agreement, and (ii) BioCryst has provided Consultant written notice of the provision Consultant allegedly materially breached.  Termination shall be immediately effective if Consultant fails to cure such breach within thirty (30) days of receipt of notice.  Termination of this Agreement under the provisions of this section 12 shall not release either party from any obligation and payment becoming due prior to the effective date of termination, if such termination is not caused by the default of either party.  </font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:3pt;text-decoration:underline">Independent Contractor</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.  Nothing herein contained shall be deemed to create an agency, joint venture, partnership or franchise relationship between the parties hereto. Consultant acknowledges that he&#47;she is an independent contractor, is not an agent or employee of BioCryst, is not entitled to any BioCryst employment rights or benefits and is not authorized to act on behalf of BioCryst.  Consultant shall be solely responsible for any and all tax obligations of Consultant, including but not limited to, all city, state and federal income taxes, social security tax and other self employment taxes incurred by Consultant, and BioCryst shall not be responsible for withholding any such taxes from Consultant's fee.  In addition, Consultant shall not be entitled to any employee benefits, including without limitation, retirement, profit sharing, or medical insurance.  BioCryst shall not dictate the work hours of Consultant during the term of this Agreement.  Subject to Section 9 of this Agreement, Consultant shall perform the Services on a non-exclusive basis and shall be free to accept other engagements during the term of this Agreement.  The parties hereby acknowledge and agree that BioCryst shall have no right to control the manner, means, or method by which Consultant performs the Services.  Rather, BioCryst shall be entitled only to direct Consultant with respect to the elements of the Services and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">the results to be derived by BioCryst, to inform Consultant as to where and by when the Services shall be performed, and to review and assess the performance of the Services by Consultant for the limited purposes of assuring that the Services have been performed and confirming that such results were satisfactory.  BioCryst shall be entitled to exercise broad general power of supervision and control over the results of work performed by Consultant's personnel to ensure satisfactory performance, including but not limited to, the right to inspect, the right to stop work, the right to make suggestions or recommendations as to the details of the work, and the right to propose modifications to the work.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:3pt;text-decoration:underline">Performance</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.  Consultant&#8217;s performance under this Agreement shall be conducted with due diligence and in full compliance with the highest professional standards of practice in the industry.  Consultant shall comply with all applicable laws and BioCryst safety rules in the course of performing the Services.  If Consultant&#8217;s work requires a license, Consultant has obtained that license and the license is in full force and effect.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:3pt;text-decoration:underline">Pharmacovigilance.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> Where Consultant is expected to engage with patients or health care professionals, Consultant shall (a)  inform BioCryst at PM_Safety&#64;biocryst.com within (1) one business day of its receipt of any safety information associated with the use of BioCryst products and (b) comply with BioCryst&#8217;s reasonable training and instructions in relation to safety information reporting including, but not limited to, reconciliation of reports as reasonably requested by BioCryst.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">15.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:3pt;text-decoration:underline">Publicity&#47;Material Non-Public Information</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.  Consultant shall not utilize or publicize the name &#8220;BioCryst Pharmaceuticals, Inc.,&#8221; the ticker symbol &#8220;BCRX&#8221; or any trademarks of BioCryst, without the express written consent of BioCryst.  Consultant acknowledges that it is aware, and that it will advise its employees and agents, that, in the event it or they become aware of material, non-public information concerning BioCryst, the United States securities laws prohibit it or them from purchasing or selling securities of BioCryst while in possession of such material, non-public information. </font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">16.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:3pt;text-decoration:underline">Indemnification</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. Consultant will indemnify and hold BioCryst harmless, and will defend BioCryst against any and all loss, liability, damage, claims, demands or suits and related costs and expenses to persons or property that are directly caused by Consultant failure to satisfy its tax or withholding obligations, or a material breach of any term or condition of this Agreement by Consultant.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">17.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:3pt;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.  Consultant agrees that all obligations under Sections 4-11, and 16-24 of this Agreement shall continue in effect after termination of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">18.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:3pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.  If one or more provisions of this Agreement are held to be unenforceable under applicable law, such provisions shall be modified to the minimum extent necessary to comply with applicable law and the intent of the parties.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">19.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:3pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.  Consultant agrees that any dispute in the meaning, effect or validity of this Agreement shall be resolved in accordance with the laws of the State of North </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Carolina without regard to the conflict of laws provisions thereof, and Consultant submits to the exclusive jurisdiction and venue of the federal and state courts located in Wake County, North Carolina. </font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">20.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:3pt;text-decoration:underline">Binding Nature&#59; Assignment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement shall inure to the benefit of and be binding upon the successors and permitted assigns of the parties hereto. Notwithstanding the foregoing, this Agreement  may not be assigned, in whole or in part, by either party without the prior written consent of the other party.  However, BioCryst may transfer or assign this Agreement, in whole or in part, without prior notice to or consent of Consultant, to an Affiliate of BioCryst or in connection with a merger, consolidation, or a sale or transfer of all or substantially all of the assets to which this Agreement relates, provided that all obligations of BioCryst are assumed by the assignee.  </font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">21.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:3pt;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement together with all Exhibits hereto contains the entire understanding of the parties regarding the terms and conditions of this Agreement and supersedes all prior negotiations, understandings and agreements between the parties, whether oral or in writing, related thereto.  This Agreement does not supersede the Separation Letter Agreement executed contemporaneously herewith and does not supersede any obligations that Consultant owes to any member of the Company Group related to confidential or proprietary information, intellectual property, non-competition, non-solicitation, and&#47;or arbitration, which shall continue in full effect in accordance with their terms. This Agreement can only be modified by a subsequent written agreement executed by an authorized signatory of BioCryst. During the performance of this agreement, the Consultant agrees to comply with all Federal, state and local laws respecting discrimination in employment and non-segregation of facilities including, but not limited to, the applicable provisions of E.O. 11246, Rehabilitation Act of 1973, Vietnam Era Veterans&#8217; Readjustment Assistance Act of 1974, E.O. 13496 and respective regulations including 29 C.F.R. 471 Appendix A to Subpart A and 61-300.10, and the EEO Clauses set forth in 41 C.F.R. 60-1.4, -250.5(a), -300.5(a) and &#8211;741.5(a), all of which are incorporated herein by reference.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">22.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:3pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.  All notices hereunder shall be in writing, and shall be delivered in person, by facsimile transmission (fax), by overnight air courier or by mail, and shall be deemed effectively given the earlier of (i) when received, (ii) when delivered personally, (iii) one (1) business day after being delivered by facsimile (with electronic receipt of appropriate confirmation), (iv) one (1) business day after being deposited with a nationally recognized overnight courier service guaranteeing next-day delivery or (v) four (4) days after being deposited in the postage prepaid certified U.S. mail, return receipts requested, and addressed to the attention of&#58; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:58.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.166%"><tr><td style="width:1.0%"></td><td style="width:40.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.649%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">To BioCryst&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">To Consultant&#58;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">BioCryst Pharmaceuticals, Inc.</font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">4505 Emperor Blvd., Suite 200</font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Durham, NC  27703</font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Telephone&#58;  919-859-1302</font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Facsimile&#58;  919-859-1314</font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Attn&#58;  General Counsel</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Helen Thackray</font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#91;****&#93;<br>&#91;****&#93;</font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Tel&#58; &#91;****&#93;</font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Email&#58; &#91;****&#93;</font></div></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">23.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:3pt;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.  The section headings in this Agreement are for purposes of reference only.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">24.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:3pt;text-decoration:underline">Facsimile and Counterparts</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement may be executed via facsimile and in counterparts, each of which shall be deemed to be an original but all of which together shall constitute one and the same agreement.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">CONSULTANT HAS READ THIS AGREEMENT CAREFULLY AND UNDERSTANDS AND ACCEPTS THE OBLIGATIONS WHICH IT IMPOSES UPON CONSULTANT WITHOUT RESERVATION.  NO PROMISES OR REPRESENTATIONS HAVE BEEN MADE TO CONSULTANT TO INDUCE CONSULTANT TO SIGN THIS AGREEMENT.  CONSULTANT SIGNS THIS AGREEMENT VOLUNTARILY AND FREELY.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Helen Thackray (&#8220;Consultant&#8221;)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">BioCryst Pharmaceuticals, Inc. (&#8220;BioCryst&#8221;) </font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.77pt;text-align:justify"><font><br></font></div><div style="padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Signature&#58; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Helen Thackray</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.77pt;text-align:justify"><font><br></font></div><div style="padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Signature&#58; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Alane Barnes</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:12pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58;  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Helen Thackray</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:12pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58;  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Alane Barnes</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-top:12pt;padding-right:2.77pt;text-align:justify"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:12pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Chief Legal Officer</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">9</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>bcrx-20250930x10xqxex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="id7f1c432a32d4a779ec4753c96f64f97_1"></div><div style="min-height:58.5pt;width:100%"><div style="margin-bottom:8pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:134%">Exhibit 31.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">I, Jon P. Stonehouse, certify that&#58;</font></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this quarterly report on Form 10-Q of BioCryst Pharmaceuticals, Inc.&#59;</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:90pt"><font><br></font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:90pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:8pt;padding-left:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.594%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.435%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.594%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.439%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">Date&#58; November&#160;4, 2025</font></div></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">&#47;s&#47; Jon P. Stonehouse</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">Jon P. Stonehouse</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:-1.63pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer</font></div><div style="padding-right:-1.63pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>bcrx-20250930x10xqxex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i53322a7485ee4ebb903a7d65d72c5fc3_1"></div><div style="min-height:58.5pt;width:100%"><div style="margin-bottom:8pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:134%">Exhibit 31.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">I, Babar Ghias, certify that&#58;</font></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this quarterly report on Form 10-Q of BioCryst Pharmaceuticals, Inc.&#59;</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:90pt"><font><br></font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:90pt"><font><br></font></div><div style="margin-bottom:9pt;padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.594%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.435%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.594%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.439%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">Date&#58; November&#160;4, 2025</font></div></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">&#47;s&#47; Babar Ghias</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">Babar Ghias</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:-1.63pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer</font></div><div style="padding-right:-1.63pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Principal Financial Officer and Principal Accounting Officer)</font></div></td></tr></table></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>bcrx-20250930x10xqxex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i9ce42f483006414e8feaed0319749892_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:134%">Exhibit 32.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of BioCryst Pharmaceuticals, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended September&#160;30, 2025, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Jon P. Stonehouse, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Report fully complies with the requirements of section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font><br></font></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.608%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.120%"></td><td style="width:0.1%"></td><td style="width:0.0%"></td><td style="width:0.294%"></td><td style="width:0.0%"></td><td style="width:0.1%"></td><td style="width:0.608%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.120%"></td><td style="width:0.1%"></td><td style="width:0.0%"></td><td style="width:0.294%"></td><td style="width:0.0%"></td><td style="width:1.0%"></td><td style="width:6.256%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="padding-right:-1.88pt;text-indent:-18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">&#47;s&#47; Jon P. Stonehouse</font></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">Jon P. Stonehouse</font></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-1.63pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer</font></div><div style="padding-right:-1.63pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Principal Executive Officer)</font></div></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">Date&#58; November&#160;4, 2025</font></div></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>bcrx-20250930x10xqxex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i10581505770d45d1a6d114655a153e1d_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:134%">Exhibit 32.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of BioCryst Pharmaceuticals, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended September&#160;30, 2025, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Babar Ghias, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Report fully complies with the requirements of section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font><br></font></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.117%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.119%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="padding-right:-1.88pt;text-indent:-18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">&#47;s&#47; Babar Ghias</font></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">Babar Ghias</font></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">Chief Financial Officer</font></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:134%">(Principal Financial Officer and Principal Accounting Officer)</font></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">Date&#58; November&#160;4, 2025</font></div></td><td colspan="9" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>bcrx-20250930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:9a36bdce-1161-4cfc-8f27-e0c5ed23a9d7,g:923a909e-42f3-4f9e-a634-f93d4ee01684-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:bcrx="http://www.biocryst.com/20250930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.biocryst.com/20250930">
  <xs:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcrx-20250930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcrx-20250930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcrx-20250930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcrx-20250930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.biocryst.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>9952151 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.biocryst.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>9952152 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncomeLoss" roleURI="http://www.biocryst.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss">
        <link:definition>9952153 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>9952154 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows_1" roleURI="http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows_1">
        <link:definition>9952154 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersDeficit" roleURI="http://www.biocryst.com/role/CondensedConsolidatedStatementsofStockholdersDeficit">
        <link:definition>9952155 - Statement - Condensed Consolidated Statements of Stockholders' Deficit</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesandConcentrationsofRisk" roleURI="http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRisk">
        <link:definition>9952156 - Disclosure - Significant Accounting Policies and Concentrations of Risk</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetsandLiabilitiesHeldForSale" roleURI="http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSale">
        <link:definition>9952157 - Disclosure - Assets and Liabilities Held For Sale</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenue" roleURI="http://www.biocryst.com/role/Revenue">
        <link:definition>9952158 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Investments" roleURI="http://www.biocryst.com/role/Investments">
        <link:definition>9952159 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TradeReceivables" roleURI="http://www.biocryst.com/role/TradeReceivables">
        <link:definition>9952160 - Disclosure - Trade Receivables</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.biocryst.com/role/Inventory">
        <link:definition>9952161 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RoyaltyFinancingObligations" roleURI="http://www.biocryst.com/role/RoyaltyFinancingObligations">
        <link:definition>9952162 - Disclosure - Royalty Financing Obligations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.biocryst.com/role/Debt">
        <link:definition>9952163 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseObligations" roleURI="http://www.biocryst.com/role/LeaseObligations">
        <link:definition>9952164 - Disclosure - Lease Obligations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.biocryst.com/role/StockholdersEquity">
        <link:definition>9952165 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensation" roleURI="http://www.biocryst.com/role/StockbasedCompensation">
        <link:definition>9952166 - Disclosure - Stock-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationships" roleURI="http://www.biocryst.com/role/CollaborativeandOtherRelationships">
        <link:definition>9952167 - Disclosure - Collaborative and Other Relationships</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformation" roleURI="http://www.biocryst.com/role/SegmentInformation">
        <link:definition>9952168 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.biocryst.com/role/CommitmentsandContingencies">
        <link:definition>9952169 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomeLossPerShare" roleURI="http://www.biocryst.com/role/NetIncomeLossPerShare">
        <link:definition>9952170 - Disclosure - Net Income (Loss) Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvent" roleURI="http://www.biocryst.com/role/SubsequentEvent">
        <link:definition>9952171 - Disclosure - Subsequent Event</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesandConcentrationsofRiskPolicies" roleURI="http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskPolicies">
        <link:definition>9955511 - Disclosure - Significant Accounting Policies and Concentrations of Risk (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesandConcentrationsofRiskTables" roleURI="http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskTables">
        <link:definition>9955512 - Disclosure - Significant Accounting Policies and Concentrations of Risk (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetsandLiabilitiesHeldForSaleTables" roleURI="http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleTables">
        <link:definition>9955513 - Disclosure - Assets and Liabilities Held For Sale (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueTables" roleURI="http://www.biocryst.com/role/RevenueTables">
        <link:definition>9955514 - Disclosure - Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsTables" roleURI="http://www.biocryst.com/role/InvestmentsTables">
        <link:definition>9955515 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.biocryst.com/role/InventoryTables">
        <link:definition>9955516 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RoyaltyFinancingObligationsTables" roleURI="http://www.biocryst.com/role/RoyaltyFinancingObligationsTables">
        <link:definition>9955517 - Disclosure - Royalty Financing Obligations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseObligationsTables" roleURI="http://www.biocryst.com/role/LeaseObligationsTables">
        <link:definition>9955518 - Disclosure - Lease Obligations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.biocryst.com/role/StockholdersEquityTables">
        <link:definition>9955519 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationTables" roleURI="http://www.biocryst.com/role/StockbasedCompensationTables">
        <link:definition>9955520 - Disclosure - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationTables" roleURI="http://www.biocryst.com/role/SegmentInformationTables">
        <link:definition>9955521 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomeLossPerShareTables" roleURI="http://www.biocryst.com/role/NetIncomeLossPerShareTables">
        <link:definition>9955522 - Disclosure - Net Income (Loss) Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesandConcentrationsofRiskDetails" roleURI="http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails">
        <link:definition>9955523 - Disclosure - Significant Accounting Policies and Concentrations of Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesandConcentrationsofRiskSummaryofRevenuesDetails" roleURI="http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskSummaryofRevenuesDetails">
        <link:definition>9955524 - Disclosure - Significant Accounting Policies and Concentrations of Risk - Summary of Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetsandLiabilitiesHeldForSaleDetails" roleURI="http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleDetails">
        <link:definition>9955525 - Disclosure - Assets and Liabilities Held For Sale (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetsandLiabilitiesHeldForSaleScheduleofAssetsHeldForSaleDetails" roleURI="http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleScheduleofAssetsHeldForSaleDetails">
        <link:definition>9955526 - Disclosure - Assets and Liabilities Held For Sale - Schedule of Assets Held For Sale (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueDetails" roleURI="http://www.biocryst.com/role/RevenueDetails">
        <link:definition>9955527 - Disclosure - Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsFairValueRecurringBasisDetails" roleURI="http://www.biocryst.com/role/InvestmentsFairValueRecurringBasisDetails">
        <link:definition>9955528 - Disclosure - Investments - Fair Value, Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsNarrativeDetails" roleURI="http://www.biocryst.com/role/InvestmentsNarrativeDetails">
        <link:definition>9955529 - Disclosure - Investments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsFairValueoftheCompanysInvestmentsbyTypeDetails" roleURI="http://www.biocryst.com/role/InvestmentsFairValueoftheCompanysInvestmentsbyTypeDetails">
        <link:definition>9955530 - Disclosure - Investments- Fair Value of the Company's Investments by Type (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsScheduleofMaturityofInvestmentsDetails" roleURI="http://www.biocryst.com/role/InvestmentsScheduleofMaturityofInvestmentsDetails">
        <link:definition>9955531 - Disclosure - Investments - Schedule of Maturity of Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TradeReceivablesDetailsTextual" roleURI="http://www.biocryst.com/role/TradeReceivablesDetailsTextual">
        <link:definition>9955532 - Disclosure - Trade Receivables (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventorySummaryofInventoriesDetails" roleURI="http://www.biocryst.com/role/InventorySummaryofInventoriesDetails">
        <link:definition>9955533 - Disclosure - Inventory - Summary of Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetails" roleURI="http://www.biocryst.com/role/InventoryDetails">
        <link:definition>9955534 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RoyaltyFinancingObligationsDetailsTextual" roleURI="http://www.biocryst.com/role/RoyaltyFinancingObligationsDetailsTextual">
        <link:definition>9955535 - Disclosure - Royalty Financing Obligations (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RoyaltyFinancingObligationsScheduleofRoyaltyFinancingObligationsDetails" roleURI="http://www.biocryst.com/role/RoyaltyFinancingObligationsScheduleofRoyaltyFinancingObligationsDetails">
        <link:definition>9955536 - Disclosure - Royalty Financing Obligations - Schedule of Royalty Financing Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtDetails" roleURI="http://www.biocryst.com/role/DebtDetails">
        <link:definition>9955537 - Disclosure - Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseObligationsDetailsTextual" roleURI="http://www.biocryst.com/role/LeaseObligationsDetailsTextual">
        <link:definition>9955538 - Disclosure - Lease Obligations (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseObligationsAggregateLeaseExpenseUnderOperatingLeasesDetails" roleURI="http://www.biocryst.com/role/LeaseObligationsAggregateLeaseExpenseUnderOperatingLeasesDetails">
        <link:definition>9955539 - Disclosure - Lease Obligations - Aggregate Lease Expense Under Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseObligationsOtherSupplementalInformationRelatedtoLeasesDetails" roleURI="http://www.biocryst.com/role/LeaseObligationsOtherSupplementalInformationRelatedtoLeasesDetails">
        <link:definition>9955540 - Disclosure - Lease Obligations - Other Supplemental Information Related to Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseObligationsBalanceSheetsoftheCompanysOperatingLeasesDetails" roleURI="http://www.biocryst.com/role/LeaseObligationsBalanceSheetsoftheCompanysOperatingLeasesDetails">
        <link:definition>9955541 - Disclosure - Lease Obligations - Balance Sheets of the Company's Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseObligationsBalanceSheetsoftheCompanysFinanceLeasesDetails" roleURI="http://www.biocryst.com/role/LeaseObligationsBalanceSheetsoftheCompanysFinanceLeasesDetails">
        <link:definition>9955542 - Disclosure - Lease Obligations - Balance Sheets of the Company's Finance Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseObligationsMaturitiesofLeaseLiabilitiesDetails" roleURI="http://www.biocryst.com/role/LeaseObligationsMaturitiesofLeaseLiabilitiesDetails">
        <link:definition>9955543 - Disclosure - Lease Obligations - Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseObligationsMaturitiesofLeaseLiabilitiesDetails_1" roleURI="http://www.biocryst.com/role/LeaseObligationsMaturitiesofLeaseLiabilitiesDetails_1">
        <link:definition>9955543 - Disclosure - Lease Obligations - Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseObligationsSupplementalCashFlowsDetails" roleURI="http://www.biocryst.com/role/LeaseObligationsSupplementalCashFlowsDetails">
        <link:definition>9955544 - Disclosure - Lease Obligations - Supplemental Cash Flows (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquitySharesReservedforFutureIssuanceDetails" roleURI="http://www.biocryst.com/role/StockholdersEquitySharesReservedforFutureIssuanceDetails">
        <link:definition>9955545 - Disclosure - Stockholders' Equity - Shares Reserved for Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationDetailsTextual" roleURI="http://www.biocryst.com/role/StockbasedCompensationDetailsTextual">
        <link:definition>9955546 - Disclosure - Stock-based Compensation (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationShareBasedCompensationDetails" roleURI="http://www.biocryst.com/role/StockbasedCompensationShareBasedCompensationDetails">
        <link:definition>9955547 - Disclosure - Stock-based Compensation - Share-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationOptionActivityDetails" roleURI="http://www.biocryst.com/role/StockbasedCompensationOptionActivityDetails">
        <link:definition>9955548 - Disclosure - Stock-based Compensation - Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationRestrictedStockUnitActivityDetails" roleURI="http://www.biocryst.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails">
        <link:definition>9955549 - Disclosure - Stock-based Compensation - Restricted Stock Unit Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationWeightedAverageAssumptionsforStockOptionAwardsGrantedtoEmployeesandDirectorsUnderthePlansDetails" roleURI="http://www.biocryst.com/role/StockbasedCompensationWeightedAverageAssumptionsforStockOptionAwardsGrantedtoEmployeesandDirectorsUnderthePlansDetails">
        <link:definition>9955550 - Disclosure - Stock-based Compensation - Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors Under the Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsDetails" roleURI="http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails">
        <link:definition>9955551 - Disclosure - Collaborative and Other Relationships (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationDetails" roleURI="http://www.biocryst.com/role/SegmentInformationDetails">
        <link:definition>9955552 - Disclosure - Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationSegmentReportingInformationbySegmentDetails" roleURI="http://www.biocryst.com/role/SegmentInformationSegmentReportingInformationbySegmentDetails">
        <link:definition>9955553 - Disclosure - Segment Information - Segment Reporting Information by Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomeLossPerShareScheduleofEarningsPerShareDetails" roleURI="http://www.biocryst.com/role/NetIncomeLossPerShareScheduleofEarningsPerShareDetails">
        <link:definition>9955554 - Disclosure - Net Income (Loss) Per Share - Schedule of Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomeLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" roleURI="http://www.biocryst.com/role/NetIncomeLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails">
        <link:definition>9955555 - Disclosure - Net Income (Loss) Per Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventDetails" roleURI="http://www.biocryst.com/role/SubsequentEventDetails">
        <link:definition>9955556 - Disclosure - Subsequent Event (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="bcrx_RightOfUseAssetsNoncurrent" abstract="false" name="RightOfUseAssetsNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_RoyaltyFinancingLiabilitiesCurrent" abstract="false" name="RoyaltyFinancingLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_RoyaltyFinancingLiabilitiesNoncurrent" abstract="false" name="RoyaltyFinancingLiabilitiesNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_PaymentsForPaidInKindInterest" abstract="false" name="PaymentsForPaidInKindInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_NonCashInterestExpenseOnRoyaltyFinancingLiabilities" abstract="false" name="NonCashInterestExpenseOnRoyaltyFinancingLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_NonCashInterestExpenseOnSecuredTermLoanAndSecuredTermLoanAndAmortizationOfDebtIssuanceCosts" abstract="false" name="NonCashInterestExpenseOnSecuredTermLoanAndSecuredTermLoanAndAmortizationOfDebtIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_AmortizationOfPremiumDiscountOnInvestments" abstract="false" name="AmortizationOfPremiumDiscountOnInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_IncreaseDecreaseInRoyaltyFinancingLiabilities" abstract="false" name="IncreaseDecreaseInRoyaltyFinancingLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_ProceedsFromIssuanceOfCommonStockIssuedForServices" abstract="false" name="ProceedsFromIssuanceOfCommonStockIssuedForServices" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_RepaymentOfRoyaltyFinancingLiabilitiesPrincipal" abstract="false" name="RepaymentOfRoyaltyFinancingLiabilitiesPrincipal" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperationsLessAssetsHeldForSale" abstract="false" name="CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperationsLessAssetsHeldForSale" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperationsExcludingAssetsHeldForSale" abstract="false" name="CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperationsExcludingAssetsHeldForSale" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentContinuingOperationExcludingAssetsHeldForSale" abstract="false" name="CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentContinuingOperationExcludingAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_RestrictedCashAndCashEquivalentsIncludedInOtherAssetsNonCurrent" abstract="false" name="RestrictedCashAndCashEquivalentsIncludedInOtherAssetsNonCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_WithholdingTaxesAccrued" abstract="false" name="WithholdingTaxesAccrued" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_TradeReceivablesTextBlock" abstract="false" name="TradeReceivablesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bcrx_RoyaltyFinancingLiabilitiesTextBlock" abstract="false" name="RoyaltyFinancingLiabilitiesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bcrx_DescriptionOfCompanyPolicyTextBlock" abstract="false" name="DescriptionOfCompanyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bcrx_AssetsHeldForSalePolicyTextBlock" abstract="false" name="AssetsHeldForSalePolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bcrx_AccruedExpensesPolicyTextBlock" abstract="false" name="AccruedExpensesPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bcrx_InterestExpenseDeferredFinancingCostsAndRoyaltyFinancingLiabilitiesPolicyTextBlock" abstract="false" name="InterestExpenseDeferredFinancingCostsAndRoyaltyFinancingLiabilitiesPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" abstract="false" name="ConcentrationOfMarketRiskPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bcrx_RoyaltyFinancingLiabilitiesTableTextBlock" abstract="false" name="RoyaltyFinancingLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bcrx_OtherSupplementalInformationRelatedToLeasesTableTextBlock" abstract="false" name="OtherSupplementalInformationRelatedToLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bcrx_LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock" abstract="false" name="LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable" abstract="true" name="SignificantAccountingPoliciesAndConcentrationsOfRiskTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="bcrx_CollateralForCreditMember" abstract="true" name="CollateralForCreditMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" abstract="true" name="LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_ORLADEYOMember" abstract="true" name="ORLADEYOMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems" abstract="true" name="SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bcrx_MaturityPeriodOfHighQualityMarketableSecurities" abstract="false" name="MaturityPeriodOfHighQualityMarketableSecurities" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities" abstract="false" name="AverageMaturityPeriodOfHighQualityMarketableSecurities" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bcrx_MaturityPeriodOfShortTermInvestment" abstract="false" name="MaturityPeriodOfShortTermInvestment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bcrx_LongTermInvestmentMaturityMinimum" abstract="false" name="LongTermInvestmentMaturityMinimum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bcrx_CollaborativeAndOtherResearchAndDevelopmentMember" abstract="true" name="CollaborativeAndOtherResearchAndDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_BioCrystIrelandMember" abstract="true" name="BioCrystIrelandMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsideration" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationContingentConsideration" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_DisposalGroupIncludingDiscontinuedOperationConsiderationRoyaltyReleaseFee" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationConsiderationRoyaltyReleaseFee" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_OtherIncomeFromContractWithCustomerMember" abstract="true" name="OtherIncomeFromContractWithCustomerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterOneYearAndBeforeTwoYears" abstract="false" name="DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterOneYearAndBeforeTwoYears" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_PeramivirMember" abstract="true" name="PeramivirMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_RoyaltyReceivablesFromPartnersMember" abstract="true" name="RoyaltyReceivablesFromPartnersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_InventoryIncludingNoncurrentPortion" abstract="false" name="InventoryIncludingNoncurrentPortion" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_RoyaltiesMonetizationsTable" abstract="true" name="RoyaltiesMonetizationsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="bcrx_RPI2019IntermediateFinanceTrustMember" abstract="true" name="RPI2019IntermediateFinanceTrustMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_RPI2021And2020IntermediateFinanceTrustMember" abstract="true" name="RPI2021And2020IntermediateFinanceTrustMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_The2021RPIRoyaltyPurchaseAgreementMember" abstract="true" name="The2021RPIRoyaltyPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_OMERSCapitalMarketsMember" abstract="true" name="OMERSCapitalMarketsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_FutureRoyaltiesPayableMember" abstract="true" name="FutureRoyaltiesPayableMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_AnnualNetSalesRangeAxis" abstract="true" name="AnnualNetSalesRangeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="bcrx_AnnualNetSalesRangeDomain" abstract="true" name="AnnualNetSalesRangeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_AnnualNetSalesUnder350000Member" abstract="true" name="AnnualNetSalesUnder350000Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_AnnualNetSalesBetween350000And550000Member" abstract="true" name="AnnualNetSalesBetween350000And550000Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_AnnualNetSalesOver550000Member" abstract="true" name="AnnualNetSalesOver550000Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_AnnualNetSalesUnder150000Member" abstract="true" name="AnnualNetSalesUnder150000Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_AnnualNetSalesBetween150000And230000Member" abstract="true" name="AnnualNetSalesBetween150000And230000Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_AnnualNetSalesOver230000Member" abstract="true" name="AnnualNetSalesOver230000Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_RoyaltyMonetizationsLineItems" abstract="true" name="RoyaltyMonetizationsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories" abstract="false" name="RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets" abstract="false" name="RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets" abstract="false" name="RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bcrx_SharesIssuedCommonStockPremium" abstract="false" name="SharesIssuedCommonStockPremium" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales" abstract="false" name="RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales" abstract="false" name="RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice" abstract="false" name="RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bcrx_RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount" abstract="false" name="RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_InterestPaidRoyaltyFinancingLiabilities" abstract="false" name="InterestPaidRoyaltyFinancingLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_TwentyTwentyRPIRoyaltyAgreementMember" abstract="true" name="TwentyTwentyRPIRoyaltyAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_TwentyTwentyOneRPIRoyaltyAgreementMember" abstract="true" name="TwentyTwentyOneRPIRoyaltyAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_OMERSRoyaltyAgreementMember" abstract="true" name="OMERSRoyaltyAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_RoyaltyMontizationsRollForward" abstract="true" name="RoyaltyMontizationsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bcrx_RoyaltyFinancingLiabilities" abstract="false" name="RoyaltyFinancingLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_RoyaltyRevenuesPayable" abstract="false" name="RoyaltyRevenuesPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_TermLoanTrancheAMember" abstract="true" name="TermLoanTrancheAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_LoanAgreementMember" abstract="true" name="LoanAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_TermLoanTrancheBMember" abstract="true" name="TermLoanTrancheBMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_TermLoanTrancheCMember" abstract="true" name="TermLoanTrancheCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_TermLoanTrancheDMember" abstract="true" name="TermLoanTrancheDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_PharmakonAdvisorsLPMember" abstract="true" name="PharmakonAdvisorsLPMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_AthyriumMember" abstract="true" name="AthyriumMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_SeniorCreditFacilityMember" abstract="true" name="SeniorCreditFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_DebtCovenantTermsAxis" abstract="true" name="DebtCovenantTermsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="bcrx_DebtCovenantTermsDomain" abstract="true" name="DebtCovenantTermsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_PikInterestPaymentIsMadeMember" abstract="true" name="PikInterestPaymentIsMadeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_BetweenTheSecondAndThirdAnniversariesMember" abstract="true" name="BetweenTheSecondAndThirdAnniversariesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_AfterFourthAnniversaryMember" abstract="true" name="AfterFourthAnniversaryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_AfterThirdAnniversaryMember" abstract="true" name="AfterThirdAnniversaryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_DebtInstrumentCapitalizedInterestRate" abstract="false" name="DebtInstrumentCapitalizedInterestRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="bcrx_DebtInstrumentVariableRateFloor" abstract="false" name="DebtInstrumentVariableRateFloor" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments" abstract="false" name="DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bcrx_DebtInstrumentPrepaymentPremium" abstract="false" name="DebtInstrumentPrepaymentPremium" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_UnamortizedDeferredFinancingCosts" abstract="false" name="UnamortizedDeferredFinancingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_DeferredDebtPrepaymentAndDebtIssuanceCostsWriteoff" abstract="false" name="DeferredDebtPrepaymentAndDebtIssuanceCostsWriteoff" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_PercentOfInterestPayment" abstract="false" name="PercentOfInterestPayment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="bcrx_OperatingLeaseRightOfUseAssetAccumulatedAmortization" abstract="false" name="OperatingLeaseRightOfUseAssetAccumulatedAmortization" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_FinancingLeaseExpense" abstract="false" name="FinancingLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_OperatingLeaseAssets" abstract="true" name="OperatingLeaseAssets" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_FinanceLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="FinanceLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_NonCashIncreaseInOperatingLeaseAssetsDueToRemeasurementOfOperatingLeaseLiabilities" abstract="false" name="NonCashIncreaseInOperatingLeaseAssetsDueToRemeasurementOfOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_IncentivePlanMember" abstract="true" name="IncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_InducementPlanMember" abstract="true" name="InducementPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_EmployeeStockPurchasePlanMember" abstract="true" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_ShareBasedPaymentArrangementNumberOfPlans" abstract="false" name="ShareBasedPaymentArrangementNumberOfPlans" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bcrx_ToriiPharmaceuticalCoMember" abstract="true" name="ToriiPharmaceuticalCoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_ClearsideBiomedicalIncMember" abstract="true" name="ClearsideBiomedicalIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_HHSOfficeOfTheAdministrationForStrategicPreparednessAndResponseMember" abstract="true" name="HHSOfficeOfTheAdministrationForStrategicPreparednessAndResponseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_AnnualNetSalesOf2MillionMember" abstract="true" name="AnnualNetSalesOf2MillionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_AnnualNetSalesGreaterThan15MillionMember" abstract="true" name="AnnualNetSalesGreaterThan15MillionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_RAPIVABMember" abstract="true" name="RAPIVABMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeMilestone" abstract="false" name="PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeMilestone" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_RoyaltyRateIfMaintainsSakigakeDesignation" abstract="false" name="RoyaltyRateIfMaintainsSakigakeDesignation" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bcrx_MaximumCustomaryReductionOnRoyaltyRate" abstract="false" name="MaximumCustomaryReductionOnRoyaltyRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bcrx_RoyaltyRate" abstract="false" name="RoyaltyRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bcrx_CollaborativeAgreementContractValue" abstract="false" name="CollaborativeAgreementContractValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses" abstract="false" name="MaximumNumberOfProductsPermittedToBeObtainedDoses" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bcrx_ContractTerm" abstract="false" name="ContractTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bcrx_NumberOfOptionalOrderingPeriods" abstract="false" name="NumberOfOptionalOrderingPeriods" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bcrx_NumberOfProductDeliveredDoses" abstract="false" name="NumberOfProductDeliveredDoses" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bcrx_LicenseAgreementUpfrontPayment" abstract="false" name="LicenseAgreementUpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_PotentialMilestonePaymentsPayable" abstract="false" name="PotentialMilestonePaymentsPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_PotentialMilestonePaymentsPayableIfRegulatoryApprovalBeforeMilestone" abstract="false" name="PotentialMilestonePaymentsPayableIfRegulatoryApprovalBeforeMilestone" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_LicenseAgreementNumberOfMilestonePayments" abstract="false" name="LicenseAgreementNumberOfMilestonePayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bcrx_LicenseAgreementAnnualGlobalNetSales" abstract="false" name="LicenseAgreementAnnualGlobalNetSales" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_LicenseAgreementRoyaltyPaymentNumberOfTiers" abstract="false" name="LicenseAgreementRoyaltyPaymentNumberOfTiers" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bcrx_CashCashEquivalentsShortAndLongTermInvestments" abstract="false" name="CashCashEquivalentsShortAndLongTermInvestments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_ReportableSegmentMember" abstract="true" name="ReportableSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_BerotralstatMember" abstract="true" name="BerotralstatMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_BCX17725Member" abstract="true" name="BCX17725Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_AvoralstatMember" abstract="true" name="AvoralstatMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_FactorDProgramMember" abstract="true" name="FactorDProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_ResearchDiscoveryAndPreclinicalProgramsMember" abstract="true" name="ResearchDiscoveryAndPreclinicalProgramsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_CompensationAndRelatedPersonnelCostsMember" abstract="true" name="CompensationAndRelatedPersonnelCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_StockBasedCompensationMember" abstract="true" name="StockBasedCompensationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_OtherExpenses1Member" abstract="true" name="OtherExpenses1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_SegmentReportingAdjustmentsAndReconcilingItemsAmount" abstract="false" name="SegmentReportingAdjustmentsAndReconcilingItemsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_IncrementalCommonSharesAttributableToDilutiveEffectOfSharePurchasePlans" abstract="false" name="IncrementalCommonSharesAttributableToDilutiveEffectOfSharePurchasePlans" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bcrx_BlackstoneMember" abstract="true" name="BlackstoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_AstriaMember" abstract="true" name="AstriaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_CommonStockConversionRatio" abstract="false" name="CommonStockConversionRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="bcrx_A.MachelleSandersMember" abstract="true" name="A.MachelleSandersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>bcrx-20250930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:9a36bdce-1161-4cfc-8f27-e0c5ed23a9d7,g:923a909e-42f3-4f9e-a634-f93d4ee01684-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="bcrx-20250930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_1f3f4ab7-3393-4a1c-b89e-584a4e8eab5e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_afd26a08-9d35-4421-86af-2afe2781e96f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1f3f4ab7-3393-4a1c-b89e-584a4e8eab5e" xlink:to="loc_us-gaap_AccountsPayableCurrent_afd26a08-9d35-4421-86af-2afe2781e96f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_7999429f-6eea-4665-957a-d79ff5287028" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1f3f4ab7-3393-4a1c-b89e-584a4e8eab5e" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_7999429f-6eea-4665-957a-d79ff5287028" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_8b8da99d-72ed-4626-a000-edc93ca9acbd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1f3f4ab7-3393-4a1c-b89e-584a4e8eab5e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_8b8da99d-72ed-4626-a000-edc93ca9acbd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_efbc9801-a9b0-466d-93d5-3009bb0b2c93" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1f3f4ab7-3393-4a1c-b89e-584a4e8eab5e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_efbc9801-a9b0-466d-93d5-3009bb0b2c93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyFinancingLiabilitiesCurrent_809adea7-a2ac-45b1-930b-e9918a8558c9" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltyFinancingLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1f3f4ab7-3393-4a1c-b89e-584a4e8eab5e" xlink:to="loc_bcrx_RoyaltyFinancingLiabilitiesCurrent_809adea7-a2ac-45b1-930b-e9918a8558c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_ed3a025f-33dd-4e23-a270-cbf9e73810f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1f3f4ab7-3393-4a1c-b89e-584a4e8eab5e" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_ed3a025f-33dd-4e23-a270-cbf9e73810f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_8d1322dc-faf5-40a6-9353-6496b7c1eff5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a72db749-2ed1-4cdf-b53a-d65b12b589a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8d1322dc-faf5-40a6-9353-6496b7c1eff5" xlink:to="loc_us-gaap_LiabilitiesCurrent_a72db749-2ed1-4cdf-b53a-d65b12b589a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c5536396-5018-4017-9b83-40e215b723cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8d1322dc-faf5-40a6-9353-6496b7c1eff5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c5536396-5018-4017-9b83-40e215b723cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_f86e3d18-ec8c-49cd-ac6a-9de72817ea96" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8d1322dc-faf5-40a6-9353-6496b7c1eff5" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_f86e3d18-ec8c-49cd-ac6a-9de72817ea96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyFinancingLiabilitiesNoncurrent_53cb4522-6b7d-434c-8a6b-90edb860ded9" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltyFinancingLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8d1322dc-faf5-40a6-9353-6496b7c1eff5" xlink:to="loc_bcrx_RoyaltyFinancingLiabilitiesNoncurrent_53cb4522-6b7d-434c-8a6b-90edb860ded9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_83c8a010-594f-48af-9726-a944a83ada35" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8d1322dc-faf5-40a6-9353-6496b7c1eff5" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_83c8a010-594f-48af-9726-a944a83ada35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_bff24c6d-aaab-45a0-a47a-f3585bcbb771" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8d1322dc-faf5-40a6-9353-6496b7c1eff5" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_bff24c6d-aaab-45a0-a47a-f3585bcbb771" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a2b50811-c266-4111-85c3-5d482928ba5f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_02e8912c-9419-4c45-b47e-20f90d500eff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a2b50811-c266-4111-85c3-5d482928ba5f" xlink:to="loc_us-gaap_ShortTermInvestments_02e8912c-9419-4c45-b47e-20f90d500eff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_c38b3805-b48b-47c7-878d-2a7c8226f8a8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a2b50811-c266-4111-85c3-5d482928ba5f" xlink:to="loc_us-gaap_InventoryNet_c38b3805-b48b-47c7-878d-2a7c8226f8a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_76853a00-48ab-4776-84f5-22ec5442c13b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a2b50811-c266-4111-85c3-5d482928ba5f" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_76853a00-48ab-4776-84f5-22ec5442c13b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_93d1d2d3-feb9-49cb-8a5f-f5d222efd2c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a2b50811-c266-4111-85c3-5d482928ba5f" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_93d1d2d3-feb9-49cb-8a5f-f5d222efd2c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f1d5ffa6-cff1-4982-8b85-92fcd26f518a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a2b50811-c266-4111-85c3-5d482928ba5f" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f1d5ffa6-cff1-4982-8b85-92fcd26f518a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ca516c4c-e6f9-4a32-94bf-8ad25feb538a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a2b50811-c266-4111-85c3-5d482928ba5f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ca516c4c-e6f9-4a32-94bf-8ad25feb538a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_30f25034-8394-4356-a5b9-a5827efa1435" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a2b50811-c266-4111-85c3-5d482928ba5f" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_30f25034-8394-4356-a5b9-a5827efa1435" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_080ca9fd-6b4a-4165-8e8c-70aaf5e1ebd8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_b65b965c-3c4f-44d9-a0d2-63be752dbfea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_080ca9fd-6b4a-4165-8e8c-70aaf5e1ebd8" xlink:to="loc_us-gaap_AssetsCurrent_b65b965c-3c4f-44d9-a0d2-63be752dbfea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_ee629d6b-1e37-4056-9134-3122d05ece9a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_080ca9fd-6b4a-4165-8e8c-70aaf5e1ebd8" xlink:to="loc_us-gaap_InventoryNoncurrent_ee629d6b-1e37-4056-9134-3122d05ece9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4c572109-724f-40fd-8990-55f93e2795ef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_080ca9fd-6b4a-4165-8e8c-70aaf5e1ebd8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4c572109-724f-40fd-8990-55f93e2795ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_98ff6fe0-6c08-4994-9541-e1f2369f226c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_080ca9fd-6b4a-4165-8e8c-70aaf5e1ebd8" xlink:to="loc_us-gaap_LongTermInvestments_98ff6fe0-6c08-4994-9541-e1f2369f226c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RightOfUseAssetsNoncurrent_e8d60ede-0265-4f9e-82e7-905829c9cc90" xlink:href="bcrx-20250930.xsd#bcrx_RightOfUseAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_080ca9fd-6b4a-4165-8e8c-70aaf5e1ebd8" xlink:to="loc_bcrx_RightOfUseAssetsNoncurrent_e8d60ede-0265-4f9e-82e7-905829c9cc90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_ca97d86e-a404-44f2-8b02-51be3941724c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_080ca9fd-6b4a-4165-8e8c-70aaf5e1ebd8" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_ca97d86e-a404-44f2-8b02-51be3941724c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_0ebf1754-6e35-48f6-a240-75eb04186410" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_080ca9fd-6b4a-4165-8e8c-70aaf5e1ebd8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_0ebf1754-6e35-48f6-a240-75eb04186410" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_233be0a7-51f0-42ec-82b5-97781397437d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_4e4d4f47-20ec-4730-b865-a556149a3b54" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_233be0a7-51f0-42ec-82b5-97781397437d" xlink:to="loc_us-gaap_PreferredStockValue_4e4d4f47-20ec-4730-b865-a556149a3b54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_633f335d-5f8f-4d54-aa5b-c79fbe138473" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_233be0a7-51f0-42ec-82b5-97781397437d" xlink:to="loc_us-gaap_CommonStockValue_633f335d-5f8f-4d54-aa5b-c79fbe138473" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_5484c62a-4124-4dd6-805d-76324208c879" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_233be0a7-51f0-42ec-82b5-97781397437d" xlink:to="loc_us-gaap_AdditionalPaidInCapital_5484c62a-4124-4dd6-805d-76324208c879" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2ec51a32-cbd5-4fc4-ac4e-0f39d71b5fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_233be0a7-51f0-42ec-82b5-97781397437d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2ec51a32-cbd5-4fc4-ac4e-0f39d71b5fb5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_cd20bd6b-2765-4c75-b666-5d4ea02a609e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_233be0a7-51f0-42ec-82b5-97781397437d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_cd20bd6b-2765-4c75-b666-5d4ea02a609e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_57bffcd2-3359-4d1f-9c38-15e508740964" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_34961e66-d228-48b0-aec4-39ff577399f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_57bffcd2-3359-4d1f-9c38-15e508740964" xlink:to="loc_us-gaap_StockholdersEquity_34961e66-d228-48b0-aec4-39ff577399f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f5921559-0d79-449f-8ea5-ba23635dc4a9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_57bffcd2-3359-4d1f-9c38-15e508740964" xlink:to="loc_us-gaap_Liabilities_f5921559-0d79-449f-8ea5-ba23635dc4a9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="simple" xlink:href="bcrx-20250930.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeLoss"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_1361b012-38fc-48a1-a3ff-2b82f994908e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_2f036074-e3e7-4728-91b2-807ca398c1d9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_1361b012-38fc-48a1-a3ff-2b82f994908e" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_2f036074-e3e7-4728-91b2-807ca398c1d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_f33684d3-3dac-43a8-9517-e66d64187ed9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_1361b012-38fc-48a1-a3ff-2b82f994908e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_f33684d3-3dac-43a8-9517-e66d64187ed9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f683c67f-3b83-4fa7-ade3-1effac0b6c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_1361b012-38fc-48a1-a3ff-2b82f994908e" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f683c67f-3b83-4fa7-ade3-1effac0b6c8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_36e4060f-e3e0-4c83-bc92-6d4b906f7388" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ed5b422c-c8c3-45ec-a6ff-7cd8f93840fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_36e4060f-e3e0-4c83-bc92-6d4b906f7388" xlink:to="loc_us-gaap_NetIncomeLoss_ed5b422c-c8c3-45ec-a6ff-7cd8f93840fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_059b229c-e7fe-4f6c-a03d-2858d149981e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_36e4060f-e3e0-4c83-bc92-6d4b906f7388" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_059b229c-e7fe-4f6c-a03d-2858d149981e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_defa81df-62be-4525-8d1c-23f9f2a0c16b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8a50f2d7-a34a-428e-8b51-33ea5c8eb8ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_defa81df-62be-4525-8d1c-23f9f2a0c16b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8a50f2d7-a34a-428e-8b51-33ea5c8eb8ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a91de775-f9ab-4bdd-bd11-42d7b8acd8f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_defa81df-62be-4525-8d1c-23f9f2a0c16b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a91de775-f9ab-4bdd-bd11-42d7b8acd8f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e04faca4-2e3c-4b05-b318-4f897247276d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_ca7e27a6-e257-4bff-a714-6d1c52320f77" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e04faca4-2e3c-4b05-b318-4f897247276d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_ca7e27a6-e257-4bff-a714-6d1c52320f77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_09ff4b98-7d94-4238-83dd-167e5d4e5446" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e04faca4-2e3c-4b05-b318-4f897247276d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_09ff4b98-7d94-4238-83dd-167e5d4e5446" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0aa14850-84df-43fa-ac59-7b998b478348" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_2b87fe89-aff9-45c7-8e04-fca37031fb20" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_0aa14850-84df-43fa-ac59-7b998b478348" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_2b87fe89-aff9-45c7-8e04-fca37031fb20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_b9d328d2-a9ce-4ed3-ae09-c95911b05b86" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_0aa14850-84df-43fa-ac59-7b998b478348" xlink:to="loc_us-gaap_CostsAndExpenses_b9d328d2-a9ce-4ed3-ae09-c95911b05b86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_f529d10c-5af7-4a20-afd3-60856ba6f05f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndOtherIncome_b41d6498-badf-4dd0-ab48-9f7e09633116" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestAndOtherIncome"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_f529d10c-5af7-4a20-afd3-60856ba6f05f" xlink:to="loc_us-gaap_InterestAndOtherIncome_b41d6498-badf-4dd0-ab48-9f7e09633116" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_b2f474a3-bd9d-4f06-9eeb-9a0be95bfea4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_f529d10c-5af7-4a20-afd3-60856ba6f05f" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_b2f474a3-bd9d-4f06-9eeb-9a0be95bfea4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_2f8142b2-91f9-4c80-9def-d54785e5aef6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_f529d10c-5af7-4a20-afd3-60856ba6f05f" xlink:to="loc_us-gaap_InterestExpenseNonoperating_2f8142b2-91f9-4c80-9def-d54785e5aef6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_69edc71e-72b2-4893-b8f2-a56e0deb159f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_f529d10c-5af7-4a20-afd3-60856ba6f05f" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_69edc71e-72b2-4893-b8f2-a56e0deb159f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncome_88b3ae3e-c7f9-4eb7-a7d9-ea0e1d32b918" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncome"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_f529d10c-5af7-4a20-afd3-60856ba6f05f" xlink:to="loc_us-gaap_OtherIncome_88b3ae3e-c7f9-4eb7-a7d9-ea0e1d32b918" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b5a6d878-06b4-41a9-89e0-ac1f6b5cb514" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_8d303e82-4c8e-41a8-86db-6f82040669f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b5a6d878-06b4-41a9-89e0-ac1f6b5cb514" xlink:to="loc_us-gaap_OperatingIncomeLoss_8d303e82-4c8e-41a8-86db-6f82040669f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_f9e54550-3612-4281-bae1-09f6f63a69da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b5a6d878-06b4-41a9-89e0-ac1f6b5cb514" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_f9e54550-3612-4281-bae1-09f6f63a69da" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="bcrx-20250930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations_18b4bdd8-3ba5-40cd-884f-2e0ef2ca6ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperationsLessAssetsHeldForSale_72c643fe-53b2-4f0f-b86f-7650d54a8312" xlink:href="bcrx-20250930.xsd#bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperationsLessAssetsHeldForSale"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations_18b4bdd8-3ba5-40cd-884f-2e0ef2ca6ef9" xlink:to="loc_bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperationsLessAssetsHeldForSale_72c643fe-53b2-4f0f-b86f-7650d54a8312" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperationsExcludingAssetsHeldForSale_485b174e-0c5e-441d-b748-d37877a2c41e" xlink:href="bcrx-20250930.xsd#bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperationsExcludingAssetsHeldForSale"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations_18b4bdd8-3ba5-40cd-884f-2e0ef2ca6ef9" xlink:to="loc_bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperationsExcludingAssetsHeldForSale_485b174e-0c5e-441d-b748-d37877a2c41e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentContinuingOperationExcludingAssetsHeldForSale_da7ca9fa-34c5-4e57-a0a5-ead591b6fff5" xlink:href="bcrx-20250930.xsd#bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentContinuingOperationExcludingAssetsHeldForSale"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_7087f974-ae8a-4103-ae03-0d4bfc8974ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentContinuingOperationExcludingAssetsHeldForSale_da7ca9fa-34c5-4e57-a0a5-ead591b6fff5" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_7087f974-ae8a-4103-ae03-0d4bfc8974ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1d365156-e1d6-4dd6-80d3-bb2dae4771b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentContinuingOperationExcludingAssetsHeldForSale_da7ca9fa-34c5-4e57-a0a5-ead591b6fff5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1d365156-e1d6-4dd6-80d3-bb2dae4771b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RestrictedCashAndCashEquivalentsIncludedInOtherAssetsNonCurrent_96ac6160-ce13-419b-b3ec-f1c094ad6c44" xlink:href="bcrx-20250930.xsd#bcrx_RestrictedCashAndCashEquivalentsIncludedInOtherAssetsNonCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentContinuingOperationExcludingAssetsHeldForSale_da7ca9fa-34c5-4e57-a0a5-ead591b6fff5" xlink:to="loc_bcrx_RestrictedCashAndCashEquivalentsIncludedInOtherAssetsNonCurrent_96ac6160-ce13-419b-b3ec-f1c094ad6c44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_af497314-0c62-438b-bfd8-3e0b7ef3549d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_d257c172-cae0-4097-8f57-a955441f5ced" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_af497314-0c62-438b-bfd8-3e0b7ef3549d" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_d257c172-cae0-4097-8f57-a955441f5ced" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_745fbdba-626a-4cee-8021-d48ed60dca30" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_af497314-0c62-438b-bfd8-3e0b7ef3549d" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_745fbdba-626a-4cee-8021-d48ed60dca30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_88862cc4-65c0-4921-ad23-9d82661a37c6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_af497314-0c62-438b-bfd8-3e0b7ef3549d" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_88862cc4-65c0-4921-ad23-9d82661a37c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities_b9bc73d8-eb6e-4cf6-bb08-7738b1d20cce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_af497314-0c62-438b-bfd8-3e0b7ef3549d" xlink:to="loc_us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities_b9bc73d8-eb6e-4cf6-bb08-7738b1d20cce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0fd174eb-0156-41f7-929e-d75dbdb4853b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_85beeee5-3a78-4b58-a864-824016085ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0fd174eb-0156-41f7-929e-d75dbdb4853b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_85beeee5-3a78-4b58-a864-824016085ecf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ProceedsFromIssuanceOfCommonStockIssuedForServices_482e07df-1553-41fe-98cc-c4de1e200774" xlink:href="bcrx-20250930.xsd#bcrx_ProceedsFromIssuanceOfCommonStockIssuedForServices"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0fd174eb-0156-41f7-929e-d75dbdb4853b" xlink:to="loc_bcrx_ProceedsFromIssuanceOfCommonStockIssuedForServices_482e07df-1553-41fe-98cc-c4de1e200774" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_fa8216c5-c668-4b97-a20d-8a5f8e733b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0fd174eb-0156-41f7-929e-d75dbdb4853b" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_fa8216c5-c668-4b97-a20d-8a5f8e733b7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_65737267-54bb-435d-9245-ccd321181f64" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0fd174eb-0156-41f7-929e-d75dbdb4853b" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_65737267-54bb-435d-9245-ccd321181f64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RepaymentOfRoyaltyFinancingLiabilitiesPrincipal_3f335b9d-dfef-4786-b23e-d00b55609e6d" xlink:href="bcrx-20250930.xsd#bcrx_RepaymentOfRoyaltyFinancingLiabilitiesPrincipal"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0fd174eb-0156-41f7-929e-d75dbdb4853b" xlink:to="loc_bcrx_RepaymentOfRoyaltyFinancingLiabilitiesPrincipal_3f335b9d-dfef-4786-b23e-d00b55609e6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_b944a974-7746-47ac-9a0e-f58c9a1ca2a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0fd174eb-0156-41f7-929e-d75dbdb4853b" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_b944a974-7746-47ac-9a0e-f58c9a1ca2a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_08e404fe-207a-49d6-b5ab-246a27da8432" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0fd174eb-0156-41f7-929e-d75dbdb4853b" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_08e404fe-207a-49d6-b5ab-246a27da8432" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d06bcf86-337b-40f6-bbfe-297a6566ef25" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_57239b98-38a5-4c36-b51c-a1c43af3bf62" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d06bcf86-337b-40f6-bbfe-297a6566ef25" xlink:to="loc_us-gaap_NetIncomeLoss_57239b98-38a5-4c36-b51c-a1c43af3bf62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_1879dfb2-9fa4-4321-a510-5a8c8e3cbec8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d06bcf86-337b-40f6-bbfe-297a6566ef25" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_1879dfb2-9fa4-4321-a510-5a8c8e3cbec8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_7ae88ee7-7139-4b97-8674-fc3be15269e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWriteDown"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d06bcf86-337b-40f6-bbfe-297a6566ef25" xlink:to="loc_us-gaap_InventoryWriteDown_7ae88ee7-7139-4b97-8674-fc3be15269e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_e1edd5b1-aae7-456e-a48c-ef242e484f67" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d06bcf86-337b-40f6-bbfe-297a6566ef25" xlink:to="loc_us-gaap_ShareBasedCompensation_e1edd5b1-aae7-456e-a48c-ef242e484f67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_PaymentsForPaidInKindInterest_2b4406e8-8394-4a55-bc3a-c72042f54be9" xlink:href="bcrx-20250930.xsd#bcrx_PaymentsForPaidInKindInterest"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d06bcf86-337b-40f6-bbfe-297a6566ef25" xlink:to="loc_bcrx_PaymentsForPaidInKindInterest_2b4406e8-8394-4a55-bc3a-c72042f54be9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_NonCashInterestExpenseOnRoyaltyFinancingLiabilities_6b94c974-c962-44a1-8b43-1e3932447498" xlink:href="bcrx-20250930.xsd#bcrx_NonCashInterestExpenseOnRoyaltyFinancingLiabilities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d06bcf86-337b-40f6-bbfe-297a6566ef25" xlink:to="loc_bcrx_NonCashInterestExpenseOnRoyaltyFinancingLiabilities_6b94c974-c962-44a1-8b43-1e3932447498" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_NonCashInterestExpenseOnSecuredTermLoanAndSecuredTermLoanAndAmortizationOfDebtIssuanceCosts_d053635c-54e6-4257-8bd2-b29f03497238" xlink:href="bcrx-20250930.xsd#bcrx_NonCashInterestExpenseOnSecuredTermLoanAndSecuredTermLoanAndAmortizationOfDebtIssuanceCosts"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d06bcf86-337b-40f6-bbfe-297a6566ef25" xlink:to="loc_bcrx_NonCashInterestExpenseOnSecuredTermLoanAndSecuredTermLoanAndAmortizationOfDebtIssuanceCosts_d053635c-54e6-4257-8bd2-b29f03497238" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AmortizationOfPremiumDiscountOnInvestments_a309353a-0a7b-4598-b76c-3f4f8d1674a6" xlink:href="bcrx-20250930.xsd#bcrx_AmortizationOfPremiumDiscountOnInvestments"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d06bcf86-337b-40f6-bbfe-297a6566ef25" xlink:to="loc_bcrx_AmortizationOfPremiumDiscountOnInvestments_a309353a-0a7b-4598-b76c-3f4f8d1674a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_0592e5d6-4965-4dae-a489-f9af6338d3b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d06bcf86-337b-40f6-bbfe-297a6566ef25" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_0592e5d6-4965-4dae-a489-f9af6338d3b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_5c7a575a-ceb2-4c7c-842d-257cb7d39e89" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d06bcf86-337b-40f6-bbfe-297a6566ef25" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_5c7a575a-ceb2-4c7c-842d-257cb7d39e89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_c9b8a274-2aba-43ff-a3b6-b560d4be6311" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d06bcf86-337b-40f6-bbfe-297a6566ef25" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_c9b8a274-2aba-43ff-a3b6-b560d4be6311" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_aec51a84-d50f-4f53-adfe-131ead0077ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d06bcf86-337b-40f6-bbfe-297a6566ef25" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_aec51a84-d50f-4f53-adfe-131ead0077ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_IncreaseDecreaseInRoyaltyFinancingLiabilities_157222ab-3db5-4ce8-ba65-796be1a40cfe" xlink:href="bcrx-20250930.xsd#bcrx_IncreaseDecreaseInRoyaltyFinancingLiabilities"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d06bcf86-337b-40f6-bbfe-297a6566ef25" xlink:to="loc_bcrx_IncreaseDecreaseInRoyaltyFinancingLiabilities_157222ab-3db5-4ce8-ba65-796be1a40cfe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_7391713c-debe-456e-9ac3-bf99449b2f01" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d06bcf86-337b-40f6-bbfe-297a6566ef25" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_7391713c-debe-456e-9ac3-bf99449b2f01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherAssets_2cca4080-3cf7-45eb-8469-804df638b233" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfOtherAssets"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d06bcf86-337b-40f6-bbfe-297a6566ef25" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherAssets_2cca4080-3cf7-45eb-8469-804df638b233" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows_1" xlink:type="simple" xlink:href="bcrx-20250930.xsd#CondensedConsolidatedStatementsofCashFlows_1"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations_c8fac497-59a1-4ade-b13b-7b9a9926c6db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7a475fc7-d466-40ea-8296-8ddfcf6c2549" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations_c8fac497-59a1-4ade-b13b-7b9a9926c6db" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7a475fc7-d466-40ea-8296-8ddfcf6c2549" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_004991af-1256-4e1d-98e2-0d36b50af614" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations_c8fac497-59a1-4ade-b13b-7b9a9926c6db" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_004991af-1256-4e1d-98e2-0d36b50af614" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9e1d1835-98ea-4769-8d02-9c66094456b5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations_c8fac497-59a1-4ade-b13b-7b9a9926c6db" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9e1d1835-98ea-4769-8d02-9c66094456b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8d889aaf-1c14-48c4-ac9b-00bd3d66580a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations_c8fac497-59a1-4ade-b13b-7b9a9926c6db" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8d889aaf-1c14-48c4-ac9b-00bd3d66580a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleScheduleofAssetsHeldForSaleDetails" xlink:type="simple" xlink:href="bcrx-20250930.xsd#AssetsandLiabilitiesHeldForSaleScheduleofAssetsHeldForSaleDetails"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleScheduleofAssetsHeldForSaleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_c3cf99b1-3f9b-4500-a9bd-72353976e66b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_098f527a-59cc-4c21-810e-d61acfdfccc2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_c3cf99b1-3f9b-4500-a9bd-72353976e66b" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_098f527a-59cc-4c21-810e-d61acfdfccc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_3d6436ce-e890-4ecc-b609-46e6d25edd0c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_c3cf99b1-3f9b-4500-a9bd-72353976e66b" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_3d6436ce-e890-4ecc-b609-46e6d25edd0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_250a3036-6cab-4096-8c91-f0d5332d71a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_ef1017b4-1563-41b4-adc0-9eb5a023da74" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_250a3036-6cab-4096-8c91-f0d5332d71a2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_ef1017b4-1563-41b4-adc0-9eb5a023da74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_25626280-587e-4658-a53d-693ca8fc220c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_250a3036-6cab-4096-8c91-f0d5332d71a2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_25626280-587e-4658-a53d-693ca8fc220c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_e1c0d811-9f07-4ed0-9c5a-e6cb49762b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_250a3036-6cab-4096-8c91-f0d5332d71a2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_e1c0d811-9f07-4ed0-9c5a-e6cb49762b4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_8d5c8daa-e14d-4fbd-b886-8ae305257d11" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_250a3036-6cab-4096-8c91-f0d5332d71a2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_8d5c8daa-e14d-4fbd-b886-8ae305257d11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_3812f92b-d182-4a9b-8f29-dbd85c909cf7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_0ab38a84-8d1e-42ea-ba13-c06ef1454720" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_3812f92b-d182-4a9b-8f29-dbd85c909cf7" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_0ab38a84-8d1e-42ea-ba13-c06ef1454720" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_a72bea96-b31d-49d8-930a-c2170cdee09b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_3812f92b-d182-4a9b-8f29-dbd85c909cf7" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_a72bea96-b31d-49d8-930a-c2170cdee09b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_c5670d80-a827-45dc-aecf-078956f1221c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_3812f92b-d182-4a9b-8f29-dbd85c909cf7" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_c5670d80-a827-45dc-aecf-078956f1221c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_b48331f7-2f2c-422b-887a-294f901165d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_7434dd48-2e7e-4f21-9227-b59c816493cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_b48331f7-2f2c-422b-887a-294f901165d7" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_7434dd48-2e7e-4f21-9227-b59c816493cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_d05c866b-3a36-46e5-b6e0-0ca3dd2af32a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_b48331f7-2f2c-422b-887a-294f901165d7" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_d05c866b-3a36-46e5-b6e0-0ca3dd2af32a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/InvestmentsScheduleofMaturityofInvestmentsDetails" xlink:type="simple" xlink:href="bcrx-20250930.xsd#InvestmentsScheduleofMaturityofInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/role/InvestmentsScheduleofMaturityofInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3599fcd0-2dfd-4fc8-902d-c18751cc4a90" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_1727e054-91d4-49e4-9b26-411d917d9dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3599fcd0-2dfd-4fc8-902d-c18751cc4a90" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_1727e054-91d4-49e4-9b26-411d917d9dc8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterOneYearAndBeforeTwoYears_fab30ad6-23f0-4be3-8e95-38c2fa7e7fb3" xlink:href="bcrx-20250930.xsd#bcrx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterOneYearAndBeforeTwoYears"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3599fcd0-2dfd-4fc8-902d-c18751cc4a90" xlink:to="loc_bcrx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterOneYearAndBeforeTwoYears_fab30ad6-23f0-4be3-8e95-38c2fa7e7fb3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/InventorySummaryofInventoriesDetails" xlink:type="simple" xlink:href="bcrx-20250930.xsd#InventorySummaryofInventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/role/InventorySummaryofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_InventoryIncludingNoncurrentPortion_9596d671-a26b-405b-bc4c-116c9f35a919" xlink:href="bcrx-20250930.xsd#bcrx_InventoryIncludingNoncurrentPortion"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_ef538fc5-fce3-4e67-82a8-c4346042b3ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bcrx_InventoryIncludingNoncurrentPortion_9596d671-a26b-405b-bc4c-116c9f35a919" xlink:to="loc_us-gaap_InventoryGross_ef538fc5-fce3-4e67-82a8-c4346042b3ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_ce4ab7a6-b331-471e-9694-9741990897b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryValuationReserves"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bcrx_InventoryIncludingNoncurrentPortion_9596d671-a26b-405b-bc4c-116c9f35a919" xlink:to="loc_us-gaap_InventoryValuationReserves_ce4ab7a6-b331-471e-9694-9741990897b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_5ebf4d3d-fe41-4e24-89a2-e7b5cd99b824" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_6c496002-f6b2-4999-a6df-fe78e0a8f69a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryRawMaterials"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_5ebf4d3d-fe41-4e24-89a2-e7b5cd99b824" xlink:to="loc_us-gaap_InventoryRawMaterials_6c496002-f6b2-4999-a6df-fe78e0a8f69a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_8271869c-48c5-448f-8a86-e332e77bca76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_5ebf4d3d-fe41-4e24-89a2-e7b5cd99b824" xlink:to="loc_us-gaap_InventoryWorkInProcess_8271869c-48c5-448f-8a86-e332e77bca76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_1654d3d9-4dec-4e96-9a96-2da7a735c220" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_5ebf4d3d-fe41-4e24-89a2-e7b5cd99b824" xlink:to="loc_us-gaap_InventoryFinishedGoods_1654d3d9-4dec-4e96-9a96-2da7a735c220" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/LeaseObligationsAggregateLeaseExpenseUnderOperatingLeasesDetails" xlink:type="simple" xlink:href="bcrx-20250930.xsd#LeaseObligationsAggregateLeaseExpenseUnderOperatingLeasesDetails"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/role/LeaseObligationsAggregateLeaseExpenseUnderOperatingLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_FinancingLeaseExpense_7f471c12-6c91-4e7d-b15a-aada6111db94" xlink:href="bcrx-20250930.xsd#bcrx_FinancingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_63b5f58e-fa1c-43aa-9383-200434023192" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bcrx_FinancingLeaseExpense_7f471c12-6c91-4e7d-b15a-aada6111db94" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_63b5f58e-fa1c-43aa-9383-200434023192" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_f3090528-0e7e-4024-b11d-f94c2e69cb18" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bcrx_FinancingLeaseExpense_7f471c12-6c91-4e7d-b15a-aada6111db94" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_f3090528-0e7e-4024-b11d-f94c2e69cb18" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/LeaseObligationsBalanceSheetsoftheCompanysOperatingLeasesDetails" xlink:type="simple" xlink:href="bcrx-20250930.xsd#LeaseObligationsBalanceSheetsoftheCompanysOperatingLeasesDetails"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/role/LeaseObligationsBalanceSheetsoftheCompanysOperatingLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_29b99fd0-044d-4ac3-be55-ade3840c7ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ad08f894-149f-41c9-8964-b61ffafaf268" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_29b99fd0-044d-4ac3-be55-ade3840c7ee0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ad08f894-149f-41c9-8964-b61ffafaf268" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c61b0116-b66f-4b1b-9e45-8c8343da7d89" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_29b99fd0-044d-4ac3-be55-ade3840c7ee0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c61b0116-b66f-4b1b-9e45-8c8343da7d89" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/LeaseObligationsBalanceSheetsoftheCompanysFinanceLeasesDetails" xlink:type="simple" xlink:href="bcrx-20250930.xsd#LeaseObligationsBalanceSheetsoftheCompanysFinanceLeasesDetails"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/role/LeaseObligationsBalanceSheetsoftheCompanysFinanceLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_174eb1df-5f7f-4580-a481-468b875968e8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_f8225051-53a2-430e-98c2-f7d021b19d1f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_174eb1df-5f7f-4580-a481-468b875968e8" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_f8225051-53a2-430e-98c2-f7d021b19d1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_c090769b-b418-4616-beaa-4185c52b971a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_174eb1df-5f7f-4580-a481-468b875968e8" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_c090769b-b418-4616-beaa-4185c52b971a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/LeaseObligationsMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="bcrx-20250930.xsd#LeaseObligationsMaturitiesofLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/role/LeaseObligationsMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_870b866f-4f14-4e04-bd5a-e5297730a02c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_0d2276e9-72ca-45c8-a9bf-e71abbee6934" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_870b866f-4f14-4e04-bd5a-e5297730a02c" xlink:to="loc_us-gaap_FinanceLeaseLiability_0d2276e9-72ca-45c8-a9bf-e71abbee6934" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_7ce1de50-5acd-4eb7-9f54-18383dfed3b1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_870b866f-4f14-4e04-bd5a-e5297730a02c" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_7ce1de50-5acd-4eb7-9f54-18383dfed3b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9d4a52ba-369f-417b-857f-d847191ff411" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_51f228e0-4561-44ee-beb8-340cc6af2031" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9d4a52ba-369f-417b-857f-d847191ff411" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_51f228e0-4561-44ee-beb8-340cc6af2031" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_772c7aca-41e2-426c-a90c-71a3324d9296" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9d4a52ba-369f-417b-857f-d847191ff411" xlink:to="loc_us-gaap_OperatingLeaseLiability_772c7aca-41e2-426c-a90c-71a3324d9296" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/LeaseObligationsMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="bcrx-20250930.xsd#LeaseObligationsMaturitiesofLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/role/LeaseObligationsMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_cf50f5cb-8a1f-4739-81de-e856ba304c6b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_1d23b188-3985-4d33-a74b-a1dcb59d8c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_cf50f5cb-8a1f-4739-81de-e856ba304c6b" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_1d23b188-3985-4d33-a74b-a1dcb59d8c5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_FinanceLeaseLiabilityToBePaidAfterYearFour_58cd39db-1a51-45cf-a3c3-3a6bdc1e85e7" xlink:href="bcrx-20250930.xsd#bcrx_FinanceLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_cf50f5cb-8a1f-4739-81de-e856ba304c6b" xlink:to="loc_bcrx_FinanceLeaseLiabilityToBePaidAfterYearFour_58cd39db-1a51-45cf-a3c3-3a6bdc1e85e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_d71f2be9-ce0d-4be0-8d01-8aa623ce6c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_cf50f5cb-8a1f-4739-81de-e856ba304c6b" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_d71f2be9-ce0d-4be0-8d01-8aa623ce6c4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_cd1abd3a-61c2-4366-b026-0d773dfacec6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_cf50f5cb-8a1f-4739-81de-e856ba304c6b" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_cd1abd3a-61c2-4366-b026-0d773dfacec6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_a33c1add-d3c5-4a03-915f-9f38ceb2cc6a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_cf50f5cb-8a1f-4739-81de-e856ba304c6b" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_a33c1add-d3c5-4a03-915f-9f38ceb2cc6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_4c9a3916-1c25-4ddf-be52-61a62220a751" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_cf50f5cb-8a1f-4739-81de-e856ba304c6b" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_4c9a3916-1c25-4ddf-be52-61a62220a751" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_163a5338-59e8-4104-9f37-80efa781a203" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_4ace90b5-182d-4980-9b1a-692cefbc151c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_163a5338-59e8-4104-9f37-80efa781a203" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_4ace90b5-182d-4980-9b1a-692cefbc151c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e57098c5-0ec9-4b47-9561-e16a132ae540" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_163a5338-59e8-4104-9f37-80efa781a203" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e57098c5-0ec9-4b47-9561-e16a132ae540" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9d6951fd-9f94-49dc-9c6f-139f684fcc3a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_163a5338-59e8-4104-9f37-80efa781a203" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9d6951fd-9f94-49dc-9c6f-139f684fcc3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_34134c42-dc2f-4bc9-a147-08f54b963f0f" xlink:href="bcrx-20250930.xsd#bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_163a5338-59e8-4104-9f37-80efa781a203" xlink:to="loc_bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_34134c42-dc2f-4bc9-a147-08f54b963f0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_7c665d4e-207c-4533-a534-53cb9f941e97" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_163a5338-59e8-4104-9f37-80efa781a203" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_7c665d4e-207c-4533-a534-53cb9f941e97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0ca283b8-a27f-4348-9f84-9e890bc2471c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_163a5338-59e8-4104-9f37-80efa781a203" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0ca283b8-a27f-4348-9f84-9e890bc2471c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/SegmentInformationSegmentReportingInformationbySegmentDetails" xlink:type="simple" xlink:href="bcrx-20250930.xsd#SegmentInformationSegmentReportingInformationbySegmentDetails"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/role/SegmentInformationSegmentReportingInformationbySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_696e0eec-d0fa-4ccd-9009-7bc91c184b28" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_537299af-9e00-4ca7-b80c-10928516ef3f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_696e0eec-d0fa-4ccd-9009-7bc91c184b28" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_537299af-9e00-4ca7-b80c-10928516ef3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_c32b48fd-88e6-4f16-aefb-fe39e08f09c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_696e0eec-d0fa-4ccd-9009-7bc91c184b28" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_c32b48fd-88e6-4f16-aefb-fe39e08f09c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_beda6712-bb67-40df-ab67-4a94ec7e38fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeOperating"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_696e0eec-d0fa-4ccd-9009-7bc91c184b28" xlink:to="loc_us-gaap_InterestIncomeOperating_beda6712-bb67-40df-ab67-4a94ec7e38fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_53890db3-a1f4-4406-9856-77a57447c29b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_696e0eec-d0fa-4ccd-9009-7bc91c184b28" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_53890db3-a1f4-4406-9856-77a57447c29b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_090e2a7a-1778-4816-b82c-5a70453693b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_696e0eec-d0fa-4ccd-9009-7bc91c184b28" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_090e2a7a-1778-4816-b82c-5a70453693b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_02753082-d5d7-4b11-bb62-6d80e86513a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_696e0eec-d0fa-4ccd-9009-7bc91c184b28" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_02753082-d5d7-4b11-bb62-6d80e86513a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_d11bc6b7-9660-45d5-ba2a-f580d6ab180a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_696e0eec-d0fa-4ccd-9009-7bc91c184b28" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_d11bc6b7-9660-45d5-ba2a-f580d6ab180a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_2f7a84ef-3c98-4553-ba80-1a17109b7041" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_696e0eec-d0fa-4ccd-9009-7bc91c184b28" xlink:to="loc_us-gaap_InterestExpenseNonoperating_2f7a84ef-3c98-4553-ba80-1a17109b7041" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_1e2dd228-f3f2-4aaf-88ae-d565b79bc5fd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_696e0eec-d0fa-4ccd-9009-7bc91c184b28" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_1e2dd228-f3f2-4aaf-88ae-d565b79bc5fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncome_cb44f96b-01e5-4416-9820-b5e5ae25eb07" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncome"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_696e0eec-d0fa-4ccd-9009-7bc91c184b28" xlink:to="loc_us-gaap_OtherIncome_cb44f96b-01e5-4416-9820-b5e5ae25eb07" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/NetIncomeLossPerShareScheduleofEarningsPerShareDetails" xlink:type="simple" xlink:href="bcrx-20250930.xsd#NetIncomeLossPerShareScheduleofEarningsPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/role/NetIncomeLossPerShareScheduleofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_96fe9ab6-63c7-42e5-973a-96d95c3bca39" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements_5a58c6d9-e45d-47cc-9c3d-cb9f66ed648d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_96fe9ab6-63c7-42e5-973a-96d95c3bca39" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements_5a58c6d9-e45d-47cc-9c3d-cb9f66ed648d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_3f581c5c-dff4-4641-8c82-bbedcf197524" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_96fe9ab6-63c7-42e5-973a-96d95c3bca39" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_3f581c5c-dff4-4641-8c82-bbedcf197524" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_IncrementalCommonSharesAttributableToDilutiveEffectOfSharePurchasePlans_b99b3627-bff1-4588-adee-96b074c1a23c" xlink:href="bcrx-20250930.xsd#bcrx_IncrementalCommonSharesAttributableToDilutiveEffectOfSharePurchasePlans"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_96fe9ab6-63c7-42e5-973a-96d95c3bca39" xlink:to="loc_bcrx_IncrementalCommonSharesAttributableToDilutiveEffectOfSharePurchasePlans_b99b3627-bff1-4588-adee-96b074c1a23c" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>bcrx-20250930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:9a36bdce-1161-4cfc-8f27-e0c5ed23a9d7,g:923a909e-42f3-4f9e-a634-f93d4ee01684-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="bcrx-20250930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0b04b4df-88ee-4769-b9f5-9f1430c2c373" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_56276740-04a5-4f3a-b285-9ade1255d590" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0b04b4df-88ee-4769-b9f5-9f1430c2c373" xlink:to="loc_us-gaap_StatementTable_56276740-04a5-4f3a-b285-9ade1255d590" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_d5e9c56a-7810-4bce-972e-e0b5b637ec33" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_56276740-04a5-4f3a-b285-9ade1255d590" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_d5e9c56a-7810-4bce-972e-e0b5b637ec33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_d5e9c56a-7810-4bce-972e-e0b5b637ec33_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_d5e9c56a-7810-4bce-972e-e0b5b637ec33" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_d5e9c56a-7810-4bce-972e-e0b5b637ec33_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_b5c6bdb5-85fa-4e55-9598-b7e55184a918" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_d5e9c56a-7810-4bce-972e-e0b5b637ec33" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_b5c6bdb5-85fa-4e55-9598-b7e55184a918" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_1385fb44-60ed-407e-8cfe-fc0d665611d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_b5c6bdb5-85fa-4e55-9598-b7e55184a918" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_1385fb44-60ed-407e-8cfe-fc0d665611d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_9010b612-c5eb-4dd1-82c7-47e96fd92986" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0b04b4df-88ee-4769-b9f5-9f1430c2c373" xlink:to="loc_us-gaap_AssetsAbstract_9010b612-c5eb-4dd1-82c7-47e96fd92986" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_415f233c-26d5-4265-93fe-24fd31116e10" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_9010b612-c5eb-4dd1-82c7-47e96fd92986" xlink:to="loc_us-gaap_AssetsCurrentAbstract_415f233c-26d5-4265-93fe-24fd31116e10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_203e17da-cf02-4427-a27a-32680cf94ba1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_415f233c-26d5-4265-93fe-24fd31116e10" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_203e17da-cf02-4427-a27a-32680cf94ba1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_4fba2ce0-90ff-4688-a8be-c9cacc87c2fd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_415f233c-26d5-4265-93fe-24fd31116e10" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_4fba2ce0-90ff-4688-a8be-c9cacc87c2fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_bf30fd16-8775-42bd-8b01-17d52aa19743" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_415f233c-26d5-4265-93fe-24fd31116e10" xlink:to="loc_us-gaap_ShortTermInvestments_bf30fd16-8775-42bd-8b01-17d52aa19743" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_93560836-c762-4d13-9c0a-b9c1202c6930" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_415f233c-26d5-4265-93fe-24fd31116e10" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_93560836-c762-4d13-9c0a-b9c1202c6930" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_33bf3197-ecaf-43d0-8b7b-fa3845f23e27" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_415f233c-26d5-4265-93fe-24fd31116e10" xlink:to="loc_us-gaap_InventoryNet_33bf3197-ecaf-43d0-8b7b-fa3845f23e27" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_55094adf-9e57-4c70-93d7-727cc86a401e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_415f233c-26d5-4265-93fe-24fd31116e10" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_55094adf-9e57-4c70-93d7-727cc86a401e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_8e934cbc-9378-4662-9cf5-c44f87da27b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_415f233c-26d5-4265-93fe-24fd31116e10" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_8e934cbc-9378-4662-9cf5-c44f87da27b8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_73845ae1-56c3-4cd6-a4d0-930ab2d8f49e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_415f233c-26d5-4265-93fe-24fd31116e10" xlink:to="loc_us-gaap_AssetsCurrent_73845ae1-56c3-4cd6-a4d0-930ab2d8f49e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_8251c3a1-7a74-46ac-ae77-0e54f2d81f46" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_9010b612-c5eb-4dd1-82c7-47e96fd92986" xlink:to="loc_us-gaap_InventoryNoncurrent_8251c3a1-7a74-46ac-ae77-0e54f2d81f46" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_26a29af1-2d56-4fc1-8606-436e28ba8632" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_9010b612-c5eb-4dd1-82c7-47e96fd92986" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_26a29af1-2d56-4fc1-8606-436e28ba8632" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_a9e603a0-0fef-44fa-8bc5-67e36fb459b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_9010b612-c5eb-4dd1-82c7-47e96fd92986" xlink:to="loc_us-gaap_LongTermInvestments_a9e603a0-0fef-44fa-8bc5-67e36fb459b2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RightOfUseAssetsNoncurrent_9958602b-5329-4384-8c32-3b9586b33ad7" xlink:href="bcrx-20250930.xsd#bcrx_RightOfUseAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_9010b612-c5eb-4dd1-82c7-47e96fd92986" xlink:to="loc_bcrx_RightOfUseAssetsNoncurrent_9958602b-5329-4384-8c32-3b9586b33ad7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_c34544c7-1991-4445-bad7-6b91f665fc4f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_9010b612-c5eb-4dd1-82c7-47e96fd92986" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_c34544c7-1991-4445-bad7-6b91f665fc4f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_80d77410-58b4-42fd-9940-700f1075e89f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_9010b612-c5eb-4dd1-82c7-47e96fd92986" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_80d77410-58b4-42fd-9940-700f1075e89f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_86c3975e-7852-488c-b65c-d85dd498c0da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_9010b612-c5eb-4dd1-82c7-47e96fd92986" xlink:to="loc_us-gaap_Assets_86c3975e-7852-488c-b65c-d85dd498c0da" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7ef9e1e-68cc-46b5-9104-ed544d6fc662" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0b04b4df-88ee-4769-b9f5-9f1430c2c373" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7ef9e1e-68cc-46b5-9104-ed544d6fc662" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_54b16604-d02b-45a2-b181-98ba02a4b63e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7ef9e1e-68cc-46b5-9104-ed544d6fc662" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_54b16604-d02b-45a2-b181-98ba02a4b63e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_5269e686-2488-4c81-abdf-e3747e311ec7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_54b16604-d02b-45a2-b181-98ba02a4b63e" xlink:to="loc_us-gaap_AccountsPayableCurrent_5269e686-2488-4c81-abdf-e3747e311ec7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_19ac92ae-8d79-45ca-8feb-7afe5c55d88e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_54b16604-d02b-45a2-b181-98ba02a4b63e" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_19ac92ae-8d79-45ca-8feb-7afe5c55d88e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f54e3228-3da9-428a-b81c-59ef029273d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_54b16604-d02b-45a2-b181-98ba02a4b63e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f54e3228-3da9-428a-b81c-59ef029273d4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_754c0627-9716-400d-9062-0c7d310f40c1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_54b16604-d02b-45a2-b181-98ba02a4b63e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_754c0627-9716-400d-9062-0c7d310f40c1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyFinancingLiabilitiesCurrent_2d073233-6c5b-4f94-be49-fecb8317c98e" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltyFinancingLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_54b16604-d02b-45a2-b181-98ba02a4b63e" xlink:to="loc_bcrx_RoyaltyFinancingLiabilitiesCurrent_2d073233-6c5b-4f94-be49-fecb8317c98e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_34898b36-6274-4528-acc2-be8411fc6ce3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_54b16604-d02b-45a2-b181-98ba02a4b63e" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_34898b36-6274-4528-acc2-be8411fc6ce3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e19213b0-7822-4d93-b4ca-798b59cb5b09" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_54b16604-d02b-45a2-b181-98ba02a4b63e" xlink:to="loc_us-gaap_LiabilitiesCurrent_e19213b0-7822-4d93-b4ca-798b59cb5b09" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3c75ebb7-3784-4d5f-bbd7-61fe118274e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7ef9e1e-68cc-46b5-9104-ed544d6fc662" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3c75ebb7-3784-4d5f-bbd7-61fe118274e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_a48ea87f-7b47-409a-9aba-7f1f813b2b41" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7ef9e1e-68cc-46b5-9104-ed544d6fc662" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_a48ea87f-7b47-409a-9aba-7f1f813b2b41" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyFinancingLiabilitiesNoncurrent_f7e74120-f740-4770-aa89-c122d460b52f" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltyFinancingLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7ef9e1e-68cc-46b5-9104-ed544d6fc662" xlink:to="loc_bcrx_RoyaltyFinancingLiabilitiesNoncurrent_f7e74120-f740-4770-aa89-c122d460b52f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_8ab463ca-3d4a-4f7d-834a-fab4a5a1994c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7ef9e1e-68cc-46b5-9104-ed544d6fc662" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_8ab463ca-3d4a-4f7d-834a-fab4a5a1994c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_95e0c45e-71e7-4a3b-bc00-aec3a902c103" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7ef9e1e-68cc-46b5-9104-ed544d6fc662" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_95e0c45e-71e7-4a3b-bc00-aec3a902c103" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a8b1560f-fb53-4f74-964a-f01391781781" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7ef9e1e-68cc-46b5-9104-ed544d6fc662" xlink:to="loc_us-gaap_Liabilities_a8b1560f-fb53-4f74-964a-f01391781781" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_b4e99915-fca7-43cc-855c-73b53dc3018a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7ef9e1e-68cc-46b5-9104-ed544d6fc662" xlink:to="loc_us-gaap_StockholdersEquityAbstract_b4e99915-fca7-43cc-855c-73b53dc3018a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_8b73010e-3e4c-4891-8a66-33a8a1cf407b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b4e99915-fca7-43cc-855c-73b53dc3018a" xlink:to="loc_us-gaap_PreferredStockValue_8b73010e-3e4c-4891-8a66-33a8a1cf407b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_c257855d-d292-4037-ad4c-fbdfa5d60a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b4e99915-fca7-43cc-855c-73b53dc3018a" xlink:to="loc_us-gaap_CommonStockValue_c257855d-d292-4037-ad4c-fbdfa5d60a1a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_c576bea5-1464-4ca9-b584-794919595217" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b4e99915-fca7-43cc-855c-73b53dc3018a" xlink:to="loc_us-gaap_AdditionalPaidInCapital_c576bea5-1464-4ca9-b584-794919595217" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_38c58cab-e701-4a7e-a00d-d4918fec1a94" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b4e99915-fca7-43cc-855c-73b53dc3018a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_38c58cab-e701-4a7e-a00d-d4918fec1a94" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d9b6cd01-6458-47e7-a891-a3eb5e70e3a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b4e99915-fca7-43cc-855c-73b53dc3018a" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d9b6cd01-6458-47e7-a891-a3eb5e70e3a0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_87a7d84f-4f31-4e0d-8475-ec309696a178" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b4e99915-fca7-43cc-855c-73b53dc3018a" xlink:to="loc_us-gaap_StockholdersEquity_87a7d84f-4f31-4e0d-8475-ec309696a178" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_c6073d4a-4da3-44ca-a40f-1d2e1d780e99" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7ef9e1e-68cc-46b5-9104-ed544d6fc662" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_c6073d4a-4da3-44ca-a40f-1d2e1d780e99" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/CondensedConsolidatedStatementsofStockholdersDeficit" xlink:type="simple" xlink:href="bcrx-20250930.xsd#CondensedConsolidatedStatementsofStockholdersDeficit"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/role/CondensedConsolidatedStatementsofStockholdersDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_25efe9fd-48e8-4eef-b778-0a3632439920" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_dc794380-37cb-4cb3-9b12-0e51db81354a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_25efe9fd-48e8-4eef-b778-0a3632439920" xlink:to="loc_us-gaap_StatementTable_dc794380-37cb-4cb3-9b12-0e51db81354a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8bc1652a-b856-4472-b808-55150fe3925e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_dc794380-37cb-4cb3-9b12-0e51db81354a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8bc1652a-b856-4472-b808-55150fe3925e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8bc1652a-b856-4472-b808-55150fe3925e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8bc1652a-b856-4472-b808-55150fe3925e" xlink:to="loc_us-gaap_EquityComponentDomain_8bc1652a-b856-4472-b808-55150fe3925e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_92e53480-b658-433f-9f49-b6c22dcf5008" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8bc1652a-b856-4472-b808-55150fe3925e" xlink:to="loc_us-gaap_EquityComponentDomain_92e53480-b658-433f-9f49-b6c22dcf5008" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_74be383d-e120-4b6f-bc1b-2e955f2b75a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_92e53480-b658-433f-9f49-b6c22dcf5008" xlink:to="loc_us-gaap_CommonStockMember_74be383d-e120-4b6f-bc1b-2e955f2b75a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_5efcce4f-9593-4cfa-aaa8-2d30a099a0ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_92e53480-b658-433f-9f49-b6c22dcf5008" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_5efcce4f-9593-4cfa-aaa8-2d30a099a0ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_14b35ec1-f6a8-43a8-a928-da15d6edc406" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_92e53480-b658-433f-9f49-b6c22dcf5008" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_14b35ec1-f6a8-43a8-a928-da15d6edc406" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_f992601d-6c83-41e4-acea-3af0c42596b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_92e53480-b658-433f-9f49-b6c22dcf5008" xlink:to="loc_us-gaap_RetainedEarningsMember_f992601d-6c83-41e4-acea-3af0c42596b7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_314b77f0-6084-45a2-88bf-e7d0c3f2bf25" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_25efe9fd-48e8-4eef-b778-0a3632439920" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_314b77f0-6084-45a2-88bf-e7d0c3f2bf25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f047730b-0461-4777-82cb-ad4cc199fb7f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_314b77f0-6084-45a2-88bf-e7d0c3f2bf25" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_f047730b-0461-4777-82cb-ad4cc199fb7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_88f196a5-cd3f-4252-bb93-be2dc915e02b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_314b77f0-6084-45a2-88bf-e7d0c3f2bf25" xlink:to="loc_us-gaap_StockholdersEquity_88f196a5-cd3f-4252-bb93-be2dc915e02b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7b2a3e49-106d-4913-a3a1-54a7a17d835a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_314b77f0-6084-45a2-88bf-e7d0c3f2bf25" xlink:to="loc_us-gaap_NetIncomeLoss_7b2a3e49-106d-4913-a3a1-54a7a17d835a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ab73fbab-7f01-4993-9e82-850d77759bbc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_314b77f0-6084-45a2-88bf-e7d0c3f2bf25" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ab73fbab-7f01-4993-9e82-850d77759bbc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_796656c3-800e-4b1c-94f8-127218efa107" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_314b77f0-6084-45a2-88bf-e7d0c3f2bf25" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_796656c3-800e-4b1c-94f8-127218efa107" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_fef63e44-4374-4a11-ad51-7eebed6433b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_314b77f0-6084-45a2-88bf-e7d0c3f2bf25" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_fef63e44-4374-4a11-ad51-7eebed6433b6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_225610df-e0b2-40b3-9d8a-cae2cfb16e3d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_314b77f0-6084-45a2-88bf-e7d0c3f2bf25" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_225610df-e0b2-40b3-9d8a-cae2cfb16e3d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_accfb519-10a0-4ee9-a1f9-8751d944f9c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_314b77f0-6084-45a2-88bf-e7d0c3f2bf25" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_accfb519-10a0-4ee9-a1f9-8751d944f9c0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_46ab6761-1796-4380-adb9-7931501af78a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_314b77f0-6084-45a2-88bf-e7d0c3f2bf25" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_46ab6761-1796-4380-adb9-7931501af78a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_6dfdbcf3-184f-48e8-ad8f-d7b0ed7e718f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_314b77f0-6084-45a2-88bf-e7d0c3f2bf25" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_6dfdbcf3-184f-48e8-ad8f-d7b0ed7e718f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_30055b06-1624-40c5-93db-38f19196ddd5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_314b77f0-6084-45a2-88bf-e7d0c3f2bf25" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_30055b06-1624-40c5-93db-38f19196ddd5" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_ecc212b3-b5d4-4ef1-9d61-07062a8e1ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_314b77f0-6084-45a2-88bf-e7d0c3f2bf25" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_ecc212b3-b5d4-4ef1-9d61-07062a8e1ba2" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_59334d04-7165-4ab8-b610-4b57dd66f46e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_314b77f0-6084-45a2-88bf-e7d0c3f2bf25" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_59334d04-7165-4ab8-b610-4b57dd66f46e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_8a912f89-3e5a-42e6-beff-8c070751abe9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_314b77f0-6084-45a2-88bf-e7d0c3f2bf25" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_8a912f89-3e5a-42e6-beff-8c070751abe9" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c7b9c78a-d922-4677-a079-4a17bcf51140" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_314b77f0-6084-45a2-88bf-e7d0c3f2bf25" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c7b9c78a-d922-4677-a079-4a17bcf51140" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ff6f4d22-beb2-4b68-85c9-954493f1d71f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_eb03bd01-7a14-42f4-be73-1d054a867bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails" xlink:type="simple" xlink:href="bcrx-20250930.xsd#SignificantAccountingPoliciesandConcentrationsofRiskDetails"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_efbaece0-5bcf-41ff-af5b-d81c5e222499" xlink:href="bcrx-20250930.xsd#bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable_2814bfa2-f526-4963-a0f5-3af4385212f0" xlink:href="bcrx-20250930.xsd#bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_efbaece0-5bcf-41ff-af5b-d81c5e222499" xlink:to="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable_2814bfa2-f526-4963-a0f5-3af4385212f0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_3aa174a8-af7c-4fc6-965a-50dfc6cd553e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable_2814bfa2-f526-4963-a0f5-3af4385212f0" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_3aa174a8-af7c-4fc6-965a-50dfc6cd553e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_3aa174a8-af7c-4fc6-965a-50dfc6cd553e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_3aa174a8-af7c-4fc6-965a-50dfc6cd553e" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_3aa174a8-af7c-4fc6-965a-50dfc6cd553e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_58aebfcb-d4f2-46f0-8b7a-8dcaf37aed3e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_3aa174a8-af7c-4fc6-965a-50dfc6cd553e" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_58aebfcb-d4f2-46f0-8b7a-8dcaf37aed3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_CollateralForCreditMember_436be52e-6602-43d8-bf87-94391fd9a4de" xlink:href="bcrx-20250930.xsd#bcrx_CollateralForCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_58aebfcb-d4f2-46f0-8b7a-8dcaf37aed3e" xlink:to="loc_bcrx_CollateralForCreditMember_436be52e-6602-43d8-bf87-94391fd9a4de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b20757f8-59be-44c8-bc6d-efb7f854ca1f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable_2814bfa2-f526-4963-a0f5-3af4385212f0" xlink:to="loc_srt_RangeAxis_b20757f8-59be-44c8-bc6d-efb7f854ca1f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b20757f8-59be-44c8-bc6d-efb7f854ca1f_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b20757f8-59be-44c8-bc6d-efb7f854ca1f" xlink:to="loc_srt_RangeMember_b20757f8-59be-44c8-bc6d-efb7f854ca1f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_32dbcab8-ad7b-415d-8144-c306d5dabca1" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b20757f8-59be-44c8-bc6d-efb7f854ca1f" xlink:to="loc_srt_RangeMember_32dbcab8-ad7b-415d-8144-c306d5dabca1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_db7c9998-abd7-4d98-94ab-fc33192753f6" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_32dbcab8-ad7b-415d-8144-c306d5dabca1" xlink:to="loc_srt_MaximumMember_db7c9998-abd7-4d98-94ab-fc33192753f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9dd7b114-aeda-4cb4-bce6-3d51eb99a65e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable_2814bfa2-f526-4963-a0f5-3af4385212f0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9dd7b114-aeda-4cb4-bce6-3d51eb99a65e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9dd7b114-aeda-4cb4-bce6-3d51eb99a65e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9dd7b114-aeda-4cb4-bce6-3d51eb99a65e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9dd7b114-aeda-4cb4-bce6-3d51eb99a65e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_787ba224-f601-4ba1-ba37-d3626030ae1b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9dd7b114-aeda-4cb4-bce6-3d51eb99a65e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_787ba224-f601-4ba1-ba37-d3626030ae1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_f5e3903b-bbe7-4a78-8259-f102ea436393" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_787ba224-f601-4ba1-ba37-d3626030ae1b" xlink:to="loc_us-gaap_ComputerEquipmentMember_f5e3903b-bbe7-4a78-8259-f102ea436393" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember_866d6a4f-c3a7-442d-8290-7f0040b6e24a" xlink:href="bcrx-20250930.xsd#bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_787ba224-f601-4ba1-ba37-d3626030ae1b" xlink:to="loc_bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember_866d6a4f-c3a7-442d-8290-7f0040b6e24a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_3d86554e-8286-4478-ad2f-2c991a2c4fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_787ba224-f601-4ba1-ba37-d3626030ae1b" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_3d86554e-8286-4478-ad2f-2c991a2c4fa0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0b77f48b-c7c0-4074-b654-b4610d21cb39" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable_2814bfa2-f526-4963-a0f5-3af4385212f0" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0b77f48b-c7c0-4074-b654-b4610d21cb39" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0b77f48b-c7c0-4074-b654-b4610d21cb39_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0b77f48b-c7c0-4074-b654-b4610d21cb39" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0b77f48b-c7c0-4074-b654-b4610d21cb39_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0e024ea1-ecfc-4410-bae4-360cd5df5d77" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0b77f48b-c7c0-4074-b654-b4610d21cb39" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0e024ea1-ecfc-4410-bae4-360cd5df5d77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_70b08625-d6e8-4e60-b52c-60c922b29029" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0e024ea1-ecfc-4410-bae4-360cd5df5d77" xlink:to="loc_us-gaap_SalesRevenueNetMember_70b08625-d6e8-4e60-b52c-60c922b29029" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_f5273cab-7f18-43e7-92ef-723efab2009e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable_2814bfa2-f526-4963-a0f5-3af4385212f0" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_f5273cab-7f18-43e7-92ef-723efab2009e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_f5273cab-7f18-43e7-92ef-723efab2009e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_f5273cab-7f18-43e7-92ef-723efab2009e" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_f5273cab-7f18-43e7-92ef-723efab2009e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_e9d8dbeb-77b3-42b7-87b5-c27e98fe8589" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_f5273cab-7f18-43e7-92ef-723efab2009e" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_e9d8dbeb-77b3-42b7-87b5-c27e98fe8589" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_e9f65704-e884-4dbe-bc7c-0a5498ed4878" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_e9d8dbeb-77b3-42b7-87b5-c27e98fe8589" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_e9f65704-e884-4dbe-bc7c-0a5498ed4878" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_64d6db69-5886-405e-b1ca-1e5d6f100ac1" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable_2814bfa2-f526-4963-a0f5-3af4385212f0" xlink:to="loc_srt_ProductOrServiceAxis_64d6db69-5886-405e-b1ca-1e5d6f100ac1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_64d6db69-5886-405e-b1ca-1e5d6f100ac1_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_64d6db69-5886-405e-b1ca-1e5d6f100ac1" xlink:to="loc_srt_ProductsAndServicesDomain_64d6db69-5886-405e-b1ca-1e5d6f100ac1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_35de4207-b780-4250-a5a7-5d668cffbc46" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_64d6db69-5886-405e-b1ca-1e5d6f100ac1" xlink:to="loc_srt_ProductsAndServicesDomain_35de4207-b780-4250-a5a7-5d668cffbc46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ORLADEYOMember_095d9289-d11f-48be-bace-f0106941299c" xlink:href="bcrx-20250930.xsd#bcrx_ORLADEYOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_35de4207-b780-4250-a5a7-5d668cffbc46" xlink:to="loc_bcrx_ORLADEYOMember_095d9289-d11f-48be-bace-f0106941299c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_5fc6513a-b922-445a-97b1-04fb8158a772" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_efbaece0-5bcf-41ff-af5b-d81c5e222499" xlink:to="loc_us-gaap_NumberOfReportableSegments_5fc6513a-b922-445a-97b1-04fb8158a772" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_81c03ca1-1abe-4e90-b763-584fbbb80c72" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_efbaece0-5bcf-41ff-af5b-d81c5e222499" xlink:to="loc_us-gaap_NumberOfOperatingSegments_81c03ca1-1abe-4e90-b763-584fbbb80c72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_98de04b4-8477-4ab4-bb46-31368577a705" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_efbaece0-5bcf-41ff-af5b-d81c5e222499" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_98de04b4-8477-4ab4-bb46-31368577a705" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_MaturityPeriodOfHighQualityMarketableSecurities_52a2a46b-fc3d-4b3a-af12-ecf2fc22aa26" xlink:href="bcrx-20250930.xsd#bcrx_MaturityPeriodOfHighQualityMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_efbaece0-5bcf-41ff-af5b-d81c5e222499" xlink:to="loc_bcrx_MaturityPeriodOfHighQualityMarketableSecurities_52a2a46b-fc3d-4b3a-af12-ecf2fc22aa26" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities_e0235cb7-4400-43d3-9d99-caa54cb5d3c7" xlink:href="bcrx-20250930.xsd#bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_efbaece0-5bcf-41ff-af5b-d81c5e222499" xlink:to="loc_bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities_e0235cb7-4400-43d3-9d99-caa54cb5d3c7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_MaturityPeriodOfShortTermInvestment_7cb55e95-8b80-45ea-92ab-f7b385754106" xlink:href="bcrx-20250930.xsd#bcrx_MaturityPeriodOfShortTermInvestment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_efbaece0-5bcf-41ff-af5b-d81c5e222499" xlink:to="loc_bcrx_MaturityPeriodOfShortTermInvestment_7cb55e95-8b80-45ea-92ab-f7b385754106" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_LongTermInvestmentMaturityMinimum_cff5f5f9-ba86-4d42-a0d7-78e313f28071" xlink:href="bcrx-20250930.xsd#bcrx_LongTermInvestmentMaturityMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_efbaece0-5bcf-41ff-af5b-d81c5e222499" xlink:to="loc_bcrx_LongTermInvestmentMaturityMinimum_cff5f5f9-ba86-4d42-a0d7-78e313f28071" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_28855b0e-4ea2-4f60-af2a-ac79b753b423" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_efbaece0-5bcf-41ff-af5b-d81c5e222499" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_28855b0e-4ea2-4f60-af2a-ac79b753b423" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b9c03c85-cac3-498c-9a38-de0235a0ceb4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_efbaece0-5bcf-41ff-af5b-d81c5e222499" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b9c03c85-cac3-498c-9a38-de0235a0ceb4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_90cfb73c-e6de-442d-88fd-586d5295f0c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_efbaece0-5bcf-41ff-af5b-d81c5e222499" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_90cfb73c-e6de-442d-88fd-586d5295f0c4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_8a0ffa3f-429c-4f04-b241-4a51d6a8c9ff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_efbaece0-5bcf-41ff-af5b-d81c5e222499" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_8a0ffa3f-429c-4f04-b241-4a51d6a8c9ff" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskSummaryofRevenuesDetails" xlink:type="simple" xlink:href="bcrx-20250930.xsd#SignificantAccountingPoliciesandConcentrationsofRiskSummaryofRevenuesDetails"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskSummaryofRevenuesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_6eb1fd83-27f4-4217-af8c-cfa53259d94d" xlink:href="bcrx-20250930.xsd#bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable_c8d1083f-37f5-44d0-9a53-5cf986f00028" xlink:href="bcrx-20250930.xsd#bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_6eb1fd83-27f4-4217-af8c-cfa53259d94d" xlink:to="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable_c8d1083f-37f5-44d0-9a53-5cf986f00028" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c4ad035a-36e6-473d-8b7e-4ed22dd367ad" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable_c8d1083f-37f5-44d0-9a53-5cf986f00028" xlink:to="loc_srt_ProductOrServiceAxis_c4ad035a-36e6-473d-8b7e-4ed22dd367ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c4ad035a-36e6-473d-8b7e-4ed22dd367ad_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_c4ad035a-36e6-473d-8b7e-4ed22dd367ad" xlink:to="loc_srt_ProductsAndServicesDomain_c4ad035a-36e6-473d-8b7e-4ed22dd367ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_48e568de-e7aa-4b31-b9d9-c0c1590b99bc" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_c4ad035a-36e6-473d-8b7e-4ed22dd367ad" xlink:to="loc_srt_ProductsAndServicesDomain_48e568de-e7aa-4b31-b9d9-c0c1590b99bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_8c73a3fe-b7c6-4577-b70e-8036cf68c1b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_48e568de-e7aa-4b31-b9d9-c0c1590b99bc" xlink:to="loc_us-gaap_ProductMember_8c73a3fe-b7c6-4577-b70e-8036cf68c1b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_CollaborativeAndOtherResearchAndDevelopmentMember_7b6ed988-0140-47c0-981b-22226213749b" xlink:href="bcrx-20250930.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_48e568de-e7aa-4b31-b9d9-c0c1590b99bc" xlink:to="loc_bcrx_CollaborativeAndOtherResearchAndDevelopmentMember_7b6ed988-0140-47c0-981b-22226213749b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_63b0c642-7fd8-4a60-8a0a-858f33da3a14" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_6eb1fd83-27f4-4217-af8c-cfa53259d94d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_63b0c642-7fd8-4a60-8a0a-858f33da3a14" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleDetails" xlink:type="simple" xlink:href="bcrx-20250930.xsd#AssetsandLiabilitiesHeldForSaleDetails"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6b09c04e-dee3-4639-8d8c-0edc5c3e99ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3691cdad-39ad-4889-a980-b4878d48e84b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6b09c04e-dee3-4639-8d8c-0edc5c3e99ca" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3691cdad-39ad-4889-a980-b4878d48e84b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5a2f922e-e162-4748-9cbf-8e8d63ff4434" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3691cdad-39ad-4889-a980-b4878d48e84b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5a2f922e-e162-4748-9cbf-8e8d63ff4434" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5a2f922e-e162-4748-9cbf-8e8d63ff4434_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5a2f922e-e162-4748-9cbf-8e8d63ff4434" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5a2f922e-e162-4748-9cbf-8e8d63ff4434_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_da76b375-bcd0-43a3-9b84-668cdb1ae678" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5a2f922e-e162-4748-9cbf-8e8d63ff4434" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_da76b375-bcd0-43a3-9b84-668cdb1ae678" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7688aba8-f1eb-45c6-9e9c-a42e72cb182b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_da76b375-bcd0-43a3-9b84-668cdb1ae678" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7688aba8-f1eb-45c6-9e9c-a42e72cb182b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_3cfadaaf-536f-46ec-bc3c-209478936e53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3691cdad-39ad-4889-a980-b4878d48e84b" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_3cfadaaf-536f-46ec-bc3c-209478936e53" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_3cfadaaf-536f-46ec-bc3c-209478936e53_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_3cfadaaf-536f-46ec-bc3c-209478936e53" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_3cfadaaf-536f-46ec-bc3c-209478936e53_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_c5457c2f-88a6-4c49-ad61-574b77234231" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_3cfadaaf-536f-46ec-bc3c-209478936e53" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_c5457c2f-88a6-4c49-ad61-574b77234231" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_3406967a-cfa0-4fcb-bb7c-b13f12d07244" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_c5457c2f-88a6-4c49-ad61-574b77234231" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_3406967a-cfa0-4fcb-bb7c-b13f12d07244" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_09206f4d-2224-47af-8279-dd7b449f4993" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3691cdad-39ad-4889-a980-b4878d48e84b" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_09206f4d-2224-47af-8279-dd7b449f4993" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_09206f4d-2224-47af-8279-dd7b449f4993_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_09206f4d-2224-47af-8279-dd7b449f4993" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_09206f4d-2224-47af-8279-dd7b449f4993_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_afb75f25-ffc0-4a95-a1d8-6b71d8cb55ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_09206f4d-2224-47af-8279-dd7b449f4993" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_afb75f25-ffc0-4a95-a1d8-6b71d8cb55ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_BioCrystIrelandMember_6715d745-9a96-4737-87f7-9f6941d39c48" xlink:href="bcrx-20250930.xsd#bcrx_BioCrystIrelandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_afb75f25-ffc0-4a95-a1d8-6b71d8cb55ba" xlink:to="loc_bcrx_BioCrystIrelandMember_6715d745-9a96-4737-87f7-9f6941d39c48" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_300e5546-2fdf-4201-9de8-37a792398689" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3691cdad-39ad-4889-a980-b4878d48e84b" xlink:to="loc_srt_StatementScenarioAxis_300e5546-2fdf-4201-9de8-37a792398689" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_300e5546-2fdf-4201-9de8-37a792398689_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_300e5546-2fdf-4201-9de8-37a792398689" xlink:to="loc_srt_ScenarioUnspecifiedDomain_300e5546-2fdf-4201-9de8-37a792398689_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_56692cda-cd21-4a5c-b264-f0716c92ea75" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_300e5546-2fdf-4201-9de8-37a792398689" xlink:to="loc_srt_ScenarioUnspecifiedDomain_56692cda-cd21-4a5c-b264-f0716c92ea75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_8e52e8c0-a548-4373-a534-77e689359774" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_56692cda-cd21-4a5c-b264-f0716c92ea75" xlink:to="loc_srt_ScenarioForecastMember_8e52e8c0-a548-4373-a534-77e689359774" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_4cc9d25f-2052-4394-b395-cc11a9db4f89" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6b09c04e-dee3-4639-8d8c-0edc5c3e99ca" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_4cc9d25f-2052-4394-b395-cc11a9db4f89" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_49907174-a0b9-4a9e-84fe-7bfc2222ce30" xlink:href="bcrx-20250930.xsd#bcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6b09c04e-dee3-4639-8d8c-0edc5c3e99ca" xlink:to="loc_bcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_49907174-a0b9-4a9e-84fe-7bfc2222ce30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DisposalGroupIncludingDiscontinuedOperationConsiderationRoyaltyReleaseFee_0a2554a3-b5d1-4d49-bbd8-86fecc2b388e" xlink:href="bcrx-20250930.xsd#bcrx_DisposalGroupIncludingDiscontinuedOperationConsiderationRoyaltyReleaseFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6b09c04e-dee3-4639-8d8c-0edc5c3e99ca" xlink:to="loc_bcrx_DisposalGroupIncludingDiscontinuedOperationConsiderationRoyaltyReleaseFee_0a2554a3-b5d1-4d49-bbd8-86fecc2b388e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleScheduleofAssetsHeldForSaleDetails" xlink:type="simple" xlink:href="bcrx-20250930.xsd#AssetsandLiabilitiesHeldForSaleScheduleofAssetsHeldForSaleDetails"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleScheduleofAssetsHeldForSaleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bff75a7c-c521-49ef-96c8-292470e55e63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_978e7ce9-72d8-4d64-9670-1760550f1aee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bff75a7c-c521-49ef-96c8-292470e55e63" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_978e7ce9-72d8-4d64-9670-1760550f1aee" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_0807113e-fe03-4301-b517-3d58d0b31f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_978e7ce9-72d8-4d64-9670-1760550f1aee" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_0807113e-fe03-4301-b517-3d58d0b31f1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_0807113e-fe03-4301-b517-3d58d0b31f1e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_0807113e-fe03-4301-b517-3d58d0b31f1e" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_0807113e-fe03-4301-b517-3d58d0b31f1e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_21ec5b30-d639-4235-82d4-4fe00e97f67e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_0807113e-fe03-4301-b517-3d58d0b31f1e" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_21ec5b30-d639-4235-82d4-4fe00e97f67e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_d80364d5-895c-4050-9d05-157361071530" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_21ec5b30-d639-4235-82d4-4fe00e97f67e" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_d80364d5-895c-4050-9d05-157361071530" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e9b5606c-e356-49cd-819e-c07ccafb45c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_978e7ce9-72d8-4d64-9670-1760550f1aee" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e9b5606c-e356-49cd-819e-c07ccafb45c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e9b5606c-e356-49cd-819e-c07ccafb45c2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e9b5606c-e356-49cd-819e-c07ccafb45c2" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e9b5606c-e356-49cd-819e-c07ccafb45c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_26a7e2d7-47ef-4bf7-83bc-1231a0e2baf0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e9b5606c-e356-49cd-819e-c07ccafb45c2" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_26a7e2d7-47ef-4bf7-83bc-1231a0e2baf0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_BioCrystIrelandMember_4e6bb152-1fbf-4ef1-8f82-54dd088ae59f" xlink:href="bcrx-20250930.xsd#bcrx_BioCrystIrelandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_26a7e2d7-47ef-4bf7-83bc-1231a0e2baf0" xlink:to="loc_bcrx_BioCrystIrelandMember_4e6bb152-1fbf-4ef1-8f82-54dd088ae59f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_b716b493-486d-4a87-aa1b-058d647df9d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bff75a7c-c521-49ef-96c8-292470e55e63" xlink:to="loc_us-gaap_AssetsAbstract_b716b493-486d-4a87-aa1b-058d647df9d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_030e042d-c5a9-4c2a-b701-d54c521d2d35" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_b716b493-486d-4a87-aa1b-058d647df9d7" xlink:to="loc_us-gaap_AssetsCurrentAbstract_030e042d-c5a9-4c2a-b701-d54c521d2d35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_96620402-324e-4395-a96c-55627836a673" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_030e042d-c5a9-4c2a-b701-d54c521d2d35" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_96620402-324e-4395-a96c-55627836a673" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_4f8cc1a5-0cd2-4a74-83ec-4cdd07c29dda" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_030e042d-c5a9-4c2a-b701-d54c521d2d35" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_4f8cc1a5-0cd2-4a74-83ec-4cdd07c29dda" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_9a7e9b2f-b18c-4737-a2c2-d72100cea1e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_030e042d-c5a9-4c2a-b701-d54c521d2d35" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_9a7e9b2f-b18c-4737-a2c2-d72100cea1e3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_c42eafc5-889c-4d0c-939e-cae46df4c876" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_030e042d-c5a9-4c2a-b701-d54c521d2d35" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_c42eafc5-889c-4d0c-939e-cae46df4c876" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_dee8974c-a525-4981-8082-f63d67faf625" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_030e042d-c5a9-4c2a-b701-d54c521d2d35" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_dee8974c-a525-4981-8082-f63d67faf625" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_43ac84bf-6432-408c-a576-de972b71e81f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_b716b493-486d-4a87-aa1b-058d647df9d7" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_43ac84bf-6432-408c-a576-de972b71e81f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_4611ac05-9499-4738-96d6-98e69e6c4fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_b716b493-486d-4a87-aa1b-058d647df9d7" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_4611ac05-9499-4738-96d6-98e69e6c4fe7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8d9d172d-f876-4c1b-86f8-cf233be5621c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bff75a7c-c521-49ef-96c8-292470e55e63" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8d9d172d-f876-4c1b-86f8-cf233be5621c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_6ac1e41e-f765-4e12-953c-1e818eb04b9e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8d9d172d-f876-4c1b-86f8-cf233be5621c" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_6ac1e41e-f765-4e12-953c-1e818eb04b9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_5b33a1c3-cfa5-41ce-8b09-b4ab51b8cc46" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6ac1e41e-f765-4e12-953c-1e818eb04b9e" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_5b33a1c3-cfa5-41ce-8b09-b4ab51b8cc46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_909d70ce-cf2b-4071-a36a-4cb7b60a642f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6ac1e41e-f765-4e12-953c-1e818eb04b9e" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_909d70ce-cf2b-4071-a36a-4cb7b60a642f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_86d3bc1d-0041-4cb2-8dd2-cf17e177fc05" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6ac1e41e-f765-4e12-953c-1e818eb04b9e" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_86d3bc1d-0041-4cb2-8dd2-cf17e177fc05" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_4ec919ea-00f9-463d-8656-a9762353d136" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6ac1e41e-f765-4e12-953c-1e818eb04b9e" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_4ec919ea-00f9-463d-8656-a9762353d136" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_bc284101-e152-44a5-95e1-618415c4637f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8d9d172d-f876-4c1b-86f8-cf233be5621c" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_bc284101-e152-44a5-95e1-618415c4637f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_96497b49-86de-4398-9096-159415d84847" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8d9d172d-f876-4c1b-86f8-cf233be5621c" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_96497b49-86de-4398-9096-159415d84847" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/RevenueDetails" xlink:type="simple" xlink:href="bcrx-20250930.xsd#RevenueDetails"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/role/RevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_5bec8462-ddd4-44b8-acf3-eba53f7e26c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_90f53df2-ea9e-4eed-a9ff-148c89b773fd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5bec8462-ddd4-44b8-acf3-eba53f7e26c4" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_90f53df2-ea9e-4eed-a9ff-148c89b773fd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_54a27ce0-2e67-4e40-a885-15ca1e2da8b9" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_90f53df2-ea9e-4eed-a9ff-148c89b773fd" xlink:to="loc_srt_ProductOrServiceAxis_54a27ce0-2e67-4e40-a885-15ca1e2da8b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_54a27ce0-2e67-4e40-a885-15ca1e2da8b9_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_54a27ce0-2e67-4e40-a885-15ca1e2da8b9" xlink:to="loc_srt_ProductsAndServicesDomain_54a27ce0-2e67-4e40-a885-15ca1e2da8b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bba63b09-4b3f-4b68-8364-30fd6145dcaa" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_54a27ce0-2e67-4e40-a885-15ca1e2da8b9" xlink:to="loc_srt_ProductsAndServicesDomain_bba63b09-4b3f-4b68-8364-30fd6145dcaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_0c573d5d-fc91-4669-a859-0479f0df3f66" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_bba63b09-4b3f-4b68-8364-30fd6145dcaa" xlink:to="loc_us-gaap_ProductMember_0c573d5d-fc91-4669-a859-0479f0df3f66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ORLADEYOMember_a856c74d-f5ef-4e8e-b769-3d8dc2e39bdd" xlink:href="bcrx-20250930.xsd#bcrx_ORLADEYOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_bba63b09-4b3f-4b68-8364-30fd6145dcaa" xlink:to="loc_bcrx_ORLADEYOMember_a856c74d-f5ef-4e8e-b769-3d8dc2e39bdd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_OtherIncomeFromContractWithCustomerMember_9de1e360-101e-42ab-a87d-1aa5a26f2641" xlink:href="bcrx-20250930.xsd#bcrx_OtherIncomeFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_bba63b09-4b3f-4b68-8364-30fd6145dcaa" xlink:to="loc_bcrx_OtherIncomeFromContractWithCustomerMember_9de1e360-101e-42ab-a87d-1aa5a26f2641" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicDistributionAxis_363663d0-10db-4a79-aee6-a5bde5903a00" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeographicDistributionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_90f53df2-ea9e-4eed-a9ff-148c89b773fd" xlink:to="loc_us-gaap_GeographicDistributionAxis_363663d0-10db-4a79-aee6-a5bde5903a00" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicDistributionDomain_363663d0-10db-4a79-aee6-a5bde5903a00_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeographicDistributionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GeographicDistributionAxis_363663d0-10db-4a79-aee6-a5bde5903a00" xlink:to="loc_us-gaap_GeographicDistributionDomain_363663d0-10db-4a79-aee6-a5bde5903a00_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicDistributionDomain_02d532b5-26db-4afe-8ed4-0bb7cc56a7e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeographicDistributionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GeographicDistributionAxis_363663d0-10db-4a79-aee6-a5bde5903a00" xlink:to="loc_us-gaap_GeographicDistributionDomain_02d532b5-26db-4afe-8ed4-0bb7cc56a7e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicDistributionDomesticMember_b1584cd3-3888-4c5b-9c25-a1aefbd47e58" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeographicDistributionDomesticMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GeographicDistributionDomain_02d532b5-26db-4afe-8ed4-0bb7cc56a7e3" xlink:to="loc_us-gaap_GeographicDistributionDomesticMember_b1584cd3-3888-4c5b-9c25-a1aefbd47e58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicDistributionForeignMember_4ae83ef1-8105-4802-8740-dfdd751ad642" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeographicDistributionForeignMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GeographicDistributionDomain_02d532b5-26db-4afe-8ed4-0bb7cc56a7e3" xlink:to="loc_us-gaap_GeographicDistributionForeignMember_4ae83ef1-8105-4802-8740-dfdd751ad642" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_5354facf-7dca-447d-93e2-c01480eeb80e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5bec8462-ddd4-44b8-acf3-eba53f7e26c4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_5354facf-7dca-447d-93e2-c01480eeb80e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/InvestmentsFairValueRecurringBasisDetails" xlink:type="simple" xlink:href="bcrx-20250930.xsd#InvestmentsFairValueRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/role/InvestmentsFairValueRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesLineItems_79c5fddf-2f9e-4813-ae48-0e6f4d26f495" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTable_30e47949-3b96-434d-89d5-2107a56c25a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_79c5fddf-2f9e-4813-ae48-0e6f4d26f495" xlink:to="loc_us-gaap_MarketableSecuritiesTable_30e47949-3b96-434d-89d5-2107a56c25a0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5c012fe6-9db9-450f-8892-228da549cdc6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MarketableSecuritiesTable_30e47949-3b96-434d-89d5-2107a56c25a0" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5c012fe6-9db9-450f-8892-228da549cdc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5c012fe6-9db9-450f-8892-228da549cdc6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5c012fe6-9db9-450f-8892-228da549cdc6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5c012fe6-9db9-450f-8892-228da549cdc6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5a9ee1e8-3bf8-479c-9940-cd369226bfea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5c012fe6-9db9-450f-8892-228da549cdc6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5a9ee1e8-3bf8-479c-9940-cd369226bfea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_6a9c75d4-38b9-4988-9a54-206b18b9c80a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5a9ee1e8-3bf8-479c-9940-cd369226bfea" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_6a9c75d4-38b9-4988-9a54-206b18b9c80a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_94ec47a7-47a6-463f-9d71-09d365c26d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5a9ee1e8-3bf8-479c-9940-cd369226bfea" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_94ec47a7-47a6-463f-9d71-09d365c26d9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_8f587638-5930-45f0-8d36-10a8efceea98" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5a9ee1e8-3bf8-479c-9940-cd369226bfea" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_8f587638-5930-45f0-8d36-10a8efceea98" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_9e58f2e4-d778-47ee-9d3a-e79cc2d4a3df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MarketableSecuritiesTable_30e47949-3b96-434d-89d5-2107a56c25a0" xlink:to="loc_us-gaap_FinancialInstrumentAxis_9e58f2e4-d778-47ee-9d3a-e79cc2d4a3df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9e58f2e4-d778-47ee-9d3a-e79cc2d4a3df_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9e58f2e4-d778-47ee-9d3a-e79cc2d4a3df" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9e58f2e4-d778-47ee-9d3a-e79cc2d4a3df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7fb36632-fc0d-4742-ba88-ba8b796e57c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9e58f2e4-d778-47ee-9d3a-e79cc2d4a3df" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7fb36632-fc0d-4742-ba88-ba8b796e57c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_ac649532-512f-4f63-8326-240075a7b59f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7fb36632-fc0d-4742-ba88-ba8b796e57c0" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_ac649532-512f-4f63-8326-240075a7b59f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ea48a1d2-993c-49a9-89d7-244cd3b32cfa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_79c5fddf-2f9e-4813-ae48-0e6f4d26f495" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ea48a1d2-993c-49a9-89d7-244cd3b32cfa" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/InvestmentsFairValueoftheCompanysInvestmentsbyTypeDetails" xlink:type="simple" xlink:href="bcrx-20250930.xsd#InvestmentsFairValueoftheCompanysInvestmentsbyTypeDetails"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/role/InvestmentsFairValueoftheCompanysInvestmentsbyTypeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesLineItems_0faeff61-b777-46b7-904b-971e3899fd72" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTable_6f93accc-3e48-461f-8fda-968305b3e43a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_0faeff61-b777-46b7-904b-971e3899fd72" xlink:to="loc_us-gaap_MarketableSecuritiesTable_6f93accc-3e48-461f-8fda-968305b3e43a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6ac9734c-9d5f-4ec7-a884-0039f3e12959" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MarketableSecuritiesTable_6f93accc-3e48-461f-8fda-968305b3e43a" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6ac9734c-9d5f-4ec7-a884-0039f3e12959" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6ac9734c-9d5f-4ec7-a884-0039f3e12959_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6ac9734c-9d5f-4ec7-a884-0039f3e12959" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6ac9734c-9d5f-4ec7-a884-0039f3e12959_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6448e757-ddeb-4b3c-b69d-de6df33a1979" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6ac9734c-9d5f-4ec7-a884-0039f3e12959" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6448e757-ddeb-4b3c-b69d-de6df33a1979" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_be405549-f449-4f46-a7ba-cef528aa1919" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6448e757-ddeb-4b3c-b69d-de6df33a1979" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_be405549-f449-4f46-a7ba-cef528aa1919" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_03102b48-98e6-4a3e-8889-5824d439708d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_0faeff61-b777-46b7-904b-971e3899fd72" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_03102b48-98e6-4a3e-8889-5824d439708d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_4d27f3c1-0342-4b8c-8a86-102887f0c25a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_0faeff61-b777-46b7-904b-971e3899fd72" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_4d27f3c1-0342-4b8c-8a86-102887f0c25a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1c84b4ce-cbf3-4802-9baf-4334bc21c317" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_0faeff61-b777-46b7-904b-971e3899fd72" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1c84b4ce-cbf3-4802-9baf-4334bc21c317" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_45c0d680-c385-4b74-b1fe-07e30b49b436" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_0faeff61-b777-46b7-904b-971e3899fd72" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_45c0d680-c385-4b74-b1fe-07e30b49b436" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fbd41b6a-d84b-45da-9cbf-94aa5edcaf35" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_0faeff61-b777-46b7-904b-971e3899fd72" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fbd41b6a-d84b-45da-9cbf-94aa5edcaf35" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList_cea46a76-b21d-4d7f-a771-6f01909c982d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_0faeff61-b777-46b7-904b-971e3899fd72" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList_cea46a76-b21d-4d7f-a771-6f01909c982d" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/TradeReceivablesDetailsTextual" xlink:type="simple" xlink:href="bcrx-20250930.xsd#TradeReceivablesDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/role/TradeReceivablesDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_4d364a30-696d-4b04-be89-13f7a7e59c13" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_9366b80f-6fcf-4fd6-9081-16b7080fc152" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_4d364a30-696d-4b04-be89-13f7a7e59c13" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_9366b80f-6fcf-4fd6-9081-16b7080fc152" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8219395e-cd11-4bb2-b3b3-6b3054a89f8b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_9366b80f-6fcf-4fd6-9081-16b7080fc152" xlink:to="loc_srt_ProductOrServiceAxis_8219395e-cd11-4bb2-b3b3-6b3054a89f8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8219395e-cd11-4bb2-b3b3-6b3054a89f8b_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_8219395e-cd11-4bb2-b3b3-6b3054a89f8b" xlink:to="loc_srt_ProductsAndServicesDomain_8219395e-cd11-4bb2-b3b3-6b3054a89f8b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_832b123d-95b0-4d93-9238-e99a1ab33e80" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_8219395e-cd11-4bb2-b3b3-6b3054a89f8b" xlink:to="loc_srt_ProductsAndServicesDomain_832b123d-95b0-4d93-9238-e99a1ab33e80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ORLADEYOMember_2ff4fb17-63dd-4bde-9ebc-fd227ee2ebef" xlink:href="bcrx-20250930.xsd#bcrx_ORLADEYOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_832b123d-95b0-4d93-9238-e99a1ab33e80" xlink:to="loc_bcrx_ORLADEYOMember_2ff4fb17-63dd-4bde-9ebc-fd227ee2ebef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_PeramivirMember_33019d97-a6c1-4bf8-b230-49d2f647d251" xlink:href="bcrx-20250930.xsd#bcrx_PeramivirMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_832b123d-95b0-4d93-9238-e99a1ab33e80" xlink:to="loc_bcrx_PeramivirMember_33019d97-a6c1-4bf8-b230-49d2f647d251" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_41d9d64c-e08d-47f4-8a58-2db05556e10f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_9366b80f-6fcf-4fd6-9081-16b7080fc152" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_41d9d64c-e08d-47f4-8a58-2db05556e10f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_41d9d64c-e08d-47f4-8a58-2db05556e10f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_41d9d64c-e08d-47f4-8a58-2db05556e10f" xlink:to="loc_us-gaap_ReceivableTypeDomain_41d9d64c-e08d-47f4-8a58-2db05556e10f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_4ebdde66-c6ba-44e1-8c3a-c9ff28eea6a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_41d9d64c-e08d-47f4-8a58-2db05556e10f" xlink:to="loc_us-gaap_ReceivableTypeDomain_4ebdde66-c6ba-44e1-8c3a-c9ff28eea6a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAccountsReceivableMember_4a64a836-0af1-4ed7-af61-006cbf6eddd9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TradeAccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_4ebdde66-c6ba-44e1-8c3a-c9ff28eea6a0" xlink:to="loc_us-gaap_TradeAccountsReceivableMember_4a64a836-0af1-4ed7-af61-006cbf6eddd9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_51b602af-259d-4651-9df2-583d04bf7505" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_9366b80f-6fcf-4fd6-9081-16b7080fc152" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_51b602af-259d-4651-9df2-583d04bf7505" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_51b602af-259d-4651-9df2-583d04bf7505_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_51b602af-259d-4651-9df2-583d04bf7505" xlink:to="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_51b602af-259d-4651-9df2-583d04bf7505_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_39056670-43e8-4a40-840a-44210d1fab91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_51b602af-259d-4651-9df2-583d04bf7505" xlink:to="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_39056670-43e8-4a40-840a-44210d1fab91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyReceivablesFromPartnersMember_7c4cc577-52d2-4a0e-984f-6b8f9da9b5fb" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltyReceivablesFromPartnersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_39056670-43e8-4a40-840a-44210d1fab91" xlink:to="loc_bcrx_RoyaltyReceivablesFromPartnersMember_7c4cc577-52d2-4a0e-984f-6b8f9da9b5fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_58595aaf-8788-41ef-96c4-9d2fb5fead5c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_9366b80f-6fcf-4fd6-9081-16b7080fc152" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_58595aaf-8788-41ef-96c4-9d2fb5fead5c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_58595aaf-8788-41ef-96c4-9d2fb5fead5c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_58595aaf-8788-41ef-96c4-9d2fb5fead5c" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_58595aaf-8788-41ef-96c4-9d2fb5fead5c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_2831e152-681e-4b1f-9c73-e4601bb6b79c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_58595aaf-8788-41ef-96c4-9d2fb5fead5c" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_2831e152-681e-4b1f-9c73-e4601bb6b79c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_b01e6b91-1c13-46e5-b6ff-58ef90a9a597" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_2831e152-681e-4b1f-9c73-e4601bb6b79c" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_b01e6b91-1c13-46e5-b6ff-58ef90a9a597" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_59c9067a-d035-43bc-9b67-e2eea155568d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_9366b80f-6fcf-4fd6-9081-16b7080fc152" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_59c9067a-d035-43bc-9b67-e2eea155568d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_59c9067a-d035-43bc-9b67-e2eea155568d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_59c9067a-d035-43bc-9b67-e2eea155568d" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_59c9067a-d035-43bc-9b67-e2eea155568d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_17e9bdd6-d624-4d6f-bca2-a823f35b77c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_59c9067a-d035-43bc-9b67-e2eea155568d" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_17e9bdd6-d624-4d6f-bca2-a823f35b77c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_BioCrystIrelandMember_4d7e96f2-f4d7-4d77-ae71-36924ce51325" xlink:href="bcrx-20250930.xsd#bcrx_BioCrystIrelandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_17e9bdd6-d624-4d6f-bca2-a823f35b77c7" xlink:to="loc_bcrx_BioCrystIrelandMember_4d7e96f2-f4d7-4d77-ae71-36924ce51325" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_0f5dbec6-c916-49c5-90e6-26de39610609" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_4d364a30-696d-4b04-be89-13f7a7e59c13" xlink:to="loc_us-gaap_AccountsReceivableNet_0f5dbec6-c916-49c5-90e6-26de39610609" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_9c2eb435-3686-44c3-8105-d162e14691ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_4d364a30-696d-4b04-be89-13f7a7e59c13" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_9c2eb435-3686-44c3-8105-d162e14691ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_97ba4646-2163-4f04-a429-6a424c74fef1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_4d364a30-696d-4b04-be89-13f7a7e59c13" xlink:to="loc_us-gaap_ReceivablesNetCurrent_97ba4646-2163-4f04-a429-6a424c74fef1" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/InventoryDetails" xlink:type="simple" xlink:href="bcrx-20250930.xsd#InventoryDetails"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_91377a5e-cb2b-4bba-adf5-d6d8c3406a60" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_0e3fca4d-c7bd-4943-b70a-7ac12aace473" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_91377a5e-cb2b-4bba-adf5-d6d8c3406a60" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_0e3fca4d-c7bd-4943-b70a-7ac12aace473" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_bd3fa5d7-ed39-4407-a514-c71d28e8b474" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_0e3fca4d-c7bd-4943-b70a-7ac12aace473" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_bd3fa5d7-ed39-4407-a514-c71d28e8b474" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_bd3fa5d7-ed39-4407-a514-c71d28e8b474_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_bd3fa5d7-ed39-4407-a514-c71d28e8b474" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_bd3fa5d7-ed39-4407-a514-c71d28e8b474_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_57100d7e-82f2-43a3-a4c6-8a6e8f6ee45f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_bd3fa5d7-ed39-4407-a514-c71d28e8b474" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_57100d7e-82f2-43a3-a4c6-8a6e8f6ee45f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_b6a1bbe9-180f-465a-9064-031784db8e15" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_57100d7e-82f2-43a3-a4c6-8a6e8f6ee45f" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_b6a1bbe9-180f-465a-9064-031784db8e15" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_18c14974-e355-4818-9774-87c15694a700" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_0e3fca4d-c7bd-4943-b70a-7ac12aace473" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_18c14974-e355-4818-9774-87c15694a700" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_18c14974-e355-4818-9774-87c15694a700_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_18c14974-e355-4818-9774-87c15694a700" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_18c14974-e355-4818-9774-87c15694a700_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_75d107f8-f5cf-4cf3-96ae-be47fd2fdd8e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_18c14974-e355-4818-9774-87c15694a700" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_75d107f8-f5cf-4cf3-96ae-be47fd2fdd8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_BioCrystIrelandMember_ce976680-b664-4cac-b5a7-f1f503b3891e" xlink:href="bcrx-20250930.xsd#bcrx_BioCrystIrelandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_75d107f8-f5cf-4cf3-96ae-be47fd2fdd8e" xlink:to="loc_bcrx_BioCrystIrelandMember_ce976680-b664-4cac-b5a7-f1f503b3891e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_0feab0fd-bdea-493c-b767-4e8dc0aeb93a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_91377a5e-cb2b-4bba-adf5-d6d8c3406a60" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_0feab0fd-bdea-493c-b767-4e8dc0aeb93a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryNoncurrent_b3e7b4ab-013a-42c0-a44e-1bc8b99e685f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_91377a5e-cb2b-4bba-adf5-d6d8c3406a60" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryNoncurrent_b3e7b4ab-013a-42c0-a44e-1bc8b99e685f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/RoyaltyFinancingObligationsDetailsTextual" xlink:type="simple" xlink:href="bcrx-20250930.xsd#RoyaltyFinancingObligationsDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/role/RoyaltyFinancingObligationsDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyMonetizationsLineItems_97a079d2-b5cc-453a-a104-51897689130c" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltyMonetizationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltiesMonetizationsTable_114d406e-aad0-4943-890b-02eb690728bd" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltiesMonetizationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_97a079d2-b5cc-453a-a104-51897689130c" xlink:to="loc_bcrx_RoyaltiesMonetizationsTable_114d406e-aad0-4943-890b-02eb690728bd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f7d3d938-a239-41ad-914b-33ccff9de4ca" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bcrx_RoyaltiesMonetizationsTable_114d406e-aad0-4943-890b-02eb690728bd" xlink:to="loc_srt_CounterpartyNameAxis_f7d3d938-a239-41ad-914b-33ccff9de4ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f7d3d938-a239-41ad-914b-33ccff9de4ca_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_f7d3d938-a239-41ad-914b-33ccff9de4ca" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f7d3d938-a239-41ad-914b-33ccff9de4ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3cb625f4-184b-4d96-aebf-7cb720946e63" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_f7d3d938-a239-41ad-914b-33ccff9de4ca" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3cb625f4-184b-4d96-aebf-7cb720946e63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RPI2019IntermediateFinanceTrustMember_6133fea5-7508-41aa-9f2f-670171bfbc14" xlink:href="bcrx-20250930.xsd#bcrx_RPI2019IntermediateFinanceTrustMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3cb625f4-184b-4d96-aebf-7cb720946e63" xlink:to="loc_bcrx_RPI2019IntermediateFinanceTrustMember_6133fea5-7508-41aa-9f2f-670171bfbc14" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RPI2021And2020IntermediateFinanceTrustMember_61463eef-0a37-4de5-b970-34c53a61933e" xlink:href="bcrx-20250930.xsd#bcrx_RPI2021And2020IntermediateFinanceTrustMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3cb625f4-184b-4d96-aebf-7cb720946e63" xlink:to="loc_bcrx_RPI2021And2020IntermediateFinanceTrustMember_61463eef-0a37-4de5-b970-34c53a61933e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_The2021RPIRoyaltyPurchaseAgreementMember_eb5f47eb-5401-454e-8f94-cb32a24b43bf" xlink:href="bcrx-20250930.xsd#bcrx_The2021RPIRoyaltyPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3cb625f4-184b-4d96-aebf-7cb720946e63" xlink:to="loc_bcrx_The2021RPIRoyaltyPurchaseAgreementMember_eb5f47eb-5401-454e-8f94-cb32a24b43bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_OMERSCapitalMarketsMember_98ee3e4d-4d7d-43c1-99fe-e9be080c5190" xlink:href="bcrx-20250930.xsd#bcrx_OMERSCapitalMarketsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3cb625f4-184b-4d96-aebf-7cb720946e63" xlink:to="loc_bcrx_OMERSCapitalMarketsMember_98ee3e4d-4d7d-43c1-99fe-e9be080c5190" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_66970fd1-5629-47a9-86a1-efced3c2e426" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bcrx_RoyaltiesMonetizationsTable_114d406e-aad0-4943-890b-02eb690728bd" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_66970fd1-5629-47a9-86a1-efced3c2e426" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_66970fd1-5629-47a9-86a1-efced3c2e426_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_66970fd1-5629-47a9-86a1-efced3c2e426" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_66970fd1-5629-47a9-86a1-efced3c2e426_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e1d90c37-8ad7-4f4b-b180-8bb102a84e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_66970fd1-5629-47a9-86a1-efced3c2e426" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e1d90c37-8ad7-4f4b-b180-8bb102a84e0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_FutureRoyaltiesPayableMember_631e02d2-53f3-4c87-b607-d52d3e9ea783" xlink:href="bcrx-20250930.xsd#bcrx_FutureRoyaltiesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e1d90c37-8ad7-4f4b-b180-8bb102a84e0c" xlink:to="loc_bcrx_FutureRoyaltiesPayableMember_631e02d2-53f3-4c87-b607-d52d3e9ea783" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_aa9db228-40f4-4c28-bb5c-ffe5f0c23f5b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bcrx_RoyaltiesMonetizationsTable_114d406e-aad0-4943-890b-02eb690728bd" xlink:to="loc_srt_ProductOrServiceAxis_aa9db228-40f4-4c28-bb5c-ffe5f0c23f5b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_aa9db228-40f4-4c28-bb5c-ffe5f0c23f5b_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_aa9db228-40f4-4c28-bb5c-ffe5f0c23f5b" xlink:to="loc_srt_ProductsAndServicesDomain_aa9db228-40f4-4c28-bb5c-ffe5f0c23f5b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_68c94071-bfd1-4c54-be20-d821c804c15f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_aa9db228-40f4-4c28-bb5c-ffe5f0c23f5b" xlink:to="loc_srt_ProductsAndServicesDomain_68c94071-bfd1-4c54-be20-d821c804c15f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ORLADEYOMember_3034fe7d-70a6-4477-98a4-d75ec2a99edd" xlink:href="bcrx-20250930.xsd#bcrx_ORLADEYOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_68c94071-bfd1-4c54-be20-d821c804c15f" xlink:to="loc_bcrx_ORLADEYOMember_3034fe7d-70a6-4477-98a4-d75ec2a99edd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesRangeAxis_c0f45ce6-825f-4fa2-9bd0-237bed939358" xlink:href="bcrx-20250930.xsd#bcrx_AnnualNetSalesRangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bcrx_RoyaltiesMonetizationsTable_114d406e-aad0-4943-890b-02eb690728bd" xlink:to="loc_bcrx_AnnualNetSalesRangeAxis_c0f45ce6-825f-4fa2-9bd0-237bed939358" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesRangeDomain_c0f45ce6-825f-4fa2-9bd0-237bed939358_default" xlink:href="bcrx-20250930.xsd#bcrx_AnnualNetSalesRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_bcrx_AnnualNetSalesRangeAxis_c0f45ce6-825f-4fa2-9bd0-237bed939358" xlink:to="loc_bcrx_AnnualNetSalesRangeDomain_c0f45ce6-825f-4fa2-9bd0-237bed939358_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesRangeDomain_060af17c-0042-482b-8876-449c3f0ec7b8" xlink:href="bcrx-20250930.xsd#bcrx_AnnualNetSalesRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_bcrx_AnnualNetSalesRangeAxis_c0f45ce6-825f-4fa2-9bd0-237bed939358" xlink:to="loc_bcrx_AnnualNetSalesRangeDomain_060af17c-0042-482b-8876-449c3f0ec7b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesUnder350000Member_85159c78-6b15-46b8-b9d0-dca9b36f8798" xlink:href="bcrx-20250930.xsd#bcrx_AnnualNetSalesUnder350000Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_AnnualNetSalesRangeDomain_060af17c-0042-482b-8876-449c3f0ec7b8" xlink:to="loc_bcrx_AnnualNetSalesUnder350000Member_85159c78-6b15-46b8-b9d0-dca9b36f8798" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesBetween350000And550000Member_fce5256b-b01c-4334-abc8-8703953758a7" xlink:href="bcrx-20250930.xsd#bcrx_AnnualNetSalesBetween350000And550000Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_AnnualNetSalesRangeDomain_060af17c-0042-482b-8876-449c3f0ec7b8" xlink:to="loc_bcrx_AnnualNetSalesBetween350000And550000Member_fce5256b-b01c-4334-abc8-8703953758a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesOver550000Member_f3f3cec5-1856-4b0c-b141-12c4d792ae97" xlink:href="bcrx-20250930.xsd#bcrx_AnnualNetSalesOver550000Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_AnnualNetSalesRangeDomain_060af17c-0042-482b-8876-449c3f0ec7b8" xlink:to="loc_bcrx_AnnualNetSalesOver550000Member_f3f3cec5-1856-4b0c-b141-12c4d792ae97" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesUnder150000Member_16705fa6-9eb9-46b2-a197-b6859136e2a7" xlink:href="bcrx-20250930.xsd#bcrx_AnnualNetSalesUnder150000Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_AnnualNetSalesRangeDomain_060af17c-0042-482b-8876-449c3f0ec7b8" xlink:to="loc_bcrx_AnnualNetSalesUnder150000Member_16705fa6-9eb9-46b2-a197-b6859136e2a7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesBetween150000And230000Member_d32d0f70-2a2e-4a6e-ad5c-7efb9d10e306" xlink:href="bcrx-20250930.xsd#bcrx_AnnualNetSalesBetween150000And230000Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_AnnualNetSalesRangeDomain_060af17c-0042-482b-8876-449c3f0ec7b8" xlink:to="loc_bcrx_AnnualNetSalesBetween150000And230000Member_d32d0f70-2a2e-4a6e-ad5c-7efb9d10e306" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesOver230000Member_0fb57c1b-9722-4c77-8c5d-3aeabe7b273c" xlink:href="bcrx-20250930.xsd#bcrx_AnnualNetSalesOver230000Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_AnnualNetSalesRangeDomain_060af17c-0042-482b-8876-449c3f0ec7b8" xlink:to="loc_bcrx_AnnualNetSalesOver230000Member_0fb57c1b-9722-4c77-8c5d-3aeabe7b273c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_a4b1a25b-af3a-4260-a2f9-18aab8f25b60" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_97a079d2-b5cc-453a-a104-51897689130c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_a4b1a25b-af3a-4260-a2f9-18aab8f25b60" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories_99998cc5-cc52-467c-b9dc-85adf9fa8bb0" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_97a079d2-b5cc-453a-a104-51897689130c" xlink:to="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories_99998cc5-cc52-467c-b9dc-85adf9fa8bb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets_8a3c3ffe-dcb4-4eaa-a251-5c3c33a26219" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_97a079d2-b5cc-453a-a104-51897689130c" xlink:to="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets_8a3c3ffe-dcb4-4eaa-a251-5c3c33a26219" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets_f43f109a-be4d-48d2-b9f0-cfe5f5f086de" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_97a079d2-b5cc-453a-a104-51897689130c" xlink:to="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets_f43f109a-be4d-48d2-b9f0-cfe5f5f086de" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_SharesIssuedCommonStockPremium_42e0a898-3bce-479d-8c0e-ed7d84c13752" xlink:href="bcrx-20250930.xsd#bcrx_SharesIssuedCommonStockPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_97a079d2-b5cc-453a-a104-51897689130c" xlink:to="loc_bcrx_SharesIssuedCommonStockPremium_42e0a898-3bce-479d-8c0e-ed7d84c13752" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales_6d25aad7-ad7b-4bcc-ba51-001bdc4366b7" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_97a079d2-b5cc-453a-a104-51897689130c" xlink:to="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales_6d25aad7-ad7b-4bcc-ba51-001bdc4366b7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales_5ed393ff-6d42-47b0-9420-780515f494a7" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_97a079d2-b5cc-453a-a104-51897689130c" xlink:to="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales_5ed393ff-6d42-47b0-9420-780515f494a7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice_129615dd-51dd-4ec0-b070-7911a4bd29cc" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_97a079d2-b5cc-453a-a104-51897689130c" xlink:to="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice_129615dd-51dd-4ec0-b070-7911a4bd29cc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount_f0b5767e-e76f-403e-b272-487cfb1b2ffe" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_97a079d2-b5cc-453a-a104-51897689130c" xlink:to="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount_f0b5767e-e76f-403e-b272-487cfb1b2ffe" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_InterestPaidRoyaltyFinancingLiabilities_789793d4-6fe3-4d14-b97e-9a819ee62813" xlink:href="bcrx-20250930.xsd#bcrx_InterestPaidRoyaltyFinancingLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_97a079d2-b5cc-453a-a104-51897689130c" xlink:to="loc_bcrx_InterestPaidRoyaltyFinancingLiabilities_789793d4-6fe3-4d14-b97e-9a819ee62813" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/RoyaltyFinancingObligationsScheduleofRoyaltyFinancingObligationsDetails" xlink:type="simple" xlink:href="bcrx-20250930.xsd#RoyaltyFinancingObligationsScheduleofRoyaltyFinancingObligationsDetails"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/role/RoyaltyFinancingObligationsScheduleofRoyaltyFinancingObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyMonetizationsLineItems_f04c1201-3d88-4cec-a308-f199b04d4fbb" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltyMonetizationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltiesMonetizationsTable_beb26dff-3b2e-43b7-8321-a194253c2cac" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltiesMonetizationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_f04c1201-3d88-4cec-a308-f199b04d4fbb" xlink:to="loc_bcrx_RoyaltiesMonetizationsTable_beb26dff-3b2e-43b7-8321-a194253c2cac" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2c33d1ba-3241-40fb-a784-957d4d5d4aab" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bcrx_RoyaltiesMonetizationsTable_beb26dff-3b2e-43b7-8321-a194253c2cac" xlink:to="loc_srt_CounterpartyNameAxis_2c33d1ba-3241-40fb-a784-957d4d5d4aab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2c33d1ba-3241-40fb-a784-957d4d5d4aab_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_2c33d1ba-3241-40fb-a784-957d4d5d4aab" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2c33d1ba-3241-40fb-a784-957d4d5d4aab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_baa8d093-217b-427c-95a1-0f2fca25be61" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_2c33d1ba-3241-40fb-a784-957d4d5d4aab" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_baa8d093-217b-427c-95a1-0f2fca25be61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_TwentyTwentyRPIRoyaltyAgreementMember_e26816c1-1aaf-4b48-8256-b7090b648400" xlink:href="bcrx-20250930.xsd#bcrx_TwentyTwentyRPIRoyaltyAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_baa8d093-217b-427c-95a1-0f2fca25be61" xlink:to="loc_bcrx_TwentyTwentyRPIRoyaltyAgreementMember_e26816c1-1aaf-4b48-8256-b7090b648400" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_TwentyTwentyOneRPIRoyaltyAgreementMember_2705369d-6d3d-4636-a559-17ca5e978c0c" xlink:href="bcrx-20250930.xsd#bcrx_TwentyTwentyOneRPIRoyaltyAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_baa8d093-217b-427c-95a1-0f2fca25be61" xlink:to="loc_bcrx_TwentyTwentyOneRPIRoyaltyAgreementMember_2705369d-6d3d-4636-a559-17ca5e978c0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_OMERSRoyaltyAgreementMember_040f58f3-8314-4491-b999-11352dd1e08d" xlink:href="bcrx-20250930.xsd#bcrx_OMERSRoyaltyAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_baa8d093-217b-427c-95a1-0f2fca25be61" xlink:to="loc_bcrx_OMERSRoyaltyAgreementMember_040f58f3-8314-4491-b999-11352dd1e08d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyMontizationsRollForward_4b4d4ce8-20cb-4bdd-b697-ac3f0843e4ef" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltyMontizationsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_f04c1201-3d88-4cec-a308-f199b04d4fbb" xlink:to="loc_bcrx_RoyaltyMontizationsRollForward_4b4d4ce8-20cb-4bdd-b697-ac3f0843e4ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyFinancingLiabilities_523da0b6-c2d0-4023-a1d9-6831a9740ef4" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltyFinancingLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_RoyaltyMontizationsRollForward_4b4d4ce8-20cb-4bdd-b697-ac3f0843e4ef" xlink:to="loc_bcrx_RoyaltyFinancingLiabilities_523da0b6-c2d0-4023-a1d9-6831a9740ef4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_NonCashInterestExpenseOnRoyaltyFinancingLiabilities_e412688c-8ec3-456e-a2f6-c1809cfc32db" xlink:href="bcrx-20250930.xsd#bcrx_NonCashInterestExpenseOnRoyaltyFinancingLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_RoyaltyMontizationsRollForward_4b4d4ce8-20cb-4bdd-b697-ac3f0843e4ef" xlink:to="loc_bcrx_NonCashInterestExpenseOnRoyaltyFinancingLiabilities_e412688c-8ec3-456e-a2f6-c1809cfc32db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyRevenuesPayable_654c0eb6-a19b-4a49-b491-5ddd43446e89" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltyRevenuesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_RoyaltyMontizationsRollForward_4b4d4ce8-20cb-4bdd-b697-ac3f0843e4ef" xlink:to="loc_bcrx_RoyaltyRevenuesPayable_654c0eb6-a19b-4a49-b491-5ddd43446e89" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyFinancingLiabilities_56a5387f-8d63-425e-8752-a92c4552e197" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltyFinancingLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_c5eb34ab-3690-419c-bdc1-c11b8ef6aaa3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_RoyaltyMontizationsRollForward_4b4d4ce8-20cb-4bdd-b697-ac3f0843e4ef" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_c5eb34ab-3690-419c-bdc1-c11b8ef6aaa3" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/DebtDetails" xlink:type="simple" xlink:href="bcrx-20250930.xsd#DebtDetails"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/role/DebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_b5e5b19e-5dfe-4c4e-902e-27fb74b1a254" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_4dc291c7-755d-4489-bbd5-7ce3cc81ccc2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b5e5b19e-5dfe-4c4e-902e-27fb74b1a254" xlink:to="loc_us-gaap_DebtInstrumentTable_4dc291c7-755d-4489-bbd5-7ce3cc81ccc2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ed000307-e1ca-4905-bfaf-08d8ba32442a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4dc291c7-755d-4489-bbd5-7ce3cc81ccc2" xlink:to="loc_us-gaap_DebtInstrumentAxis_ed000307-e1ca-4905-bfaf-08d8ba32442a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ed000307-e1ca-4905-bfaf-08d8ba32442a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_ed000307-e1ca-4905-bfaf-08d8ba32442a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ed000307-e1ca-4905-bfaf-08d8ba32442a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7d35336b-aa61-4810-9ae0-4b66740e4b6a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_ed000307-e1ca-4905-bfaf-08d8ba32442a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7d35336b-aa61-4810-9ae0-4b66740e4b6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_TermLoanTrancheAMember_e66a36e2-70bf-42ce-954d-9d646ea26fd5" xlink:href="bcrx-20250930.xsd#bcrx_TermLoanTrancheAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7d35336b-aa61-4810-9ae0-4b66740e4b6a" xlink:to="loc_bcrx_TermLoanTrancheAMember_e66a36e2-70bf-42ce-954d-9d646ea26fd5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_LoanAgreementMember_ef7b18b2-3f9c-43b5-9771-61c7a9919065" xlink:href="bcrx-20250930.xsd#bcrx_LoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7d35336b-aa61-4810-9ae0-4b66740e4b6a" xlink:to="loc_bcrx_LoanAgreementMember_ef7b18b2-3f9c-43b5-9771-61c7a9919065" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_TermLoanTrancheBMember_ea9a195d-368f-4949-8ba3-826345496838" xlink:href="bcrx-20250930.xsd#bcrx_TermLoanTrancheBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7d35336b-aa61-4810-9ae0-4b66740e4b6a" xlink:to="loc_bcrx_TermLoanTrancheBMember_ea9a195d-368f-4949-8ba3-826345496838" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_TermLoanTrancheCMember_fb51b494-d317-455e-8731-267ba645dc95" xlink:href="bcrx-20250930.xsd#bcrx_TermLoanTrancheCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7d35336b-aa61-4810-9ae0-4b66740e4b6a" xlink:to="loc_bcrx_TermLoanTrancheCMember_fb51b494-d317-455e-8731-267ba645dc95" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_TermLoanTrancheDMember_cebe837a-2665-485e-a814-35c62d7c2d1a" xlink:href="bcrx-20250930.xsd#bcrx_TermLoanTrancheDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7d35336b-aa61-4810-9ae0-4b66740e4b6a" xlink:to="loc_bcrx_TermLoanTrancheDMember_cebe837a-2665-485e-a814-35c62d7c2d1a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_220d07f2-e5db-4385-b053-dba6f5f00b82" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4dc291c7-755d-4489-bbd5-7ce3cc81ccc2" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_220d07f2-e5db-4385-b053-dba6f5f00b82" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_220d07f2-e5db-4385-b053-dba6f5f00b82_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_220d07f2-e5db-4385-b053-dba6f5f00b82" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_220d07f2-e5db-4385-b053-dba6f5f00b82_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_c9090bff-fc9b-4109-969d-4e1b719294f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_220d07f2-e5db-4385-b053-dba6f5f00b82" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_c9090bff-fc9b-4109-969d-4e1b719294f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_PharmakonAdvisorsLPMember_50116355-25b6-4da6-984b-56b198e66688" xlink:href="bcrx-20250930.xsd#bcrx_PharmakonAdvisorsLPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_c9090bff-fc9b-4109-969d-4e1b719294f8" xlink:to="loc_bcrx_PharmakonAdvisorsLPMember_50116355-25b6-4da6-984b-56b198e66688" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AthyriumMember_06717a85-bc1c-4a30-8138-08483784e0ed" xlink:href="bcrx-20250930.xsd#bcrx_AthyriumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_c9090bff-fc9b-4109-969d-4e1b719294f8" xlink:to="loc_bcrx_AthyriumMember_06717a85-bc1c-4a30-8138-08483784e0ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_da0902ad-a266-42e2-8e65-315d83ac0464" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4dc291c7-755d-4489-bbd5-7ce3cc81ccc2" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_da0902ad-a266-42e2-8e65-315d83ac0464" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_da0902ad-a266-42e2-8e65-315d83ac0464_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_da0902ad-a266-42e2-8e65-315d83ac0464" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_da0902ad-a266-42e2-8e65-315d83ac0464_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_04a19e73-a953-4d6c-af92-81c49201a45c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_da0902ad-a266-42e2-8e65-315d83ac0464" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_04a19e73-a953-4d6c-af92-81c49201a45c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_44ffc00f-aaf9-41c2-a6f2-1dcfad7b66dc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_04a19e73-a953-4d6c-af92-81c49201a45c" xlink:to="loc_us-gaap_LineOfCreditMember_44ffc00f-aaf9-41c2-a6f2-1dcfad7b66dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_2980c9fa-2382-4703-ab61-6469ea82aaa8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4dc291c7-755d-4489-bbd5-7ce3cc81ccc2" xlink:to="loc_us-gaap_CreditFacilityAxis_2980c9fa-2382-4703-ab61-6469ea82aaa8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_2980c9fa-2382-4703-ab61-6469ea82aaa8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_2980c9fa-2382-4703-ab61-6469ea82aaa8" xlink:to="loc_us-gaap_CreditFacilityDomain_2980c9fa-2382-4703-ab61-6469ea82aaa8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_b00f6c6b-e17a-4f1d-92d3-6eccf49f97d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_2980c9fa-2382-4703-ab61-6469ea82aaa8" xlink:to="loc_us-gaap_CreditFacilityDomain_b00f6c6b-e17a-4f1d-92d3-6eccf49f97d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_SeniorCreditFacilityMember_7ce1c65b-0614-4638-8944-9a968fa6af88" xlink:href="bcrx-20250930.xsd#bcrx_SeniorCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_b00f6c6b-e17a-4f1d-92d3-6eccf49f97d5" xlink:to="loc_bcrx_SeniorCreditFacilityMember_7ce1c65b-0614-4638-8944-9a968fa6af88" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DebtCovenantTermsAxis_6d804766-3d4b-4f52-b277-f02ae3e93c2d" xlink:href="bcrx-20250930.xsd#bcrx_DebtCovenantTermsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4dc291c7-755d-4489-bbd5-7ce3cc81ccc2" xlink:to="loc_bcrx_DebtCovenantTermsAxis_6d804766-3d4b-4f52-b277-f02ae3e93c2d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DebtCovenantTermsDomain_6d804766-3d4b-4f52-b277-f02ae3e93c2d_default" xlink:href="bcrx-20250930.xsd#bcrx_DebtCovenantTermsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_bcrx_DebtCovenantTermsAxis_6d804766-3d4b-4f52-b277-f02ae3e93c2d" xlink:to="loc_bcrx_DebtCovenantTermsDomain_6d804766-3d4b-4f52-b277-f02ae3e93c2d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DebtCovenantTermsDomain_b90966e6-95a0-457b-97d7-425e5dc6d01f" xlink:href="bcrx-20250930.xsd#bcrx_DebtCovenantTermsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_bcrx_DebtCovenantTermsAxis_6d804766-3d4b-4f52-b277-f02ae3e93c2d" xlink:to="loc_bcrx_DebtCovenantTermsDomain_b90966e6-95a0-457b-97d7-425e5dc6d01f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_PikInterestPaymentIsMadeMember_bc75d3a1-40b6-4020-b65c-aff68d3dd6d4" xlink:href="bcrx-20250930.xsd#bcrx_PikInterestPaymentIsMadeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_DebtCovenantTermsDomain_b90966e6-95a0-457b-97d7-425e5dc6d01f" xlink:to="loc_bcrx_PikInterestPaymentIsMadeMember_bc75d3a1-40b6-4020-b65c-aff68d3dd6d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_BetweenTheSecondAndThirdAnniversariesMember_1b895b26-f741-4153-8b31-6e7ead82f2b9" xlink:href="bcrx-20250930.xsd#bcrx_BetweenTheSecondAndThirdAnniversariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_DebtCovenantTermsDomain_b90966e6-95a0-457b-97d7-425e5dc6d01f" xlink:to="loc_bcrx_BetweenTheSecondAndThirdAnniversariesMember_1b895b26-f741-4153-8b31-6e7ead82f2b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AfterFourthAnniversaryMember_3bbf6ed0-8dea-43e1-b7b5-c1d8a2d4399e" xlink:href="bcrx-20250930.xsd#bcrx_AfterFourthAnniversaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_DebtCovenantTermsDomain_b90966e6-95a0-457b-97d7-425e5dc6d01f" xlink:to="loc_bcrx_AfterFourthAnniversaryMember_3bbf6ed0-8dea-43e1-b7b5-c1d8a2d4399e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AfterThirdAnniversaryMember_ea743cad-06fe-49ae-831c-9a0ef6ebdf38" xlink:href="bcrx-20250930.xsd#bcrx_AfterThirdAnniversaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_DebtCovenantTermsDomain_b90966e6-95a0-457b-97d7-425e5dc6d01f" xlink:to="loc_bcrx_AfterThirdAnniversaryMember_ea743cad-06fe-49ae-831c-9a0ef6ebdf38" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_a736c366-12af-4c9d-a6da-7ba2771339bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b5e5b19e-5dfe-4c4e-902e-27fb74b1a254" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_a736c366-12af-4c9d-a6da-7ba2771339bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_6da5fbc1-924d-4c44-8026-e2815209eb17" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b5e5b19e-5dfe-4c4e-902e-27fb74b1a254" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_6da5fbc1-924d-4c44-8026-e2815209eb17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_79caaeda-2519-4dbe-bced-0167346c30a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b5e5b19e-5dfe-4c4e-902e-27fb74b1a254" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_79caaeda-2519-4dbe-bced-0167346c30a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_748b0005-06ec-4a3b-be21-e2ba54322107" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b5e5b19e-5dfe-4c4e-902e-27fb74b1a254" xlink:to="loc_us-gaap_DebtInstrumentTerm_748b0005-06ec-4a3b-be21-e2ba54322107" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DebtInstrumentCapitalizedInterestRate_d15dddd8-33b2-422a-8ad2-11a171b80867" xlink:href="bcrx-20250930.xsd#bcrx_DebtInstrumentCapitalizedInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b5e5b19e-5dfe-4c4e-902e-27fb74b1a254" xlink:to="loc_bcrx_DebtInstrumentCapitalizedInterestRate_d15dddd8-33b2-422a-8ad2-11a171b80867" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DebtInstrumentVariableRateFloor_7972f458-4ea9-4f01-b88d-f78460c6c1e1" xlink:href="bcrx-20250930.xsd#bcrx_DebtInstrumentVariableRateFloor"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b5e5b19e-5dfe-4c4e-902e-27fb74b1a254" xlink:to="loc_bcrx_DebtInstrumentVariableRateFloor_7972f458-4ea9-4f01-b88d-f78460c6c1e1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_5662a1a7-9ba4-4c21-b862-36af81e6aa72" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b5e5b19e-5dfe-4c4e-902e-27fb74b1a254" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_5662a1a7-9ba4-4c21-b862-36af81e6aa72" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_c7028975-00bd-4bc4-8fe6-b325d583af34" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b5e5b19e-5dfe-4c4e-902e-27fb74b1a254" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_c7028975-00bd-4bc4-8fe6-b325d583af34" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPayment_a46030e4-9445-4224-95f6-53eeea54efdf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentPeriodicPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b5e5b19e-5dfe-4c4e-902e-27fb74b1a254" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPayment_a46030e4-9445-4224-95f6-53eeea54efdf" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments_a5c657cb-5228-4c3f-93b5-1e1df8ac2a9d" xlink:href="bcrx-20250930.xsd#bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b5e5b19e-5dfe-4c4e-902e-27fb74b1a254" xlink:to="loc_bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments_a5c657cb-5228-4c3f-93b5-1e1df8ac2a9d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_c2245ed0-8f02-4574-9cfd-494354b722e8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b5e5b19e-5dfe-4c4e-902e-27fb74b1a254" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_c2245ed0-8f02-4574-9cfd-494354b722e8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DebtInstrumentPrepaymentPremium_eaf46ffc-a202-4ec6-a95f-c985634311c6" xlink:href="bcrx-20250930.xsd#bcrx_DebtInstrumentPrepaymentPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b5e5b19e-5dfe-4c4e-902e-27fb74b1a254" xlink:to="loc_bcrx_DebtInstrumentPrepaymentPremium_eaf46ffc-a202-4ec6-a95f-c985634311c6" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseLongTermDebt_223ee7d7-5380-4286-a801-7c45e03d8dde" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b5e5b19e-5dfe-4c4e-902e-27fb74b1a254" xlink:to="loc_us-gaap_InterestExpenseLongTermDebt_223ee7d7-5380-4286-a801-7c45e03d8dde" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_UnamortizedDeferredFinancingCosts_7e932d70-0739-44f9-9efb-274dc75b12ec" xlink:href="bcrx-20250930.xsd#bcrx_UnamortizedDeferredFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b5e5b19e-5dfe-4c4e-902e-27fb74b1a254" xlink:to="loc_bcrx_UnamortizedDeferredFinancingCosts_7e932d70-0739-44f9-9efb-274dc75b12ec" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_61f6819b-a51d-4001-b2ac-8e514fe929b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b5e5b19e-5dfe-4c4e-902e-27fb74b1a254" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_61f6819b-a51d-4001-b2ac-8e514fe929b4" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_76896b11-b2fc-408a-8f7f-ad17dc29ae4f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b5e5b19e-5dfe-4c4e-902e-27fb74b1a254" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_76896b11-b2fc-408a-8f7f-ad17dc29ae4f" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DeferredDebtPrepaymentAndDebtIssuanceCostsWriteoff_b8a47c02-0115-4041-9de9-caa23ade7b78" xlink:href="bcrx-20250930.xsd#bcrx_DeferredDebtPrepaymentAndDebtIssuanceCostsWriteoff"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b5e5b19e-5dfe-4c4e-902e-27fb74b1a254" xlink:to="loc_bcrx_DeferredDebtPrepaymentAndDebtIssuanceCostsWriteoff_b8a47c02-0115-4041-9de9-caa23ade7b78" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_096143bc-e0dc-4da8-b54f-6628d5a26533" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b5e5b19e-5dfe-4c4e-902e-27fb74b1a254" xlink:to="loc_us-gaap_InterestExpenseDebt_096143bc-e0dc-4da8-b54f-6628d5a26533" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_PercentOfInterestPayment_30799dc7-dcda-4e85-9c6d-4dc9a1c6e3f0" xlink:href="bcrx-20250930.xsd#bcrx_PercentOfInterestPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b5e5b19e-5dfe-4c4e-902e-27fb74b1a254" xlink:to="loc_bcrx_PercentOfInterestPayment_30799dc7-dcda-4e85-9c6d-4dc9a1c6e3f0" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_1a0ed213-9b7f-4a96-bd98-673fc7673f12" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b5e5b19e-5dfe-4c4e-902e-27fb74b1a254" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_1a0ed213-9b7f-4a96-bd98-673fc7673f12" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_c6491f5b-7999-4cca-a729-b260015efc00" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b5e5b19e-5dfe-4c4e-902e-27fb74b1a254" xlink:to="loc_us-gaap_DebtInstrumentFairValue_c6491f5b-7999-4cca-a729-b260015efc00" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_32c83e8f-e3ba-4aa3-a672-e9c6df3fffbc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b5e5b19e-5dfe-4c4e-902e-27fb74b1a254" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_32c83e8f-e3ba-4aa3-a672-e9c6df3fffbc" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_483c589b-817a-4105-b3ce-23e2b4f53dd9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b5e5b19e-5dfe-4c4e-902e-27fb74b1a254" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_483c589b-817a-4105-b3ce-23e2b4f53dd9" xlink:type="arc" order="22"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/LeaseObligationsDetailsTextual" xlink:type="simple" xlink:href="bcrx-20250930.xsd#LeaseObligationsDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/role/LeaseObligationsDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_a23c1a95-8512-42e9-ac30-b28afb43705a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_6cdd127c-3284-4729-b4b0-49e4b56fa47c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a23c1a95-8512-42e9-ac30-b28afb43705a" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_6cdd127c-3284-4729-b4b0-49e4b56fa47c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6bb14ddf-0609-41a5-9da3-3c3f1a6a2785" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_6cdd127c-3284-4729-b4b0-49e4b56fa47c" xlink:to="loc_srt_RangeAxis_6bb14ddf-0609-41a5-9da3-3c3f1a6a2785" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6bb14ddf-0609-41a5-9da3-3c3f1a6a2785_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6bb14ddf-0609-41a5-9da3-3c3f1a6a2785" xlink:to="loc_srt_RangeMember_6bb14ddf-0609-41a5-9da3-3c3f1a6a2785_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e6fff337-e3e0-41d8-ae80-dc6dcc5ca5fe" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6bb14ddf-0609-41a5-9da3-3c3f1a6a2785" xlink:to="loc_srt_RangeMember_e6fff337-e3e0-41d8-ae80-dc6dcc5ca5fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f8ba8c31-6fb3-4fdf-8733-1f6055538c15" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e6fff337-e3e0-41d8-ae80-dc6dcc5ca5fe" xlink:to="loc_srt_MinimumMember_f8ba8c31-6fb3-4fdf-8733-1f6055538c15" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1a80538a-f798-44c6-a592-e8e4b0d01daf" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e6fff337-e3e0-41d8-ae80-dc6dcc5ca5fe" xlink:to="loc_srt_MaximumMember_1a80538a-f798-44c6-a592-e8e4b0d01daf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_d341ce43-2af7-4353-9d79-480f8741ce79" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a23c1a95-8512-42e9-ac30-b28afb43705a" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_d341ce43-2af7-4353-9d79-480f8741ce79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_OperatingLeaseRightOfUseAssetAccumulatedAmortization_204cd066-e297-4fb2-972b-71d9ae5b039d" xlink:href="bcrx-20250930.xsd#bcrx_OperatingLeaseRightOfUseAssetAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a23c1a95-8512-42e9-ac30-b28afb43705a" xlink:to="loc_bcrx_OperatingLeaseRightOfUseAssetAccumulatedAmortization_204cd066-e297-4fb2-972b-71d9ae5b039d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_bffcf403-9c03-418d-bd31-99e3e3424c6e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a23c1a95-8512-42e9-ac30-b28afb43705a" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_bffcf403-9c03-418d-bd31-99e3e3424c6e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/StockholdersEquitySharesReservedforFutureIssuanceDetails" xlink:type="simple" xlink:href="bcrx-20250930.xsd#StockholdersEquitySharesReservedforFutureIssuanceDetails"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/role/StockholdersEquitySharesReservedforFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_fe2fccc8-f4ff-4f62-ba5e-ea6ca996bbc0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_aa9cc124-7a3d-4dbb-8409-98d609f76b74" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_fe2fccc8-f4ff-4f62-ba5e-ea6ca996bbc0" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_aa9cc124-7a3d-4dbb-8409-98d609f76b74" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5bb81d7d-39f6-4e7a-a1ac-25a586d15e66" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_aa9cc124-7a3d-4dbb-8409-98d609f76b74" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5bb81d7d-39f6-4e7a-a1ac-25a586d15e66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5bb81d7d-39f6-4e7a-a1ac-25a586d15e66_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5bb81d7d-39f6-4e7a-a1ac-25a586d15e66" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5bb81d7d-39f6-4e7a-a1ac-25a586d15e66_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0dd4f2b4-f76f-4951-9d33-348237d5ef65" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5bb81d7d-39f6-4e7a-a1ac-25a586d15e66" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0dd4f2b4-f76f-4951-9d33-348237d5ef65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c4fc8cd9-bb37-4132-a7f5-eff4e3866180" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0dd4f2b4-f76f-4951-9d33-348237d5ef65" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c4fc8cd9-bb37-4132-a7f5-eff4e3866180" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_5d649581-6219-4a8e-b506-98e17792cccd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0dd4f2b4-f76f-4951-9d33-348237d5ef65" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_5d649581-6219-4a8e-b506-98e17792cccd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_fe82c842-ea88-4708-b933-71ad6781aabc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_aa9cc124-7a3d-4dbb-8409-98d609f76b74" xlink:to="loc_us-gaap_PlanNameAxis_fe82c842-ea88-4708-b933-71ad6781aabc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_fe82c842-ea88-4708-b933-71ad6781aabc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_fe82c842-ea88-4708-b933-71ad6781aabc" xlink:to="loc_us-gaap_PlanNameDomain_fe82c842-ea88-4708-b933-71ad6781aabc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_3be42dd2-5131-4ad0-bd86-c118f2b3bcac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_fe82c842-ea88-4708-b933-71ad6781aabc" xlink:to="loc_us-gaap_PlanNameDomain_3be42dd2-5131-4ad0-bd86-c118f2b3bcac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_IncentivePlanMember_c724c9d9-2c86-4fa9-970f-6cd545729bc0" xlink:href="bcrx-20250930.xsd#bcrx_IncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_3be42dd2-5131-4ad0-bd86-c118f2b3bcac" xlink:to="loc_bcrx_IncentivePlanMember_c724c9d9-2c86-4fa9-970f-6cd545729bc0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_InducementPlanMember_bd62df5d-449c-4148-9da3-a7bc92b85136" xlink:href="bcrx-20250930.xsd#bcrx_InducementPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_3be42dd2-5131-4ad0-bd86-c118f2b3bcac" xlink:to="loc_bcrx_InducementPlanMember_bd62df5d-449c-4148-9da3-a7bc92b85136" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_EmployeeStockPurchasePlanMember_6537c71e-0c1b-42e7-9c3a-660469cb0d35" xlink:href="bcrx-20250930.xsd#bcrx_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_3be42dd2-5131-4ad0-bd86-c118f2b3bcac" xlink:to="loc_bcrx_EmployeeStockPurchasePlanMember_6537c71e-0c1b-42e7-9c3a-660469cb0d35" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d2145bff-7057-4d31-af17-e4d07f968338" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_aa9cc124-7a3d-4dbb-8409-98d609f76b74" xlink:to="loc_us-gaap_AwardTypeAxis_d2145bff-7057-4d31-af17-e4d07f968338" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d2145bff-7057-4d31-af17-e4d07f968338_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_d2145bff-7057-4d31-af17-e4d07f968338" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d2145bff-7057-4d31-af17-e4d07f968338_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_19d6af8d-ade6-4b77-bfd9-142796ec6fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_d2145bff-7057-4d31-af17-e4d07f968338" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_19d6af8d-ade6-4b77-bfd9-142796ec6fc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e78dce68-aef4-4b90-a7e3-9a072cb41f78" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_19d6af8d-ade6-4b77-bfd9-142796ec6fc2" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e78dce68-aef4-4b90-a7e3-9a072cb41f78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_fab83fe9-d8f0-4a3d-9735-662783446346" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_19d6af8d-ade6-4b77-bfd9-142796ec6fc2" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_fab83fe9-d8f0-4a3d-9735-662783446346" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_b95eb006-626c-4c76-ae69-76d1cb3c2445" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_fe2fccc8-f4ff-4f62-ba5e-ea6ca996bbc0" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_b95eb006-626c-4c76-ae69-76d1cb3c2445" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/StockbasedCompensationDetailsTextual" xlink:type="simple" xlink:href="bcrx-20250930.xsd#StockbasedCompensationDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/role/StockbasedCompensationDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0818404d-150e-49cd-8da0-012a87c570f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_484b87d7-0d8b-439a-95ab-66861d07394d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0818404d-150e-49cd-8da0-012a87c570f6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_484b87d7-0d8b-439a-95ab-66861d07394d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_c8b35ad2-ca52-4a23-a1b1-ccc0d69be101" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_484b87d7-0d8b-439a-95ab-66861d07394d" xlink:to="loc_us-gaap_PlanNameAxis_c8b35ad2-ca52-4a23-a1b1-ccc0d69be101" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c8b35ad2-ca52-4a23-a1b1-ccc0d69be101_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_c8b35ad2-ca52-4a23-a1b1-ccc0d69be101" xlink:to="loc_us-gaap_PlanNameDomain_c8b35ad2-ca52-4a23-a1b1-ccc0d69be101_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_8160fc2f-6f74-4b8a-994f-a3d7be2f8961" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_c8b35ad2-ca52-4a23-a1b1-ccc0d69be101" xlink:to="loc_us-gaap_PlanNameDomain_8160fc2f-6f74-4b8a-994f-a3d7be2f8961" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_IncentivePlanMember_04675b7a-e29b-47d5-b9b0-3d5cbeb3dd9f" xlink:href="bcrx-20250930.xsd#bcrx_IncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_8160fc2f-6f74-4b8a-994f-a3d7be2f8961" xlink:to="loc_bcrx_IncentivePlanMember_04675b7a-e29b-47d5-b9b0-3d5cbeb3dd9f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_InducementPlanMember_52367452-a4c0-40df-9441-3ff5e53877b3" xlink:href="bcrx-20250930.xsd#bcrx_InducementPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_8160fc2f-6f74-4b8a-994f-a3d7be2f8961" xlink:to="loc_bcrx_InducementPlanMember_52367452-a4c0-40df-9441-3ff5e53877b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7e04a4c1-01ef-4116-8398-67ecce190af1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_484b87d7-0d8b-439a-95ab-66861d07394d" xlink:to="loc_us-gaap_AwardTypeAxis_7e04a4c1-01ef-4116-8398-67ecce190af1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7e04a4c1-01ef-4116-8398-67ecce190af1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_7e04a4c1-01ef-4116-8398-67ecce190af1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7e04a4c1-01ef-4116-8398-67ecce190af1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fba5409f-e8da-4bbe-8a0c-8340ddf16064" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_7e04a4c1-01ef-4116-8398-67ecce190af1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fba5409f-e8da-4bbe-8a0c-8340ddf16064" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_7df65285-aaa2-433a-9bb6-854bef86f438" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fba5409f-e8da-4bbe-8a0c-8340ddf16064" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_7df65285-aaa2-433a-9bb6-854bef86f438" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ShareBasedPaymentArrangementNumberOfPlans_11761963-4a0d-4a5c-aa8a-e726b54f1c39" xlink:href="bcrx-20250930.xsd#bcrx_ShareBasedPaymentArrangementNumberOfPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0818404d-150e-49cd-8da0-012a87c570f6" xlink:to="loc_bcrx_ShareBasedPaymentArrangementNumberOfPlans_11761963-4a0d-4a5c-aa8a-e726b54f1c39" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2182f312-1bf0-41b2-b572-0cad4a276630" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0818404d-150e-49cd-8da0-012a87c570f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2182f312-1bf0-41b2-b572-0cad4a276630" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/StockbasedCompensationShareBasedCompensationDetails" xlink:type="simple" xlink:href="bcrx-20250930.xsd#StockbasedCompensationShareBasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/role/StockbasedCompensationShareBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47962dad-a345-48cc-af66-288cf375a2e9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f0285664-f544-4cd5-a7d4-4d919911b745" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47962dad-a345-48cc-af66-288cf375a2e9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f0285664-f544-4cd5-a7d4-4d919911b745" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_a1823839-a805-4a9b-9b7b-785e9ecae961" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f0285664-f544-4cd5-a7d4-4d919911b745" xlink:to="loc_us-gaap_PlanNameAxis_a1823839-a805-4a9b-9b7b-785e9ecae961" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a1823839-a805-4a9b-9b7b-785e9ecae961_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_a1823839-a805-4a9b-9b7b-785e9ecae961" xlink:to="loc_us-gaap_PlanNameDomain_a1823839-a805-4a9b-9b7b-785e9ecae961_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_2bd5f2d0-7f78-4ba3-920b-639f12bac248" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_a1823839-a805-4a9b-9b7b-785e9ecae961" xlink:to="loc_us-gaap_PlanNameDomain_2bd5f2d0-7f78-4ba3-920b-639f12bac248" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_IncentivePlanMember_9950bb8a-7963-493b-b15c-39ebbf3f9d78" xlink:href="bcrx-20250930.xsd#bcrx_IncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_2bd5f2d0-7f78-4ba3-920b-639f12bac248" xlink:to="loc_bcrx_IncentivePlanMember_9950bb8a-7963-493b-b15c-39ebbf3f9d78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_InducementPlanMember_345a9a1d-dac4-44a5-9be6-2570b2e7267f" xlink:href="bcrx-20250930.xsd#bcrx_InducementPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_2bd5f2d0-7f78-4ba3-920b-639f12bac248" xlink:to="loc_bcrx_InducementPlanMember_345a9a1d-dac4-44a5-9be6-2570b2e7267f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_EmployeeStockPurchasePlanMember_fb998543-0284-4070-b0e8-2a4e2178504e" xlink:href="bcrx-20250930.xsd#bcrx_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_2bd5f2d0-7f78-4ba3-920b-639f12bac248" xlink:to="loc_bcrx_EmployeeStockPurchasePlanMember_fb998543-0284-4070-b0e8-2a4e2178504e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_3922f5ca-7165-4981-9a59-6cf5a68150ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47962dad-a345-48cc-af66-288cf375a2e9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_3922f5ca-7165-4981-9a59-6cf5a68150ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_103ea79f-4515-4b47-8c97-103c48f5c36d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47962dad-a345-48cc-af66-288cf375a2e9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_103ea79f-4515-4b47-8c97-103c48f5c36d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_b38123ec-4ca1-4d3b-8f60-3fb6ef8ee616" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47962dad-a345-48cc-af66-288cf375a2e9" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_b38123ec-4ca1-4d3b-8f60-3fb6ef8ee616" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/StockbasedCompensationOptionActivityDetails" xlink:type="simple" xlink:href="bcrx-20250930.xsd#StockbasedCompensationOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/role/StockbasedCompensationOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5d378716-8e6e-4487-8096-53bdd0c49570" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_14cae418-3c05-4060-b28b-cba8bb72998e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5d378716-8e6e-4487-8096-53bdd0c49570" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_14cae418-3c05-4060-b28b-cba8bb72998e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_28cbc68b-9db4-408d-b6f5-152e32eccac9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_14cae418-3c05-4060-b28b-cba8bb72998e" xlink:to="loc_us-gaap_AwardTypeAxis_28cbc68b-9db4-408d-b6f5-152e32eccac9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_28cbc68b-9db4-408d-b6f5-152e32eccac9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_28cbc68b-9db4-408d-b6f5-152e32eccac9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_28cbc68b-9db4-408d-b6f5-152e32eccac9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7c44640f-9896-41a8-9592-98ddd6efdf53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_28cbc68b-9db4-408d-b6f5-152e32eccac9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7c44640f-9896-41a8-9592-98ddd6efdf53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_6f8c78ba-bc7b-4269-a08b-aab23352fc88" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7c44640f-9896-41a8-9592-98ddd6efdf53" xlink:to="loc_us-gaap_EmployeeStockOptionMember_6f8c78ba-bc7b-4269-a08b-aab23352fc88" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_25a2b841-f27e-477c-a12a-2895fb5ec350" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_14cae418-3c05-4060-b28b-cba8bb72998e" xlink:to="loc_us-gaap_PlanNameAxis_25a2b841-f27e-477c-a12a-2895fb5ec350" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_25a2b841-f27e-477c-a12a-2895fb5ec350_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_25a2b841-f27e-477c-a12a-2895fb5ec350" xlink:to="loc_us-gaap_PlanNameDomain_25a2b841-f27e-477c-a12a-2895fb5ec350_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_2701eeee-5d46-45cb-b2dd-65da090fda8f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_25a2b841-f27e-477c-a12a-2895fb5ec350" xlink:to="loc_us-gaap_PlanNameDomain_2701eeee-5d46-45cb-b2dd-65da090fda8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_IncentivePlanMember_0505c2ff-305f-46f1-a1c3-6677e0e36cd4" xlink:href="bcrx-20250930.xsd#bcrx_IncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_2701eeee-5d46-45cb-b2dd-65da090fda8f" xlink:to="loc_bcrx_IncentivePlanMember_0505c2ff-305f-46f1-a1c3-6677e0e36cd4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_InducementPlanMember_455bb056-4f38-4e0b-bb37-b42665d50ef2" xlink:href="bcrx-20250930.xsd#bcrx_InducementPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_2701eeee-5d46-45cb-b2dd-65da090fda8f" xlink:to="loc_bcrx_InducementPlanMember_455bb056-4f38-4e0b-bb37-b42665d50ef2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_98ffbfbc-dafb-4788-a3fc-79c8e97e9fcc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5d378716-8e6e-4487-8096-53bdd0c49570" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_98ffbfbc-dafb-4788-a3fc-79c8e97e9fcc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cbba40a1-c2e7-4e12-bd60-9063e06d97ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_98ffbfbc-dafb-4788-a3fc-79c8e97e9fcc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cbba40a1-c2e7-4e12-bd60-9063e06d97ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c2bd8196-2345-459d-b1bc-3ae9927eb1de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_98ffbfbc-dafb-4788-a3fc-79c8e97e9fcc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c2bd8196-2345-459d-b1bc-3ae9927eb1de" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9600cf4f-88d2-486c-9e5b-c4a420aedd5e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_98ffbfbc-dafb-4788-a3fc-79c8e97e9fcc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9600cf4f-88d2-486c-9e5b-c4a420aedd5e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_43a1072c-6043-43b6-b062-b087ec78cb2b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_98ffbfbc-dafb-4788-a3fc-79c8e97e9fcc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_43a1072c-6043-43b6-b062-b087ec78cb2b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637eba4a-e592-4a87-96ab-568ecb1b1306" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_787fd894-b922-45a4-b02b-96051883f6d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5d378716-8e6e-4487-8096-53bdd0c49570" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_787fd894-b922-45a4-b02b-96051883f6d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_29eb7aac-b5cb-479f-a472-2dbccb922eaa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5d378716-8e6e-4487-8096-53bdd0c49570" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_29eb7aac-b5cb-479f-a472-2dbccb922eaa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_65b4bcf8-b799-4a09-b17e-001660be7e91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_29eb7aac-b5cb-479f-a472-2dbccb922eaa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_65b4bcf8-b799-4a09-b17e-001660be7e91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c86a603d-0343-4bab-a48b-2c666a20c04a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_29eb7aac-b5cb-479f-a472-2dbccb922eaa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c86a603d-0343-4bab-a48b-2c666a20c04a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0afef6a9-d0e9-43f2-bad9-e5ca0f9effb9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_29eb7aac-b5cb-479f-a472-2dbccb922eaa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0afef6a9-d0e9-43f2-bad9-e5ca0f9effb9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1acf03d9-c608-4092-a5d1-b763405d08a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_29eb7aac-b5cb-479f-a472-2dbccb922eaa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1acf03d9-c608-4092-a5d1-b763405d08a0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60c3c316-ce24-4543-b219-79ef577167eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_b916c8f6-06c0-472d-bbe9-b081d8d8da3f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5d378716-8e6e-4487-8096-53bdd0c49570" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_b916c8f6-06c0-472d-bbe9-b081d8d8da3f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_13a63b16-efad-4040-820f-e23170f8174c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5d378716-8e6e-4487-8096-53bdd0c49570" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_13a63b16-efad-4040-820f-e23170f8174c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_ccd357c4-6c6e-49cf-9a52-a272f1939c8f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_13a63b16-efad-4040-820f-e23170f8174c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_ccd357c4-6c6e-49cf-9a52-a272f1939c8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_f77ac148-698f-489d-90a2-04d51cdb47a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_13a63b16-efad-4040-820f-e23170f8174c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_f77ac148-698f-489d-90a2-04d51cdb47a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0afe650c-f8a6-420e-83ce-3d650d777dda" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_13a63b16-efad-4040-820f-e23170f8174c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0afe650c-f8a6-420e-83ce-3d650d777dda" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_9bba1e10-b1b1-4ff9-ab25-a3cf5864fd37" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5d378716-8e6e-4487-8096-53bdd0c49570" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_9bba1e10-b1b1-4ff9-ab25-a3cf5864fd37" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c40a5e7f-d6c3-4c38-b465-d256bbb60b20" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5d378716-8e6e-4487-8096-53bdd0c49570" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c40a5e7f-d6c3-4c38-b465-d256bbb60b20" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="bcrx-20250930.xsd#StockbasedCompensationRestrictedStockUnitActivityDetails"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b88da855-ce5f-45ce-8f6d-820a858b8f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e34eb706-e581-4182-97be-55fe3c648646" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b88da855-ce5f-45ce-8f6d-820a858b8f9c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e34eb706-e581-4182-97be-55fe3c648646" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_067c67a5-c81e-4719-a640-df4af5a8cf84" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e34eb706-e581-4182-97be-55fe3c648646" xlink:to="loc_us-gaap_AwardTypeAxis_067c67a5-c81e-4719-a640-df4af5a8cf84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_067c67a5-c81e-4719-a640-df4af5a8cf84_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_067c67a5-c81e-4719-a640-df4af5a8cf84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_067c67a5-c81e-4719-a640-df4af5a8cf84_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5784a5da-b718-4fd7-bb7e-56dcafb17bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_067c67a5-c81e-4719-a640-df4af5a8cf84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5784a5da-b718-4fd7-bb7e-56dcafb17bc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_a5021cf4-0bc5-42fb-a7fe-ef2ae7696c13" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5784a5da-b718-4fd7-bb7e-56dcafb17bc5" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_a5021cf4-0bc5-42fb-a7fe-ef2ae7696c13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_27ce87cd-f0fd-412f-94da-f46e36a4197c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e34eb706-e581-4182-97be-55fe3c648646" xlink:to="loc_us-gaap_PlanNameAxis_27ce87cd-f0fd-412f-94da-f46e36a4197c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_27ce87cd-f0fd-412f-94da-f46e36a4197c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_27ce87cd-f0fd-412f-94da-f46e36a4197c" xlink:to="loc_us-gaap_PlanNameDomain_27ce87cd-f0fd-412f-94da-f46e36a4197c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_4b735736-8bf1-49eb-8eb4-172e91e8d183" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_27ce87cd-f0fd-412f-94da-f46e36a4197c" xlink:to="loc_us-gaap_PlanNameDomain_4b735736-8bf1-49eb-8eb4-172e91e8d183" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_IncentivePlanMember_e9368a8e-67a2-4166-91b3-9534e191902c" xlink:href="bcrx-20250930.xsd#bcrx_IncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_4b735736-8bf1-49eb-8eb4-172e91e8d183" xlink:to="loc_bcrx_IncentivePlanMember_e9368a8e-67a2-4166-91b3-9534e191902c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_InducementPlanMember_f9501ffe-285c-42b1-80e2-6eae4f1b68f2" xlink:href="bcrx-20250930.xsd#bcrx_InducementPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_4b735736-8bf1-49eb-8eb4-172e91e8d183" xlink:to="loc_bcrx_InducementPlanMember_f9501ffe-285c-42b1-80e2-6eae4f1b68f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c49d3fcb-e7c0-4a36-a189-f2ee5e2dea4a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b88da855-ce5f-45ce-8f6d-820a858b8f9c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c49d3fcb-e7c0-4a36-a189-f2ee5e2dea4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a24f4652-73a9-4116-8a5e-458b7f026feb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c49d3fcb-e7c0-4a36-a189-f2ee5e2dea4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a24f4652-73a9-4116-8a5e-458b7f026feb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e0dc0a96-d8b7-4624-ac78-48581966e687" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c49d3fcb-e7c0-4a36-a189-f2ee5e2dea4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e0dc0a96-d8b7-4624-ac78-48581966e687" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_da4e2ad5-861a-46d6-84ab-432188a03612" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c49d3fcb-e7c0-4a36-a189-f2ee5e2dea4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_da4e2ad5-861a-46d6-84ab-432188a03612" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f5e7532e-fc73-42e5-bb16-8d86175a87de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c49d3fcb-e7c0-4a36-a189-f2ee5e2dea4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f5e7532e-fc73-42e5-bb16-8d86175a87de" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ea49a6e0-5c1e-4554-b346-9e4454b468ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2e25e4be-c9ff-49fc-affc-bb9c5dd717ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b88da855-ce5f-45ce-8f6d-820a858b8f9c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2e25e4be-c9ff-49fc-affc-bb9c5dd717ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e506c12c-912f-4666-9e74-33d7db40f01f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2e25e4be-c9ff-49fc-affc-bb9c5dd717ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e506c12c-912f-4666-9e74-33d7db40f01f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5e84f249-8b5b-4036-8b9e-ca0c2d3f3288" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2e25e4be-c9ff-49fc-affc-bb9c5dd717ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5e84f249-8b5b-4036-8b9e-ca0c2d3f3288" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_89113f38-8f57-4a8b-a8ac-1f6a0884d1ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2e25e4be-c9ff-49fc-affc-bb9c5dd717ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_89113f38-8f57-4a8b-a8ac-1f6a0884d1ea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f20b22d8-6624-4608-9c81-b186b8aa6714" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2e25e4be-c9ff-49fc-affc-bb9c5dd717ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f20b22d8-6624-4608-9c81-b186b8aa6714" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c30156eb-b62c-479e-94a4-9a3a6387c4a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/StockbasedCompensationWeightedAverageAssumptionsforStockOptionAwardsGrantedtoEmployeesandDirectorsUnderthePlansDetails" xlink:type="simple" xlink:href="bcrx-20250930.xsd#StockbasedCompensationWeightedAverageAssumptionsforStockOptionAwardsGrantedtoEmployeesandDirectorsUnderthePlansDetails"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/role/StockbasedCompensationWeightedAverageAssumptionsforStockOptionAwardsGrantedtoEmployeesandDirectorsUnderthePlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5675027-ba49-42b4-8e4c-62cd267d70f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62e072d0-9770-481c-8df8-29399c6c0b29" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5675027-ba49-42b4-8e4c-62cd267d70f3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62e072d0-9770-481c-8df8-29399c6c0b29" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_0bd7cb76-b4dd-4015-9c20-e393607d0a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62e072d0-9770-481c-8df8-29399c6c0b29" xlink:to="loc_us-gaap_PlanNameAxis_0bd7cb76-b4dd-4015-9c20-e393607d0a3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_0bd7cb76-b4dd-4015-9c20-e393607d0a3c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_0bd7cb76-b4dd-4015-9c20-e393607d0a3c" xlink:to="loc_us-gaap_PlanNameDomain_0bd7cb76-b4dd-4015-9c20-e393607d0a3c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_46cdfe03-8877-44e3-8214-9eecc92d460f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_0bd7cb76-b4dd-4015-9c20-e393607d0a3c" xlink:to="loc_us-gaap_PlanNameDomain_46cdfe03-8877-44e3-8214-9eecc92d460f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_IncentivePlanMember_3e0f6d1a-ac9a-480e-9c12-7b494b3b7c8a" xlink:href="bcrx-20250930.xsd#bcrx_IncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_46cdfe03-8877-44e3-8214-9eecc92d460f" xlink:to="loc_bcrx_IncentivePlanMember_3e0f6d1a-ac9a-480e-9c12-7b494b3b7c8a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_InducementPlanMember_ed4d88c7-d37c-4257-a4cd-5e66e3bcc818" xlink:href="bcrx-20250930.xsd#bcrx_InducementPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_46cdfe03-8877-44e3-8214-9eecc92d460f" xlink:to="loc_bcrx_InducementPlanMember_ed4d88c7-d37c-4257-a4cd-5e66e3bcc818" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e816c619-90a0-45fb-b9c0-223e35a222f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5675027-ba49-42b4-8e4c-62cd267d70f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e816c619-90a0-45fb-b9c0-223e35a222f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_255d4082-4bc0-4e50-9be8-68993327b9f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5675027-ba49-42b4-8e4c-62cd267d70f3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_255d4082-4bc0-4e50-9be8-68993327b9f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_35e43508-3fff-4ec5-aa10-9a26e2f52ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5675027-ba49-42b4-8e4c-62cd267d70f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_35e43508-3fff-4ec5-aa10-9a26e2f52ed3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3630da3e-a9d3-41e7-be32-63ae25d69078" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5675027-ba49-42b4-8e4c-62cd267d70f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3630da3e-a9d3-41e7-be32-63ae25d69078" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_355bc464-a51a-4065-ab50-daccf43af834" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5675027-ba49-42b4-8e4c-62cd267d70f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_355bc464-a51a-4065-ab50-daccf43af834" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6972fcdb-f0d2-4d8a-9b3d-55b901df2d87" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5675027-ba49-42b4-8e4c-62cd267d70f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6972fcdb-f0d2-4d8a-9b3d-55b901df2d87" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails" xlink:type="simple" xlink:href="bcrx-20250930.xsd#CollaborativeandOtherRelationshipsDetails"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_c9a60b2a-cc7e-43c3-baeb-d1203a0dc272" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_99bc3908-41e6-4d9a-b010-444ab15f6ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_c9a60b2a-cc7e-43c3-baeb-d1203a0dc272" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_99bc3908-41e6-4d9a-b010-444ab15f6ae0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_13ca2aac-d19d-47fb-9272-8677c77a82ff" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_99bc3908-41e6-4d9a-b010-444ab15f6ae0" xlink:to="loc_srt_CounterpartyNameAxis_13ca2aac-d19d-47fb-9272-8677c77a82ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_13ca2aac-d19d-47fb-9272-8677c77a82ff_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_13ca2aac-d19d-47fb-9272-8677c77a82ff" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_13ca2aac-d19d-47fb-9272-8677c77a82ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b7fc6f86-64a1-4ac8-b34b-c56c58eba68f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_13ca2aac-d19d-47fb-9272-8677c77a82ff" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b7fc6f86-64a1-4ac8-b34b-c56c58eba68f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ToriiPharmaceuticalCoMember_65fa30e7-d6fb-443b-89ea-b780bee642dd" xlink:href="bcrx-20250930.xsd#bcrx_ToriiPharmaceuticalCoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b7fc6f86-64a1-4ac8-b34b-c56c58eba68f" xlink:to="loc_bcrx_ToriiPharmaceuticalCoMember_65fa30e7-d6fb-443b-89ea-b780bee642dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ClearsideBiomedicalIncMember_f99902c2-f2c5-45af-a177-393eb830f623" xlink:href="bcrx-20250930.xsd#bcrx_ClearsideBiomedicalIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b7fc6f86-64a1-4ac8-b34b-c56c58eba68f" xlink:to="loc_bcrx_ClearsideBiomedicalIncMember_f99902c2-f2c5-45af-a177-393eb830f623" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_HHSOfficeOfTheAdministrationForStrategicPreparednessAndResponseMember_4d9a4f4e-6a0e-4732-bbbe-56ae80d138fd" xlink:href="bcrx-20250930.xsd#bcrx_HHSOfficeOfTheAdministrationForStrategicPreparednessAndResponseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b7fc6f86-64a1-4ac8-b34b-c56c58eba68f" xlink:to="loc_bcrx_HHSOfficeOfTheAdministrationForStrategicPreparednessAndResponseMember_4d9a4f4e-6a0e-4732-bbbe-56ae80d138fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cfac5736-1d71-4071-858b-6cd437b1d71f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_99bc3908-41e6-4d9a-b010-444ab15f6ae0" xlink:to="loc_srt_RangeAxis_cfac5736-1d71-4071-858b-6cd437b1d71f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cfac5736-1d71-4071-858b-6cd437b1d71f_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_cfac5736-1d71-4071-858b-6cd437b1d71f" xlink:to="loc_srt_RangeMember_cfac5736-1d71-4071-858b-6cd437b1d71f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a9b5ef11-e4c8-4d67-98a4-ee8e1623096e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_cfac5736-1d71-4071-858b-6cd437b1d71f" xlink:to="loc_srt_RangeMember_a9b5ef11-e4c8-4d67-98a4-ee8e1623096e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_04aa2d69-89c5-4165-a5ba-56817bdbbc22" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a9b5ef11-e4c8-4d67-98a4-ee8e1623096e" xlink:to="loc_srt_MinimumMember_04aa2d69-89c5-4165-a5ba-56817bdbbc22" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_af3bafbc-c65f-42d3-b0b1-63f25e5c8a67" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a9b5ef11-e4c8-4d67-98a4-ee8e1623096e" xlink:to="loc_srt_MaximumMember_af3bafbc-c65f-42d3-b0b1-63f25e5c8a67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesRangeAxis_3a00434b-a3dc-40da-8653-1d33cdb8f42b" xlink:href="bcrx-20250930.xsd#bcrx_AnnualNetSalesRangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_99bc3908-41e6-4d9a-b010-444ab15f6ae0" xlink:to="loc_bcrx_AnnualNetSalesRangeAxis_3a00434b-a3dc-40da-8653-1d33cdb8f42b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesRangeDomain_3a00434b-a3dc-40da-8653-1d33cdb8f42b_default" xlink:href="bcrx-20250930.xsd#bcrx_AnnualNetSalesRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_bcrx_AnnualNetSalesRangeAxis_3a00434b-a3dc-40da-8653-1d33cdb8f42b" xlink:to="loc_bcrx_AnnualNetSalesRangeDomain_3a00434b-a3dc-40da-8653-1d33cdb8f42b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesRangeDomain_a6426353-b24a-4d72-ab1c-c29b480cf306" xlink:href="bcrx-20250930.xsd#bcrx_AnnualNetSalesRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_bcrx_AnnualNetSalesRangeAxis_3a00434b-a3dc-40da-8653-1d33cdb8f42b" xlink:to="loc_bcrx_AnnualNetSalesRangeDomain_a6426353-b24a-4d72-ab1c-c29b480cf306" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesOf2MillionMember_a2244fb4-598e-43af-b88a-a86dab0dcb5b" xlink:href="bcrx-20250930.xsd#bcrx_AnnualNetSalesOf2MillionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_AnnualNetSalesRangeDomain_a6426353-b24a-4d72-ab1c-c29b480cf306" xlink:to="loc_bcrx_AnnualNetSalesOf2MillionMember_a2244fb4-598e-43af-b88a-a86dab0dcb5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesGreaterThan15MillionMember_747cebe8-406a-47dd-bfbd-e8e9da842704" xlink:href="bcrx-20250930.xsd#bcrx_AnnualNetSalesGreaterThan15MillionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_AnnualNetSalesRangeDomain_a6426353-b24a-4d72-ab1c-c29b480cf306" xlink:to="loc_bcrx_AnnualNetSalesGreaterThan15MillionMember_747cebe8-406a-47dd-bfbd-e8e9da842704" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_168d2cdb-22af-4b0e-b3e5-a3c14804b2f1" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_99bc3908-41e6-4d9a-b010-444ab15f6ae0" xlink:to="loc_srt_ProductOrServiceAxis_168d2cdb-22af-4b0e-b3e5-a3c14804b2f1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_168d2cdb-22af-4b0e-b3e5-a3c14804b2f1_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_168d2cdb-22af-4b0e-b3e5-a3c14804b2f1" xlink:to="loc_srt_ProductsAndServicesDomain_168d2cdb-22af-4b0e-b3e5-a3c14804b2f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9ef56268-c0e7-4a3b-b384-cb607d8db331" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_168d2cdb-22af-4b0e-b3e5-a3c14804b2f1" xlink:to="loc_srt_ProductsAndServicesDomain_9ef56268-c0e7-4a3b-b384-cb607d8db331" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RAPIVABMember_b6368710-b13d-490e-95d1-2a1e492677b5" xlink:href="bcrx-20250930.xsd#bcrx_RAPIVABMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9ef56268-c0e7-4a3b-b384-cb607d8db331" xlink:to="loc_bcrx_RAPIVABMember_b6368710-b13d-490e-95d1-2a1e492677b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_e92aabb5-13a1-4af2-af9b-655a3c2adf61" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_c9a60b2a-cc7e-43c3-baeb-d1203a0dc272" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_e92aabb5-13a1-4af2-af9b-655a3c2adf61" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeMilestone_a2ad192e-08fe-41c7-a1c1-31176034a4b9" xlink:href="bcrx-20250930.xsd#bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_c9a60b2a-cc7e-43c3-baeb-d1203a0dc272" xlink:to="loc_bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeMilestone_a2ad192e-08fe-41c7-a1c1-31176034a4b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyRateIfMaintainsSakigakeDesignation_8aa9a4ec-fd12-4961-a7a5-dd185ae3c4f7" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltyRateIfMaintainsSakigakeDesignation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_c9a60b2a-cc7e-43c3-baeb-d1203a0dc272" xlink:to="loc_bcrx_RoyaltyRateIfMaintainsSakigakeDesignation_8aa9a4ec-fd12-4961-a7a5-dd185ae3c4f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_MaximumCustomaryReductionOnRoyaltyRate_3ef358dd-145b-4f7e-8440-5fb5041014bf" xlink:href="bcrx-20250930.xsd#bcrx_MaximumCustomaryReductionOnRoyaltyRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_c9a60b2a-cc7e-43c3-baeb-d1203a0dc272" xlink:to="loc_bcrx_MaximumCustomaryReductionOnRoyaltyRate_3ef358dd-145b-4f7e-8440-5fb5041014bf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyRate_211c4694-77cc-4ba4-b7b9-cb5669b134b9" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltyRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_c9a60b2a-cc7e-43c3-baeb-d1203a0dc272" xlink:to="loc_bcrx_RoyaltyRate_211c4694-77cc-4ba4-b7b9-cb5669b134b9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_CollaborativeAgreementContractValue_7cc6c863-727b-4d62-95b6-890dfe9142f7" xlink:href="bcrx-20250930.xsd#bcrx_CollaborativeAgreementContractValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_c9a60b2a-cc7e-43c3-baeb-d1203a0dc272" xlink:to="loc_bcrx_CollaborativeAgreementContractValue_7cc6c863-727b-4d62-95b6-890dfe9142f7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses_66820cd5-4b6d-4a98-8be5-1dae3f75f89a" xlink:href="bcrx-20250930.xsd#bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_c9a60b2a-cc7e-43c3-baeb-d1203a0dc272" xlink:to="loc_bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses_66820cd5-4b6d-4a98-8be5-1dae3f75f89a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ContractTerm_c1a26b2c-f8f3-48f4-9f7b-645d8744d3a2" xlink:href="bcrx-20250930.xsd#bcrx_ContractTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_c9a60b2a-cc7e-43c3-baeb-d1203a0dc272" xlink:to="loc_bcrx_ContractTerm_c1a26b2c-f8f3-48f4-9f7b-645d8744d3a2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_NumberOfOptionalOrderingPeriods_239ba506-6ffb-4036-b7ca-6adc699297f7" xlink:href="bcrx-20250930.xsd#bcrx_NumberOfOptionalOrderingPeriods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_c9a60b2a-cc7e-43c3-baeb-d1203a0dc272" xlink:to="loc_bcrx_NumberOfOptionalOrderingPeriods_239ba506-6ffb-4036-b7ca-6adc699297f7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators_33e63e91-2d07-4667-bfea-293aad4e105c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_c9a60b2a-cc7e-43c3-baeb-d1203a0dc272" xlink:to="loc_us-gaap_ProceedsFromCollaborators_33e63e91-2d07-4667-bfea-293aad4e105c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_NumberOfProductDeliveredDoses_f930b3f3-58ce-4314-850f-f0e35aadd10f" xlink:href="bcrx-20250930.xsd#bcrx_NumberOfProductDeliveredDoses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_c9a60b2a-cc7e-43c3-baeb-d1203a0dc272" xlink:to="loc_bcrx_NumberOfProductDeliveredDoses_f930b3f3-58ce-4314-850f-f0e35aadd10f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_LicenseAgreementUpfrontPayment_91e0360c-1d43-4158-a5ad-0b6adb033e91" xlink:href="bcrx-20250930.xsd#bcrx_LicenseAgreementUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_c9a60b2a-cc7e-43c3-baeb-d1203a0dc272" xlink:to="loc_bcrx_LicenseAgreementUpfrontPayment_91e0360c-1d43-4158-a5ad-0b6adb033e91" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_PotentialMilestonePaymentsPayable_c8fb9deb-681f-44aa-9d6b-66d15bd159f7" xlink:href="bcrx-20250930.xsd#bcrx_PotentialMilestonePaymentsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_c9a60b2a-cc7e-43c3-baeb-d1203a0dc272" xlink:to="loc_bcrx_PotentialMilestonePaymentsPayable_c8fb9deb-681f-44aa-9d6b-66d15bd159f7" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_PotentialMilestonePaymentsPayableIfRegulatoryApprovalBeforeMilestone_f72ccca6-71da-48a8-8dd1-f85785fccecd" xlink:href="bcrx-20250930.xsd#bcrx_PotentialMilestonePaymentsPayableIfRegulatoryApprovalBeforeMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_c9a60b2a-cc7e-43c3-baeb-d1203a0dc272" xlink:to="loc_bcrx_PotentialMilestonePaymentsPayableIfRegulatoryApprovalBeforeMilestone_f72ccca6-71da-48a8-8dd1-f85785fccecd" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_LicenseAgreementNumberOfMilestonePayments_f7dab03d-f1c8-4526-ac2a-7654c7e2705e" xlink:href="bcrx-20250930.xsd#bcrx_LicenseAgreementNumberOfMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_c9a60b2a-cc7e-43c3-baeb-d1203a0dc272" xlink:to="loc_bcrx_LicenseAgreementNumberOfMilestonePayments_f7dab03d-f1c8-4526-ac2a-7654c7e2705e" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_LicenseAgreementAnnualGlobalNetSales_b6e265df-06a4-45c4-80e4-d5359ee3b26f" xlink:href="bcrx-20250930.xsd#bcrx_LicenseAgreementAnnualGlobalNetSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_c9a60b2a-cc7e-43c3-baeb-d1203a0dc272" xlink:to="loc_bcrx_LicenseAgreementAnnualGlobalNetSales_b6e265df-06a4-45c4-80e4-d5359ee3b26f" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_LicenseAgreementRoyaltyPaymentNumberOfTiers_91248096-30f5-40a5-97d1-5354250a59b5" xlink:href="bcrx-20250930.xsd#bcrx_LicenseAgreementRoyaltyPaymentNumberOfTiers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_c9a60b2a-cc7e-43c3-baeb-d1203a0dc272" xlink:to="loc_bcrx_LicenseAgreementRoyaltyPaymentNumberOfTiers_91248096-30f5-40a5-97d1-5354250a59b5" xlink:type="arc" order="16"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/SegmentInformationDetails" xlink:type="simple" xlink:href="bcrx-20250930.xsd#SegmentInformationDetails"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/role/SegmentInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_cdb8acd4-339a-46d5-b02c-880083d76457" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_12528039-c6af-4bbe-9836-bd8ac693a162" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cdb8acd4-339a-46d5-b02c-880083d76457" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_12528039-c6af-4bbe-9836-bd8ac693a162" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_5b36bab7-8c3c-48c6-a0f9-18669de3869d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_12528039-c6af-4bbe-9836-bd8ac693a162" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_5b36bab7-8c3c-48c6-a0f9-18669de3869d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_5b36bab7-8c3c-48c6-a0f9-18669de3869d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_5b36bab7-8c3c-48c6-a0f9-18669de3869d" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_5b36bab7-8c3c-48c6-a0f9-18669de3869d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_842eb035-47e2-4c32-853c-b54c288f205c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_5b36bab7-8c3c-48c6-a0f9-18669de3869d" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_842eb035-47e2-4c32-853c-b54c288f205c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_f341d0e6-b29d-4238-8aa3-00e580f8eb0a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_842eb035-47e2-4c32-853c-b54c288f205c" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_f341d0e6-b29d-4238-8aa3-00e580f8eb0a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d4b4ac8f-07de-466e-8af9-96480bbfb6f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_12528039-c6af-4bbe-9836-bd8ac693a162" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d4b4ac8f-07de-466e-8af9-96480bbfb6f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_d4b4ac8f-07de-466e-8af9-96480bbfb6f9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d4b4ac8f-07de-466e-8af9-96480bbfb6f9" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_d4b4ac8f-07de-466e-8af9-96480bbfb6f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3a1b34a6-5ea8-4323-abc0-0ce659f63271" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d4b4ac8f-07de-466e-8af9-96480bbfb6f9" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3a1b34a6-5ea8-4323-abc0-0ce659f63271" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_BioCrystIrelandMember_cb3a0766-c559-493d-a543-2dbf98b5c0bd" xlink:href="bcrx-20250930.xsd#bcrx_BioCrystIrelandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3a1b34a6-5ea8-4323-abc0-0ce659f63271" xlink:to="loc_bcrx_BioCrystIrelandMember_cb3a0766-c559-493d-a543-2dbf98b5c0bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_848241d2-1a56-45bd-b550-bb40f29cb9ef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cdb8acd4-339a-46d5-b02c-880083d76457" xlink:to="loc_us-gaap_NumberOfReportableSegments_848241d2-1a56-45bd-b550-bb40f29cb9ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_d0e95203-219e-4628-93a6-9683d82df5cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cdb8acd4-339a-46d5-b02c-880083d76457" xlink:to="loc_us-gaap_NumberOfOperatingSegments_d0e95203-219e-4628-93a6-9683d82df5cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_CashCashEquivalentsShortAndLongTermInvestments_ae49c688-f288-4b99-a031-8684f30f1ec1" xlink:href="bcrx-20250930.xsd#bcrx_CashCashEquivalentsShortAndLongTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cdb8acd4-339a-46d5-b02c-880083d76457" xlink:to="loc_bcrx_CashCashEquivalentsShortAndLongTermInvestments_ae49c688-f288-4b99-a031-8684f30f1ec1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_cd3fb8f6-6881-4e2e-8fbb-3953ae8a083c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cdb8acd4-339a-46d5-b02c-880083d76457" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_cd3fb8f6-6881-4e2e-8fbb-3953ae8a083c" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/SegmentInformationSegmentReportingInformationbySegmentDetails" xlink:type="simple" xlink:href="bcrx-20250930.xsd#SegmentInformationSegmentReportingInformationbySegmentDetails"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/role/SegmentInformationSegmentReportingInformationbySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_f8b2ce67-5c1a-4d87-a972-88001fb240c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a648f363-5f48-45d1-b70e-ef9d5fee8712" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f8b2ce67-5c1a-4d87-a972-88001fb240c3" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a648f363-5f48-45d1-b70e-ef9d5fee8712" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_16c92a41-26d7-493b-9caf-5b24146f0df5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a648f363-5f48-45d1-b70e-ef9d5fee8712" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_16c92a41-26d7-493b-9caf-5b24146f0df5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_16c92a41-26d7-493b-9caf-5b24146f0df5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_16c92a41-26d7-493b-9caf-5b24146f0df5" xlink:to="loc_us-gaap_SegmentDomain_16c92a41-26d7-493b-9caf-5b24146f0df5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_22319766-6c71-4d27-9269-739e282525ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_16c92a41-26d7-493b-9caf-5b24146f0df5" xlink:to="loc_us-gaap_SegmentDomain_22319766-6c71-4d27-9269-739e282525ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ReportableSegmentMember_25bd72c0-a254-4f79-b78d-0983ec777f13" xlink:href="bcrx-20250930.xsd#bcrx_ReportableSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_22319766-6c71-4d27-9269-739e282525ba" xlink:to="loc_bcrx_ReportableSegmentMember_25bd72c0-a254-4f79-b78d-0983ec777f13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ce42ec62-1513-4217-82c7-d0588d033c79" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a648f363-5f48-45d1-b70e-ef9d5fee8712" xlink:to="loc_srt_ProductOrServiceAxis_ce42ec62-1513-4217-82c7-d0588d033c79" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ce42ec62-1513-4217-82c7-d0588d033c79_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ce42ec62-1513-4217-82c7-d0588d033c79" xlink:to="loc_srt_ProductsAndServicesDomain_ce42ec62-1513-4217-82c7-d0588d033c79_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a4b8cb94-33e0-41b9-85f1-3ba21d640f39" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ce42ec62-1513-4217-82c7-d0588d033c79" xlink:to="loc_srt_ProductsAndServicesDomain_a4b8cb94-33e0-41b9-85f1-3ba21d640f39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_BerotralstatMember_5f1a5738-12f0-4890-9e97-d7cc2b6876b7" xlink:href="bcrx-20250930.xsd#bcrx_BerotralstatMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a4b8cb94-33e0-41b9-85f1-3ba21d640f39" xlink:to="loc_bcrx_BerotralstatMember_5f1a5738-12f0-4890-9e97-d7cc2b6876b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_BCX17725Member_ce0741de-5370-4e38-93c9-959ff1692f58" xlink:href="bcrx-20250930.xsd#bcrx_BCX17725Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a4b8cb94-33e0-41b9-85f1-3ba21d640f39" xlink:to="loc_bcrx_BCX17725Member_ce0741de-5370-4e38-93c9-959ff1692f58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AvoralstatMember_b60bc5e8-e296-4516-8926-d388d1c7559b" xlink:href="bcrx-20250930.xsd#bcrx_AvoralstatMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a4b8cb94-33e0-41b9-85f1-3ba21d640f39" xlink:to="loc_bcrx_AvoralstatMember_b60bc5e8-e296-4516-8926-d388d1c7559b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_FactorDProgramMember_00fea338-d520-46ce-8a9a-f9deab4a458c" xlink:href="bcrx-20250930.xsd#bcrx_FactorDProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a4b8cb94-33e0-41b9-85f1-3ba21d640f39" xlink:to="loc_bcrx_FactorDProgramMember_00fea338-d520-46ce-8a9a-f9deab4a458c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ResearchDiscoveryAndPreclinicalProgramsMember_5f6dc044-dc17-4799-bc91-0da1f6e56b4d" xlink:href="bcrx-20250930.xsd#bcrx_ResearchDiscoveryAndPreclinicalProgramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a4b8cb94-33e0-41b9-85f1-3ba21d640f39" xlink:to="loc_bcrx_ResearchDiscoveryAndPreclinicalProgramsMember_5f6dc044-dc17-4799-bc91-0da1f6e56b4d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_CompensationAndRelatedPersonnelCostsMember_8816d36d-73c3-4827-bf56-9a3074b4f1cf" xlink:href="bcrx-20250930.xsd#bcrx_CompensationAndRelatedPersonnelCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a4b8cb94-33e0-41b9-85f1-3ba21d640f39" xlink:to="loc_bcrx_CompensationAndRelatedPersonnelCostsMember_8816d36d-73c3-4827-bf56-9a3074b4f1cf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_StockBasedCompensationMember_ffa6e864-2059-456a-88e2-1f97e0f15a34" xlink:href="bcrx-20250930.xsd#bcrx_StockBasedCompensationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a4b8cb94-33e0-41b9-85f1-3ba21d640f39" xlink:to="loc_bcrx_StockBasedCompensationMember_ffa6e864-2059-456a-88e2-1f97e0f15a34" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_OtherExpenses1Member_5cd1c486-fcc4-4c97-8cda-cb4abc4fa78f" xlink:href="bcrx-20250930.xsd#bcrx_OtherExpenses1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a4b8cb94-33e0-41b9-85f1-3ba21d640f39" xlink:to="loc_bcrx_OtherExpenses1Member_5cd1c486-fcc4-4c97-8cda-cb4abc4fa78f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_186b5e9a-a65d-462e-8462-3ef2bf706986" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f8b2ce67-5c1a-4d87-a972-88001fb240c3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_186b5e9a-a65d-462e-8462-3ef2bf706986" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_5a965c7e-0662-41a2-a354-459d1eef11b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f8b2ce67-5c1a-4d87-a972-88001fb240c3" xlink:to="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_5a965c7e-0662-41a2-a354-459d1eef11b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_92b799ec-7b86-44d0-82e3-79dd8f7a357c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_5a965c7e-0662-41a2-a354-459d1eef11b6" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_92b799ec-7b86-44d0-82e3-79dd8f7a357c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_8d4fa5c2-5c96-4ee0-a230-6288141781a6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_5a965c7e-0662-41a2-a354-459d1eef11b6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_8d4fa5c2-5c96-4ee0-a230-6288141781a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_c4fec3a0-2a60-49f2-8a78-eda3d775d3f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_5a965c7e-0662-41a2-a354-459d1eef11b6" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_c4fec3a0-2a60-49f2-8a78-eda3d775d3f6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_0c01cd98-dd1d-48ef-b661-31b7d0ea7ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeOperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_5a965c7e-0662-41a2-a354-459d1eef11b6" xlink:to="loc_us-gaap_InterestIncomeOperating_0c01cd98-dd1d-48ef-b661-31b7d0ea7ee6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_b90f73cd-e849-4888-8afd-83e567397d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_5a965c7e-0662-41a2-a354-459d1eef11b6" xlink:to="loc_us-gaap_InterestExpenseNonoperating_b90f73cd-e849-4888-8afd-83e567397d5a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_d347ece2-9c61-4fad-9ecb-dfdc5fed1c9d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_5a965c7e-0662-41a2-a354-459d1eef11b6" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_d347ece2-9c61-4fad-9ecb-dfdc5fed1c9d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_7d946d6f-9d68-459a-9ba7-a112c4af869b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_5a965c7e-0662-41a2-a354-459d1eef11b6" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_7d946d6f-9d68-459a-9ba7-a112c4af869b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncome_aebddd9e-f0f5-49e9-99c1-955f24b7be4c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_5a965c7e-0662-41a2-a354-459d1eef11b6" xlink:to="loc_us-gaap_OtherIncome_aebddd9e-f0f5-49e9-99c1-955f24b7be4c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4c0fe836-b936-40b3-a80f-c85b3400b098" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_5a965c7e-0662-41a2-a354-459d1eef11b6" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4c0fe836-b936-40b3-a80f-c85b3400b098" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6a095c10-7b91-425d-bd01-16e50d777fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f8b2ce67-5c1a-4d87-a972-88001fb240c3" xlink:to="loc_us-gaap_NetIncomeLoss_6a095c10-7b91-425d-bd01-16e50d777fbf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_SegmentReportingAdjustmentsAndReconcilingItemsAmount_d178f016-2a2f-409b-bc9f-0b12c0b881f8" xlink:href="bcrx-20250930.xsd#bcrx_SegmentReportingAdjustmentsAndReconcilingItemsAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f8b2ce67-5c1a-4d87-a972-88001fb240c3" xlink:to="loc_bcrx_SegmentReportingAdjustmentsAndReconcilingItemsAmount_d178f016-2a2f-409b-bc9f-0b12c0b881f8" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/NetIncomeLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="simple" xlink:href="bcrx-20250930.xsd#NetIncomeLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/role/NetIncomeLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_927b92a2-7f60-4cdc-bf86-570262f81a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9827c5a6-ed9a-4175-9fcd-0750d0fa2d14" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_927b92a2-7f60-4cdc-bf86-570262f81a2a" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9827c5a6-ed9a-4175-9fcd-0750d0fa2d14" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5d907e78-f0d1-4262-90c5-21923fb5612a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9827c5a6-ed9a-4175-9fcd-0750d0fa2d14" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5d907e78-f0d1-4262-90c5-21923fb5612a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5d907e78-f0d1-4262-90c5-21923fb5612a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5d907e78-f0d1-4262-90c5-21923fb5612a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5d907e78-f0d1-4262-90c5-21923fb5612a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3c2afbb5-15e9-4e0d-8c22-e8fba86ae4bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5d907e78-f0d1-4262-90c5-21923fb5612a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3c2afbb5-15e9-4e0d-8c22-e8fba86ae4bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_40e918b5-8878-4295-a5a6-74b98e1b6cef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3c2afbb5-15e9-4e0d-8c22-e8fba86ae4bb" xlink:to="loc_us-gaap_EmployeeStockOptionMember_40e918b5-8878-4295-a5a6-74b98e1b6cef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_4921666c-b2f0-4a92-97a1-3f1422b56507" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3c2afbb5-15e9-4e0d-8c22-e8fba86ae4bb" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_4921666c-b2f0-4a92-97a1-3f1422b56507" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5f18b795-b5b2-4298-8e83-01f5443386af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_927b92a2-7f60-4cdc-bf86-570262f81a2a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5f18b795-b5b2-4298-8e83-01f5443386af" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/SubsequentEventDetails" xlink:type="simple" xlink:href="bcrx-20250930.xsd#SubsequentEventDetails"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/role/SubsequentEventDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_53259c98-6d6d-44c9-b764-d16297eaa40e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_ab69ecd3-ea4b-47b1-ad0c-242398a28483" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_53259c98-6d6d-44c9-b764-d16297eaa40e" xlink:to="loc_us-gaap_SubsequentEventTable_ab69ecd3-ea4b-47b1-ad0c-242398a28483" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_736cfa6a-f493-49b3-ae65-e7bbb3a781a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_ab69ecd3-ea4b-47b1-ad0c-242398a28483" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_736cfa6a-f493-49b3-ae65-e7bbb3a781a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_736cfa6a-f493-49b3-ae65-e7bbb3a781a2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_736cfa6a-f493-49b3-ae65-e7bbb3a781a2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_736cfa6a-f493-49b3-ae65-e7bbb3a781a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6e4ff3ff-76fd-4cd3-bd85-3d6c15179a71" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_736cfa6a-f493-49b3-ae65-e7bbb3a781a2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6e4ff3ff-76fd-4cd3-bd85-3d6c15179a71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_92ddcdf4-c14a-48b0-b6f4-d694843c4672" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_6e4ff3ff-76fd-4cd3-bd85-3d6c15179a71" xlink:to="loc_us-gaap_SubsequentEventMember_92ddcdf4-c14a-48b0-b6f4-d694843c4672" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_8596e8c8-470f-451c-bd8b-a9bdcd31b712" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_ab69ecd3-ea4b-47b1-ad0c-242398a28483" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_8596e8c8-470f-451c-bd8b-a9bdcd31b712" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_8596e8c8-470f-451c-bd8b-a9bdcd31b712_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_8596e8c8-470f-451c-bd8b-a9bdcd31b712" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_8596e8c8-470f-451c-bd8b-a9bdcd31b712_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_01adcdf7-5124-4dfa-bafb-53d02bd5c4e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_8596e8c8-470f-451c-bd8b-a9bdcd31b712" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_01adcdf7-5124-4dfa-bafb-53d02bd5c4e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_d645d284-74a0-447f-b5ea-de6c9a888a3f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_01adcdf7-5124-4dfa-bafb-53d02bd5c4e4" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_d645d284-74a0-447f-b5ea-de6c9a888a3f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_80e62bc1-80c3-40de-8c6f-932193a7dc47" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_ab69ecd3-ea4b-47b1-ad0c-242398a28483" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_80e62bc1-80c3-40de-8c6f-932193a7dc47" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_80e62bc1-80c3-40de-8c6f-932193a7dc47_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_80e62bc1-80c3-40de-8c6f-932193a7dc47" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_80e62bc1-80c3-40de-8c6f-932193a7dc47_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7c0069d1-1971-4bb6-ab1c-8a62215927b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_80e62bc1-80c3-40de-8c6f-932193a7dc47" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7c0069d1-1971-4bb6-ab1c-8a62215927b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_BioCrystIrelandMember_a3dfa427-3482-4c34-8682-8260f629ddb1" xlink:href="bcrx-20250930.xsd#bcrx_BioCrystIrelandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7c0069d1-1971-4bb6-ab1c-8a62215927b9" xlink:to="loc_bcrx_BioCrystIrelandMember_a3dfa427-3482-4c34-8682-8260f629ddb1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_f4ffce84-7506-45bc-8010-a322a779c5b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_ab69ecd3-ea4b-47b1-ad0c-242398a28483" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_f4ffce84-7506-45bc-8010-a322a779c5b8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_f4ffce84-7506-45bc-8010-a322a779c5b8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_f4ffce84-7506-45bc-8010-a322a779c5b8" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_f4ffce84-7506-45bc-8010-a322a779c5b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_890cf2cd-e15b-4315-a7ba-416b75649e03" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_f4ffce84-7506-45bc-8010-a322a779c5b8" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_890cf2cd-e15b-4315-a7ba-416b75649e03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_PharmakonAdvisorsLPMember_a40c69ca-2c00-49b6-bee8-361096e5c340" xlink:href="bcrx-20250930.xsd#bcrx_PharmakonAdvisorsLPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_890cf2cd-e15b-4315-a7ba-416b75649e03" xlink:to="loc_bcrx_PharmakonAdvisorsLPMember_a40c69ca-2c00-49b6-bee8-361096e5c340" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_BlackstoneMember_eba3697c-193a-43cd-9423-d8a39bc46b90" xlink:href="bcrx-20250930.xsd#bcrx_BlackstoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_890cf2cd-e15b-4315-a7ba-416b75649e03" xlink:to="loc_bcrx_BlackstoneMember_eba3697c-193a-43cd-9423-d8a39bc46b90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1b43d516-5fcf-4cfa-b921-a53ab8debe5f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_ab69ecd3-ea4b-47b1-ad0c-242398a28483" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1b43d516-5fcf-4cfa-b921-a53ab8debe5f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1b43d516-5fcf-4cfa-b921-a53ab8debe5f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1b43d516-5fcf-4cfa-b921-a53ab8debe5f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1b43d516-5fcf-4cfa-b921-a53ab8debe5f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_482a5bc5-b1f5-4f6d-a950-f89e2c1023dc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1b43d516-5fcf-4cfa-b921-a53ab8debe5f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_482a5bc5-b1f5-4f6d-a950-f89e2c1023dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_b8b2391b-fe99-40e4-8b67-ce578a8d8edf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_482a5bc5-b1f5-4f6d-a950-f89e2c1023dc" xlink:to="loc_us-gaap_LineOfCreditMember_b8b2391b-fe99-40e4-8b67-ce578a8d8edf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6e560ce2-e801-4384-88fc-59262960b135" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_ab69ecd3-ea4b-47b1-ad0c-242398a28483" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6e560ce2-e801-4384-88fc-59262960b135" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6e560ce2-e801-4384-88fc-59262960b135_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6e560ce2-e801-4384-88fc-59262960b135" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6e560ce2-e801-4384-88fc-59262960b135_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8fb33427-df94-4528-b259-c104f1a479ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6e560ce2-e801-4384-88fc-59262960b135" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8fb33427-df94-4528-b259-c104f1a479ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AstriaMember_5c480813-3d85-48ad-bf61-d6e85e0e183f" xlink:href="bcrx-20250930.xsd#bcrx_AstriaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8fb33427-df94-4528-b259-c104f1a479ec" xlink:to="loc_bcrx_AstriaMember_5c480813-3d85-48ad-bf61-d6e85e0e183f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_31ce7743-3f3d-44eb-8989-c170ede717d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_ab69ecd3-ea4b-47b1-ad0c-242398a28483" xlink:to="loc_us-gaap_CreditFacilityAxis_31ce7743-3f3d-44eb-8989-c170ede717d7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_31ce7743-3f3d-44eb-8989-c170ede717d7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_31ce7743-3f3d-44eb-8989-c170ede717d7" xlink:to="loc_us-gaap_CreditFacilityDomain_31ce7743-3f3d-44eb-8989-c170ede717d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_b2fe5038-6794-4092-8029-c4c25d32757d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_31ce7743-3f3d-44eb-8989-c170ede717d7" xlink:to="loc_us-gaap_CreditFacilityDomain_b2fe5038-6794-4092-8029-c4c25d32757d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_546075cf-d46a-40af-8f11-658ecbb08954" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_b2fe5038-6794-4092-8029-c4c25d32757d" xlink:to="loc_us-gaap_SecuredDebtMember_546075cf-d46a-40af-8f11-658ecbb08954" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_32305d6c-fc57-45bc-b69e-2efa5fca7249" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_b2fe5038-6794-4092-8029-c4c25d32757d" xlink:to="loc_us-gaap_UnsecuredDebtMember_32305d6c-fc57-45bc-b69e-2efa5fca7249" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_05449326-d2da-4a7c-b630-39aec955f79d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_ab69ecd3-ea4b-47b1-ad0c-242398a28483" xlink:to="loc_srt_StatementScenarioAxis_05449326-d2da-4a7c-b630-39aec955f79d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_05449326-d2da-4a7c-b630-39aec955f79d_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_05449326-d2da-4a7c-b630-39aec955f79d" xlink:to="loc_srt_ScenarioUnspecifiedDomain_05449326-d2da-4a7c-b630-39aec955f79d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_86349734-19cd-47ea-95cc-5359ec5fdde0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_05449326-d2da-4a7c-b630-39aec955f79d" xlink:to="loc_srt_ScenarioUnspecifiedDomain_86349734-19cd-47ea-95cc-5359ec5fdde0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_4ccb8ebb-3f36-4ba7-a2b9-fb7e4ac2041a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_86349734-19cd-47ea-95cc-5359ec5fdde0" xlink:to="loc_srt_ScenarioForecastMember_4ccb8ebb-3f36-4ba7-a2b9-fb7e4ac2041a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_44fa2f50-78b7-46fa-ad06-ce556ff132a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_53259c98-6d6d-44c9-b764-d16297eaa40e" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_44fa2f50-78b7-46fa-ad06-ce556ff132a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_4e430f43-6b03-4e63-8ce9-fdc0c39294da" xlink:href="bcrx-20250930.xsd#bcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_53259c98-6d6d-44c9-b764-d16297eaa40e" xlink:to="loc_bcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_4e430f43-6b03-4e63-8ce9-fdc0c39294da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DisposalGroupIncludingDiscontinuedOperationConsiderationRoyaltyReleaseFee_11b72f5d-efa7-4a8e-8a56-3640bb371f7f" xlink:href="bcrx-20250930.xsd#bcrx_DisposalGroupIncludingDiscontinuedOperationConsiderationRoyaltyReleaseFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_53259c98-6d6d-44c9-b764-d16297eaa40e" xlink:to="loc_bcrx_DisposalGroupIncludingDiscontinuedOperationConsiderationRoyaltyReleaseFee_11b72f5d-efa7-4a8e-8a56-3640bb371f7f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_83e6816e-3488-4721-bd5c-3dcae743a337" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_53259c98-6d6d-44c9-b764-d16297eaa40e" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_83e6816e-3488-4721-bd5c-3dcae743a337" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DebtInstrumentPrepaymentPremium_7b15228b-6235-4c3b-b21b-b92d96f20a63" xlink:href="bcrx-20250930.xsd#bcrx_DebtInstrumentPrepaymentPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_53259c98-6d6d-44c9-b764-d16297eaa40e" xlink:to="loc_bcrx_DebtInstrumentPrepaymentPremium_7b15228b-6235-4c3b-b21b-b92d96f20a63" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseLongTermDebt_aecbeafa-ee8e-4f70-950a-01f6a255eaef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_53259c98-6d6d-44c9-b764-d16297eaa40e" xlink:to="loc_us-gaap_InterestExpenseLongTermDebt_aecbeafa-ee8e-4f70-950a-01f6a255eaef" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_CommonStockConversionRatio_f1de2e61-acc7-4be8-a59b-d99f6956bb70" xlink:href="bcrx-20250930.xsd#bcrx_CommonStockConversionRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_53259c98-6d6d-44c9-b764-d16297eaa40e" xlink:to="loc_bcrx_CommonStockConversionRatio_f1de2e61-acc7-4be8-a59b-d99f6956bb70" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_31f5586d-f542-47ec-bcb3-f7872904f952" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_53259c98-6d6d-44c9-b764-d16297eaa40e" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_31f5586d-f542-47ec-bcb3-f7872904f952" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_2b2a4d71-b373-4a06-b78e-bff411b5a262" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_53259c98-6d6d-44c9-b764-d16297eaa40e" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_2b2a4d71-b373-4a06-b78e-bff411b5a262" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_ed06f1e7-27ee-4a74-a468-ac9859530414" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_53259c98-6d6d-44c9-b764-d16297eaa40e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_ed06f1e7-27ee-4a74-a468-ac9859530414" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_bd005088-d92e-4447-9020-21b5c2947309" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_53259c98-6d6d-44c9-b764-d16297eaa40e" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_bd005088-d92e-4447-9020-21b5c2947309" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_ShortTermInvestments" xlink:type="arc" order="101"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RightOfUseAssetsNoncurrent_7bf5ea04-b71a-4abb-b03e-9f1d8fa21a0a" xlink:href="bcrx-20250930.xsd#bcrx_RightOfUseAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_bcrx_RightOfUseAssetsNoncurrent_7bf5ea04-b71a-4abb-b03e-9f1d8fa21a0a" xlink:type="arc" order="102"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#IndividualsOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_A.MachelleSandersMember_4d15d2d5-2186-4faf-abc6-cf5a9f030575" xlink:href="bcrx-20250930.xsd#bcrx_A.MachelleSandersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_bcrx_A.MachelleSandersMember_4d15d2d5-2186-4faf-abc6-cf5a9f030575" xlink:type="arc" order="2"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>bcrx-20250930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:9a36bdce-1161-4cfc-8f27-e0c5ed23a9d7,g:923a909e-42f3-4f9e-a634-f93d4ee01684-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_bcrx_BerotralstatMember_5106cde0-cb2d-44cd-8ca3-2505051d573a_terseLabel_en-US" xlink:label="lab_bcrx_BerotralstatMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Berotralstat</link:label>
    <link:label id="lab_bcrx_BerotralstatMember_label_en-US" xlink:label="lab_bcrx_BerotralstatMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Berotralstat [Member]</link:label>
    <link:label id="lab_bcrx_BerotralstatMember_documentation_en-US" xlink:label="lab_bcrx_BerotralstatMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Berotralstat</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_BerotralstatMember" xlink:href="bcrx-20250930.xsd#bcrx_BerotralstatMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_BerotralstatMember" xlink:to="lab_bcrx_BerotralstatMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_cfcbb98e-2f8b-4c21-afcc-9648c06d1c40_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies and Concentrations of Risk</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_bdb6960a-c394-4af0-8c6b-ebaf883b8ecc_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_d64a0c28-eb27-49ce-b86a-8a40c33ea9c3_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_52fd239d-475c-45a4-9fdd-128e162eb26e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of the Company's Investments by Type</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_bf234d96-a5aa-4bae-a25b-412a7ca6aba6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025 (remaining)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_b288637a-d6d7-4fca-a3b6-80d33dabb8de_terseLabel_en-US" xlink:label="lab_bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee Operating Lease Liability To Be Paid After Year Four</link:label>
    <link:label id="lab_bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:href="bcrx-20250930.xsd#bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_be1d159d-bc1d-49a7-9043-3965daf6d99e_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_1d5b899f-1da7-461c-83f7-c3f3e2dfaee3_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_FinanceLeaseLiabilityToBePaidAfterYearFour_88b28bf8-cafc-4749-9926-f7863f346a93_terseLabel_en-US" xlink:label="lab_bcrx_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_bcrx_FinanceLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_bcrx_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, After Year Four</link:label>
    <link:label id="lab_bcrx_FinanceLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_bcrx_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:href="bcrx-20250930.xsd#bcrx_FinanceLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_bcrx_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_IncentivePlanMember_2a947601-a37e-49bd-8f2b-f725192848c8_terseLabel_en-US" xlink:label="lab_bcrx_IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Incentive Plan</link:label>
    <link:label id="lab_bcrx_IncentivePlanMember_label_en-US" xlink:label="lab_bcrx_IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incentive Plan [Member]</link:label>
    <link:label id="lab_bcrx_IncentivePlanMember_documentation_en-US" xlink:label="lab_bcrx_IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Incentive Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_IncentivePlanMember" xlink:href="bcrx-20250930.xsd#bcrx_IncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_IncentivePlanMember" xlink:to="lab_bcrx_IncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_86efb36d-848d-4f87-b28c-5b16d93c61e2_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recently Adopted Accounting Pronouncements And New Accounting Pronouncements Not Yet Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_d317ef5f-1add-4ba7-bb2d-dbec22593bcb_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) in accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_CollaborativeAndOtherResearchAndDevelopmentMember_0c66e307-7439-4b46-93ad-3fefb660e5a0_terseLabel_en-US" xlink:label="lab_bcrx_CollaborativeAndOtherResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative and other revenues</link:label>
    <link:label id="lab_bcrx_CollaborativeAndOtherResearchAndDevelopmentMember_label_en-US" xlink:label="lab_bcrx_CollaborativeAndOtherResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative and Other Research and Development [Member]</link:label>
    <link:label id="lab_bcrx_CollaborativeAndOtherResearchAndDevelopmentMember_documentation_en-US" xlink:label="lab_bcrx_CollaborativeAndOtherResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to Collaborative and other research and development.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_CollaborativeAndOtherResearchAndDevelopmentMember" xlink:href="bcrx-20250930.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_CollaborativeAndOtherResearchAndDevelopmentMember" xlink:to="lab_bcrx_CollaborativeAndOtherResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_23a2491b-0eef-4ab5-b019-5d28c706f26e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_ca9e22bb-2180-4c84-a6a1-3ec031856a02_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Shares withheld for taxes for vesting of restricted stock units</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b1b6f1d2-b52a-4c32-b113-f4271a4cd463_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_be6dea84-74f1-4b91-937a-c8a9af979eb5_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic net loss per common share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_27e29d63-6081-48f3-baa5-e2a1954d4074_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) per common share, basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_ba004f8b-3759-4158-a515-c7c6ab51842f_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_c3244152-8d38-43f0-bbdd-0857816eca77_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total shares reserved for future issuance</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_4e036b17-5a33-4dc9-bdc2-229bc3785178_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_afc3c4ab-e298-4c92-8959-25d35871ca9a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Disclosure [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_006e0f0b-0321-4553-bc22-0732e0422b72_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_44246625-5f6c-4c5e-815a-1deb169f7809_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan sales, net (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_EmployeeStockPurchasePlanMember_41ce7a16-3394-481b-924b-9ac6e4f2ad35_terseLabel_en-US" xlink:label="lab_bcrx_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_bcrx_EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_bcrx_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_bcrx_EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_bcrx_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan, (ESPP).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_EmployeeStockPurchasePlanMember" xlink:href="bcrx-20250930.xsd#bcrx_EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_EmployeeStockPurchasePlanMember" xlink:to="lab_bcrx_EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_9bc6f448-63c8-42b2-9270-da88a45c844c_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets held for sale</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_AnnualNetSalesOver550000Member_86cfc360-2605-425d-87a2-d76f0f47fba4_terseLabel_en-US" xlink:label="lab_bcrx_AnnualNetSalesOver550000Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual Net Sales Over $550,000</link:label>
    <link:label id="lab_bcrx_AnnualNetSalesOver550000Member_label_en-US" xlink:label="lab_bcrx_AnnualNetSalesOver550000Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Annual Net Sales Over $550,000 [Member]</link:label>
    <link:label id="lab_bcrx_AnnualNetSalesOver550000Member_documentation_en-US" xlink:label="lab_bcrx_AnnualNetSalesOver550000Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents annual net sales over $550,000.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesOver550000Member" xlink:href="bcrx-20250930.xsd#bcrx_AnnualNetSalesOver550000Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_AnnualNetSalesOver550000Member" xlink:to="lab_bcrx_AnnualNetSalesOver550000Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_44437dfa-4719-49dd-96c0-8471733b8e1a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_CompensationAndRelatedPersonnelCostsMember_ebcbfea7-9b7c-40ef-9061-a4a0bb7e13c6_terseLabel_en-US" xlink:label="lab_bcrx_CompensationAndRelatedPersonnelCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation and related personnel costs</link:label>
    <link:label id="lab_bcrx_CompensationAndRelatedPersonnelCostsMember_label_en-US" xlink:label="lab_bcrx_CompensationAndRelatedPersonnelCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation And Related Personnel Costs [Member]</link:label>
    <link:label id="lab_bcrx_CompensationAndRelatedPersonnelCostsMember_documentation_en-US" xlink:label="lab_bcrx_CompensationAndRelatedPersonnelCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Compensation And Related Personnel Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_CompensationAndRelatedPersonnelCostsMember" xlink:href="bcrx-20250930.xsd#bcrx_CompensationAndRelatedPersonnelCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_CompensationAndRelatedPersonnelCostsMember" xlink:to="lab_bcrx_CompensationAndRelatedPersonnelCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_f0f4be45-a885-4b10-85e5-e32a25c13516_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, unamortized discount (premium) and debt issuance costs, net, total</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_511a286d-22b1-4bb5-9222-472f553b3da6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_f058f8c8-24d5-4cf6-ba30-eab22059f038_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_86040977-b915-48af-9868-8cce5ef8e744_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_BioCrystIrelandMember_e50b825a-d674-4987-99fe-5c981e110557_terseLabel_en-US" xlink:label="lab_bcrx_BioCrystIrelandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BioCryst Ireland</link:label>
    <link:label id="lab_bcrx_BioCrystIrelandMember_label_en-US" xlink:label="lab_bcrx_BioCrystIrelandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BioCryst Ireland [Member]</link:label>
    <link:label id="lab_bcrx_BioCrystIrelandMember_documentation_en-US" xlink:label="lab_bcrx_BioCrystIrelandMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BioCryst Ireland</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_BioCrystIrelandMember" xlink:href="bcrx-20250930.xsd#bcrx_BioCrystIrelandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_BioCrystIrelandMember" xlink:to="lab_bcrx_BioCrystIrelandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_40f53908-a8d6-4ca5-b1fc-7bca60853e0f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_5b6e6bb0-180a-40f6-84c8-02bbb1c165c3_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_AthyriumMember_6fdfd93f-9f18-46b4-817d-cc95f2710092_terseLabel_en-US" xlink:label="lab_bcrx_AthyriumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Athyrium</link:label>
    <link:label id="lab_bcrx_AthyriumMember_label_en-US" xlink:label="lab_bcrx_AthyriumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Athyrium [Member]</link:label>
    <link:label id="lab_bcrx_AthyriumMember_documentation_en-US" xlink:label="lab_bcrx_AthyriumMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Athyrium Opportunities III Co-Invest 1 LP (&#8220;Athyrium&#8221;).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AthyriumMember" xlink:href="bcrx-20250930.xsd#bcrx_AthyriumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_AthyriumMember" xlink:to="lab_bcrx_AthyriumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_fa770b51-83f2-402d-9ed0-f1c7764d9990_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_37ae9303-2c71-4031-8d4c-2274fadde2e1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_ef97424f-a8af-4a81-86d8-f8f214fb5228_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade Receivables [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts and Financing Receivables [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7d3c4faf-75e1-4ceb-9fa4-268ce13cf7ba_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_RAPIVABMember_39a61463-74ec-471d-a2a3-6084323e155b_terseLabel_en-US" xlink:label="lab_bcrx_RAPIVABMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RAPIVAB</link:label>
    <link:label id="lab_bcrx_RAPIVABMember_label_en-US" xlink:label="lab_bcrx_RAPIVABMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">RAPIVAB [Member]</link:label>
    <link:label id="lab_bcrx_RAPIVABMember_documentation_en-US" xlink:label="lab_bcrx_RAPIVABMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents RAPIVAB product.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RAPIVABMember" xlink:href="bcrx-20250930.xsd#bcrx_RAPIVABMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_RAPIVABMember" xlink:to="lab_bcrx_RAPIVABMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice_88e2489a-0827-4cf6-acf9-29b15c57473c_terseLabel_en-US" xlink:label="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty purchase agreement, royalties, percentage of purchase price</link:label>
    <link:label id="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice_label_en-US" xlink:label="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Purchase Agreement Royalties Percentage Of Purchase Price</link:label>
    <link:label id="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice_documentation_en-US" xlink:label="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percentage of the purchase price under the royalty purchase agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice" xlink:to="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_f69c73bf-8d78-4065-a163-0d1668509676_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_dffbe327-13dd-45d0-9c6e-fef26c9b0a14_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_3ed9b9de-ccd9-4c2d-9088-370700a94f61_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_RoyaltyFinancingLiabilities_e4374194-1fd6-483c-88c5-d32872064f31_periodStartLabel_en-US" xlink:label="lab_bcrx_RoyaltyFinancingLiabilities" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_bcrx_RoyaltyFinancingLiabilities_e6c3617a-3199-4fad-b119-bc771e00e54b_periodEndLabel_en-US" xlink:label="lab_bcrx_RoyaltyFinancingLiabilities" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_bcrx_RoyaltyFinancingLiabilities_label_en-US" xlink:label="lab_bcrx_RoyaltyFinancingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Financing Liabilities</link:label>
    <link:label id="lab_bcrx_RoyaltyFinancingLiabilities_documentation_en-US" xlink:label="lab_bcrx_RoyaltyFinancingLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Financing Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyFinancingLiabilities" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltyFinancingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_RoyaltyFinancingLiabilities" xlink:to="lab_bcrx_RoyaltyFinancingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_b50966a6-2fcb-46a9-825d-940f2b6cde02_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_163f8ba1-eb6a-42a2-9d2d-80bcdb9ac39b_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total stock-based compensation costs included in operating expenses</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_8a373d9a-4373-47ab-a02a-4b1930ed533c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_cb4a024e-dcb4-4573-ada7-99fb3af904a0_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_40b4dc71-b23d-4d3c-83c8-2327d697fd1e_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_AnnualNetSalesRangeDomain_a46c9808-4c18-4853-af7b-d1f2730217d0_terseLabel_en-US" xlink:label="lab_bcrx_AnnualNetSalesRangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual Net Sales Range [Domain]</link:label>
    <link:label id="lab_bcrx_AnnualNetSalesRangeDomain_label_en-US" xlink:label="lab_bcrx_AnnualNetSalesRangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Annual Net Sales Range [Domain]</link:label>
    <link:label id="lab_bcrx_AnnualNetSalesRangeDomain_documentation_en-US" xlink:label="lab_bcrx_AnnualNetSalesRangeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Annual Net Sales Range</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesRangeDomain" xlink:href="bcrx-20250930.xsd#bcrx_AnnualNetSalesRangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_AnnualNetSalesRangeDomain" xlink:to="lab_bcrx_AnnualNetSalesRangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_65f18cbf-92b1-428c-b1ff-654e5f4340b7_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3807c8a4-46f5-43bc-bbe2-bac1ab2fe19a_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ec96797c-eb13-49fe-85c8-4cddc3fdbabf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_8bc77dd5-7171-49d2-9924-a3979955aa86_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_601a4feb-55ec-4131-bcf0-624ff598f832_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities and Stockholders&#8217; Deficit</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_801c972d-7361-4948-9913-962f775aac82_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets and Liabilities Held For Sale</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_b4941af4-2940-43a4-ac9e-5f299d382f64_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_94c04ed4-01b8-4ae6-a922-bb26f2c8fb06_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, stock option awards, exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_949b2eda-9b7d-47c3-984e-b76b3b08e116_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_3c2e71f1-e804-4893-be82-9d3d62402a27_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_FactorDProgramMember_444ab010-9254-452b-8191-c1be4574a68c_terseLabel_en-US" xlink:label="lab_bcrx_FactorDProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Factor D Program</link:label>
    <link:label id="lab_bcrx_FactorDProgramMember_label_en-US" xlink:label="lab_bcrx_FactorDProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Factor D Program [Member]</link:label>
    <link:label id="lab_bcrx_FactorDProgramMember_documentation_en-US" xlink:label="lab_bcrx_FactorDProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Factor D Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_FactorDProgramMember" xlink:href="bcrx-20250930.xsd#bcrx_FactorDProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_FactorDProgramMember" xlink:to="lab_bcrx_FactorDProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_242e47d0-063d-4449-8a0a-899a67e2a8db_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturities of Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_0c596cd5-e02e-4bdc-8536-f7ba55aeb5ab_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_0998254a-6686-499c-ab8e-9879048c45ea_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_10ded5ed-e2c3-496b-921d-aa0bbd4ac9b5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_8b876f65-385b-44ea-a4be-98d7ea76770b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_f0cb5e18-eee3-48c9-b6b5-6f24e0c482d3_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_349bda9c-6c70-43fc-ae38-1c690ca24b97_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_87a4e2b7-5c02-44e8-82f5-8593f1f5d476_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_37f75dc7-a38d-4a5f-99a6-08aceca3f5a2_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Obligations of U.S. Government and its agencies</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperationsLessAssetsHeldForSale_9abb037b-5485-4eff-9e65-9f7c7c25890e_negatedLabel_en-US" xlink:label="lab_bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperationsLessAssetsHeldForSale" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: cash and cash equivalents classified within current assets held for sale</link:label>
    <link:label id="lab_bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperationsLessAssetsHeldForSale_label_en-US" xlink:label="lab_bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperationsLessAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect, Continuing Operations, Less Assets Held For Sale</link:label>
    <link:label id="lab_bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperationsLessAssetsHeldForSale_documentation_en-US" xlink:label="lab_bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperationsLessAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect, Continuing Operations, Less Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperationsLessAssetsHeldForSale" xlink:href="bcrx-20250930.xsd#bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperationsLessAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperationsLessAssetsHeldForSale" xlink:to="lab_bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperationsLessAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_4f647f32-9bc6-4736-9962-8bb0a4a8d383_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_bd195e93-a2bf-4dc6-bd17-4f8fc5e457a3_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of shares to directors in lieu of cash retainer (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_0c08d7a0-5784-42b9-a612-f5b15154ed5f_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest_239c124e-9322-4e8e-9757-708c85d00d03_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Periodic payment, interest</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Periodic Payment, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_55f3e524-e56e-4865-b932-ff92c3f16228_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of right-of-use assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_PharmakonAdvisorsLPMember_7e698aeb-c894-4cf0-b4fb-3d3d9cd9648a_terseLabel_en-US" xlink:label="lab_bcrx_PharmakonAdvisorsLPMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pharmakon Advisors, LP</link:label>
    <link:label id="lab_bcrx_PharmakonAdvisorsLPMember_label_en-US" xlink:label="lab_bcrx_PharmakonAdvisorsLPMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pharmakon Advisors, LP [Member]</link:label>
    <link:label id="lab_bcrx_PharmakonAdvisorsLPMember_documentation_en-US" xlink:label="lab_bcrx_PharmakonAdvisorsLPMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pharmakon Advisors, LP</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_PharmakonAdvisorsLPMember" xlink:href="bcrx-20250930.xsd#bcrx_PharmakonAdvisorsLPMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_PharmakonAdvisorsLPMember" xlink:to="lab_bcrx_PharmakonAdvisorsLPMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f1d40b02-a51c-4844-bebd-ccd79351d196_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income (loss) before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_c08ba3d5-d16f-45a3-acde-1e805223639f_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current liabilities held for sale</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_1d48156d-0c3f-470c-9569-fc3d84c36ff1_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_294703e2-6797-4aa0-903a-e7180b783b76_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_587901d7-2acd-42a4-a32a-97470313bccd_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount_5ec054fa-f5fb-4663-a756-6f7e274cf191_terseLabel_en-US" xlink:label="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty purchase agreement, royalties, purchase price, amount</link:label>
    <link:label id="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount_label_en-US" xlink:label="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Purchase Agreement Royalties Purchase Price Amount</link:label>
    <link:label id="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount_documentation_en-US" xlink:label="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of the purchase price under the royalty purchase agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount" xlink:to="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_PikInterestPaymentIsMadeMember_1346569b-1b62-4b81-8e5d-b6336f4602e0_terseLabel_en-US" xlink:label="lab_bcrx_PikInterestPaymentIsMadeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PIK Interest Payment is Made</link:label>
    <link:label id="lab_bcrx_PikInterestPaymentIsMadeMember_label_en-US" xlink:label="lab_bcrx_PikInterestPaymentIsMadeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PIK Interest Payment is Made [Member]</link:label>
    <link:label id="lab_bcrx_PikInterestPaymentIsMadeMember_documentation_en-US" xlink:label="lab_bcrx_PikInterestPaymentIsMadeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents PIK interest payment is made.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_PikInterestPaymentIsMadeMember" xlink:href="bcrx-20250930.xsd#bcrx_PikInterestPaymentIsMadeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_PikInterestPaymentIsMadeMember" xlink:to="lab_bcrx_PikInterestPaymentIsMadeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_753b94fd-3af7-486c-81d3-d4c34aeb4049_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_9e7c2169-604d-4e75-bf07-91b3ba3a5dc1_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized stock-based compensation costs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Amount Capitalized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_PotentialMilestonePaymentsPayableIfRegulatoryApprovalBeforeMilestone_a1c361c0-bf6d-4949-a6f4-43b205cfb892_terseLabel_en-US" xlink:label="lab_bcrx_PotentialMilestonePaymentsPayableIfRegulatoryApprovalBeforeMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential payment if milestone reached</link:label>
    <link:label id="lab_bcrx_PotentialMilestonePaymentsPayableIfRegulatoryApprovalBeforeMilestone_label_en-US" xlink:label="lab_bcrx_PotentialMilestonePaymentsPayableIfRegulatoryApprovalBeforeMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Milestone Payments Payable If Regulatory Approval Before Milestone</link:label>
    <link:label id="lab_bcrx_PotentialMilestonePaymentsPayableIfRegulatoryApprovalBeforeMilestone_documentation_en-US" xlink:label="lab_bcrx_PotentialMilestonePaymentsPayableIfRegulatoryApprovalBeforeMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Potential Milestone Payments Payable If Regulatory Approval Before Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_PotentialMilestonePaymentsPayableIfRegulatoryApprovalBeforeMilestone" xlink:href="bcrx-20250930.xsd#bcrx_PotentialMilestonePaymentsPayableIfRegulatoryApprovalBeforeMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_PotentialMilestonePaymentsPayableIfRegulatoryApprovalBeforeMilestone" xlink:to="lab_bcrx_PotentialMilestonePaymentsPayableIfRegulatoryApprovalBeforeMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_LicenseAgreementAnnualGlobalNetSales_1e606e7f-8ebf-4305-a268-d8f7cc5ee015_terseLabel_en-US" xlink:label="lab_bcrx_LicenseAgreementAnnualGlobalNetSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual global net sales</link:label>
    <link:label id="lab_bcrx_LicenseAgreementAnnualGlobalNetSales_label_en-US" xlink:label="lab_bcrx_LicenseAgreementAnnualGlobalNetSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement, Annual Global Net Sales</link:label>
    <link:label id="lab_bcrx_LicenseAgreementAnnualGlobalNetSales_documentation_en-US" xlink:label="lab_bcrx_LicenseAgreementAnnualGlobalNetSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Agreement, Annual Global Net Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_LicenseAgreementAnnualGlobalNetSales" xlink:href="bcrx-20250930.xsd#bcrx_LicenseAgreementAnnualGlobalNetSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_LicenseAgreementAnnualGlobalNetSales" xlink:to="lab_bcrx_LicenseAgreementAnnualGlobalNetSales" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable_7a2d8f94-c0b9-40eb-89ac-97a8936c59a5_terseLabel_en-US" xlink:label="lab_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies and Concentrations of Risk [Table]</link:label>
    <link:label id="lab_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable_label_en-US" xlink:label="lab_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies and Concentrations of Risk [Table]</link:label>
    <link:label id="lab_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable_documentation_en-US" xlink:label="lab_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies and Concentrations of Risk</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable" xlink:href="bcrx-20250930.xsd#bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable" xlink:to="lab_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_ea2be179-583b-47a1-9ab3-a3f9a883681c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8774db67-60cb-4a17-9f2d-a97970a6a913_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_LongTermInvestmentMaturityMinimum_95865876-2cfa-4fd3-a46b-bbb2789e39f7_terseLabel_en-US" xlink:label="lab_bcrx_LongTermInvestmentMaturityMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term investment maturity, minimum (in years)</link:label>
    <link:label id="lab_bcrx_LongTermInvestmentMaturityMinimum_label_en-US" xlink:label="lab_bcrx_LongTermInvestmentMaturityMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long term Investment Maturity Minimum</link:label>
    <link:label id="lab_bcrx_LongTermInvestmentMaturityMinimum_documentation_en-US" xlink:label="lab_bcrx_LongTermInvestmentMaturityMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents long term investment maturity minimum.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_LongTermInvestmentMaturityMinimum" xlink:href="bcrx-20250930.xsd#bcrx_LongTermInvestmentMaturityMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_LongTermInvestmentMaturityMinimum" xlink:to="lab_bcrx_LongTermInvestmentMaturityMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_TermLoanTrancheCMember_83168fbd-3b4e-4073-a139-195a0158fc34_terseLabel_en-US" xlink:label="lab_bcrx_TermLoanTrancheCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term Loan Tranche C</link:label>
    <link:label id="lab_bcrx_TermLoanTrancheCMember_label_en-US" xlink:label="lab_bcrx_TermLoanTrancheCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Loan Tranche C [Member]</link:label>
    <link:label id="lab_bcrx_TermLoanTrancheCMember_documentation_en-US" xlink:label="lab_bcrx_TermLoanTrancheCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term Loan Tranche C</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_TermLoanTrancheCMember" xlink:href="bcrx-20250930.xsd#bcrx_TermLoanTrancheCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_TermLoanTrancheCMember" xlink:to="lab_bcrx_TermLoanTrancheCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_947f7997-1e64-43f3-8f5a-fa7fb8ef9238_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_afe2a017-0dde-4cd6-a11a-ee671d2d02b3_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_1a775148-f909-4f27-a0dd-414550fbf124_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturing in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_ed2e9e82-64ec-4324-b591-519e67270961_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_31e8eb97-80df-493d-9e07-ad09163aacea_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_41eb05fa-d0dc-46d6-9372-94717cdacd83_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest on lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_ce44e413-2daf-4280-93b9-806678b354d2_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_c5e34e86-7199-4256-9a5e-ed8d362a9617_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade Receivables</link:label>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:to="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_04044498-d5f2-4a7c-89a7-fe297cff844b_terseLabel_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unsecured Debt</link:label>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unsecured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnsecuredDebtMember" xlink:to="lab_us-gaap_UnsecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements_a2ada240-5c5f-420a-8607-35a93fc337dd_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unvested restricted stock unit awards (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Equity Unit Purchase Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_f10b03ce-bce1-4957-a709-f9b02dbd983c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_1f3c6308-012c-4a34-81ce-0f9769b98754_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_81ca4957-8c47-4716-9387-c45c55fad2bb_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales_4349ed59-12c2-422a-811b-3865d4dd5302_terseLabel_en-US" xlink:label="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty purchase agreement, royalties, percentage of annual net sales, based on reduction in sales</link:label>
    <link:label id="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales_label_en-US" xlink:label="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Purchase Agreement Royalties Percentage Of Annual Net Sales Based On Reduction In Sales</link:label>
    <link:label id="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales_documentation_en-US" xlink:label="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">he percentage of annual net sales of royalties to be paid under the royalty purchase agreement if sales are less than specified.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales" xlink:to="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock_de9bebc3-b984-4dbd-bc00-3983ac63c1e2_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments and Other Noncurrent Assets [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock" xlink:to="lab_us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_cc85c5b1-493d-4dc3-9832-448e96d922af_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_4ab2cb3d-2622-4fe5-88a9-a42554d78a00_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_DisposalGroupIncludingDiscontinuedOperationConsiderationRoyaltyReleaseFee_5e0eaf34-2f92-47e4-a8de-c6ae8253362b_terseLabel_en-US" xlink:label="lab_bcrx_DisposalGroupIncludingDiscontinuedOperationConsiderationRoyaltyReleaseFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty release fee</link:label>
    <link:label id="lab_bcrx_DisposalGroupIncludingDiscontinuedOperationConsiderationRoyaltyReleaseFee_label_en-US" xlink:label="lab_bcrx_DisposalGroupIncludingDiscontinuedOperationConsiderationRoyaltyReleaseFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration, Royalty Release Fee</link:label>
    <link:label id="lab_bcrx_DisposalGroupIncludingDiscontinuedOperationConsiderationRoyaltyReleaseFee_documentation_en-US" xlink:label="lab_bcrx_DisposalGroupIncludingDiscontinuedOperationConsiderationRoyaltyReleaseFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration, Royalty Release Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DisposalGroupIncludingDiscontinuedOperationConsiderationRoyaltyReleaseFee" xlink:href="bcrx-20250930.xsd#bcrx_DisposalGroupIncludingDiscontinuedOperationConsiderationRoyaltyReleaseFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_DisposalGroupIncludingDiscontinuedOperationConsiderationRoyaltyReleaseFee" xlink:to="lab_bcrx_DisposalGroupIncludingDiscontinuedOperationConsiderationRoyaltyReleaseFee" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_b3fb8cb4-36af-478e-8942-a0f502d574da_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_f056107f-8f8f-487d-b34b-35896f31d42d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9badd0d6-2656-410e-8f25-d67c3ebd7848_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units, vested in period, weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_8e74762e-5234-489c-90e0-e98ccbe89f61_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_RepaymentOfRoyaltyFinancingLiabilitiesPrincipal_342cec68-d024-417d-809f-020841db138a_negatedTerseLabel_en-US" xlink:label="lab_bcrx_RepaymentOfRoyaltyFinancingLiabilitiesPrincipal" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Principal payments on royalty financing obligations</link:label>
    <link:label id="lab_bcrx_RepaymentOfRoyaltyFinancingLiabilitiesPrincipal_label_en-US" xlink:label="lab_bcrx_RepaymentOfRoyaltyFinancingLiabilitiesPrincipal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayment Of Royalty Financing Liabilities, Principal</link:label>
    <link:label id="lab_bcrx_RepaymentOfRoyaltyFinancingLiabilitiesPrincipal_documentation_en-US" xlink:label="lab_bcrx_RepaymentOfRoyaltyFinancingLiabilitiesPrincipal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Repayment Of Royalty Financing Liabilities, Principal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RepaymentOfRoyaltyFinancingLiabilitiesPrincipal" xlink:href="bcrx-20250930.xsd#bcrx_RepaymentOfRoyaltyFinancingLiabilitiesPrincipal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_RepaymentOfRoyaltyFinancingLiabilitiesPrincipal" xlink:to="lab_bcrx_RepaymentOfRoyaltyFinancingLiabilitiesPrincipal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseLongTermDebt_30abd2b8-2777-40b5-a1d8-5755e6220e4e_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseLongTermDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseLongTermDebt" xlink:to="lab_us-gaap_InterestExpenseLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_cd2068f5-4951-4402-a77f-cafe9dc371ca_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_a3a80276-916e-4da6-9818-9bf20eb67568_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2eb24289-2946-4031-8b26-319e8616231a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_a2c67c12-b315-4e6a-9458-1c0a2b9613d1_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_14828380-f325-4566-bb61-7daa647c3491_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_label_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesLineItems_db6ed490-d060-48f1-ab1c-a5bdaba6bfdc_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities [Line Items]</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems" xlink:to="lab_us-gaap_MarketableSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_BCX17725Member_7d8083e6-3c78-459d-9b3e-e66dd5f603d1_terseLabel_en-US" xlink:label="lab_bcrx_BCX17725Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BCX17725</link:label>
    <link:label id="lab_bcrx_BCX17725Member_label_en-US" xlink:label="lab_bcrx_BCX17725Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BCX17725 [Member]</link:label>
    <link:label id="lab_bcrx_BCX17725Member_documentation_en-US" xlink:label="lab_bcrx_BCX17725Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BCX17725</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_BCX17725Member" xlink:href="bcrx-20250930.xsd#bcrx_BCX17725Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_BCX17725Member" xlink:to="lab_bcrx_BCX17725Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ed9e1481-48bf-4a5c-83b9-ba7107ef73f1_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rates on cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_0270345e-2479-46cd-a1e5-ed415210b57a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_c9761828-4c3a-4ac8-a336-9f71a2b49e65_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_716286be-f6a8-4f30-b291-fbd34f863a29_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unvested restricted stock unit awards</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_AnnualNetSalesBetween150000And230000Member_32576880-4853-4086-adab-085238f7de4b_terseLabel_en-US" xlink:label="lab_bcrx_AnnualNetSalesBetween150000And230000Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual Net Sales Between $150,000 and $230,000</link:label>
    <link:label id="lab_bcrx_AnnualNetSalesBetween150000And230000Member_label_en-US" xlink:label="lab_bcrx_AnnualNetSalesBetween150000And230000Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Annual Net Sales Between $150,000 and $230,000 [Member]</link:label>
    <link:label id="lab_bcrx_AnnualNetSalesBetween150000And230000Member_documentation_en-US" xlink:label="lab_bcrx_AnnualNetSalesBetween150000And230000Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents annual net sales between $150,000 and $230,000.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesBetween150000And230000Member" xlink:href="bcrx-20250930.xsd#bcrx_AnnualNetSalesBetween150000And230000Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_AnnualNetSalesBetween150000And230000Member" xlink:to="lab_bcrx_AnnualNetSalesBetween150000And230000Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_LicenseAgreementRoyaltyPaymentNumberOfTiers_d9e66c89-338c-4b19-aa47-605d51cffb9c_terseLabel_en-US" xlink:label="lab_bcrx_LicenseAgreementRoyaltyPaymentNumberOfTiers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of royalties tiers</link:label>
    <link:label id="lab_bcrx_LicenseAgreementRoyaltyPaymentNumberOfTiers_label_en-US" xlink:label="lab_bcrx_LicenseAgreementRoyaltyPaymentNumberOfTiers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement, Royalty Payment, Number of Tiers</link:label>
    <link:label id="lab_bcrx_LicenseAgreementRoyaltyPaymentNumberOfTiers_documentation_en-US" xlink:label="lab_bcrx_LicenseAgreementRoyaltyPaymentNumberOfTiers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Agreement, Royalty Payment, Number of Tiers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_LicenseAgreementRoyaltyPaymentNumberOfTiers" xlink:href="bcrx-20250930.xsd#bcrx_LicenseAgreementRoyaltyPaymentNumberOfTiers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_LicenseAgreementRoyaltyPaymentNumberOfTiers" xlink:to="lab_bcrx_LicenseAgreementRoyaltyPaymentNumberOfTiers" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_CollateralForCreditMember_6ef78f60-4887-477b-8529-c30c555c83c8_terseLabel_en-US" xlink:label="lab_bcrx_CollateralForCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collateral for Credit</link:label>
    <link:label id="lab_bcrx_CollateralForCreditMember_label_en-US" xlink:label="lab_bcrx_CollateralForCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collateral for Credit [Member]</link:label>
    <link:label id="lab_bcrx_CollateralForCreditMember_documentation_en-US" xlink:label="lab_bcrx_CollateralForCreditMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted cash and cash equivalents required to maintain as collateral for a letter of credit.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_CollateralForCreditMember" xlink:href="bcrx-20250930.xsd#bcrx_CollateralForCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_CollateralForCreditMember" xlink:to="lab_bcrx_CollateralForCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_e69fcabf-691c-4e6f-9d27-ed31a56d4332_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_09c612f1-228f-4983-ab14-73c08f869b12_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_73458bdd-b82f-4a30-b462-fcb464afc49e_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesTextBlock_699bba84-ad0c-4dc5-9971-ef3634e6c176_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of the Maturity of Investments</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Held-to-Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HeldToMaturitySecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_ed768972-c161-4703-b06d-1dff26a5106e_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease assets obtained in exchange for operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_7e7864fa-15e1-45b2-ba36-69d8fbf11a43_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining lease term (in years)</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_fbcd6c70-2d08-4d69-b5f2-ea250d6cb62e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Options outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ad542709-8790-4f8a-955c-74465e655020_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Options outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_32439cfe-9b7b-4bf4-ae45-a4af5844814e_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayments of lines of credit</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLinesOfCredit" xlink:to="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_OtherIncomeFromContractWithCustomerMember_3363e603-80b9-49e1-94c6-9d2a59ee3574_terseLabel_en-US" xlink:label="lab_bcrx_OtherIncomeFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other revenues</link:label>
    <link:label id="lab_bcrx_OtherIncomeFromContractWithCustomerMember_label_en-US" xlink:label="lab_bcrx_OtherIncomeFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Income From Contract With Customer [Member]</link:label>
    <link:label id="lab_bcrx_OtherIncomeFromContractWithCustomerMember_documentation_en-US" xlink:label="lab_bcrx_OtherIncomeFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Income From Contract With Customer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_OtherIncomeFromContractWithCustomerMember" xlink:href="bcrx-20250930.xsd#bcrx_OtherIncomeFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_OtherIncomeFromContractWithCustomerMember" xlink:to="lab_bcrx_OtherIncomeFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_a5d80f41-1794-4119-911a-19e74d0f4ac8_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_2c27377b-362a-4588-b652-83df4af08221_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_37308ff2-59ae-4011-8502-1c36a2a2a31c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_3148916f-fc8a-45aa-8cdd-165ed47a8643_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt fees</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fee Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFeeAmount" xlink:to="lab_us-gaap_DebtInstrumentFeeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_IncrementalCommonSharesAttributableToDilutiveEffectOfSharePurchasePlans_39975198-9639-4142-a899-725ed09c83c4_terseLabel_en-US" xlink:label="lab_bcrx_IncrementalCommonSharesAttributableToDilutiveEffectOfSharePurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issuable under the employee stock purchase plan</link:label>
    <link:label id="lab_bcrx_IncrementalCommonSharesAttributableToDilutiveEffectOfSharePurchasePlans_label_en-US" xlink:label="lab_bcrx_IncrementalCommonSharesAttributableToDilutiveEffectOfSharePurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable To Dilutive Effect Of Share Purchase Plans</link:label>
    <link:label id="lab_bcrx_IncrementalCommonSharesAttributableToDilutiveEffectOfSharePurchasePlans_documentation_en-US" xlink:label="lab_bcrx_IncrementalCommonSharesAttributableToDilutiveEffectOfSharePurchasePlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable To Dilutive Effect Of Share Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_IncrementalCommonSharesAttributableToDilutiveEffectOfSharePurchasePlans" xlink:href="bcrx-20250930.xsd#bcrx_IncrementalCommonSharesAttributableToDilutiveEffectOfSharePurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_IncrementalCommonSharesAttributableToDilutiveEffectOfSharePurchasePlans" xlink:to="lab_bcrx_IncrementalCommonSharesAttributableToDilutiveEffectOfSharePurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7bc9fa2b-cdb0-479f-a8c1-1f43007a566d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_a4198f9e-9fbe-4412-9548-f767e53904cc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less imputed interest</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_DescriptionOfCompanyPolicyTextBlock_23c14a95-59bc-47cc-92be-9380aba9ed7b_terseLabel_en-US" xlink:label="lab_bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">The Company</link:label>
    <link:label id="lab_bcrx_DescriptionOfCompanyPolicyTextBlock_label_en-US" xlink:label="lab_bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of Company [Policy Text Block]</link:label>
    <link:label id="lab_bcrx_DescriptionOfCompanyPolicyTextBlock_documentation_en-US" xlink:label="lab_bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The description of company policy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:href="bcrx-20250930.xsd#bcrx_DescriptionOfCompanyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:to="lab_bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_ecbe0b38-1cb8-4bf9-8325-10d860e9b1f0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_aa6ae165-92b2-43aa-981a-229942484539_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_cf713253-f1ef-4262-8bae-070237b2b768_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfOtherAssets_3f1593e1-ca75-47dc-8279-583f3abbadf0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gain on sale of non-financial asset</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfOtherAssets_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfOtherAssets" xlink:to="lab_us-gaap_GainLossOnSaleOfOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_TradeReceivablesTextBlock_582cd6b7-91bd-4521-9106-f6c9e0e0ac8b_terseLabel_en-US" xlink:label="lab_bcrx_TradeReceivablesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade Receivables</link:label>
    <link:label id="lab_bcrx_TradeReceivablesTextBlock_label_en-US" xlink:label="lab_bcrx_TradeReceivablesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade Receivables [Text Block]</link:label>
    <link:label id="lab_bcrx_TradeReceivablesTextBlock_documentation_en-US" xlink:label="lab_bcrx_TradeReceivablesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure for trade receivables.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_TradeReceivablesTextBlock" xlink:href="bcrx-20250930.xsd#bcrx_TradeReceivablesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_TradeReceivablesTextBlock" xlink:to="lab_bcrx_TradeReceivablesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_e869e466-f380-48ba-979e-ea80dbfd99c5_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_62a203ee-83f5-46e5-8ad4-2b5c415e4082_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_RoyaltyFinancingLiabilitiesTextBlock_b205d92b-973b-4f98-ab6e-88c9f3a58ada_terseLabel_en-US" xlink:label="lab_bcrx_RoyaltyFinancingLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Financing Obligations</link:label>
    <link:label id="lab_bcrx_RoyaltyFinancingLiabilitiesTextBlock_label_en-US" xlink:label="lab_bcrx_RoyaltyFinancingLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Financing Liabilities [Text Block]</link:label>
    <link:label id="lab_bcrx_RoyaltyFinancingLiabilitiesTextBlock_documentation_en-US" xlink:label="lab_bcrx_RoyaltyFinancingLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty monetization.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyFinancingLiabilitiesTextBlock" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltyFinancingLiabilitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_RoyaltyFinancingLiabilitiesTextBlock" xlink:to="lab_bcrx_RoyaltyFinancingLiabilitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_c4622eb3-b6f9-4b32-8261-07049f2b66a8_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Revenues</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_06c031a0-5234-445e-a089-0e490d5856fa_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_af03bb4b-efce-47d3-a705-cbf5bfe07598_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_PaymentsForPaidInKindInterest_f0ee48a7-deba-497e-9f4f-eef130172f5f_negatedTerseLabel_en-US" xlink:label="lab_bcrx_PaymentsForPaidInKindInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of Pharmakon PIK Interest</link:label>
    <link:label id="lab_bcrx_PaymentsForPaidInKindInterest_label_en-US" xlink:label="lab_bcrx_PaymentsForPaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments For Paid-In-Kind Interest</link:label>
    <link:label id="lab_bcrx_PaymentsForPaidInKindInterest_documentation_en-US" xlink:label="lab_bcrx_PaymentsForPaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments For Paid-In-Kind Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_PaymentsForPaidInKindInterest" xlink:href="bcrx-20250930.xsd#bcrx_PaymentsForPaidInKindInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_PaymentsForPaidInKindInterest" xlink:to="lab_bcrx_PaymentsForPaidInKindInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_66dd605e-a4fb-4e80-9574-872613174890_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected Life in Years</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeographicDistributionForeignMember_f0c746a7-dae9-4904-8ca0-cb96b5213559_terseLabel_en-US" xlink:label="lab_us-gaap_GeographicDistributionForeignMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outside of U.S.</link:label>
    <link:label id="lab_us-gaap_GeographicDistributionForeignMember_label_en-US" xlink:label="lab_us-gaap_GeographicDistributionForeignMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographic Distribution, Foreign [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicDistributionForeignMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeographicDistributionForeignMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeographicDistributionForeignMember" xlink:to="lab_us-gaap_GeographicDistributionForeignMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_f3302bc5-5c62-46fa-8112-496183e9432d_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9f75701d-840e-4f10-a01e-8ada4010890c_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_02de8222-1597-4604-a256-a24decc48922_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_4217fa97-2a47-4781-9809-0671b6c07e54_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_6e64e545-f8ad-4d56-a836-003a9288feb6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_92d3be33-4264-4349-8d3b-4cbef3fc2e5c_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_ef16bd15-6326-462b-94c5-6be4d644c918_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_87191e57-f8f2-429f-ac86-c97af3cfb33c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_FinancingLeaseExpense_ed44be30-18a9-44c8-ac19-5a3da45bd8c5_totalLabel_en-US" xlink:label="lab_bcrx_FinancingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total finance lease expense</link:label>
    <link:label id="lab_bcrx_FinancingLeaseExpense_label_en-US" xlink:label="lab_bcrx_FinancingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financing Lease, Expense</link:label>
    <link:label id="lab_bcrx_FinancingLeaseExpense_documentation_en-US" xlink:label="lab_bcrx_FinancingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financing Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_FinancingLeaseExpense" xlink:href="bcrx-20250930.xsd#bcrx_FinancingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_FinancingLeaseExpense" xlink:to="lab_bcrx_FinancingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_69476e9b-7024-40d3-8135-0d2b895a4062_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_InterestExpenseDeferredFinancingCostsAndRoyaltyFinancingLiabilitiesPolicyTextBlock_25e4c5ab-7261-4534-a940-23740e90cf93_terseLabel_en-US" xlink:label="lab_bcrx_InterestExpenseDeferredFinancingCostsAndRoyaltyFinancingLiabilitiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Expense, Deferred Financing Costs and Royalty Financing Obligations</link:label>
    <link:label id="lab_bcrx_InterestExpenseDeferredFinancingCostsAndRoyaltyFinancingLiabilitiesPolicyTextBlock_label_en-US" xlink:label="lab_bcrx_InterestExpenseDeferredFinancingCostsAndRoyaltyFinancingLiabilitiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Deferred Financing Costs, and Royalty Financing Liabilities [Policy Text Block]</link:label>
    <link:label id="lab_bcrx_InterestExpenseDeferredFinancingCostsAndRoyaltyFinancingLiabilitiesPolicyTextBlock_documentation_en-US" xlink:label="lab_bcrx_InterestExpenseDeferredFinancingCostsAndRoyaltyFinancingLiabilitiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for interest expense and royalty financing obligation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_InterestExpenseDeferredFinancingCostsAndRoyaltyFinancingLiabilitiesPolicyTextBlock" xlink:href="bcrx-20250930.xsd#bcrx_InterestExpenseDeferredFinancingCostsAndRoyaltyFinancingLiabilitiesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_InterestExpenseDeferredFinancingCostsAndRoyaltyFinancingLiabilitiesPolicyTextBlock" xlink:to="lab_bcrx_InterestExpenseDeferredFinancingCostsAndRoyaltyFinancingLiabilitiesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_932a48d0-9ed0-4f9a-8d3d-beff1ce30c89_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_32bf8e59-c824-4ca3-b666-53e2e367ef2f_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_a92375a7-74eb-4dcc-a552-304d1c4e8460_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_CashCashEquivalentsShortAndLongTermInvestments_6c35c32c-bc2c-48b8-a6c8-1c473db7c44f_terseLabel_en-US" xlink:label="lab_bcrx_CashCashEquivalentsShortAndLongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and investments</link:label>
    <link:label id="lab_bcrx_CashCashEquivalentsShortAndLongTermInvestments_label_en-US" xlink:label="lab_bcrx_CashCashEquivalentsShortAndLongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Short and Long-Term Investments</link:label>
    <link:label id="lab_bcrx_CashCashEquivalentsShortAndLongTermInvestments_documentation_en-US" xlink:label="lab_bcrx_CashCashEquivalentsShortAndLongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Short and Long-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_CashCashEquivalentsShortAndLongTermInvestments" xlink:href="bcrx-20250930.xsd#bcrx_CashCashEquivalentsShortAndLongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_CashCashEquivalentsShortAndLongTermInvestments" xlink:to="lab_bcrx_CashCashEquivalentsShortAndLongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_9516c289-77fb-4e45-9374-c8963b1794ac_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_TwentyTwentyOneRPIRoyaltyAgreementMember_d59b707d-4976-413c-9d62-01040ff5f5a9_terseLabel_en-US" xlink:label="lab_bcrx_TwentyTwentyOneRPIRoyaltyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021 RPI Royalty Agreement</link:label>
    <link:label id="lab_bcrx_TwentyTwentyOneRPIRoyaltyAgreementMember_label_en-US" xlink:label="lab_bcrx_TwentyTwentyOneRPIRoyaltyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2021 RPI Royalty Agreement [Member]</link:label>
    <link:label id="lab_bcrx_TwentyTwentyOneRPIRoyaltyAgreementMember_documentation_en-US" xlink:label="lab_bcrx_TwentyTwentyOneRPIRoyaltyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information on 2021 RPI Royalty Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_TwentyTwentyOneRPIRoyaltyAgreementMember" xlink:href="bcrx-20250930.xsd#bcrx_TwentyTwentyOneRPIRoyaltyAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_TwentyTwentyOneRPIRoyaltyAgreementMember" xlink:to="lab_bcrx_TwentyTwentyOneRPIRoyaltyAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_PeramivirMember_1a9d97fb-873b-4bf6-a3f0-76bc597b521b_terseLabel_en-US" xlink:label="lab_bcrx_PeramivirMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peramivir</link:label>
    <link:label id="lab_bcrx_PeramivirMember_label_en-US" xlink:label="lab_bcrx_PeramivirMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peramivir [Member]</link:label>
    <link:label id="lab_bcrx_PeramivirMember_documentation_en-US" xlink:label="lab_bcrx_PeramivirMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Peramivir</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_PeramivirMember" xlink:href="bcrx-20250930.xsd#bcrx_PeramivirMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_PeramivirMember" xlink:to="lab_bcrx_PeramivirMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_61d0eb93-0ffd-4e27-8dad-1a3cdff4e04c_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromCollaborators_22de0813-dc0a-40da-b8a7-f8dc9e5cbf83_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromCollaborators" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from collaborators</link:label>
    <link:label id="lab_us-gaap_ProceedsFromCollaborators_label_en-US" xlink:label="lab_us-gaap_ProceedsFromCollaborators" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Collaborators</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromCollaborators" xlink:to="lab_us-gaap_ProceedsFromCollaborators" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_UnamortizedDeferredFinancingCosts_4f28572d-8c6b-4f17-b63f-17a4709c140b_terseLabel_en-US" xlink:label="lab_bcrx_UnamortizedDeferredFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unamortized deferred financing costs</link:label>
    <link:label id="lab_bcrx_UnamortizedDeferredFinancingCosts_label_en-US" xlink:label="lab_bcrx_UnamortizedDeferredFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unamortized Deferred Financing Costs</link:label>
    <link:label id="lab_bcrx_UnamortizedDeferredFinancingCosts_documentation_en-US" xlink:label="lab_bcrx_UnamortizedDeferredFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unamortized Deferred Financing Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_UnamortizedDeferredFinancingCosts" xlink:href="bcrx-20250930.xsd#bcrx_UnamortizedDeferredFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_UnamortizedDeferredFinancingCosts" xlink:to="lab_bcrx_UnamortizedDeferredFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_ae0f7ea2-9924-40d1-96a7-6686cec45557_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses_3ffb4156-df98-4c30-87b2-de7899b38ded_terseLabel_en-US" xlink:label="lab_bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of doses permitted to be procured</link:label>
    <link:label id="lab_bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses_label_en-US" xlink:label="lab_bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Number Of Products Permitted To Be Obtained, Doses</link:label>
    <link:label id="lab_bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses_documentation_en-US" xlink:label="lab_bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum Number Of Products Permitted To Be Obtained, Doses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses" xlink:href="bcrx-20250930.xsd#bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses" xlink:to="lab_bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_14889322-d925-4ded-a0f7-f850df7c2db3_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Unvested RSU beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9e278352-68ca-4f1c-915a-b213df02c98a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Unvested RSU ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_97a4f0d4-8c56-49b5-b230-3484100cd21d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity of Counterparty, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_label_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity of Counterparty, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9c276877-071a-4ca3-b9d1-c71e7e0cabba_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_772582ff-1803-4ff2-838e-f2ae71ad5c12_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_LicenseAgreementNumberOfMilestonePayments_dc7b8ff0-81ad-436d-8028-7477cce699d2_terseLabel_en-US" xlink:label="lab_bcrx_LicenseAgreementNumberOfMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of milestone payments</link:label>
    <link:label id="lab_bcrx_LicenseAgreementNumberOfMilestonePayments_label_en-US" xlink:label="lab_bcrx_LicenseAgreementNumberOfMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement, Number of Milestone Payments</link:label>
    <link:label id="lab_bcrx_LicenseAgreementNumberOfMilestonePayments_documentation_en-US" xlink:label="lab_bcrx_LicenseAgreementNumberOfMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Agreement, Number of Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_LicenseAgreementNumberOfMilestonePayments" xlink:href="bcrx-20250930.xsd#bcrx_LicenseAgreementNumberOfMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_LicenseAgreementNumberOfMilestonePayments" xlink:to="lab_bcrx_LicenseAgreementNumberOfMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_AnnualNetSalesBetween350000And550000Member_c94af70e-6955-4baf-b060-87288d6241a6_terseLabel_en-US" xlink:label="lab_bcrx_AnnualNetSalesBetween350000And550000Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual Net Sales Between $350,000 and $550,000</link:label>
    <link:label id="lab_bcrx_AnnualNetSalesBetween350000And550000Member_label_en-US" xlink:label="lab_bcrx_AnnualNetSalesBetween350000And550000Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Annual Net Sales Between $350,000 and $550,000 [Member]</link:label>
    <link:label id="lab_bcrx_AnnualNetSalesBetween350000And550000Member_documentation_en-US" xlink:label="lab_bcrx_AnnualNetSalesBetween350000And550000Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents annual net sales between $350,000 and $550,000.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesBetween350000And550000Member" xlink:href="bcrx-20250930.xsd#bcrx_AnnualNetSalesBetween350000And550000Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_AnnualNetSalesBetween350000And550000Member" xlink:to="lab_bcrx_AnnualNetSalesBetween350000And550000Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestments_95e409bc-e028-4520-bf12-d49161ad16cd_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments" xlink:to="lab_us-gaap_LongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_013630eb-f3a4-40d1-80f9-a264639e4993_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_5ce0d0a9-09a7-4d68-817f-217b23d5efda_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, useful life (in years)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_8b1b5356-21f1-40ce-b99c-12fdccca68dd_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_261a3e0c-f1d1-46be-84bb-37770800ca02_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_412aac23-5ee9-4f35-b22b-92a6895b9fd3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors Under the Plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_3745f48f-504e-40d7-8fc2-991465780f54_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Lease Expense Under Operating Leases</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_2c308068-587e-4a7c-a313-5cf8a73cc6dc_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_AfterFourthAnniversaryMember_bf23fa49-9488-44a7-b55d-5b89c79849f4_terseLabel_en-US" xlink:label="lab_bcrx_AfterFourthAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">After Fourth Anniversary</link:label>
    <link:label id="lab_bcrx_AfterFourthAnniversaryMember_label_en-US" xlink:label="lab_bcrx_AfterFourthAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">After Fourth Anniversary [Member]</link:label>
    <link:label id="lab_bcrx_AfterFourthAnniversaryMember_documentation_en-US" xlink:label="lab_bcrx_AfterFourthAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents after the fourth anniversary.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AfterFourthAnniversaryMember" xlink:href="bcrx-20250930.xsd#bcrx_AfterFourthAnniversaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_AfterFourthAnniversaryMember" xlink:to="lab_bcrx_AfterFourthAnniversaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_d7be19f9-4973-49e5-965c-2aff03feaa77_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_WithholdingTaxesAccrued_f26ed49f-c8ca-4d9d-8819-d82dbbaf1277_terseLabel_en-US" xlink:label="lab_bcrx_WithholdingTaxesAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Taxes withheld on stock-based awards included in accrued expenses</link:label>
    <link:label id="lab_bcrx_WithholdingTaxesAccrued_label_en-US" xlink:label="lab_bcrx_WithholdingTaxesAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Withholding Taxes Accrued</link:label>
    <link:label id="lab_bcrx_WithholdingTaxesAccrued_documentation_en-US" xlink:label="lab_bcrx_WithholdingTaxesAccrued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Withholding Taxes Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_WithholdingTaxesAccrued" xlink:href="bcrx-20250930.xsd#bcrx_WithholdingTaxesAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_WithholdingTaxesAccrued" xlink:to="lab_bcrx_WithholdingTaxesAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_DebtInstrumentCapitalizedInterestRate_f2756b79-c9f0-4e1e-b3d3-168162d5a46e_terseLabel_en-US" xlink:label="lab_bcrx_DebtInstrumentCapitalizedInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument capitalized interest rate</link:label>
    <link:label id="lab_bcrx_DebtInstrumentCapitalizedInterestRate_label_en-US" xlink:label="lab_bcrx_DebtInstrumentCapitalizedInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Capitalized Interest Rate</link:label>
    <link:label id="lab_bcrx_DebtInstrumentCapitalizedInterestRate_documentation_en-US" xlink:label="lab_bcrx_DebtInstrumentCapitalizedInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument Capitalized Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DebtInstrumentCapitalizedInterestRate" xlink:href="bcrx-20250930.xsd#bcrx_DebtInstrumentCapitalizedInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_DebtInstrumentCapitalizedInterestRate" xlink:to="lab_bcrx_DebtInstrumentCapitalizedInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_65948add-2466-4eeb-99ce-d34101687b80_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_ToriiPharmaceuticalCoMember_00c4c277-9345-4b66-a3b4-aeb7745736ee_terseLabel_en-US" xlink:label="lab_bcrx_ToriiPharmaceuticalCoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Torii Pharmaceutical Co.</link:label>
    <link:label id="lab_bcrx_ToriiPharmaceuticalCoMember_label_en-US" xlink:label="lab_bcrx_ToriiPharmaceuticalCoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Torii Pharmaceutical Co. [Member]</link:label>
    <link:label id="lab_bcrx_ToriiPharmaceuticalCoMember_documentation_en-US" xlink:label="lab_bcrx_ToriiPharmaceuticalCoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to Torii Pharmaceutical Co., Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ToriiPharmaceuticalCoMember" xlink:href="bcrx-20250930.xsd#bcrx_ToriiPharmaceuticalCoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_ToriiPharmaceuticalCoMember" xlink:to="lab_bcrx_ToriiPharmaceuticalCoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_5aa0902d-9753-4f87-adc3-7cf8f0e3d48c_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development, Contract to Perform for Others [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_23a19625-b0eb-4a26-825a-d1abc9a7cf5d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_0317a1c5-9ab9-4d04-8291-bccf71d426e5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_24e44a82-ab55-4e9f-8686-1eddbaf68c7e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting of restricted stock units</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_62144cef-c83a-40b9-a372-b789f4dbfdb0_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of shares to directors in lieu of cash retainer</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAccountsReceivableMember_9f3d2612-2dfb-43d6-9321-076871142f7d_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_TradeAccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TradeAccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAccountsReceivableMember" xlink:to="lab_us-gaap_TradeAccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_c7b07caa-8900-40c6-8d69-38174dcc03bd_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product sales, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_f09dbca7-3afb-48e1-874c-fd0cc259be3e_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_AnnualNetSalesUnder350000Member_dff6ad63-146b-4108-a2cd-7af08b0b7870_terseLabel_en-US" xlink:label="lab_bcrx_AnnualNetSalesUnder350000Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual Net Sales Under $350,000</link:label>
    <link:label id="lab_bcrx_AnnualNetSalesUnder350000Member_label_en-US" xlink:label="lab_bcrx_AnnualNetSalesUnder350000Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Annual Net Sales Under $350,000 [Member]</link:label>
    <link:label id="lab_bcrx_AnnualNetSalesUnder350000Member_documentation_en-US" xlink:label="lab_bcrx_AnnualNetSalesUnder350000Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents annual net sales under $350,000.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesUnder350000Member" xlink:href="bcrx-20250930.xsd#bcrx_AnnualNetSalesUnder350000Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_AnnualNetSalesUnder350000Member" xlink:to="lab_bcrx_AnnualNetSalesUnder350000Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_HHSOfficeOfTheAdministrationForStrategicPreparednessAndResponseMember_82b0d9b8-e2ca-4529-86f6-d20c77de9b63_terseLabel_en-US" xlink:label="lab_bcrx_HHSOfficeOfTheAdministrationForStrategicPreparednessAndResponseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">HHS Office of the Administration for Strategic Preparedness and Response</link:label>
    <link:label id="lab_bcrx_HHSOfficeOfTheAdministrationForStrategicPreparednessAndResponseMember_label_en-US" xlink:label="lab_bcrx_HHSOfficeOfTheAdministrationForStrategicPreparednessAndResponseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">HHS Office of the Administration for Strategic Preparedness and Response [Member]</link:label>
    <link:label id="lab_bcrx_HHSOfficeOfTheAdministrationForStrategicPreparednessAndResponseMember_documentation_en-US" xlink:label="lab_bcrx_HHSOfficeOfTheAdministrationForStrategicPreparednessAndResponseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">HHS Office of the Administration for Strategic Preparedness and Response</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_HHSOfficeOfTheAdministrationForStrategicPreparednessAndResponseMember" xlink:href="bcrx-20250930.xsd#bcrx_HHSOfficeOfTheAdministrationForStrategicPreparednessAndResponseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_HHSOfficeOfTheAdministrationForStrategicPreparednessAndResponseMember" xlink:to="lab_bcrx_HHSOfficeOfTheAdministrationForStrategicPreparednessAndResponseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestAndOtherIncome_ae310be5-7904-4e55-8dc6-30637089668a_terseLabel_en-US" xlink:label="lab_us-gaap_InterestAndOtherIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestAndOtherIncome_label_en-US" xlink:label="lab_us-gaap_InterestAndOtherIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest and Other Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndOtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestAndOtherIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestAndOtherIncome" xlink:to="lab_us-gaap_InterestAndOtherIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_bac1dea2-57a4-4002-a602-b9489a5566cc_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales_2fbde91a-dcdb-49a8-a598-dece2322f850_terseLabel_en-US" xlink:label="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty purchase agreement, royalties, percentage of annual net sales</link:label>
    <link:label id="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales_label_en-US" xlink:label="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Purchase Agreement Royalties Percentage Of Annual Net Sales</link:label>
    <link:label id="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales_documentation_en-US" xlink:label="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percentage of annual net sales for royalties to be paid under the royalty purchase agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales" xlink:to="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8511d568-0f34-416a-9b0f-d07c2962bd68_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_b19095dd-daef-4d0a-9ff8-3adf1ff62224_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_fe72dbb5-d306-453f-b1da-cafca0265bb8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Principal payments on finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d429ee23-31eb-49e4-8e18-9871dad446c6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_c709d33a-09b7-4358-8606-29d804e9cb67_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current assets held for sale</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_dc236711-1a74-468a-8917-4f8fd1551f99_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_RightOfUseAssetsNoncurrent_026b77e5-d385-42c8-a1a8-ff0547ef11b4_terseLabel_en-US" xlink:label="lab_bcrx_RightOfUseAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right of use assets</link:label>
    <link:label id="lab_bcrx_RightOfUseAssetsNoncurrent_label_en-US" xlink:label="lab_bcrx_RightOfUseAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-Of-Use-Assets, Noncurrent</link:label>
    <link:label id="lab_bcrx_RightOfUseAssetsNoncurrent_documentation_en-US" xlink:label="lab_bcrx_RightOfUseAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Right-Of-Use-Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RightOfUseAssetsNoncurrent" xlink:href="bcrx-20250930.xsd#bcrx_RightOfUseAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_RightOfUseAssetsNoncurrent" xlink:to="lab_bcrx_RightOfUseAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_7c00abe9-df96-4ec3-9b3d-20b4a6ed9e63_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_49ed431f-1cc9-47c1-86f7-bfbb58af3f2a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting of restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_b66f7992-ecad-4719-899b-0091c2d4ad21_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease assets obtained in exchange for finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAbstract" xlink:to="lab_us-gaap_InvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_08e4d8ab-daab-4243-bb4a-da26a57ac8af_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_36fa348b-8ee4-4103-9caa-e65b7c85ce5e_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_17654a47-77e9-4010-aa1e-cd8907baa161_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_984a2ef1-5a8e-4638-85c0-15c0d8b545a8_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_ba0a3526-3643-46bf-9350-e8b0ac0808df_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_19b46f84-89d5-41a7-a181-bb58e6f38b33_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease assets, net</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_dddbaa35-3f27-4809-a650-cb1a50d549b4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repayment of Pharmakon term loan principal</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_b673c5af-0fee-404c-9817-59755f3d78ed_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_d9e1cff4-10b6-48b6-abfa-ef6949fae2a8_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_af2af956-cc29-4971-bcc5-422010f6669f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options, net (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_605240e6-165c-45b9-8dfc-c11a11a45407_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_f187dcd8-7306-4914-a437-2ea8ce6729bd_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock option awards vested and exercisable, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_f6ba680f-37db-4205-a312-f2f0495e2212_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award</link:label>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_18ae34c3-630e-422e-ad51-9c251f6786a4_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reconciliation [Abstract]</link:label>
    <link:label id="lab_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_label_en-US" xlink:label="lab_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:to="lab_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_f56920e0-24ab-4457-a595-6ffa15d9050e_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_c017be13-40e0-4f2b-95a0-c8ab8dbebd40_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_eb37252b-ba75-495b-9aa8-05e3fa7e6ae0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0fe5611d-a364-44f3-a3f8-a4aaf41c065b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_b8390940-cb66-4266-b199-189ba20ce63d_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_9e77071d-6a19-49a9-8e8e-b9313b41bf41_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease, right-of-use asset, accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_12f934f2-20f2-4f06-bbcb-8d475c34a12b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_935bc394-c8ee-46f2-9d49-e0df5edd479e_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_db905e27-6dc9-443a-a405-261bbf7d2a11_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalent, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_StockBasedCompensationMember_8ac03fb8-19f4-41ce-8851-6da8041879da_terseLabel_en-US" xlink:label="lab_bcrx_StockBasedCompensationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_bcrx_StockBasedCompensationMember_label_en-US" xlink:label="lab_bcrx_StockBasedCompensationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation [Member]</link:label>
    <link:label id="lab_bcrx_StockBasedCompensationMember_documentation_en-US" xlink:label="lab_bcrx_StockBasedCompensationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_StockBasedCompensationMember" xlink:href="bcrx-20250930.xsd#bcrx_StockBasedCompensationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_StockBasedCompensationMember" xlink:to="lab_bcrx_StockBasedCompensationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_09cbf98f-b5fa-41d2-a47f-d4e31fa23756_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Acquisitions of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_99ebc261-8c26-4589-9569-4f8261110afa_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_8a08f961-b9a6-4962-8dc9-276e1706e8e6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_3a1d7ca4-db78-41ee-8066-ffbdc93155d7_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_2146582b-5d0a-4dc6-ab23-a2a1ad50cb40_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_8a472d1a-8b94-4fdb-a5b1-3fe513037751_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_239243fd-c2c8-41eb-a06b-f1d8a561d477_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_3a373b32-ff4b-438e-a85d-df4f0dcc5905_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_561b093f-0a34-475a-88d0-e8baa580f9a2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_f7f0e806-15bb-47e3-819c-fe0059681f0f_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer Equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_633159a0-64f8-4838-afb3-354651353164_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5d376409-0ec6-4714-b363-59fce8f7f1fc_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">(Increase) decrease in prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_fcf45e75-39ea-4562-876f-e0023d4e0528_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_AfterThirdAnniversaryMember_66dd18c0-b9ea-43bd-8206-5b2c62a24d6b_terseLabel_en-US" xlink:label="lab_bcrx_AfterThirdAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">After Third Anniversary</link:label>
    <link:label id="lab_bcrx_AfterThirdAnniversaryMember_label_en-US" xlink:label="lab_bcrx_AfterThirdAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">After Third Anniversary [Member]</link:label>
    <link:label id="lab_bcrx_AfterThirdAnniversaryMember_documentation_en-US" xlink:label="lab_bcrx_AfterThirdAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">After Third Anniversary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AfterThirdAnniversaryMember" xlink:href="bcrx-20250930.xsd#bcrx_AfterThirdAnniversaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_AfterThirdAnniversaryMember" xlink:to="lab_bcrx_AfterThirdAnniversaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_d081cd85-9efa-4a62-9b27-d1753bae8a1d_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_8b523269-e268-4d65-9ab5-38caaef67082_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_26a604eb-1c09-474f-8129-550c561720ef_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_ClearsideBiomedicalIncMember_285c3331-39f8-47f8-acee-6a94248b149f_terseLabel_en-US" xlink:label="lab_bcrx_ClearsideBiomedicalIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clearside Biomedical, Inc.</link:label>
    <link:label id="lab_bcrx_ClearsideBiomedicalIncMember_label_en-US" xlink:label="lab_bcrx_ClearsideBiomedicalIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clearside Biomedical, Inc. [Member]</link:label>
    <link:label id="lab_bcrx_ClearsideBiomedicalIncMember_documentation_en-US" xlink:label="lab_bcrx_ClearsideBiomedicalIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clearside Biomedical, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ClearsideBiomedicalIncMember" xlink:href="bcrx-20250930.xsd#bcrx_ClearsideBiomedicalIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_ClearsideBiomedicalIncMember" xlink:to="lab_bcrx_ClearsideBiomedicalIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_388d13c9-c53a-4475-8d8e-14e7af4045cf_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront consideration to be received</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_e6f0f883-0495-4b11-9756-7beea14f32bf_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_ReportableSegmentMember_836500bf-778e-4615-a16b-ee54e6472ea6_terseLabel_en-US" xlink:label="lab_bcrx_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reportable Segment</link:label>
    <link:label id="lab_bcrx_ReportableSegmentMember_label_en-US" xlink:label="lab_bcrx_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reportable Segment [Member]</link:label>
    <link:label id="lab_bcrx_ReportableSegmentMember_documentation_en-US" xlink:label="lab_bcrx_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reportable Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ReportableSegmentMember" xlink:href="bcrx-20250930.xsd#bcrx_ReportableSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_ReportableSegmentMember" xlink:to="lab_bcrx_ReportableSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_1119da8c-4d4d-425c-8e24-e02c8ff2b821_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Secured term loan</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_f33c6674-335b-44eb-aa5b-ce64fe30e081_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNoncurrent_c1638e2d-06a2-4026-84c1-7846480f4e25_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term inventory, net</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent" xlink:to="lab_us-gaap_InventoryNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_9def1388-5dd8-4536-85aa-b42c6a6623c7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_06e7af65-63fb-4031-b18b-9e5a3f77b0c0_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_d6beb4b4-dfe6-428d-a779-dc74685cd3c4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units, forfeited in period, weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_194b04bb-f440-4131-9fe2-b5fe19709918_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_fd19b90f-9865-48ea-8672-e13885be7d7d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_RoyaltyRateIfMaintainsSakigakeDesignation_531ed906-dcb2-4d33-93c8-5b4ed37eec9d_terseLabel_en-US" xlink:label="lab_bcrx_RoyaltyRateIfMaintainsSakigakeDesignation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty rate if maintains sakigake designation</link:label>
    <link:label id="lab_bcrx_RoyaltyRateIfMaintainsSakigakeDesignation_label_en-US" xlink:label="lab_bcrx_RoyaltyRateIfMaintainsSakigakeDesignation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Rate If Maintains Sakigake Designation</link:label>
    <link:label id="lab_bcrx_RoyaltyRateIfMaintainsSakigakeDesignation_documentation_en-US" xlink:label="lab_bcrx_RoyaltyRateIfMaintainsSakigakeDesignation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percent of net sales that the company will receive if berotralstat maintains its Sakigake designation during the PMDA review.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyRateIfMaintainsSakigakeDesignation" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltyRateIfMaintainsSakigakeDesignation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_RoyaltyRateIfMaintainsSakigakeDesignation" xlink:to="lab_bcrx_RoyaltyRateIfMaintainsSakigakeDesignation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_1c5114da-774d-4d49-8580-945c174d3925_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_bd76a992-1eb0-4bc0-bc4b-555c0bdb34b9_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification from accumulated other comprehensive income, current period, before tax</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_9b1da1d5-49c9-4658-b700-90f8b6492ec7_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; deficit:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalEntityTypeOfCounterpartyDomain_545e5a66-d842-4726-9f1f-e52ea8d8f16c_terseLabel_en-US" xlink:label="lab_us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity Type of Counterparty [Domain]</link:label>
    <link:label id="lab_us-gaap_LegalEntityTypeOfCounterpartyDomain_label_en-US" xlink:label="lab_us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity Type of Counterparty [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="lab_us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_IncreaseDecreaseInRoyaltyFinancingLiabilities_231f4a95-312b-4502-b027-3c06e00f4d38_negatedTerseLabel_en-US" xlink:label="lab_bcrx_IncreaseDecreaseInRoyaltyFinancingLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Decrease in royalty financing obligations</link:label>
    <link:label id="lab_bcrx_IncreaseDecreaseInRoyaltyFinancingLiabilities_label_en-US" xlink:label="lab_bcrx_IncreaseDecreaseInRoyaltyFinancingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Royalty Financing Liabilities</link:label>
    <link:label id="lab_bcrx_IncreaseDecreaseInRoyaltyFinancingLiabilities_documentation_en-US" xlink:label="lab_bcrx_IncreaseDecreaseInRoyaltyFinancingLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Royalty Financing Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_IncreaseDecreaseInRoyaltyFinancingLiabilities" xlink:href="bcrx-20250930.xsd#bcrx_IncreaseDecreaseInRoyaltyFinancingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_IncreaseDecreaseInRoyaltyFinancingLiabilities" xlink:to="lab_bcrx_IncreaseDecreaseInRoyaltyFinancingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_f0606f05-938d-4721-bb1e-2c772ed371c2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_8fa7af6d-3aa0-4717-ac4f-eba266ac8f5e_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6edda204-1b16-4366-b523-b9b495e9f6dd_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_01ce8628-1242-49c6-a861-15f41350a3a9_negatedLabel_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Shares withheld for taxes for vesting of restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_33ba1fec-f612-49d7-8d6d-5ad9cc6cae7a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_7a122535-b3d1-4fee-a2f0-2c3d8b0385d1_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency gains (losses), net</link:label>
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_label_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:to="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_df811bec-c0d4-4892-84b5-14d662a9acfb_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_e91706c2-f4a4-4bb4-aa12-161efbfde898_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3474611e-963a-45d5-a12f-02e6fb9de246_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_InducementPlanMember_9875f0b7-8b22-4733-b613-7ee28b357fc7_terseLabel_en-US" xlink:label="lab_bcrx_InducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inducement Plan</link:label>
    <link:label id="lab_bcrx_InducementPlanMember_label_en-US" xlink:label="lab_bcrx_InducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inducement Plan [Member]</link:label>
    <link:label id="lab_bcrx_InducementPlanMember_documentation_en-US" xlink:label="lab_bcrx_InducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the Inducement Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_InducementPlanMember" xlink:href="bcrx-20250930.xsd#bcrx_InducementPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_InducementPlanMember" xlink:to="lab_bcrx_InducementPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNet_bba9c559-e3a1-4ab8-aaf7-828404386b01_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, after allowance for credit loss, total</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNet_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNet" xlink:to="lab_us-gaap_AccountsReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_ee984dd5-2ebb-4196-99f9-dfc6323367ca_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_57200f92-54fc-4e45-9bb0-acf760361ce6_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group, Held-for-Sale, Not Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Held-for-Sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:to="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_e1937b2f-b198-455b-bb92-cbeadc84671f_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities held for sale</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_e7abdb0c-561e-4d79-bc23-e300f4debb55_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options to purchase common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b5efafe9-2a1e-4c88-920b-34a0daeebd07_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issued RSU (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_e16e557f-2f79-4fac-b264-68c7bdfbbd04_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6b7c761d-3051-40c0-a854-8840b6ba1bf0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited RSU (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_addea4fa-5916-49dc-843a-8b0c30863a2e_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_OperatingLeaseRightOfUseAssetAccumulatedAmortization_5168e26c-6402-46ac-85fb-29fe96c69255_terseLabel_en-US" xlink:label="lab_bcrx_OperatingLeaseRightOfUseAssetAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, right-of-use asset, accumulated amortization</link:label>
    <link:label id="lab_bcrx_OperatingLeaseRightOfUseAssetAccumulatedAmortization_label_en-US" xlink:label="lab_bcrx_OperatingLeaseRightOfUseAssetAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease Right of use Asset Accumulated Amortization</link:label>
    <link:label id="lab_bcrx_OperatingLeaseRightOfUseAssetAccumulatedAmortization_documentation_en-US" xlink:label="lab_bcrx_OperatingLeaseRightOfUseAssetAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of accumulated amortization on lessee's right to use underlying asset under operating lease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_OperatingLeaseRightOfUseAssetAccumulatedAmortization" xlink:href="bcrx-20250930.xsd#bcrx_OperatingLeaseRightOfUseAssetAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_OperatingLeaseRightOfUseAssetAccumulatedAmortization" xlink:to="lab_bcrx_OperatingLeaseRightOfUseAssetAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_46a07e34-25e7-48ae-95d5-a6261800818c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_03cfb861-899b-4a65-b5eb-cf4ee443a383_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4b24db93-8d8c-4973-98cc-759536c55681_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_7a7a9fa9-89a1-4375-af99-9a1610c68bef_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_4dacd1c0-9422-4217-8298-f40995d7f263_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, exercises in period, intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4b837b54-8a39-4793-9276-1d1a2f277464_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units, grants in period, weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_InterestPaidRoyaltyFinancingLiabilities_edf29a1d-cf73-48ed-9421-a718360b385d_terseLabel_en-US" xlink:label="lab_bcrx_InterestPaidRoyaltyFinancingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest paid, royalty financing obligations</link:label>
    <link:label id="lab_bcrx_InterestPaidRoyaltyFinancingLiabilities_label_en-US" xlink:label="lab_bcrx_InterestPaidRoyaltyFinancingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Royalty Financing Liabilities</link:label>
    <link:label id="lab_bcrx_InterestPaidRoyaltyFinancingLiabilities_documentation_en-US" xlink:label="lab_bcrx_InterestPaidRoyaltyFinancingLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Paid, Royalty Financing Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_InterestPaidRoyaltyFinancingLiabilities" xlink:href="bcrx-20250930.xsd#bcrx_InterestPaidRoyaltyFinancingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_InterestPaidRoyaltyFinancingLiabilities" xlink:to="lab_bcrx_InterestPaidRoyaltyFinancingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_e43b5928-bc9a-4d95-97c4-a2a4bce2d785_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c54e5cb1-4dae-486d-bafa-bc790a352cce_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options outstanding, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_80831e77-dbc8-4691-b491-4174f6276a1f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan sales</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_c315beda-908f-46aa-9abb-dd943aa2fe26_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense, debt, total</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9b808026-6670-4832-ae50-645dc08b2ba4_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_204ef4e6-a781-446b-86fe-eb0b5290ab76_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_6e580782-51c9-4bed-82e6-c7292b6a2eaf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepayment premium and fees on Pharmakon term loan</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_d67bfdc3-1604-4eaa-8ca0-a2ef51116490_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepayment premium and fees on Pharmakon term loan</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment for Debt Extinguishment or Debt Prepayment Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:to="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_80dc1127-caf0-43a1-9136-fab482a6d0a7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_MaximumCustomaryReductionOnRoyaltyRate_c7c5758d-0995-4f59-bc08-481fa64637cf_terseLabel_en-US" xlink:label="lab_bcrx_MaximumCustomaryReductionOnRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum customary reduction on royalty rate</link:label>
    <link:label id="lab_bcrx_MaximumCustomaryReductionOnRoyaltyRate_label_en-US" xlink:label="lab_bcrx_MaximumCustomaryReductionOnRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Customary Reduction On Royalty Rate</link:label>
    <link:label id="lab_bcrx_MaximumCustomaryReductionOnRoyaltyRate_documentation_en-US" xlink:label="lab_bcrx_MaximumCustomaryReductionOnRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The maximum percentage of customary reductions allowed on royalty rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_MaximumCustomaryReductionOnRoyaltyRate" xlink:href="bcrx-20250930.xsd#bcrx_MaximumCustomaryReductionOnRoyaltyRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_MaximumCustomaryReductionOnRoyaltyRate" xlink:to="lab_bcrx_MaximumCustomaryReductionOnRoyaltyRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_CollaborativeAgreementContractValue_8a683a13-a1cf-48ca-ac57-a1afc29b2b02_terseLabel_en-US" xlink:label="lab_bcrx_CollaborativeAgreementContractValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract value</link:label>
    <link:label id="lab_bcrx_CollaborativeAgreementContractValue_label_en-US" xlink:label="lab_bcrx_CollaborativeAgreementContractValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement Contract Value</link:label>
    <link:label id="lab_bcrx_CollaborativeAgreementContractValue_documentation_en-US" xlink:label="lab_bcrx_CollaborativeAgreementContractValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement Contract Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_CollaborativeAgreementContractValue" xlink:href="bcrx-20250930.xsd#bcrx_CollaborativeAgreementContractValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_CollaborativeAgreementContractValue" xlink:to="lab_bcrx_CollaborativeAgreementContractValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_f0c0bf68-f095-4537-99c1-260a0b84e8d3_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncome_895395b6-61f1-4da6-81ea-a5cf565a3973_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_OtherIncome_label_en-US" xlink:label="lab_us-gaap_OtherIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncome" xlink:to="lab_us-gaap_OtherIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_49dc7f87-893b-43b7-990d-140364417bc9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_CommonStockConversionRatio_2a5d2a08-803b-40ca-8e52-ee462d765598_terseLabel_en-US" xlink:label="lab_bcrx_CommonStockConversionRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion ratio</link:label>
    <link:label id="lab_bcrx_CommonStockConversionRatio_label_en-US" xlink:label="lab_bcrx_CommonStockConversionRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Conversion Ratio</link:label>
    <link:label id="lab_bcrx_CommonStockConversionRatio_documentation_en-US" xlink:label="lab_bcrx_CommonStockConversionRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_CommonStockConversionRatio" xlink:href="bcrx-20250930.xsd#bcrx_CommonStockConversionRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_CommonStockConversionRatio" xlink:to="lab_bcrx_CommonStockConversionRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_ffdd2189-d534-4e78-92ea-8edefadddd1e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_89fe9745-a350-4981-8c59-75445870a676_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected Volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock_fad90777-0b07-4a7d-9e05-c318eb1fa6d0_terseLabel_en-US" xlink:label="lab_bcrx_LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheets of the Company's Operating Leases</link:label>
    <link:label id="lab_bcrx_LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_bcrx_LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Assets and Liabilities [Table Text Block]</link:label>
    <link:label id="lab_bcrx_LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock_documentation_en-US" xlink:label="lab_bcrx_LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of the assets and liabilities of the lessee's operating lease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock" xlink:href="bcrx-20250930.xsd#bcrx_LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_bcrx_LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_DebtInstrumentVariableRateFloor_c758155b-3948-455c-aabf-47156d35fe29_terseLabel_en-US" xlink:label="lab_bcrx_DebtInstrumentVariableRateFloor" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, SOFR floor</link:label>
    <link:label id="lab_bcrx_DebtInstrumentVariableRateFloor_label_en-US" xlink:label="lab_bcrx_DebtInstrumentVariableRateFloor" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Variable Rate floor</link:label>
    <link:label id="lab_bcrx_DebtInstrumentVariableRateFloor_documentation_en-US" xlink:label="lab_bcrx_DebtInstrumentVariableRateFloor" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Variable Rate floor</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DebtInstrumentVariableRateFloor" xlink:href="bcrx-20250930.xsd#bcrx_DebtInstrumentVariableRateFloor"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_DebtInstrumentVariableRateFloor" xlink:to="lab_bcrx_DebtInstrumentVariableRateFloor" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_aaaf93a1-b5d6-4e88-b5b6-a77dba8428a5_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Nonvested RSU weighted average grant date fair value beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_aaef9e3b-599c-4e98-9ead-dd4f64b07b13_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Nonvested RSU weighted average grant date fair value ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_MaturityPeriodOfShortTermInvestment_8b50c49d-3e26-4961-8c7e-10135b477a9a_terseLabel_en-US" xlink:label="lab_bcrx_MaturityPeriodOfShortTermInvestment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity period of short term investment (in months)</link:label>
    <link:label id="lab_bcrx_MaturityPeriodOfShortTermInvestment_label_en-US" xlink:label="lab_bcrx_MaturityPeriodOfShortTermInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturity Period Of Short Term Investment</link:label>
    <link:label id="lab_bcrx_MaturityPeriodOfShortTermInvestment_documentation_en-US" xlink:label="lab_bcrx_MaturityPeriodOfShortTermInvestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maturity period of short term investment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_MaturityPeriodOfShortTermInvestment" xlink:href="bcrx-20250930.xsd#bcrx_MaturityPeriodOfShortTermInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_MaturityPeriodOfShortTermInvestment" xlink:to="lab_bcrx_MaturityPeriodOfShortTermInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_3606373d-4934-4306-8e74-529a5a579845_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_334fbe1a-b050-444e-aa9b-2845470b9244_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_4af79edc-3e4b-443b-9942-819b859d9a50_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025 (remaining)</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_2e1cf966-8e1b-4aa8-9cb4-ff7f92eed55c_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d9a98425-2e9c-4e47-b7a6-ea7bcc0eb966_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_AvoralstatMember_5dbe5c31-5cc8-45ca-9d32-a25012a023fd_terseLabel_en-US" xlink:label="lab_bcrx_AvoralstatMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Avoralstat</link:label>
    <link:label id="lab_bcrx_AvoralstatMember_label_en-US" xlink:label="lab_bcrx_AvoralstatMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Avoralstat [Member]</link:label>
    <link:label id="lab_bcrx_AvoralstatMember_documentation_en-US" xlink:label="lab_bcrx_AvoralstatMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Avoralstat</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AvoralstatMember" xlink:href="bcrx-20250930.xsd#bcrx_AvoralstatMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_AvoralstatMember" xlink:to="lab_bcrx_AvoralstatMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_73c667f3-e5e4-45b3-8696-eb70bddb2a7a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4127a2f2-4858-495d-9186-e6fae180f949_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_a97fce24-0b2f-40c7-a4f6-bf317a129c5d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain (loss) on available for sale investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_ca3eb5c9-e444-41e9-b935-3c468306741a_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_The2021RPIRoyaltyPurchaseAgreementMember_d988776c-8bde-4709-9632-508bd6048e86_terseLabel_en-US" xlink:label="lab_bcrx_The2021RPIRoyaltyPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">The 2021 RPI Royalty Purchase Agreement</link:label>
    <link:label id="lab_bcrx_The2021RPIRoyaltyPurchaseAgreementMember_label_en-US" xlink:label="lab_bcrx_The2021RPIRoyaltyPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2021 RPI Royalty Purchase Agreement [Member]</link:label>
    <link:label id="lab_bcrx_The2021RPIRoyaltyPurchaseAgreementMember_documentation_en-US" xlink:label="lab_bcrx_The2021RPIRoyaltyPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the 2021 RPI Royalty Purchase Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_The2021RPIRoyaltyPurchaseAgreementMember" xlink:href="bcrx-20250930.xsd#bcrx_The2021RPIRoyaltyPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_The2021RPIRoyaltyPurchaseAgreementMember" xlink:to="lab_bcrx_The2021RPIRoyaltyPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_OMERSRoyaltyAgreementMember_49941a89-ac47-4111-aea0-89bba5da8ac8_terseLabel_en-US" xlink:label="lab_bcrx_OMERSRoyaltyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OMERS Royalty Agreement</link:label>
    <link:label id="lab_bcrx_OMERSRoyaltyAgreementMember_label_en-US" xlink:label="lab_bcrx_OMERSRoyaltyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OMERS Royalty Agreement [Member]</link:label>
    <link:label id="lab_bcrx_OMERSRoyaltyAgreementMember_documentation_en-US" xlink:label="lab_bcrx_OMERSRoyaltyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information on OMERS Royalty Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_OMERSRoyaltyAgreementMember" xlink:href="bcrx-20250930.xsd#bcrx_OMERSRoyaltyAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_OMERSRoyaltyAgreementMember" xlink:to="lab_bcrx_OMERSRoyaltyAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9bec7108-e4ce-4f4b-a858-760cd4d094b1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_76c20636-00df-4a2d-ad66-dcd7cbbb91f9_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Increase in inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_RoyaltyMonetizationsLineItems_7a2694e4-943a-447f-8d8e-620edf1874d1_terseLabel_en-US" xlink:label="lab_bcrx_RoyaltyMonetizationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Monetizations [Line Items]</link:label>
    <link:label id="lab_bcrx_RoyaltyMonetizationsLineItems_label_en-US" xlink:label="lab_bcrx_RoyaltyMonetizationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Monetizations [Line Items]</link:label>
    <link:label id="lab_bcrx_RoyaltyMonetizationsLineItems_documentation_en-US" xlink:label="lab_bcrx_RoyaltyMonetizationsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Monetizations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyMonetizationsLineItems" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltyMonetizationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems" xlink:to="lab_bcrx_RoyaltyMonetizationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_a3ca61cd-43f3-4c05-8e14-8bc653609bc4_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_AnnualNetSalesRangeAxis_3f68ab3c-dffb-47c3-abfb-1a3bfe575197_terseLabel_en-US" xlink:label="lab_bcrx_AnnualNetSalesRangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual Net Sales Range [Axis]</link:label>
    <link:label id="lab_bcrx_AnnualNetSalesRangeAxis_label_en-US" xlink:label="lab_bcrx_AnnualNetSalesRangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Annual Net Sales Range [Axis]</link:label>
    <link:label id="lab_bcrx_AnnualNetSalesRangeAxis_documentation_en-US" xlink:label="lab_bcrx_AnnualNetSalesRangeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Annual Net Sales Range</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesRangeAxis" xlink:href="bcrx-20250930.xsd#bcrx_AnnualNetSalesRangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_AnnualNetSalesRangeAxis" xlink:to="lab_bcrx_AnnualNetSalesRangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_6939213a-9c3f-4bb0-bcad-984f733b96e2_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_TermLoanTrancheDMember_9bff7782-745f-453d-aaff-f450b4fa8fe4_terseLabel_en-US" xlink:label="lab_bcrx_TermLoanTrancheDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term Loan Tranche D</link:label>
    <link:label id="lab_bcrx_TermLoanTrancheDMember_label_en-US" xlink:label="lab_bcrx_TermLoanTrancheDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Loan Tranche D [Member]</link:label>
    <link:label id="lab_bcrx_TermLoanTrancheDMember_documentation_en-US" xlink:label="lab_bcrx_TermLoanTrancheDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term Loan Tranche D</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_TermLoanTrancheDMember" xlink:href="bcrx-20250930.xsd#bcrx_TermLoanTrancheDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_TermLoanTrancheDMember" xlink:to="lab_bcrx_TermLoanTrancheDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_d8c563e6-aa77-4330-9efb-e78ce08bc108_terseLabel_en-US" xlink:label="lab_bcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration to be received</link:label>
    <link:label id="lab_bcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_label_en-US" xlink:label="lab_bcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Contingent Consideration</link:label>
    <link:label id="lab_bcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_documentation_en-US" xlink:label="lab_bcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Contingent Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsideration" xlink:href="bcrx-20250930.xsd#bcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsideration" xlink:to="lab_bcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_be181a30-7293-48d1-b1fb-77a693bb7d1a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_35f26f9d-4b24-4f52-86c7-c03ef8e0126e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvanceRoyaltiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdvanceRoyaltiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advance Royalties [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvanceRoyaltiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdvanceRoyaltiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvanceRoyaltiesAbstract" xlink:to="lab_us-gaap_AdvanceRoyaltiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_AnnualNetSalesUnder150000Member_4f5229bf-6457-43cd-b3fb-9ca806c729ce_terseLabel_en-US" xlink:label="lab_bcrx_AnnualNetSalesUnder150000Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual Net Sales Under $150,000</link:label>
    <link:label id="lab_bcrx_AnnualNetSalesUnder150000Member_label_en-US" xlink:label="lab_bcrx_AnnualNetSalesUnder150000Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Annual Net Sales Under $150,000 [Member]</link:label>
    <link:label id="lab_bcrx_AnnualNetSalesUnder150000Member_documentation_en-US" xlink:label="lab_bcrx_AnnualNetSalesUnder150000Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents annual net sales under $150,000.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesUnder150000Member" xlink:href="bcrx-20250930.xsd#bcrx_AnnualNetSalesUnder150000Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_AnnualNetSalesUnder150000Member" xlink:to="lab_bcrx_AnnualNetSalesUnder150000Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_0a5d59df-f3d6-4910-84d1-f9142bebee02_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_dcf1c87c-ce04-4a43-a134-0a72a12a4842_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of Product Sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_ProceedsFromIssuanceOfCommonStockIssuedForServices_c2ca6ac9-fe02-418d-9db9-cf01052c03b7_terseLabel_en-US" xlink:label="lab_bcrx_ProceedsFromIssuanceOfCommonStockIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued to directors in lieu of cash retainer</link:label>
    <link:label id="lab_bcrx_ProceedsFromIssuanceOfCommonStockIssuedForServices_label_en-US" xlink:label="lab_bcrx_ProceedsFromIssuanceOfCommonStockIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Issuance Of Common Stock, Issued For Services</link:label>
    <link:label id="lab_bcrx_ProceedsFromIssuanceOfCommonStockIssuedForServices_documentation_en-US" xlink:label="lab_bcrx_ProceedsFromIssuanceOfCommonStockIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Issuance Of Common Stock, Issued For Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ProceedsFromIssuanceOfCommonStockIssuedForServices" xlink:href="bcrx-20250930.xsd#bcrx_ProceedsFromIssuanceOfCommonStockIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_ProceedsFromIssuanceOfCommonStockIssuedForServices" xlink:to="lab_bcrx_ProceedsFromIssuanceOfCommonStockIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_58ea9066-fa87-454c-98be-1c4260737569_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_314ddbe3-9862-4861-b0f3-4cd87ea8af1d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_008424b9-db45-4d9f-a20b-2bc4c1f0870d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.01 par value; shares authorized - 5,000; no shares issued and outstanding at September&#160;30, 2025 and December&#160;31, 2024</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_00b6cb5c-0b37-40c9-9b52-97308bd0d7af_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_d9cd04e8-f837-479e-a11d-e7263850481c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating cash flows for operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_d9242638-ac39-48e6-8f2d-487a27a0d7fa_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total stock-based compensation costs</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_1bce7e00-9d7a-4863-b11e-34ea7e1ca42d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.01 par value; shares authorized - 450,000; shares issued and outstanding &#8211; 210,522 at September&#160;30, 2025 and 208,543 at December&#160;31, 2024</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_02fc20a4-38c3-49e5-be51-3afcfe1a22d5_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease assets, net</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_c80cd5ec-d45e-417b-a6f9-598d12020efc_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4ba6044d-ddbb-49fe-b2ad-f4e8911dcb3d_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_59bb5791-04b9-4bba-8135-4d991dc9dd3a_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperationsExcludingAssetsHeldForSale_db46780f-08e8-4b41-9c16-c88af015e984_terseLabel_en-US" xlink:label="lab_bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperationsExcludingAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net decrease in cash, and cash equivalents, and restricted cash</link:label>
    <link:label id="lab_bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperationsExcludingAssetsHeldForSale_label_en-US" xlink:label="lab_bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperationsExcludingAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect, Continuing Operations, Excluding Assets Held For Sale</link:label>
    <link:label id="lab_bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperationsExcludingAssetsHeldForSale_documentation_en-US" xlink:label="lab_bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperationsExcludingAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect, Continuing Operations, Excluding Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperationsExcludingAssetsHeldForSale" xlink:href="bcrx-20250930.xsd#bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperationsExcludingAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperationsExcludingAssetsHeldForSale" xlink:to="lab_bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperationsExcludingAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_RestrictedCashAndCashEquivalentsIncludedInOtherAssetsNonCurrent_85cd5a64-c046-4bf6-a38d-6c41cef24ee4_terseLabel_en-US" xlink:label="lab_bcrx_RestrictedCashAndCashEquivalentsIncludedInOtherAssetsNonCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash in other assets</link:label>
    <link:label id="lab_bcrx_RestrictedCashAndCashEquivalentsIncludedInOtherAssetsNonCurrent_label_en-US" xlink:label="lab_bcrx_RestrictedCashAndCashEquivalentsIncludedInOtherAssetsNonCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents, Included In Other Assets, Non-Current</link:label>
    <link:label id="lab_bcrx_RestrictedCashAndCashEquivalentsIncludedInOtherAssetsNonCurrent_documentation_en-US" xlink:label="lab_bcrx_RestrictedCashAndCashEquivalentsIncludedInOtherAssetsNonCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents, Included In Other Assets, Non-Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RestrictedCashAndCashEquivalentsIncludedInOtherAssetsNonCurrent" xlink:href="bcrx-20250930.xsd#bcrx_RestrictedCashAndCashEquivalentsIncludedInOtherAssetsNonCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_RestrictedCashAndCashEquivalentsIncludedInOtherAssetsNonCurrent" xlink:to="lab_bcrx_RestrictedCashAndCashEquivalentsIncludedInOtherAssetsNonCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_54259192-8ee0-4155-bbf5-ee635f3adb47_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_6e3af133-946d-415f-9985-faca2aa244fa_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets_d0da163e-c34e-4c35-b709-2a481e5f31d7_terseLabel_en-US" xlink:label="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty purchase agreement, royalties, percentage of sublicense revenue in other markets</link:label>
    <link:label id="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets_label_en-US" xlink:label="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Purchase Agreement Royalties Percentage of Sublicense Revenue In Other Markets</link:label>
    <link:label id="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets_documentation_en-US" xlink:label="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percentage of sublicense revenue in other markets of royalties to be paid under the royalty purchase agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets" xlink:to="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_93e21854-ee86-4133-81be-031b796c57a2_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_acdf4f86-f3e2-4b19-a723-9ad6fa37562d_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_9ba8ef6e-78c1-4283-af19-673ddedc1997_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_PercentOfInterestPayment_97e1ce88-8b79-45dd-824c-934728506778_terseLabel_en-US" xlink:label="lab_bcrx_PercentOfInterestPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percent of interest payment</link:label>
    <link:label id="lab_bcrx_PercentOfInterestPayment_label_en-US" xlink:label="lab_bcrx_PercentOfInterestPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percent of Interest Payment</link:label>
    <link:label id="lab_bcrx_PercentOfInterestPayment_documentation_en-US" xlink:label="lab_bcrx_PercentOfInterestPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percent of Interest Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_PercentOfInterestPayment" xlink:href="bcrx-20250930.xsd#bcrx_PercentOfInterestPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_PercentOfInterestPayment" xlink:to="lab_bcrx_PercentOfInterestPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_e2ff7cf0-6ca1-4f03-a757-f9c856fb153f_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_ee08090e-4da6-4466-a107-e9f3e9193cf9_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_ORLADEYOMember_dda8eebe-9b47-4093-9a17-a31df6ba7ad5_terseLabel_en-US" xlink:label="lab_bcrx_ORLADEYOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ORLADEYO</link:label>
    <link:label id="lab_bcrx_ORLADEYOMember_label_en-US" xlink:label="lab_bcrx_ORLADEYOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ORLADEYO [Member]</link:label>
    <link:label id="lab_bcrx_ORLADEYOMember_documentation_en-US" xlink:label="lab_bcrx_ORLADEYOMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents ORLADEYO.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ORLADEYOMember" xlink:href="bcrx-20250930.xsd#bcrx_ORLADEYOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_ORLADEYOMember" xlink:to="lab_bcrx_ORLADEYOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_a49abfe5-08bf-47ce-9a70-1c1190b61899_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_DeferredDebtPrepaymentAndDebtIssuanceCostsWriteoff_00a5ef40-58de-46db-ae4e-e7b458b0e1e0_terseLabel_en-US" xlink:label="lab_bcrx_DeferredDebtPrepaymentAndDebtIssuanceCostsWriteoff" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepayment and debt issuance costs writeoff</link:label>
    <link:label id="lab_bcrx_DeferredDebtPrepaymentAndDebtIssuanceCostsWriteoff_label_en-US" xlink:label="lab_bcrx_DeferredDebtPrepaymentAndDebtIssuanceCostsWriteoff" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Debt, Prepayment And Debt Issuance Costs, Writeoff</link:label>
    <link:label id="lab_bcrx_DeferredDebtPrepaymentAndDebtIssuanceCostsWriteoff_documentation_en-US" xlink:label="lab_bcrx_DeferredDebtPrepaymentAndDebtIssuanceCostsWriteoff" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Debt, Prepayment And Debt Issuance Costs, Writeoff</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DeferredDebtPrepaymentAndDebtIssuanceCostsWriteoff" xlink:href="bcrx-20250930.xsd#bcrx_DeferredDebtPrepaymentAndDebtIssuanceCostsWriteoff"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_DeferredDebtPrepaymentAndDebtIssuanceCostsWriteoff" xlink:to="lab_bcrx_DeferredDebtPrepaymentAndDebtIssuanceCostsWriteoff" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e429f621-0276-4ab3-936b-1877b5d33add_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_16459ec9-a5dd-4e55-911d-8ed26e4b94f7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Options cancelled or forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_AmortizationOfPremiumDiscountOnInvestments_2cbdd26e-b2cc-4600-a462-b9d554b3d3ce_terseLabel_en-US" xlink:label="lab_bcrx_AmortizationOfPremiumDiscountOnInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of discount on investments, net</link:label>
    <link:label id="lab_bcrx_AmortizationOfPremiumDiscountOnInvestments_label_en-US" xlink:label="lab_bcrx_AmortizationOfPremiumDiscountOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization Of Premium/Discount On Investments</link:label>
    <link:label id="lab_bcrx_AmortizationOfPremiumDiscountOnInvestments_documentation_en-US" xlink:label="lab_bcrx_AmortizationOfPremiumDiscountOnInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of amortization expense attributable to the discount and premium on investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AmortizationOfPremiumDiscountOnInvestments" xlink:href="bcrx-20250930.xsd#bcrx_AmortizationOfPremiumDiscountOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_AmortizationOfPremiumDiscountOnInvestments" xlink:to="lab_bcrx_AmortizationOfPremiumDiscountOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeographicDistributionDomain_3e449f2d-7734-4f0a-bcce-fd486cf74e1c_terseLabel_en-US" xlink:label="lab_us-gaap_GeographicDistributionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographic Distribution [Domain]</link:label>
    <link:label id="lab_us-gaap_GeographicDistributionDomain_label_en-US" xlink:label="lab_us-gaap_GeographicDistributionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographic Distribution [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicDistributionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeographicDistributionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeographicDistributionDomain" xlink:to="lab_us-gaap_GeographicDistributionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1c763c6e-d1c4-4b9d-95d5-06f43b5d414e_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative and Other Relationships [Line Items]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_RoyaltyReceivablesFromPartnersMember_0ae2466e-ede0-4c29-91f1-3d24609aa5cd_terseLabel_en-US" xlink:label="lab_bcrx_RoyaltyReceivablesFromPartnersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Receivables from Partners</link:label>
    <link:label id="lab_bcrx_RoyaltyReceivablesFromPartnersMember_label_en-US" xlink:label="lab_bcrx_RoyaltyReceivablesFromPartnersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Receivables from Partners [Member]</link:label>
    <link:label id="lab_bcrx_RoyaltyReceivablesFromPartnersMember_documentation_en-US" xlink:label="lab_bcrx_RoyaltyReceivablesFromPartnersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to royalty receivables from partners.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyReceivablesFromPartnersMember" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltyReceivablesFromPartnersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_RoyaltyReceivablesFromPartnersMember" xlink:to="lab_bcrx_RoyaltyReceivablesFromPartnersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_b1aaaa13-3dc7-4397-a46a-8ddd20908c4b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_8a256594-b28f-4d21-8885-22758e60b110_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_614fa4f2-79da-4c84-a71f-d7e21330a434_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, exercisable, weighted average remaining contractual term (year)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_AstriaMember_9b72593e-dcfb-4055-97d4-5a6626b6d6f1_terseLabel_en-US" xlink:label="lab_bcrx_AstriaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Astria</link:label>
    <link:label id="lab_bcrx_AstriaMember_label_en-US" xlink:label="lab_bcrx_AstriaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Astria [Member]</link:label>
    <link:label id="lab_bcrx_AstriaMember_documentation_en-US" xlink:label="lab_bcrx_AstriaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Astria</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AstriaMember" xlink:href="bcrx-20250930.xsd#bcrx_AstriaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_AstriaMember" xlink:to="lab_bcrx_AstriaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_AnnualNetSalesOf2MillionMember_e053dcdf-b90d-402a-ae71-179c1a6b1cd3_terseLabel_en-US" xlink:label="lab_bcrx_AnnualNetSalesOf2MillionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual Net Sales Of $2 Million</link:label>
    <link:label id="lab_bcrx_AnnualNetSalesOf2MillionMember_label_en-US" xlink:label="lab_bcrx_AnnualNetSalesOf2MillionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Annual Net Sales Of $2 Million [Member]</link:label>
    <link:label id="lab_bcrx_AnnualNetSalesOf2MillionMember_documentation_en-US" xlink:label="lab_bcrx_AnnualNetSalesOf2MillionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Annual Net Sales Of $2 Million</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesOf2MillionMember" xlink:href="bcrx-20250930.xsd#bcrx_AnnualNetSalesOf2MillionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_AnnualNetSalesOf2MillionMember" xlink:to="lab_bcrx_AnnualNetSalesOf2MillionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_SeniorCreditFacilityMember_30d0f672-8f52-41da-bfdb-bd2e14ce2215_terseLabel_en-US" xlink:label="lab_bcrx_SeniorCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Credit Facility</link:label>
    <link:label id="lab_bcrx_SeniorCreditFacilityMember_label_en-US" xlink:label="lab_bcrx_SeniorCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Credit Facility [Member]</link:label>
    <link:label id="lab_bcrx_SeniorCreditFacilityMember_documentation_en-US" xlink:label="lab_bcrx_SeniorCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents senior credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_SeniorCreditFacilityMember" xlink:href="bcrx-20250930.xsd#bcrx_SeniorCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_SeniorCreditFacilityMember" xlink:to="lab_bcrx_SeniorCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_MaturityPeriodOfHighQualityMarketableSecurities_1c100305-eaf4-4383-8036-dd31f170087f_terseLabel_en-US" xlink:label="lab_bcrx_MaturityPeriodOfHighQualityMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity period of high quality marketable securities (in years)</link:label>
    <link:label id="lab_bcrx_MaturityPeriodOfHighQualityMarketableSecurities_label_en-US" xlink:label="lab_bcrx_MaturityPeriodOfHighQualityMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturity Period Of High Quality Marketable Securities</link:label>
    <link:label id="lab_bcrx_MaturityPeriodOfHighQualityMarketableSecurities_documentation_en-US" xlink:label="lab_bcrx_MaturityPeriodOfHighQualityMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents maturity period of high quality marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_MaturityPeriodOfHighQualityMarketableSecurities" xlink:href="bcrx-20250930.xsd#bcrx_MaturityPeriodOfHighQualityMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_MaturityPeriodOfHighQualityMarketableSecurities" xlink:to="lab_bcrx_MaturityPeriodOfHighQualityMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_794d5aa5-4c8e-4bdd-8aa7-f95685f2500e_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_54574de4-a60a-4c59-ac40-c8881870b38e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Unobservable Inputs&#160;(Level&#160;3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_d11facbd-99bb-484d-9b16-ea1078d1e55b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTable_436d87c8-eca3-4b89-8e90-c5050c174f7c_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities [Table]</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTable" xlink:to="lab_us-gaap_MarketableSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_88ec45c4-3d47-45a3-9fe8-27a1e63220eb_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_14d5e0f9-a247-4572-b8cd-a32e58dc89cd_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities_a963f5d6-cc4e-4e57-9019-088742acfa86_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of non-financial asset</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Other Assets, Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities" xlink:to="lab_us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_f5c571cb-b07a-41ac-9e5e-4edc1408e365_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivables_70fe0ff7-54c0-42f1-b7a8-19d7eeebe6c5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Increase in receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations_81efb976-521d-4d52-b8c5-1653025f4f33_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net decrease in cash, and cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect, Continuing Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_02b2fafd-c500-4cbf-be6a-3c61fa1fbc6e_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_de903906-c3cf-488c-9396-922d6e7b5b88_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_e4e2cdef-27dd-475e-9bdb-9a3691d4f62b_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_da6c099c-91ce-48b4-9506-1fa47290953e_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_fbd51b7c-de07-43d7-ad9a-86fa0bc3ad51_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of stock option awards cancelled (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_538f65d6-86ae-40ef-be7f-5cbaa1212b38_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from common stock issued under stock-based compensation plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_b8719a32-77e0-42d8-b545-3492507e0f05_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation [Abstract]</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeographicDistributionDomesticMember_0e7dd7d1-6b83-4e2e-9baf-7ea66e52ca9d_terseLabel_en-US" xlink:label="lab_us-gaap_GeographicDistributionDomesticMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_us-gaap_GeographicDistributionDomesticMember_label_en-US" xlink:label="lab_us-gaap_GeographicDistributionDomesticMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographic Distribution, Domestic [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicDistributionDomesticMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeographicDistributionDomesticMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeographicDistributionDomesticMember" xlink:to="lab_us-gaap_GeographicDistributionDomesticMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_TermLoanTrancheAMember_e691b64d-e07b-432f-a4c0-0b49b16be4cf_terseLabel_en-US" xlink:label="lab_bcrx_TermLoanTrancheAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term Loan Tranche A</link:label>
    <link:label id="lab_bcrx_TermLoanTrancheAMember_label_en-US" xlink:label="lab_bcrx_TermLoanTrancheAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Loan Tranche A [Member]</link:label>
    <link:label id="lab_bcrx_TermLoanTrancheAMember_documentation_en-US" xlink:label="lab_bcrx_TermLoanTrancheAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term Loan Tranche A</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_TermLoanTrancheAMember" xlink:href="bcrx-20250930.xsd#bcrx_TermLoanTrancheAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_TermLoanTrancheAMember" xlink:to="lab_bcrx_TermLoanTrancheAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_b6790e15-d7ed-4cc6-bfc3-cb68525a0e89_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_ff17ea25-4cc1-4beb-bc0d-8101e8d149a0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual life</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_edbf31f5-1295-43b9-963b-2c7fa4884761_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Withholding taxes paid on stock-based awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_505b10a4-b168-463f-babe-bbf4eb950525_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4eb663e7-aa7d-49bc-a7b7-f39a607c8163_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_f108d8a5-1a02-4b1a-bc0d-20529c355647_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_6bb62f06-4bc3-4d05-bd0c-72435a1a9050_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_099e0c46-e93f-4bb5-9a73-aca404c31d94_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPayment_d4a6a46b-2163-48a5-9c8d-b264c60c4350_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, periodic payment</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPayment_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Periodic Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentPeriodicPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPayment" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_RoyaltiesMonetizationsTable_984cfb98-bad7-4330-ad31-c1c8b9530c85_terseLabel_en-US" xlink:label="lab_bcrx_RoyaltiesMonetizationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalties Monetizations [Table]</link:label>
    <link:label id="lab_bcrx_RoyaltiesMonetizationsTable_label_en-US" xlink:label="lab_bcrx_RoyaltiesMonetizationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalties Monetizations [Table]</link:label>
    <link:label id="lab_bcrx_RoyaltiesMonetizationsTable_documentation_en-US" xlink:label="lab_bcrx_RoyaltiesMonetizationsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalties Monetizations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltiesMonetizationsTable" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltiesMonetizationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_RoyaltiesMonetizationsTable" xlink:to="lab_bcrx_RoyaltiesMonetizationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_SegmentReportingAdjustmentsAndReconcilingItemsAmount_ddbcbcc0-60dd-4518-aa9f-0038c682d22c_terseLabel_en-US" xlink:label="lab_bcrx_SegmentReportingAdjustmentsAndReconcilingItemsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments and reconciling items</link:label>
    <link:label id="lab_bcrx_SegmentReportingAdjustmentsAndReconcilingItemsAmount_label_en-US" xlink:label="lab_bcrx_SegmentReportingAdjustmentsAndReconcilingItemsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Adjustments and Reconciling Items, Amount</link:label>
    <link:label id="lab_bcrx_SegmentReportingAdjustmentsAndReconcilingItemsAmount_documentation_en-US" xlink:label="lab_bcrx_SegmentReportingAdjustmentsAndReconcilingItemsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Segment Reporting, Adjustments and Reconciling Items, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_SegmentReportingAdjustmentsAndReconcilingItemsAmount" xlink:href="bcrx-20250930.xsd#bcrx_SegmentReportingAdjustmentsAndReconcilingItemsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_SegmentReportingAdjustmentsAndReconcilingItemsAmount" xlink:to="lab_bcrx_SegmentReportingAdjustmentsAndReconcilingItemsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_0a97798a-0856-4da9-9a64-739967bd0e61_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Price per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_OperatingLeaseAssets_7742a26b-65e1-4451-8178-edf1144816d1_terseLabel_en-US" xlink:label="lab_bcrx_OperatingLeaseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_bcrx_OperatingLeaseAssets_label_en-US" xlink:label="lab_bcrx_OperatingLeaseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_bcrx_OperatingLeaseAssets_documentation_en-US" xlink:label="lab_bcrx_OperatingLeaseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information on operating lease right-of-use assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_OperatingLeaseAssets" xlink:href="bcrx-20250930.xsd#bcrx_OperatingLeaseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_OperatingLeaseAssets" xlink:to="lab_bcrx_OperatingLeaseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_f384e615-c0b2-40f3-90ca-ebf479ecb1df_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Quoted Price in Active Markets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_9897fbad-c5db-4d3b-81d7-ef404fff9ed1_negatedLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Foreign currency (gains) losses, net</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss), Foreign Currency Transaction, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets_4750b2c4-2e6b-4088-a3a8-01258373493e_terseLabel_en-US" xlink:label="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty purchase agreement, royalties, percentage of annual net sales in other markets</link:label>
    <link:label id="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets_label_en-US" xlink:label="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Purchase Agreement Royalties Percentage Of Annual Net Sales In Other Markets</link:label>
    <link:label id="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets_documentation_en-US" xlink:label="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percentage of annual net sales in other markets of royalties to be paid under the royalty purchase agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets" xlink:to="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_8b047526-2b2a-40b7-afa4-249a51cc4cab_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted net loss per common share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_97700a8a-a0b1-408b-8386-bd902f4487b2_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) per common share, diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_93dc290a-fba2-4905-94fe-30b371a37244_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_c77cb5e8-48d6-4516-902b-8b28de64499e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade receivables</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeOperating_fee49fc4-341b-49d8-b4a5-cf52c0778b64_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOperating_label_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income, Operating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeOperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOperating" xlink:to="lab_us-gaap_InterestIncomeOperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_d4b586c5-bac6-4575-8bce-b838fd96d7bd_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_1ca4f7f4-2150-4a18-931a-8d8c9ff4d86d_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_25fb1bd5-c2d1-4e1f-bebc-a66e0c80721f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_RoyaltyMontizationsRollForward_721f4ea3-7b9e-447e-9c23-0c6dba5cb3eb_terseLabel_en-US" xlink:label="lab_bcrx_RoyaltyMontizationsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Montizations [Roll Forward]</link:label>
    <link:label id="lab_bcrx_RoyaltyMontizationsRollForward_label_en-US" xlink:label="lab_bcrx_RoyaltyMontizationsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Montizations [Roll Forward]</link:label>
    <link:label id="lab_bcrx_RoyaltyMontizationsRollForward_documentation_en-US" xlink:label="lab_bcrx_RoyaltyMontizationsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Montizations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyMontizationsRollForward" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltyMontizationsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_RoyaltyMontizationsRollForward" xlink:to="lab_bcrx_RoyaltyMontizationsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e20ea3fb-1f36-4734-a0a7-d349541e4bb9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_NonCashInterestExpenseOnRoyaltyFinancingLiabilities_816bee16-9b5b-4809-b5ff-361e665893e4_terseLabel_en-US" xlink:label="lab_bcrx_NonCashInterestExpenseOnRoyaltyFinancingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash interest expense on royalty financing obligations</link:label>
    <link:label id="lab_bcrx_NonCashInterestExpenseOnRoyaltyFinancingLiabilities_label_en-US" xlink:label="lab_bcrx_NonCashInterestExpenseOnRoyaltyFinancingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Cash Interest Expense On Royalty Financing Liabilities</link:label>
    <link:label id="lab_bcrx_NonCashInterestExpenseOnRoyaltyFinancingLiabilities_documentation_en-US" xlink:label="lab_bcrx_NonCashInterestExpenseOnRoyaltyFinancingLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of non-cash interest expense on royalty financing obligation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_NonCashInterestExpenseOnRoyaltyFinancingLiabilities" xlink:href="bcrx-20250930.xsd#bcrx_NonCashInterestExpenseOnRoyaltyFinancingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_NonCashInterestExpenseOnRoyaltyFinancingLiabilities" xlink:to="lab_bcrx_NonCashInterestExpenseOnRoyaltyFinancingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_FutureRoyaltiesPayableMember_458b2386-00e7-435e-9a5c-d9ce66228fdf_terseLabel_en-US" xlink:label="lab_bcrx_FutureRoyaltiesPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future Royalties Payable</link:label>
    <link:label id="lab_bcrx_FutureRoyaltiesPayableMember_label_en-US" xlink:label="lab_bcrx_FutureRoyaltiesPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Royalties Payable [Member]</link:label>
    <link:label id="lab_bcrx_FutureRoyaltiesPayableMember_documentation_en-US" xlink:label="lab_bcrx_FutureRoyaltiesPayableMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents future royalties payable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_FutureRoyaltiesPayableMember" xlink:href="bcrx-20250930.xsd#bcrx_FutureRoyaltiesPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_FutureRoyaltiesPayableMember" xlink:to="lab_bcrx_FutureRoyaltiesPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_975df67b-7eab-4670-9c97-13ae6ff4b55b_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other expense, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_DebtInstrumentPrepaymentPremium_35bfc13f-9d15-463d-ada8-b08201e73579_terseLabel_en-US" xlink:label="lab_bcrx_DebtInstrumentPrepaymentPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepayment premium</link:label>
    <link:label id="lab_bcrx_DebtInstrumentPrepaymentPremium_label_en-US" xlink:label="lab_bcrx_DebtInstrumentPrepaymentPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Premium</link:label>
    <link:label id="lab_bcrx_DebtInstrumentPrepaymentPremium_documentation_en-US" xlink:label="lab_bcrx_DebtInstrumentPrepaymentPremium" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DebtInstrumentPrepaymentPremium" xlink:href="bcrx-20250930.xsd#bcrx_DebtInstrumentPrepaymentPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_DebtInstrumentPrepaymentPremium" xlink:to="lab_bcrx_DebtInstrumentPrepaymentPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_39705cf2-7690-46ef-b447-82ccb016422f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_befacfbd-1718-4ea0-bbd4-2377152bd155_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_NonCashIncreaseInOperatingLeaseAssetsDueToRemeasurementOfOperatingLeaseLiabilities_29702baa-0bcc-4740-abf3-dea746cd67d9_terseLabel_en-US" xlink:label="lab_bcrx_NonCashIncreaseInOperatingLeaseAssetsDueToRemeasurementOfOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash increase to operating lease assets due to remeasurement of operating lease liabilities</link:label>
    <link:label id="lab_bcrx_NonCashIncreaseInOperatingLeaseAssetsDueToRemeasurementOfOperatingLeaseLiabilities_label_en-US" xlink:label="lab_bcrx_NonCashIncreaseInOperatingLeaseAssetsDueToRemeasurementOfOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-cash Increase In Operating Lease Assets Due To Remeasurement Of Operating Lease Liabilities</link:label>
    <link:label id="lab_bcrx_NonCashIncreaseInOperatingLeaseAssetsDueToRemeasurementOfOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_bcrx_NonCashIncreaseInOperatingLeaseAssetsDueToRemeasurementOfOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-cash Increase In Operating Lease Assets Due To Remeasurement Of Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_NonCashIncreaseInOperatingLeaseAssetsDueToRemeasurementOfOperatingLeaseLiabilities" xlink:href="bcrx-20250930.xsd#bcrx_NonCashIncreaseInOperatingLeaseAssetsDueToRemeasurementOfOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_NonCashIncreaseInOperatingLeaseAssetsDueToRemeasurementOfOperatingLeaseLiabilities" xlink:to="lab_bcrx_NonCashIncreaseInOperatingLeaseAssetsDueToRemeasurementOfOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_NumberOfOptionalOrderingPeriods_809b1b0f-43a2-4f33-b77b-b61b948dea43_terseLabel_en-US" xlink:label="lab_bcrx_NumberOfOptionalOrderingPeriods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of optional ordering periods</link:label>
    <link:label id="lab_bcrx_NumberOfOptionalOrderingPeriods_label_en-US" xlink:label="lab_bcrx_NumberOfOptionalOrderingPeriods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Optional Ordering Periods</link:label>
    <link:label id="lab_bcrx_NumberOfOptionalOrderingPeriods_documentation_en-US" xlink:label="lab_bcrx_NumberOfOptionalOrderingPeriods" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Optional Ordering Periods</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_NumberOfOptionalOrderingPeriods" xlink:href="bcrx-20250930.xsd#bcrx_NumberOfOptionalOrderingPeriods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_NumberOfOptionalOrderingPeriods" xlink:to="lab_bcrx_NumberOfOptionalOrderingPeriods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0056c39b-2c55-4276-9c72-5a430a9c4d64_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_RPI2021And2020IntermediateFinanceTrustMember_418bd49e-1d6c-44a0-a36f-0ba9a3e0383c_terseLabel_en-US" xlink:label="lab_bcrx_RPI2021And2020IntermediateFinanceTrustMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RPI 2021 and 2020 Intermediate Finance Trust</link:label>
    <link:label id="lab_bcrx_RPI2021And2020IntermediateFinanceTrustMember_label_en-US" xlink:label="lab_bcrx_RPI2021And2020IntermediateFinanceTrustMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">RPI 2021 and 2020 Intermediate Finance Trust [Member]</link:label>
    <link:label id="lab_bcrx_RPI2021And2020IntermediateFinanceTrustMember_documentation_en-US" xlink:label="lab_bcrx_RPI2021And2020IntermediateFinanceTrustMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents RPI 2021 and 2020 Intermediate Finance Trust (RPI).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RPI2021And2020IntermediateFinanceTrustMember" xlink:href="bcrx-20250930.xsd#bcrx_RPI2021And2020IntermediateFinanceTrustMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_RPI2021And2020IntermediateFinanceTrustMember" xlink:to="lab_bcrx_RPI2021And2020IntermediateFinanceTrustMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_f82c148c-c6fc-4f1a-94b2-5230ee50df4e_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_beb0eea9-ea11-4410-a78a-cfbb99df0fe5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of stock option awards exercised (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_b755be8e-2cb6-42fa-a3c3-3bc0c0a027cb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_39179e3e-9b13-48f0-8f70-df43ab405bc5_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets held for sale</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_e7e57b43-7aef-4308-a001-edd6f0870d98_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Current assets held for sale</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_OMERSCapitalMarketsMember_84a926e6-8b70-45f4-bef3-bce52dff0826_terseLabel_en-US" xlink:label="lab_bcrx_OMERSCapitalMarketsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OMERS Capital Markets</link:label>
    <link:label id="lab_bcrx_OMERSCapitalMarketsMember_label_en-US" xlink:label="lab_bcrx_OMERSCapitalMarketsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OMERS Capital Markets [Member]</link:label>
    <link:label id="lab_bcrx_OMERSCapitalMarketsMember_documentation_en-US" xlink:label="lab_bcrx_OMERSCapitalMarketsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information on the rights of OMERS Capital Markets to receive certain royalty payments under the OMERS Royalty Purchase Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_OMERSCapitalMarketsMember" xlink:href="bcrx-20250930.xsd#bcrx_OMERSCapitalMarketsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_OMERSCapitalMarketsMember" xlink:to="lab_bcrx_OMERSCapitalMarketsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8b345689-270d-4bb7-b5fc-3c3ff0db0d74_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of stock option awards granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_ShareBasedPaymentArrangementNumberOfPlans_4127e854-ac44-4edb-b636-2b4a1dd417a6_terseLabel_en-US" xlink:label="lab_bcrx_ShareBasedPaymentArrangementNumberOfPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of plans</link:label>
    <link:label id="lab_bcrx_ShareBasedPaymentArrangementNumberOfPlans_label_en-US" xlink:label="lab_bcrx_ShareBasedPaymentArrangementNumberOfPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Number of Plans</link:label>
    <link:label id="lab_bcrx_ShareBasedPaymentArrangementNumberOfPlans_documentation_en-US" xlink:label="lab_bcrx_ShareBasedPaymentArrangementNumberOfPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Number of Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ShareBasedPaymentArrangementNumberOfPlans" xlink:href="bcrx-20250930.xsd#bcrx_ShareBasedPaymentArrangementNumberOfPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_ShareBasedPaymentArrangementNumberOfPlans" xlink:to="lab_bcrx_ShareBasedPaymentArrangementNumberOfPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_RPI2019IntermediateFinanceTrustMember_13618d0b-d875-4a46-b75a-9f7d51cbcb0c_terseLabel_en-US" xlink:label="lab_bcrx_RPI2019IntermediateFinanceTrustMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RPI 2019 Intermediate Finance Trust</link:label>
    <link:label id="lab_bcrx_RPI2019IntermediateFinanceTrustMember_label_en-US" xlink:label="lab_bcrx_RPI2019IntermediateFinanceTrustMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">RPI 2019 Intermediate Finance Trust [Member]</link:label>
    <link:label id="lab_bcrx_RPI2019IntermediateFinanceTrustMember_documentation_en-US" xlink:label="lab_bcrx_RPI2019IntermediateFinanceTrustMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents RPI 2019 Intermediate Finance Trust (RPI)..</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RPI2019IntermediateFinanceTrustMember" xlink:href="bcrx-20250930.xsd#bcrx_RPI2019IntermediateFinanceTrustMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_RPI2019IntermediateFinanceTrustMember" xlink:to="lab_bcrx_RPI2019IntermediateFinanceTrustMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b1e38f54-9b49-4641-90e1-8a247c67bf39_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeMilestone_c9034d4f-bd31-444b-977b-62f8012fd0dd_terseLabel_en-US" xlink:label="lab_bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential milestone payments receivable if regulatory approval before specified date</link:label>
    <link:label id="lab_bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeMilestone_label_en-US" xlink:label="lab_bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Milestone Payments Receivable If Regulatory Approval Before Milestone</link:label>
    <link:label id="lab_bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeMilestone_documentation_en-US" xlink:label="lab_bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of potential milestone payments receivable if regulatory approval is granted.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeMilestone" xlink:href="bcrx-20250930.xsd#bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeMilestone" xlink:to="lab_bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_TermLoanTrancheBMember_3f1ec6ed-c409-49d6-b743-e43f39feaa41_terseLabel_en-US" xlink:label="lab_bcrx_TermLoanTrancheBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term Loan Tranche B</link:label>
    <link:label id="lab_bcrx_TermLoanTrancheBMember_label_en-US" xlink:label="lab_bcrx_TermLoanTrancheBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Loan Tranche B [Member]</link:label>
    <link:label id="lab_bcrx_TermLoanTrancheBMember_documentation_en-US" xlink:label="lab_bcrx_TermLoanTrancheBMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term Loan Tranche B</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_TermLoanTrancheBMember" xlink:href="bcrx-20250930.xsd#bcrx_TermLoanTrancheBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_TermLoanTrancheBMember" xlink:to="lab_bcrx_TermLoanTrancheBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_NumberOfProductDeliveredDoses_2afd6fd1-28f3-4363-a5a1-64ad838604d8_terseLabel_en-US" xlink:label="lab_bcrx_NumberOfProductDeliveredDoses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Doses delivered</link:label>
    <link:label id="lab_bcrx_NumberOfProductDeliveredDoses_label_en-US" xlink:label="lab_bcrx_NumberOfProductDeliveredDoses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Product Delivered, Doses</link:label>
    <link:label id="lab_bcrx_NumberOfProductDeliveredDoses_documentation_en-US" xlink:label="lab_bcrx_NumberOfProductDeliveredDoses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Product Delivered, Doses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_NumberOfProductDeliveredDoses" xlink:href="bcrx-20250930.xsd#bcrx_NumberOfProductDeliveredDoses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_NumberOfProductDeliveredDoses" xlink:to="lab_bcrx_NumberOfProductDeliveredDoses" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_ConcentrationOfMarketRiskPolicyTextBlock_d9caf926-19c9-4e15-ac2a-68f57b906b51_terseLabel_en-US" xlink:label="lab_bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Customers and Other Risks</link:label>
    <link:label id="lab_bcrx_ConcentrationOfMarketRiskPolicyTextBlock_label_en-US" xlink:label="lab_bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration of Market Risk [Policy Text Block]</link:label>
    <link:label id="lab_bcrx_ConcentrationOfMarketRiskPolicyTextBlock_documentation_en-US" xlink:label="lab_bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents concentration of market risk policy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:href="bcrx-20250930.xsd#bcrx_ConcentrationOfMarketRiskPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:to="lab_bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_384a6882-977f-4b0e-bb40-765afe57def1_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_ContractTerm_63f7d581-67b9-4060-8983-818de4aa5d25_terseLabel_en-US" xlink:label="lab_bcrx_ContractTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract term</link:label>
    <link:label id="lab_bcrx_ContractTerm_label_en-US" xlink:label="lab_bcrx_ContractTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Term</link:label>
    <link:label id="lab_bcrx_ContractTerm_documentation_en-US" xlink:label="lab_bcrx_ContractTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ContractTerm" xlink:href="bcrx-20250930.xsd#bcrx_ContractTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_ContractTerm" xlink:to="lab_bcrx_ContractTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities_2dea07d9-25f2-486a-af37-ed702a095ded_terseLabel_en-US" xlink:label="lab_bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average maturity period of high quality marketable securities (in months)</link:label>
    <link:label id="lab_bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities_label_en-US" xlink:label="lab_bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Average Maturity Period Of High Quality Marketable Securities</link:label>
    <link:label id="lab_bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities_documentation_en-US" xlink:label="lab_bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Average maturity period of high quality marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities" xlink:href="bcrx-20250930.xsd#bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities" xlink:to="lab_bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_OtherSupplementalInformationRelatedToLeasesTableTextBlock_5c0a9303-00e7-4c21-a937-8b932bc55f34_terseLabel_en-US" xlink:label="lab_bcrx_OtherSupplementalInformationRelatedToLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Supplemental Information Related to Leases</link:label>
    <link:label id="lab_bcrx_OtherSupplementalInformationRelatedToLeasesTableTextBlock_label_en-US" xlink:label="lab_bcrx_OtherSupplementalInformationRelatedToLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Supplemental Information Related to Leases [Table Text Block]</link:label>
    <link:label id="lab_bcrx_OtherSupplementalInformationRelatedToLeasesTableTextBlock_documentation_en-US" xlink:label="lab_bcrx_OtherSupplementalInformationRelatedToLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Supplemental Information Related to Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_OtherSupplementalInformationRelatedToLeasesTableTextBlock" xlink:href="bcrx-20250930.xsd#bcrx_OtherSupplementalInformationRelatedToLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_OtherSupplementalInformationRelatedToLeasesTableTextBlock" xlink:to="lab_bcrx_OtherSupplementalInformationRelatedToLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_f90edc98-aa0e-4e9a-be6b-92b7b8ffc973_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_efe2a793-839f-4ed7-a9f5-9d90f9d9833c_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_66b1c280-b635-4015-b6aa-b70014fcf47c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_SharesIssuedCommonStockPremium_c89ab8be-dfaa-411c-977d-357d61c8505f_terseLabel_en-US" xlink:label="lab_bcrx_SharesIssuedCommonStockPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued, common stock, premium</link:label>
    <link:label id="lab_bcrx_SharesIssuedCommonStockPremium_label_en-US" xlink:label="lab_bcrx_SharesIssuedCommonStockPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued Common Stock Premium</link:label>
    <link:label id="lab_bcrx_SharesIssuedCommonStockPremium_documentation_en-US" xlink:label="lab_bcrx_SharesIssuedCommonStockPremium" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information on the amount of the common stock premium.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_SharesIssuedCommonStockPremium" xlink:href="bcrx-20250930.xsd#bcrx_SharesIssuedCommonStockPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_SharesIssuedCommonStockPremium" xlink:to="lab_bcrx_SharesIssuedCommonStockPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_AnnualNetSalesOver230000Member_e94be24f-50b5-4946-a417-e43ee6f542a9_terseLabel_en-US" xlink:label="lab_bcrx_AnnualNetSalesOver230000Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual Net Sales Over $230,000</link:label>
    <link:label id="lab_bcrx_AnnualNetSalesOver230000Member_label_en-US" xlink:label="lab_bcrx_AnnualNetSalesOver230000Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Annual Net Sales Over $230,000 [Member]</link:label>
    <link:label id="lab_bcrx_AnnualNetSalesOver230000Member_documentation_en-US" xlink:label="lab_bcrx_AnnualNetSalesOver230000Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents annual net sales over $230,000.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesOver230000Member" xlink:href="bcrx-20250930.xsd#bcrx_AnnualNetSalesOver230000Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_AnnualNetSalesOver230000Member" xlink:to="lab_bcrx_AnnualNetSalesOver230000Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityAbstract_8cb0bea6-fe24-40a7-9c0a-ba8493d5be50_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability [Abstract]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_OtherExpenses1Member_2b59361e-5032-4761-ba89-5d8c4cdf6ec8_terseLabel_en-US" xlink:label="lab_bcrx_OtherExpenses1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-program specific and indirect costs</link:label>
    <link:label id="lab_bcrx_OtherExpenses1Member_label_en-US" xlink:label="lab_bcrx_OtherExpenses1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Expenses 1 [Member]</link:label>
    <link:label id="lab_bcrx_OtherExpenses1Member_documentation_en-US" xlink:label="lab_bcrx_OtherExpenses1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Expenses 1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_OtherExpenses1Member" xlink:href="bcrx-20250930.xsd#bcrx_OtherExpenses1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_OtherExpenses1Member" xlink:to="lab_bcrx_OtherExpenses1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember_defa3b6f-8a95-48bb-8ca3-8530c571302c_terseLabel_en-US" xlink:label="lab_bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Laboratory Equipment, Office Equipment and Software</link:label>
    <link:label id="lab_bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember_label_en-US" xlink:label="lab_bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratory Equipment, Office Equipment and Software [Member]</link:label>
    <link:label id="lab_bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember_documentation_en-US" xlink:label="lab_bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to laboratory equipment, office equipment and software.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:href="bcrx-20250930.xsd#bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:to="lab_bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments_50af0503-aeaf-4bad-851a-6df6cda1ec77_terseLabel_en-US" xlink:label="lab_bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, prepayment fee, percentage of principal voluntary payments</link:label>
    <link:label id="lab_bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments_label_en-US" xlink:label="lab_bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Prepayment Fee Percentage of Principal Voluntary Payments</link:label>
    <link:label id="lab_bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments_documentation_en-US" xlink:label="lab_bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percentage of principal paid voluntarily for prepayment fee of the debt instrument.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments" xlink:href="bcrx-20250930.xsd#bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments" xlink:to="lab_bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_098a3658-ada6-448c-9b7d-8ff071e9a365_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_7fb86b5e-8190-4e8c-80d0-59c873d74f07_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_TwentyTwentyRPIRoyaltyAgreementMember_9a6d2daa-5eb2-4502-b5a4-4888fcc24501_terseLabel_en-US" xlink:label="lab_bcrx_TwentyTwentyRPIRoyaltyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020 RPI Royalty Agreement</link:label>
    <link:label id="lab_bcrx_TwentyTwentyRPIRoyaltyAgreementMember_label_en-US" xlink:label="lab_bcrx_TwentyTwentyRPIRoyaltyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2020 RPI Royalty Agreement [Member]</link:label>
    <link:label id="lab_bcrx_TwentyTwentyRPIRoyaltyAgreementMember_documentation_en-US" xlink:label="lab_bcrx_TwentyTwentyRPIRoyaltyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information on 2020 RPI Royalty agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_TwentyTwentyRPIRoyaltyAgreementMember" xlink:href="bcrx-20250930.xsd#bcrx_TwentyTwentyRPIRoyaltyAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_TwentyTwentyRPIRoyaltyAgreementMember" xlink:to="lab_bcrx_TwentyTwentyRPIRoyaltyAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_14dc7fdb-66f5-4ca0-84ad-27ffcdf0984b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_caffbe87-7ef7-4114-ab6a-7f7e7d83af65_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_eb9efd1e-a8ed-496c-a902-980dcf5377f4_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_e4ca623c-1a07-43a2-b5be-4d07fd0a1bf7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, operating lease, term of contract (in years)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesAbstract_label_en-US" xlink:label="lab_us-gaap_ReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesAbstract" xlink:to="lab_us-gaap_ReceivablesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_6b0e6d50-8b4b-43ce-97d5-845cf1c16ec7_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_253d36ac-e3cc-4a9f-9f8c-c1217eac5fa5_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_cb89303d-a4b6-46f4-ac9c-cde8bfbd9213_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_7d32d24f-dec2-4fc8-9a42-acc6a187c363_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_LicenseAgreementUpfrontPayment_e1213ff7-b434-494a-aaa3-3e3230aafa85_terseLabel_en-US" xlink:label="lab_bcrx_LicenseAgreementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront payment</link:label>
    <link:label id="lab_bcrx_LicenseAgreementUpfrontPayment_label_en-US" xlink:label="lab_bcrx_LicenseAgreementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement, Upfront Payment</link:label>
    <link:label id="lab_bcrx_LicenseAgreementUpfrontPayment_documentation_en-US" xlink:label="lab_bcrx_LicenseAgreementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Agreement, Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_LicenseAgreementUpfrontPayment" xlink:href="bcrx-20250930.xsd#bcrx_LicenseAgreementUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_LicenseAgreementUpfrontPayment" xlink:to="lab_bcrx_LicenseAgreementUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_1250f665-2a35-446a-b67c-739d39f92dfe_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_a03801b4-4aaf-4f66-9555-c5f31699dfee_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories_9bbcf9bb-059b-4844-a795-8fdfaa3eb704_terseLabel_en-US" xlink:label="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty purchase agreement, royalties, percentage of annual net sales in key territories</link:label>
    <link:label id="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories_label_en-US" xlink:label="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Purchase Agreement Royalties Percentage Of Annual Net Sales In Key Territories</link:label>
    <link:label id="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories_documentation_en-US" xlink:label="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percentage of net sales in key territories for royalties to be paid under the royalty purchase agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories" xlink:to="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_RoyaltyFinancingLiabilitiesNoncurrent_d62020a6-a494-4fc2-98bd-a14d2fa4a12b_terseLabel_en-US" xlink:label="lab_bcrx_RoyaltyFinancingLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty financing obligations</link:label>
    <link:label id="lab_bcrx_RoyaltyFinancingLiabilitiesNoncurrent_label_en-US" xlink:label="lab_bcrx_RoyaltyFinancingLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Financing Liabilities, Noncurrent</link:label>
    <link:label id="lab_bcrx_RoyaltyFinancingLiabilitiesNoncurrent_documentation_en-US" xlink:label="lab_bcrx_RoyaltyFinancingLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying amount as of the balance sheet date of obligations for future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyFinancingLiabilitiesNoncurrent" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltyFinancingLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_RoyaltyFinancingLiabilitiesNoncurrent" xlink:to="lab_bcrx_RoyaltyFinancingLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_b9e93f6a-250a-4c6b-bbd6-bac04edb1ce5_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_a2d76b71-5551-4606-9375-fc9f8f008fd7_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of long-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryValuationReserves_cc9d1925-b963-4893-ba66-bf59edccd40f_negatedLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Reserves</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserves_label_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Valuation Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryValuationReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserves" xlink:to="lab_us-gaap_InventoryValuationReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_020f2ed2-790f-40a4-97c4-a97af937c4fb_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_4303c118-2368-4695-99db-f2ec855d0079_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e1b50bcf-f919-4be9-909f-0ae14b1118d5_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected life in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterOneYearAndBeforeTwoYears_091f1e34-fcbd-4a0f-949f-b019be80f3d0_terseLabel_en-US" xlink:label="lab_bcrx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterOneYearAndBeforeTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturing after one year through two years</link:label>
    <link:label id="lab_bcrx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterOneYearAndBeforeTwoYears_label_en-US" xlink:label="lab_bcrx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterOneYearAndBeforeTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date After One Year and Before Two Years</link:label>
    <link:label id="lab_bcrx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterOneYearAndBeforeTwoYears_documentation_en-US" xlink:label="lab_bcrx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterOneYearAndBeforeTwoYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of investment in debt securities maturing after one year through two years.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterOneYearAndBeforeTwoYears" xlink:href="bcrx-20250930.xsd#bcrx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterOneYearAndBeforeTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterOneYearAndBeforeTwoYears" xlink:to="lab_bcrx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterOneYearAndBeforeTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_AssetsHeldForSalePolicyTextBlock_928cdd54-a3d7-4bec-bcf6-306923c80e90_terseLabel_en-US" xlink:label="lab_bcrx_AssetsHeldForSalePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets Held For Sale</link:label>
    <link:label id="lab_bcrx_AssetsHeldForSalePolicyTextBlock_label_en-US" xlink:label="lab_bcrx_AssetsHeldForSalePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets Held For Sale [Policy Text Block]</link:label>
    <link:label id="lab_bcrx_AssetsHeldForSalePolicyTextBlock_documentation_en-US" xlink:label="lab_bcrx_AssetsHeldForSalePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AssetsHeldForSalePolicyTextBlock" xlink:href="bcrx-20250930.xsd#bcrx_AssetsHeldForSalePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_AssetsHeldForSalePolicyTextBlock" xlink:to="lab_bcrx_AssetsHeldForSalePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_36895a7a-69f3-494e-a3cf-b4f45d40342a_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities held for sale</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_8da117b6-0c36-453f-9e9e-4db0c10f5b21_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Current liabilities held for sale</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e59afb89-a890-4356-a521-a7d65fe1a9bc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_e21571ee-66b7-420b-b456-a52bd2264827_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_InventoryIncludingNoncurrentPortion_43ebeef9-ec90-4f22-8244-fbe20d729812_totalLabel_en-US" xlink:label="lab_bcrx_InventoryIncludingNoncurrentPortion" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total inventory, net</link:label>
    <link:label id="lab_bcrx_InventoryIncludingNoncurrentPortion_label_en-US" xlink:label="lab_bcrx_InventoryIncludingNoncurrentPortion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Including Noncurrent Portion</link:label>
    <link:label id="lab_bcrx_InventoryIncludingNoncurrentPortion_documentation_en-US" xlink:label="lab_bcrx_InventoryIncludingNoncurrentPortion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inventory, Including Noncurrent Portion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_InventoryIncludingNoncurrentPortion" xlink:href="bcrx-20250930.xsd#bcrx_InventoryIncludingNoncurrentPortion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_InventoryIncludingNoncurrentPortion" xlink:to="lab_bcrx_InventoryIncludingNoncurrentPortion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3c865c4d-a2dd-4d44-b27a-ebf436635b22_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_57dc947f-d18c-47fb-b70a-2d398d8061db_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative and Other Relationships</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a742cb22-623f-440a-943b-252695e77798_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_540b8598-6d96-41af-89a3-0f081ebce175_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value stock option awards (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_b070e265-eb41-4d18-ab60-d15427405b44_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Benchmark</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_AnnualNetSalesGreaterThan15MillionMember_f99d9714-67ee-40df-8d54-94165f7b13dd_terseLabel_en-US" xlink:label="lab_bcrx_AnnualNetSalesGreaterThan15MillionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual Net Sales Greater Than $1.5 Million</link:label>
    <link:label id="lab_bcrx_AnnualNetSalesGreaterThan15MillionMember_label_en-US" xlink:label="lab_bcrx_AnnualNetSalesGreaterThan15MillionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Annual Net Sales Greater Than $1.5 Million [Member]</link:label>
    <link:label id="lab_bcrx_AnnualNetSalesGreaterThan15MillionMember_documentation_en-US" xlink:label="lab_bcrx_AnnualNetSalesGreaterThan15MillionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Annual Net Sales Greater Than $1.5 Million</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesGreaterThan15MillionMember" xlink:href="bcrx-20250930.xsd#bcrx_AnnualNetSalesGreaterThan15MillionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_AnnualNetSalesGreaterThan15MillionMember" xlink:to="lab_bcrx_AnnualNetSalesGreaterThan15MillionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_88ff7499-e35e-408b-9a0d-86f3ab918b91_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Receivables</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_528a5c00-2e1b-4c5b-81d8-206151a2153c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_c167e1b0-5999-4c55-9b6a-e6c1838c5214_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_52c1deab-3fec-44aa-bcea-a829b09ae26f_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share, amount (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_2aaa9d16-57e0-4156-8e2b-0d7594da7e5f_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_PotentialMilestonePaymentsPayable_60bdefaf-f575-45bb-bc68-790fc54bf2cc_terseLabel_en-US" xlink:label="lab_bcrx_PotentialMilestonePaymentsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential milestone payment</link:label>
    <link:label id="lab_bcrx_PotentialMilestonePaymentsPayable_label_en-US" xlink:label="lab_bcrx_PotentialMilestonePaymentsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Milestone Payments Payable</link:label>
    <link:label id="lab_bcrx_PotentialMilestonePaymentsPayable_documentation_en-US" xlink:label="lab_bcrx_PotentialMilestonePaymentsPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Potential Milestone Payments Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_PotentialMilestonePaymentsPayable" xlink:href="bcrx-20250930.xsd#bcrx_PotentialMilestonePaymentsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_PotentialMilestonePaymentsPayable" xlink:to="lab_bcrx_PotentialMilestonePaymentsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_bfa14024-7320-4928-aad9-64c36463b58e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Interest</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_DebtCovenantTermsDomain_14ed704c-7311-45b7-b5d8-9aa9bb7be378_terseLabel_en-US" xlink:label="lab_bcrx_DebtCovenantTermsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Covenant Terms [Domain]</link:label>
    <link:label id="lab_bcrx_DebtCovenantTermsDomain_label_en-US" xlink:label="lab_bcrx_DebtCovenantTermsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Covenant Terms [Domain]</link:label>
    <link:label id="lab_bcrx_DebtCovenantTermsDomain_documentation_en-US" xlink:label="lab_bcrx_DebtCovenantTermsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Covenant Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DebtCovenantTermsDomain" xlink:href="bcrx-20250930.xsd#bcrx_DebtCovenantTermsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_DebtCovenantTermsDomain" xlink:to="lab_bcrx_DebtCovenantTermsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_fb803de2-dfe1-4b09-bf3e-e253c051759b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Obligations</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_a9d73c4b-6c07-42b8-98f9-70a31c67e64e_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_A.MachelleSandersMember_label_en-US" xlink:label="lab_bcrx_A.MachelleSandersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">A. Machelle Sanders [Member]</link:label>
    <link:label id="lab_bcrx_A.MachelleSandersMember_documentation_en-US" xlink:label="lab_bcrx_A.MachelleSandersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">A. Machelle Sanders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_A.MachelleSandersMember" xlink:href="bcrx-20250930.xsd#bcrx_A.MachelleSandersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_A.MachelleSandersMember" xlink:to="lab_bcrx_A.MachelleSandersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_RoyaltyFinancingLiabilitiesTableTextBlock_8c9c87ba-be61-4a9d-80e2-bc06e6342711_terseLabel_en-US" xlink:label="lab_bcrx_RoyaltyFinancingLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Royalty Financing Obligations</link:label>
    <link:label id="lab_bcrx_RoyaltyFinancingLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_bcrx_RoyaltyFinancingLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Financing Liabilities [Table Text Block]</link:label>
    <link:label id="lab_bcrx_RoyaltyFinancingLiabilitiesTableTextBlock_documentation_en-US" xlink:label="lab_bcrx_RoyaltyFinancingLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure for royalty financing obligations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyFinancingLiabilitiesTableTextBlock" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltyFinancingLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_RoyaltyFinancingLiabilitiesTableTextBlock" xlink:to="lab_bcrx_RoyaltyFinancingLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_BlackstoneMember_34c6e38a-5668-4146-b052-61383b2a6634_terseLabel_en-US" xlink:label="lab_bcrx_BlackstoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Blackstone</link:label>
    <link:label id="lab_bcrx_BlackstoneMember_label_en-US" xlink:label="lab_bcrx_BlackstoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Blackstone [Member]</link:label>
    <link:label id="lab_bcrx_BlackstoneMember_documentation_en-US" xlink:label="lab_bcrx_BlackstoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Blackstone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_BlackstoneMember" xlink:href="bcrx-20250930.xsd#bcrx_BlackstoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_BlackstoneMember" xlink:to="lab_bcrx_BlackstoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_7544d8a3-c730-4457-9dc5-144b5c7c8149_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_label_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivableTypeDomain" xlink:to="lab_us-gaap_ReceivableTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_9add9487-369f-4ad2-8334-9f1218a5c3f3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_11838b16-8686-4779-9b16-492ae7bf0792_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b073a437-0511-45ba-9c95-8038f4692e99_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_649e61ab-fe4d-4870-8581-6b429c54337b_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory obsolescence</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_5aec6c7a-4d9d-455d-8824-f7eabb04389a_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of product sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Product and Service Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList_0950c5f8-d264-4f5b-8fd1-e61cd299df5b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_9ada040e-25a2-466f-97f7-8ed04f755980_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_8ab42f0c-616d-41da-ba1b-db6c554e621f_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Birmingham lease restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalent, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_7d46c473-f69d-42f8-a124-33a86ac20f9d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_919861e6-fb33-4254-8bcd-10c81aea35d3_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_df9ba78c-1058-4e09-94bb-c58196032cd9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_29d63de6-ae2b-47ff-8233-bb85ae9bf676_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected Dividend Yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_4ddf411a-65c9-491b-8741-bb10654795ff_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_6e82da8a-a6fc-4674-8737-ecbe750b40b2_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_286f4a38-c83a-4c71-89ef-f093c4ad3e56_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_614c333d-d59a-4ea9-b9e0-33800cf5eac5_terseLabel_en-US" xlink:label="lab_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies and Concentration of Risk [Line Items]</link:label>
    <link:label id="lab_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_label_en-US" xlink:label="lab_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies and Concentrations of Risk [Line Items]</link:label>
    <link:label id="lab_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_documentation_en-US" xlink:label="lab_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies and Concentrations of Risk</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems" xlink:href="bcrx-20250930.xsd#bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems" xlink:to="lab_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_08f26a3d-8b1c-4c2f-b0a5-2db248685a53_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_RoyaltyRevenuesPayable_8562c6c3-d3c2-46d9-83e7-53260081ac4d_terseLabel_en-US" xlink:label="lab_bcrx_RoyaltyRevenuesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty revenues payable</link:label>
    <link:label id="lab_bcrx_RoyaltyRevenuesPayable_label_en-US" xlink:label="lab_bcrx_RoyaltyRevenuesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Revenues Payable</link:label>
    <link:label id="lab_bcrx_RoyaltyRevenuesPayable_documentation_en-US" xlink:label="lab_bcrx_RoyaltyRevenuesPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents royalties revenues payable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyRevenuesPayable" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltyRevenuesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_RoyaltyRevenuesPayable" xlink:to="lab_bcrx_RoyaltyRevenuesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_LoanAgreementMember_5ef95e6f-a966-460f-b9cd-0070c7d0cd48_terseLabel_en-US" xlink:label="lab_bcrx_LoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loan Agreement</link:label>
    <link:label id="lab_bcrx_LoanAgreementMember_label_en-US" xlink:label="lab_bcrx_LoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loan Agreement [Member]</link:label>
    <link:label id="lab_bcrx_LoanAgreementMember_documentation_en-US" xlink:label="lab_bcrx_LoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loan Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_LoanAgreementMember" xlink:href="bcrx-20250930.xsd#bcrx_LoanAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_LoanAgreementMember" xlink:to="lab_bcrx_LoanAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_243e1082-bd14-44e6-a7ab-b99f7e1bba8c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, beginning balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_73482a6a-109e-4181-b2cd-c732cdd2358b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, ending balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4cd4c366-81bf-4d07-afb5-7ee2eb97e7af_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_50eb641e-14bb-40ee-bdcd-8dcc59e8c00d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_d82c5b96-2699-48dc-8567-a3aea03f63b4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_f66e1836-6c9a-4de9-a9b2-6c36f537c2bc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining lease term (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_DebtCovenantTermsAxis_f51cb53f-05fb-430b-970e-4853777f7754_terseLabel_en-US" xlink:label="lab_bcrx_DebtCovenantTermsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Covenant Terms [Axis]</link:label>
    <link:label id="lab_bcrx_DebtCovenantTermsAxis_label_en-US" xlink:label="lab_bcrx_DebtCovenantTermsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Covenant Terms [Axis]</link:label>
    <link:label id="lab_bcrx_DebtCovenantTermsAxis_documentation_en-US" xlink:label="lab_bcrx_DebtCovenantTermsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Covenant Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DebtCovenantTermsAxis" xlink:href="bcrx-20250930.xsd#bcrx_DebtCovenantTermsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_DebtCovenantTermsAxis" xlink:to="lab_bcrx_DebtCovenantTermsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeographicDistributionAxis_d70a4e11-56c6-4528-8b34-6fc846dcadc1_terseLabel_en-US" xlink:label="lab_us-gaap_GeographicDistributionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographic Distribution [Axis]</link:label>
    <link:label id="lab_us-gaap_GeographicDistributionAxis_label_en-US" xlink:label="lab_us-gaap_GeographicDistributionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographic Distribution [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicDistributionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeographicDistributionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeographicDistributionAxis" xlink:to="lab_us-gaap_GeographicDistributionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_a8c43f8f-36aa-47ee-8143-d66d2bfec115_terseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:to="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_NonCashInterestExpenseOnSecuredTermLoanAndSecuredTermLoanAndAmortizationOfDebtIssuanceCosts_b13977f0-858b-47b8-ae77-1257144f0b22_terseLabel_en-US" xlink:label="lab_bcrx_NonCashInterestExpenseOnSecuredTermLoanAndSecuredTermLoanAndAmortizationOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash interest expense on secured term loan and amortization of debt issuance costs</link:label>
    <link:label id="lab_bcrx_NonCashInterestExpenseOnSecuredTermLoanAndSecuredTermLoanAndAmortizationOfDebtIssuanceCosts_label_en-US" xlink:label="lab_bcrx_NonCashInterestExpenseOnSecuredTermLoanAndSecuredTermLoanAndAmortizationOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Cash Interest Expense On Secured Term Loan And Secured Term Loan And Amortization Of Debt Issuance Costs</link:label>
    <link:label id="lab_bcrx_NonCashInterestExpenseOnSecuredTermLoanAndSecuredTermLoanAndAmortizationOfDebtIssuanceCosts_documentation_en-US" xlink:label="lab_bcrx_NonCashInterestExpenseOnSecuredTermLoanAndSecuredTermLoanAndAmortizationOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Cash Interest Expense On Secured Term Loan And Secured Term Loan And Amortization Of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_NonCashInterestExpenseOnSecuredTermLoanAndSecuredTermLoanAndAmortizationOfDebtIssuanceCosts" xlink:href="bcrx-20250930.xsd#bcrx_NonCashInterestExpenseOnSecuredTermLoanAndSecuredTermLoanAndAmortizationOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_NonCashInterestExpenseOnSecuredTermLoanAndSecuredTermLoanAndAmortizationOfDebtIssuanceCosts" xlink:to="lab_bcrx_NonCashInterestExpenseOnSecuredTermLoanAndSecuredTermLoanAndAmortizationOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0e5ce179-ce88-4756-8101-fba947fa4eb5_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Options, grants in period, gross (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3ba76f09-d1c6-4abd-8edb-a8fbffa7be60_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance-based stock options issued in period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_f8136d27-4208-4dfa-98d4-05ed6f536886_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade receivables</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_RoyaltyFinancingLiabilitiesCurrent_a215285a-3b3e-4ae5-ba80-6120aa0cca2d_terseLabel_en-US" xlink:label="lab_bcrx_RoyaltyFinancingLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty financing obligations</link:label>
    <link:label id="lab_bcrx_RoyaltyFinancingLiabilitiesCurrent_label_en-US" xlink:label="lab_bcrx_RoyaltyFinancingLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Financing Liabilities, Current</link:label>
    <link:label id="lab_bcrx_RoyaltyFinancingLiabilitiesCurrent_documentation_en-US" xlink:label="lab_bcrx_RoyaltyFinancingLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Financing Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyFinancingLiabilitiesCurrent" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltyFinancingLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_RoyaltyFinancingLiabilitiesCurrent" xlink:to="lab_bcrx_RoyaltyFinancingLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_AccruedExpensesPolicyTextBlock_7099f385-bd64-4725-ad99-77b45fa67a89_terseLabel_en-US" xlink:label="lab_bcrx_AccruedExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_bcrx_AccruedExpensesPolicyTextBlock_label_en-US" xlink:label="lab_bcrx_AccruedExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Expenses [Policy Text Block]</link:label>
    <link:label id="lab_bcrx_AccruedExpensesPolicyTextBlock_documentation_en-US" xlink:label="lab_bcrx_AccruedExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents accrued expenses policy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AccruedExpensesPolicyTextBlock" xlink:href="bcrx-20250930.xsd#bcrx_AccruedExpensesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_AccruedExpensesPolicyTextBlock" xlink:to="lab_bcrx_AccruedExpensesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_6bf5a3e9-493e-4b2e-b231-c9ac2111eacc_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_0c55c5d6-4cc8-4652-993b-56c52cb4d718_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating cash flows for finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Interest Payment on Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_a69f95fe-181d-43fe-a732-0ebac7f2fcb7_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_b96c0946-d3cc-427e-8040-7080580d88d4_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_label_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseNonoperating" xlink:to="lab_us-gaap_InterestExpenseNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_82a2310e-4afb-42c4-aeb9-1421cb7085a8_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_e4420b06-0fb1-42e1-a0a0-debaad61aeab_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_ResearchDiscoveryAndPreclinicalProgramsMember_04e082c2-aaf0-42c5-b908-b789be1ea0a6_terseLabel_en-US" xlink:label="lab_bcrx_ResearchDiscoveryAndPreclinicalProgramsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research, discovery and preclinical programs</link:label>
    <link:label id="lab_bcrx_ResearchDiscoveryAndPreclinicalProgramsMember_label_en-US" xlink:label="lab_bcrx_ResearchDiscoveryAndPreclinicalProgramsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research, Discovery And Preclinical Programs [Member]</link:label>
    <link:label id="lab_bcrx_ResearchDiscoveryAndPreclinicalProgramsMember_documentation_en-US" xlink:label="lab_bcrx_ResearchDiscoveryAndPreclinicalProgramsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research, Discovery And Preclinical Programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ResearchDiscoveryAndPreclinicalProgramsMember" xlink:href="bcrx-20250930.xsd#bcrx_ResearchDiscoveryAndPreclinicalProgramsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_ResearchDiscoveryAndPreclinicalProgramsMember" xlink:to="lab_bcrx_ResearchDiscoveryAndPreclinicalProgramsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentContinuingOperationExcludingAssetsHeldForSale_6b84646e-fb9d-44da-a1a0-b16b3b210f71_periodStartLabel_en-US" xlink:label="lab_bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentContinuingOperationExcludingAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentContinuingOperationExcludingAssetsHeldForSale_78702968-fa89-4fc3-bc5f-4512454b71ae_periodEndLabel_en-US" xlink:label="lab_bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentContinuingOperationExcludingAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentContinuingOperationExcludingAssetsHeldForSale_ce3bb057-05ad-4834-a557-a9da0af0a4da_totalLabel_en-US" xlink:label="lab_bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentContinuingOperationExcludingAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentContinuingOperationExcludingAssetsHeldForSale_label_en-US" xlink:label="lab_bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentContinuingOperationExcludingAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation, Excluding Assets Held For Sale</link:label>
    <link:label id="lab_bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentContinuingOperationExcludingAssetsHeldForSale_documentation_en-US" xlink:label="lab_bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentContinuingOperationExcludingAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation, Excluding Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentContinuingOperationExcludingAssetsHeldForSale" xlink:href="bcrx-20250930.xsd#bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentContinuingOperationExcludingAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentContinuingOperationExcludingAssetsHeldForSale" xlink:to="lab_bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentContinuingOperationExcludingAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_762f0126-1bf3-4d14-a4d8-51713a88accd_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_fee49083-7630-4cc0-8d41-dfc9719049ce_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryNoncurrent_a647922b-a2e2-462a-a4c3-248abe9254d1_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, net, noncurrent</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryNoncurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Inventory, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryNoncurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_2afc3f79-47b5-4397-8f95-d594c6d816e8_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_3bcdd1df-240e-430a-9de4-6a4958acd5d6_terseLabel_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product Concentration Risk</link:label>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductConcentrationRiskMember" xlink:to="lab_us-gaap_ProductConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_4a8b9cd4-f66a-4a38-b9de-30ec8b6d13c6_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum aggregate principal amount</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_b6299f7a-2c7e-4c44-9e50-b4d4db4f5aea_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales and maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_bfde6024-15e2-4204-b837-361e717b5ba9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2070f0b4-5aea-415c-838d-3f5c2e34cd34_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_865d1288-344c-419a-884d-8ee519872dd6_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Inventory, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_359c5c14-7e9a-4631-8ffb-d4b849fb7612_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_fc4a6d0d-0f5c-40d4-82af-c47f097ae423_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_3a49629c-7d48-4864-8f44-337b540a0a69_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_06e79bc6-e309-4559-a3a2-30e037859c29_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Vested RSU (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7a1b0d57-4303-4868-9e2f-e0c1a02635bb_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a33adb99-1b43-467f-83dc-6713c7dd6b5c_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_9924fb81-6a1d-48f7-b57e-ee15355b0807_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_6f715fa0-c047-4ab3-8237-a29d9275e005_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_RoyaltyRate_23720b7b-b775-48aa-bffe-8b2dcaa55c04_terseLabel_en-US" xlink:label="lab_bcrx_RoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty rate</link:label>
    <link:label id="lab_bcrx_RoyaltyRate_label_en-US" xlink:label="lab_bcrx_RoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Rate</link:label>
    <link:label id="lab_bcrx_RoyaltyRate_documentation_en-US" xlink:label="lab_bcrx_RoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyRate" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltyRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_RoyaltyRate" xlink:to="lab_bcrx_RoyaltyRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_21d1fb62-45c9-4873-98a2-3d4ddb268bff_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_BetweenTheSecondAndThirdAnniversariesMember_458f32b3-29b5-4652-9e25-af8a2ee684cc_terseLabel_en-US" xlink:label="lab_bcrx_BetweenTheSecondAndThirdAnniversariesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Between the Second and Third Anniversaries</link:label>
    <link:label id="lab_bcrx_BetweenTheSecondAndThirdAnniversariesMember_label_en-US" xlink:label="lab_bcrx_BetweenTheSecondAndThirdAnniversariesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Between the Second and Third Anniversaries [Member]</link:label>
    <link:label id="lab_bcrx_BetweenTheSecondAndThirdAnniversariesMember_documentation_en-US" xlink:label="lab_bcrx_BetweenTheSecondAndThirdAnniversariesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents between the second and third anniversaries.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_BetweenTheSecondAndThirdAnniversariesMember" xlink:href="bcrx-20250930.xsd#bcrx_BetweenTheSecondAndThirdAnniversariesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_BetweenTheSecondAndThirdAnniversariesMember" xlink:to="lab_bcrx_BetweenTheSecondAndThirdAnniversariesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_1e253efd-bac5-46b7-838d-0d2f9bb806cd_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Dilutive potential common shares (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>bcrx-20250930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:9a36bdce-1161-4cfc-8f27-e0c5ed23a9d7,g:923a909e-42f3-4f9e-a634-f93d4ee01684-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.biocryst.com/role/Cover" xlink:type="simple" xlink:href="bcrx-20250930.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_a8da7384-a21d-4ab4-9fa8-71169507c806" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_3a612a3e-d76b-48a6-9169-1edaecea4b3d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a8da7384-a21d-4ab4-9fa8-71169507c806" xlink:to="loc_dei_DocumentType_3a612a3e-d76b-48a6-9169-1edaecea4b3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_b7222584-268d-40f1-85b3-8aeef86f2bad" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a8da7384-a21d-4ab4-9fa8-71169507c806" xlink:to="loc_dei_DocumentQuarterlyReport_b7222584-268d-40f1-85b3-8aeef86f2bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_6c335559-4123-43b0-aa9a-2e9dc2dc4771" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a8da7384-a21d-4ab4-9fa8-71169507c806" xlink:to="loc_dei_DocumentPeriodEndDate_6c335559-4123-43b0-aa9a-2e9dc2dc4771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_197b1d8a-127e-4f7f-a1cb-f05b697762ab" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a8da7384-a21d-4ab4-9fa8-71169507c806" xlink:to="loc_dei_DocumentTransitionReport_197b1d8a-127e-4f7f-a1cb-f05b697762ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_5ba570b8-9ee6-48ae-accd-e4b6efc32ba2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a8da7384-a21d-4ab4-9fa8-71169507c806" xlink:to="loc_dei_EntityFileNumber_5ba570b8-9ee6-48ae-accd-e4b6efc32ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_ec4a4bce-b2ea-4654-bfbd-5fa1551c8e8f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a8da7384-a21d-4ab4-9fa8-71169507c806" xlink:to="loc_dei_EntityRegistrantName_ec4a4bce-b2ea-4654-bfbd-5fa1551c8e8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_0029c45e-7873-4d44-82a0-0e56b93f4c59" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a8da7384-a21d-4ab4-9fa8-71169507c806" xlink:to="loc_dei_EntityIncorporationStateCountryCode_0029c45e-7873-4d44-82a0-0e56b93f4c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_febc7ddb-2383-4210-aa92-ab6ae516ec03" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a8da7384-a21d-4ab4-9fa8-71169507c806" xlink:to="loc_dei_EntityTaxIdentificationNumber_febc7ddb-2383-4210-aa92-ab6ae516ec03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_515e94b5-4a00-4771-aca1-194f367fc08b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a8da7384-a21d-4ab4-9fa8-71169507c806" xlink:to="loc_dei_EntityAddressAddressLine1_515e94b5-4a00-4771-aca1-194f367fc08b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_33444110-ef0e-412f-8c19-8ffc3eb0e2ec" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a8da7384-a21d-4ab4-9fa8-71169507c806" xlink:to="loc_dei_EntityAddressCityOrTown_33444110-ef0e-412f-8c19-8ffc3eb0e2ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_aef73a1d-0a92-4172-a80f-d5176337f3c6" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a8da7384-a21d-4ab4-9fa8-71169507c806" xlink:to="loc_dei_EntityAddressStateOrProvince_aef73a1d-0a92-4172-a80f-d5176337f3c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_edfc1e7a-aa81-44e6-84d1-a9c06a7b1384" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a8da7384-a21d-4ab4-9fa8-71169507c806" xlink:to="loc_dei_EntityAddressPostalZipCode_edfc1e7a-aa81-44e6-84d1-a9c06a7b1384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_2e0ad113-faa2-42b0-953a-748a1aca2acf" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a8da7384-a21d-4ab4-9fa8-71169507c806" xlink:to="loc_dei_CityAreaCode_2e0ad113-faa2-42b0-953a-748a1aca2acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_c6960344-805d-4c63-8bc2-d962ce0d24a1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a8da7384-a21d-4ab4-9fa8-71169507c806" xlink:to="loc_dei_LocalPhoneNumber_c6960344-805d-4c63-8bc2-d962ce0d24a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_48e1616c-9d5f-4219-a4e7-79e875198f24" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a8da7384-a21d-4ab4-9fa8-71169507c806" xlink:to="loc_dei_Security12bTitle_48e1616c-9d5f-4219-a4e7-79e875198f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_b80910bc-9055-4bb6-a107-6a3d4fd82cd3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a8da7384-a21d-4ab4-9fa8-71169507c806" xlink:to="loc_dei_TradingSymbol_b80910bc-9055-4bb6-a107-6a3d4fd82cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_ef8fb75b-5024-4f31-9b34-aecd6f51e89a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a8da7384-a21d-4ab4-9fa8-71169507c806" xlink:to="loc_dei_SecurityExchangeName_ef8fb75b-5024-4f31-9b34-aecd6f51e89a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_ee13b4a5-5c9e-4236-820f-844937d10859" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a8da7384-a21d-4ab4-9fa8-71169507c806" xlink:to="loc_dei_EntityCurrentReportingStatus_ee13b4a5-5c9e-4236-820f-844937d10859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_3cc3db6a-3d32-4520-9417-fb0a3038b854" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a8da7384-a21d-4ab4-9fa8-71169507c806" xlink:to="loc_dei_EntityInteractiveDataCurrent_3cc3db6a-3d32-4520-9417-fb0a3038b854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_9943e4c2-88d0-4292-a330-ac9ae2ae9e74" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a8da7384-a21d-4ab4-9fa8-71169507c806" xlink:to="loc_dei_EntityFilerCategory_9943e4c2-88d0-4292-a330-ac9ae2ae9e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_7cf98c55-7dab-4a30-9322-cbb2dc501ca3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a8da7384-a21d-4ab4-9fa8-71169507c806" xlink:to="loc_dei_EntitySmallBusiness_7cf98c55-7dab-4a30-9322-cbb2dc501ca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_b0fb4122-b750-4b2e-9652-c71c45815b48" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a8da7384-a21d-4ab4-9fa8-71169507c806" xlink:to="loc_dei_EntityEmergingGrowthCompany_b0fb4122-b750-4b2e-9652-c71c45815b48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_56706eb5-9949-4a49-8db0-b9fba37d72b7" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a8da7384-a21d-4ab4-9fa8-71169507c806" xlink:to="loc_dei_EntityShellCompany_56706eb5-9949-4a49-8db0-b9fba37d72b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_5ff1b26c-e7b3-4c13-b8b5-48cc6d7a32e2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a8da7384-a21d-4ab4-9fa8-71169507c806" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_5ff1b26c-e7b3-4c13-b8b5-48cc6d7a32e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_3664d244-cb3b-4665-b687-9097bce83b56" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a8da7384-a21d-4ab4-9fa8-71169507c806" xlink:to="loc_dei_EntityCentralIndexKey_3664d244-cb3b-4665-b687-9097bce83b56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_c197d758-1701-4709-b393-c0c543ea8ca8" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a8da7384-a21d-4ab4-9fa8-71169507c806" xlink:to="loc_dei_CurrentFiscalYearEndDate_c197d758-1701-4709-b393-c0c543ea8ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_9e414eaf-1818-4317-bae1-c1f8cc37aecd" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a8da7384-a21d-4ab4-9fa8-71169507c806" xlink:to="loc_dei_DocumentFiscalYearFocus_9e414eaf-1818-4317-bae1-c1f8cc37aecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_fea655e8-38b6-4914-ae9d-3aa23c4d0d50" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a8da7384-a21d-4ab4-9fa8-71169507c806" xlink:to="loc_dei_DocumentFiscalPeriodFocus_fea655e8-38b6-4914-ae9d-3aa23c4d0d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_06e8e40e-9d4b-43f3-820e-903bc4efadce" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a8da7384-a21d-4ab4-9fa8-71169507c806" xlink:to="loc_dei_AmendmentFlag_06e8e40e-9d4b-43f3-820e-903bc4efadce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="bcrx-20250930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_02d4b0f5-a97e-429f-9278-3448c2e85987" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_56276740-04a5-4f3a-b285-9ade1255d590" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_02d4b0f5-a97e-429f-9278-3448c2e85987" xlink:to="loc_us-gaap_StatementTable_56276740-04a5-4f3a-b285-9ade1255d590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_d5e9c56a-7810-4bce-972e-e0b5b637ec33" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_56276740-04a5-4f3a-b285-9ade1255d590" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_d5e9c56a-7810-4bce-972e-e0b5b637ec33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_b5c6bdb5-85fa-4e55-9598-b7e55184a918" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_d5e9c56a-7810-4bce-972e-e0b5b637ec33" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_b5c6bdb5-85fa-4e55-9598-b7e55184a918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_1385fb44-60ed-407e-8cfe-fc0d665611d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_b5c6bdb5-85fa-4e55-9598-b7e55184a918" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_1385fb44-60ed-407e-8cfe-fc0d665611d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0b04b4df-88ee-4769-b9f5-9f1430c2c373" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_56276740-04a5-4f3a-b285-9ade1255d590" xlink:to="loc_us-gaap_StatementLineItems_0b04b4df-88ee-4769-b9f5-9f1430c2c373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_9010b612-c5eb-4dd1-82c7-47e96fd92986" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0b04b4df-88ee-4769-b9f5-9f1430c2c373" xlink:to="loc_us-gaap_AssetsAbstract_9010b612-c5eb-4dd1-82c7-47e96fd92986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_415f233c-26d5-4265-93fe-24fd31116e10" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9010b612-c5eb-4dd1-82c7-47e96fd92986" xlink:to="loc_us-gaap_AssetsCurrentAbstract_415f233c-26d5-4265-93fe-24fd31116e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_203e17da-cf02-4427-a27a-32680cf94ba1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_415f233c-26d5-4265-93fe-24fd31116e10" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_203e17da-cf02-4427-a27a-32680cf94ba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_4fba2ce0-90ff-4688-a8be-c9cacc87c2fd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_415f233c-26d5-4265-93fe-24fd31116e10" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_4fba2ce0-90ff-4688-a8be-c9cacc87c2fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_bf30fd16-8775-42bd-8b01-17d52aa19743" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_415f233c-26d5-4265-93fe-24fd31116e10" xlink:to="loc_us-gaap_ShortTermInvestments_bf30fd16-8775-42bd-8b01-17d52aa19743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_93560836-c762-4d13-9c0a-b9c1202c6930" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_415f233c-26d5-4265-93fe-24fd31116e10" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_93560836-c762-4d13-9c0a-b9c1202c6930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_33bf3197-ecaf-43d0-8b7b-fa3845f23e27" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_415f233c-26d5-4265-93fe-24fd31116e10" xlink:to="loc_us-gaap_InventoryNet_33bf3197-ecaf-43d0-8b7b-fa3845f23e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_55094adf-9e57-4c70-93d7-727cc86a401e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_415f233c-26d5-4265-93fe-24fd31116e10" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_55094adf-9e57-4c70-93d7-727cc86a401e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_8e934cbc-9378-4662-9cf5-c44f87da27b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_415f233c-26d5-4265-93fe-24fd31116e10" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_8e934cbc-9378-4662-9cf5-c44f87da27b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_73845ae1-56c3-4cd6-a4d0-930ab2d8f49e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_415f233c-26d5-4265-93fe-24fd31116e10" xlink:to="loc_us-gaap_AssetsCurrent_73845ae1-56c3-4cd6-a4d0-930ab2d8f49e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_8251c3a1-7a74-46ac-ae77-0e54f2d81f46" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9010b612-c5eb-4dd1-82c7-47e96fd92986" xlink:to="loc_us-gaap_InventoryNoncurrent_8251c3a1-7a74-46ac-ae77-0e54f2d81f46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_26a29af1-2d56-4fc1-8606-436e28ba8632" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9010b612-c5eb-4dd1-82c7-47e96fd92986" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_26a29af1-2d56-4fc1-8606-436e28ba8632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_a9e603a0-0fef-44fa-8bc5-67e36fb459b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9010b612-c5eb-4dd1-82c7-47e96fd92986" xlink:to="loc_us-gaap_LongTermInvestments_a9e603a0-0fef-44fa-8bc5-67e36fb459b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RightOfUseAssetsNoncurrent_9958602b-5329-4384-8c32-3b9586b33ad7" xlink:href="bcrx-20250930.xsd#bcrx_RightOfUseAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9010b612-c5eb-4dd1-82c7-47e96fd92986" xlink:to="loc_bcrx_RightOfUseAssetsNoncurrent_9958602b-5329-4384-8c32-3b9586b33ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_c34544c7-1991-4445-bad7-6b91f665fc4f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9010b612-c5eb-4dd1-82c7-47e96fd92986" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_c34544c7-1991-4445-bad7-6b91f665fc4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_80d77410-58b4-42fd-9940-700f1075e89f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9010b612-c5eb-4dd1-82c7-47e96fd92986" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_80d77410-58b4-42fd-9940-700f1075e89f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_86c3975e-7852-488c-b65c-d85dd498c0da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9010b612-c5eb-4dd1-82c7-47e96fd92986" xlink:to="loc_us-gaap_Assets_86c3975e-7852-488c-b65c-d85dd498c0da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7ef9e1e-68cc-46b5-9104-ed544d6fc662" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0b04b4df-88ee-4769-b9f5-9f1430c2c373" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7ef9e1e-68cc-46b5-9104-ed544d6fc662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_54b16604-d02b-45a2-b181-98ba02a4b63e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7ef9e1e-68cc-46b5-9104-ed544d6fc662" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_54b16604-d02b-45a2-b181-98ba02a4b63e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_5269e686-2488-4c81-abdf-e3747e311ec7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_54b16604-d02b-45a2-b181-98ba02a4b63e" xlink:to="loc_us-gaap_AccountsPayableCurrent_5269e686-2488-4c81-abdf-e3747e311ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_19ac92ae-8d79-45ca-8feb-7afe5c55d88e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_54b16604-d02b-45a2-b181-98ba02a4b63e" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_19ac92ae-8d79-45ca-8feb-7afe5c55d88e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f54e3228-3da9-428a-b81c-59ef029273d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_54b16604-d02b-45a2-b181-98ba02a4b63e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f54e3228-3da9-428a-b81c-59ef029273d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_754c0627-9716-400d-9062-0c7d310f40c1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_54b16604-d02b-45a2-b181-98ba02a4b63e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_754c0627-9716-400d-9062-0c7d310f40c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyFinancingLiabilitiesCurrent_2d073233-6c5b-4f94-be49-fecb8317c98e" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltyFinancingLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_54b16604-d02b-45a2-b181-98ba02a4b63e" xlink:to="loc_bcrx_RoyaltyFinancingLiabilitiesCurrent_2d073233-6c5b-4f94-be49-fecb8317c98e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_34898b36-6274-4528-acc2-be8411fc6ce3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_54b16604-d02b-45a2-b181-98ba02a4b63e" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_34898b36-6274-4528-acc2-be8411fc6ce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e19213b0-7822-4d93-b4ca-798b59cb5b09" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_54b16604-d02b-45a2-b181-98ba02a4b63e" xlink:to="loc_us-gaap_LiabilitiesCurrent_e19213b0-7822-4d93-b4ca-798b59cb5b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3c75ebb7-3784-4d5f-bbd7-61fe118274e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7ef9e1e-68cc-46b5-9104-ed544d6fc662" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3c75ebb7-3784-4d5f-bbd7-61fe118274e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_a48ea87f-7b47-409a-9aba-7f1f813b2b41" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7ef9e1e-68cc-46b5-9104-ed544d6fc662" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_a48ea87f-7b47-409a-9aba-7f1f813b2b41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyFinancingLiabilitiesNoncurrent_f7e74120-f740-4770-aa89-c122d460b52f" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltyFinancingLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7ef9e1e-68cc-46b5-9104-ed544d6fc662" xlink:to="loc_bcrx_RoyaltyFinancingLiabilitiesNoncurrent_f7e74120-f740-4770-aa89-c122d460b52f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_8ab463ca-3d4a-4f7d-834a-fab4a5a1994c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7ef9e1e-68cc-46b5-9104-ed544d6fc662" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_8ab463ca-3d4a-4f7d-834a-fab4a5a1994c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_95e0c45e-71e7-4a3b-bc00-aec3a902c103" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7ef9e1e-68cc-46b5-9104-ed544d6fc662" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_95e0c45e-71e7-4a3b-bc00-aec3a902c103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a8b1560f-fb53-4f74-964a-f01391781781" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7ef9e1e-68cc-46b5-9104-ed544d6fc662" xlink:to="loc_us-gaap_Liabilities_a8b1560f-fb53-4f74-964a-f01391781781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_b4e99915-fca7-43cc-855c-73b53dc3018a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7ef9e1e-68cc-46b5-9104-ed544d6fc662" xlink:to="loc_us-gaap_StockholdersEquityAbstract_b4e99915-fca7-43cc-855c-73b53dc3018a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_8b73010e-3e4c-4891-8a66-33a8a1cf407b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b4e99915-fca7-43cc-855c-73b53dc3018a" xlink:to="loc_us-gaap_PreferredStockValue_8b73010e-3e4c-4891-8a66-33a8a1cf407b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_c257855d-d292-4037-ad4c-fbdfa5d60a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b4e99915-fca7-43cc-855c-73b53dc3018a" xlink:to="loc_us-gaap_CommonStockValue_c257855d-d292-4037-ad4c-fbdfa5d60a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_c576bea5-1464-4ca9-b584-794919595217" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b4e99915-fca7-43cc-855c-73b53dc3018a" xlink:to="loc_us-gaap_AdditionalPaidInCapital_c576bea5-1464-4ca9-b584-794919595217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_38c58cab-e701-4a7e-a00d-d4918fec1a94" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b4e99915-fca7-43cc-855c-73b53dc3018a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_38c58cab-e701-4a7e-a00d-d4918fec1a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d9b6cd01-6458-47e7-a891-a3eb5e70e3a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b4e99915-fca7-43cc-855c-73b53dc3018a" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d9b6cd01-6458-47e7-a891-a3eb5e70e3a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_87a7d84f-4f31-4e0d-8475-ec309696a178" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b4e99915-fca7-43cc-855c-73b53dc3018a" xlink:to="loc_us-gaap_StockholdersEquity_87a7d84f-4f31-4e0d-8475-ec309696a178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_c6073d4a-4da3-44ca-a40f-1d2e1d780e99" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7ef9e1e-68cc-46b5-9104-ed544d6fc662" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_c6073d4a-4da3-44ca-a40f-1d2e1d780e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="bcrx-20250930.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_25a49ae8-ad36-467e-a6c5-84d5191fc39b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_268a013a-1186-4e05-b79d-fbed21bebfc0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_25a49ae8-ad36-467e-a6c5-84d5191fc39b" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_268a013a-1186-4e05-b79d-fbed21bebfc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_ef15e669-bcea-40c0-8d6b-d8e42c42982c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_25a49ae8-ad36-467e-a6c5-84d5191fc39b" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_ef15e669-bcea-40c0-8d6b-d8e42c42982c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_e3a9b681-4e15-4e7a-a11f-bb37bbb81bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_25a49ae8-ad36-467e-a6c5-84d5191fc39b" xlink:to="loc_us-gaap_PreferredStockSharesIssued_e3a9b681-4e15-4e7a-a11f-bb37bbb81bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_c0f4c190-03f8-4b32-bf52-e8796d0fc678" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_25a49ae8-ad36-467e-a6c5-84d5191fc39b" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_c0f4c190-03f8-4b32-bf52-e8796d0fc678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1945b664-94bd-422d-9368-dc929be3888a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_25a49ae8-ad36-467e-a6c5-84d5191fc39b" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1945b664-94bd-422d-9368-dc929be3888a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_890b4a37-97d5-4272-aacc-0b4a5ec477b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_25a49ae8-ad36-467e-a6c5-84d5191fc39b" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_890b4a37-97d5-4272-aacc-0b4a5ec477b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_ad31e10d-ac09-40cf-b7c4-d19a1b3ee362" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_25a49ae8-ad36-467e-a6c5-84d5191fc39b" xlink:to="loc_us-gaap_CommonStockSharesIssued_ad31e10d-ac09-40cf-b7c4-d19a1b3ee362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_0f8ee33e-7898-4831-962f-b0428029d9a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_25a49ae8-ad36-467e-a6c5-84d5191fc39b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_0f8ee33e-7898-4831-962f-b0428029d9a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="simple" xlink:href="bcrx-20250930.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeLoss"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_3d1a0c65-02d9-45fb-a4c7-3842eef338d1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_5e42827e-e665-4254-9953-41c4188a971d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3d1a0c65-02d9-45fb-a4c7-3842eef338d1" xlink:to="loc_us-gaap_RevenuesAbstract_5e42827e-e665-4254-9953-41c4188a971d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_79330d89-8fd3-434d-ae80-4ef988970fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_5e42827e-e665-4254-9953-41c4188a971d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_79330d89-8fd3-434d-ae80-4ef988970fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_62de0e8a-dee4-41dc-a5c4-0dc62e986803" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3d1a0c65-02d9-45fb-a4c7-3842eef338d1" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_62de0e8a-dee4-41dc-a5c4-0dc62e986803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_57762369-59fd-48c9-bcf2-e754e2cea51e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_62de0e8a-dee4-41dc-a5c4-0dc62e986803" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_57762369-59fd-48c9-bcf2-e754e2cea51e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_61224af7-b7be-4a75-b11a-c7a25442d56a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_62de0e8a-dee4-41dc-a5c4-0dc62e986803" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_61224af7-b7be-4a75-b11a-c7a25442d56a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_9394f75c-36af-4928-9776-56da732ff55c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_62de0e8a-dee4-41dc-a5c4-0dc62e986803" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_9394f75c-36af-4928-9776-56da732ff55c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_9344f554-8eca-4f32-b0a6-404e0719fbe8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_62de0e8a-dee4-41dc-a5c4-0dc62e986803" xlink:to="loc_us-gaap_CostsAndExpenses_9344f554-8eca-4f32-b0a6-404e0719fbe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_fc25f6be-4d6a-4320-8f9d-e3cf0674cd48" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_62de0e8a-dee4-41dc-a5c4-0dc62e986803" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_fc25f6be-4d6a-4320-8f9d-e3cf0674cd48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_43db04a1-f639-4879-87a3-88873e2140b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_62de0e8a-dee4-41dc-a5c4-0dc62e986803" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_43db04a1-f639-4879-87a3-88873e2140b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_b5c6d12b-81ad-4864-9d6a-2d702a958596" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3d1a0c65-02d9-45fb-a4c7-3842eef338d1" xlink:to="loc_us-gaap_OtherIncomeAndExpensesAbstract_b5c6d12b-81ad-4864-9d6a-2d702a958596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ba80c7c8-f47a-4c0a-8f00-46e7ec484831" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_b5c6d12b-81ad-4864-9d6a-2d702a958596" xlink:to="loc_us-gaap_OperatingIncomeLoss_ba80c7c8-f47a-4c0a-8f00-46e7ec484831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndOtherIncome_b1586cf8-82b2-4ac3-9528-f7ff828efb3d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestAndOtherIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_b5c6d12b-81ad-4864-9d6a-2d702a958596" xlink:to="loc_us-gaap_InterestAndOtherIncome_b1586cf8-82b2-4ac3-9528-f7ff828efb3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_85354107-6069-4797-9c5e-0c8b84d4692c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_b5c6d12b-81ad-4864-9d6a-2d702a958596" xlink:to="loc_us-gaap_InterestExpenseNonoperating_85354107-6069-4797-9c5e-0c8b84d4692c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_8fbbffd5-94d5-4211-94f2-3e2161d1d206" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_b5c6d12b-81ad-4864-9d6a-2d702a958596" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_8fbbffd5-94d5-4211-94f2-3e2161d1d206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_e19923db-ee61-412d-bb21-4bfee0fd2b1a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_b5c6d12b-81ad-4864-9d6a-2d702a958596" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_e19923db-ee61-412d-bb21-4bfee0fd2b1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncome_b8c12c4f-5e7d-441b-a052-ac9a25a62e25" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncome"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_b5c6d12b-81ad-4864-9d6a-2d702a958596" xlink:to="loc_us-gaap_OtherIncome_b8c12c4f-5e7d-441b-a052-ac9a25a62e25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_97a2f548-705a-49a0-b857-3732ea7365a8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_b5c6d12b-81ad-4864-9d6a-2d702a958596" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_97a2f548-705a-49a0-b857-3732ea7365a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5083a4b4-b03c-4b55-902a-4333d70181cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3d1a0c65-02d9-45fb-a4c7-3842eef338d1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5083a4b4-b03c-4b55-902a-4333d70181cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8a9fd186-085b-4dde-9f0c-c812d2769723" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3d1a0c65-02d9-45fb-a4c7-3842eef338d1" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_8a9fd186-085b-4dde-9f0c-c812d2769723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f65535dc-e4e6-4c8c-a99f-3c46986e891c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3d1a0c65-02d9-45fb-a4c7-3842eef338d1" xlink:to="loc_us-gaap_NetIncomeLoss_f65535dc-e4e6-4c8c-a99f-3c46986e891c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_3967aca5-30c0-40e4-bebe-1e650805bf22" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3d1a0c65-02d9-45fb-a4c7-3842eef338d1" xlink:to="loc_us-gaap_EarningsPerShareBasic_3967aca5-30c0-40e4-bebe-1e650805bf22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c746f02d-9ffd-471f-83d8-50bb846150a8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3d1a0c65-02d9-45fb-a4c7-3842eef338d1" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c746f02d-9ffd-471f-83d8-50bb846150a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_cbb69df2-463e-43c2-a994-0c1e91167003" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3d1a0c65-02d9-45fb-a4c7-3842eef338d1" xlink:to="loc_us-gaap_EarningsPerShareDiluted_cbb69df2-463e-43c2-a994-0c1e91167003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_22d95f18-5ef7-48e3-8e07-df8f8124e63c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3d1a0c65-02d9-45fb-a4c7-3842eef338d1" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_22d95f18-5ef7-48e3-8e07-df8f8124e63c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9af54dd9-0776-4d76-acc4-463d0b9582a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3d1a0c65-02d9-45fb-a4c7-3842eef338d1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9af54dd9-0776-4d76-acc4-463d0b9582a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_97954628-e0c8-4469-8dec-dce6d29184b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9af54dd9-0776-4d76-acc4-463d0b9582a7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_97954628-e0c8-4469-8dec-dce6d29184b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1300a052-5172-4b51-afdf-48fd411bb20e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9af54dd9-0776-4d76-acc4-463d0b9582a7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1300a052-5172-4b51-afdf-48fd411bb20e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="bcrx-20250930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_eed2b324-8c72-41b6-8c2c-320b7fa3646e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f7697aef-03fb-4ef5-bd76-89ce756b56d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_eed2b324-8c72-41b6-8c2c-320b7fa3646e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f7697aef-03fb-4ef5-bd76-89ce756b56d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_39b66029-07bf-44f7-a15b-961ba5326679" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f7697aef-03fb-4ef5-bd76-89ce756b56d5" xlink:to="loc_us-gaap_NetIncomeLoss_39b66029-07bf-44f7-a15b-961ba5326679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_eb68a29e-6ac8-43ab-a435-fc36b301e42c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f7697aef-03fb-4ef5-bd76-89ce756b56d5" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_eb68a29e-6ac8-43ab-a435-fc36b301e42c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_98156fa3-7b79-46a4-8cbe-8c64bc84eaac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_eb68a29e-6ac8-43ab-a435-fc36b301e42c" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_98156fa3-7b79-46a4-8cbe-8c64bc84eaac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_a126c7e6-cb77-436c-b198-1679b73ab3c9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_eb68a29e-6ac8-43ab-a435-fc36b301e42c" xlink:to="loc_us-gaap_InventoryWriteDown_a126c7e6-cb77-436c-b198-1679b73ab3c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_f0fc98cf-bebf-4a91-9924-b6f33d103fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_eb68a29e-6ac8-43ab-a435-fc36b301e42c" xlink:to="loc_us-gaap_ShareBasedCompensation_f0fc98cf-bebf-4a91-9924-b6f33d103fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_PaymentsForPaidInKindInterest_99676504-cd35-4137-a0f6-8f364b132020" xlink:href="bcrx-20250930.xsd#bcrx_PaymentsForPaidInKindInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_eb68a29e-6ac8-43ab-a435-fc36b301e42c" xlink:to="loc_bcrx_PaymentsForPaidInKindInterest_99676504-cd35-4137-a0f6-8f364b132020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_NonCashInterestExpenseOnRoyaltyFinancingLiabilities_b15473bd-1a36-4a75-b246-b8931699fb05" xlink:href="bcrx-20250930.xsd#bcrx_NonCashInterestExpenseOnRoyaltyFinancingLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_eb68a29e-6ac8-43ab-a435-fc36b301e42c" xlink:to="loc_bcrx_NonCashInterestExpenseOnRoyaltyFinancingLiabilities_b15473bd-1a36-4a75-b246-b8931699fb05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_NonCashInterestExpenseOnSecuredTermLoanAndSecuredTermLoanAndAmortizationOfDebtIssuanceCosts_ea705b90-9eb8-487e-8348-d1e52554f7ee" xlink:href="bcrx-20250930.xsd#bcrx_NonCashInterestExpenseOnSecuredTermLoanAndSecuredTermLoanAndAmortizationOfDebtIssuanceCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_eb68a29e-6ac8-43ab-a435-fc36b301e42c" xlink:to="loc_bcrx_NonCashInterestExpenseOnSecuredTermLoanAndSecuredTermLoanAndAmortizationOfDebtIssuanceCosts_ea705b90-9eb8-487e-8348-d1e52554f7ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AmortizationOfPremiumDiscountOnInvestments_0b27d3c1-fe1a-4819-bd17-e302f2fe44fe" xlink:href="bcrx-20250930.xsd#bcrx_AmortizationOfPremiumDiscountOnInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_eb68a29e-6ac8-43ab-a435-fc36b301e42c" xlink:to="loc_bcrx_AmortizationOfPremiumDiscountOnInvestments_0b27d3c1-fe1a-4819-bd17-e302f2fe44fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_1a410e1d-c218-41e9-971b-1f6f2a3dcca2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_eb68a29e-6ac8-43ab-a435-fc36b301e42c" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_1a410e1d-c218-41e9-971b-1f6f2a3dcca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherAssets_5e4f15fe-0936-4e69-9cdd-bf7e77797878" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfOtherAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_eb68a29e-6ac8-43ab-a435-fc36b301e42c" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherAssets_5e4f15fe-0936-4e69-9cdd-bf7e77797878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_04048125-b9db-40d0-b35b-fe20b9818488" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f7697aef-03fb-4ef5-bd76-89ce756b56d5" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_04048125-b9db-40d0-b35b-fe20b9818488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_6a50853a-9549-4482-a8bb-71fccb7bb82e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_04048125-b9db-40d0-b35b-fe20b9818488" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_6a50853a-9549-4482-a8bb-71fccb7bb82e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_efcd619e-6c4b-49d3-aa68-98f3fdeb8936" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_04048125-b9db-40d0-b35b-fe20b9818488" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_efcd619e-6c4b-49d3-aa68-98f3fdeb8936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f3e4b656-f6c1-4bbf-8f1f-8fbac403515d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_04048125-b9db-40d0-b35b-fe20b9818488" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f3e4b656-f6c1-4bbf-8f1f-8fbac403515d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_IncreaseDecreaseInRoyaltyFinancingLiabilities_0a0e2f3f-b506-4e37-abef-c292c4d840ef" xlink:href="bcrx-20250930.xsd#bcrx_IncreaseDecreaseInRoyaltyFinancingLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_04048125-b9db-40d0-b35b-fe20b9818488" xlink:to="loc_bcrx_IncreaseDecreaseInRoyaltyFinancingLiabilities_0a0e2f3f-b506-4e37-abef-c292c4d840ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_47205020-25c4-433e-a576-a4aad16a0e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_04048125-b9db-40d0-b35b-fe20b9818488" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_47205020-25c4-433e-a576-a4aad16a0e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5533ebb7-8a69-4ca2-b841-55695e3f8e62" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f7697aef-03fb-4ef5-bd76-89ce756b56d5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5533ebb7-8a69-4ca2-b841-55695e3f8e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4757f38d-0020-4325-895f-898a26b57557" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_eed2b324-8c72-41b6-8c2c-320b7fa3646e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4757f38d-0020-4325-895f-898a26b57557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_9c207a01-b9bb-4837-bf36-bab054e257ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4757f38d-0020-4325-895f-898a26b57557" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_9c207a01-b9bb-4837-bf36-bab054e257ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_9927517d-7dd4-4199-9ddc-207761e35df6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4757f38d-0020-4325-895f-898a26b57557" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_9927517d-7dd4-4199-9ddc-207761e35df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_c62f01e1-c8c4-48e3-befd-0e0aa29019df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4757f38d-0020-4325-895f-898a26b57557" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_c62f01e1-c8c4-48e3-befd-0e0aa29019df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities_9e665516-3b30-4205-a60c-a28b7bf11aca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4757f38d-0020-4325-895f-898a26b57557" xlink:to="loc_us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities_9e665516-3b30-4205-a60c-a28b7bf11aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6f8a1e96-8eb7-4ec9-96a4-998e6184cc43" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4757f38d-0020-4325-895f-898a26b57557" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6f8a1e96-8eb7-4ec9-96a4-998e6184cc43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6e54c8c7-aa77-4f45-9974-2973eb702116" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_eed2b324-8c72-41b6-8c2c-320b7fa3646e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6e54c8c7-aa77-4f45-9974-2973eb702116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_6bbf0a76-3dbb-4c60-83b3-d6c74dc8e25f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6e54c8c7-aa77-4f45-9974-2973eb702116" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_6bbf0a76-3dbb-4c60-83b3-d6c74dc8e25f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ProceedsFromIssuanceOfCommonStockIssuedForServices_5ab89fb8-0a7a-4895-a847-bd87b58e245b" xlink:href="bcrx-20250930.xsd#bcrx_ProceedsFromIssuanceOfCommonStockIssuedForServices"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6e54c8c7-aa77-4f45-9974-2973eb702116" xlink:to="loc_bcrx_ProceedsFromIssuanceOfCommonStockIssuedForServices_5ab89fb8-0a7a-4895-a847-bd87b58e245b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_ab8beb5e-d264-40e6-ad20-0b164443740e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6e54c8c7-aa77-4f45-9974-2973eb702116" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_ab8beb5e-d264-40e6-ad20-0b164443740e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_e7088a7d-7b56-42fc-a83a-b12ae09db239" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6e54c8c7-aa77-4f45-9974-2973eb702116" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_e7088a7d-7b56-42fc-a83a-b12ae09db239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RepaymentOfRoyaltyFinancingLiabilitiesPrincipal_b3a21b9a-e573-4134-8e3a-ea1322e0a34b" xlink:href="bcrx-20250930.xsd#bcrx_RepaymentOfRoyaltyFinancingLiabilitiesPrincipal"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6e54c8c7-aa77-4f45-9974-2973eb702116" xlink:to="loc_bcrx_RepaymentOfRoyaltyFinancingLiabilitiesPrincipal_b3a21b9a-e573-4134-8e3a-ea1322e0a34b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_f0fa3ae0-984e-44f4-9435-f9db3e322fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6e54c8c7-aa77-4f45-9974-2973eb702116" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_f0fa3ae0-984e-44f4-9435-f9db3e322fa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_bf733107-b953-436a-b0f3-ac538f9ffdc5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6e54c8c7-aa77-4f45-9974-2973eb702116" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_bf733107-b953-436a-b0f3-ac538f9ffdc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a5e07fc2-ff4e-438d-b8b0-b41490fd5342" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6e54c8c7-aa77-4f45-9974-2973eb702116" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a5e07fc2-ff4e-438d-b8b0-b41490fd5342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9f60464e-41a4-4743-bdf9-22d522c44854" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_eed2b324-8c72-41b6-8c2c-320b7fa3646e" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9f60464e-41a4-4743-bdf9-22d522c44854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations_fdf04ac8-b5f5-4b9e-9ec2-129bfb35b123" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_eed2b324-8c72-41b6-8c2c-320b7fa3646e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations_fdf04ac8-b5f5-4b9e-9ec2-129bfb35b123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperationsLessAssetsHeldForSale_066b1fc7-fd49-4610-968e-eced463b7f27" xlink:href="bcrx-20250930.xsd#bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperationsLessAssetsHeldForSale"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_eed2b324-8c72-41b6-8c2c-320b7fa3646e" xlink:to="loc_bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperationsLessAssetsHeldForSale_066b1fc7-fd49-4610-968e-eced463b7f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperationsExcludingAssetsHeldForSale_4dca0c85-7c3d-4f43-9259-3faa00744994" xlink:href="bcrx-20250930.xsd#bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperationsExcludingAssetsHeldForSale"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_eed2b324-8c72-41b6-8c2c-320b7fa3646e" xlink:to="loc_bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperationsExcludingAssetsHeldForSale_4dca0c85-7c3d-4f43-9259-3faa00744994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_90d80a7d-ce90-4f68-a0b7-16aa5ad109ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_eed2b324-8c72-41b6-8c2c-320b7fa3646e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_90d80a7d-ce90-4f68-a0b7-16aa5ad109ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentContinuingOperationExcludingAssetsHeldForSale_8a7f91e9-fc3a-4cbb-ab12-39c3f8a91495" xlink:href="bcrx-20250930.xsd#bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentContinuingOperationExcludingAssetsHeldForSale"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_eed2b324-8c72-41b6-8c2c-320b7fa3646e" xlink:to="loc_bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentContinuingOperationExcludingAssetsHeldForSale_8a7f91e9-fc3a-4cbb-ab12-39c3f8a91495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentContinuingOperationExcludingAssetsHeldForSale_b4e89d68-78da-4eec-9b8d-e6581a2c3edf" xlink:href="bcrx-20250930.xsd#bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentContinuingOperationExcludingAssetsHeldForSale"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_eed2b324-8c72-41b6-8c2c-320b7fa3646e" xlink:to="loc_bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentContinuingOperationExcludingAssetsHeldForSale_b4e89d68-78da-4eec-9b8d-e6581a2c3edf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_315eb8c4-9315-4e69-a6bd-4522c5f6f812" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_eed2b324-8c72-41b6-8c2c-320b7fa3646e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_315eb8c4-9315-4e69-a6bd-4522c5f6f812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_def47a70-da5f-41e8-9512-f631f54d7bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_315eb8c4-9315-4e69-a6bd-4522c5f6f812" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_def47a70-da5f-41e8-9512-f631f54d7bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_dcb1e0ce-edc1-403e-b3ae-15965951a0c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_315eb8c4-9315-4e69-a6bd-4522c5f6f812" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_dcb1e0ce-edc1-403e-b3ae-15965951a0c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RestrictedCashAndCashEquivalentsIncludedInOtherAssetsNonCurrent_1ce048e0-a86a-44c9-940e-9085cd63cab5" xlink:href="bcrx-20250930.xsd#bcrx_RestrictedCashAndCashEquivalentsIncludedInOtherAssetsNonCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_315eb8c4-9315-4e69-a6bd-4522c5f6f812" xlink:to="loc_bcrx_RestrictedCashAndCashEquivalentsIncludedInOtherAssetsNonCurrent_1ce048e0-a86a-44c9-940e-9085cd63cab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentContinuingOperationExcludingAssetsHeldForSale_5153710c-00a3-4b95-a2c2-57ed053be25a" xlink:href="bcrx-20250930.xsd#bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentContinuingOperationExcludingAssetsHeldForSale"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_315eb8c4-9315-4e69-a6bd-4522c5f6f812" xlink:to="loc_bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentContinuingOperationExcludingAssetsHeldForSale_5153710c-00a3-4b95-a2c2-57ed053be25a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_cd4c5c7b-4a5a-43da-821a-0197587c0178" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_eed2b324-8c72-41b6-8c2c-320b7fa3646e" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_cd4c5c7b-4a5a-43da-821a-0197587c0178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_5d283da3-d7de-4dfb-bdf3-f9a85a31fe82" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_cd4c5c7b-4a5a-43da-821a-0197587c0178" xlink:to="loc_us-gaap_InterestPaidNet_5d283da3-d7de-4dfb-bdf3-f9a85a31fe82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_8baa7866-d8aa-47c2-a84a-d5154263adf5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_cd4c5c7b-4a5a-43da-821a-0197587c0178" xlink:to="loc_us-gaap_IncomeTaxesPaid_8baa7866-d8aa-47c2-a84a-d5154263adf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_WithholdingTaxesAccrued_7daf5cdb-e880-46b3-aec9-0d6f229b07e1" xlink:href="bcrx-20250930.xsd#bcrx_WithholdingTaxesAccrued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_cd4c5c7b-4a5a-43da-821a-0197587c0178" xlink:to="loc_bcrx_WithholdingTaxesAccrued_7daf5cdb-e880-46b3-aec9-0d6f229b07e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/CondensedConsolidatedStatementsofStockholdersDeficit" xlink:type="simple" xlink:href="bcrx-20250930.xsd#CondensedConsolidatedStatementsofStockholdersDeficit"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/CondensedConsolidatedStatementsofStockholdersDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_cc0e67f6-bf2e-4ac6-9a6d-c1e99fea974c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_dc794380-37cb-4cb3-9b12-0e51db81354a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_cc0e67f6-bf2e-4ac6-9a6d-c1e99fea974c" xlink:to="loc_us-gaap_StatementTable_dc794380-37cb-4cb3-9b12-0e51db81354a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8bc1652a-b856-4472-b808-55150fe3925e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_dc794380-37cb-4cb3-9b12-0e51db81354a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8bc1652a-b856-4472-b808-55150fe3925e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_92e53480-b658-433f-9f49-b6c22dcf5008" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8bc1652a-b856-4472-b808-55150fe3925e" xlink:to="loc_us-gaap_EquityComponentDomain_92e53480-b658-433f-9f49-b6c22dcf5008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_74be383d-e120-4b6f-bc1b-2e955f2b75a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_92e53480-b658-433f-9f49-b6c22dcf5008" xlink:to="loc_us-gaap_CommonStockMember_74be383d-e120-4b6f-bc1b-2e955f2b75a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_5efcce4f-9593-4cfa-aaa8-2d30a099a0ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_92e53480-b658-433f-9f49-b6c22dcf5008" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_5efcce4f-9593-4cfa-aaa8-2d30a099a0ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_14b35ec1-f6a8-43a8-a928-da15d6edc406" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_92e53480-b658-433f-9f49-b6c22dcf5008" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_14b35ec1-f6a8-43a8-a928-da15d6edc406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_f992601d-6c83-41e4-acea-3af0c42596b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_92e53480-b658-433f-9f49-b6c22dcf5008" xlink:to="loc_us-gaap_RetainedEarningsMember_f992601d-6c83-41e4-acea-3af0c42596b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_25efe9fd-48e8-4eef-b778-0a3632439920" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_dc794380-37cb-4cb3-9b12-0e51db81354a" xlink:to="loc_us-gaap_StatementLineItems_25efe9fd-48e8-4eef-b778-0a3632439920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_314b77f0-6084-45a2-88bf-e7d0c3f2bf25" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_25efe9fd-48e8-4eef-b778-0a3632439920" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_314b77f0-6084-45a2-88bf-e7d0c3f2bf25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f047730b-0461-4777-82cb-ad4cc199fb7f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_314b77f0-6084-45a2-88bf-e7d0c3f2bf25" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_f047730b-0461-4777-82cb-ad4cc199fb7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_88f196a5-cd3f-4252-bb93-be2dc915e02b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_314b77f0-6084-45a2-88bf-e7d0c3f2bf25" xlink:to="loc_us-gaap_StockholdersEquity_88f196a5-cd3f-4252-bb93-be2dc915e02b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7b2a3e49-106d-4913-a3a1-54a7a17d835a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_314b77f0-6084-45a2-88bf-e7d0c3f2bf25" xlink:to="loc_us-gaap_NetIncomeLoss_7b2a3e49-106d-4913-a3a1-54a7a17d835a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ab73fbab-7f01-4993-9e82-850d77759bbc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_314b77f0-6084-45a2-88bf-e7d0c3f2bf25" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ab73fbab-7f01-4993-9e82-850d77759bbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_796656c3-800e-4b1c-94f8-127218efa107" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_314b77f0-6084-45a2-88bf-e7d0c3f2bf25" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_796656c3-800e-4b1c-94f8-127218efa107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_fef63e44-4374-4a11-ad51-7eebed6433b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_314b77f0-6084-45a2-88bf-e7d0c3f2bf25" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_fef63e44-4374-4a11-ad51-7eebed6433b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_225610df-e0b2-40b3-9d8a-cae2cfb16e3d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_314b77f0-6084-45a2-88bf-e7d0c3f2bf25" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_225610df-e0b2-40b3-9d8a-cae2cfb16e3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_accfb519-10a0-4ee9-a1f9-8751d944f9c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_314b77f0-6084-45a2-88bf-e7d0c3f2bf25" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_accfb519-10a0-4ee9-a1f9-8751d944f9c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_46ab6761-1796-4380-adb9-7931501af78a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_314b77f0-6084-45a2-88bf-e7d0c3f2bf25" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_46ab6761-1796-4380-adb9-7931501af78a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_6dfdbcf3-184f-48e8-ad8f-d7b0ed7e718f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_314b77f0-6084-45a2-88bf-e7d0c3f2bf25" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_6dfdbcf3-184f-48e8-ad8f-d7b0ed7e718f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_30055b06-1624-40c5-93db-38f19196ddd5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_314b77f0-6084-45a2-88bf-e7d0c3f2bf25" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_30055b06-1624-40c5-93db-38f19196ddd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_ecc212b3-b5d4-4ef1-9d61-07062a8e1ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_314b77f0-6084-45a2-88bf-e7d0c3f2bf25" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_ecc212b3-b5d4-4ef1-9d61-07062a8e1ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_59334d04-7165-4ab8-b610-4b57dd66f46e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_314b77f0-6084-45a2-88bf-e7d0c3f2bf25" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_59334d04-7165-4ab8-b610-4b57dd66f46e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_8a912f89-3e5a-42e6-beff-8c070751abe9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_314b77f0-6084-45a2-88bf-e7d0c3f2bf25" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_8a912f89-3e5a-42e6-beff-8c070751abe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c7b9c78a-d922-4677-a079-4a17bcf51140" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_314b77f0-6084-45a2-88bf-e7d0c3f2bf25" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c7b9c78a-d922-4677-a079-4a17bcf51140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ff6f4d22-beb2-4b68-85c9-954493f1d71f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_314b77f0-6084-45a2-88bf-e7d0c3f2bf25" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_ff6f4d22-beb2-4b68-85c9-954493f1d71f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_eb03bd01-7a14-42f4-be73-1d054a867bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_314b77f0-6084-45a2-88bf-e7d0c3f2bf25" xlink:to="loc_us-gaap_StockholdersEquity_eb03bd01-7a14-42f4-be73-1d054a867bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRisk" xlink:type="simple" xlink:href="bcrx-20250930.xsd#SignificantAccountingPoliciesandConcentrationsofRisk"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRisk" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_04cb6f79-ef5e-47f9-b474-e6c342e05c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_c98dea59-7d51-4ac4-a308-31803fb14864" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_04cb6f79-ef5e-47f9-b474-e6c342e05c2b" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_c98dea59-7d51-4ac4-a308-31803fb14864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSale" xlink:type="simple" xlink:href="bcrx-20250930.xsd#AssetsandLiabilitiesHeldForSale"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSale" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_bc30b778-759e-43ff-a61c-8321388447fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_7fc44b10-e977-4ca4-a1a6-dfbcdc317019" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_bc30b778-759e-43ff-a61c-8321388447fb" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_7fc44b10-e977-4ca4-a1a6-dfbcdc317019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/Revenue" xlink:type="simple" xlink:href="bcrx-20250930.xsd#Revenue"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/Revenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_54afbec7-6b05-45c5-beb1-ea5cc12d1ea2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_985f9d6e-d56c-4e94-9ea1-811e13e784a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_54afbec7-6b05-45c5-beb1-ea5cc12d1ea2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_985f9d6e-d56c-4e94-9ea1-811e13e784a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/Investments" xlink:type="simple" xlink:href="bcrx-20250930.xsd#Investments"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/Investments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_99999ce0-09de-4908-b38e-01ad5caed178" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock_576677e6-0a9e-4d09-b975-5ed5717a24b5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_99999ce0-09de-4908-b38e-01ad5caed178" xlink:to="loc_us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock_576677e6-0a9e-4d09-b975-5ed5717a24b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/TradeReceivables" xlink:type="simple" xlink:href="bcrx-20250930.xsd#TradeReceivables"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/TradeReceivables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_bcce0d08-1445-4797-bc70-d2c69d549c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_TradeReceivablesTextBlock_bd9d24a6-c458-4d15-8a36-fa05e330c4bb" xlink:href="bcrx-20250930.xsd#bcrx_TradeReceivablesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_bcce0d08-1445-4797-bc70-d2c69d549c4f" xlink:to="loc_bcrx_TradeReceivablesTextBlock_bd9d24a6-c458-4d15-8a36-fa05e330c4bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/Inventory" xlink:type="simple" xlink:href="bcrx-20250930.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_ed3d64f4-1941-4d7e-91dd-cefdc9bfcc36" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_6ddf93ab-153c-42ca-bca0-9a21b7d6a59e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_ed3d64f4-1941-4d7e-91dd-cefdc9bfcc36" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_6ddf93ab-153c-42ca-bca0-9a21b7d6a59e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/RoyaltyFinancingObligations" xlink:type="simple" xlink:href="bcrx-20250930.xsd#RoyaltyFinancingObligations"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/RoyaltyFinancingObligations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvanceRoyaltiesAbstract_8aeafaa0-a06b-41fb-8ce0-c4fd976c8644" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdvanceRoyaltiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyFinancingLiabilitiesTextBlock_90572bb7-6ba0-4eae-b4d7-96fb475493f0" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltyFinancingLiabilitiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdvanceRoyaltiesAbstract_8aeafaa0-a06b-41fb-8ce0-c4fd976c8644" xlink:to="loc_bcrx_RoyaltyFinancingLiabilitiesTextBlock_90572bb7-6ba0-4eae-b4d7-96fb475493f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/Debt" xlink:type="simple" xlink:href="bcrx-20250930.xsd#Debt"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_dba84f68-5c5d-442f-b341-ddea1440aa31" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_8fabd9d0-3a39-4d70-9a2a-36c160429145" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_dba84f68-5c5d-442f-b341-ddea1440aa31" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_8fabd9d0-3a39-4d70-9a2a-36c160429145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/LeaseObligations" xlink:type="simple" xlink:href="bcrx-20250930.xsd#LeaseObligations"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/LeaseObligations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b07189e8-44bc-4e99-a540-59d9f7e960f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_697543d2-3508-4a56-bf78-46aec0255522" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b07189e8-44bc-4e99-a540-59d9f7e960f2" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_697543d2-3508-4a56-bf78-46aec0255522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/StockholdersEquity" xlink:type="simple" xlink:href="bcrx-20250930.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_27ba9c76-3310-43ba-9de4-e04680f9168a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_57582593-9873-4509-8f28-8fcc0415ccdd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_27ba9c76-3310-43ba-9de4-e04680f9168a" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_57582593-9873-4509-8f28-8fcc0415ccdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/StockbasedCompensation" xlink:type="simple" xlink:href="bcrx-20250930.xsd#StockbasedCompensation"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/StockbasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_63fc9edc-7e3f-42ed-bbbc-d0f89e3ec8b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0e9a0d39-1f6c-46c6-9672-f77ad50eb1a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_63fc9edc-7e3f-42ed-bbbc-d0f89e3ec8b9" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0e9a0d39-1f6c-46c6-9672-f77ad50eb1a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/CollaborativeandOtherRelationships" xlink:type="simple" xlink:href="bcrx-20250930.xsd#CollaborativeandOtherRelationships"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/CollaborativeandOtherRelationships" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8aa0123f-059b-4b1d-a979-ea3d63a104bc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_ced3e69d-3fe1-4bc2-8111-8750f9ac28b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8aa0123f-059b-4b1d-a979-ea3d63a104bc" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_ced3e69d-3fe1-4bc2-8111-8750f9ac28b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/SegmentInformation" xlink:type="simple" xlink:href="bcrx-20250930.xsd#SegmentInformation"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/SegmentInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_6ee444f8-8a9d-4325-b0dd-26934578d7a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_edf33c5a-4b6c-4111-8e21-e963ac9f9db8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_6ee444f8-8a9d-4325-b0dd-26934578d7a0" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_edf33c5a-4b6c-4111-8e21-e963ac9f9db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="bcrx-20250930.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_24db25f4-d26f-4074-84b6-e5769e957168" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_23e1cead-fce5-43fb-8e2f-12f1bed5c5ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_24db25f4-d26f-4074-84b6-e5769e957168" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_23e1cead-fce5-43fb-8e2f-12f1bed5c5ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/NetIncomeLossPerShare" xlink:type="simple" xlink:href="bcrx-20250930.xsd#NetIncomeLossPerShare"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/NetIncomeLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_571599a4-a465-43a2-9d3a-9188936ed29e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_66ad9eb6-3a6a-4b5c-8923-6cd9b2ea8a00" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_571599a4-a465-43a2-9d3a-9188936ed29e" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_66ad9eb6-3a6a-4b5c-8923-6cd9b2ea8a00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/SubsequentEvent" xlink:type="simple" xlink:href="bcrx-20250930.xsd#SubsequentEvent"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/SubsequentEvent" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_676809a2-4d7a-480a-9c9a-4ea95ba45426" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_3370cff7-3ca7-426d-b5c2-cdd7a2a40a53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_676809a2-4d7a-480a-9c9a-4ea95ba45426" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_3370cff7-3ca7-426d-b5c2-cdd7a2a40a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskPolicies" xlink:type="simple" xlink:href="bcrx-20250930.xsd#SignificantAccountingPoliciesandConcentrationsofRiskPolicies"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7e2b5d17-986a-4980-8409-930b84e0bfd6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DescriptionOfCompanyPolicyTextBlock_4966e0ee-f506-49fc-a92c-09bdd372de5a" xlink:href="bcrx-20250930.xsd#bcrx_DescriptionOfCompanyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e2b5d17-986a-4980-8409-930b84e0bfd6" xlink:to="loc_bcrx_DescriptionOfCompanyPolicyTextBlock_4966e0ee-f506-49fc-a92c-09bdd372de5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_8973b91a-de99-4ef3-abb3-78ac4856022e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e2b5d17-986a-4980-8409-930b84e0bfd6" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_8973b91a-de99-4ef3-abb3-78ac4856022e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_0ca495b0-fde5-45ae-9c91-61432e85bb60" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e2b5d17-986a-4980-8409-930b84e0bfd6" xlink:to="loc_us-gaap_UseOfEstimates_0ca495b0-fde5-45ae-9c91-61432e85bb60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AssetsHeldForSalePolicyTextBlock_f267cdf5-8387-457a-b121-6efcae3e3b5b" xlink:href="bcrx-20250930.xsd#bcrx_AssetsHeldForSalePolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e2b5d17-986a-4980-8409-930b84e0bfd6" xlink:to="loc_bcrx_AssetsHeldForSalePolicyTextBlock_f267cdf5-8387-457a-b121-6efcae3e3b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_195d372a-0efa-48b0-acdb-05d907966d60" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e2b5d17-986a-4980-8409-930b84e0bfd6" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_195d372a-0efa-48b0-acdb-05d907966d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_6d3420ec-903f-4161-8342-64efe24468fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e2b5d17-986a-4980-8409-930b84e0bfd6" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_6d3420ec-903f-4161-8342-64efe24468fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_ff034fda-4abe-48f5-8d5c-bf467567fe0d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e2b5d17-986a-4980-8409-930b84e0bfd6" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_ff034fda-4abe-48f5-8d5c-bf467567fe0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_d566f0f7-0bc1-4d1d-babb-10c7d582c19c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e2b5d17-986a-4980-8409-930b84e0bfd6" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_d566f0f7-0bc1-4d1d-babb-10c7d582c19c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_d06613ec-c639-41df-b3fa-fe81760da005" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e2b5d17-986a-4980-8409-930b84e0bfd6" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_d06613ec-c639-41df-b3fa-fe81760da005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock_1ef5a0f5-fc60-4406-af71-1621fe318151" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e2b5d17-986a-4980-8409-930b84e0bfd6" xlink:to="loc_us-gaap_ReceivablesPolicyTextBlock_1ef5a0f5-fc60-4406-af71-1621fe318151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_608df4dc-483a-469b-ab1c-b9b84cabf0e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e2b5d17-986a-4980-8409-930b84e0bfd6" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_608df4dc-483a-469b-ab1c-b9b84cabf0e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_19dc55f6-9975-48db-bf8c-bf5fb4b95866" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e2b5d17-986a-4980-8409-930b84e0bfd6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_19dc55f6-9975-48db-bf8c-bf5fb4b95866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AccruedExpensesPolicyTextBlock_98c8cf55-4ab2-4356-bda3-9faa8da6a99b" xlink:href="bcrx-20250930.xsd#bcrx_AccruedExpensesPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e2b5d17-986a-4980-8409-930b84e0bfd6" xlink:to="loc_bcrx_AccruedExpensesPolicyTextBlock_98c8cf55-4ab2-4356-bda3-9faa8da6a99b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_f452c581-5665-44f9-a443-815fed6c3320" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e2b5d17-986a-4980-8409-930b84e0bfd6" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_f452c581-5665-44f9-a443-815fed6c3320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_db4d2693-d84e-4cd6-9f75-37b41d5b0ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e2b5d17-986a-4980-8409-930b84e0bfd6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_db4d2693-d84e-4cd6-9f75-37b41d5b0ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_274950bb-7b9d-4168-bc8e-15b6cf8106b1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e2b5d17-986a-4980-8409-930b84e0bfd6" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_274950bb-7b9d-4168-bc8e-15b6cf8106b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_55a9d021-8561-4ea2-9b23-246c024dae7c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e2b5d17-986a-4980-8409-930b84e0bfd6" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_55a9d021-8561-4ea2-9b23-246c024dae7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_7fbbd32a-8daa-4350-8625-54710fc0f79a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e2b5d17-986a-4980-8409-930b84e0bfd6" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_7fbbd32a-8daa-4350-8625-54710fc0f79a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_InterestExpenseDeferredFinancingCostsAndRoyaltyFinancingLiabilitiesPolicyTextBlock_f2bcca54-3b92-4023-b866-220b9df48b4b" xlink:href="bcrx-20250930.xsd#bcrx_InterestExpenseDeferredFinancingCostsAndRoyaltyFinancingLiabilitiesPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e2b5d17-986a-4980-8409-930b84e0bfd6" xlink:to="loc_bcrx_InterestExpenseDeferredFinancingCostsAndRoyaltyFinancingLiabilitiesPolicyTextBlock_f2bcca54-3b92-4023-b866-220b9df48b4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_b787b3c4-bc81-4e13-8a98-ae4c22403b16" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e2b5d17-986a-4980-8409-930b84e0bfd6" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_b787b3c4-bc81-4e13-8a98-ae4c22403b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_c6b8ef04-399b-4e52-80a8-ab4dc2dc027f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e2b5d17-986a-4980-8409-930b84e0bfd6" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_c6b8ef04-399b-4e52-80a8-ab4dc2dc027f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_843e17c1-8e2e-4d74-add4-db62c75c997b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e2b5d17-986a-4980-8409-930b84e0bfd6" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_843e17c1-8e2e-4d74-add4-db62c75c997b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_4998abbe-ba0e-4890-a38c-496b59215c34" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e2b5d17-986a-4980-8409-930b84e0bfd6" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_4998abbe-ba0e-4890-a38c-496b59215c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ConcentrationOfMarketRiskPolicyTextBlock_11f43af9-d417-46be-acc1-141e0bc708f3" xlink:href="bcrx-20250930.xsd#bcrx_ConcentrationOfMarketRiskPolicyTextBlock"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e2b5d17-986a-4980-8409-930b84e0bfd6" xlink:to="loc_bcrx_ConcentrationOfMarketRiskPolicyTextBlock_11f43af9-d417-46be-acc1-141e0bc708f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_d88dd870-d369-4e03-9e90-650d83d90b46" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e2b5d17-986a-4980-8409-930b84e0bfd6" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_d88dd870-d369-4e03-9e90-650d83d90b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskTables" xlink:type="simple" xlink:href="bcrx-20250930.xsd#SignificantAccountingPoliciesandConcentrationsofRiskTables"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3352d00c-f03b-4e32-91ea-4d7358ca64f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_52fff742-4ccd-4ade-9f1b-b33d3a732157" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3352d00c-f03b-4e32-91ea-4d7358ca64f4" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_52fff742-4ccd-4ade-9f1b-b33d3a732157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleTables" xlink:type="simple" xlink:href="bcrx-20250930.xsd#AssetsandLiabilitiesHeldForSaleTables"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_c01057fe-05c2-426b-94ed-325ef9b0c0e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_05b2a1b1-d978-45c0-b405-74b9ef11674f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_c01057fe-05c2-426b-94ed-325ef9b0c0e3" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_05b2a1b1-d978-45c0-b405-74b9ef11674f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/RevenueTables" xlink:type="simple" xlink:href="bcrx-20250930.xsd#RevenueTables"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/RevenueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f49c3615-bfa6-442d-bed6-98a82447c5cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_32d833be-a3b6-4494-9166-9a187c39fb7b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f49c3615-bfa6-442d-bed6-98a82447c5cb" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_32d833be-a3b6-4494-9166-9a187c39fb7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/InvestmentsTables" xlink:type="simple" xlink:href="bcrx-20250930.xsd#InvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/InvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_1a555cb9-e602-4161-a1ee-a9bf59add846" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_ada456a0-8764-4ecc-a9bf-473a8af74643" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_1a555cb9-e602-4161-a1ee-a9bf59add846" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_ada456a0-8764-4ecc-a9bf-473a8af74643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_d368a898-0d58-42ef-85d8-50c142c60227" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_1a555cb9-e602-4161-a1ee-a9bf59add846" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_d368a898-0d58-42ef-85d8-50c142c60227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesTextBlock_8acce67d-22ed-4402-9c7f-b38d1fcccc0e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HeldToMaturitySecuritiesTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_1a555cb9-e602-4161-a1ee-a9bf59add846" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesTextBlock_8acce67d-22ed-4402-9c7f-b38d1fcccc0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/InventoryTables" xlink:type="simple" xlink:href="bcrx-20250930.xsd#InventoryTables"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_c9feed45-f0ef-4e2c-95c9-e19b166e1d5c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_b2e7e0bc-d82c-4d6d-877d-f8392f7693d1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_c9feed45-f0ef-4e2c-95c9-e19b166e1d5c" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_b2e7e0bc-d82c-4d6d-877d-f8392f7693d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/RoyaltyFinancingObligationsTables" xlink:type="simple" xlink:href="bcrx-20250930.xsd#RoyaltyFinancingObligationsTables"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/RoyaltyFinancingObligationsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvanceRoyaltiesAbstract_474c5836-5b46-4cd7-a7f6-80a67f88f1ff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdvanceRoyaltiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyFinancingLiabilitiesTableTextBlock_335d5252-30ab-4719-8c30-3b26b4b5c920" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltyFinancingLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdvanceRoyaltiesAbstract_474c5836-5b46-4cd7-a7f6-80a67f88f1ff" xlink:to="loc_bcrx_RoyaltyFinancingLiabilitiesTableTextBlock_335d5252-30ab-4719-8c30-3b26b4b5c920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/LeaseObligationsTables" xlink:type="simple" xlink:href="bcrx-20250930.xsd#LeaseObligationsTables"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/LeaseObligationsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_1025dde2-40f9-4bb3-964b-01cdf97f7aea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_79b6e6fb-16a5-43fe-9069-db718cf241a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1025dde2-40f9-4bb3-964b-01cdf97f7aea" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_79b6e6fb-16a5-43fe-9069-db718cf241a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_OtherSupplementalInformationRelatedToLeasesTableTextBlock_255c9051-4ccb-4906-8200-ad3609a4b6c7" xlink:href="bcrx-20250930.xsd#bcrx_OtherSupplementalInformationRelatedToLeasesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1025dde2-40f9-4bb3-964b-01cdf97f7aea" xlink:to="loc_bcrx_OtherSupplementalInformationRelatedToLeasesTableTextBlock_255c9051-4ccb-4906-8200-ad3609a4b6c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock_2a8fa0f2-4074-4f46-b53f-1382a9c26d01" xlink:href="bcrx-20250930.xsd#bcrx_LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1025dde2-40f9-4bb3-964b-01cdf97f7aea" xlink:to="loc_bcrx_LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock_2a8fa0f2-4074-4f46-b53f-1382a9c26d01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_deec3615-cb49-48b5-b739-ab1742902168" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1025dde2-40f9-4bb3-964b-01cdf97f7aea" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_deec3615-cb49-48b5-b739-ab1742902168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="bcrx-20250930.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_b3c9462c-b0a2-467b-9646-76f2bd7c316d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_04375204-0605-429a-b0cf-4b29f8d8c698" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_b3c9462c-b0a2-467b-9646-76f2bd7c316d" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_04375204-0605-429a-b0cf-4b29f8d8c698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/StockbasedCompensationTables" xlink:type="simple" xlink:href="bcrx-20250930.xsd#StockbasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/StockbasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7e2212db-de5e-4a85-ae95-9173b627c161" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_8014e857-424b-4e8f-83d2-9ec7d79bcc7b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7e2212db-de5e-4a85-ae95-9173b627c161" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_8014e857-424b-4e8f-83d2-9ec7d79bcc7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_ce0ab0eb-c92f-464f-90f3-2a3755cdae02" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7e2212db-de5e-4a85-ae95-9173b627c161" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_ce0ab0eb-c92f-464f-90f3-2a3755cdae02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_544dce50-4161-42d1-8e7c-0a42efae369c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7e2212db-de5e-4a85-ae95-9173b627c161" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_544dce50-4161-42d1-8e7c-0a42efae369c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/SegmentInformationTables" xlink:type="simple" xlink:href="bcrx-20250930.xsd#SegmentInformationTables"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/SegmentInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_b46cf190-420a-4b6a-a5ee-654792421f72" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_541e2e33-8195-4676-b7ef-1145e1c6e433" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_b46cf190-420a-4b6a-a5ee-654792421f72" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_541e2e33-8195-4676-b7ef-1145e1c6e433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/NetIncomeLossPerShareTables" xlink:type="simple" xlink:href="bcrx-20250930.xsd#NetIncomeLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/NetIncomeLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b9cec150-e4f9-49c7-8911-ae976e57d1e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_5651da1f-9de9-47f0-8a7d-6006f44f5f85" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b9cec150-e4f9-49c7-8911-ae976e57d1e5" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_5651da1f-9de9-47f0-8a7d-6006f44f5f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3ef38764-8022-49f3-8c2d-e22751e34916" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b9cec150-e4f9-49c7-8911-ae976e57d1e5" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3ef38764-8022-49f3-8c2d-e22751e34916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails" xlink:type="simple" xlink:href="bcrx-20250930.xsd#SignificantAccountingPoliciesandConcentrationsofRiskDetails"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_dc9fac06-358b-4ee9-b0f0-8197c50e2a9b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable_2814bfa2-f526-4963-a0f5-3af4385212f0" xlink:href="bcrx-20250930.xsd#bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_dc9fac06-358b-4ee9-b0f0-8197c50e2a9b" xlink:to="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable_2814bfa2-f526-4963-a0f5-3af4385212f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_3aa174a8-af7c-4fc6-965a-50dfc6cd553e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable_2814bfa2-f526-4963-a0f5-3af4385212f0" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_3aa174a8-af7c-4fc6-965a-50dfc6cd553e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_58aebfcb-d4f2-46f0-8b7a-8dcaf37aed3e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_3aa174a8-af7c-4fc6-965a-50dfc6cd553e" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_58aebfcb-d4f2-46f0-8b7a-8dcaf37aed3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_CollateralForCreditMember_436be52e-6602-43d8-bf87-94391fd9a4de" xlink:href="bcrx-20250930.xsd#bcrx_CollateralForCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_58aebfcb-d4f2-46f0-8b7a-8dcaf37aed3e" xlink:to="loc_bcrx_CollateralForCreditMember_436be52e-6602-43d8-bf87-94391fd9a4de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b20757f8-59be-44c8-bc6d-efb7f854ca1f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable_2814bfa2-f526-4963-a0f5-3af4385212f0" xlink:to="loc_srt_RangeAxis_b20757f8-59be-44c8-bc6d-efb7f854ca1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_32dbcab8-ad7b-415d-8144-c306d5dabca1" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b20757f8-59be-44c8-bc6d-efb7f854ca1f" xlink:to="loc_srt_RangeMember_32dbcab8-ad7b-415d-8144-c306d5dabca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_db7c9998-abd7-4d98-94ab-fc33192753f6" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_32dbcab8-ad7b-415d-8144-c306d5dabca1" xlink:to="loc_srt_MaximumMember_db7c9998-abd7-4d98-94ab-fc33192753f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9dd7b114-aeda-4cb4-bce6-3d51eb99a65e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable_2814bfa2-f526-4963-a0f5-3af4385212f0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9dd7b114-aeda-4cb4-bce6-3d51eb99a65e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_787ba224-f601-4ba1-ba37-d3626030ae1b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9dd7b114-aeda-4cb4-bce6-3d51eb99a65e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_787ba224-f601-4ba1-ba37-d3626030ae1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_f5e3903b-bbe7-4a78-8259-f102ea436393" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_787ba224-f601-4ba1-ba37-d3626030ae1b" xlink:to="loc_us-gaap_ComputerEquipmentMember_f5e3903b-bbe7-4a78-8259-f102ea436393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember_866d6a4f-c3a7-442d-8290-7f0040b6e24a" xlink:href="bcrx-20250930.xsd#bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_787ba224-f601-4ba1-ba37-d3626030ae1b" xlink:to="loc_bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember_866d6a4f-c3a7-442d-8290-7f0040b6e24a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_3d86554e-8286-4478-ad2f-2c991a2c4fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_787ba224-f601-4ba1-ba37-d3626030ae1b" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_3d86554e-8286-4478-ad2f-2c991a2c4fa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0b77f48b-c7c0-4074-b654-b4610d21cb39" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable_2814bfa2-f526-4963-a0f5-3af4385212f0" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0b77f48b-c7c0-4074-b654-b4610d21cb39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0e024ea1-ecfc-4410-bae4-360cd5df5d77" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0b77f48b-c7c0-4074-b654-b4610d21cb39" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0e024ea1-ecfc-4410-bae4-360cd5df5d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_70b08625-d6e8-4e60-b52c-60c922b29029" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0e024ea1-ecfc-4410-bae4-360cd5df5d77" xlink:to="loc_us-gaap_SalesRevenueNetMember_70b08625-d6e8-4e60-b52c-60c922b29029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_f5273cab-7f18-43e7-92ef-723efab2009e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable_2814bfa2-f526-4963-a0f5-3af4385212f0" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_f5273cab-7f18-43e7-92ef-723efab2009e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_e9d8dbeb-77b3-42b7-87b5-c27e98fe8589" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_f5273cab-7f18-43e7-92ef-723efab2009e" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_e9d8dbeb-77b3-42b7-87b5-c27e98fe8589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_e9f65704-e884-4dbe-bc7c-0a5498ed4878" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_e9d8dbeb-77b3-42b7-87b5-c27e98fe8589" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_e9f65704-e884-4dbe-bc7c-0a5498ed4878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_64d6db69-5886-405e-b1ca-1e5d6f100ac1" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable_2814bfa2-f526-4963-a0f5-3af4385212f0" xlink:to="loc_srt_ProductOrServiceAxis_64d6db69-5886-405e-b1ca-1e5d6f100ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_35de4207-b780-4250-a5a7-5d668cffbc46" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_64d6db69-5886-405e-b1ca-1e5d6f100ac1" xlink:to="loc_srt_ProductsAndServicesDomain_35de4207-b780-4250-a5a7-5d668cffbc46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ORLADEYOMember_095d9289-d11f-48be-bace-f0106941299c" xlink:href="bcrx-20250930.xsd#bcrx_ORLADEYOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_35de4207-b780-4250-a5a7-5d668cffbc46" xlink:to="loc_bcrx_ORLADEYOMember_095d9289-d11f-48be-bace-f0106941299c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_efbaece0-5bcf-41ff-af5b-d81c5e222499" xlink:href="bcrx-20250930.xsd#bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable_2814bfa2-f526-4963-a0f5-3af4385212f0" xlink:to="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_efbaece0-5bcf-41ff-af5b-d81c5e222499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_5fc6513a-b922-445a-97b1-04fb8158a772" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_efbaece0-5bcf-41ff-af5b-d81c5e222499" xlink:to="loc_us-gaap_NumberOfReportableSegments_5fc6513a-b922-445a-97b1-04fb8158a772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_81c03ca1-1abe-4e90-b763-584fbbb80c72" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_efbaece0-5bcf-41ff-af5b-d81c5e222499" xlink:to="loc_us-gaap_NumberOfOperatingSegments_81c03ca1-1abe-4e90-b763-584fbbb80c72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_98de04b4-8477-4ab4-bb46-31368577a705" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_efbaece0-5bcf-41ff-af5b-d81c5e222499" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_98de04b4-8477-4ab4-bb46-31368577a705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_MaturityPeriodOfHighQualityMarketableSecurities_52a2a46b-fc3d-4b3a-af12-ecf2fc22aa26" xlink:href="bcrx-20250930.xsd#bcrx_MaturityPeriodOfHighQualityMarketableSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_efbaece0-5bcf-41ff-af5b-d81c5e222499" xlink:to="loc_bcrx_MaturityPeriodOfHighQualityMarketableSecurities_52a2a46b-fc3d-4b3a-af12-ecf2fc22aa26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities_e0235cb7-4400-43d3-9d99-caa54cb5d3c7" xlink:href="bcrx-20250930.xsd#bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_efbaece0-5bcf-41ff-af5b-d81c5e222499" xlink:to="loc_bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities_e0235cb7-4400-43d3-9d99-caa54cb5d3c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_MaturityPeriodOfShortTermInvestment_7cb55e95-8b80-45ea-92ab-f7b385754106" xlink:href="bcrx-20250930.xsd#bcrx_MaturityPeriodOfShortTermInvestment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_efbaece0-5bcf-41ff-af5b-d81c5e222499" xlink:to="loc_bcrx_MaturityPeriodOfShortTermInvestment_7cb55e95-8b80-45ea-92ab-f7b385754106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_LongTermInvestmentMaturityMinimum_cff5f5f9-ba86-4d42-a0d7-78e313f28071" xlink:href="bcrx-20250930.xsd#bcrx_LongTermInvestmentMaturityMinimum"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_efbaece0-5bcf-41ff-af5b-d81c5e222499" xlink:to="loc_bcrx_LongTermInvestmentMaturityMinimum_cff5f5f9-ba86-4d42-a0d7-78e313f28071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_28855b0e-4ea2-4f60-af2a-ac79b753b423" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_efbaece0-5bcf-41ff-af5b-d81c5e222499" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_28855b0e-4ea2-4f60-af2a-ac79b753b423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b9c03c85-cac3-498c-9a38-de0235a0ceb4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_efbaece0-5bcf-41ff-af5b-d81c5e222499" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b9c03c85-cac3-498c-9a38-de0235a0ceb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_90cfb73c-e6de-442d-88fd-586d5295f0c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_efbaece0-5bcf-41ff-af5b-d81c5e222499" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_90cfb73c-e6de-442d-88fd-586d5295f0c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_8a0ffa3f-429c-4f04-b241-4a51d6a8c9ff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_efbaece0-5bcf-41ff-af5b-d81c5e222499" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_8a0ffa3f-429c-4f04-b241-4a51d6a8c9ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskSummaryofRevenuesDetails" xlink:type="simple" xlink:href="bcrx-20250930.xsd#SignificantAccountingPoliciesandConcentrationsofRiskSummaryofRevenuesDetails"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskSummaryofRevenuesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d6cca8f8-e390-4762-81e0-491c34fc86a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable_c8d1083f-37f5-44d0-9a53-5cf986f00028" xlink:href="bcrx-20250930.xsd#bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d6cca8f8-e390-4762-81e0-491c34fc86a1" xlink:to="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable_c8d1083f-37f5-44d0-9a53-5cf986f00028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c4ad035a-36e6-473d-8b7e-4ed22dd367ad" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable_c8d1083f-37f5-44d0-9a53-5cf986f00028" xlink:to="loc_srt_ProductOrServiceAxis_c4ad035a-36e6-473d-8b7e-4ed22dd367ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_48e568de-e7aa-4b31-b9d9-c0c1590b99bc" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_c4ad035a-36e6-473d-8b7e-4ed22dd367ad" xlink:to="loc_srt_ProductsAndServicesDomain_48e568de-e7aa-4b31-b9d9-c0c1590b99bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_8c73a3fe-b7c6-4577-b70e-8036cf68c1b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_48e568de-e7aa-4b31-b9d9-c0c1590b99bc" xlink:to="loc_us-gaap_ProductMember_8c73a3fe-b7c6-4577-b70e-8036cf68c1b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_CollaborativeAndOtherResearchAndDevelopmentMember_7b6ed988-0140-47c0-981b-22226213749b" xlink:href="bcrx-20250930.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_48e568de-e7aa-4b31-b9d9-c0c1590b99bc" xlink:to="loc_bcrx_CollaborativeAndOtherResearchAndDevelopmentMember_7b6ed988-0140-47c0-981b-22226213749b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_6eb1fd83-27f4-4217-af8c-cfa53259d94d" xlink:href="bcrx-20250930.xsd#bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable_c8d1083f-37f5-44d0-9a53-5cf986f00028" xlink:to="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_6eb1fd83-27f4-4217-af8c-cfa53259d94d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_63b0c642-7fd8-4a60-8a0a-858f33da3a14" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_6eb1fd83-27f4-4217-af8c-cfa53259d94d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_63b0c642-7fd8-4a60-8a0a-858f33da3a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleDetails" xlink:type="simple" xlink:href="bcrx-20250930.xsd#AssetsandLiabilitiesHeldForSaleDetails"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_12913207-1c9e-4cad-9ba0-efa4b41b1d19" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3691cdad-39ad-4889-a980-b4878d48e84b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_12913207-1c9e-4cad-9ba0-efa4b41b1d19" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3691cdad-39ad-4889-a980-b4878d48e84b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5a2f922e-e162-4748-9cbf-8e8d63ff4434" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3691cdad-39ad-4889-a980-b4878d48e84b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5a2f922e-e162-4748-9cbf-8e8d63ff4434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_da76b375-bcd0-43a3-9b84-668cdb1ae678" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5a2f922e-e162-4748-9cbf-8e8d63ff4434" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_da76b375-bcd0-43a3-9b84-668cdb1ae678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7688aba8-f1eb-45c6-9e9c-a42e72cb182b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_da76b375-bcd0-43a3-9b84-668cdb1ae678" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7688aba8-f1eb-45c6-9e9c-a42e72cb182b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_3cfadaaf-536f-46ec-bc3c-209478936e53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3691cdad-39ad-4889-a980-b4878d48e84b" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_3cfadaaf-536f-46ec-bc3c-209478936e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_c5457c2f-88a6-4c49-ad61-574b77234231" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_3cfadaaf-536f-46ec-bc3c-209478936e53" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_c5457c2f-88a6-4c49-ad61-574b77234231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_3406967a-cfa0-4fcb-bb7c-b13f12d07244" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_c5457c2f-88a6-4c49-ad61-574b77234231" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_3406967a-cfa0-4fcb-bb7c-b13f12d07244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_09206f4d-2224-47af-8279-dd7b449f4993" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3691cdad-39ad-4889-a980-b4878d48e84b" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_09206f4d-2224-47af-8279-dd7b449f4993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_afb75f25-ffc0-4a95-a1d8-6b71d8cb55ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_09206f4d-2224-47af-8279-dd7b449f4993" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_afb75f25-ffc0-4a95-a1d8-6b71d8cb55ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_BioCrystIrelandMember_6715d745-9a96-4737-87f7-9f6941d39c48" xlink:href="bcrx-20250930.xsd#bcrx_BioCrystIrelandMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_afb75f25-ffc0-4a95-a1d8-6b71d8cb55ba" xlink:to="loc_bcrx_BioCrystIrelandMember_6715d745-9a96-4737-87f7-9f6941d39c48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_300e5546-2fdf-4201-9de8-37a792398689" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3691cdad-39ad-4889-a980-b4878d48e84b" xlink:to="loc_srt_StatementScenarioAxis_300e5546-2fdf-4201-9de8-37a792398689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_56692cda-cd21-4a5c-b264-f0716c92ea75" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_300e5546-2fdf-4201-9de8-37a792398689" xlink:to="loc_srt_ScenarioUnspecifiedDomain_56692cda-cd21-4a5c-b264-f0716c92ea75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_8e52e8c0-a548-4373-a534-77e689359774" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_56692cda-cd21-4a5c-b264-f0716c92ea75" xlink:to="loc_srt_ScenarioForecastMember_8e52e8c0-a548-4373-a534-77e689359774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6b09c04e-dee3-4639-8d8c-0edc5c3e99ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3691cdad-39ad-4889-a980-b4878d48e84b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6b09c04e-dee3-4639-8d8c-0edc5c3e99ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_4cc9d25f-2052-4394-b395-cc11a9db4f89" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6b09c04e-dee3-4639-8d8c-0edc5c3e99ca" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_4cc9d25f-2052-4394-b395-cc11a9db4f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_49907174-a0b9-4a9e-84fe-7bfc2222ce30" xlink:href="bcrx-20250930.xsd#bcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsideration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6b09c04e-dee3-4639-8d8c-0edc5c3e99ca" xlink:to="loc_bcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_49907174-a0b9-4a9e-84fe-7bfc2222ce30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DisposalGroupIncludingDiscontinuedOperationConsiderationRoyaltyReleaseFee_0a2554a3-b5d1-4d49-bbd8-86fecc2b388e" xlink:href="bcrx-20250930.xsd#bcrx_DisposalGroupIncludingDiscontinuedOperationConsiderationRoyaltyReleaseFee"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6b09c04e-dee3-4639-8d8c-0edc5c3e99ca" xlink:to="loc_bcrx_DisposalGroupIncludingDiscontinuedOperationConsiderationRoyaltyReleaseFee_0a2554a3-b5d1-4d49-bbd8-86fecc2b388e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleScheduleofAssetsHeldForSaleDetails" xlink:type="simple" xlink:href="bcrx-20250930.xsd#AssetsandLiabilitiesHeldForSaleScheduleofAssetsHeldForSaleDetails"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleScheduleofAssetsHeldForSaleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_e37803c0-2c08-4ce3-9da4-34cbb7088aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_978e7ce9-72d8-4d64-9670-1760550f1aee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_e37803c0-2c08-4ce3-9da4-34cbb7088aaa" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_978e7ce9-72d8-4d64-9670-1760550f1aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_0807113e-fe03-4301-b517-3d58d0b31f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_978e7ce9-72d8-4d64-9670-1760550f1aee" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_0807113e-fe03-4301-b517-3d58d0b31f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_21ec5b30-d639-4235-82d4-4fe00e97f67e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_0807113e-fe03-4301-b517-3d58d0b31f1e" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_21ec5b30-d639-4235-82d4-4fe00e97f67e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_d80364d5-895c-4050-9d05-157361071530" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_21ec5b30-d639-4235-82d4-4fe00e97f67e" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_d80364d5-895c-4050-9d05-157361071530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e9b5606c-e356-49cd-819e-c07ccafb45c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_978e7ce9-72d8-4d64-9670-1760550f1aee" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e9b5606c-e356-49cd-819e-c07ccafb45c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_26a7e2d7-47ef-4bf7-83bc-1231a0e2baf0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e9b5606c-e356-49cd-819e-c07ccafb45c2" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_26a7e2d7-47ef-4bf7-83bc-1231a0e2baf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_BioCrystIrelandMember_4e6bb152-1fbf-4ef1-8f82-54dd088ae59f" xlink:href="bcrx-20250930.xsd#bcrx_BioCrystIrelandMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_26a7e2d7-47ef-4bf7-83bc-1231a0e2baf0" xlink:to="loc_bcrx_BioCrystIrelandMember_4e6bb152-1fbf-4ef1-8f82-54dd088ae59f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bff75a7c-c521-49ef-96c8-292470e55e63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_978e7ce9-72d8-4d64-9670-1760550f1aee" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bff75a7c-c521-49ef-96c8-292470e55e63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_b716b493-486d-4a87-aa1b-058d647df9d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bff75a7c-c521-49ef-96c8-292470e55e63" xlink:to="loc_us-gaap_AssetsAbstract_b716b493-486d-4a87-aa1b-058d647df9d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_030e042d-c5a9-4c2a-b701-d54c521d2d35" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b716b493-486d-4a87-aa1b-058d647df9d7" xlink:to="loc_us-gaap_AssetsCurrentAbstract_030e042d-c5a9-4c2a-b701-d54c521d2d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_96620402-324e-4395-a96c-55627836a673" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_030e042d-c5a9-4c2a-b701-d54c521d2d35" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_96620402-324e-4395-a96c-55627836a673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_4f8cc1a5-0cd2-4a74-83ec-4cdd07c29dda" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_030e042d-c5a9-4c2a-b701-d54c521d2d35" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_4f8cc1a5-0cd2-4a74-83ec-4cdd07c29dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_9a7e9b2f-b18c-4737-a2c2-d72100cea1e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_030e042d-c5a9-4c2a-b701-d54c521d2d35" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_9a7e9b2f-b18c-4737-a2c2-d72100cea1e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_c42eafc5-889c-4d0c-939e-cae46df4c876" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_030e042d-c5a9-4c2a-b701-d54c521d2d35" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_c42eafc5-889c-4d0c-939e-cae46df4c876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_dee8974c-a525-4981-8082-f63d67faf625" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_030e042d-c5a9-4c2a-b701-d54c521d2d35" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_dee8974c-a525-4981-8082-f63d67faf625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_43ac84bf-6432-408c-a576-de972b71e81f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b716b493-486d-4a87-aa1b-058d647df9d7" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_43ac84bf-6432-408c-a576-de972b71e81f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_4611ac05-9499-4738-96d6-98e69e6c4fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b716b493-486d-4a87-aa1b-058d647df9d7" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_4611ac05-9499-4738-96d6-98e69e6c4fe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8d9d172d-f876-4c1b-86f8-cf233be5621c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bff75a7c-c521-49ef-96c8-292470e55e63" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8d9d172d-f876-4c1b-86f8-cf233be5621c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_6ac1e41e-f765-4e12-953c-1e818eb04b9e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8d9d172d-f876-4c1b-86f8-cf233be5621c" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_6ac1e41e-f765-4e12-953c-1e818eb04b9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_5b33a1c3-cfa5-41ce-8b09-b4ab51b8cc46" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6ac1e41e-f765-4e12-953c-1e818eb04b9e" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_5b33a1c3-cfa5-41ce-8b09-b4ab51b8cc46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_909d70ce-cf2b-4071-a36a-4cb7b60a642f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6ac1e41e-f765-4e12-953c-1e818eb04b9e" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_909d70ce-cf2b-4071-a36a-4cb7b60a642f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_86d3bc1d-0041-4cb2-8dd2-cf17e177fc05" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6ac1e41e-f765-4e12-953c-1e818eb04b9e" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_86d3bc1d-0041-4cb2-8dd2-cf17e177fc05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_4ec919ea-00f9-463d-8656-a9762353d136" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6ac1e41e-f765-4e12-953c-1e818eb04b9e" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_4ec919ea-00f9-463d-8656-a9762353d136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_bc284101-e152-44a5-95e1-618415c4637f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8d9d172d-f876-4c1b-86f8-cf233be5621c" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_bc284101-e152-44a5-95e1-618415c4637f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_96497b49-86de-4398-9096-159415d84847" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8d9d172d-f876-4c1b-86f8-cf233be5621c" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_96497b49-86de-4398-9096-159415d84847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/RevenueDetails" xlink:type="simple" xlink:href="bcrx-20250930.xsd#RevenueDetails"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/RevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b98011fa-ee74-4b36-8a10-00973bbbd614" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_90f53df2-ea9e-4eed-a9ff-148c89b773fd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b98011fa-ee74-4b36-8a10-00973bbbd614" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_90f53df2-ea9e-4eed-a9ff-148c89b773fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_54a27ce0-2e67-4e40-a885-15ca1e2da8b9" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_90f53df2-ea9e-4eed-a9ff-148c89b773fd" xlink:to="loc_srt_ProductOrServiceAxis_54a27ce0-2e67-4e40-a885-15ca1e2da8b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bba63b09-4b3f-4b68-8364-30fd6145dcaa" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_54a27ce0-2e67-4e40-a885-15ca1e2da8b9" xlink:to="loc_srt_ProductsAndServicesDomain_bba63b09-4b3f-4b68-8364-30fd6145dcaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_0c573d5d-fc91-4669-a859-0479f0df3f66" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_bba63b09-4b3f-4b68-8364-30fd6145dcaa" xlink:to="loc_us-gaap_ProductMember_0c573d5d-fc91-4669-a859-0479f0df3f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ORLADEYOMember_a856c74d-f5ef-4e8e-b769-3d8dc2e39bdd" xlink:href="bcrx-20250930.xsd#bcrx_ORLADEYOMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_bba63b09-4b3f-4b68-8364-30fd6145dcaa" xlink:to="loc_bcrx_ORLADEYOMember_a856c74d-f5ef-4e8e-b769-3d8dc2e39bdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_OtherIncomeFromContractWithCustomerMember_9de1e360-101e-42ab-a87d-1aa5a26f2641" xlink:href="bcrx-20250930.xsd#bcrx_OtherIncomeFromContractWithCustomerMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_bba63b09-4b3f-4b68-8364-30fd6145dcaa" xlink:to="loc_bcrx_OtherIncomeFromContractWithCustomerMember_9de1e360-101e-42ab-a87d-1aa5a26f2641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicDistributionAxis_363663d0-10db-4a79-aee6-a5bde5903a00" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeographicDistributionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_90f53df2-ea9e-4eed-a9ff-148c89b773fd" xlink:to="loc_us-gaap_GeographicDistributionAxis_363663d0-10db-4a79-aee6-a5bde5903a00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicDistributionDomain_02d532b5-26db-4afe-8ed4-0bb7cc56a7e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeographicDistributionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeographicDistributionAxis_363663d0-10db-4a79-aee6-a5bde5903a00" xlink:to="loc_us-gaap_GeographicDistributionDomain_02d532b5-26db-4afe-8ed4-0bb7cc56a7e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicDistributionDomesticMember_b1584cd3-3888-4c5b-9c25-a1aefbd47e58" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeographicDistributionDomesticMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeographicDistributionDomain_02d532b5-26db-4afe-8ed4-0bb7cc56a7e3" xlink:to="loc_us-gaap_GeographicDistributionDomesticMember_b1584cd3-3888-4c5b-9c25-a1aefbd47e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicDistributionForeignMember_4ae83ef1-8105-4802-8740-dfdd751ad642" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeographicDistributionForeignMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeographicDistributionDomain_02d532b5-26db-4afe-8ed4-0bb7cc56a7e3" xlink:to="loc_us-gaap_GeographicDistributionForeignMember_4ae83ef1-8105-4802-8740-dfdd751ad642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_5bec8462-ddd4-44b8-acf3-eba53f7e26c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_90f53df2-ea9e-4eed-a9ff-148c89b773fd" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_5bec8462-ddd4-44b8-acf3-eba53f7e26c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_5354facf-7dca-447d-93e2-c01480eeb80e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5bec8462-ddd4-44b8-acf3-eba53f7e26c4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_5354facf-7dca-447d-93e2-c01480eeb80e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/InvestmentsFairValueRecurringBasisDetails" xlink:type="simple" xlink:href="bcrx-20250930.xsd#InvestmentsFairValueRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/InvestmentsFairValueRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_43c72845-27e1-421d-ad01-7a0f5810d38e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTable_30e47949-3b96-434d-89d5-2107a56c25a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_43c72845-27e1-421d-ad01-7a0f5810d38e" xlink:to="loc_us-gaap_MarketableSecuritiesTable_30e47949-3b96-434d-89d5-2107a56c25a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5c012fe6-9db9-450f-8892-228da549cdc6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesTable_30e47949-3b96-434d-89d5-2107a56c25a0" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5c012fe6-9db9-450f-8892-228da549cdc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5a9ee1e8-3bf8-479c-9940-cd369226bfea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5c012fe6-9db9-450f-8892-228da549cdc6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5a9ee1e8-3bf8-479c-9940-cd369226bfea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_6a9c75d4-38b9-4988-9a54-206b18b9c80a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5a9ee1e8-3bf8-479c-9940-cd369226bfea" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_6a9c75d4-38b9-4988-9a54-206b18b9c80a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_94ec47a7-47a6-463f-9d71-09d365c26d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5a9ee1e8-3bf8-479c-9940-cd369226bfea" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_94ec47a7-47a6-463f-9d71-09d365c26d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_8f587638-5930-45f0-8d36-10a8efceea98" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5a9ee1e8-3bf8-479c-9940-cd369226bfea" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_8f587638-5930-45f0-8d36-10a8efceea98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_9e58f2e4-d778-47ee-9d3a-e79cc2d4a3df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesTable_30e47949-3b96-434d-89d5-2107a56c25a0" xlink:to="loc_us-gaap_FinancialInstrumentAxis_9e58f2e4-d778-47ee-9d3a-e79cc2d4a3df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7fb36632-fc0d-4742-ba88-ba8b796e57c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9e58f2e4-d778-47ee-9d3a-e79cc2d4a3df" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7fb36632-fc0d-4742-ba88-ba8b796e57c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_ac649532-512f-4f63-8326-240075a7b59f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7fb36632-fc0d-4742-ba88-ba8b796e57c0" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_ac649532-512f-4f63-8326-240075a7b59f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesLineItems_79c5fddf-2f9e-4813-ae48-0e6f4d26f495" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesTable_30e47949-3b96-434d-89d5-2107a56c25a0" xlink:to="loc_us-gaap_MarketableSecuritiesLineItems_79c5fddf-2f9e-4813-ae48-0e6f4d26f495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ea48a1d2-993c-49a9-89d7-244cd3b32cfa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_79c5fddf-2f9e-4813-ae48-0e6f4d26f495" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ea48a1d2-993c-49a9-89d7-244cd3b32cfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/InvestmentsNarrativeDetails" xlink:type="simple" xlink:href="bcrx-20250930.xsd#InvestmentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/InvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_3ea9b5c1-c6ab-4fa9-8261-b1b67849816d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_f7c06d08-4d5a-43cc-8251-ea71f9b42821" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_3ea9b5c1-c6ab-4fa9-8261-b1b67849816d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_f7c06d08-4d5a-43cc-8251-ea71f9b42821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_369561fc-a2f2-4fbe-af27-19aade2a7a74" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_3ea9b5c1-c6ab-4fa9-8261-b1b67849816d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_369561fc-a2f2-4fbe-af27-19aade2a7a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/InvestmentsFairValueoftheCompanysInvestmentsbyTypeDetails" xlink:type="simple" xlink:href="bcrx-20250930.xsd#InvestmentsFairValueoftheCompanysInvestmentsbyTypeDetails"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/InvestmentsFairValueoftheCompanysInvestmentsbyTypeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_17e9339e-8447-43eb-8f5d-c17e9fb91fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTable_6f93accc-3e48-461f-8fda-968305b3e43a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_17e9339e-8447-43eb-8f5d-c17e9fb91fa1" xlink:to="loc_us-gaap_MarketableSecuritiesTable_6f93accc-3e48-461f-8fda-968305b3e43a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6ac9734c-9d5f-4ec7-a884-0039f3e12959" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesTable_6f93accc-3e48-461f-8fda-968305b3e43a" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6ac9734c-9d5f-4ec7-a884-0039f3e12959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6448e757-ddeb-4b3c-b69d-de6df33a1979" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6ac9734c-9d5f-4ec7-a884-0039f3e12959" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6448e757-ddeb-4b3c-b69d-de6df33a1979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_be405549-f449-4f46-a7ba-cef528aa1919" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6448e757-ddeb-4b3c-b69d-de6df33a1979" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_be405549-f449-4f46-a7ba-cef528aa1919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesLineItems_0faeff61-b777-46b7-904b-971e3899fd72" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesTable_6f93accc-3e48-461f-8fda-968305b3e43a" xlink:to="loc_us-gaap_MarketableSecuritiesLineItems_0faeff61-b777-46b7-904b-971e3899fd72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_03102b48-98e6-4a3e-8889-5824d439708d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_0faeff61-b777-46b7-904b-971e3899fd72" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_03102b48-98e6-4a3e-8889-5824d439708d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_4d27f3c1-0342-4b8c-8a86-102887f0c25a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_0faeff61-b777-46b7-904b-971e3899fd72" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_4d27f3c1-0342-4b8c-8a86-102887f0c25a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1c84b4ce-cbf3-4802-9baf-4334bc21c317" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_0faeff61-b777-46b7-904b-971e3899fd72" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1c84b4ce-cbf3-4802-9baf-4334bc21c317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_45c0d680-c385-4b74-b1fe-07e30b49b436" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_0faeff61-b777-46b7-904b-971e3899fd72" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_45c0d680-c385-4b74-b1fe-07e30b49b436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fbd41b6a-d84b-45da-9cbf-94aa5edcaf35" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_0faeff61-b777-46b7-904b-971e3899fd72" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fbd41b6a-d84b-45da-9cbf-94aa5edcaf35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList_cea46a76-b21d-4d7f-a771-6f01909c982d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_0faeff61-b777-46b7-904b-971e3899fd72" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList_cea46a76-b21d-4d7f-a771-6f01909c982d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/InvestmentsScheduleofMaturityofInvestmentsDetails" xlink:type="simple" xlink:href="bcrx-20250930.xsd#InvestmentsScheduleofMaturityofInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/InvestmentsScheduleofMaturityofInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_b03589f0-a5e6-4d3d-9f2f-026184c31f7b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_ac252df7-445a-46c2-975b-b917d19684f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_b03589f0-a5e6-4d3d-9f2f-026184c31f7b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_ac252df7-445a-46c2-975b-b917d19684f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterOneYearAndBeforeTwoYears_e92f90eb-a8ce-4faf-81eb-b4e5b701424f" xlink:href="bcrx-20250930.xsd#bcrx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterOneYearAndBeforeTwoYears"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_b03589f0-a5e6-4d3d-9f2f-026184c31f7b" xlink:to="loc_bcrx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterOneYearAndBeforeTwoYears_e92f90eb-a8ce-4faf-81eb-b4e5b701424f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_dd871607-2757-403e-a4bb-c5da0d1cd02b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_b03589f0-a5e6-4d3d-9f2f-026184c31f7b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_dd871607-2757-403e-a4bb-c5da0d1cd02b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList_21092634-4cd8-45e4-9216-5faa019e4027" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_b03589f0-a5e6-4d3d-9f2f-026184c31f7b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList_21092634-4cd8-45e4-9216-5faa019e4027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/TradeReceivablesDetailsTextual" xlink:type="simple" xlink:href="bcrx-20250930.xsd#TradeReceivablesDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/TradeReceivablesDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_a81aee25-4f98-4483-9698-4ccc2c9ddee5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_9366b80f-6fcf-4fd6-9081-16b7080fc152" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_a81aee25-4f98-4483-9698-4ccc2c9ddee5" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_9366b80f-6fcf-4fd6-9081-16b7080fc152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8219395e-cd11-4bb2-b3b3-6b3054a89f8b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_9366b80f-6fcf-4fd6-9081-16b7080fc152" xlink:to="loc_srt_ProductOrServiceAxis_8219395e-cd11-4bb2-b3b3-6b3054a89f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_832b123d-95b0-4d93-9238-e99a1ab33e80" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_8219395e-cd11-4bb2-b3b3-6b3054a89f8b" xlink:to="loc_srt_ProductsAndServicesDomain_832b123d-95b0-4d93-9238-e99a1ab33e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ORLADEYOMember_2ff4fb17-63dd-4bde-9ebc-fd227ee2ebef" xlink:href="bcrx-20250930.xsd#bcrx_ORLADEYOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_832b123d-95b0-4d93-9238-e99a1ab33e80" xlink:to="loc_bcrx_ORLADEYOMember_2ff4fb17-63dd-4bde-9ebc-fd227ee2ebef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_PeramivirMember_33019d97-a6c1-4bf8-b230-49d2f647d251" xlink:href="bcrx-20250930.xsd#bcrx_PeramivirMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_832b123d-95b0-4d93-9238-e99a1ab33e80" xlink:to="loc_bcrx_PeramivirMember_33019d97-a6c1-4bf8-b230-49d2f647d251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_41d9d64c-e08d-47f4-8a58-2db05556e10f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_9366b80f-6fcf-4fd6-9081-16b7080fc152" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_41d9d64c-e08d-47f4-8a58-2db05556e10f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_4ebdde66-c6ba-44e1-8c3a-c9ff28eea6a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_41d9d64c-e08d-47f4-8a58-2db05556e10f" xlink:to="loc_us-gaap_ReceivableTypeDomain_4ebdde66-c6ba-44e1-8c3a-c9ff28eea6a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAccountsReceivableMember_4a64a836-0af1-4ed7-af61-006cbf6eddd9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TradeAccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_4ebdde66-c6ba-44e1-8c3a-c9ff28eea6a0" xlink:to="loc_us-gaap_TradeAccountsReceivableMember_4a64a836-0af1-4ed7-af61-006cbf6eddd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_51b602af-259d-4651-9df2-583d04bf7505" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_9366b80f-6fcf-4fd6-9081-16b7080fc152" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_51b602af-259d-4651-9df2-583d04bf7505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_39056670-43e8-4a40-840a-44210d1fab91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_51b602af-259d-4651-9df2-583d04bf7505" xlink:to="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_39056670-43e8-4a40-840a-44210d1fab91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyReceivablesFromPartnersMember_7c4cc577-52d2-4a0e-984f-6b8f9da9b5fb" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltyReceivablesFromPartnersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_39056670-43e8-4a40-840a-44210d1fab91" xlink:to="loc_bcrx_RoyaltyReceivablesFromPartnersMember_7c4cc577-52d2-4a0e-984f-6b8f9da9b5fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_58595aaf-8788-41ef-96c4-9d2fb5fead5c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_9366b80f-6fcf-4fd6-9081-16b7080fc152" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_58595aaf-8788-41ef-96c4-9d2fb5fead5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_2831e152-681e-4b1f-9c73-e4601bb6b79c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_58595aaf-8788-41ef-96c4-9d2fb5fead5c" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_2831e152-681e-4b1f-9c73-e4601bb6b79c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_b01e6b91-1c13-46e5-b6ff-58ef90a9a597" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_2831e152-681e-4b1f-9c73-e4601bb6b79c" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_b01e6b91-1c13-46e5-b6ff-58ef90a9a597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_59c9067a-d035-43bc-9b67-e2eea155568d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_9366b80f-6fcf-4fd6-9081-16b7080fc152" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_59c9067a-d035-43bc-9b67-e2eea155568d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_17e9bdd6-d624-4d6f-bca2-a823f35b77c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_59c9067a-d035-43bc-9b67-e2eea155568d" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_17e9bdd6-d624-4d6f-bca2-a823f35b77c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_BioCrystIrelandMember_4d7e96f2-f4d7-4d77-ae71-36924ce51325" xlink:href="bcrx-20250930.xsd#bcrx_BioCrystIrelandMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_17e9bdd6-d624-4d6f-bca2-a823f35b77c7" xlink:to="loc_bcrx_BioCrystIrelandMember_4d7e96f2-f4d7-4d77-ae71-36924ce51325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_4d364a30-696d-4b04-be89-13f7a7e59c13" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_9366b80f-6fcf-4fd6-9081-16b7080fc152" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_4d364a30-696d-4b04-be89-13f7a7e59c13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_0f5dbec6-c916-49c5-90e6-26de39610609" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_4d364a30-696d-4b04-be89-13f7a7e59c13" xlink:to="loc_us-gaap_AccountsReceivableNet_0f5dbec6-c916-49c5-90e6-26de39610609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_9c2eb435-3686-44c3-8105-d162e14691ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_4d364a30-696d-4b04-be89-13f7a7e59c13" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_9c2eb435-3686-44c3-8105-d162e14691ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_97ba4646-2163-4f04-a429-6a424c74fef1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_4d364a30-696d-4b04-be89-13f7a7e59c13" xlink:to="loc_us-gaap_ReceivablesNetCurrent_97ba4646-2163-4f04-a429-6a424c74fef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/InventorySummaryofInventoriesDetails" xlink:type="simple" xlink:href="bcrx-20250930.xsd#InventorySummaryofInventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/InventorySummaryofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_9fb210d9-4889-4b1f-a92a-942b32856bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_979ef98f-0ec6-4c2e-bd1b-0bfd58ec8b64" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_9fb210d9-4889-4b1f-a92a-942b32856bf8" xlink:to="loc_us-gaap_InventoryRawMaterials_979ef98f-0ec6-4c2e-bd1b-0bfd58ec8b64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_2fe31bb9-4a35-4bf5-9811-ff26790c8abf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_9fb210d9-4889-4b1f-a92a-942b32856bf8" xlink:to="loc_us-gaap_InventoryWorkInProcess_2fe31bb9-4a35-4bf5-9811-ff26790c8abf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_8929c26a-9a4f-4d79-8c16-f14f07adb681" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_9fb210d9-4889-4b1f-a92a-942b32856bf8" xlink:to="loc_us-gaap_InventoryFinishedGoods_8929c26a-9a4f-4d79-8c16-f14f07adb681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_d47c6974-de3d-4521-ac5b-85679e6c6346" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_9fb210d9-4889-4b1f-a92a-942b32856bf8" xlink:to="loc_us-gaap_InventoryGross_d47c6974-de3d-4521-ac5b-85679e6c6346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_1f466ed8-0b93-472f-b09f-a54fd5398a25" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryValuationReserves"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_9fb210d9-4889-4b1f-a92a-942b32856bf8" xlink:to="loc_us-gaap_InventoryValuationReserves_1f466ed8-0b93-472f-b09f-a54fd5398a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_InventoryIncludingNoncurrentPortion_47a980af-d559-43d7-b009-3f08677d5f22" xlink:href="bcrx-20250930.xsd#bcrx_InventoryIncludingNoncurrentPortion"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_9fb210d9-4889-4b1f-a92a-942b32856bf8" xlink:to="loc_bcrx_InventoryIncludingNoncurrentPortion_47a980af-d559-43d7-b009-3f08677d5f22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/InventoryDetails" xlink:type="simple" xlink:href="bcrx-20250930.xsd#InventoryDetails"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_ee44f888-2b15-4692-bb92-c2713293c263" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_0e3fca4d-c7bd-4943-b70a-7ac12aace473" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_ee44f888-2b15-4692-bb92-c2713293c263" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_0e3fca4d-c7bd-4943-b70a-7ac12aace473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_bd3fa5d7-ed39-4407-a514-c71d28e8b474" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_0e3fca4d-c7bd-4943-b70a-7ac12aace473" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_bd3fa5d7-ed39-4407-a514-c71d28e8b474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_57100d7e-82f2-43a3-a4c6-8a6e8f6ee45f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_bd3fa5d7-ed39-4407-a514-c71d28e8b474" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_57100d7e-82f2-43a3-a4c6-8a6e8f6ee45f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_b6a1bbe9-180f-465a-9064-031784db8e15" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_57100d7e-82f2-43a3-a4c6-8a6e8f6ee45f" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_b6a1bbe9-180f-465a-9064-031784db8e15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_18c14974-e355-4818-9774-87c15694a700" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_0e3fca4d-c7bd-4943-b70a-7ac12aace473" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_18c14974-e355-4818-9774-87c15694a700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_75d107f8-f5cf-4cf3-96ae-be47fd2fdd8e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_18c14974-e355-4818-9774-87c15694a700" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_75d107f8-f5cf-4cf3-96ae-be47fd2fdd8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_BioCrystIrelandMember_ce976680-b664-4cac-b5a7-f1f503b3891e" xlink:href="bcrx-20250930.xsd#bcrx_BioCrystIrelandMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_75d107f8-f5cf-4cf3-96ae-be47fd2fdd8e" xlink:to="loc_bcrx_BioCrystIrelandMember_ce976680-b664-4cac-b5a7-f1f503b3891e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_91377a5e-cb2b-4bba-adf5-d6d8c3406a60" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_0e3fca4d-c7bd-4943-b70a-7ac12aace473" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_91377a5e-cb2b-4bba-adf5-d6d8c3406a60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_0feab0fd-bdea-493c-b767-4e8dc0aeb93a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_91377a5e-cb2b-4bba-adf5-d6d8c3406a60" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_0feab0fd-bdea-493c-b767-4e8dc0aeb93a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryNoncurrent_b3e7b4ab-013a-42c0-a44e-1bc8b99e685f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_91377a5e-cb2b-4bba-adf5-d6d8c3406a60" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryNoncurrent_b3e7b4ab-013a-42c0-a44e-1bc8b99e685f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/RoyaltyFinancingObligationsDetailsTextual" xlink:type="simple" xlink:href="bcrx-20250930.xsd#RoyaltyFinancingObligationsDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/RoyaltyFinancingObligationsDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvanceRoyaltiesAbstract_10d0d71b-0b26-4e7d-be5f-ed97fb56a349" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdvanceRoyaltiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltiesMonetizationsTable_114d406e-aad0-4943-890b-02eb690728bd" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltiesMonetizationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdvanceRoyaltiesAbstract_10d0d71b-0b26-4e7d-be5f-ed97fb56a349" xlink:to="loc_bcrx_RoyaltiesMonetizationsTable_114d406e-aad0-4943-890b-02eb690728bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f7d3d938-a239-41ad-914b-33ccff9de4ca" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltiesMonetizationsTable_114d406e-aad0-4943-890b-02eb690728bd" xlink:to="loc_srt_CounterpartyNameAxis_f7d3d938-a239-41ad-914b-33ccff9de4ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3cb625f4-184b-4d96-aebf-7cb720946e63" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_f7d3d938-a239-41ad-914b-33ccff9de4ca" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3cb625f4-184b-4d96-aebf-7cb720946e63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RPI2019IntermediateFinanceTrustMember_6133fea5-7508-41aa-9f2f-670171bfbc14" xlink:href="bcrx-20250930.xsd#bcrx_RPI2019IntermediateFinanceTrustMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3cb625f4-184b-4d96-aebf-7cb720946e63" xlink:to="loc_bcrx_RPI2019IntermediateFinanceTrustMember_6133fea5-7508-41aa-9f2f-670171bfbc14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RPI2021And2020IntermediateFinanceTrustMember_61463eef-0a37-4de5-b970-34c53a61933e" xlink:href="bcrx-20250930.xsd#bcrx_RPI2021And2020IntermediateFinanceTrustMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3cb625f4-184b-4d96-aebf-7cb720946e63" xlink:to="loc_bcrx_RPI2021And2020IntermediateFinanceTrustMember_61463eef-0a37-4de5-b970-34c53a61933e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_The2021RPIRoyaltyPurchaseAgreementMember_eb5f47eb-5401-454e-8f94-cb32a24b43bf" xlink:href="bcrx-20250930.xsd#bcrx_The2021RPIRoyaltyPurchaseAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3cb625f4-184b-4d96-aebf-7cb720946e63" xlink:to="loc_bcrx_The2021RPIRoyaltyPurchaseAgreementMember_eb5f47eb-5401-454e-8f94-cb32a24b43bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_OMERSCapitalMarketsMember_98ee3e4d-4d7d-43c1-99fe-e9be080c5190" xlink:href="bcrx-20250930.xsd#bcrx_OMERSCapitalMarketsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3cb625f4-184b-4d96-aebf-7cb720946e63" xlink:to="loc_bcrx_OMERSCapitalMarketsMember_98ee3e4d-4d7d-43c1-99fe-e9be080c5190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_66970fd1-5629-47a9-86a1-efced3c2e426" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltiesMonetizationsTable_114d406e-aad0-4943-890b-02eb690728bd" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_66970fd1-5629-47a9-86a1-efced3c2e426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e1d90c37-8ad7-4f4b-b180-8bb102a84e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_66970fd1-5629-47a9-86a1-efced3c2e426" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e1d90c37-8ad7-4f4b-b180-8bb102a84e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_FutureRoyaltiesPayableMember_631e02d2-53f3-4c87-b607-d52d3e9ea783" xlink:href="bcrx-20250930.xsd#bcrx_FutureRoyaltiesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e1d90c37-8ad7-4f4b-b180-8bb102a84e0c" xlink:to="loc_bcrx_FutureRoyaltiesPayableMember_631e02d2-53f3-4c87-b607-d52d3e9ea783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_aa9db228-40f4-4c28-bb5c-ffe5f0c23f5b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltiesMonetizationsTable_114d406e-aad0-4943-890b-02eb690728bd" xlink:to="loc_srt_ProductOrServiceAxis_aa9db228-40f4-4c28-bb5c-ffe5f0c23f5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_68c94071-bfd1-4c54-be20-d821c804c15f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_aa9db228-40f4-4c28-bb5c-ffe5f0c23f5b" xlink:to="loc_srt_ProductsAndServicesDomain_68c94071-bfd1-4c54-be20-d821c804c15f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ORLADEYOMember_3034fe7d-70a6-4477-98a4-d75ec2a99edd" xlink:href="bcrx-20250930.xsd#bcrx_ORLADEYOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_68c94071-bfd1-4c54-be20-d821c804c15f" xlink:to="loc_bcrx_ORLADEYOMember_3034fe7d-70a6-4477-98a4-d75ec2a99edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesRangeAxis_c0f45ce6-825f-4fa2-9bd0-237bed939358" xlink:href="bcrx-20250930.xsd#bcrx_AnnualNetSalesRangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltiesMonetizationsTable_114d406e-aad0-4943-890b-02eb690728bd" xlink:to="loc_bcrx_AnnualNetSalesRangeAxis_c0f45ce6-825f-4fa2-9bd0-237bed939358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesRangeDomain_060af17c-0042-482b-8876-449c3f0ec7b8" xlink:href="bcrx-20250930.xsd#bcrx_AnnualNetSalesRangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_AnnualNetSalesRangeAxis_c0f45ce6-825f-4fa2-9bd0-237bed939358" xlink:to="loc_bcrx_AnnualNetSalesRangeDomain_060af17c-0042-482b-8876-449c3f0ec7b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesUnder350000Member_85159c78-6b15-46b8-b9d0-dca9b36f8798" xlink:href="bcrx-20250930.xsd#bcrx_AnnualNetSalesUnder350000Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_AnnualNetSalesRangeDomain_060af17c-0042-482b-8876-449c3f0ec7b8" xlink:to="loc_bcrx_AnnualNetSalesUnder350000Member_85159c78-6b15-46b8-b9d0-dca9b36f8798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesBetween350000And550000Member_fce5256b-b01c-4334-abc8-8703953758a7" xlink:href="bcrx-20250930.xsd#bcrx_AnnualNetSalesBetween350000And550000Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_AnnualNetSalesRangeDomain_060af17c-0042-482b-8876-449c3f0ec7b8" xlink:to="loc_bcrx_AnnualNetSalesBetween350000And550000Member_fce5256b-b01c-4334-abc8-8703953758a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesOver550000Member_f3f3cec5-1856-4b0c-b141-12c4d792ae97" xlink:href="bcrx-20250930.xsd#bcrx_AnnualNetSalesOver550000Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_AnnualNetSalesRangeDomain_060af17c-0042-482b-8876-449c3f0ec7b8" xlink:to="loc_bcrx_AnnualNetSalesOver550000Member_f3f3cec5-1856-4b0c-b141-12c4d792ae97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesUnder150000Member_16705fa6-9eb9-46b2-a197-b6859136e2a7" xlink:href="bcrx-20250930.xsd#bcrx_AnnualNetSalesUnder150000Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_AnnualNetSalesRangeDomain_060af17c-0042-482b-8876-449c3f0ec7b8" xlink:to="loc_bcrx_AnnualNetSalesUnder150000Member_16705fa6-9eb9-46b2-a197-b6859136e2a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesBetween150000And230000Member_d32d0f70-2a2e-4a6e-ad5c-7efb9d10e306" xlink:href="bcrx-20250930.xsd#bcrx_AnnualNetSalesBetween150000And230000Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_AnnualNetSalesRangeDomain_060af17c-0042-482b-8876-449c3f0ec7b8" xlink:to="loc_bcrx_AnnualNetSalesBetween150000And230000Member_d32d0f70-2a2e-4a6e-ad5c-7efb9d10e306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesOver230000Member_0fb57c1b-9722-4c77-8c5d-3aeabe7b273c" xlink:href="bcrx-20250930.xsd#bcrx_AnnualNetSalesOver230000Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_AnnualNetSalesRangeDomain_060af17c-0042-482b-8876-449c3f0ec7b8" xlink:to="loc_bcrx_AnnualNetSalesOver230000Member_0fb57c1b-9722-4c77-8c5d-3aeabe7b273c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyMonetizationsLineItems_97a079d2-b5cc-453a-a104-51897689130c" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltyMonetizationsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltiesMonetizationsTable_114d406e-aad0-4943-890b-02eb690728bd" xlink:to="loc_bcrx_RoyaltyMonetizationsLineItems_97a079d2-b5cc-453a-a104-51897689130c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_a4b1a25b-af3a-4260-a2f9-18aab8f25b60" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_97a079d2-b5cc-453a-a104-51897689130c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_a4b1a25b-af3a-4260-a2f9-18aab8f25b60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories_99998cc5-cc52-467c-b9dc-85adf9fa8bb0" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_97a079d2-b5cc-453a-a104-51897689130c" xlink:to="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories_99998cc5-cc52-467c-b9dc-85adf9fa8bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets_8a3c3ffe-dcb4-4eaa-a251-5c3c33a26219" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_97a079d2-b5cc-453a-a104-51897689130c" xlink:to="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets_8a3c3ffe-dcb4-4eaa-a251-5c3c33a26219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets_f43f109a-be4d-48d2-b9f0-cfe5f5f086de" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_97a079d2-b5cc-453a-a104-51897689130c" xlink:to="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets_f43f109a-be4d-48d2-b9f0-cfe5f5f086de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_SharesIssuedCommonStockPremium_42e0a898-3bce-479d-8c0e-ed7d84c13752" xlink:href="bcrx-20250930.xsd#bcrx_SharesIssuedCommonStockPremium"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_97a079d2-b5cc-453a-a104-51897689130c" xlink:to="loc_bcrx_SharesIssuedCommonStockPremium_42e0a898-3bce-479d-8c0e-ed7d84c13752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales_6d25aad7-ad7b-4bcc-ba51-001bdc4366b7" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_97a079d2-b5cc-453a-a104-51897689130c" xlink:to="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales_6d25aad7-ad7b-4bcc-ba51-001bdc4366b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales_5ed393ff-6d42-47b0-9420-780515f494a7" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_97a079d2-b5cc-453a-a104-51897689130c" xlink:to="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales_5ed393ff-6d42-47b0-9420-780515f494a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice_129615dd-51dd-4ec0-b070-7911a4bd29cc" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_97a079d2-b5cc-453a-a104-51897689130c" xlink:to="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice_129615dd-51dd-4ec0-b070-7911a4bd29cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount_f0b5767e-e76f-403e-b272-487cfb1b2ffe" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_97a079d2-b5cc-453a-a104-51897689130c" xlink:to="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount_f0b5767e-e76f-403e-b272-487cfb1b2ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_InterestPaidRoyaltyFinancingLiabilities_789793d4-6fe3-4d14-b97e-9a819ee62813" xlink:href="bcrx-20250930.xsd#bcrx_InterestPaidRoyaltyFinancingLiabilities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_97a079d2-b5cc-453a-a104-51897689130c" xlink:to="loc_bcrx_InterestPaidRoyaltyFinancingLiabilities_789793d4-6fe3-4d14-b97e-9a819ee62813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/RoyaltyFinancingObligationsScheduleofRoyaltyFinancingObligationsDetails" xlink:type="simple" xlink:href="bcrx-20250930.xsd#RoyaltyFinancingObligationsScheduleofRoyaltyFinancingObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/RoyaltyFinancingObligationsScheduleofRoyaltyFinancingObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvanceRoyaltiesAbstract_5d7be495-6fcd-47de-891e-7e88e1bf493b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdvanceRoyaltiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltiesMonetizationsTable_beb26dff-3b2e-43b7-8321-a194253c2cac" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltiesMonetizationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdvanceRoyaltiesAbstract_5d7be495-6fcd-47de-891e-7e88e1bf493b" xlink:to="loc_bcrx_RoyaltiesMonetizationsTable_beb26dff-3b2e-43b7-8321-a194253c2cac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2c33d1ba-3241-40fb-a784-957d4d5d4aab" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltiesMonetizationsTable_beb26dff-3b2e-43b7-8321-a194253c2cac" xlink:to="loc_srt_CounterpartyNameAxis_2c33d1ba-3241-40fb-a784-957d4d5d4aab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_baa8d093-217b-427c-95a1-0f2fca25be61" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_2c33d1ba-3241-40fb-a784-957d4d5d4aab" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_baa8d093-217b-427c-95a1-0f2fca25be61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_TwentyTwentyRPIRoyaltyAgreementMember_e26816c1-1aaf-4b48-8256-b7090b648400" xlink:href="bcrx-20250930.xsd#bcrx_TwentyTwentyRPIRoyaltyAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_baa8d093-217b-427c-95a1-0f2fca25be61" xlink:to="loc_bcrx_TwentyTwentyRPIRoyaltyAgreementMember_e26816c1-1aaf-4b48-8256-b7090b648400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_TwentyTwentyOneRPIRoyaltyAgreementMember_2705369d-6d3d-4636-a559-17ca5e978c0c" xlink:href="bcrx-20250930.xsd#bcrx_TwentyTwentyOneRPIRoyaltyAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_baa8d093-217b-427c-95a1-0f2fca25be61" xlink:to="loc_bcrx_TwentyTwentyOneRPIRoyaltyAgreementMember_2705369d-6d3d-4636-a559-17ca5e978c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_OMERSRoyaltyAgreementMember_040f58f3-8314-4491-b999-11352dd1e08d" xlink:href="bcrx-20250930.xsd#bcrx_OMERSRoyaltyAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_baa8d093-217b-427c-95a1-0f2fca25be61" xlink:to="loc_bcrx_OMERSRoyaltyAgreementMember_040f58f3-8314-4491-b999-11352dd1e08d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyMonetizationsLineItems_f04c1201-3d88-4cec-a308-f199b04d4fbb" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltyMonetizationsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltiesMonetizationsTable_beb26dff-3b2e-43b7-8321-a194253c2cac" xlink:to="loc_bcrx_RoyaltyMonetizationsLineItems_f04c1201-3d88-4cec-a308-f199b04d4fbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyMontizationsRollForward_4b4d4ce8-20cb-4bdd-b697-ac3f0843e4ef" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltyMontizationsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_f04c1201-3d88-4cec-a308-f199b04d4fbb" xlink:to="loc_bcrx_RoyaltyMontizationsRollForward_4b4d4ce8-20cb-4bdd-b697-ac3f0843e4ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyFinancingLiabilities_523da0b6-c2d0-4023-a1d9-6831a9740ef4" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltyFinancingLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltyMontizationsRollForward_4b4d4ce8-20cb-4bdd-b697-ac3f0843e4ef" xlink:to="loc_bcrx_RoyaltyFinancingLiabilities_523da0b6-c2d0-4023-a1d9-6831a9740ef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_NonCashInterestExpenseOnRoyaltyFinancingLiabilities_e412688c-8ec3-456e-a2f6-c1809cfc32db" xlink:href="bcrx-20250930.xsd#bcrx_NonCashInterestExpenseOnRoyaltyFinancingLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltyMontizationsRollForward_4b4d4ce8-20cb-4bdd-b697-ac3f0843e4ef" xlink:to="loc_bcrx_NonCashInterestExpenseOnRoyaltyFinancingLiabilities_e412688c-8ec3-456e-a2f6-c1809cfc32db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyRevenuesPayable_654c0eb6-a19b-4a49-b491-5ddd43446e89" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltyRevenuesPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltyMontizationsRollForward_4b4d4ce8-20cb-4bdd-b697-ac3f0843e4ef" xlink:to="loc_bcrx_RoyaltyRevenuesPayable_654c0eb6-a19b-4a49-b491-5ddd43446e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyFinancingLiabilities_56a5387f-8d63-425e-8752-a92c4552e197" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltyFinancingLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltyMontizationsRollForward_4b4d4ce8-20cb-4bdd-b697-ac3f0843e4ef" xlink:to="loc_bcrx_RoyaltyFinancingLiabilities_56a5387f-8d63-425e-8752-a92c4552e197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_c5eb34ab-3690-419c-bdc1-c11b8ef6aaa3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltyMontizationsRollForward_4b4d4ce8-20cb-4bdd-b697-ac3f0843e4ef" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_c5eb34ab-3690-419c-bdc1-c11b8ef6aaa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/DebtDetails" xlink:type="simple" xlink:href="bcrx-20250930.xsd#DebtDetails"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/DebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_e65d9866-bde7-48e4-9e7d-845d942a8c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_4dc291c7-755d-4489-bbd5-7ce3cc81ccc2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e65d9866-bde7-48e4-9e7d-845d942a8c3b" xlink:to="loc_us-gaap_DebtInstrumentTable_4dc291c7-755d-4489-bbd5-7ce3cc81ccc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ed000307-e1ca-4905-bfaf-08d8ba32442a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4dc291c7-755d-4489-bbd5-7ce3cc81ccc2" xlink:to="loc_us-gaap_DebtInstrumentAxis_ed000307-e1ca-4905-bfaf-08d8ba32442a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7d35336b-aa61-4810-9ae0-4b66740e4b6a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_ed000307-e1ca-4905-bfaf-08d8ba32442a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7d35336b-aa61-4810-9ae0-4b66740e4b6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_TermLoanTrancheAMember_e66a36e2-70bf-42ce-954d-9d646ea26fd5" xlink:href="bcrx-20250930.xsd#bcrx_TermLoanTrancheAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7d35336b-aa61-4810-9ae0-4b66740e4b6a" xlink:to="loc_bcrx_TermLoanTrancheAMember_e66a36e2-70bf-42ce-954d-9d646ea26fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_LoanAgreementMember_ef7b18b2-3f9c-43b5-9771-61c7a9919065" xlink:href="bcrx-20250930.xsd#bcrx_LoanAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7d35336b-aa61-4810-9ae0-4b66740e4b6a" xlink:to="loc_bcrx_LoanAgreementMember_ef7b18b2-3f9c-43b5-9771-61c7a9919065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_TermLoanTrancheBMember_ea9a195d-368f-4949-8ba3-826345496838" xlink:href="bcrx-20250930.xsd#bcrx_TermLoanTrancheBMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7d35336b-aa61-4810-9ae0-4b66740e4b6a" xlink:to="loc_bcrx_TermLoanTrancheBMember_ea9a195d-368f-4949-8ba3-826345496838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_TermLoanTrancheCMember_fb51b494-d317-455e-8731-267ba645dc95" xlink:href="bcrx-20250930.xsd#bcrx_TermLoanTrancheCMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7d35336b-aa61-4810-9ae0-4b66740e4b6a" xlink:to="loc_bcrx_TermLoanTrancheCMember_fb51b494-d317-455e-8731-267ba645dc95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_TermLoanTrancheDMember_cebe837a-2665-485e-a814-35c62d7c2d1a" xlink:href="bcrx-20250930.xsd#bcrx_TermLoanTrancheDMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7d35336b-aa61-4810-9ae0-4b66740e4b6a" xlink:to="loc_bcrx_TermLoanTrancheDMember_cebe837a-2665-485e-a814-35c62d7c2d1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_220d07f2-e5db-4385-b053-dba6f5f00b82" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4dc291c7-755d-4489-bbd5-7ce3cc81ccc2" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_220d07f2-e5db-4385-b053-dba6f5f00b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_c9090bff-fc9b-4109-969d-4e1b719294f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_220d07f2-e5db-4385-b053-dba6f5f00b82" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_c9090bff-fc9b-4109-969d-4e1b719294f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_PharmakonAdvisorsLPMember_50116355-25b6-4da6-984b-56b198e66688" xlink:href="bcrx-20250930.xsd#bcrx_PharmakonAdvisorsLPMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_c9090bff-fc9b-4109-969d-4e1b719294f8" xlink:to="loc_bcrx_PharmakonAdvisorsLPMember_50116355-25b6-4da6-984b-56b198e66688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AthyriumMember_06717a85-bc1c-4a30-8138-08483784e0ed" xlink:href="bcrx-20250930.xsd#bcrx_AthyriumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_c9090bff-fc9b-4109-969d-4e1b719294f8" xlink:to="loc_bcrx_AthyriumMember_06717a85-bc1c-4a30-8138-08483784e0ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_da0902ad-a266-42e2-8e65-315d83ac0464" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4dc291c7-755d-4489-bbd5-7ce3cc81ccc2" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_da0902ad-a266-42e2-8e65-315d83ac0464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_04a19e73-a953-4d6c-af92-81c49201a45c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_da0902ad-a266-42e2-8e65-315d83ac0464" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_04a19e73-a953-4d6c-af92-81c49201a45c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_44ffc00f-aaf9-41c2-a6f2-1dcfad7b66dc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_04a19e73-a953-4d6c-af92-81c49201a45c" xlink:to="loc_us-gaap_LineOfCreditMember_44ffc00f-aaf9-41c2-a6f2-1dcfad7b66dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_2980c9fa-2382-4703-ab61-6469ea82aaa8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4dc291c7-755d-4489-bbd5-7ce3cc81ccc2" xlink:to="loc_us-gaap_CreditFacilityAxis_2980c9fa-2382-4703-ab61-6469ea82aaa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_b00f6c6b-e17a-4f1d-92d3-6eccf49f97d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_2980c9fa-2382-4703-ab61-6469ea82aaa8" xlink:to="loc_us-gaap_CreditFacilityDomain_b00f6c6b-e17a-4f1d-92d3-6eccf49f97d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_SeniorCreditFacilityMember_7ce1c65b-0614-4638-8944-9a968fa6af88" xlink:href="bcrx-20250930.xsd#bcrx_SeniorCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_b00f6c6b-e17a-4f1d-92d3-6eccf49f97d5" xlink:to="loc_bcrx_SeniorCreditFacilityMember_7ce1c65b-0614-4638-8944-9a968fa6af88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DebtCovenantTermsAxis_6d804766-3d4b-4f52-b277-f02ae3e93c2d" xlink:href="bcrx-20250930.xsd#bcrx_DebtCovenantTermsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4dc291c7-755d-4489-bbd5-7ce3cc81ccc2" xlink:to="loc_bcrx_DebtCovenantTermsAxis_6d804766-3d4b-4f52-b277-f02ae3e93c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DebtCovenantTermsDomain_b90966e6-95a0-457b-97d7-425e5dc6d01f" xlink:href="bcrx-20250930.xsd#bcrx_DebtCovenantTermsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_DebtCovenantTermsAxis_6d804766-3d4b-4f52-b277-f02ae3e93c2d" xlink:to="loc_bcrx_DebtCovenantTermsDomain_b90966e6-95a0-457b-97d7-425e5dc6d01f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_PikInterestPaymentIsMadeMember_bc75d3a1-40b6-4020-b65c-aff68d3dd6d4" xlink:href="bcrx-20250930.xsd#bcrx_PikInterestPaymentIsMadeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_DebtCovenantTermsDomain_b90966e6-95a0-457b-97d7-425e5dc6d01f" xlink:to="loc_bcrx_PikInterestPaymentIsMadeMember_bc75d3a1-40b6-4020-b65c-aff68d3dd6d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_BetweenTheSecondAndThirdAnniversariesMember_1b895b26-f741-4153-8b31-6e7ead82f2b9" xlink:href="bcrx-20250930.xsd#bcrx_BetweenTheSecondAndThirdAnniversariesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_DebtCovenantTermsDomain_b90966e6-95a0-457b-97d7-425e5dc6d01f" xlink:to="loc_bcrx_BetweenTheSecondAndThirdAnniversariesMember_1b895b26-f741-4153-8b31-6e7ead82f2b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AfterFourthAnniversaryMember_3bbf6ed0-8dea-43e1-b7b5-c1d8a2d4399e" xlink:href="bcrx-20250930.xsd#bcrx_AfterFourthAnniversaryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_DebtCovenantTermsDomain_b90966e6-95a0-457b-97d7-425e5dc6d01f" xlink:to="loc_bcrx_AfterFourthAnniversaryMember_3bbf6ed0-8dea-43e1-b7b5-c1d8a2d4399e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AfterThirdAnniversaryMember_ea743cad-06fe-49ae-831c-9a0ef6ebdf38" xlink:href="bcrx-20250930.xsd#bcrx_AfterThirdAnniversaryMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_DebtCovenantTermsDomain_b90966e6-95a0-457b-97d7-425e5dc6d01f" xlink:to="loc_bcrx_AfterThirdAnniversaryMember_ea743cad-06fe-49ae-831c-9a0ef6ebdf38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_b5e5b19e-5dfe-4c4e-902e-27fb74b1a254" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4dc291c7-755d-4489-bbd5-7ce3cc81ccc2" xlink:to="loc_us-gaap_DebtInstrumentLineItems_b5e5b19e-5dfe-4c4e-902e-27fb74b1a254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_a736c366-12af-4c9d-a6da-7ba2771339bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b5e5b19e-5dfe-4c4e-902e-27fb74b1a254" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_a736c366-12af-4c9d-a6da-7ba2771339bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_6da5fbc1-924d-4c44-8026-e2815209eb17" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b5e5b19e-5dfe-4c4e-902e-27fb74b1a254" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_6da5fbc1-924d-4c44-8026-e2815209eb17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_79caaeda-2519-4dbe-bced-0167346c30a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b5e5b19e-5dfe-4c4e-902e-27fb74b1a254" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_79caaeda-2519-4dbe-bced-0167346c30a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_748b0005-06ec-4a3b-be21-e2ba54322107" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b5e5b19e-5dfe-4c4e-902e-27fb74b1a254" xlink:to="loc_us-gaap_DebtInstrumentTerm_748b0005-06ec-4a3b-be21-e2ba54322107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DebtInstrumentCapitalizedInterestRate_d15dddd8-33b2-422a-8ad2-11a171b80867" xlink:href="bcrx-20250930.xsd#bcrx_DebtInstrumentCapitalizedInterestRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b5e5b19e-5dfe-4c4e-902e-27fb74b1a254" xlink:to="loc_bcrx_DebtInstrumentCapitalizedInterestRate_d15dddd8-33b2-422a-8ad2-11a171b80867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DebtInstrumentVariableRateFloor_7972f458-4ea9-4f01-b88d-f78460c6c1e1" xlink:href="bcrx-20250930.xsd#bcrx_DebtInstrumentVariableRateFloor"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b5e5b19e-5dfe-4c4e-902e-27fb74b1a254" xlink:to="loc_bcrx_DebtInstrumentVariableRateFloor_7972f458-4ea9-4f01-b88d-f78460c6c1e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_5662a1a7-9ba4-4c21-b862-36af81e6aa72" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b5e5b19e-5dfe-4c4e-902e-27fb74b1a254" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_5662a1a7-9ba4-4c21-b862-36af81e6aa72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_c7028975-00bd-4bc4-8fe6-b325d583af34" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b5e5b19e-5dfe-4c4e-902e-27fb74b1a254" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_c7028975-00bd-4bc4-8fe6-b325d583af34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPayment_a46030e4-9445-4224-95f6-53eeea54efdf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentPeriodicPayment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b5e5b19e-5dfe-4c4e-902e-27fb74b1a254" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPayment_a46030e4-9445-4224-95f6-53eeea54efdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments_a5c657cb-5228-4c3f-93b5-1e1df8ac2a9d" xlink:href="bcrx-20250930.xsd#bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b5e5b19e-5dfe-4c4e-902e-27fb74b1a254" xlink:to="loc_bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments_a5c657cb-5228-4c3f-93b5-1e1df8ac2a9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_c2245ed0-8f02-4574-9cfd-494354b722e8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b5e5b19e-5dfe-4c4e-902e-27fb74b1a254" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_c2245ed0-8f02-4574-9cfd-494354b722e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DebtInstrumentPrepaymentPremium_eaf46ffc-a202-4ec6-a95f-c985634311c6" xlink:href="bcrx-20250930.xsd#bcrx_DebtInstrumentPrepaymentPremium"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b5e5b19e-5dfe-4c4e-902e-27fb74b1a254" xlink:to="loc_bcrx_DebtInstrumentPrepaymentPremium_eaf46ffc-a202-4ec6-a95f-c985634311c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseLongTermDebt_223ee7d7-5380-4286-a801-7c45e03d8dde" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseLongTermDebt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b5e5b19e-5dfe-4c4e-902e-27fb74b1a254" xlink:to="loc_us-gaap_InterestExpenseLongTermDebt_223ee7d7-5380-4286-a801-7c45e03d8dde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_UnamortizedDeferredFinancingCosts_7e932d70-0739-44f9-9efb-274dc75b12ec" xlink:href="bcrx-20250930.xsd#bcrx_UnamortizedDeferredFinancingCosts"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b5e5b19e-5dfe-4c4e-902e-27fb74b1a254" xlink:to="loc_bcrx_UnamortizedDeferredFinancingCosts_7e932d70-0739-44f9-9efb-274dc75b12ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_61f6819b-a51d-4001-b2ac-8e514fe929b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b5e5b19e-5dfe-4c4e-902e-27fb74b1a254" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_61f6819b-a51d-4001-b2ac-8e514fe929b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_76896b11-b2fc-408a-8f7f-ad17dc29ae4f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b5e5b19e-5dfe-4c4e-902e-27fb74b1a254" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_76896b11-b2fc-408a-8f7f-ad17dc29ae4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DeferredDebtPrepaymentAndDebtIssuanceCostsWriteoff_b8a47c02-0115-4041-9de9-caa23ade7b78" xlink:href="bcrx-20250930.xsd#bcrx_DeferredDebtPrepaymentAndDebtIssuanceCostsWriteoff"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b5e5b19e-5dfe-4c4e-902e-27fb74b1a254" xlink:to="loc_bcrx_DeferredDebtPrepaymentAndDebtIssuanceCostsWriteoff_b8a47c02-0115-4041-9de9-caa23ade7b78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_096143bc-e0dc-4da8-b54f-6628d5a26533" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b5e5b19e-5dfe-4c4e-902e-27fb74b1a254" xlink:to="loc_us-gaap_InterestExpenseDebt_096143bc-e0dc-4da8-b54f-6628d5a26533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_PercentOfInterestPayment_30799dc7-dcda-4e85-9c6d-4dc9a1c6e3f0" xlink:href="bcrx-20250930.xsd#bcrx_PercentOfInterestPayment"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b5e5b19e-5dfe-4c4e-902e-27fb74b1a254" xlink:to="loc_bcrx_PercentOfInterestPayment_30799dc7-dcda-4e85-9c6d-4dc9a1c6e3f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_1a0ed213-9b7f-4a96-bd98-673fc7673f12" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b5e5b19e-5dfe-4c4e-902e-27fb74b1a254" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_1a0ed213-9b7f-4a96-bd98-673fc7673f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_c6491f5b-7999-4cca-a729-b260015efc00" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b5e5b19e-5dfe-4c4e-902e-27fb74b1a254" xlink:to="loc_us-gaap_DebtInstrumentFairValue_c6491f5b-7999-4cca-a729-b260015efc00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_32c83e8f-e3ba-4aa3-a672-e9c6df3fffbc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b5e5b19e-5dfe-4c4e-902e-27fb74b1a254" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_32c83e8f-e3ba-4aa3-a672-e9c6df3fffbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_483c589b-817a-4105-b3ce-23e2b4f53dd9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b5e5b19e-5dfe-4c4e-902e-27fb74b1a254" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_483c589b-817a-4105-b3ce-23e2b4f53dd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/LeaseObligationsDetailsTextual" xlink:type="simple" xlink:href="bcrx-20250930.xsd#LeaseObligationsDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/LeaseObligationsDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_7c769602-5a6b-4695-99d8-8daf84802284" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_6cdd127c-3284-4729-b4b0-49e4b56fa47c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7c769602-5a6b-4695-99d8-8daf84802284" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_6cdd127c-3284-4729-b4b0-49e4b56fa47c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6bb14ddf-0609-41a5-9da3-3c3f1a6a2785" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_6cdd127c-3284-4729-b4b0-49e4b56fa47c" xlink:to="loc_srt_RangeAxis_6bb14ddf-0609-41a5-9da3-3c3f1a6a2785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e6fff337-e3e0-41d8-ae80-dc6dcc5ca5fe" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6bb14ddf-0609-41a5-9da3-3c3f1a6a2785" xlink:to="loc_srt_RangeMember_e6fff337-e3e0-41d8-ae80-dc6dcc5ca5fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f8ba8c31-6fb3-4fdf-8733-1f6055538c15" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e6fff337-e3e0-41d8-ae80-dc6dcc5ca5fe" xlink:to="loc_srt_MinimumMember_f8ba8c31-6fb3-4fdf-8733-1f6055538c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1a80538a-f798-44c6-a592-e8e4b0d01daf" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e6fff337-e3e0-41d8-ae80-dc6dcc5ca5fe" xlink:to="loc_srt_MaximumMember_1a80538a-f798-44c6-a592-e8e4b0d01daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_a23c1a95-8512-42e9-ac30-b28afb43705a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_6cdd127c-3284-4729-b4b0-49e4b56fa47c" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_a23c1a95-8512-42e9-ac30-b28afb43705a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_d341ce43-2af7-4353-9d79-480f8741ce79" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a23c1a95-8512-42e9-ac30-b28afb43705a" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_d341ce43-2af7-4353-9d79-480f8741ce79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_OperatingLeaseRightOfUseAssetAccumulatedAmortization_204cd066-e297-4fb2-972b-71d9ae5b039d" xlink:href="bcrx-20250930.xsd#bcrx_OperatingLeaseRightOfUseAssetAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a23c1a95-8512-42e9-ac30-b28afb43705a" xlink:to="loc_bcrx_OperatingLeaseRightOfUseAssetAccumulatedAmortization_204cd066-e297-4fb2-972b-71d9ae5b039d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_bffcf403-9c03-418d-bd31-99e3e3424c6e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a23c1a95-8512-42e9-ac30-b28afb43705a" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_bffcf403-9c03-418d-bd31-99e3e3424c6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/LeaseObligationsAggregateLeaseExpenseUnderOperatingLeasesDetails" xlink:type="simple" xlink:href="bcrx-20250930.xsd#LeaseObligationsAggregateLeaseExpenseUnderOperatingLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/LeaseObligationsAggregateLeaseExpenseUnderOperatingLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_71b0b06a-86e3-4fc7-8478-a7d461e35874" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_f6251d69-0cfe-4938-aef2-f7a6f3de146a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_71b0b06a-86e3-4fc7-8478-a7d461e35874" xlink:to="loc_us-gaap_OperatingLeaseExpense_f6251d69-0cfe-4938-aef2-f7a6f3de146a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_b7bc12b9-fd05-413c-a32e-a5ef2930ed11" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_71b0b06a-86e3-4fc7-8478-a7d461e35874" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_b7bc12b9-fd05-413c-a32e-a5ef2930ed11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_0e4cdc94-2f5e-4466-9c42-5b70883f4c82" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_71b0b06a-86e3-4fc7-8478-a7d461e35874" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_0e4cdc94-2f5e-4466-9c42-5b70883f4c82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_FinancingLeaseExpense_62fd97a1-c2c1-4b23-ae6f-e088845664a6" xlink:href="bcrx-20250930.xsd#bcrx_FinancingLeaseExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_71b0b06a-86e3-4fc7-8478-a7d461e35874" xlink:to="loc_bcrx_FinancingLeaseExpense_62fd97a1-c2c1-4b23-ae6f-e088845664a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/LeaseObligationsOtherSupplementalInformationRelatedtoLeasesDetails" xlink:type="simple" xlink:href="bcrx-20250930.xsd#LeaseObligationsOtherSupplementalInformationRelatedtoLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/LeaseObligationsOtherSupplementalInformationRelatedtoLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_dd6f1c57-aa16-4680-8fa7-0a245be1e2cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_a32389f4-3735-493c-86f2-084e0a2d1f67" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_dd6f1c57-aa16-4680-8fa7-0a245be1e2cd" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_a32389f4-3735-493c-86f2-084e0a2d1f67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1e3fc83d-ab9e-48a8-b8e4-da3b8be856c1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_a32389f4-3735-493c-86f2-084e0a2d1f67" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1e3fc83d-ab9e-48a8-b8e4-da3b8be856c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_11af3963-079c-440b-af43-9d82a3364cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_a32389f4-3735-493c-86f2-084e0a2d1f67" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_11af3963-079c-440b-af43-9d82a3364cdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_03975387-a4bb-4029-9b9e-2ef42c1ba8dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_dd6f1c57-aa16-4680-8fa7-0a245be1e2cd" xlink:to="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_03975387-a4bb-4029-9b9e-2ef42c1ba8dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_15b563c7-04dc-4465-be83-398c8e17b6ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_03975387-a4bb-4029-9b9e-2ef42c1ba8dd" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_15b563c7-04dc-4465-be83-398c8e17b6ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_cc43e8be-9048-42b2-94e3-62eba4c8cce8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_03975387-a4bb-4029-9b9e-2ef42c1ba8dd" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_cc43e8be-9048-42b2-94e3-62eba4c8cce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/LeaseObligationsBalanceSheetsoftheCompanysOperatingLeasesDetails" xlink:type="simple" xlink:href="bcrx-20250930.xsd#LeaseObligationsBalanceSheetsoftheCompanysOperatingLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/LeaseObligationsBalanceSheetsoftheCompanysOperatingLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_e1458b16-e56a-4890-98db-b8ff200567e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_OperatingLeaseAssets_3bcc31d8-8558-486a-88ba-03f460b5dd6f" xlink:href="bcrx-20250930.xsd#bcrx_OperatingLeaseAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e1458b16-e56a-4890-98db-b8ff200567e3" xlink:to="loc_bcrx_OperatingLeaseAssets_3bcc31d8-8558-486a-88ba-03f460b5dd6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_1589aeda-9b5a-480f-9dab-c9b2347d28b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_OperatingLeaseAssets_3bcc31d8-8558-486a-88ba-03f460b5dd6f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_1589aeda-9b5a-480f-9dab-c9b2347d28b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_6cbe9404-f109-44cc-9970-d366e277febe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_OperatingLeaseAssets_3bcc31d8-8558-486a-88ba-03f460b5dd6f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_6cbe9404-f109-44cc-9970-d366e277febe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityAbstract_34a5ee04-0c44-4cce-af88-8458e9bc4cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e1458b16-e56a-4890-98db-b8ff200567e3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityAbstract_34a5ee04-0c44-4cce-af88-8458e9bc4cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b92a9f17-195a-430c-b893-2dffa6da0150" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_34a5ee04-0c44-4cce-af88-8458e9bc4cc5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b92a9f17-195a-430c-b893-2dffa6da0150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3c38913c-4e71-454a-ab0b-fa1699c0c1ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_34a5ee04-0c44-4cce-af88-8458e9bc4cc5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3c38913c-4e71-454a-ab0b-fa1699c0c1ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_2aad18e2-a58e-4f68-9b8d-71079f0aed0c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_34a5ee04-0c44-4cce-af88-8458e9bc4cc5" xlink:to="loc_us-gaap_OperatingLeaseLiability_2aad18e2-a58e-4f68-9b8d-71079f0aed0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/LeaseObligationsBalanceSheetsoftheCompanysFinanceLeasesDetails" xlink:type="simple" xlink:href="bcrx-20250930.xsd#LeaseObligationsBalanceSheetsoftheCompanysFinanceLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/LeaseObligationsBalanceSheetsoftheCompanysFinanceLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_3d55f739-0b8c-4d97-af82-d2d08c1c6356" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_c02cbd46-422e-434c-962d-3b05c85b08f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3d55f739-0b8c-4d97-af82-d2d08c1c6356" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_c02cbd46-422e-434c-962d-3b05c85b08f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_8111f753-87b8-47d5-ae53-8e5cdb9e831b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3d55f739-0b8c-4d97-af82-d2d08c1c6356" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_8111f753-87b8-47d5-ae53-8e5cdb9e831b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_5408b07d-8bf9-49e3-bfa9-d54becb884a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3d55f739-0b8c-4d97-af82-d2d08c1c6356" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_5408b07d-8bf9-49e3-bfa9-d54becb884a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_5082ea75-d582-4a31-89a2-2ecb38e42042" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3d55f739-0b8c-4d97-af82-d2d08c1c6356" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_5082ea75-d582-4a31-89a2-2ecb38e42042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_5086ae25-db1e-4dd1-9edf-44ef9c92d6f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3d55f739-0b8c-4d97-af82-d2d08c1c6356" xlink:to="loc_us-gaap_FinanceLeaseLiability_5086ae25-db1e-4dd1-9edf-44ef9c92d6f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/LeaseObligationsMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="bcrx-20250930.xsd#LeaseObligationsMaturitiesofLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/LeaseObligationsMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_0dd6cff9-0ded-4f2b-8190-ecce3274d685" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_8803d92a-1c93-4997-a0c6-78dfe693da11" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0dd6cff9-0ded-4f2b-8190-ecce3274d685" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_8803d92a-1c93-4997-a0c6-78dfe693da11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_e2682d8b-8233-478f-8687-b68a6f50e51f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_8803d92a-1c93-4997-a0c6-78dfe693da11" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_e2682d8b-8233-478f-8687-b68a6f50e51f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1be5720d-b6c0-4604-ac89-81a6199c9554" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_8803d92a-1c93-4997-a0c6-78dfe693da11" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1be5720d-b6c0-4604-ac89-81a6199c9554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0cd50792-fb2b-4324-93ab-4f0c52213288" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_8803d92a-1c93-4997-a0c6-78dfe693da11" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0cd50792-fb2b-4324-93ab-4f0c52213288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1867963e-2901-4996-b700-f5e41c58dc3f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_8803d92a-1c93-4997-a0c6-78dfe693da11" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1867963e-2901-4996-b700-f5e41c58dc3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_a984edde-2422-4836-ba11-1c6e04ad0a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_8803d92a-1c93-4997-a0c6-78dfe693da11" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_a984edde-2422-4836-ba11-1c6e04ad0a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_e76a5a4f-bf56-42dc-8e76-31cb902f4b20" xlink:href="bcrx-20250930.xsd#bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_8803d92a-1c93-4997-a0c6-78dfe693da11" xlink:to="loc_bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_e76a5a4f-bf56-42dc-8e76-31cb902f4b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_736f19e3-995c-464c-9d6c-c9cdc233312a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_8803d92a-1c93-4997-a0c6-78dfe693da11" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_736f19e3-995c-464c-9d6c-c9cdc233312a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_284edc9b-bbe7-464e-ab37-8d7d3319edad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_8803d92a-1c93-4997-a0c6-78dfe693da11" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_284edc9b-bbe7-464e-ab37-8d7d3319edad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_2cd2dd18-bbe9-40fc-975a-86d386598bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_8803d92a-1c93-4997-a0c6-78dfe693da11" xlink:to="loc_us-gaap_OperatingLeaseLiability_2cd2dd18-bbe9-40fc-975a-86d386598bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_97ccfd28-552d-44f9-b77b-5d7bc80650ef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0dd6cff9-0ded-4f2b-8190-ecce3274d685" xlink:to="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_97ccfd28-552d-44f9-b77b-5d7bc80650ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_2429c852-feb5-4baf-8e6c-55534a9fc10b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_97ccfd28-552d-44f9-b77b-5d7bc80650ef" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_2429c852-feb5-4baf-8e6c-55534a9fc10b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_26231569-b624-441d-9667-1fa8731e3ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_97ccfd28-552d-44f9-b77b-5d7bc80650ef" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_26231569-b624-441d-9667-1fa8731e3ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_938976de-666f-49a1-bd93-333770080976" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_97ccfd28-552d-44f9-b77b-5d7bc80650ef" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_938976de-666f-49a1-bd93-333770080976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_aee4f335-c6dc-47f6-a5da-76100b0078b1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_97ccfd28-552d-44f9-b77b-5d7bc80650ef" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_aee4f335-c6dc-47f6-a5da-76100b0078b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_b16a7199-e586-4a9b-b2b7-a35010fa65f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_97ccfd28-552d-44f9-b77b-5d7bc80650ef" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_b16a7199-e586-4a9b-b2b7-a35010fa65f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_FinanceLeaseLiabilityToBePaidAfterYearFour_089d88de-7044-4cb2-9a4c-7ca825d301c0" xlink:href="bcrx-20250930.xsd#bcrx_FinanceLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_97ccfd28-552d-44f9-b77b-5d7bc80650ef" xlink:to="loc_bcrx_FinanceLeaseLiabilityToBePaidAfterYearFour_089d88de-7044-4cb2-9a4c-7ca825d301c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_3e5f9851-2b45-491f-b685-21557112664a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_97ccfd28-552d-44f9-b77b-5d7bc80650ef" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_3e5f9851-2b45-491f-b685-21557112664a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_ec8013aa-5352-4a1f-abd8-7513cdcf7148" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_97ccfd28-552d-44f9-b77b-5d7bc80650ef" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_ec8013aa-5352-4a1f-abd8-7513cdcf7148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_36468512-a00a-417e-9bf9-c9302a62f19f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_97ccfd28-552d-44f9-b77b-5d7bc80650ef" xlink:to="loc_us-gaap_FinanceLeaseLiability_36468512-a00a-417e-9bf9-c9302a62f19f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/LeaseObligationsSupplementalCashFlowsDetails" xlink:type="simple" xlink:href="bcrx-20250930.xsd#LeaseObligationsSupplementalCashFlowsDetails"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/LeaseObligationsSupplementalCashFlowsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_81662f39-0b68-4530-a930-08229f2fb3b5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_ad55c928-b206-4625-ae20-739aa97c44c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_81662f39-0b68-4530-a930-08229f2fb3b5" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_ad55c928-b206-4625-ae20-739aa97c44c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_92c110dd-4f3b-4e48-90ac-415ab414f328" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_81662f39-0b68-4530-a930-08229f2fb3b5" xlink:to="loc_us-gaap_OperatingLeasePayments_92c110dd-4f3b-4e48-90ac-415ab414f328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c8103244-b65e-47d9-823c-bb5eb32d0b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_81662f39-0b68-4530-a930-08229f2fb3b5" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c8103244-b65e-47d9-823c-bb5eb32d0b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_ff563373-132e-4a72-a10c-85f6bbce8fef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_81662f39-0b68-4530-a930-08229f2fb3b5" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_ff563373-132e-4a72-a10c-85f6bbce8fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_NonCashIncreaseInOperatingLeaseAssetsDueToRemeasurementOfOperatingLeaseLiabilities_9f78dab0-4c3d-4778-ad41-363b7d46b124" xlink:href="bcrx-20250930.xsd#bcrx_NonCashIncreaseInOperatingLeaseAssetsDueToRemeasurementOfOperatingLeaseLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_81662f39-0b68-4530-a930-08229f2fb3b5" xlink:to="loc_bcrx_NonCashIncreaseInOperatingLeaseAssetsDueToRemeasurementOfOperatingLeaseLiabilities_9f78dab0-4c3d-4778-ad41-363b7d46b124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/StockholdersEquitySharesReservedforFutureIssuanceDetails" xlink:type="simple" xlink:href="bcrx-20250930.xsd#StockholdersEquitySharesReservedforFutureIssuanceDetails"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/StockholdersEquitySharesReservedforFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_36961dbd-b81a-4fa7-86c1-d0708ea310e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_aa9cc124-7a3d-4dbb-8409-98d609f76b74" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_36961dbd-b81a-4fa7-86c1-d0708ea310e4" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_aa9cc124-7a3d-4dbb-8409-98d609f76b74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5bb81d7d-39f6-4e7a-a1ac-25a586d15e66" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_aa9cc124-7a3d-4dbb-8409-98d609f76b74" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5bb81d7d-39f6-4e7a-a1ac-25a586d15e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0dd4f2b4-f76f-4951-9d33-348237d5ef65" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5bb81d7d-39f6-4e7a-a1ac-25a586d15e66" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0dd4f2b4-f76f-4951-9d33-348237d5ef65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c4fc8cd9-bb37-4132-a7f5-eff4e3866180" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0dd4f2b4-f76f-4951-9d33-348237d5ef65" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c4fc8cd9-bb37-4132-a7f5-eff4e3866180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_5d649581-6219-4a8e-b506-98e17792cccd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0dd4f2b4-f76f-4951-9d33-348237d5ef65" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_5d649581-6219-4a8e-b506-98e17792cccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_fe82c842-ea88-4708-b933-71ad6781aabc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_aa9cc124-7a3d-4dbb-8409-98d609f76b74" xlink:to="loc_us-gaap_PlanNameAxis_fe82c842-ea88-4708-b933-71ad6781aabc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_3be42dd2-5131-4ad0-bd86-c118f2b3bcac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_fe82c842-ea88-4708-b933-71ad6781aabc" xlink:to="loc_us-gaap_PlanNameDomain_3be42dd2-5131-4ad0-bd86-c118f2b3bcac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_IncentivePlanMember_c724c9d9-2c86-4fa9-970f-6cd545729bc0" xlink:href="bcrx-20250930.xsd#bcrx_IncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_3be42dd2-5131-4ad0-bd86-c118f2b3bcac" xlink:to="loc_bcrx_IncentivePlanMember_c724c9d9-2c86-4fa9-970f-6cd545729bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_InducementPlanMember_bd62df5d-449c-4148-9da3-a7bc92b85136" xlink:href="bcrx-20250930.xsd#bcrx_InducementPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_3be42dd2-5131-4ad0-bd86-c118f2b3bcac" xlink:to="loc_bcrx_InducementPlanMember_bd62df5d-449c-4148-9da3-a7bc92b85136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_EmployeeStockPurchasePlanMember_6537c71e-0c1b-42e7-9c3a-660469cb0d35" xlink:href="bcrx-20250930.xsd#bcrx_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_3be42dd2-5131-4ad0-bd86-c118f2b3bcac" xlink:to="loc_bcrx_EmployeeStockPurchasePlanMember_6537c71e-0c1b-42e7-9c3a-660469cb0d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d2145bff-7057-4d31-af17-e4d07f968338" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_aa9cc124-7a3d-4dbb-8409-98d609f76b74" xlink:to="loc_us-gaap_AwardTypeAxis_d2145bff-7057-4d31-af17-e4d07f968338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_19d6af8d-ade6-4b77-bfd9-142796ec6fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_d2145bff-7057-4d31-af17-e4d07f968338" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_19d6af8d-ade6-4b77-bfd9-142796ec6fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e78dce68-aef4-4b90-a7e3-9a072cb41f78" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_19d6af8d-ade6-4b77-bfd9-142796ec6fc2" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e78dce68-aef4-4b90-a7e3-9a072cb41f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_fab83fe9-d8f0-4a3d-9735-662783446346" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_19d6af8d-ade6-4b77-bfd9-142796ec6fc2" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_fab83fe9-d8f0-4a3d-9735-662783446346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_fe2fccc8-f4ff-4f62-ba5e-ea6ca996bbc0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_aa9cc124-7a3d-4dbb-8409-98d609f76b74" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_fe2fccc8-f4ff-4f62-ba5e-ea6ca996bbc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_b95eb006-626c-4c76-ae69-76d1cb3c2445" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_fe2fccc8-f4ff-4f62-ba5e-ea6ca996bbc0" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_b95eb006-626c-4c76-ae69-76d1cb3c2445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/StockbasedCompensationDetailsTextual" xlink:type="simple" xlink:href="bcrx-20250930.xsd#StockbasedCompensationDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/StockbasedCompensationDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0a256e13-3082-4799-a729-397e52ae956b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_484b87d7-0d8b-439a-95ab-66861d07394d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0a256e13-3082-4799-a729-397e52ae956b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_484b87d7-0d8b-439a-95ab-66861d07394d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_c8b35ad2-ca52-4a23-a1b1-ccc0d69be101" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_484b87d7-0d8b-439a-95ab-66861d07394d" xlink:to="loc_us-gaap_PlanNameAxis_c8b35ad2-ca52-4a23-a1b1-ccc0d69be101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_8160fc2f-6f74-4b8a-994f-a3d7be2f8961" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_c8b35ad2-ca52-4a23-a1b1-ccc0d69be101" xlink:to="loc_us-gaap_PlanNameDomain_8160fc2f-6f74-4b8a-994f-a3d7be2f8961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_IncentivePlanMember_04675b7a-e29b-47d5-b9b0-3d5cbeb3dd9f" xlink:href="bcrx-20250930.xsd#bcrx_IncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_8160fc2f-6f74-4b8a-994f-a3d7be2f8961" xlink:to="loc_bcrx_IncentivePlanMember_04675b7a-e29b-47d5-b9b0-3d5cbeb3dd9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_InducementPlanMember_52367452-a4c0-40df-9441-3ff5e53877b3" xlink:href="bcrx-20250930.xsd#bcrx_InducementPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_8160fc2f-6f74-4b8a-994f-a3d7be2f8961" xlink:to="loc_bcrx_InducementPlanMember_52367452-a4c0-40df-9441-3ff5e53877b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7e04a4c1-01ef-4116-8398-67ecce190af1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_484b87d7-0d8b-439a-95ab-66861d07394d" xlink:to="loc_us-gaap_AwardTypeAxis_7e04a4c1-01ef-4116-8398-67ecce190af1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fba5409f-e8da-4bbe-8a0c-8340ddf16064" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7e04a4c1-01ef-4116-8398-67ecce190af1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fba5409f-e8da-4bbe-8a0c-8340ddf16064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_7df65285-aaa2-433a-9bb6-854bef86f438" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fba5409f-e8da-4bbe-8a0c-8340ddf16064" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_7df65285-aaa2-433a-9bb6-854bef86f438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0818404d-150e-49cd-8da0-012a87c570f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_484b87d7-0d8b-439a-95ab-66861d07394d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0818404d-150e-49cd-8da0-012a87c570f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ShareBasedPaymentArrangementNumberOfPlans_11761963-4a0d-4a5c-aa8a-e726b54f1c39" xlink:href="bcrx-20250930.xsd#bcrx_ShareBasedPaymentArrangementNumberOfPlans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0818404d-150e-49cd-8da0-012a87c570f6" xlink:to="loc_bcrx_ShareBasedPaymentArrangementNumberOfPlans_11761963-4a0d-4a5c-aa8a-e726b54f1c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2182f312-1bf0-41b2-b572-0cad4a276630" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0818404d-150e-49cd-8da0-012a87c570f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2182f312-1bf0-41b2-b572-0cad4a276630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/StockbasedCompensationShareBasedCompensationDetails" xlink:type="simple" xlink:href="bcrx-20250930.xsd#StockbasedCompensationShareBasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/StockbasedCompensationShareBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_93b613dd-8e43-4d80-99e5-fe6642fdae68" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f0285664-f544-4cd5-a7d4-4d919911b745" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_93b613dd-8e43-4d80-99e5-fe6642fdae68" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f0285664-f544-4cd5-a7d4-4d919911b745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_a1823839-a805-4a9b-9b7b-785e9ecae961" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f0285664-f544-4cd5-a7d4-4d919911b745" xlink:to="loc_us-gaap_PlanNameAxis_a1823839-a805-4a9b-9b7b-785e9ecae961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_2bd5f2d0-7f78-4ba3-920b-639f12bac248" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_a1823839-a805-4a9b-9b7b-785e9ecae961" xlink:to="loc_us-gaap_PlanNameDomain_2bd5f2d0-7f78-4ba3-920b-639f12bac248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_IncentivePlanMember_9950bb8a-7963-493b-b15c-39ebbf3f9d78" xlink:href="bcrx-20250930.xsd#bcrx_IncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_2bd5f2d0-7f78-4ba3-920b-639f12bac248" xlink:to="loc_bcrx_IncentivePlanMember_9950bb8a-7963-493b-b15c-39ebbf3f9d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_InducementPlanMember_345a9a1d-dac4-44a5-9be6-2570b2e7267f" xlink:href="bcrx-20250930.xsd#bcrx_InducementPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_2bd5f2d0-7f78-4ba3-920b-639f12bac248" xlink:to="loc_bcrx_InducementPlanMember_345a9a1d-dac4-44a5-9be6-2570b2e7267f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_EmployeeStockPurchasePlanMember_fb998543-0284-4070-b0e8-2a4e2178504e" xlink:href="bcrx-20250930.xsd#bcrx_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_2bd5f2d0-7f78-4ba3-920b-639f12bac248" xlink:to="loc_bcrx_EmployeeStockPurchasePlanMember_fb998543-0284-4070-b0e8-2a4e2178504e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47962dad-a345-48cc-af66-288cf375a2e9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f0285664-f544-4cd5-a7d4-4d919911b745" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47962dad-a345-48cc-af66-288cf375a2e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_3922f5ca-7165-4981-9a59-6cf5a68150ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47962dad-a345-48cc-af66-288cf375a2e9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_3922f5ca-7165-4981-9a59-6cf5a68150ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_103ea79f-4515-4b47-8c97-103c48f5c36d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47962dad-a345-48cc-af66-288cf375a2e9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_103ea79f-4515-4b47-8c97-103c48f5c36d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_b38123ec-4ca1-4d3b-8f60-3fb6ef8ee616" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47962dad-a345-48cc-af66-288cf375a2e9" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_b38123ec-4ca1-4d3b-8f60-3fb6ef8ee616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/StockbasedCompensationOptionActivityDetails" xlink:type="simple" xlink:href="bcrx-20250930.xsd#StockbasedCompensationOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/StockbasedCompensationOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bc9f7efb-141d-4f69-95bb-758ac77ea46e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_14cae418-3c05-4060-b28b-cba8bb72998e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bc9f7efb-141d-4f69-95bb-758ac77ea46e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_14cae418-3c05-4060-b28b-cba8bb72998e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_28cbc68b-9db4-408d-b6f5-152e32eccac9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_14cae418-3c05-4060-b28b-cba8bb72998e" xlink:to="loc_us-gaap_AwardTypeAxis_28cbc68b-9db4-408d-b6f5-152e32eccac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7c44640f-9896-41a8-9592-98ddd6efdf53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_28cbc68b-9db4-408d-b6f5-152e32eccac9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7c44640f-9896-41a8-9592-98ddd6efdf53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_6f8c78ba-bc7b-4269-a08b-aab23352fc88" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7c44640f-9896-41a8-9592-98ddd6efdf53" xlink:to="loc_us-gaap_EmployeeStockOptionMember_6f8c78ba-bc7b-4269-a08b-aab23352fc88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_25a2b841-f27e-477c-a12a-2895fb5ec350" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_14cae418-3c05-4060-b28b-cba8bb72998e" xlink:to="loc_us-gaap_PlanNameAxis_25a2b841-f27e-477c-a12a-2895fb5ec350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_2701eeee-5d46-45cb-b2dd-65da090fda8f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_25a2b841-f27e-477c-a12a-2895fb5ec350" xlink:to="loc_us-gaap_PlanNameDomain_2701eeee-5d46-45cb-b2dd-65da090fda8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_IncentivePlanMember_0505c2ff-305f-46f1-a1c3-6677e0e36cd4" xlink:href="bcrx-20250930.xsd#bcrx_IncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_2701eeee-5d46-45cb-b2dd-65da090fda8f" xlink:to="loc_bcrx_IncentivePlanMember_0505c2ff-305f-46f1-a1c3-6677e0e36cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_InducementPlanMember_455bb056-4f38-4e0b-bb37-b42665d50ef2" xlink:href="bcrx-20250930.xsd#bcrx_InducementPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_2701eeee-5d46-45cb-b2dd-65da090fda8f" xlink:to="loc_bcrx_InducementPlanMember_455bb056-4f38-4e0b-bb37-b42665d50ef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5d378716-8e6e-4487-8096-53bdd0c49570" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_14cae418-3c05-4060-b28b-cba8bb72998e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5d378716-8e6e-4487-8096-53bdd0c49570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_98ffbfbc-dafb-4788-a3fc-79c8e97e9fcc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5d378716-8e6e-4487-8096-53bdd0c49570" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_98ffbfbc-dafb-4788-a3fc-79c8e97e9fcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cbba40a1-c2e7-4e12-bd60-9063e06d97ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_98ffbfbc-dafb-4788-a3fc-79c8e97e9fcc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cbba40a1-c2e7-4e12-bd60-9063e06d97ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c2bd8196-2345-459d-b1bc-3ae9927eb1de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_98ffbfbc-dafb-4788-a3fc-79c8e97e9fcc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c2bd8196-2345-459d-b1bc-3ae9927eb1de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9600cf4f-88d2-486c-9e5b-c4a420aedd5e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_98ffbfbc-dafb-4788-a3fc-79c8e97e9fcc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9600cf4f-88d2-486c-9e5b-c4a420aedd5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_43a1072c-6043-43b6-b062-b087ec78cb2b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_98ffbfbc-dafb-4788-a3fc-79c8e97e9fcc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_43a1072c-6043-43b6-b062-b087ec78cb2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637eba4a-e592-4a87-96ab-568ecb1b1306" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_98ffbfbc-dafb-4788-a3fc-79c8e97e9fcc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637eba4a-e592-4a87-96ab-568ecb1b1306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_787fd894-b922-45a4-b02b-96051883f6d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5d378716-8e6e-4487-8096-53bdd0c49570" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_787fd894-b922-45a4-b02b-96051883f6d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_29eb7aac-b5cb-479f-a472-2dbccb922eaa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5d378716-8e6e-4487-8096-53bdd0c49570" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_29eb7aac-b5cb-479f-a472-2dbccb922eaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_65b4bcf8-b799-4a09-b17e-001660be7e91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_29eb7aac-b5cb-479f-a472-2dbccb922eaa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_65b4bcf8-b799-4a09-b17e-001660be7e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c86a603d-0343-4bab-a48b-2c666a20c04a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_29eb7aac-b5cb-479f-a472-2dbccb922eaa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c86a603d-0343-4bab-a48b-2c666a20c04a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0afef6a9-d0e9-43f2-bad9-e5ca0f9effb9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_29eb7aac-b5cb-479f-a472-2dbccb922eaa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0afef6a9-d0e9-43f2-bad9-e5ca0f9effb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1acf03d9-c608-4092-a5d1-b763405d08a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_29eb7aac-b5cb-479f-a472-2dbccb922eaa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1acf03d9-c608-4092-a5d1-b763405d08a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60c3c316-ce24-4543-b219-79ef577167eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_29eb7aac-b5cb-479f-a472-2dbccb922eaa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60c3c316-ce24-4543-b219-79ef577167eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_b916c8f6-06c0-472d-bbe9-b081d8d8da3f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5d378716-8e6e-4487-8096-53bdd0c49570" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_b916c8f6-06c0-472d-bbe9-b081d8d8da3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_13a63b16-efad-4040-820f-e23170f8174c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5d378716-8e6e-4487-8096-53bdd0c49570" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_13a63b16-efad-4040-820f-e23170f8174c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_ccd357c4-6c6e-49cf-9a52-a272f1939c8f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_13a63b16-efad-4040-820f-e23170f8174c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_ccd357c4-6c6e-49cf-9a52-a272f1939c8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_f77ac148-698f-489d-90a2-04d51cdb47a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_13a63b16-efad-4040-820f-e23170f8174c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_f77ac148-698f-489d-90a2-04d51cdb47a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0afe650c-f8a6-420e-83ce-3d650d777dda" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_13a63b16-efad-4040-820f-e23170f8174c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0afe650c-f8a6-420e-83ce-3d650d777dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_9bba1e10-b1b1-4ff9-ab25-a3cf5864fd37" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5d378716-8e6e-4487-8096-53bdd0c49570" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_9bba1e10-b1b1-4ff9-ab25-a3cf5864fd37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c40a5e7f-d6c3-4c38-b465-d256bbb60b20" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5d378716-8e6e-4487-8096-53bdd0c49570" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c40a5e7f-d6c3-4c38-b465-d256bbb60b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="bcrx-20250930.xsd#StockbasedCompensationRestrictedStockUnitActivityDetails"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a1967460-d522-494c-b505-694e5f3b3503" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e34eb706-e581-4182-97be-55fe3c648646" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a1967460-d522-494c-b505-694e5f3b3503" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e34eb706-e581-4182-97be-55fe3c648646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_067c67a5-c81e-4719-a640-df4af5a8cf84" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e34eb706-e581-4182-97be-55fe3c648646" xlink:to="loc_us-gaap_AwardTypeAxis_067c67a5-c81e-4719-a640-df4af5a8cf84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5784a5da-b718-4fd7-bb7e-56dcafb17bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_067c67a5-c81e-4719-a640-df4af5a8cf84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5784a5da-b718-4fd7-bb7e-56dcafb17bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_a5021cf4-0bc5-42fb-a7fe-ef2ae7696c13" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5784a5da-b718-4fd7-bb7e-56dcafb17bc5" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_a5021cf4-0bc5-42fb-a7fe-ef2ae7696c13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_27ce87cd-f0fd-412f-94da-f46e36a4197c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e34eb706-e581-4182-97be-55fe3c648646" xlink:to="loc_us-gaap_PlanNameAxis_27ce87cd-f0fd-412f-94da-f46e36a4197c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_4b735736-8bf1-49eb-8eb4-172e91e8d183" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_27ce87cd-f0fd-412f-94da-f46e36a4197c" xlink:to="loc_us-gaap_PlanNameDomain_4b735736-8bf1-49eb-8eb4-172e91e8d183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_IncentivePlanMember_e9368a8e-67a2-4166-91b3-9534e191902c" xlink:href="bcrx-20250930.xsd#bcrx_IncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_4b735736-8bf1-49eb-8eb4-172e91e8d183" xlink:to="loc_bcrx_IncentivePlanMember_e9368a8e-67a2-4166-91b3-9534e191902c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_InducementPlanMember_f9501ffe-285c-42b1-80e2-6eae4f1b68f2" xlink:href="bcrx-20250930.xsd#bcrx_InducementPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_4b735736-8bf1-49eb-8eb4-172e91e8d183" xlink:to="loc_bcrx_InducementPlanMember_f9501ffe-285c-42b1-80e2-6eae4f1b68f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b88da855-ce5f-45ce-8f6d-820a858b8f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e34eb706-e581-4182-97be-55fe3c648646" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b88da855-ce5f-45ce-8f6d-820a858b8f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c49d3fcb-e7c0-4a36-a189-f2ee5e2dea4a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b88da855-ce5f-45ce-8f6d-820a858b8f9c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c49d3fcb-e7c0-4a36-a189-f2ee5e2dea4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a24f4652-73a9-4116-8a5e-458b7f026feb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c49d3fcb-e7c0-4a36-a189-f2ee5e2dea4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a24f4652-73a9-4116-8a5e-458b7f026feb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e0dc0a96-d8b7-4624-ac78-48581966e687" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c49d3fcb-e7c0-4a36-a189-f2ee5e2dea4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e0dc0a96-d8b7-4624-ac78-48581966e687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_da4e2ad5-861a-46d6-84ab-432188a03612" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c49d3fcb-e7c0-4a36-a189-f2ee5e2dea4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_da4e2ad5-861a-46d6-84ab-432188a03612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f5e7532e-fc73-42e5-bb16-8d86175a87de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c49d3fcb-e7c0-4a36-a189-f2ee5e2dea4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f5e7532e-fc73-42e5-bb16-8d86175a87de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ea49a6e0-5c1e-4554-b346-9e4454b468ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c49d3fcb-e7c0-4a36-a189-f2ee5e2dea4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ea49a6e0-5c1e-4554-b346-9e4454b468ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2e25e4be-c9ff-49fc-affc-bb9c5dd717ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b88da855-ce5f-45ce-8f6d-820a858b8f9c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2e25e4be-c9ff-49fc-affc-bb9c5dd717ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e506c12c-912f-4666-9e74-33d7db40f01f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2e25e4be-c9ff-49fc-affc-bb9c5dd717ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e506c12c-912f-4666-9e74-33d7db40f01f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5e84f249-8b5b-4036-8b9e-ca0c2d3f3288" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2e25e4be-c9ff-49fc-affc-bb9c5dd717ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5e84f249-8b5b-4036-8b9e-ca0c2d3f3288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_89113f38-8f57-4a8b-a8ac-1f6a0884d1ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2e25e4be-c9ff-49fc-affc-bb9c5dd717ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_89113f38-8f57-4a8b-a8ac-1f6a0884d1ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f20b22d8-6624-4608-9c81-b186b8aa6714" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2e25e4be-c9ff-49fc-affc-bb9c5dd717ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f20b22d8-6624-4608-9c81-b186b8aa6714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c30156eb-b62c-479e-94a4-9a3a6387c4a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2e25e4be-c9ff-49fc-affc-bb9c5dd717ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c30156eb-b62c-479e-94a4-9a3a6387c4a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/StockbasedCompensationWeightedAverageAssumptionsforStockOptionAwardsGrantedtoEmployeesandDirectorsUnderthePlansDetails" xlink:type="simple" xlink:href="bcrx-20250930.xsd#StockbasedCompensationWeightedAverageAssumptionsforStockOptionAwardsGrantedtoEmployeesandDirectorsUnderthePlansDetails"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/StockbasedCompensationWeightedAverageAssumptionsforStockOptionAwardsGrantedtoEmployeesandDirectorsUnderthePlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a9acc969-0679-4092-896f-6944cdcd5f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62e072d0-9770-481c-8df8-29399c6c0b29" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a9acc969-0679-4092-896f-6944cdcd5f3e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62e072d0-9770-481c-8df8-29399c6c0b29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_0bd7cb76-b4dd-4015-9c20-e393607d0a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62e072d0-9770-481c-8df8-29399c6c0b29" xlink:to="loc_us-gaap_PlanNameAxis_0bd7cb76-b4dd-4015-9c20-e393607d0a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_46cdfe03-8877-44e3-8214-9eecc92d460f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_0bd7cb76-b4dd-4015-9c20-e393607d0a3c" xlink:to="loc_us-gaap_PlanNameDomain_46cdfe03-8877-44e3-8214-9eecc92d460f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_IncentivePlanMember_3e0f6d1a-ac9a-480e-9c12-7b494b3b7c8a" xlink:href="bcrx-20250930.xsd#bcrx_IncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_46cdfe03-8877-44e3-8214-9eecc92d460f" xlink:to="loc_bcrx_IncentivePlanMember_3e0f6d1a-ac9a-480e-9c12-7b494b3b7c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_InducementPlanMember_ed4d88c7-d37c-4257-a4cd-5e66e3bcc818" xlink:href="bcrx-20250930.xsd#bcrx_InducementPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_46cdfe03-8877-44e3-8214-9eecc92d460f" xlink:to="loc_bcrx_InducementPlanMember_ed4d88c7-d37c-4257-a4cd-5e66e3bcc818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5675027-ba49-42b4-8e4c-62cd267d70f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62e072d0-9770-481c-8df8-29399c6c0b29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5675027-ba49-42b4-8e4c-62cd267d70f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e816c619-90a0-45fb-b9c0-223e35a222f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5675027-ba49-42b4-8e4c-62cd267d70f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e816c619-90a0-45fb-b9c0-223e35a222f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_255d4082-4bc0-4e50-9be8-68993327b9f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5675027-ba49-42b4-8e4c-62cd267d70f3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_255d4082-4bc0-4e50-9be8-68993327b9f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_35e43508-3fff-4ec5-aa10-9a26e2f52ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5675027-ba49-42b4-8e4c-62cd267d70f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_35e43508-3fff-4ec5-aa10-9a26e2f52ed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3630da3e-a9d3-41e7-be32-63ae25d69078" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5675027-ba49-42b4-8e4c-62cd267d70f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3630da3e-a9d3-41e7-be32-63ae25d69078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_355bc464-a51a-4065-ab50-daccf43af834" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5675027-ba49-42b4-8e4c-62cd267d70f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_355bc464-a51a-4065-ab50-daccf43af834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6972fcdb-f0d2-4d8a-9b3d-55b901df2d87" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5675027-ba49-42b4-8e4c-62cd267d70f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6972fcdb-f0d2-4d8a-9b3d-55b901df2d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails" xlink:type="simple" xlink:href="bcrx-20250930.xsd#CollaborativeandOtherRelationshipsDetails"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7fd09ecf-d359-4410-a53d-e9e89e15258f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_99bc3908-41e6-4d9a-b010-444ab15f6ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7fd09ecf-d359-4410-a53d-e9e89e15258f" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_99bc3908-41e6-4d9a-b010-444ab15f6ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_13ca2aac-d19d-47fb-9272-8677c77a82ff" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_99bc3908-41e6-4d9a-b010-444ab15f6ae0" xlink:to="loc_srt_CounterpartyNameAxis_13ca2aac-d19d-47fb-9272-8677c77a82ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b7fc6f86-64a1-4ac8-b34b-c56c58eba68f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_13ca2aac-d19d-47fb-9272-8677c77a82ff" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b7fc6f86-64a1-4ac8-b34b-c56c58eba68f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ToriiPharmaceuticalCoMember_65fa30e7-d6fb-443b-89ea-b780bee642dd" xlink:href="bcrx-20250930.xsd#bcrx_ToriiPharmaceuticalCoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b7fc6f86-64a1-4ac8-b34b-c56c58eba68f" xlink:to="loc_bcrx_ToriiPharmaceuticalCoMember_65fa30e7-d6fb-443b-89ea-b780bee642dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ClearsideBiomedicalIncMember_f99902c2-f2c5-45af-a177-393eb830f623" xlink:href="bcrx-20250930.xsd#bcrx_ClearsideBiomedicalIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b7fc6f86-64a1-4ac8-b34b-c56c58eba68f" xlink:to="loc_bcrx_ClearsideBiomedicalIncMember_f99902c2-f2c5-45af-a177-393eb830f623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_HHSOfficeOfTheAdministrationForStrategicPreparednessAndResponseMember_4d9a4f4e-6a0e-4732-bbbe-56ae80d138fd" xlink:href="bcrx-20250930.xsd#bcrx_HHSOfficeOfTheAdministrationForStrategicPreparednessAndResponseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b7fc6f86-64a1-4ac8-b34b-c56c58eba68f" xlink:to="loc_bcrx_HHSOfficeOfTheAdministrationForStrategicPreparednessAndResponseMember_4d9a4f4e-6a0e-4732-bbbe-56ae80d138fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cfac5736-1d71-4071-858b-6cd437b1d71f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_99bc3908-41e6-4d9a-b010-444ab15f6ae0" xlink:to="loc_srt_RangeAxis_cfac5736-1d71-4071-858b-6cd437b1d71f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a9b5ef11-e4c8-4d67-98a4-ee8e1623096e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_cfac5736-1d71-4071-858b-6cd437b1d71f" xlink:to="loc_srt_RangeMember_a9b5ef11-e4c8-4d67-98a4-ee8e1623096e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_04aa2d69-89c5-4165-a5ba-56817bdbbc22" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a9b5ef11-e4c8-4d67-98a4-ee8e1623096e" xlink:to="loc_srt_MinimumMember_04aa2d69-89c5-4165-a5ba-56817bdbbc22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_af3bafbc-c65f-42d3-b0b1-63f25e5c8a67" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a9b5ef11-e4c8-4d67-98a4-ee8e1623096e" xlink:to="loc_srt_MaximumMember_af3bafbc-c65f-42d3-b0b1-63f25e5c8a67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesRangeAxis_3a00434b-a3dc-40da-8653-1d33cdb8f42b" xlink:href="bcrx-20250930.xsd#bcrx_AnnualNetSalesRangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_99bc3908-41e6-4d9a-b010-444ab15f6ae0" xlink:to="loc_bcrx_AnnualNetSalesRangeAxis_3a00434b-a3dc-40da-8653-1d33cdb8f42b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesRangeDomain_a6426353-b24a-4d72-ab1c-c29b480cf306" xlink:href="bcrx-20250930.xsd#bcrx_AnnualNetSalesRangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_AnnualNetSalesRangeAxis_3a00434b-a3dc-40da-8653-1d33cdb8f42b" xlink:to="loc_bcrx_AnnualNetSalesRangeDomain_a6426353-b24a-4d72-ab1c-c29b480cf306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesOf2MillionMember_a2244fb4-598e-43af-b88a-a86dab0dcb5b" xlink:href="bcrx-20250930.xsd#bcrx_AnnualNetSalesOf2MillionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_AnnualNetSalesRangeDomain_a6426353-b24a-4d72-ab1c-c29b480cf306" xlink:to="loc_bcrx_AnnualNetSalesOf2MillionMember_a2244fb4-598e-43af-b88a-a86dab0dcb5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesGreaterThan15MillionMember_747cebe8-406a-47dd-bfbd-e8e9da842704" xlink:href="bcrx-20250930.xsd#bcrx_AnnualNetSalesGreaterThan15MillionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_AnnualNetSalesRangeDomain_a6426353-b24a-4d72-ab1c-c29b480cf306" xlink:to="loc_bcrx_AnnualNetSalesGreaterThan15MillionMember_747cebe8-406a-47dd-bfbd-e8e9da842704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_168d2cdb-22af-4b0e-b3e5-a3c14804b2f1" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_99bc3908-41e6-4d9a-b010-444ab15f6ae0" xlink:to="loc_srt_ProductOrServiceAxis_168d2cdb-22af-4b0e-b3e5-a3c14804b2f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9ef56268-c0e7-4a3b-b384-cb607d8db331" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_168d2cdb-22af-4b0e-b3e5-a3c14804b2f1" xlink:to="loc_srt_ProductsAndServicesDomain_9ef56268-c0e7-4a3b-b384-cb607d8db331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RAPIVABMember_b6368710-b13d-490e-95d1-2a1e492677b5" xlink:href="bcrx-20250930.xsd#bcrx_RAPIVABMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9ef56268-c0e7-4a3b-b384-cb607d8db331" xlink:to="loc_bcrx_RAPIVABMember_b6368710-b13d-490e-95d1-2a1e492677b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_c9a60b2a-cc7e-43c3-baeb-d1203a0dc272" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_99bc3908-41e6-4d9a-b010-444ab15f6ae0" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_c9a60b2a-cc7e-43c3-baeb-d1203a0dc272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_e92aabb5-13a1-4af2-af9b-655a3c2adf61" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_c9a60b2a-cc7e-43c3-baeb-d1203a0dc272" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_e92aabb5-13a1-4af2-af9b-655a3c2adf61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeMilestone_a2ad192e-08fe-41c7-a1c1-31176034a4b9" xlink:href="bcrx-20250930.xsd#bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeMilestone"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_c9a60b2a-cc7e-43c3-baeb-d1203a0dc272" xlink:to="loc_bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeMilestone_a2ad192e-08fe-41c7-a1c1-31176034a4b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyRateIfMaintainsSakigakeDesignation_8aa9a4ec-fd12-4961-a7a5-dd185ae3c4f7" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltyRateIfMaintainsSakigakeDesignation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_c9a60b2a-cc7e-43c3-baeb-d1203a0dc272" xlink:to="loc_bcrx_RoyaltyRateIfMaintainsSakigakeDesignation_8aa9a4ec-fd12-4961-a7a5-dd185ae3c4f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_MaximumCustomaryReductionOnRoyaltyRate_3ef358dd-145b-4f7e-8440-5fb5041014bf" xlink:href="bcrx-20250930.xsd#bcrx_MaximumCustomaryReductionOnRoyaltyRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_c9a60b2a-cc7e-43c3-baeb-d1203a0dc272" xlink:to="loc_bcrx_MaximumCustomaryReductionOnRoyaltyRate_3ef358dd-145b-4f7e-8440-5fb5041014bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyRate_211c4694-77cc-4ba4-b7b9-cb5669b134b9" xlink:href="bcrx-20250930.xsd#bcrx_RoyaltyRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_c9a60b2a-cc7e-43c3-baeb-d1203a0dc272" xlink:to="loc_bcrx_RoyaltyRate_211c4694-77cc-4ba4-b7b9-cb5669b134b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_CollaborativeAgreementContractValue_7cc6c863-727b-4d62-95b6-890dfe9142f7" xlink:href="bcrx-20250930.xsd#bcrx_CollaborativeAgreementContractValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_c9a60b2a-cc7e-43c3-baeb-d1203a0dc272" xlink:to="loc_bcrx_CollaborativeAgreementContractValue_7cc6c863-727b-4d62-95b6-890dfe9142f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses_66820cd5-4b6d-4a98-8be5-1dae3f75f89a" xlink:href="bcrx-20250930.xsd#bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_c9a60b2a-cc7e-43c3-baeb-d1203a0dc272" xlink:to="loc_bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses_66820cd5-4b6d-4a98-8be5-1dae3f75f89a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ContractTerm_c1a26b2c-f8f3-48f4-9f7b-645d8744d3a2" xlink:href="bcrx-20250930.xsd#bcrx_ContractTerm"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_c9a60b2a-cc7e-43c3-baeb-d1203a0dc272" xlink:to="loc_bcrx_ContractTerm_c1a26b2c-f8f3-48f4-9f7b-645d8744d3a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_NumberOfOptionalOrderingPeriods_239ba506-6ffb-4036-b7ca-6adc699297f7" xlink:href="bcrx-20250930.xsd#bcrx_NumberOfOptionalOrderingPeriods"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_c9a60b2a-cc7e-43c3-baeb-d1203a0dc272" xlink:to="loc_bcrx_NumberOfOptionalOrderingPeriods_239ba506-6ffb-4036-b7ca-6adc699297f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators_33e63e91-2d07-4667-bfea-293aad4e105c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_c9a60b2a-cc7e-43c3-baeb-d1203a0dc272" xlink:to="loc_us-gaap_ProceedsFromCollaborators_33e63e91-2d07-4667-bfea-293aad4e105c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_NumberOfProductDeliveredDoses_f930b3f3-58ce-4314-850f-f0e35aadd10f" xlink:href="bcrx-20250930.xsd#bcrx_NumberOfProductDeliveredDoses"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_c9a60b2a-cc7e-43c3-baeb-d1203a0dc272" xlink:to="loc_bcrx_NumberOfProductDeliveredDoses_f930b3f3-58ce-4314-850f-f0e35aadd10f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_LicenseAgreementUpfrontPayment_91e0360c-1d43-4158-a5ad-0b6adb033e91" xlink:href="bcrx-20250930.xsd#bcrx_LicenseAgreementUpfrontPayment"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_c9a60b2a-cc7e-43c3-baeb-d1203a0dc272" xlink:to="loc_bcrx_LicenseAgreementUpfrontPayment_91e0360c-1d43-4158-a5ad-0b6adb033e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_PotentialMilestonePaymentsPayable_c8fb9deb-681f-44aa-9d6b-66d15bd159f7" xlink:href="bcrx-20250930.xsd#bcrx_PotentialMilestonePaymentsPayable"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_c9a60b2a-cc7e-43c3-baeb-d1203a0dc272" xlink:to="loc_bcrx_PotentialMilestonePaymentsPayable_c8fb9deb-681f-44aa-9d6b-66d15bd159f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_PotentialMilestonePaymentsPayableIfRegulatoryApprovalBeforeMilestone_f72ccca6-71da-48a8-8dd1-f85785fccecd" xlink:href="bcrx-20250930.xsd#bcrx_PotentialMilestonePaymentsPayableIfRegulatoryApprovalBeforeMilestone"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_c9a60b2a-cc7e-43c3-baeb-d1203a0dc272" xlink:to="loc_bcrx_PotentialMilestonePaymentsPayableIfRegulatoryApprovalBeforeMilestone_f72ccca6-71da-48a8-8dd1-f85785fccecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_LicenseAgreementNumberOfMilestonePayments_f7dab03d-f1c8-4526-ac2a-7654c7e2705e" xlink:href="bcrx-20250930.xsd#bcrx_LicenseAgreementNumberOfMilestonePayments"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_c9a60b2a-cc7e-43c3-baeb-d1203a0dc272" xlink:to="loc_bcrx_LicenseAgreementNumberOfMilestonePayments_f7dab03d-f1c8-4526-ac2a-7654c7e2705e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_LicenseAgreementAnnualGlobalNetSales_b6e265df-06a4-45c4-80e4-d5359ee3b26f" xlink:href="bcrx-20250930.xsd#bcrx_LicenseAgreementAnnualGlobalNetSales"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_c9a60b2a-cc7e-43c3-baeb-d1203a0dc272" xlink:to="loc_bcrx_LicenseAgreementAnnualGlobalNetSales_b6e265df-06a4-45c4-80e4-d5359ee3b26f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_LicenseAgreementRoyaltyPaymentNumberOfTiers_91248096-30f5-40a5-97d1-5354250a59b5" xlink:href="bcrx-20250930.xsd#bcrx_LicenseAgreementRoyaltyPaymentNumberOfTiers"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_c9a60b2a-cc7e-43c3-baeb-d1203a0dc272" xlink:to="loc_bcrx_LicenseAgreementRoyaltyPaymentNumberOfTiers_91248096-30f5-40a5-97d1-5354250a59b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/SegmentInformationDetails" xlink:type="simple" xlink:href="bcrx-20250930.xsd#SegmentInformationDetails"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/SegmentInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_846a4bb6-ca10-4e43-bdb5-94e00abd0b25" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_12528039-c6af-4bbe-9836-bd8ac693a162" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_846a4bb6-ca10-4e43-bdb5-94e00abd0b25" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_12528039-c6af-4bbe-9836-bd8ac693a162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_5b36bab7-8c3c-48c6-a0f9-18669de3869d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_12528039-c6af-4bbe-9836-bd8ac693a162" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_5b36bab7-8c3c-48c6-a0f9-18669de3869d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_842eb035-47e2-4c32-853c-b54c288f205c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_5b36bab7-8c3c-48c6-a0f9-18669de3869d" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_842eb035-47e2-4c32-853c-b54c288f205c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_f341d0e6-b29d-4238-8aa3-00e580f8eb0a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_842eb035-47e2-4c32-853c-b54c288f205c" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_f341d0e6-b29d-4238-8aa3-00e580f8eb0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d4b4ac8f-07de-466e-8af9-96480bbfb6f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_12528039-c6af-4bbe-9836-bd8ac693a162" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d4b4ac8f-07de-466e-8af9-96480bbfb6f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3a1b34a6-5ea8-4323-abc0-0ce659f63271" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d4b4ac8f-07de-466e-8af9-96480bbfb6f9" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3a1b34a6-5ea8-4323-abc0-0ce659f63271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_BioCrystIrelandMember_cb3a0766-c559-493d-a543-2dbf98b5c0bd" xlink:href="bcrx-20250930.xsd#bcrx_BioCrystIrelandMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3a1b34a6-5ea8-4323-abc0-0ce659f63271" xlink:to="loc_bcrx_BioCrystIrelandMember_cb3a0766-c559-493d-a543-2dbf98b5c0bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_cdb8acd4-339a-46d5-b02c-880083d76457" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_12528039-c6af-4bbe-9836-bd8ac693a162" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_cdb8acd4-339a-46d5-b02c-880083d76457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_848241d2-1a56-45bd-b550-bb40f29cb9ef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cdb8acd4-339a-46d5-b02c-880083d76457" xlink:to="loc_us-gaap_NumberOfReportableSegments_848241d2-1a56-45bd-b550-bb40f29cb9ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_d0e95203-219e-4628-93a6-9683d82df5cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cdb8acd4-339a-46d5-b02c-880083d76457" xlink:to="loc_us-gaap_NumberOfOperatingSegments_d0e95203-219e-4628-93a6-9683d82df5cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_CashCashEquivalentsShortAndLongTermInvestments_ae49c688-f288-4b99-a031-8684f30f1ec1" xlink:href="bcrx-20250930.xsd#bcrx_CashCashEquivalentsShortAndLongTermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cdb8acd4-339a-46d5-b02c-880083d76457" xlink:to="loc_bcrx_CashCashEquivalentsShortAndLongTermInvestments_ae49c688-f288-4b99-a031-8684f30f1ec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_cd3fb8f6-6881-4e2e-8fbb-3953ae8a083c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cdb8acd4-339a-46d5-b02c-880083d76457" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_cd3fb8f6-6881-4e2e-8fbb-3953ae8a083c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/SegmentInformationSegmentReportingInformationbySegmentDetails" xlink:type="simple" xlink:href="bcrx-20250930.xsd#SegmentInformationSegmentReportingInformationbySegmentDetails"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/SegmentInformationSegmentReportingInformationbySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_fbcff22b-15a6-48bc-8801-e6ab431a9bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a648f363-5f48-45d1-b70e-ef9d5fee8712" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_fbcff22b-15a6-48bc-8801-e6ab431a9bf7" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a648f363-5f48-45d1-b70e-ef9d5fee8712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_16c92a41-26d7-493b-9caf-5b24146f0df5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a648f363-5f48-45d1-b70e-ef9d5fee8712" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_16c92a41-26d7-493b-9caf-5b24146f0df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_22319766-6c71-4d27-9269-739e282525ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_16c92a41-26d7-493b-9caf-5b24146f0df5" xlink:to="loc_us-gaap_SegmentDomain_22319766-6c71-4d27-9269-739e282525ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ReportableSegmentMember_25bd72c0-a254-4f79-b78d-0983ec777f13" xlink:href="bcrx-20250930.xsd#bcrx_ReportableSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_22319766-6c71-4d27-9269-739e282525ba" xlink:to="loc_bcrx_ReportableSegmentMember_25bd72c0-a254-4f79-b78d-0983ec777f13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ce42ec62-1513-4217-82c7-d0588d033c79" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a648f363-5f48-45d1-b70e-ef9d5fee8712" xlink:to="loc_srt_ProductOrServiceAxis_ce42ec62-1513-4217-82c7-d0588d033c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a4b8cb94-33e0-41b9-85f1-3ba21d640f39" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ce42ec62-1513-4217-82c7-d0588d033c79" xlink:to="loc_srt_ProductsAndServicesDomain_a4b8cb94-33e0-41b9-85f1-3ba21d640f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_BerotralstatMember_5f1a5738-12f0-4890-9e97-d7cc2b6876b7" xlink:href="bcrx-20250930.xsd#bcrx_BerotralstatMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a4b8cb94-33e0-41b9-85f1-3ba21d640f39" xlink:to="loc_bcrx_BerotralstatMember_5f1a5738-12f0-4890-9e97-d7cc2b6876b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_BCX17725Member_ce0741de-5370-4e38-93c9-959ff1692f58" xlink:href="bcrx-20250930.xsd#bcrx_BCX17725Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a4b8cb94-33e0-41b9-85f1-3ba21d640f39" xlink:to="loc_bcrx_BCX17725Member_ce0741de-5370-4e38-93c9-959ff1692f58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AvoralstatMember_b60bc5e8-e296-4516-8926-d388d1c7559b" xlink:href="bcrx-20250930.xsd#bcrx_AvoralstatMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a4b8cb94-33e0-41b9-85f1-3ba21d640f39" xlink:to="loc_bcrx_AvoralstatMember_b60bc5e8-e296-4516-8926-d388d1c7559b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_FactorDProgramMember_00fea338-d520-46ce-8a9a-f9deab4a458c" xlink:href="bcrx-20250930.xsd#bcrx_FactorDProgramMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a4b8cb94-33e0-41b9-85f1-3ba21d640f39" xlink:to="loc_bcrx_FactorDProgramMember_00fea338-d520-46ce-8a9a-f9deab4a458c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ResearchDiscoveryAndPreclinicalProgramsMember_5f6dc044-dc17-4799-bc91-0da1f6e56b4d" xlink:href="bcrx-20250930.xsd#bcrx_ResearchDiscoveryAndPreclinicalProgramsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a4b8cb94-33e0-41b9-85f1-3ba21d640f39" xlink:to="loc_bcrx_ResearchDiscoveryAndPreclinicalProgramsMember_5f6dc044-dc17-4799-bc91-0da1f6e56b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_CompensationAndRelatedPersonnelCostsMember_8816d36d-73c3-4827-bf56-9a3074b4f1cf" xlink:href="bcrx-20250930.xsd#bcrx_CompensationAndRelatedPersonnelCostsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a4b8cb94-33e0-41b9-85f1-3ba21d640f39" xlink:to="loc_bcrx_CompensationAndRelatedPersonnelCostsMember_8816d36d-73c3-4827-bf56-9a3074b4f1cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_StockBasedCompensationMember_ffa6e864-2059-456a-88e2-1f97e0f15a34" xlink:href="bcrx-20250930.xsd#bcrx_StockBasedCompensationMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a4b8cb94-33e0-41b9-85f1-3ba21d640f39" xlink:to="loc_bcrx_StockBasedCompensationMember_ffa6e864-2059-456a-88e2-1f97e0f15a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_OtherExpenses1Member_5cd1c486-fcc4-4c97-8cda-cb4abc4fa78f" xlink:href="bcrx-20250930.xsd#bcrx_OtherExpenses1Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a4b8cb94-33e0-41b9-85f1-3ba21d640f39" xlink:to="loc_bcrx_OtherExpenses1Member_5cd1c486-fcc4-4c97-8cda-cb4abc4fa78f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_f8b2ce67-5c1a-4d87-a972-88001fb240c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a648f363-5f48-45d1-b70e-ef9d5fee8712" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_f8b2ce67-5c1a-4d87-a972-88001fb240c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_186b5e9a-a65d-462e-8462-3ef2bf706986" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f8b2ce67-5c1a-4d87-a972-88001fb240c3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_186b5e9a-a65d-462e-8462-3ef2bf706986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_5a965c7e-0662-41a2-a354-459d1eef11b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f8b2ce67-5c1a-4d87-a972-88001fb240c3" xlink:to="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_5a965c7e-0662-41a2-a354-459d1eef11b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_92b799ec-7b86-44d0-82e3-79dd8f7a357c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_5a965c7e-0662-41a2-a354-459d1eef11b6" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_92b799ec-7b86-44d0-82e3-79dd8f7a357c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_8d4fa5c2-5c96-4ee0-a230-6288141781a6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_5a965c7e-0662-41a2-a354-459d1eef11b6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_8d4fa5c2-5c96-4ee0-a230-6288141781a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_c4fec3a0-2a60-49f2-8a78-eda3d775d3f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_5a965c7e-0662-41a2-a354-459d1eef11b6" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_c4fec3a0-2a60-49f2-8a78-eda3d775d3f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_0c01cd98-dd1d-48ef-b661-31b7d0ea7ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeOperating"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_5a965c7e-0662-41a2-a354-459d1eef11b6" xlink:to="loc_us-gaap_InterestIncomeOperating_0c01cd98-dd1d-48ef-b661-31b7d0ea7ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_b90f73cd-e849-4888-8afd-83e567397d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_5a965c7e-0662-41a2-a354-459d1eef11b6" xlink:to="loc_us-gaap_InterestExpenseNonoperating_b90f73cd-e849-4888-8afd-83e567397d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_d347ece2-9c61-4fad-9ecb-dfdc5fed1c9d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_5a965c7e-0662-41a2-a354-459d1eef11b6" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_d347ece2-9c61-4fad-9ecb-dfdc5fed1c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_7d946d6f-9d68-459a-9ba7-a112c4af869b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_5a965c7e-0662-41a2-a354-459d1eef11b6" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_7d946d6f-9d68-459a-9ba7-a112c4af869b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncome_aebddd9e-f0f5-49e9-99c1-955f24b7be4c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncome"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_5a965c7e-0662-41a2-a354-459d1eef11b6" xlink:to="loc_us-gaap_OtherIncome_aebddd9e-f0f5-49e9-99c1-955f24b7be4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4c0fe836-b936-40b3-a80f-c85b3400b098" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_5a965c7e-0662-41a2-a354-459d1eef11b6" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4c0fe836-b936-40b3-a80f-c85b3400b098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6a095c10-7b91-425d-bd01-16e50d777fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f8b2ce67-5c1a-4d87-a972-88001fb240c3" xlink:to="loc_us-gaap_NetIncomeLoss_6a095c10-7b91-425d-bd01-16e50d777fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_SegmentReportingAdjustmentsAndReconcilingItemsAmount_d178f016-2a2f-409b-bc9f-0b12c0b881f8" xlink:href="bcrx-20250930.xsd#bcrx_SegmentReportingAdjustmentsAndReconcilingItemsAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f8b2ce67-5c1a-4d87-a972-88001fb240c3" xlink:to="loc_bcrx_SegmentReportingAdjustmentsAndReconcilingItemsAmount_d178f016-2a2f-409b-bc9f-0b12c0b881f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/NetIncomeLossPerShareScheduleofEarningsPerShareDetails" xlink:type="simple" xlink:href="bcrx-20250930.xsd#NetIncomeLossPerShareScheduleofEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/NetIncomeLossPerShareScheduleofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b5d2475f-9867-423e-996a-5be9f81320b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_3ff7f21d-27e8-4809-a2ba-e9ab4cbd9808" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b5d2475f-9867-423e-996a-5be9f81320b8" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_3ff7f21d-27e8-4809-a2ba-e9ab4cbd9808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e18ae52b-a19b-4d00-94ce-a23d924a563c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_3ff7f21d-27e8-4809-a2ba-e9ab4cbd9808" xlink:to="loc_us-gaap_NetIncomeLoss_e18ae52b-a19b-4d00-94ce-a23d924a563c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_dad2b009-2e5c-4529-9cd5-7136c71587de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b5d2475f-9867-423e-996a-5be9f81320b8" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_dad2b009-2e5c-4529-9cd5-7136c71587de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e404b304-c85c-4b93-b0eb-e9c8e717bab8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_dad2b009-2e5c-4529-9cd5-7136c71587de" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e404b304-c85c-4b93-b0eb-e9c8e717bab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_02f571d0-75e1-4a34-b7e6-762eb8ca8afc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_dad2b009-2e5c-4529-9cd5-7136c71587de" xlink:to="loc_us-gaap_EarningsPerShareBasic_02f571d0-75e1-4a34-b7e6-762eb8ca8afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_b4e8a245-df90-4d82-9cd7-a953f2e0b2f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_dad2b009-2e5c-4529-9cd5-7136c71587de" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_b4e8a245-df90-4d82-9cd7-a953f2e0b2f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_123f0792-f590-4a2c-97fe-f35acfc1d93e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_b4e8a245-df90-4d82-9cd7-a953f2e0b2f3" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_123f0792-f590-4a2c-97fe-f35acfc1d93e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements_50353d6b-eeff-4968-824a-fd05be0dce89" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_b4e8a245-df90-4d82-9cd7-a953f2e0b2f3" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements_50353d6b-eeff-4968-824a-fd05be0dce89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_IncrementalCommonSharesAttributableToDilutiveEffectOfSharePurchasePlans_a3fa45da-4f21-46c1-a768-b3499b7ce145" xlink:href="bcrx-20250930.xsd#bcrx_IncrementalCommonSharesAttributableToDilutiveEffectOfSharePurchasePlans"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_b4e8a245-df90-4d82-9cd7-a953f2e0b2f3" xlink:to="loc_bcrx_IncrementalCommonSharesAttributableToDilutiveEffectOfSharePurchasePlans_a3fa45da-4f21-46c1-a768-b3499b7ce145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_aa71ce6e-cdc6-41c9-97ff-cb0a2d114400" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_b4e8a245-df90-4d82-9cd7-a953f2e0b2f3" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_aa71ce6e-cdc6-41c9-97ff-cb0a2d114400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_aa4e09dd-dbdc-4aa9-9ade-7d2aa6e56d37" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_dad2b009-2e5c-4529-9cd5-7136c71587de" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_aa4e09dd-dbdc-4aa9-9ade-7d2aa6e56d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_7ac003df-d820-4317-8f4e-fb4a62ed3ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_dad2b009-2e5c-4529-9cd5-7136c71587de" xlink:to="loc_us-gaap_EarningsPerShareDiluted_7ac003df-d820-4317-8f4e-fb4a62ed3ef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/NetIncomeLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="simple" xlink:href="bcrx-20250930.xsd#NetIncomeLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/NetIncomeLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_480313e2-d0ac-42fd-bb9d-c7078754a752" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9827c5a6-ed9a-4175-9fcd-0750d0fa2d14" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_480313e2-d0ac-42fd-bb9d-c7078754a752" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9827c5a6-ed9a-4175-9fcd-0750d0fa2d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5d907e78-f0d1-4262-90c5-21923fb5612a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9827c5a6-ed9a-4175-9fcd-0750d0fa2d14" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5d907e78-f0d1-4262-90c5-21923fb5612a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3c2afbb5-15e9-4e0d-8c22-e8fba86ae4bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5d907e78-f0d1-4262-90c5-21923fb5612a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3c2afbb5-15e9-4e0d-8c22-e8fba86ae4bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_40e918b5-8878-4295-a5a6-74b98e1b6cef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3c2afbb5-15e9-4e0d-8c22-e8fba86ae4bb" xlink:to="loc_us-gaap_EmployeeStockOptionMember_40e918b5-8878-4295-a5a6-74b98e1b6cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_4921666c-b2f0-4a92-97a1-3f1422b56507" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3c2afbb5-15e9-4e0d-8c22-e8fba86ae4bb" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_4921666c-b2f0-4a92-97a1-3f1422b56507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_927b92a2-7f60-4cdc-bf86-570262f81a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9827c5a6-ed9a-4175-9fcd-0750d0fa2d14" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_927b92a2-7f60-4cdc-bf86-570262f81a2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5f18b795-b5b2-4298-8e83-01f5443386af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_927b92a2-7f60-4cdc-bf86-570262f81a2a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5f18b795-b5b2-4298-8e83-01f5443386af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/SubsequentEventDetails" xlink:type="simple" xlink:href="bcrx-20250930.xsd#SubsequentEventDetails"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/SubsequentEventDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0ebdf62a-3355-4b2a-9dcd-ab089f5b6dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_ab69ecd3-ea4b-47b1-ad0c-242398a28483" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0ebdf62a-3355-4b2a-9dcd-ab089f5b6dd6" xlink:to="loc_us-gaap_SubsequentEventTable_ab69ecd3-ea4b-47b1-ad0c-242398a28483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_736cfa6a-f493-49b3-ae65-e7bbb3a781a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_ab69ecd3-ea4b-47b1-ad0c-242398a28483" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_736cfa6a-f493-49b3-ae65-e7bbb3a781a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6e4ff3ff-76fd-4cd3-bd85-3d6c15179a71" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_736cfa6a-f493-49b3-ae65-e7bbb3a781a2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6e4ff3ff-76fd-4cd3-bd85-3d6c15179a71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_92ddcdf4-c14a-48b0-b6f4-d694843c4672" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_6e4ff3ff-76fd-4cd3-bd85-3d6c15179a71" xlink:to="loc_us-gaap_SubsequentEventMember_92ddcdf4-c14a-48b0-b6f4-d694843c4672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_8596e8c8-470f-451c-bd8b-a9bdcd31b712" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_ab69ecd3-ea4b-47b1-ad0c-242398a28483" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_8596e8c8-470f-451c-bd8b-a9bdcd31b712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_01adcdf7-5124-4dfa-bafb-53d02bd5c4e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_8596e8c8-470f-451c-bd8b-a9bdcd31b712" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_01adcdf7-5124-4dfa-bafb-53d02bd5c4e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_d645d284-74a0-447f-b5ea-de6c9a888a3f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_01adcdf7-5124-4dfa-bafb-53d02bd5c4e4" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_d645d284-74a0-447f-b5ea-de6c9a888a3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_80e62bc1-80c3-40de-8c6f-932193a7dc47" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_ab69ecd3-ea4b-47b1-ad0c-242398a28483" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_80e62bc1-80c3-40de-8c6f-932193a7dc47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7c0069d1-1971-4bb6-ab1c-8a62215927b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_80e62bc1-80c3-40de-8c6f-932193a7dc47" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7c0069d1-1971-4bb6-ab1c-8a62215927b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_BioCrystIrelandMember_a3dfa427-3482-4c34-8682-8260f629ddb1" xlink:href="bcrx-20250930.xsd#bcrx_BioCrystIrelandMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7c0069d1-1971-4bb6-ab1c-8a62215927b9" xlink:to="loc_bcrx_BioCrystIrelandMember_a3dfa427-3482-4c34-8682-8260f629ddb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_f4ffce84-7506-45bc-8010-a322a779c5b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_ab69ecd3-ea4b-47b1-ad0c-242398a28483" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_f4ffce84-7506-45bc-8010-a322a779c5b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_890cf2cd-e15b-4315-a7ba-416b75649e03" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_f4ffce84-7506-45bc-8010-a322a779c5b8" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_890cf2cd-e15b-4315-a7ba-416b75649e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_PharmakonAdvisorsLPMember_a40c69ca-2c00-49b6-bee8-361096e5c340" xlink:href="bcrx-20250930.xsd#bcrx_PharmakonAdvisorsLPMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_890cf2cd-e15b-4315-a7ba-416b75649e03" xlink:to="loc_bcrx_PharmakonAdvisorsLPMember_a40c69ca-2c00-49b6-bee8-361096e5c340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_BlackstoneMember_eba3697c-193a-43cd-9423-d8a39bc46b90" xlink:href="bcrx-20250930.xsd#bcrx_BlackstoneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_890cf2cd-e15b-4315-a7ba-416b75649e03" xlink:to="loc_bcrx_BlackstoneMember_eba3697c-193a-43cd-9423-d8a39bc46b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1b43d516-5fcf-4cfa-b921-a53ab8debe5f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_ab69ecd3-ea4b-47b1-ad0c-242398a28483" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1b43d516-5fcf-4cfa-b921-a53ab8debe5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_482a5bc5-b1f5-4f6d-a950-f89e2c1023dc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1b43d516-5fcf-4cfa-b921-a53ab8debe5f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_482a5bc5-b1f5-4f6d-a950-f89e2c1023dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_b8b2391b-fe99-40e4-8b67-ce578a8d8edf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_482a5bc5-b1f5-4f6d-a950-f89e2c1023dc" xlink:to="loc_us-gaap_LineOfCreditMember_b8b2391b-fe99-40e4-8b67-ce578a8d8edf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6e560ce2-e801-4384-88fc-59262960b135" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_ab69ecd3-ea4b-47b1-ad0c-242398a28483" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6e560ce2-e801-4384-88fc-59262960b135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8fb33427-df94-4528-b259-c104f1a479ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6e560ce2-e801-4384-88fc-59262960b135" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8fb33427-df94-4528-b259-c104f1a479ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AstriaMember_5c480813-3d85-48ad-bf61-d6e85e0e183f" xlink:href="bcrx-20250930.xsd#bcrx_AstriaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8fb33427-df94-4528-b259-c104f1a479ec" xlink:to="loc_bcrx_AstriaMember_5c480813-3d85-48ad-bf61-d6e85e0e183f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_31ce7743-3f3d-44eb-8989-c170ede717d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_ab69ecd3-ea4b-47b1-ad0c-242398a28483" xlink:to="loc_us-gaap_CreditFacilityAxis_31ce7743-3f3d-44eb-8989-c170ede717d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_b2fe5038-6794-4092-8029-c4c25d32757d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_31ce7743-3f3d-44eb-8989-c170ede717d7" xlink:to="loc_us-gaap_CreditFacilityDomain_b2fe5038-6794-4092-8029-c4c25d32757d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_546075cf-d46a-40af-8f11-658ecbb08954" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_b2fe5038-6794-4092-8029-c4c25d32757d" xlink:to="loc_us-gaap_SecuredDebtMember_546075cf-d46a-40af-8f11-658ecbb08954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_32305d6c-fc57-45bc-b69e-2efa5fca7249" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_b2fe5038-6794-4092-8029-c4c25d32757d" xlink:to="loc_us-gaap_UnsecuredDebtMember_32305d6c-fc57-45bc-b69e-2efa5fca7249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_05449326-d2da-4a7c-b630-39aec955f79d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_ab69ecd3-ea4b-47b1-ad0c-242398a28483" xlink:to="loc_srt_StatementScenarioAxis_05449326-d2da-4a7c-b630-39aec955f79d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_86349734-19cd-47ea-95cc-5359ec5fdde0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_05449326-d2da-4a7c-b630-39aec955f79d" xlink:to="loc_srt_ScenarioUnspecifiedDomain_86349734-19cd-47ea-95cc-5359ec5fdde0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_4ccb8ebb-3f36-4ba7-a2b9-fb7e4ac2041a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_86349734-19cd-47ea-95cc-5359ec5fdde0" xlink:to="loc_srt_ScenarioForecastMember_4ccb8ebb-3f36-4ba7-a2b9-fb7e4ac2041a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_53259c98-6d6d-44c9-b764-d16297eaa40e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_ab69ecd3-ea4b-47b1-ad0c-242398a28483" xlink:to="loc_us-gaap_SubsequentEventLineItems_53259c98-6d6d-44c9-b764-d16297eaa40e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_44fa2f50-78b7-46fa-ad06-ce556ff132a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_53259c98-6d6d-44c9-b764-d16297eaa40e" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_44fa2f50-78b7-46fa-ad06-ce556ff132a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_4e430f43-6b03-4e63-8ce9-fdc0c39294da" xlink:href="bcrx-20250930.xsd#bcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsideration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_53259c98-6d6d-44c9-b764-d16297eaa40e" xlink:to="loc_bcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_4e430f43-6b03-4e63-8ce9-fdc0c39294da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DisposalGroupIncludingDiscontinuedOperationConsiderationRoyaltyReleaseFee_11b72f5d-efa7-4a8e-8a56-3640bb371f7f" xlink:href="bcrx-20250930.xsd#bcrx_DisposalGroupIncludingDiscontinuedOperationConsiderationRoyaltyReleaseFee"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_53259c98-6d6d-44c9-b764-d16297eaa40e" xlink:to="loc_bcrx_DisposalGroupIncludingDiscontinuedOperationConsiderationRoyaltyReleaseFee_11b72f5d-efa7-4a8e-8a56-3640bb371f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_83e6816e-3488-4721-bd5c-3dcae743a337" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_53259c98-6d6d-44c9-b764-d16297eaa40e" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_83e6816e-3488-4721-bd5c-3dcae743a337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DebtInstrumentPrepaymentPremium_7b15228b-6235-4c3b-b21b-b92d96f20a63" xlink:href="bcrx-20250930.xsd#bcrx_DebtInstrumentPrepaymentPremium"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_53259c98-6d6d-44c9-b764-d16297eaa40e" xlink:to="loc_bcrx_DebtInstrumentPrepaymentPremium_7b15228b-6235-4c3b-b21b-b92d96f20a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseLongTermDebt_aecbeafa-ee8e-4f70-950a-01f6a255eaef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseLongTermDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_53259c98-6d6d-44c9-b764-d16297eaa40e" xlink:to="loc_us-gaap_InterestExpenseLongTermDebt_aecbeafa-ee8e-4f70-950a-01f6a255eaef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_CommonStockConversionRatio_f1de2e61-acc7-4be8-a59b-d99f6956bb70" xlink:href="bcrx-20250930.xsd#bcrx_CommonStockConversionRatio"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_53259c98-6d6d-44c9-b764-d16297eaa40e" xlink:to="loc_bcrx_CommonStockConversionRatio_f1de2e61-acc7-4be8-a59b-d99f6956bb70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_31f5586d-f542-47ec-bcb3-f7872904f952" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_53259c98-6d6d-44c9-b764-d16297eaa40e" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_31f5586d-f542-47ec-bcb3-f7872904f952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_2b2a4d71-b373-4a06-b78e-bff411b5a262" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_53259c98-6d6d-44c9-b764-d16297eaa40e" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_2b2a4d71-b373-4a06-b78e-bff411b5a262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_ed06f1e7-27ee-4a74-a468-ac9859530414" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_53259c98-6d6d-44c9-b764-d16297eaa40e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_ed06f1e7-27ee-4a74-a468-ac9859530414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_bd005088-d92e-4447-9020-21b5c2947309" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_53259c98-6d6d-44c9-b764-d16297eaa40e" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_bd005088-d92e-4447-9020-21b5c2947309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_A.MachelleSandersMember" xlink:href="bcrx-20250930.xsd#bcrx_A.MachelleSandersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_bcrx_A.MachelleSandersMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>thackray-biocrystseparat001.jpg
<TEXT>
begin 644 thackray-biocrystseparat001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS
M[QEXPU_0/&6AZ/9#3&M]7<HCSPR%H2,9)PX#=?:O0:\E^)FCWVN>.?#4D>A7
MU]IVGR,;MXXP596VG"\\]*7VD/HSL;'Q#=6-M=WWB*]TQ-+3;]GO;='C1N2&
M#!F;&"/6I;CQ?IUWI=[)H>HV=S>0VK7,:G+*5'0D CC\:Q[:ZDM/#ESH\/A;
M4YM,M[;R8HIH0&FW$_*!NZ <$FN<\%V6NZ%X;U[P]=Z%?-$(Y&LKE8O]8I&!
M'R<Y!Z>U$KV=NV@1W5^YUG@?Q]9^)="TV6^N;.#5KN)I3:1L1PI(R 23T%<U
MK/Q2U6P\/7.K6D>CSI%J_P!B41R-(#$1PQ(8;6]C^0KF_#GAWQ!8ZEX!>;P_
MJ"+I,<ZWC>6/E+L<=^:J?\(5XFO/"6K:>NB74=Q-KJWL:R@*&BQUSGVJM.;^
MNZ_0G[/]=G^I['J'C'3(_#VJ7]A?V4LUE$=RR2[460CY0Y[ G S6>GQ&TRTA
M\/P:G- NH:M&KE;=MT:#&2V[G(R,"N0UGPWK6IR^,]9@TN[C34-,2RMK1E D
ME?&"Q7/ %%AX=UR"_P#AW?OI-ULTRW>WNTP-T3$8!(ST]Z2W^[]?^!]XWM]_
MZ?\ !/5-7OI]/TF>\M;)KV2)"XA614W <]6X%<?8_$G?\*Y/&=[9JC#?LMHV
MZL'*J,G\,FNNUV:2'0KPQ6L]S(T3(L4"[F)(P*\KT?PAJ^J? ZX\+7&GW%CJ
M<)9T6X4*KMO+  @GKTI=_E_P1]CN/#WBJ[N_$EWX>U5+<7\-M'=H]LK*CHW4
M88DY4X&<\Y[4WQ]XDUGPSH\E_ID&FF.%0TC7\Q7S.?N1JO);ZD#D=>V+I>E:
MJOBS5O&']EW"O'I:6MK93$(\K@98=\#( !J[J=[?:_:1:9KW@JXDL[RS#LR,
MLGDS'.4;IC'&&%.6VF__  _Z"CY_UM?\3K-"U";5="L=0N+8VTUQ LCPDYV$
MC.,UH5@>"=$N?#G@[3=)NYO-GMXR';.<98G&?;./PK?IRM=V%&]M0HHHI#"B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@!**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I
M:2EH **** "BBB@ HHHH 2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *6DI: "B
MBB@ HHHH **** $HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4444 %%%% !1110 4M)2T %%%% !1110 4444 )1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?3BM&YTZRO8DBNK.WGC0Y5)8E8+] 1Q5FBIN58CA@BMH5A@B2*)!A410JCZ
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !2TE+0 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!%+;03M&T
MT,<C1MN0LH)4^HJ6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MYW$G^]TP.G>DO\OR&_\ /\#O:*X"TUO5-,UCQ-I>L:O//+;1)/I["&)"T;Y
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M264#"G"_05VVL:KJ=E\2?#^F0WS#3]1AN#+ 8T.UD7(*MMW=^Y/2A=/G^'_
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M] U3^V_#]AJ?E&+[5 LIC/\ "2.10M@>YHT444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8?BS
MP_)XHT&?2!?&TAN!ME=8@[%?09(Q6Y10U<:=CD[GP?>ZAI,.D7VOS?V>D8B>
M.UA$+2J !AFR3CCG&*?K7@:QU*PTZ#3[B;2)],Q]BN+/ :(8QMP>"#Z&NIHH
M$M#DM2\%W.J>%+C1;K7[J:6Z(\^\EB0NP!SA5&%4<>E%QX-NKK5= OY-9^?1
MD*Q*+88DW !BWS>BCI76T4=;AY&#JWA6RU?Q!I>L3.ZS:?NPJ])0>@;V! (J
MKXB\'?VSJEMJUAJUWI&J0(8OM-L%;?&3G:RMP1GUKJ** ./U;P//JD>CJ^N3
ME]-N1=B66%7::49P6P0 ,'H *A\:W>D:O:OX/GF>;5[E$:.**)@R<\2;L84#
MKUKMJ* VU*]C:1V&GV]G$,1P1+&OT Q7.:GX1N[_ ,7V?B*/6!#-9QO%!";4
M,H5A@Y^8$GGVKJZ*.MP6BL<U%X/2?7H-9UF_EU*ZM<_98V0)# 3U94&?F]R3
M6;??#J.\L=>L%U:>*SUBX-S)&(U9HY" #ACU7Y1Q^M=O10!S9\)C_A(-/UE=
M0E%Q:VQMG!C!$J$@_AT]^/SJA;> 7T_5YY].\0ZC9Z;<S&>;3H]A0L3EMK$9
M4$^E=G10'D4H+.YBU2>Y:_D>U>-5CM#&H6(CJ0W4Y]ZIZ_H]YK"6T=OJ?V..
M*5977R!()2IR <D<9%;-% &#XM\-_P#"5^')='DO/LRRE"\JQ!F!4A@5R>#D
M#FJ4G@ZXFFT2]EUJ1]2TD.D=RT _>HRA2'7/7 Z@UU=% 'FNM>&1X6T;7KJ+
M6=4/]LW(:9XXU(@+$ N<+G  P>V.U1>%=!?2M2MYM!\6VNIP22C[7;P65NBE
M.[%H@"&';->GT4+0'J<+<_#6*?0=0T--8N8M.N[DW018E+1L7#D;CU&?:KUS
MX,EN;"ZL6UJY>UNXTBG2:)'R%4+E< ;6(')P1[5UE%%M+!UN<XOA&&#Q%9ZO
M:7<D#6]F+(Q;0P:,'(Y/0UH>(="L_$NB7&E7P;R9@/F0X9&!R&'N"*TZ*'J"
MTV,"V\.RC4K34=3U)[V>RB>.V(A$83< &8@9RV!CL.O%3>'(]2CM;E=1O);L
M?:&,$LL0C<Q\8!4>ASCOC&:V:* .0USPAJ^K:ZNIVOBNZT_RTV10Q6L3JGJ1
MO!Y/K5A_!WVOP^NGZGJMU?7B7 N8[]U59(Y5/RLH' QTQZ$UT]%"T YVV\,/
M!<:CJ+:B[ZQ>PB'[9Y0'DH.@1,\#//7DUD:9X$UK3WB1_&VH36:R^9);_984
M\TYR=S@;N3U.<FNYHH6@&))HVHS7-V)M<F>QN#_Q[^2@:->ZJX['W!//6M>W
M@BM;>.W@C6.&)0B(O15 P *DHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBL3Q1XILO".E?VEJ,%V]H&VN]O
M'O\ +ST+#(X]Z&[!:YMT5BZ5XEMM9\.KK=E:W;VSKOC4JH>1?4#=C\R#Q6)?
M?$[1]-\.P:]=V&JPZ;.VV.5K=>2>G&[.#S@XH>FX+78[6BJ.D:HFLZ;#?Q6]
MQ#%,H>,3J%8J>0< GK4&E^(],UC4]3TZRG\RYTV18[E<8VD@XQZ]"/PHMK8.
MES5HI&.U2<$X&<#J:X^R^(^F:CKUYH=IINJ2:E9@F>#RD!3'N7P>HZ&CR#S.
MQHKFX?&EE/I>HWRV&I*-.D*7,+PA9$P-Q."W(QZ&E\)>-=.\:6LEWI,%Y]E1
MBGG31A%+#&0.<]_3% '1T5S?BSQKIO@RVCNM5@O/LTC;1-#&'4-Z'G/Z4A\:
M6R2:<)]+U2"/4)$C@F>%2F7^[N*L=N?>A:[ ]#I:*Q->\5Z3X=>WAOIV:ZN6
MVP6L*&264^RC^?2HV\764%[9V=]:WUE<7C[+=9X.'/IN4E0?8D&@#?HKB]4^
M)>E:+IT.H:AI^JP6D\GEQ2M OSGV&[.#ZD5J+XJ0M,C:1JJ216_VD*T*?.F0
M#M(;!(SG&<T =!17#6/Q4T34M%NM8M+'59=/M7,<\ZVX/ED $Y&[=P".<5TF
MF^)-(U;0%URTOHFTTH7,[':% Z[L],>] &K17)1_$/29]*EU>WM-3FTJ(D->
MQVV8\ X+ 9W%1ZA:T+OQ;IEOX:'B"#S;[3MN\R6BAR%]2"0?PZT/34/(W:*Y
MWPYXVTCQ9HDNJ:*TURD3%7@"A901VVD]^HYJA?\ Q'TS3/#Z:[>Z=JL.GL^P
M2- N0<XY7=GJ#VH>FX+78[&BL6R\3Z?=>'?[=F\RQT\IY@ENP$RGKU/^-4K?
MQSI]UIS:G%8ZFVF+D_;/LIV%?[P7.\CW"T/3<%J=/1573M1MM5TRWU&S8O;7
M$8EB8C!92,C@US5C\1]#O?%I\,-'>6NJC(\JXB"@D#. P)!.*+:V#I<Z^BN?
M\6^,](\%Z?%>ZLTWER/L588][?7'IR!GW%:6D:I'K.F0W\,$\,4RAXQ.H#%2
M,@X!/6A:AL7J*R]+\0Z;K&H:E8V4_F3Z=-Y-PN,;6QGCU]*R?%7C_2O!US;0
MZK;WP%R=L,D40=7;T'S9SSZ4=O,#JJ*X_7_B+I?AAK(:M8:G ;T[8 (5;<W'
MR\-P>1756LYNK6.<PRP[QGRY0 R_7!(_6@":B@D 9/ KE-7^(6B:-I,^JS"Z
MFL()Q;R7$$6Y=_3C)&1GC(R,T =7145M<)=6L5Q'GRY4#KD<X(S4$NJ6L<EU
M"C^=<6L0ED@CY< YQUXYP>]#TW!:[%RBL+PIXNTSQEICZAI1F\A)#&?.3:<C
MVS6[1:P!115#6M6@T+1KK5+I)7M[6,R2B)06"CJ<$CH.:&[:L$KE^BLSP_KU
MEXET6WU;3S(;6<93S%VM^(K3H:L"=PHHHH ***R]1\06&FW26CM+/>2#<MM;
MQF23'J0/NCW.!0!J45CIXB@6XBAO;.]L&E8+&US&-C,>@W*6 /U(S56_\::7
MIOBRR\-W27*WUZ,P,(P8V'USQ^5'D!T5%5=1OX=+TVYO[C?Y-O&9'V*6; &3
M@#K4.AZS:>(=%MM5L1*+:Y7<GFH4;&2.0?I0!H4444 %%%% !115>\O[6PC1
M[N=(ED<1H6/WF/0#WH L4444 %%%% !115"ZUBSL=0M;*ZD,4EUD0LZD([#^
M'=TW>@/7M0!?HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MDS1".8JG^N4$,HX8$'^+/MBNL\7:A>37>J"UU*^>2'31)%;V$K1"TDP3YDC
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?)GQZ_Y*G=_P#7
MM#_Z#7UG7R9\>O\ DJ=W_P!>T/\ Z#0!YG1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5QWQ495^&
M>N;F S;D#)[Y%=C56]TVPU)%2_LK:Z1#E5GB5P#ZC(I-75AQ=G<YVY\1:=X?
M\!6ES>W$8+62+%%G+S.4 "JO4G)'2O-M+LK[P;H_@Z/6[F/3K-WFEE>YAWQP
M3N<H'&0 =N>2>#FO9;70='L9A-9Z38V\HZ/#;HC?F!5NYM;>\@:"Z@BGA;[T
M<J!E/U!JF]6^Y*6B1Y-<P:+I^B2>1JHU>WU'6H&A^RLL=K'.3G!92PV9&6 [
M^]8]]%"R?$^WOFL96%O!,JQ*/+$VR0DJ#GYACKUXKVQM,T][$6+V-LUH.D!B
M4QC_ (#C%0RZ#H\^?.TFPDR IWVR'('0<CMVJ6M&OZZ?Y%)]?ZW,[P986=OX
M8TNY@M88YY;&!9)40!G 7@$]3C)_.N7\7007GQ<\*6\TLB*;>?/E3M$W0_Q(
M01^=>A6EG:V%N(+.VAMX021'#&$4$]>!Q5:?0=&NKHW-QI-A-<$@F62V1G)'
MN1FJ;O*Y*5HV.$\26%GI?Q(\$".XN2SS7.1<WLLW\"XP)&./PZUARSV=YJWB
M_1O$NOV.ESW%VVP7L(WO!@>68G9AG'8 'FO5[G0='O;@W%UI-C/.<9EEMT9C
MCIR1FI9M+T^YFAFGL;:66'_5/)"K-'_NDCC\*2VU\RK_ -??_F>>%?LWQ*\+
M6ZW33S1Z),BR2\.YPN"1ZG&:Y_0C8:YH-C8ZEXFM;+7;2^\V2V%NJWOVD.<X
MRVYLYQD#I]*]@DT;2YKX7TFFV;W8((G:!3(".GS8SQ4@TRP%\;X65M]K(P9_
M*7S,>F[&::?]?.XO+^MK'DUC8Z?#JOQ22.VMT5(4VA44!<Q.3CTR>?K74^!9
M=+N/A]X3?5GLWN/*3[*;DKN,H!QLW<[L9Z<UTQ\-:"6=CHFFY?[Y^R)\W?GC
MFIX='TRWCCC@TZSB2)_,C5(%4(_]X #@^]):*WI^ /7\?Q+M%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MKYUKPIH]U?74#:C=6JS21@JK'/<+Z4+7^O7_ "#^OR_S.DHJN]_9QW*VTEW
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M--M%\?Z,-*AA%M=V<PU"*(#RY(<#86 XZG@_6O.[=(K?X(6=_"J)=1ZPI2<
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M9I]S+<6>G6EM/-_K)(8%1G^I R:;5[_UW_S$MCCO@_%!'\/[4I'&LK37&\J
M&($S@9J/XE(9=:\&1+<O;N^K*%DCV[EXZC<"/S!KN+/3;'3O-^Q65O;><YDD
M\F)4WL>K' Y/O574/#6@ZM<BYU+1=.O)U&!)<6J2,!Z98$TV[M/T_ ._G?\
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M-:&#3Q%JRM-:ME[B:0,G[QBQ^1>!@ =NO:NAM]1T9?C9)/\ :[)5_L1=[EU
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MJM!KFDW-Z;*#5+*6[&<P1W"-(,=?E!S3KK6=+LKE+:[U*SMYWQLBEG5&;/3
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M8QZG9/=C(,"W"F3C_9SFH?\ A)=!)N1_;>FYM?\ CX'VN/\ <\X^?GY>>.:
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M)$\FFVJR6MVR#)A#_=<CTY.37H<,$-NFR")(E_NHH4?I3R RD, 0>H-'5-=
MZ-/J9\>NZ;/'$UM=Q7)EQY:PL&+9^G3\:XO2+FRBU;QCI_B0P">:Y>11< 8E
MM2H" 9Z@=,>M=_#:6UNQ:"WBB)ZE$"Y_*EEM;>=U>6"*1U^ZSH"1]*307/%8
M[:.PN?ALFK^2MZ)Y@QGQY@BQ^[#$\],8S6E97.ECQ1\2\36GS6Z%/F7D^4V[
M'XXS7JTME:W$@DFMH9''1GC!(_$TS^S+#)/V&VR>O[I>?TH>M_G^-O\ (:TM
M\OP/#])FTXP_"R\G:V)42Q2S-@D;4(56/L<8STK8UR2T@O?&^IBW:ZT&6"WB
ME2W<HLEP7 8[AV *[B.U=7XB\):CJ/BC0[_3X-*CL=-D>1HI&93*77:PP$(X
M'YUV2VT"P&!88Q"1@QA!M_*J;OKZDK33T_ \BBDA3XB:F-1O+">*?PX=_E(%
MA.' 51DG=@=S6%;75E!\&_"QBF@CF76HV;:P##$[<G\,?A7NYL;,@ VL! 7:
M!Y8X'I]*9_9>G[=OV"UQG./)7_"DM/Z\VQ_U^%CA/$[S>%O%=IXCTZ S0:M'
M]BN5B&=TQ'[A_P 2<9]*[G2+ :9I=O:9#.B_O''\;GEF_$Y-9:Z7K-WK@?49
MM/&D6LHDLX+:)Q(Q P#(2<<9. H_E70T+8'N>2QG2!XX^(5N\JPVTME )3:X
MW#*8<@#J>>:T_"-S=V_BVWTZ[FLM40:<3;:E:IL=8@P_=RKTSZ?C7H"V-HDI
ME2U@60]6$8!/XT^*W@@9C%#'&6.6**!GZT+1+^NX/6_]=O\ (XWQE<-8^+?"
MU[>X_L6.:59V892.5DQ$S?CT/8U7LEAB\=^(M2LY8DTA].C%Q(K 1M<Y;G/3
M.W&3[BN\DCCFC,<J*Z'JK#(/X4P6MN(# ((A"?\ EGL&W\NE*VGW_C_7Y#OJ
M>3>'=1LE_9\G!NX 5MKE2"XR"9'P/QIEYJ:6OAOP%J,E^T.DV\,:W%Q"BRB"
M3R@%9@00,<\XXKU<:;8!"@LK8*3DKY2X/Z4];.U2%H4MH5B;[R",!3]13ZM^
MGX7_ ,Q=$O7\;?Y'B/BZR\/+X.U/4K#51J?VW4[:02R(@17WJ'\O"CJ/O8KI
MOB/'I%O8>&KB-+*.1M3A=9%"@D<;CGZ 9/L*]':PLWC6-[2!HT^ZIC!"_04/
M86<J(DEI ZH,(&C!"CV]*%I;U3^ZW^0/7[FOO/,],DTJ+XN^+65K-%.G1DD%
M0"Q^]^/K7-:7J5M:?"KP3J%Q?1;;#4-[6\D@59<%_E+'Y5('(W8%>W_V;8;B
MWV*VRW4^4O/Z5C:WH-S--93Z5'I^VW=F>SN8\12$C&[*@D,!G'!ZTEI^'X.X
M/7^O*QS/PYFT;5?$OB'7+.:P:YO9$=;>)XY)8$ P2S*2!N/. 2.!6Y\0-(GO
MM#74M/13JNE2"[M3CD[?O+GW7(K3TW1ME]'J5W9V-O>1Q-$JV8)4*Q4G+$ G
M[H[#'-)KMKK]Y)#;Z7=6%O92*RW<DT;M, >GEX(4'KUS3>R2!;NYR.IR:AX@
M^'6M>(=,BD6ZU&%6MD(Q(+9<97ZD;S^(I^J2Z?K4O@RY\.-#]JBO(V'D@ Q6
MWEMYBL!T7H,'OBO0;:VBL[2&U@0)#"@C11V4# %$5K;P.SPP11LWWBB $_7%
M/1/3^K"UMKY_B>,W,UO:^$/B79SLD<[7LK+"W#$,BX('H<=:]0\'W,-UX-T>
M6"0.GV2-<CU"@$?F#6JUI;/(TC6\3.PVLQ0$D>A-2JH50J@!1P !TI+16]/P
M5AO5W]?Q/$Y;F"#X7>/[>:5$F.IW>(V."<R#'%7YKNUC\5_#?[+<6Z-]@E1B
MC =8!@''O^M>KO8VDF_?:P-O.6W1@[CZFF#3;$,K"RM@5^Z?*7CZ<4DK?A^"
M:_4'K?Y_B>-Z*=*U72(=!UKQ!=6FM6U^96LA BS&82$JRL5)8'CG/2O4_%:V
MK>$=0BOIIHK:2#RY)8N74-@9]^M:WV:#S_/\B/SNGF;!N_.I&56&& (]"*;U
M5@6CN>0SW&N-:Z[IBO9ZC>_V.3;:EIZ[6:,'[CKG ?!.,58\/#PWXFOM$N(-
M=EO+RQMVB^P"WC38A7#)* @^48Z$]:]2BMX(-WDPQQ[CEMB@9/OBH9K;R8)W
ML+:V%RZG&[Y%8_[1 )_0TGM_7G_F%OZ^[_(\2T4Z=/\  R_TZ+R&U)[N9+:%
M /,\[S3LV@<YZ<]JU?$,PEB\5V;-#;WL.CQI?2SY=[HB(D")3PHSU///IBNS
M^'_A2[\+Z)]AU-+"6=)I)(Y[?+'#L6(.Y01C-=6]K;R2>8\$328V[B@)QZ9I
MR5U;^M@3L[^;_.YXUI<FEW'C3X?.[6CR'2)%G+;<EO+ 4-ZGTS6CXI>S?5_%
M5C9QV]B\&E1QSM,NXS)ARBPIT4 ]3SSCCO7J']FV.Y6^Q6^Y>A\I<C]*D>VM
MY)?->"-I,;=[("<>F:)>]^/XA'W?P_ \CTF[C_M'X<74LP\M=,9'D8\;O+4X
MSZU*PSXS^(=OH;0)?2Z;%Y2Q$ M)L?.,=\UZM]DMML:_9XML9R@V#"GV]*1+
M.UBF,T=M"DISEUC 8_C3D^9OY_B$=%;T_ \PO)+#6/ 7AN+1_+&K075N(8T
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M:W;.35E?$]YX=T#PQ%?7MI!!>6X+ZA-:OY4>$78C8?@G)^8G''2A:_A^(/\
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M5\;D*9SMX&.<U7\3>$?$?B/PQ%IUQJE@UVTZ3S2>4RQKL.0J*"3C/<FA>?\
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MMN'$D10Y1@3QG.#^%5+=V\_^ 3'I?R_X(ZQ\;:O+KB:?Y5M>QW-J\L4\5I/
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M;!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC:%%->1VEC8(!F66.)8^/<@"DTOQ%HVMF3^RM4M+WR_O_9Y0^WZXK2(#*58
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M#&>AJJOQ!\0'POK^M2V6F1?V->/!)"K22>:J[<@-\N#SUP<^@H ],=E1&=B
MJC))["LW1?$&F>(8)Y]+N1<103&"1@I #C!(Y'/45D-XFNM2UV'1M&%LEQ]C
M6]N);E6=8T8X50JD$D_48'K63\*S,UMXF-PBI,==N=ZH<@-QG![BA;O^NM@O
MI=?UI<[F[N;>TM9IKF14AC0O(6[*.IK)\-MX<U"S&KZ!:6:Q3%D\^&V$1;!P
M>P/45R]K<ZQ/\3O$MM+?P/:6UA"5B-N>$8.<*=_!SU)!SZ"L#PCXCU#PO\.-
M*OUBM9;%]1:WDC(;S"'E(W!LX&">F#GU%$=?Z\[ ]-/ZVN>R45PFK^.YTO-8
MM]+:S$FEX5H[F.1VN9-H8HNP_+P0,G//:NBMM<:\\(+KB6DL3O:&X^SR##JV
MW.T^^>*3=HN0TKNP[4+_ ,/VFHQ2:A/IZ7L8_=M,5\Q ?0GD5?M+ZTOT9[2Y
MAG53AC$X;!QGG%</\(HA=^#H]>N<2ZEJ<CRW$[<L?F("Y] !C%;.K2Z?X*LK
M[4[2U7SK^XC40 [%DF8A >G&>,_2J:MHR4[ZHZ>BN2G\0ZQH_B&QTO4X;&=-
M25Q:SP;X@LJJ6\MP2W! ^\/^^:Y]?'_B(^#=6\0/8Z8C:5>O;S6X:1O,57"G
M:W&#SG)!SZ"D,]-HKC)/%>JVWBC2M+EM[*1-6LY9[<*74Q.@!"NW.X'/4*,>
MAK(L_'?B.[\%W_B7[#I@33[J6.:U4R$R(C88J^1@@<\@Y]J/Z_&P;['I5%<-
MK7C2_AMY+S3X[."P&GK>P3WH)%TQ!81H%8$' &3SUZ56?Q[JLUQX0^QZ?9"W
MU]"2TLSEHV";B, 8QTYR<^@ZT6UM_7]:!?J>A4=:X%?%OB*YL_$]O96^GRZK
MH4P&#&XCN$*;AA=V5;J.IK1T_P 1W^KV/AV;3[BQ=M0C,MR3;OA4 ^;:/,^4
M@_+R3S],4+7\/Q!Z?UV-^UT72K&Y-S::99V\[9!EB@5&.>O(&:O5C>(]4OM+
MM;9K&WC=IIUCDGF/[JV0]9'&1D#TR/K7&2?$C5%\)>(M2@M-.N;G1;HPLZNZ
M13)@$.HY.>>F?QHO^']?J.VOJ>F45Q-YXNU/2K6RDU%=.5M3DC2S*>81%E-S
MF0?Q8QQC&?:KOA7Q/=:SJ6IZ?=PQLUFRF.[@B=(KA&'4!LD$=",FG;6Q-]+G
M4T5QNM^,GM]:O-)L);2*XLX%ED>ZC=P[-DJBA",=.6)XXX-0P^,]3O\ 1]'N
MX;"/3Q>"3[5<7RL8[5D[;<J6W'IR*5]+C\CN*H:QK.GZ!ILFHZG<"WM8_O.0
M3C\!S7':3\19=2\.:;<?9(!JE]?MIZ(&/E;U)R^>NW SCKV]ZC\87NM2>!_&
M-EJUG$JV]F3!>0*4CN%93G"DL00>#R:4G9-CBKM([ZTNH;ZSAN[=M\,R"1&P
M1E2,C@U-7GNC>)-0TB3P=I=U%:O9ZM:%(S&&\R)D12,DG# Y]!CWK7\?>)M2
M\*:)%J.GVEK< W"0R">1EQN8 8 '/7U'XU4E9Z=[$Q=U=]KG5TV21(8GEE=4
MC0%F9C@ #J37'ZEXIU'2-0M]+OI--CN[MWDAF59&2.!0.67JS9., @=\CI6#
MK7B;4]=^&GB<E(K2YL4DBDE$+F.XCVDAH\D$9]3NQSUJ6]+HI+5([C3O%&DZ
MIJ3:?:W#FY$?G*DD+IYB9QN0L &7W&:V*\]M_$#Z'I?ARRN);!M1OK;]S<M;
M,JPPJJDY 8LQR1P"H/MBJ.H?$K6K+PSJ%^FEVDEQ87JVTDCF2.*9&.%DC!&3
MGN">/4U36MOZWL2G=7/4**X37?$_BG0=6TBUFL]'EAU2_%M'(DLH9 1GE2,9
M'/(/X5)=^+=1L]271+F?2X-32W-Q//Y<LD(!8A%5 0V2.22>/?-+^OU&=O67
MIWB+2M6U*]T^QNA-<V1 N%"G"$YQSC!Z=JY;3?']WJ]II5K#8QVVM7\LL;1W
M ;RXUC/S2 <%@01@<9SUJ'P;]K_X69XQ%]Y/V@+:AFA!",-G! .2,CMDX]3U
MHMJ'0]"+ $ D DX'O2UP'B:XU@?%'PO9VU_!%:R1W$HBDMRX#+&02<.,\$@=
M,>]7AXEUG5+#4=3T.*PDM+&5XEBGW[[G9]\A@<)SD#ALX[47TO\ UV"VMCL:
M*SM"UB#7]!L]6ME81740D56ZCU!]P>*XV+Q]J<.M:);:A;642ZI=/;O9+N^T
M6G786.X@YP#C QGO3MK8+Z7/0Z*XK3?&5SJ6LS6<36(DBO#;R6,FY+B.,''F
M\G# ]< # YR>E=!XBU&]TO2'N;"S%U<;U0*QPJ D NWL!R?I2Z7#K8U:C:>)
M9EA:1!*X)5">2!U.*Y7PKXMGUG7]7T>Y:SG:QV/'=6894E1A_=);!!]S6C=:
M#=S>(SJ4.JM#;2VQ@GM?(#%^#M*OG*8)SP.:&!9O?$>BZ;"DU[JMI;Q.Q57E
ME"AB#@@$]\FI+'7M)U.9H;'4K6XE49,<<H+ >N*\]\=Z7=Z%\*VM+W4#J)AO
M8#%(MN(V">:N%P"<GW[YJQ=6-]XB^(N@:QI^EW=E;Z=&_P!JNKJ(PF52"!&%
M/+<]^E"_K[@>QZ517GB>/=4@UC1;>_MK*(:I=M;-8C=]HM>NPNVX@YQR,#K5
MC2/$OBC7-:US38;;2+9]+NXXF9VDD#(P))'W?F'!Z =O>C^OZ^\'H=T"#G!!
MP<'VH)"@DG ')->3^'-7\70^!]<UBTN+"_N8-0N6:&>V<%PK8.&$G' X&.W6
MNQMM=O=470&TZXLIHK^#S[B0V[8\O .5&_Y<DXP<_I1O^'X@]']_X&FOB?0G
MMH+E=8L3!/+Y,4@G7:\G]T'/)]JU:YE_!5A)IEQ8NL/EW-U]IFVP 8Z<(,_)
MT SR>OK6IKU_=Z9HT]U8V1N[A  D6<#DXR3Z#J:.@=2W=V5I?P^3>6L-S$>=
MDT8=?R-+:V=K8P"&TMH;>(=$B0(H_ 5P47CS4S=Z_81QZ7?7&FV2WL4T+O%$
MZX.Y3]_D8/0X/M1:>/-6%AX2U*]MK+[-KLB0O%"'WQ,X^5@Q.,9ZC'XT+^OF
M#.XU+4K32-/FOK^80VT(R[D$X_*ET[4+;5=.M[^SD\RVN$$D;[2-RGH<'FN+
MUG7]0UW1?$ATI+,6%@LML_G;C).ZCY]I! 0#/&0V<=JV/A^P7X=Z$S' %DA)
M_"A;-OR_&_\ D#W2]?PL=-17$VWBK7-4TVWUS2M-@NM+FNS +8!OM!B#E#+N
MSM'()VX/'>KC:_JNJ7FKPZ$MCMTMA&QN0S>?)MW%1M(V =,_-SVH UM4\0Z7
MHMS9VU_="*:]D\JW3:27;TX%%MXBTJ[UZYT2"Z#ZA;1B2:(*?D4\=<8[UP'B
M778O$NB^#M32$PL^M1K)$3DQNH<,N>^"*O2WL.F?&#6[^XR(;?P^DTA YPKL
M3^@HVW\_RN&^WE^=CT6BO/;3X@W<M]HLCPV\]EJC!7CMHI#)9[AE"['Y6'3)
MPN/>KL?BO6]3TYM:T73[>[T]+OR!;8;SY4#;6D#9P,')VX.0.HHL!VF1NVY&
M<9Q533M3MM5@>:U9RB2M$V^-D.Y3@\,!^=<3IUUKDWQ:UZW^VVTD-M80-%!)
M"R@*Q8A0P8X.>K8.?05 GCCQ+=_#^_\ $5M9::MS87,L<]NRR2*8T."5(8'(
MY/3G':A/2_\ 6]@ZV_K:YZ317-RZY=_;+)[>YLI-/%F;N\E\EL[<#:4._ W<
M]<XQWKG[;XB7<\FCW:6]O<66HSB)[:"*0SVRMG:[-]UAQR,#&1R:+:V%?2YV
M&F>(M*UF^O[*PNA-/8,$N%"D!"<X&2,'H>E:E>::4VIQ>-/B%)HZVS7R-:M&
MEPK%'(C/!VD$9]:UM*\5:GK?AS0;NRDL1?W\NRX1K=RL( /F#'F9!4C')Y)'
M3-"U2^7XC>C9VM%9/B/4K[2=&>YT^Q^V7.]4"%MJJ"<%V_V1U-<QI_CVZDF\
M36LL5K?RZ/ D\4MBK!+@,I.-I+$$$=B: .]JO<6EE//#/<6\$DT1S%)(@+(?
M]DGD?A6#X7\13:ZP=;G3KRV,(D,]GE2CD_ZMD))!'KGGT%8WBJXU@?$KPK9V
ME_!%;2^>XCDMRXW+&W+8<9X) Z8]Z+:I!T;.KTCQ'I6NSWL.FW0G>RD$<^%(
M"L1G&2.?PK4KR72;_4]*UCXC7^GBT+6UVDK"X5B'Q']T $8SSSDX]#70O\0$
MNAI$%J;>TN-0L?MQDND:1(DS@#:I!))]QTH6J7R_%7_S#_@G<U U[:I'+(UQ
M$$B.V1BPPI]#6+X/\0S^)-&>XN[,VMS#.\$BA6"/M. Z;AG:1@BJ#^#M4.E7
M-E'XC*,;X7=I(;)6\GYMVUAN_><D\G';THZ@;-SXJT"SO39W.L645T!DPO,
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^8<MD\\]*NT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)Q2Z)CZV+-%9TOB#18+2*[FU>PCMIN(IGN4"/]&)P?PI[:SI:R6T;:E9B2Z
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M@,.H)'?VJ>D,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M18^TVG.\=D&:]:SD9%9C>&]">*.)]%TYHXL^6AM4(3)R<#''-:2J%4*H  &
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M:3\3XU2S5%N9-BC: OR<8].?UKUZVTK3K.666UL+6"2;_6/%"JE_J0.:J_\
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M9M9QM'@0$YV8)X![CT/I6D^BZ5):K:OIEFUNHPL30*4'?@8Q5U55$5$4*JC
M & !5-WN2E:QR'C6"2XOM'^QZG;V>I0O++;)=H&AG^4*RMGH<-P1[UPUSK4G
M]G>'+R=8]&TV+4+F.Z?RO/MXYLG:W8;,EL'H*]BNK*TOHS'=VL-Q&1@K+&'!
M''&#]!^5(UA9O9_8VM(&M<;?(,8*8]-O2I0SQOQ)IMC;^!O$%YI^M1ZM!=WU
MM.[6\:B"-_,7=L*DCGJ<'KUKVB!HGA4PLC)V*$$?I40TZQ6Q^PK96XLR,?9Q
M$OEX]-N,5-%%'!$L4,:1QH,*B# 4>@ JNE@ZW.!^*DMO';^'A*\2L=7A/SD
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MG'RGGBA:NP/N=Y<7$-K;R3W$BQ0QKN=W. H]35#2_$.DZU+-%I]['/)" 9$
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MU?4);-899'C1%**P8Q@+&H+XW>M4]&_+^KB6J7F>GVOBC1+UYT@U*!F@3S)
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M\@;DG'?).,=JYC^V=*'P0U*W34;07+:P62(3*'(\Y6R!G/3GZ4NO]=[#6O\
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MRF&>+?&^[&3P00>,9]ZM6NGR?;%OKXP27BQ&)6BCVA5)!(&23R5'?M6C10M
M"BBB@ P*3 ]!2T4 &!Z48HHH 3 ]!2XHHH J6]BL%W/=,YDFFP"Q&,*,X4#\
M?QK \7^%[_Q'=Z/+;7UO;)IMXEV%DA9R[*>F0PP*ZJBCL B@[0&QG'..E+BB
MB@ Q1BBB@ HHHH *,#THHH Q-8TB_N]2L;^POHX'M0X,,T6^-]V.3@@@C'7W
MJU::?(+H7M\8)+L1^6&BCVA5)R0,DGK[UHT4 )@>E+110 8'I28'H*6B@ Q1
M110 8'I1BBB@ HQ110 8'I1@>E%% %2]L4OA&DK'R58,T8'#D'(R?8BK=%%
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M2;S7O#%]I-C+!%)=QM"TDP)"J002 .]3>'-.N-)T"RL+MX))[>(1EX00K <
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M6CLPN0FX!I<="N"2,=AG-'6W]?UJ'F=G16=KVLV_A_1+K5+H$Q0+G:.K$G
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MI>CW4.C7:6=N8)K665S%<#C:V_R\H1S_  FNTM+&UL(?*M+>*"/^[&H458H
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC1;W2+62YB9M2DQ&X;Y%CQDN3TQZ>M61JFG1:S>W#^(83'#;J9;,R)M@&?\
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MA!DB1\<#<H.*0VMNQ!,$1QQR@KGH/'&CW'C2?PTEW!]HAB#,6<#=(3C8H[D
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MMH5=QM=A& 6'H?6H?['TS:5_LZTP3DCR%_PH_K\4_P!!IV_KU_S/-+V^M/\
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MC(Y65548P0.#7+Z,UE>_ 1--MGA?5WGQ:PI@R^;YHP0!ST[^E>VR6@M[:?\
MLZUM4G<< CRU8_[14$_I7.^ ?"4WA7P]!I]^EE-<P,VRYA4DD$YZD CK36[^
M7YW%LE_70Y^/[3!\2M?B:4+?3:%"D+'CS)!Q\OKS6)X:32];L=$L;OQ'=QZO
MIDZL=.%M$DR2C[^?EW%3SDD\BO93;PM.LYBC,JC D*C<!Z9IJVELD[3K;Q"9
MOO2!!N/U/6A:?UYM_J#_ *^Y(\>TR?1(K+XG1I+8)&TLHC4,H!'E?P^V[T[U
M"^HZ?%H7PL>.\ME:.ZB\TB105_=D-N]/0YKV#^R-, (_LZT^;K^X7G]*/['T
MS ']G6F!T_<+Q^E"TM\OP!ZW^?XGFNE3Z;;/\0K?4O)$MQ=NT<,@&^9#$ NT
M'E@3TQWK)MFO_#5QX8_X2/59M+M_[*\F.Y:!)$BD+9*.7!"G;M&?8U[,]E:R
M3+,]M"TJ?=<Q@L/H:=/;074?EW$,<J==LBAA^1I+2WR_!-?J#U_KS3_0\1U;
M3M"TA?"*6NH+>0OKRS+/<!%.QF!.W '[O/X5[?!'!%$!;I&D;'</+  .><\>
MM12Z;8S[/.LK>38-J[XE.T>@R*L*H50J@  8 ':JZ6_KI_D'6_\ 77_,\_\
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MQ);TOZ_@>ZZAK^C:3*D6HZM8V<C_ '$N+A8RWT!-%_K^CZ5)#'J&JV5H\_\
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M9O\ K^NAW%%5K+4+/4HGDLKF*X1',;-&P8!@<$'W%6: "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH ",C!JM#IUC;3&:"SMXI3U=(E5C^(%6:* ()+*TEF,TEK"\I7:
M7:,%B/3/I2-86;P) UI T*'*1F,%5/L,8%6** (1:6RAP+>(!SEL(/F/OZT0
MVEO;0F&"WBBB/5$0*/R%344 00V-I;Q/%#:P1QO]]$C #?4#K4L<4<,:QQ(J
M1J,*JC  ]A3J* ,AM'DM]>.J6#QH;C:EY$X.)0. P(Z,!^!Z<=:UZ** *T^G
MV5UM^T6=O+M.1YD0;!_$5*\$,L)ADB1XB,%&4%2/3%244 <KXX\,W.O>"+S0
M='2SMWN0$_>DQH@SDD!5//'3%3>#/#\VA>';&SU"VL?MUK"(//MB7WJ!@'<5
M4CZ?K7244+2X/6Q7-C:%Y7-K 6E&)"8QEQ[^M,ETO3YDC26PM9$C&U%>%2%'
MH..*MT4 0R6EM- ()+>)X5QB-D!48Z<=*%M;=)_.6WB67;MWA &QZ9]*FHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.MZZ_P %;?5AK=XM_'>NKS@KNE43,N"<<#&.F.E;&DZGID'Q:\7NUY:QHUE
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MCITI/^$U\->5<2KK%J\=NVV9XV+B,^Y'0>_2O./[3T\7WPR,EU"LL,;>:SL
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MS/%YL EA9!*OJI(P:@B\;Z%-?6]JETY-S,UO#+Y+>5)(O50^,$T =#17-?\
M">Z TNHQ1W$\KZ=_Q]+';.QCZ\].1Q3YO&VBPWNF6OFSR/J:A[1H[=V24'T8
M#'3F@"]J.D?:KR#4+:7[/?P#:LNW(9#U1AW%:E4(=8MI]8N-+19_M$"!W)A8
M)@],-C!_^M5V218HVD=@J*"S$]@*.@=1U%8<7BS2Y@I3[2=\;2Q#[.^9449+
M)Q\PY[54?Q_X?CT&SULSW']G7<GE13"V<C=NVX(QD<C'- '3T5YMI^IQZ1\3
M_$XFDO9H!:PRB-0\Q7))8A><#Z5NZKXF\+7NF:5=7=Z[6MW=(;1HO,&Z53@
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M2E3/((H8T4L\CG^%5')-4K7Q=HUWI<^H17#^3;S&WE5HF#K+Q\FTC.>1Q[T
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+)*D]Q]CE^<LLF0X1<9!Z=16K8)>Z'9^,-'OK&_GGO)YKFTFBMWD29'0 *&
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M9?Q)_MF\M[E-/NM+2&*98&8%P<X( )'XUCKH&KZ;#!XA-M,85U^34I+)!EQ
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6]N[BVCEM_*6Y+9CRKDC:<;>>V!TK3UKQNFE>-M+\/\ V.\?[3&\DDL=L[C
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MH\KZ9:W=O;7,S3@7;L9'+<ER&Y&3VKHZ*=_Z_$5CS7PI<QR_$[Q=@3(+H1K
M[0NH<J&#8)&.*Y_1M,L7M?\ A%?$.G>(9-0AN"RQ)-*;:7YRRR!@=JCG/->U
M44EI8;UN>4PROH>F>.]*U2*9;N[>YNK>7RV99HFB 7# 8XQC!-4M)22UL/AC
MJ\D4IL;6&9)Y40OY9>,JN0.<$]Z]3UW3IM6T.\TZ&Y6V:YB:$RM%YFT,,'C(
MYP?6JOA30YO#?ARTTB:]6\%JNR.40^62O8$;CS[T1T_#\+H):_C^-CS19GAB
M^)#365XB7DFZ!C;.1)E< #CDY-,OKZ'[%\./DN#]DD62X_T>3]TH1E);Y>/F
MXKVBBA:6^7X ]?Q_$\M\28TCQ_/J6IQZTVEW]K''%<::\G[ME)RC*G.#G.::
MFF1^%=:\+:E;6-[#X?MX;B$Q-NE>W:3E78<GG]*]4HH6@/4\]\%2EOB!XOG6
MUN4M[QX'AF:!E1PJ'/)'N*D\1QRP?%?PSJ#0RFU6VGB:1$+ .<8!QTS7?44+
M2WE_E8._F><Z/<G0)?$NCZS!<22WE[/<VS"%G%S')T4$ C(Z8-=+X.TVX\/^
M"=.L=0<F:V@_>\[MO4X]\=/PKH:*%HK>GX ]7_74\*%["WPQ\;60AN?M-WJ4
M\D$7V63=(K,NT@;>^#^5;>I:M;3>+/ 5S$MP\5O%()F%O)B/='M ;Y>.1BO6
MJ*%I^'X*P/7\?Q/#M2-SJ&EZ;=/:W-K/;>($>;3K>V98K==S9<X'SL>N[..>
M@I+R[NT^(?B77-.$\D<#6TXM9+=PEXB(0ZC(^\N<CWKW*BA:?UZ?Y ]?Z\V_
MU/*_%&IQZCJ&@>*(8=7DTJ&.2&Z6R\R*>W9PI!*@!CZ'%=5X)T_3+:UO+[2[
M6_AAOI1,TE\[F29L<MA^1^-=5136@C@_'5M?Z5J^F>*=&A,UTC?8+F$''FQ2
M'"GZJY4TWQ!IMSH4_A;4(DEN+'3)66[2-2Q&]<>;@<G!S^=;Z^'[V7Q$VH7V
MMSW5BCB2VT[R41(7QC<6'S/CMGH>>U;]):+^OZ[C>K/.;[3I=?U7Q%J^F1R&
MVN-%:S0E2GVB4AL<'!XR!GWKFI9WE\/_  [CBLKV1]-O(OM:+;/F+8/FR,>U
M>UT4+3;R_!M_J#U_'\4E^AY?X+O(6\1>.6:WG=;FX,T2/"Z><@3!P2/PJ#2;
M*_AU"/2=%N[V?3IK.96@OXCYFF.RX7;(0,C)QMYKU>BE:ZMY6'?6YX[X6LM.
MO8M)T75=-\0C6-+EC/E2S2FWC=#_ *Q6SLV\9Q^%:NA:M:P>.?&]Q+YZ0RI$
MT;FW?#A$(;''.":]-HIO42T."^$EU&_@Y;,K+'<0SRN\<L3(0&D8J>0.HJJM
MY%_PO1Y-LOE_V6+7S/)?;YN\G;NQCI7H]%/JG_7871K^NYXX]G:VFL:YH7B2
MT\03)J%R\L!LY)3!<H_\)"<*1TYJ[K$,@OM7T<6=QI\2:0B6[V\1>6]PI^1I
M<' 7IMX)SU[5ZM14VTM_6UBKZW_K>YY%9V\4OA/PNTESJFD7]EIH6._@B9@C
M84&.1,?,#C]*M6$NLV%YX8\1ZS9-';BTEM;J."(XA9FRLNP9(# <^F:]3HJK
MZW)MI8\@\56[2:3XXUB".?[+JMM#;VB+$V9I%5LMMQGVR?2DNM1BE\0?#R2)
M+AEM89%G(@<",E54!N.,D$5[!126GX?U^(WK^/XV_P CP[4#<7^D:=<M:W-I
M-;:^KRZ;;6S)%;KYQRYP,N2/F+9QSP!756%V-"\<^)I]0MKE(]06)[7$#,)<
M+@@8!P<]C7H]%'2W];+_ "#K?^M[_J>*:CI]QX=\'>$M/OHYOM2:P+V2*.)I
M/)C+.>2H/3<!75>-+>_T[7]+\1Z&F^>\7^S)UZ963E)#ZE3S]*]!K A\/WK>
M()=1U#6IKRU5]]I8F!$2W.,9W#ESUQGUH_SO^2M]P>?]=_S-;3[--/TZWM(A
M\L,80>^!U_&O&?$_VK4_#VL VES:W$&L(XT^UMBJ%1*O[YR!ER1SG.!Z=Z]O
MHH^U?^M[ATL<%XRAO['4M'\5Z-;2SW$0-G<0*,&2*3[I(_V6P?SI?$Z2Z)I?
MAZT2V$D8NU$U^T'G/:D@DR*N#\Q)/)! ST-=Y10!XE*IL-!^)%M)'?RF[(%L
MTT+N\Q:+ / YR:TM;U& Z=\.\)<-]FN899PMNY\M5B*DMQQSQ7K=%"TM\OP!
MZ_C^)XIXO-SJVC^,[<6EQ9SK<*T5G:6Q'VI0$Q-(^/G)'88QCO71070TOXCC
M6+R*XCL+K1XH(I_)9@9%<DJ< D''K7I-%"TM_72P/7^O.YXGKNG76F?#V^-S
M;SI-JFM)>06B1,[)&)58D@ XX&3]:U==DCT_QO)K%_'K3Z/JMC#'#<::TH\M
MDW91T3YL'<",^]>KT4>7];6#S_K>YB>$M,L])\.6UII]K/:V@+/'#<.6=0Q)
MYSR,YSCMFMNBBFW<$%%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MVA7VJ3QWL8L'\N[M3;DS0-C(#*,@ C'.<<]:?_PG&GC4K*Q>SU%)+^$S6;-
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MT-@R)>W$$:M';%\;0V6![CH#BI[GQGI\'B'^PDM;^XOS;FY1(H/E=00/E9B
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M(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!#=0&YM98%FDA,BE?,CV[ESW&X$?F#65X7\,6WA32VT^TN[NX@,
MC2C[24)4L<G!55ZDYYS6W10 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% &1XD\/P^)]%FTJYNKJWMIQME-L4#.OIEE; ^G-7=-LAING6]DL\LZP
M((UDEV[B ,#.T ?I5JB@ HHHH Q];\/1Z[+;--J.I6\4).^"UN/+CG!QQ( ,
ML./4=36M'&D,21QJ%1 %51T %.HH **** "BBB@ [5S^A>$K?0=7U/4H-1OY
MY=2<27"3F,H6' (VH",#CK7044 %%%% !1110 4444 %4-8TFVUO3GL;LRK&
MQ5MT3E&4@Y!!'N*OT4 9EII#V^S[3J=[?B,@H+GR^".A^1%R?KFM.BB@ HHH
MH **** ,6\\.1W&L-JMMJ-_8W;Q+%(UNZ%9%7.T%75EXW'G&>:TK6S2U#'>\
MLK_?ED(+-^6!^  %6** "BBB@ HHHH **** "BBB@#+UG0K?6OLKR7%U;3VL
MAE@GMI-KHQ!!Z@@\$C!!J>TTXV[+)/>W-[*HPLEQL! ]@BJOXXS5VB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MWL]\8]JZNDMOZ[E/<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MDOU%DNJ7,CV;(/W@8_)(#U(X^E;_ ,:+B)?AGJ=IOS<7'E"&(<LY$B$X ZX
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MTJ=Y[4DJ)6A>,-]-X&1[CBO+O!FH?\(T_BOPMJ1AMHX_,N;14E,D:JZDL@?
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ KE=6^'^CZSJ<VH7-QJJ33$%E@U"6-!@ <
M*K8'2NJHH XC_A5>@?\ /WK?_@UG_P#BJ/\ A5>@?\_>M_\ @UG_ /BJ[>B@
M"EI&EV^BZ7#I]J\[PPYVM/*TCG))Y9N3R:NT44 %%%% !1110 4444 %%%%
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M6^N<721++(D<;-A3G+8 .%X//;C-%@N;-%9&G^)M*U2[6VM+GS'=2\9V,%D
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MT%);8L#GN"K9_//X4["N:5%<UXAUG6='6YOH[6Q.GV^WY9)6\V?.,A,< \X
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M2X]3&%X_$5SOA+3M8U+P]X6CN;6WM[*P5+E9TDR\OR$*NW'RGY^?7'O7HM
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH 6BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1
MBBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@
M Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1B
MBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@
MQ1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BB
MB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q
M1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB
M@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1
*BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>thackray-biocrystseparat002.jpg
<TEXT>
begin 644 thackray-biocrystseparat002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "FM(B,JLZJ6.%!.,_2G5YOH5M9^)V\<0Z_#')=PZG-;Y
ME W06P0>24)^Z,98$8YR: .M\3:]_85K9;$5KB^OH;&'?]U6D;&X^H !..,X
MQD9S4^C'6P;N/6?L+A)?]&FM R^9'@'+(Q.T@Y'4YKRV:.35_A]\.+W7;:*X
MOYM6LXI)9XPSR1$OM!)Y(90I/KFO8H[>&&V6WBB2.!5V+&BA5"^@ Z"@!WF)
MNV[UW'C&>:!(C.R*ZEU^\H/(^M>/Z'HMI;>#O%6N65D&UC2[_53I\HR6@(W
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M7SB!U8#OUI?"RSZ9XGM-"\0:)9QWS:=+#::E88\F]@4IN#KC*L,*>>/F..M
M&OKVO^(?#^@6%U<+I<UU-J<=K-Y0?8(Y)=J[03G<%(SGC-=BKHY8*RMM.#@Y
MP:\2AA0_!C28/F6/_A(E3Y6(('VYAP1R/K74KX>L="^*^FPZ%;+;VU_IUP=4
MMXO]6RJ5$;LO3<68C/4\^] &KXFU[Q!X:\ ZEK$JZ7-J%HS,%C#^5Y>_"Y&<
M[L$9YQG-=%.VI'4=.-LUF+%M_P!K$N[S3\OR>7CCKG.>W2O(V18OV>/$,:#"
M)<W2J/0"Z.*Z_P 0PQ+\4? DX0"5TOE9NY @&!^I_.@#K+35[74Y=1@L)DDF
ML93;R'JHEV!L<>FX9]\BGZ6U\-)MVU5[0WH3]^UKGRMW?;NYQ]:X#PEI.E>=
MX[0V-HK?VI/$N(U4A/)C.T=P.IQ6+I>H?9?!OPUM;JX@@TV[1UFDN8]\)E"'
MRE<9 .26QDXR >U 'LBR(T?F*ZE,9W \8^M".DBAD96![@YKS:X\+"UM-7L=
M(UVT%U=WUO=1V<D&+-)02WEE03@2;,D9]#CD5L^ [\3SZW9W&B#1]5@N4:^M
MXF#0NS1@+)&1V95!QU]: .PDD2)=TCJB^K' I2R@ D@ \ YKC->^PWOCRRL#
M&MQJ$>FRS>7>$&UAA9U4R%,99\C  (XW9(XSP-A##??#7X=F9S)(NOQP!U<A
MA'YLR@ @Y PH Y[#TH ]P5U?.U@V#@X.<'TKFO%'B*\T;4M!@M%M9(K_ %*.
MRN-^2Z!E9L@ \?=[^M<5J);PGK'Q 'AVW2T\O1H+J.&W0*J2XD!D"CC.!GWQ
MS4VK6.C+8?#C4-.B@)?5+8+<+C?(&C<L6;JQ+ $YYS0!ZM7,>*O$5YHEYH4=
MFMK(E]JD-C<"3)=%?)R ",'"GKZU<\97UYIG@O6K[3P3>6]E+)$0,D,%/./;
MK^%<!JMEH_\ 8'PXU&QC@:235[+%R,%Y-RL7W-U8EADY[T >L[AZBJ5YK%E8
MZAI]A/,HN;]V2",$9;:C.Q^@"]?4CUKSN&&SAN?BG!)' D"[',; !1FU!!QT
MY//UJC:V%A=R_"1KNTMIA)I\B2&6-6W 6@(!SU .3]: /4H3J7]LW(F:S_L[
MRD-NJ;O.#\[]^>-O3&/>K@D1G9 ZEUZJ#R*\SF:73O&OC^YTE +M=#AGA"#.
MZ7;*00._(%&@:9I6J6WA7Q#;:U:QRQ% AM( LMPSJ \4IW$MW+9&002>] 'I
M@DC+E ZEQU7/(IU>5Z0;C0O$&AQZM86NH6-U>R-I>O6F!*7E20[)U(R259N0
M<?*,]*]0AN(;C?Y,T<GEN4?8P.UAU!QT(]* )*Y2S\1ZE<?$._\ #<D5H+>T
MM$NO/4-O<.<!<9P,<\\_2NKK@-- ;XX:\I (.C6X(/\ OF@#0DU_6]5OM7A\
M.IIY.E7:6SQ7@;_2#M5GPZGY,!L#Y6Y'O77$@=2!7 ?#_2].@\1>,)(;&UCD
MAU=HXF2%08U\J/Y5(' Z\"M+XA^'#KOAW[3:6\<NK:9(M[8[T#;GC.[8?4,
M1CIT]* .NR,XSS31(C.R!U+KU4'D5YM+J[:_X9USQSHUO^_CTIH-.8Q_.I"%
MY6'J0QVX]8CZU4U:VMH?!?@[6_#Z(NI?:K(0SQ??N!+@2(YZL&!);/<9H ]5
MW#&<B@LHQE@,],GK7ET4-G%-\5()(X$@78_EL %&;4$''3D\_6J$&FV6HO\
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M%@K E3@@'H:\/AM()?@CX=W*<QZXJHP8AE!OG!P1R.*Z=[;3/#7Q*UD6T?\
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MM9KF!'V//&K[@NTN <GH/J:JZ8;\O?"_N+24"Z80"W4@I%@%5?)/S]<X]10
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M%C+E45V=8PS%@BEN2JYP,]AT'2M6D5U=0R,&4]P<BEH **** "BBB@ HHHH
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M ORH"MU48)X'')/>O:++0]+TV*2.SL+>!)%".$0#<HZ*?89.!T%0?\(MX?\
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MHNV-MH."2>WJ:W;?4["[BEEMKZVFCB_UCQRJP3ZD'BO'9[J:U^'^M2KDV/\
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M1D+\V6]N0#K[G3[*]LC975I!/:$!3!+&&3 Z#:>*9'I&FPV+V,>GVJVDF=\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M95:1@ [>='P,]3[5UPT+2!"\(TJQ$3L&9/LZ;6(Z$C')J<Z=8DVY-G;YMO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MMK(XUJ!H(88P<3QWZR@-QU#YW$]\$GI72RW*6_QBNGF/F-'X7#.D?WFQ.Q(
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MRWCH'6W:51(P]0N<XKR7Q-J6I2_#OQW8:Y:V<>I68@6:\LR?*N]VW:<'HX4
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MO$TR*561D!90>H!ZXJ:B@!D,,5O$L4,:1QJ,*B*  /8"GT44 %%%% !1110
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MQ8#@ACG@'"YK+NGL/^%*^-9(VM]S:O<D,I7)/VD%.?ITKV];:!%55AC54SM
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P +Z??7MC=:JL=W9+OG@,4A=1P<A0N3P0>,\<]*B_X61X/\NPD&N0&.^8)
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M2CJLRXS\K$!6/J <CTJSJ/BW0M)NY;:]U!8Y(51I\(S+ '.%,C $1@GIN(H
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ML=6:=;220O;L%FCEA>)XR1D JX!''-7Z "BBB@ HHHH **** "BBB@ HHHH
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M9L?4*1^8KMY YC81E5?!VEAD ^XXS5/3-+ATN"58R7EGE:>>9OO2R-U8_@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH ***H:CK%EI3VT5S(WG73E((8T9WE8 L<*H)X
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M="NM9DOBEG:2&*X)A??"XZJZ8W*?8CO0!OT5B6/BW1M1UG^RK>Y<W;1&:,/
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M0POP-KR ;5Y(!R>,\XK)UJZNH?B?X4AAOK@6EW;WAEMUD_=N41"IP.OWCUH
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M<#QZ5V5% 'E][J&DW?A[6]>\.^&[G4[@6/DR/J,$S>:"R_N]DG,@4;F(''
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M" ?G(''!!(&2 03@$54U'Q[H&FW9M9;B>6?[)]M5(+:23S(L@;D(&&'.>,X
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M/FUN!8=1:,^<BILS\QPVW^$D8)'8G%;= !1110 4444 %%%% !1110 4444
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M444 %%%% !5>2SAFO(;F0%WASY0)^5"006 ]<$C/H3C&3FQ10 4444 %%%%
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M;TP"<]N]=1X[CNFG\.^(;;2+C5;*QED^UV*0GSC'(FW>L;8)*D=.O/XUWM%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]J2>PDT8!KU+D+F-"F\,"I8$%>>#GCI5<>-K1;_2K.;3=2BDU6,R69,:,)%
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MDE<$@ KM;))P-IYKE=%UF#3_ !_XYU&_BN[.WM+*TEFCN&WE<"0DKAF&#Q@
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M6#?E78W$ N;=X3))&'&"T;;6QWP>WU'/IBEM[>&TMH[>WB2*&)0B1H,!5'0
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MSN#8/'&:]0HH X+7_"^H6/A#PZVC+]JUGPYY!MP3CSU51'*A/8,N?R%+XO\
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M8^@)('YFO(/$.OW/BKX)7>L7]C);R"Z1HVWJ5Q]L";5VG)PHVDD#/;->Q5Y
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW=%)N&W=D;<9S[5R<_CVTM](BUU[*?\ L"241_;PR_*I;:)2G7RR>_7D'&*
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M2>]AD58XY00/+"'YB#DX/M6O110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4CNJ(SNP55&22< "EJIJ-A::C:&"^@$]L"'>%EW*^.S+_$.^/4"@"2*^
MM)K5KJ*Z@DMU!)E20% !UYZ<5."" 0<@UYW\/FT5?%GBZ/2HY+#=-"3I<ENT
M'EA4P90A P')/3L!GK6IX8OVM/%WB'PN3_H]D8KJR!_@BE7YD'LK@X'8,!T
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !6?K%SJ=I:QR:5IT=_+YH$D3W A(3G)!(()''!Q]:T** .?
MTW1YY/%-QXDO8$MKB2S2RC@5]Y"!RY+D<9)(&!G '4YXS?#MB]U\0/$_B#'^
MC,(=/MV_O^4"9"/8.=OU4UV$B"2-D;.U@0<$@_F.120PQ6\*0PQK'$@"JB#
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC*QMG[P;! 88Y'2L>7QSX@;1O$FHV^C:>!H-W-%,CW;'S(XD5CL(3[Q!)Y
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M8!3@?-VSGVZT =A17$6'CR9]#FEO;&)=5BU<Z,((I3Y<MQN !#$9"8.XY&0
M>#5VZ\2ZEH0U>77-.7[%96RW$-Y;'"SD\>5M)R&S@=<'/:@#JJ*Y&Q\5:B_B
MBRTNYT[S;6]B=A=6T4H6V=1G9(74 @CHW&2,8KKJ "BN0\3>*M1T--7N$L[:
M&TTVV6:.2\D*_;FVLS1Q$=" N,\\GIWHN?&L9U#2;&&2TLY=2L!>P-?,0LI.
M,1*1CYN<GKCC .> #KZKWU_9Z9:/=W]U#:VT8RTLSA%'U)I-/EN)]-M9KR 0
M74D*--$#D1N0"RY[X.17 >+=>O?$'P]\5W6FP6QTR"&YM0TK'?-L!6212.%
M.< YW;>V: /1898YX8YHG#QR*&1AT((R#1++'!"\TTB1Q(I9W=@%4#J23T%<
M;;^)6M;32]&L_*%VNE0W,DDT<CHBL-J#"#))*MW& .^:P/%?B'5==^&MM>'3
MSITLFHV\%U;W =3D7" ;<@91NN2.AH [RU\5:!>Z@FGVVKV<EZ[,JVZRCS"5
M&X_+UX'/TK8KCKF^;3?'FA6L^BZ;]KU>.?S;^+_6#R4R%Y7.,,!G/KQ69/XZ
M\0_V7XEOK?1=/V:!=2QSA[MCYD<:*YV83[V"3R !P.>< 'HE%<K=^+P]W;66
MGA%N)K%+YGGC=U1'.$!5!DDD-W&,=^E4]/\ '5U?V.D0-I+VFM:E<2VZVUSN
M5$$0W/+D@%DVX(X&2P'')H ZNVU73[R]N;.UO;>>YM=OVB*.0,T6<X# =#P>
M#Z4DNJZ?!J5OITM[;I?7 )AMS(/,< $DA>N  >:XSPE]K_X6CXT%ZD F$%@-
MT.=KC;)AL'D?3)Z=32^-7NH_B!X(>QMXY[K=?"-))-BDF ?>;!('<X!/'2@#
MOJ:[I'&TDC*J*"69C@ #N:X:T\?W%E#K]OXBTZ.VU+1A$S):R%X[E93B,H2
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M<Y.1@ 9(!UUI=V]_9PW=I,DUO,@>.1#E74\@@^E35S/P[_Y)OX;_ .P=!_Z
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M>F.D.NDW=M)#>>?(#/%"P*ADV?*<  \GI^->@ZEK&G:0D3ZC>PVPFD$47F.
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MI=^7<NR)(H5E(W*I(/S9Z'I4-CHFM6OCG4]=D2PDANK&&W15G=6WQECDC80
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MQ97"J #R 1G'2L^ZT/5K?QS)XBTX65Q'/8)9R07$K1%-KLP8,JMG.[&,#ZT
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M \L%64! 2 3RW3'?-1VWAKQ9H6N:D-!U#2SHVI73W;+>HYEM9'.7,87A@3R
M2/YY $%PLWQATZZ9'A$GAJ60K*NUD!GC.&'8CO1-XWU'_A#F\96MI;RZ.K-(
M;4AA.UN'*F0/G:&P-VS;TXW9K2?PY?GQ[:ZSOMY;&+2VT]UEE;S7W.K%S\N/
MX<8SSG/M63:>"-7L_!UUX+6YM'T:0O%#>&1O/CMW8L4,>W:S $@-N'4''&"
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M>7(CH'4@-R#@X-1:WXK-AXHCT%+FQLKB6T%Q;O?!MERY9E\M6! !& 3U/S#
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MJI_@"J&D(]V8C/LB^E<CH.L^(] \):WJFEZ;876G6.K7TUS'+,RS2()6+>6
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MW=G&>V[\: )J*\P\,>+-3T[X>PZKJ4\-]=WVI26EK'Y9C+3/<N@W-N(VCK@
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MC-:% #)(HY2ADC5RC;D+#.T^H]#3Z** &+%&DCR)&JO)@NP&"V!@9/>GT44
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/W5QCIG)Z5')XE\3&_\ !ULKZ:C:[#-),'M74PE8?,7CS#G&1D<9*]1G@ ]
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M9]J@9)PH)Z5</3CK7E%I+JESX-^)DE_J"W*QSZC!@P[3\MNH!!SP H QC\:
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M8/3))SBN@B\0ZMI/C2YTK6KBTN;,Z4^II);VYB:'8X5DY9MPP<YXZ4 =K17
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M;D.\:E58[(^0"3C/IDTGCX7)\3>"A9F$7)U&41M,"44^0_) Y..N,C/3(ZT
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MSN.1A1Z=ZS_#G@_7M"$&F2>)OM.@6K V\!M@L^P'*QM)GE1QVR0,<#BNVHH
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MU&_AL+<R E$>1L;F QD !CCO@"LZ76=5T;QOI^@75TEW;ZO;3-9W$D(#PS1
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M))P!CDGK7/1^&+NT\6:KK=EJJQ)J440EMI+;?AXU*J=VX?+@\C&<CJ* //\
MPCJVMZ#\.O!=_#=VQT^>[BLI;,P99DEE9=_F9SN!YP!CZUU=_K^OZJ^NKX>C
ME$NF3FVMU6*-TGE5%8B0LP(!+!1MQC&<G. V+X>74/@W1?#J:U%MTN[CNDG-
MD<R;'WJI'F<<GDY_*K%QX+U6W\27FK:!XD;3(]1*M?6S6BS(\@&/,3<?D8@>
M_OF@#JM,GNKG2K2>^M?LMW)"K3P;@WEN1\RY'!P<\UQ=Y_R7C3/^P!+_ .CA
M7<VMNMI:Q6Z,[+$@0,[98X'4GN?>N9OO"NI7'CB'Q-:ZO:PR0V;6:02V+2+L
M+;B21*ISG'^% &!\2E%AXM\#:M9#9J;:LED63AI('^^I]0/TR:LKXGUG_A&O
M'-R;F,W.A7%PMK)Y(^98X5D <=#DD@D8K=M_"0E\1PZ_K-\VHWULC):((Q%!
M;!OO%$R3N/=BQ_"LN]\!WTS>)K>TUQ;?3M>5WEA-H'>.5H_+)#[ONG )&,^A
M'6@!P\3:AJ%WINEVPF2XETF+4;B:VCC9@7.U0H<X R&)Z]AQUK:\)W6NW6B
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M#P .^: .PCBCA0)%&J(.BJ,"GUY7K/C3Q#IWAGQE;K<P#5O#LL6V[, (FAE
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M!21@CDX]@/2M+7/!XUWP[8:?-J,EO?V#I-:ZA;)M:.5!@-M)/!!P1GFNGHH
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M<LLHRI)W?-D$<DUU%% '':IX#35/#VM:>^H;+O6I5DO;P09)VA0JHN[Y0 H
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M2LZQA77<6!VA0!@D\# ]<\Y@3X?0Q^&M&T)-5NA;Z3=1W4$FQ-[-&VY W&"
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M,-'<1YR-R'N#T((/;D54O? =G=:-#IL=]<P!+\:C+.H0R37 ??N;(Q][L .
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ML76H+&P94DCCC4L.C,$49(Z^F><9 H X;Q7KVJZ98:WJ5IJL]Q<V6I1+']E
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M8&#P.*CT(ZUX@\/Z!XD@USR9KATN;R%P&@:!L[H57L1P W7(.<YK1\.^"8M
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M=V<CTQGD4 =-161J6NM8:S8:9'IMU=RWBNX:%D"QJF-S/N8$#YEY /) K7H
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MR3 2P2 DY5L>K-U!Z_2GIX"TI+C4KC[1J+3ZE D%Q*UTVY@H.&_WN3SV[8%
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MRE&5 0H  XP">_?G-9B?#S2H]$L](2[U(6EG<)<0 W&XHR'* $@_*IZ#\\T
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MDRFXRG:1N))XW9&%'')SVP!"@$DD#J>]8ESX6M)-;FUBTNKNPO;B)8KE[5E
MG5?N[@RL,CH&&"!WH \VCU/4O$NF^!'U"Y>.^76;BUDNX5 +^6DJ;U!! ) ]
M.N:W[#^T=%\5^(?#<FIWFHZ<VD#4('O)/,D@9F="F\\D';D9Z8^M=/=>#M)G
MTW3;*%9K,:9();*6WDP\+X()R<ALY.=P.<G-6(?#MK%#?CS[A[J_4)<WCE?-
M< 8 Z;0 "<   9)QDDT >=V]U>67PH\ 36=[<6Q:[T^&58FVB1'< JW?'MFN
MAU>_F_X374+#5KVZLM-_LQ9+![>5X]TF6$ARI&YQ\F%.>.@Y-:;>!=-;P_IF
MB_:KX6>FS1S6P$B[E9#E,G;R ?\ Z^:YC7;7S?&>H37Z>+=/S'#!;W6BB1X[
MF-03E_+# ,&=Q@@<<]S0!-82:U%X-\,KKVK7\6J7ERKW%H!BXN?E8^2A7:8^
MBLQ)&,')%<[KUQ>7WPP\?VM]/=E=.U!H[=9+EF>-,1L$9P<N!N/!)_' KM;/
MP>=5TRT.JW^K^=97;7&G74LRK=Q(5 *NRC!R=W!&=I /(-7!\/\ 0Q9ZW:-]
MLD@UCFZ22Y9ANP 6&?XOE!R<GCTXH S_ !";G2==\&06>H7J6\]^T4T33LXE
M7RG;YBV6/('!./:H])EN?&3^*FDU"\LYK'49=/LQ;3M&(!&JX<J" Y9B3\V1
MC K<F\'V=P=):6^U!Y-+E\Z"1Y@S-)@@LQ(.>"1CI[4Z;PC9-JE[J%K=7MC)
M?J%O$M9%59\# )!4[6QQN4J?>@#@]-U_6O$G_"NKJ;4KNR;5%NX[R.W(59#'
M$^&QCJ=N1V&01T%7K*;7XK+QKH^EWMQ>W&G7T(LOM=R?,*.L;O$)3R"0652>
M02.:Z^;PCIKWFBW$+36HT966RB@*A(PR[#D$'.5XY_GS4)\%V)DU607NH+)J
M<T5Q.ZRJI$D14HRX7C&Q1Z$=: *7@C6[/5KO4TB;5+:ZA$2W&EZFSM):M\W*
MEB<JWJ#V]P*7QU=W5C>>%I+2ZGA,^MP6TPCD(62-@Y*LO0]!6[I^B06%_<Z@
M9IKF^N42.6XGV[BB9VJ H  !9CT[\TSQ#X>L_$EA':W;SQ&&=+B":W?9)%(A
M^5E///7MWH Y2>[OQXM\:646HW<<,&E0W$ $I;R9")"2F[.,[16/8W.J6FC?
M#O7&UO49[C4KBVM;J*:<F*1)(68Y3IN!4'=U]Z[*+P-IL-Y?WBW>HFZO[46M
MQ*]R6+J 1GD8SR>HX[8I3X'T\Z9HVGB\OA;Z-*DUF Z91D!"Y.WG )'/KSF@
M#FFN9?%OAWQM>W%Y=P_8I[NQMHH)VC6)84QEE!PQ8Y)W9X(%0Z!J-W=6?@[P
M["0(6\-0WC*+Q[8RL%C0 .BEOE&3@8SD>E=1<^ M+GU'4KN&ZU"S&IH5O8+6
M?9%.2,;R,'#8[@C/?/-17GPYT2[TG2K%9=0MY-)7;97D%TRW$*X P'YXP ,8
MQ0!S.KQ>*-%T71[6[\0R>>WB2"V22WFWM]FD8%4E9E!=@/7J,9S7HFCZ6='L
M3:F_O;[,C.);V7S)!N.=N[ X':LJY\$:=<Z=8V3W5_MM+I;U93/NEDG7[LCN
MP)8C\N@Q@#'2*"% )+$#J>] 'F7C6_O(;?Q;=6.JWTUQ86Z20BUE:&+3RJ;B
M'^;$C,><8; (!P"*MW<NHZCX^T*S.KWUO:7VC2SS0V\@0;@8^1@9!^8\]1V(
MK9O_ (?Z/J%SJ\LDU_''JZ;;NWBN2D3MMV[]H_BQ^''(JQ;>#K*UU33]0CO+
M\SV%L;6$O*''EG!8'().2!],<8'% ''6<.O:OX#\16ECJ^H-J>CZM=06,QN&
M\R5(F!$;L#EL@E<GVKH]!UF'Q=?Z9J.G7%PEA;V(EF03-AI9#A8WYY*!'SGN
MRU*8+;P'9W-Q:V>M:H-1OS--%;1+,ZRR<M)@;<+P,]AQQ5[PEHB:)H[J+5+6
M>\N);VXB3!"22,6V\<':,+QQ\M $GBVX:T\*:E,FJ+I3K"0MZT?F>23QD+W/
M. /4BN7TFYOO^%B76C++J=K83Z(MTL5U<^;(D@E*;P6+;"1VSVR0#78:]HEE
MXCT2YTG44=K6X4!MC;6!!# @]B" ?PK*M_!%A;ZO%JRW^J/J"6IM#<2718NF
M=PW C!(/(&,=\9H \_TR^UA/A_X/\32:]J4M]-J,$,R/.3%)&\Q1E9>C<=SD
MCM@8%=98W,OBO6?%44UY=V\6F3"RMHK>=HBA$88RG:1N)8\!LC"].3F^O@#2
MT\.6&@I=7RV-A.MQ HD7<KJVY<G;D@-DU/<>"M/EUZ;6(+N_L[JZC6.\%K/Y
M:W048!<8Z@<97!H I?"G_DEOA[_KU_\ 9C5?Q1---K.I00:C>RO#I>]+.RE:
M#[*Y+'SI) PSG  4Y/RGCK72^'= L_#&AV^D6#3M;6XPGGR%V_/M]!@52OO!
MFF7^N3ZL\M[%-<VXM[F."X:..X09QO Y.,GH1Z4 <;=ZA<ZKX9^&%_>2>9<W
M&I6DDKD8W,8),G\:WM._Y+)KG_8(M?\ T9)5N/P#ID.F:-81W>H"'2)EGM29
M@Q#J"%)R#P 2,=/:M*#P[;6_B:YU];BY-W<0K!(K,NPHN2HQCC!).<]Z (_&
M%PUKX5O9$U7^RVPJB[\LR%,L!A5')8YVC'.2*YO1K_5(?'6M:9 MXL']DQ7=
MM:7]R9F64LZYW%F*@X&1N]^*ZWQ!H-EXET:;2]0$GD2%6W1/L=&4AE93V((!
MK$NO"4.ER7FO6 U#4=973VMUCFO6 N2-Q4,>!G)QV [#/- '*V-UJ^K:;X2:
MRU35!J\]SLUJ-93^[0!O-+(V5CPX 7 &<X&:U-.LM0UCQ_XILY_$.K16NG7%
ME+!'!,%',>]E/&"IY!'?/.<#&1HVCR+8VUKHNH>.K2_@C5([>]5UMHF   ;S
M%V%!Z*Q..!7H>G>'+;3==U+6(KFZ>YU'8;A9&4HVP;4P HQ@<<?CF@#A],D\
M2>*O#&G^)=.U"&SNGG-P\DNH2^2(U<AHGA";  HQGKD9SFK)?7?&"^(AIMY]
MDN[+4);.TE74)(A;F/&"T2H5<,<D[LY#8XQ6U;?#K1;/6)KZVGU&&">;[1+I
MT=VRVCR9SN,??GG&<>U.O_A]I%[K\VL1W.I6,]R +N.QNVACNL<#S .O''!%
M &,@U34/B-%I=YK=T+>;PZES,EE-LC,OFA6:,@ @''!ZX[\FN;FNM9C^%NK:
MT?$&J-?:)?3PVK^?@.L<^T>:!_K,C@[L_P \^FKX8M(_$8UR*>XBNEM/L2(A
M41K"#N"A=OKSG^G%4&\ Z8WAR_T%KJ^:QOYVGG4R+N9F;<V#MR 6YH I7U]>
MZUXTO]"C)6&TL(9U1+^2U=FD9P7#1J20NU1C( ).<Y&,:Y3Q-8W/@K3-2\12
M/=RWD]M=RV;C;*HC=E+949<#'48R,XS74ZUX%TW7+JROI;S4;74K2/RDO[.X
M\F9D[JQ P1^'<U-+X.TZ232'2>[C.E.TMOME#$NP(9W+ EF.3DD]R>M '"ZF
M+E=!^)NASZC?W-KIMNLUJ\]R[2+OM]Y4OG)7<.AXQQ6K>'4M&\-^&KBQL]2U
M+2TMM]_;6MX_VGF--KI\P9E7YLH"!\P]*Z4>#M.:XUV::6YF&N1B*]1W&UE"
M;!C !7"G''\Z+;PC;V46GK:ZIJD4EC&\4<QG#LR,$!5@ZE2,1KCCC'K0!+X/
MO[/4_#%K=V&H37]NYD*33Y\S[[?*^>=R_=/TK<JCI.DVNBV L[-6$>]Y&9CE
MG=V+,Q/J22:O4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 5A6?B-KKQCJ/A]K%HC9VT=P)VD!\P.6 PHZ?=/4_A6[7G%SHZZW\6=;M9+Z
M^M8O[(M2QLYS"[?/)CYASQZ \]\T >CU#=74%C:37=S*L5O"ADDD;HJ@9)/X
M5Y1I'B+6OLVE>'[N\>Y)UN]TTWDT[0O<QP*2@,B@D$G R.3MQGDTWQQHFI6'
MP^\7QZCJ'G69$-S96@O)97MLL%8,[8+(3R <@8/I0!Z_17">)HI/#6K^&]6A
MO=0&EK=?8[Z&2]E=-LH(CD;<Q^ZY R>S>PQAZ/JUU]M\0: ]Y?\ G:I(EQHT
MLMW([_9924W(2<@)M9_7!&: /5Z*\^F:\USQ1KOA^&601:9;V\< .I302+O0
MMYN5!+G.!ECQM]SFO;W6MOK.D>%=2OX+^XCTR6>>6.[DMA<R++Y?WD!8E5'*
M\<DD]!0!Z317E6K6GB#1M)T*SNO$5P\Y\2P6ZO;W#,RV\AW".1F'SL..6'(Q
MD5N^'!/IGQ'U[1EOKVXL?L5O=HEW</,8Y&9U;:6)(!V@XZ4 =Q16!XSTF^UG
MPO>V^EWUU9ZBJ&2UEMYVB/F#D*2I&0>ASZYK#T;Q"GBE=.U2S:Z6#3]/:XNK
M=)W&9SE1"XS\Q4I)G=D\J>] '=T5Y++J.H7'P>3QQ!JETNM)']N+B=_).)/F
MB,6=NS&5QC/&<YYKH=)NKFZ^)6IVDL]VEK+HUM<?9FN'Q%([N&*C/RG  XQT
MH [FBN0^&%Y=7_P]TZXO+F:YG:2X5I9I"[L%GD49)Y.  /PI_B!OM/BNRL5O
M+J=C9RO_ &7;2-#G+*!/)*K A1RH')).0"10!UE%>.6VJ:Q??#[P)=R:Q?1W
M=QK:6<\T<W,L?FRK\V?O'"+U!SCGK6C=:Q>>#=4\<):W5W>066EPWUO%>7#S
M^7*V]3@L2=I(!(SCCC% ':^(/$;:#>Z- ;%ITU*^2S\T2!1$S G..2>%/^-;
MM>6Z]IJ11_#^_P#MUW<SS:O;&626X=UF+1.V_:3M!STP!@' XKU$D*I)(  R
M2>U "T5Y-#J%[!<^$+VTU.^O([W56MY]0EF9([U'60_+!N("#:,'CIP,'-+-
M:WE\OQ#$NMZNHTR0O9B.]=/*86X<<J02 ?X?N^U 'K%%>9ZCJ%_::'X-\;37
MUX;5(;?^UX$G=8F26,#S2@./D=@3QR"<]*Z[P\6O;G4M8\^=[>ZG,=K&TS-&
M(H_DW*I.!N8,V1U!6@#>HKBOB')=PR>%S::A=VAGURWMY?(DVAT8,2".AY4=
M<BLVRTEY/B!KOAY]7U@Z6;&WNQ%]OEWK(S.IVR9WJ/E!P"!GVXH ]'HKR70O
M$FJW7A;P58SW;S2ZE=7<$T\URT32B%I BF106!.U>1R=N,\FK'B2QU[0/!/C
M"1];ECC6);JPB@O)))K3J&'F, Q0D9 [<B@#U*L3Q=X@;PMX8O=:%DUX+5-[
M1+($R,XSD_X&N2U"SNK3QOX5@AUG55CUBWN4O5-VQ#[(U=2H/$9SD90 X/KS
M6%K4EQ!X$^)6D/=W-S;:?,%MC=3-*Z(Z1N5WL22 2<9- 'L<;^9$CXQN4'%.
MKSB_M+_PSXL\+WEGK&I72:K<FTO;2YG,D;@QLP=5Z(5V_P ( Q^.:>F'7_%G
MA:T\166I16-Y]H:=[A[^7RT59"&B>';LVA1CUXSG- 'J=%><Z;IMSK'Q!\56
MEQKFKI;:?<V4UO%#=LH!,>\J?]DG.5Z<_3'6>+M7GT'P?J^JVT8DGM+626-2
M,C<!P3[#J?I0!M5@:KXBGM]3FTK2K!;_ %*&S^V/"\_DC86*J VUOF8AL X'
M')%<IK$UYH?A[PQXAT[4;VXN9KFTCNEEN'D2\2; ;Y"=H.6!!4#'0<<59LM,
M@/QJU5O,N\KI5O,/]+EQN,LG!&[E?]G[H]* .YLKE[K3[>ZFMY+5Y8ED>"7&
MZ(D9*MCC(Z5B:SXMBTQ-!FM[4WEKK%Y#:QSI(%5!("5;U/ )_K5GQA ESX,U
MJ.0N%^Q3'Y'9#PA/4$'MT[]*\[NK)8OAY\-DAFN$:?4M-8NTK2%"83]W>2%'
MH ,#TH ]>HKRR[U:^\(ZAX[BL[N[NH;+2X;ZV2\G>?RI6#AB"Y)VY4$C..*W
M+#2M776=&U>VU2./3WC*W4;ZA+<B]5URC*'4*K \Y7J#CI0!VSNL:,[L%51D
ML3@ >M<[IWB>?7;<WNBZ4USIVXK'<S3"+S\'!,:X)(R#@MMS].:9\1([N7X=
M>($L@QG-C)@+U(Q\P'_ <U+X#EMIOA_X>>T*F'^SX%&WL0@!'U!!!]Z +^B:
MPNM64ER+2XM&CGD@>&X #JR-@YP2.V>">*TJXWQ;JQMM<\.Z-;S&"'5=0:.\
MF@;:^$BW!-PY4L=@R.<=*S;B6^TOQOJOA^WO;PZ;=:(^H1[IV=[657V'8[$D
M*W!QG@CC% 'HE%>.0G48_!O@'6TUS51J%]>6=K/(UTS*\<H(8%#E">^X@G/4
MFMQ$N=+\7^)]&M]3U$VAT:.^C\ZZ>5XI=TBDHSDE<[1QTH ]'HKQAAK&G_#S
MPQXS@U[59]2'V,3P2W+-%<1R,J%"G0GY@=W7J<],7?&NHWEMHWBK5=-U2^N;
MFPNX]EQ',T,-D5,8, 4-B0\DM\N/GP3D8H ]:HK@;ZVN-0^+4FER:IJ4>GRZ
M%Y[V\%TT:[_/VY!7!7@#E2#QUP3G$M4US5/A5)<VFIZC+J>CWUQY16ZD5[J*
M&9@8I"I!;*#&3SG'O0!ZS4-W=V]A9S7=U,D-O"ADDD<X"J!DDUS6@ZI!XJUB
M/6=/NISIMO9HB*LS!))9 '.Y<X)1-@Y[N?05D_&N.[D^%NI_95=E5XFG5.IB
M#@M^'0GVS0!T%CXAU#5;)-1L-#E:PD7?$9YUBEF3LRH1@ ]1N93ZXK2T75$U
MK2HK]+>:W$C.OE3@!T*N5(8#H<J>*5)UN]%CN-+FB6.6!9+>39N3:1E3@$9&
M/>O+9/$.MZ]\*M U^2^^PWEYJL*$:>#$H4W!0@@D[LXR<\'- 'L%%>?2Q/IO
MC?2/"@U+4Y+&\CN=0E>XNW:21QM"Q*_#!!RVT'T[<5B:[J&J:99_$#1XM0OC
M;Z9:17MA<?:7\VW+J24\S.Y@"I(!)XXH ]<HKA-0NKM/&O@:-+VZ2.]M[H7$
M8F;9+M@4J2N<$@DG.*YB*PU/4_!OBK4_^$FUF*]TG4;XV;+=L%40DE0X_B!
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M@D22&1D966TR""I!ZBG/J%]_9GPRNOM]WYMZUNET?/?$X:V+'>,X8E@#D\T
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MBRU74DOI(KI_)82-(\41PR1N[#+, >IZ@B@"UKOB&ST&.V$ZRSW5W+Y-K:0
M&2=^N%!(  '))( '4U5NO$%_IJVSZCHDBQ7%Q%;A[:=91$9'" R9"D#+=1N%
M<QKY:+XZ^%)+HXM7T^YCM2W3S^=P'N5VUZ'-Y(B)GV>6,9WXQUXZ^^* )**X
M#2'F\9'Q8UQ?WMK/9:E-86@M[EXOLZQJNU\*0"2Q+$MG(XZ<5@Z9K>K^(S\-
M[NZU"\M9-36[CO$MY3&LVR)\-@<9.,Y[9XQ@4 >NT5Y9:Z;//=>.='?6M9^Q
MZ4Z26>+^021L]N).9,[V ;HI)'J#445]JNLGX:&36+^ ZK:2_;/(EV>:1;;L
MD>N<\]LY&"!0!ZQ17DXGOM NO&>@2^);Z'3K>"VN+2_N"US/;&4E3&"3N8DC
M"C.1GCFM/39;U?'^JZ1OO[.RFT2.Z2"6\:62-_,=-X)+;&('(!/0'K0!Z+17
MC.F3ZC%X)\">(FUK5);^YU&UMY_,NG:.2*20JRLF=I]=Q!.>_2NDO-3;P9X\
MO)-1O+V?2M5LFFLTEN'<13Q EXD4G +J01[C H ]"HK,\/V-QIVAVL%Y/+-=
M[=\[RS-(=YY8 L2=H)P/85IT %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 5BWGAFSNM:.KQ3W=I?M"+>26VEV^9&"2%8$$<$G! !&>M;5%
M '/ZEX*T'5/#T6ASV6VRA<20^6Y5XI 2=ZOG.[)))SDY.<YIL?@G1QX>O=%N
M/M=Y!>KMN9KNY>6:0#IER<\=@.!^)KHJ* ,BY\-:=>^&Y=!O%FN;*5-DAGE9
MY'YSDL3G.0/I@5-)H>G2:Q9:JULOVNRA>"!P,;$?;D8_X#@>F3ZU1N_$4MIX
MUTWP^;(&.^MYIEN?-Z>7MR-N/]H<YK?H YO7? ^D:_JL.JS->VFH1)Y7VFQN
MG@D>/.=C%3R*-8\"Z'K-G80213VSZ=_QZ7%I,T4T.>N'!SSWSG/7K6]=R3Q6
M4\EK")[A8V:*(OL#L!PN[MD\9JO%J'E6FGG4E2TO+O:GV</OQ*5+% P^]C#<
M^U &7-X*TJ>PL+-GNPEC<K>1OYY9VG7I([G)=OJ<>W JW;^';2V\13ZZLMPU
M[<0K!(6<;61<E1MQ@8)/3FM>B@#,UW5Y-%L4NHM*O]2+2K&8;&,/( ?XL$C@
M?7O5;PMHXTG39W:UCMKJ_NI;VYB3!VO(V=I(X)"[02."036Y6#XH\6:?X3MK
M*?4"0EW=QVJX/W=QP7/^RHY/X>M $4/@C1[=);>(7"Z=)/\ :&T[S?\ 1_,W
M;LA>H&[G;G;GM4^H^%-.U+78M8D>[ANTA^SN;>X:,319W!' Z@$D_C6Y7(1^
M,[FXM(]8MM*6;P^9)TFNUN )(DB+ RF,C!3*-T;.,''8 &UX>\/:?X8TI=-T
MQ95ME9F"R2L^"Q).,\ 9)X&!4.I>%=-U36[;6)3=17L$)@\RWN'B\R(G.QMI
M&5SS69#XD\27;Z;/9>&(I]/OXHIUN!?A3 C$$^8I7[P5LX4GH1GO5]?$4O\
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M&?)N/[(X'V?[3)T#;L;L[L9YQFK;>&=.?6K;5V^TF^MH3!%(;A^$.,@C.#G
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MT7!79_=P5&,>@K O6GTCX-^#_%UC=7?]NC4#&)FG=C(A:7]W@G&WY!Q]?4T
M>X7'B/5XM;U738_#DDIM[0W-C(+I +PC:"G_ $S.YL MUP3VIVG>*C<6>DW6
MH6+6,>I8B3=('\J?G]VQ'!#8.UAP>!QD9WOLT#^:S6\>Z=0LN5'SC&,-ZCDU
MQGQ; M_A;JLD.(WMO(D@*C&QEF0KCTY H [FBF1,S0HSC:Y4%AZ&GT %%%%
M'*3>*M1'CB7PO;:3;23I8B_6:2]9%:,OLQ@1DAL]NGO6SI5]J%T]W%J.FK92
M02!4*3^:DJE0=RMM7OD8([5Q-Y;7-U\>72VOY;)QX:4F2-$<D?:3QA@1_P#J
MJSXFN-1T'1O#FEW-_++]OUF.TO+T'8SQN[MC(QM+84'&, D"@#OZ*X*6V?2?
MB=9:58-*FE:KITSW5K%(RK$\97$J8.4)W!3MQGZU7^$^DQS^$M%\07-U?7&H
MO;RQ,\MT[*5,K=5)QGCKC/)H ]%HHK@O&-JUU\0O!]H;R]A@NQ>I/'!<O&'"
MPY' /!Y(R,'GK0!WM%>*:O;W&@Z9\1=%M+N[?3K"T@O+$O.[/:R.K%E5R=V.
M,]>GU.>NU.1U^('@8)-(HNK6\$X60@2!84*Y /."3@^] '>T5Y7X7T&'4K/Q
M%?75]JCSZ?K&H16S#4)EV(/E R&R>.YR>!S6(;"XL_A7X<\8V>HZBVNP&U(9
M[IV6=7D5#$4SM(.[TR<<DY- 'M]%<!HR1^,-7\7P:LTOFV=^;.V19"IMHA&I
M61,'Y68EFW=>G85@Z9J/B;5_!GAC6)+*/7&ABN5O=/>4))=*) B3H#PS +T/
M7?QR10!Z[17EEKKEMJT_A/2["X=-+OX+QQ'J(;=)-&ZCR9/F!)7+\$G) //%
M6KC0->TG1Y['3]3MM5=-36ZCTN9VC5H2K$VH=F8XXW 'CY>>* /2:*Y3P'J=
MEJ.GZA]EM+RQFBO&6YL+O[UK)L7*+_L=",<<\8Z5U= !6;X@UJW\.:!>ZQ=J
MS0VD1D*KU8] ![DD#\:YBWE3Q#\1_$>D:JIDM=.M;46ENS$*PD5F>3 ZMG:H
M/;'&,FN,UE[J^^"_BF#4Y9;IM(U*:RM+F5R7DB29%5F/\1Y*Y/\ =]: /5=-
MN]<DU2XM]2TRWBM1&LD-U;W&\,3UC*D @CUZ$'MTK7J"SLX+&W6"W0I&,D L
M6Z^YJ>@#)U'6TM[#5I;)8[JYTV,M+"9-@W;-^TM@X.W!Z=Q3_#FJMKGAG2]6
M>(1->VL=P8U.0I90<9[]:X#0]-M+=OB1)%%M>.YF53N)X-NI/?GDDYJAIMH-
M*T7X8ZK:W%T+NZDMK2<F=RKPO;L2FS.W VC&!VSUYH ]4MIM1?5+V*XM88[%
M!']EF67<\I(._<N/EP< <G-7:\YM4O'\5_$>SM=2EMI/LEK]FFGF9EMG>&0[
MADG: QSQTJ7P;J&SQ,VE:IHTVC:W'9$M$DGF6UV@9098VS][/7/S?,,DXH ]
M!HHK)\2:A/IVB3/9J'OYB(+1#_%,YVKGV!.3[ T 5=!\76'B#6]<TNV!$VE3
MK$Y)_P!8"/O#V#!U_P" ^]=!7DU_#<>"_%GAG7#IYL].,:Z+?2&<2;E;F*1L
M=PX)+'UKI_$CSCQQH<=W')<:+);7 DMXD,G[X;=KO&H)90"0#@@%AG!(H [*
MBO&]9TO4]+^$FNW=U=:I!.VH!K/S;V;?';&X58U*EL#Y&.5QT(R,CCH-<M(O
M#^MZ)I-K<RI;:W?2O=/>7$DBR2+%\J$EL@,>=H(!(QTXH ]$HKRW6(K_ ,%V
M%['_ &Y&+*_U.S7R5#JNG0R,5D(8N2$8J>A&WG&*T+[PY<Z4=<NDU=;>UNM)
ME(T^T,D8$J#/GHV_*G! ., Y&: /0J*\>^PF#PY\-]5AOK]+Z^FL[2XF%T^7
MBD@8LN,X'W1@@9SSUYJS>7=SX1U'Q]%H\D_E6NDPWL$4DK2B*4B0,XW$GL"?
M7% 'K%%<'8>'W?4M$URSUR&*TEB,<JP>83J*NF5+,7/SCE@W7K7%&WDA^$\_
MB 7U^VIV&K-]FF>[D.P?;=A&,X;*D@[LDYZ\"@#VDWUL-2&G^:INC"9_+'4(
M"%R?3D_H?2K%>?P:;:-\<;^4Q?/_ &+!/G<>7\YQGKZ #'3BO0,YH *K/?VZ
MZ@NGB13>/"TZQ9YV*0N3Z#+ ?GZ59KS\Z;:/\='E:++_ -@I/G<?OBX(!Z^@
M''2@#H?"7B&?Q'8WT]Q:):R6M_/9F-)#(,QMM)R0.ISVK?KPV\LA%\.?&6MQ
M7%U'?V&NWDMK)'.Z")A<#D*" <\YR#79W4DGB/QWJ^A7,EN(K:QMWM[>;?\
M,'W;Y%VL.0=JY[8&,9.0#OZ*Q?"=G=Z=X:M;&^U;^UKBVWQ/>%=IDVL1@\GD
M?=)SU%;5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8-S
MH[VWBJ/Q!9IO:6W%I>0@@%T#;D<>K*2PQW#'N #O5S^J>)OLVO6^@:;:B]U:
M:(W#1M)Y<<$(.-\C8)&3P  23Z=: ([OP'X;O==?69].!O),&8K*ZI,1T,B
M[7_$&KU]X;TS4-334Y(YHKY(S#]HMIWA=H\YV,4(W#///3MBJ_\ :VKVNKZ=
M8WVF0&*\D=/M5M.66,K&SX92H(SMXZCKTX!WJ ,:\\*:+?Z3;:7-9D65JZR1
M0Q3/&%93D'Y2"3GGGOSUJ4^'=-;78M:,4QU"*'R$E^T2<1YR5V[L$$@$Y')K
M4HH YJ#P!X9M=>?68--$=V\OG,%E?RC)_?\ +SLW9YSCKSUI;WP'X;U#7&UB
MXT[-Y( )BLKJDV.GF("%?_@0-=)10!EW/AS2KO7(-:FMB=0@B\E)5E=<INW
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MA(KF2W92>?E/RM_P)2K?CCM6;XE\=3Z7XIM_#.DZ7]OU6:RDO CR^6NU0VU
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M15FDD,\KJP!(=B,Y8\^YK;\+ZSJ.LV5TVJZ5_9MY;7+0/"LXF4X56#!AP>&
M/H016Y0!YE\//A]8Q^$M".O:7<)J>G.\GV>>9S$DN]B'$>[83@CG'ZUU.H>
M/"VJZU<:Q?:/#/?7$7DRR.S8=<;>5SC.,#.,\#TKI** .5F^&_A2?P];:#+I
M9;3+:4S16_VF4 .<\D[LGJ>IXS5L>$='M=>D\16]E(^L^3Y8F>ZE)=0N IRQ
M&.!V]^M;]% '(>&;:_UG4K?Q)KVA+I>JP6C6?EEPY.9-S$$$_+A5QW^9^V">
MOHHH *P[KPCH]SJ[:LD$MKJ+KMDN;.=X&D'H^T@/_P "!K<JFVHP'4)=.AD1
M[Y(!.8BV,*20I)P<9(/;L: ,_2?".B:)?7=_9696^O 1<74DKR2R ^KL2>PZ
M>@IV@>$]%\+BY&CVKVXN7\R8&>20.W][YF//O4/@SQ!<>)_#B:G<VT=M*9YH
MC%&Y91LD9.I S]WT%=!0!SM_X&\/:E=7<]S8D_;61KN-)G2.X*'*F1 0K8/J
M.>^:FUWPAH?B,6/]I699K!]]J\4KQ-$>/NLA! X''L*W** .(U7P/I&C>%O%
M'_".Z4\=]JME-$\<,CL)796"_*6VCECSQC)K'^'?P^L8_"&A?\)!I5PFIZ<[
MR?9YYG,22[V*N(]VPG:1SC]:]/HH *PO$.D/XA-KILR8TU)X[BZ8G_7;&W+&
M!Z%@I)]!CG/&[10!GQZ+80Z[/K20D7\\"V\DF]L%%)(&W.!R>N*T*JQ:C:SZ
ME<Z?'*&N;:..29!_ 'W;<^YV'CZ>M4H]4N-.T26^\1"UM&CD8$02%U*E\1X)
M ^8Y7CU- &O15*Y?4EU2Q2V@MWL&\S[7))(1(G'R;!C!R>N2,5=H QQX8TH>
M(CKXAF_M,Q^29_M4O^KSNV;=VW;GG&,5;U72;#6].ET_4K9+BUEQN1LCD'((
M(Y!!Y!'(J[10!EVGA^PLVED3[0\\L0A:XEN9'EV#HH<G<HR<\$<\]:?HFA:?
MX=TQ-.TN%X;2,DI$TKR!<G)QN)(&23BIGU&W&I'38Y$:^$!G\HG&%SM!)[ G
M^1]*RO!WB"X\2Z++>W5M%;2QW<]N8XW+@>6Y7J0,]/04 =!7#^+=*N-3\=>$
MYEL[R2SLFN6N)X"R>47C 0[@0>HYQGCKQ7<55N=1M;.[L[6:4+/>2-' G=V5
M&<_DJG]/6@"JGAW2TT^]L6M1+#?[OM?FNSM/N&T[F)R>,#KP  ,8K.M? ?AZ
MSGL+B.UG:?3PPMI9;N5W0, "-Q8DC P!T&3@<FNEJ&Z>:*TEDMXTDF5241W*
M*Q]"0#C\C0!CQZ!I^@:3JHTNVN-UV9)I(Q-)*9)7'+ ,QY)ZUA^ /"D-IX/T
M.+4[.ZCO+%%8VUQ*Y2.8?Q!,E>^01P#R,&M'0/$.K^(_"&AZU9V5H);V1&N8
MI)6 CAW$,5.#E@ , X!KJ: ,:[\+:5>:G+J+1317<\8BGDM[B2'SD'0/L(W8
M[$\CUI\WAS3)7LG2*2V:QB:"V-K,\(CC.W*X4@$?*O!!Z"M:B@#G]1\$^'=5
MT2#2+O3E:TMW\R$*[*\;Y)+!P=VXDDDYY)YS3X_!^BPZ;;6$-O+%%;3_ &F)
MX[B19!+M*[RX;<QPQ')/'%:<FHVL6I6^GO*!=3QO)''W*I@,?IEA^=8_A[Q#
M=:OKGB#3KJUA@_LNYCA4QR%]X9 ^22!ZCC'YT :VGZ7::6DPM8R&GD,LTCN7
M>1R -S,>2< #V  ' JY110!E7_AS3=1U*+4I8Y8[Z*,Q+<6\[PN8R<E"5(RN
M><'H>14=[X4T74- &A7%F3IG>W25T#<[OF*D%OFY.3R>36S10!'! EM D*%R
MJ# ,CEV_$L23^-2452G?4AJUHD$%NVGLCFYD>0B1&XV!5Q@@\YR: *$GA#1)
M;W4;QK1Q/J*;+HI<2*'^7;G 8 -MXW  XXSS3#X,T,V>F6GV:?R-+=9+-/M<
MW[EE&%(^;G X&>U;](<X. ">P)Q0!BMX2T5[G5;A[:5I-6B\F])N9")D *@8
MW8& 2!C&,\59L="L;"[%W&LTER(O(66XG>5ECSG:"Q. 2 3ZX&<X%8FC^(]:
MUW0M;FM-/LEU.QU":RA@>=O*<QD#)?;GG)[#M76+G:-P ..<4 +6?J&B6.IW
M=G=72S--9N9("EQ(@1B",X5@"<$CGL36A10!F:]X>TSQ-IK:=J]NUQ:,P9HA
M*Z!B#D9VD9YYKC/%/AY9=>LOM?AS4M3TJVL_*MI["^87$<C-E@Y,BLRX5<<G
MOGMCO+S4;6P>V2XE"/=3""%>[N03@?@"?PK'@\0W3_$"Y\.2VL*01Z<M[',L
MA9GW2%,$8 'W3Z]N: ,K2O!-G>:3>V&I6VIII%T8VCTZ]U!Y'1E))8LKG )V
M_+N(&P'J<#H=9\-:3X@T<:5JMK]JM 05$DC%U8=&#YW ^^<UK44 85MX.T&U
MT&XT46"RV%S_ *])W:1I3QRS,2Q(P,'/&!C&*ATSP+X?TC3;JPL[258+J/RI
M2US*SF/^X'+;E7D\ @5T=% &"W@W0WLM,LVMY_L^F.LEF@NYAY+*,*1\W. 2
M!GH*L1^&]*CU>[U46[M=WD0AN&>9W61!G"E"2N.3V[FM:B@#F]$\!>'/#MU)
M<:78- [!@O[^1A$&Z^6"Q"9]5Q2GP+X>.A2Z(;28Z=++YSP?:YL,^[=G._/W
MN>O7FMFSU&UOWNDM91(;6<V\I7HKA0Q'X;AGWR*M4 9,OAK29M9MM7DMG:_M
MX1 DQF?)0'< PSA\'D;LX//6JWA/PU!X8LKRWM4,,-S=-<+!YK2"+(4$;FY)
M)4L>V6QVR=URXC8HJL^#M#' )]S@X_*L'P9X@N/$WA_^T;FVCMI?M$T)CC<L
M!Y<C)U(&>GH* .@K*O/#FE7^LV^KW%L3?V\9BCE65T^3.[:0" P!Y&0<'FM6
MB@#G3X&\/G1[W23:3&QOIC/<Q&[F(D<G))._/)Y/K1K/@;P_K[V<NH6<DD]F
MNR&=+B1)0O\ =+JP8CZD]37144 0V=I;V%G%:6D*PV\*A(XT& H%3444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5YOHV;#X[^)([T[7
MU&PMY;$M_&B *X7W#9./;->D5FZQX?TO7HX5U*T68P-OAD#,DD3>J.I#*?H1
M0!<N)XX0@;!D<D1)W=@"<#\ :\DB?^UO@I<>+7F:/Q%$DUY]N4XECF21OW>>
MRX&S9TQVKU&PT:RTUS)")Y)2NWS;FXDG<+Z!I&) Z< XJH/"6AK=33K9;?/F
M$\L*S.(9) 0=[1;MA;(!R1U - ''PV0UGXGQ1:HD^RY\,QSW-H9G">89@&&W
M/ XQCIQ7+SV$<7P@UG4Q-=->Z-?SQZ?,UPY:V6.YPH7GTX]2..@&/8&\/Z:V
MMMK)AD&H-#]G,XGD!\O.=N V,9YQCKSUJG_PA7A\Z/<Z2;)S87,AEF@-S*5=
MR<DGYNYY/J: .7O]'M=9^+T^GWTEU)92Z LTEN+F14=O/*] >!P.!@<"L71V
M%MH\N@7MY>W,%KXH>STV#>";N-%W"&1FZQJ2=Q_V<8/2NDD\.S7'Q22^DL+Y
M=,BT=;..[2Z*$2"4MC<'#D;3U/>NCN_".A7VE6^F7&G(UK;2B:%5=D9),D[P
MX(;<222<Y.3F@#S*]$\7A'XFV98VR64WF00VL[A("858JA&/ER>F .O%;G]G
M0:5X]\%R6K3!]3M+J.^+RL_V@+"K+N!..#T].G2NI;P)X99;]?[*C5;]56Z"
M.Z^:  ,'!]AG'7'.:MMX8TEKO3[MK>5KC3E*VCFYD)B!&"!\W<<'/4<4 <%&
M#X<U;7_!2@E]9=9])D?+'RY?DE7)_P">.&<#TKTRVL+6TAMXH845;=/+B.,E
M5XR,]><#/K7/:-%JFM:Q!K6N:(FE2644D-K TZ3N2Y&]]R\ 810![MGM74T
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M,*.WE_+$"/ESC/S'G'>L.SL)O&N@ZK?3:U:Z?J=IJ,XDN_L[-<6'E2G:H;S
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M+*9Y#O4= 06Q@=N.* /.;*PF\:>'-0U&76[73M3M=0G,EY]F9KBQ,4IPF[S
M NP ;<8()SDY-:MA#:^,M:\8:9K,A-S:RI;VX'RO;0F)2LL8/W6+%FW=> .@
M%=%/X$\,7.O_ -N2Z1"VHE@[2;F =AT9D!VL1ZD&G:OX(\.:[JD>I:EI<4]X
MB[/-W,I=?[KA2 X]FR* .3&EZ;+\4_#K$B^']@R-]KF 9YRCQA9&/<XYS[U9
MTC2K?6_$7Q$TZYW".>Z@3>APR$VZ893V(/(KK[[P[I&I7ME>7=C')<60(MWR
M5V XR, X(X'!R.*J7&EQ>'H=4U?0](DO=3N</) +ME-PP('5R5! ]N@Q0!R/
MA2X;6[;2O#%]"HO?#\[C4P!P3%\L1_[:;@^>^QA7IM8?A[3YXFOM5O[2.UU#
M4I%DEB1@YC55"(A8?>( ))]6(&0!6Y0!YKH\$'B^P\82ZMD7]MJ5S:PR%B'L
MDC4>68SU3^]D8R2<YK&LC=>)KGX:RZU)=>9J-C>?:U6=T$RK$-I(!&-P.21C
M.[TKTJZ\*Z->7]Q>RVC">Y0)<F*:2-;A1P!(JL _''S \<=*EN?#FE7FI6.H
M36S?:;$%;5TE=!"",$*%( R.#QR.* +6FZ?;Z5IMOI]HKK;V\8CC#N7(4=,D
MDDUR6MH4^+?A4K)*!-9WH=/-;:=JI@[<X!^8\BNWK-N=!TV\UBUU:>%VOK52
ML$HF==@/W@ #CGOQS0!Y)<Z5!+X&^(%])+=O<Z;JUX]G(US(3 R!"I7GKVR>
M<<5UEM>KK_Q$CTC5E2:V@T2*[AMI0"DTCMAY"O1L  #/3)]:Z,>#="%A?V/V
M.3[+J$C2W<9N92)G;[Q;YNI[^N*6]\':%J L3<V;F2P7;;3)<2)+&OH)%8,1
M[$XH \LNK5+3X/\ CZ*WDFC%KK5V(BDS @"1  2#DC'KFNK\1Z3;ZK\3]%L;
MN2Y:TNM*NO/A2X=5< Q@< \=>V,]ZZ0>!O#0TN\TU=+1;.]E,US$LCJ)7)SS
M@YQGMTX'%6SX:TIM4M-3:&5KVTC\N"5KF4E%[C[V"#WSU[T <);Z4OB35/$W
MAU[NVA;3#%:6<=Q$\TUM!Y*;)8V\P$,6+'=U) R3P*LZ5)'J'C*#PYK=\FK0
M6^AQ2VS3)A+QR[+),5)(9L*N#SC)(ZUU&M>!_#?B'48M0U32HI[N)=@E#LA*
M_P!UMI&X>QR*DUOP=X?\1+:KJ>FQRFT_X]V1FB:,>@9""![=* .&UOP_IEI=
M^!=/\^34TM]6EMOM%VPD<KLD)C+8Y"D ?\!QVK:6W@E^,EW;/&K0-X:B0H1P
M5^T.,5TEYX6T2^TVSTZ?3XC:6;K);1H2GE,N0"I4@CJ?KFD?0=/M-1EUNTL6
M?4UMO)3;.RAT'*QX)VA<^V 3F@#@=)0V?V_X<3[VN/MPDAF8DO)8N3(9"W4L
MH5HMW8[*]41%CC5$4*B@!5 P !VKG/#]O?ZAJ4GB'6=)33+QK9;6&V,JRO&F
MXLQ9UX^9L<=@H/4D5TM '"*UKXB^(GB+0M8598K6RM_L5O)TVN&,DJ@_Q!BJ
M[NHP,8R:I,R0^*?"7A::^GU#2#:71\VZ;<;R:+"A7. 'VC<<=#P>< UU>N>#
MO#_B2ZM[K5M.2>XMQMCE#M&X']TE2"1['CDU9OO#NDZA96MI<62"&T96MO*)
MB: J, HR$%<#C@B@#S+78Y["V^(^CVTLZ:5::?'>6J)*RBVE>-BR*0>%)7=M
MZ#/3FM--/ATKQIX$GM7F$NI6UQ%>LTS-YZK;AUW G'##C&,=J[>3PSI$VEW6
MFRVK/:W9W7(:9RTQQCYWSN;@ <GH .E(WA?2&N-.N&MY3+IH*V;FYES$",''
MS=QQSVXZ4 >9V6EV5M\/OB1-;0BWF@OM36)X&,;*J*&505(X! XZ5=U"S@\/
MZ%X8N+9[E/[>O-/M=4N&N'.^/83CKA-QPIQCCBNZD\&Z!*VI,VGJ#J>?MFV5
MU$N<;L@'C=@9QC..<U:D\/:5/H0T2>T6;30@C$$K,X"CH 22>,#'/&!B@#E_
M(;0OBMIUGI*"'3M1T^:2[M(QB)&C*[90HX4G=M..M2?"UU3P6Y=@H_M&\&2<
M?\O#UTUCH=AI[2/!'*99(Q$TTUQ)++L'10[L6 &2< ]3GK6)JG@'1;KPO-H5
MM8JMK++YP62XE(CD))\P<Y)!.<9 )ZT =97GOBF.TU/7]:MT4WUS:Z0/,BN&
M"P60;>0Z<$^:V.V,!1\PXKT"-/+B2,%F"J!ECDG'K6/?>$]"U+5O[4O-.CEO
M#%Y+.68!T_NLH.UL=L@XH \ZC1]8@^%;7MU=NUY;NMR1<./-'V4DYP>I[GKR
M>:TX-+MKCQ=J'@\-:K8V&GP&QM+Z-[C<CES)(A,@.X':-W)&!C'.>K@\#^';
M5-/6#3S$-.):TV7$@\HG@D?-R2.,G/''2I-?\'>'_$\UO-K&G)<36_\ JI0[
M1NH]-RD''MTH =X2L9M+\,VFGW&KMJTEMOA-XR;2^UB,'D\KC;G/:MNH;6UM
M[&TBM;6%(;>%0D<:#"JHZ "IJ "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *,XHKS^);'Q+X]\6:'KB)-]GMX$LX90#LA>/+R1@_Q;S@L.
M1A1VH ] Z45YM;&VD\=Z%X;N+B34-%BT226T>[(D%U.L@0LW&'(09!QT;(]:
MYGQ-!+:>$_B3I,;2?V3IT]N]@ Y A:14>2-?]D%A\O0;J /;ZIZ=JEIJL,LU
MG*)8HIG@9UZ%D.&Q]#D?A7$3Z39:3\6-%2SAV#4M.NUO=S%OM&TQD%\_>/)Y
M/K7('3+"'X&^*98;:&&=+J\ >)=C;5N" ,C&5 [=* /<JCE,@@<P*C2X.P.V
M%)]R ?Y5YOKVFV.@:IX:MK>%HK'7-21=4D:5F%PZQ'RU?)Q\S8R/XL<YK1T^
MV;1OBY-IVF((=*N](%W<6T8Q'',)=BNJCA2PR#CKMSVH K_\)_JC?"ZP\6)8
MV?GW$R1RQ%VVH&G\H8[D].X_I7H9..M>*1?\FWZ9_P!?,/\ Z7"NHO@NO_$7
M6- U![ I'8P-:6U];&8.C;_,=!O7!S@$\G@=.: /0^E<YX=\07FK:YXAT^[M
MX(AI=S'#&8F+;U:,/DDXYY':N/L$6V\2^%/"6H:HVK:;'9W3I-.N%NYXY-JJ
MP)(;RUW8Z] >PK6\!6=MI_B[QQ:VD2Q0)?PE8TX"Y@4X [#)/':@#:N?$%[;
M^/[#0#;P?8[JREN?.W$R;D*C&.@'S>_X5T=>?^)=,M-7^*NA6=]&9;9]*N]\
M>\J'&^/@X/(]NE8MAX/34[#QQX3M7<:;:72?V2[N6^S3&(.R*QYVAB 1Z$CN
M: /6J*X'PEJ47C2YTW4);-(6T>W,4\13'E7A.UT'IL"$X])%/:N[BFBGC\R&
M1)$R1N1@1D<'D4 /Z45P5D+?Q!\2?%6F:W;17,5E!:K96\ZAE$3H2[J#QDMP
M6Z\ 5QQCNKOPMH-O>W%S)':>,5L+6X,S;Y+9964?-GGH1GK\HH ]NHSSCO5#
M1]%T_0+#[#IEN+>V\QI/+#LP#,<G&2<<]NE>47S6TEGHVM:5EHI?%,874KAP
M;J?=.4=1@#$>,J 2<J!P* /9LT9YQ7FEAX<TO6OB=XPBOXI)X81IT\:&=P%D
MVR,&&#UR/U/K6;8V"^,O#>I7MYK%G8:G9ZA,T]X+4F[L6CF8J _F#"[  !C&
M">IR: /7:*S-=B2X\,ZA'*BRAK23(9>IVGM]:\T#H?!/PKG+J;AK^R3?GYRO
ME/N&>I&<9]\4 >O9HZ5Y*_A_3=2UKXE17L+3QP")XDDD9@CFUW;@,_>R<@]N
MV,T_1M3?5M1\ Z5J[^=9W.@_:RLW*W5R$0#=G[Q5=S8/<YZ@4 =IX<\07FKZ
MWXAL+NW@B&EW20QF)BV]6C#Y)..>?2NCSFO&;B;_ (1G3_B4^E#[-'#J%J/W
M0/[J-UB$A4 @C"LV,8QCC&*ZJS\,62:]:ZK;ZI91P7MF\)M--MC#'>)C<')$
MAY7^][XSS0!WF:.G6O.OA)H.GCP;H>O&)WU1[-X6N'E8DH9"=N,XQD#MZ^IJ
M]JEU!>?%:ST+55CDL&TEKBU@F ,<L_FX;@\,RH!CT!:@#MZ.O2O,+Z&TT34_
M"7AFVNY[C09]3N8[GSWW+O"%HX,X *!FQMY^[@]#1?V7]G>,/$^CV*F+1KCP
M\;Z6"(E$AN-S*"H'W=RJ20,9VYH ]/R**\8&CV</A/X::G"LD=_<W-E:S722
MLLC0R0MN3<#D+P.!T[8K9M],L]-\7>-=)L8OLUA)I,-R8(F*J)") 6&#P3@9
MQUQS0!Z=D45XI'I%I%X)^&^J1+)'J,][8VTETDK+*8I$8.FX'(4CL.G:M2[#
M^$_$OC6/P[ ( F@)?1P1C*^>#(-X7UP!GUQ0!ZOFC->4:K;P6G@?PIXBT$ :
ML9[+;<)_K+OS2JR)(W5]VXDYSR,TC>']-U/Q!\2H;V!IXH5@>)))&(1C:[MP
M&?O9)(/;MC- 'K%&:Y_P)<S7?@#P_<7$C232:? SNQR6.P<D^M<?HUKI7C#P
M]KT^N7+6^IVNJ3B>[1PD]D(I,QA&()10BCIP<MW)H ]0SBBO/]*6U\3>.?%M
MAKELERMF+>*UM[A,A(7CW%E!Z%F)R1SP!V%<E"MW?^&?!@U"XN9C%XG:QAN#
M,P>6W4S!22#U^4#=U^4<T >U2S100O-+(L<4:EG=C@*!U)/85#I]]!J>F6NH
M6S%K>ZA2:(D8)5@"/T(KS%M*L;'4_B1H]O:Q+IPTN"Y6U*YC64Q2Y8*> 254
M_4 U4N]+L5\!?#3R(A;M/?::)C;GRR^^$[B=N,DX'/7CK0![%D8SGBL3Q?K%
MUX?\)ZEJ]G!#/-9P-,$F8JI &3T'/TX^M<G%IFFZ?\2;#PJ+-$T-=*FO+:UD
M)>.2Y:8;SAB<E5R0.VXXQ6/?+/8^&/BCH\18Z18H?L0)RL1D@#R1KZ*I(P.V
M: /5["X:[TZUN7 #2Q)(0.@) -6*HZ. ="L 1D&VCR/^ BO+-1T:.*Y\4> X
MH(Q-JLJ7^DL1CRPX_>$$=!&8VP/1@.] 'L-8PU6XTC0Y[_Q&]G T<K#_ $9F
M*E2V(Q\V#N(*C'J:YOP7=V_C""PU26S2)M.LOL<B!-ICN3Q,HQTVA5QC_GH:
MXNXM+:7X(W7G0I+Y&NL(VE&\I_IP4X)Y^Z2/H: /3KOQ!>VWC[3=!^SP?8[R
MTFN/.W$R;D*C&.@'S>_X5T?6O/-;TG3Y_B=X;T[[-&MB--O0;>(;$(W1Y4A<
M<9ZCH>]6/APT.G:9XBL_,6&RL=>NK>W5WPL4>5*H,]!EC@>] '=UR7B?QD=.
M\$:IX@T1+>\^PNZ'S7(0E6V-C'7!^G3K75R1I+&T<B*Z."K*PR"#U!%>("QL
MK7X">)Y(+6WBF:>[0M'&%8JMR0!D=AQQVH ]O1MR*>Y -.SSCO7G4VG6VA_%
M/P\^G1&.34-/NQ=G>2;@H(V4N2>2"3R:Q] T]?%7A'2_$,VM6=GJ5O<B>XNX
MK0_:EF#$-$[>9D@D[=F,$;0!TH ]6O;VWTVPN+V[E6*VMXVEED;HJ@9)K TG
M6=<U[38M5L["TMK*=?,MHKN1O-EC/W6;:,1Y'./FX(^E5OBCI]YJGPSUVTL5
M9[AK<,JIU8*RLP'KE01BM;PEJ%IJGA'2;RR=7MY+2/;M/W<* 5^H(((]J )]
M!U*YU72ENKRR-E<>;+$\!?=L*2,G7OD*#GWK2ZUPOBG4TN?%_A#3'8/H][<W
M2W.?]7++''^[C;L1NR<="5'I6+J=F=/U_P ::/9*T>C/H'VYH8F*I;W)WJ-@
M'W=P3<0.I&: /5,BBO'6T:R@T7X9:A"DD5[=O:VL]PDK+))$]LQ9"P.=O P.
MW;%6I=.M=,U'XD:78QFVL4TF&Z2"%RBI*8I<LH!X)VKGUQ0!ZQFC(SCO7C4V
M@P:9X9\ ^(]*,R:W)-I\+RB5F-Q%(@#QL"<;=O;L!2>*&MI-#UG6=,S(\&OQ
M#^T;EQYZRB:-&CAP,K&HR!D\C=Q@YH ]FSBBO.6T33M6^+NLVM]";FUDT>"1
MX))&*,QD<<C.#T''0=>M8>FZ/<:S\%M(U&W3[3JNC32W%H)/F,JPSN/)/J"B
M[<>H% 'L5%<EX8O++Q3J$OBVW13:M;I;6DC+@XQND;/^\VSV,9]:ZM'26-9(
MW5T895E.01Z@T .HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MA$\PG<;3C?G.1_=Y'.,9[UT5% &;::!I=AJ<^HVMJ(KN=0LLBNWS@#"@C.,
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MCG%NK8"@]P&W ?2L^+0]*UWXJ^*H-6L8+R);&R*QSKN49$@)P>,^AZC)QUH
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MB[(BXP0<=<9X[5U$,T5Q&)(94D0]&1@1^8KSC7K'3I_$OP^LT@@-JTMSOAC
M"-FV)(('7/&1W!YX-:'@2W@T_P 5>-M/LXD@LX=0A>."-0J(7@0M@#@9- '5
MWIU :EIWV:>TCM"[BZ2929)!M.T1D' .>3G/%6I+JWBSYD\288*=S@8)Z#ZF
MN*\5P0CXF>!+CRT$QFO$+X^8K]G8XSZ9KEVT#2+FR^*)FT^VD^SRS-"&0$1-
M]F5MR#HISSD<T >Q45C^$Y9)_!NAS2N7DDT^!F9CDL3&I)-;% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %5-0TNPU:W%OJ-G!=1!@X29
M P5AT(ST/N*MT4 4H[*+3+%XM*LX(V)+!!\BLQ_B8@9/N>3Q4.A:-%H>G?9H
MW,LLDKSW$Q&#+*[%G<CMDG@=A@=JTZ* "H;JTM[ZV>VNX(YX'&'CD4,K#T(/
M6IJYC7/$4]MXJTOPY9S6MK<7T,L_VBZ0NN$(&Q%#+N<YSUX"G@T ;=EI.G:;
M9&SL;&WMK4@CR88PB<]>!Q53_A%?#WV V']B:?\ 8R_F&W^SIY9;UVXQGWIN
MCW&M'4[^SU9+5D@6)K>>V1D$H;=DE23M(*XQD^N><#1@U"RN9Y8+>[MY9HN)
M(XY S)]0#D4 4=2\,:#K)MSJ>CV5X;<8A,\"OL'H,CI[5JJH10J@!0,  < 5
M!]OL_MOV+[7!]KQGR/,&_'KMSFJ&G^)--U>_U&QL;N&2>QD\J0A@1OV@D 9Y
MQD ^^1VH 2;PGX?G=WDT:R8R$M)^Y \PDY._^]SZYJWJ.CZ;JVG_ &#4+"VN
MK3C]S-&&48Z8!Z8J+29KA-"@EU._M+F=4)FNH!LB;!/(Y. /KVJW;7MK>0>?
M:W,,\//[R*0,O'7D<4 -T_3K+2K*.RT^UAM;6,82*% BK^ J2WMH+2(Q6T*1
M1EV?:BX&YF+,?J22?QJ./4;&6:.&.\MWEE3S(T652SK_ '@,\CWJ2Y>:.VD:
MWB$LX4[$9MH9NV3V'J>?H: ,^U\,:%8ZK+JEKH]C!?S9\RXC@57;/7D#OW]:
MGL=%TO3&G:PTZUMC<,6F,,2KYA/4M@<GZUSVEZQXE@\:_P!A:W'I]Q!/9M=P
MW-C&Z>5M8*4<,QSG=P>.G3TU[/6&U37+VTLROV73G$5S*1G?,5#>6OIM!4D^
MK =C0 D'A'PW:K&L&@Z;$L4WVB,):H-LG]X<=?>I!X8T)8+F :/8B&Z;=<)Y
M"[9CZL,?,?K5R'4;*XNI+6&\MY+B/[\22J77Z@'(K/T_6&;7;K0KW:+V&);F
M)U&!/ Q*[L=B&!4CZ'^+  'WWA?0=2L+>QO='L;BTM_]3#) I6/_ '1CC\*G
MO-$TO4-+&F7>G6L]@ %%L\2F-0.F%Q@8[8Z5;GN(;6%IKB6.*)>6>1@JCZDT
MR.^M);3[7'=0/;8)\Y9 4P.IW=* &:=IMCI-E'9:=:0VEK']R*% BC\!56]\
M-:'J5X+R^T>QN;E1@330*[@>Q(S5Q;ZS<3%;J!A",RD2 ^7QGYO3CGFG6MY;
M7T FM+F&XB)P'B<.N?J* (+#1M+THR'3M.M+0R<R&"%4+_7 YJO_ ,(SH7]M
M?VS_ &19?VGU^U>0OF9Z9W8SG'&>M7;N_L[!%>\NX+9&. TT@0$^G-+/>VMK
M;BXN+F&* XQ))(%4YZ<GB@"H/#VC"2[D&E68>\&+EO)7,P]'./F_&FS>&M#N
M-(&D2Z19/IRG*VI@7RU/J%Q@'Z5HPS17$0EAD22-NCHP(/XBN6U?Q(\GBM/#
M.GW]M9W#6+W37,@#[6#JB(%)')))/? XZY !LGP[HITA-(.E61TU/NVA@7RA
MW^[C'7FB7P[HL\5M%-I5G)':L&MU>%2(B.A7CY3]*33[^2&VL[36KS3UUAXQ
MYD4$N%=O5%;YL5F:IK6HV7Q!T#2$> Z?J$%R[CRSY@:)5(^;.,'=Z=J -B;1
M-*N-0.H3:;:27AB,!N&A4R>6>J[L9QR>/>DL=#TO3) ]C86]NRIY:F- -B]=
MJ_W1P.!QQ61X7UK4=3USQ+8W[P,NFWB0PF&,I\AC5^<D\_-ZUO0:A974TL5O
M>6\TD7^L2.4,4^H!XH 34--L=6LWL]1LX+NV<@M%/&'4D'(X-07>@Z3?+;"Y
MTZVD^S#; 3& 8AC&%(Z#'&!4XU/3S&9!?6VP$*6\U< ^F<^QIXO+4M$HN829
M1F,;Q\_T]: 'P6\-K!'!;Q)##&H5(XU"JH] !T%4;[P_I&I72W5[IMK/<*NP
M2O$"Q7^Z3W7V/%68=1LKB=X(;RWEF0D-&DJLRD=<@'(J6&XAN%9H)8Y55BA*
M,& 8'!''<&@"O?:3I^I:<=/OK&WN+,@ P2QADP.G!XX[4NFZ78:/9)9:;9P6
MELF=L4"!%&>IP.]6Z* .+N_#<^H?$X:Q=Z:LNFKI8LTD:1=RR^:7W 9R!M)&
M>O/3%=%<>']&N[&"QN=*LI;2 YB@>!2B'V7&!6E10!3O=)T_4K-+2]LH+BW0
MADCD0,%(Z$>A'8BI+.QM=/@\BSMXX(LEBL:@9)ZD^I/K5BB@"*&V@MWF>&%(
MWG?S)2JX+M@+D^IPH'X"JMMH>E63W+VVFVD+76?M!2%1YV>N[CYOQJ_10!AV
MO@WPS9/&]MH&FQ-$YDC*VR_(WJ../Z5/)X9T*;6DUF72+)]23!6Z:!3(".AW
M8SD>M:M% &7?>&]$U._BO[[2K.YNXAM2:6%68#TR1TJUI^FV.DV:VFG6<%I;
M)]V*",(H_ 5:HH IKI&FIJKZJMA;+J$B"-[H1+YC*.Q;&<=/RJ&T\/:/871N
M;33+6";<S!HX@,%OO$>A/?'6M*B@"EJ\FHPZ5<2:1;P7%^J@PQ3R%$8Y&06
M..,U5T'3[NVCN;W4E@&I7T@EG6 EDC 4*J*Q )  ZX&26.!FM>B@#-N?#VCW
ME\;VXTRUEN6 #2O$"7 Z;O[V.V>E.U70M)UQ(4U73K6]6%]\8N(@^T^HS6A1
M0!3LM)T[3I9Y;*QM[>2X<O,\485I&]6(ZU%=Z!I%_=-<W>G6TT[)Y;R/&"SI
M_=8]U]CQ6C10!G:CX?T?5VMFU+2[2[-J=T'G0JWEGVR..@_*FCP[HHM;JU_L
MFR^SW;F2XC,"E9F)R2PQ\QR>IK3HH Q)[*30K:,^'=%M)6DF47">:(6,>"-P
M;!W$<8!QQWJ#PWX8BTOPNVDZ@D-T+B6::YC9=\;&61G*X(Y W8Y'.*Z*B@#.
MTO0-(T2S>TTO3;6SMY"2\<,04.3QSCK^--TGPYHN@M,VDZ59V+3',AMX50M]
M<#I[5IT4 4]/TC3=*$PTZPMK3SW,DOD1*F]CW.!R:+C2--N]0M]0N+"VFO+8
M$03R1*SQYZ[6(R*N44 9K>'M'?4&OVTRU-T[!VE\H99AT8^I'8GD5I444 9#
M^%?#TD-S"^B:<T5U)YUPAMDQ*_\ >88Y/UJ<:%I(OH;W^S;7[7 NR*?RAOC7
MT#=0/:M"B@#*B\,Z%!K+ZQ%I%DFI/G==+ HD)/4YQU/K6G)&DL;1R(KHP*LK
M#((/4$4ZB@#-TCP]HV@B4:1I=I8B8YD^SPJFX]LXHMO#VCV=X;NVTRUBN"YD
MWI$ 0YZL/0GN1R:TJ* ,W_A']'%Q=7 TNS\Z[&VXD\E=TP]&./F_&HY?"^@S
MZ2NE2:/8MIZMO6V\A?+5O4#& ?<5K44 9,/A;0+=;A8=%L$%P@CF"VZCS$
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M T:07 DTBP<7)4SAK9#YNT87=QS@<#/2@#S[Q';:7X;T_P ,7L<46GZ?=WD
MU.[BB4[B(7\II200P#D'+9YP>M=+X8TW2+7Q%K%]IFL27\U\L4EVJ-&848 A
M6&Q0 Y&<^N 3VKHVTRP;3CIS6-L;$KL-L8E\O;Z;<8Q[4FG:7I^D6@M=-LK>
MSMP21%;Q"-<GJ< =: .2UN[L&^(!M0T$6H1Z.S2W%Z^84MVDY"QY&YB5Y.0
M .O2N5\*QW^H> ?!<NA:K9KK5C!.\5I>9:*X4':R-CE6 9<$<@$]LUZM<Z3I
MMY>6]Y=:?:SW5O\ ZB:6%6>+_=8C(_"H/^$;T/[/%!_8VGB&%F>)!;(!&S?>
M*C'!/<B@#-\":A'J/AA9$TPZ9)%<SQ3V@8,L<HE;S I'!7=G&/IVK)>WMF^.
M*!H8BQ\/&3E1G=]I'S?7WKM[>W@M($@MH8X84&$CC4*JCV Z56.CZ6VH?V@V
MFV9O?^?@P+YG_?6,T >7Z=Y&J_!SQ0=8"_VM#+>O>LW$D=RK,T9'<$#RPOL
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M6@MRVI68%RI> F=?WJA2Q*\_,, G(["J-YXOT"T\.W.O?VK:3Z=;AMTT$RR
ML/X 0>6]O>@#<HJEI6IVNL:;#>VDT4L<B@DQ2!PIP"5R.XS5V@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M) [@8Y]*[FWM;>T0I;010J3DK&@4$_A226=K-(TDMM"[LGELS("2O7:3Z>U
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MW*VI^4_1L<>M3:FL:V7Q>M[<*$6-'\N/H";4%C@>I!S]*]6;3;%S&6LK9C&
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MU>PU=)@LD=H('MI(TW] 3E2..>?ZV?!.K6&F_";0]0O+N&&TMM-A,TK-PF$
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI&QG"@<L< G ["@"::V@N-GGPQR[#N7>@;:?49Z&I:\QT_6/$&N:3XM_LCQ
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M30=1U";XA^*M-N;UY[2TBM'MHV51Y7F*Y8# &>0.N3Q6?XM\6+'?^&XM'U@
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M0HI))4?-UXZT <"FIV<7QG\V2=5COM A6U+ CSB)W)"^N 0?ISTYKDIVFO/
M_CG^R\71B\3R7,\$!#-+ 'B9\ =00I^H!KVS SG R.]  '0 4 <!K%Q:>(O&
M?@W4-#NX;@VS33W$\+AA';-'@AR.FYMH /?/H:XN[N+!O@SXZ,<MN7DU>Z(V
MLN6)G!3Z\#(KW)(XX\[$5=QR=HQDTNU?[H_*@!D,T<UNDT<B/$RA@ZMD$>N:
M\T\':_HUGXV\=O<ZM8P+)?Q,AEN$4,!'@D9/.#Q7I^.*3:OH/RH \LD#Z[XU
MUCQH-.GFT33-%EL[9&0HVH-\S/L!&2N"5!QR2,9K.TS6M/N?%'PZNH=1@DM_
MLUS"L%LG[FU)A0+"IP6+# !#$G@' S7LM-"*,84#'3 Z4 >-&>5_!/CK3K$/
M-J4&OW%U+9Q9\QH!<([<?[2!L>O.,\UU7AR_\)>)?$-EK&CW=UJ.H0V[(96D
MD/V:-NJR \9)QA3SU(X!-=X  20!D]:1(TCSL15R<G QD^M '#_$R.39X4N>
M?L]MXBLY)SV522H)]@S+^==U574M.M=6TZ>PO8_,MYUVNN<'V(/8@X(/8BGV
M<4\-JD5S/Y\B#'F[=I<=B1TSZXX]ATH S/$VJZ?I=C -5BCDL+N<6L_FKN15
M96.6']W(&<\ $GM7 Z5I%GX:^(NE0^"M3,VE:@)7U+38I_.A@0+E91R=F6P!
MZ]!Q7K! .,CITID<,46[RXT3<<G:H&30!XWI-WX>O-$O/"7BJ6_.LQWLHDTW
MS)%:Z<S-(CQXZ[L@YSZD\<UT_BE+[P]XUT_7-*@:4ZO"=*N$ R!-@M;R-[ [
M@3V%=]Y:&02%%W@8#8YQ]:4@'&0#CI0!YSXQ:#PKJ'A&YNI+J/0;,36US<Q%
MLPNZ*(Y'QSSAP3_M'UK#\7_\(S_PKS7[_1Y6E@U"]LWENI969+F19TW;-W7"
MCDCCKZ''L3*KJ58!E/!!&0:0(JJ%"@*.  .!0!PWBO5=*TSQ#X9RME9BZ>=H
MM6<#9!^[ (7^$NX( +9&!T/2N!N[ZS/PF\:6KW.^0>(')$R[7(-U&P)&!@D
MG&!WX%>\%5( *@X.1D=*-J\_*.>>E 'G6KSP-\5=,BT^YMTGDT"YBA*.!\Q9
M#&./Q(^E4_!.N^'=1\,:!H%_:B37]+DC1M/EC/G0W$9P93QP!DL6]_7BO4=H
M]!2"- Y<(H<C!;')H \>LKWP]+;:YX4\7SWRZ@VHSLUCOD'VU7E,D;1A?O9R
MH&/2O7HML%HF_P#=JD8SO?.T =SW^M/,:%PY12Z\!B.13J /)_ &EZ)XD/C&
M"\?[7&_B*ZD^SK=N(Y(\KABBL%92>Y!!Q[5H>*+^S\,^/],N=5EGT_09=,-G
M;W,!*1P3"3=L;;]T,H7'^Z/3CT< #H *1T21"CJK*>H89% 'D6N1^&[/1_#7
M]F'9IUSXJ@N@]S(2)LAM\@#\A,_AWZ$$]#XMELK7Q_X$4/!%_I=T^ 0OWH&&
M?Q8]>Y-=[M'H*, ]A0!YEH5]9V-GXWT?Q)+'%=R7]U.T<Y -S;RJ!&R _>&T
M;0!G& *R= FN_".M^"V\62FWL_[!>TCFN#A(+DN&VNQX4^6JKSZ8KV)HT9U=
MD4LOW21R/I0Z)(NUT5E]&&10!P7P[O;.YU_QH+6:-U?5O.79T93$GS#U!.>>
M]=_2!0N< #)R<"F3"4PN(&192/E9UR ?4C(S],T ><Z/J]CX?\4_$/7]3N?L
M^DK>VL)E*LP$BQ*K<*"2<NHX%>C03Q7-O'<02+)#*@='4Y#*1D$?A6?;:%!9
MZ.^G6\LB"5FDFGX,DCLVYW)QC<22<XX[8P*OV]O%:6L5M @CAA01QH.BJ!@#
M\J /(X;G3V\&?%4^=;%I+V]P=RY;,*A?K\V<>^:NW-W81S?"TQW%LH#<%748
M!MBI_-N/K7J>U?0?E1M7T'Y4 >4F]LOMWQ9_TF#!A3^,<_Z)M/\ X]Q]>*A^
MU:?#HWPH*3VR%98<[748S;,&_P#'C@^]>N;5]!^5&U?0?E0!X_=ZI9:=I?Q2
MTJ[N$BU"XDN9H;8_ZR2-K5<.J]2O!R>@QSBK;R":UT*^T+Q);Z9K=OH<)$=Y
M@VUW#W1@>0593DCD9_+U,Q1LQ9D4DKM)(ZCT^E#Q1R !T5@#D;AF@#)\)7LF
MH^$=)NY;#[ TMJA^R@<1<< 9[8Z>U>3^+-;L+KPSXL@ADCT^2WUE#+I\:9DD
M*SQ;KB4D$A6QD$;1P!DDXKW&F[%))*CYNO'6@#SNVOM)'QCU*XN9[9%ET.W:
M&28A=R[WS@M[8_"N3:QM]+\*Z(]TB1:/-XU^T6BS#"+:,9-AP>BD M]#FO3(
M/#MVOCR^UZ=K5[6YM([40X)9=C,P;D8).[IV]:=XLT"]UZ31C:RV\:Z=J,5^
MWFY/F; PV#'3.[K^E &-;0VLGQ>NM:L9(18PZ*(;^X1AY9E,@9 QZ%@BDGT&
MWU%<5'>6H_9ST96N(0RW4 P7&01=@D?4#)^E>WQQI'&$5%1?[JCBG;5]!^5
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M!TQK>+;-= ;3;EA\I!88)[CK5K^U;&PTVR>>]:43HJPOL+27!VYR$49)(!)
M'K7+>)D,7PH\1W5V/*NM1LYYW1^&#.F$C_W@H1..I6L<ZO#HWBOPCK&I3*NA
M2Z&;..[)S%!<DH3N;HN54+D^A]Z -OP5XA>]NO%D]YJS7%C9:ALBFN L8BC$
M:D@C"XP20<C/'/-=/8:_IFIWD]G;7.;J!0\D$L;12!3T;:X!*GUZ5Y+=7$E[
M9^.9]*AGNUBURUOGAMU96G@3RF?81CKM)X/.,BM>[DT'Q9I.K:CX.^W7NM?V
M3-;K=/-.3$K#(B_>'&\G. .F">.,@&KXK\6(=1\+IH^K3*MUK$,$JQQ8BN8C
MNW;7*_, 0!\K8YYKT"O'=0\3:+JGASP%'9RCSK/5[);BU$9\RU*(RLKKC*X(
M/UQQFO8@<@&@#FT\6V5WXMO?#433QW%O C-,(FX=RP !*D< 9R>.<=C6#X%\
M;6G_  C>GQ:_K:R:G=7<\*M-P7(G=4!VC:N0  .,XXJ6"]@TWXQ:P+QS#]KT
MNV,!93APC2;B#TP,\GM7$BYM%^!+*LL0G_M??M!&[/V[=G'7[G/T]J /7=1\
M2Z/I,LL=[>"-H$62?",XA0\!I"H(0'!Y;'0U2U+QEI^G>)-,T5O,>6]C>;S$
MC9D5%'&" <DDCIT')QD9X?Q;K%I=3^.M.C_T.=M+!06\.^74P8&(<M@YC7.W
MY>G)+ <5-#J5M#KOPYU&1I!:-I5Q;B3RFYD,<6%'&23@X]<<4 >JU@PW]BWB
MN_5-<>::"T4S::N&6 !B?,X&=QZ8SVZ5O5P=I=6P^-6JYGC'_$EA0_,/O+*Y
M(^H!!/M0!#HFJW?C*^U&6UUJ[T^>PU9XH8TA)B>WC*@JZL "6RQR3N&1CIBN
M[O;R#3[.:[NI/+MX5+R/@G:HZDX[5Q?PRN[>>/Q,D4\;LVOWDJJ&&2A888>J
MGL>E=TRAE*L 5(P0>AH S!XBTIM'BU9;L-83%5CG5&(8L<+CC/)( ]21ZTE_
MXCTG2WD2\NQ&85#S$1LPA4]#(0"$!]6Q7%^&=-OK+Q%+X/EA<Z/H]Q_:-K,>
MC0ODPQ?\!?S#G_IDM.\/ZA:Z+JOC/2_$LL<,MSJ,MY%YYQ]JMI$55"9^_@+M
MP,XX% '</K>FIJ%G8M=H+B]5GM5YQ, NXE3T.!SP:=8:O8ZG+=16=P))+63R
MITVE6C;&<$$9'%>3Z=;W'A/3_AA<>(7:VBLOM<=Q+-G$'FQ-Y2.>W!"\^E=1
MX$O8;KQ?XU:,28DOH9$WQLN5\A!GD4 =M>WMKIUG+=WMQ';VT2[I)9&"JH]S
M659^,O#NH-*MKJ]M(8K=+I_F("Q-]ULGUR/?FIO%,L</A/6'E=43[',,L<#)
M0@#\Z\\G##X+>%[RPMY+F/3Q83WL-H2)3''M,@&W!W!OF]01F@#OU\6:(T=Z
MYO=AL5#W221.CPJ>C,C ,%]\8JP->TUM-M=16Y+6ETRK!*L;$2%CA<<9YXQZ
MY%<SX9E\(^(M:EU?1%N;^5K(VUQ>323LJQE@1$1(<$DY. ,C'.,C-/P18WUM
M?R^&KN*3[%X;N7-M,_29)!F 9[[$=P?0[* .NO\ Q+H^F2RI=WJQ^25$S[&9
M(=W3S& *IG(^\1UK%UG4+ZW^)'A6U@OY?L%_#>-+;C;L8QHA5LXR?O'OC@5S
M^B7UMIFE^,M#\1.L=]+?7<PBE^]>0RCY#&/X\CY<#)! %<_J&E:M%#\/="&J
M+8ZW#I5Y&9&;F)VCCV1L>HR 4R.>#CD4 >OV^O:9<VUS<QW:_9[9F6:5U9$1
ME.&&2 ,@@@^E)I^O:;JEW/:6MSFZMP&E@DC:.10>A*N <'UQBO.M2\0KKWPW
MAETZP>*YTB]MWU'2;5L2(D,H+K'M/*\9##T]170>%KKPGKVO_P!MZ!]KO+M;
M0P2WLLLY$:%@PB/F'!8G)P.F#G&1D [.XGCM;>2>8E8XU+,0I. .IP.:SH?$
MNCW&A_VU#>J^F_\ /RJ,5/.,CCD9XSTK5KS72M+O-/\ %MUX.$#?V$+E=9@D
M_A2(L6,'MB<!@/[N: .WOO$.EZ:2+JY*LL0FD58G<QQG^-PH)1>#RV!P?2E?
M7]*26PC-[%G4/^/1ER5GXS\K#@\<]>E<AHVHPZ#X\\6V^OSQVOVZ6*ZLY[A@
MJ3PB,*54G@E2,%>O.:Y>VM)O#7A3P/=ZH'M;&VUR69C*I'V6"02^7O\ [H^9
M>O3.* /4W\3:+%_:/G:C#%_9NTWGFY3R=P)7.<=0"1ZT:5XGT77+J6VTS48;
MF:*))G1,Y".,J?\ /3O7G$^J6=QJ?Q1E20B*XTN#R7="HD_T:0<$CG)88]<C
M&<UWO@8V[^!M":W\L@:? C%,<$(,@^X.>/7- &IJFJV&BV$E]J5W%:VL?WI9
M6P!_B?:J-MXMT&\^V?9M4@E-FR).%R2K/]P8QR3T &>>.M9OQ.=$^&NOJ[*#
M)9NB G[S$< >IK!\5SQ6GAWPEK<,4L^CV,\;WGV%F#)$86C#C80<(6[4 ;^O
M>(H+WP9XANM$U-XKS3K69F*Q[989%0L R2+E<X[CITJ[I.LQ0>$]%N]0N':>
MYLX6X1I))7,88X502QZDX%<?>3>%[SPGXPUK0?.F^UZ7)#/?RS3,L[B-@B+Y
MA^8C../4#KP,^XU.VTC_ (0G6M3>Z_L$Z-]BENK620"UF(B(+F,Y .S;]1[4
M >D1^)]%FTN/4HM0B>UDE\A&3)9I,X\L*!NWY_AQGVI]OXATFYL+B]BO4\BV
MD,4^Y2K1N,?(RD!@W(XQDY'K7GM]?>'-(T^POM*L#%IVH:V)CJUX)9%CE*'-
MP YSD_<#'"YR>1C-"SDTFXC\=66IW]_'!+J=K*+S88Y(\B$1S9V@+A\-T' )
MQB@#U.WUS3;E+MEN?+%H UQYZ-$8@1D%@X!' S]*;8>(-+U*^EL;:YS=Q()&
M@DC:-]AX#!6 )7W'%>8W\_B.[\->([*22'7CI[V4\>HV"['O85EWO$VTXWJJ
MD_*>C#UKIO#%]X1\1Z];ZOH8O;V_AMVCDN9I9S]F0\^6V\XW$_P\]">W(!W=
M9#>)]&2[2V:^16DF-NCE6$32]/+$F-A?((VYSD8K0O$FEL;B.W?9.T;+&Y_A
M8C@_G7D"R1:C\$#X49-OB.)%L_[/8XG%PLH(;;UQ_'OZ8R<]: .Q\1^)47QE
MIGAS[3<VT$\$\MS) CA\J%"*K 'CYB21Z >H/3:-9WFGZ5!:W^HOJ-Q'D-=2
M1A&<9.,@<9 P,]\9[UQNH74-O\6O#4-Q=Q&:+2[F.5BP'SDQXSZ$[20*]!H
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MPP2-L8N%<, ,JP&<*1N)&,5=&HZ=<^,+2%-8NDO38O(-,P51D)4^8ZE<AAD
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M=*S6V^%T2<#DF-V4*_'/RD\<]*Q/!>J3@>+7U74I)H;#6)HUFN7 $42QQG'
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M,!-A .[:%P1V_.O5:* .8^';[OAUX?4I(C1V$,;+)&R$,J '@@?G5#XM_/\
M"_6X5!:66-4C11EG;>IP!W/!/X5VU% '!7UU:R_%W0;A)8VB&E7 $@.5#,R%
M1GH"0#BI?AM(C)XH52/FU^[E4=-R,1M8>JGG!Z&NXHH IZM>2:?HU]>Q1^;)
M;V\DJQ_WBJD@?CBO*O&5AH.I)%XA\)2O9>--\9@@M@8YY6+#<LT/4#&<E@.G
M)(KV&B@#R_5-1M/#WQ"U1_$XU"'3]4M[<VEW:O/Y6Y%*O$PB.<Y.1D=SZU"9
M[/P/XDT#53I=U8^&'TV>RC&QY#9NTPD#..67> .#R#P>E>K44 >9^*YK.3P_
MHNJ:?IKVNFQ^)+6\D=+8H7CW?/.R8##))Y(R1@]ZOW-U%<?%[1IHV*JVC3H&
M=2N&9T*@@]"0"<'FN]HH \>T]MOP=U/P=J,3'Q%$EQ:_8V'[RXE=V:.1!_$I
M+*VX<#!)/%;>F)_9_P 5+"&\G1Y;;PNEM+.QX,HE!(W'N0"V.N.:]&HH XCX
M6NI\-7L8."NJ7;;2,$*TK%3CT(.17;T44 <-X+N(I/&OC4I(I$M["\1!X=1"
MJDKZ@$$9%'B>XB3XG>"RTB@0B]\TYXCW1*%W'MD\#/6NYHH X:6&2W^.5M<R
M@B&[\/O!"QZ%TG#,!^# U&MY:Z/\6=9NM3D6T@NM,MEMYIAM24JS[E5CP2,C
M@<UU^I:7#J/V>0L8KFUD\VWG4?-&V"#]002".X/T(NKG:-Q!..2!B@#SWP_I
M[:#\,_$,UW"UK;3O?WL-NZ[3# VXHI7^'Y1G';.*WOA[9W&G_#S0+6Z!69+*
M/<K=5R,X/TSBM?5-,CU:%+6Y;-F6#30X_P!=@@A6/]W(Y'?ITR#>H XKXEHW
M]EZ)<&)W@M=<L[BX94+".)7.YFQV'<UD:_IDOBKQ-?ZAX>='1?#US9&\B;Y)
MII/]7&'Z-C!)(Z9%>F44 >7^%M1\.>(/[%MWTW5&U[3F0R6MTUSBQD489R6.
MP#@X'?(&.N,BZM;W5?"/Q!M]*1I[EM=-TD"=;B%?))V^H(1@,=<8KV>B@#S_
M %6XMO%_B+P?=Z',)7L[I[JXD4<V\/ED,C_W68E5VGG@\<&J5_X<NKCQ/X@\
M*K%(FBZ^BZB]PHXA8#;*H_VF=8C]&8UZ;10!Q'@2?49M$;5O$$+Q7=G";!L@
ML6$!(DD'?YV!^NP5TF@Z]8>)=(BU339'>VE) WH48$'!!!Y%:3 LI 8J2,9'
M45!96<5A;^3#N(+,[,QRSLQ)9C[DD_TXH Y_XC6\UW\.?$$%O$\LK64FU$&2
M>,\#O7.:EJ=GJ'B'X>7,+DP)+,S,\94*#;E0QR!@%N 3U/2O2Z* /'=6AN[Z
M3XC)I4;W$_VRQN8X8F(-PD2QF0(1R?N$<=^.M=/X8O\ POXDUNUU32+74;B^
MMX622XNVN,VJL.8R9"06)[#/0G/3/=T4 %>;>(H_!OC"UNX_$@33M1LKB:&"
MY;,,X"2,%>)CS(" #@9&<\9KTFB@#QUY]<TWPYX'USQ/%J,T-G]HCU%X3(L\
M:2<0RN$(;A0-W?YCGFNKTS1O#7B?1=>73+2X%EK$8CFO9S+NN'"D!@)?F^7(
MPW<_2NWHH X3P:FM:MH,L^JH]OJ5G;2:5&[_ ,4B$K),#Z,RI_WQ[USGA.YT
M'4-)T;P[JNEZJWB'2WA5K"9[G9%+%P)@<^6J@98'\ #D ^O44 <#X/GB'BOQ
MS)$HDD>]22-1P956%1\I[C<"/8UR%OJL-W!X(O1#<0"WU7$UA;6+I#8Y20>6
M %R6SCJ23R0 #BO;:* /*8YH#IWQ2^9<W#S>5ZR@VP4;?[WS9''>H;'65\,Z
MMX5US4UF_L6?PY%I[7*1M(+:X4JQ#A02N< =.J^U>N44 >8>)IH;:TT'Q#8Z
M/=Q:#:ZC+-<QV<;P2E)(V7[1L7:P^9B3W(.>]=)X0.@7MWJ&L:#;7+)=B,37
M\[39N64$  2\G:,#/3G'8XZNB@ ZUX]+X9UB?2=;\*VB2PQ:#=-J.DS@??9O
MWL$:GN%)D4_\!KV&B@#AUGDO?AOK.N7T)M[G5;&2;R6ZHIBVQI]<8./[SFN?
MO)XQX'^&2EQNAO\ 3VE'>,)$RN6] I(!STKUBB@#AK2:-OC5?D."K:)#$&[%
MQ*[%0?4 @X]*[FBB@#S72KRPTO4O'=GJJ8EO+YY8K5XSONXFA10(UQ^\R01@
M9K"M+:?P(_A:3Q.M^NFC1OL,UQ:22XM)_,WX?RCG:00O<94>E>ST4 8'A"WT
MJ'2IYM&L9K6RNKE[A6F,FZ<L!F4B3YADCOUQGO5/XED?\*WUZ/J\MH\<:CDL
MQ'  [FNKHH \X\62M!X=\)ZU;P7-UI>GSI)=QV3,LBQ&%H]XV$'Y"W('O[UD
M>(H--UOPEK.K^$-/O;QI#;/=W$AG+WB12!C&HEY;:HYQ]!GD#UZB@#S2]\1:
M9KWQ#\#WVFO-<0*EZ'=+=SY9:-  W'!SU';C-<SJEXD'PW\<Z \5P=4_M.YD
M^SK"Q/EO.&5\XQM(/![].M>XT4 >:R>(8/#/Q$O]0UF.Y32M9L+9;.[-M(RH
MT>_,1 7<I._=@BH/$$]OHFH>&-:DTJ\LO#<<-S;21V2R1-9^8R,DC)'AE#;.
M1VSSS7J-% 'D>N)80:;IWB+P_IMZVCQ:[#?ZA(1*TERH4@S;'^8JI(Y[XST
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5S/BN_EU'_A-M/;3[VUE?3@;6*VLF#7V8"=\D@7G:3MVY&,8.<XJZURLVO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-9T09=E7ZG%
M.K@?C3&C_";7"R*Q58BI(S@^<G(H [U75QE6##U!S2UY'X/\,ZK)XN\.>(+"
MQ_LK2(=%BBO#O1?MTAC.#L0G."5.YL'Y:Z?_ (3*XA^)\6@W,2II5]:NMC/_
M ,]+B)CYH_+C'JOO0!VM%<)HOB&^\3^+?$T!OGT_2]$E6U58@FZ63G>[LP.
M,< 8'KFLWQ;XCU;1=(\/RV/B);HW6O1V<]Q;112%X'+';@*1O"A1\HY/;F@#
MTVF&:(3"$R()2-P3<,D>N*R?#DT]W9-?/?7%U;7)$EN+F)4DC7H00JKZ9Y&1
MG':N$\9^";.Z\;^';G1A,FOMJ O+R\\UB4M5SNW<X SM11QW'K0!ZI17'?$3
MQ1>>&],TV+3@BWNJ:A%8132+N6'>3E\=R .![^U5]5U[4?#?CSPYH\MY+>V.
MM)-"3*B"2&5 "'4JH!!W8((]QZ4 =S2$@ DD #J37EW@3Q+K'B+S+>[UN]^V
MQZI.JXM(Q"]O"Z;D9O+QDAB."#SGM5OXY1 _"S4IP\JO$\6W9*R@[I%!R <-
MP3US0!Z."" 0<@]Z165U#*05(R"#P:X7X@Q!_@_J+[Y4:+3PZF.5DYP.N",C
MV/%;?@3_ ))]X<_[!EM_Z+6@#H**** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@!&94&68*/4G%,$\1( E0D]!N%8OC>-)/ ?B!716']FW!
MPPSSY;5YM\*K"RU;PGX=L[S0DC2W@>^CU%XX]TDL=UD;6!+#'0YQD'TH ]GH
MKSC4/%6J^'?B=#;ZG?!_#5^S6L6^-%^S7 C2098 $AMQ !)[^E4K#Q3XBN=5
M^(,5S?O$NDV4=Q91"&,& O"TF#E<L1@#G/>@#U2BO*/"WB7Q;JD-C<-/<W&G
MSZ&;FZNY;1(UAN>=HC;8 V<#(PV/6NI^&>L:AKWP]TO5M5NC<7ERLC2/L5>D
MC*,!0!T H ZZBO,=$\4:YXF^'VM^+8=0-F\1N)+*U6)&C1(AD*^5+,6P<G(Z
M\8J"]\=:Q#I'A/QMYS1>'KO;%JUF(T(A+942!BN[:&Z\^GK0!ZK17G'C_7]<
MT/P)=:_8:E-!++=Q&WC:&-A'"S!<8*9)(^;GD9QVK0OM3U&/P7XCUVRU:\98
M+.X-JMS;1H\4L!D#''EKPQ5>&';WH [>FQR)*F^-U=>F5.17#^ ]6U#Q'I>G
MWMQJEW,PLXC>PSVR1I(\D>[*813@>H)!R?2J%UI=Y\-?!;#P_97$ELVIBXNK
M>T8S2P6Q #>7OSN/RJ3D?Q-TZ@ ])IBRQN<+(A/H&%<]X+U^S\2:1/?V.JMJ
M-LTY"&2,))"-JYC< #D')Z=".O6O//!$0@\?_%&2VQ!-"ZF*1$7,9_>GC((Z
M@=J /9Z*\OT/Q=K<.H-X3\37AAUV*XADMKN*)%34+9Y%!(!7 (!((&#Q[&KW
MAS4]=USQ3XPTN369HH=-O8([9EABW)&<LPY3DD#&3G&?6@#T*BO// >I:]XA
MFUN2\UN=DTW7+FR6/R(0'A1<*"0F=P+ Y]JE^''B;4=4\"3ZSK-T]W<)<S1C
M$:(2%;"J H R>![DT =]17">%O%FH:YX0UO[<1:Z]I4MQ!<K& =CKDH0",$8
MP,D<X-:'PVU:_P!=^'^E:KJ=R;B\N49Y'**G(=@,!0!T H ZNFF6-6VLZ@^A
M->;>$O&MUJ'B"#1-<N[K3=?CEE-QI]S @BN$P^WR&"Y('RGKR >O6KWC!43X
MD^"9Q8FZE'V[Y(PF\XB7'+$#CKUH [KS8PVWS%W>F:3SX?\ GK'_ -]"O/H[
M:#5?B_?1WFEO;";PX(W6;RRS!IV!.49NHXZYXI1H&C'XOO9G2+#[+_PCRMY/
MV9-F?M!&=N,9QQ0!Z(#D9'2BHK6VBL[2&U@7;%#&L:#/10,#]!4M !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %8GBSPW#XM\.W.B7-S+;VUSM\QH0-^%8, ,Y Y [5MT4 4-.TUM-
MT*WTR*Z=OL\"P1S,HW *NT$CH3Q7/:G\/-.U*TTA5G:UO-,G2XCOK>)%FD=1
MU8XYSU/J:["B@#GH_"D=EKE]J^EW36EQJ*J+R/RP\4K*" ^W@JV">AP>X-8J
M_"[38?#6AZ%;ZA>1V^CWHOX9#L9WE#,PW<8QECP!Z5W=% &?I^FRV5S<SS7T
MMR9]H",BHD8&X_*% ZEB23DUR=_\-&U'7[G59?%OB!/M,BM+:PW CA9!TC*@
M<KC(_$^IKO** ,CQ'X<L/%&EBPOQ(H259H9HFP\,BG*NIYY'T[U6'A:.?Q!:
MZ[J-TUY?64+16F4"1P[N&<*.K$<$YQCH!7044 <]X4\)VWA.RN;6"YEN4GNI
M+O=,J[E=_O8P!QQ3O&'A:'QEX?ET6ZNYK>UF96D,(7<=K!@ 2#CD>E;]% &%
MK'AH:UX2D\/7%]*D,L(@DF1%WLH],\ \>E7=#TH:'H=EI23O/'9PK!&[@!BJ
M@ 9QQG K0HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@"CK.FC6-%O=,:9H8[N%X'= "P5@5.,\9P:YK3? #:5X8M_#UKK]^FGPY7
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
H% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>thackray-biocrystseparat003.jpg
<TEXT>
begin 644 thackray-biocrystseparat003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MGG%.KRO7S<:)JU_JU]86NM>'IM1BEDN8L"[TZ5&10,$?,@95P!@X8]CSZI0
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M<,Z@\=3Z]*#(BNJ%U#MT4GDUYKIOAG1M5^)_C"&]L8YHH1I\T<9)"K)L<[@
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MJQY"D$Y X.<]:[C2&M-?^('B^RUJ&&>2S$$-M!.H8);M'DLH/]YB<D>BCL*
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M=&TJZU*^D$=K:Q-+(WH ,\>I]JS/"FCC2+.]/VF&62ZNWGD2W&(86("^6@[
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M>W>VT:SBDMD9(72(!D#=<'K^/6MJF2.PB=HU#N%)5<XW'L,]J ,C_A$?#_\
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M%&@W/(P'4 8 '&2P'K4FBZA)<O>V=Q<V]S=6<Q21[<$*H))16_VPFTL!Z^]
M"IX>TN"UN(H;"%A- ;=EE8L&CP?W>3DA.>@X]J=X>T2W\/:)#IEJ%6&)G8*B
M[54NY<A1SA06( ]*TL@DC(R*7(]: *EWI=E>S1SSP*T\0*I,I*NH/4!A@@'
MR,X.*'TRP?37TYK.!K)U*-;F,;&4]01TYHU+4K32-/FOKV4101#))ZD]@!W)
M/ '<FL;6-9U"V\7^'](LFM_*O?.EN@\19TBC4'((; RS(O(/4T +>>'?[+\.
MW%KX4MK:QNFV!2/EW(&&Y=V"02NX \X)S6%;>"8(-2LKK0M)N_#TL5PDEPZW
M@$4L8.63RD=E;<.,D+C.<\8/H .1D4@(/0@T 9XT'21-?S#3[?S=07;=OL&9
MAMVX;U&!BG3:)I=Q]A\ZPMW%@<V@9!B$XVC:.W'%7^E)D8!R,&@"D^BZ;):W
MUJUE"8+\LUVFWB8L I+>I( 'X5&_A_2)&L"^FVQ_L_)M,QC$.1@[1VZ#\JTL
MCGGI1D$XS0!1;1].>WOX&LH3%J&XW:[?]=N4*=WK\H ^E<UK7AA+J\@L[C18
MM1\-PVRK!8P,L9@G!;+X8J#\I !#9'/'.:Z:TN;Z6_OHKFQ6"VA9!;3B8/YX
M*Y8E0,I@\<]>M7<B@#F?"?A^?0YK\J]U%ITYC^RV-Q=-<&WP#N.XDXW9'R@D
M#;G/.!T5Q;PW=O);W$230RJ4DCD4,K*>""#U%/R/454MM3M;RYO+>UD$TEFP
MCFVGA7(SLSZ@$$CMD4 )9:38:?(9+:V1)60(9#EGVCHNXY.T=AT%12^'](FT
MHZ7)IUNU@9/,-N4&PMOWYQZ[N?K4VE7%[=:7!/J-D+&[=<RVPF$HC.>F\<'B
MK@((R#D4 (JJB*B*%51@*!@ 53?2=/DU9-5>SA:_2+R5N"N75,DX!_$_F:NY
M'K10!FR^'M(FTHZ7)IULU@9/--N4&PMOWYQZ[N?K3=1\-Z+JTMM+?Z9;3R6H
MQ S)S&.X!]/;I6F"#G!Z5S<FLW^KZEJNGZ#):HVFJL;SSJ71KAAN\O@]%7&[
MO\P Q@T ="D:V]N([>)%5%Q'&HVJ,= ,=!6'::;=ZEK=EKFJVJVLUI:M%#:B
M42>7))CS&W#@\*%'MNZ9Q6K>ZE:Z>UK'<RA9;J5884'WG<^@]ADGT -8T.LW
M\_Q"N]'1K=M-M-/2XF(C(D661R$4MNQC:C'H.U &M'HNF17]Y?I8P+=WBA;B
M8)\T@ P 3] !^%/73+%-*_LM;2);#R?(^SA0$\O&-N/3'&*MT @C(.10!2L]
M)L+"7S;:V5'V",-DDJ@Z(,]%]AQ1IFDZ?HMF+33+.&UMP2WEQ+@9-7"0#@D4
M$@#).![T 07=C:WRQ+=6\<RQ2K-&'7.UU.58>X/2B_L+35+&6RO[:*YM9EVR
M12J&5A[@U8HZT <WJ7AXV.@&S\-6MO;%I8S-&#L,T(8;TWX)!*Y )Z9ZCJ,?
M3_!D-GK5A>:%IMWX?CAFWW2?:\Q3I@_((5=D.21S\N,=Z[L$$9!!%+D9QF@#
M'D\*Z#*-0#Z3:-_:)S=DQC,W3[Q^H!^M6#H>E&]M+TZ?;_:;2,Q6\GEC,2''
M"^G2M"N;\::S?Z-I-LVE-;_;[J]@LX4GC+JS2. >C#&%W-WZ4 6I?"'AV9[]
MY-&LV?4/^/IC$,R]"<_4@$^N*OQ:78074=S%:0I/%#]GC=4 *QY!V#T&0#CV
MJWD#&31F@ HHZT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5Y_=6-CK7Q3O;N[$2V.A::J7!? 5Y)<L=Y[JL:C@_WO3KWSL5C9E0N0"0
MJXR?;GBN.\+^%O\ D*WGB#2H&U"^OY+EBY65=F0(USWVJJ]1P<XH Y307N8+
M73=%B+Z?8>)-7O+V! 3&8;! '$:#^#?\IXQA7.,&MCPU;:/K7C_Q!=6MM;_V
M?:VT>FPPA (Y3Q),P7H1S",]P![5W&I:+I>L" :EI]K>"!]\0GB#[&]1GI5*
M>QFTZ]\S0M)T]7OI"U]<NWED$+\K$!<R'VR/J,YH X_P79V^J^%=*TB5=YT7
M4YI7D+$>1Y-Q((QG/4CC!_AW>U,\(>';'7=#OM>O[5C:WFIOJ5G;1,4&U'_=
M,0,9R$7 Z<D_Q&O0-/TBSTVQDM(84V3.\LY*C]Z[DEV;L223_+I5FWMX+2VB
MMK:&.&")0D<<:A510,  #H!0!Y-/+]N^$5QK^HH+S7]>0BS &YXY9&(ACA[K
ML&&X[AF-=';E[[XD:;:WDZR2:'I0,C9^_=3C'XGRXG/T:NMM]%TRTN!<6]A;
M12@L59(P"I;EL>F3UQU[T^/2["+4IM1CLX%OIT"2W C D=1T!;J10!R_P_EC
MU(:YKV]6DU34'=.>1!'^ZBSZ9$;'_@5)K&HQZAX\30KN81:78:?_ &C=(QP+
MAF<HBMZH,$D=R5!]*ZG3M,L-(M!::=9P6EN"6$4$81<GJ<"F7&C:9=ZE;ZE<
MZ?:S7UN-L-Q)$&>,=>&/(H \LTO51::%JVKZ6([&[\1ZY'86A  ^S1;S$K[>
M@/RS,!TR>];,5KI$_P 5-*T^P5$BT2SEGFDW9\^>3Y$#,?ON%69LG)R6[YKL
MV\,Z$VDMI3:18G3V?S&MO(7RRV<[L8QG/>I[?1=+M+S[7;:=:PW'DK )8XE5
MA&.B @=!Z4 >46^I1:1X)UOQ5ID5K!J.MZH5@N B@VT$DHBC8G' VH7YX).3
M7;Z9X;CA\2V5[*UM;RV5M(L-O!(9)9=^ TLTA +].!CKDY/;=B\/Z/#I#Z3'
MI=FNG."'M1"OEMGU7&#4NFZ3IVCVWV?3;*WM(<YV0QA 3ZG'6@#D_B3':ZC#
MH>A7*0LE_J*/*90,)!"#+*V3TX4+G_:K.OHX+SXA7SLJP:'X;TG9.(_D >7]
MXRKC&/D1,X[$C^+COKK3+"^N;:XN[.">:U8O!))&&,3'J5)Z'@?E0VEV#17D
M1LK<QWN?M2^6,3Y7:=_][Y0!SVH \P\.N]MX:\'>&DE%J-:>XO;SRGV^7",S
M-"N/NY\Q%..0 W>K.F7VC1>(_&'B."&!=-TJQ^QPQ*H5)=B^9,57H0<Q+GO@
M>HKO;CPWHEW;6EM<:18RP69S;1O I6'M\HQQ3_[!TCR[Z/\ LRTV:@2;L>4O
M[_(P=_K^- &'\-]%M]%\%:?&D4"W<L0EO&B0 F5B793C^Z6(QVQBL][FP?XK
M:CJ-R\,,.AZ6(WD; )DDS(Q]3MC1?IN]Z[BWMX+2WCM[:%(88QM2.-0JJ/0
M54?0M)DGO)GTVT:6^4+=.T*DSJ!@!^/F& !@T <7X?TXV?CR\T?5;99KB"67
M6-.U%0-\D4I9&CE/4E2^![!>FVMSQKJEQ:0:5IEI.UO/J]^EE]H4X:)""SE3
MV;:I ]V![5O6FFV5B[O:VL43. K,BX)4=!GT&3@=!FF:GI&G:S;+;:G8V]Y
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M00L4*_=Y[,[1CWZ5C7\L,WB;Q;K=Q$G]B:!IRV"Q+\JRLJ^:\6!_#DQ@COM
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MFW\RUA?[,P>#=&#Y38(ROH<$CCL: .#TK3+2+XJQQQ%=^E:0L4L@."\LK95
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MMH);B*XDAC::$,(Y&4%DW=<'MG JIJFA:3K7D_VIIMK>>0VZ(SQ!]A[XSTH
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MP>=.&!^RQ.V\KG^!$C5EQW(8\_-0!ZQ>:O96-S96TTZ_:+V3R[>)2"TAP6)
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M:L<8P.@W#\0#T2N:&MZE)\1CH48M6T^+3_MDSA&\Q69]B+G..<,>G:NEKC/
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M(<!0*X35I-+'Q7\$SVCV@\VQO%5XF7#1[$\L#';EL?CBNH\8QK)X*UU60/\
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MW&*6"ZM[I&>WGBE13@M&X8 _A7F-GJ-C>>(?AEJ%O;?8+22PO(HHI2/W8$2
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M\(!).!CJ?6NKNM1MC\2;ZPUO5!8I<:7!]A,HB\N5,OYR@R*1DDKD#J ,YP*
M/1&N8$,0>>-3+_J\N!OXSQZ\#-4;WQ#I-AHEQK$U_;FP@4L\R2!EX[ @\GMC
MUKS1O#^AVFJ_#NPLY'U&Q2XO88Y[K:[2Q")SMW  -'GH.A&.H-1:E:6]MI7Q
M:LK:"..VB5)8X44!49K52Q Z DT >M:??P:G80W=NZO'*@;Y6#8R,X.._-6:
MR_#CVK^'['[(T+(((]WE$8!V ]N_(K4H **** "BBB@ HHHH **** "BBB@
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M=W$\4$*S. !O=5+D9&0H.3].U $WA?0+;1](L ^FV=OJ$-LD,LD*+DD !L,
M"02,^_>M*STG3=/FEFLM/M+:67F1X850O]2!S6/I^I-ICW,VL>)-,N-.G(?3
MYW=(G*X^<,1A6 .,$#ZU!XOUO4-*G\-OI]Q!]GO]6@M)P8]Q>-PQRK9P/N^G
M?K0!N)H>DQZ@VH)IEFMXS;VN%@4.6QC.[&<X[U;F@AN$"3Q)(@97"NH(#*0R
MGZ@@$>XKFK76=2;XF7^B3S0M81Z9'=Q*L6UE9I&4Y.3G[OMUZ5HZ9?"VTJ:Y
MU/7+&Z1)Y,W2;8HT7<<(3N(RHX/- %Z^TRPU.-8[^RMKN-3N5;B)9 #Z@$5#
M?:#H^IFW-_I5E=&W_P!29[=7\O\ W<CC\*F@U*QNKN>TM[VVFN8/]=#'*K/'
M_O*#D?C37U?38[HVKZA:+< X,1F4/G&>F<].: &KHNE+82V"Z;9BSF),EOY"
M^6Y)R2RXP<GUIUII&FZ?IYT^ST^UM[(@@V\4*K&<]<J!CFJ7BJ_N].\(:KJ6
MG2Q+<6MG+<1M(F]3M0MT!'7'7^=-\/:]:ZEING1RZA:R:I+913S0+(OF L@)
M.P'('/I0!-9^&=!TYXGLM%TZV>$LT;0VJ(4+8W$8'!.!^0K490RE6 *D8(/0
MU4GU;3;6\CL[C4+2&ZE($<,DRJ[YZ84G)K._X3#1/^$BN=$.H6RW5M")9MTJ
MJ%))^7D_>P"2.PQZT 6AX;T(00P#1=.$,#%XH_LJ;8V/)*C'!^E2_P!B:3]H
MGN/[,LO.N%*32?9TW2*>H8XR1[&D.NZ0MNDYU6Q$+L520W";6(Z@'.":L"]M
M#=+:BZA-PR;Q$)!O*^N.N/>@"K;:!HUDULUKI-C ;;<(#%;HIBW?>VX'RY[X
MZU8M=.L;&2>2TL[>W>X?S)FAB5#(W]YB!R?<TRUU;3;VYEMK34+2XGBYDBBF
M5V3MR <BC^UM-_M :?\ VA:?;3TMO.7S.F?NYSTH ?>Z=9:G"L-_9V]U$KAU
M2>)74,.A (ZCUJ'^Q-)^T37']EV7GSC;-+]G3=(/1CC)_&BXUS2;02&YU2RA
M$<@B<R7"+M<]%.3P3Z5<DECBB:61U2-5+,['  '4D^E %$Z!HS:8VF'2;'[
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M]"1Q3KC3;&[GCGN;*VFEC^Y))$K,OT)'% '(>"XX;;QSXZMK=$CA2\MG$<8
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M&XMX+NW>WN88YH9!AXY%#*P]"#P:K?V/I@  TZTP(O( \A?]7G.SI]W/..E
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MC:5N I\TK[&4*O\ VS]ZQO#-SX7\1Z7X6636[F;4].DB\K3%,2302J-KAD5
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MK:V'_"[-27R+?(T2!\;1PWF.N<>NW ^E<9I6I+I7@CPC>RW,MOHUKK5XEU-
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M5QAGCB56(]R!3S96K+,IMH2)_P#6@QC]YV^;U_&H+S6=,T\(;N^MX0Z&0%W
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M<B,98'J#QSFG165K 8S%;0QF)2D92,#8IZ@>@]JKVFMZ7?\ G_9;^WD-N,S
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M8[CS%B*-(!AV^ZI]&/& >34=_P")]!TN6:*_UBQMY(4$DJ2SJ&120 2,\9)
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M11QG)*(@ .?84Y(HXL^7&J9Z[1B@#S[0=1\)>*=:T/4[#4[J_P!3M8Y#%#O
M:T5DPXE50,#@+SWQBO0)Y8X('EE=8XU4EF8X 'N:(K>"!I&BACC:0[G** 6/
MJ?6GLBNI5U#*>H(R* /'G^UZ+IO@GQEH-O\ ;I'TZ#2;V")O]:'1?*R>VV3
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MOVMF.0>VTY/M7N<2Q*FZ%4"N=^4 PQ/?CKGUH 9>7MM80>==3+$F0H)ZLQZ
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M[)YFL6*_;(S+;YG7]X@4L6'/W0 3GIQ5.Z\<:!!X9OM?AOX[JRL]RR&#+-O
M^YCJ#TZ^N>E<1+;Z#I>M?#JST^/[/IR7=Y);QW3DML:-RKX?D!F(*Y]15?49
M8;J'XNP6DB2NT*.L<3!B?]& 8@#W!!]Z /5-(U.'5]+@O8&5ED0$X[$@$C]:
MNUD>&-0M-3\-Z?<64Z3P^0BB1.5)"C.#WQT^H(ZBM>@ HHHH **** "BBB@
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M.#@]#5B_U2STQ8C=S;&F?RXD52[R-@G"JH)8X!/ Z"@"TR(Z%'564]01D&G
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M\;)YR#JT>X#>/=<TW_A*-%_LV[U'[<OV2SE:&YDV-^Y=<;@XQE<9&<]* -;
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M4<QO%& YRH )()' Z9 XKTZLW7+35;W3Q%HVJ)IMUYBMY[VXF!4=5VDCKZT
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MRCX(##U&>WH>]>0:1/X>FTF[\'^*[;4I=;2[EW:?YUR%O"9FD21-K;<$D'/
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M !4[?U-;OQ/_ .28^(O^O)Z +-CXZT'4-=BT>*XF6ZG0O;F6W>-+@ 9/EN0
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M?8T >AR>/_#T6E/J,MU+'#'=?8YE>W<-#-D#8XQ\G4<G ]ZLV?B_2[^^O;&
M7GVNUA%P8)+21'EC)P'C# %QD8R*XCQ)!:77@R:XT7P_>6Z7>IVDN/LDGG7&
MR56:1DP6  !P6P3@]L9WLN_QEANUM[G[,=!:#S_L[B/S#.KA2V,9V@G&: -7
MP7XG'BWP]%J@MIK?S6<A7C*C;O8+@GACA1G'>MZXF%O;R3%)) BEMD:EF;V
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M:B\5Z8[:C'(;B"?38UENH9(&WHC E6  .X'!Z9Z'-4(_B)X<D73I#<7"6VH
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M,FF(\UQ(=4A,]GY-M(XF4+N^7 Y)!&%'/(XH Z.BN=TGQOHFKZ=?WD<LUO\
MV>_EW<%U"T<L+=@R'G)[8SD\#GBG+XPTU=0N+"ZBO+2\AMOM?D2P$M)#G!=
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M &O12,H92IS@C'!P?SKRSPU=6,^I^+X=;\1WD L]5DAMC+K$L1BB"@C +@$
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M0GU+1+Y+R.W+!?/0??0$\ D8Q]*U;3Q5;W\(%KIVJ"[8?\>UQ8RPE6]&=EV
M>^3[9K?HH X2%;WP[\2]6U&^MKB;3M8M+<1W%O \RPRP@J8R%!*@[BP)&#TZ
MUS=YH.H67AMI1I]ZSZAXM755MHK=W>&#S5.6"@[3M7<0?7'6O7Z* .)'F_\
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MN_LO)-NSQE-L;'ECD]1Q@'.#@5#X2E@O(=*TR_\  UQ;ZUIYC$T]S9 01,F
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M YZ\9N>+#>ZEH.CZG!HMY'%;:]:WK6R6Y-QY*M\SM&N3NR2<=<8S@Y ]"HH
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M62]TC48W6&TDV901,XXRYP0I(QD]* .JL?'&EW\^F+'%=+;ZJ[I8W3HOESE
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M3MM853$LCC.5P2 "-K9R0!M/-8=E]H'Q3U#4Y=/OHK631X8A(UNY'F*[LR9
M() 8=,@GIFN/L-'U>Q\%^%;Y_#UQ?-H]Y=_;=+E@_>/%,[X9%888@%2 /7ZT
M >HZ)XCL]=EOK>%)H+RPE$5U:W"@21,1E<X)!!'(()!J'7?#8\0S*EWJ-_!9
MI'A8;*X: F0DY9F7DX&W Z=<@\8B\*_99UN;ZS\-G189M@ FM4@GF(SDNJ]
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M-\8[X(([$$$$>U7ZS=!@6VT>!$TR'3$.YELX451$"Q(!"\;L')QQDGD]:TJ
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MVJ6+'))+$\DDGDGW-35@6/BRUO?$;:&]C?VER8#<P-<Q!%N(PP4E>21@D<,
M>>E4KCX@:7;Z?'J0M;Z739;LV<=Y$BLCR;BG W;L%@5!QC/L0: .LHKG[OQ9
M;VYO1%I]]=&PB26[$*INA#+N *LP).WG@&N@H **PM4\4VVFZC/8)9W=[=6]
MI]MFCMPGR19(!R[*"25; &3Q]*(_%EC=0Z6]A%/>/J=L;JVBCVJQB 7+'>R@
M8WJ,9SS[' !NT54TV_74]/BO$AFA$F?W<R@.A!(((!.#D5;H **** "BBB@
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M>V?7I5&]L=8M-)^(6B1Z'?7$NJS7-U:3QJ/*=)(54#=G[P*D;<9R1VY'JU%
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MGB[\LE1+YN[&?]WG/3MG-=U10!Y;X/M+RQL['P[J/@5!J5CMA.J&WB-J\:'
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M23PR0RKNCD4JP]01@US.G^![;3HEM(M:UI].C78E@]V#&J=E!V[]N.,;NG%
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M5_9\4EU+JEJ;RWC#*A\H!22=Q'/SJ,?7L":P+6QU&+Q%X\NGTRZ\G48X19L
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M5XY&4GEB0?E)[$=<'VIOBVROKKQ1X3N+6QGG@LKUYKF2,#$:F-D!Y//)[9H
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P#PM7QI%Y,?ES6EB9$V\,2)<Y'O4WPB4)\,=)51@![@#_O_ "4 =JS*@RS
M#.,DXI:X/XII"NE:'=/"7>#7+)E*KN8?O!D #DY]*TM.\<0S:Y=:/JVF7>C7
M<5N;N,7;(RRP#JP9&(R.XSQ0!U5%<@GQ L?[1TF">V>*WU9_+M)_-1CO(RJN
M@.4W#IU]#@UU] !17.V'BG^TWMY;.PDFL;BYEMDN$E4[&3?DNO502A ZGD9
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MNC1+.V:ZU 6IO'3>$5(]VT98]R<@#V.2* -">TMGNH;NXP6@_P!5O/RHQXW
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MX>_L6<ZI#<1EX?.AX5;@2D[M^/NCUSFM7Q')J">/(=0TG1[^XGBTP17,EA/
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MK*$5&W;NJD*#QDB@"W)\1$GNM.M])T6\U%M1T]K^T*O&@D Q\O)^4C/.<<C
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M_;;B)55=ZCG=DY4=!6)XRTO6_&/@\^'(-">T:X\I9+J^FB*0!6!+*(W9F;C
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M>.^>*76O!NLZ\_CN!;8V@U9K26PGDD0JS0*O#!6) ++Z=#^% $VMRW5S\3/
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M L"P#?-\P  !SSV%37'BV.SM+'[7;+:W][)*D=M<SK&J^62&9GZ;>G(!SN&
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MI)Y@L[=(2^,;B!R?Q.: ,2W\;75[KM[I=GX<O9387D5M=2&:-1$CJ&\S[W(
M.<#)QUQP#6F^)NF0&PN2L+Z9?7*VT<\=TC2J6)"NT74(2.N<@$9 JQX<TK48
M/$_BV>^L)8+34YXY()#)&=RK$(SD*Q(.1D<=*S/"5OXQT*QM_"]SHUN]M9GR
M8=9%RFQH >#Y7WMX7C'3/4^H!?F\>7.=?6T\.7<[Z*^+A6GC3*[-Y(.3DXZ
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MSP%IU[I'@?2--U&V-O=VENL,B%U;D=P5)&*Z.@ HHHH **** "BBB@ HHHH
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M;#D]LCWP =)17.7_ (AU"WG2"WTD<6!O)KB[E,,$9R (M^T_/G/7& ,UE_\
M"PC+I'A?4K31Y9HM>E6%5,ZJT3E6..1\WW3SQ0!V]%<7;>+M>NM2U?1H_#EN
M=6TX1R%?[0_</'("5._R]V[Y2,;<>XJ2U^(%E>^']#U&-(H9M85FABNIQ&D>
MP?.6?!X!XX&22.!R0 =A17.^%?%/_"1MJ,$EJL%SI\_E2&*7S8901E7C? W
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MPPT; D$'\0>>XK7H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.QC2[6=M\@5N=I# 8SV'/3![C17U>:V:XUB&"VGD/RVL$GF+"H[%\#<QY)X
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M36K33K:18&CCMK6=G$KG'SLQ7Y1QP!GJ<]J .0T#6!HOP<\(SR:7;W\,LEM
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M7/F.^Y<L&7 VXX[GK6]6=H%M<V7A[3[2\2-+BWMXX9!&^Y<JH&0<#CCTK1H
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MIUD$L;X]?-+,?RZ4 7+WQ9<0WDFFQ1V":E;VT<]PL]PPC5GSMC4A<G[IR<#
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-I]TDKPRPR*P!*G[RE@"5(P0<?RK%LO%?B#4=>U2Q@TBP2WTN^C@NI9+MO\
M4L@8LOR<L <X.!VR>H .VHK@E\?WDT>E:C::8UUIM_.B&*&&4SPQ/]V8G;M(
MQ@D=L]35Z[\67\NEZWJVDVMK+8Z0TR,)W8-<M$,R!2!A0"" 3G)!X Y(!N7'
MA[1[O6[?6KC3K>74K9/+AN73+HN2>/S/YFKEY>6VGV<UY>3)!;0H7DED.%11
MU)-<O9>+[JXU;PM:26D(BUW3WN]RN<PLL:,5QW'S]?:JD_C*\?POXNO)=+M)
MWT.XFMWA:4A)T2-7).5/4-]W]: .WAECN(8YH762*10Z.IR&!&00?2GUQ6H>
M+-5M;_PSI^GZ5:2MK5M))&SW!18V2(/@@*<+R.1DX!XI)?%^J#[18K:6D>K6
M-M')=QGS98S,REA$I1>.,'<>FX<'F@#MJJ6.JZ?J9G%A>V]U]GD\J4PR!PCX
MSM)'?D<5S5AXSGUAM'LK/3WM-4O[1[R>&]5A]DC1@A++P6)<X XR,GCH:?PY
M-P=6\9_:XXHY_P"V3O$1)7/E1\C/KU_&@#LFU&R34TTUKJ(7KQ&98"PWE <%
ML>F35JN9FUN9/B+#HG]G6I#Z9)=179D/F'#HNP_+\HR<]3T%<V_Q$UR/PO=^
M(GT6R6RT^^>VNT^U,795E$9,?RX.,YR<9YX]0#TJBJ]_>P:;IUS?W3[+>VB:
M:5O15!)/Y"N1NO&M_INBZ5XBO[&!=&OWB$BHY,MHDN-CL>C#E=P&,9XW8H Z
M73M"T[2KJZN;*!HYKMM\[&5V\QO[QR3D^]3ZCJ=CI%F]YJ-Y!:6R?>EGD"*/
MQ/>N57Q1XBO/%6L:+I^CV#?V9);;Y9;M@&CE!)(^3[V!TZ<'D\5@>.->O?$?
MPJ\0:EI\%L=)*R0QF1CYDJ(^QI0>@&X'"X.0,Y&<4 >I*P=0RG*D9!]12UR5
MUXGDANO[(T\0_:K:SBGEDGCD= 7R$3" G)VDDGIQP<\9I\?:M)8>&IX_#Q@G
MUBX:UDM[N5HG@D4,>A3E3MSNZX_A)H [^BLVPDUF70E>^M[.#5BK;HXY&>$-
MD[3G )&,']*XGPMXRU&+X>:1JFJ"&ZOM5NQ;VBJY7S)I)7X8D':H )XS@+]*
M /2**YF#Q'=VGC"'PYJ\$(DO+=KBRN;?(279]]"IR0P!!SD@CTZ4>*O$FH:%
MJ&B6MGI\%T-3NOLNZ2<H4;:S#C:>/EY.<CT- '345QS>*=4AF@TF\M[*VUK[
M,;FXV>9/#&I=ECQM7<=VTGG&,=Z9IGC>ZU*TTFV;27LM9U"6:+R+D,J1B(9>
M7D LN"N.!DL!D8)H [2F2RQPQ/+*ZI&BEF9C@*!R2:Y67Q7J.EV$YUC2Q!=#
M4%L;1D8F.ZW<K(,991C<2,$_*<9J&V\6ZG)=:S93:2LYM+3[5;W(26&"X7^*
M,EE.UAZ<Y![4 :W]C^'_ !!:V5_'''<VZR"[M9(965 YY\Q=I !Y//7D^IK=
M' Q7 R>-+RQ\">'?$,.FV<5C>?9UNU#%5LTD( < #E5) QQ6]JOB/^R)]3GG
M1#INFV0N9Y%R7WG<0@'0G"Y_X$OK0!T%%<=:>+=2/B/3;"XTWS;6_1\SVT4O
M^B.HR%D+* 0>@88Y'2M#Q/XFB\/2Z9#--;VRW\YA%W=9$,1"EANY')Q@9([\
M\8(!T-%<C?\ B?5-*@T)[NRM2VI:J-/<1RDA59GV2*<<@J@.#_>ZTL_C0:;K
M7B2VU*%$M-&LH[WSHB2SJ^_Y=I[_ "XZ\Y[4 =6[K&C.[!4499F. !ZFJ^GZ
ME8ZM:_:M/NX;JW+,@EA<.I(." 1P>:Q[75/$!U33([K286L;Z)WDE@D)-DP4
M,JOG[^>F0!R.E<%X<\1ZGX7\"S:G%I]K+I5OK%PER7F*RE7NBF8U (X+#J>>
M>!U(!ZS=W=M86LEU>7$5O;QC+RS.$51ZDG@4D$UMJ-E#<P/'/;3*LL3CE64X
M96'Z$50\4 'PEK0(R#8S\?\ ;-JX30O%6L^'?"O@^6^TFV_L"YMK.S^T1W!:
M>)FC4*[KMV[2>P)(SZ\4 >HT5R;>)]1U"+6KG0[2VGATF=[=DF=@US)& 9%4
MCA,9V@G.2#P!S5'_ (3^XO[GPM_8VG0W%MK\,TD;S7!1HVC3<58!3@ \$@GH
M<#I0!W5%>?3^/M4LO"OB2_N=.M/[1T"Y,,\,<K&*9<*0RL1D</W';WK?N_$-
MQ:>,=%T8V\30:G!/*)=Q#1F,*2,="#N'Y4 =%17(^'/%T_B26":S^Q26YGDB
MN[<.1<66T/MW@]22H'08W<9ZU;\9>([KPQIUG=VU@EX)[R&U93+L9?,8*"HQ
M@GGN10!T=%<79^+M8MO%KZ!KVD6\,L]H]W8R64YE64)]Z,[E7YQ^5-LO&=^?
M$&A:5J%K:13ZO!+(;9)"9K%U3>$E'?(R,X7D=* .VHKCM.\8W<EEXF_M*UM[
M:_T21D-O&[/YB[-T;C@'#] ,=J)O$VO1>*++0/[+L?M-SISW?F&Y;8CJRJ5/
MRYP-W49SQT[ '7NBR+M=0R]<$9%.KSAO'OB$>%]6U<:-8;M$N9H-00W38D,1
M^;ROE_NG.6QZ8-;U_P"+<Z@FG:<(Q<&S2\>2>.1U57)"+A 3D[6R<\8[YH Z
MFBO/T\?ZM)9^'9!X=,$^J7;V<L%S*T;12*K'(RG*';G=UP>A-+<^+]=&C^,K
M=[:QM]8T& 3+)&[20NC1&12,@'< I&#QF@#OZ*Q?",M[/X3TN:_:-YGM8FW(
MQ)8%%.6)_BZYK UKQO?Z)ONKJQMX+9=26S2VFDQ<3Q%U3ST[8RV0,=!U% '<
MT5R-WXEUQO&=YX<T_3+%I(K%+R*XGN6"D,Y7Y@%R.5/ S]15?3O'S:CX;T.Z
M2R1-5U>Y>TBM3)\B21LXD8MC.U0C'ID\#OF@#JH=5T^XU&;3X+VWEO(%#30)
M(&>,'IN Z?C5RO/]"^VCXQ:Z+Y8/,&DVP5X,A9%\Q\'!Y!ZC&3TZ\UTFM:M?
MV5_;VUM!!%;/#)+-J%V<0P[2H5#@CYF+>HX!ZT ;E%>?+\1+V?PGX=UJWTF&
M0ZIJ*:?+%]I/[MC(T9*_+A@=AQDC&1UK2LO$FNS:SK>AW&G6"ZG9VT=W:^5.
MS12HY8!68J"""N,X[YQ0!U]%<?IGC"ZU;PEI6IVUM;C4+ZZ6V-H[-B-PQ$BD
M]<HJNQXYV^];'BC7D\->'Y]4E0,D3QHQ.=J!W5-[8YVKNW'V% &Q17%ZOXMU
M+2?">JZ]''IU_;V<:36\UO*?+N4/#8(SM(/N?UXTKOQ%<6GB[0]'-O$T&JP3
MRB7<0T9B521CH0=P_*@#HJIVFJZ?J%Q<V]G>V]Q+:L%G2*0,8R<X#8Z'@\5S
M=OXIU?4M-L]:TG2H[S2[FZ$2Q*^)S#O*^=D_+CC.WT[CH,"&^U;3?&7Q"N='
ML[2=X3:S/]IE**0ML#M&T$EC[X% 'I]%9^A:JFN^'].U:.,QI>VT<X0G)7<H
M.,^V:T* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *XB_T
M'Q1I?C&]UOPU+IL]MJB1B\M+]W39(B[5D1E!_AP"/;\NWJE!K&G76IW&FV][
M#+>VRAIH4?+1@\#=CI]* .=N_#VMS^+/#.JO-9SQZ9'<BY=I&1I&F"@[%"D!
M5V\ MTQSWJI!X7UR.W\9HR:?NUQW:WQ<OA-T0C^?]W[9XSZ>]=U10!Y;-9:I
MHWBCX;:>8;66\LM.N[>15F8(X2*)258KG/&<$>WO6U>>$-1O-,\7S_Z(NJ^(
M8/LX0RMY4$:QF- 6VY)^9F/'4X[9KJ+G0]-N]4M]2GM5>]MP1#,6.Z,'J%YX
MSW]>]:% '#'PIJ]K?>&];LS:'4M,LOL%W;-,PCGA('W7VY!##<,KSTXK4TK2
METG5M9\0ZM-;07.IM"C*)/W<4<:[47<P&2223P.H';)Z6J>J:3I^M6+66IV<
M-W:L0S13(&4D'(.* .4\ :#%IAU:ZM;@SV#74L6F*?NQ0!RS*OL96<9[A5-4
M3X,U]_!'BG1&&FBYUB]N+B)Q<.4196SAOW><CV'/M7H4,,5O!'!!&D44:A41
M% 50.@ '04^@#C[S0-9NO$GA/4A'8K%I"3+<*;A\L9(PGR?N^<8SSC-4-"\.
M>,/#IET*RN],?P^9G>WNI"_VJWC=BQ0+C:Q&3@D^_/2N_HH XZV\/ZS;^(_%
MNH[+!HM7BA2W7[0X93'&4^?]WQG.>,XK,MO!FO66A>#(XFTY[_P_(1(C3.(I
M4,;(2&V9!YSC'XUZ)10!GZM'J4FD.FG&V:]RA GRL3@,"ZG 8@%=PZ'K7$OX
M NH[3Q2NE6MEIJ:U8?95L4G;R5E(<-,<)\O# 84<X[9X]&HH XB7PSK<E[X,
MGV6 &AJPN1]H?YR8?*^3]WSZ\X]/>L:7P1XKDTAK)I=)FFBUE-26\DED\R["
MR[P)/E^0A?E&-PP !C&:]0HH Y2VT/5XOB#=:_(MDUK-IL=F LSA]Z,S;MNS
M !+8^\<>]2^!M#U'P]HMQ9:E]E,CWD]PK6\K.,2.7P=RK@C.*Z:JE_JECIGV
M;[=<QP?:9TMH=YQOE;[JCW.#0!S]GHFKVGCG7=;\NR>VOK:"&%/M#AP8]W+?
M)@ [NQ.,=ZY[2_ .M:5H7A.2.6Q.L^'7E55$K^3<PRY#J6V94XQ@X."/>N^7
M6M,?4YM-2^@:]@B\Z:$."T:9QEO3\:=INJV&L6K7.FW<5U ':/S(FW+N4X(!
M[T <W-X3N=5O==U2^,-O>:CIATR".-S(L,>&)+-@9)9\X X"CK6MX3L=3TSP
MS8:?JHM1<6D$=N/LKLZE44*#E@#DXSC'&<<]:NQZQITNKR:5'>PO?Q1^;);J
MX+HF0,D=N2.M7: .)M/#^OZ7-XDM[,6$D&L7<EU%=22L&MRZ*I#1[3NQMR,,
M,].*J3^"=7\.WFCW_@^>T>2RT]=-N+74&94N(E.X-N4'#AB3T[_@?0:ANKNW
MLK<SW,JQ1@@;F/4DX 'J22  .2: *^E1:A'9!M4FADO)&+R" $1Q^BIGD@ =
M3U.3QG PO#^@:E8Z[XFN=02S-IJTZRQB&9F=0(PA# H!R!G@UO:7K&GZU;/<
M:==QW$:2&)RG5''56!Y4CT/-&I:QIVCQ1R:C>PVRRR"./S7P78G  '<_2@#C
M_#&@>,M @A\/O>Z9+H=LVV"]^?[5Y .1&4QMW8^7=G@=B:S=0T#Q'X;\/^+[
M.VDTZ;0;J*\O(Y9&<3P>8C,\>T###.<'(QG)STKT+^V-._M@:1]MA.HF(S?9
M@^7"# W$=AR.M2WME;:C9RV=W$);>52LD9)PZGJ#CJ#Z4 <%::)JUSIG@'7=
M'2TFFT[31%);W4K1*Z2PQC(95;!!4=N<TJ^#O$/_  CWC/3Y)-->779YI87$
MCHJ>9&J'<-IQC;G S7>65C;:;9Q6=I$(K>)0L<8)(11T ST ]*L4 <3)X<UQ
M]:\'7H33PFBP2QW*_:7RY>,1_)^[YQC/./3WI-1T'Q/IGC&[USPS+IT\&IQQ
MI>VE^[H%>,;5D1E!_AX(]OR[>B@#A]0\,^(+?Q+I?B;3;BSO-2BM'LK^"X9H
M8YHV??\ (P#%=K= 0> .?6]X2T/5])U3Q!=ZE]BV:G>?:HUMY&8I\BK@Y4?W
M>O?T'2NJHH Y>YT35'^(UKK\2V9LH=.DLRK3,)"S.KYQL(Q\N.O>N<F\#^()
MOAUKGAT_V:MUJ%[+<))]H<HJO+YF#^[SD8QTYKTB66.&)Y976.- 69W. H]2
M:KZ;J=EK%A'?:=<QW-I(6"31G*M@E3@]^010 S4-/76="NM-OE")>6[P3"-L
MX#J5."0/7KBN/3PCK5_X1L/">L-9-8VCPK+>12L7N(86#(-A7Y6.U0?F..2,
MYKLTU2QDU672TN8VOHHEFD@!^948D!OS%6Z .7T71-4L?''B+5[A;/['J8MQ
M$(YF,B>4A7Y@4 YSG@\>]<J? WB>S\$:OX*LVTR;2YO,%C=S3NDD2.V[8Z!"
M"02?F#?AVKU*B@#@[OP]XKT[Q!%KV@RZ9)/<V<=KJ-E=.ZQN8\[)$<*3D;B.
M1TJSJ_A_Q!J%UX:NC+83S:=>F[NB\CQ@Y5EV1@*W #<$GG'/6NSHH *\SM?A
M]K:^!=.T66ZL([[1+U;O39XR[+(R.S#S 0, AMI SCKD]*]#U#4;+2K*2]U"
MZAM;:,9>65PJC\34)UO35GTZ%KR(2ZDK-9H3S, NX[?HO- &1%HE[J?BK3]?
MU:&WMGTZVEBMX(9C+\\NW>Y8JO "X QW)XZ4WQ7HFJ:MJOAZYL%M#'IM\+J7
MSYF0L-C+M7"-_>SSZ5U%% '&^(=!\01^*[?Q-X9FLFN3:_8KNSOF98Y8PQ96
M#*"0P+'MT-0:YX9\27K:+KEI>V/_  D6FRR/Y3AA;/'(H5X@>6 PJX8]\G S
MQW-4K+6-.U&ZN[6RO8;B:T8+<)$^[RR<X!QWX/% '+ZUX:\0^(O#Z/<WUI9Z
MY;W45Y9"#<\$#QYPI)&6SN;)P.HXXYNVMOXLOM*O?[9&EQ74EL\$-M:2OY19
MAR[NRY'L ..>3GCJ** .5T?PJX^&\'A76A V+'['*T#EU(VXW D Y[].#45E
MX-EF^'<_AW6+SS[V]MC'=W:#):0J%##UVA4'OMKKZ* .2\-6OC6+[/:^(;C2
MS;6HP;BT+F6[P,+N# !.Q.,Y(QP*T_$%C=Z@(($L;"_T]PZWEI>-@.#C:5^5
MAD$'KCK6U10!YP? .IV/A33[/3I;<W&G:T-4M;2:9S%'&&;$ DP3@*QYQUJ>
M;P5J^LZMXCFU=[&*TUK38[1EMG=WA9=V",J P!;KQG'05Z!10!R/ANS\9V\%
MM::Y-I;0V2;5EM7<R79 PN_(P@Z$XSDCL.N%)X'\0R?#74/#7_$L%W<WS7*R
M?:9-@4SB;!_=YSQCI[UZ710!2U&SDU/0[NR<K%)<VSPD@[@A92/;(&?:N2M/
M"FK7GAS0?#^K)9Q66E-;F62"9I#<^0!L !1=H)52>3TP.N1W5% '%Z=X=UOP
MY>Z]%I0L[BPU6Y>]B,\S(UM-(/G! 4[ER 1@@]O>JUKX'O-(U#P8FFFUDL-
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P  6@#M4%T;)1(T(N]G+*I*!\>F<XS[UR6D>+M2U'PU?SS06D6M6M^VGM:
M,4$N\*H)SD@A@V[L#G!Q7:5R\7A'R?']QXA2XQ:SPHTEKZW*AD$O_?MBOZ]A
M0!5U3Q9?K=:K9Z3%'+<Z6BK(&LYY5GF*!]B^7]S@KR2W+=.,F!O'<DEWI-G,
MD.AW5_8_:4358V :7=M, .5PP/.3S@C IUYX=\3Z9XNOM8\,7FF&VU01F\M=
M1$F$D10HDC*=RH&0<=.OI:UCP[J&J6[:??V^FZSI\EJJNMZ[1,MQEBTBX1L
MAA@ @C P: ,_4-3\1-XY\)V1EM;9+JRGN)[<HS 2JB!@2&Y WD#\SGC"ZEXX
MU(VM]?:)IS7L5E=/;BT6SG>2YV/LD*2*-JG(; (;..HS@.C\&:M87'A&>RU&
MWN)=%M)+.=[L-^\5U0;EQW!3H3T[TVS\,^+-!U?48=$U'2_[#O[I[K%W&YGM
M'D.7\L#Y6&<D!B/YY -6+Q#>ZSK-]IVC)!"=/AB>X>\C8GS)%W+%M!!7"X))
MSC(&#S6?\(=Q^&.E;U"MON,J#G!^T2<4^/PSK>B>,;_5]$GLI[/5(XA>07SN
MKQR1KM$B%5.[(ZJ<9/>K_@/0+_PQX4M])U">VFEA>5@UN&VX>1G[_P"]0 R#
M7KZ7QUJVB"QM ;:PBN(9?,;=+N9@ QV_*.#P >M<W!\0?$#^#]'\4OI>G_8K
MJY6"X@65O-PTIC!0G@8..#U]JZ2'0]4@\?:CKZBS:WN+".UCC,S!\HS,"?DQ
M@[L=\>]8$?@76X_AKIWA?S=/-S:723--YKA&59O-X&S.3T_7VH VK+Q#K:^,
MKCP]J-I8>8^GF_M7MY7V@!PA1R1UR1\P'X5@1?$'Q ?!6G>*GTO3_L4ET(+F
M!97\P@SF(%">!@XZ]>>E='+HFK-\0(O$2K9>0FEM9&(SL&+%P^[.S&,C'Z^U
M8"^!=<7X8V_A7S=/-S%="8S^:^PJ+CSNFS.?X?U]J -JW\3ZG:>,)M&UR"QC
MA;3GU"&:U=VV*CA61]PY/(.0!TZ51A\;:M<'1;^WTF6YT_4Y8U>&*RG$MK'(
M,K*TA&Q@.-P &,\$]:T+WPY?W_C>#6)UM/L(TR2PFB$S%SYC!B1\F,#&.O.<
M\=*I>&/#WC#0X;?1+C5=-FT*S(6"X5'%VT2GY8R/N#@!=PSQ[\@ H^*-=O\
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M]'XW^(CZ9'#)>J;)H8YLA'86X^4D=,],]JF\,^'/%^@PP:')JNG3:!:L%@N
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_(P[GD=R:P]+\6:G_P )1X?TR[N;6[&J6LSW(@B(2WGC56*QR E74%BIY)!
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ML[VF4(#.=KJ'!.?,/(([5;O?!^MP>))=;T#Q!'9SWL4<>H17%IYL<S(-JR*
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M%V*<X!YQTH P/#_@O6] V:7'XE\SPY#)NAMFMO\ 2%3.1%YN?N^^,XXXJ)O
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MJO@W4M9\.'3[W7Q+>27$4\UTUH-O[M@RHD88!5R/4DY/X7Y/#EW)XUM_$?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0,L5^4CV/.:KZMJWB'2+'PI))>+YNHZK!;W<<D"[@DFYM@(P!@+@G&2<G(H
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M;GW)H U:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%BQ.[=D')/X?G73T4 >?CX<ZA_8EAHK^*)7T_3KJ*XLP;-/-18VRJ,^<,!P
M<#IWKM=1TVVU72;G3;Y?.MKF%H90>"RD8/3H?I5NB@#D[3P;.MEI6G:GJOV_
M3]+E26V0V^R1S'_J_-?<0VW@\*N2!GOEX\(SPZQKU]::LT46L*IDMV@#!)!'
MY>[.02,#...>^.*ZFB@#BQX#G70/#FDKJZ!-#N8KB*0VO,IC!"AAOZ8)SC]*
M'\#7UKX@OM0T3Q+=:7::C)YU[9I;I('DQAGC9O\ 5L>YP?Y8[2B@#G+?PL]K
MXQ77HKY1&NGKIZVIA)Q&K;@=^[.[/?'3MWKHZ** ..D^'6F-H7B'2UFD5-8F
M:8/C)MB3O4(,]%D+.!QRQK0\0>%8]9\&2^&8+G[);20I!YGE^8P1<=.1SP.:
MZ&B@#F[_ ,+3WNMZ-JZ:JUO=Z?#)!(8X 5F1]N0 Q.T_*,'FJ:^";@:?XGLS
MJL97Q \CRM]EYBWH(SM^?GY0,9[_ )5V%% ')P>#KF'5?#U\=4C8Z+:-:(GV
M4CS5954DG?P<(OXYJJWP[AN=+URQOM0:1=4OSJ*RPQ>6]M/\N&0[CP-@Z^_K
M7;44 8%OX>N9=6LM4U>_BO;NPB>.U,5MY*(7 #N1N;+$ #J  3QS6.?AS%<>
M'M8TB]U)Y%U#4'U))X8O+>WG9@V5^8Y (X]L\UV]% '(0^$-4D\0:1K6I>(S
M=7.FQ2P@1V2Q+*'VY)Y.#\O./PV]ZTOP_FF\-^(=&?6%\O6[R2[ED%KS&7(+
M*HW]/E&,^_7MW%% '-7/AJZN/$.B:S+J,>_2898Q$EL<2B10&/W^#\HQ_6O/
M-)OENKB74+3QQ9V>I37$LO\ 9U]I,<U[$68XC/*R,0,+@#@<#@"O:*3:N[=@
M;NF<<T <I<>']6US2;F+4+ZWBBU2SC2[LI+7S1#(4 <QMO&#GU! (!]<]!%I
MD$&C)I49D%NEN+93N^8(%VCGUQWJY10!P5I\.;NVM- MV\2SLNAS;K4K:1K^
M[VE-IZY;!QNZ<?=K3N/!\VHM:1ZGJ4=U;6FH_;X,VVV9"'+JGF;B-H) ^[D@
M8S7544 <A\4I8XOACX@\R14W6C*NXXR3T ]ZETW0WU2/0]0O]2AO8K",2VBP
MP[%,A3:)'.X[B 3C&T9)..F.I9588901[B@ *,  #T% '-Z%X3&EVFM6EY=I
M?6VK74UU-&8/+P9?OK]XY7'3O[U4M/ TD6BV>@7FJF[T2SE1XH'@Q*RQL&CC
M>3=AE4A>B@D*!GKGL** ,+Q%X6L_$=SI4]RSH^G77GH4_C4J0T9_V6XR.^,4
MGB;P[+X@?262^6V&G7T=\H,._>Z9 !^88'S'/>MZB@#DSX.N;3Q+J&K:1K+6
M,>IA3?6K6XE5W P)$)(V-CU# ]Q68GPR-OX:T.PM-?NK?5-$9C9:DD*Y4-]Y
M"G1E/H3VZUW]% ''ZCX%?6=!%KJ>MW,^JI<1W<.IK$J-#+'G84C'RA1D\=]Q
MYR:FL?">H1^*[;Q#J&O&YNHK)K)HXK18D=2X;/5B.0._Y=*ZJB@#$\3>'AXB
ML[.-;MK6XLKR.]MY0@<"1,XW*>J\GC(^M0&Q@T6YO/%.NWR2W$-IY3S1P%(X
M(%.Y@J LW)Y)R2<#&,5T5'48- '&>%K'3-4\5:KXQTT.;:]BC@AD*LJS$ ;Y
M54@<'$:YQSY9]:ZN^@DNK">WBD6)Y8R@=DW!<C&<9&?SJQT&!10!P\/P_N+3
M3_#45IKC176@;T@G^RAEDC==K!D+=<?Q _A6MX;\*GP^^KA]2EOH=1NWNVCF
MB0;6< -D@<YQ[#VKHJ* .)'PRTG_ (1"#P\9YC%#>K=K.3\_RMPN<]/+_=_2
MNFU.QO;LV/V'4FL%@N4EF5(E?SXQG,1S]T'CD<C%:%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ME@9%V!4SMVX&<\GN>M3^)O#T'B?0Y=,N)YK<,Z2)-"0'C=&#*PSQU ZUKT4
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MJ5=&W*<')'7!]>*[6B@"IIM@FF6,=JDLLQ7)>69MSR,3DLQ]2?P[# JW110
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MVBS]C=F2<3*#&!N&023M-2:GX>U_4+WPW>23V,TVG7C7=T2[QJ2R,FR,;6X
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M/5/'>EZ7JUUI;6FIW-[;0+<-#:V;R,R%MNY1W YR1Q[YXH Z.VMH;.VCM[=
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M!+"&:6$'!9-A;=@\$=1Z51M_B3H=QIQU$0ZC'8?9EN5NI+1A$^YP@16Z%]S
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M82XV;=OS=<Y&,9Q6_IEG/:?%29S;7C6BZ'#9K=- ^QI$D8D;L8S@@YZ5W5%
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M6UW(<1B:)0IB+'@$CD9ZT =88]?LM7TV,7B7VFRR.MRTD 6:/]VQ4Y7"[2P
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MPEXL,;R6.CW4BWNQ2QBBE4*9,#LN.?K79'7]+:TCN8+Z"Y27_4B"17,Q/0(
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M".9'/+.?=F))^M7J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ML"RCI((P&].M9&FZ]<7_ (MUC1S:1)!IJ0DW"REB[R L%*[1@A0">3]X5O4
M5X["SANI+J*T@2XD^_*L8#M]3C)I#IMB6=C96^7^\?*7YN_/'-6:* *XL;18
MEB%K (U8.$$8P&]<>OO2'3K$N[&RMRSYW'RERV>N>.:LU2N]0:UO[&U%E=S"
MZ=E,T* QP;5SF0YX!Z#KS0 \Z9IY0(;&V*@D@>2N!G\*QTTO6[OQ 9M4NK Z
M1:S>=96]O$PD+;<#S23CY<D@ =<'C&*Z*B@ HK!\/Z]<:UJ.MP/:1Q0:==BT
M25)2_FL%#/U48QN [\YK>H **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHS=LNULG#  # ;/2N@30[=?BE>Z&+K4/[+NM&2\GMC?2D/*)F3=N+;AD=0"
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M9(L32;<G&2%!.,U7B\5:1)=6UL\T]M+<G; +NUE@$K==JF10"?8'-<_\1_\
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M:SH*ZO)MU.Z>X:5H<[=T@<AANRY(&TDD9'ISGN:* .<O_"TE_K&AW[:I*O\
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M"*=S8!)ED+=A\OMD[FK^"[WQ#;>(+N\GBM]2U&P.GVBJQ9+6'K@G')9N6('
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M?JEB;Q83(!)%@+\K*1URP&<C&&)QBJ5I\21=Z7I-ZFC2XOM16P<+.I6)FD9
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MV''3>=H]<=NE7K'Q8]YXIM]%.F21K/8M>+<>:",*RJ?EZ[26X;OCICFN;LO
M^K3>"- \/:DMOY:7RW6JXE+&50S2L"<?,6E(^@[UT6G:-J,7C_6=8N4@^QRV
M\%M:,')<1H"S#;CC+L3U[#B@#7UC6+;1K:.6</))/*L%O!& 7FD;HJYP/4Y.
M  "3@"L&[\;-81>('N-/0_V+;)<3-%<[D8D,3'N*C$@ '&#]Y>>:;XST#4M2
MU?P_JNGP17BZ9-*9K.2<P^:LB;=P8=U]#U!--UWPU>ZUX9@T5+2QL;.XO(6N
M[>W8@);JV]P& &68J!P!U/)ZD L67C*2ZU[2-,;298AJ-K)<"8R@^64"EAMQ
MDKEPH;C)' QS5'3_ !;JDO\ PE6K75K;+I>D.\$2I<'YFA&Z1LE.^<>Q3'J:
MO0Z+J4?Q N]7\JU6QCTV.SL_G.0,LSC:!QEMG/HN,>F OA'Q!_PJD>'7BM3?
M7$JF[ G(WJ\V^8E\=6RPQC@>O2@">XU.[T7PMX;L_#^FI;3ZY<*%BN+IG>W\
MP&:0Y(.<#=ST!QP>E='9>(Y[G6]6TB733%=V%O%<(!,&6=7WXP<#'*$<^M4K
MS1M7N?&VAZDT=H;*PLY5)#$".9RH8A>_R*5'(ZD^QBGT:YU#XBW=W$Z#3'TR
M*TO&!^9G61W\L?56Y/8''4Y !T6DZB=1T.SU*: VAG@69HG<'R\C."1P<>M8
M%QX[ABT!O$<=DSZ$LRQ_:6DVNZ%PGF)'CE,GN02 2!TSNZ[IKZMX<U+2X9?(
M>[M9+=) /N%E*@_AFN8D\+W^L:#H>@7T$=EI=@(#>(L@<W)B VQICI&64$DX
M/ &!UH O7.MZK-\1;?0;2" 65O:?;;N4RG<P8E%7&W YW-C/.T<CORMAXJ&G
M7GB+Q-'827PO=6BL5,<@4+#&P@3!/WF+F1MH[<DC(ST=GH^O6FM^+=36.U\^
M^ %BQD)RJ1!8E/'RC<7)Z]:SH_ ]]I^C^#M(L4MWM]-N1=W[R.1OF"-A^F6_
M>-NQQT R.H .HO?$,4&HW%A;)'+/:PB>[DEE\N&V0YV[WP<$X)  / R<#&<B
M/QYNC\..^DS)_;43R+&9/WD05<_=Q\V24 Z??&<52M?#&IV/BS7+B72['4[3
M4KE+J&XN;@CR2$5=K1E3G&W@C\QVV8M!NI_'AUV_,3PVFGK:V87/WV8F5]O\
M.<(!R>,T :NBW]WJ6F+<WNFRZ=.SNIMI7#,H5B 21QR #^-<I8^,=1-CXLUR
M_@MXM,TMI8+=8YB^]X0=QY49W,=O_ <8[GN)O-$$GDA3+M.P-TW8XS[5YW!X
M+UB?X;Z9X8NUMT\RZB;4MLI+-'YGFS'<!RS/Q@= >M $G@C57T:#PYX7:PD=
MKNSEN9+S> #*"'E.WKM+R$!N,GH".:U=6\<I8:)J&M6FGM>:;92>3YJR[3/)
MO"8C&#N7>0I8D=#C..63>'M5D\8:GJ$/V:WM?[)6PL) QW1$[BV% X^;9SGH
M@&.>,)/"OBB;PQX4TA[2QMX-*N8&NH%N2PG$2DAV.WH7"MM&?K0!U-]XK>Q\
M36NAG37EN+BT:Y'E2@D8(4+@@=23SD#"L3@"K?A77SXFT-=2-H;7,TL.SS X
M/EN4)# #()4]JRCX>U-?$'B7Q ! VH36:V>E9;A%5">?3=*Q/?@"M/P?I$V@
M^$M,TNX2));:!8V$;%ANQ\QSW).3T'7\2 49-;U6X^(J:%:P0"PM+07=U+YI
MW-O)1%(VX'1FQGG Y'0\KI7BH6%SK7B..PDOO[4UJ.R5DD"!8E801 9^\Q.]
M]H[')(R,]#::-X@M-0\8:@D=J+O46/V)S*>0D06$'CY0#N)Z_>_.FG@F\TZP
M\&:5I\=NUEI4QN;UI'(W3",A7QC+?.S-CCH.1V .DOO$<-O?7=E;)'++90B>
M\EFE\J&W4@E0[X/S$ G !X&3C(S;T/5#K.@V6J-:RVGVJ%9?)F^\F1G!KD;#
MPQJFG^)]<DFTNPU*UU"]^VP7=Q<']R=JC:T94Y*[>"/S';O%4^6%D*LV,,0,
M GOQ0!P'@1SXU>Y\8ZD/.BDN9(M)MW&4MH4)7>%Z>8Q!RW7C XKH-631?#E[
M=^+;Q5BE^S+;.T<>7D^?*J .68D@ 5C>%=&UWP19R:%;V$6I:3',[V,Z7 CD
MC1V+;)%;K@D_,"<^E7_$F@ZGK5EI4KF%[BQU2'4&M5;",J9'EAB!DC.X$@9(
M[#H 6E\2RP:YIFEZCI_V675(Y7M<3!R&C4,R., *=ISP6'!YZ9PY/B6L=A/=
MC1W>*#5/[.=EN%VG]X(]P)')W;OE]%R2,C.C-H>I7WB-_$=PL:3V5G)!I5FS
MY".X^:21AQN. N!D #J2>,JS\ SPZ9X/TF4Q/9:9,U]J)W<S7.TE<<<C>[$Y
M[ "@#=T_Q6VH:WJVFC3G@%A;Q7"RS2@!UDW8W#&4X7.#DX/('2LBV^(TD_A[
M2->DT.6'3M0N4MRS3C>F]RB,%V_,O3/3KQGK63KUGK6CZ)XPGE6W%]XAOUL[
M$I(2[K($AB!X^7:NYN_.>F.>D'AR;4IM$M[FV%GH^C%)8;4N&>:5%VQD[> B
M]1SDG&0,<@%V^\4);MJ9M+;[3#I49DOIC)L5"%WE%X.YPO)' &1DC-4)/'!A
MLO#5Q-I;HVN8*Q>;EX1LW\C'S'&!@=R!7.3^$_%LG@35?#JQVB27-[+))<K<
MG?=QRS[GS\OR?(2#R3QBNI_X1RYNO&VG:M>I;BSTS3S%:QQDX6=V^=@#V"*H
M!]SP* *X\<7+:3XCO1H4F_0Y622'[2O[P+&)#A@" P! (&>>YK9376FO='C@
MLGDM=2MWG^T"0?NL*K %>I!W8R. <>HKG]%T6^TOP)J]MK8MTN[][J6;RG+[
MWF9L<XY)!50H'8=<X%S0M,UK1_!ELS06]SKT&GQ6Z0O+MC4H@&S=@]2"2>YX
MZ 8 .LHIL9<Q(9%"N0-P4Y /?![TZ@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBO.?$UTMO\5-$LKK5KNTTVZL9Y)XQ?R0QLZD;3PPQ
MU[4 =HFA:='KCZRL,G]H/'Y32F=SE,YV[2<8R2<8ZUI5R^G76DV)U35+/6+N
M\L+5!'<)]HDO%C=0')7ECG:XR!Z#TJ./XBZ Z:9*S7<=KJ0'V>Z>U<1,Q7<$
MW8QN(!X'<8Z\4 =917.VGC32;K^TPRWMO)IJ"6XAGM)%D$9!(<)C)4X/0=N<
M53MOB3X=NKG3(EDNTBU/:+6YDM76!W89$?F$;=WMZ\=>* .NHKB=#FDB^)_B
MZ*6[G:VBM;.54FF9DBW"0MM!.%'&>.*UH_&6DO+8;S<16VHN([*[EB*PSL>0
M%;MGMN W=LT =!161IWB.QU35M2TRW6X%WIQ47*21%-NX$K@GKD D$<4R+Q/
M8W%E:W,$=S(UV7^SP+%^\E"_>8 ]%']XD#D<\C(!M45A6?B_2+_3'O8)9/DN
M39O T1$RS@X,13KN_3'.<<U/I'B*QUB[O;*$30WMBRK<VLZ;9(]PRI]"".A!
M(H UJ*J:GJ,.DZ9<:A<K*T%NADD\I"[!1R3@<G YK*_X3'2\Z+@7)&M*&LF$
M)VR97=R?X3MYP<4 =!17,^(]=TA=%UR'47U""UM(_+NYK:-]R;EW?*R9.<$'
M/;(SUK*U^9D\5> GM+J[6WGGD1D,[[94%NS+O7.&/N>: .Z90Z%3G!&#@D'\
MQTJAI.B:?H<4T6GPO$DTK32!I7?<['+-\Q/)/7UKF_#<DP^)GC*V:YN)((X[
M%HXY9F=8]R.6V@D[03S@5V,LBQ1/(P8JH)(12Q_ #D_04 /HKD;?XD>'KJVL
M;J)KPVEY/]G2Y-HXB23>4"NQ&%)(Z'U&<9K8OO$-I97<UJD5S=W%O$)IXK6+
M>T2'."WN<'"C+'' H L1Z-IT6KS:LEJ@OYD5'G.2Q5> /;J>E7JX_6/'EI:V
M.@7>EQR7]MK%Y'!%/"A*A226XZ[L*P"]00<]*N1ZCI4_CH0"74%U9=+,IMG$
MBP^3YB_-M/RE]QQD9/!% '245Y8NJ1^(KCQ/<:DVNVJ:7? 6TMD'1K:..-&/
M R"22Q((.0?88[I/$^GRZ%8ZQ$)Y+2^:-;?;&2S>8<)\O49R/IWQS0!LT45R
MUKXH_M3QGK'APV5W'%9PPYF"E<L^\D[@<JN%&#P<Y]J .IHKS'X?^-+2Q\%:
M'#JL]_--<W,MNUY)&\B"1IY BO*>,GCOZ9Q79ZMXIT_2%NWF2YFCLE#WDEO"
M7%NI&<MCVY(&2!@D8(H VZ*BMKF"]M(;JVE66"9!)'(IR&4C((]B*Y#Q5KMZ
M_BW0_".FW#6LNH"2XN[I -\5N@Z)G@,Q&,]J .THKG+[PU*D,#:3J>HV\\5Q
M%(XEO9)EFC5U+HPD9L94$9&#^&15B_\ %.GV#WBE+FX6Q :\>VA,@MP1N^;'
M4XYPN2!@D<B@#;HK N_&>B6DVE1-<22_VJC/9O! \B2@*6X8#!.!P!R<CBJ0
M^(>C-:WLJP:FTUBY6ZM5LG,T( W;F7'"X.0>_:@#K**YR[\<Z#9C2B]S,ZZK
M$9;-HK>1Q*H3?P0/O$8POWB2!BH[+Q_X?O=*U/4&N)K5-+.+V*Z@:.6 ]MR$
M9Y[8ZT =/16);^*;":]N[*6*[M[RUMUNGMY("7,1) =0N=PR",#D'M6=:?$7
M0+Y=+DA:\^S:G((;>Y:U<1&0DA4+XP&..GYXH ZRHKFVCN[:2WFW^7(-K;'9
M#CZJ01^%9NG^(['4M:U'2(%N!>:>%-PLD14*&SM()^\" <$5:TO4X-7L1>6R
MRB%F95,B;2=I() ],@\]Z %TK2K+1=.BT_3XC#:PC$<>]F"#T&XD@>U7*Y[Q
ME>Z59Z-'_:\]]!;R7,*J]GO#;]XV@LO0$X') -+?>,M*L-:ET=UO9=0CM_M/
MD0VDCLZ;MHVX'S<YY' P<D4 =!5&QT;3M-N;NYL[5(IKN0RSR#)+L>IR?Y=*
M;H>M6/B'2(-4TZ1GMILXW*58$$JRD'D$$$?A4>OZ_8^&M-.H:CYRVH=49XXR
M^TL<#..@R0,^] &I162/$5E_PDBZ 4N%OVMS<A6B.TQ@X+;NG4@8ZU1N_'.C
M6$<$EV;N);B\:QB)MG(:525(! QU5A[X.,T =)17'CQ'HFL:YX=+MJ]M>S2W
M(M()(98%<HC!_,! 4X"D@'GD5)I'C)=6U+Q!;2V%[!;Z;-Y.\0,6("!B<+DY
M.[@#G&* .LHKC=,\6>'-%\):%/'=W\FG7TBV]G/<))*[LS$#>Q''?J>@XZ5K
MZ5XKTS5[K4+6/[1;7%@%>>.\@:%@C E7PP'RG!Y]N<4 ;=%<T?'>C(-/>07J
MPZEG[#*MH\@N<#/RA 6''(W 9'(KI: "BL(>+-.:\U>T6.[-QI*+)=1B Y"L
M"5*_WL@$\9Z>M/MO%&GWFE:;J5NMQ);:DZI;%8CEL@D$CJ!@$\] .: -JBN,
M7Q)I&FP>+=6LAJ=Y+8OOO+>0.-KK&#A%?&U<#)/3OSQ6+KNOS75AX$UJ22\L
MS<:C MS&I=$D#0LY&P'YQD#'!/I0!Z;17/6GBS2M5M=64"^@?3AMNX9+:1)H
MU9<JP4#=@C)!'/%4+#Q9X=T7PQH#+=7SV5_LALI9XY)'<G.-[8ZX!X)SZ"@#
ML**QM$\36&O75]:VRW,-U8LHG@NH&B=0PRK8;L0#CZ5KR/Y<3R;6;:I.U1DG
M'8#UH =17E5I>6_BG3]?U'6;G7;$:?J=QMN+(RH8H(B%\O"YZC)88SR3VKK+
M/Q/HVF:3X;@1[Z2WU.**.PEE1G:3* J'<]&*\\^] '0W]A;:II\]C>Q":VN$
M,<L9) 93U''-.M;6"RMDMK:)8H8QA448 JG/KEE:W=Y;W#/$+.W%S/*ZXC5#
MG!W>ORMQUX^E5[7Q187.M)I$D=S:WLL)G@CN8BGG1CJ5/J.ZG##TH VJ**YC
MPOJ[>(H[W7BSFR%Q+!8Q)G!CC)1I,#[S,RMCT& .^0#IZ*\K\,ZI#K?C(?VK
MJWBG2M:+M.FC7C>1;2(,X"+CYU QGG)()QC-==)JCZ+XWLM(ED9[/6(I9+;>
M<F*:/#.H)_A93D#L5..#@ '3445Q'COQ%;CPCXCBLWOS+9VTB/=66Y1;S;,J
M"RD'()7.,@9^;% ';T5RVF>([:ST?1;)UN;O49=+CNC! N^3RPJAG.2.Y ZY
M)Z9J8^.-$^RZ-=1R3RV^L.L=G*D+%7<]%)_A/!X..A]* .CHK*O?$.GZ==74
M%VTD8M;7[7-(4)1(\D Y'<E6P.IP:DL=8CO;Z6S-K=6]Q'&LI6>/ *L2 002
M#T/&<COB@#1HI"0 22 !U)KGQXSTC-G(S3I9WLHAM;UXB()G/0!NV<<$@!NQ
M/% '0T5P6M:J=2^(L/ANY@OSIW]F23.D ="\AD1 ^5(.U1G!Z9.>H&.QTJP.
MEZ7;6)N[F[\A GGW3[Y7]V.!D^] %RBO-'N8!\6=7TW4M;N[?3TT^&>&)M3D
MA42,Q#$8<=ATK>@UK1_#OA_4=>.JWEYHXE)#EY+HQE3L8*V6.W<O4G )/- '
M6T5S+>.]%34X["07L<L\32VQ:TDVW(&,B+CYR,C@=<Y&12?\)]H:Z#J&L3-=
MPP:?*8;N*2U?S87&#AD )&01STYZT =/17-V7CK1+_7XM&1[F*ZG0R6S3VSQ
MQW( R3$Q&'P/3KU&:R/!VHIIY\:SZC?R_9++6)?WMU,S^5&(HSC+$G R>* .
MJU/0M.UB6UEOH9)'M)!-!B9T"..C *0,\GGWK1K$@\4V$NJ0:=-'=6MU=1M+
M:I<Q%/M"J,G9[@8)4X8>E)IOBS3-5T[4;ZV^T"'3I'BN?-B*,CH,NN#SD"@#
M<HK&D\26J0PM%;7D\TL N1;10DRK&>C,IQC/8'DX. <&FVWBS2;_ $NQO["9
M[R.^#?9HX4)>3;][@XQMQ@YP >.XH NOHVG2:RFKO:HU^D7DI,V253). .@^
M\>>O-7JYB>_M?&GA?48=+O-2MY4D-O*+1Q;W4$J,"4RWW3V)Z8-7(-0?1['2
M],OI);_5FM1O$*@M*8U422<D #+#_OH4 ;=%5=.OX=4L(KVW$@BE!*B1"C#!
M(Y!Y!XZ&K5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>
M>>(2R_%O0KY]/OYK&VL+B.::*PEE17;&T953GIVKT.B@#D9]0MI(=8@TS2+]
M(Y;62>XF:PFBWRE BJJLH+L0.< X"CUKE#;7B^ /AY:G3=1^T6.H6+W40LI2
MT*QJ0Y8;> ,UZS10!YU?)-_PG?BBZ-I=K;2: L*3M;.L;.OF$@.1C.&'>L>S
MMSXH^%/A'0[.WN#=?Z$[R- ZK D95FDW$8^Z"!@\[ACO7J>I6C:AIES9I-Y)
MGC:,R;=Q4$8) ]<&JWA[1_[ T"RTE;AKB.SB6&.1E"L548&<=Z .)N]*O=5\
M5^/;2&"Z@_M+2H;6VN9('6)G"2 X?&."P[]^*K74%WXG^'NB^&QIUY::M#+:
M1W"RV[HMMY++ODWD;2,*=N"<[ACOCU*B@#@?&>FZE:>*-,U;0R$N-45M'N_F
MP0C!G28>K1X<_3BH/%UBV@Z_H&JQZ)<:EHEI:2:?/;VL9DDMU)0HZH.2/DP?
M:NIL?#9M=<N-4N=5OKYF=VMH+AE,=J&ZA  .W&3G R.YSN4 >6:YIY?2M/U_
M1?"<RVEKJ@N[C3Q!Y=Q=1F-HWD,?7<-_ /) SWKJO"CZ;?7%QJ>F^'IM-21%
M1Y[JU\B:8CM@_-M7U/&3QT-=310 CHLB,CJ&5A@@C((KQ]_"FO+X8O["..57
M\+733:$<DFX*L)4R.^(SY0]V8=J]AHH X3Q'8WC?"C64>SGDU34K6662WAC:
M5_-D'"849.T;4SZ**KZJL\FK?#Z9+&_:.UD9[@K:2GR08"@W_+\OS''->AT4
M <5X?CG3XG^+IY+2[C@N(K-89I+=UCD*(X?:Q&#@D=Z[-W$<;.P8A1D[5)/X
M <FG44 >-1V=^/@G8Z<=*U(7R:FLC6_V&7S HO#)G&W.-G.?ZUU&F/<>'?'O
MB.XU"VNWL-8\BZM+J*VDE&4CV-$P4$JPP" 1R/?BN]HH \B_X1_4M$\*^')Y
M+"Z<1>)O[2FMH(C*]M YDP-JY/ 9<@="372KY\GQ@M[XV-ZEJ= : RM;/L60
MS*^PL!MSM![UW%% '$>!1*FL>+1/9WD"W.K//"T]K)&LD?EHN06 !Y4U3\):
M)>Z?XGO-#D"G1-$N&NM/.[)S.N5CQ_TS!E'/9U/:NWU2RDU'2[BSAO9[*25-
MJW%N0'C/J,BHM&TA-&L3 +B>ZFD;S)[FX8&29\ ;FP .@   P  * -&N'LC/
MIGQ3\03SV%ZUO?V=H8)XK=GC/EB0."P& 1D<=3V!KN** /&8;._3X+Z1IS:5
MJ0OHM321[?[%+YBJ+LR%B-N<;3G-:;&/1?%>O6NN>&-0U2SU:X%W9W5M9M.K
MAHU5HG'\)&W^+C&<X%>IT4 5-*MUM=*M(%M(K-8XE46T6-L7'W1CC Z5Q_C#
M2+^S\9:'XSTZSEOA8I):WMK",RM ^<,@_B*DDXZFN[HH QK;Q%!J01=-MKR6
M1B,^=:2P+&.Y8NHZ>@Y/ZCF/#[S^%]8\56.JV5Y-'>ZA)J-I-#;/,MPDB@&/
M*@X9=N,''!]*] HH \ETCP_J/AU/AKI]U:W4LFGO<R7;PP/*D'F1OA6900,%
MPO7MZ5L6 GC\3?$&=[&_6*Z2#[.YLY<3;8-C;/E^;YN.*]"HH \<L9'TN+X4
MK>VMW#+;+<130O;.)$86Y!^3&<#KG'3FM+6+;5$O/&/BC2-*>Y%Q:VMK;PR6
MQ9K@HW[R41L,MM5OER.2O<8SVFK^'&U7Q!H^K"^:%]*>1XHQ$&#EUV-N.?0\
M8Q6[0!YEICR1?$E]32PUV2QN-"$8NKJVD):02ECE2,IQ_#A?9<$9R;6SOXOA
M/X,LGTO4A=VFJ6LD\'V*4O$J3%F8C;D #G/>O8Z* .!\:V&I6OB'2=<T$A;R
M]!TFX#<9CD!9),=S&P+8ZXS7;V5G#I]C;V=LFR"WC6*-?15&!_*LJT\-F#7Y
M]5N=5OKW+L]M;3LOE6I88.P #G&1DYP"?4YW* .,^)\,]SX16"UM+FYF:]MG
M$=O \K;5F1F.%!P  :C4R_\ "X'O_L=[]C_L$0_:/LDFSS/.+[=VW&=ISC\.
MM=O10!QGPRAGMO"TT%S:W-M*+^Z?9<0/$2KRLRD!@,@@BNCUS28->T*^TFY'
M[F[@:%CCID8!'N#S^%:%% 'D7]F>+7TG0O%+VCGQ#ILR6'V5B<20',+NP_VG
M/F9_NJ#VK>\8:<]E:>#;*UM;RZ6QUFVFF>&V>4B-4<-(VT''+ GZUW]% '%>
M*$F?Q_X*N([2[E@MIKIIY8K9W2(/ 47<0,#+$#FH?#K3Z7XJ\90W6GWP6YO!
M=13+;.T;Q^2@RK 88Y&-HR?;K7=T4 >.6-G?P_#3P#9R:7J0N;+6+:2YA^Q2
M[H41V+,PV\  CFND> S_ !%\1RW%A>MI]QHL<!D^SNB2%3(70.0%SAAW[UW]
M4M7TNWUK1[O3+LR"WNHFAD\M]K;2,'!H \GT#5=.-CX5AUS^V+>WT?;);^=H
M\L:*VS8GF3<J54-C< H/!.!Q7LM<W:>&+U%$&H^)=1U*S&!]GFCA0.!V=D0,
MP]>1GOD$BNDH X;Q/I&J1^,]-U+1HVQJ5N^EW\B_\L4^^DWU7$@&>[ =ZB\$
M^'[_ $?6+[2IX671](N)&TIB20RS@-@9_P">8+IG_;/I7?44 >9Q6-[=CXFP
M1V%XKZ@K?9#);N@G_P!&"?*6 !^88J"XDN;S0OAZ$TK55:QOK8W*O8R@QJD#
M(S,-N0 QQD]>HR.:]3HH \_M1/%XZ\;W+V5\+>XLK989/LDA65D1PP4[?F(+
M#I6%;6M['X%^'-L^F:B)['4K>2ZC^Q2[H517#%AMX +#\Z]=HH XK14F7XJ>
M)+AK2[2WGL[1(IWMW6-V3?N 8C!QN'>NT9@JECG &3@9/Y4M% 'FOAY;B/P9
MXTBET_4(Y;B_U&:"-[*56E20G85!7)SD=*G_ + NM8^#.E6$44UMJ]C8V\ML
M)8FC>*ZA52HPP!'*E?H37H=% ' :II&L:_\ #'4I5M1%K>J(EX;9SC:5*,D)
MST^1 I]R?6I?"]YINMZE:74'@^\TZ]ME;SI[ZT,1MR5(*1L>6)/IQC.<< ]U
M10 A&01ZUP?PQ\S1?AI]BG@FENM(FNX9X85W.S+*[84=R01CUR*[VJ<>FPP:
ME-?0%HY)P!.J_=E(& Q']X#C(ZC .<# !R]RUOXUN] NK2QOH#I]XMX\]W:/
M;M$ K QC> 6+$@$+D8!)/3,?BFV>_P#B1X*AA!)M6N[R8C^",1A!GZLP%=Q5
M2VTZ&WO;B]),EU. K2OU"#.U!Z*,GCU))R: +=>0Q/?Z3X,\9^%K_2]2DU&8
MWTMK+#:22QW:2AF5@Z@J#SR"0>@Y/%>O44 >:VEY?QZAX?L;O2=5AL#HL:^9
M:VKK*]P" 89)!S$H !Y*@D\G%0^&?#=SK/P3MM"N;:YT_4;9&,+W$9C:*X21
MG1QGG ..>X)KU"L77O#[Z[+:@ZOJ%E;Q[UG@M7"K<JP *L<9'3J"#R?K0!SN
MEB;5/A]>ZUKNE/=3ZQ;J]Q8P LQAVA51,<G(W.,=W-'@NTU/3/$%S8P7]_J/
MAP6BO;RZC"RS6\N['DAV +C;SS]W 'U[J-$BC6.-0J* JJHP !T IU %#7+&
M74] U*P@E\J:ZM984D_NLRD _@37F\]I>^(/A18>#FTZ\M=:C%K:2K);NJ0>
M4Z;I?,QM*[4)!!.<@#FO5Z* .(E\T?&6&Z^QWIM1HC6QN!:R&(2F=6"[]N.@
M)ZXKMZ** /.(I!;?%_6=1NM-U%K&3388(YQILTB-(K$D JA['KTI?%LO]H?#
M_P 3:;H^BZ@L)A*PK]AE1IYI&+-LC*AL G);&,L?2O1J* .!U3SI_&W@2ZCL
MKYH+>*Z\^06DNV+?"%7>=ORY(QS7,^(TF3PY\4I);2[ABN726"2:W>-9%$:*
M2I8 'D&O9*Q_%&@CQ-X=N]&DN6MX;M=DDB*&;;UXSP#0!S6HVY\3ZUX0>RM[
MA!ILYO+F:6!X_*41E?+RP&69B.!V!/IGGKO0]6UGPSX_LK*SNH[NYU@7EJD\
M#Q+<HGE'"E@ <^6P_+M7K%K$\%I%#)()710I<+MW8[XJ:@#@M3#^,M6\)SV=
MI>6YL+S[;=-<6[Q&!0A!C.X#+%B!@9X!/3%0:QHEY#\0#:62J=*\20A]23/^
MK,!7<P'I(C+&?KFO1*P]!\-G1I9;BYU6^U2ZD!19[UE+1QYSL4   9Z]S@>@
M  .3\0[]"^(4VJ:CH5[JFCZC910K+9P-.]M+&S\%%YVL'Z^M4]7L3H]YX?UZ
M#PG,=$CCN8+C3;6 &:W65D99?+7N2GS =,^M>J44 8'A6.R:UN;RPT1M*@N9
M-X66#RI9CCEW7J/09YXSW%97C?3+/4]1TU9GU6PNX8Y9+75M/1V-NV5!1]H(
MPP[-P=I%=I10!A>#9=7F\*63ZZ@743O\PB/RRXWG:Y3^$LN&([$GITK=HHH
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MA9E,8YQ][..O%<GX2UW5/%D&FZY9ZM9_9)MYO=-*JS0H2PCVLOS!^!G=P><
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M#VGE@_-CJNXKCW/%90LY]&\2ZGX'A@8:;KTGVVU=%^6&)C_I<>>W ^7T\T4
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M,E '=>&+Z?4_">C7]TP:XNK&":5@, LT8).!TY-:M8/@@@^ ?#A!R/[+MO\
MT4M;U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MKM% %1=+TY+E+E;"U$Z !91"NY0!@ '&1Q2-I&FO%+$VGVACED\V1#"N'?\
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M("%<CE0<9 /O@?E3F8*I9B H&22> *BM;J&]LX+NVD$D$\:R1N.C*PR#^1H
M8^G6,EXMV]G;M<K]V9HE+CZ-C-1+HVEHDJ+IMFJS?ZU1 H#]^>.?QI;^YOX)
M;);*P%TDLX2X8S"/R(\'+X(^;! &!ZU=H BM[:"TA$-M!'#$O1(T"J/P%2T4
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5YMXQEDED\6
MM:7]Y<W%CI@D6.*9H(]-81NX;<I^>1N&QMX"@$@&O2:YR^\#Z'J.IW]_/%<>
M9J$(AO(X[ETCG 7:"Z X) . : .?TW6)M=\1Z#HVHW$@AE\.QZBRI(8_M$S$
M*<E2"0HR=O3YL]AA+AY]$U/PSX5GURZN[6]O;E9KAY"LNU(_,C@+@Y_B7G.2
M!COBMJ\^'N@7FG:;:-'=Q-I@VVEU#=2+/$,8($F=V, #'MQBK.H>"="U/0(=
M&N;5S;02":)Q*PE23)/F"3.[?DDDD\YYH YKQ,]UX.TN:&UUFY>'4M5M8@)'
M+-I\,K;7VL23@[6QGH3QTJWJ"W&@_$/P]96%Q='3]9BN8;JW>=W"&- ZRJ6)
M*MS@D'G([UNQ^#]%&@7.BSV\EW:W7-PUU,\LDIXPS.QW9&!@YXP,8J>R\.VE
MG.MP9KJYNDA,$5Q<S&1XD.,A2>F<#)ZG R3B@#S/2KB\TSX;ZAXQ;4]4N]1T
MYKY($FNF>(CS61=Z'AMO7)YX] ,:>O:7!;77P_O8[NZN)9=4A\R62X9Q,6A=
MMY!.,^F,8!('%=MI?A72M(T>YTF"*22PN2YEAN)#(&WYW_>[')R*S(/AQH,$
M5A#NU%X=/G$]I$]_*5@(! "_-P!G_(H QX9+IO$7Q'M3J%[Y=O;6SV_^D/F
MF%V.PY^7YN>*Q['[79:)\.-;75-1EO;^>VMKKS;IV26.2%B04SMSD YQG/))
M->@?\(EIHO-7NPUT)M618[QA.WSJHVJ /X<*2.,=:A/@G2#I^DV.;L6^DR++
M9*+AOW3*,*<]\ D<YZT <IK,VIW%QXUMIWU'^T8D0Z+]C,F #'E NS@,9,[L
M]CS\M6-8M;FSN_AS!>R227:WY,[22F0^8;=RWS'J,YQ[50GT?S_$6K3:CI'B
MNTO;F[9DET>[=8)HP D;95P Q51G<!S[5UMIX36ZL='?6+F]GO=-D>6WD>XR
MZ$EMN\CAV"$*2<@X/KF@#!N=2D\%>-M3CO;B\N;'5K0W&FQRW+OMN$X>W3<3
M@MN4C\17:Z%I\NEZ):6EQ<2W-PD8\Z:61G+O_$<L2<9S@=A6$ZS>*/$5M'>:
M!<VEIHMZTZ7-V$Q/(JE8S%@D[?F+9./NJ.YQUU '%^(Y;B#XE^"TBNKA(;AK
MQ9H%E81R;8"5)7."02>:YR>;_A+/A]XUU:\N+D3PM?00QQSL@MTB4A4V@XY
MRV1SNP>, >A7_AZQU+6=/U6X,_VO3RYMBDI4)N&&X'!R..:S+OP!H=U=ZG.!
M>0+J:L+V&WNGCBF)&"S(#C=@]>_?- '-:=>W.H7^@>'04-N/#D%V(FN7@\UC
MA"<H,G: ..GS9[#%;5+'6M(L/#%A=^(KF:X_X2%+5I;>X;=Y#HSB.0G[[#Y>
M6'3%==J/P^\/ZE8:;:R1741TQ=EG<0W4BS0KC&!)G=C Z$U8F\&:/-:Z;;%;
MA8].G%S;[;AMWG#/[QB3EVY/+9SDT <;):FWO?B#H)N[V;3H],BN8HY[N21H
MW:.3=AV8M@E 2,X_"J]Q')IOPC\(7%E>7L$CRZ9OV74F&#F,,I!/W<?P]/:O
M04\+Z:NK:AJ3":2XU"$070>4E)(P" NWH, GIZU2_P"$"T3^PK;1O],-E;2I
M+$K7<A92F-@W$YPN!A>@]* ,3Q%IEO<?%SPR9&N1YUG>%MEU(F-HB QM8;??
M&,]\U!+J4W@WQ?K-E=3W=W!JMM]ITA)[F1_WP.QK=2QX)9D(QT#>U=?=>&;&
M[URSUF62Z^W6<;1P.)B JL &&WH<X&<BLI%F\4>([62]T"YLK;1;J26.:["9
MGDP40QX).W#%B3CD)C/. #H-&T]]+T>TLI+F:YEAB59)YI&=I&QRQ+$GDY^E
M<;KNG6]Q\8O#SN9PSZ==%BEQ(GW6CQC## Y.0.O?->@5DZIX;TW6-2L=0NDF
M^U66\1/%,\?RMC<K;2-RG X/I0!YI/IYN-.^)E\M[?6\UE>S3VYMKEX0LB6Z
M,&.TC=T'!R/:MN/5[[7M>TG2)F1EET"+4&C:Y>#SI';:QR@R=N!QT^;/88Z5
M?!>E+;:O;AKOR]79FO0;AOWI8;3_ +N1QQCBH-2\ :%JECIMM.ETCZ8NRSN8
M;AHYXEQC <')& !S0!9\(6&HZ7HS6&J:FNHSP3NJR[BS(APRH['EF /4]1BL
M[Q)J4DOCCPWX<,LD-I>I<7$YC<HTWEJ-L>X<XR=Q Z[0.F:Z73--M=(L([*S
M1EA3/WG+LQ)R69B26)/))YJEK_AG3?$D=L+Y)5FM9/-MKB"4QRPOZJPY'N.E
M 'G\<<.BZQ\3%35Y],B6.RVWAW3/!NB.-H)R3DX49XR .U:>E?:!\2+C1Y$O
M+;3;K01.UK+>.[;Q-LWDACL8@D':QSP<YK<?X>^'YH]52XANKC^U4C2\,UW(
MQDV ;3RW4$9!ZCMQQ5BR\%Z18ZO;ZLGVR2_@@-N)Y[N21G3.</EOFP>1G@?@
M* /.O#-X^B?"CPG]EEDB.JZ@EI/))<R*JJ7E.%.3Y>XJ%RH!^;UP:[S0-'U/
M2?$=Z\^H1_V?=PAXM/\ /DF,4BD!G5GY"G(R.F<5)'X \.)X?NM":SDETVX8
ML8)9W<1_,6 3)^3!)(VXZU=\/^&-/\-Q2+9M=2R2 !IKNX>:0J.B[F)PHR>!
MQS0!C_%2>>T^&^L7=I<W%M<P1J\4L$S1LIWJ.JD=B:9J\L\?Q1\.V\=U<I!=
MV-YYT2S,$8J(]IVYQD;CSBNIU33+36=+N=-OX1-:7,9CE0DC(/N.GUK$M_!.
MC6-[8ZFS:A/>:=&ZPSS7<LDFU@,@\Y88'"].3QDT >=QV.HW?PQU?Q"/$6L)
MJ>E7-Y+:R?;'V@12L=K+G#Y"X^;/8=.*ZC1-3F\6^+=0T_53-#%9Z99RQVT4
MKQ!GF0M(YVD$D':H],'N:B\"^%UN?#UY;:O!J,22ZC//+97 9(Y5,I9"01R"
M,94'![BNOO\ PW87^K0ZJ#/;:C%$81<VTFQFC)SL;LPSSR.#TQ0!YC-J>LR^
M&8[:;5;Y9M-\7)I4=VDQ#SP"50-_9S@X.0<[><\UUNB1R:1\4]3T>&\O);&;
M28;TQW-R\VV4RNA*ER2,@#('%;5WX.T>[TRTTYHIH[:UN!=1K',RDS!MV]FS
MEFW$G)/).35F+P[91>(FUX-<-?M;BV9VE)4Q@DA=O3J2: +&LZ>VJZ/=V*7,
M]M)-$RI/!(T;QMCA@5(/!P:\E/B2[71O#&K//?"71)1!XAC%Y)M51)Y!:1<_
M,=^7&>RG->T5CMX7T=K76;;[(HBUAF:] _Y:%D"$^W _,D]Z .&\=J;GX8^)
MM5\Z9H[Z>)H%:5F18EFC12H)P V"_ YWCTK5C@ETCXK6EE#?WTMOJ.ESRW$<
M]R\@,B.F'4$X0X8C"@#VKI=6\-:9K6@C0[N.0:<%1?)BD*?*F"HR.< @?E2/
MX:LI=<MM9>2Z:^MH3!%(9C@(<9!'0YP#S0!YW;Z_?:7X2U(/J%SMD\62::UW
M+*7>"W,P4D,W3"C /;.:ZO5=$72H==N(-4N?LUSI,H&G2R-(H=5.95+$D<,
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MMH;62"*.]D01LT3MD$$$#/.W.WU!P,=OK'AZQUR>QFO#/OL9Q<6_ERE L@!
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MU7D-O))!!_ST<*2J_B<"N.TKQ,_B#2=2GTKQ%YIAL7,D4MNL=S:3C^\F!QU
MR#R#RU '? @C(((]J4D $DX KSGPW>ZO:?#3PQ<#48 ERL'VFYN,!X8F0D[
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M(I(\;T8 ;6&""#@>G/6@#L:*\TM_&FM3_#GPOXA,D"W=_?06]R@B^1DDFV'
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MVR:U: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/XUSTGPSOU\*7_A2U\0I'H4[EK>.2SWS6ZEPY0/O 9<YZKGGK7HU% $<"R)
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M!E1PNW>P4'GD\GH!^5;]<K\0-*U'6O#L5EIEL)YQ>03D-(J +'(KGDGOC H
M:_C"ZM'CM-3TRWTW4+B67[/%<Z@@C>% N96< [<EP-N"<^W-0:?\0K6]TR65
M[,I?IJ TU;:.4.DTQ^Z4DP 4(RV[' 4\<<KXJTO7O[:T?Q-X>MXI[RSCD@N-
M/N)1'YT,FTD!^0&!4'T_K6\0Z+XG\1:#:7PCM++6K"_BO[.R,OF1C8"#&\@
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M2&)R%CD>/;@*<KT8D CCJ!)<^,M3/B34]$TWPU+>7%@L$A8W:1ATD)!8$\#
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH ***XN[UN]USX@3^%M/NGL[33K9;C4+B(#
MS79_N1*2#M&/F+=>PQUH [2BL!M)U"RU;3IK/5+IM.21_MEM<2"3*^6VU@[?
M-PVWC)'?C'.)X1U"Z\?6%QKT]Y=6VF27$D6GVUM(8CY:';YCL/F+$@\9P .A
MZT =U17$Z-K5XGC/5/!6J74D[QVJWMC><)*\!.TJQ7 W*W ('(Z^^'X1O=1U
M/X:RZYJ'BN\M;R-[C_2G:(HFQV"[E*X(P!D=30!ZE17E>M>*==NO@,OBOS)=
M,UD0))F+Y0<S!,[3D89?F'INK0UC4]5\-^,O"UC9:M<:C'JDIBNK&Y".RQ@
MF92JAEV\YSP: /1**I:OJ*:3I-S?NA?R4)6->LC=%0>Y) 'N:YKX>:]J6IZ?
MJ.F:ZRG7-)O'M[O;T8$[HW'^R5.!_NT =E12,P52S'  R37*3_$SPC;IYDFK
M 1B8P/(()"L;@X^<[<*,\9. <'T- '645S^J^-_#VC7;VE[J&RX2V-T8TB=R
M8P0-PV@YZ]!VR>@-/O/&&BV%L;F:YE-ND:2RRQVTDBPHP!4N54[."#SC .>E
M &[16%<^,=!M=0%@]]ONFMOM210Q/*9(\@ KM!W9W# &3^54S\1?"PTZ*_\
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M<MT.T@* O#'@GIG% '345YOX#\;65OX4TR'6]5N)KZXO)[?SYD>0;S.ZHKR
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M^B^'9+J32K".V>[D,DSAF8N22>K$X&2>!QS5^_OK;3+&:]O)?*MX5+R.03M
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=_IZ74UJ=/NHS,+24*K,8\!B5XZ'.>G>O1J* ,KQ,RIX5U8MWLY5  R22A
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M-Y4?<X&23Z#IS[@=Q7D5N(=4^ M[J5SQKD!FGEGQB>.^24XYZAL[5 ]"!TH
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MW0-,^^[D5VE\QW?C )."N#QMR>U:]GH6CWWB;XCQSZ?:S0J('1&C#*I:VR6
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MK&X8QMC.UL=#R.#0!-1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MTYA<JBS VR$2*HPH;CD   #M3SX?T;SK6;^R;$RV@Q;/Y"YA'HAQ\OX5I44
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI:Q$ I&#@R.Q.%7/&>I/ !K9KSC0 \7QU\6+=Y$DVGVLEIN[P@ -CVW_ *T
M=3#XF6/6[?1]5M'L+VZ5FM27#Q7&W[RHX_B YP0#CIFMZO.OBLDDUQX,AM,_
M;SX@@>+;U"*&+GZ 8S445Y>_V=\2(C?WI%A)(;1C<ONAQ;AQM;.0-W.,T >B
MRW,$$T$4LJK).Y2)3U=@I8@?@I/X5+7E)MQJGB'X87-W<7;SW6F3M-(MU(A8
MBW1L_*PP26.2.3WS5BTTG4?$FM^,K"3Q+K-NMG>(MH8+DIY3&%6!..J@G[O
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MMS;3R1JTD!<,8F(R5R.#@\9%<EJSW%QX<\5ZU;7]W"!;3+9M%.V%$*'+J,D
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M;Q1M*R[ <RRM(W(]6)-7: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J
M.L:39Z]H]WI5_'YEK=1F.10<'![@]B.H]Q5ZB@"C=F2PTSRM.M1)*J"*WA'"
M XPNX_PJ,<GT'&3@&MX8T&+PUX=L])B<R>0I,DI&#)(Q+.WXL2:UZ* "LO5-
M LM5NK:\D\R&^M<^1=P-LDC!ZC/0J>ZL"/:M2B@#(M/#UK;ZF-4N)KB^U!4,
M<=Q=,"8U/4(J@*N>Y !/<FJ%]X%TF_U#4[MY;Z,:G%Y=W!%<%8I3LV!RO]X#
M\.!D&NFHH YM_ ^CO;:- IO8_P"QP5M)$NG#JA4*RELY*D #'MQBN>\/Z-+?
M>+?&3RMJ]C;WMS'L(B:)+B(1*IPSIP<Y&5(;WZ5Z+5+5+F^M;19-.L!?3F5%
M,1F$6$+ ,V2.PR<=\4 9]YX3TV[_ +(5?.MH](8/91V[!5C(7:.,'/'&#Q6?
M>_#G0K]=6CE:^6WU60S7%O'=,L7FG&9 O3<2 ><CCI76T4 <OJ?@'2-3OK2_
M\_4K2^MHO(^UVEX\<LL><[7;.6&>>>?>I-9\"Z)K5E86\B7%J^G'-G<VD[1S
M0YZX?KSWSG/7K7244 <W/X)TRXTRSL'FO2EK=+>"0SEI9)U.5D=VR6(QWXZ#
M& ,6QX<MAXC?7A=77V][46A;<NWR@2P&W;C[Q)S_ $XK2DO(([N*T:11<3([
MQQ]V5<;C^&Y?SK(\,>(W\0C5O,LOLCZ=J,EB5\W?O**IW9P,9W=/:@"FWP]T
M*7PY-H,Z7$UE)<&Z7?+\\4I)8NC#!!R2?Q/8T\>!-,.@7FCSW6I74=ZH2YGN
M;II9I4'1"[=%&3P,=3ZFNGJ&XN[>T\GSY50S2"*,'^)ST _(_E0!DR>%K274
M])U&2YNVN-*1TMF+K@!@%;(V\Y  Y]..:DTCPUI^B7U_=61N%-[.]Q)&\S-&
MKN<N57H,D9-;%% $-W:P7UE/9W,8DMYXVBE0]&5A@C\C7,VOP\T:T?27$^I2
M/I1;[(TEZY*(5V[.OW<<8'4<'(KK** ,"W\)6,!M%DN;RXM[.?[1;6\\@9(I
M.<,#C<<;C@$D#L.!@@\)6,)M5DN;RXM[2X^TV]O/(&2.7G# XW'&XX!) [#@
M8WZ* .='@W3@=6/VB]W:K(LMRPFP=ZXVLI &TC:!QZ587PQ8N]Y+>O-?3W=K
M]BEEN"NXP<_(-H4 ?,3G&3GKP*VJ* .4_P"%?:.+72HEN-2672R?LMRMX_FH
MI4*4W?W2JJ,#T^M-?X<Z&^G:CIX>^6UU"Z%U/&+IB#("&R,YQ\R@GN<<DUUM
M% &,WANUD\0V^N27%T][!;FV4EEVF,D%@5"X.2 <UG:3\/M$T34#<637RVXE
M,T=@UTYM8I"<[EBZ9SR,YP>F.*ZJB@#DYOAWH<FNW&JHU] ;M_,N[6"[>.WN
M6]9(QPV>XZ'OG)KK*** .#\56<][\2O"DD4>HQQ6L5V)+NV@<K$SJ@3+;2O.
M".<CUK9O/!.D7^D7>GW(N)#=W"W4UUYNV9IEQM?<,8(V@    #&*Z.B@#G+;
MP1H\&J3ZB_VNXGN+46MQ]HN6D69.?O@G#'#$>@'0"H]!\":5X=D!LKC462,,
M+6&XNVECM<@@^4C< X)&3DXR.YST*7=O)>36B2JUQ"B/(@ZJK;@I/UVM^534
M <F?AYHK:0FFF2]\F.]^WQN)L21S$DEE<#(R234MUX$TF\U"]O9Y;XR7]N+>
M]5+ED2Y 4J"ZK@$@''I[5T]% 'F7B#P_#IEYHE@+/Q)_96GV;QP7^E3R23H[
M%1L<*=VW:@[$=!QBM;1?#*:EIFIV&IR:S?:'>Q(JP:U)NFW DLR]&4?<QNYR
M,@#OV]% &!X=\(V/AO)@NM0NY-GEI)?733&*/^XF>%7@=.N!GH*WG8(C.<X4
M9. 2?R')J&.[MY;N:UCE5IX%5I$'50V=N?K@U#I-S?7>FQ3:E8"PNV+;[<3"
M4)AB!\P !R,'\<4 <'X&\-"_\/ZE:ZJNJ06\^IW$TMC<1M%',C2EE/S*&VD8
MR 0#W')SV/\ PCEI_P ).OB 37 O5MOLH <;/*W;MNW'KSGK[UL44 8,_A*Q
MDU2\U"WGN[*:^0)>+:RA5N !@%@0<-CC<N#[U?ET73Y=!?1/LR+IS6YMO(48
M C*[<#\*OT4 9DN@V4GALZ @>&P-M]DVQ'!\K;MVYQZ<9ZUF7?@;2;S3=)M&
MDO(Y-( %C=PS;)X  %P& Y&  00<XYJQI'B-]3\4:[HLEB8#I0@(E\T-YHE5
MF!QCC 4=SUK>H YJ#P/I=NVL.MQJ#2ZO&L=Y(]RS%P$V<9X!(SSC(SQ@8PX>
M"]/$.B1"XO NBX^Q?O!\F%VC/'S?+QSVKHZI:;<W]S'<&_L!9LEPZ1*)A)YD
M8/RR<#C(YV]10!S/B/PU]DTKQ+?Z=;7>H7VKPK%=6_F@>8H&S*],%4+8 (SC
MGFL;1=*D>^LWT>]\;0O%+&9(]6D<6XC##>K"0?-E<@;<\D<@<UZ910 5@WOA
M+3K[Q -::6\AN6A$$RP3F-+A 20' ZXR?3KCI6]6#X@\31:-X<U;5K6$7QTP
M-YT2R;,%5#$;L'H"/6@#CO$/A2WT2V\':+I$&K/9V6JB=Y85EF:%-C_-N (7
MYF''3GIC-=]I^C6^GW=S>^9+<7MT%$US.0795SM7@ !1D\ #DD]35JRN/MEA
M;W.W9YT2R;<YQD XJ>@ KF4\!:"NG:EISPSS66H2-+);R3L4C9FW$QC/R?-\
MV1SFNFJ&VN[>\61K>59%CD:)RO0.IPP_ \4 9UAX>M[.\BO)KFZOKJ&(PPS7
M;AFC0XR!@ 9.!ECDG R:UZ** ,!_"5C*9(YKF\ELY+O[8UG)(#$9=_F9Z;@-
M^&VYQGMUIZ^%K1-6U34X[N]CNM2C6*X=)0/E4$+MX^4@$X(YY]:G\2ZP_A_P
MY?ZNEH;K['"TS1"0)E5&3S@]AZ5<TZZ^WZ9:7A39Y\*2[<YV[E!QG\: ,>Z\
M':;=#1B9+F*31_\ CSDA<*R\!>3CD$#!'0]P:Z&BB@#GM1TA[?Q7:>);2,R.
MMLUE>1+]YX2P=64=RK \=PS8Y !LW/AVTGU.?489KFSN;F(0W+VSA?/09V[L
M@\C) 8889ZU?U"_MM+T^>^O)1%;P(7=B,X'L.Y[ #J:I:AK4NE^'+G6+G3IS
MY$+3O;1,K2! "W.2!D <@$^V: *&O:"E[X;3PKIT'V:QF18)7086&W!&X#U8
M@%1]<GWZ**)((4BB4)&BA54= !P!67#K\4OA6UUTVTQ6XMHITMXQN<F0#:@Z
M DE@.P^E9.D^-)[CQ*F@:UH5UH]]/"TUKYDR3).J_> 9#@,.I'_UJ -?5_#U
MKK-[I]W<37"2Z?+Y]OY3@!7P1DC!SP2,'CFHH?#-K;ZOJ>J175VEWJ2(EPP=
M<$("$P-O& 3^?.:MZ?JR7EW=6,B>3?6I4RPEL_*V=KJ>ZG!Y]00>E:% ',1^
M ]&BT'3])C-RL6FR^;8S"7$MLW^RV.G)X.0<X/:K;^%K&6QU*WFFN99-3C\J
M\N6<>;*FTKMR  HP2,*!C)/4DUN44 <\W@ZP:/14-S>8T;!LOWB_)A=HS\OS
M?+QS_.D?P7I;7&KS))>1?VL#]JC2<["2H5F"G@,5&">OIBNBHH YP^"]/-MH
MMO\ :+SR]&96LAYB_(57:N?E^;"\<U)'X2L5:)9+F\GMH;LWD5M-(&C2;<6#
M#C=@,20,X'IQ6N]Y EV+,.K731-,L0/)4$ GVY('_P"JLKPIXB;Q+IMS=O9_
M9&@O)K5H_,W\QMM)S@=2* -VL6\\,6=SK7]LP3W-CJ#1>1+-:N!YL><A7# @
MX['&1ZUM44 <_J'@W2=0\-+X>99X=-#!FCADP7(;?EF.23N&XG.2>N:W88VB
MB5&E>4@???&3]< "GT4 9FN:#8>(;)+:_1SY4JSPRQN4DAD7E71AT(I+/0;6
MUGN+F5Y;R[N8A#+<7)!9HQG"8 "A>2< #).3FI[FYOH]4LH(+ 36<HD^TW)F
M"F# !7Y,9;<<CCIBKM ''P_#70X;6PM3/J<D&GW*W%HCWK_N"N<*N.0HW?7@
M<X%2:YX:L;6/7]:MDO6O;ZS9)(86=UE<1E%/EKG+8./\YKK*P?#7B-]?FUB*
M2Q-H^FW[69!E#[\*K;N ,?>Z<]* ,;P3X;C;PCX<_M$Z@TEA!$ZV5XI18)U3
M!.TJ&."3C)(';H,:\O@[2[B^UFZN#<2G6(1;WL;O\CH%*J  .,!C@CGGO5S7
M=;AT.S@ED0R2W-S%:6\><;Y9&VJ">P[D\\ \'I1H]]J=V]Y%JFE"QD@EV1ND
MXECG7&0RG /L00.?6@#*M/ .D6EWI5W]HU*:XTQ62WDFO'8[" -IYY7Y1Q^>
M:2Q^'VB:=JTE[:M?1PR3?:#8+=.+7S<YW^5TSGGT! XX%7/%_B-_"VA-JBV)
MNU66.-E\T)MWNJ YP<\L*+GQ&]MXUL/#QL24N[:6X6Y\T<;-N5VX_P!H<YH
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MPRSRK&,>9<2F1V^K&KE%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)SEB<G);.<G/6@#G;BQD\/\ CSP5IEKJ>I2VLB7_ )B7-V\GF80,N[)Y(W$
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MPU>:#9Z++8/]DL2&M2)Y!)"?57W;A],XJ:;P3H,^AQ:/):S&RCE$VT7,H9Y
M00[.&W,<@'))Z#TKH:* &H@CC5 6(4  L23^)/6G444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MOQ!B#_!_47WRHT6GAU,<K)S@=<$9'L>*V_ G_)/O#G_8,MO_ $6M '04444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ",RH,LP4>I.*8)X
MB0!*A)Z#<*Q?&\:2> _$"NBL/[-N#AAGGRVKS;X56%EJWA/P[9WFA)&EO ]]
M'J+QQ[I)8[K(VL"6&.ASC(/I0![/17G&H>*M5\._$Z&WU.^#^&K]FM8M\:+]
MFN!&D@RP )#;B "3W]*I6'BGQ%<ZK\08KF_>)=)LH[BRB$,8,!>%I,'*Y8C
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
.4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>thackray-biocrystseparat004.jpg
<TEXT>
begin 644 thackray-biocrystseparat004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MA4$^6IY*KG[J\#@8'%:$LL<$32RR+'&HRS.< ?4TB3Q2Q^9'*CIUW*P(]>M
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M2&_P/D6W\^3AO]C<$![8X[U[/#9VUO;M;PP1QPLS,450 2Q+,<>Y))^M5(=
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MA];V\,8>WU,0B4( S#RG+$X]6&3[UWJZ=9);VMNMI"(;0J;>,(-L148&T=L
MXIE[I&FZE-!-?6%M<RP-NA>:)7,9]5)'!^E '%>'K:QA^)/CL^3;I*K6GE':
MH8%K8EMOUYSCKS7(:7IME;?#;X=ZK#;1)J!U>R0W07]X5:1E9=W7;@XQTKV&
M;0])N+^2^FTRTDNY(O)>=H5+LG]TMC)'M4/_  C&@?8X;3^Q=/\ LT#^9%#]
MF39&W]Y1C /N* .7L+&S?XN^)86MH3%<:3;-,A08D)>0$L._ %<1I6F6-O\
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MQRS0]%5AZJ,+GOC/J* ,#X8_\@/5O^PW??\ HXU)J6JZ+KM_&MSJ=E'I6FW
MGD,DZCSYHS\HY/W$;DGNP Z YZ.RT72]-AFAL=.M;:*8DRI#"J!R>I( YK-3
MP+X2C=73PQHZLIR"+&,$'\J ,/XGEVT_PR]OGS_^$@LC#QSG+?TS7=.BR(R.
MH9&&&4C((]*RKO2#J6NV5[>;?L^G,TEM$#G=*R[?,;_=4L /]HGTK695=2K
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M+#>H7&,^]<EJWA6[NO$5[<7WA/0]>M9BBVDLTHBDMHU4#RR"C9&=QR#GGIP
M #HO V@GPUX.TW39/(:XCA4W$D"@+))CEL_Q=AD\G%86OVUB?B[X=DNH;?:V
MG7C,TJK@E3'@DGT&?I72^&=#C\/Z4UK%##;H\K2BVMV)B@SCY$SSCC/09))P
M,X%V]TG3M1GMI[VPMKF6U?S('FB5S$WJI(X/ Z>@H \INM(T[4-&^*EQ>6<,
M\T$]RT+RKN,3+;*P9<_=.0.1SP/2KT>IB;Q/X<M-6OXK>"Y\.Q26LEU&KI+.
M3^]'S<;]NSWP3ZUZ /#>AK'=1C1[$)=G-PHMUQ-_O\?-^-)>>&-"U#38=-N]
M'L9K*#_50/ I2/\ W1CC\* *'@G2K'1="DL--U"2^M([F3RW;&U,G)1,<;5)
M(]CD=JB\7Z/X>\42V?A[6D/GW"2W%G(C[)(VC*!BC?WOG!QSP#D<5TEM;06=
MM';6L,<$$2A8XHU"JH'0 #@"J]_H^FZJ8SJ%A;71B!$9FC#%,XSM)Z=!T]!0
M!YK:7?BSPW+XF\+2:E)K)M-$>_TV]9?W\;?,JQOZMD$C/)Q[X$^A6'A_6K;P
MKK%OKD1FA 6&&VCC$DI9<212 99AU+9]"37HFGZ3I^E)(MA9PVXE;=(8UP7/
MJQZD_6JMGX;T/2KZXU+3]&LX+V4'S)8(%1WSR1GCJ?\ Z] 'DEOX9T*[^%GB
MR\GM(5N[*]U VMP/OV[)(QC5#U7G' QG-;5U+'?#4XKM8_[8@\-P+J<M^VZ.
M/<C-MCCX^8MG<V0!\O!-;_@KPB+"VO3K.D6ZW<FI37D;DK("'D+IG'\2Y[].
MQKI[K0='O=1CU&ZTNSGO8TV)<20*SJOH"1G')_,T >66MI8ZO_PJ8WD<5RTE
MI)%.7PQ<"SSL?U'J#US[UHZQ9Z):W?B72M+MK:W^P:(L5Q]J.8H8F$C*D4?'
M)))9L@ [>":[V/PMX?B6T6/1-/46>?LV+9!Y.3D[>/EY]*EN= T>]U%-1NM+
MLY[U$\M;B2!6<+Z9(SCD_F: /,;1;.]F^$\UVMO.6L9%F>4*V2+0$!B?KGFM
M&;SK'QMX_N-%A07O]B030B)1\\NV7:<#J20/K7<GPSH36%K8MHU@;2U?S+>
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *S;OP[HE_<_:;S1M/N)S_ ,M9K5';\R,UI44
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M%UO3M)O+R"*YO2Y DD"B-%4G<Q/0$@*/4GV-7/\ A(-%,5Q*-7L/+MFVSO\
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MU&:[?P9J":KX-TF\CL?L"26Z[;;.1&!Q@'NO'!],4 :%_K&F:7M_M#4+6TW
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M7RV,FIV:7;.(Q TZARQ&0N,YSCG'6N3\1K!:_$CP!;QB.*-/MR1QK@!5$
M'IVKBO$&LZ9<^'-0>TN+:PCB\2(\EFS[IS(+E0\TA8Y0'J   !CGG% 'KUWX
M@T6P-P+S5K&W-N%,PEN$7RPW W9/&<<9ZU>@GBN8(YX)4EAD4,DD;!E93T((
MZBN TJ+3+SXO>()?+M9E;2K5PQ52"&,F3^((Y]#5WX1.'^%VB[6#!5E48.<
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MS6U?3M1DL=JR^8'VJIW9P.N[IBM^@!JQHI<JB@N<L0/O' &3Z\ #\*ABL;2
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MU+RV$$LT65#XP-V.<>N*T** ,;0--U"U2:\UF>WGU6ZVB9K9&6)%485$#$G
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MY'D,O #^8S%@0  #G@#'2@#GX[&*T^*\^F0/.EC+X?:9K;SW*"0SA2P&?E)
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MU<W4AV!@ PQNP<@ '.>E &1X]U6>Q/AZRCED@M]3U:&TN9D8J1&03M##D;B
M,CG&:IF*32?B=;Z/9M*=)U33)I+BU\QBL+HP'F)SE,AMIQC)YZUUVKZ/8:[I
MTEAJ5NL]LY!*DD$$'(8$<@@]"#FH[+0K.QFEG0SRW,L8B:XGF:238,X4,3P,
MG/&.>>M ')?"[3[>WL]<GC602#6KZ($RLPVB7C@G&>.O6D\;3:CI^M/J$FFS
M:MH:V02>&SG*7-DVYR9D7(W9&!D'(V<8YSU>B^'=-\/).FFQS1I<2M/(KW#R
M!I&.6;YB>327OAVQOK^6]D:ZCGF@%O*8;ET$D8+$*0#C^)N>O/6@#C+?44\1
M>([;1H+J.XT\:';W=JMP[I]H#E@TA"D$D!4Z]"3WJEJVF:EI>G>$--NO$5W=
MSKKJVDMQ!.Z%HBKML?YCN88 W'GCUKL]7\">'M;AL([FQ,9T]!':26TK0O"@
M&-JLA!Q@=*FN/!VB7-MIMLUM*L.FRB:U6.XD39(,_.<,-S<GDYSD^M '*:[I
M,7@>^\.ZS:W5\VEVUV;:_2XNY)%"3$A)&W'^!R!D]C[4OBM)&^&7B;7(;FZ@
MENT>ZMVBN'39& %CQ@\!E&\CU<YKN]4TNSUG2KG3;^$36EQ&8Y4)Z@^_K[U'
MJVB6&MZ/+I-]"SV,JA'BCD:,%1VRI!Q[4 <J;T:EX]L/#U](WV-=#6\2'>5$
M\I?:2V/O;5' _P!HGL"*-[YVB7OAOPJNL27EO=75TLDMY(V6*J'C@9E.2,/T
MSSM /'%=/J_@G0]<M[&*]MYB]AQ;7$=Q(DT8Q@@2 [N1ZFGZAX+T#4_#\6B7
M6GJUC"P>)0[!T?).\/G=NR22<Y.3G.: *_A71[S0[O5;:XU1+FWED6>WM 6/
MV16!!4,Q)VDJ2!VP:Y_Q:5O+_P 3);W%Q>7-GI08Q>:88M.;:[!U8<F1L C
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M4HJNX!D(0[0 3D$9 '44 >D45YK!XEU^YMO!=U9ZG#,VO9^U1-;*ZP_N][%
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MXTD:1H2(V#9P%?H2,<BN U>S\0V_C?P?:7WB66<SW-ZZF&UCB50L+%<J=V2
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M(PD:D 'YB<DDD^P  ?"%R=0\,W9U2/=H43QHOV4XFW1^62?GX^4=N_Y5U=%
M'&2^%]1TZ#Q)=6>NR076K2I.);>QWO RA5PJECNRJXYZ9SD5U&E"]71[(:DR
MM?B!!<LH !DVC=C';.:DNKVUL8A+=W,-O&6"AI7" D]!D]S4] '*CPA/#JNO
MW=KJ[10ZP SV[6X8))Y8C+9R"1@9QQSWQQ57_A!+@:%X:TH:O&$T&YBN(I#:
M<RF-2JAAOX&&.<?I7:44 <6W@:_M-?OK[1/$USIEEJ,OGWMDMND@:0\,\;-_
MJR>YP>?PQV,,*6\$<,8Q'&H11G. !@4^B@#E1X1N-,UV]U7P[JB6'V]_-O+2
M>V\^"23_ )Z !E*L>^#@^E7KWPU%K6CWUAK<YO!>Q>3(47RU1>H\M<G;S@Y)
M)R!S@ #52\M9+N6T2YA:YA56DA5P70-T)'4 X./I4] ',6WA6ZD_LE-9U1=0
MBTF02VP%OY;/(JE5>0[CN(!/0+SS5:/P5<QZ7XGLCJT9&ORRR2M]E/[HR($8
M+\_/R@8SW]>E=A10!R4W@ZYDC\,J=5B']@E60_93^^(0Q\_/Q\I[=^?:N=\(
MP7&KWGCFUL=8MX8;C69D<+$))%4QH"Z-N !/(R0PROU%>GTU8T0Y5%7Z#% '
M)CP.++7+#4-&U.33XK73ETUH!"L@:%6W+M+?=;/?!SZ50L_AS/9:)H.EIKI>
M+1K_ .VPF2T!W$%\*<,./G;)ZGVZ5WM% '*2V,/A?6]<\8:GJJ)9W$$23I]F
M;]TL>0I!#$G[QSQ^50^$=,TZXUW6O%5@CBWU-T%N6!57 5=\JJ<8WL!GU\L'
MN*ZJXO+2WDA@N+B&.2=MD4<C@&0^B@]3]*GH KW]O)=6%Q;Q2K$\L90.R;@N
M1C.,C/YUR(\!3KX=\.Z.NKILT.ZBN8I#:<R&/.T,-_3DYQ^E=M10!Q<G@>_M
MO$-[J.A^);G2[749/-O;1;=)0TF,%XRWW&(')P?Y5H0>%I+;QE'KT5\HBCT]
M=.6U,)/[L-N!WEL[L]\=.W>NDHH XM_ U_:^(+Z_T/Q+<Z79ZC+YU[9K;I*&
MD(PSQLWW&/<X//X8O2^%9X/$B:WI.H);2_84L'AN+<S(8T8LI&'4A@2>23GT
MKIJ* .3FG\.^!-(2RU.Z8_VE/*SM)$TCW<SY9\A0>3G 'T JSX%\/IX:\)VE
MB$D21AYLBR-N92W1">^U0J?1171$ XR <<BEH P?%/AR3Q%!IYM]0:QNM/O$
MO()1$)%W*",,I(R"&/<5D_\ "O(KF3Q&NIZK/>6VNQQBXB,2(5=$"AP0.V 0
M,<=\UUMS>VMD(S=7,, E<1Q^:X7>Y. HSU)/:IZ .7T+PUK.F(@U'Q-+JC6R
M%+3S;545.,;GVG,C8XR2.I[G-9%C\-9-,L-#2RUH0W^CR2&*]6U^:6)V9FB=
M=^"I+?ACC!YKOZ* .;M/#5Y:>)M6UM=3A:;48(H6C-J=J>6#M(^?)^\<UE6G
MPY%CH.@V<&JE=0T&1GL;X6_\+9W(Z;OF5@<'!'0=*[FB@#'TS0OLFKWFL7DZ
MW.I74:0M(D?EHD:9*HJDD@98DY)R3[ 5DO\ #W3'LO$]J7<IKSL[9&1 2/X1
M_O[G[<GVKJ;JZM[*VDN;N>*"WB7=)+*X55'J2>!4BLKJ&5@RD9!!R"* ,#4_
M"ZWO@B7PS!=F"*2U^RM.Z>8Q7&&;J,L>3D]S6;JO@>ZO'TB_T_79--UO38/L
MPO(K<.DT7&4>-C@CC/7@\^F.RHH X_4_ TFI6%@[:U<+KEC<_:XM3,2D^80%
M8&,8785 &T8X Y/.:UWHE]X?GUSQ9=:I<WUS)IHA>WLK14)*!B"@RQ'+9[^^
M1Q7<U!;WMK=O,EM<PS-"^R58W#&-L9PV.A]C0!Y-X=EFLUM3H'C?1M7NMJ*;
M*/2XQ-,.,AW1@Z^[,..IKK#X&O[37[Z]T3Q-=:98ZC*9[RR6W20&0_>>-F_U
M9/?@\_ACLPJJ20H!/7 ZTM '+:KX2GU.SU+3#J,7]DW\2Q&VFM?,: ! F8W+
M\'@$9!P>?7/26UO':6L-M%GRX46-<G)P!@5+10!Y]%\-+F'1[#2T\2SBUTW4
M5OK(&U0LA#E\.2?G.6//'7D&MBW\)W5OJGB*^7549]:CC1@UK_JMB; 1A^>#
MSTY].E=+/<0VL#SW$T<,*#+R2,%51ZDGI2Q2QSPI-#(LD4BAD=#D,#R"#W%
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ME<F>) G+I(=HVD $CU%9)\$:U=:'XKT21[:WCO\ 4I=1L;Q)2S!VE65 R;>
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M0@CL?ESW'-5/"ECXVT>UM/#U[%IS:?8[8X]528^9) OW5\K;PVT!<DX'7GN
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M$^YP<?E7$-\0I5\ GQ3_ &0F([HVTMM]JY'[_P G*MLYYP<8'%=S7E-SX/\
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M>(KV\U'4K#1["WNI]-5!<F6Y,:F5EW"-"$.3C&2< 9'OC.MOB%#?6WAN[M+
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MP<^U= NBZIH?CO5=<T^W6^LM8AB%S")0DD4T2[58;N"I7KSD'UK(U3P/J?\
MPKC5M%LT@EU35[Y[Z<F7;%&[S+(0"1D@!0HXYQGB@#MK#3HDNGU.?3[2WU.:
M,12R6[E]R*3M&XJI/7TKGKK6=:_X6I;Z)'#:MIW]E/<%6G92V944L?D()'("
M^YR1T'70N\D*M)$8G(Y0D''XBN8U#1]63XBV6OV,-O-:G3GL9Q)*4:/,BOO
MP=W0C''U% '':+X@O?">B^+]0M-&CN=/LO$-Y)<G[0(BJ;E!\M=IW$#G!VCT
M)[=MJGBZ&VU%M.LGL3=);)<L;VZ\A KDA #M)).UNW QZBN;D\)Z[)X*\8Z1
M]DA%SK-_<7%N?/&U4E(QN..",<X!JW=:/XITCQ%!K^A6=I=_:K&*TU#3[BX\
MHAH\['1\$<;B.G\^ #IO"WB!/$_AZVU5;6:T:7<'@E^]&RD@C/<9'![C%;-5
M--6^6Q0ZD\1NVRTBP_<3)X52>2 .,GKUP,X%N@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBO.?$?B*UL/B&FF^)KV\T_1YK1#I\T5Q)
M;PR3;CYGF2(0<@;< G Z]Q0!Z-16!I8.@:9?SZEJLMW9_:/-M[B9_,;RF5 J
MC'WCNR!CEN.I--_X3/28[F]M;H7=I<V=M]KD@FMV+F'./,4+G<,\''([XH Z
M&BN2M?B1X=N[O3($END34PHM+F6U=89'89$8D(V[_;/7CKQ5N\\:Z/8O=&5Y
MC;6=REK=721DQ02MMPK'K_$N2 0,\D4 =%17-:MXZT;1]3N--N!>R7D$ N'A
M@LY'8QEL;EP/F'7)' P>:=<>.-&MO/D=IS:VUREI<72Q'RX9FVX1CU!^=03C
M )P2* .CHKF/^$M)\?2>&Q8W.R*S%PTPB)#%GV@C'11ALGU^G+="UO08=-UW
M4H+^[^R6^H3?;)+TR?NI0%W(JN,A1D *!UZ4 =316+;^)["75$TR9+FTO)8C
M/#%<PE3,@ZE.N2.Z_>'I64WQ*\.K:/=[[TVD5R;:>?['($@<,%_>$CY!DXYY
M]J .OHI'4.C(<X88."0?S'(KS?P-9SZX/$_VW5]89K37+JSMF6_E'E1)MV@#
M.#C)Z@T >DT5Y]X?\67>D:_XA\.^)[]9QI$ OH=1= K26I'.\*,;ER!D#GT]
M>DL_%=A>7QLA%=Q79M/ML<,D)#2PYQN7&<\D#'!Y'% &[17)^&/&\&M^&6UJ
M\MY[.+SY$4/&?F'G-&BKC.YSA1@9^8X%:NF^)+'4M5N=*"SV^HVR+*]M<1['
M,;<!UZAESQD'@\'% &O17,^(O%AT/7]"TM;&XG.HRR!GCC+!56-FP/5L@<>F
M?:N=L_$4>A>//&INY-3NK>*.REBMXUDN&B4QNSD+SM7/)Z#]!0!Z116(_BK2
MS!I<EO(]TVJH9+**!<O,H7<2,X  !&<D=0.M8^L_$&SM/"T&LZ;!<70GO%LP
MOE$&)S($8.#R"#D8[G';F@#LZ*ACN!):"X$4RY4MY;)A_ICUKG3X^T0>'TUS
M-W_9[7!MO,^SME9-VS#+U7YN,D=: .HHK/DUBUAU 64HDCD^SFY9V7"(@X)9
MN@__ %^AJA#XPTJ2XL(W^T01ZB=ME<30E([@XR I[$CD!L9[9H N:9H&FZ/<
MW=Q8PR1RWDGFW#-.[^8_]XAF(SP.:TZPT\6::\.L2 7&=(;%XGDG='\N[@?Q
M?+SQFN>\5:D+R7P-J>G7=REM?:I!PDC(LL3Q.X#)G!Z*>10!WM%<[K^O6<=M
MJ=BGVV6:WMR]RUD&W6P()4EE((/&<+EL<XQ4/PXN)KKX<Z!/<323326B,\DC
M%F8^I)Y)H ZBBO--*\46_AS7?&IU&;4KJWM;Y& 19+DP1>2K,3UVH"2?SQTK
ML[CQ-I\,MG! 9;RXO8#<P0VR[F>(8R_. !\PZGG/&: -BBN;?QUHBZ5I>II)
M<26>IS+!;2) Q!E+%0C?W3D$<XY%:LVKVMOJ#V<I=&2W-R\C+B-(P<99N@Z'
MKZ'T- %^BL*#Q;ILVK6FFNMS;S7R-)9FXA*+<!1D[2>X'.#@X[58\0>(;'PS
MIXOM2\Y;8NL9DCB+A2QP,XZ D@9Z4 :M%4I=4AAU&VL72837$;RKA,JJKC<6
M/;&Y?SK-7QCI)O;"W<SQQZBVRRN9(B(;AL9 5O<<C. W;- &_16-%XFL9KF&
M.*.Y>&>X>VBN5BS$\B;MPR.1@HPR0 2.":S/#_C:'5WUZ2ZMIK*UTR[DA,LZ
M;55(T0L6/0'+,<>F* .LHK$M?%.GW&M1Z3(ES:WDT1GMTN83'YZ#J5SW'&5.
M&'I7(>/O$T-WH%C/IDNH)&^J6\45Y 72&;]\ ZY!^9<!N2-IQP30!Z513)95
MAA>5@Y5 20B%C^ &2?H*X[2O%GAK1?!NEWT5]?RZ9=7#06]Q=+)([,TK+\[$
M?*,YQNQP* .THK%TGQ3IVLZG=Z; MU#>6J+(\5U;O"S1MD!U# $J2"*NZCJE
MKIB0FX9C)/)Y4,4:[GE?!.U0.O )/8 $G % %VBN=3QMHAL;RYDFDB:RN5M)
M[>2,^:DS$!4VCJ6)&",@^O!IQUNTUJTUK3XFNK:]L8\7$3$Q2Q;D+(P93T('
M!![&@#H**XOP/K2P?#?PW<7TTUQ=75NBH.9)9WP2<=R< DD\  DFKDWQ!T"V
MTF^U"YEN84L)Q;W<36[^9!(2  P . <C#9VG/6@#J**P]/\ %>F:EKDFCQ?:
M8[M8?/03V[QK-'G:70L!N )'Y^E<C\1_$T-QX.EFTR74$"WL,,=[;%TB=A,J
MNNX'D8W#)&TG@'- 'I5%8.J>+]+TJ:^BE^T3'3X5GO3!%O%M&V2&;\%)P,G
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M,IP?E8 XKB/'&D:SIFAWWB:U\2ZG'JMLPEAMHY?]%8;P%A\K&&R"!D\D\^U
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MRMD&39_=4+D9Y/ [D:_AO78!;7<=MH6OIY4;W=Q/>V+0O<R]PH;&YSS@#@
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M33IFHB_D^UHEL;*7S&,DSLN%VYP00<]*]=HH I:/*)='LVV2H?)0%98VC8'
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MJKO4#<2,GD  GZ5YU-K%D?B%JUKKFJR:3#?:=;M9?:!$J2P[6\Q"9%(!#$Y
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MW<M_X=TR\N&#33VD4LA QEF0$\?4UH5D>%"#X/T0@Y!L(/\ T6M:] !1110
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M_9EGF#B(^0O[OG/R\<<^E7J* "J#:'I+P^2VEV31;S)L-NA&\]6QCJ?6K]%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_+=D!/OA1^-:4<=UX?TB>>[O)=6U68?*?+6,S.!\D:(.%7^66)/4T[P;X?\
M^$7\):?I#2"26%"9I!T:1B6<CVW,<>U &[6)XKU1]*T&5H&9;NX9;:V*(78.
M_&X* 2=HW.0.RFMNLBZTBZNO$=CJ9OHQ;6B.$M3!G+. "^[=]X $#C@,W7-
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M["P<G[IP"5QGCJ*M0>#;B#5?#M[_ &L)/[%M7M45[89E5U56)(88.$&./SH
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M,8YS@)\.[F/PA8^'1KY>WLKF*:%WM!D+&^]%.&&3GJ>X P!0 ?\ "1ZKX?\
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M:\/V_AG14TVV;<@DDE8A=J[G<L=J_P *@G '88Z]:UZ "BBB@ HHHH ****
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MKEWT])_L]M$57&4&)&R!D_/N7D_P'UH >_B&R3Q1%X>*S_;9+9KE3Y9$>Q2
M?F/4Y8=,UJ&.,MN**6]<<UQE]_R6?1_^P+<_^C8ZR9?$VMV5YH3R:FMU)=ZU
M]@O(K>%6M$1BX54D*ABZA5S\QP0P/:@#TNBO/KK6M:LM7\5Z1<:M(MQ%9I>Z
M1)Y$1)1LKMQM^8B3"^I##H>:M>&/$%[XCTOPX\=[,ERT;RZF#''G,?R-&1M^
M4F0\8Q\JMWYH [>JFIZE;Z1I\E[=>9Y2%5(BC:1B68*H"J"222!@5;IKHD@
M=58 AL,,\@Y!_ C- '-CQUI)U1],$&J&^2$7#6XTZ;>(R<!L;>F>*FL_&6E7
MVK:?IT"W9FOH)+B$O;M&NU#A@=V"""<8QQWQ6#;?\EZOO^Q=C_\ 1YIOB.VF
M?XI^&X;&=;-WL+X^:L88KEHR2 >-V3U.1DY(- 'H%(RAAA@"#V->;V7C'5K3
MPWJ$=W/]MU"W\0'1(;GRT1G#.@#E?E7<%8\< D#-=!HK>)X_$\\5ZEQ+H<EL
M'CEO#;B:*<-@J!"<%"O.2,@T ;6IZKIVA68N+V98(V<1HJJ6:1ST554$LQ]
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MHQ_6MZB@#C#\/+6XT77-+OKZ6:+5;YM0,D:>6]O,=I!0Y/0JN,^_)S6GX?\
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MR8W9.<Y^48]/>LQO A%GXCLH=8G2SUR2:22$Q*1$TH D(/!/3C/ R>#7844
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MS+($"2*"QS@+\OWN N.G.22:ST^'4:>&;+01K=\UK97$<\!=(RR"-MR+PH&
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M@!S)( 1ERV2<ACGN22<U5U3P,;OQ$VNZ9KM_I%]/&L5X;4(R7*KP"5<$!@.
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M(X&<E0<#-/NM5UR^\6^&K*WU9K.UU32Y;B9(X$8HZK&<J6!Y^<]<CV-:&H>
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M"RTB*ZFN8K2(1))-MW;0, ?* /\ /6M2@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHKE=?GNF\1VUDFHS+"]G(RV-CQ<O)N $A8\+&HR/F(!8]^E &
MCX@\1P>'4L&N+:XF6]O(K-&B"D(\C!06R1Q],]*$\1P-XP;PV;:X6Y6R-Z)6
M"^6R;PG!SG.2>H'2O/+C5[W7OA=X*U+49!)=S:U9>:X4#<5G*YP.,G':NG;_
M )+>G_8N-_Z4B@#M:*Y+XF7^H:3\/M5U'3+V2SN[>-722-5.?F (^8'L>V#5
M'49]7T75],TLZO=7TFMW,CY;RXS"L<6YHXSMX!..N2 #SGYJ .H\0ZW#X<T&
M[U>XMYYX+6,R2) %+;1U/) _6KUK<+=6D-PH(66-7 /4 C->;^((/$-IX \;
MP:Q,LME]D=]/+RAYD0H=RN0 " 1P>3@\GBMB>XN#+H5FNH2K!)II;[#9<7,L
M@" /NZ+&H)Y)49(!STH [*26.%0TKJBEE4%CCDD #ZDD#\:?7C<VHZEXA\"^
M M0OM1N5NIM>BMYFB*IOVRR*&8 8+#RP?3/:NIN;W5M8UW7-$L+BZ3^RH8(D
MEBG2-S*\>_S'RIW=0,=.&X/& #NZQM"\10:]/JD,-M<0/IUT;643A02P4-D8
M)X^85S5AJVNWOB#1_"NKW,<%\FEO?ZC+9-_KF$@B55;'R@\LV,'. ,#-.^',
M$EMJGC*&2XDN&36F'FR8W,/*CQG  SC S0!UVK:M;:-9K<W18AY4@B1,%I)'
M8*BC/<DCKQW/%0Z1K$FIRWL,VF7MA-:2B-EN$&V0$9#(P)##'IT/!KEOB?:O
M-'X99;NXB!U^RCVQE<9,GWN0>1V[>U375]J-]XHO?#MM/=F/3[*&1I(YTBED
M>0O\Q)7D*$'  &2<YXH [>BO.[?5?$\=QH7AO5Y(WU26VN)[N:SF5#*(V54
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M=,,,5WMM5A@891A3P.E9-MJ%SXD\8>(])%]<V5OI"P1(+8A7:21"YD)(.<<
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M025$N F) %YRN1QM ]*[#5=0OM!^(>ER7>HS'0=4C>V6)]H2"Z'S+DXSAE#
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M6LZIIFHB%;>>>UE7-R@Z>8&4@L/7']*ZZHXIXIU9HI%<*S(2ISA@<$?4$$4
M<UJ'@:SN;G3+VROKS3M1TY6CBNX65W=&Y99-X(?)R>><DFK?A_PO%X>N]3N8
M]0O+J349_M$WV@IC?@#(VJ,< >WH!6]10!B>(_#47B1;!9KZ[MA97<=Y']GV
M<R(<J3N4\ ]JHZ[X(AUC5K76+?5=0TS5H(?(:[LW56ECSG:ZE2I&<D<5U-%
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MIVGVUC:ILM[:)88ESG:J@ #\A4]% '*/X#M#;Z_;1ZIJ,5KK;RO/ C1[4:0
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M-"O=3NH+R[F;49_M$ZSE"OF8 RNU01P /PK3OK.'4;"YLKE2T%Q$T,B@XRK
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MTF5=C-O)"G;]T[<$8YXR>*[?7)S;:!J$ZWT5@T=M(RW<J[E@.TX<CN ><>U
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M\=<UL4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MT\JQB218DS_$S'  ^IK(L_$9NO&.H>'FL7B-I;1W(G:0$2!V(& .GW3U/X4
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MN:QO"GB'_A*-#&I?9&M/W\L)B9PY!C<IU'^[0!;US1K/Q#HMWI-^K-:W2;)
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MVVR&A0WL<K7LMJUT68H9"R L2 HXR,%SG) QTX\)V,#1_8+B[L$CLTLA';2
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ML8VGX4"1Y R[$3)Z]2PP"16SIVC6^G7-W=J\LUY=E3/<2D;W"C"CY0   3P
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M'VM(C</F=VEVEF;.Y@H& ">I]AB;P)=WPO\ Q+HUS/-<VVEZAY5I/,Y=_+=
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MLM8\.:"D<NN32,->M6MUAN9-UO!)*H,+,3EUZXW=C0!ZM17$.TS_ !<N]/\
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M>R@#OD Z3PIKO_"3>%]/UK[/]G^V1>9Y6_=LY(QG ST]*V:X[X4_\DN\/?\
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MYV>ASC.1UKJ]&W>,KSQ:E]=74$UEJ+V%JL$[QFW1$7;(H4CYF8LV3UX'08H
MW_$/B.30M1T2V%EY\>IWJV9E\W;Y1*LV<8.>%/I6O?W$EI87%Q%#YSQ1EQ'N
MV[L#.,]J\IAUB_U_PG\-=2U,YO)=;19'QC?M690WXA0?QK<LI?\ A++KQG]N
MGN$.G7+V-M#%.T?DHL8/F *1\S,6.3V '2@#K/"^M?\ "1^&-.UGR/L_VR$2
M^5OW;,]LX&?RK6KD_AC_ ,DR\._]>25UE !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N!\4V<=_\
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MSR 7#8W+(K;\AP/XAR1WKH8O#^EQZ?=V1M%E@O,FZ$Q,C3DC!+LV2W  YZ
M#I5#0_ V@>'%E&F6LT1D0Q[FN9':-#SM0EB4'3[N.@]* .$\):%=ZE\+;76+
M75KL:]/:RV\4UU>R>6VZ<@*1G@G&-PYRV>N*Z7P1JD-QK6J65QI-UHNKQP0F
MXT]WWP[07 EA8<$$G!P!RH[YK<M?"&B67ATZ!;VTJ:83N$/VJ4E3NW_*Q;<O
MS<\$<U<L=&L]/NI;N,2R74J+&\\\K2.47)5<L3@ DG [DGK0!S,]U_:_Q2N-
M OP38VVDK<PVY8A9G:0JSD?Q;0 !GH23UKEKS[1/\/?B%I5[+-<VNCRW$=C-
M+(Q8+Y6X(6SEMN['.>H]*]+U/P]IVJWEM>W$<B7EKD0W,$K12(#U7<I&5/H<
MBF3^&-(N-"FT62V<V$Y8S1K/(K2ECEB[A@S$D\Y//>@!?#-G!9^&[".!657M
MXW;+EN2@SR37GWA[3;2U\,_$>2&,JR7^HQ+\[$!?*4XP3Z]^M>GV-C!IUE%:
M6P<01*$0/(TA  P!EB3^M91\':&9M4D^R2*=4W?:PES*JN6 #$ -A20 "5P3
MWH X#3K3^R;3X8ZE:W-V+B]2"VN-UPY22)K4G;LSM !48P.V>O-6K:TO_&VE
MZU<)JT5AJ-KJ<\2W.7\VQ\J0A0 &  V 9'0Y).:[0^#=#,&E0&WG\O2BILE^
MV3?N2!@8^?G XYSQQ5>\^'_AF^UU]9GT[_3)2#-LF=$F(Z>8@(5_Q'/?- %?
MQ_!>WWPMUF*T8S74E@3F-<>8, M@>XSQ[UH>"+JVO/ N@S6;*T!L(57;VP@!
M'U!!'X5O5ST/@O1K2YFEL5O+%9G,DL%G>2PQ,QZG8K  GVQ0!E>+=5QXD\+Z
M.DI2PU*^ECO9(FV[C'$66(L/[S8!'?;CU%9=XEQI?C+7]"LYKE-)N- ;4!''
M,Z_99PY3]V0<H& S@'&0?>NVU#P[I6IZ7'IUU9J;:)UDB",4:)U.0Z,I!5@>
MX.>M-C\.::EO>0LDTAO4$=Q,]PYED4 @+OSN &3P"!R?4T >8I:/#X2^'6KQ
M:AJ":A>75G:SSBZ<EXI(VW+M)V]ASC.>>O-:PM?[+\3^,M(L[F]CLCHT=XJ_
M:Y2T<W[P%E<MN!.T9P><5U[>"M!;3M-T\VT_V73)%ELXQ>3#RG7[I!WY..V<
MXJ'6/#MA#'J^KVUK<R:K=63VQ*S2N9!M(5=A;;U/IQDF@#SQ["YT[P'X.\6V
M.HZB^LEK%)/,NG=;F.3:IB*$[<<]AGC)R>:L^,;IUT/Q/J^F75Q<W%EJ48&H
M/*8_LC*\2F"$#.Y1D[L[0=Q^\175^!_#%O;>%- 74+:Z6\L((_\ 1[F5RL,P
M7#,JD[<\G!' SQBKMW\/?#-\VI?:-/=DU%_-N8Q<2B-I,@[P@;:K\#Y@ ?S-
M &+>::FI?%ZZT^YN;YK&30DF>W6[D5"QG*]F^48 X& <<UAV-CJ6L?"**YM;
MFZGU/1[R=[;,[YN(X9V_<N0?F!1=N#[5Z)#X5TBWU;^U(H)TO?LWV7S1=2_Z
MK.=N-V.O.<9SSUK/>V/@NP@L_#7AV[OXKB=RZ+>$B)FR2S&5B0"3SCW/U (_
M#FHVOBS5AXBLG<V,-JD$'S$!I' =\CH2H*+['>*P_%KM8_&3P5?WG&G/'<6L
M4C?=2=U.![%N *[7P[H\>@Z#:Z=&L8,:EI#&NU6D8EG('8%B3BK&J:38:U8/
M8ZE:175L^"T<@R,CH1Z$=B.10!S7Q,UK4O#WA)M3TNY6*=)XHBLD2NK*[A3D
M'TSZUD:GHRZM\57TB\U#4FLY?#_FR)'=O&&?SPNX!2 O0<+@''(KJ9O!NDW4
M,5O>F]O+:)E=(+J\ED3*G(R"WS8/][-6SX=TP^(AKQBF_M(0^0)?M,F/+SG;
MLW;<9YZ=: ./T"WC\6OXK@U&:X6>QU&33[4B9E>UB1%"2(<Y#$DL6ZGZ"L?P
M[K.IZM<_#'4;^65;J]CO4NBK%1.$B8(S <'. W3OQ7H5UX4TF[U*XOS%-#<7
M48CN6M[B2(3J. '"D!L#C/7'&<4NJ>%=(U>TL;:XMFC2P8-:-:RO T&!MPC(
M00,<8% 'FVN33Q>'_B>L-Y=Q"SN$:W\JY=3%^Y0D+@\ DGCIS6KJ&F3>'?%7
MA'5--OK^2;4[G[)?Q37+R+<(T1;?M)PNW;GY0 /2KWB_P;96G@SQ)'H&F3/J
M.JPA&2)W?S'P "03@<#D\9[DDUT6BZ%8P1V-[Y5RUQ!!Y<0NI7<P @!@H8G:
M>,9ZXXSB@"C\1--NK_PA=SZ>\JW]B!=P".1E\PH0S(<'D,H(Q[BN2;Q5:6OC
M2P\51&5O#VI61MBWFL56Z\OS@57IDKF/C^($=N?6.M9">%]%CTBSTI+"(65E
M,D]O$.B.K;PP_P"!9/XF@#C?$5A/HVE^#5^T7$=U)K]J+H)</L<R%F=2,X*@
M@  ] !BK.A:;:#XP^*YA&?,6VLI0=[?>829)YYZ#Z5UNK^']-UXVAU&&67[)
M.MQ!LGDCV2+]UOD89(]ZCE\,Z3-K9UEK>07[0B%I4GD3<HSC(# $C)P2,CL:
M /(]-M/L/PHT+7K>YNTO[?5@L;+<.$5&O61DV [2""<Y!)S]*]=\3J6\*ZMM
MDEB9;25E>&1HV4A200RD$<BJ0\">'1H4>B"SG&G12^<D'VV? ?=NSG?G[W/7
MKS6U>6%O?Z=+87(D:WEC,;@2LK,I&"-P(;]: /*D7^POA[X<UQ-0O%N=5CTZ
MTO;F>ZD*)$V"6QG"<?+N&" <YSS6_<^&M5T^XUAM/UZVL!J&FO'!9KO$<<X(
M F4ECM^\%.T=P>M=0OA?1AX;_P"$>:S$ND^6(OL\TCR (.@!8DC&!CGC'%4M
M.\!^'=,TNZTZWLY#;W48BE\RYD=R@Z*'+;E ] 10!QL6HA[#Q+I]WIE]X?UZ
M#1I)FMX;AO)=4#8FA=3_ 'B >_0'.#52;3[C2?#G@;Q/8:AJ#ZK/)807"R73
MNES%*JAD*$[1C/&!V).3S7<ZYH%O;>'M9DM(+J[U"XTZ2TB:21YI""IVH"Q.
M!N/)_$GBH?!WAJVMO#>@->6]T+RQM8P(;J5V6"81A7*J3C/W@".@)Q@&@#G(
M+2^\;V.O2)JL5CJ%IJD\$=QE_-LA$^$P P !4 GL<G.:OZ<R>+?$GB72-4NV
MD:RM[:*V\IC'M62'<9T&?O%B<'G& /7.Y??#_P -:CKKZS<:=F\DQYQ29T2?
M'3S$!"O^(.>^:EUKP1H&OZG#J5]9O]LB3RQ-!.\+,G]UBA&Y?8T <E=Z/:'X
MA>"(IKJ74'&GWD4EW)(0\QC$8!)!]<].N>]:GQAMXI_A?J[2KN,0C=.2,'S%
M&??J:Z*_\+:-J,FG/<60W:<"+7RI&C$:D %<*1E2  5/! Z5<U72[+6]+N--
MU& 3V=PFR6,DC</J.1]10!R-V\;?$C3?"TBNNDKI4MXL)=BL\WFA=K9/S!5W
M'!XYSV&)?!<MW:^*/%F@M++-IVG7$#6;2N7,8ECWM&&/.%.,#L#6U/X2T>>W
ML8F@E#V#%K:X6XD$T9/#'S,[CGODG/>M#3],M-+ADCM(ROF2&61V8N\CGJS,
M223P!SV '04 <-XL$=]JGB**"6:]N+32@6A:0Q1:>2'8.K#),K8R,#@+RPR*
MS4>YU6\^%[W.H7P;4+"4W?EW3IYQ^RALD X!R3\PP>>M=Q?>#="U+5IM3NK-
MGN;B$03[9G5)D'0.@8*V,\9!Q^ IEMX'\/V;:4T%I,C:4&6S(NYOW88;3_%S
MD8'.> !TH Y+2-#?5+3QQX7@OKN"&VO@+"3[0Y>V9H5<8;.[;N/3/0GUJYX5
MU4>+1HD,D;P3Z-&S:E"'(*7*YB$;<\@E9'P?[J>M;USI\'A6+4-7T71;S4+Z
M\E1KB&.[8M*>%W8D;:,#TQP*M>&]+>QM[N\N+:.WOM2N6NKB-"#L) 55)'!(
M55!(X)W'O0!2\;PZM+I]DVD0P7<L-T)9=.FF\H7L81LQANF<D-@\?+S7$WNK
M6MYX8TZZTU=0L)X?$UM!<6MP[+);,SIOB)SRF",#I@@=L5Z=J>D6FK?9C<B8
M/;2^="\,SQLC[2N<J1GAB,'@YJG<^$=%N]&N=*N+5I+>YE\^9C*WF/+D$/OS
MNW# P<\8 Z<4 <QJ6H7.E?$C7I;0R.(?#'VQ;?>2C3"23G;G&2%45-X>TVTU
M/0?"_B1=8N8[LI'+<7"RY^V/(N&CD!XQO. /X<8&*W[#PAHNG:LNJP6\IOQ;
MBV,\MQ)(SIDGYBS'<<GJV3P/05!I/@+PYH>I-?:?8&&0LSHGG.8HF;J4C)VJ
M3D\@=\4 ><76GI)X.^(FJ"XNXKNQUJ\FM6AN'C$3J$(;"D GZYXZ8YKUL7@'
MAX7MS<" ?9/-DGQ_J_DR6Q[=:SAX)T :=J6G_99S:ZE*TUY&;R8^:[?>)._(
MS@9QUK7CTZUCTP:=Y9>T\KR3'*Q?*8Q@EB2>..30!YEI4DUKXE\!2VK7 MM0
MBN%EN9YCYNH+Y&\22IR!D@,,DD9QQTJE>O'XJ^#GB7Q!?M(VHL;OI(0;81N5
M6)1GA=H&1_%N).<UWEM\/?#-I]@\NQE)T]RUJ9+J5S$",;1EC\F/X?N^U%U\
M/O#=W-J+O:3(FHY-W!%=2QQ3,>K-&K!2WOCKSUYH Q=/NUUGQQ!H-\2UE9Z'
M#<Q6Q8A9G<[2Y'\6T  9X!)/7&.3FA:P^$?CU;6YNHGM-;O!%*EPZOQ(H^9@
M<MD=<YS7IUYX*T*];3Y&MYHI]/3R[:>WNI8I43NN]6#%?8FHO^$!\-_V3?Z5
M]AD^Q:A.9[J(74H\QR<DDAL]<<#T% &%JVFVEQ\8?#\DL99WTJX9CO89*M'M
MZ'W/'O6?+JU_H4_Q0NK.6>:6P6&2V6:1I?*)MPQ(W$\ DG'3BNZO/"^D7]UI
M]S<V\DD]@&6"0W$@8*V,JQW?.#@9#9!I]GX;TJQO]1OH+=_/U+'VLR3R2++@
M8&59BO3C@=.* .'UE6T?0?">OZ-<3O>S7=I%,QE9OMT<V P?)^8G.0>V.,52
METI-0F^(Z7-[J+I8N'M5^VRCRF^S!P1\V3AN@.0.PKOM/\(Z/I9MA;02^5:L
M7MH9+AY(X"<C**Q(7@D#T!(&*%\(Z*IU4K!.#JHQ>_Z9-^]XQ_?XXXXQQQ0!
MREG=?VY%X2CNIIM0OY]$6ZDT]VV0ON6,&>5O8D@8#'+9 &":P&NKF\^!NE27
MD\D\RZM%%OD<NVU+W:H)/)P !SZ5Z&? OA[=IS+9S*VG0_9[9ENY01%_SS8[
MLLG'W6R*:O@#PTND?V4M@ZV/VC[3Y274J@/NW @A@0 W('0'G% &IX@MXKKP
M[J4$R[HWMI RY(S\I]*\ZT**RM_AQX)M_/N5EO3 WV.!L_;2(R3&Q)PJ#[S=
ML+C!SBO4_*0P^2PW1[=I#G=D8QSGK7-CX>^&ETRVT]+*9(+6836[+=S"2%AG
M&Q]VY1R> <<]* .=\-V?]IV'C31]3N)+2UMM1=8C#=-_H:F)&_=N<$ $DXP!
MUXQ2_#>YFO+F>#69)3K6E6\=O'$VY!+;D92XVD\L^>2>5QC@DYZ5/ GAV/[;
MY=C)']M=7N!'=2IO*XQT8==HS_>QSFKT_AO2[CQ!!KLD$O\ :4$7DQS+<2+\
MF<[2H8*1GG!!H \]T6UU#Q9X2T[Q+'K4%C?I.;B>['F,Z%7.^%EW@;,?+MQC
M&#BI]4O;C1O$<L^O6<T^EW&J1O::W93%OLV)% @F3.53<I4XR#GIFNJB^'_A
MF#7GUF+3MEU)+Y[JLSB)I,YWF/.S=GG..O/7FKA\*:2TLK-'.T<MS]JD@:XD
M:)I=V[<4)Q]X XZ9&<4 1>-KB&V\'Z@\^I7&G(R*GVFV7,H+,  @_O,3M'3&
M>HKE]-CGB^(FK:489-/LI]"CN?LD-TWR/YKKORN-CX&#M)Z=37<ZQH]AK^E3
MZ9J=N+BSG $D9)&<$$$$<@@@'(]*RX? ^@07RWR6L_VP6YMC.UW,9&3.?F8M
MECSPQY'8\4 >;:7'+!X$\ ^(!?7SZG-J=I!)*]T[!XI)"KH5SMP1[9]ZZ>Q>
M/Q9>>-?[2:0OI]R]E;1"0K]GC6,$2+@\,S%CNZ\ =!71#P-X?&D6.E"TG%C8
M3+/;1"\F'ENIRI!WYX/(R>*=>>"]#O=7DU1[>>.[FC$4[P7,D0N% P!(%8!\
M#^]F@"G\,?\ DF7AW_KR2NLJAHVC6'A_2H=,TV$PVD(Q&AD9\?BQ)J_0 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 445QFO16FI>-8-.*&_N5TUW-A.P
M6VB1G \YC@G?P5& >_W>M &EXM\0W7AV'2Y8+2*=+S48+*0O(5,8D<+N  ^;
MOW'XT+XANO\ A83>&WM(EM_[,-\DZR$LQ\P)M*X '4]SVKSN"[N+WX0^!I[J
M=YICK-DIDD8LQ"W!49)Z\ 5V#?\ );T_[%QO_2D4 =K17"_$J R/X5VSW,)D
MUZWA<PS,F48.2, X[#GJ.U4)=.M;/QO;>#[=H(]-_LU[R"VOP]PDTK3-OP"X
MR5 ! ). Q(]: .H\7>(;KPY;:=-;VD4Z76H06<ADD*F,2.%W  '=^8_&NAKR
MG7-*FT/P=I>F3:N=3^S^)+14<H5,*F56$7+,3MSU)Z8':IO&8M[UO&CVQ>\N
MK'35+O.^Q-/81,Z^3@%O,/#$\#ISVH ]&GU"UMKZTLI95%Q=%A#'W;:,L?H!
MW]QZU:KRU[.VU/QK\/[J]A2>>YTB=YI'Y+D1Q$$_0L3^)IMO83^.++Q"\NK6
MMCJ%GJD\0N3"QGL1&_[O:WF+M78 >@!RV<\T >I2&01,8E5I #M5FV@GW.#C
M\C6%X+\03>*/"EIK%Q;);2SO,K1(Q8+LE=.IQGA:YW198O$WC;Q#I^LLMXFF
MV]I';1NNU2LD>]Y@O9F8]>J@  CFK7PB01_#+2T!)"RW0RQR3BYEZF@#3U/7
M[]M9O-&T.VMY[^TLUNW%RY5&W,P6,$="=IY/ XX.>-ZSDGFLH);FW^SSO&K2
M0[P_EL1RNX<'!XR*\_LM.LX?BSXEGBLHWFATVVGB&.?,)E.?J2!6?H&G3>)/
M"^@>*$U^UM;V.6.XN;N.W8S2/G$D#GS.06.W;CCC ' H ]6HKRJVL)_&^FZ[
M-+J]K8:C::G/']I,+&>P$4AV;6\P;5V 'H <DG)S1XIEN].NM1U/5+$:UH,L
M,2RWMH=MUIA$:[F"'^$Y#X!R-QSD4 >JT5'%-',BM&X8,H<8]#T-<KXH^RW7
MB;0]/??=W+)/*FG.0+>50%!DF)!X7/  )RW3C( .NHKR318]:OOA_##8/;75
MQ9ZY<(MC=RGR[N*-Y/W&X]@/F&>/D&>*M0SS:UX8D30-/%GJ%MK&;O0]2?:D
MC+'EH PXVD8=>W'3% 'J-%>1R>)(!HMM;VUO-H8N/$*6>J6MV"5M28MVP%2/
MW;%4Y! PQ'0XK8NO"NH:;'KL.G:_:6LFI01F"Q2%HH(I ZKN'SMM$F=AQC.<
M]10!Z)17EUE<3:A9^(M'BT\>&/$C6UNK0,^;5\NP1XV3^%R2AP >G4@U6DO8
MY?#WC2RN='N/#^N6^CF:2VMYL0L$64I-$R$<%B01[ '/- 'K5%>2S:5#;R_#
MR[AFNX[G4 EM=RK<N&FC:V+%3SP,@8QC';%1W=Y/X3'Q)@T=Y8;>RBLYH(PS
M/Y!E0B1UR>.!N^HH ]>HKAK#PVD6OZ7K%IK5K#:7,#PO;V4+HM^K(65BWF'Y
MEP6W]>O-<+%9+!\([;Q MQ=G5+/5O]'G:Y<E!]NV$8S@@@G.>O?M0![2-0M3
MJATT2J;M8?/:,=53. 3]3G'T-6J\^L]-L?\ A=6L3&WC$@TJWF#XY#^9(-WU
MP /PK/\ #$\^E>(M&TSQ!IH6^E$GV+6[-]\.I?(2?-[AROS<YY!Q@&@#U&BN
M,\;:A)%KWA/2I&9-.U*_>.[8' ?;&62,GT9L9'?&.A-8][;R:7XVUS1;%I8=
M(NO#[7SP0R,BV\ZN4!3:1LW <@8R5)H ]+HKA_AGHEI#X5T77-UQ)J%UI<,<
MLLEP[!EP& VD[1CU S^9K/N-#M-<^*^LZ=J$EW+8MI,$K6XNY%0L9'&>&R!P
M.!@9YQG% 'I%%>+Z/J>HVMCI/A^\U#=IW_"0WNG)=7@+K-%$K>4CD,-P+Y&,
M\[0.1D5:\9^'YO#_ (%\9;-9+1R1PW4-C:J\"69+;3M^<_*^"=O3(/% 'KU%
M>?364.@_%71#:2S(NH6%V;TR3,XF,?EE6;)QD9/3MQTKGXI!&W@O5=->5X;O
M63$=2GDQ<WT;B4G>H&-G P"<X X6@#O](\17%_XL\0Z/<VL,$>E+;LDJ2EO,
M$BLV3D#& HX^O)JY-J=S?Z##J'AY+:[:<HT7GR%$:,L,MD _PY(KCEMX;OQC
M\2()XUDB>QL]R,,@_N9*P9[.&T^ >AW-KO@F(L'=HI&3>6EC4[@#AN">M 'L
MM%>?7H;Q'X_UO0;N6S\NVLX&MK>ZA9]RN&WRH ZX8' W<D8&,<YHW.F:YIFF
MZ,(98/&,>FP3PWEK,?+DF'F8$J!BP9TV%.3D\XY- 'I]5=1U"UTK3Y[Z]E6*
MWA7<[G^7U/0#U-9?@Z_T^_\ "6ESZ:\_V5XML2W/^M&TD%6SU(((/TK"^,%M
M!<?#>^>:)7:*:W9"P^Z3/&"1^!(_&@#9OO$-U9^.-)T'[)";:_@GE$_F$N#&
M%R-N,#[PYR?PKHJ\\\0:39R?$CPAIPC:.T^QWX,<3E,C$9(R.<$]>>?I6/I\
MMM9>&/$.DSWE[%:0^)_L-G! ^YW4F)EMP6/"L2P.2, F@#UEW2*-I)&5$4%F
M9C@ #J2:AL;V#4M/MKZU??;W,2S1-C&Y6 (/Y&O+Q;'[9\1]*N;6"&S73()T
MLH7+0QN8I22HP "=JDX Y%=G\/K2WM?A_H'D1+'YNG6TDFW^)C$N2: .EHKR
MS0-'@FO/%^HR&\N;K2=9FEL4>ZE(5UA0@8W?-G.,'/  IV@:4^MZ%X8\40Z_
M:V]PKPRW%U%;L9;HMA9()6\S!RQVXQP0, =* /4:*\MCGFT?Q+:1Z_IPN+:\
MU5C8:_9ON+-([;()UZ@#.P=5X7CC-5CA/ ?Q-4L0+74+PV_S']SB%"NS^[@]
M,4 =UJWB&ZT[QAX?T9;2)[;53.&G,AWH8XR^ N,<\<Y]>*U[;4+6\NKNW@E6
M26T<1S@?P,5#8^N"#^-<)=L7\4_#%F8LS0W)))R2?LHJ7X?Z996WB7QE)#;1
MI)'J[(C <@&*,D?B230!Z!7*:/XDU?6K+Q((-/M$U#3+V2SMXC.QCD*HC LV
MT$9+>G^-4]2NUU+XK6GAZ_ ;3X])>]C@?[D\QEV?,.C;5!(!_O9["N1%G'9>
M ?B?#;/-"MOJ5T\7ES,I7$,9 R#G Z8Z8H ]BA,I@C,RJLI4;U0Y ;'(![BG
MUYEK&GQZAXL\!6L\UU]GN["Z6XC2X=%D"PI@8!X^\>1@G-)!I<6K>(]>\)^?
M;I;Z9;6\%E#=H\SI$T0)E0^8#NW$@MR1A1F@#TZJM]J%KIR0M=2K&)ID@C!Z
MN[G"@?YZ FO/M,<MXNT?PKK6IC5[6'1GDCEF3"7DZS%"64D[BJ+W)ZEO>JGB
M?P]IMA9^$[!;B74$@\310A[EM[1(X=C$#_='RC\,=J .U/B&Z7XA+X;>TB%N
M^FM>K<"0ER1(J;2N !U/<]NE=#7"R6\(^,EG;"-?('AN6/9CC;YZ#'TQ6)9J
MVD76M?#YRYFO[E9-/F=BSM:2Y+G<>=T060 GN$H ]5KE-/\ $>K:T]O?:3I]
MO<:2U]):2EI=DJ(CE#,,\$;E/R]<8^@Z0V=L;+[&85^S;/+\OMMZ8KQ5=/MK
M?]G_ %N\MU>"Y66Z_>PR,C$"Z8 '!&1CL>* /<:*\WURQMM UWP[80-<K9Z]
MJ/\ Q,I)+AW\YTB)1#DX =L9 P#C'3BDNK9],\=:SHMBTL.D7>@->R00R,BP
M3JY0,FTC9N'4#&2,T >DT5XM%IZ1^"?AUJ\=Q=IJ-S>V5M+<K</O:*0$.G7
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MHRI5"1RI'''3I7(7NC_V'=>!M=TJXN_[0OKRWM+W?<.XN89(R6W*3CY0N1@
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M^9F)+$C P<Y&!CI5:R\#^'-.T>?2K73@EI<%3*/.D+L5(*_.6W<$<<\5T-%
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MBC4L[L<!0.22>PKE]:\72VEMX8O=.@AGL=:O;>#S)6(94E4L&"@=<#N>/0T
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ME@G]WD].Y]3SUH \MN0D_P $K3Q;92?\5%$D=TM^O^N>X,H5T8]6!)*;#QC
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M5RPC_N\GIGG'<\]:I6/@CPSINMOK-GHUK#J#DL94!X)ZD+G"DY/( ZF@#/\
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M^(-(C:/6Y;BPA>=7):XBD0>8C<\KM!/L!Q@4 >PEU#A"PW$9"YYI6=5SN8#
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M848P*S;5.?XNI]1GB@#7L_%^I266BZ_<C3X]"U0*OE'<MQ"\AQ$ =Q$A)(!
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MRJ^E 'M2LKJ&4AE/0@Y!KFI/$%[?^*M0T'2?L<<NG0Q2W$EUN8N9 2JHJD<
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M((XHT& J@8 %3T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5GZQ-J45FJZ3;PRWDKA$:X)$4?!)=\<D#'0=
M20..HT*I:KJMEHNGR7U_.D,"8&6.-S'@*/4D\ 4 <UX?U_7Y?$NH^&-?AL4U
M"&T6\MKRQ5O*DB9BO*,200PZ9YY_'<T361J9O;6=%BU#3YO(NHE/ ) 977_9
M92"/Q':LSP]<Z9/J]S?-J-E<:QJ"C,,$ZRF"%,[4&TG@%B2>A9S["LW1 _\
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MD:E\.O&.AZ9I.J3WWA[5IGA_LVZ;>]KA"V^-NNP8Y_7).1GV2:/XDT#7-/\
M$.O-8ZA#J<[W<8\I)T=9BT31EE+'Y0BJ1GI@4 >N)=VTDS0I<1-*N<HK@L,=
M>*3[=:?9WN/M4/D)]^3S!M7ZGH*X#Q __"'>-M/\216SRPZM;'3KI HWO< ;
MH"<?Q,04].14?B+R_#>I>#K2^O5M-/DEN#=7>Q?+-XRAE=MP(&YFE(ST)]J
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M+Y(VW(MS"L@4^HR.*OURWCO6=2T+2+.[TZ6%"]_;P2B2+>2DDBJ=IS@'GT-
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M36]0LDU&:[N(8T#+%Y@25D&Q"<G@#UKIKW4[#3$5[^^MK17.%:>58PQ]!DT
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M?5(H8?AG\1X(D1(8/$#[$4 +&-T!.!V&2?UKV!=%TI989%TRS$D"A8F$"YC
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M@S$\<X[5Z;>:?9:@BI>V=O<HIW*LT0< ^HR*=/96MS:_9;BVAEM\ >5)&&3
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MA" 3$"+^T[/>2< +YRYR>U=)::':VFMWFK+%"MS=*J,8H@F5'.6(Y9CZGL
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M5O>:? +&:3RA%(BE_,3=(I .Y@<9&>_:H[SP]I,_@71]"\/3SM>),9]$N9I
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M-;G@BU,W=R3'<L%:2V,06#&>J[1QCN?>NN^'4\4_PX\.F&5) NG0(Q5@<,$
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M&D:,$@/(SAAEL9VJ!@8Y-:^E7.I6L&IOX@GM52WN#Y-PB^5&T'EH0QR3@Y+
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MN!3YH(KF%X9XDEB<89'4,K#T(/6LZ/Q/H,UU%;1:S823RRM!'&EPI+R* 64
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M]6LI?L\2S3;9U/EHPRK-SP".<FI+36]+OA/]EU"VE^S@&8+("8P>06'8$=Z
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M-YFXKT4DJ.>I->D1V\$3%HX8T8\$JH!--@M+:UW_ &>WBAWG<WEH%W'U..M
M'CVDW6@ZIX<N_#7BC5+R/5X;Z7S],#*DLTWG&1&B^7<V[*D$']*Z70+;3;OX
MK^-8YHK6:016!5756(PC$G'L0OX@5WIM;<W(N3!$;@#:)2@W >F>M*MO DAD
M6&-7/5@H!_.@#C?BB]Q!X<L+M$=[&UU6UN-151G-LCY?([@$*3["HM1$>H?%
M3PQ?Z1/'*L5E=&_EA<,I@8+Y08CU<DK]">U=V0""",@U#!:6UK&T=O;Q0HQR
M5C0*"?H* .+^'-Q!->>,EBFC<_\ "0W!PK \;(QG\P?RI/&]U;V'C7P/>7D\
M=O:QW=RKS2L%12UNP )/ R:[:.V@A;=%#&C8QE4 -/>*.4 2(KA2&&X9P1T-
M 'FUBUA<>._B+)*8'(L[1<OC(4P-N'/0=,CZ5SVDZQ'I6C_#O4-1OYK71SID
MMJUY%M*P3G9MWD@@9567/;GH,U[-]DMB6)MXLMU.P<T-:6SP- UO$T+?>C*
MJ?J.E '/>#+71(HM2NM"N9;JVO+MIY;EG#1S3$#>R$  CIDCC.?0US=C)'X.
M^+>ORZM(MO8>(8X);.[E.V/S(U*M$6/ ;DD ]17I,<:11K'&BHBC"JHP /84
MV:"*YB:*>))8VZHZA@?P- %"?5(KE9;33+B.>\,3%3$P98CM.TN>V3@ =3Z8
M!QY8)8-2^ 8TH9_MR$BW^S$XN%OA-GIUWEOFSZ$GIFO8;>V@M(A%;01PQCHD
M:!0/P%(+2V%T;H6\7V@C!EV#?CTSUH X/3E@'QEO1<M;O=)H%OO;C._S'W'V
MX(_ UQF;"']GR\DB-NC+J9*LNT$$7WR\^R]/:O<#:VY<N8(BQSEB@R<TW[':
M[=OV:'&<XV"@#@T32W^->HBZ6U8OH<+Q^:%.[]Y)N(SUX_2N9T>:R\/Z5IL<
MT4$-E=>);N71KRZ9E@LX<-L? (R&&\*"0#NS7>IX7N'\>7>LW5OI\NG364=H
MD+$LR[&9@V"N/XL8SQZUU$D$,T8CEB1T!!"LH(&.G% 'A>I7MD_@#XG6YOH[
MB0ZB9E9MH+AEAPX  &"0<$#G'&:[C4&L;?XJ>#5M3;QJVGWB 1D %<1E1QVZ
MD?C7=M:V[[MT$3;CN;* Y.,9/X4UK2'&Z."%9%'R,8P=I[4 ><FPNM*\6:AX
M.AMW.D:])_:$3J/EACR/M49] WR@8Z>;7H>I60U#2;NQW>6+B!X=P_AW*1G]
M:RO#^E:Q#,VH>(KVTNM1,?D1_9(FCBCCSDX#$DLQQD\#Y5&.,G?H \\^%FH+
MIOAF+PIJQ2SUG26>&6WE;:9$W$K(F?O*0>H]*PH&BEM_BK(;EYK*&%XK4R3M
M)$@,#%E3)('S'M["O6;JQM+U0MW:P7"KR!+&' _.G"V@6 0"",0CI&$&T?A0
M!Y3JL4%G\+O"&J6=M$;."739M4>% 2ULF&;=CD@.0Q'U]ZZ&^5+_ .+'AR_T
MB:.58]/N?[0DA8,IA;;Y(8CU<L1]">U=ND4<<?EI&BI_= P*9;VMO:1F.V@B
MA0G)6- H)]<"@#PZ;5=/M_@G=:7+=PK?VVK'SK;=^\BQ?AB67JHP1R>.1ZUV
M5M_9,_QEU9KC['()-%MY(C)M(8;WW,,]>".?2N^^Q6N^1_LT.Z0AG;RQEB.A
M/J1VKFX_#-S)X]O];O8;":PN;2*W6)B7=3&S,&P5QSNZ9X]30!A> K_3/"GA
M=Q?WD=GIM]K5RFD"4D!H6<^6%] <$@],$'O75>-;NUL?!.M7-[9/>VJ6DGFV
MR,5,JD8(R.0.>2.@YJ_JFE0:O;):W 4VX<,R[ 20.P)Z9Z''."1Q5X@,"" 0
M>"#0!Y3IFJV,GQ/T&8ZO97,<VB2PI]FP(5.^,B-3R20.2"2>^!6"AL(O@*T\
M9MUD&L;PZD [A?<'/KL_2O;UM+9%15MX@J*54!!A0>H'H#2?8[7;M^S0XSG'
MEB@#@M,UNTT[XI>*H=<NH;9KB"U?3Y+APJ26ZH=P0GCARQ(]2?2K/P>FMY/A
MM81P21MY4MPK(I^Y^_D(!';@@UVLEI;2F(R6\3F$YC+(#L/MZ?A4D<<<,8CB
M141>BJ, ?A0!Y*-0T7^U?%_A[Q=J\U@]U>O(()"JK=6SJHC*$J2QP-N <C Q
M5J]O]+M-:N=)0C2[F/P_#&9KQMUQ<QX;;"BL=I8'.XX8DG&.,UZ;):V\TT<T
ML$3RQG,;L@)3Z'M3FAB>596B0R("%<J,J#UP: /%_#WB&TTJW^'>I:A<H-&3
M3);-KDG,5O=%4QO/0':&7)Z9;WK5\9/X=?P>9M)2 6-YXAMII9@V8[J0RH9'
M4DX8<8)''!KU!K2V>V^S/;Q-!C'E% 5Q].E*UM;LB(T$91!A5*#"CV]* .)@
M>VC^.$L4+1+O\.IE$(&2)SCCV'Z58\;ZI8:=J_AE+M;>&:6[D^SW]VY$-HPB
M;)(! 9F!*J"<9.>U=<MM L@D6",..C!!D4Z6&*=0LT22*"& =00".AYH \(U
M&\LG^&OQ&MS>I/)_;9E!?:&96:##X  &X@XP.<'%=OJQ@M_BKH*:<;>.9M&N
MTB5" #RA0<=LY(_&N^:UMWW;H(FW-N;* Y.,9/OBD%K;A@PMX@R]"$&10!X?
M=:WI<OP :QN+J%-7MIHUN[:9@)UG%TID9E/.3ECGWKV?4KRW30;R]*&ZMEMG
ME*0G)E4*3A2.N1TJPUC:-*\K6L!D?&]S&,M@Y&3WP0/RJ>@#Q?3M9TR77?AM
M<P:A9I:K'<1I:6[;DM UOA(F<Y9I,X7D@DCA:W-)N8-_Q./GQX6Y<GYAP/LR
MC^8(_"O1DM+:,*$MXE",64*@&">I'O0+2V 8"WB&[[WR#F@#G_AVZ2?#CPX4
M96 TZ $@YP0@!%=-38XHXEVQHJ+Z*,"G4 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M5>\OK73X/.NYTACW!07.,L>@'J3V Y-6*X7QK<2:;XT\':I=';HT$]Q'<RG[
MD,LD>V)V]!G<,GIN]Z .I@UW2KJRFO(;Z%X(&V3,&YB;^ZPZJ>1P:Y/P;JU_
MXPM=.UZ#73%F25KS3?*1X_*+.$4<!E8!5.[)SSQV#M*$7_"S_$&M6MQ$ND'3
MH(KF<./*>X5F.=W0E4P#Z;A2_!^XAG^%^CK%*CM&L@<*P)4^:_!]* -E_%VF
MMXN?PRL^V[6V\UG_ +K,P55&1@GJ?; K"\'>-+==-DA\1:[ ;]]4N;6 SLB,
MZK*408  '3'3K2RWUMI_QLD^US)#]IT**.#><>8PG<D+ZD Y/H.>E</=75@?
M@EXN>.>V\Q]8G;*LN6/VH%3[\#(]J /9M2UO3=(7=?WD<'RE\-R0HZL0.BCN
M>@JCJ&I64U_H@A\10VWGR^9%!&R/]N0J< 9YV]\KZ5QFH:[I>D_$/5AXAU*:
MRT_4[2W;3[M9"(9416#Q[AD9RQ./]KW&8M0CT;1W^'5GI^ZULH]3D:WCN9#O
M\LI)AOFY )(QGID#VH [N7QAX<ANOLLFMV G\];?9YZD^:W1/K[5>U'5M.TB
M*.34;V"U21Q'&9I N]CP ,]3["N*\*MIUW\3?'0S:S2^?9LHRK'Y81R/HP_
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M%O,U[$T=PGF0M&=_F)P2PVYRHR,GH,BO/M0U/2_#GQ$U6V\07<NEZ??V=O\
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MQ222-P0C#D@^G'/-)9:_I.HW7V6TOX99RGFK&&P73^^N?O+[C(KRCQ!Y]_\
M\+4M-&99[DO92>1"P+2((T\T #KD!@?RKI=<N[/Q/K/@B[\/W,4\\5[]I9X6
M!,5KY;>8&Q]T'Y5P>_% &MX1U._NM:\5VVH7S7$5AJ B@+JJ[(S$K8^4 =2>
M35+5O%8E\;>$[/2=8#VM[-,MQ BJ5F01,RNK$9(R.JG%<EJDMQ?:'\4X-&D$
M]XUY&WEPMEFB"1"3 ')^4./TK6U;Q/X>UCQ/\/[S3+^UDA6YFXC89A#0, K
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MZ1Z3?73+<$%#%)%Y3N&WD9 X!R#C%4-'N=-7XJ>-WDFM 1:689F9>@1P^?\
MQW/X9KD]%GM#X&^&%Q<R0FTM]099Y)""D1VRA=Q/"\[<9]J /7=(\1:/KUK+
M<Z5J5M>0Q-MD>*0$(??TIMOXET6ZN)((=3MC+'%YS*7V_N_[XSU7_:'%>;^)
M],N=2U;QIJ7AJ+S8)=%CMYC;_=NK@2%G52/O,(OE./[V.M;.A:MX.\2ZSI.K
MV-]=7FH644C 22L/L2,F'\T< #@+@]^1T)H ZBW\9>&KJ18X-<L)&:%YUVSK
M@QH2&;/H"#S[&K]CJ]AJ,TL%K<J\T*JTD9!5D#9VD@@$ [3CUQ7F/@^+0;KX
M(N+Z9(K?=<QW%S;E?,@WW##=GM@;#] .M:_A[7KW1M4U>'Q#J-EJ5G9:?'=#
M7+9,$Q!FPDJKD;OO,-O4$^M 'HE%5=.U&TU?3K?4+"=9[2X0212+T93]:M4
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M-M4#RKDYVDX!7^\,\?+GDXIR^+_#S:/%JPU>U%C+)Y22E\;GSC;@\[L]L9H
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MP.<^W6@#8VC&,# [4;5_NC\JS8_$&E3Z7;:G!>I-:71 MWA!<RGGA5 ))X/
M&1@^AJS8:C::G;F>SF$L:NT;':00RG!!!Y!!X(H L[5]!^5(8XS()"BF0# ;
M'('IFG5D7/B?1;.Z:WGOT1TE6!VVL4CD;&U&<#:K'(X)!Y'K0!J/%')MWHK;
M3E=PS@^HIVT$YP,U1OM:T_391%=7&V7RVE\M$9V"#JY502%'J>*B@\2:+=Z>
MU_:ZI:W%JKB,R02"0;SC"C;G+'(P!SS0!HM#$TBR-&A=?NL5&1]#59M.B?5D
MU&0EI8XS'$, ! <9/J3Q^ Z=3G/;QCX>CTRYU&75;>&VM9/*G:4E&B?^ZRL
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M8 X.#S[4 3V-E#IUE%:6X(CC&!DY)).23[DDD_6K%%% !1110 4444 %%%%
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MG!.U@,@C:.!DDFNMM]1T^X^-+W2W$.S_ (1U KN=N#Y[,1ST.T@_3GI7H5%
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M$:[PH?'S;>F: /%]/UJPN;_X=WT5R%@CFEC:TMH"(;)F@8"$<%BX/!R23C(
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MDGM1$;EHKV"15 15C."PQM((]/2@#O[OQAH%C?/93ZG%]J2#[08D5G8H2 "
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MAQL<$93DC.X#&?<5QMCX@MK;P3X$C: QQQ^7;SZC+:,QL)%A(.T%<;R<IG!
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M<5Z.S!5+,0% R2>@H Y=?#FO66K7]SI?B.)+6]G-Q)!>6/GLC$ 81PZ\84
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M\<$U7C\7:'-I,6IQWI:VFN#:Q8A?>\VXKL"8W%L@\8[$]* -NBN3UW7K?4_
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M%4[CGL,G@^AH U+^QCU&T>UG9_(DXE12!YB]U/L>^,59JEI&KV.NZ7!J6FW
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M(LL<=M9>0"Z\J6)=R<'GC'([T:=?:;/XKUI+?5KJ:Z@BA%S9R,?)MA\V"@(
M!;!S@GH*EM_%>C7.HVM@ERZS7:L]J9()$2X &3Y;L K\<\'ISTH VJ*R;?Q)
MIEU=V]O#+,S7+ND$GV>01RE02VU]NT\*W?G'&:3Q/KT7AGPY>:M*AD\A!Y<0
M.#)(Q"HOXL0* +SV,4M_%>2,[O"I$2DC:A/!8#U(XR>@SC&3FS64ERNB:7#)
MJUX9+F5E5V56;S)6'W8T&3C@X4 G R<G)IEMXIT6ZL[ZZ6]6..P<QW8F1HVA
M;T96 (SD8XY[9H V**RK/Q#INH:@^FQ32Q7RQ>;Y$\#PN4)QO4.HW#/IG!ZU
MP$6HZI_PK?QW<?VM>FZT^_OUM[@R?O$6,?*H..!QVQ0!ZI16)9ZQ!9Z#I37<
MLTMQ/:HRI'&\LLA" L=J@D]1D^X]:?;^*-&N]'758+U7M&D\D$(V_P S.WR]
MF-V_/&W&?:@#8HKD]7\?Z3IWA_6=2@$]Q/I8Q/:_9W62-R,IO4@%5/7<>,=Z
M?>ZUI=W)X?:YU/4+">>Z4P0)')#]I?:?D=67.SDGG .!S0!U-%9=CXBTS4=4
MO],M9I7O+#;]IB:WD3R]WW>64 Y R,9R*1?$>F/90W<<LSI.S)"BVTGF2%<Y
MVIMW$#!YQB@#5HKS[QUXDCO_ (;7^K^']5N(7MKB*)FAS%(C^<B.C@@,IPQX
MX/2NM_X2'3/^$B_L#SY!J?D^>(3!)@Q]-V[;MQGC.>O'6@#4HJG9ZG::A/=P
MVSNSVDODS;HG4*^ < D -P0>,]16-+XN@'C@>&!;W8D^Q^>TRVTC#+.JK@A2
M-OWLL?E! &>M '2T5YMX3\:66E:?J<>OZM<R/'K=U;+-,CRB-!)L0.R@K&.P
MS@=:[?4M=L-*8K<-,\BQF5H[>!YG5!_$50$@<'D]<''2@#2HJMI^H6FJZ?!?
MV%PEQ:SH'BE0Y#"K- !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5PGCFYN-$\4>&?$;
MVUQ<:59&X@O/(C,C0>:JA9-HY(!4@GL#[UW=% 'FGBF0ZOH=GKN@Z3,;.TUJ
MVU&X"6K1RWL:9WN(R S8RI!(R=AQP 3H7!@UWXBZ#KFFS!K'3;*Y-Y= $(1(
M%"1D]R"&8CMCG&17=T4 >)PY7X':7:F*472:HKM!Y3>8H%X7)*XR!LYSZ5V&
MF75NOQ7\0W3N!;OIMJJ3$?(Q4N6 ;H2 1D"N\HH \.T@W&E>"_ ^JW%EJ$MA
MIKW<.HPVPD2: 2,=CE5PV!CGV;WK9UN&VGT1?$?A?1KV:"WU6TO[IG27SK](
MMV[:LGS':"I!/7!]*]8HH X>[U2P\6^'-?N-#TV:62;2IH#=R6C1/(Y1ML2[
ME#/@DYQP"1USQS-Q?/#H'@77#9:G-I>F6YM=16".6.6(M"B[P!ABJLI!(XY/
M6O7J* /)=?@M;K05\0>&='OI;2+5[.^O7=)?.OHXB2Q"2?,P7*X)ZX/I6K%K
M%IK'Q8T74+!;J:T;29XO/%K*%#&1" 25XZ'KP#QUKT6B@#*\3:)%XC\,ZCI$
MIP+J%D5O[C]5;\& /X5YLW_"436OA_QM]AE&L1,NF363<!XG'EL[#_KOAO\
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M^YAU)(ZCIGH<"[L_#NJZ'+.FBZG8V5]>1'[?%'+'=+*JL5GP07"J<#<1W)Z
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M"EE9V9<XQD!AQ7&Z+'J&D>&_ >KRZ=?-::1=WJZA;"V?S8A,75)/+QDA0V>
M>&H ['PQJDM]\3O$\'VB^-O#:VI%M=%@(7._=M4\ '@Y'!]:ZS4M:L]*EM8+
MAG:YNW9+>")"[RE1N; '8 9)/ KDO#MV+SXI:]>Q6MZ+2YL+40SR6DD:.5WY
MY91CJ.O7M5SQCJ$UGKWA^-K2X%C*\PGO[6T,\T!VC:B[58IOR06 S@8XZ@ S
M_'OB"+4_A1K6K:)J%U!);@IYD3-#)'(KA61AP01R"*NZ]/<P?$KP;%%=W"07
M*7@F@$I$;[(@5)7H2"37#W%O=_\ "J?'.F+IFIBYEU6X:&*2WD9Y \JE<'DN
M< DD$^YKL=>E\_XA^"+J*&X>WB6\,LJP.5CWQ!5W''RY((YH [6[N[>QM)KN
MZF2&WA0O)(YPJJ.I)K*M_%>DSZDVGO++;70MS=A+J%HMT(."XW <#N.H[BJ/
MQ&TW4-5\":C;:7'YMX/+FCA_YZ^7(KE/Q"D54@\51^(-.N;W3/#EW+>6]E*7
M2_LVB(?;D0 L/F+, "%R,#D],@&M8^,-(U"ZL[>&2<-?0M<69D@=5N8U )*$
MCG@@XZX.>E-?QKH4>A7FM-<S"PLIWM[E_LTF8G4X8%=N[@\9QBN!TZXEN?$?
M@'4OL6K/Y4=Q%= V,D45M(T( B2/:%10<C.,8'+''%/4VN(/ OCWP]_9VH/J
M4^I74\4<=HY5XI) R.'QM(([ Y]J /5+[Q%86$DL<GGRM# +B800M(8HSG#,
M%&>=K8'7@\4Z[U^RM%C^6XGDDA\\0V\+2/Y?]X@#@?7KSC-<+XF@6YOWU32K
MS5-&UV#3XS#)]F=H;Y?F(A>,KAF!R,?>&X'!JO<W5UHOBFWU;Q)HU\UGJFE6
ML;MIZ22"SN(]Q:,K&<[3O.#S_.@#O(/%>D7EE8W5C.UXE\C26ZV\99G52 YQ
MVVD@'.,$@=>*T-.U"WU2QBO+4N89,[=Z%&X)!RI (Y!X->>ZEHNDRVNC1VUO
MJ/A>5%N)["\MD8?9LLF5F7! \S(;:V/NXZYKK?!<^K7/A6TEUN)([\F02%8O
M+\P!V"R;/X2PPQ'OVZ4 3:AXITS37NUE:>06:AKMH('E%N",Y<J#CCG'4#G&
M*P_&WBD66E:,=/EF>+5+^UB^T6L;N# [Y;8RC[Q48&.><CFJ7A^=_#.K>+-/
MUJVN66\U&74+21(&D6ZBD51Y:X!RR[=NWKR.U8;Z-?>'_AYX$TF[@N);RTU>
MUN+A(8FE,*"1G;)4'A0P&?:@#T;0=+33DN98;W49K>[D$T<%Z[,;?CE5W_.
M3S@GCVJ"T\9Z+>W-E##/(4OW>.SG,+"*=DSN"MC'8X]<<9K:>4FV:6%/,.PL
MB]-W' ]J\<AN[F]B\&7\FEZK'<6NJ_Z7:0Z?)%!9Y20"-(PH!&2/FY]R,XH
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M\KTK1KWP[;_#:POK>X:6SGN9KD)$T@MUD23:&900,%POX5Z[,C202(KE&92
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MW1N(M0DBT^\)Z+<LGRRIZ!F4J1T^8'@YSUU</\3;=[^PT#3H 3<7.MVH0#J
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MU&67# $D#TK0L[Z&_P!/AOH/,,$T8D3=&RL5(R/E(R/IBN#US1KZV\>-:V"
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MO:(([A99;9DC=7'&UB,,1T.* -RBL_4=8MM.GM[9UDFN[G=Y-O"NYW"C+'L
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M5K9]\,H8*4=<?*<D#G Y'- '445S\/C'2YHW*I>+)]J^RQ126KH\\FW</+#
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M%% !1110 4444 %<5XQMKVV\6>%O$4-O/<V.G27$5Y% A=T69 HD"CDA2.<
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MJI;Q6SN\,'FJ=S*H.WY5W$'UQUS73&26'XLWNI?8+][1= 6,2K:2;7D65W*
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MK>W,N?F"@[<* 2/?'6O8** $4AE##.",\C%>?6:SQ^+/B!.]C?"&Z@MQ;O\
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M-YJ=SJGAKP;:+H6KQ7NF:K9&]@-A(!"(@0Q#8PR\9!4GCTKUNB@!I<+&7(;
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MUMI;!+ZX@C#) 2 2#SEL @G:#C/-<W-'K<^M?#NZU2PG-W:I,^HM;P,T<+/
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M=Q,@=G:(8ZY5V3CKQ4R^%M8MO&%O,$+VFNVX?6R&)6.6)PZ@>H96,6/[H]J
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ME;.N_=@8'K6+*]Q<_%+2=3_LZ_CM%TF:)Y'MGPCM(C*I(! )"D^W0X/%<O\
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M''&<GI7/>*X]<UC0_$UI<:'JTE]%J*-:1V\)%NUNLL9#K@@2.5!)^\P/8 4
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M %&"TW)MP@9QGJ1DE0P'OUJ[<>(H8KD6D5G=W-\(!<26L*IOB0\ ME@H)((
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0V1@D<':PSTH Z&BO)? WCFR\.^ -)74[;5&M3/-'-J7D%X(6:=P-[DY[CD
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MF32F&2]:UQ%;L'*?O#GC)'8'&1G!XK7U3QG8Z9-J<8M;N[&EP)<7S6ZH1 C
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M&WGK[=:U-3@GTCQUJ&JW7A2XU[2=8A@:-X+5)9;61%V%61\$*1@YXP:],HH
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M,@#..U9>J>&;_7&\;ZI;6\D9U32UL;*&5?+>9E1LL5."N2P4;L'@GIBO2:*
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M:-.M+VT^)6L:A+8SBRDTZW@CG2/Y7>,N6  .1]X8KEET/6A\&+70_P"R+O\
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M2S265-EP%\L[,@]?D/)&,XY[UMS3ZMK?CCPEJR^'-3MK:TBNTNOM C4Q&1$
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M@;K&HQV3A9S'M.W:21@;L9P0<?C0 V7Q[80>'M8U:6QOA_9$[V]Y;JJ&1&4
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MVZW#VYE79*K*2I5_3Y3G(R,=#6))XD@O?AUH6I>)M$GNDO'LR=A3;YKE"DF
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MR0.]<E=>*[?2/ OBW6?#VB26US::A<)<),RC_2,*'E.&((R1P#SCMF@#T@L
M0"0"3@9[TM>;>(KAU\=> ]2ETV<79-ZIA3:TC_Z.<#(.WJ>Y &3G'-=!9^.K
M"32-7OM0MKC3Y-)G\B[MY=KN'PI4+M)#;MR@8/4T =317/#Q2(-;M-)U'3Y[
M*YOHW>S+NC)*5&6C)4_*X'..GH35&7X@6D7A+4?$3:=>>1IUS);7$(*>8&1]
MC$?-@C/O0!U]%<C-XFU$?$FWT"/3G:S.FM=-()$RQ,B+NP3P%^88ZG/3BM;Q
M9#'<>$-9CE0.ALIC@^H0D?K0!K>8FU6WKAONG/7Z4ZO.+&^TNT\"?#V/5-+E
MO!.UA':R+MVP7!C&QS\P/ W= :WIO&3_ -N:KHUGH6H7=]I\<<I16B59%?=@
MAB^ /E[X//3@T :&N^&;+7Y+2>::[MKNS+&WNK2<Q21[L!AD<$' R"#TJ72]
M&M],E+F[N[RZ*;?.O)O,<+GH!P%!(&< 9P,YP*YV+XDV<^F:5JT>DZC_ &3?
MRQP&\<(HAD=MH!7=N(#<$@8]":N_VCIW_"Q+JU31Y_[:BTGS!=$J!+!YG"+\
MW]_/4#I0!U-%<'X=\=W-SX+_ +=U739PTEV\$*0%7WLUPT:(.>WR@LV/6M&?
MQF\=MXCB72Y/[3T2!9I+<RKLD5D+*ROZ84YXSQT- '5,RJ,L0!G')[TM>>S>
M(;>[\">&[_Q+HL]U]LFLMI4IM$S["DIPV0NXGC!/J*ZBZ\0;=4N=,TZRDO[R
MUB6:X1'5!&&SM7+'[S;20/0<D9&0#:HKCY?B+I8T;2=4@M+Z>#4;U;$!(UWP
M3%B"DBYSD$'@ ]/<5HZ)XH&K:SJ.DW&FW6GWUDL<K17#(V^-\[6!1B/X2",\
M4 ;]%9>J:!8:U<VLE_%YT=L'VPL3M+-CD@=< 'KZUY[X&\,:9K5IXNAN8/GA
MU^[M[>96(>!%V[0ISP 3P.E 'JH92Q4$;AU&>15?4;6.^TVYM)I988YHFC:2
M*0QN@(QE6'0^]<U!J]@GBGQ/]BT28:Q9VT#7$CNJ_:E(?RPIW$   \D \].*
MY#Q%JUSXG^!JZOJ5GY=Q(]K,CY4@EKA.5P<@8..><4 >EZ)HEKH-A]DM7N)<
MMODGN9C++*V -S.>2< #V  K2K$U3Q''8WLEA;6YN[R*$3R1"9(PJDD*,L1\
MS;6P/;G'&9O#GB"Q\4Z#:ZQIQ<VUPI($@PRD$@J1Z@@B@#5HKS;6[2#PM\5]
M%UPQ*-.UA6T^8'[D-R?FCD Z M@KD>_K71W-A:ZUXY@EDA5UT>#<S8^]-(<H
MI]=JJ6P>\BF@#IJ*\Z\,65J?BWXWB-O&8H8K+RHRN53?$V_:.@W=\=:?\*K>
M)$\5.$&^/Q#=P(QY*QJ5VH#V4>G2@#T*BLS5=;@TN>RM?+>>]OI&CMK>,@%R
MJEF))X"@#)/TZD@52T_Q0E_=:EIPL)X]6T[89;)F3+JWW71L[64C//!&,$"@
M#>WIYGE[UWXSMSSCZ4R.VABGEG2,"67 =SR2!T&?09/'3D^M>>?#:PM_$7AS
M1O$.IZ:PU2)Y;A-0\P!IF=W# [3DJ!@8;C@8Z5MZ[XEU+3_&^A:+;:>TMO>1
MSRNZR("^Q1\H!/ &X$GOCCO0!U@8$D @D=1Z4M>6:5K/_"+ZYX^N+;1[J\@M
M[Y)YEMMBB.,0*S-EF&3U.!DUVLWBJS\NP%FOVF:^MOM<,9D6,>5@?,Q8\9W
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M#$?W<8/;- 'H*L&4,I!!&01WI:PO!/\ R(7AS_L%VW_HI:W: "BBB@ HHHH
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M77S""P7/) ZG'XBG4 <=XDTK48?&FA^)["V>\BM8I;2\MHV D\N3!#ID@'#
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M1KG7OAUK-A9H7N3$LL:#J[1NK[1[G;C\:ZRFI+&[.J.K,AVL <E3C.#Z<$4
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MM$8!WBE4*63<0"RD XSS3M/TRZ;QGJGBR6RGB5[&*RM[8[?-D"L79B,X&20
M"<\'.*ZZB@#DOAIIVH:/X"TS2]4LI+2\M499$=D8'+L1@J2#P13/$MAJ?_";
M^&-9L=.DO8+1+J&<1R(IC,JH%8[B/ERISC)'H>E=A3?,3S#'O7>!NVYYQZXH
M \\BTK6 OQ!SI%R/[6W&R^>/][^X$?\ ?XY'?'%4%T?Q!HO_  C&LP^'SJ7V
M;1X]+U'3F>/S8RN")$))5OF!'7I^GJE% &9H9NGL#-=Z?'I[RN76U0J3&N
M&*\%N"3C@9 R<9KF=2T34]#\?OXMTBR;4+:^MEMM1LXW5905QLE3<0&P!@KD
M>V:[FD#*6*AAD=1F@#,M-0O-0EC*:;<6=N.9'NPH9N.%50Q/7J3CVSGC"\%:
M9?6DOBA-3TZ2"*_U>:ZA\UD821.B*.%8X^Z>#ZUU[R)'MWNJ[CM7)QD^@IU
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MDR:O/%&SPQ'[PBZMO() Z 9SGC!@U#PJVEZQX9U31+3S(M&B>S>T5@&:W=0
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MKG#ID^OZ9XAT*XT;4-(UK6(#<_;+V6*43-%L5?FB.%"Y08P."3R<UT?AN_\
M%-])!'K/AR'2C /](G%PDHG;!'[M5Y4$\Y/0#'.<@ ZF:&*XA:&>-)8G&&1U
M!!'N#7EWPK\,:)JWPTM);W38))Y9;A6N-NV;B9P,2#YA@  8/:O4)I&BA9TA
M>9E&1&A 9OID@?F:\_\  5OXB\+>!X-(N/#-R]_%),P_TJW$1WR,PRP<L!AA
MGY3]#0!EZ-XAET_1?'&@Z_%<:Y:^'V()=E,DUJZ,P#EB,D!3D]>:[.'Q%;Q#
M1M,TZSB%Q=V'VJ"V>81*D2A1M!P<GYA@ = 22*YY?!6IV/@CQ8) E_XB\0QS
M-.(&"QJS(51%+D?(N>IYZU-J7AW^V-&T?3M9\-7,\=O8H%N+:>);BSN% 'RM
MO'!P#D$C@9'H =#_ ,)*9/[-MHK"3^U+^!IQ9RN%\E%QN,C#. "P7@')/'<C
M+N?B"MGI-M>W&A:E&\FIC3)(BJ@QR%MNX9(+J>H*@Y]JPX]#\8Z'-X;U]8?[
M;U&UL9+#4;8SJDCQL^]&#M\I9< 'GG'OFM/Q/9^(];T;29#HY-S'K%M>M:QS
MQDP0QL"0S,P#,<$\9'.,\9(!->:_%/J?AZ/7/"MS;W<^HO%:/-)$X@=5;#Y5
MCU4'M^/2IIO'%P;[7K*R\/7MQ<:/L,JF6- ZLA?(.2.G0=3GD"E\6Z?J6H:W
MX6N;+3I9XK&_^TW)$D:[%,;+C#,,G+=L]*K6.FZM;^)?&UZ^E3^1J20?9")8
MLR%(?+(QOXYY&<<4 2Q?$**9-"O!I%XFDZQ+%!#>.R#;+(,JI3.[&01N]?48
M)L6VK6'_  FVNP0Z',-4M;.%Y;@&/=<QDML5?FQC@_>(KFAX>UY/ 7@O2_['
MF-YI5_:372":'Y4B)W$'?@YSQ_2MVVL-5@^(>N:LVE3FRN=/A@A<2Q9=T+DC
M&_(SN&,^E $%E\25O+#0]3;0[R'2]6N$MDNGD3]W([%4!7.2,C!/\ZO:UXW&
MCQ:O='2YY;'2&C6[F+;&.X*28U(^< ,,\CVS7+6_AKQ!#\-?"NCG1Y3?:;J-
MO/<1B>' 2.4N2#OP<@\?TI?%.@>*-=M/%EE/HOVV2Y'_ !*KF2YC$<46U?W:
MH3E9,ALM@ YY; % '2W'B/5!\2[30X+)'L'TQ[HOYH!?]Y&N[&. N3QWS[5'
MIOB70[(>+-1?36TP:==?Z?(X4M,X12&PI.200 ,\Y]341T[7$\=:-KHTG="V
MDO8W""X3-LQD1P6_O#"D?+GG\ZR;OP9JVNZ9X[TZ>V>Q_M>Z2XLII)$96**F
MW=M8D9:/TZ'\* .J;Q6UEJNFV.K:;)9#4R4M)?-#CS ,^7)C&UR.F,@X(S61
M-\2'33=9OXO#E^\&CW<EO>$RQ*45 I9A\WS'YN@SP.2,BI+S3]6\62>&QJ6E
M2Z<=,O8[^Z:26-@TD:L D>UB2"S9R<<#UXK*_L#76\(^/+ Z/,+G6+VYFLU,
MT.&62-44D[^.5).?UH ](@FCN;>.>)MT<BAU/J",BN<EU+3Q\1TL&T=SJBZ4
M\T=\=GS1"108UYS]X]\=/>MG18YHM#L(KB%H9H[=$>-BI*D* >5)';L:YZXT
M_4O^%IV^L)ITKZ='I,EH9UDC_P!8TBN/E+9QA<9QU_.@"C_PLT?V(VM'P_?+
MIL%X;6[F:2,&#$GEYVYRW)&<<#/4\X[VO*)O#/B&7X4ZUH0T:4:A=ZA)/%&9
MX<%&N!*"6WX' _.O58W9XE=HVC8C)1L97V."1^1H \NU.#1X_CE(NH:>D]O)
MX?$IC%F9P9?M!&\JJGG QNQ[9K?MM3T/0M#U[Q'H^E3+:V^1/;P0B#=Y*DL^
MQ]NW[Q![D*.#5>>RUFW^+4GB"/0KNXT[^Q_L >*: ,TGG;\A6D'RX]>?:K.O
MIK>M^'?$=E!H$ML+JPD@@CDEA\RXFD0KN)5RJJH"CDY.>G H 4^/7CO=(BFT
M"^6'5XB;.571C)($W["N<KD="<>^*4>/1%IOB&>]T:[AN]! >ZM$DC<E"F]7
M5L@$%<^XQT-4;K2=9EF\".FD3D:4VZ\'FQ?N_P!R8\#Y_FY.>.WY5F^(=.U*
MUM_B?J-S820V>H:8OV:5I(SN\NW96R Q(Y/&1^5 &[#\00-5TBWO]#OK&RU?
M:EE>RLA1Y"N0A4'<N>V<$^@[9_AV[T_P]XA^(E[.4MK&UNH9I"JX 'V=6. .
MY)/U)J2/3;[Q/I/@Z"33Y;2WTZ:VU"::5T(8Q1_*J!6).6(.2!@ ]^*J7G@[
M5-=3Q]8W%J]E%K3Q/9W#R(RDQQJ!N"L2!N3TZ'\* .E;Q:UG?Z5!JNFR64.J
MMY=K,90X$I&5CD ^XQ&<8W#(QFG:5XM749-=AN+(V4VC/LG2:4<C;O#Y X0C
MD'Z\<5DW>FZQXJMO#EMJ>ER6#Z=?0WUY*\L;(SQ X6/:Q)W,0<D# SWXIOB?
MP]+=^.]+FLIECCU*![;58<?ZZVC*N#^9\LGTEH OMXVECU#1]/?0+T7>JVKW
M,,?F1_+M )0G/!&X9S@#L35+_A8D[:/JEZGAJ]:72)9(]1A\Z,"$( Q*L3\_
MRG( _''&;NL:=J5Q\1O#NI06$DEC907,<\XDC 4R! O!8,<;3GC\ZQH=%UL:
M-X^MVTB<2ZQ-.]FOG0_.'A$8S\_'(SSV_*@#I+OQ?91BQCM3#)/>VOVR)9YQ
M HB.,%F.<$YP  >_8$UCQ?$^QGTG3;Z#3+R7[9J7]F/&A0F&?G*GYOFX&01P
M1C)%9@TCQ-H=QX>UNPT47[PZ1'I>H::\\:2+LY$B,25.#N[]#^6AX@L/$&KV
MWAR8Z-MEM]:AOYK>&:,_9X45AM+%E#MSGCCDC)QD@%Y?&ER\?B&W;19+?5-(
M@6X^S33H5E1E8JV]<@?=.1VQWK0\%:I?:SX/TK4-1B"3W%I%*7# ^9N0$M@=
M,D]*Q6T35;CQEXIN38/%::CI<=I;SO)'@NH<'(#%@/G';L:UO MOJ5CX-TO3
M]4L#97%E;1VQ0RK(6**%+?*2,'''.?I0!M:A?0Z9IUS?7+$0V\;2N0,G &>/
M4UP'@R[U71O'&IZ'KTQ:75X5U>VR>$<@+-"#WVD+CV&>]=-XFMKO5+G3M,&F
MRW&ER3B2^E62,#:N2J8+!CEPA.!T!'.:Y_QEX1GM[C1-7\*:1YFK:?>B0A)5
M0-"01(C%V'W@>V: .IO=>>/5)=+TZS^VWT-N+B9#*(UC0DA06P?F8JV!CL<D
M<9YJ\\;ZE<7GA Z;I,T<&KRRF6.[/E2@I&Y,94CCD Y[X&.M%Y;>)-%\;S>(
MM*T1]1L]5M(H;NS^T1QS6\D>[:V2VTC#$'!J?7M-\07.H>%-86P2ZN+"[FDN
M;:&95V+)&R##-@-MR 3U.,@=J .V!)4$C!QR/2J&N:M'H6C7.I2P3W"P@?NH
M$W.Y)   ^I'TJE8:WJ$_BB^TB\T@VT$,*S6]VMPLBSC@-E0,I@D@9Z[3Z4WQ
MG%K<_A6[C\/9_M$E-JK((V9-PWJK'A6*[@#V]J ($\81P:CJUAJEHUK/IMD+
M^0Q2>:CPG=D@X!R-I&"/IFKFDZY<:G-;[K );7-J;F&YBG$J$97Y20!AOFSW
M''!-<A::-KEGXMU'5K+PQ%;VUSH?D1PR7,9)G5G8+( 3EF) )R1CDMGBKGA?
MPO-HWBO[9I5C=Z/HT]LYN].FF1XOM!9=IB568+QNR1@=,#K@ [#6-3BT71[O
M4IXII8K:)I&CA3<[8[*.YK)L_%,LFOR:)=Z9)#?"P%_$D4RN)(]VTKD[<.#C
M@\<]:L^+HM9G\*:C%X><)JS18MR6"\Y&<$\ XR 3T.*Y32M(U>T\>VFN1>&6
MM+)M(>UE5KN-YA)YBOESD[F(& <G/&2.P!8C^)J/X>T_Q V@WR:3<S^1+.70
MM"3(8P=@.6Y SCUXS6S8^+#-XEFT34-+GTZ9;0WL+RRHZR0AMK$[2=I!(XYK
MC$\,^(5^#]EX>.C2_P!I17BRO&)X<!1<^;G=OQ]WCZ_G70:EHNHZG\0H[UM/
MG339-%FL))_,CRCR.K?=W9X (R!U_.@!W_"R-.6YTEGB3[!JLZV]M.EPC.K/
M]PR1CE5;L<DC(R!3+CXARI!KLUOX<OYET29DN\RQ+M14#EA\QR<'( STYQD5
M7\(IXOTVSLO#NHZ!;(EB$A_M=;A#'+"F "(_O[RHQS@9Y/I42:+K8T[Q_"=(
MF#ZP\K60\Z'YPT C&?G^7D9Y[?E0!T\GB>":?3;3383=W>H6WVN*-GV*D&!\
M[G!P,LH& 22?8D<=X)U>TT&S\8WEW:_8D'B!HA;*5'[QDB4*#D+RQZ\#!R<<
MU)::+XAT+6?#NOP:1+>"/1(](U"Q2:(2Q%2&$B$L$89!&-PX_2J_A3Q->Z;X
MC>.QCL[Y]<36-.$TRNLA0)A&VDXSM(],GTYH Z:U^(&FG5M0TW4?)M9;.R-^
M98KA9XG@!PQ#  A@>JD?3-<_XJOIM3UGP)?3:.;9)M7C>"=W5I%0QN=CC'RD
M\' +#@YP16G>V/B#QMX4U33-0T6/0#<6C1*'N$F9Y3@@Y3H@QSW.>@QSGW<'
MBO6+7PFEQX:D@N=)U**:[9KJ'8ZI&ZEDPQ)!SGD \@<\D 'I;*KJ590RL,$$
M9!%>1>%O$TGA'PUJ\T7AZ\NM*M-9O3<SVQ15MXQ*1\J$@M@<G P!WZX]>KSB
MRT37K3PWXD\.?V4QEU.[O&AO#+&8!'.Q^9OFWY4,<KMY(_$ '21>+HIO%-EH
MRVC>5?V9O+2],@\N9!C(4==PW X].:TM*U1M3>]_T8QQ6UR]NDF\,)2O#$>@
M!ROU!].>5\7^'GL?!VC?V1,JZIH4ELNG22#_ %C?+%Y;8[.#@_A77Z3IZ:5I
M5M8HY?R4"M(W61NK,?<G)/N: .?\9^(-3T6[T"WT^T25=0U&.WD<R!3C#-M
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M:/;PA)'1B0"..H"WGC2_3Q%J.B:=X;N;ZYLXHIN+F.,2([$9!)P,8X!Y/H*
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MCRWW$;&3SBM#X>:]%IO@K7-9N;IFT.+4)6T^%IA)+# 2 D9R?E.3@*QR,\T
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MLD\/W^DR6,S6AO+9VF63S8PX4A@OW6!(XR?K0!TE%%-DD2&)Y)&"(@+,S'
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MD(Z< 9P3TX]-JS\?V-SX9L-5DA%K/>7+VB6T\RJ$F0L'#/T"C8QW>F,#) H
MZZBN:\->,(/$&IZGIABCBO-/*%S!.)X9$<95D< 9]"" 0:Z6@!,@=Q1D'H17
MFOQ-M[ ^*?!,]Y9I.AU%UD'V<RLZ^6>-H!+#..,&M[2(_#TGB&YFTC1&M+RP
MM1EEL3:&592WR8=5W<Q#GID]>M '6T5Y^/B9-_PC,7B-O#MPNEBY-O=.;A=\
M/[XQ;@H'S\XR..O&>:V;;Q7<GQ1_8=]HLUK)-:O=VC>>CF94(#*0.$;YAQDC
MWH Z>HS/")Q 94$S*7$>X;BHX)QUQR/SKSX_%*=?#L7B(^%[T:.LSQ7=QYZ%
MH LACW!.KC@9QP,XR<&K6VW/QMM;F!8_W_AV1VD4#YQY\>"3WXH [NBN.N/'
MJPZ ?$B::TOA]92K723?O?+#[#*(]O*9Y^]G'.*OQ>*"_C)- >S5$FLS>6UW
MYV5G0$ A1C[PR"1GIS0!T5%<O+XRAM[037$,,)GOI+*SWW(5)BF[<Y8@;5&Q
MN>>G&<C-.S^(VG/#K?VV..&;2&B$GD7"S13"3 C,<GR@Y) Y P>M ':51U?2
MK?6]*N--O#)]FN4,<JQOM+*1@C(YP:PM*\;P7WBD:!/%;+<26YN()K.[%Q&X
M!PRDA058=<8(QWKJZ *UA9Q:;80643N8H$$:>8VYMHX SWXJSG->=?&2VM)?
M"^G2W,$4FS5;4$N@8A2^"/H1GBJ6GQ6M]\5+"[\&0"WTNSBF@UMX(_)@=\?N
MX]N &D!Y) X&.>U 'J58VB^%])T"XNKBP@D6:Z<O))+,\C<DG +$[1DDX%9F
MN>-[?2[C4;>V2TN)M.C#W$<]ZL#$E=VR,$'<VW!YP/F SUQFKXTO]5\4>&8]
M)MHFTO4[&6\'FRE)&*A058;3C;NZ<Y/ICD [I)X9)9(DEC:2+'F(K E,C(R.
MV14E<9;>(K2WU3QC-!X?:*\TP1/=.C1B2[_=%E).<<*.,D]:;9^/Y)-'@UB^
MT26QTZZM[>2UGDN8_P![+*0!'C@J!G.X\8YXH [6BN)C^(D/VW5K&2RCFN["
MQ-^@L;M9XYXAP<.0N&!ZJ1],TU?B%<"#P_>3>'KA;'6UC6"5+A&<3/'O5-G'
M!P0&)'3) % '<45REGXV19M>@UJP.F2Z-"ES-B83*\+*Q#*0!S\I&,=?6H(/
M'\+:_8:7-:P%M1C=K9K2]2<AU7=Y<@  1B.G)&>,T =E17GZ?$N9M!BUUO#M
MQ'I@O#:W,K7";H?WOE!@H^_SC/3&>">:T8]>UB7XH7&B?9K?[!!IZ3@B<AB'
MD(+D;>HVX"_CGG  .OH)QUHKF/B+;PW'PY\1":)) FGSNN]0=K"-B"/0CUH
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ME&8-F.3)7AAWZC'2N^HH XCQ+I?B+6M!TVY-E =0M-7MM0%@DX^6.-@3'YA
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MKF/6(8DL\2QY8K"8SGYOEY.?I[\4R?PQK=S\,-#TVW6.TUW1EM985F<-&\L
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M-ZR+@EER,C;G]>/0** ./DTC6;;XCV>LQ01W=K)I(L+B8R",QN)=Y<KW!!.
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MAU:PO(KJTED'RJ0<,#Z@HS9'>@"IIWC>?4-'UJZ&FPI>:9?-8&T%WN\R4,%
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MB;!;PW/GF1\CYRVT!0,8 YZG/04 8OQ5N;^W\(A+2.(Q37=M%,SS%#@S(-H
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MYX+@RH[H,M&V54JV.1U!^M<WHD%UX@\9^--/UO3;&XL6DM8)XVN6<(@A#*J
MQC<-S$]5P2<9K:DTK4?$6O:#J.IV']GII)DF:,S+(99F3: I4_<&2<G!/''6
ME\-Z9J=EXO\ $VH7=EY5KJD\,D#"56("1!#N /&<9&,]: $\?ZOJ>@Z#9OI,
M< ,M];VSM)(5*J\BKA<*>O3/8'.#6-?O>6WQ?LI[?3()=1F\/RAXTFVH6$R<
MM(5S@=,[2>G%=#X[T6_USPZD.FI')=6]Y;W21R/L$GER!BN[MD U4&FZS)\1
M++7IK!%MH]*DM)!'.K$2-(K\9QD +C/'/;% !9>/[>?PW%J-W:I:7CW[Z:;:
M6X&Q;A68$&3&-H"ELXZ#H3P;?A[Q:-:UO4=(FMX4N+-4D6:UN//@F1NZOM'(
M/!!'YURB^#?$8T&=[5(+;5[7Q!+K-DLL@:.57+?NW(Y&58@_ASZ=MH-QX@O0
MUQKEA;Z;A=J6D-QYY)[NS[0!Z #WR>F !NL>(TTS6M.TB-;<W=^DKQ&YG\E#
MLV@J#M;+'>,#'0$]L'!UKQ'XABU;PE;P:?;6QU&XE6X@EN6#;DC<[-P0_+P#
MNP<X' '-:GBS1EUQH;*_T*/5M):-_, =5FBER-K(6*XXW9(8'IUK 3PGXBLM
M,\'.'CU*]T:ZE>99[DJ3&ZNJC?@Y**RC..<<4 :GB#QO=:#:ZM?2:-_H6EM&
MLLDTYB:<L 6\D%,. &]1D@CBDN==UD_$^RTBVAM6TY]+>ZPT[*S_ +R-2Q^0
M\KSA>^3DCI6%XA\*^*=7M_%EI+9V5V^H)BPO9+G'DQ[5_<JA7Y?F!YR <Y).
M,5MG1]>3QIHVNK9VC*-,>PNH_M)_<$NK[@=OS\+C''/H.: (=1^)5M96AU&"
M"VNM.2Y\B01W@-UM#[#(L(4Y4$$XW E>:[6ZNX+*RFO+B01V\$;2R.>BJ!DG
M\A7!Z#I?C/PUY_AZUM;&XT@SR/9ZF]QM>VC=BQ5HMIWL"QQR >,FNTUG3(]9
MT._TN9V6.\MY+=V'4!E*D_K0!SDWCB6RTS2]:OM+$.BZ@\:K.+C=+ )/]6TB
M;0 #D9PQQD=:#XQU:?Q+JNBZ?X;:YDTV2W$LC7B(#'*"2PR.H SM[\\CC.;_
M ,(SKFK>"=/\'ZM:QQQVSP1W%\DJE)H875@4'W@[!%!!  R3D]#L:'I6I6?C
MWQ+JEQ:!++4EMA XD4L/*0J=P!XSGCK[XH U_$>N0>'-"N-5N%!BA**<MM4%
MW5 6.#A06!)P<#)P:Y_Q+XEUNP\'Z[J-M8V:RVEH)[>X6Y,D4BD-EE.P9*X^
M[T.1SBNBU^.ZFT::.SLX+V1V0-;7! 26/>OF*<@CE-V,]\5PT?@"ZCT+Q;IV
ME1/IVGZK:A+/3IY@ZPS;6WL-I8(K$KP">F>.!0!TD6N:M#:Z-;-I:2W5Y"SO
M/]H<P0HB [I)/+R&;(P,>O/%<]JWCS4;[P18ZOI%K!!+/JL=A<![@G81.$.Q
M@OS!L?>XP#G!-6KG3/%-S<^'9IM,LY[.VA:.ZTU[S"+)A0DK';A\8;C!QG(R
M:RT\&^)%\%76FM;69NX=<&HVZK<'$ZB?S",[?EXX&<^^* .KU#Q8UG>MIJII
MJZE%;K//'<ZAY,2[BP55<IEB=I_A&!C/452L/B';ZI;:&;:U2WNM629DAOYO
M)"M$55DW!3N8EN,#D GV->_T[Q9I7BL^(]'T^SOEU"UC@U#3GNO+*.A;8Z2%
M<' 8@\?ASQ;UK1KS6[.TL_$&AVNKVDL<C7,<+JK6\I(V>4S%20%W MD$]<<X
MH Z;3+FXN]/BGN[0VEPV0\!?=L()'7 STZXJW6'X/TJ_T3PK9:=J5T]S<PAA
MO=]Y"EB44M_$54A<^U;E !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5!=7UI8K$UW<P
MP":588S*X7>[?=49ZD]A4]<UXPUA=(_L7S=*@OHKO5+>U#2L!Y#NV%D *G)'
M/<4 =+17(3^*=:E\4:MH&G:);2W%E;Q3QRS7A1'#ENN$)!^7@ 'W(K7\*Z^G
MBCPO8:U' T NH]QB9L[&!*L,]^0>: -BBL7Q9K-WX>\-7FKV=@M\UHAED@,I
MC)0?>(.T\@<XQV-9S^,&3Q7H>D?9[5K;6+5KBWNEN3DE5#%0FSN#D'(R : .
MCNK^SL3$+N[@MS-((HA+(%WN3@*N>I)/058KS3QQ?S:CI&CWDEC'B'Q/;1VW
MER;FE5)BN?F"A<D''.,8.:Z/2O$NI7/B+5-"O]+MX+ZUMH[N#R;HR1RQN64
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M[YC"[ED7: IPP/!8>YK/E^(ZB"SU&UM(;O3;FX$.V&8M<K&6($OEA<;>^,Y
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MNWCY>6 .=OL>>F:LWQ(46]IJ5K:0W>FSW(A*PS%KE8RQ42^6%QCOC.<$'KP
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M57.<8&<9KT"@D $DX [T <+XRT2'6_$>@M9W@CNVDEM+Q8R"9;(KF5&]!D(
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M?3/ 6D^']0TK3]0BADD2^MGE#)+$Q=@4++]X%EX..AYZ5Z#10!YBGP_UG3]
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M'\NY(BF7"D.I /9Q\OL>:U8O$^K1>+;'1]0TVU@BU.UEFLY(YR[*T>TE9!M
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M8Y*[<<[O7M0!SOA_QM?6?PWT;6M:EM0VHW B^U2,P2(N[DO)Q\JC&  <<@9
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M>:['PQH6MZ+IFNPW,5@\U]?W-["([ERH\ULA6)08QSR :R)?!6O2?!U/!_\
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M'*!G8Q& WX'FO.M/\'>*8%\*-*FCQRZ+.[3LLTCFYWQLC3$E!\YSDJ>I_B%
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MPVZ8 ;7&W"A>>1NSZ"JZ^$M=32/!%H%T\OH$D;7!^T/B0)$8_D_=]\YYQZ4
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ML=T?-2:2,NI(*[0F01U)QSUXJ[;^-KBQN?$=OXAM+>W?1K9+PO9RM(LD3AB
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MMV,@Y.![T =[167X;UE?$/AK3=86(PB\MTF,9.=A(Y&>^#6I0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %<?XST]TUGPUXE0%DT>Z<7&/X8)D\MW^BG:3[ GM7844
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MG'((]ZD\,:3XSTZ.UTS5]1TN;3;(*L=S;K(+FX1?NJX/RKT&2,YQCOFNSHH
M\^/@/4+[1O%6G7MS;VYU?4#J%K/;2,[0.-A3(*C.#&#P>YK0MM,\;:CI%W::
MWJ>FVLYM9(8)M,$F6D92HE<MC&,YVKWYR,"NQHH \\T_PAXDAU#PE=3/HL*Z
M)%-!+%;^80ZR(JEP2!ECMS@XQD\FK*>#K^]U[1-8U"'3K;4]/D+7&H6<C>9=
MIL*[&78HP<@G).,<=>.ZHH X'1_#'BWP_-<:1IVHZ:?#LL\DL,LJO]JM5=BS
M(@'RM@DX)/&<D'I4\'AG7M%\1ZW<:/+I\VEZR_GRQW;NDEM,5VLR[5(<' ."
M5^M=O10!SW@?1+WPYX.TW1]0EMY+BTB\LM!G:1^/)_(5#XL\*RZW=:9JVFW2
M6FM:5(TEK-(I9'5AAXW YVL.,CD=JZ>B@#%MCXBNU6._M["Q7(\R2UNGF9AW
M"AHTVY]<DCT[C(G\,ZQ+XJ\0:E%<V]M%J6FK902QR,98'4/MDQM ZOG&>,5V
M-% 'G6G>#O$L%WX1GFDT6+^PUEBD2#S&$JO&$,@) RQQD@XYR=QS4[>$-;;2
M/&EF3IX?7Y9'A;SWQ$'C$?S?)V SQ]/>N^HH XNY\-:S-<>#Y5%@/[$),X,[
M_O"8C'\OR>^>?I[TL7A_Q#::_P")]4M7TY7U1K5K</*Y"^4 I5_DZ,N>G3/X
MUV=% ')>'/"7]C>)=2UB.VM-.BO8(XWL;.0M&TBEB93E5 )! P!V)ZFNMHIL
MD:2QM'(H9&!#*PR"/0T <';6E^^M^+O%6GR6D4DT4=GITMZ2(2(A\[L1SM+D
M@$==N>AKKM#N;V\T*QN=1A2&\EA5ID0$*&QS@'D#O@\CO5]454"*H"J   .!
MBEH Y'4_#^N2^-CJ]G<6+V<EA]DV76\O:MN)+QJ!@[@0""5Z#GBL73?!'B&R
MT?P?92RZ9(V@W)E<K)(H==K* /D.3\Q.>/3WKTBB@#S_ %3P#>ZY=>,H[V:V
MAM->BMUA>*1F>%H1\I8%0#DX. >V/>GR:!XPU._\-7>IR:,DND7#22O#)(_G
M@QE-P!4;3SG&3]>U=[10 $@#)X%<&=,T[7/B7;:OIE_'/;QV8?4$MW5XI75O
M]'+$?Q F0_\  %KNR 001D'J#5/3-(TW1;4VVEV%M90%BYCMX@BECU.!WH P
M9_#VI:?XWN/$>CFUF6_MD@O;6YE:/+)]R16"MR 2""/QK,O? 5XWAF>*SN+;
M^V9=876F:3<(6F$@;9D#(4* N<9XSCFN^HH Y#3=!UY?'K^(]0DTY8IM,2S>
M" NQ1ED9^"0,CD<D#.>@QST>K6\]WH]Y;6PC,TT+QIYC%5R1CD@$]_2KE% '
MG_\ PAVMCPUX.TP'3S)H-U!/*YG?$HB1EPOR<$[L\],=ZEM_#GBW0M=U/^P;
M[2FT?4KIKMEO5D,MK*_+E O#@GG!(_GGNZ* .5M?#^IV_P 06UQGMY+(Z8EA
M\TS&8E7+[R-F.<XQGW]JSXO#GBS0O$&IOX?O=*?2-4N3=R1WRR&2VE;&\H%X
M<'&<$C^9/=44 <E+X?U>R\9)KU@]K>JVF)I\L=W,T3Y1RPDW*C YW<C _I4N
MG:5IGAS1;V#6KVTW:M<S7%XTSB..620?,BACT"@#'7 S7452U'1]-U=(4U*P
MMKQ89!)&MQ$'",.XST- '/?#C1#H_A:(O<2W#7!W123##BW'RP*?3$84X]6-
M;7B33KK5_#>HZ=8WAL[JYMWCBN!GY&(X/'/Y<UJ44 <!9^&M>L]=T+6;M]%M
M;?3+"6UN(+82%50[3N0D#.=AZ@;?]JL#2;;7#IG]OVUMX7OM,DN7U*-YKV:'
MDL65S& T22 $<]0>O.37KU8L'@_PU;:C_:$&@:9'>!MXF2U0,&]0<<'WH S-
M-TK5)O')\420V\-G=Z7%;&!I6\Z,AC)DC;C/S$$9[?A5&#PYXLT+7]3.@7VE
M-H^IW+7;I?+(9;65_OE O#@GG!(_F3W=% '#7GAKQ-I7BF76?#-[83+?010W
M]OJA<!FC&U959!]['!' _IV%A#<6]C%'=W N+C!,D@7:"Q.3@<X49P!DX ')
MJS10!S&K:#J<WC;2M?TZ:T"06LMI.EQNR%=E;<N!R05Z$CZUCCP?K9\/>,M.
M8Z>)->N9YHF$[XB$B!,-\G.-N>.N>U=_10!Q">&O$4&OZ-J,,VFO':Z8+&2&
M=I&6"3(S-%A1N)  (.W@8S699^ M?L_!GA_2Q=::][HNJ+>Q9+B.5 TAPS8R
M"1)V'&._6O2J* &1"00H)F5I=HWE!@$]\#TKA_&6G:=XFUK1+6TU&,:C!=21
M7"P2*S"U9#YZ. <J"-HR>A9?6N[JE::/IMC>W5[:6%M!=73;KB:.)5>4^K$#
M)H Q/$?AN[O-=T77](D@34-+,B>3.2L<\,@PR%@"5(P"#@\]JJW7@R;5E\2W
M5_)##?:U8_8$$+%TMXPK <D L2S$G@=AVR>RHH X"#PQXIGU#PG=WTND1'1/
M,21(6D?S%:+R]P)4<GKCC'J<\=_110!R;^"HIO&>H:M-(KZ=?6RK-9D</.%:
M,R'_ +9-M_'V%3^#O#ESX5\,BP>X6]O%) E=BH95&R)<XX C5!T/.:Z6B@#S
M=? NN+\*K3PF)-.-W!.CF;SG\LJL_F_W,Y[?K[5T%WH>J7/CS2=> LUMK2SE
MMY4,S;R9"I)7Y,$#;W(SGM7444 -<L$8H 7Q\H8X!/N><5YP? NO'X:-X8WZ
M;]I-[]H\[SGV;?M'GX^YG/\ #^OM7I-% '(Q>']6TGQ?J.NZ6MG-%JT40O;2
M>=H]DT:[5='"-D$<$$#U]JS[KP%=Q^%K6TL+FV;4XM876)7F#+%+-YA=EX!*
MKS@<'H*[ZB@". 3""/[04,VT;S&"%SWQGM7!:SX-\0W]UXLCAN]->VUNV$4,
MUQO,UN!'M\O &-F<G(/!).TUZ#10!Q%]X7U75-'CTK5K'1=2L_L$<)CDD>,P
MSKN!=#L8XP4YX/R^^*;<>#[^;0K;0;Z#3M;TZ+3HK<F]D:.19UW R*0C8R"O
M?(VUW-% 'GC>"_$>BSZ+J7A_5+2XU&STY--O$U'>([J-3N#97)5@2<=>#^=_
M6/#OB'5$T"62XL);JQU--0N,N\<?"LOEQC:QQANI/4$XYX[2B@#E]:T'4[KQ
MAHNNZ=+:+]CAGMYX[C=]V3:=RX')!7H<9]174444 >8MX%\4G1XK!KO299+;
M64U-+J0R>9=;9=X\TX^5@..-W  XQ6_8^']9M/$WB757^P2)JL$$<2B9U*M$
MC+EAL. =V>"<8[UU]% 'GZZ18:+\*E\*>)[VR5EL7BQ%+EI O(:-6 )8';@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3]F39G[01G;C&<<4 >B Y&1THJ*UMHK.TAM8%VQ0QK&@ST4# _05+0 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
HB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>thackray-biocrystseparat005.jpg
<TEXT>
begin 644 thackray-biocrystseparat005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX!YQZT&1%=4+J';HI/)KR2[\/V>F6_P_US1HC%K$]Y:0S3(Q+7$+QYE#\_,
MJY]@.,"FV=I:>+]!UO\ M76+6QU"TU*<W,WD#[5:&.8F,JY;( 0*!@8QD>M
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M$,LXZ,?5AQ@GD5##X?M(O%4VOK!!'=R6_P!G+QQX>124)+M_%C8H [#/7/
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M'U!]Z /;5NK=[A[=)XFF09:,."RCW'4=:C34;&5PD=[;NQ0R!5E4G:#@MUZ
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M.JZE.L5M A8Y."QQPJ^I/0"N>U+Q3./%'A-+"^M'TG4VN!<;0'/[N%G^_G
M(&>.W6@#H#X<T,VT5L=&TXP1-OCB^RIM1O4#& ?>G7>@:-?W<-W>:38W%S"-
ML4TMNC.@] 2,BB34;;4-$N;G2]5L]OENL=XKK+%$^/O'!P<'!(S20:C;V6CV
M4VI:K9L7B0&[+K''.VW)9><8/) !/% %NTL[73[5+:RMH;:W082*% BK] .*
MGJ.">&YA6:WE26)QE7C8,I^A%24 %%%% !1110 4444 %%%% !1110 4444
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M58F.,Y1/LZ84^H&.* //=,U+0+J7QOH7B^XMX9Y=2E,L5S+Y;2VI"^24.02
MH& O0_6AM1L(/'FK:;K>J2Z/;W.G6PL5N3$%D@",)$+2JW(8G(SS[XKT6;2M
M.N;R&\GT^UENH.(IWA5GC_W6(R/PI;[2M.U01C4+"UNQ&=R"XA63:?49!P:
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M\ *Y([X ]ZZI$2*-8XU5$4 *JC  '8"H[JTMKZW:WN[>*X@?[T<R!U;Z@\4
M>1//:7%_\4H;B]LKQY-,AD!C"A'9;>3)5<G[N ,Y)&.M3^(-&TB'X 27L6GV
M:W$FBVQ:X$2[V.%();J3EC^=>GMH^F.'#:=:,'18VS IW(OW5/'('8=J4Z3I
MK68LVT^U-J#N$!A78#Z[<8H XSQ%!J@UM=1\.WME-?P:6@NM*OA^[N;<LY!5
MOX6R&&>G3-8EKXBLO^$F\/7%Y=S:#I5]X>C&GF4Q[$DW?/&6D4@';Y?/&0!Z
MXKTN;0](N/+\_2[&7RUV1[[=&V+Z#(X')XJ6]TRPU*W%O?V5M=0 @B.>)74$
M=#@C% &-X)T[2M+T%K;1+N>ZT_[1(\<LC*RDDY;RRH V;LXP,9S5GQ?=6=EX
M.UFXU"&::S2SE\Z.%BKNA4@@$=.O7M6Q'&D,2QQ(J1H JJHP% Z "AT61&1U
M#(PPRL,@CT- 'E>F7]J/B1X5;[?I^Q]&EACBM7!6-<Q%(]Q.7/OQGT%:/A]8
MY-5^(RHJ,PN\   X_P!&4?S!KN8-(TVU\C[/IUI%]GW>3Y<*KY>[[VW XSWQ
MUI;;2M.LYFFM;"U@E;[SQ0JK'ZD"@#R*VUFVLOA]\/;A[[R=,MY(EU":#8_D
M,876,N"&  ?!Y'! /7%6?%VG>'F\&^-]2TW5&U6:ZM8I+F7?$\*R+PA78H ?
M'7'.",]1GU5-,T]+.2S2QMEM9"2\ B4(V>N5Q@YJ-=%TI+!;!-,LULU.X6X@
M41@^NW&,T 1:+I>FZ?9I+86=O T\<9DDBC ,N%X+$<MQW-:,D:31/%(BO&X*
MLK#((/4$4V&"&VA6&")(HD&%2-0JJ/8"H[[[7]@N/[/\C[9Y;>1Y^?+WX^7=
MCG&<9Q0!YQX>M;BTU23X>30N;+3KL7\4K#Y7L=WF1)GN1+A3ZA#5_P -2PW/
MB;QW8:Z(S.UR&99\8:Q,8"8S_ /GSV!)[FNFT#3M2@\_4-<DM'U6Y5$D%H&$
M4:)G:B[N2,L[9/=O85>O-)TW4)8Y;W3[2YDB_P!6\T*N4^A(XH \BT0W-CI/
MPOGU:4HD=Y<HDUP<8B:.00@D^J[<?A76>#;ZSNOB)XY^SW$,F^:T9=C [@(
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M7()'MBNAIL<:0Q+%$BI&@"JJC 4#H *=0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%<_XMOFCTV/2[:Z2#4-5D^QV[$\IN!+N!D9VH&;Z@#O0!F>%/&KZ]XGUO2K
MB 0K#LN=.8_\O%J?E\P>HW*3GT<5U=W?V=@J->74, <[5,KA=QQG SUX&:\S
M\96UYX.U#P[XNFNK$VNF2+87$=M:M#_HDGR\YD;=M."!Q6GXGU:PTGX@>'M7
MEU2R$3V%Q'Y5Q<K$A0E#YB.Q"EL[1C.2.1TH [#_ (2#1?LAN_[7L/LPQF7[
M2FP9Z<YQSVI4UW2)(+B=-4LFAMI/)G<3J5C?^ZQSP>>AYKR;7-,TRQ^#&NS1
MWNFW9NM26Y9[.59(X=]TC"-7'7:#[=371>,I+'PUXA\,7NY=+T9YIUN;NUAC
M"QS-&JQ.^5(Z!UW$< ]<4 =W;:MIUY8-?VU_;36:YW3QRJR#'7+ X&.]1P:]
MH]S;3W,&JV4D%N<3R+.I6(_[1SQ^->8:Z=)TS2;C6M$U*[O=/DUNUNM7O8#'
M+'@9W,@5=A*GRV; (X'<'%[4X_#.H:9XKUG3M8;5[J;0IH[F=9(FA50A*!MB
M@!^N,\X!]J ._B\1:)-=K:1:O8/<M$)UA6X0N8R-V[&<XQSGTJ73M7TW6('F
MTS4+6]B1BCO;3+(JL.Q()YKS&[M-..D?"S,%MAYX0?E7Y@UL=V?7)QGU-,UQ
M;A=5^*4&DK_I+:?9.(H?O-\C[\ =RO'Y4 >G6NNZ1>SRP6NJ64\L2[Y$CG5B
MJ_WB >GO4:>)="DFM84UK3VDNR5MT%RA,Q!*D*,_-@@CCN*X_1KGPGXGUK0]
M5L]=FU.^@AD$-NIB!@B=,.)D1%(7@##=\8ZUQ]O#8P_ FPNHTMTE76$<2J &
M!%\0#GV7]* /5XO%VCS>*I_#R7D!O8(E=P9 /F8D! .[8&2!TXK=K@[2\MK3
MXS:Q'<3QQ/<:5:"%78 R8>3.T=\>U=;I&M:;K]C]MTJ]AO+;>4\R)LC<.HH
MIVVL-JGB.]L+1PMMIFQ;J7 )>5AN\L>@52"3URP'&#59+N0Z#K,O_"663'SY
MA#?B./98@@;489VL4R/O$$YYK(^&Z/'<>,X+@?O_ /A([EV#=T94*?AMQ7-0
M+:GX8?$M (3&FI:IM'&%./EQZ>U 'HEQ<.)-#5?$5K"SL"ZM&A.H#8>$!/R\
M_-\N>GI1'K$EIXI70[Y@WVN%[BQFQ@N%(\R,]LKN4@CJ#ZJ2>/U9K?S_ (8R
MYCWFX0*_&2OV9N_IDBM+Q@CR?$?P$L.?-6>[=B.T8APV?;D#\10!VEU=VUC
M9[NXB@A! +RN%4$].37)>._$LUG\.M2UWPYJ=LTENH*3QA9ESN"D=<9&>^?I
M5;QIJL6B>./"5]J<@BT8&YB>=^(X9V11&SGH.-X![9-9'CIM ;X5^,+K0O*:
M"ZD$L]S%)NCGG+H&*G)!Z ';QG(Z@T >C7^KZ;I84ZA?VMKN!9?/E5,@=3R>
M@[U4U:[5H],>VUZUL%FNHBK.$<7:'_EDF3U;(P1D^E<OKFK:8/'LUIYUM97A
MT<;[V=\F:%I#B*)"=I.<DM@]A@]N1L+FSG^&/PV<30O)#K=E$S;@2A#-E<]N
M,<4 >N7?B#1; W N]6L8#;!3.);A%\K=]W=D\9P<9ZXH/B'11<VEL=7L//O%
M#VT?VA-TRGH4&?F!]JY+2[:QD^,/B?S(;=F&G6A(90>OF;OS&,UQ=K'90_ 3
M1+E%@65=4A82C&X,+S .?4*,?2@#V6[UK2[";R;S4;2WDP#LEF53@\#@GOVJ
M6]U"RTRW^T7]Y;VD (7S)Y!&N3T&2<5YOXKEO=)U#Q)K&DW5IJ5BIB&LZ+=<
M-_JDPT+CD$H5P",$@XYKOM:TJ#Q'X<O-+ND*PWMNT;!ARFX<'Z@X/U% $O\
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M6TL\_:)8IU=8B.QP3@^W6O-+W2-/TCP%X!TI;VRU"$:]:++/"RM',3OW8/\
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ME6'4O&RJ[(2,!EQD>XSD5PW@SQ3//I6MZCXCU>"."QU2XLDDE"0H$C( )/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MT]1L&#0!Y1>>(+BUT/6+;Q/I^GW<]KJEG$^HP%DMI&;84FDP<CRP%+*#CH.
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M%PBB0]'"C(]ZXO3_  MXAMK5=.O+C0;VW7(^VSV+-<."2264MM+')YSC/.*
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MA\.KKLT$EEJ5@D6E7A8 6TBC]Y W. 6.#NZGH>@ ]CCM;>&)HHX(DC8Y**@
M)]<4OV:#:%\B/ Y V"@"0LJH7+ *!DDGC%>'VMW9R_"#XB 7$+9U2_9?G!SD
MKM(^O:O<"JE=I4%<8QCC%1_9;?&/(B_[X% 'G=Y+8P^./AP+>2W0&UNU4(0
M5,*X'';/ZUG^$-9T"Y\)1>&O$:I+K]I?/YVG2Y\Z6Y\UG5U'5LY!W= ,Y.*]
M4^S0 @^3'E>GRCBE^SP_:/M'DQ^=MV^9M&['IGKB@#R@:CHBZMXN\/>+]4GL
M7NKUY%A<A5N[9U4)L.TEB -N <\#%:6FQ:?;_%W3H HC-OX618TN&!ECQ,
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MVJO\.[^UO_A_H7V6=9A#800R%>0KK&H9<^H/!':N7>64^+OB1I=G-Y6KWUI
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M:10!A68<\#C)QQ73:1JNE^)?&<^KV6OZ2VIG2&L;>SL[HR%CNWER652<'&
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M/8XYKD?"^MR^(]*M/%$^OSV AFFDO+=TQ;M!YCJB?,  0%4[@2<YSUX /1,
M]J" ?KZUFVOB'2KRXGMX[L)/!'YLL4Z-"ZQ_W]K@';_M=*J6'C3PWJEY;VEC
MJ]M//<+(\2H3\X0D,0<8XP?RS0!E:;X;\2Z?;#37U?2KNR5F(N+C3V:Y(8DG
M=\^PMDGYL>Y!KJK"Q@TW3[:QMUQ#;Q+%&#U"J,#]!5*T\3:/>W\5E!>JT\Z&
M2 ,C*)U'5HV( <#U4FD;Q/HR:A#9/?*LTTIAB+(PCDD'5%DQM+<$;0<Y% &M
MM&",#!I:YZY\=>&+1+EY=9M]MK)Y<Q3+[&QDYV@\#(R>@SS5B/Q9H,VJP:9%
MJEN]W<+NA122).-V WW2<<XSG% &R !T'6FI&D8(1%4$YPHQS67J/B;1])D9
M+Z]6$(RI)(48QQ%L;0[@;4SD?>(ZBHKWQ?X?T^[GM+G5;=;B",221*2S*#TX
M ))]AS0!MD ]128'H*YC5_'>D:=I6DZA!*;N#5+J*"VDA1G4AW 9B0.,#/'4
MD8Q72PRI/"DL9)1U#+E2#@^QY% #BJD8*@CTQ1M&3P.:S-2\1Z5I,KQ7EUL>
M.+SY%2-Y#''G&]]H.U>#R<#@^E33ZQI]O!:S/=(R79 M_+!<S9&[Y N2W&3Q
MVYH NX'H*38GF;]J[\8W8YQ678^)M#U%+AK35+63[*"UP/,"M"!UW@X*XQSG
M&*;#XIT6>>X@^WI%+;Q>?(EPC0D1_P!\!P,K_M#(H V*0*HQA0,=,#I6!;>-
M_#5W<V5O;ZQ;R27O%N!G#GL,XP"<< \GM5S4_$6E:0T@OKORS$@DEVQL_E(>
MC/M!V+P>6P.#Z4 :A /44C*KJ5905(P01P:S$\1:3+JT>EQWJ/>RPB>.)03O
MC/1P<8*^^<5:M=1M;RYNK>"4O+:.(YUV$;&(! R1Z$'Z$'N* ,;QCX?N_$.E
MVEE92V\'DW<-R6E!(_=N&"@#UQU[5T$2!(P/+1">65.F>]5-4UG3=%@2?4KV
M&UCD<1H9&QN8G  '4FJ.G>,?#NK7=W:V.KVLTUHN^90V-J_WLG@K[C(H VA&
M@<N$4.1@MCDTN!G.*PK#QKX;U.YAM[+6+::6:.26,*3AD0D,<]."#^'/2K-I
MXDTB^O8K2"\!GF0R0*Z,GGH.K1E@ X[Y7- &K@9SCDTUT612KJ&4]01D&LN]
M\3Z-IT[17=\D1218I'*L8XW;&U7<#:A.1PQ'4>M.U/Q%I6C;_MUUY8C022%8
MV<1(>C/M!V+P>6P.#Z4 :>T  8&!T%+5"ZUK3[2"&:2XWK.N^(0(TK2+@$LJ
MH"2,$<@8Y%1IXBTB72(M6BOX9+&8A8I4.[>Q. J@<EL\;0,YXQ0!HLB,RLRJ
M2OW21TH>-)%VNBLOHPR*X/1/$9NO&_BV*?6)O[,L[6V=!<((OLI82;A@J".@
M^\,].M;&F^(M$TSP]I!NO$:W:70$=O>7+ /<G/7@#\\8]: .FP/2DP/05F:3
MXCTC7#=#3;Z.=K5@LZ@%2F1D9! X(Z'H:KGQCX>5X!)JL$0N03;O-F-)P.IC
M9@%?M]TGK0!!XT\/W?B30ETZSF@@)N(IFDE!/^K=7  'J5Q6_"FR( QHC'E@
MG3/?L,U)7/\ CFYN[+P-K=[8W<EK=6UG+-'+&%)!52<?,".WUH WRJD$%00>
MHQ1@9S@5S'A[QGH>H"QTK^UX)M6:U1WBR=SL%!;!Z,1SD#)&#6C_ ,)1HO\
M9MYJ'VY?LEE*T-U)L;]RZ@%@XQE<9&<],T :V!Z"C ]*YR\\::=:^)=-T4>;
M))>P-<"58G*A !C! Y)+#Z#KC(KI*    8 P*,#.<<UFZ=K^F:M]K%A<^>;-
MS'<!8VS&XZJ1C[WMUIH\1:4UC:WB77F0W8)MA'&[O,,9RB ;F&.<@=.: -(1
MH'+A%#MU8#DTZL=_%>AIH_\ :[:C%]@#^6T^"51LXVMQ\ISQ@XYXJVVKV"ZN
MFDM<!;YXS*D+*0608R0<8(&1TH N!5&,*!C@8'2E(!ZT5Y_\2O%B:?X0U%])
MU::VO[>5(A)!%E"^]0T9<J5#8)X!##% '?[1D' R.A]*-J[=N!MZ8QQ5&_UJ
MPTR01W,S>:4,GE11-*^P=6*H"0H]<8JQ97UKJ5E%>65Q'<6TR[HY8F#*P]B*
M )L D''(Z4M4-2UK3M'>U6_N1";J40P95CYDAZ*,#J>P[TV#7=-N=5N=+AN"
M][;*&FA$;90'H3QT/;U[4 7]B!R^U=Y&-V.<4N!Z"LD^)M(^SV\RW3.+DN($
MCA=WEV_>VH!N('<@8%4-9UW1[SPQ%?1^)!I]I<RH(;VW8;F(<90 @\D@J1C(
MYH Z7 ]!2/&D@ =%8 Y (S@U0&N::=<.BBY']HB/SC;[&W>7TW=,;<\9Z9XZ
MTO\ ;FG"*YE-SM2VE\F4LC#$AQA1D<DY& ,YR/6@#0(!ZBFNBNI5U#*>H(R*
MHZ9K>G:P;A;&Y$DEL_ESQ,C))$V,@,C ,N1TR.:LWEY;:?9RWEY/'!;0J7DE
MD;"J!W)H F(!&"!CIBD5%1 BJ HZ # %9D'B72+@W:B]6)[1!).EPC0M&AZ,
M0X!VG!YZ55MO&_AJ\N;*WM]7MY);W_CW SASU SC )'(!Y/:@#>P/048 Z"L
M^RU[3-1O[RQM+GS;JR(%S$$8&(GH#D<$]O6I[#4+75+47-G+YL)8J'VE<D'!
MZ@=""/PH L+&B A$503D@#&32X'H*S=3\1:/HUQ!!J.HP6TUQN,22-RP ))Q
MZ8!YK*MO$&BZWK>CSZ=XDWB:"9XK*(C;<KT+,",C:5..G- '48&<XYI"H;J
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MP 1>@+=<>F36CXLU>YBO?"%SI>IL+._U2*&182ICGB9'8'.,_P (Z'% '9@
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M#+XZ7X>OO">N:=97-OX5CU&ZEN99#*XWRQ;4G8/EE7<7Y/'.?XJ]<(SUHZT
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M=2XN#<1I'<7\LLS+*5^Z@\P\E1U(Z9 ^ECXA7L>G^!]1N9=.CU"-0FZ"5"Z
M%U&]E')"_>(']WMUKIP,# HH \KT_5;+_A9UY=-J<MY!<>'5V7<D.R-R)7)V
MD*!M QSSZ9)K'M)[6'X4?#U#)$CPZS9-(N0"FV4ER1VP#R?>O;** //O%L6H
MZ%XLL]=T.+S6UF+^R[E5Y E()MYR.X4[@3_=KN-.L8=,TVVL;<'R;>)8TR<D
M@#&3ZFLFUT/4FU^34-4U@7EK%*\EA:+;+&+?<"N68'+D*6 /'WC[8WZ .#\=
MSVJ>+?!(N)(@$U)Y&WD?*/*8!CZ#=CGUI=>EMXOBUX00/&I2UO589 VEA'M!
M],X./7%=W10!XCJ&HZ%';^+O"=]KMM96U_JTDKR7:2+-%N9&?:NW:PR#M;<.
M"#]>LN+W3Y_BYH$\5U!+#_8T_ERB0,#N9"N#ZE<D>HS6IIOASQ+I2-90>(K2
M;3VE>0-<Z>7N1O8L1O$@4G)/)7\#72V%C#IMA!96X(BA0(N>I]S[T >-74B2
M_#;QD83YBQ>*'N"(_FQ%]JC;> /X< G/3 ->SVEW!?VD=U;/OAD&4?!&X>HS
MV]#WJ>B@#A/$ES%I_P 4_"]W<[T@>SNX%<(6!D)C(48'4X.!WK'T6]M]-T#Q
MAH'B!E349+R\D\F3[UY'*"4:,=7SG;@9(( KU.C SF@#!\$V%[I7@C1;#423
M>06<:2@G)4@?=_#I^%8/B::U'Q8\%B62+,<-\#N(^0LD87/H3A@/7FN\HH \
MKO\ 4=(T'Q[K]IXJ:]M;+4UA>PFBDG6&5!$$>+$1QD$'@C^+W&4>\L/ _BK0
M-0GL[C3_  P^DR6-NTH>3[)(91(-^<LNY0O7D8QV->JXS01GK0!Y9XDN["RB
MT'Q#9Z;<P^&X=1GENWM$>%B)8RHN=JX8#<6Y[@YZ$4FL-X:N? ?C/5M 29UU
M"QV2WLLLS"ZD",JJOF')(! R.N<<D''JE'2@#SWQ-;R2^ =%\1Z8!-?:$D-]
M#L.?,C5 )H\^Z;N/4"F^*;74&^'\FJ1V=Q-<RWT&J7=I$2LK1+(C>6,'.Y8U
M0<=U)KT2B@#A_"]WX2\0:^FM:"+R\O([4PRWDTMP1"A(/E'S#@L3S@=,$\<9
MW?&%G>:AX+UNST_/VR>RFCA ."6*$ #W/3\:V\8Z44 >8>'M2\*^*)-)-I;Z
MA)X@L 2+>XFN?^)?)MVN7W':!QC'.>!CTY>ZU^S/P+O?#MQYL6NV*K'>VDD3
M;U<7"DNQQC#9SNSR3ZU[OBN?\:>'I_%/A:[T:WNHK4W.P-,\9?:%8-P 1Z8Z
MT <_?:C:Z+\9/M&HRF"&\T-(;=RI(ED6=B47 Y;# X'/-<;]KA/P,:)BR2C6
M,['4@_\ ']OXSUPO)QT%>WQ"3RD\[89 /F*CC/MFGT <'<WD%I\9[.XF8B&\
MT'R+=U4L)7\\-M!'7@Y^G-<3-KEI>Z/X<N%#6(M?$T3SZ5!;D)8CS7R9#MSO
M.<]0#N.!Q7N5% 'G&EW^EZ;XY\<?VN\4"WC6SQ1W"[6N8A;JI"*>7YR,#//'
M6L**QF\/^$OAOI^I'R+B'65F>*1OFBC;SB WIM#JI]#Q7LF!10!Y*^H:'IWB
M+Q1H7C'[?$=2NVFMMDEQY=[!)&JA%$9PS#;MQC/0=J]-TBVBL]%L;:"V>UAA
M@1$@=R[1*% "DDDD@<=3TJ[BB@#@I;S^POBY=W>L2K!I^H:9%%974QVQ*\;,
M7B+'@,=V[GK7'ZO:+:>#->GEVKI^H^*([JSB<</#YL>]P#_"=K-Z8YZ&O;2
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M\1WMDSW$\;:BC_OAMN6"@84]@%P!T.*[S4-9L=*(6YDE,A0OY<,#S/M'5MJ
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M$#Q,QC+%]VV-5W= ,\$C'-=>FOZ7)I5KJ<5VLMI=@&W>)6<RY&0%4 L3@$X
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MV]FRI;J+CF1R%^=F'S9S@YX'&:U_$$LMEJ^JZOX:U%UU!YXA>:!>1[DU E4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *\]U^XDC^*^CZ=)JMY;:==6$TTT2
MW;QHTBD;3P>.O05Z%7F_B,1-\7=%NKG3[JXL+?3IXY95L9)HU=F&T9"D9X-
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M@H+$J0/0''KVR*TK*[MKZP@N[.19;::,/$Z]&4C@UYKX6M;K3-;T8>'Y;_\
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M-_&-OX'T(:O=V<US;^:L3"$J&4GH><<<4 =)7)Z=X0U#25^R67BK4$TT.S+
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MCO0!UE%%% !15/3]4L]5CFDLIUFCAF>!W7IO4X8 ]\'C\*N4 %%%% !1110
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M^&_A\^)+G7(1>6UQ=G-W#;W3QQ7)[[U!Y![CH><CDT =7$SM C2!0Y4%@IR
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M&=&<)(00I.%^XO"@ ?B:A^'VF;O'7Q)>VN9XKJTN2+662[EV*Q\X R#=B0#
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M/B%X4DT'X9>,&;5KFZL[B>.YM+5F95M 9%!0?-\R_-T/ P.,\UV_PZL+>R\
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MUQ+1EO;Q0MQB9Q'+QC+)G:3CU'OUYK'C^$/@N*RCM$TN18XK@7,;"ZEW(_\
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MV;5)5FO$-W)^]<-N!)SD<\\5V%% '+ZM\/O#NM:!8:-?6CR6VGJ%M'$S"2$
M  !\YZ #GT'I4MWX$\/W_AM]!O+1[FS=A(S33.\I<# <R$[MV.,YZ<=.*Z.B
M@#)T#PY8>'+/[/8_:'R IDN9WF<@?=7<Q.%&3@# &3QS6M110 4444 %%%%
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M[L]4EU*YLM4B9-0 \HZ>2V!!$P)+8[XVJ,9Y)KI/$U[<GXD_#643R*UY%NN
MC%1*<*?F X/4UVEQ\+O!ET^I/-H<3-J+^9<'S'Y;.[*_-\AS_=QU/:KDW@/P
MY/>:7=R64AGTM0EDXNI1Y('IAN?<G.>] 'D\UFNH^/?B9:7,]R;6TT]IH8%N
M'5%D\L,&P".AYQTS6%+<7<7PR\!^(Q?WK:J=5\CSWN'.(E=P$ SC&$';GFO=
M/^$#\.C4-4OQ9S"ZU2-HKV07<V94/4'Y\#TXQBJS_#/PG)H]GI+:;*;"SE::
MWA^V3XC<\DCY\^OYGU- 'GOQ+N-3T+Q?>ZQJ%D^J>&+BW2T=[>0B;3&VC)0@
M_(Q+;LGA@P!->S1W,4^F)=13!89(1(LK#&%*Y#'/MS63J'@S1=4EN7NX;AQ=
M;!<QBZE"3A  H=0V#T'U[UMM!$]NT#1J86784QP5QC&/3% 'SG/J5Q:_\(;J
M%AJ4U[(VN/;OK1!B>^4R#<I7)+( =N6/J ,5UFJVBZE^T#-I5Q-<BPFT@R2V
M\4[QJ[8QD[2/;ZXKL8_A/X(BM(K:/0T5(IQ<(PGEWJ_LV[./;.*U)/!>@R>(
M&UXVDHU-H3!YZ74JD1XV[0 V ,>@]^M '@MMXIUNR_9P:2WO;CS7U4V7GASO
MCA*[R W4<\?0XKK=1TBPT7X\^![?3E*6YL9"%WE@?DE&X9/&>I]3SUKT:T^'
MWA>Q\.77A^#2P-*NFWRVSS2."W'(+,2IX'((Z5':?#GPQ9ZC8ZBEG.][8H$M
M[B6\F=T4=!DMR #C!X XH D^(F5^'7B!U)5X[&5T93@JP4D$'L017B;I-;:#
M\+]3AO[]+_4+LP7%P+IRS1F15VC)P!@GH.]?0VJZ7::UIEQIM_&TEI<(4E19
M&3<IZC*D''XU@O\ #CPM)9Z9:-I\I@TMR]DGVR8>2Q.[(^?U ZT <3X.MDA^
M,/C?PXKS'26MHW^SO,[ ,53)!))!^=N<Y_*L_P $BXM]5UWX;:JTUQ=1ZBD\
M5S(Q+M:C#$ENH^55 ]Y:],;PMIVCZAJGB32-->;7KB!\E[N3%PP'RH=S%0,J
MHZ<5#X8L[B_U!_$^JZ/_ &9JMQ9Q6CQ,P9@%)9CD'H68 9YP@H WM2TV#4])
MN-.E!6&:(QY0[2O'!4CH1U'TKYO(UZ]^'FKZ0'N$U7PE>2S7-R&;=+'N VEL
M_-QYC<YXC7UKZ<K/CT/38GU-DM4!U-MUW_TU.P)S_P !'\SWH \]N-1BU;X8
M:MXK.I-X>.I6\02[2,EH44*I"J"#EGW@$<D%?05A^%+RXA^,]E:11-:6-_H:
MS2VV0!,<<2.@RJN<9P"<9Z\FO5;SPKHM_P"&$\.75DLFE)$D2P;B,*F-N"#G
M(P.<U1L?AWX5TW4K/4;+24@N[.+R89$E<$+SU^;YCSU.3T]!0!YKX%TJX\4:
M#\0-'-Y.LBZC(EG)YK9@9=VS:<Y R "!VR*U/A9J#^*-#TNTO;:07?AN25;L
MOD%YN1&">_!8M_M(I]*]"T'PEHOAF6\ETBU>![Q_,N"UQ))YC<_,0['GD\U>
MT_2;'2GO&LK=(3>7#7,Y7^.1@ 6/UP* /$_!9\1^-/#YUZTN[*#6+;6C/<7M
MS=NKK$ ,P% A CVGIG'!XS5R/1SXC^./C'09]1OK?3&L4=HK6<Q_,RPGCL.6
M)/J>N1D'T6V^'GABTU^;6K?3O*NYG\V14F<1.^<[C'G:3GGIUYZU=M/".BV/
MB6Z\16]K(FJW2[9YS<2'>O'!4MMQ\HP,<8% $MPC>'_",J67F7#Z?8D0>:VY
MY#''\NX]R<#->"/K&HV'PE\/>,K>YF?Q#<:XPEN2Q+SJ3*/+;U3Y%^7H.U?2
M-<W!X"\-V]Q#+'8$1P7)NX;<RN8(ICU=8R=H/IQ@=L4 >?W^FVC?M,Z8#"?G
MTS[0PWG_ %@,A!Z^PXZ5W/Q'L-6U3P/?66B7*P:A*4$8,FSS<,"8PW8L 1[]
M.]7Y/"&B2^)X_$CVTIU:-=B7'VF487GY=N[;CD\8QS5_5-*M-9LC9WJ.\.])
M/DD:-@RL&4AE((((!X- 'AS:O:Z_\+?&T-QI4VE:K8Q1"\L,LL4;@D*T:_P@
MX.4Z C/.<UJ+%9Z3\&?"\\>JRZ8US):O+'$AE>_.#^Y"E@ &[\A>.>*]/@\)
M:+#::E;-:&==3_X_6N)&D>?Y=H#,QSP.!Z=JSYOAMX3N-!@T6?2_-L+>02Q(
M]Q*61@"!A]V[&">,X]J .&\ O/)XY\?:'/&;?3U176PCF)CA+ Y"D8QG/.,#
M\JYSP%86\?[/WB/4XT9;U4N56578%0H5ACG ((!SUKVC2O!7AW1-8GU;3=-2
MVO)XQ'(R.VU@!C[N=N>.N,]?4TW3/ WAO1[2^M+'3%CM;X.)X#([(0XPP"DD
M*#QD+CH/04 >-F]NA;_!N47<XENK@I<-YIS*HEBP&Y^8?,>OJ:WK#2;*Y_:8
MUN.:(LJZ:MP,R-_K,PG/7W/'2NVM_A9X0MO[/*:;*7T^3S+1VO)BT)R&^4[^
M@(R!TSGU.=:Y\(Z'=^(X_$$MCG4T01^<LCKN4'(#*#M;&!U!Z#T% 'AYU6_U
M/X<^./%=Y/-'KEGJR):SAR'M%62,!$_NC#,"._?-;/B*\U#5_&GPTD>ZN+*?
M5;)7O/L[E"25!8<=^6 /;/M7IUWX#\.7US=2SV!*7DRSW4"S.L,\B\AGC!VD
MYY/'/?-6-1\(:)JVM66L7EH[WUB,6TJW$B>5]%5@/TH \V^(G@<^%_ D.HZ!
M=W\LVD79NY!<7#.98F;+(W3<H.#SVW>IKN_"%S:^(C+XLMHF2._ACB@!X^11
MEB1Z[RRD]Q&M2>)[O6?MEOI5GH*ZAIM_;S17,YD $+%<*&4D?(<\D<XZ<\':
MTG3+?1M'L],M5VV]I"L,8]E&,GWH \O^*P?_ (6'\/X([B>!+R[>*X\B5HS(
M@>+ )4C^\WTR:B\+%],^+?C3PK;-(VABR%RMN[EUBD*QD@9)QG>WY#TJ_P#$
M[P_J&N>-?!<]OIMS=6-A<O)>R1 CRT9H^000<X1C\O(XKM=*\(:+I U!K2WF
M$VH\W5Q)<2/-+Q@9D8[A@'C!XH \M^#OAX^)/"5AK>IZIJDMQIVI226T:W1"
M' 7A@<[LG]..F<\XFLZC=_"+6O&D]U*GB*/7%\NZ#$/"H\L>4OHF&;Y>GJ*]
M[\.^%](\*6#V.BVK6UJSF0QF9Y!N/4C<3C\*HS> O#<]Q++)8$QS7(O);82N
M())Q_&T>=I/KQ@]Z /,M4LX-9^//A!]0MB#?:+Y]Q%O88?RYCCKD8P.!Z5(6
MUCQGXY\<Z-&\"WEFL<.F-/=/$;-5)_>QA48DD[23P>0,X->IZMX1T/7-5L]4
MU"Q\R]LP5AF61T8*<Y4[2-RG)X.1R?4U4U3P!X;UC74UNZL&&H!0C30SR1&1
M0,8;8PW#''/;CI0!Y_->7>N?%"Q\(^);Q)(3H&$\EOW4UTRC=,O3) #[3CC'
M&#6;\0_#@TE_AOIEYJ$^J2Q:D+:2ZF8AI$\Q#@C)Q@'&>N .:]5U_P ">'/$
MKV<FI:>#+9@"WEAD:%XU'104(./;MVJ34O!7A[5M,L]/N]/#6]E();?9*Z/&
M^<[@ZD-DGDG/)Y/- '!:BG]F?M#^%]/LGDALVTMRT*R-M8A9P"03R< <GT%<
M8NKZAJ/PL\6>,+JXFC\06VM(EO.'(>V4-$/+7T7#L-O0]\U[@W@K0&U^SUTV
M<G]I6<8BMYA<RCRT (VA=V,?,V>.<G/6HKGP%X<N[BXEFL"4N;A;FXMQ*XAF
ME'1VC!VD^O'/?- 'FWB6YNM5\?\ PX:XEN+8ZG9A[R."5HMQ*@D':0>Y'K6C
M\([]=.O/'=I<WABTO3-4<1?:)CL@3=(#\S'@845Z#J/A'1-5URRUF\M7DU"Q
M_P"/:47$B^7SGA58#].:IP?#WPQ;6NKVT>GOY6KY^W*US*_G').3N8X.23D8
M- '16MU;WMK%=6L\<]O*H:.6)@RN#W!'!%2U2TG2;+0]*MM,TZ$0V=LFR*,$
MG ^IY-7: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+B-PD2<!5SDDG@5Z+7+>)O MKXGU&.\GUG6[)HXA$(["\\E" 2<D8///7V%
M&'8W5]I'AVT;3O#6IMKLFG6UC(6A54C:-2 SL3R%+L>,YZ55OM)U/_A?EEKP
MTZZ;2X=--N]RL>5#X<X]3]X#(%7/^%0Z?_T-'BS_ ,&A_P#B:/\ A4.G_P#0
MT>+/_!H?_B: //+;PCXC3X/^*-$;0[T:C?:JMQ!#L^]'NC.<YP/N']/6M/QJ
M9[+7_A('M)C/!A7M\ /N7R05Y(&<@]\>]=A_PJ'3_P#H:/%G_@T/_P 35:X^
M"6AW4\$]QKWB66: [H9)-0#-&?525R.@Z>E &79^'M6OO&7CSQ8^F7=M;7VF
MM8V4$L>V6=O+1<[.H&4'7'WO8UAVW@3Q WPS\)J=-N%U#0=4:YN+)@ \D9EW
M$KSAB!CC/KWXKN?^%0Z?_P!#1XL_\&A_^)H_X5#I_P#T-'BS_P &A_\ B: (
MO#?A^_N?B_K_ (QEMYK;3IK5+2V6=#&\IVQ[FVGD %".0,YJMX'\'WGA_P"(
MGB.V1@- CF2^LXAT6:567CTVKN7'^X:MS?!O2;F%X9_$GBF6)P5='U+<K ]B
M"O(I(O@WI,"[8O$GBF,'&0FI8S@ #HOH /PH YZU\,WVA_$'Q/#JOA:\US1]
M<G^T02VY!16)8[9 6  ^;&3_ '1CK3]4\,:AH'Q/36?^$<N-4T*^TZ.SEM]/
M.XVQ554*!E<J-@ZX&&/<5T7_  J'3_\ H:/%G_@T/_Q-'_"H=/\ ^AH\6?\
M@T/_ ,30!V.@6,&FZ);6MMIT>FPJ&*VB$$1 L3@XXSSDXR,DX)ZUYKX:\-ZK
M\,_'.M2Q:;<ZAX<U=A(DMFOF26[ L0K)]X@;F&0#V^E;/_"H=/\ ^AH\6?\
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MAI)'$L6#SMRI]\D &M__ (5#I_\ T-'BS_P:'_XF@_"+3AU\4^+/_!H?_B:
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M2-E"DT6IPVH"S*__ "S&<@[#DDE3Z G&0:Q\/ZW_ ,(!XCTZ/0;F*8:\;Z"
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M9' .0:OZ%#J'A34_$]G<Z;=WEOJ%_+J-E-;Q[UD,H&8F/\!!&,M@8/6N^HH
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M3H=-WDN+2)5'E G@-MXW8ZXXSZ]3HT44 %%%% !1110 4444 %%%% !1110
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MD<4 :M%<;<?$2TMO"USKCZ9>E;2]-A<PH4)BE$@C.3GE<D<C)YZ5,WC66/Q
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M#(;GC@=Q0!WR.LB!T8,I&0RG(-.K.T71;#0K)[;3K46L,DK3M"&)5';E@!G
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MK\K$J-P*D$''U-95E\2(;RST/4#HM_#IFKSI;1W;E,)*Y(0%=V[!(QNQCZT
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MJ#J+MT:-SCT& _\ O%2.E>@T4 <IX2T[5]-\)%]90W&M21@3+&PRVQ1&@!)
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M.^,9)]J[L8CC^9\A1RS8'XFB.1)8UDC=71@&5E.00>A!H \\\(V_BSPS8_\
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M5W]%  .E<='8ZKI_Q,U/4TTR2YL+^P@C6=)4 C:,OE2"0<D,,8&/4CDCL:*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M N-1BMT2YF'1Y HW'WY[]Z ,:]\9/#9WNH6.DW&H:?8W/V:>2!LRLP8*YCC
M.\*3@\C[IQG%7+7Q&]UXCU;1$LL7-A!%.K&7Y95DW;>V5/RG/%<UH5EXN\+7
M>HZ):Z1#>Z=<7DMS9ZBUTJ+ LK%BLB'YF*DD_+U]NHO/I^MZ7\1+W4[33?M]
MIJ-C! 9_/2,021EOO@\[2&SE0?I0!/I_CRVU/1]!O+>V$<^M-(MM#<S!%!3=
MNRP!Y^7@ $G/UJKXC\5:U96F@M;Z6()+_5ULIDEF&5 =N%.,$.(S\W8'ISQC
MZ-X5OA\/]$\.^(O"ZWUO$)A<QQW$9DA8MNC=&W#!PS [3G^1?)X6\20>%=#B
MVS:C/I>NK>Q07%PAF%JI<*C.3M+A6'?'8'B@#KI/$,\NI7&F:=IZW5_9P1S7
M:-<"-(BX)5 VTY8X)Z 8P21D5E/\1[(Z+I.IVVG7D\>H7Z:>\?RJ]M,6*E7!
M.<@@],@^HS3+33-9T'QOJVLQZ:][9:W! \T=O-'OMIXEVX^=E#(1W'.1TQ6/
M-X-U>ST73$@LOM%W)XE&MWJ12H%A4R%B@+$9(&T<=2#0!T$7C._EUF_T4>&[
MD:K;Q)<10FYCV21,2 Q?HN",$<G/3(R1):>/-/NO"^GZR8F@>^F-M%;S2*I$
MRE@RLW0 ;&)/H. 3@5'#8:G'\3KW6FTV;[!)I4=JD@DCR9%=G/&[."& !]?S
MKF+3PIXGM/!NE/:V*1ZUH^JSWT=K/,FRYCD:3*;E) )63&3T(_&@#;D^)EK!
M9:^\FGM+=Z*BRS16MPDL<D;#(=)#C([$8R/0U=_X36=# +O19+$7L\4&GR75
MPBI<%XV?)(R4P$(P1DDJ,<G%'7(?$WB;P+K5M+H L;F[M3;V]D+J.1RQZN[Y
M"@=, $GK[ :&L:=)JGAK3-/O_#G]HVS[4O;1Y(]\0"$!U.X#(8#HV<$T ;^F
M7EQ>PS&ZLFM)HI6B*%]X;&,,#@9!SQ_3I5N1BD;,J-(P!(1<9;V&2!^9KSZP
M_P"$@\">#[ITL+G58(K]F@MKF\036UECH7.0Y!!PH)/S >U>AT >=_\ "TR/
M#\'B%O#6H+HOG-%=77F1YM\2&/.P'+#(&2.!G&3@UMZOXUMK":\@LUMKJ6SA
M6:99+M8<AEW!4R#N8KSC@<CGFN*\+V>HZ_\ !Z3P_;:?(HO9[J 7CNGE(C7+
M[G(W;LCYL#;R0.<<C<;3/$?A3Q;?7>BZ,FM:3J4< :/[4D,EM)%&(\Y?AE*J
MO3G^H!;/Q'AN6T1=*T:]OCK-K+<6F'1,F, LAR>""<$G ],U;3QC<S_;(H-'
M+7MA;Q37ED]RHFC+IOVJ "'P#UR.>!D\55O=,UR?QMX5U.6P$L5C#=+=R0R(
M$1I@NT*&(9@NW!.!GKCM5'QCX7NM>OKZXMM&GM]8M]O]DZS:7"1$?(O$OS!B
MH?=D;3QTYH ZBY\02/J]YI6E62WMW91)+<AYO*5-^2B X.7(!.,  8R1FL>3
MXCV1T;2-3M=.O)X]0OUT]HQM5[>8D@HX)SD$'IP?49IEGI.L>'?&^K:K'9R:
MI9:Q! 9C;O&CPSQ)L^Z[*"K#G@Y![8YK'F\&ZO9Z1I*061N+IO$HUN]2*5 L
M2EV8JI8C<0"HXZD&@#I+7QG*]SK=G>:)<V][I4"W)MUFC<S1,&P5;( /RG()
M^A-5;+X@M<KX>N9M#N;?3M;9(H+IY4.V5T+*I4<X."-W'3IC!J&YTK6&\8^(
M]132IFMKW24M(&$L0+2+O[%^!\XY/H:S_P#A']=7PCX$T_\ LF4W.C7MM-=J
M)HL*L2,K8._G.X$?TH V=;^(=EI,6H7$<,5S;:=+Y5UBZ1)B1C?Y<9^_MSSD
MKR#C-4D:TN?C+IFH6BH5N_#LLGFJN#(OFQ[2?7@TRPM?%OAC7-6LK+0X-5TO
M4+V2]MKMKM8OLS2G+)(IR2 V2"H)_II-I>JCXF:=JK6CRV4.DO9RW2M&H,C.
MK9V;LX^4]N] '0:YJRZ'H]QJ#6T]SY6T"&!=SNS,%  ^I'/8<UDQ>+7&I:OI
MEUIC"_TZU2[,=O,LBRQMG&UFVX(*G(('MFIO&D&MW/A>YB\/D_;RR'8LHB9X
M]PWJKG[K%<@'M[5S%EH>LVOBO4]1@\.):V-YHZVZQ1W,>]9 SG##."QW#)R1
MWW$\4 :%E\1#=0>'[V70[J#3=:D2"*Z:5#LE<$JI0<X."-W'TQ@F;Q%K8U32
M?$=C9:8FHV]C"\-VSR!09-FXH@(.YE!4G.T9(&<YQA)X<UY/!/@C3/[)E-UI
M%_:SW:B:+ 2(,&(._G.>!_*K%II/B+0+KQ5IT&D-J%AK%Q/>VMU'<1IY4DJX
M9) Q!P"!@J&_P .@^'?_ "3?PW_V#H/_ $ 5TU8'@BQOM+\$Z/IVHVX@N[6U
MCAD02!^54#J..U;] !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(G1ANVL\148!VGHQQD>M9NE2#2O'_P 0[JUM8F,5O8SF('RPY$<A/(!Y/TH
M]#HKDO\ A-P=)\+ZD-//D:]-#"H\[YH&D4L,C;A@ #W%1ZUXYET6VU&_ETAQ
MINGWB6LLLLICDD+;<O$A7#J-XYW#.&]* .M%Q ;DVPFC,X7>8MPW!>F<=<>]
M$]Q!:Q&6XFCAC! +R,%&3TY->=7<UWIGQ@U231]'%]=RZ'"YB658%8^<^69S
MWX Z$].W(I^+M?M/%WPODU'["UM=VFJ6]O-;S@%[:9;B-77/T/4=0: /5:*Y
MK6?%T.GZA<:=:BREO+:!9I4N[T6R_-G:JDJV6.TGH .,GFK_ (:U^V\4>';/
M6;6.2**Y0GRY1AD()5@?H0: -:BN/UC7=:M_B+HVC6EO;-93VL\[;IRK.5VC
MGY3@#=P.<^V*EN?&,QL=5U'3=+^W:?I<LD4[B?9)(8_]9Y2[2&V\CEER0<=L
M@'5T55TW4;;5],M=1LI/,MKJ)98GZ95AD5S$NMZQ)\4?[!%K:MIRZ7]I(,Y!
M8-*$+$;",C:0%]SSS@ '6PW$%R',$T<H1BC%&#;6'4''?VJ2O(O#OB27P?X:
M\07D6BF?2[/7[P7$B3+'Y49FV_(F#NQD<<#T/IW&L>+H;#49].M?L,EY! L\
MBW=Z+9<-G:JDALL=I[8'&3R* .EHK)\,>(+;Q3X=L]9M8Y8HKE2?+E&&1@2I
M!^A!K6H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "N3\5Z'J%QK_A_Q%I2+/<Z3)*LE
MJSA/.AE4*^TG@,, C. ?6NLHH XBZ\+7NLZAXBU>:$6=QJ&D'2[6"1U+*N')
M9RI(Y9AP">%]\#/ET3Q%<>'_  7:RZ0J3:->VTUPJ7*-^[BB:,D$D<DMD#T'
M)SQ7>1:KIT\LL4-_:R21 F14F4E .N0#Q5N@#SO4_"&I:YK7C))86MK36;&"
MWMK@NIVO$&Y90<XRP_ 'I6OX?O?&DZQ0Z[H]K:?9E/G3P72RF\8 @!$P-@)P
M26/;'?(ZVB@#E?AYI6HZ'X433=3M?(N(KB=^)%<,KRLXP0>P;!JQX[T.Z\2>
M"-4TBQ:,7-S$!'YK$+D,&P3@^E=%10!R<VF7_B+7=#OK_3WTZWTIWN#'+*CO
M+,4**!L)&P DY)!)QQ7)7_A3Q2W@KQ)X7MM,MW6ZOI+FVNVNE"R(\PD V]0P
MYSG XXSTKUFB@#S_ ,7>&KKQ-]H%UH/^G1PJVF:E:72I);2[>C.2K;0W/ .<
MGCIFX^CZROC?P]J,L)NH;'39+:ZN0Z*7E?9\P4G.,J<_6NTHH \PF\+Z]-X!
M\7Z/_9I6\U;4;FXM@9X]NR5PPW'=P0!R/IC-:%UI_BG1?% U_1=+BU""_LX;
M>^T^6Z6&2*2/.UU?E2,,017?T4 <9KFBW6O6EI:>(- @U2VDCD>9;>5%>UER
M-@C9BI.%R"P()(SC!P,Y?"E]-X7TG0_$>E'7[:.*;SI#.GVB!MX,.UV*Y(0E
M2P(Y ZUZ)4$UY:V\T,,]S#%+.VV)'<*TAQG"@]3]* ,GP=IFHZ/X5L[#5+I[
MFZBWC?(^]@A<E%9OXBJE03[50UW3-2NO'WAK5+:R,MEIZ7*W$GF(#^]15& 3
MDX*\_IFNLJ"ZO+6QC62[N8;=&8(&E<*"QX !/<^E '%WECXI\/\ C74M5T33
M;?5].U=8FG@>Z$#V\J*$W D$%2H&>_'YSZQI.N7?B#PC?-;)<'3IIIKQXG55
M7S(V0*@8@G&[J<<#UKM** /*==\+>*]5TOQ#:2Z9:W=Y-?K/:7TET 3;K*CK
M$BD?)@+@C@$Y/)-=,FEZW!\1AK@LH'M+K2XK6<BXY@=)&8\$98$-@'CD<XKL
M*JW.I6%G*D5U>VT$C_<2655+?0$\T >=-X(UG4O"_B.Q>);*]N-<?5M/>216
M0G<K('VDD?=(/ID=:WY],U'Q%KN@ZEJ&F/8)I!DN&B:9':69DVA4*DC:,DY.
M">..N.O5U;.U@<'!P>AI: /+9_"FOS?#/Q#H0TW%]J%_-/"#/'MV/,)!DYXP
M!@^]:7BWPW<>)OM'G:!(+V.%3I>I07$<4UM+MZ.P8':&YXW9R>.F?0** .*M
M-(UJW^(%KJUS;M<P1:&+"6Y5T!DG\P.6"DC@X/XGICFL&?PGK\OPLUOP^-.Q
MJ%[?2S1 SIMV//Y@).>,#CZ_G7J=% 'GU_=7,7QCTR:+3YIF;09O,A5T#H/.
M3U8*><=ZDC\,WD5KJMS=Z/;ZB=;U+S[W3W=#LMPFU0"WREP55NN,D@'C-=2_
MA[3I/$":ZT<W]HQQ&!91<2 ",G)7;NVXR >E:E 'G>GV.M> _#&L3:98-<6:
M7(ELM-O+T9M;<*/,&_+#J&(4$\8ZG(KT&&0RP1R%&0LH8HW5<CH:)(8I@HEC
M1PK!E#*#@CH1[T^@#D?$_A:ZU;Q)I.I64JQ)LDLM2SUDM'&XK]=R@>V\GM3?
M"WA2XT'Q!K,SNITUIWDTV%?^60FVO,,=AO48';GUKI9=4T^&[6UEO[6.Y;I"
M\RAS^&<U:5E<95@1DC(/<<&@#S8^&]=;PCXXTW^S6%QK5[<SV@,T>-LJ*HW'
M=P1MR>O7C-:4VCZO+XE\%WPTYA!I5O/'=DRQY5I(U08&[G!7)]CWZ5W%% 'G
MN@:9XO\ #$M[H%I86ESI4MU+-9ZD]R%-LDC%BKQX)=E))&, ^HK2L--U2S\?
M:_J[Z?(]G=VEO# RRQ[G:+?G(W#&=W'ZXKL** .7^'>DW^@^!=,TG4H!#=VB
M-&X#AE/S$@@@],&LSQOX3E\5^)-"6XT]KC2;:.Z2Z<2HK RHH0H"<Y5ESGMQ
MC-=W10!YKJ.D^+]4^&>J^&M0LOM.H%3;VUX9XP+B,,-KR?-E6VCGKDUL:CI6
MIW_C7PWJ8TYUL[.UN8;DM+'N4RJ@& &YQM.?KQFNRHH \UL?"VO67P_O? AM
M5DB99;:VU/S4\OR)&)W.N=X=0Q& ""0.>];'B3PE=7%OX>;0I_LUWI4@@69C
MR+9T\N3ZD###W45U:7EK)=O:)<PM<QJ'>$."ZJ>A*]0*GH XS1/!LFB^-;ZZ
MMRD>A.D=Q;6J_P#+.Z*&)V'_  !1]=Y]*C/AR^O?%OBR2ZMFBTW6-/BLHYQ(
MA(VJZL2N<C._CZ<XKMZ* .(\*#QM:6UGHFK:;910606-M5CN@_VB-. %BQD,
MP !)(QR1S@5SW_"+>*M/\ :WX(@TR*[MW$PL+\72H&CD8OM=3R&!8^Q]:]8J
M"2\M8;F&VEN84N)\^5$S@-)@9.T=3@ GCTH \\U=-:/B;2Y-,TB*ZU+3],V7
M7V34%BDB\PC:K%T*NIV,0,9!!/'&8WTC4]1\-V]GHVC?V+K.@7\=_%:W5PLT
M=P6#[MTJDY+AWSG!SCH#FNNUOPOX>O[HZOJ,1@N(X]KWD5U);-L'9G1ER/K6
MGI=I86=A&NFK']FD D5T;?YF1]XL22Q(QR2<T 4=!NO$%_NN-:TR'2E"[4M4
MN1.S-W9F   [ #U.>U0>-;/6K[PZT.A'-UYT321>;Y1FB# O&'_A+#C-;<5Y
M:SW$UO#<PR3P8\V-'!:/.<;@.1G!Z^E3T >>:?H.MV?B37+^/0[6WLK_ $R*
M&*&"X7,;IO&W& ,DN"3T'/)JLOAK74\&>"M+_LTFYT:_MI[H":/&R(,#M.[D
MG/ X]\5Z910!YW;:)XCT*Z\4Z?::;'?Z=K,\U[;W'VE8S!)*N&1P><9'!7/^
M'3>"M/OM)\%Z1INHPQQ75I:QP.L<F\?*H&<X'I[_ %K>HH X#Q8-2E\;6$VA
MZ:E]>6-FYF,%XMO-$LC *&WJRLAV.0",Y&>,<YTFAWFL>'(=.L-%;1M8T/48
M=4BM[FY69+A]S,2TJYR6^?.>0<=C7::KX1T36=02_N[61;U4\L7%O<202%?[
MI:-E)'L:MPQ:5X>LUB5X+.%Y  TLN#(YX&68Y9CP.22>* .=OO#UQXK\06.H
MZG92Z?;V5E<VZQ/(C2.\ZA&/R$@*%!QSDD]!CG)C\+Z]=_#M/ M_:*JH$M3J
M22H8FMU<$,%SO#[1C:1C/.<5Z310!PMEI&N^&O&NL76GZ='J&E:P8I0?M"QM
M:RHFPAMW52 #D9(]#6A\.=(U/0? VGZ7JT$4-U;[P5CEW\%V89(&,\]LUU5%
M '.>-]#NM<\/;=-*+JEG/'>6+.< 31MD ^Q&Y?\ @58\7@:XM/&&GW]O.IL9
M+8?VJ#P;FXC?S(I,>I=F8_[N.]=W10!R=YI>HR?$W3M8CLRVGV^GRVLDOF*#
MN=E8$+G.!MY^M9-GH.M1>'_'-H^G,)M9NKJ:T'G1X(EB6-0QW<$$9/MTS7H5
M% &3X8M;FQ\+:597<)AN+:TB@D3<&^9$"G!!Y'%8FLZ;KMQXUAN5L8-1T?['
MY<4<TX1;:XW$F1E(.[*X (!(P<8R2>QHH \JL/"WB2U\'>#-+FTN,W&C:G'<
MSB.Y0@Q)O!P3CYCOX'3CDCI6_P"(=.\1:?XPM_$_A^RAU%9+,65Y82SB%BH<
MNCHYR,@LP(/;].VHH I:4=1>R$NJ)%%<R,6,$3;UA'9-V!N/J<=2<<8KFO%>
MEZ_!XCTSQ-X=MX;VXMH9+2ZL9I1%Y\+E6^5SP&#*#S7944 <U(_B2]TI([BQ
M2WFO90DJ03J_V*# #'<<;W//08&>^WYJ'A;0]4\.7FJ:%';,?#;,7TV5I59K
M?<,M&1G)3<3M/7U]:[2H?MEM]M^Q?:(?M?E^;Y&\;]F<;MO7&>,T >8IX8\3
M+\--'\//I41N].N[=LI=*0Z12[RV3C&0!@=>N<5T7BS2]>;5]&\2^'[>*XO;
M!)8I["XE$?GPR;<@/R P*@^G]>KN[RUL+9KF\N8;:!/O2S.$4?4GBIZ .#\3
MZ?XF\2>$3#+ID4-Y+=V\JV<=RK"&..17.Z0XW,<'H,#CW)O3:=J;_$NTUQ=/
MD^PQZ4]HS&2/<)&D5^F[H-N/K[<UUU03WEK;2PQ7%S#%).VR))'"F1O10>I^
ME 'F@\'^(VT._>VACM=5@\1R:W8+-(K1RJQ/[MBI."59@?PY[CIXYO$^KZ%J
M)U+1HM/D>U>&&RCNUF:1V&-Q? 50.PR>ISV%=710!Q,'AU9/A#'X?UY1:&WT
MU89I"X81-&HQ("#V*AA]*U?!5E?6OAFVGU9_,U6\47-X^,$R,H &/]E0J_\
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M]M=1-#*OJK#!_G7*^&;7Q-X6TN'09["/5+6T'E6E[#<+&QB'W1(C="!QE=W
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M(+0^:]P?XG<8)=CR3UKF+/QAIFA>#M%G\-V4^I:3=Z@+*!FW0E1)*V-H<98
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MTNV)\A]ZR?._SYV@Y[<CMWKKM=UJ+0[.&5XS-/<W$=K;0@X\R5SA1GL.I)[
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M"(J2(V4Z%=PW'OSMYJ@?ANT]KXBM-.1]#T[4K:+R;(R!UCND??YH520J\(,
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MRCMD@C!Z#M6GX>F\;.(8-?L;"!;5?WEQ;7'F->D# VH5 0$\DD^V!G@ R/\
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M8,)-.>)89+8L8KTRX""-F PVXA2.<=<XH Z^34;**_BL)+N!;R8%H[<R#S'
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MEW,S(!L>,$*2VX+@8ZX%=5X8TRXTGP]:6][+YU^R^;=RG^.9_F<_3)('L *
M+6L7MQIVCW=Y:V4E]<0Q,\=M$<-*PZ**YW3O%=Y/XLG\.RII]Q=+I_VU7MY2
MJHX<(T3_ 'B""0<^G:M7Q;I=_K?A34=-TR\%G>W$6R*8D@ Y!()'(!&1D>M<
M_8>'?$4'B^QUQH-%MX8M*:P:SMY)-L?SAQM.P9!QCH,9Z-CD HV?Q#UJ?PUH
MWB.;1[./3;R\6UG47#&5=TIC#*-N" 0.IR>>!72-KU[J6L:KIVC0VK_V6$6=
M[DG$DK+N$:XZ87&6.<$XP<&N8B\#^((_AMI?AO.F&[L[U+AI/M$FQE6<RX'[
MO.3G'3WK6M?#_B#0_%^JZCI0T^XT_6"DUQ#<S.C6TRKM+*0AWJ1V.T^XH /A
M%_R2K0.,?N7_ /1C4_Q_J>KZ=_PCR:9)!&EYK%O;3%\Y8$E@,CH#MY]N*N^
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M.G'O0!Z17FL<NMP_$SQG_8-E97%R;>P9C=S&-!A)./E!))[=!QR?7TD9VC<
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M7>VX * "3M&<G'(Q@\KK-EXGTW0/"VFZZVFO#9ZYI\$4]LSEYU60!2P( 0X
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M39AOS&T$;+M;RERI!8[@.,'C// H [:ZT32[[4K74;O3[:>]M<^1/)&&>/\
MW2>E7Z\^G\=ZG#X UOQ +6T-SI5[-;&+#;)1')LSURI.<]_3WK>GUR^OM=O=
M&T<6RW%C;1SW$URC.NZ3=LC"AE/(4DMGCC@YX .CHKD&\6:@D&CV=WIQL-9O
MX9)IH3&]TMNL9 8[8N6R67'(X)R>,'*NO'FOV7ARXO;C0E2YMM3CLBTR2PI<
M1NZJLL:L,\[NA/&.IH ]$HKBCXB\3)XPE\./9Z49IK$WMK,LDFR)0X1ED&,N
M<D8QMS[5%8^/9W\.K/>VD:ZH=5DT@QP!WC,R,V7  +%=JEL=>,>] '=45P-Q
MXSUZQL_$32Z0)AIEF;RVO&MIK6&=0"60AP2'&.@)S[5/:>+-;76_#<.H65BE
MEKL+F+R78R0R+%YGS9X((SP.GJ: .WIDTT5O!)-/(D44:EG=V 50.I)/05QO
M@*_UG4+[Q,^I75O,D&L36ZA(F4KL2, +EB N.W7))S4?Q;:\3X?WAMI8DC,M
MNLH922P,\8P"",=>>N10!U&G:[IFK7%S;V5VDL]L0)HB"KQY&02I .#V/0UH
MURLFIW">*H=$MX]/&MRV)NKN]\@[5A5]J+MW!F)+'@L ,,>^*QK_ .(.HV7A
MGQ-.=/M3K/A^4)<1-(PB=6 *2+QG# YVD\<\T >AT$@#)X%9.BS:W.US)J]O
M90PL5:U%M(S-M(Y$F1C(/IQ7/W]_K7_"VM/TV&ZMUL#I<MQY31,<GS(U))##
M)]/3)ZYH ZG3=8T[6(YY--O(;I()C!*\+;E60 $KGID BKM>1Z?K.L^']+\=
MZKIEK92P66O75Q.MP[!I%"QEE3;T..<G\J[&^\5R2ZDNG:8 D_V*.\>62TEN
M%42$A%VQ\Y.UB22,8'!SP =)>V5OJ%G+:7<0EMY5*R1DG# ]0?4>U9[7FA>%
M[6WL'NK6PA"X@@>3&%']T$_=''L*9X5UB]UW0(+W4=,FTV\+,DMO*C+@J<97
M< =IZCCO7*>(Y-?\(>,[KQ3::4^M:/>6T4-W#!S<6OEEL,@_B4[B2!W],9H
M[VSO[/48//LKJ&YASCS(7#KG /4<=Q5BN%TWQ;X=MO"<NM^'L3P:AJ"HENJ%
M2ES*54JR@$CGYC@$G)QG(J>U\0^(I]6O]+33EE*V?VFSOVLI[>!W!P87#G(;
MN"">.<<8H Z34=$TO5Y;674=/MKM[5_,@::,/Y;>HSTZ#\A5^N0T;Q7>:YX7
MT2_MEMDO]0G\F6%D;;$5W>:"-V<J$;KU( XS5+4O&^IFVU&\T33S>I8W3VXM
M!9SN]UL;;)MD4;4.=P (;.WG&<  [RBN%N?%/B:Z\3W6B:/I>GK(FG17T37T
MLB\.Y!5P!D-P>.W<]J;XC\:ZIX?M[Z^N;:R@AM;R.&.SE8F>[A+(K3(P;Y1E
MS@%3]WDC- '>45Q]YXBUY_'%UX;T^STX;-.6\BN)Y'(YD*?, !_=/ ^N>U5]
M)\=SZIH&A/\ 9(8]7U6ZEM!%N)BC:(OYC^I4",D#J<@9'6@#N**Y*Y\2ZMH=
MCJTVMZ=&1;3PPV4]N2$O#*0J_)EF0AF /7U&:=I7B'5YO%/]E7EA)-926QFC
MU"*QFMTC<'!C<29YQR"#^% &C+;^'?#=Q<ZO<26FG27) GNIYA'YI' W,QP<
M=!GI5BU\1:)?3I!9ZSI]Q,XRD<5RCLP]0 <FN=^+0S\*_$&?^?<?^AK7*_$;
M49+SP/I5G/I5YI@>:V*ZQ<A#'8D%3OS&S,"?NC@#YNHH ]>HKE]3\32+K#:1
MIK(9X[1+J2=K26Y3#E@B[8O7:QR3P,8!SQC#QUK[6OAMG\/I:W6J7;VD\%V[
MQE'56(*@KG8=N<G)P<8- 'H-%<1;>-[NPC\5)K]M;^?H(CD+61;;.DB;D #<
MAL_+Z5/:^)-</B.RT^73C/:7L4A^U16-Q$MG(HR%D+C#*>@8;>1T% &UJ?B?
M1-&E$>HZE!;'<%+2$A48C(#-T4D= 2,U=T^_M-5L(+ZQG2>UG0/%*G1E/>O.
M_"G]HRVGC:6[BTZ_6/6;AF@GC8!Y$2/;R=V% 48&">!S27WB36M0\,^ [^R>
MTLEU:^MTGA6-B.59PH^884;.1U/'(Y! /3J*XN]\77:^(+[0K>?3HM4M88WA
MMKI64WQ9=Q,1W   Y7'S'(.<5V;E@C% "V. 3@$_6@!:*\Q;Q[XL?PM>>(X-
M%TQK/3KF:.[A^T/YCI&Y5C&<8X SENO/ P,ZMYXNUR[\26VE:#8Z?(EYHYU*
MVGNI7'\2 ;P!P/FZ#/4<CF@#N:*Y*V\0:SK+:M'I,5@)=*<6\HF#NL]R$#.B
MD$;%&X+N(.3GCCG-_P"%@SW6C>&M>M+>&/2M4NEM+LS!B]I(6*]00"-Z[<G&
M.#WQ0!W=Q<16EM+<SR+'#$ADD=NBJ!DD_A3+*\M]1L8+VTF6:VGC$D4B]&4C
M((K$U'6=0@37YK:&UGM]-M\JLFY"\NS>RD\\!2O;DMCC&3GV?BZ>ZTSPI;VT
M%NFIZY:+<!2#Y5O&L8=VP#D@;@H7(SGKQ0!TMGK&G:A>W=G9WL,]Q9E1<)&V
MXQ%LX!QT/!XJ[7E^FZS-X=\4_$34]52*62W%AQ;@J)28RJ  Y*DDJ.^/>MV'
MQ9J=IKJ6^HV32:6]K).]_#8SPK:L@W%9/,&"" <,,<C&.: .FU+6-.T=(6U&
M]AMA/(L40D;!D<G 51U)YJ[7E7B_4]5UOP9H6KO%:Q:?>ZG8S1P;6\V.-I5*
M,7S@DC&1M&-W4XY]3E\PQ/Y142;3M+#(![9'I0!1CT338M7?5DM5%_(NQ[C)
MW,O]T\]/;I6A7F?AGQ=J=AX _MC59(;VZNM1EM;:-5,9>9[ET4$DD!1[#A1W
MKHV\17^E>+M-T/5TMI8]5CD-I=6R-'B2,;FC=69OX>0V?;% '4T5D>)[W5--
M\.WE]H]M#<WEM&95MY<XE &2H(Z''3\N^:HVGB.74X?#LFG26TRZG$;B9BC8
M6$*"S#YN"&9%P<\M[8H Z6BN%D\:ZE/X1N?%^G6MK-I,#2.+9@PFE@C<JT@?
M.%/RLP4J>!UYXT+'Q5-J'C"+2;<0-976C+JEO<;2& 9PH##/(P<]O2@#JJ*Y
M_P ':]<>(M&FN[J&**6*\GMB(L[3Y;E<\^N,U2USQ'K5IXPL= TRPLI#>6DL
M\<UQ,P"LA4'< .GS=LD^W6@#K:*\TE^(FL6?AS7IKW3[./6-!NXH+J!2S13)
M(RA'0YR,ALX.>GOQU%UK][;^.K704AMY(;FPEND<DJRLC*NTGD8.[KCCWH U
M+[1-+U.[M+N_T^VN;BS8M;R31AC$3CE<].@_(5?KSO3/&WB:]\.7'B)](T\V
M%HMX)H8I7,SO$S!=G&,$K@YYZD#H#IVWBB]O-#O]6T^]TG4;*&R:XAGMT8#S
M%!+1NN\D< <]>>G'(!U5[96NI64UG>V\=Q;3+LDBD7<K#T(I+*QM--LXK.QM
MHK:VB&V.*) JJ/8"N3/C&]&G^#+X6]OLU]X8YH_FS$9(C)E3GD#&,$57\0^-
M=3T".ZO+FVLX8(+]+>.RE),]S 61#,K!L*,L< J?N\GF@#O**X^Z\1>()?&M
M]X<T^STY3%8I=Q7%Q(Y'S.R_, !_=Z#ZY['G[_Q=K6L^$?"6IVC6]C)?ZS#:
M7<6UG&Y96! .1\I:/D=2#C/7(!ZA13(Q*($$I0R[1N*@A2W? ]*\XT7Q9J.D
MZ-XRUS7;B&YM].U2>$1PQE&+*(T15RQ 4\#ZG.: /2J*Y*]\1ZIH&K:)#K,5
MH]GJTXM!);*RFVN&!**<D[U."-PV].E;/B2YO++PUJ=U8211W4%M)+&TJ;U!
M52>F1GI0!-?:QIVF36L-[>PP2W<HAMXW;#2N3@!1U-768*I9B  ,DGM7DNHS
MZC-X"^'5U=/%=7,FJ:;)'C*ELQ$_,Q)YSU/Z5UVD>(=9GU[7-#O[6P-[8PQ7
M%N\#NL<B2;L!L@D$%>H'.>@H Z/3=2LM8TZ'4-/N$N+289CE3HPSC^8-6J\]
MM/B#M\$>&]8NTM--3593$\[HQM[7AR,@$=2H7D@9.>V*[+1KF\N]/\V]-LSF
M1MDEL<QR1Y^1QR>HP>IH T*S+O3M(\1VUO)<10WL$4GF0MNRJNIQN&#U!!Y[
M56\6:J-*T)]ES';7%VZVMO+(P4([\;\GCY1N?_@-<C\,KRUTG5]=\%V]['=6
MUE+]LTZ191)FWDY*Y!YVN2#_ +U 'I*@*H49P!CDYI:X^^\57[ZCXEM=,AM@
M=!@CDD%R&)N&:,R;001L&T8W<\D\<<YY\<:Y+:>$I[?2K ?\) 3M5KASY>8C
M(N?E'IR>>^ : /0**XH>)]:\]M(FCLXM8MK99[MX;6>Z@#.SA$4( PR$R23Q
MD8#<X;:^.+RZT[1HY]*GTW5M129I()[663R%B(#-L4!F!++CIPV<\8(!V]4&
MT32VUE=8;3[8ZDL?EK=&,>8%] W7N:XF\\>:_8>&KZ^GT-5N+/4([7?-'+#'
M<1NZJLD:N,_Q<@GC'4UH/XB\2Q>,&\//9Z69+FR:\M9EDDVQ!7"LLG&6^\,8
MVY]NM ':$ XR <<CVI:X6Q\>W#>'GFOK2)=435WT<I '>-IE8Y<  MMV@MCK
MQBF3>,M>LH/$/FZ2)UTZQ:^MKUK::UAF"@EHR'!(<8Z G(]* .]HKAK/Q=K8
MU3PP-0LK%+'7HB$\EV,L4@B\P$YX(.",#IZFG^!;_6;_ %3Q0=1NK>:.WU>2
MW54B92NV.+ 7+'"X[=<DG/- ';4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7->
M*M"U#6;[09K(VH33=06\D$TC*7PK+M&%/][.?:NEHH Y>RT35;/QMK>N;;-X
M+^WAABC\Y@RF+=@M\F.=W;ICO7.Z;X%\1:5HWA2VANM-EDT.:9I(96D\F</G
M:_W<ATR<<'KU%>E44 ><2^ -;N/"WBG2)=0L"^JZB=0MY%C< ,71\.,G RF.
M,]>IJ_JWASQ0VN6/B71[W3(]86U-I>VUP)/LTT6XNH!'S J2><<^W2NXHH X
MS6/#GB#5(]!DEN;&6[L=334+@EGCC.U67RXQAB!ANI/4$XYXNZWH6HZCXN\.
M:M;FU%OI33M*DDC!G\R/9\N%(XZ\]?:NFHH \SO? ?B6XTC5M-6^TMQ<ZHNH
M17,HD,LH$JN$DP.-H7 (SP ,"NDBT'5!\0D\0RO9M;_V6+!U1F#EO,\PN!@@
M#/&,^^:ZBB@#(\4:;<ZSX6U32[0Q+->VTENK2L0J[U*Y. 3QGI6$?#&KG4_!
MUUFQVZ%#)'.OG/F4O%Y65^3MC//T]Z[2B@#SN_\ A]J&KV_BJ&YNK:V.K745
MY:30LSM!)$%"[@5&1\@SCU/UJY_8/BO4?$OAO6-3DT>)M*6X69;=I7\WS$5=
MRY"XZ=.WJ<\=Q10!YG?^ _$4_AWQ+X>MKO3%L-3NY;N"9_,\U?,<.488P,'/
MS G/H,Y&G>^&?$MEXI'B'0+S3#<7=K';ZC;7BR+$Y3.V1"N2" 2,'M]:[FJ&
MJZWINAP1S:E>1VR22+$A?.68G   Y/)H YG7?"NO3RZ/K&DZK;#7].\U7:Z1
MA;W*2D%T(&6500-O4C'?K2:[X;\2:_X96UN[K3CJ#W<%PX0ND$2Q.K!$X)8G
M'+''7IP!7;44 <N^AZH_Q!@\0XLQ;QZ:UDT7G-OW,X?=]S& 5Q^OM6 ?A_K$
MN@WL OK6TU-=;DUJPN(BTBQR,Q.QP5&1AB#ZYZ=CZ/61;^)]&NM5CTR*^4W<
MJL\*E& F"_>*,1M?'?:3B@#$NM&\6:UX5U:RUBYTI;V\LY+2*.T,@@3>,&1B
MP+,?08&,'GFFR^&-7DO/!\^;$#0PPG'G/^\)B\KY?D].>?I[UV,LL<,3RRNJ
M1H"S,QP /6L=O&'A]=!BUQM4A&FS.4CN.<.P8I@#&3\P(Z4 4_#6@:EH6L:Z
MTD]K)I^H7\E]'M#>:&<*"K=@!M[9SGM3O'6A7_B7PO-I.GO;1R32Q.9+AF 4
M)(K] #G.W';K72T4 <GJ/A[4CXML/%.FFT6_2U:RN[6:5A'-"6W#:X4D,K<_
M=YSCBL[5_ U]J/A[Q/$DMHNK>(70S.7;RH4155%!VY; 7K@9+'ITKO:I:AJU
MCI;6BWMPL)N[A;:#()WRMG"\>N#UH GM!,MG"MPL:S! '$;%ES[$@']*Y[4]
M U*7QQIOB#3Y[4)%9R6=Q'.&SL9U;<F.IRN,'%=/10!Y_P#\(9K3>&?%^EL]
M@)-=NY[B-Q,^(A*JK@_)R1MS[Y[4^[\*^);+5=/US0+O38[];!+"^M;LN8)D
M0DJRLHW!@2>W?\^]J-[B%)XX&D42R E$SR0.IQZ#(Y]QZT 5]+@O(+%1J%RE
MQ>,2\K1J50$_PH"20HZ#/)ZGDUF/;^(;36K^ZL_L%U8W.PI;3S/$T;!0"P8(
MP(.!QCMG/.*VHKF&=&>*5716*EE/ (ZC/L>*QD\:^&9)9(TUNR;RVV/(LH,:
MMZ%_N@^V: .<D^',UQH&KI]MBL]7U#45U2.6V4F*VG0@H #@L..20,EB<#I7
M0^'X/%._SO$MSIN]$V)%IROL<G&7<OSGC@ 8&3UXQMVUU!>VZW%M,DT+YVR(
M<JV#C@]^E2T <OH7A$:+XGUG4UN-UK>2F:VMQT@>0+YQ_P"!,BGVP?6LRU\,
M^+-"UK4DT+4M,_L74;I[MEO(W::TD<Y?RPORL"<D D?SSW=% '+6?A_4;;Q_
M/KC/;O92:='8@-*QF^1F8.?EP<[L8S[Y[5SNJ^ _$=]I?B?34OM,:+5;T7D-
MS,)#-@.C+$^. J[, C/'89KTNB@#E+?0M9C\=R>(9C8O&^EK8E$D=3N5V?=@
MJ<#+8QD^OM7/Q?#W6[?PUID5M?64&MZ3J$U]9S N\+B1F+1N, @$/C(STKTN
MB@#CM2\,:SXF\+WUEKFH6UO?S^6T!L%8Q6SQMO1ANY8[AR>.  .F3>\/6WBW
M>K^);O3&$*[433E<>:W3>Y;&./X0,9.>PKHB0.I SQS2T <YXZT.]\3>$+_1
M;%K>.2\0(99V8!!N!S@ YZ>U9>O>&_$/B;PN/#ES)IMA:2I''<W$,CSR,BD$
MA%*J%)QU).*Z"7Q3H,)U(2:M:*=, -Z#(,P9Z;O3_'BM*VN8+RUBNK:5)H)D
M#QR(V5=2,@@]Q0!QFI>$M;TW7;/6/"-W91R1V2:?<6FH[S%+$A)1MR\AAD_7
M^<^I^'-<O[OP[=2W5G//IUXUY<EF>-6)1EV1KAL* W!)R<<\DUV-% '#77@>
MZU74/& U"2W2RU^&&)#"[-)"8D*AB"H!Y(/7MCFKWAVQ\9PF&+Q#J&ES0VJX
M1[-9!)='! ,N[A>N2%!R<=A@]710!Q^A>'=9TNT\2Q3?8'?5;V>\AV3/A#(J
MJ%;*=MN<C\JSQX)UB/P9X6TR*>Q_M#0;N&X!9G,4P167&=N02'ST/2O0** .
M'\3^$=2\46=]8:A#I5Q')L-E>EG2:R?8H9E4*<_,"P&\=<$UVL,9BACC+LY1
M0I=NK8'4^]/I'19$9&&588(]10!Y7X2TW5=;\"ZYH\)M(K.^U*^@>Y,C>9'&
MTK!\)MPQQG!W#KTXYZF+PS>6GCFPU:U%JNF6FE'35B:1O,V[E8,/EQQM QG\
M:W].TC3M'B>+3;&WM(Y&WNL$80,WJ0.]7: .0L_#NKZ!X@UJ\T8V4]EJT@N7
MANI7C,$^,,R[5;>K8!(..G6GIX$LT^'$GA#S2\;V[H9R,'S6)?S,=OG.X#MB
MNLHH YZ+0[V#P/+I'GQW&HSVKI-<2L562:0'>YP"<;F) QTP*YX^"=:M;#PE
M=Z?<V*ZSX?M_LI65G,%S$4","0NY3\H(X.#ZUZ%10!Y[-X#U36+CQ8=6N[.&
M'7H;=5%IO9H'B7Y3EL9PV#[X[9K2TW1O%>H6,NG^++[39+0P/ 3IZN'N0RE"
MTA;A>"3A1UP<C&#V%% 'F;>"O%S^$;'PU)>:1)!IMS ]M=DR;Y(HG#*KIC"D
M  <,<X[=:]+3<$7>06QR0,#-+10!YS'\.]2D\'7/A^XU"UC\B^:]TVYB1BR2
M>:95,@/'\17 SP>M;Z:'J.JZ_I&KZVEG"^E)*88K25I \LBA2Y+*N %SA<'[
MW7BNGHH @O+VTT^W,][=0VT((4R32!%R3@#)XYKD? &@VVG'5KZTG:;3[B[D
M33U.-L4 8L0G^R9&D(/<!375ZAIMCJUHUIJ-G!=VS$%HIXPZD@Y'!XJQ'&D,
M:QQHJ1H JJHP% Z "@#@K+P5J^F^%M2\(6UQ9MHMR9HX+EW836\,I)=-FW#$
M;FP=PZ\CCF[<^%=2T_Q3IFK>'VL1!;Z9_9<D-V7&R(,&5EVCYB,8P<9]:[*B
M@#F?!'A_4/#>E75GJ%Q;SM+>SW*-"I'$CEN<]^>PX]ZQ_$+7B_%SPV;*."20
M:;=Y2:0H"NZ/^( X/3L>GXUWU49=%TR?4X]3EL+=[Z(8CN&C!D4>@;J!0!R6
MI^ KG5?#_B:.6Y@BU;7)8YF=<M%%Y6WRDS@$@!!DX'WCQVJ>+0?$MQXQTWQ%
M?2Z4C6UE+;26T!D(RS*?E8@=UZD<>AZGM** ./\ #?A[7-!\'7>EK/9+?F::
M:VF5F9 9)"^&!4' )QQU]J@M/ V=;U74FM[/3!J6G-93V]C(SI*[')E;*J-P
M' XYR<FNWHH \X@\&^*FTWPI9W-UI"#0+F)E,?F-YT:1L@8Y PV"/EZ=3GM4
M>I> _$EYI/B'34OM,9-1U 7T-S,)#*P$B.L;XX 4+@$9XXP*]+HH Y2UT+6(
M?'-SX@F-C)'+IL=GL21U.Y69]V-IP"6QC)QUYZ5AP> ]:@\%:3I2W%A]OTO5
MAJ43%G,4O[UWVM\N5^^1P#T]Z]'HH CA$H@C$[(TVT;R@PI/? /:N$?X?W=Y
MIOBO1;Z[MO[+UF[DO(9(U8S1R/L(R#QA60'CK[5W]% '(GP_K&LMH2^(6L=F
MDW"W9>UD9C<S(I5&(91L&6+$9;G S71ZI9?VCI-Y8[]GVF!X=^,[=RD9_6K=
M% 'GW_"(>(G\->%=,FETMI-#O+:<LCR*)$@4J!]T_,V<YP />M>WT+5;?QMJ
M^N@630WEG%;QQ^<P8&,L03\G0[OPQWKJJ* .'T+POK6B^#=(T*1-*O8[57BN
MX9G;RKB-LD8RAP03T((X]^-;P;X:_P"$6TBXLE*+'+=RW$=O&Q:.V5B,1H3@
MD#&>@Y)XKHJ* ,.?3M0NO%EM>SI:-IEM Z1(9&,@D;&7*[<=!M'/ 9O7%9?B
M#PQJ=SXRT/Q!HOV&&2P62.X$SLIN(GQE/E4XQC(/J>E=A10!Y=?6VIZ_XLUZ
MXTAO#]U#'LL+B&]FFA<;%RZ/Y?WTRQY<>HQCKIK8ZSXE;PSJ:6VF6W]D7<K2
M1QW#&*4!6B_=$)]W!R,^F/>NGOO"OA[5+T7M_H>FW5T,?OIK5'?CIR1DUK*J
MH@1%"JHP !@ 4 <;K7AWQ#!XM_X2+PO>6"RW%NMM>VFH!_*E"$E'!3)##<1Z
M4S7/"NOW1T?6-.U6U'B+3FE):>-A;3I+C?&0,LJC"XZGCU.:[:B@#B->\.>)
M?$'A1[*\NM._M":Y@E81EU@A6-U<*N068DKR3CKTX%7YM#U27Q_9^( +,6\.
MGO9M%YS;R697+#Y,8!7'OUXZ5U%% 'G+?#_5I]#U. WUM::BVN/K6GW$):18
MI"<A7!49&,@GOGIQ@ZL^D>+=8\,:M9ZS<Z2MY=V4EG%%9F00KO7!D8L"Q/H
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M>JMK5D]M/:KIBI(+J)T)E=L#85/0 '.<_P#Z@#0HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJO=WMO8JCW,GEQNX
M0.0=H)X&3T&3QD]R!W%6* "BBLC5?$VD:)=6]MJ-R\,UR2L"^1(WF$=0NU3D
M^PH UZ*S]+US3-:68Z=>Q7!@;9,BG#Q-Z,IY4_45H4 %%%% !1110 444=*
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MZK)I;W$QOHT\QX$M)78)G&[ 4_+GOTJYIVL6.JM.MG*[/ P65)(GC9"1D9#
M'I0!?HHHH **S;#7M.U/5-0TZTF=[K3B@N4:)DV%P2O4#.0,\9[5I4 %%%%
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M^"1GVYYKH['P3J-K=>$YY=8MY?\ A'[=[?;]D(\X-&L?7?\ +@*/7G/T#)_
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M%B"-&H&/)0@#'0#/3\3R:ZO7KJ]L?#^H7>FVOVJ]AMW>"#&?,<*2!COSV[T
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M;R^3,-I4H^T,5((!! 89';I5^H(+*"WN;FXBC"27+!Y2/XF"A03[X 'X"IZ
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MY(!##C%9FF:SJ6B?"_P%+I\L*)<S6-I.)(MQ,<A .TYP#^!Z]J /4J3:-P;
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MWEH8P"/,X^4G/O\ E79T4 <]I7AJ;2O$^KZI%J1:TU*59WM#",K($"9WYY7
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M\'J,J,CTK85E=0RL&4C((.0:6@#GXO#LUWJUMJ>MW4%Y<6L,D-O'# 8HT\P
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M"C)[FM6@#F;KPI+>^+4UNYO87B_LY].EM1;$!T=@S'=OXY'IT_.L$_#?5/\
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M'<A?NG8QX8= >>/QSH-X?O8F46FJ*8#;>1/#>V_GK,2S,9&PR_,2QSVYZ=,
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M1'[L64"N5]"Q 8GU ]*9>^"(+OP%#X72^FA\E8BMV &8RHP?>P/!RPR0?4T
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MY1W[\^U3:IX/FU3P;9^'7U-4%OY&;@6^2XB*E?EW<<J,_CTH S9+OQ+#X_\
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M>'K*+79A<Z'-YEO<FW0@KL*%-G^Z>I).?RH ZK5$F.BW:PW4D$P@;;.@7<I
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MZ0JBG!/RK]YC@<D]N,9.5\0>'9=;U'1[M+Y;?^S+G[2B&'?YC;2N"=PP,,:
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M&06BI$-I8AL9)Q\W3=^..  8%MXTU8?#KPUK]\;DPW3$ZG>65NKO F'PP3!
M7<%!.#@9[FM&'Q3+/!X?LK+6(+Y];O)TBU&-%^6"-6?[H&/,VA5Y&,Y)'&*O
M:-X1OM!T/2--L=: _LT.@:2UW+-&W\+J''0\Y!'0>^:5S\-;271U@M;^2RU*
M/47U.&]MH@HAG;KMC)(V8P-I/..30 SQ3;ZY;> O&L6JW<-W:?8IC8S!0LVP
MQ'<) JA<@]"!R.M26FM7$NI^'?"]I.;5I-'%_/<*JLX1=B*J;@1DL222#P/?
M(OW'A.]OO#.IZ9J&N275YJ,!MYKQK=5"QX(PD:D ?>8Y))R><\ )/X-=I=$O
M[;41!J^DPFW2Y\C='-$1@H\>[D< \,,'GVH Q'\6:_:1^*M*\F34-0T2:V9)
M[>$>9-;3$,6"?=,BIOX  ) X[4^/QQ&/#E[JVF:P-7C>XM[6V66-4EMY9'"%
M9% 3H3NYQG&,]ZWAX5FCCU"X@U,Q:O?W,-Q/>+#\O[K:%0)G[FU<8R3\S'/-
M4[OX?6.J0Z[_ &G*&N-96%9I+6/R0ABR491ECN!.<DG. .E $NDR>*8_%+17
M4-S-H<EMN\Z\^SK+#,#T B/S(1ZC(/>IO$FNSV6MZ!H5HXAN-8GE4SE0QBCB
MC+N5!XW'Y0,Y').#BG^'O#^JZ:ZR:SXCN-9>)=D&^W2$(#U)"\LV.-Q/KZFI
M?$GAJ/7_ +!<)<O::AITXN+2Z10VQL8(93]Y6'!&1]: .>N?$.M:7KVO>'I+
MQ)Y8=(.JV%Y+"NX*"59'5=JDAAP0!P><UI>!Y=?U+1].UK5=6BN(;[3H)!:I
M:JGER%02^\')R#R,8!Z5/)X5DN7U.\NKZ.35+^S%C]H6W*I##S\J)N)Y+$DE
MCSCL,5H^'=)?0?#UCI+7(N5LX5@27R]A** !D9/.!0!EW6L76H>.&\-V=T]G
M':V(O+F>-%:1B[%41=X( X))P>PXYKA;+4M7\/?#?QSJ-E>Q#4;/7+QC.\ 8
M.=R G;G )SGN/:N[U?PE-=>*+?Q'I.J'3M12#[+-N@$T=Q#G<%9<CD'D$&LQ
M_AU(_AC7]$?7)736KR2ZEE>W7*;V!(4 CG@<].O H 7Q3XJET/6+2+4;NZTO
M29[4%-2BMUDC%P6(V2DJVT8VD=,Y//%68-9OM2U^T\/QZBL3QZ3'?W-[:JCF
M9G;8/+W KMR&8G!ZKC%:%WH6I7+R8U2W,,]FMK/;SV7F1L06^<#>,$AL$'(X
M%8\_PY6V.C7'A_6;C2K_ $NS%BMP8EG$\ YVR*< \\@\8)^F ".[U/Q1HI\*
M0:I>VKW5YJ9L[O[/&#'+'M=E;D JV%7...M.DU_7DUGQQ968^W2Z9:V\VGP&
M-=V^1'8KQC=RHP.O:M#5?!LFHZ7I\4>KS1ZG8WJWR7\L2R%Y0"#N3@;2&(P,
M8 &.E0P^";N'4M:U$>(;G[7JD,*/(($'EO$#M8#\3@<>^>I ,_3/%=QJND:U
M>:!J4NJ7=M9Y33KR!8KF"X&[Y7557(/  ]0>>>-#P;XD@\0W5RUKK4UW'%$J
MS65Y D5S;2Y.=RA5X(P.XR#R>TTGA":XU&]U6;4DBU6XLA9)<VEMY810V_<5
M+-N;('4XP,8I9/#$ZW]_KDNHI'J\NG-8QW5I9X\L9W;RA9B[ @8&>V,<T =3
M165X;BU*'P_:1ZO<-<7RJ0\K(%9QN.TL!P&V[<@=\UJT %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MDAPI;,A_A!Q@'UJ[7':Y?:MI'B?PE8Q:I)+:WMU-%<B6*/?*!$[C)50!@@=
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MM(B.BLZJSG" GECC.!^ )H Y/4_ <&I^'M5TQ[Z1)M6G6>]NQ&"[LI7 4=%
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MU8:IHL MK:_AC4EHL ;)$.588 _&NGTC36TNR,4MY->W,C>9/<S8#2O@#.%
M &   !@ ?C5^B@#D=0\$2R>)I]=T?7KS1[B\1([Y((XY%N HPK8<$*P'&[G^
M>;=]X32YU+0;N&]>%=&9FA0IO\PLI1B[$Y/!/ODDG-='39)$B4-(ZHI8*"QQ
MR3@#\20/QH P]&\-G2=8UF_:]-P-5E6:6)H@H1@H4;>>FT#@YK*T3P VA3?9
M;;7[\Z"DQFATIE38AW;MOF8WE,\[<CWSSG;A\1VTWBR?PZ(+A;N&U%V9'4"-
MD+;1@YR><]NU;% ''7O@-KFZU\V^M75K9:VA^TVJ1(1YAC\O<&/(& "1WQUQ
MQ4T'@LV]]X<N5U6:3^PH'@A$L2GS%= C;B,=E&,8]\UU=% '*Q>#GBC\1K_:
M9/\ ;I+3'R!^Z)0(=G/]T=\\\^U26/AB]TRTL;>TU@>7:V*V)CGM@Z2HO"LP
M##Y@.,@XY/%=-6>=7A;[=]FAFNOL2MYGDJ#N<#/EKSRW3VR<$YH P!\/[2VM
M?#L.G:A=63Z&9/(E148N) 1("", G)Z#CTJI?_#5+VRU[3UUV^BT_5[@W3VZ
MHA\N8E23N(W$94<9%=/'K</D:=+=6]Q9B^5=@N$"E)&&1&_)VMV],\9S@'3H
M YR#PQ/#XJ&OG5'FN18"P*RPKAEW;]QVD?-N/; QQCO62WPUMG\-KI+ZI<K-
M!?-J%I>Q($EMYF8L2.Q&6/'H?H:Z&Q\16U_XDU+0T@N([G3XXY)'D4!&#[MN
MTYR?NGL*V* .5E\%1ZGX>OM,U_5+K5);U%22Z94B9-IRGEJ@"KAN>^3UR.*;
M8>#[^+3KFVU+Q1J&I2O;/;6\TB(AMPPQN&T?,_\ M,2?IDYZRJFIWZ:7IMQ?
M2Q2R10(TD@B +!0,DX)&>!]: ,RT\.,NOPZWJ%VEU?06K6D4D< BRC,&);D[
MFRH] .<#FE\3>'3XCBT^/[:UJ+*\BO4*1ABTD9RH.3TSU_G5:'QM:7&B)K,.
MEZK)I[P^>LRP YCQG=C=GI[5TP.0".AH YCQ+X/.NWMAJEIJMQI6L6(98KRV
M4-E&^\C(V0R\9P>E1ZEX+;4_#Z:7/J]R\INH[N>\>-3)-(A4KP,*H^51@#H!
M]:ZNB@#D;WP.;O5]6ODUFZMX]8M4M[Z"*--LA5"@92P)7@G@?G34\!^7:^&U
MCUN\2YT)&BAN!''EXV0(5(*X'RJ,'DC'<UL>)_$5MX5T*;5[R"XFMX2H<6ZA
MF&2%'4@8R16Q0!S<?A:2+7M:U:/42)-5@C@=#""(P@(4KSDG#'.>IJBO@+9X
M=T'1EU5Q#HMU%<P2>0-SM'DH&YQCDYQC/'3OV5% 'DFH7D<_C'5I9?%ESH-X
MMRL45K=:='-O5%"AXBZ$[6.X@*3USU->C>''U&30X6U67SKK<X\TP>29$W'8
MS1_PDK@D?H.@U:* .97P9;?VQKEU+=S2V6LJ!=6#*OELWE^63NQNP5[9Z\U%
M9>"S#8Z;IM[JDM[IFF2I+:PR1 .2G^K$C@_.%XQ@+T&<UU=-61&D>-74NF-R
M@\C/3- $-]9Q:AI]S93;O*N(FB?:<':P(./SKE#X#D;P_HNDOKEQ(FDW,%Q!
M(\*9/DX\M,# VC'/<^HKLZ* .:E\(177B'4=4O;D3QZA8BPGM?*PAB&X\'.<
M_,?SJMX=\%7.A-!!-XDU#4-,M/\ CSLIU0"+'W=S@;GV]@3@<<<#'744 8OB
MOP\/%/A^?1Y+I[:*=D+R(@9L*P88SP.5%0S^&GN?%5EKTU\&DMK5[7R!#\CH
MY!;.23G(&/ZUT%% '%Z)\/WT.<6UOXAU!M!27S8M)=4*(<[MOF8W[ >=N1GO
MGG/*?;$N/$6IW \876B:@]Z^W3[O2XYY5"X12A9-Q#!0P"DC#8ZY)]?JA8ZH
M+N"[FFM+FQ2VGDB8W:A-ZI_RT7G[AZ@T <_#X<O=2;2-?GO/LGB&TA>%IQ!\
MD\+$_+)%GC(PV P*L3S4U[X&LM1\/ZUIMS<RM/K+^9=W:@!BXVA<#H%4*H ]
M!U))-:-[XCM;'Q+I>ARP7!N-265H954>6/+7<V3G.<8[=ZV* .:N_"MQ?7NA
MWEQK$LMQI,K3!WA7]\[*5.X#  P2 !CZFLF]^&JW=AK6G+KU]%8:G=F]\A8X
MSY4Q=7)W$9(W*.,_G73^(->M?#6CS:K?1SM:0#,KPJ&*#(&<9R>3VS5;_A*(
MQ';RR:5J<<$\D:+*T*E1O8*I.&) RPYQQ0!$?"I'BFWU^/5;I;A+-;.="J$7
M"JY<$\?*<DYVXXXXJBGP_LY=%UW2M0NI+JVUB[>]D(0(T4K$'*'G&"JD9STY
MS7844 <_;>&YVOK"]U74O[0N-.1UM&, C 9EVF1P"=SXXR,#D\<UE2?#X2^$
M]7\//JLAM]4NI+F640C>I=][!><8R!C(.!G\.UK'UWQ%;>'WTU;J"XD^WWD=
ME&T2@A7<X&XDC Z^O2@"G?\ AJ\OXK^WDU8&UU"W$%Q"]L& ^7:63YOE8CUW
M#@<5MVMA!9:7!IT*L+>&%8$!;D(%VCGZ"K-% '!6_P -#;Z;I%@/$>H&'2+L
M7%E^ZBS&H##:?E^8X8C)_*M./P:\8\2 :F3_ &]GSLP#]UE/+^3G^[ZYYY]J
MZJB@#C'\ >6FA3V.KS6FIZ-;"SANUA5A+  !LD0\'IG(QSS6GX=\+G0+_5KQ
MM4N;Q]2G$\JRHBJK;0N1M /0>N/;O705CVOB2RN_$M[H"Q74=Y:QB4M+"5CE
M4XR4;HV-R@_6@"EK?A(ZCXAL]?T_4I=-U6VB-NTJ1K(LT).=CJ>HSR#G@UGC
MX>C^P_$&EMK=U(FN3O-<.\4>4+@!MN .2%'MZ 5VM!Z4 8#:#?J\;0ZLH46:
MVDL4UJ)(Y I.&V[AAL,1UQZCIC'G^&]K#;Z*VB:K=Z5?Z1 ;:"[15D,D1Y99
M%8;6!//L375:3J#:IID-ZUE=632@YM[M DJ8)'S $XSC/T(J[0!RVI^#!J.B
M6MH=5NEO[6\2_CU!U5W,Z\;F7 4C!QM   P.U11>"'34=7U"37KY[K5+$6DK
MA$7:0& <8'!&XX P/7/6NNHH YB;PBU[>27]_J)DO_[/ET^*Y@@$3(DF,N>3
MN;(!'0#G YJ>#PU+_;<.LWM['<ZC;6CVL$JVXC&UB"6<!OF.5'3 &3@<UT%%
M '%P_#JTC\(VN@/J$[&RNOMEE>*BK+!-O+AO0\LPQCH<>]:\'AZ7^TGU:\O5
MN-4^RFUAE$&R.%"<G";CR2!DD]AC'>74O$5MI>NZ3I,T%PTVINZ0R(H\M2J%
MCN.?0=@:MV>H-=WM];&QNX!:R*@EF0*D^5!S&<\@9P>G- '+Q_#X1>%-'\/I
MJL@M]+NH[F&4PC>Q1]ZAN<8R3G &>/QNZGX0DUBUO=/O]2\[3+V=9I(&@&Y,
M$';&^?E!*YY!/)P1744V.1)5+1NKJ&*DJ<\@X(_ @C\* "0.8V$;!7(^5B,@
M'Z=ZXI?AM:_\(7:>'7U*Y!L;@W5E?1 )-!+N9MW'!Y9AT'!]>:[>FR2)%&\D
MC!$0%F9C@ #J30!R%UX$FU3P]<V&K^(;Z]O9C&RWQCC0Q&-PZ;44;<;ADYR3
MW/ P]? B3:U<ZEJ6K75\;S3OL%W"\<:I,F6_NCY1\QX'YFK^F^*X=3O[."+3
M=02VOK<W-K>M$##*G!Z@DH2"" P&<^O%;] '")\.;C^S-+TR7Q/?266E7<5S
M9*8(MZ"/.Q68@[L< ''3L>,;,7AB6'Q'JFM1ZB?.U"V2W9&A!5%3.TCGK\QS
MV/H*Z*JVH79L=.N;M;:>Y,,;2""W7=))@9VJ.Y/:@#E$^'XC\+Z+H*:JX@TB
MZCNH93 -[M&VY W.,9)S@#/'3OS.J7<<_C/59)O%=QH%VDR116UUIT<PD5%
M$D1D0X5B6("D^O? [Z]\46VGWFB6MQ9WB2ZNXCBR@Q$VTMM?G@X!X&:W* ,C
MPT^I2:)$VJS>?<;G"S&#R&E3<=K-'_"2,<?H.@UZ** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "N!\16]Q+\6?#")J5Y#')9W;;(RFU2OE] 5/7)R3S
MZ8KOJPM8\,Q:OK6EZLM]=6EUIXD13!M_>)( &4[@<?='(P10!SMGJFK>*-&\
M0ZI8ZI-8S65Y<6]E$B(4'D\ R @EMQ!SSP",8/)Z7PCKC>)/"6EZS)$(I+NW
M61T'0-T./;(./:J/_"&1V]UJK:=J5S96NK.9+RVC52/,889XR1E&8=>OJ,5T
M%C96^FV%O8VD2Q6UO&L44:]%51@#\J .)FM[B3XWQJ-2O$C&A&81*4*#_2%!
M4 J< X&>_'6N56?5]+\'>--<TW5Y;1]/UZ]F2!(D*2D2+D2;@201QP5Q[]O2
M[[PQ'=^*;7Q!%?W5K=0VQM9$BV[9HBX?:V02/F'4$&LMOA_ _AS6M$?5;LV^
MKW,ES</L3>K2'+!?EP 2!U!Q0 M]JNHQ?$?P[91WCC3[^RN99+;8N-R!,'=C
M=_$>^*RM)\373^*H-(UJ]O=+U?[7,?LL\:_9KZ#Y]@A?;V!0]0<@@YKI)/"P
ME\0:3K$FHW!GTR!X(TV(%=7 #%N,Y.T=,=*B3P@K_P!G1WVHSWEMIUT+NV22
M-0RN,[06 Y5=W P#P,DT =-7FWC:TMO%TVKZ;-#>/'9VI@M)(+6255NVPY?*
M@C*XC'K\SBO1Y%9HV5'V,00& S@^M9V@Z.=#TW[&;R:[S+)*9IE4.S.Q=B=H
M /+'M0!@^&/%-YK?PU_MB&W,VKV]K)'+;$8)NH@04([98 X_VA6#9:YJ^H3>
M##IVO33R:I$SZI&J1-Y6V/<S8*_N]K_)CWQUYK6F\-2>$M,\4:GI]QJ5_)J(
MDN7L80@/G,,%H]JY!_,\=S6#H)N8Q:0^'?&>IW\D7EI]BN-*54*C (D;RU*
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MN8L?!D=O;:99W>I7-]8Z7(LMG#,J@JR#";V R^W/'3H"<XKIZ /.(-;UC7_
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)-'#M\QU3>P1=QQDGH![UR7B2XNFUY[6+4;C8-.:2.QL/EF63<?WSL<*$
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MBO-@$D-N0SJISP9,+M#$=\]10!W=%<'XEO\ 5O GA_Q'K']I?;;58HVT^WN
M6>!R0C%FZLFYE;!Z<BG:[=:EX5U7PU/%J5S>VNI7R:=>13D-N:125E3 ^0@J
M<@<8/3O0!W5%>8-K>KCP)X]NAJ=Q]ITG4;N.SF^7=&D:(57I@CD]:NW-WK%W
MXT\/:='K=U;VM_I$D\R1I'D.OE_,I*\$[CUSCL!UH [^::.WA>:9UCBC4L[L
M<!0.I)I]>,:[=ZC>_"KQ)!>:I=S2:5KOV&.<L%>:(7$2@28 W<.?K@5V^K?:
M8M<M=-&K7DT7V*1UM+5@+IY-XQ*S\*$49 R0"?7I0!V%%>36_B/Q!J/@_P
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MC2-6&'BGYVR MPRDD#.=O3@9H ]%)P"<$X["JFDWTNI:7!>36-Q8R2@EK:Y
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M//?S_P!AZFCVC0L0(X;K&Z,YQG# ,N,XSS0!U&K7\NFZ;)=0V%S?R(5 M[8
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M",8QSZUB3^$9+"'0[71+_4;5;.\-Q*(Y56.<,X:7SACYLY;  &"W0 <=A10
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M?;)"4.Y\$%G+*22=S9]22:N:=X;AT[Q'JFMI>W4D^I",312;/+ C!";<*",
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MVDCN9MT<;!,DHN/ESGGDYP._-96B3O>?&'Q7YQ/^@V-G;P ]D<-(V/JV/R%
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M&2,D#..Z@E2?I0!T=%>>:Y->^&X_"VK6&HWET;N^M[.\CFG:1+E)A@N%)PK
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M>%/#=UK+64MVEOMW1QNJXR0,DGMDCH#]*3P3_P B%X=_[!=M_P"BEK'^+?\
MR2W7/^N<?_HQ* .U'(HKSR_MM2\.>.?#_DZWJ5[::S)+:WEK<S;E!$9<21@
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MI:R6$5U=&46\LJ./O$G;DJO ) /2K/AO58]1O=4TVXAUC1M8CL09M/N;EY
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M,#:WICC!R".N: .;AM=0N/$WBCP?'J=_'9FRBN[*Y6Y?S;.1]R[0^=Q7<NX
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MUOF01S265V\'GH.BR;2,CMZXH V-'%T-$LTOKJ*ZNUA59KB$861P,%A]3S7
M:5)KUUX7\70Z=>S7-];^(98;=;FZ*L\2-$3"LA.4RNY01T)[=:]*A@BM[>."
M!%CBC0(B(,!5 P ![5@0^"],@L[ZUCFO52]O!?2L+@AO/W!MZD=.57@<<=*
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M]W)+YS%;AG=0\3+G!7YB N.,#&*V]9O!X.\>V^LWUU<C1-5MW@D62=VCMKE
M7!"DX&]0PP!U'O0!Z!17F]U-?Z=)X6TFXE:-];N+BXNEN+B0 /MWK;[LY"C<
M% &,[ .Y!KZK_:O@ZQN8)-8C-IJ&J6B1Q>:^;"&1B''F$[@C%< C&W)QCK0!
MZA17*:)H>H:3XJN+AM1B2PN[7C35D>0"56&95+G@88 @=R#2^*'CEU[0[(W$
M\LLAF<:9$=JW("@;Y'R-J)G/?)(P"10!U5%>26FH:X/AE?\ DW%P[V>NR6TN
MR=GF%JMP T<;G#,VT[1_$1P.<"NATK2Y[CQ[?W-LVI0^'Q8QA(VFFAC-RQ8-
ML0D<;-N3CANG.: .ZHKQC27NM-^$C^,/[3U.;5+>.YB5Y;IW15:X9-Q0Y#%1
MELD$^N0 !U,FFZCH]_#XALM1A6T%E-YEFL\LRWS>67C8%C]X;2=PY(S0!WU%
M>::)8:GK&D^&?$MOK4,$C&&:[G\^1_M:O@/$R$[02QP,?=(P!4=OJ%SI?BBT
MM?$=O=K]IU-S8:U:SL]O=!V;RX95!^7 (4 @C*@CIF@#TV21(8GED=4C12S,
MQP !U)-,MKB*\M8;F!M\,R+(C8QE2,@_E7/_ !#MX[CX=>(EE!(73IW #$<J
MA(Z=>0.*YF*X^RW'@#P\LD\5AJ=M)/<'SGS*T<"E8]Q.0N3DJ" < =,@@'I=
M%<3H$MUIOQ(UK0(Y9I=*^Q0WT*2.7^S.S,K(I.2%.TMCH.<8J+QG%-/XZ\&V
MD>H7UM#>2W<<ZV]PR!U6!B. < ]?F'(SP00" #NZ*\<U"*^T&'X@Z):ZGJ+Z
M?9Z6FH6;M=R&2UD97R@DSNP2N<$_UK2OXWT'3O#;1:AJ)/B&\LK:^FENG8*N
MPDA.?W9<X4[<<=,4 >HT5P;Q3:5\3+71K.:Y_LK5=-FDGMQ,^()(V $B'.4R
M& .".>>M<9:+=CX4>%_$0U;4_P"UOMT,?V@W;G*O<%&!4G:V0>X)/TXH ]OH
MKS^TLO[-^*=UH]O>7_V&]T,W4J27DKGSA,$WJS,2IP<<$=JXM(-1B^#.F>-8
M-:U5]=M DJ,]V[)*#-M,;)G# YZD$D]\<4 >V?;8&O)K*.17NXHEE:+/(5BP
M4GTR5;\JR?"7B&3Q-I4]Y+9BT>*[FM3$)/,YC<KG.!UQZ5SN@Z=;_P#"W_%4
MVV42+:V4O^N?&YA)G(S@CT!X';%9.BZ+=ZY\-M>MM.N[BUU%-6OI+62"9HSY
MBS,0I*D9!Z'/K0!ZM17$^&M9B\9W>F:E:M-%;V5GF>(2L +ESM\MAGDH$;(/
M]]31\3WN(O#=G+:WES:2_P!I6L>^"4IE6E52"!PPP>AR* .VHKSE=-G\._$_
M3;"RU#49].UJRN3=P3W<DFQX]I$JL3E2=P'!'\JYW39;W2OA%/XRCU#4KG5[
M6*[BB,UT[H ;AD#,A.&*_>R>?7@   ]HHKSO7DD\/2^$M4T:ZN9&N]1@LKE7
MG:1;N*53EV!)RPQN#?7M40NY_"_B[7]%DGN)QJL"7.D"XG=P'8B)H@2> '96
MXZ*3Z4 =Y=SW\>HV,5M9)-:2LXNIVF"F !<J0N/FR>.V*CU_4Y-&T"_U.*V%
MRUI \YB,FS<%4L1G!QP/2N2U6VDTCQKX!LH+Z]:$FZAE62Y=A-MMV(9P3AFS
MDY//-9#R+XL\$>.-3OI9_M-O+?6T*),R_9DA0A5 !QD]6_O;L'C H ]'T:_.
MJZ%I^HF,1F[MHYR@.=N]0V,]\9J]7E^EWEQ?W7AGPZ6B^SGPU!=K#+*\:S.=
MJG[O+;0,X_VB>P([#PAIU_I&D2Z?J&JC49(+APCY9FBC.&6-F8DL0#U/8B@#
MH**\XUF4:!XXU&"\N+V33]=TYFM(UNG!2ZC.&CBY^0N&4C&.147@NYNM4L-.
M\.ZA/<'5-%NYEU-Q<R;G\OA"6SDA]Z-SP0C"@#TRLN#5)[?2;B^URWBTX0O)
MD";S!Y8;"MD <L,<=><5Q?@_11JNK>(9[S4]6?\ L[Q!,ELGV^3"J(H_E/.6
M'S=^F.,9.>:U!&OO@MJ+WD]S<R6^N,J233NS8%XJ#))R?EXYH ]FEO+>&[M[
M6255GN-WE)W;:,L?H./S%3UYWJNC62?%KPT@$^#IUWDFYD+?*T9'.[..3Q5*
MW@U7QKI&K7=OJD=AJ-OJ4\27/GR!K/RI2%78"%QL R#UW$F@#U&BO-[?3O[:
M^(VMZ?>ZC?R63:7:S&*&\EC3>Q?)7#94<9P"!Z@UM_#&^NM1^'.CW-[<27%P
M8W1I9#EF"R,H)/<X4<T =;17F\>E#6/'_C/3[N_U(V<=M9R1PI>R($9ED)(P
MV0,C.T';[' QF^'_ !#?ZK8_#G3-0NIFAU2UGENI?,*M<-$GRH6')S]X\\XY
MR,Y /6'=(HVDD8*B@LS,<  =S6=<:C=2V%A=Z/:)?1W,D18M+Y6V!N3(,CD@
M8.WO7G.O)-;2^/?#IDGFTA-".H0(\K-]FD*N"@.<[24W;2<#!XQ4^I0G3O!'
M@.2SN;N$R:EIBR!;J3$BOMW*PW8*\#CH.U 'J5%<'!CQ;XE\7:5>W=Q"]@8K
M>U2&5D,"O%N\X $98L3@GH% ]<P2W-S=>*M-\+O?I?0QZ-Y_F3RM']LD#^6S
M'9]X@+G'3YB>P( /0Z@6]MWOY;)95-S%&LKQCJJL6"D_4JWY5C>$-.O](TB7
M3]0U4:C)!<.$?)9HXSAEC9F)+$ ]3VQ7*VD$6G_$GQSJ,,4LD]K86MRB"9\.
M^R4X(SSG  !X';% 'I5%>27UW=Q_!^Q\:V=_<-KL<<-X\WG,5F9G4/$R9P4^
M8J%QQ@8KUI"6125VDC)'I0!A>)/%FG^%Y-+2^)SJ-VMJF#]S/\9_V02H/^\*
MT]4NY+#2KJ\B@$[P1-((B^S=@9QG!Q^5<'XATRX\9P^(8QI<MS;2PG3[&=98
MU$;1MEG 9@?]<H!]1$*T/#7B"7Q%\+YKFZRNH06LUK>HW59XU*MGW. WXT =
M'X;U<Z_X:TW5S"(#>VR3^4&W;-PSC.!FM2O+]$DB?P;\/K-KFX>2:S#+IL/R
MB\"P\EVR-J)D,>N3@8)Q6-=W>I?\*O\ $&Z_O(9]/\1-:P-%=N3'']HC79N.
M"Z@,0-PZ8XH ]IHKSJ4R^&_B1<1V5Q>3PSZ#/>2P3W+RB2:.10K ,3M)!(PN
M![57T2QU/6]%\,^)K?6H;>4M#/=W'GR/]J5N)(60G:,L< #[I&!0!Z!JU[+I
MNDW5]% LYMXFE,9DV;@H)(!P>>*YB'QW=-X1A\4RZ!*=*>$7#^1<K)-'%W8H
M0H.!R<$FNB\1?\BSJW_7G-_Z :\OM-(UR^^ MH+76HXK<:7YDMN;<+YD04EH
M_,SE<@$;L=Z /6[*]M]1L+>^M)!+;7$2RQ..C*PR#^1J>O--.U2QUO1/!0LX
M[FWBFM9#%HD;86540)F23(Q&G49SNR.":PIKO4G^&,Y;4;R&XL_$9LXY([IR
M5C^U!-A8_? !P-P[#B@#VBBO-=?T)='\2^%;2RU76$AO]3G,X;4)7W PL<#)
M..1P>HR<$5GSZK>>$[3XBV]A<W+0:8]J]IY\K3-!YT:[R"Y)P"2V#F@#UJBN
M&AT2_M-:LM7M-:M[2REMI(I8O/DF2Z)0LDF7.-RX+;NI&:S_  E?SV?B33]'
M\0V5[8:V+61$F%PTUKJ> I:0-G[XVYP1D!C]* /2:CGGBMK>2>>18XHE+N['
M 50,DFN>\9S1)9Z;!)>W,#3W\2+;VP^>\QD^3G(VJ<9)R!@'/6N U(3S>%/B
M=IEYO6WL<26]N+EY%A+0*^ QP=N>=O0&@#V""9+BWCGB.8Y%#J<8R",BI*S/
M#MK%:>'K".+?M,"-\\C.<E1W8D_A6G0 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 5EWN@VM[J)OS+=PW)A%NSP7#(&C!)P0#CJQYQD9X(K4HH P+SP9H
MEY!I<0@FMAI8*V;VEP\+Q*0 5#*0<$ 9YYID7@7P[%I^J6']G[[34Y#)=0O*
M[([''(&<*>!R,'@<T[Q!XAN-%U?0;1+..6'4[S[*TIE(:,[6;A<<\+ZBN@H
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MYY6E4AR2P^8G@DG(]ZJ>'_ VA>&)C+IL$X.TI&LUS)*L*GJJ!B0H/MS71T4
M<OI?P^\.:-JK:A86<D3>895@\]S!&YZLL9.T'\..V*N0>$]+@DA(%Q)%#<&Z
MB@EG9XTE))W@$^I) Z G( K<HH @O+2#4+&XLKJ,2V]Q&T4L9Z,K#!'Y&L7_
M (0K1/['M-,\B<Q6<BRVTIN9#-"ZC"LLA.X8  QG&.,8KH:* *.G:1::8\\L
M(=Y[@AIYY7+R2$# R3V Z <#GCFN4\9:?-J'C3PBZ6U\UM9SW$EQ/;(X\G=$
M50[E_P!K''/'7BNYHH Q)?"FE7&FW]C/'-+'J/\ Q^2-,PDGXVX9@<XQQ@8
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M<YXXJUINBV&D37TME"8WOK@W-P2[-OD( )Y)QT' XH T**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH ***YSQ!K][I'B#P]8PV\#VVIW36\LCL=Z81F^4#C^'J3^% '1T5#
M<FX%L[6@C:<#*+(2%8^A(Z9Z9YQUP>E5M&U>WUO34O;<,H+-')&_WHI%)5T;
MW# C\* +]%%<AXT\6:EX3GT^X^P6TND7-PEO<7CRLIM2QP&90IROOD?K0!U]
M%8FNZK?V4^FVNEVUM=75Y,4,<LI0+&!EI,@'A>!]64=ZV5+!%WD;L#..F?:@
M!U%%% !110"#T- !11GG'>C(H **,C.,\T$@=30 4453FU2TAU6VTQY1]LN(
MWECB'78N,L?;) _&@"Y17-^%/$%YKDVNQ7T%O"^G:D]F@A8L&4(C DGJ?F/8
M5TA('4T %%4[_5+336M5NI0CW4ZV\*]W=NP_ $GV%7* "BN?U;6[E/$%MX?T
MSR%OY[26[\VX1GC1$*J 54@DEG]> #UK3TF;4)M*MGU:WAMK]E_?10R;T#9_
MA/IW_&@"[11G%% !15#^U8)M0O=-M)(Y+^UA262-FPJ[]VP,1G&=A/3ICUK-
M\$:_<>)_"%CK%W#%#/<^9NCB)VKMD91C//110!T-%!('4T4 %%(Q(4D8SCC)
MP*Y[P?K]YX@L]2DO8((9;/4KBRVPDE2(VVYR>N>?3Z4 =%111D4 %%)D8)R,
M#K60VJ3ZMX<EO_#3VD\[EEMGNBPA<JY4DE><?*<$=>* -BBD!(4%L XYQTI:
M "BBB@ HHSSCO6!JVMW,?B"TT#3?(6_N+66Z\VX0O&B(54 J""268=^ #UH
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MGW'K69H/B"]U+Q/XCTJ[@MXDTN6!(FB8L7$D>_))QSR.WYT =)1110 4444
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M&(Z@8O)^TC*OMY[COR>>O-5AX.T :5%I8TY!80R>;';B1]B/G.0,\'//UYH
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MH_\ @2CH:Z_PA=6?C1+;7FM$C2"Q6S50NTQRL 9E'LORJ,=/G'<UV'V&U_M
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M<6%W&)+>XC,;J?0]Q[CJ#V-4-!\):#X8\[^Q=+@LS-_K&C!);T&3DX]NE;-
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MQA$-M$-L<8)(0>@ST'M5J@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%+(ZQQM(YPJ@DGT KQJW:T1? 6I:;MBM+C5W\F>=PUW<1NLI=I7&!@GJO/\
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M&X4,]QN/SA5)QM3Y<GKGC(&: .YI RGH1^=+7E]X@\#^,=3L[&SB$'B>(-8
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M&6:(]4)_N^U:2G*@^HKEM)\1W<OB_P 3:9J4MG'::8+4P2*"A(E5F.XLQ!/
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M<O8DY8 #G@\ X%5;33+&Q\._"S4[:VBBOYKFTCDN57]XZ/;-N4MU(X QT
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MO;2.F>^.M '"6[7>L:/X<U3PK;6MM=VL-V/["U'[CIYBI(JL.A5E 5L8PW.
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M,$=JZ*HX((;6WCM[>)(H8U"I'&H55 Z  =!4E !1110 4444 %%%% !1110
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M)-J,'P]UV72MXO5M&*&/[P'\1'N%W&@#=@U"RNKB6WM[RWFFB_UD<<JLR?4
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M==C*5"A<$G=GGCBND;Q!HZZ=<ZC_ &I9M9VP)GG2966/ZD'@^U0:5XHTG5M
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M[E98;>W ?:S#(W95CL4D9W Y%9=_+97'PQ\?QM<VUS)'X@:5&7;T:2#YU Z
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MLUO%;RZ?:200_P"JC:%2J?08P/PH XJ'3M/N/C7J@EM+>3_B2P2%7C!&XRR
ML1ZXP,]<&N5TZ6*W^$OA.Y-[!#'9:]O6*>4(DX6XFQ'N/"X7YAGCY![5Z_\
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M\*H4;F8LV . ,L< =.E7J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L
M^[US2=/N1;7FI6EO/Y;2^7+,JL$ R6P3T'K6A7!>(FM#\7O!ZRF$R"UO3AL9
MSB/;^/!Q]#0!T+>,_#":?#?MK^G+:3.8XY3<*%9AU'7MD9],UHWNIV.G0K->
M744,;_=+-][C/'KQSQ7EMN=._P"$?^*Y!M<FXNLD%>0;=<?^/9_'--AURVTG
M5/"5[JVI366DW7AV*W@OD8>6EP-K.K,00NY0O/\ LT >H#7-+;3X+]-0MWM)
MSB&5) RR'GA<=3P>!Z'TI!KFE-81WR:A;O:R.8XY4<,'8$@JN.I!4\#T/I7G
MQTK1Q8Z:/#&NRZ9<R7]Q=:;>7&)(;F0J!(NUL91LG&,?=8CMED5S<Z]H^EF6
M^M_#WB&VU*[6UN(0)+6YF4L),!OO*^YCZY!^E 'HG]NZ2=/2_&HVQM'?RDF$
M@*L^2-H/=L@C YR*?;:OIUY8R7UM?6\EK&6$DRR#:A7[P8]B.^>E>9KXG0V.
M@G6K#3K&^&M7,(U$NWV.*5%??,O(SOW,H#'&XD]L5E>;8W?@GXDV<FK%3_:C
M7'G% 2RXA*LRJ -KL,9P 1D]C0!ZW#XCT6>Y6VCU6S^T-@K$TP5V!Z$*>2#V
M(ZU0T_6].L]/U+4+WQ19WEFM[(!<,\:);# (AW X8KZGDYKG=$U#2?$GCZUU
MH:SHK7,.FM:K9VEZLSR,6#LW0':N..,\DG%<K?7%HWPL^):K+"1_;=WM 8=2
MT>,?7M0!Z[::_H]_J<^FVFIVD]] NZ6WCE5G0=.0/?\ *FW'B+1K.9HKG5+2
M%E?RV\R4*%?&=I)X#8YQUQ7'ZA+8P_$SP,ML]NBM8WB*(R "NR,J..W7'XUR
M@NM&N] U3PE<>(](MXVUN27[5=W0BN$5;@2-F-A]_<"H.<$'/'2@#VN*6.XA
M2:&1)(I%#(Z,"K ]"".HJA?>(-(TR8Q7VI6UO(H5F$D@&P,< M_=!/ )QFM"
M/88U,>W9@;=O3';%>0^,]6T^9/B#8Q20Z?=K: 31GYI[]A!E6 ;($87CY1G@
MDE: /3[S7]'T^X:WO-4LX)EB,S1RSJK!!U8@G@<CFGVFLZ9?Z7_:EKJ%M-8;
M2QN4E!C '4EN@Q@Y]*\\M+O3;[X@^"9EFMILZ),5;(/S#RP"/?AL?0USUQ>"
MW\-ZW/"1+IMKXW,VHI%\P%J'5F) _AW '\Z .\A\327OQ1M-,LM5CGTV33)9
MY+=%7*2!T"DG&[D,<=J[4D*"20 .23VKSIM9T>_^,VC7%EJ%G<++HT\8DAE5
M@Q,B,JY!ZXR<5VVO?9?^$=U/[<9!9_9)?/,?WA'L.['OC- "V>MZ7J%Q]GL[
M^":;R_-"(X)*9 W =UR1STIL6OZ1-?+91ZE:M<N65(Q*,N5^\%]2.X'2O.+:
M7Q#:F?0H+ZTUPS:'<MH^K6X"SQ#"A4DP=O)V8;N5^N(;V:VUOX/>'++271=:
MAELHK:%3B6"YC=5DRO52H$A)/;)H ].U#7=)TI]E_J-M;-@,1+(%V@G )]!G
MC)XJM<74;>*+""/7H8F\F1FTP!&:X!QA\_> 7GIP<UQ%CKFB6&O>--!\7RQ0
MRWMX98UN<@75J\:HBIW;&TC YR>.<U<NWLX/B?X*ABC6UQI=TBV[D!XQMCVH
M1Z@ C\#0!V7_  D&C_;UL?[2M?M+2&%8_,&3(!DH/]K_ &>M8NG:IJ+_ !-U
MC29[OS+&&P@N(8O+4>6SLX/(&3]T=37G-[KVE76B:)<6]S;:?;P>*8I9--#9
M>V N&WR3LV2I)RW\*@-CFNWTJZMY?C-K2I,A9M'M<+GG[[GIUZ$?G0!VUS<P
M6=N]Q<S1P01C+R2L%51ZDG@5F1>*_#\]W;VD6M6#W%S'YL,8G7=(F,Y STQS
M].:F\0M&GAK5&F*B,6DNXN>/NGK7E3_V:?AM\,5?[+M.I6&\';@Y1@^?Z_K0
M!ZOI>NZ3K8F.E:E:WH@;9+]GE#[#VSBDM=?TB]OOL5MJ5K+=;2XB20%F4<$C
MU ]17G6N^=<>-/'%II$B_P!H3>&XQ&D3#>T@\P<8_BP0/Q%3Z%J/A;Q0V@7-
MEJ-S=:S8H3;698*UFVS:XD4*,*,8YX/ &<B@#5^)'BT:-X4U"32=9@MM4MV1
M54!'.XLN4P<C=M)..O>NB>Y1O%D%NNNQ*RVKE]* 0N_*XE)^\ .GH<UX_<ZU
MITG[/]]I=[<Q)KEO(5O+69@)Q/\ :0S,5/))^]G_  KNKF\LY?C-HTD-Q"_F
M:)/M*.#OS(A&/7(!Q0!UB>(-'DOUL4U*U:Y9VC6,2#+.OWE'JP[@<BM*O#&U
M[2;K1O!]S;75M8VD/B-'.FHV39J6FR9F;+!B23_"/F( .,U[D"&4$=",\B@#
M.?Q!H\=\+)]2M5N6E\D1F09\S&=G^]C^'K3M0US2M).-0U"WMCMWD2R!<+G&
MX^@SW/%>.ZUKFEW7A]Y+>XM]/2#Q,DDNGALRHPN1OFF+9*Y/(QM R!DUT5GX
MAT2P\5^+],\57$,":FT<UN]UE4NK1H0@1#WQ\PVCG+'WH ]$O-6T_3X8Y;N\
MAB209C+./G&,\>O'/%(=8TT:='J/V^V-E+CRYQ*"CYZ;3WSVQ7GT>M:=X5^(
M5J=5']EZ1<Z'#!IDES\D<.QB6B)/W6(*$Y_N@>E,N9-.TCQ!X(O+"W%IX52:
M[C1R"L:32+^[D.>@8EPI/][T(H []?$&C-ITNH#5+3['$Q26<S*%C8=0Q/W2
M/0U*=8TQ;FTMSJ%J)[Q=]M&95W3+C.4&?F&.>.U>;:U92W6J_$6ZTP>98SZ$
M(I?*Y66Z$;\#'5@FT'_>%1'7](N]0^&+6^HVTJQ%EE9) 5C8VI4*QZ*V>,'F
M@#T";QCX:MTWS:_IJ)YQM]QN4QY@ )7.>HW#/IFH]0\8:3IOB6RT*>ZB2ZN8
MWE.YPH11C&2>Y)&!7G6=.;P9\5W!MB[7MX,Y7)_<KM_\>SCWS6J-1M;;QEX$
MO+FZC2&;19HTE9N'<B+Y0>['T')H []M<TI+T6;:A;BX:3RA&7&2_P#<'JW?
M'6J5KK$EOXIE\/WSAY)+?[79S8 ,D8;:Z''&Y21R.H8=P2>'CN;K1]8AETN^
MMM8T&]UUHI=.F %S8W+3-O:-AU ?<Q!_A]B36UXB1Y?B[X,,/_+"UOY;C':,
MHBC/MN(H [NL?Q#<I!!:(==BTB22ZB"NX0F?YAF(!N[=..1FI]$U[2_$>GB_
MTB]CN[7>4\R/.-PZCGFN6^*<L$6B:.TSQH1K=D07('24$G\J .EO/$^A:?)<
M1WFL6,#VRAIE>=08P3@;AGC/;UJR-6TXZ:FI"^MS8R*&2X$@V,#TP>ASVKC+
M5[%OC;J;,UN771(<$E<@^8^?T(S[&N+T'5HM(\)> ]5N'W:'9:G>I>,GS+ S
MM*L+L!T W=>V1[4 >C^*_$6? 6MZKX?U2+[18P2,)8PLFQU&2K*<X/L16OIV
MLV<D6GVEQ?0?VC<6RRB!I%$C_*"S!>I'TKC/%-WX>N_ /C74=%,#K=6C?:+V
M)LQW$NPJ &Z$@8''KZYJ/4=0LK'Q1\.]2NKN""Q^Q749N9) L89H8]H+'@9P
M<?2@#T"UU?3;V&XFM;^VFBMF*3O'*K")@,D,0>"!SS7)S^*C<?$C0M.T[5XI
MM/NK6YDGMT53RBJ4;=C.#N..QQWKA-0U$2^'_'$EFQG@3Q'%<WD48.][3$6\
M[>I4[?H1GM75:AKNB:C\5/!MS8ZE93I):7B>9%*I!W+&54GUZX'6@#J-/UK3
M[2QU._O/%%G>6:7K@3L\:):C (AW X)7U//-7[3Q!H]]J<NFVFIVD]]"NZ2W
MCF5G4>I Y[C\Z\EN[BS;X9_$]5EA(_MF[*@,.I$>,?4@UTU]+8P_$/X?K;O;
MHK6=XBB,@ J8T*CCMG.* .TNO$.CV4S176IVL#(P1_,E"A&(R%8G@$CD \U>
M@GAN8$G@E26)QN22-@RL/4$=:\7NKG2+C2_%7A&X\1:1;)=ZU)(;F\NA%-$#
M(KO\C#D@J0IR >#QW]H@,301M"RM$5!1D((([$8H S;[Q1H.F-<+?:S86[6X
M!F62=08\G R,\9[5(_B'1H[:TN'U6R$-XP6V<SKB8DX 0Y^;\*XZ,:8/C7JP
MO1:AVT6!D\X+S\\@8C/MC/M7'?8K6P\(Z-'/Y2:7/XU66P24@+]D,C;2 ?X2
M,GZ-GO0![!%XET2XT]+^#5;26U>0Q)+'*&#N.JC'4\'@4K^(]$BTI=4DU>Q3
M3V;:+EIU$>[.,;B<9SQBN3U&2+1?BUHT]RD5OI%SIL\%M)@+&MVTBNV3T#,B
M\'OS4&C:!#K>J_$&V.&T'5)HXXBG*&;R<3.G;.\CG^\I]* .[?5-/B-J)+VW
M4W9Q;[I /-.,_+Z\<\51T.\BFAU*X&OP:I MY(1(FP+:K@'RB5X.T<Y///-<
M[X!N=0U>VA;5XG6YT-'TZ0N.);A3M>0>OR*F#_TT<5Q=W.Y\!^.VL?W\4?BB
M22[B@^9FM]\1DX'8@'/MF@#M[KQ4;CXC>'=.TS5X9K"[AN7N+>,*<[$!1MV,
MX.3@C@XK7L-9T^UM=5O[OQ19W=E'>,/-9XT2T&U3Y)8'!(ZY//-<MJ>OZ'J7
MQ.\#W5AJ5E/&\%ZHDBE4_>C3:I]">< \U@W-Q9GX?_%11+ 1_:ET0 PZF.,#
M\R#^- 'JUKXAT:^U*33;35+2>^C3>]O',K.J^I'7N/SHN?$.C64S176IVD+(
MX1_,E"A6(R%)/ ;'.#SBN'NY;&'QM\-Q;O;HIM;M5"$ %3 N!QVS^M<Y<7.C
MW6C^)?"-QXCTFV2YUJ20W5Y="*:(>:KO\C#E@RD*<@'@\=P#VF&>*YA2:"5)
M8G&Y'1@RL/4$=:I7^OZ1I<ICO]1MK=PH=A)(!L4G 9O[H)XR>*O1&-H4:$J8
MBH*%.A';&.U>4^,-6T][KQ]IZ20Z==KIBK*&^:?4#Y#%=BMD!%!P=H)ZG*XS
M0!UGB#5=0L_&_A*TM;S;8:A+<)<0A%/F;(6=3NQD<XZ>E+X=U34;GQUXMTR[
MN_/M;$VAMD\M5\L21LS#(&3SCKZ5R_\ :5G/J7PJD2[B=3'*-V\8)^R[?_0N
M/KQ6UX7N(7^*?CI%E1G_ - ^4,">(6!_*@#L-2FCM]-N99+V.R41M_I,A4+$
M<8#'=QP?6LZRUK3K+2M+2^U^TN9KF!3%<NZ1F[^7)D50<8(!/' J;Q.T:^%-
M7,Q41_8IMQ<\?<->9++8R^&_A*LSV[CS8 0Y!Z6S ]?1L#ZT >G6GB71+_3Y
M[^TU:RGM(&V2S1S*41O0G/'4?G7)^%?$%WXETZP\2CQ)!;VR^9)J&GNL9CCB
M)8)\W#(PP#DD@\\=J=X=NK2'XE^/?W\**$L7?YP ,1,&)_3-<?873I\%/!EY
M$WFV%CJ=O-J:Q_-M@69RQ8#L&VDCVH ]>M=<TJ]%P;;4+>3[.,S 2 &,$9!8
M'H,=S50>,O#+%<>(-,^:-I@?M28**Q4MG/3((S[5SU\(;[XK:%J.F3PR0PZ;
M<_VE-&X*>2VWR0Q''+;F'T)KG/#$6EGX 7]P$M#*ECJ*F7"[E+-)QGMD!?TH
M ](C\5:!->+9QZS8-<M#YXB$Z[C'MW;L9Z;>?IS4VG:_H^K6D]WI^IVES;P$
MB66*966,@9.X]N.:\UO/[-.E?"L'[+M\^$X.W&#;G/\ X]C/OBC5=2TZQU[X
MH27-JM_;BPLC+9QR;3+^[=6R5Y&,C)'(% 'I%MXBT>\\[[/J5M(88O.D D&5
MC[/_ +OOTK"B\9:5XC\&WFHV.OV^D F2-;N5D)@Q(R*Y5\#Y@F0#ZUSFD:K9
MR_%K2IAK%K>"?09(8WM@!#N\Z,B./&2< $D$DCDG%8UO?63?LZZO8M<0FZMH
M[M)H2PW1.;B0J&'8GJ >: /7I]3LM.M8'O;Z)?, ".Y ,IQDD =>.>*CD\0Z
M-%ID>I2:K9+8RG$=P9UV.>F <X)SV%<9;WXL_BAIMQ?3(NGWN@K#I\[,/+,H
M<,Z ]-Q7:?<*/2N4\0V\<'@CQW<!HQI-WK=N]EDC:[>;#YK)Z@L&Z?W30!Z_
M8Z]I&IWMS96.I6ES=6W^NBBE5FC[<@>_%6[N[@L;26ZNI5B@B4N[MT4"N(FD
MLX?C1I*0/ F[0ID"H0,CS4*C ]LD?C7<72EK295&28V  ^E 'G^L^.'U+P?I
M>N>']06 3:C;12Q@([>7)*%PV0=I*\^O-=IIVO:1J\MS%IVIVEW);';,L$JN
M8S[XZ=#^1KQ]=1TZX^!OABU-U;N8KVRBGC+ [2)AN5AZ@ DCT^M=-JM[8V7Q
M2U:0QK/$OA-GDMH6&Z8+*QVC'?;P/K0!W-IXAT>^N?L]KJ=K+*4,BJDH.Y <
M%E]0.Y'%4_#OB[2O$TM_'I]Q&YM+AX<;OF<*%R^WKMW$@'OCWKSC3=9TZ;Q-
M\.+F'4;3[,+>YB2VMCF.US H2'<<LS] 03DD#Y1FNI^'%Y;"Y\5:>9D^V)K]
M[*T&?G5"XPQ'8'/![T =EJ.IV&D6C7>HWD%I;KP99Y BY],GO5,>*- -U=VO
M]LV'GV:&2X0W"YB4'!+<\ '@^E<]\7FB7X6:YYK(,Q(%W'J=ZXQ[U3UK^S3\
M4O!"I]EQ]DO-@&W&-L93'XYQ^.* .RM=?T>]TEM5MM3M)=/3.^Y69?+7'7+=
M!CWIJ>(]&DMKJX&J6HBM,?:6>4+Y.>F_/W<^]>6R:KI=AIGCHW,$%W;'Q'%E
M&D(CC9O)Q*Y4YVJPR?4C'>MGPW>65Y\4]>@DU*#41>Z7;8957RY@#(&V <%1
MG&<MUP230!WAUS21IL6HG4K3[#*0L=SYR^6Y)P &S@Y/ J^>0<'![&O-?"EI
M?0:O_P (7=12-8Z!<_:XIVY$L#<VR$]RK%_QA%>ET <%X9\:V]N-7@\3:_:1
MSQZW<V=J;AXX2T:;0  ,>O7WKL;_ %6PTN)9+Z[A@5LE=[8W8Y.!WQ7F%@NB
M'P]\1+74TMFN)=6O087 ,S[@/*VK]XDL?EQWZ5%97LGA/7=#M_%FI7&G12^'
M[>VBNRP$:SQEC)&S$$ X*G/?:/:@#UJUN[>^M8[JTGCGMY5W1RQ,&5AZ@C@U
M-7/>#+'2;#P\D6AB8Z:TKR0O*Q.\,<EES_"3G'8]1P170T %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %,:&)G#M$A<=&*C-/K,OO$6C:9=_9+W5+2"X\
MLR^5)* P0=6(["@"]]EMP"!!%@]?D'-$EK;RP>1)!$\7_/-D!7\JIV6OZ3J.
MDG5;34+>6P7=NG#@*N.N2>F/>EL-=TS4Y;B*TO(Y);;'G1'*O&#R"RG! /8]
M#0!;EMH)XO*E@CDCQC8Z C'TI'M+:6$0R6\3Q 8",@*@>F*I6?B'2+^]%G:W
M\,EPT?FH@./,3^\F?OK[KD4@\1Z.=1CT_P#M"'[3*S)&I.!(R_>56Z,P[@'(
MH T#;P-$L1AC,:XVH5&!CI@5D^)-'N]6TIH--NXK*Y\^.8M)#O2;80=D@!!*
MG !P>GY58;7]+6]6T-X@F:7R%&#M:3^X&Q@L.XSD4-K^EI>+:->()FE\A1@[
M3)_<#8P6]LY% &18^';ZXO;:YUF'18VMI/-C&GVS!F< @$NQR!ST Y]<9!Z3
M[+;X(\B+![;!6?-XDT:"]^R2ZA"LOG"W.2=HE/(C+?=#G(^4G/(J'4?&'AW2
M9IX;_6K*"6W4-*CRC* G R.V?2@#6-M"1\L4:L!\K!!E?I7&:?X6\0VULNG7
MD^@WUNN1]MGL6:X<$DDLI;:6.3SG&><5TVGZ_I6JM<KI]]%<FV.V<1'=Y9]#
MZ'VJS97]KJ5FEY9SI-;2#*2H?E8>H- "V%E#ING6UC;@B"VB6&,'KM4 #]!4
MC00LY=HD+LNPL5&2OI]*PO#_ (QTSQ%<ZI%:2X%C<M!E@1O"JA9^>@W,1^&>
M]7K/Q#I%_=K:6U_%).Z&2-,X\U!U9,_?7W7(H O_ &>#(/DQY& #M'&*%@A0
M,%B10PP0% S2S31V\+S32)'%&I9W=L*H'4DGH*S(?$^B3FZ"ZG;HUJ@DG$K>
M68T/1R&Q\I_O=* -&&UM[< 0P11!1M&Q N!G..*D(# @@$'@@]ZQ;;QAX=O+
MVTL[?6;.2XNUWP1K(,R#&>/?'..N*LSZ_I=M=_9IKQ$E\U(3P=HD;&U"V,!C
MD87.>10!=AMK>W+F""*(N<N40+N/J<=:%MK=)WG2")9G&&D" ,WU/4U277]*
M=;XK?1'[!@78SS!D9&X=1QS]*AF\5^'[>.TDFUFR1;N(S6Y:8#S(PI8N/]G
M)STH U'MX998Y9(8WDCY1V4$K]#VI3#$T@=HT+CHQ49K+_X2G1#IL&HIJ,,E
MK<(9(I(\OO4?>8  G [G''>M&TO+:_M(KNSGCGMY5#1RQ,&5AZ@B@!?L\'S?
MN8_G8,WRCDCH3[TX0Q"3S!&@?^]M&?SKDV\96>L?\)%I^EW;P76G(RI,$!)<
M)N)4,""!P.>O..QIG@OQA8:AH'A^TU#5X)-<O+*.5HF<!Y&*!CP.,XYQZ4 =
MBR*ZE74,IZ@C(J/[+;D >1%@=!L%9]SXDT:SNS;7&H0QR+(L+Y)VI(V-J,W1
M6.1@$@G(JH?&&FCQE_PC7F?Z4MOYSL0< E@JJ..2><^F!^ !N"")7WK$@?\
MO!1FDCMX(I))(X8TDD.795 +'W/>LGQ7XGLO">B2:C>9/S+'&@!^=V. /89/
M)K!U/Q,;/Q[HQ.KA-#N;"YFE1PJQAD* '=C=_$>,]: .S:SMFE:5K>$R. &<
MH,G'(R?;%/,,1D\PQH7_ +VT9_.J-GKVDZAI']JVNH6\M@,YN XVC!P<D],'
MUIVG:WINJRSQ65VDLUN0)HL%7CSR-RG!&>QQS0!:%O ,XAC&7WGY1RWK]?>I
M:Y7Q7XEN=.U71O#^E"(ZMJ\K+')*NY((D&Z20@$9('09&3]*GU#3O$%I9+-I
MVN3W<Z2(9(KJ"$B1-PWA=B*5;;G'4>W< &\;> ER88_G(+_*/F(Z$^M+);PS
M/&\L,;O&<HS*"5/J/2J.H:_I6E.R7M['"R()),Y/EH>C/C[J\'DX'!HNO$&C
MV,EM'=:I:1/=*7@5YE!D4 L6'^S@$YZ4 7IK>&Y0)/#'*H.0KJ&&?7FG211S
M1M'(BNC#!5AD$?2L'_A.?"_V"6^_MRS^SQ2&)VW\JX&<8Z].>G3FKEQXET.U
M6U:XU>RC%W&9;<M.H\Q I8L.>5P"<]* -&**."-8XHUCC4854& /PID=K;P[
M?*MXDVDE=J 8)ZX^M9^F^*-"UC3[B_T_5K2>TML^?*L@VQ8&3NSTXYYIUKXC
MT>\>9(K^(/!$)I%DS&5C/1\-CY3_ 'NE %_[+;@$>1%@]?D%.\F(! (DPARO
MRCY3[>E8L/C/PU<3V<,.MV4DEZ=ML%E!\PY(P/J00/7'&:O6NMZ9>ZE<Z=;7
ML4MY:_Z^!3EHL]-P[9[>M %E;2V6X-PMO$)B,>8$&['UZU3M-)6+5;G59V62
M^GC6$,!\L42DD(OXDDGN?0  6;'4+34H6FLYUFC5VC9EZ!E.&'U!X/O6;97M
MK+XDU81Z^ESY$40EL 4VV9&[+$CD%L=">,4 7=,TN#2X95B +SRF:5@H4,Y
M' '  "J /0#J>:MR11RX\R-'QTW#.*I66N:;J%S]FM;I9)C'YRIM*EH\@;QD
M<KDCD<&IK[4K/38T>\G6(2.(XP<EI&/\*J.6/!X'I0!+]F@SGR8\GC.T4OV>
M#RFC\F/RWX9=HP?J*XOQQXD<>!)M9\/:ML:&ZAB9X0K9S,B.C!@2I&X^A!KH
M=-\3Z%K=Y<V.F:O:W-U;C]Y'#(&9>V?<9[\B@#3%O"L*PB&,1+PJ!1M'T%(]
MM;R1K&\$31J=RJR @'U KE/!&LW5QI&N3ZSJ'FBRU>[M_M$VU L4;;1G  '
MKH-/US3=5GG@L[M))[?'FQ$%70'H2IP0#V/0T 7EC1 P5%7<26P,9/J:CBM+
M:#;Y-O%'MSC8@&,]>GK@5C:]XNT[P_J>E:?=/B?4)2B\'"*%9BQ./;&.^?8U
M=OO$&DZ:2+R]CBQ&)6ZG8A_C;'W5X/)P.* +OV6WP1Y$6#VV"C[- ""(8\CH
M=HXIT4L<\22Q2+)&ZAD=#D,#T(/<5FW'B31K2[-K/J$,<JRK"V2=J2-C:C-T
M5CD8!()R* .=L?#'B*U1K*XN-!O[?>["\N[)FN&#,6.Y=VUCSUR![5UNFV$.
ME:9:V%N"(;>)8DSCH!CMQ^50ZCK>FZ3_ ,?UVD1V&0K@L0@ZL0,D*.Y/ ITV
ML:=!9P7;WD1@N,>0R'?YV1D; N2W'/&>* ,./PU<OX]OM;NX[*:QN;2.V6)B
M6=2C,P;!7'.[IV]373O#%)C?$C8Z;E!Q5*'7=*N-+&I0W\#V9;:)5?(W9QM_
MWL\8ZYXIEOXBTB[LKB[AU"%H;9_+G).#$_\ =93R#R.",G(H ORP0SPF&:))
M(CU1U!!_ TY$6-%1%"JHP%48 %4(M>TN6"YF%XBI:D"?S 4,1/0," 03D8'7
MD>M2V.JV6I/,EK.'D@($J%2K1DC(#*0"#CGF@"V%5<X4#)R<#J::D,4>=D2+
MGKM4#-4]0UK3M+=4O+I8Y&1I!& 68HOWFV@$[1D9/09J&7Q+H<$5G++J]DJ7
MH!MF,RXE&,Y7GD8[]* +\5I;08\FWBCVYQL0#&>O3UP/RI?LMO@CR(L'J-@J
MGI6OZ3KD4\FEZA!=) ^R4QMG8>O-<GKWBM7\3^%+?2-8)AO+XQSPH@V3Q[&.
MY6*Y8 @#*G'- '<?9H,@^3'D=#L'%<98>%_$5K%]AN;C0;^WW,?MMU8LUPP9
MB277=M9N>N0/:NVDD2&)Y975(T4LSL<!0.I)["J%CKVEZE=O:VE[')<)&)3%
MRK%"<!P#U4_WAQ0!/IUA#I>F6MA;@B&VB6),XSA1@=/I4[0Q-)YC1(7*[=Q4
M9QZ9]*SHO$>CSWL=G'J$+32EEB&<"4K]X(W1B.X!.,57N_&?ANQ-T+G6[)#:
M,J3CS03&QR0#CO@$X[8YH V#;P';F&/Y0 ORC@>@I5AB1RZQHK'JP4 US^K^
M--)TB]T:V>=9#JK_ +ITY01["V_(XP< #US[&IKCQGX:M9Y()]<L4ECDCB=#
M,,J[YVJ?0G!X_.@#<9%=2KJ&4]01D5']EM\ >1%@=/D%4+SQ'H]A.T-WJ$,3
M(RI(6/RQLWW0[=%)R, D9R*QM=U'4+3XB>$[*"]D6QOQ=BXM]J[6,<6Y3G&[
MJ?7' H ZC[-!DGR8\MU^4<TY(8HP0D:*#U 4#--N;F"SMI+BYE2*&,99W. !
M6:_B?18K:YN);^.**UV_:#*K)Y.[IO! *YQWH THK6W@B,4,$4<9Y*(@ /X"
ME%O"$*"&,*>HVC!JLVL:<FH6U@UY$MU=(7@B)P95 R2OK@<\5!/XCT>VO5M)
MM0A29I1" Q^42'D(6Z!CV4G/M0!?^S6Y !@BP.GR#BE$$(8L(HP6SD[1S7#6
M?BQ-(\9>+8-?UM4T^S:T^RB<*NS?&S,!M )Y^IP.:[F":*Y@CG@D26&10Z.A
MRK*1D$'N"* !((8]FR*-=@VIM4#:/0>E!@A(8&*,AFW$;1R?7ZUG3>)-&M[S
M[)-J$*2^<L!R3M64]$+?=#'(PI.>14NI:[IFD9^W7D<)"&1@<DJ@ZN0,X7_:
M/% %N2UMYH?)E@B>+^XR K^5.:&)D5&B0JO12HP*JSZQI]M:P7,EW&8K@ P%
M#O,N1GY N2W'/&>.:9%KNE3Z2-4BU"W:P/ G$@VYSC&?7/&.N>.M %P6\(8,
M(8PPZ':,BI*S(/$&E7,%U-%>QE;3_CY4@AX>,_.I&5XYY'2C_A(=(\FPF_M&
MW\K4&5+23=\LS-T"GH2?2@"\;: C!AC(R3C:.IZFE$$*N'6*,,.A"C-8UWXS
M\-6/VG[1K=DAM6"3CS0=C')P<=\ _3O4.K^--)TC4=&LY)U<ZHQ,<B<H(PC/
MOR.,'  ]<^U &\EO!&%"0QJ$)*@*!@GJ13UC169E10S?>(')^M9]QX@TJUN/
M(FO$1]Z1DX)57?&U2V,!CD8!.3D5I4 ->-)1B1%<=<,,TS[/!D'R8\CH=HXJ
M6B@"+[-;[67R(MK###8,$>AJOJ-O='3K@:4UM;WYBV02S1[D4]L@8.*NT4 9
M.A:9=V,$T^IW,5UJ=TP>XEBC*(,*%544DD* .YZDGO6M110!$UM;M<+<-!&9
ME&%D*#<!['K2SV\-S'Y<\,<J9SMD4,,_0U)10  8&!THHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *X'Q!<60^,'A))I8/,2TO,*[#*L1'MZ]S@X_
M&N^HH \1DO -#\57-BS7-O9>+Q>W<5H^7-NOEEF4#T(W9_V3Z5IZRFB>*-!U
M_4O!]Q=ZGJTFD-;/<K+(P\O<&\G!XWL-V!C(]LC/K=-1$C7:BJHZX48H X;3
M?$?ASQA'8S:)''-K$%K(L1$9#Z?NCP0QQ\O("X[]N 37,^%+SPQK.B:#HFI-
MJ#:_I<L(.EO+(KPW$7'F8' 4<MGI@^O%>OJB(6*JJECDX&,F@(@<N%7>1@MC
MDB@#RJ&ZFTG789-$U.#5='O=;:*XTBX -Q9SM,V^2(CG ;<Y!&-O/?-"74VD
MZZLNB:G!JNDWFN-%=:-< &>TG,QWR1$<X# O@C&WGOFO5?+0/OV+OQC=CG%'
MEIYF_8N_&-V.<4 >'^)M<T^Z\-Z^D4L>GO;:\C3:=&F7)%Q'NGF)!(#8R"-J
M]!DFNN@NM+O_ (V7 ,EM,9/#T2*KX).9F)7![[2#CTKT/:O/RCGKQUI: /.O
M$=OJ7A_QIY^CQ/Y7B>(6,K(/^/>Z4'9/_P!^]^?^N8KO[.UAL;*"SMD"001K
M%&H_A51@#\A6+IVC:M_;4E_K6J0WD<+R?8(8K?RQ"K=V.3N8+\H/'!;KGCH*
M /&KC[3=^$_B9H>FLQUF35;B=;5 ?,:$B+)QZ,H8#UZ"MW6[VR\5OX(F\/SQ
M2746IPW)$3#=!;*C><' ^Z,80@XY(%>D8&<XYIJQHA8JBJ6.6(&,GWH Y3XE
M)>'P1<RV<,TY@F@GEAA^_)$DJLX'_ 0:Q++4?!NMW$^O:7?3WUU#ITL<MU+-
M)MMXF&=C[L $MT4\\$]J](IJ(D8(154$Y.!CF@#Q6WO-/A^&?PTQ<6R%-7LB
MV'4;2-V\GTZ\_7FM74KN;2=7O=1T'4[?4+275D6_T"Z ,@F\Q5WP$<@\*X!R
M.">V*]7IOEIO#[%W@8#8Y% 'F+ZI9:5XR^(5K?7"PW%[!;R6L+??G46Q4E!U
M;!!!QTQS6/IM_IK67PC6:YM_W2L&$C ;6%N0.O\ MX ]\5[,8T9MS(I.,9([
M>E. P,"@#S/6]3T_PS\2)6UVYGT[2KW3H8[*ZB9HX5>-Y"\9*]"=X:NN\'V.
MEZ?X;@@T2":'32[O )F8EE9B=PW<@$DD>QSWK<=$D7:ZJPSG##-.H \RL=2L
M['7_ (C6EW<1PSO()E20X)C^S*-_^[GC/3.!U(K$BO-/A\ ?"[;<VR,FI6A;
M#J-O[MP^?3D\^YYKVC SG'-% 'AWC#6K"[\,>,[:&2/3YK?55,NGQIF2<K+%
MFXD)!(5@ 05VC@9)SBNQ74[./XSQS/.%CO\ 0(DM6(/[YOM#G"^O!!^G/3FN
M_P!JG/RCGKQUI<#.<<T <5\6>/AS?O@[8YK:1R!G"K/&2?H ":S]1U72K[XL
M^%)XKNVEC.GW9C;<.22@4C/K@X/<=.*]%(R,'I10!X@;T+X?\1W=FSW%K8^,
MFO+R.T?+_9@4)90/1OF_X"3VKNO"TWA;6/$4VMZ#<W&H7+6@@GO#+(R*FX,L
M9W<;NI]0!SC(SVM-1$C7:BJJ^BC H \]\<VTVD>./#/C(PR2Z=8B6UO_ "U+
M&&.12%DP.=H).?:NMB\3Z/=I'_9VH6U_++CRXK699&;/?@\#U)X%:],CABBW
M>7&B;CD[5 R: //M U&VTGQ3XSL/$<\-O)<W?VN)KE@JSVIC55"D_>"[2"!T
M)KF--MSH^D_#&RUATBF34)I%BN6 :.)ED,8(/(P"@]C@=J]I:-'*ED5BIRI(
MS@^U.H \WTF[TQ?B-\07DN+0?Z/:!F9UZ")@_/UV@_AFN7TB[L#X7^%,MU-
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ML%GK$5O+83SH?+N(!%M:,<=0Q;Y>^X^M>F[5Y^4<]>.M(R(Y4LH8J<C(S@T
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *P/%OBFW\)Z;;74ZH6NKN.SB\R3RXU=R?F=L':H
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2D\/7%]*D,L(@DF1%WLH],\ \>E7=#TH:'H=EI23O/'9PK!&[@!BJ@ 9QQG
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C 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>thackray-biocrystseparat006.jpg
<TEXT>
begin 644 thackray-biocrystseparat006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6NK:;<Z??0K-:W,9CEC;NI% &;KFJ:A:W&F6NDI:SW5Y*0R3%@%B RTN1V'
M]RRC(K9,@BC7SI$#' )^Z"?;->??"&%W\.W,]S<RW4]M<R:=%+*02L$+$(H_
M,D^O'H*FTQ8-<^(_B[3M;MHK@6T-LEI!<(&46[H2Y4'U?.2/0#L* .]R <9I
M<@]#7B=F)_[ \(-=L95M/%QM+.YEY=K96E5!N/)&1C\!79>'Q OQ<\7+!Y8S
M:61<)C[W[S.<=^E '=4TR()!&74.1D*3R?PIU>5^&X]$\3^"YKS79_*U>VU*
M22\G1PMS#.DQV(#U'R[5"CMP.: /4GD1"H=U4L<#)QDTI8#&2!DX&>]>?:%!
M:>)?$?C:SU^VBN)X+M;=(YE!\NU,8V%<_=!.YLCOSVKE-,AFU;2?AI+K!>XG
M>]N(/.=B'F@"2A,GJ05"_4'WH ]J\V,QF0.I09R0<CBN'M=>\7>(-$L=:\/K
MHBV=ZKMY=\LBM H)VL65CNR!R,#!(Y.*J^&M+T^W\3^/=%BLK==+CDM9$L_+
M'DJS0!F(3H,D _45R<FFV"?LR+<I:0).]I%(\J(%9F$P )(Y)P2.?4T >WLZ
MH,NRKQDY./K2-+&@)9U  R23T'K7GGB#0]-U?XN:;;7]JDT%QHMQYT;$XDQ)
M&!N]<9_, ]J@TCPOH<_Q$\6:9-IL$MC'8V 6WD&Y!\D@S@\9 '!ZC\: /2RZ
M!E4NNYONC/)^E.KPRSL+5/A)X1UWR@=6BU"U2.]8DRJ@N-FP,>0NWC;T]J]S
MH :\B1)ND=44=V.!2EE !+#!Z'-<=XB-E>>-])L/+%QJ*6<\R17+#[-'&2JM
M(RX)9^P QP6R17GUK##=_#+P>LCB1HO$T<*/&Y4K']JD4!2#D# &.>,#TH ]
MQ5U?.U@VTX.#G!KFO%GB*\T2XT1+);61;W5(+&X$A)9%D)Y4 ]< ]?6N/U!?
M^$3\5>,O^$=M8[8KX<2\6"! %,P:4!]HX)P/QJ+4[/1V\+_#G4K..%Y9-7L#
M]J&#)(6!+[FZDEADY[B@#URFR21Q+ND=4&<98XIU</KRZ??^.OL1CCN+Z+2'
M>5;T@VT$#28+A,99R5QU VCD],@';E@JEF("@9)-"NKH'1@RGD$'(->.Z//<
M3_#;X?3/.+F*.\07%FT@W7"CS H )PVS ;:>R>PK3G\+I#IWC_5YK&."TO;:
M1K*$XW(%A^=L X7<XW8Z\9.": /3ED1S\KJW /!SP>E"2)*NZ-U=<XRIR*\A
MNK+3O#WP[\,ZQ!%';'4!IL&JWC@N&@*@_O!D97=M!_V>.G%6_$5@/#>F^)-:
MT?58S=7.F!I+73X1'&$5U!G 5CA]A8 Y&0..E 'J:R([,J.K%3A@#G!]Z=7!
MZ3HVE-XBT37]/UBR'F0/#%#IUN(TNXRN?GPQR%QD'L>.]=Y0!F?VS!<WNI:=
M82Q27]C&C2*Q^5&?<5!QSG"Y(]"/6J/@CQ!/XD\'Z7JUZL,5U>1L[1Q9"C#$
M< DGH!7/>'+#3XOBAXWE%I:I-&;,Q/Y:AE+P-N*GL3SG'7FN-TK3+*V^&?@+
M68;=%U(:M:(+K_EH$:9E9-W7:03\O3VH ]R:6-'5&=0S?=4GD_2J;ZO91ZY#
MHYF!OI;=[D1@\B-6523Z9+#'K@^E>4^.6LKO0_'E[8A6DM9(TGNKM@SQS(J;
M4@  **,@[B?O%L ]:WI+33[CXQZ=<7%M:R%O#[RM(\:G,BS1@-D_Q <9ZB@#
MT:DR,XR,TM>=^*EM/!?C6Q\9FW465W&UAJ3)'EE8_-%*,=R1L)]"* /0]PP3
MD8'6D21'0.CJRGHP.17F.JVSZ,?"%G>V\<-KJ^JO-JP50$>=U9TB;U7>0 #U
MV"I-2T];/Q[KFGV-N@TN\\.O<W=JJ#RQ.'*H^WH&8 CWVY[4 >EY'J.:6O'@
MUN?!7PHD)B-Q]OLE5N-VWRGW =\9QGWQ7L- '-7>OWUM\0M/T(QVWV"ZLIK@
MR<^8&0J,=< ?-Z5T8=&0.K H1G<#QBN#\0V%KJ7Q9T"VO(5GMVTN[WQ/RK_-
M'PPZ,/8\5SFG-IMGX7U32KA9OLB^,'LK&SAD"1L?,5TA8D$"+.<C'3IS0!Z^
MDD<B!T=64_Q*<BER,=17F?A_2K74O%7C_0M0CM#:SBTWV]NN(T=X6W%0?XN!
M\W!R,X%+X) U6RT_PUJ%M$T_AB9X[P&,;2Z96 @?[2G?GU3WH ]*,B*ZH74.
MW12>33J\@L[2T\7Z#K?]K:Q:V.HVFI3FYF\@?:K0QS$QE7+9 "!0,#&,CUKU
MR'/D1[F+':,EA@GCN.U "O(D2%Y'5%'=C@5SGCC7[[PYX>74K".VD87$,3B;
M)&V214R,$<_-ZU3\1&RN_&VD6'EBXU%+2>9(;EA]FCC)56D9<$L_8 8X+9(K
M@XY=WP$BC\U7$6JHB[3P$%_A0.3@8''L* /:VD1/ONJ\9Y..*&D1&56=59N%
M!."?I7G.J^'M*UKXR2V>HV:3VT_AW?+$Q(5S]H !..I QCTP#V%9MO867BAO
M%NDZGJ%E9SVM\\/[Z &>VMU"^2\;EAM4 9! QG)[T >L/+''MWNJ[C@;CC)I
M7=8U+.P51R23@"O*=92PU!/$,4<GV^ZM- B2[NM2QMC4QNRF./ (=_O,<@ [
M>I&*-%U+^T=<\!Z9JL@ELY?#RW4:S'<L]WMC^]G[S*A9AG^]F@#L?#'B"]U?
M5?$-I>I;(NFWBP0M!GYE,:ODDGD_-VQ72Y''(YKRS1_"FEZXWQ#\/F"*.VEU
M ",(HQ"YA4AE';#'/Z5>\'W?_"5/I4&H64<=SX;5H[Q#&,+>#,:[>,8VJ[\?
MWT]* /1J:\B1@%W5<G W'&33JX#24M]?\?\ C'3]<MHKDVXMXK:"= P6V:,D
ME0?[S9R1WP.PH [XD+U(&3CFA65U#*P8'N#FO$(;:6^\+^"DU%I)UC\3M9V\
M[N=\EJ/."@MU(.T#W %>QZ3H^GZ%IZ6&EVJ6MHC,RQ)G"EB2<?B30!<) ZD"
MC(SC/-<OX_\ #/\ PDOAF5;>&-]3LV%U8LZ@XE0[@O/9L;2/?VK M]8;Q-HF
MI>,]+L\7-EI+P6"M'EUG*;Y0..<-L3ZJ_K0!Z,)$,AC#J7 R5!Y'X4NX>HKR
M/4H+<?"SPSX@T-5_MI)+)X+A/];/+(RK*KMU;<6;<#U(YZ5IVD-G%XI^)L,L
M<"6YAM79& "\VY))'3KW]: /2NM(2!U.*Y?X;'/PU\.'.?\ 0(O_ $&K'C?P
MY'XI\(ZAIA1#<-$7MG8#Y)EY0CTY !]B: .@R,XR,U2U5M1^R(=*>S6<3)O-
MWNV>7N&_&W^+&<=LUY+_ ,)%;OJOA[XA?88XK&.)-,U-EA^=977)('HCA%SU
M^8CM6QXPT6'3_ ^ER2VL45[)K-K=3[% Q+).I<<=<9VCV H ZM]>OT^(\7A\
MQ6WV*73'O%<;O,WK(J8)SC'S'M2^#]>OM=36A?QVZ26&JS6*>0#@J@7!.3U.
M36=<?\ELL/\ L 3?^CXZB\!7,%I%XQGN9HX84\1W9:21PJKQ'U)X% '=5Q?Q
M+\:7?@70;35+:TANA+=K;-'(Q7&Y6(((_P!WI[UV8(90RD$$9!'>O)OVAL?\
M(!89Z?VK%_Z+DH ]52Y@E:18YHV:(XD"L#L/OZ4HN("I831D+U(8<5Y'=:=%
MI7[1&BVNB6L5O:W&DLVH0P(%1D_>@%P..H3GZ5F:7I1\+_$?Q'X$CLPVF^(X
MUGM"$XCC)/F#V"J9 /=%]: /<E8,H92"#T(I'=(T9Y&5449+,< "DAACMX4A
MAC6.)%"HBC 4#H *\N^,.K/INK>"UNR5T.35 ]^3]P[60J']1R[8/]WVH ZC
MQYXND\*^"Y_$.GQV]ZL+H"C.=KAF"\,/0FMS3]4CN=!LM3NFBMUN+>.9MSX5
M2R@XR?K7D_Q(\.Z1X>^%GBS^R;QY5O[R"]D@,JLD)>5?N #A3@_E[4U'N+OX
MH_#O3KQ=^EKH8GAB<91YO)?<<="0 OT_&@#V<S1+"9C(@B W;RPVX]<^E$4T
M4Z;XI4D0_P 2,"*^?-$T[5O$7@CQ/HEA?+;1P>("-*68_NI&4L_D#/ 7@$ \
M9^M1:QXFU.7X3^)T_LDZ1K$6HPP:NMN-B-N 4L /N[MJAL'!SG^*@#Z'AN(;
ME"\$T<J@X)1@P!].*DK@O">CB/Q1_P )!9ZM8&QU+3(U2PLXBJ,$*[9?O'D
M[>G>N]H B:YMUN%MVGC$S#*QEQN(]AUKC_%WC>;1?$NC^'-.MX)=0U,2,))V
M_=Q!5) (!&2Q&.HQUYKQX2W%S\'O&FM:CD:^FO(3.>)8G5X@ IZKC+@ =*Z3
M7+1;WXJ_#B75+* WEY8"2^5XE_>2"/G<,<D$=^F* /8]$GU*YT:UFUBSCL]1
M9,SP12>8J-GLW?L?Q[US6O\ C6ZT3XA:!X=%K!);:JK$S%B&BV@Y]CTKM*\@
M^(=M;WGQI\"V]U$DL#K*'CD&58<\$=Q[4 >M1W,$L/G1SQO%_?5P5_.E^T0X
M4^='\WW?F'->(:':M;Z]\6--LH0NB);2%8%7]VDQ1N%'0?Q<#T'H*Y(F'_A5
MGPT&8_._MB3'3=M\]L^^.GZ4 ?3<EU;PR+'+/$CL"55G ) ZX%84NKZVOCF'
M3(],@;0S:F26^\\;TEY^7;G/IV[YSQ7EWQ)@U+0_%6L^(Q:VVN>'KF.&TU2U
M<#S;/"KMVD\I]\,&'&6Y'0UI2M%/^TGI4\<>U9]$\P@K@G(?K[XQ0!ZVUY:H
MH9KF%59@H)< $GM]:?+-%;Q-+-(D<:]7=@ /Q-?+)TRQ?X7>/;UK6(W-MK2+
M!(5YB!E4';_=R#@XZ\>@KO->UB\_X3/X:P7MQ$+";3Q*&NP6A>Y:(J"PR,D$
MKCT+9H ]HDN8(H//DFC2' /F,P"X/3FA[JWC@,[SQ+$.LC. H_&O&=8\%:[8
M^&[.PT77;2_U+3=5FOK2Q:/;&R[0QA 8D$KN) )'#GIBJ9%_XQ^'^DW7ANU@
MTO6+#5)K@Z1*!Y4\R<R! W'5LA3TRPSQF@#W5'21=R.K+ZJ<BG5Q'PJU>#6O
M"#W$6E_V9*EY+'<VJC")-D%]@[*2<X['([5<^)EWJ%C\-]=N=+9UNTMCM:/[
MRJ2 [#T(4L<]L4 =-%<V\[ND4\<CQG#JC@E3[^E(]Y:QQM(]S"J*0"S. !GI
MS7A4?F:7??!R314$=Q=V^RZ\H8,L3"(OOQU W2'GOS6-+I5A<R?&*6:TAD>U
ME#0%E_U3;Y?F4=CQUZ]?4T ?2G6BN6^&TLD_PU\.R2NSN;&,%F.3P,#^5=30
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %4=6T;3==L&L=5LH+RV8AC',@89'0CT/O5
MZB@#'?1TT[0?[)T"W@L(V4QHT:A5@!ZN .K=QZGJ:N:5IEKHVDVNF64?EVMK
M$L4:^P&.?4^]7** "FR1K+&T;@E6&#@XIU<AXC\8G3?%VD>&+:6TMKK4(WE-
MS> M&BC@*%#+N9B"!\PZ=\XH W]*T+2]#CDCTNQAM(Y&+.D*[59CU./7WI+_
M $'2]3NHKJ\LHY+B)2B3#*N%/5=PP=I].E5])O-8?5[^PU2WMA'!%%)!=6^X
M+/N+ALJ<[2-HXR>N<\\:$>H64TLT45Y;O)!_K460$Q_[PSQ^- %>^T'2=2TD
M:5>:?;RV"A0MN4 1=OW< =,=L4VQ\.Z-IEW]KLM+M(+CRQ%YL<0#!!T4'L*G
M.K::H0G4+0"1]B$S+\S>@YY/M6=XB\6Z7X:ETZ"]G07.H74=O!%N )W, 7/H
MJ@Y)_#O0!NUC-X3\/MKHUPZ/9G5 <_:O*&_/K]??K6A/J-C;0QS7%Y;Q12D"
M-Y)54/GI@D\T^2[MHI4BDN(DD?&U&< MGT'>@"E?>'M(U*\%W=V$,EQY?E&3
M&&9/[C$?>7V.13KK0M*O9K26XL89'L_^/8E<>3_N?W?PJ4:OIIMY;@:A:&"%
MMLDGG+M0^A.< UROQ*\:W?@SPG#KFFQ6MVKSI'MDR596!(8%3[>^<T =&OAW
M2$GO)TL(EFO0%NG&0TP'0,>_ISVJ+_A%-!_LC^R/[+MO[-R#]DV_NNN?N].O
M/UJ_:W]K=L\<-S!)-'CS8XY S(?0@=/QI6OK1;Q;-KJ 73#<L)D&\CU"]: *
MO_"/Z3_:,&H&QB-Y GEQ3G)=%_N@^GM0N@:4M]<WRV4:W5TNV>9<AI!V#'N!
MV]*LMJ%DK2JUY;@Q M(#*/D ZD\\8J>.2.:))8G5XW 974Y# ]"#W% &/_PB
M6@?V;%IW]DVWV&%_,CM]O[M&SG(7H#GFME5"*%'0# KA=?\ 'M]I'Q!T+PRN
MDJ(M2D_X^Y90<J,@[57IT')/X5:UOQA<0^.]-\'Z6D"WUU;/=2W%PA=(D ;:
M-JE222I[C ]: -_4O#^D:Q<VUQJ6FVUU-;$F%YHPQ3/7&>WM5;_A#_#ODB$:
M-9B,7!N@JQ@#S>N_C^+T/;M69\/O&P\::1<R3VRVNH6-PUM=P*VY0X[J?0^_
MH?K774 9\>AZ9%JCZFEG&+YT\MKCJ[)_=)[CVK.3P)X4C.5\/Z?CS?."F$%0
M_J!T'7H.*XWQO\0_%WA&8:I_PC5LWAM;@0M)+*?M#\XW8!^0'!QD'MG&<5T.
ML^-6B\2>'O#NEI%]NUF-IQ+<(66"%4+9* @DG:0!D=#0!V(      Z 5G7WA
M[1]2U&WU"]TVUN+NW&(II8PS*,YQGTSS]:Y?P_X\O?$7AB^GL-*6?6[*[>QD
MM%DVQF0'[Y8_=3'///&.3C-+P1X^UW5/&>I^$O$^D6]EJ=I#]H5[5B8V3*^I
M/9U(.?7@&@"YXD\'QK;:99Z3X9TJ^T:"626XTQBL):1AA75B",C+9!QG(YXI
M_A[P/IUO-<3-X=MM)M;BW:":PCN#*)P2IS(!\O&"!C.0QR>U9$WC;QUJ6MW<
M7ACP[I=]I<4[0QW$E\@<A6VEF7>"!D$CCIBO3ESM&[!..<4 44T73(](.DBQ
M@.G%/+^RL@,>W^[M/&/:H='\-:)X?M);72=,MK2"8YE2*,#?V^;U_&M)Y8X@
M#(ZH#P-QQFE\V,R&/>N\<[<\_E0!DZ/X4T#P_<3W&D:1:64T_$CPQA21UQ[#
MV'%;%0F[M@Z(;B(.Y*HN\98CJ!ZXIMW<);P\W$$$C_+&TQ^4MVXR,_3- %6;
MP_I$^I/J4NG6[7TD7DM<;!O*=,;NO0X^G%0?\(EH'V""P_LJV^QV\GFPP;?D
MC?KN4= :I>"/$4^N^![+6]5:VAFE,OFE/DC7;*Z#&2<<*.IK3U?7]-T70YM7
MN[F,6D:[@ZL#O/95]23P* (+CPAX=N[NYNKC1;*6XNH_+GD>(%I%QCD_3C/6
MIF\-Z(\MA(VE69?3QBT/DC]P/1?3H/RJ_)=6\4'GR3Q)"/\ EHS@+^?2I%97
M0.C!E89!!R"* %KF;^VUK6=;;3KO3K2+0(9HIQ<^?ODN-F'">7M^7YP,DGHN
M._'03W=O:[?M%Q%#O.%\QPN3Z#-<_P"*-<U#1]7\.06OV<VVHZ@MI/YB$N 4
M9LJ<X'W>X- &[J&G6>JV4EG?VL5S;28W1RJ&4XY!^H]:98Z78Z:DBVENL?F$
M&1N69\# W,<DX'')K%TW7-0N/B!K.AW M_LEI:03P&-"'^<L"&))!^[V KI'
M=(T9W8*BC)9C@ 4 84/@?PM!&(X]!L @G%P$\D$"09P<'TW-@=!FM_&!@5'#
M<0W$?F031RI_>1@P_,4D%S;W(8V\\4H4[6,;AL'T.* *LVB:;<:I'J<MG&]]
M$NR.X/WT7N >P]JIOX0\/265S9OI%JUM=2^=/&R9$DG]\_[7OUK6^TV_VG[-
MY\7GXW>5O&['KCK56U-__:^H"YN+1[/]V;6*)2)8QM.[S"3@Y(XP!Q0 RQ\/
M:-IMZUY8Z9:6]RT0A,L405M@Z+D=JMPV=M;W%Q/#"B2W+!YG48,A"A02>^
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M_P"QCOO_ $,5T%KX6T"R-LUKHNGPM:EC 8[=08BWWBO'!.!FK5AI&FZ5YO\
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M*FA:3%HYTA-,M%TTKM-H(5\HCK]W&.O- ''K:6$7QQ"Q0VZ^?X;<2JJ@!_\
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MQ-;:QATFQN3/:F*4O)<$*0A<$ +MR3WY ].=J_TVRU6U^S:A:0W,&X-LE0,
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M;A]]!:@[3ZCV/')]:]+O+*UU&U>UO;:*YMW&'BF0,K?4'@U4_P"$>T7?:/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!4-U=VUE 9[NXBMXAP9)7"*/Q-35P]Y=.OQHT^VON+1]&D-AO^Z;CS!YF/\
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M#XMV5M;Q1VT=C%*D,: *KM:,2P4< DC- 'J&EZE;ZOIEO?6KJT<T:O@,#MR
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M&T\03-OEC%JFUV]6&,$_6B\\/Z+J%G#9WFD6%Q:P<Q0RVZ,D?^Z",#\*TJ*
M*,VC:7<M;M/IMG*;8 0&2!6\H#IMR/E_"EBT?3(+B>XBTZSCFN!MFD2!0T@]
M&.,G\:NT4 06=C::=:I:V-K!:VZ9VQ01A$7Z <"IZ** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@:C:F&WD\J:3S5VQOG&UCG@Y(X]Z9#K^D3VEQ=1ZC;&"V.)W\P 0GT?^[^-
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MATD1LJRD9!![@BI* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MP*\+2*]NCKJML^X$ AA<\G/J%_2O<@0P!!!!Y!%1_9K?&/(BQUQL%2    #
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M%<?X2MBWCKQAJEHP;2;N2V6)T.4EF2,B1E['JH)'4@^E=??JSZ==(H)9HG
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MIF"Q2(=WF,3C:H');((V@9R.E2:?K6G:HEPUI=*YMFV3HP*/"<9PZL 5XYY
MH \O\/?"_P ;^&H;B'3?&=C!'<3FYDSIJR$R$ $C=TZ=JW#X9^)AZ_$"S/\
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MNHH9F@D:/.%<8R.?J/SK0H **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ>(EP8U^\&*G;\N<D8-;8NHW^-EHTA6.1O#KHR%AE7,Z-L^N 3CT&:[W HH
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MN0-QX). !@\UPNDSW6F>!_#&HBQO9;;0];N9-0@\ARZ([S /@CYMH<$XSC-
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M]MJ=E%>6<GF6\HRC[2N><=" >U1ZAJ]EI9@6[F*R7#F.&)(VD>1@"2%502<
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MB!@[2,#!^8_+GC/!KGO!/C:RM= BAU[6))+V74;BW6696?\ Y;,J!V4;4S@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&TU!1;V19;HS*T30$#)WJX!7\14UIXETR[U*/3EDFANY8S+%%<0/"94'4IO
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M_LH+RW8M!<1K+&Q4J2K#(.#R.#WH FHJI?ZE:Z9$DEU(5\QQ'&JJ6>1ST55
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MQPC2C-LA,!;S/,7:V6W#''3C\Z //O$GA[4M:_X3?5]#MWDAN_L/DQJ,?;3
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MC);S,#:V ,@$Y!Q705Q/BI9#\0O!4R6]S)%;S73321P.Z1!X"B[F P,L<<T
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M=6DBS$L.(4!RS<Y)QD X]:S98[@>"?AK!]AOO.LKZQ>YC%I(6A5(65RPV_*
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MDWNEBR\^.-G%O*LA<!@ =JL#UZ9K'GTNZA\+?$34%M;D)K9F^Q6RP.9'_<[
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M"/:KM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJSVTQDD:$D2%MBJ6X/!^3CTK:T7Q!HEAX4T-K"6\N;>^_<Z>DI+SSGD\ECZ
MG+$  4 =716;HNN6>NV]Q+:>8K6UP]M/%*FUXI5^\I'3N.02.:77[FSM/#^H
M3:@]PEFMN_G/;JY=4VG)&SD$#N.G6@#1HKE8O%NA:/IOAZV,E\T>HVR?8B\,
MDK.HCW#<V#ER .,EB3TK3T+Q)8^(1>+:I<0SV<ODW%O<Q&.2-L C*GL000:
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M?SHPRMM.&!5CW(.: /2J*P].\5Z=J6N3:/&EW#>1P_:$6XMVC$T6=N],]1G
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M$Y+'W)], =  !BK-8R^);)]'TW4XX[B2WU%HUMPB LV\94D9X!'/L.N.:V:
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M*WD2)-: 07;EFB/E$L!\Q&,Y(P<8/'%=EJFJ6FCV#WM[(4B4JH"@LSLQ 55
MY+$D #WKD_"0O'\>>+KZ73+ZVM+TVC6\UQ%L#A(=IX)S^&..^#Q4_P 1M.U*
M\TC3+W2[9[N;2M4M]0>U0_-.D9.Y5]3SD?3UH SH+^2?XTP))!?V8_L.5W@N
M9,H?WL8#*%9D'&0<<\<UOMXUTV.XTX2PW45IJ<HALKYT7R9W(RH!W;ANP=I*
M@'L:YJX^V>(O']O>6^DZK;V4^A7%F;BXMC%Y4CNI&0V",8/U[9JMX0B9+/3=
M!U+P"8]7T\QQR7\EE&;;$>!YRR]2Q R .=Q[#) !VFF>*K/51JPBM[J)]*D,
M5RDRJA#!=V!\V,8P<]#GK5&?6-'O/$GA?[3;ZC%J%TDTM@K!D0 QY?S #M)V
MXX.2"1P*S]9\/:A_PGJSV$6=+URV%OJQ[)Y1!5C_ +Z%HOQSVJQXE@N)/B'X
M.N8K2YEM[1KLW$T<+,D6^+:N2!CD_EWQ0!?U/QMI>E075W-'=26%G.+>ZO8D
M#10.2 0>=QP6 )4'!X/(.+.J^)[73!=E;6[O!91B6[-JBMY"D9YRPR<<X7)Q
M@XY&>1\-W>M>%Y=3\-W/AW4+UWOIY[&\BC!MY8Y7+@R2$_(02<YR?0'O#=6\
MN@^-M9?5?"4^NV&K/'/;W5I9I.8W$:QM&X8_*OR@@DXY^N #LE\6:?<K =.C
MGU'SK1;U1:A<B%CA6(9EZD$8&3P>*UK*[CO["WO(@PCGB65 PP0&&1D>O->>
MZ_H,%S-:[+#4="U.TL UE>Z- [)$2SDV[! 58#"D@@ [C@C-;VF>(M1LCX=T
MG7=+NAJ%_:CS[J&(&WBF"DE&(/#':>!Q^'0 ZB::.W@DFE<)'&I=V/0 #)-<
M_8>-=.U"[TV 07D*ZI"\]A++&-MPB@,=N&)!VD'# '%;&J/=QZ3>/80I->+
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBLJ^UV*TU(:=#:7%Y>?9S<M# 4!6/.T'
MYV7.3D#&>E &K16(?$]JRZ<EO;7-Q=ZA;?:HK1 HD6+ )9]S!5 +*.3U.!FL
MZ\\91W/A'6]1TNVN3>Z<DT<UM($62VE1"?G!;! X.5)R.F: .LHKR*WO6T;3
M_!NNP:'?C4]2^RV-Q<>?$!="15=G9?,^=FPVTM@C)SCBN^A\513:Y=:-_9E^
ME_;VBW9B<1?.C' VD/@G.1Z9'7I0!OT5SEAXRL]3\.6FMVEE>O!=SBWBBVQB
M4L7V<C?@8(.><C!.,"HKSQWIMG]KE:VO'LK.]6PN;Q%3RXI25&""P8@%U!(4
M]>] '445RNJ>.[/3=:NM(72M7O;ZVMUN3%:6P<O&6VY7)&<$'^F:EU7QK8Z3
M:75])9WLVGV<HBNKN%$*0MD Y!8,=I(!V@XY]#@ Z6BLV+68YM;738[2[9'M
M!=+>B+_1R"V @?/W^^/3FN:^+J9^&6K2!Y%>,1,I1RO_ "U0<X/(P3P: .WH
MK-CUF.;6IM-@M;B7R%4S7*;/*C8_P$[L[L8) ' (/<5ES>.-.MVT^6:VNTT[
M4)Q;VVH%4\EW;.W^+> V#ABN#ZX(- '345A:3XIM=7N=6MTM+NWFTJ3R[A+@
M(ISMW#&&/!'()P/>F0>+8+M+,6VG7TMS=6GVU;;$:R+#D ,P9P.<\ $GUQ0!
MONH=&0D@,,$@D'\QTJ.WMH;2!8((PD:YP![G))]2222>Y-1Z?>IJ.FVM]&DD
M<=S"DRI(,,H8 @$=CSS2:EJ-KI.G3W][*(K:!=SN03@>P'))/  ZDT 6J*Y^
M'Q9 VLG2;C3M0M;TVINXHY8T;S8P<':49OF!(X.#S5#2OB+I>K62:A'8:I#I
MK6\D_P!MFML1#8VTID$G>3T !STZY% '7T5@0>++4Z^FBWMG=Z=>2P-<0"ZV
M;9D7[V&1F ([@X..:X_QUKT6L:1X?N[2SU 6DVLVGV>\R%BE7S1SM#;MI ."
MRX_,9 /3Z*Y>/4-*_P"$[U**WT^]DUN#3D:1L[4EBWMM5-S!<[L\X'UIW@3Q
M)=>*O#,.J75C);&9Y"I+(59?,< +@D_*  20,GI0!TU%9=_KD5IJ"Z?!:W%[
M?&$SFWM]FY8\XW$NR@9/ YR<'T.,RU\=:7?V6CSV,-W<2:MYHM;<($D_=Y\S
M=N("[<8//TS0!T]%<G/\0M(MO"S^()+>^%M%<FUFB$0,D,H?RR&YVC#8YR1S
M5I?&%MY),NF:G;SO=_9+:VG@"273;=VZ,$XV[<G)(Q@YQ0!T5%>=^&KQC\3/
M&<KVE]$8K2T9K>5M[YQ(?DPQ&#Q@ ^W%=QI6H?VKI5M?BUNK3ST#^1=1[)8_
M9E[&@"Y17-ZMXTL=*FU6/['>W0TF%)K][=4Q K L/O,"QV@M\H/'OQ46HZIH
M<WBKPND]O=37ET)I=-N$W")1Y19RW(!RO8@]>U '4T5RMMX\L[W5IM.M=*U>
M:6WO5LKATMOEA8@$.YSPG/7K[5NZIJEKH]E]INF;:76*-$&6DD8A511W)) _
M^M0!=HKF6\<:;;/J\>HP7=A+I5N+JX2=%8F(YPRE&8'D$8SG-3V?BNWN=6?2
MY;"^M;T68ODBE5&,L6[;E=C,,@D @X/- &_4+VD,EU'<NFZ6($1DDD+G@D#H
M#@D9ZX)%<MI7Q%TK5K-+]++4X--,$T[W\]N%AB$;%65F!.&XR!CVZ@@8NOZF
M]_X[\"RG3]1LUEN9F1IV 21/)<\JKG#<@_, >?8@ 'I-%9]AJHO[W4+;[#>V
M_P!CE$7FW$6Q)LJ#NC.?F'.,^M<O\1TP?"DH>16'B*S3Y7(!!8Y!&<'H.M '
M<45BWGB.*"^N[*TL;S4;BSC62Y2U"9B# E0=[+EB 3M&3C'J,PKXST>;1],U
M*TE>ZCU240V<<2_/(YSE<$C&-K9R1C!H Z"BN<M/&NFSW>K6UQ#=63Z2F^^:
MX0!(5V[@2RD@Y7D8[4J>,+1;W3;>\LKVQ34SMLY[A4"2MC(3Y6)5B.0& STZ
M\4 =%17&W'Q'T^&'5I4TG6)TTF4QWGEVZ_NP%#%_F8?* ?KP>,<UUMM<17EK
M#<P.'AF19(V'\2D9!_(T 2T5Q]IKVA6>I>+;V"QOTNK$Q/J1*DF3$>5**6Z!
M!Z"I;'Q_I][<Z+']@U*"#6(PUI=30JL3,4W[#\V0V,\XP<<$T =717G%R_\
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MD/Q$LM:30=7CL9-&DMY)[HAY?,\U7R_S$] 0!^0Q7I5&><=Z /*K'POJ^I_
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M[8B.$5OLE_$& W2]4X3/.0V1QG(KTZB@"*ZC::TFB7&YXV49]2*\HLM$U]?
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M@G]>?:NFHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7RT8#:F\8(X[ D8]A5;P[KOB'4T@CU/PY<Z;);I_IDLSHRR,%QB$*Q+9/.2
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MA:/R+B/S@RL&+ @XZC&1U/? ![!<W$-I:RW-Q(L4$*&21V. J@9)/L!7._\
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MDF(V1KZ*I<*.P SU)S8'C2UMWUZ+4K66UFT2!;FY56$BO&RE@4/&?ND8('-
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MF@#?UWPU9^(6M/MD]ZB6[,?+MKEXEE##!5PI&Y<=OKZFM=$6-%1%"JHP% P
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M]S;Z=>M/<R))&H52FW@,P)//IVKMZ* ,[74GG\.ZA%;V[S3RVTB)$I4%F92
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M0F$)E3S2,A-PW$>N*S=0\/VVI:QI^J33W(GT]F:W5' 12R[6)&.202.>G;%
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MU120H+' R3@"@!5^Z/EV\=/2N8\*:+=6NHZ[K.IP&._U*^<HI8,4MTPD0X)
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M#@YP $53\Q!R3P.X!=T7Q)I$/AR7Q)G44@U2];R8+F3S9))"WEJD2@D ,4R
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M9 8XD4/(,$_>V\<\ MU)XKG9?!^LGP)=VK6/F:KKFJK<ZJBS)E(6FW,H8G!
MC 7 /<UT7]F:K+\28=3FLT^PV^F"WAF$@V)([[I<+][.%C XQC//8@'4W$WV
M>WDFV,X12Q52 3CZD#\S7,Z1XYM=8BTZXBTV_BM+RW>X>ZE11%;*HW#S&S@$
MJ0>,]?K5_P 86NI7_A+4K'25#7MU"8$)8+M#G:S9/HI)_"LWQ1X6FN/AE>>&
M=!VQ2?95@@#-@,%()4G_ &@""?\ :H M)XPMY+K242RNC!JKLEI*0H,@5"^_
M83N"$#J1W&0,YKG-.U6#7+OQ5J_B2T\G1[0MID:3,KHJKQ,,*22SLP' .=H
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M.ODL[LPW=^-/<X3_ $:;>8]K_-_>&,KD=*T!XDM)=3U?3K9)+B[TNWCGFC3
MW%PY" D@9^3OQR.>M<W<>![RR^'5KH.G3I/J4=[;W;W,HP&E^T++)(1GI]XX
MZX %6H_"EU%XSFGC*C2)],A@N79LR3R++(Q!'^UORQ[Y('7( (]4UL:9J?A?
M788Y(;77)H[*Z@<8.Z5"T3,.SJ5VD^C8[#';UQ?CFR?6=7\)Z3",NFJIJ,I'
M\$,"DDGZLR+]6K8T;6K^_P!:U?3[_239"R=3;RB=9!<1,6"MQ]T_(3M/(!%
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M.XJ0PY4$^U8FC>%;T?#[0_#OB/PN+ZWB$PN8XYXS)"V[='(AW#!PS [3G^1
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M$Q\N=N,9.,\X/%8K1>(M8\;>&-9F\.R6,%E#=1W0FNHF*-($&1L8Y'''<\Y
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M5-+TM+W3],EDBE8W&R27R_\ 6&-=I!QR!DC<0>G!(!UM0W=Y;6%NUQ>7$-O
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M!P ,YH VJ*H:UJ3Z1HMWJ$=E<7KP1EUMK==TDA[ "L:S\574OB:\\/3V%O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZPT+7;7QDVLIHUA:V4FC"R^RP7()B<2,X'W0#G=UX YZ]^_HH \RA\):]#X
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M@Q+$3RFY>5S[9Q7&^$]'\8Z#9VWAVX;3GTJR;;%J2R-YSP Y">7MP&Q\N<X
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M60[[:4L5;! PV,>V01TZ5N6>OW$_C?4?#\MO$([:TBNHYE8Y8.S+M(]MO7-
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MK=PNZW=M#*$@=1DI(74#!'1N,D8Q0!TFGZE8ZK:_:=/NX;JWW,GFPN'4D'!
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MEW;B#SG 'J>@DD\=W\Y\)_V;I$,P\0V[RIYMR4,3+%YFT_+TY&6&3@'"DXH
M[JBN%L/&VLE?$&G7N@K)K^D"-UM;.4M'=))]QD8C('KD<8_"K=CXMNYO$FIZ
M$4L+NZM;%;R.6WF*QMEBIC?[Q5@1UYX/04 =?17G5A\0-8N-'\-:W<:1:1Z9
MJ]U%:.%N&,J/(Q56 VXV@@=\_2MZP\27;^,M5T'4H+:U%K;)=VLJN3]HB)(+
M<XQM(P1SUH Z>BLW0+ZZU31+:_NX8X7N%\Q$0GA#RI.><D8)';..U:5 !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ML5+,WS9/ ' ';)ZRB@#@]1\*:_+H/AN;3[BRMM?T$*(M[L]O.OEB-U8[00&
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M<*,\G)/ J+POIWC6QCM=,UFZTM["R"HMW;E_/N47[H92-J]!N.3GD=\UV=%
M'-^-="O=>T>VBTYX!=VE];WD:W#%4<QN&VD@$C/K@U6CT36S\0(?$,J:>8%T
MDV+HD[AMYD$F0"F,#&.O/7 Z5UM% 'F<?@KQ-;Z%#:HVF2/%K<FI26KW$GDW
M,3LS>6Y\O((+ ]""0#5B3P3KMW!XUM[FXTY$U^(&%HBY,<GE!,,"/NC'49)Z
MX'2O1** ,[0XM0@T:VBU-;9+J.-49;9V9!@ ?>8 GIGH.N.<9/GZ^"/%G]D6
M-G)+I$MQ8ZTFI&[>63S+T+(6S)\ORL 0/XN@ P!SZC10!RMCHFKVOCS5=<D6
MR>VN[*&W0+,X?='N.2-F "6]3C'>I/ >AZAX<\,)IFI?93+'/-(&MY&=2))&
M?^)5QC=C\*Z:B@#C;CPUJFD>,+OQ'X=-K*-11$U"PN9&C61DX61'"MAL<$$8
M-;+6=_K%I<6^K1PVUK-"\+6]O*9"X<;26<JN."< #WSVJ]J&J6.E1127]S';
MI-,D$;.<;I&.%4>Y-6Z //HO!NM7/@B'P5J3V<FG1-'"U]'(WF26Z.&5?+VX
M5R%"GYB!UYZ5KV6B:M9^.M;UOR[)K6]M8884$[!P8]W+#9@ [NQ.,=ZW;[6-
M.TV>U@O;V&":[E$-O&[X:5SP HZFKM 'FD?@?Q!'\,=.\,?\2PW=K=I.TGVF
M3RRJS^;Q^[SD].GO5C3Y=2C^+/B=K2TMYB;"R\Q))RFUL28P=IR.N>,].*]#
MK/@T/3;;59]4AM52^G $LX8[G Z \\@=AV[4 <6/ ^L:;!H36$UC>-:WMQ>Z
MA;73M'#<2S9.\85ON$G;D>_!JI=^!?$L_A?Q-I'FZ4SZKJWV^*3S)$ !DC<@
MC:<?ZO&.>N<\<^GT4 <I<:-JDGC_ $_Q"ZV,=E;:?);2@W#;P796)'R8P-N.
M2/PJA::/9W_Q/GU?3[U9;(6L4]U%$P:-[H!TB?([B,MD?[A]*[>6*.>)XI45
MXW4JZ,,A@>""/2JNEZ1IVB62V6EV4%G;*2PB@0*,GJ>._O0!+?65OJ5A<6-W
M&)+:XC:*5#T96&"/R-<OX;TCQ!X2TQ=%B6UU73K?*V<TDYAF2/.0CC:0<=-P
M/3M7844 >;2^ =9;P#XGT=)K$W^NZA->',KB* 2,IV[MF6QMZ[1G-;OB3PYJ
M.L1Z'J=JUM!K6D3B>-'D8PR KMDC+;<@$?Q;>/2NLHH Y0>&;C4]?O-;U-8K
M>:733IL$,,AD\M&8L[EB!DDX  ' 7KSQST'A#Q8VA>%-,F&D(- OH)0RSR-]
MHCC1UW?<&TX(^7GKG(Q@^F44 ><^'I-67QEX[73K:UE+7D(5IIBFQ_(3D@*<
MK].>/?CKO#&@Q^%_"]AHUN_FBTBV[V^7>Q)+'VRQ)]LU%HT?AR/6M432'MVU
M%2IU 12%FW'.WS.?O?*>O(K2O]4L=,^S?;;F.#[5.MM!O./,E;.U1[G!H YO
MPAX?U?1=:\17=^MEY.J7INH_(G9V08QM(*#T'.:G\1:)JFH^*O#>IV2V9M]+
MEEDE$TS(S[XRF% 0CC.>3[5U%% ')S^']2T[QS<>(](%O/%?VR6][:SRF,[D
M^Y(C!6[$@@@>N>U<KXIT"?0?#EG(&ADU+4?%5M?2\D1B5Y1A0<9V@!1G&3@G
M'.*]6JAJ>BZ=K*0IJ-JMPL+B2-7)PKCHP /4=CVH Y^]\*3>(]9FO]92*"'^
MS9M/AAAD+L!-_K'+$#!P  .>Y/H(?#&F>-M.@M=*U6ZTJ33[(*B7<!?S[A%^
MXK*1M7H-QR>,COFNT50JA1G &!DYI: .5\(:!J>CVVMPZD+0"_U*XO8S;RL^
MU93G:=RKR/UJOX7TF3P[X'@\/^)Y],%O'$UHI68[9T.[.=P&"5/W1G&"<\\=
ME5#5-$TO6TA35-/MKQ()!+&L\8<*WJ,T <_\.-&?2?"T337,MR\YS%+*,-]F
M7Y8%]OW84X]6-6?$VAZA?:WX?UC3OL\DNDS2NUO/(8Q*LD9C.& .",YZ<^U=
M,!@8%% '$:CX%D\00>(9]3G2WO=7MX[>+R"76V2([DY(&X[SN/ [ =,F]X?B
M\:$QKXBDTH+;*0&LF<M=-@@%]P 0<Y( /..@&#U-% 'FT7P_U>3P=_9\UQ90
M:I::NVK6,T4CR1B3S&<*^54XPQ4XSZ^U=!_8NHZIXDTW7M3M[6"72[>9+6WB
MG,@:64*&9GV#  7 X/WB?:NIHH \T7P/XA7X9VWAG_B6&[BO1<&3[3)Y947'
MG8_U><]NGO[4:K;ZMK?C34Y]'M](NS:VT5C<I)>S6TB,079"T8S(N&7EN!SC
MG=7I=8NI>$?#NKWPO=0T6RN+K&#-)""Q'H3W'UH PK2+4-9T:"PE\/Z1]@M6
MDL[S3C-O@8*$V-"VS!V\C! P<CJ*UO!?AZ3PQX?_ +->3*"XEDAA$A=;>-F)
M6)6/)"CN?>M#2]0TBX:>PTJXM7%@5BDAMB-L)QPN!P.G2M&@#A'\$7MW-XNT
M^[EM?[(UYS,LJ,QFC<QJF-N-O!4-G)SC&.>)!X:UO5]*T32M=%D(=,N(9YKB
M"5F-T8?N84J-N3@MR>A SG([>LNV\1Z/>:E_9UOJ$+W90R+$#RZ@X+*>C 'J
M1F@"IXVT&?Q/X,U/1K:6.*>ZB"QO)G:&#!AG'..*S;O1?$&H>*O#.LW$>FH-
M-6X^TQQW#]95"X3*<XQG)QG/05V-% 'G-QX#U>_L_$T4MS:VD]_J4>I6$\,C
M2&&6,)MW H.Z=L]?:NE\/KXKE<2^)#ID/EIM6+3V=A*W'SL6 P..%&>O)X%=
M#10!ROBKPM<ZIJFEZ]H]Q%;:WI;-Y)G!,4T;##1OCD ]B,X]*T;:37[S8EY:
M6>GH"#(T-T9V;'\*Y10 ?4\X[9Y&K//#:P//<2QPPQC<\DC!54>I)Z5GP>)-
M$N75(=6LW9R BB9<OD@#;ZY) X]: ,#3O#^M>'-4U[^R5L[FPU:Y:]07$S1M
M;SN,/D!3N4D C&".GO52V\"WFCW'@N+3&M9;/0!-YS32LCRM+&58JH4CJQ;D
M^WO7?44 <7;>'=:@U7QA>-'8%=:$?V=1<OE"L0B^?]WQG&>,^GO7.2:;JN@:
MG\,=+>.TEOK);J A9F\MPMO@D,5R#C/;K^=>KUGWFAZ;?ZA;7]U:K)=6N3!*
M6.8L\';SQD<''6@#D=8\&:QJMKXCOH;JWM-7U5((84$C&-(8CG8S@ _/E@Q
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M88WLBNN8P'QSSF3ID=.M:$?BG7-/\:Z?HVNZ=916FK+)]AFM96=HW0;BDF0
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M /E//S$YX],=ZW+#39]"\5>)/$.IW-A!I^HBWVLTY!B\M2@W%E ^;=Z\=.:
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M+Y@&[ST80^60/X<<!@?;&.]1Q^$]9O\ P_I7A_6I;&2RT^:%GN87<R720D%
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M:$<33)N$;MZ@*[CZA?2CP?X6F\):#/9).MW-YK^09&("P@D11DX)P%QV/)-
M'.Z?\0-=N/#WASQ#<:;IZ:=JEW%:RQI(YE4R.4#KVP#C@Y)]N@U=6\8:ANU@
M:):BX?2G,1B:TGE-U($#LBL@PGW@ 3G)[ <G-@\"ZW!X \/^'1)I[3Z7>PW+
MRF5PLBQR;P!\F03G'M[U>;PYXKT?Q-J-]X<O=*.GZK(L]S;7ZR$P3;0K/'L^
M]D 9!(Z=J &3^,/$5UKMEI6EZ-:PS7ND'4(UU"1T:)PR@I(H7(P6(P,\XZ5-
M!XPOKO6KO2(WTV'5+*6%)-/FW>9.A5&>2-B1E1N; VG[O.,\6E\.ZI'XZT_6
MO.MY[:VTUK&1I)&$LA9E8R8"XZKTSW[52\2^#K_Q.)8+R+3@R72RV.IK(RW-
MH@8-@ )R>#CY@.1GIR 9T<VKP?$?QN^BPV;W M;%RUVS!!B.3 PO))^HQ^E7
MI/'%Q<^'?!^KPZ=;&+6KVV@E65R3 TF<E1CG&#@Y';BM"UT#5K7Q7XDU<"R>
M+5((8H4\YPR&)64%OD[[L\=,=ZQX?!&MP^$/">C"33VET2_ANI)#*X658RV
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MWC@+Q$E7VJ%SR!C..GZUI44 <QH7AZ]T_7?$5Y>M:R6VKS+*(XV8LFU FTY
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MY10!1T:VN++1K.TNO*\Z"%(BT3$JVU0,\@8SCI7%:OX%UR_7Q9:PZG8_9-=
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MW8">,'<K;P"0X/?!R#VKJZPF\9: F@0:X]^%TZX?RXI3$XW-NV8VXW?>XZ4
M<_JO@.\O?#6KV<-Q;#4=7OX[VZF?<$38Z,J* ,D (%R<=2?:M:XT/4I_'6G^
M(,VBPVUE):O#YC%B7*L2#MQP5Q[^U:[ZYIL>N1:*UT/[1EB:9(-I)*+C)SC
MZCO6A0!Y'XOT'4-"^'?B?[3+:EM1UN*_C,98B,R7$/RD$#.-O7O[5VMQX>OM
M8URSU34Y(+9["WFBM%M79R))5"M*695QA1@+CN3FMR_TO3]5A$.HV-M>1 Y"
M7$2R*#ZX(JS'&D4:QQHJ(HPJJ, #T% 'G-EX$\1V]EX9@?4M+#:'<EU9+=SY
MRE64NWS<N=V<>N3FKZ^$-6&E>,+,RV6[7Y)7C8.^(?,C$>#\OS8 SVS7<T4
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M,<[CQV]36=9^$M6T:'6],TJYM#IFJ32SQM/N$EFTH^<*H&)%SR 2N/>NVHH
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M<90$#IP2?SX^@K<H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***X[Q3
MXM_L+Q!9V%Y>II5E<VY:+4)H-\33[L"-FR HQSSC.>HQR =C17'KKVKP>+/#
M>DW,EI)'J.GRS7!C0G;+&J9*-G!4ECV_&L/4?&NOVO@OQ?J<3V)N]%U22TB+
M0-M>,>7@D;_O?.>>G'2@#TRBN'O=7\467C33M'-UIKPZO;3R0G[,_P#HC1;2
M?XOW@PW^SD\\=*R[KQGXALO _BR[:6QDU30+Q[<3&W8).@"$'9N^5L/ZD<4
M>F45PM[K/BBR\7Z1I9N=->'6;>=HO]'<?9'B"MDG=^\&&Z?+DCM3=/\ $GB*
M31_$MN?L%SJVCWOV=)W'D0O&0C>8X+<;59B1GG;0!WE%<)8>*M2GUK7]+ANH
M+I;33X[VTNI;5E#;MP((!&]<KPRXZ]35*QU?Q[J?@:/Q):7&D/)+IHN8K+[(
MY9I!R1NWC[RYP.QP.>20#TBBN6T_Q%+K?_".OI5S"\-[;F[NF:+.(@ ,#GY6
M+L!SGHWI74T %-DD2*-I)'5$0%F9C@ #J2:YRYUNZO?&4GAO3YDMC;V0N[BX
M:/>V6;:B*"<=B23GL.^1RNL^(=3UGX<^-;*Y:"WU+2%N+6Z>.,E)T\LD,H+9
M3<I'<XP: .VT_P 4Z3J>J?V;;S2BZ:W%U&DL#QB6(G&]"P 89(Z>M:\D:2QM
M'(BNC##*PR"/0BLGPQ#/'X=TXW4T<TGV:/8R1;-JE%XZGTZ_I5K6KNZL-"O[
MRRM3=7<%O))#;CK*X4D+QZGB@"6RTZRTZ,QV-G;VL;')6")4!/K@"K-<)I7B
MR76=(U#4-)UNSO8[>R:1D>WV36\Z\[9$W [3@@?0\GBF_P#"7:M_8'@;4Q]E
MW:Y<6T%W'Y1P/,B9R4.[C!7'.>M '>UCSZEHNHZV_ANY6.XO$@^UM;S6Y9=@
M8 -EAM/S'MZ&L4ZSKNNQZ]+X>>UC?2[I[."&>/<+B5 I?>V1M4EMHQSQDGG
MS+M=4N/B[ MK);6=[)X:_>/(AF6(_:!G"@KNYXZCU]B >BXP,"BN;\#:Y>:_
MX:%SJ(B^VPW$UK,T*E4=HY&3< 2<9 !Q71MN*'80&QP2,@'Z4 4],U:TU>WE
MGM&<QQ3/ Y>-DPZ'#<,!D9[]*NUY+KWB/7=4^$FN7TEW#;W5OJ3V4C6\) >,
M3K$0,L2,@\\GTKK=0US4(=<C\/Q3,UVME]KGN8+3><,Y1 J;L#[K9))Z#UR
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MR,Z?;LD,:B/#&3:&<[LX(&Y1TZ[O2M6@"O?7UOIME/>73E(($+R,$+%5'4X
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MJZ.)(U=<[6 (R,<4ZN6FU^ZO/%-MX<LI4@F.G?VA<W#)O(4L$55'3).22<X
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M Q^7V SWQ@YVD_$#4[G3(;&]MHDUT:O-I,Q@C+Q[HD,C2*N<G*@8&>ISTXH
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MV2X:WD\V)DRR@$E<CYEYZCBH]5OK&W^QV][ \Z7LZPQJ(#*N[!8%L @#CJ:
M,#P#H=IIMOJ6HV?F"VU&[>6U5^D=ON8J%'92S2./9Q78444 <UJ/AFX/BV'Q
M+I-U%!>_9C:7,4T9:.XBSN7H058'H>>.*JW/@J2;POKNFQWT:7VN/(]Y=M 2
MN77;A4W# "@ 9)Z9YS77T4 4])M)[#2K6TN)HYI((EC,D:% VT 9P2<=/6EU
M.VN+S2[JVM+HVES+$RQ7 7=Y3$<-C(S@]LU;K"?Q?I*:C;69DF(N;AK6*X6%
MC"TRYS'O QG((],@C.0: *,/@\3^(+G6M0:V6ZN-/:PE^QQ&,2JQ!+MDG)X
M YQSR>,9$'@#7!I/AW3Y_$%J8M!O(IK8I8D;TC5E ?+\MA@." .>IQCT*B@#
MBO\ A#=9T[Q%J-]H&OI8V.J2^?=VTMJ)2DN,,\1W  MCN",]CTJ_'X7NH/&D
M6O0W\7DQ:9_9R6\D+,VW>'W%]W)R/2NFJ.XG2VMY)Y-^R-2S;$+G'L "3^%
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MB9;2VDG\H^C%%(4^QY]JLZ7K%AK,4TNGW G2"4PR$ C8X )4@C@@,,CMTZT
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M<A..">/F%=)%X5O-,U[5-1T34HK6/5")+FWGMC*JS 8\Q"'7!(Z@Y!(S58>
MTM3X9CTV^6WMM!=Y$26#S&G9U96+,&7!.YCP.I_"@";PEJVJ7&M^(]$U6YBN
MY=*N(A'<QQ>5O26,. 5!(R,D9JQXCUZ:QUC0M$M&6.[U>>1!,Z[A%'&A=R!W
M;H!GCG)SC!?H_AVXTOQ-KNL27\<PU9HF:%;<IY1C0(,-O.>!SQUI?$WAD:\V
MG74%T;/4M-N/M%I<[-X4XPRLN1E6'!&0?>@#.LM9U2/QIJ'A*\NEDD-BM_8W
MPB4-Y9?8RNH^4L&Z$ 9!Z52^$45R/ EM+-=F6-Y[G;&8P-I^T29.>IS706>@
M31:S=:Y=74,VJS6RVL;I 5CAB4EMH7<2<L22=W.!TQ3/!WAR?PKH$>DRWZ7B
M1O(Z2"#RC\[LYS\S9Y8^E %'QCXG/AV^TP7<T]CI%P)!/J,4'F"&0;?+5L@A
M5;+<X[#IR:K/K^JV^K^#H/[0M+N#5GG2XDA0%) L;.CQD'C.!W-=#J>G:A=7
MT4UK>VZ6XA>&>UN;<RQS!B,'AA@C!'?(8USO_"O39:/H%MI&I+:WFBW,EQ!-
M);^9&WF;O,4QAAA?G. &X ')ZT 5KKQM?Z._C/[3Y5RND7%K#9@KLRTZI@.1
MV#..?05T5O!XBMM;"W%W;WFDR6I,CL@CDCG!Z(%'*$9X.2,=:QG^'2WJ^)XM
M5U62ZAUX1&15A$;1/&BA64@GH5R!CL <]3HZ+X?U^SB U;Q*-2EAC,=L39B-
M5)&-\@#9=L<=0.3W.: ."\):MK>@_#OP7?0W=L=/GNXK*6S,&69)967?YF<[
M@>< 8^M>QMG:=I .."1FN%B^'MU#X-T7P\NM1;=*NX[I)S9',FQ]ZJ1YG')Y
M.?RKNL-LQD;L=<<9^E 'DGB'7]<U+X3^+[B>_2&YLM1GLM]M%L#Q+(J;<$DC
M()R<D^]==?ZQJ,.N6WAV":>6Y-FUY/<P0Q^9MW[$"JQ"CG.3ST''.16_X5\\
MOA/Q#H-UJJNNL74MWYT=ML,+NP;&"YW $#TJ35_!FJ7]SINKVGB(V?B"RC:%
MKQ;0-%/&QR4:+=TR,CDD?E@ RKOQ'XST[1M':_M[6UO)M=CTYS)&#]H@=OED
M&UR$)'!')ZXQQ5R"_P#%,GC+4_#+:Q9_+9Q7T-X++YH@S,I0)NP>5R"3P/7.
M1>U+P=?ZE8:7%-K@>ZM-1BU*:XDM<B:2/HH4, BXP,#)XZYR3<C\.7D?C2Z\
M1#48"9[%;,0?93\H5BP;=OYY8YXZ>G6@#EX/'>HCP'I&M:BKQQO>2VVIWMG;
M^9Y"1M(GF!,' +(N3@XR>.E=EX:OFU+1Q=_VE;ZE%)(YANK< *\>?ER!T8#@
M^X/ Z5CZ)X0U70-(L[&TUR%OL]S-,V^R.V992S%&7S.S-D$'L.#S56?PQJGA
M[0)8?#>I):7]SJ;7LB160:*4L,&(*2?+3A<MGC!/?% '='...M>:3^+_ !#%
MX(\9ZD+BS^W:-J,]O"WV8[#&BICY=W7YB<DGZ5Z77#2> +N7P[XETAM9AVZ[
M=R73RBS.8M^T,H'F<\*,?CUH ='K6NV'C30K+4+RUN+/6;6=_*C@V&W>)5;A
MLDL"&P<@>N!THTO5O$?B/0M/\1://:B.YN<_89E 3[+O*DE\;O,P-WIVP>IT
M+CPO>7.O^'M5?4X =(BEC\L6AQ-YBA6.?,^7A1CK^-9^C>!-0T*66PL_$4B^
M'&F:5=.^S+YD88[FC67.0A)/;.">1UH KVK2I\2O&CP2^5*NF6;(^T'! E/0
M]:AC\7ZQ)X.\$ZSYL(GU:^M;:[3RAM992=Q7N#QQ716OAF:#Q;J^MR7T<D.I
M01P/;"W*E%0,!\^\Y/S'/'Y5@0?#G4X]%T?27\2*UKH]]%=6>VR ;;&255SO
M^8\@9&!C/!/0 N2:OJ'B6/Q0NGWBVEMI4DEB@,0<S3+&&<OG^'Y@H"X/!.>P
MPM"UG4M'\!_#E;.2 6]_-;6=PKQ;F*LC-E6S@?=QT[]:Z'_A"K^RUG5[K1]:
M2UL]8R]Y:S6OFXE*[3)&VX;2>^0P]J@B\ 7<6@>&-*76HR-"NH[E)&L\^:4#
M*%P'&!ACZF@")M5\4:AXG\5Z3:ZE96L>F16\MO+]DWL-Z.VT@M@\@9/MP!GA
MMKXUO]0T+P5-L2VDU]PEQ<JN5A(C9L*#QN9EP,YQSUK:M_"]Y;>(?$&K)J<!
M.KQ11^4UH<0^6K*ISYGS<,<]/PKC=;TV/PWHOA?PG=>([:RC@\QUO;VR4VLH
M086.17;:7R^X?,!\N>H% '5^%-6UF_U_Q!8WUQ;S6>EW(MX94MRKRDJKY9@V
MW*AMI 4<X/'2I/'>LZEH6CVEYITD*%[^W@E$D6\E))%4[3D 'GN#53P5<7PN
M9;0:KI&KZ8L9=;G3+40)%)N'R':S*Q()/'(QSU%:OBWP[-XGTN"RBODM!'<Q
M7)=H/-R8V# 8W+CD<T <[XEM[Z3XL>%A#J!B5[6],8\E6\O"Q9Z]<_I7>7 E
M-O(+=T2;:=C.A90?4@$9_,5@ZAX;O;[Q=I.NKJ4$?]G0RQ" VI;?Y@4,2V\8
M^Z,<?G703+(T+K"ZI(00K.NX ^XR,_F* /,M(\7>)O\ A [;QAJ-W92PS0>6
MMC';;29WF$<;%]W3GD<<=\\ULOK?B+1-1N;O4+6XN/#\5A+<SSS)%')!)&"V
M%",=RL 0 02#CFIK#P##%\.3X-U&^-U;>68UGBB\IU^;>K8W-R&P?P'%2:;X
M3U5[&:R\3>(GUFV:![=(Q;+!E64J6<@DLVTD=AR3@GD &7J6O>(;+1/#NM?;
MH =5OK.*:T\@%(HYF'"-][< <9)(/) '&-"SUO5+CQ!XQTMKE=FEQV[VD@B&
MY?,C9R&[-R /I^=<GXBT+4O#&@>'+'4/$0OK&VURQCM$>W6)UC608#MD[MH&
M,@#ISGMV-SX2O3XEU35=/UA;6WU:".*\A:V$C$QJ55D?< O!P<@_X &5I?C+
M4M4TCPM %;^T-6L7O+B2VC0E%3:#L5SMR2XZYP >/1MQXE\4:-X?GN-;L)XX
MH-2$37T$*/)]C()\XQJ6 8$ 'C'.<=JD_P"%;W,&@:!;V/B"2VUC0U9+6_6V
M!5D8 ,CQD\J<#O6Y'H6MQVELY\0"74DN1-//):_NI4",OE"-6&U?FSU)R,\T
M <AXJU>\U'X>M?Z=XBBN[674[>.*YMD7,D+21KL?T();(XSCH <5T5YK&IR:
M]+X?M)KAIK2S2XGNH((F=FD9P@VN0H "$G@YR.1W@N?AU#/H&KV,5XEK<ZE?
M1WYD@M\112(4(VQ[NGR#//))/'2I-6\&:I<ZQ::[I?B(V&M1V_V:YF-HLD5S
M'N+ &/(Q@DX.2<=SUH JV?B;Q%*WA_0M4M8].US4#.US(NUPD,7\:#)&Y\K@
M$D#YN#@"CP;%<P_$?QS'=7 N) ;'$NP*67RFQD#C..., XZ"KFJ>"+F\;2-0
MMM:DBU[3)'D6^EA#K-Y@Q(KQ@@;2   "-H Q5O0?#-[I7B36-:N]52ZDU181
M)%';>6JF-=H(^8G')X^G)H S/B=YOV+PWY&SSO\ A(;+9OSMW;CC..U-M-4\
M2V7C.7PSJFHVMR+VQ>[L;Z&U\LQ.K ,C)N((Y!!SGW]-_P 4>'CXBL;2*.[^
MRW%G>17L$AC\Q?,C.0&7(ROJ 1]:B734TW4+GQ1KE[%)<6]FT7F1Q&.*WA!W
MN0I+$DD DYZ*  .<@&#HWB?5]0\+K;S7$<?B9=3.G3H(AL20-EB%[KY0+CU]
M:[QE<P%%DQ)MP'(!P<=<5Q?ARSTG6_&NH>,-*D:6TEMHH$E&1'-*,[I #U(3
M8F[_ 'AV-=O0!XE</?S_  #\27-]J#W;23W .] #N%T03D>OIT':NY76=:TO
MQW8Z9J5W;7%CJ-C/.J1P;#;O$5X#9)8$-W[CMTJK+\.KI_!^K>&4UT+97L\D
MD1-F"T*O)YC G>-QSP#QQG@]MJY\-7=WXJTC7)=1@_XE]O+ T"VIQ*)-NXYW
M\?=&.#^- &!:^(_%>K:=I&NZ382SP7<J/+9ND2QBV8]5<ONW@8//!.>!78^(
MKN?3_#.K7MJ,W%O9S2Q#&?G5"1^HKF=$\":GH,AT^U\33'PVLA>/3VME\Q%)
MSY8FSG9GVSCC(ZUV[*'4JP!4C!!Z$4 <;\*((HOAGHLD9WO<1&XFD)RSR.Q+
M%CW.>/PJWXEU-/#$=O\ 8(HUOM<U2&V#N,J)'4*9"!C.$CZ9Y(%0Z1X2U+PQ
MYMIH&K6\>D/(TD5E>VK2_9BQR1&ZNIVY).#GZU9USPBFO:,MM<W\JW\=REY!
M>JHS#.GW65>@4=-OH3SDDT 4WUG5=)\;VGAVZNDNH-4M)9;*YDA >*6/!97"
M[0RX((Q@]N>M<Q%XP\6?\*]TOQ:]Y8L3>"&>S%MA9E:X,7W\Y7'&, ].<YKN
M(?#]U+K,.LZE>6\^H6UL]O:^5;E(HMY!=BI<DD[5'48 QWS6&OP\NE\ 6_A0
M:U%LAN!.+DV1R<3><!M\S^]QG/3\Z +-KJFOVOCY] O+^UN8[K3'O8'%KL\A
MUD"%<!LLOS9Y.>.M<JOC#QHOPYM?'#76G200,S76GK;$&:,3%&(?=\I Z#';
M))Z5W4GAZY/C2V\2R:E %@L6LV@^S$!E9@S-NW\<J.QX]>M<7\/M#F\2?"C3
M].N-0@;29I9#-%'#^]9!.S&/?NP 2.3MS@X]Z -CQ7XFU?3(-;O+>]A@2SLD
MNK"WCB\YI@%+.TXP2B9&T'*]SD]*EN_$&O7/BGP_I]C<6=O;:KILETQ>W+M$
MRA#_ 'OF^_P./?/2GZEX"NKV[\2^1KIM[+7H D\)M0[QL(_+!5RWW<=5Q]".
MM6;3P=?6^LZ#J,FLQS-I5F]IM-GCS0P7)R'^7[HQP??- &+'X@\5W/@GQ#/:
M7%O-K&A:A/;;OLXVW<<>UC\N?E8JW&.X]ZZ.RUM]:U#1SI5YOL9;+[;<L44E
MD; C'^R6._\ [X853LX['X>VVJ7NNZW;BVU74WN0[6YC"2R ?)]YLC">W>I?
M 6@6VB:+<S6T<L,=]<RW$,<N<PPLQ,: '[H .[;V+&@#K*XSQ9XK.@Z]:6E]
M>2:5IMQ;DQZCY DB-QNP(Y"00HQSVSGJ,5J>$8]:BTJ9-;OSJ$PN&\FZ:V%N
MTD6!@E!T^;<!Z@ ]Z?JVCW]_=SF.]M38W%J+>6RN[4S(2"QWC#CLV",<X% &
M2FMZK#XN\-Z9-=030ZCILLUP8T!'FQJGS(P_A)8GO7*>*=9O]6^&GC..]DCE
M;3]:2SA8)LRBRP$;L=_F//Z5U!\!2V*>&FT75?LUQH<#VJO<P><LT;A0VX!E
MP<J",'BHC\.6ET#Q%I-QK4LB:Q>_;?-\A0T4FY&&><-S&OIWZ4 $FK>)M#\;
M:7INIWME>V.M"9(6BM3&;29$W@?>.]2!W(/TK!D\7^+$^']WXI-]8[]/OI(I
M+86N%N$6?RR-V[*<=,9/').>.XBT"[N=6L]5U>]M[F[L8I$M%@MS''&[C#.0
M78DD#'4  GUS6&_P\NI/ FH>%VUJ+9>W+SM<"R.5W2>80%\SU[YZ4 6DU77=
M.\?Z?I-_>6UU::G:3S(D=OL-N\97@')+ AN_<=NE9]MXMU[_ (1?Q/?21+>7
M6F:S)9J+2W.1 K1AF5,DLP5G;!)Y'I6_=>&[R[\6:1KKZE #I\$L)A6U.)/,
MV[CG?Q]T8X/XU4T[PCJ>EV>K1VVN1K<7^J'4EE%F0(V+*60KYGS*0N.H/)H
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M*.>N#WH ZO5M6TG3-5TVVO8";O4)Q#;N+<L-^">7Q@< ]\UM5YIXCM]436/
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M1\)I?$/VQ?[0M[\P%O)3;(GVL0\C']T]L<T >GTC,JC+, ,@9)[G@5Q-U?\
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M8D]68^@&3^%<QIGB#4YO%VIZ)#?RW%N-*2^MKB\M CJY=D/R@)N0X!''XD4
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MHH X9? >J2Q:'%>^*99TT:Y6:W9;-%=E52H#DDY.#C=@=\@GD=S110!QFH^
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M5JD"-PB%%*,?NC!.1CUY';KU15^ZH'T%4[C4A;ZK9V!M+N0W2R,)XXMT46P
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M@Q*YDD60\*2P&U>P/)XPCZIXK?Q-X9TN\O(M/EU#3YWO(H8DDV2QA,LK'/\
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M-\O!W"3.W'^K([UJZ-HD6DM>S^8T]Y?3>?=3L "[;0H '90H  _4DDU6\/\
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MW1WC"N"[L[9P<'ECV%1:GX6>\\56VOVFK7-C<QVILY5C1'$L1;?@;@=ISWH
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M@M\WS9R#G/6N5^(VDVFB?#G5@UWF]U&_MYY[AMJO(_G1Y*CL%51@<X"\YY)
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M.MK76'L8M:TV::X$4*-L=8D8,NX'G+GKD>U '<G4&&MKIOV*[*FW,_VORQY
M^;;LW9^_WQCI5VN(L+S6+#XCVVAWFKRWUHN@FX??"B%IEE5"_P HSR,\9QR:
MS=/U7Q7XAT/2O$.CM*'N)EFD@FDA%LUN6.Y.[A@/XNN0>W  /2:*\ZG\3W5M
MXN?2M9OKW2+B344&GN\2FSN[?<O[L/M.'(W9R0<D8..*]%H *H:IJ]OI0MEE
M5Y)[J7R;>"/&^5\%L#) &%4DDD#BN'@US6=>\!ZIXLL-3DM9X'N9;2UV(8A'
M"S (X(R2P0Y.1C=QC%5=7N)?$6M_#C5H[RZLQJ!>811^6?)+6K-E=R')YQSD
M8Z 4 =_HFL+K5E)/]BO+)XIFAD@NX]CJR]>A(8>A!(-17OB.SM=4_LN"*>^U
M'8)&MK50S1H>C.20J@]MQ&>V:U44JBJ6+$#!9L9/N<5YW\*G:XOO&MS=\ZBV
MO31R[OO!% $8^@&0* .PL?$%K?:K)I9@NK>^BA$\D,\6W:A. 0PRK<_W2>E:
MU8?BK4X?#OA_4?$/V=9;BQM)#&#WS@[3[%@N:YK5]6UGP[IGAW7#J<M]'=W-
MO!?V[HFQEFXW1X *E21@9.1UR>: /0:*\U-UXAO[SQQ;+XCN;==)=6M&B@BW
M#, D"G*D%<GTR?6HX]=U]-.\#^()=7DD_MFXMK:ZL1#&L&V6,G*\;@P(SG=C
MV XH ].HKS>$>*M?UGQ;IUKXGEL_[-N46T9+:(G+1*X5LK]W)^I]>U&B^*-3
M\1Z#X7O[B]^R_;;>?[1:V:9N;B9&V H,$*@(8DD@#*@G% 'I%%>3Q^*?$=SX
M"\.Z@NIF*^FUU-/N':!#YJ?:&C^8 <'"C.TC/-;UA+K,?C;6O#4FO74\;Z;%
M>V]S)%%YEN[.Z$* @4K\H."#0!W5%>=Z%K^K:GX>M-)GU&:/Q)'J1LKZ54CR
MGEG?(X&W;M:,#!QU=:]$ P ,Y]Z ,>[\1VEOJATNWBN+[4%0226]JH)B4]"[
M,0JY[ D$]A3K#7[:^U233#;W5M?11"9X;B+;A"< A@2K<_W2>G-<=\()FNK+
MQ-<W?.IOKEP+O=]X$!0J_0#('XUKC7;RZ^)%SX<^RV\1@TXW27Z,3($=PNT*
M1C.0#U(XZ4 =A17D>G^)O$5A\,#XYO\ 6GO'A@GC^Q&W18WD,YCC=B #P>H&
M!C XY)Z/6[[5O"NI>&YSJDVH6FI7T>G7<4J)]^0';*FU1MP0<CD8/XT =S17
MF9\0:V/!/CR[_M6;[7H]_=1V<_EQ[E2.-&52-N",D]1GWJS<:AK]]XNT/2K?
M6Y+2VO\ 1GN9BD$;,K@QC<I(ZG<>N0,GCI0!Z'6/XD\267A72FU/48[@V:,J
MO)"@;86(49&<\D@<5B>!-4U>6\U_0M:N_MMSH]VL27FP(9HG0.FX#C< ><54
M^-'_ "2K5L?\]+;_ -'QT =#9^+=,NM:31Y1<V6I2QF6*WNX3&95'4H>C8[@
M'(K=KBM0\+ZMK_C;1-:U V=G::,LK0QV\K2R2R2 #))10JC ..<UAZ5K.OQZ
M'KGB2_UZ>>#0[V_0V8MXP+E(LA S 9!R!R/ZT >HT5YSJFM:UH7A;0O%/]IR
M78GDMOM]JR)Y3I-@'RP!E2I88Y.1USUHB_X2C7O$7BW2[;Q/+9+ITT(M&2VB
M)!>(.%;*_=R>>YXY]0#T:BO,?#_C?5?$UCX=M6CEBN[RQN+F[:U,:.S12B+"
ME^ "<L<<\#'&:-:O_&>B>#Y)+O4!#=QZM%#;3%8W>:VDE55$H P&&2"5QG%
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M8,."""#C!'H35ZB@#F+CP18ZA;ZZNH3--/K4"074L:B/"("$VCGD9)R<\^P
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MB8YP%SN!4'.>N>@XJ_+?77BS0?&=W]ON+6.PFNK"VBA("KY2?,SC'S%B3P>
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHKD]?DEF\36]BM_=.C64CC3K%S'
M,7W "9I 0%0#( ) )/0XQ0!UE%>1VVOZ]J/@OP!?'6;B&YU#4DM+ID5/WJ_O
M.3QU^0>WJ#5NX\1ZCX/F\=HU[<ZE#I=I;75H+QM[(\H8$$@#Y=P!QVYQ0!V^
MM>(X]%U/1[*6SGE_M.Y^S),A78C;2WS9.>BGH/QK:KS+Q#ILEMJO@&ZDU*[N
MI9-33SC+*621S"YWA>B=^%P,'IP*])GA%Q \1>1 PQNC;:P^A[4 <_;^+#>W
M5JUEI5W=Z;<74EI]MAPP1T8J69>HCW*PW>W3!!/1DX!(!/L.]>-^'M3G\.?"
M73KFTN9UN-0U1K$2.^];</=NID"GC(&?QQFNOO;F]\.>/_#UC;W=S<Z;K*SP
MS07$IE,4D:;UD5FR1D9!&<>U %E/'<#^&=<UO^R[T1Z1<3V\\&8_,S$!N/WM
MN/H3T[UTMC="^T^VNU4JL\2RA3U 8 X_6O+H?^2:?$W_ +".J_\ H-;5KJLU
MUKOAGPP)I;>U?1!?3-$Y1YB-B*@8<@#+,<$'@=LY ._HKS)YO$-V/&WAFSU.
M[-YI*Q7&F7@;]X1)&7$3G^+!4KDY.#GJ*B7QAYVN^$=7@N[H:-?0)#?1F8F.
M&>12(<\YSN1U;M]TGKR >I5$]Q$DRP%P9F1I%CR-S*I )'XLOYBLSPWYLVFM
M?2S32"]E:XB65R?+B8_NP >GRX)'J3[5S$MD)/CDK&YN@/[!\[:LS!01<*,8
MZ;3@9'>@#I?#?B*+Q);7LT=I-;&TO9;-XYBI;?&0"?E)'4^IK:KQ5CJ%AX)\
M:ZY8:O>6D^GZ[>S0QPD"-B)5SO&,L".,9Q[5V5UJ.H:]XKU'1;=FCAL[&"4+
M%>M;.7EWDON526"[5 '3).0<C !W%8VH>)+:RU6+28()[[4Y(_.^RVP7*1YQ
MO=F(55SQR<GL#1X5BUJ#P[:P>(+JVNM4BW)--;G*O@G!Z#G&,\=:Y'P&S-\2
M_B#]K/\ IHNK<*&Z^1L;9CVQ0!UUMXA$NM1:1<Z=>6=U+ \Z&4*T;*A4'#JQ
M&?G''7VZ9V:S]:NX=,TNZU22)9)+."6:-?XCM0L0/J!7GNHZOJVG_##3?',&
MI7$VH>7;W=U 7)AF25E#1"/HN-^ 0 ?EY)R: /4J*X"&+4M8^('B;2)=>U*"
MRBM;66)8&5&B+^9D*0O X'N<#)QP>=MM8UU_ASX;\62Z[>O?&\@@DB!5898S
M/Y3!U Y)'.<YSTQ0![#17G9MM6UWQ]XHT8^)-3M+*WM[66$6Q1&C9Q)P&V\#
M(Y[G YP,&EH.O:KJ?A_18=5U20W4>H7-G<16JE9]2\K<HV%2-@!P6;('')&:
M /4:*\?N]>UU?AIXBN4U2\M[O3-=:SA=F5I/*\Z-0CMR3@.1D'/'6NFB%_8?
M$Q='DUB_NK/4-)EN)%F<?NY5D50T>T#9PQX% '=5C7WB*+3_ !'IVCRV%\WV
MX-Y=XD.8$< G8S9X8A2<8KC=*U34DTW4_"=YJ-U)XAAU%;6.Z:3]X\,A,B3#
ML,1*YP.,H0>M>A_8H#+;RNK/);J1&SL6VY&">?XL<9Z\GU- %B@]/6O-IM>N
M+'Q8;#Q!)J6G23ZF/[/OD<M97,.\;82 =JN0"#D9SSG'%>BS1M+ \:2O$S @
M2)C<ON,@C\Q0!6TF]N-0TR&ZNK":PFD!W6TS*73!(Y*DCG&?QJ[7D-OKFNW'
MPN\':D-:NDO;O5H8+B7Y3YJO<,I#<9Q@#@$#'%;UO+K6G>,O$.AVFJW%X6T9
M+ZT-^ZMY5P6D3J  %)521T% 'H%1PSQ7,0EAD62,D@,IR"0<']0:\[\/ZPFJ
MW%UI=Y/K6EZO'ISBZTZ\F?<S97]]#)G!'!&5(Z\ 5@V$FHZ9\&/"UYINK7EM
M//<VD;_,'4AY0I&",@<] 1F@#V:BN N8=0\/>-?"MBFNZE>P:C=7AG%W(K;E
M$)95P   K#(P._IC&;?^*M2T*/QRZWCNME?VEO:-.=XMA,L8+<]0"Y;!] *
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MF=NT%.V3USUYS68OP]TY?"EIX<74-1%A:SB>+YX]^X/O )V<@-S_ /6KKJ*
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M4)C# !CE54L2 !DY_/FC7?$8T/4-'M7LI9AJ=XMHLJLH6-B">>YX4]OQK<H
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M^LP>/>LK9+8^3!!W'((-<[\1= BL_ ^L_9Q>7FHZI=6KS2+'NEDV21C@1J
MJ*>@_6O19YXK6WEN)Y%CAB0N[L<!5 R2?PIX(90P.01D4 8]GH=N=0AU:XO+
MG4+B.$Q6\ER$ B1L%MH55&6P,DC/&.*S[?P'IEK9OIL=S>?V,T_G_P!F%D,
M.[?M'R[]F[G;NQVZ$BNIHH P-0\*0:DVII-J-^MIJ8 NK163RV&P(0,H67*J
M <$?@:D'ABT3Q/#KT=Q<I<0VGV)(5*>4(LAMN-N>H!SGM6W10!RT?@33HM)U
M?2XKW44L]4:4RQ"52(A*29 F5X!R>N2.Q%37'@VRGATC;=WD-YI"[+2^C9!*
MJ[=I4Y7:P( !!7MZ\UT=% '.7G@O3[[1M4TZ>YNV.JL#>W09!+-@!0"=N
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M>FLENY6\D3>(#CAMO?'I4=IX:L;'Q#?:U!)<K/>E6FB\X^4SJNT/M]=HQ_\
M7JUK6CV>OZ-=:5J$9>UNDV2*K8./4'L0<&@#BM'NK^/XA0:4L^IPV-UH;SE;
MR<R.TBR(HE 8ML)#'C\P"*YNUO-8C^&6D^)WU_4Y;^'4Q'M>?]W)&;PQE77H
MV0>_3 QBO0;;P-86VJ6FJ"_U66_M;=K99Y;LLSH2#\P(P<$ XQC/4&HQ\/\
M2QX8C\.B[O\ ^SHY_/5?,7<&W^9][;G&_G_ZU %6QNI/%'C#Q+83W=U;V^DF
M&W@BMIVA.YTWM(Q4@DY( !R,+TY-)\(@5^%VC G<0)@3Z_OGK3N?!EA/K_\
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M<F:0*.B@G@#Z#GOFH_&%D=3\.SZ<;"]OH;K]U-%9RQ1OL(.>9"!C@#@YY^M
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M2?RMV[9N .,X&>OI6E7,_#O_ ))OX;_[!T'_ * *Z:@ HHHH **** "BBB@
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M/HS1HT9C9%*$;2I'!'IBG44 <OHG@'1/#]X)['[:(D=G@M)+MWM[=CG)2,G
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4'15+$[5]AB@#G/'.GV]WXY\$-*)<M=SQDI,Z8'D.>-I&.>XYJBNC0:MX_\
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MEJ$1G?R8FD \N;9G:,-\I/HPKHO"R/-8SZK(\Q.IS-<QI)(S".(\1A03\N5
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MZ>GB-]? G_M%X1;L_GOM,8.0NW.W&3GI5>X\(Z5<7]Y>!;B![Y0MXMO.T:7
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M-H&E56&YCEE)!(!X&#BNW;X=^&G\,IX?:QD;3XY/.B5IW+129)W(V<J<DGC
MY/'-64\%:&OAVZT.2WEGL[O_ (^&GG=Y93Q@ER=V1@8YXQQ0!EZK:VY\3V6D
M0SW=VRV,KC3#.ZH S@>?)*6W<'*@88\D@<&N1BU+4;KX1^$=0FU&\-Y_:MO#
M)*+A@94^TE,/@_/P!UKT"3P1HDM[9WK1W?VFUA, F%Y*'EC)W%9&W9D&><-F
MH4^'_AZ+1H-)CM[A+*"X%U%&MU(-L@;<"#NR "20.F><4 9]RYC^-,3A2Q7P
MU*0H[_Z0G%8FB0:MXF\,:)XGM]8@M+OS%N;BZ^T2,'&3YD+1_="_PX[8&.:[
MX^'=//B&/72)SJ$=O]F63SWQY><E=N<=1GIUK,L_A[X<L-:?5+6TEBD>7SS
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M)+YA+7OG,JO'(/X@2YP/X<<8Q0!ZM17FMOH\&K^-_'=C>W%]):QQV;1Q?:Y
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M,T7P]IOAZ&6'3(I8HY9&E=7GDD!=CEF^=CR36I10!F7N@6-]J'V^0W,=T81
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M&#9Y/.>]8U[;WFN:K'H<^@&WT:PN(9Q=RR(R3"/#(L:CD'>%SG^$$=ZZVB@
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M,ZGKC:Q=::&O7 $K)*Z+,!T\Q 0K_B#[UJIHE@FOOK:PD:@]L+5I-[8\L-N
MVYQU[XS6A10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 445P_C6^9/%7AC2YY[:&
MPOFN-_VJ(R0R3*J^6C#<N<[G(!.,@<9 H ZK5KR?3]/DO8(/M"P R2Q+]]D
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M]-Q\S)(]3Q0!W%%<GXS>SEO= L+@2SW-Q>EK>RWA8;@I&Q/G$@_(H^;H3D#
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M77POTV.ZCAN/LOB=8(BRA@D?VLKM7.<+CC'IQ772:1I$?QILPNG62QIH,D@
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MCE64$;3[GMFI+?68;NY\$VSZ6VF:3)JE]#?64A#1QWB[BD>1PR^87*]L@>E
M'K,4\4\0EAE22,]'1@0?Q%(ES!)(L:3QL[)O50X)*^H'I[UYAK6GI!XI\:V5
MM ATB?P[]JNH=H\M+OYPK = Q1<GUP#52UTRQT_3OA7J-K;117T[V\<MPH_>
M2*UH<JS=2.!P>F !0!ZTUU;K<+;M/$)V&1&7&XCZ=:YNQ\179\<Z[I%_):1V
M-C;6\\,@!0_O"X.\DX_A'3%>?>);BRG\-ZMJ&FF..-?$D9,UR^^XDN%G16V=
M/+50" /F.WT%=''HVD>(/BMXBBU.SM[ZW&FV;(DP#IR9!N Z9]#U&>.M '0>
M--=O]!T_3KK3_LS+/J%O;2^:A;Y)'"DK@C!Y[YKI!-$9#&)$+C^$,,_E7B\<
M4MM\,=/MS([V,/BF*/3W=LDVRW6$P3U'!Q[8KJ/%GV?P9XRLO&BVV;2[C.GZ
MGY4>6!/,4@QWW#8?9A0!Z"DB29V.K8X.TYQ0[I&NYV55]6.!65X:TLZ7HT:R
MQ1I>7#-<W>P#!FD)9OJ 3@>P%<W\6;6"X\)VK2Q@LFIVFQ^C)F90<'J.#VH
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MNZ\2>"M+UB]6);F[B,CK$"%!W$< D^GK6^[I&I9V55'4L<"N.^$W_)+/#_\
MU['_ -":H/BS;03^$('EC4O'J-IL?^),S(#@]1P3TH [475N?-Q/%^Y_UGSC
MY/KZ4HGB:#SQ*AAV[O,##;CUSZ5YW+X>T9/C##9KIMJMK/H3RS6XC CE=9U"
MLZ]&(R>2#^E8NF2:=9^%IM-N(G:%?&,MII]JDOEQ;UF+(CG! C&"2,'H,#-
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M8N)H;>%)3J-XA=$ 8J)VP,CMTXK?\:00W'@?78YXTD3[!.VUQD9$;$'Z@\T
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M%U:2>!/A_9W(>XO9+J864<DNV',?FC,G!R%7&U1R3MQCK69?R(/AI\0[;[1
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M'0G R15B71=+GTO^S)=/M7L1TMVB!0<YSCUSSGUYJP][:QHKO<PJK(9%+2
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MEO-!TG4+G[3=Z=;S3^7Y)D:,;C'DG83W7D\'CFK*ZA9/>-9I=P-=(,M ) 7
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M(W,+"(R @C&_G+#@@'J*F\5PZ?HVA^(M1TC6+B]2_N+,ZL86C,441<*Y7RU
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M_:KQ5NBPDB6X."GS."-N3* >@/3IFO1;W0='U*SBL[[2K&YM82#'#-;JZ)]
M1@?A4USI>GWNG_V?=6-M/9;0OV>2)6CP.@VD8XH P?!^EZ5IMUK+Z3J<M\EU
M<B>?#(88Y2.0FP  D8)'N/6L&(I;?$WQBUND"WQTVU:T5PH+2XEQC/4DXKO[
M*PL],M$M+"UAM;:/A(8(PB+] .*1M.L7U%-0>RMVO40QI<F)3(J_W0V,@>U
M'DDXBO\ X V-[9D_VS T3PRK_KA?^<%;WWLQ8'US7=^/KJQM/ .H/K,4LMLR
M1QRQP2>669G50-W\*[B,GTSUZ5M1Z'I,6H-?QZ99I>,V]IU@4.6QC.[&<X[U
M:N;6WO;:2VNX(I[>1=LD4J!E<>A!X(H \VM&@F^*^J6M]/ITPN?#T8EA@ \L
ML)7PI!)W$+WXX(X%<YIFGV5O\,/A[J,5M"EZ=7L@;D*/,(,I4C=UQCC'3%>O
MQ^'M$B$?EZ/IZ>7"8$VVR#;&3DH..%R<XZ4A\.:&;:*V.C:<;>)M\<7V5-J-
MZ@8P#[T <9XADD\$>-SK=C:>;;^((?L<L:+UOD!,!..SY*GZ9-=MH^DPZ5HE
MOIH"R+''MD8J/WK'EV(_VB23]:RXK#7+_7MVJQZ?%I-C<&6R2W9FDE.TJAD!
M&%VAB<#/..F.>C90RE6 *D8((X(H \+N-*TY/@KXJN5LX!/;ZE=>1*$&Z+;<
M_*$/50/0>I]:[._T^STOXI^$CI]M#;O<65\LIC4*90%C8;B.6YR<GO77CPYH
M8M)+0:-IPMI&WO#]E38S>I7&"?>I/[$TG[1!<?V79>?;C$,GV=-T8]%.,C\*
M /*M 71O$G@VR36/$$]MJUG?>;/;1^2EREXLAX&4WDL>GJ#BM.ST72KGQ1\2
MHYM/M9(T$!5&C!"EK7+$#L2<DGK7H(T'1QJW]K#2K(:EC'VO[.OF],??QGIQ
M0-"T@/<N-*L0UR,3M]G3,H_VN/F_&@#RB"RM(/ GPTU*.");Z34]/5[D*/,8
M,I4@MU(P ,9Z #M6WI^BZ%K'C;X@#6[.TN8HY;?<;A0?*0VRY8$_=Z?>&#Q[
M5W1\.Z(UO#;G1M/,,+;HHS:IMC;U48P#]*==:#H][=K=W6E64]PH"B66W5F
M'09(SB@#R/P]?7.F6_@2#Q!J$UC9RV-TMM<3JN!+Y@\K>7! /D\ G!Y([FK7
MB;0M#L? ]XNG7KW\#:_;S>:Q39#(\L?F+$4 "C!YQT)/O7K&H:98:M:&TU*R
MM[RW)!,5Q$)%R.AP1BH9-!T>6PAL)-)L7LX?]5;M;H8X_P#=7&!^% #]-TC3
MM'BEBTVQM[..60RND$80,Y !; [X _*KM-1$C14C5511A548 'H*=0 4444
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MK>DR6/VY-4LFM-VSSQ<(8]WINSC/M4S:C8I' [7MNJ7! A8RJ!(3T"\\_A7
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MFL:9$UHLFH6JF\(%MF91YQ/39S\V?:GV^I6-U>7%G;WD$MS;8\^%) 7BSTW
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M@X/?%16_B'1KNZ>U@U2TDG1#*4649V#JP]0/4<5YQ<S^)WT_Q/H,TMKJU_\
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M'J* .V.MZ4%LV.I6FV^P+4^<N)\]-G/S9]J76I+B+1+Z6UF\F>.!WCDVAMI
M)'!X/2O(8M=TJ3P-\-(4U"W:2UU*R%PH<'R"(W4A_P"Z<^N.A]#7KFNR)'X>
MU*1W54%K(2S' 'RF@#!\&>+K/4]!T*WU#5[637+RQCG> R(LCDKN)V#\\ =*
MW)O$&CP7HLI=2M4N#((O+:0 [R,A#Z,1T'4UY7!)96_@'X6/&]O&PU.TR5(!
MR8W#_KC-5/%&MZ9<^&/$2VT\&G^1KR-+8@[IG=;B,//(6R54XR-H ' R<XH
M]DBUC3)]2ETV+4+62^B&9+995,B#U*YR*0:SIAM9;D:A;&"*3RI)!*"%?.-I
M/][/&.M<;XNGDT/Q'HOC+38&NXKA/[-NHXN3,DG,##_MI@9]'JMXN)\+?\(C
M<WUS/'IEM=2_VA>0+G9-*AQ*00< NSY..-U '?:?JEAJUNT^GW<-S$KE&:)P
MVUAU4^A'H:Y[QCXKAT.[T?3EOH;:?4+M8I9&==T,.UF+@-QR5V@D8YI?"$6@
MR:AK&IZ%>2WWVUXS<W?F!XI)%!&%P ,@8SCU'?-4/'MS!#XE\$++-&C?VOG#
M, <>4XS^9 _&@#8\/7Z0PW]O>>)K357MY#*)!Y:R0P,,H) O&>OS8&16=XO\
M0SPZ3H>I:#JD36UUJMK;O)"$E2:)Y K -R/49%48=3L=)^+FO_VA=16WVO3;
M0VXD;!FPT@(0=6.2!@9-<?87UI_PICP5_I,0,>MVJN"X^4BY8D'TP.?I0!Z&
M^L7UO\4WTR:] TK^Q&O?*9% 1Q,JEBW7&,]\<FMV#7]'N=,DU.#5+.6PBSYE
MRDZM&N.N6!P,5RS7$/\ PO.)/.CWGPXP"[ADG[0I_ES69%I]UIGBJ_\ !4=N
MYT?5IAJ43@?+%#G-S$?8N% 'I,: /2HI8YXDEB=7C=0RLIR&!Z$&J/\ ;VD_
MV@MA_:5K]K9S&L7FC<7'51ZL/3K5N\69K*=;8A9S&PC)[-CC]:\R\%ZUX9U3
MPEX?T744277=-G0'3I,_:([M&(,I7KU+,6Z<G- 'H5YK^D:?/Y%YJ5K!("H*
MR2A=N[[N?3/;/6G7>N:587(MKS4K2"<HT@CEF56V 9+8)Z =^E>>:'=VB>'?
M'.D^(9(TO1>W<ES',0&EBD7]VZ@]05PJX] *JZ7;RVGB#X7VFLE#J,6FW0E2
M8@NK>7'M!S_$,8^H- 'H#>,_#*:?%?MK^FK:2N8TF-RH5F'49SU&1GTS5R\U
M[2-/D$=YJEG;R&,RA99U4[ ,EL$] ._2O-;8Z=_9OQ6(-MS-<9.5Y!MQ_P"S
M9_'--M9-/EUOX527;6[H^D3 -(00T@AAQR>^>GO[T =EXB\1QW'P]U?7/#>K
M6\C6UK++%<P;95#(I..<C/'>I(]0:>V\,F77XK*YN%CDDMV5"][F/E0#R.><
MKZ5PU[9PV>F?%B[L_+CTBYM]D&S C:<6["7;V^\P!Q_$".U:&K7-K_Q;%_.A
MR;F/:VX<C[.P_G@?6@#OK_7](TN98;[4K6VD)48EE"XR<#.>F3TSUI^HZK8Z
M=&!=WT-L\BMY>]ADX') [@9&>P[UY@NH:(=1\6^'?%VJW%C+<W\L@MW(5;JW
M<*(RAVDL< +@'/RC%:&B:G::!\2-1M=9F-C#+I-FFE/?2!?W4:GS$WDXW;B"
M1G)QF@#H?AUK-[KOA0WM_>+=S?;+B,3*JJ&1965<!>,8 K=.N:4+RXLSJ5I]
MJMT\R:'SEWQK_>89R![FN2^$D]K+X/GBMI(R(M2NP40CY 9F*\=N,4>,&N/#
MWB_1O$UE:O<&Y1])N84'+E_F@)],2#:3V#T =4GB'1I=-&I1ZK9/8EQ&+E9U
M,98G&-V<9SQ5)-5M+?5M:N9_$5O-:VL4;26:A/\ 0L;LEB/F);'0^G%<AX0T
MZ^TW6[CP5=!I;+3+E=3CN-NU)(W^9$ [8FWL/^N=6]->%_B9X[AB=&E:PLQL
M4C)(23/'KR/S% ":QXWDU'PKHFMZ!?K"ESJ=K#/$ CMY<D@&UL_=)'X\UVFF
MZ[I.LR7$>F:E:7CVS!9E@E5S&3TSCIT/Y5Y#_:.FW7P7\(6QNK>3RK^PBG0L
M"%(D&Y6]P <CT^M=G;2VR?'"ZBADB!?P]%E4(Y(G?MZA<?AB@#H/$OBG3O"]
MM:RW\JJUU<QVT2$XR68*3[!0<D^WN*P7\5_8?B'<PWNM6Z:!_8J7T;.45%=I
MBF=_4Y"\<]Z=\4)$M]#T>YF=8X(-<L9)9&.%1!*,L3V'O56"[TZ]^-IN$FMY
ME'AQ&C?(/_+=^0?]TYSZ'T- ':IJVG2:8FII?6[6+J&6X$@\M@>!ANG7BC3M
M5L-6A>73[R&Y2-S&YB<'8PZJ1V/L:\8TS4DTSP5X9U![B5-&L==O!>26V&^S
MJSS+&Y&#A06';N,=J]&\)1^'[C5]6U;0[Z74)+P1"[O!(&B=E!"@8 7<%ZX]
M1F@"_JWB_2=&U[3='N[F..YO=[?.X41HJD[B3ZG  [Y]JNWNOZ1IMPL%[J5K
M;RL5&V64+@M]W.>F>V>M<IXOO+;3_B1X)NKR=(+<)?H9)#A=S1IM7/J<<#O7
M.17^A2W'BOPWXNU6YLYY]2FD^R,0OVJ!R#$8_E+,=H50 <_** /2;[Q1H&F2
MS17VLV%O) H:5)+A5* G R,\9-1W'B_PW:Q2RSZ]IR1Q2")V-RF%<C.T\]<<
MXKC[&UTR7XO-9SPQ2;?#,$?DW.V1^)6R&SG+8QFJ]B=..H_%$DVV.%8_+]W[
M, 1],Y_&@#OU\1:*^JQZ6NK637\B;TMUG4NRXSD#/IS].:?-KFE6]X+2;4+=
M+@R+$(VD .]L;4_WCD8'7FO+?-LH/ OPK=)+>-O[0L<D$ Y,+!_UZ^_6KM]<
MW6C:I=:AI-];:MH\^M(E[H]P!Y]O<F95W0L.3\P5PI'3F@#U6LZWU_2+N]6S
MM]2M9+E@Q2-902^W[VWUQWQTJIXRAU"X\%:U#I6[[>]E*L(3[Q8J>![^GO7#
M:G<6FO\ @7P8FAR1_P!HQWEF;:.,C? 4P)00.0%4,&^GTH W-2\3#4_&=SX8
ML=>CTUHK(.MQ$8W=KEI"H3#@@[=O*C!.[J*ZN*=M-T:*76+VW\R&%?M-R0(H
MRP'+8)^4$^]<E975N?C;JL0GC,G]B0+MW#.1*Y(QZ\C\Q6A\1-0LM.\*B6_M
M([B!KNW3,K,L4+&1=LDA4@[5(!([XQWH VH?$&CSV]S.FIVOE6I N&:4+Y.>
M1OS]W/O45MXGT&\OX+&VUBQEN[B(310I.I=T(W!@,Y(QS].:\WAU*Q;Q5XZ\
MS5H+S[3HD++*-JI+M27<4QP5&0,Y/7!)-,CDL;?P?\*'C>WC;[;:9*D \P.'
M_-L9]Z .^\7>(;;2="U(1:K;VFHQ6KRQ;BK%6P=F0>.2,#/7M5SPK>7&H^$-
M%O;J3S+FXL8)97P!N=HP2<#CJ:\ZL]9LK?0OB)I6MW,,&KO=7KF&X8*TT31X
MA* _>7:  !Z#UKNO 4\5Q\/_  \\,B2*-.MU)4YPPC4$?4'B@#0F\0:/;WHL
MYM2M4N#((O+:4 AR,A#Z,1T'4U)J&M:9I(']H7]O;94O^]<#Y1U;Z#N>@KQS
MQ1K6FW/ACQ$MM/!IY@UY&EL0=TSNMQ&'GD+9*J<9&T #CDYQ720>)-&TWQYX
MIMO$EW!!:ZI!;R6,]R=L5Q;>5M9%8\<,6X[[C0!OZCK%]%\1/#5E;7RMI>HV
MMU*\2HI#&-4*L&ZX^?L<5LOXGT&*TFNGUFP6WA<QR2FX7:KCC:3GKP>.M>:>
M+()6UWP=I_A:2/3;A=-OELHILJ57;%M0Y.Y2R@@'J,^HJ3Q5XBT77/@7JC62
M0VA@6.":Q8@-;2K*FY"/7.>>_6@#TRSU[2-0U&XT^SU*TN+RV_UT$4JL\?..
M0#QSQ2/K^D)?+9/J5JMRTGE",RC)?^Y_O>W6N.U9[>+XJ^'H["2VBE;1[N.(
M(0!U0H,#MG) ^M<W%+!?_ 2?1Y?^0[#NMWM6/[\7OG9''7<6(;/H<T >K'7-
M)%W<VAU.T^TVJ;YXO.7?$OJPSD#W--3Q!HTFG+J*:K9-8NXC6Y6=3&6)P &S
MC.>,5QWB(:AX:\2Z#X@B@-W<7EL=(O$0<22D;X6/H/,# GL&JKX-TZ]TW6)_
M!=R'ELM'N?[0BN"H"R12#=$F/:4R-[>6* .AT#5-1N/'WBK3+J[\ZTLDM&MD
M\M5\OS%<L,@9/('7TK;M]?TBZU#[!!J5K)=D%A"LH+,!U('?'?'2N!=I[GQ9
M\3K;3)0=1?3+9;=4;YO,\B0#'ODC\Q4?AN_\*^)8O#31ZE=W&KZ?M,.G[@LE
MHX7:^Y0H(0 $'/!X R2* -SXC^+%T3PEJLFF:S;VNK6R H/E=@W'RX.0&(.<
M=>]=3<:K96$4)O;N*)I$+*&;E@!EB!UP.Y[5XO-K-D_P%US2=2N84U^%YA?6
MLS 3-.9R^[:>3D8.?;VKJ]6U_3-&^(>FZPVK6'EW6AF'9=7 ACV^:&5T?!!)
M.01Z*#Z @'>0ZYI-Q9R7D&J64MM'C?-'.K(N>F2#@9I^GZMI^K)(^GWD-R(G
MV2>6X)1O1AU!]C7D\J6OAOP)X:NK;5(KW2K/6#-J5UIC"1(0_F$$8!RJ-(O4
M9X!P.*[7PHOAZ\UW4M8T/4)=2GN8HTN[L2!HB5^XO  + 9Z<@8SU% '27VJ6
M.FB,WMU%!YA(C#MRY R<#J<#GBH#X@T9;6TN3JMEY%XP2VD\]<3,3@!#GYCG
MCBN:\3ZOI]EX[T6VN'M["Z>SG:/4[EL!4+(&BC!(4NV <G. .AS7GUK<Z?-\
M-= M)IX9#%XK194EP"H-TY(8'&/E.2,#@].: /:-,UW2=::X73-2M+QK=MDP
MMY5?8>V<?0_E7*^+O%HMKWP_!H^LP"2XUFWM+F% CF2,OAP"<]" #CIGM6-K
MTD__  GOBN'174:C)X57R4A(W-*'DQ@#^( C'X5FW_B#P_=^"?A^+6]M%:UU
M;3Q)"7 >WV?*^X=5P>I/]: /9"0JEF(  R2>U9]EKVDZE<_9[+4;:>;R_-"1
MR EDSC</5<]QQ47B:ZM[7PEJUU<VK7ELEE*\D$9(,J;#E01TR.]>;Z;J]A-X
MY\"SQZI:2Q/IUS#'%;8\J$E(ML0/+,PZ$$YX!PN: /2[CQ%HUI,T5SJEI"ZO
MY;>9,JA7QG:2> V.<=<5%<^+/#MF'-SKFG1[(A,VZY3A"0 QYZ$D8]<UY2ES
MH]YX?U'PG<>(](MX_P"W))OM5U=B.=56X\QLQL/O[@5!S@@Y]JZN2+2[OXW>
M1*EI,K>&PJQL%8',YXQ_NG\C0!V-[XAT;3F07FJ6D&\*09)0!AN%)/8'L3UJ
M34-9TW28Q)J%]!;*06!D<#('4_09&3VKS$:AHD6K^+O#OBW59M/-U=O(D+D*
MEU;.BJFP[220%VX!SP,<U(FHZ?X;\9R66MZA>:1I]UI-HFG2W#*%*1JP>)V8
M$!P6R1GG/TH ]4@GBN8(YX)4EAD4,DD;!E8'H01U%25A>#K#3=-\+6=IHZSK
MIR;S;^>Q+%"Q(;GG!SD>Q%;M !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4R2&*7'F1
MH^.FY0<4^B@#,N]'CO[^SEN-IM;)_.@@4<&7! =O]W)P/7GJ!C3HHH *1E5U
M*L 5/4$=:6N?U3Q?IFE>)=/T.>3%S=H\A)!VHJCN<=22./Q],@&['#%$28XD
M0GKM4"FSVMO=!1<012A3N42(&P?49KA=&\8PZ9JOB>+Q)KL:PVNI""U:XV)M
M3RT;&% X!;K[\FNPO=:T[3O*^TW2*TJEXT4%V=1R6"KDD#(R>@S0!<EABGB:
M*:-)(VX9'4$'Z@T)%'&24C120 2J@9 Z5SVL>-]&TFTTJY%U'<1ZI<1PVSQ'
M<C!CR^X<8 R?<C%=#%*DT22QL&1U#*P[@]#0 20Q2D&2)'(Z;E!I)K>"YB\J
M>&.6/^XZAA^1JI=:WIEEJ5MIMS>Q17MUGR(&/SR8Z[1WQW]*D_M2Q^V7%H;J
M,3V\8EF0G'EH>C'T'!Y]CZ4 87BKP_?:U?:%+:"T$&FW@NI$F=AY@V,FP *0
M.&Z_I711VMO% ((X(DA'2-4 4?A5*T\0Z3?W+6UM?123B/S1'R&:/^^H/WE]
MQD4P^)]$73)M3.IVPL89#%+/O^2-QU5CV(]Z -18XT38B*J^@&!3(K6W@A,,
M,$4<1.=B( ,_05(I#*&4Y!&0:HZCK>E:3)!'J&H6UJ\[;8EED"ES[ _S[4 6
MH+:"U4K;P1PJ3N(C0*"?7BA+6WB>5XX(D:7F0J@!?Z^M9D7BK0I]-BU&'4X)
MK6;=Y;Q$OOVG#8 Y.._'%./BC05@LICK%EY=]_Q[-YRXE_W>><8.?3O0!H?9
M;?&/L\6.N-@IXAC#(PC3*#"G:/E'H/2L,>-_#!L[B[&N61@MY/+E82?=;&0,
M=>0"?H#Z5??6],CTZWU WT)M;G:()$;<)BW*A,<L3Z#F@"^RAE*L 5(P0>]1
M_9H,J?)CRH 7Y1P!TQ6-J.N:7>>&+Z[@U^"P@ >$WVY1]GD'!R&Z,#_">:F;
MQ%HVG):6U[K5J)Y8/-4RR*K2(%R9".PQSV% &G]EM]K+Y$6UQAAL&"/0TY88
MD8,L:*P4*"% ^4=!]*J:3K.G:Y9?;-+O(KNWWE"\39 8=0?0^U2Z@)3IUQY,
MS02^6Q210"5..N""/S% $Z1I$NV-%1<DX48%8$^DZS?^(2][?VAT**2.>"UC
M@(E:10"-[DXVAQN&!G(7T.<7P+XYTZ_\.Z#:ZMKEJ^NWENKM$\BJ[L<]AP">
MPKJM0U[2M*=DO;V*%D3S'!R?+3^\V/NKP>3@<4 :#HLB%'4,K#!!&013(8(;
M:(101)%&.B1J% _ 55DUK38KJSMGO81->C-JN[_7#&?E/0\<\=JA?Q)HD27S
MRZI:QK8$"Z,D@7R21D!L],CIZT 7DM+:,Y2WB4[S)\J ?-TW?7WJ5T5U*NH9
M3U!&163:>*="O]233K35;6:\>/S5A20%BN,Y'X$''45C>/?$\.D^%M9-EJPM
M-3M;9G1D4/LDVY56R"JEN, X)SQ0!U7V6W( ^SQ8'0;!2FV@8R$P1DR8WDH/
MFQTSZU7T>:2XT2PFE8O));1N['N2H)-<[X\U2^T@>'I[2_:VBFUFVMKE=J[7
MB8G<"2,CIU!'>@#KF57&&4$9!P1W'(I)(TEC:.1%=&&&5AD$>XK&LO&'AW4K
M6\N;+6;.XAL^;EXY 1$/4^WOTXJR/$&DMI*:JM_"=/<@)< Y1LG P?<\?6@"
M_%%'!$L4,:1QJ,*B# 'T I'@AE;=)$CGIEE!J0'(!'>N?OO%^FV'BNT\/2R8
MNIX7F9B#A "H SCDDMT]N>HH W&MX'DCD:&-I(\[&*@E<^A[4GV:#RTC\B/8
M@PJ[!A1[#M7">'O&4&GS^(H_$NO1*+?6I+6U>Y*(1&$C(&% & 6ZX[\UVE_J
MUCID:O=W"QAP2H +,P'4@#)('<]J )I+=-K-%'$L^T['9,X..*Q_#^E:M;R/
M?^(+VVN]3>,0@VL1CBCC!)P 23DDY)XZ*,<5K65]:ZE917EC<17%M,NZ.6)@
MRL/8BLWQ7XDM/"?AR[UB\RR0(2D:@YD?^%1Z9/?M0!M5$MO EPTZPQB9QAI
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M@ G') __ %FEKC=3U74G^)5AHMGJ36]C'827VH+Y<9PH8+& S*2,G<3[#C%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7!^*+RWT[XH^$KJ\E$,#6U["KMT+D1X4>K'' Z
MGM7>4A .,@<=* /)%N=/>P^+#&>V+.THSN7+#[, /J-V1]:GTW7].BO?"5M)
M/!93R^'HRNID;WE^X#;Q Y7?E=QR&/0 <UZIM7T'Y4;5R#M&1TXZ4 >&Z5?V
ML/PN\#323!(;#Q&GVJ1QM6 >9-]\GA?O+GTR/6O<(94GA2:,YC=0RG!&0>G6
MG;5QC:,>F*6@#D_B!I=S=:%'JNFIG5M&E%]:>K[?OQ_1TW#'KBN<\20:EK/P
MKUG6;.UF:ZU4Q7?V;'[PVJLNV/'O$I8CU=AWKL->TG6-6NHH+;58K72)(FCO
M81!NED!Z['S\N1D9QQG/7IO*JHBHBA548  P * //M:NK/Q/XC\%7GA^ZBN)
M8+IKF22%@3%:F,AP^/N[CM7![_0UR&IZG96OP^^(VCS7"+J3:K>RBU_Y:>6\
MBLK[>NT@CYNGO7MZ1I'NV(J[CD[1C)I#%&6+%%); )QUQTH ATZ>*YTVVFA<
M/&\2E6'0C%<7\2I[-+WP<EU+"H_MZ%R)& ^4))SSVR1S]*[VD(!Z@&@#S;Q%
MJ5CX;^(\%QK$\VGZ->::(;>[A)2))Q*SNK%>A8,IR>N*S-6A\/6%GX-CTL>5
MITOB1;B,W+D^8I23=( _(0L>.W0CJ*];>-)%VR(K+Z,,BE(!Z@4 >?Z3<Z<O
MQ?\ %3O-:AAI]H&9F7/&_=S[#;G\*Y7PWKFG6'P^\"+<&UCS>3HNHW!S'8L#
M+R>0-S*=J[N!G/.*]JVCT'Y4%%(P5!&<XQ0!XJE_:#P-\4;9KQI)&N[F13,H
M1G#PQA6(P "Q!QP,XXK<N;NPF\8?#,F>V<"SN2,NIP3 @4_F./<5Z=M7G@<]
M>.M&U?0?E0!PO@"YMI?$7C:.":)_^)OY@5&!X,2 GCW!Y]17:W0+6<X ))C8
M #Z5* !T %+0!XE;6]EJ_P $-$T*P,#Z]YD"P0QX\V"=9@7=@.4VKN+$XX^M
M=5H.H6^D^,/&5EXAGAMY+FX6Z@>Y8*L]KY84!2>"%P01VS7H(C179U10[=6
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M67H2.10R(^-RJV#D9&<&@#(\.:=:6-I<3VTLUQ)>SM<3W4RX:=R -P&!A<*
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MR^A&12E58 $ @'/(H \^GU73T^(>GZ9=,8+&PTM+G3K1U(:>9V* JAY9D1<
M=1O)[5S5K?G4OAMKEY9!4U+Q9JK6T:CGRQ*_E!2PXRL:,QQTS[U[,54L&*C<
M. <<B@*J@!5  Z "@#E]3\*Z9;^%-4AALX3<R:9+:M<&,>8Z[#P3Z9Q@=!@
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M$M=*U&^*WL\C;4*(A<1,>@#L%!]1D=ZQ[7Q!8OXY\5^(I8BB:'I:6L*%2&9
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M&X-_LXS6/X[U:WTN[\/&ZBABCEO2O]I31[ULCY;8([;FSM!/ SD@XKSK4KN
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M3FNFEFM#,JQ@E$C"[EZ(B<YXY'7. #IO&VKWV@^"]5U73H/.N[: O&I7<!R
M6([A02WX53TQ+^\CT34=*\2SZEIEP^^Y:6.(^8FQB"I55*G>%!'N>F*=_;DF
M@WUCI7B'4H+A[F*:1[W[/Y$2$,@16^8A<@OC)Y*_A7!>3?:)!X]/@EY)=&-H
MLMJ(/FCBNFSYOD$=<+\Q"]#@=L4 >K_VWI9O%M!?VYG:0Q!-XY<#)3/3=@9V
M]:PKZ^NI/B5I]C#?2Q65II\M[?1[@(VW$)$#QD=)&Z_PUB:A8VNH6OA7PQX:
M9)[.RNX+RYNH6W)%%%\W+#_EH[8P.I^8FC2M=BMW\?\ BDJSR6TTD*+M.!';
M)M5<^K/YAQZ$'N* .NT;4S>PZA?OJFGW>G"=OLTMMPL<:@!@[9()#!LD<597
M7=*>&:;^T+<10H))'9PJJASALG^$X.#T.*\R4PZ5X:\ 6%_-Y>A2S-+J=S(-
ML3S;#(H=CQL:9B<G@[1VK?\ '-_I\7@_6M6TT1_:]0BBTU;X#Y7#ML!#="J^
M8QR./<XH TI/%T&A^&K2_P!8U&RO)[V7;9M9@JDX=OW>,DX&TKENG4_7H+G5
M;"S$1N+N&/S5+(&;EE'5OH,C)Z"N)U$VA\7^"M"C21+*QMWO4B9"&<HHAB&W
MKD;V8^@7)Q6%=>+%M= \<ZJZM-KHN9K,0LI_T:%3Y<.[LJ_,7_VBQ_  [[5_
M&FBZ3HD6J?;(IXKE_*M1$^1/)NV@ CMGJ>@J>35/M/B*QLM/U73RJQ//=VA^
M:9HR $9<'Y1N/)(YS7&O!:6NK> /#498VEC"UYC809GB411D#O\ -(SGV&3Q
M2_VA=W>O>/\ 5M-C>;4K&T_L^Q0(25,49<_]]22<#OLH [R36]+ANQ:R7]NL
MWF"+:7'#GHI/0,>P/)I)M>TBVNI[6;4[2.>"$SS1M,H:.,'&YAG@9(Y->=W%
MG#J7@#0O"6A2?:KB\>WFO;F-MQA5766661NSEA@ \DD^APZ^NGCU'QQXTF4M
M%ID(L=/C*]9(5)+>X\V0@?0GL, 'I5A?VFJ6,5[8W$=Q:S+NCEB;<K#V-6*P
M_!FG1:3X,TBPBR5@MD0L1C>V/F;Z$Y/XUN4 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%'2@ HKC=&\476M_$*^L(5V:3::>DL3=YV=R!)],(=OJ#G
MN,;=SXHT.S:7[3J<$20R>5-*QQ%$_P#==_NJW3@D'D4 :]%9/_"3Z%YD:#5K
M,^9 UPC+*"IB499]PXVCUS4L>O:7-I]K?17L<EO=C-NR98S?[BCECP> .U &
MC15"+6],FTQ=22]A-FS;5E+8!;=MV\\[MPQCKGCK5>3Q3HD5I+=3:C%%%#-Y
M$GFY1DDXPA4C(/S+QCN/6@#7HK';Q7H"'4 VK6H.G ?:_P!Y_JLY S^((X[C
M'6KG]K:>=,AU+[9#]BF17BFW?*X;&W'KG(P.^: +E%8\GBG0X;.:[FU&**&&
M;R)3+E&23C"E2,@_,O&.X]:GAU_2;C4+NPAOX)+NT3?/$C9:-<D9/X@CVH T
M:*Q?#GB:S\3P7=S8!S;PW#0I(RE?,"\%@"!@;@P_X#[U5\4^(;.QTG5+=+^>
M"\@M6D:2VA:0V^5)4N0K*F<?Q8XY]Z ([;PQ>6MA/IS7.GWMI+-)-NOK(ROE
MV+'?\X#D9QGC@ =JV-#TBWT#1+/2K4L8+6,1J7ZG_/I6#X7\201>"?#4NJ7<
MLU_?6$<@58WFEF(C!=MJ@L>O)QW'K3]8\>:78:+IFJ6AEO8-1NXK6!X(789:
M0*V[ R"/F^4\DC&* .KHK*O/$6FV$*R7$DXS%YQC2UE>18_[S(JEE'N0*<WB
M'21I]I?)>)+;WF!;&!3(9LC/R*H);@$G XP<]* -.BN(\"ZQ/JOB#Q:CW]S=
MVUM>QQVXN%V&,&(%EVX&W#$C& >.:H?$3Q!K?A;7-(U*QNI7TN-))]3L]BL&
MA5X8RR\;@1YN>O:@#T:BL3Q%K#V7AUKG3F22[N@L5B>JM(X^5O=0,N?936!X
M!\222?#72]=\0ZH\UQ>$JTCH,LYD951$1>2>   2: .ZHK%_X2W0A87U[)?B
M*&P;9=>=&\;PG&<,C -R.1QSVJ.T\9^'KY;QK?4XW6S2-YR590HD^Y@D<DGC
M R<\=>* -XC/6BN1\0^)+:\\*^)%TG49[;4M.L9)V7RFBFB(C9E)61<X..N/
MH:?X7\7Z5>6>BZ7+J/FZM<6,<F'5OWK",%\.1M9AR2 <CG- '5T51U:&_N;$
MP:=<K:SR,%-P4#F)>Y53P6[#/ )SSC!Y309-=T?X@7'AV]U:;5].ET[[=%/<
MH@E@82!-A*@ @\D<=O8T =SC P*0 #H*6N*\6:;XD>RU+5[/Q-+IK6<3RVMK
M%#&T)5%S^]+ EBV#T( !'!P<@':T5P3^*=1U(>"],4&QO=>MS=7CQCYH8TB#
MLJYS@LQ"Y/(&>_-6=/U?57USQ%X7CN@]W9K#-97<ZAB(91SN QN*$-C^\-H/
M<T =I17 VO\ PD'ASX@:5I4VN7&LZ;JMO.\@NHT$EL\04[P44?*2P7&.,UH:
MOJ.IVGQ*\-6$=Z1IU]#=M+;"->6C12I+=3RQ]!P* .NHP!THJGJ.J66E1127
MDWEB6011*%+M(YZ*JJ"6/!. .QH N45A2>,O#\.C76K3:BD5G:RF&=I(W5HI
M!U1D(W!N1QC/-2V/BK1-1UA]*M+Y9+U8S+Y>Q@'0'!*L1AP"<':3B@#8JK:V
M$=K/<7 9Y)[A@9)'QG ^ZHQT R<?4GJ37#_$SQ7%9^"]5;2M4NK>]MW6(3VT
M3%!)O :,R;2H."> 0<\>U=W<W45E9R75P6$42%W*H6( ZG !)H GHK)C\3:1
M-H4>MQ73/ITA 2987.[+;1@8R<DXZ47_ (ETK3&E6ZN) 88Q+-Y<$DGDH>C2
M;5.P<$_-C@'TH UJ*S&\0:4MWI]M]L0R:BI:S*J62<!=QVN!M/'/7I4MCK-A
MJ5W>6MK/ON+)U2XC*,K1DC(R"!U'- %ZJMQ81W5W;SS,["W;?''QMWX(W'N2
M 3CG'?&<$5M1U_3=*G%O=3OYYB:?RH87E<1J<%RJ D+GC)XI6U_2AIMIJ O8
MWM;PJ+9XP7,Q;D!0 2QQDX ['TH TJ*P1XU\.F.]9M4C3[$K-=)(K(\(7KN4
M@$=1V[TEGXU\.ZA]H^RZFDGV>*.63Y'&%DX3&1\Q)XP,G/&,\4 ;])@>E9EC
MXCTK49+R*"ZVRV0!N8IXVA>($9#,K@$*1SG&*99^)M)OM273H;EUNWB\Z..:
M&2(RIW9"Z@./=<T :]%<]XF\5V_ANXTJWE@N)9-0NEMT,<#NJCDL25!YP#A1
MR?3 -7;SQ%IE@=L\LN\0B=HX[>21TC/1G55)4<'J!T/H: -2C %06=Y;:C9P
MWEG/'/;3*'CEC;<K ]P:SM1\5:+I+RK>WGEK RK/((G:.$MC:)'4%4SD?>(Z
MCUH V**S;[7M.TZ7RIYI&E\OSC'!"\SA.FXJ@)"^YXXJO/XMT"VL;"]EU6V%
MMJ$BQVLH;<LK,<#!'ZD].^* -JBN<7QWX;?[6JZB3):E1+#]GE\SD$@JFW<X
M(!.5!&!4S>,_#J:;I^HMJUNMIJ#B.UE)($C$XQTR.<YSC&#G&* -VBL/2?%.
MB>)VO+32-4WW%N,2A4*21YZ, Z\CT."*YSP3XNAM?AWH=]XAU&9[F]FEA6>2
M-W,LGG.%7*@\D  #VXZ4 =]@9S@9]:6JCZG:1ZG!IS.XNIXVEC3RV(*K@,<X
MP,9'4]QZBH;K7-.LM7L]*N)V2]O QMX_*<^9M&6P0,<#D\\4 :-%9%KXGTB]
MBU"2WN7==.8K=_N)!Y3 9((*]0.<"J9U72[OQ1I@CUJY2Y>TDECT]00DR':=
M[J5R".V2#S0 [^P;Q_'*Z_/<P/;QV36D-N(SN0,X9GW9QD[5'3H*Z&O/-3\:
M'7/!7BZYTI[^PGTM;E89?L[(Q,2 G)9< [B?EX; [5N^'O%NDWJ:;I1U#S-4
MDLTDVLK?O2%&_:Y&UB#U )([T =-16#XN\3P>%-'6]E@FF:29((UCB9QN=@H
M+$#@<_CT')K U'Q$;'XDZ:TVHW4>E3Z3/,;:2-E&]9$ (CVARW)X()]* .]H
MK*L_$NCZAHHUBUODDL2Q3S-K [MVW;M(W;MW&W&<D<5 /&&@^1J$TE^(!IX!
MNTN(GB>($9!*, V".AQS0!N45SJ>.O#3W4%O_:L:O<1&:$NCJDBA=QPY&TD#
MJN<CTJ]HWB'2]?6X.FW)E:VD\N9'C>-XVQD JX!&1T..: -2BL+5;RP3Q-HE
MI-K,]K>.\K0V43?+=?(<AQ@\* 2.1R*KW/C_ ,+VBW32ZLA%I)Y4_EQ._EG
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MF6&%YBL?]\A 2%X/)XX/I0!I45@W'C7PW;"T,NL6V+R$SVY4EO,0#)(P#_\
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M=0.57?&",J=N"77@;><8)H [Z/Q)I<UQJ=O'-*T^EA3=Q_9Y-T88$J0-OS9
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M:W#G4'@^T)&('VM'_?#[=I'.,YZ\59L]3M;^XO(+=I&DLY?)FW1,H5\!L D
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M#F.\U'^R_ =GXBTF^N[^ULK1+AFN6+/=VP +%L@?/MRP; .1@\$BJ/A:9?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO(K?P[>64MY+?7,EA).LC0X\F/RHT\LD* &W8 4<G&3S6<WAF]\-^-+2^\/
M2>&];NHWOK51\MM,"&$J#L&Q@^Y^F #K?^$Y\/FYCMA=SF>6W-S'&+*<L\0_
MC V<K[UOPRI/#'-$VZ.10RMZ@C(->>WL3+\>M*F2)A;QZ*\)D"G8KER0N>@.
M.U>B*H50J@!0, #H* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@!&94&68*/4G%,$\1( E0D]!N%8OC>
M-)/ ?B!716']FW!PPSSY;5YM\*K"RU;PGX=L[S0DC2W@>^CU%XX]TDL=UD;6
M!+#'0YQD'TH ]GHKSC4/%6J^'?B=#;ZG?!_#5^S6L6^-%^S7 C2098 $AMQ
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M0 4444 %%%% !1110 4444 %8GBSPW#XM\.W.B7-S+;VUSM\QH0-^%8, ,Y
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MA8R!UC9$#288L%9@.FXYXQTKJJ* .;A\(0^=HSWU[+??V.=UH\J*)-VS9EV
M&[@] !S@G)%5=?L;NX\6:7JD6FZK.=+$GDFV-KY4GF*%;/F2JW0>@_&NNHH
MXI8;]?&+>(_[!UPS-9BR,&ZRV>6'+C_EOG.2><_A0(;\>,3XC_L'7/.-F++R
M-UEL\O?O_P">^=V3US^%=K10!'!(\UO'(\,D#LH)BD*ED/H=I(S]"14E%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
&1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>thackray-biocrystseparat007.jpg
<TEXT>
begin 644 thackray-biocrystseparat007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-I+\;Y(=D+>9X<83J ,M_I"_>_#U[5QFCZ=:Z7\#AXFLK8C5X;>:+[6A8R)
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M90;920OIGD\>]8MAIEE8>%OAAJ]M;I'J,M[:0270_P!8\;Q.&0MU*\#CH.U
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MFC7&ON+LR0YMK5GB9DAV[L"/?M."<#O0!ZTLL;Q^8KJR==P.1^= D0L5#J6
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MSWK$U0VQ^*G@EXS%YSV-Z7*XW,NR/;GU'WL?C5GXJJ'\)6Z$D!M4L@2I(/\
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MHUS\S DMOP,G&%SC\*Z)Y$CQO=5W' W'&33+BYAM;=IYG"QC'/7)/  '<DX
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M++]1VH S-&\*Z!X>FGFT?2+2RDG_ -8\,84L/3Z>W2K>J:1IVM6JVVIV4%W
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M/*'EXSGIZYYSUSS5UKNV1@K7$2DOY8!<#+?W?K[4_P Z+S/+\U/,_N[AG\J
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M,:*RV2G3H2+'_CU&#^X_W/[OX57\4^(1H-K8B/RS<7][#91&0_*AD;!<C(R
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MY"D[_P"\N[:"#VXZ<5IZQI6EV]CXKU2QUE+JXO/#UP)8+4((654.V1@G\7)
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MWH>H:KJ\MK::YX<FU"*2[4?+=V$R>6H*YX=054@<'GTYKT'_ (1_1_MC7?\
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MNG/G=:"!1$<\_=QB@#S/Q;H>E6?A'QQ=6>HK>RW5HEQ-!&B>3"X&U74+PKL
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M^COGTZU:[C3RTG,2EU7T#8R![4 >+W6C:;'\)?%]\EG +JSU>Z^RS!1N@VW
MV^6?X/PQ77WEU;WOQ(U;2=8O;>W5].@^Q1W42,DL1W^;MW<9W8SCD@#^[79?
M\(OH'V*:R_L73_LLS^9+#]F38[?WBN,$^]&H^&-"U>"W@U'1[&ZBM_\ 4K-
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M%XMY>Z38W%THP)IH%9P/0$C-%KX<T2Q>=[32+&![A/+F:*W53(O]UB!R/8T
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MBV[O,3;NVYW#&<XQ]<TKR)$A>1U1!U9C@"O#+/2[>7P;X>6[@BMVU_7/ML,
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MQ?NW#0*9!]&QFKU% #9(TFB>*5%>-P596&0P/4$=Q2111P0I##&D<4:A41%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 5#<W5O90F:ZGB@B! +R.%&2< 9/O4U</\1;B"PF\,ZC/?6]N+75%
M<17,@CBES&X.7/"D+D@GC/'>@#IEU*TU2"6+2M5M6N0"5,;K+M(/.Y0>F>".
M#[@U'X=UM->TUY_+$5S;S26MU#G/E31G:RY[CN#W!!KG_!4&GW'B#Q'KMKJ&
MFW+ZE-&PAL[A)C BH%^9EZ,Q&2!QP.34?P_1_P#A(/&\JY^S/K3*GIO$:A_U
MQ^5 '=5Q/C_6M>\,Q6>L64L3:-'.B:FAM]\L,1(!D0YYQW!!ZYKMJBN;>&[M
M9;>YC22"5"DB.,AE(P0?;% &%J^HWUS=:3::#>P"6Z/GRR-%YJ"V Y?@CDDJ
M%]<GL#C4O-6T[28T_M'4;:V)7(:>58]P'4\UPWP9BMT\+WQBD,K17\UJCM)O
M*PQL1&@)_A )('^T?6K>BW8@^*/BVTU9D1YX+:2R\W $ELJ$.%SV#ELCU- '
M8R:II\3VR27]JCW6!;JTR@S9Z;.?F_"G0:A975S/;6]Y;RW%O@311RJS1YZ;
M@#D=#UKQNVC?3/!_A6:Y?RM+A\6^9:22'"QVA:41DD]%.<@],$5UOAS4K&[^
M+GB?[/=PR^;8V?EE'!$FWS-Q7^\!D9(H [6\U33].>%+Z^MK9IFVQ">94,A]
M%R>3SVI(]6TV:]ELHM0M'NH1F6!9E+I_O+G(_&L3Q_H\^L>$;G[$/^)C9,M]
M9-C)$T1WKCZX*_\  JXEM9U%=>TSQKI]JXMO$=O_ &;' 4Y23;NMY']<OY@)
M_N%: /36U[1TM([IM5LA;R,427SUVNPZ@'/)&#^5.;6=+6S@O&U*T%K<$+#,
M9UV2$G "G.#D^E<=JUQI6A>*?#FDA[>SN8-/F$.HWDA")&-@=57(5I&P#D],
M$\YQ7#1RZ?/\'[2"2:&4P>(@KAR 45KPGD<;<KDXXXH ]C3Q-H$BADUO3F!9
MT!%TA^9!EQUZ@ D^@I7\2Z%':PW3ZSIZV\R&2*4W*;74'!8'/(![UQWBW3-(
MM_&_@B-;*RA2:_N'=5C50[>0<$XZ\A?TJKKEUHUEXAU[2;1++29HM&5)'; -
MQ&WF%8X8\[1@DY."26QCO0!Z'-JVG6TD$<]_:Q/.I:)7F4&10I8E<GD  G([
M"L^\\8:!9^'+G7AJEK/IUN&W303+(&8?P @\M[>]>:Z4VG:A'\(]YMKC;#)$
M^<-RMK]T_1L<>M2ZFL:Z=\7K>W"A557\N/H";8%C@>X.?I0!ZKI>I6VKZ=#>
MVDT4L<B@DQ2!PIQDC([BK4DB11M)(ZHBC+,QP /4FN>TOQ1H4>FZ) VJVGF7
MT:Q6P$@/FNJKE5/0D9 ^IQUK=NUB>TF68(8]AW!QQC'?- %2UU_1[V<06NJV
M,\IB,X2*X5CY><;\ _=SQGI2VNO:1>^?]EU2RG^SC=-Y<ZMY8[%L'@>]>2Z;
M9Q0_L]66I:?9H]W';H;B6"-6F:$7"F9<D'(VJ<@\8'2ND@;PMXBU'^V+'7)-
M9OAILL1"M$5C@(SB541<?-C ;G/;@X .SB\1Z'/>06<.LZ?)<W">9#"ERA>1
M?51G)'TI;CQ#HMI-)#<ZO80R1ND;I)<(I5GSM4@G@G!P.^#7D*:5I][\$_"S
MZ9#;_P!MF>T^QRQ >;YXD ?D<\*&)] OM76Z/I^EWGQ:\8QW-I:3L+:P8))&
MK<X<DX/?(4Y^E ':3:WI5O?I83:E9QWDC!4@>=0[,1D +G.2.U+<:UI=G<BV
MN=1M(9R5 CDF56R>@P3U/;UKR?2[G0]8\-7WA[Q/KEU!JD.H2FXTT&))I9O.
M+HT7R;V+97!!/ITK2UZ>]T2]UK5],N+;5M):^B_M31[@8FBF_=J&B<=SB,A3
MZ<4 >C7^M:5I;HFH:E:6C/C:)YE0G)P.I]>*+K6M*LI7BN]2LX)$B,S++.JE
M8Q@%R">%Y'/3FO-I-1TK_A)/&6A>*M<?3/M<P=$F,2)<6K0JH",Z$DC## /!
M)P,YJS8Z?ID'Q/\ #EM'"6CB\./Y0NP#+A9(PA;/.[;GKSUH Z[6/&>AZ/X?
MCUE]0MIK6=@EN\4JLLS$X 4CC&>I[ &MNWN(+N!)[::.:%QE9(V#*P]B.#7B
MMP\,7PQ\1A&1;>V\6-]TC;&@NXS^ YKVJVN8+RW6>VE2:%_NR(<JW;@]Z *L
MVN:3;WJV4^IV<=TS!!"\ZA]QZ#&<Y/8=Z+O7-(L))H[S5+*W>&/S95EG52B9
M W,">!D@9/K7C_BW5]-N/"WBQ+2:WL/*UM?-M6?=//,LT0:9MQ^1.. HZ*#G
MDBNNC73;WXW+,BVTX;PX)4<!6!/V@_,/P/7T- ';IJ=A)IPU%+VW:Q*>8+D2
MJ8]OKNSC'O7+:7XEFU'XF7NE6^I6UWI<>EI<HL 4[)#*5(+#))P!QQUZ5Y_8
MWZ:=X2\-RRLJZ%;^*+@7A'W(E$LGE%O1 Q4^F0/:NQL-0TR?XX79M;NUD:;0
M8AF*13O83-QQU(7'X8H [RZNK>RMWN+N>*"%/O22N%4=N2:CLM2L=1A>:RO+
M>YC1BCM#(&"L.H..A]JYOX@:A8:?8:0U]!&YDU6W6WEGD9(K>4$LLLA!&57!
MX)P3@<=1Q<5Q97EQ\4K637(P)[:&0W40'W?LOS.JKU4'CC.>.23F@#U&'Q!H
MUQ*L4.K6+R-@JBW"$L#P,#/.:1/$.BR7,=LFKV#3R2M"D:W"%FD4 E0,\L 0
M2/<5P.BS:9XF\0>$[M]2T,3:3921M;07L4[SR.B@!5!X5=I;GG...]2>#=.M
M+B+QO+9VMH^HPZ[=FU<HI:-_+785/\/);\S0!WJ:WI4FH_V<FI6;7O/^CB=3
M)QU^7.>._I1/K>E6M]'97&I6<5U(P5(9)E5V)Z  G.3V%>8>%[KPWX@\/^&+
M6\UN[?5M-GA*:6#$D\5S'\K94('*_>)).",DG-06%UH6JZ'K/ASQ5KES;7Z:
ME.;C3\Q)).QF+QM%E-[Y&S&TD\ =,4 >QR2)#$\LKJD:*69V. H'4D]A7GGB
M+X@)>_#C5M=\+ZE;I<6;D+D+(VT2^7NVGH&Y(R.E>AQ@B) =V0H^\<G\?>O$
M)KVU_P"&?_$%G]HB^TPW-P)8MPW1YO#C<.V>V>M 'L=KK.F7M[/8VVHVD]Y;
MC]_!%,K/'_O*#D?C2)KFDR7XL$U.S:\+,H@$ZERR]1C.<CN.U<??1VEG\6O#
M"VJ0Q!]*NTVQ #<H,94<=1U(_&N-;7-)N-&\&75G=6EC8Q^(D=;#S=TELI:;
M<TSL20223C@#=CG - 'JFF^+M'U;7]0T>TO('N+(JC@2#+N02P4=]H R1ZX[
M5KW5W;6-NUQ=W$4$*XW22N%49X')KB?"UY;1_$OQM:O/&MQ/<6CQ1,V&=?LR
M\@=<<'FKWC_4+#3[313?0Q,TFJP+;S3R,D-O*-Q61\$9 P?E)P3CIU !OQZW
MI4MC+?1ZE9O:0MLEF$Z[$;T8YP#R.#ZUYW:_$$R:#IWBR;Q%:1VTLC+<Z01&
MQ&]F6)5(^=6X!)8D8W' QBKG@?4+4^-/'"'4H+EFFMYO,4JH=?(7<X _ASQG
MGMR>M<W'*@_9LT>3>NR.2U+MGA0+M<Y],4 >N3ZYI-M91WL^IV<=K)G9,TZA
M&QUP<X-*^M:5%%;RR:G9K'<C,#&=0)1C.5.>>.>*X+5?$-E:?$J.:_UPZ?I=
M[I:I87RF+R&=97\Q-[JR@GY#VSM'7BLN^TKP]91^![;36,^FMKS&&2X*L)%*
M2$[.!E"YXXP>V01D ]7L;^TU.SCO+"ZANK:3.R:"0.C8.#@C@\@BN=?QEI^I
MMKMAI&HVPO\ 3HR Q8/N<(6.U<C<%X!/3.?2NDM;2VL;=;>TMXK>%22L<2!%
M&3DX XY))KSS2[VUM_$?Q&M9KB*.X>59%B9@&*_95^;'IQUH WO!GBJVU7P]
MH::AJMHVMWMDEP]OYB+*Y*Y)"#G'7H*W+S6]*T^X2WO=2L[::0@+'-.J,<\#
M@GOVKRBVCL[?P!\+9XDACE;5;,%U #'=&X;GWXS^%68[W1;JY\7^'?%FNRZ?
M)-J,KM:RF)/M%NV/*9"R%F.T* %.1M&* /7:X71-?U3Q4^L2:;JUI:75A>2V
MR:=+ 'VA&*@S<AOFQG*D 9QR0:[#38EATNTB43!4A10)SF0 */O?[7K[UYQK
M6A^&O%D%YXGTK55T+7[!I8Y;ZWG"%'C)4B9>X.WOR1CJ.* .]LM2,'AVQO=;
MEAM)WMXC<&1@BK*5&X<^^>*E77-(>PCOUU2R-G(VQ)Q.NQFSC ;."<\8KS%_
M$NH*/ >M>)[F;2X+JSG2>Y6- L5PP38SAU(7<@;L,;CT&:A\5V/AV#P)JM[I
M=XU[:W&LVUQ/>.Z-$93,GF&-E '3&2O&>.H. #U6QUK2M3N+BWL-2L[J:W.V
M:."=7:,^C 'C\:2WUS2;N\^QVVIV<USACY,<ZLWRG#< YX/7TKAM9T^QL/B7
MHU_I-HBI;Z5>/J26:!=UN%7R@0N.2V=OKM/I7.6&KZ6]_P##>YM[VQ@LD>81
MV<,N_P"R(T# )([$L7)XYQDC !QF@#UE?$.BO<I;+J]@T\DQ@2,7"%FD !*
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M4C <%03N)P1D@#%<;976AZIH^N>&_%>N7%K?+J4YN-/)B22<F8O$T64WOD;
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MJ6%0JK''NCF!^;#Q@ KCL<D'O70U%;.LEK$Z,&5D!!!R",5+0 4444 %%%%
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MU"Y^S6FHVTT^SS B2 ED_O#U7W'%0#Q9X=:=(%US3C*\K0HHN4.Z10"RCGJ
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M31]%92O'85A:!I.L0SM?^(;ZUO-0\OR(S:PF.../.3@$DEF(7)Z?*HQQD[]
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M%H?%"B9)AC://F)W ^@(SZ9&>M=UIL]E/\8_$%N)8)!-I5LKQ[@=Y#29!'?
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MEU;5;31=)N=3O7*6UO&9'(4DX'H!U-<%X9T^]L]?D\%S0N=*T>Y_M&WF/*O
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M46[*25<M]T$XPI/8'!I=1\:^&M)ENHKW6+:*6UV^>FXLR;LX! R<\$XZX&:
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M.HZF-F #C'.5)XYH U<#T%(T:.5+(I*G*Y'0^U8,WC7PTMW]A_MNW6Y:X6T
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M;2N2#@]0.A!'X5:H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MF ))RW Z<9QD5Z)0!CI0!P>@>)M \60Z6NGVF_6;2!EVR6S*VFL4VOEB/EY
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M@UQ&HZE;6_PH\5:"[/\ VK#JDS26HC8NJM=JRL1CA2",'H<X%>[  =*,#TH
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M\"Z_YC!0VG3J,GJ3&P ^I/%:=C8Q6*2A&9Y)I#++(^-TC8 R<8'0 <=@*M4
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MREC:(K$?O KT(YS[C*ZKIUG8S63:)J,OA75+/35-LEP=\$T!=R(9%;.6!&<
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M+)M9'Q)A1N*N1M<@GG!)'>N"-PL'@'XBZ5+',EXU]J#K&T3#<)#^[P<8.[/
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M **** "BBB@ HHHH **** "BBB@ HHK,U'7]/TR[2TF>5[IXFF6""%Y7\M2
M6PH.!D@>YX% &G16!-XV\.P6.F7KZD@MM38+:2A&*R$Y[X^7H>N.AJ?2?%&D
MZT;X6EPZO8L!<QW$+P/%D9!*N 0".0>E &Q17G?B/Q,EUXC\'#3+Z_CAN]1
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MY\BW>40*1D%]H.WCGGG'/2G'Q+I O-,M1>!I-44M9,D;,DP"[CAP-OW1GDT
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MG\:6UI\/+_Q#HT_VG_1W^S21PLZK(,CYQCY<'KNQR,&@#KZP=&T&_L]0EO\
M5]:DU6X&]+8M;I"L$;,"5 7[Q^51N/91P.<Q>'-/ G_M6#4M6DAGMUCDM+TR
M;?,&#YBB4;E)Z<84^E32>,=$CNA"UT^#=_8?.$+F(3]/++XVYSQUQGCKQ0!N
MT5SMYXXT"RO;ZRDNIGN[%5:>"&UED=0<X("J21P<D9 [XJ1_&6@I'I,GVUFC
MU; L7CMY'68GD#(4@'V.#P?2@#>K#U[1=2UB:V2UUV73[':Z7D$4",UPK8&
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MY'((!![4 :U%>>^";B?Q?86'B"34M5MKU+F=YHE$BVTL7F.JQ[6&PX4+ROS
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M,A9-D3!]K$8."0#BI_B3:7\VBZ9>V$$MR-,U6VO[BWB7<\L4;$L%'<C(./\
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M8Q92YA*!PP/R\^O&>*]#^(>G7^L> -6L],0R7CQ*\<?>3:ZL4_$*1CWKJ**
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M2X'N;B"X@N3;)UG2.16*#U/&<=\4 9M[K;W/Q4\+00/J=O%-;7;S6TZO''(
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M-=U<:]:1+;>0LMY+<Q&>&&V4,SQC&7Y( 'S#DD=0.M &G16=H>NV'B+3%O\
M3I6>$NT;*ZE7C=3AE93R"#VJ35]5M=$TJYU*],@MK:,R2&.)I"% R3A03^-
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MU'1)-5CDFCBCG-M)%+$RRI,&"^64Z[\D# ]10!NT5SA\;:3$VIQ7:7=K<Z;
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M5,@?)@?,>>V< $G&*CL_'N@WN@_VO#/*(A<BS,#Q%9EN"P41%#R&R1[=\XH
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M9(P&&>,CK6)8>--*U"[TV"(7")JBNUA/)'A+D(,MMYR..?F R.E<[I'G/?\
MQ$M6O+PQPS+Y)-S)OBS;AL*V<KR>QH Z[0=$.C6KK-?7&H7DQ#3W=QC?(0,
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M>V*02N1D1A_[W./0GH36;H]\=)\:?$">07ES;VGV.41*YE=5,)9M@8^Y.!^
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MH)X&19HC$J'&1Z@C%1_#W2]1M6N(M2D$T6C-)I>GRYR9(@VXN?? B3V,1]:
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M;J)98FQC*D9'!Z5QNN7&IWGBF>UDTK4IM*FTT?9&M(R@DF);<LS$J5 &,*Q
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MW15'6O))WUB?X::1X>D\-ZLNJ:7<V<<R+;$QLL,B_.C_ '6!"YX/'?CFN_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ I&95QN8#)P,GJ:6N"^(HBAUGP9>_9VEF3650>6N78&*0
M[1]2![4 =Z2!U.**YS2==@\33ZOHU_I<UG=6+(MQ;3LK95UW(P9"1R >AR"*
MB\%:S/J%MJ>G7DC2W>CWTED\K?>E0<QN?<H1GW!H ZBBBN%^)'A674[&#7-)
M@636=*D6Y2$CY;M%.6B<?Q9 X]^.] '=45PEK>Z5\3%TJ>WA$FEVNVZG+#D3
M$$"W/T^\X]D'(-;T^OB/4;K2M*T]KVXL84>>.-UC6,,#L0$_Q$#('3&,D9%
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M986"?97NYKC> D"*0/F[\YX_W6]*R&\<6\%KINHW6GW$&D:E(D=O>,5^4O\
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M<@TM<S\._P#DF_AO_L'0?^@"NFH **** "BBB@ HHHH **** "BBB@ HHHH
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MYZ#(Y-=;;W,%W'YEM/',F<;HW##/ID4RYG@C"PR7:6\DWRQY=0Q/^R#U/X4
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MB>/-N[%"I8YY'RG.W=CW[]GJAG&D7IM;=+FX\A_*@?&V5MIPISQ@GC\:MT4
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MGS0-@K_K'!)5ANP*IZP-0_X3+79],T/5+BWN;:&UNY=,N;<%W"DD2"7HZJX
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M-:>>EYYZNI<8W(5'/&1\W3/U%;9FB79ND0>8<)EA\QZ\>M1HEM]MD=1&;K8
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MD,9_>2[@F"W4G(Z#K72KKCS3:2MM#!-'?0-<O*)R!'$ IW#Y?F&74#[O7ZT
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MR0F,/A"H0;@=PSCZ#-4-&M]<\/VVCRZMX0\RWTQ%2*9-867[-O 5F2(J,GG
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MW=D'@'')%=E10!B^$M,O]&\*Z?IVI7;75W!&5>5G+$C)(&X]< A<]\5M444
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M^7C&,\9JQ<^'=:E/@MEM[7.BL&N@;@_-^Z,>$^7GKGG% %FQ\57]RGB6QO\
M2;4:CHJJSPQ7):&='C+KAB@(X!!!6L6[\3ZH^@^!+C1[.SL[;5KB!7MQ(5"
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4R:&*XA>&:-)(G&&1QD$>X
MI]<OK7B34[#Q=I>A6FG6TPU"">2.:2X*[6C"Y# *<#YAR,D^@H Z=5"J%&<
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M4MQ]EL&OK>[1988)=OWHF+*=KCJ,9R/2@#MZ*\^7QUKB:?X7U271K1K+7##
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M84^03F,0L8?,"@;3\H]>H Z&I+?QS<6=OXD77+.&.[T.2)6%I(6282J#$%+
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MV[()QP.A)Q0!W=%<C?\ BZ?39M%L=2^Q:;>:BLQ,MPY,"NA4",'C);=D$D<
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M#G/E[<;=PZ!L\=<'I7?44 <IINDWVE>-/$FO7KV,>G7\5N$83MNC$*L,L"H
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M5TXS:%=6TT[&Y<+((D*87]WU.[//3'>MBPT34[?X@ZIKDRV@LKNTAMT"3,9
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MADM[IF\F>)\%D+ 9!!4$'%=?10!Q'B3P_P")?$G@:\TVXDTX:E>21,4$CK!
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MQW-I+NV31G*M@E3@]^0:M4 >?Z/X2UC3_!VC>'M1L-(U.SMX)8;RW>5BLA+
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M8 @]0: ,OPY>W^H>'[2ZU2&&*]=3Y@@SY;88@,F[G:P 89YP16K110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5Y]XF:_3XJZ#_ &9%;R7;:7=A/M#E
M8U^:/EL D_0=?;K7H-<QK6A:E+XMTKQ!IIM)6L[>:VDMKF1HPRR%3N#JK8(V
M]-O/J* .=G^(>L6/AS7IKW3K./6=!NH8+N!69HIDE90CHW! (;.#GI[\=/<:
M_=6WCRTT$PQ/;75C+=+( 0ZE&4;>N#G=[5CZKX#N-5\.>)8I+J%-7UR2.9Y
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M7(OAUI?AKS=/-Q97J7#3>:X1E68RX V9R<X_7VJ75_!?B+4'\5Q1WFFF#7(
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M/'.K_9[F !>"1\P(*YSB@"[9^.-1ET^SM[O2&M=:N]1?3X(YD>.*0(-QG4,
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M7[L;#[B\  D9XXZG-7_"^B:IH1\0/=-9?\3#4);^$QR,P0NJC:V5' VCD>M
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MOJ;6QNHHU1OLV[8, #@MR>F>@ZX[9K1H **** "BBB@ HHHH **** "BBB@
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M9?('.%X'<G&:R&\<>(=.M_%5CJ=EIQU?1;3[=$\)<07$)4G."2P(*X(SU^E
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M@/!8#!XXSFM.77]9U4ZY_P (Y#:,VDR?9UCN4)-U.$#L@.Y0@^8+DYYST Y
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MX+9RXCC<Y=MY498G&.!C;WS707VDZ;J9B-_I]K=F)MT9GA5]A]1D<&K8 4
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M.6?: ,GW.*L44 <3>>#[[5]2TRZU(6 N=.OQ<Q:C 6%PT2L2(B-O0@A2=Q&
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M/)Y.\\_3CUUO$7A?5[CQ':^(_#NIP66IQV_V2>.ZB,D-Q%NW $ @@@DD$>M
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MCP.> .3CG:H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *;)&DL;1R(KQN"K*PR&!Z@BG44 1
MV]O!:0)!;0QPPH,)'&H55'H .!4E%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%4M2U2WTI+9KA9F%Q<);IY43289S@$X' ]2>!0!=HJM#
M?6\]W/:*^+B'!>-A@[3T8>JG!Y''!'4&K- !1165=^)-)L-9M=)N[HP7EV2M
MNLD3JLIQG"N1M)]LYH U:*HZGJ]GH\,<MZ\J))(L2E('DR[$*H^4'&20!GJ3
M5U6#H&&<$9&00?R/2@!:*0D 9) [<UFP:_I]QXAN-#C>7[?;P">1&B90$)P"
M&(P><],]* -.BJ6J:I;Z1:+<W*S-&TJ1 0Q-(V68*.%&<9/6KM !1110 452
MU;5+?1M/>]N5F:)&52((FD;+,%'RJ">IJ[0 444A8#J><9QWH 6BLS1=?L-?
MCO)-/>1EM+E[27S(FC(D4 L,, >-P[5-<:I;VNJV6G2+,9[P2&,K$S(-@!.Y
M@,+UXSUH NT444 %%5)]3L[;4+2PFN$2ZO Y@B/638 6Q] 15N@ HHHH ***
M* "BBB@ HHHH **0D*,D@#WI: "BBB@ HHK+UOQ#IWAZR2[U"2187E6%6CB9
M_G9MH!(&!R<<XH U**** "BBB@ HHHH **** "BBB@ HHHH ***0$,,@@CU%
M "T444 %%%4]0U2VTU8?/+&6=_+@AC7<\K8+84=^ 3Z "@"Y16=HNMV6OZ?]
MML6D,8D:)UEC,;HZG#*RGD$&M&@ HHHH **BN+B.UMI)Y=_EQJ6;8A<X'H%!
M)_ 55T;6+/7]'MM5T]V>TN5WQ,RE21DC.#R.E %^BDR,XR,]<4M !115+3M4
MM]4^U_9UF7[+<O;2>;$R9=<9*Y'S+SP1P: +M%%175U!96LMU=3)#;PH7DDD
M;"HHY))]* ):*PX?%VCRW-K;F6YADNV"6PN+.:(3$\_*74 \<_3FMR@ HHI"
M0,9(&>![T +15*+5+>76+C2U687$$22NQB8(58D##8P3P>*NT %%%% !16-X
M@\5Z)X6B@DUJ_6U6=BL649RQ'7A03QD<^XJW;ZQ876C)J\=RHL'B\Y9I 4&S
MUPP! H O451NM6M;.RBN;@R(LSK'%&4/F2.WW5"]<GT[<YQ@U5T/Q-IGB!KJ
M.RE=;FTD,5S;31F.6)AZJ>WN.* -BBFR.(XVD;.%!)P"3Q[#K5;2]1AU;3+?
M4+=95AN$#H)HRC@>ZGD4 6Z**I3:I;P:O:Z8ZS&>YC>1&6)B@"8SEL8!YXS0
M!=HHI,@$#(R>@H 6BBB@ HHK,T_7]/U/5M2TRU>4W6G&,7*O$R;2X)7&X#/
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M(1)YL^YF8NN1D$NW (QQZ5=M_#-[!XPF\0'58I'DL$LO*:U[*Q8.2''.YCD
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M;RBU*SC#%E3?O/ R 3CD ?6NCU*"[N=.G@L;M;2YD0JD[1>9Y9/<+D9([<T
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ML>,M[ ]>N?;%S4?!U_J5GI23:X'NK/48]2EGDM<^=(@P%"A@$7'&!D\=<Y)
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M/RXU9\<(N3M4 #C/J>]0R^'+F3QW!XD74(E2*R:R^RFW))1G#D[]_7*CMTH
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MVU"*2/4(8HFMA;E2@CW;2'WG)^8YX_*LBS\":EI>HWD6E^)IK70;R=YY=/\
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M579-P7(QG&1G\ZYK1_"NIZ%H6CZ;::S"ZZ=$\+^;:$I<1G& R[^",=<_AUH
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M\FD\'W_AUM97RKR]-XTPM?F4F42E0-^,;@/P_.NX1TD171E9&&593D$>HIU
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MS!CU].,5VU% ')VG@Z[N-,N['Q-KT^MI/;M;#,"0!$8<G"YR_ ^8GC'&,G-
M> -3DLM%LKOQ3+-!HUY'<VK"S02%45E578D[B V-V!WR"3D=RSHA4,P!8X4$
M]3UP/R-5(M2$NL7&G?9+M3#$DOVAHB(7W$C:K]V&.1VR* *GBC0(_%'AJ]T6
M:=X%N5 \U "4*L&!QWY XK/NO"5S-J>F:U%JQ36[.)H'N7MPT=Q$QR4>,%>
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M_"WAV3PW:7L#WJW0NKR6\R(?+VM(VYA]XY&>G]:VIYEMX))F5V"*6*HI9C]
M.35'0-<M/$FAVNKV(D%K<J6C\U=K8!(Y&3Z4 8UAIQT#QQJUT018ZX(I%?M'
M<(-A4^F\;2#Z@CJ1F;2=&_X1BYUS4[K4%G34;G[4Z+;E2K[0H5<,2V0H &,D
MUL2:D(]9@TW[)=L986E^T+%F%-I VL_9CG@>QJ[0!S?@O1)M'TN[GO$V7VIW
MLVH7"9SY;2'A,_[*A1]0:I/X(N;;5M8N=)UM[*SUC+WEHULLH\TKM,D;$C:3
MWR"#^6.BU+5K?3&MHG62:YNG,=O;Q8WRL%+'&X@#"@DDD#\Q3=$UB'7-.%Y#
M!<VXWM&\-U$8Y$93@@CZCJ"10!S<?@*:+1O#.G)K)9=!G2>-Y+8$R%%*@'##
M"X8^I]ZMZMX/FURUN]/U#4HYM,N+I;@1-;9EAPP;:DF[ Y'7:2,GVQU5% ''
M3^"+R'Q+>ZMHGB*XTJ+42K7ULENDHD<#&]"WW&QU.#5Z?PJS^)M&U:"]$46E
M6\EO';M$7WJX4-E]V<_*,''US71T4 <=#X&>SLM5TFQU4P:+J4DCR6I@W20^
M9_K%BDW *#SU5L9.*NWOAB>:.>SM+VWATN:R2R-C-:>:B*H8!E^<8.& YR/E
M%=$SHA4,P4L<+DXR?054CU(2:S-IOV2[4Q0K-]H:(B%MQ(VJ_=ACD>XH P5\
M%BWU/PS<6E^8[?0+=[:"&2+>9%9%0[FW#G"C&!U]:@'@:X_L;Q+IIU9"FO3R
MS2O]EYB,BA&"_/TPHQG]:[*B@#RKQ1Y-KK&D:-?>)H=(%CI^$N;ZQ1[6Z8D+
M\HD.T.H3D[L_/QP376^#)]1EM[B.YU.VU2QC"?9;VWM/LZOUW*%!*L!A<,O!
MW$=JZ=E5AA@"/0BEH X/Q$VA>-];L] A=[B]TN_$MWL1U\A IWJS$ $."$P#
MSN)_A-;WB'PRNMW6F:A!=-9ZIIDK26MR$W@!AM=&7(W*PX(R#Z$5I+J%NU[<
M6T(:66!0TQC7(0D9"D_WB.<=<8SC(S2'B%#H5IJO]EZKMN71!;?93Y\>YMN7
M3/R@=2>PH J_\(E#=+K,NIW'VB[U>U^QSRQ1^6J0[6 5%)8C[S'DG)/I@#*M
M_ 5^K^'GO/$DL[Z&Y\C9:)&&3R]F",GG'4\^P'.>N34('U%]/8LERJ>8J.,>
M8G3<OJ 3@]QQGJ,VJ ,#PYX<FT&]UB=[]+E=3NVO&00;/+<@*0#N.1A11X@\
M,KK-_IFJ6UV;/5-,D9[:X\O>I5AAT=<C<I'N#Z&K.L^(K/0[G38+M+@MJ-TE
MI"8X\J';.-QZ#H??BK,&I"?5KS3Q:7<9MDC8SR18BDW9X1OXB,<^F10!4TK0
MA8ZE?:K<SK<ZC>A%EE6/8JH@(5$7)(')/))))]@,5_ASIA\/Z[I*32HFJSM.
ML@'-L2V] @SP%<LP''+'UKLJ* .<\1>%%UKPS!H5M="RMX6A*MY7F'$3*RCJ
M.ZC-/_X1RX/C6'Q(]_&7CL38F!;<@,I<.3G=P=P'X?G5K0O$-GXA&H&S2=/L
M-VUG*)H]A\Q0I. ><?,.N*UJ //O'<P'CSP-'%?06MP+JY8-* P'[DCE<C(/
M3J.O%;4W@JSU&WUL:O+]KGUB-8;B2-/+"1H,(J#)Q@DMDDY)^@'2E$8Y95)]
M2*J6.I"^N+V$6EW!]DF\DO/$467@'=&?XEYQGU!H PM!\+ZSI8C&H>*9]56V
M0K9K-;*@C."H9RIW2$ D<D=3WP0:-X1NM$\%IX>M]88/"^^"[6 !D_>>9RNX
MAN21VXKJJ* .3N/ EGJMQJUSK+Q7$VIV2V4WV:'R5V*2P;!9B7R1R3QM QZR
MVOA2Y<:3'K&J#4(=)D$ML!;^6SR*I5'D.X[B 3T"\\UT]4K/4A>7M]:BTNX3
M:2*ADFBVI+E0V8S_ ! 9P3ZT <T/ ]P-(\3:>=60KK\TLLK_ &7F(R($8+\_
M/R@8SW]:=#X*N[;6;'4K?79(98=.33;@);*1+&A)5EW$[&YYZ@^E=A6)K'B>
MUTB2XB%K>7LUK +BXBLT5VBB)(#$$C.=K<#)^4\4 <_;_#J:V\*Z+H2:XS1Z
M5>QWD4DEJ"248LB8##C).>I/M76:QI%KKVB7>DZ@N^WNHC%+MX//<>A!Y%6[
M>>.ZMHKB+=Y<J!UW*5.",C(/(^AJ2@#E=!\)ZAIT<<&L>(I]8M;>,QV\,MND
M852I7+D9,AVDC)P.3QGD5K;P"8-!'AJ35#-X>64,MJ\'[[RP^\1&7=@ID8^[
MG'&:[.B@#GU\.7$?C.X\1)?Q[IK);(6YMR0JJQ93G=R<L<^WIUK%;X>3/X$N
M?"IUA?)GN#.9Q:_,,R^:0!OQ][]/SKNJ:702",LN\@D+GD@8R?U'YT ><I)<
MR_&F]CM-4LX[I=#A20/#O5V$KD@*'!!'!ZG@\^M:M]\.[2ZT&&S@U"YM=2AO
M6U&/4XP/,^TL26<KT(.2-O3  [5TFG7T>HO=LME<V[6UR]N3<P^7YA7'SI_>
M0YX;OS5^@#CK_P %7^K^%M0TG5/$4EW=WZ+%+>&U5 D8.=J1J0!SU)))S[#%
MZX\-75UXET76I=1CWZ7%+$(EMB!*) H8D[^/NC'I[UT=% '*0^#YI;C19=5U
M)+UM'8O;RK;>7,QV%/G?<<C!R0 ,D GISDP?#2YM](TK3%\2W'V?2;];RR_T
M6/*X+':Q_B/SGG@>H->@T4 <Y9^&)]/\4:KK-KJCA=2$;2VSPJR^8D?EAMV0
M<8 .T8Y'7M65;_#F*+P?8:$^IN9]-NOMEC?)"%>*7>SY*Y(899@1QD>_-=Q3
M2Z!PA8!R"0N>2!C)_4?G0!@Q>';AM3EU>]OH9]4-H;2&1+8I%"A.YB$+DDDX
MR=W8 8YSCQ_#^:+PIH>@IJZ^7I%W%=13&URSF-MRAAO]3SCK[5W%4HM2$NL7
M&G?9+M3!$DOVAXB(7W$_*K]V&.1VR* */BGP]_PD_A^33&O'M)#)'*D\:!MC
MHP93M/!&1T-9:>#+X:[=:Q)X@DDN;O3Q93*UJ@0X+$, #D ;CQG.>I/2NOJE
M'J0DUF;3?LEVIBA6;[0T1$+;B1M5^[#&2/<4 <N/ <Z^'?#NCKJZ!-$NHKF*
M0VO,ACSM##?TY.<?I3V\#7-MJ>L3:5KC65EK&Y[RT:V$H$K+M:2-B1M)[@AO
MY8[*B@#*\-:*?#OARQTC[6]T+2%85E= I( P.!_]>M6BB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ KS_Q-;WEU\5- AL;W[%,VEW8\\1"1D&Z/[H/&
M?KD>U>@5@ZOX<>_U[3];L[YK6_LHY(5W1"2-XWP6#+D'JHP0PH XVW\8Z[I*
MZMH6I3K?:G::K:V$%ZD2(9$N &5BN0N\+GT&<9[YT[BY\8:>-=E,DRZ;'IKW
M%K<7JV[30W" DIMBX9".<D9!XK3O? 6FZEH>HZ?>33O<:A.+J>]4A91,N-C+
MC[NT* !Z#ODDI;>$=0_LF]M=3\276I7-Q;/:)<30(@AC88;"KC+'CYF)Z#WR
M <_9:YXBMT\"ZE=:Q]IAUL1075I]G14!> N'! W;LCGG!SP!4TNM>*=?T_4+
M[PZ+E;BWOI8+6(BW^S.L4FPB3<?,RV&.1C&1CID[#>"G-AX;M!JA"Z Z/ WD
M#,A1"@W\_P!TG.,<U#_P@,MKKE]=Z5XBU#3K#49C/>V$*H5>0_>9&()C+=RO
M/H1Q@ SM2M;RX^+>@,^H75L\FE7#F.,1,(CNBRBDH<@GJ3D^A%.EU76+JX^(
M6GRZI*BZ;!&UG)!&B-$&@,A .#WXR>?3!KH;CPPTGBNPUV*]$/V*V>UBMA""
MFQL9R<YS\HQC&,=*9;>$EBU3Q#>37K2IKB*D\0C"[ J>6-IS_=/.<\^E '*V
M6J:CX>^&OA*\\W4KC3I+6!KZ:VACDEMHC -NU0G*!L9)!8#O7:>%-0CU30(K
MR+5TU6*220QW2J%+)O.T,   P& >!R*H:9X3O]'TS2K6U\03NVG(88S- I1X
MMH5495V\ *#G.<]\<5I^'] M_#]G<0P-N>YN9+N9@H53(YR=JC[HZ #GIU)Y
MH R+C5-4C^*-KI"W:C3Y])FN!#Y0^619$4$MU/4\<5Q\_B/Q7%X$U?Q&==!E
MTG4YHA +2,)/&DX3:YQD<=-N#ZD]N_N/#CS>,;?Q$M]LD@M'M%@,65*,0Q).
M<YR!6/)\/?-\(ZIX=?5G-OJ-T]S+*(!O4N^]@.<8R/3IG\ "IXJM+B;XH^#O
M+U.Z@$D=\5$:Q'RL1)G;N0]>^[/MBK=AJ6K>*QXCDTW5'L#IM]+I]JB11L&D
MC526DW*206;&!C@>O-:E]X:N+_Q#H^LOJ06?2TE6.,6_R2>8H5RWS9[#&",>
M]1+X2DLM6U2]TC5'L8]5.^[A\D2 28P9(R2-CD=<[@2,XH Y2U\8Z[XC3P-<
M6-XFG)KBW*748@5]KQQMEE+9_B4D#Z9SR#HP2>)T\<Q^&9_$IDC_ +$^TO<I
M91)(9/.";@"" <>N1R>.A&NW@BWANO#CZ?=&T@T%76V@$>\/N38V\DY/'ICD
MD\U<?P[(?&9\2)?8E^P_81 8LKLW[\YSG=N_#';O0!P$OB/Q7%\.M3\0-K@-
MUHEY- 46UC"W@CFV$R9'&1_<VX]^W4>)]3U2"^O4M]4-NB::9[6WLXEEG,OS
M9>4,A"QC"@$D G=WQ0_P^$GA'5O#KZJYM]3N9+B640 .I=][!><8STR.!GKV
ML3^"9)M:O-176[F#^T+-+2^BBB3$P0$*RE@2G#'./7M0!S$]_J.OZA\,K^34
MKFU?4(I)I4MPFP2?968L RGGYB.<@ \8/-;<GB:_TOQ=XICO;C[1IVF:3'?1
M0K&JD?ZPL,CDD[/_ *U30_#_ ,C3/#MM%K=VMSH3'[/<^5&24*>65VD8^[T/
M)^M:,?A2/_A)=2U:>Z\^/4+1;.:U>/Y3&N<<YSD[CGUSVH YG4O$>N:1X$TK
MQJVH&X206T][8^4@B\J8J-L9"[P5WC!+'.#GVG-WXDU/Q9XNTJ'7C9P:?#;2
MVS16L;,A=';'S @C(&<@G@8QSG2L_ JP:1:Z%<:G)=:':3)+#:R1#>0C;DC>
M3/S(I XP#P 215R#PQ+;:]KFK1ZC^]U:..-T:#*QB-2JE>>N&.<]3Z=* )?!
M.L7'B#P5H^JW87[3<VRO+M& 6Z$@=LD9JWXBUA?#_AO4M7>,R"SMWFV#C<5&
M0/Q-<Y#X7U30M,\-Z5I&M70CTZ<!U$"[+B#<-PE/;"[L8ZDCCC(Z^^LK?4K"
MXL;N(2VUQ&T4J'HRL,$?D: .$U37-;T#0=!\1RZB;R&ZFMTO[0Q((PLV!NB(
M4,"I(P"3D=>>:DTZX\3:OXT\0Z>OB!;:TTJ\M2BK9HQDC:,.T9ST!SC/)Z>F
M#IV7@HPV&FZ7>ZI)>Z7ILJ2VL,D0#G9_JQ(X/S!>,8"]!G-7=(\./I7B'6=7
M-\9CJKQO+$8@H0HNQ=ISGH.<Y_"@!/&OB$^%/!VI:TD2RR6T8\M&^Z79@JY]
MLL,^U9&LZEK'A75O#LDVI2:A9:G>IIUS'+%&I21P2DD9500,J<@YX]^:ZC6=
M(L]?T:[TK4(_,M;J,QR*#@X]0>Q!P1[BLBT\*R[M*&JZF^HQZ4V^T#0A"7"E
M5>0@G>P4G! 49.<$XP <9IT5T?"_Q-DN-3N[GR[F_AVS>60V+= &)"@Y P,
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M<(NXXRQC8 #W)[5D^&-$_M?PWX7N+[44O+2PAAN+>*.,+^]6/"F1@3N*9.
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M^>,G-=MI#WTFCV;ZD%%Z8E,P5=HW8YXR<?3)QZFL ^"W/_"39U,_\5 NV?\
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M>O'I@X&<5LT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\H))'X XYP1=\17_ (ST#P7XDNY;]H1;2POIL\GE/,8W<*Z2 #;P3P1S[\4
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M.AR<YXQ6CU+5SXCT+PEJ&I![@Z?+=WUY:KY9N&1@@5?[O));&#QQ@9%7M1\
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ML;1YHC&6GA)#;7W(1U&<J : .3TKQ7JKZ'I=I/?R&YU#Q!<:=]K=5W1Q(\A
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MC?+C!"@< $8R#GFK4/A&RBUO5M1^T73Q:JH%U9,RF!V">7NQC=RO&,X[XZ8
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M9M'B>& ?N]KAU"MO^3DD*.F.E10^"H(+;7H%U2_QK;O)<L?*RI90AV?)Q\H
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MJ [,8![D$GIG&!6G>^%HKG6K;6[>^N;35(8#;/<1A#Y\1.=KJ5P>>1C&#^5
M'!7WB?Q$GA;4X?[4D2_TC7XM.^U+$G^DQ-(@!<8X;:_.W;^M=/IEQJ6G?$^?
M1)]6NK^SN-)^W 7(3,<@EV$+M484@]/:KE]X$T^]T,Z7]LO(D>\%]//&4\R>
M8.'W,2I'4#@ #  Z<5=7PU&/%J>(VO[MKI;/[%Y9\ORS'N#'(VYSN&<YH Y[
MQY;23^*_!86]NH5?4'0K$X SY+G=C'7MD]B?6I].O+OQ1K?B2R74KJRBTJ5+
M.W\A@&W[ QE;CYN3@ _+A>G-;GB#PW!X@;3Y7N[JTN+"X%Q!/;%=RMM*D896
M!!!/:J[>$HH=;N-6TW4;NPN;N)(KORMCK/L&%<AU/S@<;OS!H B^'^O7GB/P
MA;7NHJHO4DEMYV085WC<H6 ]\9^N:Y75M>U6Q:"]@U6>[E_X2".UED@ %HL#
M2[/)PWWF /+*"0P(+=J]%TG2[31-+M].L8_+MH%VH"<D\Y))[DDDD]R:Y1OA
ME8'3GT]-8U:.R%Z+ZVA62/;;2>9YGR_)DC.>&W 9]>: .F\0?\BUJO\ UYS?
M^@&N(T2YGB\$^ X$U!H()K&,2VMN#]HNL0#:L9'W0#RQR !C) KO+[3UO=(G
MTXSS1I-"83*I!< C!.6!&<=R#7.CP!:Q0:"MMJ^I6\^B1M!:W$9BWF)E"E&!
M0J1A1SC/% ',)J_B2\^'&MW]O?W:ZAHNIW**#L\R:"&3YHW(!!;9D9'<#DU?
M/BY;?X@6,YU.X?PW?Z>61F*^5%<A/. SC/,1S@GJ1^'4^'_"MIX=348[>YN[
MB*^N9+EX[F0.%9^6 XR<^^3[U23X?:$GAFPT#R7:SL;I+J+<V6+JV[D]P02O
M^Z<4 :WAZ*\3187OYII+F;,S+,1NB#'(CX'\((7WQFM2BB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHKCM8U&]O\ QO\ \(Y;DB*/31>,J7;6SR%I
M"@(=5+87;T&.6&<T =C17E^H-XMTFQ\,6>H:_B[EUQ;.62U97\R!E=E\PE!E
MP /8\$@YK7\._;5\8>*?#MQJM]=6D$5K/!)-+F6,R!]P# #C*@@=J -6U\6&
M_N;-[+2KNYTRZN)+=;Z'#*C(64LR]0A*L WZ<BNDKQKPUJ<_A[X2:#+:74Z3
MZIJ:Z?YKOO6W#W,@9U4\ [0?Q(KK;VXOM \?Z'I=O>W<NG:W#<1NDTAE:WEB
M0.)$9\GD'!!R.G% '<45Y!IVK:U8?#B[\9W&NW]Y=6/VR-+60KY,G[YD1G &
M25.#P1P,<=^YBTR\L-0LM3AUZXGLQ;.+NWG;S/M;[=RNG.(SP3A1@CM0!TU%
M>::5)XJ\0:%H?B73[Z"&69TN;GS;YS \!SOB\K9M4@< @YR.2:B)U?4&\>QO
MXBU.,:7,6M#$ZH4/D!P#A?N@GH,9YSGL >H45Y>FI:Q%9^ ?$$FLW<LVLS6T
M%W;$J(&66!F.$ X((!SG/7MQ5@S^(_%MMKDVCW:VMY9ZC-:6C_;6C2$Q,%P\
M00A]V,G=GAN,4 >D5'-/%;H'FD5%+J@+'&69@JCZDD#\:X!?[8U/XASZ1<Z[
M=PVKZ'#=.EDZA5D:1E;RVVYV_+U^][XXKG)KJ]USP%X+N=0O[J2Y7Q)%:O*L
MA0R!;AT#-CJV$7GUYH ]FHID,8AA2,,[!%"[G;+''<GN:\NO-:U*UDT:^MM5
MNKUY_$*6<]W&VVTDB>1E\I(R<':,#>HZJ?F)S0!ZI17G.M:O>?VUXMM+W4+B
MP>TLXI=&$,A3S"48EE _UK>8-NTYZ 8Y.7)J6O(OA+0[Z:9]0U.SENKWSIA;
MN71$)B5HT^7!<G@9PO7K0!Z)17EGB#_A+?#_ (1OVN-;V.FIV_V-HIO-E6"2
M55\N5F0$XR<$')[FM&34;_PSXZU*V?4;W4;/^P)=3,-RRG$L<@'R8 V@@] ,
M4 >A45Q.B6VI:MH_AOQ#'X@E26X2.XOT<EH9TD7)C5,X0AB I'/'.36=#J]]
MH&I^)] O[RYN[QU2XT=YI3F2.4B-(P1TV2D GKA@30!Z/15>PMGL]/M[:2XD
MN)(T"M-*<M(>['ZFO/CKUQ9^+!IWB"34M.N)]3_T"\5RUE=P[_DAX.U7V\$$
M Y&<\XH ])HKS:/4]1_L/XBC^T+K=I<TYLG,AW0[;=74 ]2 Q[YJWIVMW6KZ
MKX:T.YNYHTN-"74KB2-RDEP_R*%W#! ^9F.,$\=LY .C\2>(X_#=O9S2V<]P
MEU=Q6@:(J!&TC!06R<XY[ UMUYCXQL-1T_P=9V=YJ_V^9/$%KY,[I\\<9F4H
MK\_,P!')Z\5L:/+?:;\3;_1)-4O+VSETN.^47;!C')YK(=N , @ XZ>E ';4
M5@>+[F2VTJWV:G]@$EY#&Y1"TDREN8HP.=[#@$=.3QU'*6.I>(I'\<Z9IIN/
MM-B;=M/@O)U>2,R1AF3S"6&3@[<DX)% 'I51S3Q6Z!YI%16=4!8XRS$ #ZDD
M"N0\$Z[9ZMJ.I112ZI;74,<0GTG4RQEMF!?+ L3N5LCD$CY1TS5;XE6WGW/A
M$^?<1[M>@B(BE*@@JYS@=_E&#VH Z&V\1QW'B^[\.FSGBFMK5+HS.5VR*S%1
MMP2>H/7'TK;KSF73'OOBWJ%FFHWEJ@T"W#2V[@2MB:0#YR#CUR.3Z]<T=#\5
M:O?^&?!]E-<>;=ZG<74$]PTOE-(L!D &\*=K-M7) SP<8)R #U2L'Q)XJM_#
M+Z>MS87MQ]ONDLX#;",@ROG:IW.N,X//2H/"]EKVGWNJPZK=Q3V+2))81FX:
M::%2#N5W902,CY2<GKDUA_%42F/P>(61)3XEM-C.I90</@D C(]LB@#J8M=F
M-_;6MQH>I6OV@LL<LI@9-P4M@[)&() ..,<5GV/C1=2U'4K&RT'5IIM-F$-Q
M@VZA6(R,;I1GBKUI'KD.L^9J5Y9RV/D%4$$+0XE+#[P9VSD<#'OZUQOA./57
M\;^//[.NK. ?VA'D7%LTN3Y0Q]V1<"@#LO\ A)[&#0KG5]22;3(+5V29+L+O
M0@XQA"P.>,8)SD8ZU6N?%O\ 9]B-1U'1=2L]. !>YD$;>4I_B=%<LH]>"1W
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M9/AB[@OO#.GW-MJ)U&&2$%;MNLO;)]#ZCL<UK4 %%%% !1110 4444 %%%%
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M4K^RUS589]1E$UR1Y#!F P,!HCCCCBNGJE:W=W/J-];S:>]O;P,@@N&D5A<
MKEB .5P>.>M %$>%=.ET:]TO4#-J4-](9+EKM@7D8X Y4 # 5<8 Q@8J";PD
MEY9+I^H:QJ=[I^ &M9GC E4=%=E0.P]<MSWS7144 9&M^&M+U_3(["\@*QPN
MLEN\+>6]NZ_=:-A]TCVIEKH$L01;[6M1U*)""L=SY04D="WEQJ6_$D>U;5%
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M%-IERS0/*67<A0!CGECR>6)KC[J?6!X#\7:S_P )%JOVO1]6NEM")\*%CD4
M, /F!'&#QZ <Y]*;PM:-KECJ_P!JO?M5E T$69 PV-C=NR"220#DFJ1\!:8V
MA:IH[7=\UGJEP]Q= R+N9W.7P=O )QP/3C% %+5M2G_X3;3[34KB6TT.?2Y)
M4DBF:(-<AUR&=2",(>!G!)/4XJU\/$UC_A%TGUNYO)KF660I]KP&$0=A&2,
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M50 [@2=Q/IA=4"Z_XG^&VI7'VJ"348IY9(XKF1/+)M"V%PPV\G!(P3WKJ_\
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M$3 J0Z$ ;2-J^W'2K-CX-T^QUZ+6Q=:C/?I;?96DGNF82J&+ L.A()/M[9H
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M!V$[001U R>Y.:73X8M+\>^/M0C%W+)86MK<1QF[E(<^3(V&&[YAQP#G';%
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M021LC%@&!!VL5/X$<CZB@# \3^*XM \+ZCK=O;'4%L25ECCD"88'!!)]#P<
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M[68JKH8R=HY?(P!MQQ6A9SW+Z_\ $.R:]O#!:I;M;J;F3,):W+G8<Y7+<\4
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MX GC'% ':T5S'BN8?;]$M?MURAFN'/\ 9]KE9+T+&3MWAEV*N0Q).#@#N!7
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MR,R1LR(78 D*" 2?3FN2U'3/[!.K:A'XGN+"SETUP(KEFN!;R+_R\*78DX!
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M 'U)ZYKT#PU%)_99O9I+AGOI&N0DTK/Y:,<H@#$[<+MR!WS0!LT5Q27CZ_\
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M;*19;6X:Y8S0NHPI5R<C  &.F.U:FG:/;:;-<7"-+-=W.WS[F9LO(%&%'
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M9[XS0!E6_@C2+6)K5#='3C.;C^SWF+0>86W9P><;OFVYVY[5=D\/6DGB:/Q
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M0 5Q7BK_ )*1X"_Z[WO_ *3-7:UEZAX>T_4]6T_4[E9C=Z>6:V9)F0(6&&.
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M=J . \+:;#;^&_'LEO)=0R1:IJ"1O'=2*4"A2"/FZY YZ^]0F2[N?#WPO?\
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MMK=!'$KR,Y50, 98D\4 >/:TX\2_ 6]\37EQ,^H769F99F"Q_O\ ;Y07.-H
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MK ,/H:=0!SL/@;P];VNF6T5G*D.F/YEHJW4H\INF?O<GD]?6K<?AG2X=3O\
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M<Y  .<]!Z5<CU-K.PTW^V3!;W]VR0F*)BRF8C)52>2!@GZ"M&21(HVDD=41
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MIVDWGVB.YGE1_M+*I$90#)'+;B3_ '0.YQUE% !1110 4444 %%%% !1110
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M^6O(Y(SEN#G-;\VCVFJ_%W5+*]-Q-9R:+#*]N;A]C,97'3/3 ''3OC-=!<^
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M3],@,%I'G9%YC,%SS@;B<#VH X_6-/AOOB_I]M</.UO/HTYEA$[A&Q)&.@.
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MTJ+[)=H4FB>9\RC&,-(26QCIZ=J -NQM(;#3[:SMMWD01+%'N8L=J@ 9)Y/
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MGR07]K:K%LFF\P0MM ?8-S*N<'[N.*U+70=,L[Z\O8+4+<7N/M+EV;SL# W
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MRHQQ@&I'\)Z$]A8V/]G1+:V,@EMHD+(L3@Y#C!'S9).>O)]:UVD16"LZ@GD
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MH6DQ:%H=IID)S';IM&!@#G. ,G YX&3@8K1I%96&5((SC@TM !1110 4444
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M#I%! OVCPV?-15 #_OU'([\<?05QSVMJ/@:X:&+9!KA"9481?MP!QZ#''TH
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MG]XJ_P *G&,]"0.]4OA3IFAZ?\.]&\0W$-K!=):2))?2L%*Q^8<@L>@X'TH
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M<-SY<5OL$R[@A^R_> /1O<<T >IT5SO@&:2?X>^'997+NVG0;F)R2=@ZUT5
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MXYJ&YGN)M0TN2RU&R6S=Y!-&PW/<#:<"-@>"""3UX%6X[^SF#F*[@<1C+[9
M=H]3Z4 55\/:,FDMI*:59+IS=;40*(CW^[C'7FF26']D:3=_V!I]J+PJ6CC<
M[%E<# WL 3[9I;FXGFO=,DL=2LDM'E<3(XWM.-IPL9!X((R>O J*T\4Z/>ZC
MJ%E#?0%[!UCF8R* '(R0.>W&?<XH 30+&^C-SJ6KQV\>IWNP21V[%DB1!A8P
MQ +8)9LXZN>U2WOAG0M2U.'4KW2+*XO8<>7/+ K.N.G)';MZ5=-_9BW%P;N
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M2/;J3)]>.:V(88K>%(88TBB0;51%"JH] !TJ%M1L5O19->6XNCR(#*N\_P#
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MU[P7I&JWNS[3=VZRR;%PN3Z"MZ@ HHHH **** "BBB@ HHHH **** "BBB@
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M;F[L+6>>'_52RPJS1_[I(R/PJMJ&G^2MYJ6DZ?IYUMX=D<TZ;?,QT5W W;:
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ML"+;_4#[,G[K_=X^7\* /)-<O["X\/27>GRP6UM_PE*/MGDWW,DPN%#ODD;
M.<+@G;CD=*[2"1)?C9(\;JZ-X;C964Y!!N&Y%=*_AO0I6NFDT73G:[8-<%K5
M"9B#D%^/F((SSWJ==)TU;_[>NGV@O=NW[0(5\S'INQG% %RO/OA/+'_86N?O
M%XUV\SST^<5W[QI+&T<B*Z,,,K#((]Q6/_PA_ACG_BG-(YZ_Z#'_ /$T <_K
M6MZ5?^*?#JVKQO>$W9M+F:3%NH0!)&P#^\;J ,C^(Y Z\(DMM-\-WM3<PR11
M^+@I$;;5$9NN" #\JGDCFO9)M T:XM[:WFTFPD@M3NMXWMD*PGU0$87\*?\
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M#G!':NNJ"SLK73[5+6RMH;:W082*% BK] .*GH **** "BBB@ HHHH ****
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MI+K6]*L;J.UN]2L[>XD("12SJK,3T !.>>U89U?4D^*D>BM<(=-DT=[L1"(
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MJ<]!0!T%9R^']%6>29=(L!+(XD=Q;)N9QT8G')]ZM+?6CWKV2W4#7:*'> 2
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MC.B!G6.)"P!D<G  _/)/89-32>(]#AC$DNLZ>B&(S!FN4 ,8."V<_=R<9Z4
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M>1[DD#*Q81D+GH21VZ\CUKT5E5T9'4,K#!!&015:'3;"W1%ALK:-8U94"1*
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M?ZFZVA8;;JPG?S"PR.'49D!SR,GTKU.JL.F6%O<FYALK:*=A@RI$JL1]0,T
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M)QU&.>U '4VWB70[QIEMM7LI3!"L\NV=3Y<;#*LW/ (P<^]1R^+-!BTV_O\
M^T[=X+!=USL?+1\9 *]<GMZ]J\\O!!8_"#PIJUE"/L]L-/EU"6T16D\A,,YZ
M'.UR&P>X)K0G_P"$<UBS\1ZQH>I3ZM?2Z%/;S7"2!D5=I*(P  WDYP.H .>U
M '<Z!K=KXAT2TU.T="L\2.R*X;RV90Q0D=QD53TG7!K%UJ-XDRPZ583O:AS@
M"5T_UCDGHH/RC&.5)/&*B\!7]I?^!-$:TN(YQ%801.8VW!7$:Y4^X[CM6/\
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MI8;K6K"&2%TCD1[A049L[5//!.#Q[&I6\0:.E^MBVI6HN6E\D1F49,F,[/\
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M@#ZY..!6Q:W=O?6L=U:3QSV\@W)+&P96'J"."*\U6*2[T?P9/HFOP:=KL.C
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M8@WHS:_Z0O[\?['/S?A7G3:[:Z5XMTJXUG59K#3;[08([.^5E$7FJS&1"Q!
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MXDSG;&H49^@J2N"\:^+%MO['31]8$<TNL6]M*D:JRS(9 LB!B""1T.TY'.:
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MINI6UU+;$"9(G#%<]#]#CKTJ&;Q9X?MV N-7M(%9F199I D;LIPP5SA6(/4
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M ZX';(-'^T;.Z\3V*0>($#FU=_[,3:3,IVD2'^(8[>N:L7?B;1;&21+O4[>
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MVH O26EM-"(9;>)X@<A&0%<_2LG7K#7KZ6V@TG4;6RLG5TNR\!>7:0 #$00
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *X/4[LZ3\8+"]U.01:7=:0]I:SR'$:7'FAV4D\
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MC'975K?P36K:!,BSHV8V;ST) ;H< '.#Q@^E>B[5V[=HVXQC'&*18T0 *BC
MV\#MZ4 >%^?IW_#/&WS;;<=2!(W+DG[=G_T#GZ>U=CJUQ WQ:TV.RN;=)Y-
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M6R.FD^(4.HW6E@[+J%4P9U'7Y24R!T*'TX]@9%=2K*&4]01D4*JJH55 4#
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M#["@#LZ\FTB\MH/ GB[0=>=%U87%[YT$O^LN#*28W1>K;L@+CN *]8 "@ #
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M6GF>9L7?C&['./K0!Y=INNZ+IVI^+O#?BX!;B]U*6>*&:-F^VV\@41A,#YB
MH7 YX%:*W5MIWQALA<*+-;GPZD%O$W=Q/GRUQU(!'3MSTKT QHSJY12R_=)'
M(^E+@$@X&1TH \9\/77A[4/#L/A?Q)+?MX@M+DK+IGFR*\LXD++(F.Q)W;LX
M&23QS6EI^M6>FS>/])UZXCM]3N+NXG@2X.#<V[1!8@F?OX"XP,XKU/RT\SS-
MB[\8W8YQZ9H:*-V#,BLP! )&2 >M ',?#::.?X;>'C$X8)81(V.S!0"*ZF@
M 8 P** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LZ;7--M]8@TB6Y"W
M\ZEXH"C9=1U(XP0.Y[5HUQGQ%M9K;3K'Q/91L][H-P+K:@^:2 _+,GXH2?\
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MX8KFWD@F19(I5*.C#(92,$'\*\]\&6.HPZJ?#5]&[67AF9C;3N<^>DB_Z/\
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MW ] -PVY['CK4%[<V_B;X<^&M(TME76X+BR46HXFLY(BHD9UZH% ;DXZCU%
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MG;P.QR<<9MZ9>6=SXFUA+?7&NY(EA6:Q!4I:'#="!U;!)!)Z5R.JRV6E>*O
M%VMDVG:9&E[%'&(2/+WQKY:E0,AFQ]WKGCK56[2;4O%/Q+L=+F7[?<Z7;16X
M5P"SB*0$ ^H) /ID4 =]!XGT:YO(+6*^0R7&?LY*LJ3XZ^6Y&U\?[)-5;OQQ
MX9LC=B?6;8&T8).%)<H2,\A0>@Z^G?%</?7-MXG\ >&-+TIE768+JRQ;#B6R
M>(@2%UZH% ;DXZCU%6;6ZL?^$D^)SO-!AXH1N+#Y@+;:?KAN/KQ0!Z9#-%<P
M1SP2+)#(H='0Y#*1D$'N,4^N8^',BR?#GP]M<,4L(4;!SM8( 0?0CTKIZ "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBLV77M.@UJ/1Y)V&H21&9(?*
M<[D'4@XP<?6@#2H(!&#TK&M_%6C76F7NHPW3M:6+,ES)Y$@\ME^\""N<COCI
MWJNNIZ;)XO94UB[:[CTTR/I:JQ01[P?-*;<[^0N,YQQB@#H:*\O\1^-I=;^%
M6N:SH\U_IL]J[B-Q"T9*K+L^\RXR0,D*<CIQ7<:?XHT;4M5DTJUOEDOHXO-,
M>QAN3."RL1AQGC*DT ;%%4]1U2STJ&.6]F\M99%BC 4LTCGHJJH)8]> .QIN
MEZS8:S%-)83^9Y$IAF5D9'C<=596 (/(ZCO0!>P,YQS17'ZE>7L'Q4T*S2^G
M^Q7-C=/);9 3<FS!X&2?F/4FM8>+=$-Y%;"]^:6X-K')Y3^4\PSF,28V%L@C
M&>H(ZB@#:H(!&",UC?\ "5Z-_P 3,?:GSI?_ !^C[/)F'C.2-OISQVYZ5-'X
MATR:ST^[CG=H-08+:N('_>D@D8&W(! )R>,#/2@#3HK)3Q)I<EW#;)/(SS2/
M%$PMY-DCH&+*K[=I("-T/\)J(^+M#72+K53>D65I,T%Q+Y+_ +IU^\&&W(QG
MG(H VZ*P+N_TY_%>DP'6IXKMH97BL(C\EPI4$LXQ_"!D<CK3/#7BZV\2WFJP
MP6]U$+*[>V4RVTB;MJIDDD8!W,?E)S@ XH Z+ /6BN/\;>)&TF\T/38S=)_:
M%\L4\D,$C$1;78A&4'YB5 P/F )/'6K-C?V?AN">WO-8O[\,3=QI+;R336T#
M=%?:I;:"&P7YZCM0!T]%8MUXMT"RM;&YGU6W6"_(%K(&W++D9&".W7D^E6M)
MUO3M;TL:EI]R);,EAYA5DP5)#9# $8(/6@#0I&!*D [21P1VKG[/QUX:U"^@
MLK758I;BX:1(U"-@F,$N,XP, 'J><'&:GA\5Z+<7T5DET_GS1M+ K02*)U49
M)B)4"3CGY2>.: -&QL8K"W,419MSM([N<L[,<DG_ .MP.@P!5D@$8(S7*Z)X
M[TS5M)O]4F\ZRM+2>2,O<0.@VJVP<D8W$_PCGD#&:U;76K#69+RQL[N:*[MU
M7S4:%HI8@P^5MLB]#@X.".* -6BO-?#^MI<_"/2+W7_$5W93W,F&O8W_ 'KL
M)SA1P>#@+TZ&NTU+Q+I.D320WERXDBA^T2K%"\ICBY&]MBG:O!Y..A]#0!->
M:4EQJ%MJ,+^3>VX9%DQD/&V-R,.X) /L0#Z@Z%<QJOC:PT[5M!LHTGN5U;?(
MDT$#R)Y0C9]RE0=Q)"\#/!).!5JSO+"?QC?0P:S<37<=K&)=/S^ZA&XX<#'#
M'.#SVZ4 7;_2TU.YMC=-OMK>19E@QPTBG*LQ[@'! ]0#V%:%8R^*]$:Y@@%[
MC[1*88)6B<12R#/RK(1L8\'@'G!J"\\;^'+&YOK:?4E\^Q"FXBCC>1DW9QPH
M)/W3G&<=\4 =!1@#H*KV5[;:E8P7MG.LUM.@DBE0Y#*1D$5Y]H'CBPT.?Q)%
MXDUV1O)UN6"!IU+F.()'C.Q<(N2>2 ,YH [S5[>_NM*N(=+OEL;UU_=7#0B4
M(<CJIX/&1^-1:+I<FEVCBXNC=WL\AFN;DH$\Q\ 9"CA0%50!Z =>M,/B321J
M]KI7VO=>747G0(L;,)$QG<K ;2/?-6K?4K6ZO;JSA=FGM2HF4QL I(R!DC!X
MP>#0!;P,YQS1C-9&I>)](TB6>*\NF5[>(3SB.%Y?)C.<,^Q3M'!Y..A]*;>>
M+-!L+FUM[G4X4ENXC- HRWF(!G(P#VQCUR,9S0!LT5G:-KNF^(+-[O2[GSXD
MD:%\HR,CKU5E8 @C(X([T:EKNGZ3D7<LFY8S*R0P/,RH/XBJ D+[GC@T :-%
M8<GC'P[$VGAM6MS_ &A&TEKM)82J%+$C ] >O?CKQ54_$'PN+":\_M,^7!(T
M<R_9Y?,C*X+;H]N]0,C)(QSUH Z:C SG%8EYXO\ #]@UDMSJMNAO8C-;<D^8
M@7=N&.V.GKP!R:S;WQ3I^O\ @G7+[P]JS>9:6TV9(EV20R*A(!5UR.G<?2@#
MK:*YO0-;B@\$^'KO4[IWN+NRM\$AI))I#$&.% +,>I. >A-63XNT-=*N]3:^
MVVMFYCNB87#0,.SIMW+^(% &V0#UK"U[1M5U>X@BMM:^Q:8T;1WMNEN&>93_
M '9"<H<9&0._K5Q]<T]+6QN6E?RKYE2W(A<ERPR.,9&0"><57O/%6BV%RL-U
M>&/,PMS*8G,*R'HC2 ;%;M@F@#71%CC6-%"HH 50,  =J< !TKG=0\=>&=+N
M[FUO-6BCGM2@F0(S%"YPN< ]Q^'?%7/$VLCP_P"&M0U01O(]O;R2(JQLX+*I
M(SM!P..2< >M &M0!@8%<-X>NU6RTWQ%=ZYJ02YM(XKBSN(I"L]PZJP:)&7.
M?O<1C:1]#70Q^*=%DL[ZZ^W+''8'%V)D:-X.,_,C ,,CD<<]J -BBL;1_%FA
MZ_=-;:7?K<2K ER55&'[M_NG) 'X=0>#BH-5\;^'-$NKBUU'5(X9[>'SY8PC
M,53.,X4'\NO!/0&@#H**Q;_Q9HFFJSW=X4B38))EA=XXMV"OF.JE4R"#\Q'!
M'K4>H^-/#NE7<MK>:I$EQ%")FB56=MA. 0%!R?8<]3V- &]163:^)]%O="36
M[;489=.D("3+GEB=H7&,[L\;<9SQBEMO$ND737BI=^7)9J'N(IXWBDC4]&*N
M <'L<8- &K@9SCFC SFN,OOBAX7M]+N;RUO7OGBLVO%BMX)&+H#C.=N ,D9S
MT!R>*LW6NZ=?6WA^6YU:[TR:YNHFBA2-XS<OM_U3*RY*'/7@<=: .JHKGKSQ
MQX;L9[Z"?4U\ZQV_:8XXGD9-P)'"J2> 2<9QWQ6@^O:6FGVE_P#;$>VO"HMF
MC!<S%AE0B@$L<9/ Z ^E &C@9S1C-9>F>(])UBZGM;&\62Y@)$T)1D>,@X(9
M6 (/(Z^M.U'7M.TNX6WN9G\]HFF$,,+S/Y:X!8J@)"@D#/3- &E1C/6J]A?V
MNIV$%]8SI/:SH'BE0Y#*>]4G\1Z6EVML9Y"[3_9@ZP2&,RYQLWA=N<\8SP<^
ME &KU&#16.OBC1VL]1NQ=-Y.G.4O#Y,F82!N.Y=N> <YQTJ63Q!ID<5M()WE
M%S#]HB$$#RLT> =^U5) Y')'>@#3P!T%%8,_C7PY:K9M-JL*?;+?[3 "&R\>
M 0<8SR",#J<@=:ETOQ7H6LZ3-JEAJ44EE Q6:1@4\MAU#!@"I]B* -F@C/6L
MJQ\1Z7J%[<64-PR7=O&)9(+B%X7"'H^UP"5]QQ44'BS1;B\AM([MC-<1M+;@
MP2*+A%&6,1*XDXY^4GCF@#:H  Z"N:\.>-+'Q!IE[J)2:TMK::5"]Q"\:A$8
MKN+, ,\$D9R.]:-CXBTO4=1ET^"=UO8HQ*UO/ \+["<;PKJ"5SQD9% &ICG/
M>C ]*\]\7^*XY+CPR-(U2Z07&MVT#F*)EAN8R^' D*X8<?PMR,]:[;5-4L]&
MT^6_OY3%:PC=)($9@@]3M!('O0!<HK/_ +;L/LUC<>;(8K]E6V(A<[R1D<8R
M. 3SC@5GZ+J.F2W6NW%OKDMY'#<9N%F?]W9D(,JIP %P,GD]: .@(R,&BLBT
M\3:1>WT-E%<LMQ/&98$FA>+SE'4QEU <8Y^7/'-8'AO5YK?7_&O]JZI(]EIU
MU&4DN6 6&,PJYZ  #DT =M16/:^*-)O)YK>&:8W$5N+DP/:RI(T1Z.J,H+#/
M'R@\\5SR>--*\0> +O5KJ_O=$M7,B?:EC>-XU$C*I1BI!8A>0N<$D4 =S16?
M<ZM8Z=';)//(\DR_ND2-I99  ,D(@).,C)Q@9'K5.7QCX?@T,ZS+J<2V"OY3
M2$-E7!P4*XW!@>,$9H W*,<YK(T_Q1HNJ:M-I=G?++>11^:T>QEW)G&Y20 Z
MYXRI(J]?:A:Z;;^?=S"*,L$7@DLQ. J@<L2>@')H LD ]1167:>(=,OA>"WF
MD:6SQ]H@,$BS1Y&1F,KOY'3CGM7(^$[ZZ\8I'K"ZIJ5G<0:A,6A6)Q;R6ZR,
M@B(8;"< 9(^8'/T !Z%17-S>+;9/&R^&1#=B4V9N&F6VD(!+JJX(4C'+9;[H
MP!GK7.>%?&MGIEIJ\?B+6I'DCURYM8Y9U9MB*X1-Q5=J#L"<#.: /1\#.:,9
MK/U+6[#2N+J23?L,A2&!YG"#JQ5 2![XQ5BPO[35+"&^L;B.XM9U#QRQG*L*
M +%%<1X8UB6VU'QF^KZH[V>G7X"RW+ "&/RD8C@  <GM6_!XHTFYEN84GF$]
MO +B2&2VE23RCT<(RAF'!&0#0!L8&<XHK!_X3+0?[/L+\7S&UU"016DJP2$3
M.3@*,+U.#CUQQ6HFHVKZG)IRNYNHXEF9/+; 1B0#NQCD@]^Q]* +5%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !7&?$"WN+1=(\36%M)<7>CW8+0Q
M#+RP2_NY$ ]>5/\ P&NSHH \QTS1-6TWQG/H\ZM+I^M>7J]W*/N13(1YT8]F
M?R>/[N:U6EC_ .%WH=PQ_8#0[NV_SPVW/]['..N.:[FB@#Q&XG"_!#Q)H[1S
M+?Q7=PC0M"P.YKDLH''S$J<\9XYKL=1N;:3XJ>%)8)4:(6%TA=#E1N\O8"1P
M,X.![5WM% ''^/=373?[#:6V40OJ"J]^T'F_8OD;#J,'#'[H)&!GD'I6=\/)
M57Q%XO@Q>$OJ"SJ]S"ZET,2 ,20 "3GCCZ5Z#10!P^LRQCXO>&LL,)87:,>R
MLQCV@GL3@X'?%<1=ZM'?Z1HTYMKBSDM/$T4EQIEO9LL=FHG;+,0OS.V0V<\E
MC@#FO;Z* //O$%C?VGCB"YTR"0P>)+,V%VP7'DNGS+*P/<1F48/=0*/ 6FW]
MG>7&BWL3_8_#D\L%C*_/G+)AHV^J1MM_X&:]!HH \IT9YM,UW2CX>U$WVDWM
MZ_VC1;M0TVG%@Y>1&^\J YZ\'=P3NK)U*]CM?!/Q%T*2.?\ M.74KR=+=86)
M:*0J5?.,;2.^?;J17ME% 'GE]=0S?$+P'*I956SNP^]"I0O'&%# @;22#@'K
MBK/@*86^M>+M.FCF2Z;6Y[D*T3 >4RQ[6W8Q@X..>QKNJ* .%\>W$4?B+P:'
M<#R]5\V3_83RG7<WH,D#)J'2[]/#_P 1/$YUJ98+?4Q;W%A=2G$<J)'M:,-T
MW*?X>ISFO0** /%DTY]'\,^$8;R-HD;Q7]NCMY%(-O;$RE2R_P (&Y2<]-W.
M*]G+*J%RP" 9)SQCUIU% 'E?AZTFU3X:^,M/TW OKF\U'RE^Z6\QFV'Z,, '
M_"K/AC4O#7B2YTC;IVJ/KE@0SP7;W.+!PN')+G:/0 <G(X'./2Z* /'K35!I
M7P_U^UETMKJXM]:F:>&XM'D2%&N<B4KCY@ 0X /.*UO#U_;I\4=4N6NKR>"Y
MTB!DN[B!D5PKR%FSM"A1QZ#ZYKTNB@#Q)'4?L\Z;;$$7"W40,.T[P1=ASE>O
M"\_3FNB\1ZI%/XDU[3C#):M+I*FWFM+8O)J65?Y=X4X1,XP,'YB<X%>ET4 >
M0:?>);V/PKU"6*Y6UM()+>=_L[G9(;78!C&3E@0,=36Q=)+??$CQ+;V4OE7-
MQX>2W@D)P!-F3C/J-RDCM7H]% 'C\Y77O@WI_A6VC:'Q%"MK:?8V7$UO+%(@
M:0CJJ@*S;NF#UYKH=+N+:+XG^,99I(U0V5HHD?@,563> >^,C([5W]% '&?"
M@X^&6B1-E9(H2DB,,,C!CP1V/2L32[JRTY?'FG:G&?M-YJ5Q)#9O&?,NXWB1
M5\M<9<$@CC->G44 >8W_ (>U'0?AGX>U%1NUOPO"ER5#?>C"XFASZ%,CZJ*[
M?PW;30Z5]IND*7E](;NX4]59\80_[JA4_P" U!JN@W^JZO$\FM21Z-Y:B?3%
MMT_?,&W9,A^8*> 5[@>YK>H \N\5ZBLVL^+M*:WFLYFTI1";:U+2:EF)^KA3
M\B$[<#'4Y..*KZ9=P3ZO\+'^8"WTV=)#)&5\MC;QJ,Y'&6! ]<<9KUFB@#A_
M <L;>(/&81AB35C*F.CKY2#</49!&1Z5E:SJ-IX=^(VI3>(QJ,6F:G;0"SO+
M9YQ&K1A@T3"(YR2V1D=SZUZ;10!Y=+;:9IOB+X>0:?8MI]A#->ND$I;,2/&V
MQFW<KN8Y ;D$XZBIK">V7Q#\2I&>,)*L)1CTD M@IQZX;CCOQ7I=% 'C6GW=
MK:1_"22\=8XX()XY3(/]4XML?-_=P<=>E:MQ:H]]\0]>M<#3KS3%MXY5^[<S
M+$X++_>QN5<CJ<@=*Z[6?#EUJGBC0M9BU"&!=):9A"UL7,OF)L.6WC&!TXZU
MT5 'D]I-)IS?#G6Y]QTBVTLV=U( 2+25XD 9_P"Z,KM)/3OBM[1M+BU7QSXI
MU1%671=0M(+1B.8[IPK!R#_$ I"Y''4=C7=50UJTO[[2IK?2]3_LV\;'EW7D
M+-LP03\C<'(R/QH XOP-9:FFH/HVIJSVWA>1[:UG8Y^T;U!B;V*0MM/^_7/:
M3+HW]G7G@_Q3I^J7&KK=S;;/?<F*^#2M(DB[3L )())P 02:]5T?3/[*L?)>
MX>YN)',L]Q( &ED/5B!P.P '0 #M5^@#A-&D@_X7!XBY7<VGVL:-UW%2^]0>
MY&5R*V_'4B1^ M?#-AI-/GC0=V9HV 4#N2>U=!10!Y;<326UO\.->&Z72M-B
M,5_L!;R&DMPBNX'0*<@YZ9J358DO/$?BKQ!92JVEMX=-DTR'*7%P2Y&TCAB%
MVKD9Y;'7->G44 <YX!,9\ >'UCP#'I\$;J!@JX0!@1V(.<UD>9 ?C@S,5/\
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MM%5VX#;8W#@'O@D XZ5R]E=6VE_#[X>:G/-+!<Z=.4^:%WC7,;ATD"@LI*\
MX."1QC)KVJL#7M!O]1U*QU+2]9;3[NT22,+);B>%U?;G<F5.?E&""#U]: ,7
MP%?Z'J&K:_?6&KPW=_J$Z7%Q;QJZ"%%4(H < GIRV!DGH*37M5B@^(4%C/#)
M9K+II*7UO;&2:Y/F<VZL%.T#&X@<\C!&.>ETW2KJ&Y%[J=\M[?",Q*\< A1$
M)!(5<L>2JYRQ^Z,8K5H XCX1R9^&>CP-'+') C1R+)&R$,';CD<_A6 7FTSQ
M#]H\.:B;F"ZUDI?^'[M [(YF(>>(_>0 CS/[O?/:O5J* /)+N_BTT?$S2[E)
MA>W@EGMHEA9O-C:U W @8P"#DYXQ3VB@N-+\-W%IKD_A[7+7181#<7$>V"9<
M -%(K@ X9<^O.1G%>L44 >4?VJS>)/AMJ&N6L.FRM8WOF1E=B0MLC Z_<'3&
M>F<53UG2;V=_&/B#1[6:XL)M0T^X2&W)4W8MR&F:/')R>C#J5.,UZ%J?ARZO
M_&&CZZFH0Q1Z:DR"W-L6,@E"AOGWC'W1CBNAH \KNTT3QGHFKW/A2WU"XU9]
M*FMOM=R]P#&&&?(S*<%B<\#@=21D9V_"_BC1O$JZ1'#I<C:M91[94GLV0Z>=
MFU_G9<#.-H .3GT!QW-% 'C<"7LOPSUW3+*TNI=2L=8ENIK54=&=%NQ)M#8'
M+*,C!R:TY)-$\8:7J-UX5M]1GUH:7<6ZW-T]P#;%T($69#C<6[#.,$YZ9]1H
MH \;O/$.GZCX0\$6L$5PMWI^K:>MW:?9G\RV,?#!E"\8P<>HZ5Z]<6\-]9RV
MT\8D@GC,<B,/O*PP01]#4U% ' > ;/4XV.E:I'(8O#<DEE;3/_R\;L&-_P#@
M,)5?^!FN<U&RO-:T?XG6.DYDN[B[CDA1>LR*D>X+ZYVLO'?BO8J* /.M9N[;
MQG<^#I-%?=<VNIQWEP ,-:PJC>8D@_@))5=IZGZ5ES7XM3\3KB/3H]4)EB=+
M1T++.HA1&./XE4YSCT[5ZS10!Y=HM]!-\5=-O(KJ\O8+G0I(4N6M62-G\Y&V
MJ H"J #].A)-8\,X'[/>J:2T<RWUND\$D+PLI$C3N0HR.3CG SQ7M-% 'G<M
MY_97Q(TO6[R0#1+S1!9Q79/[J&82;R&;HNX8Y/4C':N:\2V+CPE\0-0B5OL.
MK:A;-8Q!3F8H8Q)(J]PQ#'/<+GIS7M-% '"7US;R?%[0)8I4:/\ LNX3>ARN
M69"HR..0"0*D\?"ZM=4\+:T(Y)=-T[4"]ZL:EMBNA02D#LI8Y],UV]% '#6B
M1:A\4I?$5C/&VEP:,+:>Z1AY4DAEW@!NC;5!)(Z9 H^%,T;>#FBW8E6^NF9&
M&& :9V4X/.""#7<T4 <+>W"Z?\9K:XN$E6&YT,V\4BQ,RM()PQ7(&!@<G/0<
MUQ]R\<GPI^($28:6XUB\>) /FD#2@H5'4@@9!'I[5[510!Y9J&KV6A^.9;_7
M6OUT?5=/MEM+ZTDF\M'CW[HV\HYR=^1D>OO7=>%;*PL/#MO!I>GR6%CEWA@D
MW;@K,3DAN5W9W8/(SS@\5LT4 >22:@MI8?$JXCTZ/5";U)$M9(RZ2ILC0MM_
MB52"3C^[U%7=$O89OBU;7<=U>WT-UH)C2ZDMF1'<3AB% 4 *!_\ K)KTZB@#
MR&;POJUU9:_X0M$D@MM+N6U/2[A> 6?]Y#$OLLGF9/;"^M=KX:U%W\,3>*M5
MMY+:6\A%W+%L+-%$B?*H Y/ +8ZY<UU-% %;3[Z#4].MK^V+&"YB66,NI4[6
M&1D'D=:LT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MT[5F4D;(_,D=)/K@8!_W?6N8EM)A\,OB3:1VLHDN=<E>VA6,[I4,D>TH,<C
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !36=$&795^IQ3JX'XTQH_P )M<+(K%5B*DC.
M#YR<B@#O5=7&58,/4'-+7D?@_P ,ZK)XN\.>(+"Q_LK2(=%BBO#O1?MTAC.#
ML0G."5.YL'Y:Z?\ X3*XA^)\6@W,2II5]:NMC/\ \]+B)CYH_+C'JOO0!VM%
M<)HOB&^\3^+?$T!OGT_2]$E6U58@FZ63G>[LP. ,< 8'KFLWQ;XCU;1=(\/R
MV/B);HW6O1V<]Q;112%X'+';@*1O"A1\HY/;F@#TVF&:)20TB CL6%9/AR:>
M[LFOGOKBZMKDB2W%S$J21KT((55],\C(SCM7GWC/X9>%[C4[-S9R3ZUK6J+O
MG>=_E3)EE(4';@1JRCCN* /6J*X[XA^)KOPSI6F0Z8J)>:G?Q6$,KKN6'?U?
M'<@#@?X8JOJNO:CX;\>>'-'EO);VQUI)H294020RH 0ZE5 (.[!!'N/2@#N:
M0D $D@ =2:\N\">)=8\1>9;W>MWOVV/5)U7%I&(7MX73<C-Y>,D,1P0><]JM
M_'*('X6:E.'E5XGBV[)64'=(H.0#AN">N: /1P00"#D'O2*RNH92"I&00>#7
M"_$&(/\ !_47WRHT6GAU,<K)S@=<$9'L>*V_ G_)/O#G_8,MO_1:T =!1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (S*@RS!1ZDXI@G
MB) $J$GH-PK%\;QI)X#\0*Z*P_LVX.&&>?+:O-OA5866K>$_#MG>:$D:6\#W
MT>HO''NDECNLC:P)88Z'.,@^E 'L]%><:AXJU7P[\3H;?4[X/X:OV:UBWQHO
MV:X$:2#+  D-N( )/?TJE8>*?$5SJOQ!BN;]XETFRCN+*(0Q@P%X6DP<KEB,
M <Y[T >J45Y1X6\2^+=4AL;AI[FXT^?0S<W5W+:)&L-SSM$;; &S@9&&QZUU
M/PSUC4->^'NEZMJMT;B\N5D:1]BKTD91@* .@% '745YCHGBC7/$WP^UOQ;#
MJ!LWB-Q)96JQ(T:)$,A7RI9BV#DY'7C%07OCK6(=(\)^-O.:+P]=[8M6LQ&A
M$);*B0,5W;0W7GT]: /5:*\X\?Z_KFA^!+K7[#4IH)9;N(V\;0QL(X68+C!3
M))'S<\C..U:%]J>HQ^"_$>NV6K7C+!9W!M5N;:-'BE@,@8X\M>&*KPP[>] '
M;TV.1)4WQNKKTRIR*X?P'JVH>(]+T^]N-4NYF%G$;V&>V2-)'DCW93"*<#U!
M(.3Z50NM+O/AKX+8>'[*XDMFU,7%U;VC&:6"V( ;R]^=Q^52<C^)NG4 'I-,
M66-SA9$)] PKGO!>OV?B32)[^QU5M1MFG(0R1A)(1M7,;@ <@Y/3H1UZUYYX
M(B$'C_XHR6V()H74Q2(BYC/[T\9!'4#M0![/17E^A^+M;AU!O"?B:\,.NQ7$
M,EM=Q1(J:A;/(H) *X! )! P>/8U>\.:GKNN>*?&&ER:S-%#IM[!';,L,6Y(
MSEF'*<D@8R<XSZT >A45YYX#U+7O$,VMR7FMSLFFZY<V2Q^1" \*+A02$SN!
M8'/M4OPX\3:CJG@2?6=9NGN[A+F:,8C1"0K850% &3P/<F@#OJ*X3PMXLU#7
M/"&M_;B+77M*EN(+E8P#L=<E" 1@C&!DCG!K0^&VK7^N_#_2M5U.Y-Q>7*,\
MCE%3D.P& H Z 4 =733+&K;6=0?0FO-O"7C6ZU#Q!!HFN7=UINOQRRFXT^Y@
M017"8?;Y#!<D#Y3UY /7K5[Q@J)\2?!,XL3=2C[=\D83><1+CEB!QUZT =UY
ML8;;YB[O3-)Y\/\ SUC_ .^A7GT=M!JOQ?OH[S2WMA-X<$;K-Y99@T[ G*,W
M4<=<\4HT#1C\7WLSI%A]E_X1Y6\G[,FS/V@C.W&,XXH ]$!R,CI145K;16=I
M#:P+MBAC6-!GHH&!^@J6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "L3Q9X;A\6^';G1+FYEM[:YV
M^8T(&_"L& &<@<@=JVZ* *&G::VFZ%;Z9%=.WV>!8(YF4;@%7:"1T)XKGM3^
M'FG:E::0JSM:WFF3I<1WUO$BS2.HZL<<YZGU-=A10!ST?A2.RUR^U?2[IK2X
MU%5%Y'Y8>*5E! ?;P5;!/0X/<&L5?A=IL/AK0]"M]0O([?1[T7\,AV,[RAF8
M;N,8RQX ]*[NB@#/T_39;*YN9YKZ6Y,^T!&142,#<?E"@=2Q))R:;-H\<_B.
MUUB25F:UMY((8<?*I<J6?ZX0#Z9]:TJ* ,CQ'X<L/%&EBPOQ(H259H9HFP\,
MBG*NIYY'T[U6'A:.?Q!:Z[J-TUY?64+16F4"1P[N&<*.K$<$YQCH!7044 <]
MX4\)VWA.RN;6"YEN4GNI+O=,J[E=_O8P!QQ3O&'A:'QEX?ET6ZNYK>UF96D,
M(7<=K!@ 2#CD>E;]% &%K'AH:UX2D\/7%]*D,L(@DF1%WLH],\ \>E7=#TH:
M'H=EI23O/'9PK!&[@!BJ@ 9QQG K0HH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@"CK.FC6-%O=,:9H8[N%X'= "P5@5.,\9P:YK3?
M #:5X8M_#UKK]^FGPY7 CBWNC,69"VW.#D@XP<5V=% &!J'A.QU@2+J9-S&;
M^*_C4J!Y<D84 #U!"X.?4_A2_P"$%@&I>)KX:A.)/$,*PW(V+B-50H-GH=I/
M7/-=910!BZ5X>CTCPG#X?ANI'AAMS;I,ZC?MQCG'!-9^A>"O[ T33M&MM8NV
ML+&42*C(FZ3#E]K,!TW'MCI7544 <DO@*UM]+U32+"_N+32M3D>2>VC"DIOX
M=8V(^56],'&3C%6==\%Z?K7@L^%$=[+33''$! !N5$964 G/=1R<UTE% '-^
M)O"$/BGPQ'H5Y>S10JT;-+"JAV*'(ZY Z>E/O_#$FIV6HVMWJUPT5[:/:%$C
M15C5_OL !RQ]3GZ=:Z&B@#G=%\+-HT&E6T>JW,EKIT0BCB,:+Y@"%5WL!DX#
M' X&>:T]2TZ2^:TDBO9K62UF\Y3& 0_RLNU@1ROS>QX&"*OT4 9.BZ!;:+)J
M$\)#7.H7!N;EPH4%]H7A1T&![G.222:Q=,\ PZ5JOB#48-3N6GUP?Z2'1-J'
MYL%!CC&X]<UV%% &+J'ABQU6;2+F]&^\TN99K>X "L"."#[$=1]/2H-#\*1:
M%K>MZK%>2RRZO*LLR.HVHR@@;<<XP>^:Z&B@#GO#/A2+PNNJBVO)9CJ-Y)?2
M&51\DKXSC&/EX''ZU2T/P%;:%HL&D17TMQ91W;73QW$:-YI/.UN,;0<,/<"N
MNHH Y*+P%9VFO:OJEC=26@U6V%O<6L4:B+ & X&/O 9YZ<GBGZ)X+.AZ+INC
MV^L7;6%C('6-D0-)ABP5F Z;CGC'2NJHH YN'PA#YVC/?7LM]_8YW6CRHHDW
M;-F78 ;N#T '."<D55U^QN[CQ9I>J1:;JLYTL2>2;8VOE2>8H5L^9*K=!Z#\
M:ZZB@#BEAOU\8MXC_L'7#,UF+(P;K+9Y8<N/^6^<Y)YS^% AOQXQ/B/^P=<\
MXV8LO(W66SR]^_\ Y[YW9/7/X5VM% $<$CS6\<CPR0.R@F*0J60^AVDC/T)%
M2444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
*4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>thackray-biocrystseparat008.jpg
<TEXT>
begin 644 thackray-biocrystseparat008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$N])BNKNUV PK<&1E!V] 6523ZXS2_""RM(/A]97,-K!'/+)<"25(P&<"XD
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MK>YB=R@#=5V@( !VX[T >B:[KLFGZIH^D6OEB\U661(Y)5+)$L<;2,Q4$$]
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MZ6:XFBM@+M+D.0T;,6R=Q.W;CD$ #I7JNJVTM[H][:POLEFMY(T;T8J0#^M
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M^Y'8]14XT#2AJ%Q?BRC%Y<+LFG&0[KZ$]Q[58?4[".PEOWO(!:0J6DG\P%%
MZDGI4>FZM::IHUMJL$@%M<0)."Y VJRAAN]#@T .TS2K#1K);/3;6*UME)*Q
M1#"KGK@=J9J.C:=JS0/?6D<LD#%H9.0\9/!VL,$9[X/-7(9HKB)9894DC;HZ
M,"#^(IMQ=6]J@>XGBA4G :1PH)].: *%SX<T:\TQ--N--MI+%#N6W9!LSG.<
M="<\Y]>:THXUBC6-!A5& ,YXH:6-0I9U 8@+D]2>@%-AGAN%+0RI(H)4E&!
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MK-$WJI(X/ Z>@H \FN](TZ^\-?%*ZN[2&>>"]NVA>1=QB9;=&!7/W3D#D<G
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M>']'T".5-(TRTL5E;=(+>()N/OCK5U+:".YEN$A19I@HDD"X9PN<9/?&3^=
M'E,<6F^)QXOTO7]8@LKF/495E$J1B6.%2#"Z,W( 4 @CH<^O-ZST33+SXKM#
M=VJ7D;^&[>23[5$"9G\UAOD4C!; '4<5W%[X:T/4=3AU*]TBRN+Z''EW$L"L
MZXZ<D=NWI4[:+I;:@^H'3K4WKIY;7'E+YC+_ '2V,X]J /';:"W?X:>$DFBC
M>.#Q0L">8 VV+[5(-N3VP ,>PKVN)(#;+'"L?D;=JJ@&W'3  XQ6?_PC.@C3
M)-,&C6 L)&WO;"W3RV;.<E<8SGO6G'''#$D42*D:*%5%& H'0 =A0!XW#!90
M?"OX@B**".<7NII\J@-L#]/7 R./<5M?V;9:7XZ^'\UC;1037=K=I<2(N&G
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M>VOFO8-,M([EG,AD6( [SP6_WCW/4TMWH&CWVIPZE=Z9:3WT"[8KB2%6=!Z
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MP,%FGBC9@6 =P"0.2>>PJ'^U-/-K'<_;K;[/)PDOG+L;Z'.#7FD=KIVJ^,?
M$LT5O=>=HT_G,0'\PJD6 W][!)X/0U+H/AFR\0^'/'?AUDCBMFURY2W"KQ V
MR-E*CMACG ]Z /2C>6JF$-<P@S<Q N/WG^[Z_A3KFZM[.$S74\4$0X+RN%4?
MB:XCP7J=UXLGM;[4K8Q7.BQ/9W"LN!]MSME(^BJ,8[2D=JT?&-G?W=UH[Z-J
M-M;:Q;2R3VL-XA:&YPFUT;'(.UL@CD<^] ">*O$-WIW_  CTVE7%I):W^KP6
M4QV[R4<G)5@V ?EQT/7M72V]Y:W@<VUS#.(V*.8G#;6'4''0^U>3:C>1:OX8
M\-Q3Z4-.DC\7QV]W:*^Y/-\R0R;6'526)_$BKE[_ &5H/BKQVKVS0:9_84$M
MQ!9 1LW$JDKC&&QQF@#TJVU&ROFECL[VVGDCX<12*Y0^X!XKAXO%FNMX'\7Z
MHTMD;[1KV\AB/V=O+9(0,?+OSD\]SU[UF:9=0Q?$?PH?M.GQH^B2Q1PV\F?+
M3,?EHSD_.?0X&>PJ* C_ (5K\3^1_P A'5?_ $&@#TO3+B>]T&SN2Z"XGMDD
M+%<J&90<X!'&3TR*PO WBA];\,6-UJ]U:)J5S-<((T(CW[)G0;5))/"CUK:\
M/<^&=*_Z\X?_ $ 5X]!H6D7?P,NKXV<)U=+BX^RW**//$XN7$2HWW@22!@>O
MO0![7=ZA96"HUY=V]L'.U#-($W'T&3S5@'(R*\M2YM[GQGX@T;Q/JRV,TUC;
M+$LHB"30&+]X%,BGI)OR!_3CM?#EI#IW@VTM-)NKB\A@MREK-<L"TBC.PY
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MMWB5H\#H-I&*5M3L%L!?M?6PLR-PN#*OED>N[.*?;WUI>-,MM=03F!S'*(I
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MJ:+5M-G\_P K4+23R%#S;)E/EJ1D%N> 1R":?9:C8ZE$TMA>V]U&K;6>"57
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M7L^F64MT\9A:>2!6=D(P5+$9VD$C'2GV^K:;=W+6UMJ%I-.H):*.9688.#D
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MGVJ*QU.PU.-Y+"]MKM$;8S6\JR!6]"0>#0 NG6$.EZ9::?; B"UA2&//7:H
M'Z"I5@B6=YUB03.JH\@4;F5<D GN!N;'U-5[;5M-O+F6VM=0M)YXAF2**969
M!TY .13%UO27=475+)G9795%PA)"G#$<] 0<^E $_P!AM/L7V+[+";3;L\@Q
MC9M]-O3%5SH6CMIPTYM*L38AMPMC;IY8/7.W&,TZ+6=*FN8K:+4K.2>:,2Q1
M+.I9TQG<HSDC'.1Q4EEJ=AJ22/87MM=)&VQV@E5PK>AP>#[4 1_V+I7VM[O^
MS++[2Z['F\A=[+C&"V,D8[4U-"TB/3I-/32K%;*3[]LMN@C;ZKC!J2TU?3;^
M9X;/4;2XE09=(9E=E&<9(!XYIAUS2%>)#JMB&FD,40-PF7<=5'/)'H.: )K+
M3[+3H3#8VD%M$3N*0QA 3ZG'>J</AG0;90L&B:=$!-YX"6J#]Y@C?P/O8)&>
MO-6K[5-/TN-9-0OK:T1CA6N)EC!/MDBG2:A90M$LMY;H9E+1!I0-X W$CGD
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MH"?J30 V+2M.@OI+Z&PM8[N7_63I"HD?ZL!DU';:'I-G>/>6VF6<-RY+--'
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M8IA,NQR3@!6S@DGCB@"W14%I>VE_$TMG=0W,:L4+PR!P&'49'<>E3T %%%%
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M-"\3ZZVF-<3 B.9H46:T,2A2C2(3P0W /!.>I->I"*,3-,(T$K*%9\?,0,D
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MA:,[_-1$4J.@&[^+&*9X5FU'1]>T'2+F>SUO29[.7^R=4A&V:&)54E9 ."I
M0;AW SS0!Z75&36M*AOUL)-2M$O'8(L#3*'+$9 VYSG'.*O'IQ7D_A'5?#NH
M>#(=#\1M%)KMKJ#M<6$CE;B2[$S,K*H(9LD@YZ8SG@&@#TJ^UK2],D6._P!2
MM+5V (6:94."< \GIGBGW&J:?9S10W-];0RS F-))54N "Q(!/( !)]A7#^&
MKFV_M;QYIWB%HEF:^>:07! #V+1JL9YZJ K#V)-<QHMC(EO\*8-;C5[G?=#;
M<*-WE^4YB!!]%V<>N* /7+36M*O]/DO[/4K.XLX\A[B*=6C7'7+ X&*I7WB[
M0=/TF]U.35+5[>S3=,8I58J2#A< ]3C@=ZX(P:?-J'Q&L9M0_LVV:_L<7$6/
MW$K)'M<CICS,9S[TFIWNLOX:\=:3KEO:3ZE;:-O_ +1L@0ES$5EV;E_A<?,<
M>_IB@#MGUN#5;#1KNQU^RL5GN8BZEHY?M (^: $GAB2.1R,=*?#XST.;Q'?Z
M+_:%LEQ8QHTI>95&YM^4&>I4)DXZ9%<?XAO-/O-!^'UQ;W%O,%UJQ02(P.#Y
M;9&?RS6KH]W;VWQ?\503SQQS7-K8>1&S -+A9<[1U..^.E '6?VWI/V:WN?[
M4LO(N6V02_:$VRMG&%.<,<\<50A\8:-/XHN] 2]@^UVL:-(#*!\S%OD'JP"Y
M..F17DUOJNGP_!?P[927D"W5MJT/GPEQOAVW9+%QU4#U..H]:[G3;RSC^+WB
M"*>>$&[TZR\A&8?OA^\SM'\0YYQ0!T.EZI;6FCFYU'Q'8WT9N)%6\!CB3ESM
MCX."5^[ZDBM"SUC3-0NKBULM1M+FXMCMGBAF5VB/HP!R/QKQF86C? Z^!\DJ
MFNL$Z?*/MPZ>GR_I7;F*UM?C5916Z10A_#TJ[8P%R!.FT8'ISC\: .KDU_1X
MK@P2:K9),&*E&N%!R.HQGJ.XK05E=0RD%2,@@\$5XIHSZ3JWA;0O#DFO:,1I
M^K_:?M,M[&)9D29V'[HG<'?."#V)//2O:U4*H50 H& !VH I7^M:7I;!=0U*
MTM6*[@)YE0[<XSR>F>]75974,I!4C((/!%>8^*=4TYM<\86*26]A>+I")<2S
MMNDO%*2%$B0G  R02 22V,#&:ZSP!<Q77P^\//#,DH73K=&96SAA&H()]0>#
M[T 5O%FLZAI&O>&4@NXX;*\OC!=*T8)*B-VSN/0?+_\ 7K;M=?T:^L9;ZTU:
MQGM(21)/%<(R(1ZL#@5RGQ$2V?6/!@O5B-K_ &QA_.QLYBDP#GCKBL75],M(
M_$?C>ZT^&%-,/AXQWFQ0(VN\.1[;@F,^FX>M 'HUOKVCW1E%OJME*88EFE"7
M"G9&PRKMSPI'()[4ZSUG2]0CGDLM1M+A(#B9HIE81\9^;!XXYYKS&_CM=*^%
M'A35[2W6*",:=)J5S:PJTGD* S$\'<%<AL$'G-3ZQ=>$3I_B+Q%%?7'B,R:5
MY-ZMO.@C:/<-BN8E7:W)YZA0WM0!Z/8ZSI>IR/'8:C:W3HH9UAF5RH/0D ]#
MZT+K6EOJ']GIJ5FUZ20+<3*7R.HVYSD=Z\Q&H^9\1D:SU>QN;R?PQ-#:FT($
M0E\Q2B(<DL1UY)/? %7_  =JWA36O"GA:RN#%+K&GO$%LMY%Q#=(-LCLF0V,
M[F)/&.3S0!J^&O%P237H_$FLV41M]:EL;1I62 ,JI&0H!/)RQ[D\UW%>-RP6
M4W@SXKS/' \HU"\&\@$C$*%>?][./>O5-!D\[P[IDF_?OM(FW9SG*#F@"S=W
MMK80>=>7,5O%D+OE<*,GH,GO4"ZUI3::VI+J5F;%<YN1.OEC'7+9Q7*>([I[
M+XH^%I;T[-+D@N889&X1+I@,9/0$J"!]2!7+>)+0+%\4KB$(=+DLXB.A3[6(
MCO*]MV"F<=R.] 'JUGJNG:C-/#97]M<RV^T3)#*KF/(R-P!XR/6JGB;Q)8>%
M-"N-5U&55BB7Y$S@ROV1?<G\NO:D\-6.GVNB64]E;6\9FM8=\D2 &0!>,D?>
MZGKZUA_%H$_"[7, G$<9/T$B$T &J>)Y;?QIX;CMM5M&T._AO'G9=A7]T@.?
M,ST!)SC'2NB3Q!HTFE'54U:Q;3AD?:A<)Y61U^;.*X_7[G3M5^)7@5XY;:[M
MV2_9&#!T8A$P1V."/S'M7)ZV+4>!/BE"!$$CU9F11C"L5BY'H2<T >OIKFDR
M)=.FIV;):/Y=PPG4B%O[K<_*?8TL&M:7<V$E_!J5I)9Q$B2=)E*(1U!;.!CW
MKA/&+6'AVY\+ZG&%T_1_M9^V7=I"AV,82D+OE2"!DC)!QGZ51U:;PG8Z9K&J
MVUR^M1ZA?62W-RUPHM5G#@([-$  %PK/CK\H/6@#T-O$FBKIUWJ']J6C6MF,
MW$B2AA'QG!QT/H.IJ+1_$^EZQX=@UJ.[MX[:2))'+3+^Y+ ':YSPW(X->?VE
M]#-XP\=1C4[>]GNM&A*-  %E94E!V $Y X'4XZ$U437;:T\'?#J^;46CTFT2
M.&_N+;;)]FE-OM0OD,!@D@Y'&1[4 >I+XAT5M-?41JUB;)&*O<?:%\M6'4%L
MX!]JEMM8TR\O[BPM=1M)[RW_ -=!',K21_[R@Y'XUY1XRM?#K> ?&NIZ5J3:
MF]VMN]S=>9&\)E5@ $* *'QC=CU7/-=-?Q6EG\6O"R6B00[],O$Q& NY08RH
MXZCJ?SH Z]];TI-173WU*S6]<[5MS.HD)QG 7.<XYQ5+Q-KMMI.DW@75+.SO
MUMVDA$[*3G!Q\I(SDC'UKS3P]<Z'K?A.TT;Q!KEVFLV=YF72PT27!NUD)#(-
MF]B2<YSW.3UK2T[5K-(?B-I^N3P1:FUW<GR[E@IDM3$%AVYZK@8P.Y]Z .Z\
M'ZA<ZMX+T34;V0275U90S2N%"[F9 2<#@<FL[Q?K.H:/J_AD6UW'#:7FHBVN
ME:,$LFQVSN/0?+_]>I/AQ/%/\-_#IAE20+I\*,48'#! "#[@UF?$A+9[WP>+
MU8C:_P!N()/.QLP8I ,YXZXH ZJTU_1K^RFO+/5K&XM821+-%<(R(1_>8' _
M&BWU[1[MI%M]5LI3%"L\@2X5MD;#*N<'A2.<]*\]U72[2/Q=XON]/@A33?\
MA'6COO+4")KK+%<]MX3KZ!AZU3NHK;3/@_X7U>TME2*)=/DU&XM85:7R%(9R
M>#N ?#$'(X- 'J5EK.F:BD[V6HVERL!Q,8IE;R^,_-@\<<\TECK.EZG*\5AJ
M-I=2(H=EAF5R%/0X!Z'UKSK5KOPB]EK_ (CBO[GQ$S:.T-XMO.@1H2PVHYB5
M=K')Y/S!0WI5:+4ED^(MB]IJUA/<S>')X;;[*P\I9-Z%(U))+$=>3GO@4 >G
M#6M*;4!IZZE:&])(%N)EWDCJ-N<Y'I7*^'?%PBNO$$7B36;*$6VKM9VK3%(
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MV%OM\FRMH]KF1=D2C#G@L,#K[T^.SM89FFBMH4E;.YUC 8Y]35$^)M!"1/\
MVUIY6:3RHR+E"'?CY1SR>1^=">)M#ETV/48M6M)+.1F5)DE#*Y7J!CKC!Z4
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M0&3.Q7;YGP,G ZG Z^E %CR(O)$/E)Y0  3:-N![4D]M!=($N(8Y5!R%D0,
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ KEO%5U'J%[8>%X+VWBNKUO/F63#8@C(8@KD9W-L7&>06
M]*ZFF&&(R>88T+C^(J,_G0!YCKDTW@KXEZ-X@U'4;5K;6%.F7A2+R0I'S12$
M%CG!R"W&!4NL:WIV@?$C4YYM3TT?;])A1HM0N/(52&?9L8@AE.6W =..N:])
M>&*4@R1HY'3<H-<G>>']?37;V[L[C2+RSNRF(-1MV+6X5=NU"IP5ZG! Y8\\
MT <;J%EH^E>"/A]IT>J6.HV\6N6JM<I(K)+Q)NYS]T$X^F,UL>(=0L?#7Q'L
M9=1NGTK1[O36BM[J$*D2W'FEY QVD+N&TYXSMKL]'T&WTRVE5XK9YIY3/,8H
M!''O*JORISM&%'<GN3S6E-;PW$7E30QRQ_W'4,/R- 'DE])H_AL>'-3T^XO8
MO"_]HW3SWJG>JR2H LHR#A-V]<XQR2.",Q^,$\-GX=^+=2T>\:\2^EM6GNWE
M#12RK*HPG09 QG'MW!Q[ T4;Q&)XU:,C:4(R"/3%-%M L2Q"&,1I]U @P/H*
M .#U;^SO^%O>%%3[+QIUT$ V\#,93'_CV/QKE)KPP:#XMN+1GEMK/Q<MU=QV
MN&?[.IB9V YS@C/I\I]Z]H^SP;@WDQY'0[1Q2I#%'G9$BYZ[5 S0!YK//X4U
M:#7-<TS5)-3NO[$F@GN3(#''%C*HX  #$Y(!YX-9B2V,'A;X3M');QL+FVR5
M(!YMV#_FV,^]>M1VEM#"8HK>)(B<E%0 $^N*7[-;X \B+ Z?(* .(\'7EM#X
MZ\:6$DR+>2:A'*D!/SE/(3YL==OOTZ>M&NWEMI_Q=\/S7DR01RZ9=11LYP'<
MO&0H]6/H.37=!$#EPBAR,%L<D4,B.RLR*2IRI(Z'VH \JT>ZM1X'\::/K[QK
MJ2W5Z;J*4C?+YF3&ZCJ005"X] !7<^%+6_M? VDVNI;C?QV$:3!N6#;!P?<=
M#6R]M!).D[P1M,G"2,@++]#VJ6@#PR/4-.G^ N@6C7,#O#=V<5Q$6'R'[0"5
M8=C@$D'MS74:PQ;XH:E;:5+&E[+X2D2 1L 3)YIV?B,\>U>C&W@(P88R,DXV
MCJ>II1!"KAQ$@8="%&: /*_"]]X6\1:?X9MY+^\EUC37B\O3-VR2VF0!7W*%
M!" 9SG@CWXKHOBY+'%\+->\QU3= %7<<9)9>!79);P1S/,D,:RO]]PH#-]3W
MISQQR@"1%<#LPS0!P/BO4+.U\9^ ]4N+J"+3U>[1KIY (P7@^4%N@SCBL.'4
M[&>Q^*S1W41#J\BY;&Y3: !AGJ">AZ'CUKU=[6WDB$3P1-&#D(R C/KBE\B(
MAAY28<[F&T?,?4T >7:C>6P\,_"TFXBP;ZR.=X[6[ _J0*C;4]&AU[Q?H'B[
M59K WMTTJ1NP5+JV>-478=I)("E< Y].<UZH;: @ P1D#H-@XHDMX)9(Y)(8
MW>,Y1F4$J?8]J /+M7@DTEIKOPYJ<5O<66CP)>Z-J_S+<VJJY3)SN5P"ZYZ9
MZ^]V+5+>/XF>'+Z\3^SUO?#;+%#,<,)&EC;RAGJPZ8Z\5Z'+:6T[J\MO%(Z'
M*LZ E3ZBI&1&969%++]TD<CZ4 <-\1[YM)N/#>J7,EQ%I%K?M]MF@7)AW1.B
M.1@\!F]._KBFZ=<>#HH_$.N0WQO[2\BC34+IY \,Y"E5C4 !2^#@@?W@.IKO
M'19$*.H96&"I&014:VT"0K"D$:Q+]U @"CZ"@#S;P)(/"GB*7PMK+*EU/ LN
MDR23;S]ER<6V?[T9)Z?>!SVK%-V__"#>.;*R9I;^#7[FYFM(CF4VXN49^/0I
MNQGJ,]:]E,,3.',2%AT)49%*J(K,RHH9OO$#D_6@#S_3+[PCK^L0ZWI^KS:G
M>PV4BM(T@"V\+#)$HP .<8#<YY'0UR-C)8P?"+X?2*]O&PUJR=F! .X2G<3[
MXZ^U>U1VMO"CI';Q(KG<X5  Q]3ZTOV6WQCR(L#ML% '$:#>VUO\6O%]K-.B
M7%U'8M;QL?FE58GW%1W [GM4GB36-/L_B!I5K/);Z?=/83,FI7#?P%U!AB!.
MTN2 <D' '0YKMA&@?>$7?C;NQSCT^E(\4<C(SQJS(<J2,E3[>E 'AMO?V@^!
MMA#]J3?!K2+(&(4J?MQ;!'&#MYQV!S7=7US#_P +ITE%GBWMHEP%!8<DR(1^
M>"?PKMS;P%=IAC*Y)QM&,GJ:/(AW!O*3<.AVC(H \>L9H+GX&:MHFI$'7H?M
M$,]JY_?->-*S1D#J2S%"".M;VNIJ/AG4/"WB0P/=WOV8:1J*1\M,TB@QG/\
MUV&,_P"W7H1MH#<"X,$9G P)-@W >F>M2,JL,, 1D'D=Q0!YEX4T[4-,U^Y\
M%W8:6SM+A-76X"[4='^81@=L7 9@/135$:CHBZKXN\/>+]4GL9+J]DD6%R%6
M[MG50FP[26.!MP#G@8KUO:H8M@;B,$XYQ_DFF26\$LL<LD,;R1\H[*"5^A[4
M >;:-J5GX>^(]W:ZQ*;&WET>TCTI[Z0+B.,'S$WDXW[B"1G)Q6A\);BUE\+7
ML=M)&PCU2[RB$?(#*Q7CMQTKN9;>&?9YT,<FQMR[U!VGU&>AIR1I&NU$55Y.
M%&!0!Y?I?]A)/\1(=96US)J#F2*4+YCQ&%-N >3DYVX[].:9)HNJZ+\,_"^N
M/"[:WX;A6>2(_?: C$L)]_+_ %05Z@]M!).D[P1M,G"2% 67Z'M6)K>DZSJV
MHI;)J%K#H$L.R[@,!,\G/S*KYP%9<*>,XSZY !+X8C>33I-4G1DN-3D-VRL,
M%$( C4^A$80$>N?6N9N+VW@^,.JLQ$QC\-*3"A!=\3.2H'KC'YUZ#TIGDQ>9
MYGEIO_O;1G\Z /%K#6]+FO?AS=V]]:0VD<TJK96[;DL@T#!8W<Y8R9PO)&3T
M6MW5-(F7Q9KOA..)AI_BF$7@E"96W882Y/U(\L@_WF%>EK;P( %AC4!BXPH&
M&]?K3]JE@V!N (!QR!_D"@#A?A_<W^I6*76LQM'<Z-"^ENS_ ,<J-B60>H(2
M+GUW5U>BZYIGB+35U#2+R.[M&8J)$SU!P1@\BKP4*I"!5SD]._K533-,@TNW
MDCA W2R&61@H7<QP.@X    'H!]: .#UJPGL_'&HZ1! S67BZSVNP7*PRQX2
M9CV&86!&>K*!WJS\/1?W,266JQOO\-^9IHD<<32 X#CZ1"/G_IHU=^54L&(&
MX=#CI0%4;L*!N.3QUH \7N'BG^%_Q.2V9),:Q>MB,@\90YX[<'\JZ#6]2TK4
M_&WP\EBNK6Y@9[ME8.&5B(."#T/S=_4>HKT58(D!"1(H88.% S2?9X/E_<Q_
M* %^4<#VH \8UIII=-^),6F 3B/5;:>>" Y9X0L1EP!Z@-GUP:ZW7)K;7O&'
M@F^T*YBN)(Y99I)8&!"VAC^;=CH"=H&>_P!*[Q(8HV+)&BD]2J@4V&V@MM_D
M01Q;SN;8@7<?4XZT >(:IJ=C;_"SQYI,MU$NHC5;QOLN[]YM,X8-MZ[<$'=T
M]Z[.74[&+XQ:;=/=PK!=^'VBMI-XQ,YN$(5#_$<<X%=V;6W9W=H(B\F [%!E
ML=,^N*D*(SJ[(I9?NDCD?2@#B?B;-';67ANZGD6*W@\06<DLKG"QJ&;+,>P]
MZK076GW?QM:=9K>0#PXC1L2#C,['(_X"?R-=^Z)(A21593U##(--,$+,6,49
M8]25&30!XAI>IQZ9X*\,:B\\J:-8Z[>"\DML-]G5WF6-R,'"@N.W<8[5Z-X2
M3P_<ZOJVK:'>RW[W@B%W>"3=$[*"%48 &X+UQZC-=2((0C((HPC##+M&#]:6
M*&*")8H8TCC7HB* !^ H X"PBTV[^,OB.&=+69SIEJ-CA6)PSEN#_P !S^%<
MY87F@7NE:SX6\6ZC=Q:B-1G,VG[MKW1:8R1M%A=S9RN,'MZ8KV(0Q"3S!$@?
M^\%&?SI&MX&G6=H8S,HPLA4;@/0'K0!YYH6O6&D>.O%.GZ_<I;7UQ+ UH+EN
M9[?R@JK'_?(;?P,DECQUKE]'GALOAU\,;ZYD2&T@U3][-(<)&")@"QZ 9QR:
M]HN(0V)D@ADN8P?*,G&"?]K!(_"L'P9X;F\/^"[+0-2^S7)M5*%DRR2 L6!(
M8<=??I0!R^E:KIMUXX\?NEW \,MC:.C%AMD412 LI/WEY'(XY%8,<UA)\./A
M<L\MNR_VK:!@[#H$D!!]LX!KV?R(L,/*3Y\;OE'..F:3[+;X \B+ [;!0!YU
MK^H6/AKXD6KZE=/I.D7>FF*VN8@J1+/YK/(K':0I8%3GC.VLO5K3P]9:;X0B
MTMMVG3>)TFC>X?(E#(^YES_ 6/I@]1P17K4UO#<1>5/#'+'_ ''4,/R-#01/
MC?$C8&!E0<4 <'I;6'_"Y/$S,UMO&FVNXDKD??#?IMS[8KC-&U---^'?@34Y
MKB5-'L[^Y2]FM\,;?<94C<C!P 6].X]J]O\ L\&XMY,>3U.T<T>1"(VC$2;&
MX9=HP?J* /(/&"^&Y? 'C75='OGOFO88!<7C2AHI9%8!57  W 8SCU&>:Z+4
M);&'XJ>#5MGMT5M.O$41D %<1E0,=NN/QKO%MK=(5A6"(1+]U @VCZ"E%O &
M#"&/(Z':.* .'^%]Y;'2]5T\3(;R#5KTRP _/&#,V-P[9SQGKSZ4NHW=NGQJ
MT:)IXA)_8]PNTN,Y,B$#\@?RKN51$+%44%CEB!C)]Z:8(6?>T49;^\5&: /+
MM&N[5?!WC;2/$#QIJ"W=XUS%*0&E609C=0>2"-H7'H *ATZV-OXI^'-CKAB?
M4(]&N$F2<@L'V1@*<]3C(_ UZL]M!).DSP1M*GW)&0%E^A[4YH8F?>T2%Q_$
M5&: .:\?P11?#/Q##'$B11Z9,$15 "@1G  [8KD[VQT_4+;X<MHJVYOX;N";
M?;XW+;",F<L1T4\ Y[D#J:[SQ7I=SKGA74])M&B26]MWM]\K$*@92"> <XST
MJ;1-._LW2[:&6"W2Z2%(Y7A'#E1C.< GIWH \XTFZM?^%>>,=&UYT75$N+T7
M4,I^>5I"3&RCJVX%0I'H *5[76-.MM,GM=<M[;Q/8Z!;_;[#40&ANX1OX)SD
M,K!P6'J,]:]3>V@>=)W@C:9!A9"@++]#VI)K2VN"IGMXI2IRI= V#[9H \T3
M5[9?%_@/4KN$:7#<Z-.L<$IQL8B(B,9ZGL!U/I31<6?]L_%93-!M^SPEAN&/
M^/4@_KQ]:]19$<J616*G*DC.#[4S[-!S^YCYZ_*.: /)4EL;?PU\)VCDMXV%
MQ;9*D \VS!_S;&?>H]4OM,AN_'?AR;7-)A_M6XYDU&Y\EX&>) WRD?.JC!4@
MCGCC&:]>^S6^ /(BP.GR"N0B\-^(K:[NT^T:'?VMQ</.L]_9NTZ!CG:0&PX4
M8 ^[P * -V-K2Q\(!H&^WV<%D2IA(8W"JG8C@EL=O6O+-.UK3)M8^&UW!?VD
M=HGGHMI;MN2S#6Q"Q,QRQDSA>2,D<+7KNDZ9#H^F16,&-B%FX4*-S,6; ' &
M2< <#I5E;>! H6&-0K%AA0,$]3]: .)^* @_L[P\]V(_LB:_9M.9<;%3<02V
M> O/.>*Q_$.FSW_C'6+WPJ$\]?#D]O/-;$;7G8YA3(XWX!/J!M]17J+HLB%'
M4,K#!4C((IL,,5O$(H8DBC7HB*% _ 4 >4:A/:Z]\,?"=MHSH-6BN;);:)#B
M2WEC($F1U7:H?=[5<M&TYO&'Q-9VMB1;VZL25X7[-AA],CGWKTE+:".=YT@C
M65_OR*@#-]3WH^S09)\F/GK\HYH \=T'5XM.;X:WNIW")H_]DO;I<.W[N*Z*
M*!N;HIV@J,^I]ZV_#VLZ#%XI^(EQ<W=FVG>9;S2G(=&C\@!FP,[AG(/7.?>O
M1WM;>2$PO!$T1ZHR J?PIDMJCVTT4:1Q^:,,?+!!XQR.AXXYH 9I=U8WNEVM
MSICQ/8R1*T#1#";,<8'88[=JMU6T^Q@TVPAL[<$11+M&>I]2?<G)JS0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-&NWMFWQ:\&[;F EK2]QAQSN6/;^>#CUQ0!O:=J\D7B:Z\.7LGF3I;K>6LQ
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M=M?HT3 JQ!$*A6^@;//8YK!\*W?AG5]!T70-6;4&\0:;-$K:6\L@>.YC./,
M'&WJQ;.,$T >C7/C3PU9I<-/K=DJV[^7,1*#L;K@X]._IWJ9/%.A2:K!IB:M
M:/>SKNBB60$N,;N.Q..<=<<UPMC=:<=8^*#-/:X(0$EUY7[,%/X;LCZUF?;+
M"'X?_"[%Q;(4U*Q+8=1MQ&X<GTY//N>: /4-0\1Z/I4OEWVH0P$%0Y<_+'N^
M[O;HN>V<9J34=6L; "*YO!#+*C,@1=[[1U<* >!D9)&!QFO,4U#08M3\4^'/
M&%U>6\UWJ$LL4&^0+>6\F/+V!?O' "X'/ _#1TC4[3PQ\1]2M];D&G6]UIED
MFE/>2?*(XT(>+>3@L&;)&<GK0!+X>\0R:E\.H[S5/%0LYY=0ECCU B/,BK<$
M*JKC:=R@#@=Z[G4M:T[2%W7UTD/RE\8+$*.K$ $A1W/05XR;ZR'P/N8Q-&A3
M7.$;Y2/]-#=#_L\_2NFU36M-T3XC:DWB*^N++3]3LK<V%XDC+"X0/OC++QG+
M;A]?<9 ._DUS3([>WG^V1R1W*>9"8<R>8@P2PVYRHR,GH,BK5I=V]_:17=I,
MDUO,H>.1#E64]"#Z5YE+I>G6,.B1>%]9;P]?6UK.VGK?DO%<V[2;F1PYW8)"
ML.X!Z<<=KX+U"?5/!^FWMS8I932QDM!'G8,,1E<_PG&X>Q% %F7Q)HT-Z+23
M4(5F,PM^2=HE/2,M]T.>/ESGVJ:#6]-N=5GTN&\B>^@&Z6 'YT'8D=A7CGB'
M7-/N_#VJ>5+'I[6WB%'GTZ-/G4BY7=/,2"1NZ@C:O(')KLO%KW.B^)=&\6Z3
M;-<_:XSIEQ$H(\P2?- Q],28!)[/0!UI\0Z2ML)_ML90S&W7 )9I1G**N,EA
M@Y &>#Z51U;7=*N_"EW>P>(H=.MR&B&H*R_N7!P1AOX@01M/-8/B2YL?#-SX
M2L;IH(6:68#5[D?+;OY9WMU WR%FQNXR2<'I7&O?6@^&'Q)MFNF>7^U+IAYR
M[';?LVDC  +8) P._% 'H&MZEJ%IXV\&VMOJ,ALK]KA+B+8F)=D!96SC(YYP
M#CIQ6Y-XDT:WO/LDNH0I+YP@.2=JRGD(6^Z&.1\I.>17':YJ%F?&7PY<7<&T
MFY8'S!@@VY4'\3Q]:Y3Q/K=A=^&_$4<4D>GO;:ZC3:=&F7)%Q'NGF)!(#8R"
M-J]!DF@#M&\61Z'X_P!?@UW6TATJ"TMI+=9]BA&<OD+@ M]WODX%6?&NNSQ^
M'=)U70M4 @N-1M8S)!L=)HI) I&2#V],5GVU_I=M\6-9N[^>V@BNM(MC;RW)
M""1 7W[2V,]5R/I7+W-JNB_#:U6?%I:W'B=+FR@E^0QVQN0R_*>@VC=CL#0!
MZWJ>NZ9HX)O[Q(<)YC9!)5/[QQG"^YXJ]#-%<P1SP2)+%(H=)$8%64\@@CJ*
M\PU#6-*TCX@Z]!XGOKBRLM4A@>PN!(RPS1K'M>/*\9#;CC_:]^>[\,65EIWA
MNRM=-MYK>QC0B"*<L7"$DC.[D9!S@\C..U #O^$DT87RV9U"'SGF-NO)VM*.
ML8;[I?\ V<Y]JJ6'B_3=1\5ZCH$,G[^Q6+<Q! =VWDJ..P4<^_M7EE_KVG7F
MBZ7/%-%IZ6OBB&2?3(TYM0+D[I)F()#-RW55^; !QFNVT&^MH/BUXK@FD\N:
M^M["2VC92&E58W#$#K@=_3O0!H?$/4=0TKP_;7>G7LEM)]OMHGVJIWH\JJP.
M0<<'MBMK4?$.DZ3(T=]>QPND?FR Y/EIG&]L [5R#R<#BN8^+%Q#!X1M_.E2
M/.I6A&Y@,@3*3^0!-8OBC6;"76O%VG+)'87+:0F'1-\VI@QN5"9!&Q<D':">
M2<@"@#T1M=TM-0M[ WT/VNYC\V"(-EI4QG<OJ,=Q4=OXCT>ZM;RZ@U"&2"R)
M6YD4Y$)'4-Z$=QVKSV:15^&O@SQ9IX:>;08;9Y?+4EG@:-8YT'KP<_5*?9Z?
MJUEXON-(N(7-IXIC&HW& -MLR,//B..NY#&F>Y.: /4(9H[B!)HF#1R*&5AW
M!Z&LX>(]'-['9C4(?.DD,4>3\KR#JBM]TL,'Y0<\58U6.ZFT>^BL7V7;V\BP
M-G&URIVG\\5Y---!K/P/L= M"$\0P_9[5+/.)XKJ.10S%>JXPS$_W230!Z5J
M'C'PYI4T\-]K=E!);[?.1Y1F,L< $=B?2KNKW$%MH]W+/J*:?'Y3#[8S*!"2
M,!OFXXZ\UQED]A/\:=7@F>VFF.C01[6VDDB1RPQ_WR2/I72^,I(HO!&NM,Z(
MG]GSC+' YC8 4 );^(-'T_3M*BO=>MI9;FV5X9YG5&N5";C)CC (!8GH*NZ3
MKFEZ];R7&EWT-W%'(8W:-L[6'8CL:\R%WI[VOPD$EQ;,%1"0SJ=I%KCGTPV!
M]?>NB\(W-M)\2?'<<,\3$S6C!48'.( &/Y\'WH ["^U*STV-7NYQ'O)"+@LS
M8&3A1DG YX%11:[I4VDKJL>H6SV#_=N%D!0G.,9]<\8ZYXZUQ7B_5+?0?B'I
MM_K=Q<VFBW&G/:QW<3,J0S^8&(<KT#*%_P"^?;C'O)M%\/7'AK6K!+A?"O\
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M  D.D?:;VV^WPF>Q7?=1@\PKZL.PHT'Q!I7B;3%U'1[M;JT9BGF*I7YAU!!
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M'?48VF209*+&%R#G'.25P/0Y],Z7B&6X@\-ZE/:7#6]Q%;221RJJL595)'#
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MS+"N_)= -Q88[8[]^U43X^\++IS7YUB'[.LC1.=K;D9<;MRXW+C(R2,#(]:
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?9@O'K\V1]:]3HH \ETC6[2VM_ MK,4LV?0P@U,1>9)O"QAK=." Y(R<@GC
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MC''B) %SQC!!)(QSBK^B7EM_PCGQ)/GQ_-J-ZZ_,/F5H452/4$@@'N:]1HH
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MFUE2:WE0/'(C;E=2,@@]QBO(K)(;CX2:OX5>#?KD\]W$FGLA$N]YV,;E3R%
M*MOZ #K0!Z%JOCCPWHEU<6VH:I'%/;QB66,([E5)P#\H/^03VJ>_\6:)I>XW
MEX8XT95DF$+M%$6QM#N%*IG(^\1U'J*Y;2T2U^+RP32K+)%X;AM3,1PTBRL6
M7/\ >Q@XZXK%M[K2++4?$'AOQ;9ZJ]Q=ZA//;11?:'BOH96W(%"';D9VG. ,
M#G@X /1=1\4Z-I4D\=W=L&MXA//Y4,DHAC.<,Y12%!P>3C@$]JLW6M:?:1V[
MO.7^TKN@6"-I7E7&255 21@CD#'(]:\TUZ[02^*M$^P3:;(NC(D$5K;M))?_
M +AN&E"DE$)V]N^3@XJ/3M<7P]JGA77M1ANAHD_AV/3FN/L[D6\ZE6.Y<9 ;
M &<<[1V% &]XK\31367A;5]'UITL)];@M[@HP1'C^;>KY 88*\@X[Y%=7H_B
M/2=>ENXM.NC++:,%GC:)XV0D9&58 X(Z'H:X;Q3/I\MAX6ELK!;.T?Q+!=!?
M(\HO'\Q:9DP"H).<L.X)ZUJZ/-&?B_XB*N"LFGVJJPZ,RE]P![D C/IF@#KK
M_4K33(XVNI=AE?RXT52[R-@G"JH)8X!/ Z GM5:T\0Z9?6ES<VLTDHM7\N>)
M8)#+&W]UHMN\'GICIS7->+FGTSQUX6UV=7.CVXN+>YD )6W>10$D;T4XVEN@
MS[T:+'&WQ \1^)(9472);2WA,^?W<\J;B7!Z,%4JN1QDD=C0!7\$7EUXNL--
M\1'5-2MKD22O<VWEN+::,NZH@##9\H"_,G/!SR:W9O%ULGC9?# @NQ*;0W#3
M+:R, 2ZJN"%(QRV6/RC &>M9GPD=?^%:Z3 3MFA6021L,,A,KD9!Y&1S3+V=
M=/\ C-;7%PDJPW.AFWBD6)F5I!/N*Y P,#DYZ#F@"EX5\:V6F6>K1^(=:E>2
M/7+FUCEG5GV('")O*KM0=@3@9S7575Y8'QEI]HVLW$=\+>5ETY&_=S+QEW&.
MJ]N1UKS*Z>.3X4>/X4PTUQJ]V\48'S2AI04*CJ00,@CT]JZN^NX)OBCX2FCE
M5T_LZZ4N#D OY>T$]B<' [XH ZJ/Q'I<MY#:QSR,\\KPQ/Y$GER.H8LJR;=I
M(VMW_A-:M>4Z.TVF:]I9\/:BU[I5[?,+G1+M TNG%MY>5&^\J YZ\'=P3N%>
M@^(]:CT#0KJ_8!I$0B&/G,DA^ZO'/7KZ#)[4 <O=>,+VU^)EE92*!X?NO,TY
M)?6]4!^OI@E!_M!O2NSO]1M-+MA<7DPBC+K&O!)9V.%50.6)/0#FO//%7@V3
M_A7$GD^(KN::Q7^T+9V6#8URI+[@1&&RS%L?-GYN]-\1^(;37/ GAWQ#(TUK
M<VVHVMPR>0[B"89#+*BC<%P6&0,\KCK0!V:^,= ::[@.HI'-:*6N(I8WC>(8
MSEE8 CCD>O:HK'QSX:U)G6TU6-]EJ+QB495$1( ;) '4@8Z\]*Y/2-:\/ZC?
M>*M5@UFWEU"^LE#VJH\8CCC0J,;U4N27Y..X&/6FD%W+\"]!;3K:6XFT_P"Q
MSW%I!E97$4BO(@Q@AN,^O'% 'HECXCTK4+VXLX;EDNK:,2RP7$+P.J'H^UP"
M5]QQ4=OXJT6YU"*Q2\*3S1M-")87C69!R6C9E < <_*3QSTKA;M-%\::)K%S
MX5MK^XU6329K7[7=-."@89$&93@DG/ X'4GD9M^&]5\->)+S2I4T_4VUFPRT
MD=XUP!I[;<.2SG;VP .3QQP< '0O\0O"L=N+AM63R/.,#2B*0HC@[?G(7"C/
M&6P#ZU?M/%6BWVLMI%O?![T(9!&8W4.H."48C:^#UVDUY=,\<GP?\;P)S+/J
M=XT48'S2;Y<H0.IR!D?3VKJ-6N;:3XA^ Y(94:)+>\#.ARJ[XD" GMD@@9ZD
M4 =1<>*]%M;N.VGO"ADG^S)*87\DRYQL\W;LW9!&,YR,=:JW?CSPS927L<VJ
M+OL2!<I'%)(8\C.2%4Y ')(X'&<9KS[P[+H\FBIX0\2Z;JD^O6LS(;)GN3%<
ML'+)*I!V!3PQ8XQR:VK2>W7Q1\29'= LL-N$8])-MOM.T_Q8;@X[\4 ='JWC
M:PTW4]!M(X[BY35RSQS06\DJ>4(V?<I4'<3A>!DX))P*Z8'(!&>?48KR#3YA
M9Z3\*[Z=)OL]FKPW#)$SF)VMB@5@ 2#NXQBO3[/6K.^U:^TR'SA=6*QM,'B9
M5'F#<N&(P>.N.E &C1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3QMHVIV-^T^H7=S>V,T5K)*EQ'*@"J&4$ K@ @XQ5>%+D>&/AE$VGWZR65S
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MYB%]>F3QG!KG]<E_X1_XAWM]JVDZA>Z3J=K L-S9122^1+'N!1E3G!W9!_\
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M<M(['+,Q[DG_  &  *M44 %%%4=2U:UTL0+.7::YD\JW@C7<\KX)PH^@)).
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M8Q1DL Q&03G8V N3P>*2YU^TC>VMHH[BYNKJ SQVUN!YGE\9<DD!1R!DD9/
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MMK0>99XH\@Q")G&T'!W$[3[#- '745@ZKXMT_2([J::.ZEM[+'VR:"+>MMD
M_-WX!!(4$@$$XS574/'^AZ?>FS_TVYN/L?VY$M;1Y/,B) #(0,-USD<8!R:
M.HHKE].UC0Y?$VM317%\EW;VD,EXMR)$BBCPQ4JK8 .,Y(']:LZ?XPTW4;VP
MM42YA;4;=KFQ>:/:MS& "2N"<<,#AL'!Z4 ;]86K^'9=8U6">75[R/3UC"3:
M='M$5QAL_,<;L=B >0,="<\;IS3GPS\2$-[>DVM_=^1(;J3S(@L",H5\[@ >
MV:W=!\3VNG>'O!]C>BZ>ZU.P@6&3865W\H$@N3P<9//7MF@#K;FW6ZMW@=G5
M'&&V,5)'<9'(_#FF2VH.GO:6SFU!B,4;P@ Q<8!4$8X[<8XJ*+5(9M8N-,6.
M7SK>))7?;\FUB0O/K\K<>WN,V+B)9[:2)F=5=2"8W*,/HP((_"@#,T#0FT6W
M?[1J-SJ5[-M$UY<[0[A1A5PH  &3QZDGDFMBO+/ 7C[3M.\$>'H=8FU!GN,Q
M/J$L$C0B5I&PKS'C)^O'?%=9?>/='L=4O-,:+49KRS\LS1064CD!S@,,#E1W
M8<<CG)H Z>BN>U'QGI6E(\]S]H%A%.+::^6/,,4F[;ACUP&X) (!X)!!I-3\
M::5I4FH"47$L>FA#?RPQ[EM@XRN[G)X(/R@X'6@#HJPM>\.RZO>6-_::M=:;
M?66\12PJKJROC<&1@0?NCG@CUJW>:Y:VD\-M&DMW=SQF:.WMP&<QC&7Y( '(
M&21DG S7$>)?$MCJ:>#-=TR_N19S:RL,BHTBA@$DW(T8ZL&4#&"<].M '::9
MI$UI,+J_U&;4;P(8UED1(PBD@D*J@ 9*KG.3P.:U:Q]#\2V.O3WUM;I<P75B
MZI<6]U"8I$W#*G![$<BMCI0 45SEGXVTB^N-/2+[0(-2=X[&Z:/]U<,F<@'.
M1]TXW 9QQFJMQ\1M#MX]2<1ZC*NFRF.\\NRD)AP 2S @84 ]3UP<9Q0!UM%8
MC^*M-36M-TH>>\VI1&:TD6/]W*@&XD-TX'..M7K75(;S4;VRCCE$EFRK*S+A
M<LH8 'N<$'VR* +M%-DD2&)Y975(T4LS,<!0.I)K!B\8Z6\^GK(MS!!J3!+&
MZFBVQ7#$9 !Z@D<C<!GMF@#H**\_U;4CJ_Q'/AJ[MM0.G+I9D*0[DS(TNSS,
MJ0< #@]B37;:;9?V;IEM9?:;BZ\B,1^?<OOD?'=C@9/O0!:HKE++Q.=8\8:W
MX=:QO(H+*.%?.7*$LX<EMRG*C 7!ZYS7.?#SQI:6?@CPY!JDM_+-=RM;F]DB
M=X_-:5]JO(?XCP._OB@#TZBL35O%%CI"W;2174Z62![Q[:+>+=2,Y;GTYP,D
M#!(P16K:7<%_9P7=K*LMO.BR12*<AE(R"/PH FHKFO%7BE_#UWHUK'8SW#:C
M>+;ET7(08+$=>6(4X'U/UM:CXHL]-CN'>WO)_LL0FNA!%N-NA&<MSUP"=HR<
M<XQB@#;HKE[OX@:#:RVD2275T]Y:M=VPM;5Y/.C !^3 ^8X/0=.^*1/'^D33
M3V]O;:I-=PV\=RULEC)YNUP2,*0/3D].V<\4 =317)Q_$70)K;3KN)KM[*^=
M(DNQ;/Y,;L<*KMC"G/'L>N*TK_Q-9V,MXI@NIUL0INW@C#"'<-P!&<G@@\ X
M!R<4 ;5%%9^H:Q;:?<6]JRR37ESN,-M" 7<+]X\D  9')('('4B@#0HKFYO%
M]I-X:U34]/2:6>P$B36[1$20RJI.UU/0=#GICD9K+\"V2ZGIFB^(Y9]4COWL
M$^U>9*1%=LZ!BY4Y!P2=I&,9QTP* .XHK"\8^(#X6\*:AK"VLER]M$66-!W[
M%O10>IKE]?UAD\6>!M0D:_MXYGNEFM\OB3$#%?W0)#')XXSS0!Z+17+-XLT7
M5O#.M7$QO[>"R62"^C,$B7$'R9)POS#Y3D,/KGBK5CK=A;:3HT%BEW=FZLEF
MM8LAIFA54R[%B.F],Y.26[T ;]%5=.OX=4L(KR!9%CE!($B%&&"0<@\@Y'2K
M5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 5Q7C&UOK;Q9X6\106\]U9:=)<17<4"%W
M1)D"B0*.6"D<X!.#TKM:* .+TVT>7Q_JWBH0W,6G_P!G16:!H'#SN&9V8)C<
M0 54''/.*7X5PW%I\.]+LKRTNK6ZMU=98KB!HV4F1B/O 9X(Z5V=% '/>.M'
MN]?\#ZQI=B0+JXMV6($X#,.0N??&/QK-TG7[OQ58I:-H.HZ;>"W>.ZFO+8Q+
M;L4((C8_?);&,<8&3C@'LZ* /)$L-0OOA ? \^EW4>M)&MB5:W?R?ED&)A+C
M84VC=G.<C'7BNBT^*:T^*>HSO;7QM1HT%NMR;60H[H[E@&Q@G!'3KVKN:* /
M&C9:A_PHV72QI6I?;S?EQ;?8I=^W[;YN<;>FSG/X=:Z.'4X+/XQ:K)+'<F.7
M1;8ADMI'(_>2'!"@D$^X[8ZUZ%6%;^'/L_C"Z\0_;7:2YMTMF@,8V!%)*X/7
M.2>?TH \Y;PYJFBZ=8Z]_8DU];KKEYJ$^DHFZ5+><%5PG=E #;?]HCUK3\0V
M$>O?#OQ-+H/A:>REN[>,*'M/)N+ID;)RGWB .!GD\X'3/J%% 'FGB&XFB\4:
M5XHE\.:AJ.C3V+6<T M"T]LV_>LAB/S8/(/&1^66:Y:J^E^'Y=,\-7-C"WB.
MWOG@AL6$@C7[\LJH#M)]^<8SSD#TZB@#@&MKJY^(GB1X[*[$-SHL=O#,]NZQ
MO(#(2H<C'\0[UJ?#AIT\!Z19W-C>6D]G:QV\J74)B.]1@X!Y(XZ]#VKJZ* ,
M7QA_R)&O_P#8.N/_ $6U<3(D]IIGPRUH6=W<6EA HN?LL#3.@DM-BML4$D9/
M.!7;:WH$FMOL;5;RWLY()+>XM8@FR9'&#DE20<<9!K6@@BMK>."% D42A$0=
M%4# % 'D][%J%S9_$T#1M31M2B06BFU8F4FW5 !@'G/7T[XP:V?&D-S??!P6
MEK87TUU)#:JMNEK(905DC+ IC(P%/7TKT.B@#SGQA8+?:Q-J.FOK6E:W;V2M
M:7UK:RO'=#+$0R)M(.#_  G!^;VJ*TFUC0?'%MK.MZ9=20:GHUO;RO8V[SBT
MN$R6C*H"0I+'! (S7I=% 'C-W9ZE<?"_QQ9+HVIBZO-9N9;>$VCEY5>8,"
M<C //3CK71ZE?7OAWX@KK[:5J5]H^I:;';%[2U>26WE1V8!H\;@I#GMUKT.B
M@#S[Q,+V8^$M671;N."VU8S2VT$!DEAC:-U#,B9YR03CIGFG7-I=ZA\3=0=;
M6]MX;GPX+-;IK=]B3&1VV[P-N0&!X./>N_HH \E^P:AJ?P@3P1-IEW#K2)'8
MLKV[^4NR1?WPEQL*[5W9!Z\=>*Z'34FM/BAK=S+:WWV4Z9;0I<&UD*R,A<L
MP7!.&'3KVKN:* ..^%EO<6?P[TRTO+6XM;F'S5DBN(6C9<RL1PP'8BE^)6G:
MEJ'A:.32[=KJXLKVWO3:IUG6-PQ0>I[X]J["B@#SFXOY->^(7AO4+/3-7CM%
ML;N&6::QDB\EWV8#;@,8QUZ>A.#C,\)0)!IEEX7UCP//+J]BRPBYDL@UJX4_
M+/YIXZ<^N>!S7K-% 'F%QH^I7MU\1-$2RNXY=6&^TN6B(@<&W5?]9T^\-I'7
MGIC-7/#-[::K+8>?X'NK#5;(;KB>ZL-J6[ 88Q/_ !DG@;><')KT.B@#SOPA
M'<6WP\UR">POX9S<7SK%):2*[B1W*%5*Y;((Z5F-;7J^ _AW:G3=1^T6.H63
MW40LI2T*QHP<L-O !(^O:O5Z* .'LS+%\5M:OGL[X6CZ7!$D_P!DDV,Z,Y90
M=O)PPZ=:Y.RLM0A^%G@VR?2M2%W::U!-<0?8I=\2).SLQ&WIM(.:]DHH \UU
MS2[W6O&OB2WMK>[B2_\ #7V&&Z>WD6+SBTAV[R,=&%/\*7%MJ9TVUNO ]Q9Z
MQ9%?/GNK(+% RC#/'(?O$XXV\\^@S7H]% 'EWA_3[S3M>TFX\.KJEMI]W,[:
MEHU];N(;/*L2\;.!L^;@ $[MW' ./4:** .&TXW&E_$OQ5+<:??&WOX;22"X
MBMV>,B.-E<;@.H.!MZG/ KE+6QU"+X1^$K!]*U(7EKJEO)/!]BEWQJDY9F(V
M]-ISFO9** /(_&!U;6+#QIITFC:J9BG_ !+X[2V989X]B_O&<8\Q\Y&TDD8
M"Y!K;#7<7Q \/ZLVE:B;6;1I+3*VY)CD,B,!)_<R 3EL?G7H-% !7"^.['4K
M/5](\1:"$_M+<=,E1S@213<*3Z['P^/3=7=5AP>&PGB*75[G5+^[&_?;VDT@
M,-LQ7:2@ !S@D<DXW'UH YWQ%HUQHFK^#=4L+:XNM.T0RV]S#"ADD$<D802[
M1RVTC)P">3[U!?Z'=Z]KWBC6+*"9(+G0#ID EC:(W$IWL6VL <#*KDCG)QTK
MT6B@#R6&YO+VU^':Q:)JX.ES)'>>99.GE,MNR'[P&1G^(?+[YXKUJBB@#BF6
M9/C&UZ;.\^R#0OL_V@6TAC\SSM^W<!C.WG_Z]<C<66H2?![Q3IZ:7J1O;G4;
MAX;?[%*'D5Y]ZD#;TV\Y[=Z]CHH \XURZU"_UO5+&32M4-G-I2BQ:TMG3[1(
M5?<)I."NTD81B!R<@DBLVPAU"VT[X9WTFC:GLTR-[>ZC%JQDC9K;RP2G4+NX
MR0/7I@UZS10!Y7&HT7Q'KVG:[X0OM5AU*\>[L[FWLQ<)(D@&8G/12I!'S'&/
M;DZUE;36OQ4L7_LN:WM(_#PL]T%L_P!GBE\U6\M7"[<!1QVXKOJ* //6_M&W
M\=>,KVSTNXG>32H4M/.MW$-Q+&LAV;B,'EE'7G-9&GF]N/$_@;5#I.NN8H+F
M*]>>U:-89'B0!1&<"- 01D *1CDG->LT4 >9:?#=+H/Q&C;3]05[R[NI+56L
MY09E>%44H-O.6!''\JNSZ'-JWP?TNW59+/5-.L;>XMFGC,;07,* C(8#'(*D
M^A->@5AZWX;_ +<O+:2;5+^&SC1DGLH) L5RIQP_&<=N"."10!'X/6YFT1=6
MOX1#?ZH1=S1YSY8*@(G_  % H/OD]ZWVY4CVI>@P** /(++2KW4?@W!X(;3K
MR+5WQ;RK-;.L<'[[>9#(1M("\C!.3@"NIT:.:+XJ^()GM+Q;>:RM8HKA[9Q&
M[1[]P#D8/WAWY[5VU% 'DNCP+IJWWA?7/!5SJ5W]KF:VNOL8EMKJ-Y"ZL\AX
M7!;G/3'<\4>+5U74K3QGI4NC:F9!;A=/CL;9E@G3RQ\[.N [9R-A)P  %)S7
MK5% 'F37NHZ!XLTWQ%+HNJ7.EWNCQV,JP6S23VLJ.6!:,<A6#?7/7'2K?B5K
MN^D\(W":->PI'K2W3PQVK.T,.R0;I-@(4DL"1U&?8UZ%10!Q>@1SI\3_ !9<
M/:7<=O<PV:PS26[K'(8U</AB,'&X5V,S2+!(T2!Y I**3C<<<#-/HH \;B?5
M+U?!VH7&AZW]MM-3S?0BS:.*WRD@"QQ\+L!(^< C'WFS6K'#=_V9\2D.G:@&
MOI)C:J;.7,X-N$&WY>?F&/UZ5Z?10!YSJ^FW,GPJT;4K>-[?5] M8+V$3H8V
M5XHP)(V! .&4,I_"NP\.6<]KI"27B;;Z[9KJZ&<[9'YVY[A1A![**AU/PV-5
MUJ"]GU2_%I&BJ^G)(!!*RMN#.,9/.,C.#@ \9!W* ,?Q9I=QK?A'5]+M9!'<
M7=I)#&Q.!N92 #['I7%7D-WXJ\&>']"&G7MIJ=O<VANA-;.BVWDD%W#D;3PI
M"[2<[A[X]-HH XD></C*]W]CO?LAT1;7[3]ED\KS?/+;=^,=#G/3WKMJ** .
M'TXW&E_$_P 337&GWS6U_;VCP7$5NSQD1HX<%@,9!(^7J<\"N2MK'4(O@]X:
MT]M*U(7MMJ<,DMO]BEWHJW)<L1MZ;3G->RT4 >72;=$\7:[!K/A6^U:QU:=;
MJSNK:R^T [HU1HI!_!C;QGC&<XKT72K<6NE6L"V<5F$C %M"!LBX^Z,<<=.*
MN44 <9X_AN?/\,7T%G<W45CK$<UPMM"TKHGENN[:H)(!8=*P;ACHOC/6FUKP
MK?ZG8:PT5Q:SV]G]H,;>4J-#(!G;]T8[=:]1HH \\%I):_$#PJT6BS6=I;Z?
M<Q.EO:L8;9I"A1"RC:.AS@XS5W3_ #H/BIX@O)+.]6UDT^WC2?[+(4=D+E@K
M;<$C<.G7M7;44 >-)8Z@OP/L-,.E:E]OCOT=K;[%+O"B\\PG&WILYS_6M7Q5
M8W$FKZIJ_AX:OI_B",1JBK:R/;:HOEJ55U*[>,E"205QDUZA10 V(N8D,H D
M*C<%.0#WQ7%:W!>:5\3-,\1FWN+C2Y-.DTZ<P1-*UNQ<2*Y503M.-I('&.:[
M>B@#SI-,N5/C_75M;H0ZQ"D5I;B!_-D\N IO\O&X;F) R <#/>NE\#"2/P+H
M=O-!/!/;V,,,L4\31LKJ@!&& [CK7044 <S\0["ZU/X>Z[964#SW,MHXCB09
M9SUP!W/'2L'4)Y]0\3> [Z+2]42"V>X:=I+*0>4&@**7&/ERQQS@]^G->B44
M >8^3=9^)A_L[4,7R?Z)_H<O[_\ T81_)\O/S<?KTHFTFWU#PWX2MKV'6],O
M[330(=2LX)5DM)52-6C<!3PV.C#!V]>:].HH PO!LFL2>%;)M>4#4</YC>7Y
M9<;SM<K_  LRX)'8D].E;M%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4R66."%Y9
M7"1HI9F8X"@<DFGUS?B]GN[:VT46UY)!J$PBNY8(781P<EP64<;L;/4;\]J
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M3.93(QV, P"C R0,DG'2JGA'P]J&D:]?Z;/%MT/3KF2YTMNQ\\9*CVCS*O\
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M/[*?LK_OMMOY9V\<_-Q^O3F@#KF\163VUA+9K+>O?P_:+6&W WR1X!+_ #$
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MG/S'GDYKK*S/#S,?#NG*\4L3I;1HZ2QLC*P4 @@BM.@ HHHH **** "BBB@
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MZV:2U2*+?N"*#MR3UP1[<Y) R: .FHKF;7QSI,_A[4M9N$N;*+39GM[N&YC
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MARVT$_-OV[@1NVX]\$&L#5;A]<^)-SH&HZ-=7>FQZ2&6 M%@,\S*9AF08X4
M'[PYX&: /1:*XRS\8Z3I'@-M52#4Y-/TQS9R^;M>=3&PC)8EOFY[@FM"^\8V
MMEXBDT)-.U*ZU!;3[6L<$((D3=MP"6 ZYY.!QUS@$ Z.BN<M/&NE7GANWUN-
M;@1W$WV:.V9 )FGW%/*VYQNR#WQ@9SCFL#2KEY_C7?A[6\M"-"0M%<N&RQG/
MS+AF7!&!QW!H ]"HKEO%/B:\T36= L+739KD:C=&-Y$:,<*C-M 9A\QP.3@8
MSSFKMUXFBAN;NVM=/O;Z>RC62ZCMA&3#N&X*=SC+8YPN3T]1D W**I:1JUEK
MNDVVJ:=.)[2Y3?&X&,CH01V(.01V(J[0 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<
MGXNFU>/5M#2VLKVYTAY)1?\ V @3 [1Y8SD$(3G)!'09..#UE% '$_#FQOM,
M@UZUN]*GL4?5[BXAWE=K1N05VX)S@?AZ9I^H0W1^*VE7ZV5T]E!IT]O)<+$2
MBN[H5'OPIY'%=GD9QWHH \Y^Q7XU/XC2_P!G7FS4H8ULSY)_?E;?RR!_P+UQ
MZ]*@>PU#^P_AS!_9MX9=+FMVO5$)_<A(#&Q/K\Q[9KTVB@#R#Q':>(]9T?68
M;S0=1N-1AU5)+<QE?(%LLR%3$-WS,5!R<;N3D@8%=6D-[)\68=4?3[J.S.A_
M9FE9,JLQF#["1D=.XXSQFNTHH QO#6OMX@L;B:73+O39[>X,$MM= !U(56!X
M[%74U@VRW>A_$/Q+J%QIM[-:ZE!:?99;:+S0S1*X93C[IRPP6P/>NQMK6&TB
M\J!-BY+'DDL3U))Y)/J:FH \KN/"^IZ5X2\.68LI9[M?$,>IW45NN]8$,K2,
M,C@[0P''4YQ70:?%<V_Q-U[4I+*[%E-86\44WDL0[(7+ <9_B'UKM** /&]'
MT77]&T#P+JO]D7DTNA27<5]8*O[W9,2-Z G#8&#@'O\ 6NCTO^T'\:>*=4?1
M=1ALKVPME@>2, LR*^1MSNR=P[<=\5Z#10!Y-;:5JD7@3P!8OI=[]JTS4[>:
M\C$))B1 X9CZ_>'3.:V9;5U\9^+KV]TZ9M,N=)CA#RCRXY=BR;UW'[HPV,G
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ML9B=W4\@MGC!]_PYJ#P?!=V]MIVAZCX$2'4[ QQR:FUO$;9D3 \U7SN+D#@
M=3SCG'IV1G&>:* /+9?#FLWND>/= 6PEAFU'4)+ZTNI-ODR K$47.<Y)0@\8
M ZUL>&;MKR>":7P(VBW-JK&ZGEM8P =I&V IEGR>^ ,9[D5W5% 'FWA_3]1M
MO@I?:1/IMW'J/V:]B6V:,[F:1I"F.QSO'/;O1<V5^VG?#Q!IUX7TV6%[Q1"<
MPA8#&<^OS'MGUKTFB@#@[6WO(?&GC6\>PN_LUY:6R6T@A)$K1HZL!^+#KUK$
M@TO5(O!/P^LFTN]^TZ9J-O->1B$DPHB.K$^O+#IG->KT4 ><7\.OV_B?QIJ&
MCZ=*UQ<:;!'822Q?))+&'W 9XXW#&>":BTFTU ^/M#U=="U9+=]-EM[BXO64
MR"0LAR^6.!P<#CV&*],HH \IMM,UB'X1:_X<DT:]%\/MD47R@K.9)792F#R,
M,,DX%:AL=1TSQ;H'B9;*ZGLCI']F7D,<9,ML=P</LZL,C:<9/0\UZ%10!Y1X
MC\-:E>Z%X]U&VL+EI]?-O':6@3]X5B55WL/X=QW'!P< 9Y.*Z'48KJZ^(OA;
M4(K&[-I;VEU'/*86 C:0)M!S_NGZ=Z[7(SC(SZ4C.J#+L%&0,DXY)P!^= &/
MX<U]M?M[MY=,N].FM;@P2070 ;H&#<'H58&L#QWI>H+JVC:SH<J0ZH\ATR0G
M^."8')]S&1Y@'LU=G;6L-I&4@3:&8LQR268]22>2?<UE6OABUMO$%QK+WFH7
M,TK%HX;FY9X;<D8)B3HN1QGT) P": ,'Q%H=UIFN>$M8TJTDN;+11+:S6D/+
MB&1 @=1_%MVC(')'2JU_X<O->U/Q7J\$$D"WVB'2[2.=3&TSD.2Y4\J,LJC.
M#P>V,^A44 >60C6+Y_ ++X<U.(:2^R[\Y40J1 8R1EN5SW.,\8SV[7Q?:6U_
MH1L[W29-3LYY42>"($NJ9^^N"#E3@\<\<<UO44 >1:IH7B#_ (5_XJT6!M4U
M2RE:%-(%VA^TD94NK;@#M!& 6QT/MGIM3BO+GXC>'M1MK&Y:V@L;F.25X654
M>39L#=_X3GTKMZ* /'Q;>(K^'PO?W_A[59=6LM6$E^S% JC;(,1+OP(^5Y&!
MTR2>:ZS0XKJT^('C#4)[&Z2UNDM/L\ODDB7RXV5POT)'U[5VE% '(_#"QN]+
M^'FDZ??VLUK=VR,DL4JX(.]C]#P1TJ/PY;W4/Q!\774UG<Q6UZUJ;:9XR%D\
MN+:V#VP?7KVKLJ* /*/"VFWFCVB>%]1\#K=WMM(T<&K&WB:VECW$K([D[@0#
M]T DX[9XZ2&&Z'Q=NM0-E="Q?2([1;DQ'895F9B/IAAST]Z[.B@#QO4=+UU?
MA_XK\,1:!?RWDNHS3PRJJ^5+&\X=2K9Y..V..^*ZY([QOBLFK2:=>16?]A?9
MFD:+<%E\[?L^7.3M[C([9S7;9&<9YHSSB@#QV#0]>MO#^FZA!I-U)<Z3XAGU
M"2Q9=KS02._*9X+!6R!GUKI]-:_O_BJ=9&BZA;Z?+HB6PFN(U3:XF9L$%LC@
M],9]L$&N[!!&110!QWC:TOFU;POJ5I83WL=AJ)DGCMP"X5HG4$ D<9(SS571
MXM0\,>+?$4EYI]Y/8ZM*E[;36T9F*R; KQ.%^Z1@8)^7'<5W=% ',^ = N/#
MGA&WL;L!;EI)9Y(U.1&9'+[ 1QP"!QW!KIJ** "BBB@ HHHH **** "BBB@
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M#/<R^2^W+AY7=<$''(([T )XZU&<:EX:T"&1XTU>_P!EPR,5+0QJ7=,CD;N
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MMXP8X60$,[\_*"5/YUU=Y.]K9S3I;2W+1J6$,.-[X[+N(&?J17):=YOP_P!
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC>2VTP61I(,'YT*$ANF, ]3B@#KZ*YJR\6FXU>#2Y],FM[JZL3?6JF12'0$
MHQ_A<;AQR/>H]/\ &T&H>%;[7%T^YB^QRR026<C+YWF(VTI@' 8G  SSD>M
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M5%)^<J#STYX&3Q0!TM%<I<>/+);W1+>RL;R_768'GLY8-FUPJAB.6!!Y'WL
M9Z\5H>&O$:>(H+W-G-975C=-:W-O,58HX /!4D$$,#D4 ;=%<GXL\1ZEH^M^
M';"QL3-'J%V8Y7\Q02%1FV 'N<9R>PQWXNS^)7:[OK33M-FOY]/16NT215V,
MR[A&I)^9\8..!R.>: -^BL[0M;L?$>BVNK:=(7M;A=R%A@@@X*D=B""#]*T:
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-:W=K;K%)&SJW([Y4D50GTC4E^)%_=BPDETW4M+CM&N4E11"RL^[<"=W1N,
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MDX Z#H* ,6.QU*/XJ7NKG39SI[:1':I.'CPTBR,Y&-V[HP&2.M<M)X<\0O\
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MO$/A@P:6\8U"VN(KNW60X1WC8,%)]^?QQ63)#XCUCQKX;UF3P])80V=O=17
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MCG=DK@=,<]>*RM DMM(\=?$6Y6 K#!]DG>."/);%N6;"CJ3S]2:4:1KDFI^
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M/)V@?ED9]5KB+"SUO0O$/BB:+2'O$U2X6XM)HYHQ&"(E3;)N8,O*YX#<>_%
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M8*X8$>HS]*W(M::>\TR"&W21;VV:Y,B396-!MYZ<YWC'X^E85_X1N+KQY+>
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M>K/BG0T\2>%]1TASM-S"5C?^Y(.4;\& /X5Q<W@K6[PZ#JLTD::O<;X-=92
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MY^?Y>1GGM[\5&-#UL6_P^3^RI<Z,%%[^^B^3$!BX^?YN3GCM[\4 )=/=ZO\
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MX:/RU#%63;UYQ][J#5*_^(4UAH?B;4'T8.^A77V>2-+KB0;5.[<5&/OCC!H
MVM0\&Z/J.JOJA%Y:WTJJLLUE>RV[2@# #^6PW8''/-:UC86VFVPM[6/9&#DY
M8LS'N68DEC[DDURZ>-+VW\5Z?I&KZ$]C;:H'%A="X$FYU&[9(H'R$CIR?YXZ
MZ8RK"Y@1'E"G8KN54GL"0#@>^#0!6?5=.BU!-/DO[5+U_N6[3*)&[\+G)JY7
MD_AS4H8_!=WK7B/3K:Z2WUB>X@993)*UU]H*(%!4 <D*#NZ=@.G9/XHNM/\
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M>(O&5WH46LW0T@-9:4D;/-<3F'[3N&XB'Y2&('OUX]Z?>^,+N/Q'8:/8:/\
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M1!]4A::*2*[W! F#(#E!D@,#QU]JZ6\>>*RFDM4C>=4)C65RJDXXR0"0/PH
MGHKS_P ,^-+X^ M&U3588IK[59EAM$CF.9I9&;ALK\BJ 3QNPJ_0'>L_$TH\
M5'PYJEFEK>26_P!JMI(9C)'.@.&&2JD,#VQTYS0!T5%9^MZQ;:#H]QJ=V3Y,
M &0" 68D*JC/')('/'-<]:^-Y9?$']CM8VL\LULT]O+8WGG1LR]8W8J-C8Y!
MY!% '8U6OM1LM,@\^_O+>TASCS)Y5C7/U)KB+'XCWMUI/A_69= $.EZM<QVI
ME^UAI(GD8JI";?F7( )R#STQU6[GU.X^,<=D]I:36JZ'(5CDN6V['G0.V/+/
MS$*!MZ8_BH [R*6.:))8G62-P&5T.0P/0@]Q3ZX6#Q1'I?A.?4]#T.)_#FF-
M)&!%/MD:*-BLCQIM((!#8!8$@$\<9GOO'%V=;MM,T711J1O-,.HVDQNA$LBY
M7 .0=H.[KZXXYR #L719$9&&58$'G'%97A_PSI7ABS:UTJW:)'.79Y&D=O3+
M,2<#L.@K*D\6:E-:ZE+I>B"[DTL!;N'[3AFFV!WBBVJV]E# 9X!)P*=>^,DC
MN!9VT=K'>BTCNI(M2NOLWEA\[4/RL=_RMD8X_$4 =516/X7\01^)_#MKJT=M
M-;><"&@F'S1L"01[\C@]QBL6ZUG6O^%IV^B1PVK:=_93W)5IV4MF5%+$;",C
MD!>^3DCH #K+:\M;Q9&M;F&<1N8W,3AMK#JIQT/(X]ZFKR/1/$%WX3T7Q??V
MFBI<Z?9^(+M[@_:!$4CW*#Y:[3N('.#M'H3V[;5/%T-KJ#:?9M8M=);+<M]M
MN_LZ!7)" ':Q).UNW Z]10!TU%8WA;Q!'XH\/6VK1VTMJ9=P>"7[T;*2",]Q
MD<'N,5LT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !7+>-/"UQKZZ9J&F3Q6^LZ3<?:
M;-Y@3&V>&C?'(5@ "1SQ74T4 85M?>(+V(0RZ.NG2D8>9[E)47U* <L?3<%_
MI65;Z-JOA_QIK.JV-J+_ $_6%B>2,2JDD$Z+MS\V 488SSD$=*[!9(W9U1U9
MHSM< Y*G .#Z'!!_$4Z@#S>3P3J=EI&@VUM%%<7,&O#6;]ED"KDERRIGDXW@
M#.,[><9K<M-,U.W^(>JZVUEFRN;"*WBQ*N\M&6/(SP#NP.:ZRB@#QVZTG5?#
MG@_P/IMW:QF^M_$J,$68%9 [3N &[<-CD=:ZK5/#NM:OJFK:[:L-,U!M(;3M
M.#N"Z,S%VD8KD+SM P3C!/M72ZKH&FZW):2:A#)*UI*)X-L\B;)!T8!6'(R>
M?>M,# Q0!YSIOAWQ!;^)/#VJ_P!C6%K#9V<UO<PQW>]]S["7SM&YF*GJ?<GF
MJLGA#7Y/A=J/AS['$+^YOFN$/GKY85K@3<GKG QTZUZA10!Q7C[3IM3L-)N=
M/N/L6NV]]$+-^&93)\LBG'4>668_[E==96<.GV%O96R[8+>-8HU]%48'\JHQ
M>&=%@\0SZ_'I\(U6=0DEUR6(  XSP. !Q6K0!R7BSPK=:EJ^D^(M&FAAUK2F
M;RQ/D1W$3##QN0"1D9P<'&>GI3\7:9K?C'1K;2TTK[ XNX9YIKBX1HU",&(7
M82S$XXR%KN:* .432M27XH2ZX;5?[.?2UL0_FC=O$I?.W^[@X]?:J6E:+K?A
MB\\06UC:17UCJ=W)?6LAF">1+(/G60'G;D9!7<<=J[BB@#SH>"]1\.0^"VT6
M&+4#H*3PSQ22^291,F&=200,-SCT-8GBG1]9TOP'\0KG4X;5(]1E6YB,,Q8C
MB-2,%1Q\O7.3Z"O8*H:QHMAK^FR:=J<+3VDN-\0D9 V.<':1D>U &#/I-_X@
MUK0+N^LQ9V^DNURP,JN9IBFQ0F/X!DG)P3QQUKJW8K&S*A<@9"C&3[<\4V"%
M+>!(8]^Q!@;W+G'N223^-24 >9P>!M7O?AU>Z!=".RU'[?)?VLPD$D8<S&5
M<<]\'CWYK=FTK4_$.LZ%J&J:>MDND,]PT0F60S3%-H"$?P#).3@GCCK77T4
M<KX&TG4=&LM4AU&W2)KC4[B\C*2!P4E?< ?0CO\ SJUXTL-7U+PQ/;:)*J7A
M>-MK2&/S4#@O'O'*[E!&?>N@HH X71M$UK3_ !M=:P=)L;:PGTR* 6]O<9,3
M(SD*!M ).X<\ >]9*^#]?7X/V7A?[)"=1@GC9CYX\O:MQYN0W7H,=.M>H44
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M]HR1/=MEI/)!V*2?NKGD@#C)Y.,\9Q5N@ HHHH **** "BBB@ HHHH ****
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MRL+Y_+>T6Q+/'#(C!P[,P!)) &,<#U)KM8HHX8DBB18XT4*J*,!0.@ ["G4
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M+.'8@LY0IMZ*H'/'S>M9.I^%=3A\?Z5XBT"#3888;:2UOHY)6B-Q&Q!4 *A
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M8)?N$XPVW&.<9XR5G\4^*)K[Q9:V5OI,9T/8R/-YCB13%YFW (Y(XSQCT/8
M[^HKFYAL[6:ZN'$<$*-)(YZ*H&2?R%>>7OB#6-8UCX?7-A=06EMJT4MRT$D)
MDP_V8M\Q#+N #$ <<\\\"NWUV\N=.\/W]]:QQ2SVUN\JI*2%8JI.#CGM0!:L
M;VWU*PM[ZTE$MM<1K+%( 0&5AD'GVJ>N#E\=M::+X3NKZ6TTY-9M!++>31,U
MO#)Y:,(_O#;NW'!+=$-=?I$UW<:7#+??9S<-NRUN<QL-QVLO)X*X/7O0!=HK
MBM+\87&L:W<6%O<6$=S:W[P7&F31LMPL*L0)5)8!L@!N%QAL9R.:U]XUU>:P
MN]2T*P-[';7;P)9"QG=[E4DV.5F7Y%.0Q P>!SR<  [ZBN4M_$>H)X]_L2_2
MVBLKFQ-Y9/Y;+(Y! >-B6(W*""<#D'M4+>*[V*VTF.40_:]6DFDMFCM)7"6Z
M#(=HU)9F*E.,C&_VY .QHKSG4_&_B32O"7B#49M)B%QI<J"&>:"6"&[B8@!E
M1OF!&<$9_'FMJXU+Q79;6O(=(BMIKH#[4'8I:0;"290S+N;< HVD#G/M0!NZ
MMK6FZ%9_:]4O([6#<%#.>I)P  .2:O$A5))  Y)/:O)?%'B2X\1?"?Q.UQ'"
M9M/U6.RWPJR+,%GA97"L25R''&3]:Z>/Q'X@TSQKIVCZ]:Z<;/5EE^QS63/N
MBD1=Q23=][*]& 'TH Z;2]9T[6X)9]-NX[F**9H'>/. ZXR,]\9[5>KS+PWK
MB>']"\27/E^9+-XJN;:% "<R22JHR "2!G) &>..:Z31M<UJ?Q//IE[9-+8&
MV$\.HQV,MLH?=@Q,LA/..00<8H Z.[N[>QMVN+F58XE(!8^I. !ZDD@ #DDX
MJKI6N:=K:3MI]R)3;R&&9"C(\3CJK*P!4_45R?Q*^W^9X6%K<P1Q/KUJNUX6
M8[_F()(897@<8S[BEOM8\2P>,Y?#^E6FB?:IM*^WFZF21%>0.L?SA23CL!DD
M9'/&" =W17(6WB#6];&L_P!C#3U?2IC:,LR.XN+A4#.H(9=B@L%!(8]3CL<U
M?B#>ZE8^$;_2+*V\C79F@D2X=MT3JKY ('0,A&>_I0!Z#17!VGB#Q==ZGX@T
M1$T87^E>5(MT8Y?*D21"RKY>[(/RD$[L>QKH_"6N'Q+X3TS66A$+W<"R-&#D
M*W0@>V0: -FBN!O?&NKSV%UJ>A6!O8K>[>!+(6,[O<JDAC=EF'R*<AB!@\#G
MDX&G;^(]03QZ=$OTMHK*XL3>64GELLCX(#HQ+8W+D$X'(/:@#JZ*XYO%=[%;
MZ3%*(?M>K/-);-':2N$MT&0[1J2S,04XR,;_ &YR=2\<>)=*\+ZU?S:1%Y^G
M744<4\L$L$5W%(ZJ&1&^8,"V""<>_- 'H]%<+K6O^+?#D<%_J::*-,?4(X)G
MA25FMX'( =B6 )#'!XQR#[5TEM?W=SXEO;2,P&PM(HP[;#O\YLG;G..%VGI_
M&* -:BN>U#79SXKM_#>G&%+M[-[Z::="ZQQ!@B@*",DL3W& IZUQGBGQAK$O
M@CQA9AX++6=%9(;B2)"5EBEQL>/+90LI[EL8/L0 >BSZUIMMJ]KI,MY&NH70
M9H;?JS!1DGV&!WJ_7G?B0:FGCWP* ]K-?[=0 ?8T<0S$O)&6/ [9Y]L\6+3Q
MU>VVDZQ_:UO;OJ6GZHFF)]E5Q',\A01L%^9A]_D#)X.,]* .\HKBE\2^(H=1
MU"V?3UN;9+!KJWOC936L8D7K$X?))QR"#[5:\%ZQXB\0:=8ZOJ,.F0Z=>6*3
M(D!?SEE/7.>-I'([CWH ZNBN,U'Q!XC;QQ<^&]*MM,4KIRWL5Q<LY"YD*?,%
MQG[O0>N<\8.*/B+K9\,Q77]F6:ZI;ZVNCW\#2-L#EU7,9]"&&"3Q[T >FT5Q
MZ:]KT6M6?AV\_LL:M=":Y\Z!9&BBMD("DJ2"7);&,XX)]C5_X2O77B\3:9#:
MV;Z_H:K,J['\J[B92R%1NRK'!&,G!]<\ '=53L=5L=2FO(K.X662SF-O<* 1
MY<@ .TY]B.E8FF^(KC6;'PY<:?+:O_:,)N;@F)L+$%&[;\W!#LJX.>I/:LJ/
MQMJ$.B^+;ZYL8#)HU^;95MU9@4VQDNW=L!RQQCA?QH [>YN(;.UFN;AQ'#"C
M22.>BJ!DG\A3+&]MM2L+>^LY1+;7$:RQ2 $!E89!Y]JYF#Q)>W/A[5M6L;O2
M=4M8+7S[2>WW(KL Q='&YB",+Z?>J*S\7W-Y9>$[6&.V34]=LQ=,2I,4"+&K
MN0N03RP4#(ZYSQR =G17!7?C75=.3Q387%M9R:KHMG]OBD&Y(;F#:6SMR2K
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M^E:-% &1I^EW U-]7U)X&OF@%NJP [(H\[B 3RQ)P2>.@X&#G(\-:>USXO\
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MGI4T,%S.AC$TI($:D8)&!UQT_/MBM2L_6-<TW0+1;K4[H6\+.L:L5+99C@#
M!/4B@"KK&AIJ?@^ZT06UNBSVAMEB+'RX\K@8.,_+U''8=*XO6K74M-\%:#X7
MU74]);4);B.&*>Z1C!<)$-^'R05/RJ,@DDXZ9./3JKWMA9ZE;-;7UI!=0-R8
MIXPZG\#Q0!P^C?V]!>7>ESP^'9I+Z!W>>PGE,BL %5IB^XD8X!SGC XZ68_
MMQ/\,;;PI>7J0W5HD8@O;;)V/&P9'P<=P,C]?3K-/TO3])@,&G6-M9PDY,=O
M$L:D^N !5N@#D+?P_P"(M9TB\T_Q=J-C+#-;/;!-.B=-^X8,CEC]X#H   23
MSQA/#>C>,-/2WLM8UFPNK"R4"%X(G2>X"C"B5B2 .F=H)..3UST&FZYINKSW
ML-A=">2RE\FX 4C8^,XR1SQZ5H4 >=R>!-7E^'^M^&VN+$2ZE=RSB<,^V,22
M;R,;>2.GOGMCG;OM!U.^\7>']98V:1Z;#/'+%YC$OYJJ"0=O;;WZY[5<F\8Z
M!!H$VN2WX3389'B>9HG&'5BI&W&3R".E7)]=TVVUBSTB:Z"W]ZK-!#M)+A1N
M8YQ@8'K0!RF@^$O$_A[.BVFM61\-+(S0EH7^V0QDEC$K [>Y 8Y([#IBW%X8
MU6+4/%USYEF1KBH(EWM^Z*Q>5\WR\\<\?3WKL:* .#B\%ZO;V/@[[/>62WOA
MY&A)D1VCE1HO*+8&"#CG'ZUUFM6<^H:!?6-NT?G7%N\*M(2%!92N3@'IG.*T
M*H:SK6G^'],EU+5+D6]I%]^0J6Q^ !)H Y^U\/:M:^']%TB2/2[ZTM+$V=Y:
MW!;R[C 0(X.TXQM;@@_>_&M/PCX?'A?PW;Z2)?,$3R. "=J!G+!%SSM7.!GT
MK;1@Z*ZG*L,@TM '$WW@^^UC4=-N=2%A]HT_4!=0ZC"6%P8@Y982-O0@A2=Q
M&!G&:BLO"GBC0]4O[?1=9L4T*^N7N2EQ S3VC.<N(B#M(R21NZ9Z'G/=T4 <
MSXL\(KXDATOR[E[:>QN PF!)=H6!25,]?F0D9]0*9XN\,7NKMI>H:)?16.KZ
M5(SVK2INB967:\;@<[2 .G3%=310!Q.N>&?$7B+P5J.EZC?V']H7X1"85=;>
M!58-\H.68GG))'4>G-WQ#H.L:K=:!J%G<6<=SID[2RVTX9X)2R%<\8.Y<DJ<
M=374T4 >=R?#[5;GP_XHTJXU6TQJ^H"_BD2W;Y'W1L0PW?=S$!@9/.<GI70I
MHE_J6NZ=K&L_94DTU)!;6]L[.ID<;6D9F4'[N0%QQDG)XQT=% 'GP^']]<^&
M]:TRYOH;>YN]5?5;2ZMLL;>4N'7((&<$=>X/:NA\/VGB=7\[Q)?Z?*\:;(X]
M/B=$8G&7<L>6XX   R>O&)[[Q5HNFWB6UW>>6[3K;[_*=HUE8 JC.!M5B"#@
MD=1ZULT <UXNT'4-=?1?L4EM&NGZC%?OYS-E]F?D&!QG=U_2D_L+4C\0HO$9
M:T%L---@T.]B_,@D+ [<=1C'XY[5TU% '(V?AO5=!UK6KG19K-[/5IOM3Q7)
M93;W!&&==H.\' .T[>1UJI_P@DVGVWA.STN6 VV@SF=S.2&G9E8-T! R79OT
MKN:* .5LM U2S\4^(]7#6;IJL4*11^8P,9B5E!8[><[L\=,=ZM^"M#N?#7A'
M3]%NY(99+-/+\R+.'&20<$<=>E7WUS34UV+1&NA_:,D33+!M))08R<XP.H[T
M_5M7L-"TV;4=3N%M[2$9>0@G'X $F@#D;'PIXHT/4[ZVT76;%-!O;E[G9<0,
MT]HSG+B(@[2,DD;NF>AYSJ^+/"*^)(M+\NY>VGL;@-YP)+-"RE)8\]?F0D9]
M0*Z.*5)X4EC.4=0RG'4'D4^@#EO%WAF^U=]+U'1+Z*QU?2I&>V:5-T3HZ[7C
M<#G:0!TZ8JCKOACQ)XB\'WFG7^H:?_:%X\18Q*ZV\"QN' 53EF)(Y)(ZCTKL
M+V\@TZQN+VZ?R[>WC:65]I.U5&2<#D\#M2VEU#?6<%W;OO@GC66-L$;E89!P
M>1P>] &+XGO=$70)]/\ $EW:6Z7MM(C0&8;I!CYA&#@L1D8P,YQ2^"]&GT/P
MG86EY*\U\8Q)=2R'+-(0,Y/? POT45K7&G6-Y<6]Q<V=O//;,6@DEB5FB)ZE
M21D'@=*LT <QK'AR[?Q;8>)])E@6^@MVLYX+@E4N(&.X#< 2I#<@X-9VI^ Y
M=5T'Q1%-=11ZIKY1I)%4F.+RU58T'<@!>3QDL3@=*[BJNHZC::3I\U]?3+#;
M0*7DD()"@=3QS0!S=QX?UR]\2>&]8NIM/+Z6L_G)'O4.95"X7(.-H&>>OM6;
M<> +W4+/Q+!<WL-N^J7R7]K/;EF:VE0+LR"!GE!Z=3]:[FRNX-0L;>]M7\RW
MN(EEB?!&Y6&0<'D<&IZ .3LM,\77&FW4>NZAIDLYMW@A2S1XXV+#'F2$Y)..
MB@ <GVQI>$=)NM!\*Z=I%V\,DME"L'F1$[7"C .".#[5:NM<TVSUBRTF>Z"7
MU]N^SP[22^U2S<@8& #UK0H \_N&OE^-LK6,=M*P\/1[XYY&C!'VA^0P5L?E
M3KWP'?/HB6UM<VIO9M976;R:3<J-('#;% !.,!5R3T&>]=B-(TQ=2.I+I]H+
MXC:;D0KYA'INQFKM ',:YX<O+OQ#I/B/398(M3L4>&2&8GRKB%_O(6 RI!Y!
MP?<5:T707LM8U76KQHSJ&I&,.L1)2*.-=JH"0">K$G R3T&*W:* .9\)^$D\
M+S:H4G,D-Q<L]K'VMX22_EC_ (&[GZ8]*IZ=X<U[3%\0RV]U8I<ZEJ*WT)R[
M*@R@:-N!D%4(R/[U==<7$5I;2W,S;8HD,CM@G"@9)P.:BT^_MM4TZWO[.3S+
M:YC66)]I7<K#(.#@CCUH Y&#P3+;R^([NUAL;";6+,6QM;=V,(?#@RL=HRQW
M] H^[UR21&G@G4+>P\*7%M<VRZQX>A^SJ6W>3<Q% CJW&5R "#@X/K7=T4 <
M9?\ A"\U*W\27<KVJ:IK-C_9Z@,QCMHMK#AL L<N6/ [#C&22>%M5DF\(2>9
M9#^PA^]&]OWW[HQ?+\O'!SS]/>NSHH S]-CU9)K\ZG/:R1-<$V@@0J4AP,!\
M]6SGD5A^(_#NIZMXJ\/:M:R6B0Z1++(4E9MTV]-I'"_+CGUKK** .8;0M2/Q
M$7Q&&M/LHT[[!Y.]M^#('WYVX[8Q^M2>,M!O]>TZRCTZZ@AGM+Z*[\NX4F*<
M(3\C@<XR0?JHKHZS]/US3=4O;ZSLKH33V+JERH4CRV89 R1@\>E '(3^"]>F
ME\7.^H:>W_"0VB0$")U\IA$8\]3P <^I]JN2>%M5DG\(2>99#^P@?-&]OWV8
MC%\OR\<<\_3WKLZ* ."O;/1_%/C_ $F_TO48K@V4+_VA]EE5T=%=6BCD()P1
M*-P'^RU=[5:RTZQTY)$L;.WM5D<R.((E0,QZL<#D^]3R1I-&T<B*Z,,,K#((
M]Q0!Y3X*T;4/$?PGAT9WM8M,NYYUEG5V\T1?:'+(%QC)P1NW< ]#CGL;/P]?
M6OCVZUP-:BQFL8[)859MZ!&9@W3'\6,?K6[8:98:5 8-.L;:SA)R8[>)8USZ
MX JU0!Q=GX4U;1/[<LM)N;0Z;JLTEPAG+"2SDD&'V@ B1<\@97'3)JUJ?@FV
MN/A\OA>QD,'V:!%LYV^]'+'@HYQWW $X]37544 <YK7AN:\\!W7ARRFC$EQ:
MM;&>?/)889S@<DDD_4U!<Z%J=S86]A=6VE:AI_V)+>XM+EF"F1<X=6V'MVQG
MISQSU5% '"1^![^SL_!]I;7D,R:!(9'><L&ERK+M7@X #<9)Z 5<LO#6K:!J
MFMOHL]FUEJT[792Y+!K:=AAV7 .]3@':2O3K77T4 </!X%FTN[\(+IDL'V+P
M^LP83,0\YD0JQX&!R2WN3CBM3P]H5]I7B#Q!J%T]LT6J7"3HL3,6CVH$P<@9
MR!G-=)10!RUYX<OK;QI_PDVCR6[2SVHM;RTN69$E53E'5U#%6'3H01Z51O?!
M%U+X.U_2X+BW_M#79I)KJ=PP1"^!A0,DA5  SC/7VKMZ1F5$9W8*JC)). !0
M!6TV*X@TVWANA$)HXU1O*8E3@8R,@5:K(L/%&CZGJ?\ 9UK=EKLP"X2-X7C\
MR(G&]"P =?=<BM>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *XCQ[<ZK#JOA2&POHK
M>&YU58I4>$N'(1V!.&&5!7IQSCGC%=O7.^*_#UUKG]D3V-W#;W6FWRW:&>(N
MCX5E*D @]&]>U '-+'K#_%/Q!'I<]E%=G2K/=/<1,Z YDZ(&!Y/^UQ[T]?'>
MJW/@;POK\-O9I)J=];VEW&ZL0N^7RV*<\=#C.>O>MRR\/ZG9^,-2UTW-K*+N
MSBMA&592#'N(8GGJ6/';UK$@\ :I!X(T/P\M_:%]+OX[SSS&V) DAD"[<\9)
MQG)Z>_ !;U;QA<0>*+[0HKNRL+V..-K"*^B;;?%ER=K[E&<_+CKD9YZ#N*X_
MQ+X4OO$UIJ>FWK6$UC>%3;O*C&6Q.Q5+)V8Y!8?=P2<Y'%=;#&(88X@S,$4+
MN8Y)P.I]Z ,_Q#J\>A:#>:DY3,*?NP[;0SD[44GMEB!GWKSKP9=V/AKXBSZ'
M;:O!J%IKELMVLL<XD_TU!B;.#P7'S_A@=*[[5=-O[_6=*GCEMA86<IFDA=6W
M2/M*J<C@;=Q(&#DXZ8K/\:^&+WQ)'I4FG7<%G>Z=>K=Q7$J%R"H(VX!&0<\\
M]J );W7+V7QLOAJR:&W8::;]KB6,R;CYFP*HR.AY/U XZURR^//$DG@;3]?%
MKI@FN=22R,.V0*09C$2#N[D$@\]>AH\2S7&I^-EMH-6T*VO-.L5#V^J1-M+2
MDEFB(=6(VJH/4#IW-6!I>L^*_#46F^;HD"Z?J$,L5QIZ.;:18BKA47/&#\IP
M2!CUR  :4FO:[8ZE!HFH2V;ZA<+-=">RLY95CMU9%4&,'.\L_7. !W)JO;^,
MM9@LK>UU333;ZG<ZD]E;RBUDV31*A?SQ%G?]U2-N>O?%:'B?PQJ>IZCIFN:+
MJ,6GZU8*\>98S)#-&^-T;C@XR 01_P#J@U?P=JVM:-;//KBQ>(+6Z6\M[R&'
M$,3A=NP1DD[""0<DDDY]J ,[4?%OBG2]"\374EA"PTR);BRO9[62&.X0C+*8
MRV0RGC.<'VJS<>(?$]IXCT&Q;^RI(=<AE\I?+D!MG2,/EFW?O!C/ "]AD=:L
M:AX9\1:YX3U33M6U:R>^OX/LX:"!D@@3N0I8EF/<DCM@#G,]UX:U*YUOPOJ/
MVBT7^Q5E#IACYQ>/RS@_PX'/>@#,@\;ZAIMAXDCUA+:XO=(O8;6-[:-HTG,P
M3R\J2Q'+C.">!Q5R#6_$HUR6T-HMS8R6C2QWKV,MNL,R_P #JS'<I'((Y[>]
M5[GP!-J8\5Q7][&D.N2131M;@A[:2)5"')^]RBGMZ=ZT=)TGQ8ENXUS6K*\D
MBB:. 6]NT0=B,;Y3DY./X0 .>_& #G=/\;>)9="\)Z_=)IGV/5[N&TGMHXGW
MJ96*AU<M@8('RX/'?TT_#MQK$_Q-\60W&H0R6MJ+1%B^SD$(T;LH4[^""QR2
M#GV[0Q^!-3B\'>'-"6^M"^C7L-UYQ1L2B)MP7;VSG!.3T]^-JQ\.WUAXVU36
MX[V#['J<<'GVYB)</$A4;6SC!SDY&>.U '2UQ"^+=8CG\;1M90W,FAK&UK%;
MHVZ7=%YF&Y.3R!QCI7;UR%OX9UBUU7Q/J%OJ%M#-J[0O PC8_9VC0(,\_,"!
MST]* +'A3Q"?$1DNK75M/U+3O*4J]O$8Y(Y<G<LBEB1QC&0#UZ]:Z<D $DX
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M2?:1&V$#R>81MSR0>.M;6H^']1O_ !/X=UCS[5!I*S"2+#'S3*@0X/;&,]Z
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MGR N,)QD$[NO3-'45U*;XK:2MK-;P7C^'YM\LB&14/FQY(4$;N>@R!SGG&"
M>B56O[ZWTRPGOKMREO A>1PA;:HZG !-<7IGBC7;WPG+/(;!;VSU9]/O;MSY
M<211R;7F"LW7;C"YZG\*9;>(KO5]-\<:;<N)ETR$K#.8&A:1)("XW*>XYY
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M=!'<7L<+-!%*^Q7<#@$]AFN1TCQ/J-SXP30Q>VUY%<:4UXERML0B2JZJ0I!
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M6C(65AMRYVG*\DY]@.W85GV&H6FN64S1PR&%99('2X@*;BIP>&'(XZT ><>
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M502I"D\ \=JY:T\,Z_X6\,:+I&D:\7DMKS<X-BI%Q&SEF1CD[ -Q.[.>,#G
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M3Z@_C#2M*FODO[>^TZ2>218-J),A7/E.  \9W$?Q=!S6'!_R3;XG?]A'5?\
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M-H=,D;6QQT(]0:N7?A*1]?T?5;'5'MY+"V>UD$D0E::-RI)R2,/E<[B#UZ4
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MH0!EQCIZ8YK6U>_\2W/Q!;P]IFK6]E;RZ,UVDC6@D:.02JF>3\W7V&">,X-
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M.C?$#^R]8U+S-+O+)I[&1XT3$D?,J,0!DA<,.G&>N* .SJO>7L%C:SW$Q8I
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MG:K+@@#'4YR<]L=710!E^'-"MO#6@6FD6C,T-NI 9AC)9BQX[#).!VK4HHH
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M$1"@"G.>C'/OTQ5?PYX+N]":"&X\2:AJ.G6G_'G9SH@$>.%W.!N? Z9X'''
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO;:/;12W&YFGG2WAC3&Z21SA5&<#\SP 34>C:O)JHNUGTR\L)K68PNERHP_
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MSD+SG(QSQWH NT444 %%%8'B#Q9:^'IX8'L-3OYY5+^7IUHT[(N< L!]T$Y
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M3*@2-XPC*8P "H^8C!)]R3S5J3X>V4N@ZWH[ZIJ)M]8NGNKELQ;@[D%@IV<
MX'8]*T9O"L=QKND:O+J5ZUQI<;QQ+B,*X< -N&S/(4=".E $_BK1K+Q#X;O-
M(OYFA@N@L?FH<,C[P4(]]X6N(L]<\3>$]9TO1?&D$.J:?<W26]AK< VL)3D(
M)4[,>F?KUYKO];TB+7-*DT^>:>%'>-_,@?:ZE'5P5/8Y45GR>%S>7=E+JNJW
M>H16,PN((94C1?-7.UVV*-Q&<CH,\XH YJ6]\1^*(M>?1+A[:ZL;^6SM&$ZK
M&C18'[Q"IW;CDG/8C&.IO65_J/B77M7T>>^:PDTRRMMPLGX:>:,N7W$9*K@
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MO;J+S)KL 1L!LQ;L<KD'D]ZV_$&AL=3T/7+"'=/H\CKY"#'F6\B['51ZCY6
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M (W'@ +WQGF@#D+#5M>A\/> ]?FUVZN)=3O+:TNK9U00NDJMDX"YW @'.?P
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M.3T':N%U6/7++5?!6FG7;Z![^2=+T*ZMD^2SG!(SP>!G(X!P3UM(NI:/X_\
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M$KH(GD5R5#$!LKQR.<>] %/1?#EOH=[J5U!=W4SZC/\ :)Q,4(WX R-JC'
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M'(8'L00"*TJ* .<T?PA%I%M,AUC5[Z>2(PI<WUP)9(D/9/EVCH,G!)P,]!4
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M"S*58N64EB03DD]R>O-:>G7=W=BZ^UZ>]EY5P\46^17\Z,8Q(,= ?0\C%7:
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M/$RR2MU?:[*"??"BK\7AJ"#7[W6H[V\6\O(5@D.Y"NU<[<#;QC)_/G-3>'=
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MN[>XN'EW90LLBEB2A&TYVX!':N?N=5U-/A;XTNUU*]%UIVJ7<=K/]H;?&J2
M*N[.2 .QS7?Z?X7MK*>SFFO+R^>Q0I:&[=6\@$8.,*,G'&YLG&>>3G,O/ASH
MUZFKPR7.HK::K(TUQ:)<8B\QL;G"XZG'?(SS@'% &5JL.H:I\1K32!KNIVEE
M=:%),Z6LH0JXD10RG'!YZ\GJ.AKLM2N7T/PS=W2E[E[&S>0&4Y:4HA/S$=SC
MGZU3B\*6<.O6FL)=7OVFUMOLD8:4,IB)!*G().2 <DYK<=%D1D=0R,,,I&01
MZ4 >?:7:^(K^#PYKUKJD4<<HBDOFEU"26.ZCD49"Q% B-DC;MQ@\<UA2MJL_
M@OQQJ+>(=6%SH^IWGV-DN-NT1JI4, /F7MM/'7C)S7::)\/=(T"\$ME<ZE]E
M1S)!827;-;0,>Z1GC(SQG.#SUJ5? ^GKI&L:9]KOC;:O-)/=@NF6:3A\';QD
M <#\,4 8+3:A8^+O!MP-6OI1K23)>0R2YB.(/,4HGW4(([#IUS61!9ZWK'A[
MQ?>#Q3J\-UI.J7BV128*H$0!4. /F7C&.@YXR37>3>$[22XT:YDO+TR:,#]E
M(9.Z[3N 7YLKQ_\ 7YKEO"&@-J2>+(+Y]6M;6^UJZD:V>(PI<0N1@@LF[##(
M.TCB@!D.ISZSXE^%^IW2!+B[L+N:0 8&YK>,G'MS3K*\OO%'@[7]>34KRSU"
MWN+H6@BG94MQ"2$5HP=K9VY;<#G<>G&.PN_#%E=:SI6I^;/#+I:NEK'$56-%
M8!6&W;SD #VQQBJS^"M.,^I-!<7EM;:FQ>^M() (IV(PS'(+*6'!*E<T <J^
MN7ZP>#?&EU<7,6G7T<4.IVJS,(8WE4".;;G 4/P>V&'>D\77>HI\/=>\16.J
M7ULT]U&UGY<YPL(D2,;<] _S/QCAQZ5O>*"NHP2^"X-"O7AO+58_M2P 6D$9
M.T_/GAE R%QUVUKZUX8L-<\._P!A3F6'3]J+Y=NP4[4(*C.#@ J.GI0!RU]:
M7UK\2=.TR/7=5^R:K87#W*-/G#1LF#'QB,G<0=N..F#S65:^(M3TKP_JMC]O
MFG,/B<:3!=74Q+QPN4/S2$$Y 9@&(.,@]J[V;PU!/K]CK4MY=M>6430Q'*!2
MK8W9&WG.!^7&*I?\('HTFFZQI]U]HN[75YS<W23./]:<?.I !4_*O3@8H QK
MW3?$6E#7;D:J;;3I-+DDAMQ?27,T5P@SO1I%R%(X(]<8Q6597&IV5I\.M7.M
M:C<3:IY%O=Q33%HI%>W+9V]-P(!W=3W)KKK#P/8V.F7=D=2U:[-S ;8SWET9
M9(XCU1"1A0?89Z<\##CX*L#9:):?;+X1:*R/9 .F5*KM7/R_-A21S0!B^!+"
M*'Q=XSE66Z9H]3"@/<R,"#"AY!.">>">@X'%:?C#6)[76/#6C12O!'JUZT<\
M\;;6"(A;8#U4L<#(YQG'/-:=EX:L;#7[[6+=[E9KYE>:+SCY1<*%W[?7  J7
M7= L?$-G';WJR PRK/!-$VV2&5?NNC=B* .0N;G4=*\::IX?@U"\:PN=%?4(
M7>4R26LJ/L(5WR=IR#@YP>F*N_#FSO+CPYI&OWVM:E>7%WIT:R0SS;H<\'>%
MQG=V)SSS6XGAJW O));NZGO;N 6\MY(4\T1C.%7"A5'S$\+U.>M6="T:W\/Z
M-;:5:2S/;6R[(O.8,RJ.@R ,@>] '(^+["*Z^)O@G?+=+YGVU6\JYDCQMAR,
M;2,'GDCDC@\5E/I\M[XI^)#1ZE?69@6VD0VDQB;>+7()8<D#'3H>^>,=YK7A
MNQUV[T^ZN)+F*XL)&>"6WF,;#<NUE)'8C@]_>J\?A&SBNM9N4O+T2:PJK='<
MG(5=@V_+QA>/_K\T <IIOB+4]=7PEILCAGO]$^WW!^U/;&>0>6,!T4L/O,Q
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M*-C<" O.<#\N,5F:;\.M%TG4VNK.?48[4S?:!IHNV^R+)G.X1_7G'3('' H
MPM'AU"^U[Q1/=:_J[0Z-J@D@@CF"K(HB5S&PQRASC:,?G1I"^)->T/P_XEL]
M2@@EE:.YO'DU"5H98F_UD7D[-BD9P".05ZDY-=EI'ARVT;4=2O8+FZDDU&7S
MKA964J7P!D *,< #TK*TOX=:+H^I&YLI]1CM?.\]=-^UM]D23.=PCZ<'D \
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M_P J[FW,$!!V@MSZ^^*OR>%[:;6=+U66\O'NM-C>. EDQM< -N 7G( _+C%
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MME<FYAN)=T8>,(59%Z)]XCCM6D_@'3)-$U;2'NKYK35;EKJ[!D7+.Q!;!V\
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M 'H-0M=0+>1VAE47$D;2K'W*J5!/X%E_.O);K4M23X.>)+U=3OQ=V6IW"07
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M:S?Z_P"!--U#4R&O&#QR2 8$A1V3?CWVY_&NIH **** "BBB@ HHHH ****
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MNI++3;FZBA$[PQM((R^W=@9QG!Q0!@?\(!HW_".PZ%YE\;"&1)$5KIF8;#E
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MG6WE60P2F&3;_"X )'ZB@#%L?!>DV6CWNFR->7L=[$8+B6]NGFE>/!&W<3D
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(DL8C((7G:6.&29I3"I ^7<>3R"Q]V..* $\:7$=MX2OFDU.;30P2,7,";I
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M92P8N&SE3N /'I0!O6\"6L"0Q;]B# WN7/XEB2?QKD_&S:O!>:=>6.GMJUC
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MR9I"<EF3..>XZ'N#0!ROA[6;OQ5XDL-.UKS$0>'K>_:W5C&)II2 [D C('
MZ D]\8YS7FN;GP7XCTN^FN+J'1O$%O!9W$DK%_+:6([6;.6*AR,G)Y%>KZEX
M<T_4[ZUOW66"^M%*0W-O(8W53U7(ZJ?0Y%1W/A/1KOP_/HDUJ6LKA_,E'F-O
M>3<'WE\[BVX YSVH Y;6M+@F^*'AVP\VY2W_ ++O VRX<.PWQ\;\[OQ!!]ZT
M/AO+-_9VN6,EQ-/%I^M75I;F>0R.L2D%5+').-Q'-;">$]+35+/4E%T;NSB:
M&&1KJ1B%8Y;.6^8D\DG))J?1O#]AH)O#8+,OVRX:YG\R9GW2M]YOF)QG Z4
M2ZW_ ,@#4?\ KUE_]!->:^%O"-QXO^%7AG3]0U*--'6..:6VAMB))@K$A#(7
M( SUPH/TKU&^LHM1LIK2<R"&92C^6Y0D$8(R.15;1-$LO#VEQ:;IRR):0C$<
M;RM)L'7 +$G% 'GGC:>1K3QE=V%[=W-Q80(RR+,T,>FLD8;8A4Y=R?F/ &"
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M6YN)5B@A0O)(YP%4#))H SH_#6DPZZVM16FR_>-8V=9&"L%!"Y3.TD D XR
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M(]'>SD-DDHFV"YE#/(""'9@VYCD#DD]!Z5LV-[!J.GVU];-OM[F)9HFQC*L
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M)?#W@;Q#$FM-*#>6EQ!:VRO"EF))D5E4;VRK<G:>!Z<UWC^ _#$GAQ?#[Z/
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M66SVKIQ#6B12/&L) P"H4@=.*@O/".CW U:4V/G3ZI%Y5V)+J51.H& &.3@
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M]: -A6#*&4@J1D$=Z6LOP[HT?A_0;72X3^[@#!0"2%!8MM&23M&<#/. *U*
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MY5F0^']-UCXD>-;34(&N+8VEDYADD8IN99><9ZCMZ=J /2Z*Y+X87,UW\,]
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M@]=O4XZ5ZW63+X8T.:XOIY-*M3-?KLNG\L S+Z,>X.!GUQS0!YU:Z99:;/\
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MM]^NV[;G,XZ8?^]QQSVXI/\ A&-%\FSB6PCC6R#+:^62A@#8R$((*@X' ]*
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M^ A;<!PC '\:WO$<WV7XBZ!=2/'=6WV.Y7['YB*R$E/WP#D _P!SKGYN,C.
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ML++4)M0M;</'%<S$$NH<XP1P0.@/H!6]0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M4KO2-.O[F"YO+&WGGMSF&26,,T9_V2>GX5=J.6>&#9YLJ1[VVKO8#<?0>IH
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MRZ$EU$U]%")9$WCY=QPJ_P"\<$X],>M78]1LI;M[2.\MWN4^]"LJEU^JYR*
M(FT;2VU&#46T^U:]MX_*AN#$IDC3^Z&QD#D_F:O5D:?XDTW5[_4;&PO(9)[&
M3RI"&!&_:"0!GG&0#[Y':ETR^-OI%I_:^JV$UVRG?/"1''(0>J@D_2@"W?Z9
M8ZI"D5_:0W*1N)$$J!MCC(##T(R>1SS5>7PYHMQ9"SGTJSEMA)YOE20JR[_[
MQ!ZM[]:O?:8!<" S1^<1D1[AN(]<=:9#J%E<W$MO!=P2SQ?ZR)) S)]0#D4
M5_["TG[>+[^S;3[6(_*$YB7?L_N[L9Q[56M_"7ART$(M]"TV(03>?%LMD&R3
M^\..#[UH1ZC92W+6T=Y;O<(<-$LJE@?0C.:LT 9J>'=%C^U[-*LU^V<7.(5'
MG?[_ !\WXU:LK"TTVT2UL;:&VMT^[%"@55^@' IUS=VUE%YMU<101YQOE<*,
M^F335O[-VC5+N!FDY0"0$MVX]>A_*@"Q6<= T@W=Q=G3+0W-RNR>7R5W2KZ,
M<9(]C5R*Y@G9UAGCD:,X<(X)4^^.E,M[^SNYI8;:[@FEB.)$CD#%#[@'B@"B
M?"^@&S@M#HMA]FMW\R&'[.NR-O[RC& ?<4ZY\.:)>ZC'J-SI5G->QQ^6D[PJ
M75?0'KW/YU<6_LWO&LUNX#=*,M )!O ]=N<T2ZA9074=K+=V\=Q+_JXGD =_
MH,Y- %!?"OA]5M571-/"VG-N!;(/*/JO'!^E2ZOX>T;7TB35]+M+Y8CF/[1$
M'VGOC/2K,^HV5K,L-Q>6\,KC*I)*JLP]0":+C4;*TE6*YO+>&1QE4DE52P]0
M": )HHHX(4AAC6.)%"HB# 4#H !T%/JO=W]G8*K7EW!;JYVJ9I @)]!FI))X
M8E1I)8T5V"J68 ,3P /<T 5UTC34U5]56PMAJ#H(WNA$OF,H[%L9Q_A4-IX>
MT>PNC<VFF6L$VYF#QQ 89OO$>A/<CK4S:MIR0+.VH6JPLY19#,H4L.HSG&?:
MK4<B2QK)&ZNC#*LIR"/8T .I&571D=0RL,$$9!%+5:'4;*XN9+:&\MY+B/[\
M22J67Z@'(H H+X3\.I;06R:'IRP6\GFPQBV0+&_]Y1C@^_6K4.C:9;ZA+J$.
MGVT=[*-LEPL0$CCT+=2*DDU*QA.);VV3]YY7S2J/GZ[>OWN1QUI]W=V]E 9K
MJYAMX^GF3.%4'ZDT 4=,\,Z'HMW/=:9I%E9W$_\ K)((%1F'7&0.F>U:M<OX
M(UV^UVWUIK^2WD:SU:>SB>W0JC1H%VG!)ZY)ZGK72R311%!)(B%SM7<P&X^@
M]30!%>V-IJ5I):7UM#<VT@P\4R!U;Z@\5'8:58:6CI8VD5N'QO*+@MC@9/4X
MJ:UO+6]B,MI<PW$8)4O$X< CJ,CO3;?4+*[EEBMKNWFDB.)$CD#%#[@'B@"E
M:>&-"L=4FU.TT>Q@OYL^9<1P*KMGKR!W[^M(/#&@BVN+8:-8""Y??/%]G7;*
MWJPQ@GW-75U&Q=@JWMNS%6< 2J3M4X8]>@/!]*(]0LI9U@CO+=Y7C$JQK*I9
MD/1@,]/>@"E?^%]!U2RM[*_T>RN;:W_U,4L*E8_]WCC\*EN] T>_M8+6[TNS
MGM[?'DQ20*R1XZ;01@8]JL17D%[;226-W;R[<KYB.'56'K@]O2L4^([?0]'T
MG^W-4LY[V\DCMUD@PJ3.QP64$GY0.2<]O<"@#4?0]*DO;>]DTZU:ZMAB&9H@
M7C'HK=1^%/M](TVUU"XU"WL+:*]N0!/<)$H>3'3<P&352/Q-I,OB Z)%>0O>
M+ )V59 <!CA1]3R<>GU%7_[0LOMOV+[7;_:\;O(\P;\>NW.: +%5-0TNPU:!
M8-0M(;F-7#JLJ!MK#HP]"/45G^*=:&CZ%?36]Y9PZA';236\=R<^854G&W<"
M>F.*G\-WTVJ>%M(U"Y*F>ZLH9I"HP-S("<#ZF@"<:/IJZ<^GBQM_L<F=\'EC
M8^>N1WSWSUI]AIUEI=LMMI]I#:P+]V*% BCZ <4MSJ-E9/&EW>6\#2<(LLJJ
M6^F3S3KF]M+)5:[NH8%<[5,L@4,?09H GK+N?#>AWE_)?W.D6,UW+$89)Y(%
M9V0C!4DC)&./IQ5N;4+*VACFGO+>**7'EN\JJKYY&"3S5:]EN7N=,DLM0LXK
M9Y<S+(NXW"%3@1G/7.#WXH ;%X;T.":VFBTBQCEM4\NW=8%!B7T4XX'TIT7A
M[18(+N"+2K)(;PDW,:P*%F)ZEQCYOQJU/?6=M+'%<7<$4DGW$DD"EOH#UI[W
M,$3(LDT:-)G8&8 M@9./7 !- &78^$_#VFRP2V6B6$$L&?*=(%#)GK@XR.@_
M*MFH(;VTN+4W4%U#+;C),J2!D&.O(XXHM;VTO4+VEU#<*.IBD#@?E]* &7^F
M6.J0I%?VD-RD;B1!*@;8XR P]",GD<\U6E\.:+<60LY]*LY;82>;Y4D*LI?^
M\<]6]^M.US6;?0=(GU&Y#,L>%2-/O2.Q"HB^Y8@?C4BW7V'3UGU>ZMH'/WV+
M!(U)_A!;K]3UZX'2@!G]A:3]O%]_9MI]K6/RA.8EWA/[N[&<>U5K?PCX<M%A
M%OH6FQ"";SXMEL@V2?WAQP?>M/[9;?9TN/M,/D/C;)O&UL],'H<T07EM<R2I
M!<0RO"VV18W#%#Z''0_6@"FGA[1H_M>S2K-?MG%SB%1YW^_Q\WXU:L;"TTRT
M2UL;:&VMT^[%"@55^@' KF/&?BB;1QIT>F7MB9Y-2MK:Y@?YY!'(X4D ,-IY
MZD'K77T %9EUX=T:^O3>76EVDURRA6E>(%G Z!O[P]CFEL9;E+G4VO=0LY8$
MFS"L:[3 FT<2')YSDYXXJU'?V<UQ]GBNX'FV"3RUD!;:>C8ZX]Z (=4T;3=;
MLOL>J6%O>6V0WE3QAU!'0C/0U-96-IIMG%9V-M%;6T0Q'%"@55'L!4TDB11M
M)(ZHBC)9C@#\:A%_9FW-P+N P@X,GF#:#Z9Z4 6*SK[0-(U.Y6YO=-M9YU78
M)7C!;;W7/4K[=*L7&HV-HL;7-Y;PK+Q&9)54/],GFI&N;=)DA>>)97Y5"X#-
M]!WH K7NBZ7J5O#;WNG6MS!"08HY8E94(Z$ C Q31H6DB^>^&FVHNW3RVG$0
MWLG]TMUQ[5:2[MI/-V7$3>5_K-K@[/KZ=#207MK<NR07,,KJJN5CD#$*PRIX
M[$=/6@"C_P (QH/]DR:4-'L1I\AW/;"!1&3USMQC.>]-M?"V@6+E[71K"%S%
MY)9(%!V<_+G&<<GZYK3FGBMH6FGE2*)!EG=@JJ/<FHTOK22S^V1W4#6N"WG+
M("F/7=TH H?\(KX?^QPV?]BZ?]E@D\V*'[.NR-_[RC& ?<5'J?A^!X+ZZTFV
ML;76YK9X8;UX 64D8&XXR0/3GZ5J6][:7=N;BVNH9H1G,D<@9>.O(XI+6_L[
MX,;2[@N O4PR!\?E]#0!YS:> 8[N*.VN/!&B:5.@ .HVUUN="/XXP$#;NXW$
M8/)ST/IU5[?4+*[FEAM[NWFEB.)$CD#,A]P#Q5B@!" RE6 ((P0>]8MOX.\-
M6D:);Z#IT:I+YZJMLF!)@C<..O)QZ52U[6]0TWQEX8T^%[<6&I23I<!HSO&R
M%G!#9P!D#MVZUT5M=VUY")K6XBGB)(WQ.&7(Z\B@#C/#GA+;J_B*ZUK1X2M_
MJ!N8&<H^8]J@*X![%2<'(YKK-0TG3]52);^SAN!$V^(R("8V]5/4'Z5+:W]G
M?&06EW!<>6=K^5('VGT.#Q5/2;B>+1XY-5U*RN9O,96N(!Y<3'>0J@$GD<#K
MU% #Y] T>YTU=-GTNSEL5.1;O"IC!SG.W&,YYI?[#TH7\5]_9UK]LA79'/Y0
MWHOH&Z@>U2OJNG1P&=[^U6$.8S(9E"AQU7.>OM6?KFM_V-8)K :.;3(R/M17
MDHA./,4CJ%SDCTR1R,$ VZKW]A9ZI926=_:PW5K*,/#,@=6YSR#[BIU8,H92
M"",@CO45TMRUK(+.2*.X*_NVF0N@/N 02/Q% %-?#VC1W45TFE62W$,8BBE6
M!0R(!@*IQP/840^'M%M[.YLX=)LDMKHDW$*P*$E)ZEAC!/UKG_!'BN_UFWU>
MW\0"SL]6TNX:*YMXD95C7&5DRS'<K#D'CI6MX9O-8U"P:^U0VBQ3.S6J0P/&
MWDY.QGW.<%EP<=LT 3V?AG0]/TR73+/2;*"QFR98$A4))GKN'?\ &D/AC06B
MM8CHU@8[0YMU-NN(3_L#'R_A5VWU*QNUE:VO;>98O]88Y58)]<'B@ZA9"%9C
M>6XB8[5?S!M)] <T 6:1E#J58 J1@@]Z@N+ZSM-WVFZ@AVKO;S) N%SC)SVR
M0,^]6 01D<B@"EIVCZ;I"2)IMA;6:RMOD6"((&;U..I]ZKZ=X9T+2+Z:]T[2
M+*TNI^))88%1FYR1D#UJX+^S>584N[<RL6"H) 22OWL#/.._I5;1YKE-#BEU
M34+.ZG4,9KJW&R(X8],DXP.#SU!H ;::!I&E$36&E6\+Q*WEK#&J[<]0HX"Y
M[XQGO7-^!_"(TW3IAK&DVZWOV^:Z5R5D#;I"Z'C^)<@9(X[&NIN+Y9]*N;C3
M+NUDD1&,<G^M3<!W"D9_,5D^"_$?]N>%=&N[^YMAJ5]:B=H58*6ZY*KG.* -
M+5_#FBZ_Y7]KZ59WWDG,9N(5?;],T_4M!TC6+!+'4=-M;JU3!2&6(,J8X&!V
MXXXJ&R\2:7J&N7VD6UU%)=6002A7'#-N.T>I 7)],U=M]1LKN5H[:\MYI$SN
M6.56*XZY /O0!!-H6DW&DKI,VF6<FG* %M6A4Q #D87&.*!H6DB^AOAIMH+N
M!!'%,(5WQJ. JG&0/85?9@JEF("@9)/:H+74+*^1WL[N"X5#AFAD#A3[X/%
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M]1C@\9->OG2]/-Y!>&PM3=0)Y<,QA7?&G]U6QD#V%5H_#6@PJ%BT33D43"X
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MV3/))QD8 #9&3C->RD C!&0:RX/#>A6RQK!HNG1+'-YZ!+5%"R?WQ@<-[]:
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M:0-/<S1PPIRTDC!5'U)J6N'\8W3VOCKP4UT=NDM<W"R,WW!<&/$.[WR6Q[T
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MG<^:B@H1]\!PI"GG!&..:75)K[0K^]U.W:UUKP[-K$;7=HXVW5G<B1%!0_Q
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MSD^+WAFXMO);SM-O,R1X^< QXY'4=<4 ;VF>-O#^JB]:#5;,1VEP8&=YU ;
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MW3,$6!YU#ECR!MSG)]*+K6M*L99(KO4K.WDBB,TBRSJI2,$#<03PN2!GIR*
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MA:VFX%AY\RID#J>3T%9VL>,-%T2ZTNWN[ZW5]1?$),JA=FTL9">FWC&>Y(H
MU;33[*P#BSL[>V#G+"&)4W'WP.:2^TRPU-$2_L;:[1#N59XED"GU&1Q45YKF
MDZ=Y?VW5+*V\P IYTZIN!X!&3TI]YJVFZ<5%[J%K;;@67SIE3('?D]/>@!9]
M+T^Z@B@N+"UFABXCCDA5E3Z CBK*(L:*B*%11A548 'H*(W26-9(V#HP#*RG
M((/0BJE]K&F:65&H:C:6A89 GF5,CIGD]* %N=)TV\NX;NZT^TGN8/\ 532P
MJSQ_[K$9'X4KZ7I\ET;I["U:X8;3,85+D8QC.,]*+G5-/LS"+J^MH#-_JO,E
M5?,XS\N3SQSQ3[*^M-2LX[NQNH;JVDSLF@D#HV#@X(X/((H A71M+2TEM%TV
MS6VE.9(1 H1_JN,&GG2]/:YCN386IGB $<IA7<@'3!QD5'=ZWI-A<"WO-3L[
M>8[<1RSJC<G X)[G@>M.NM9TNQE>*[U*TMY$B,SI+.JE8Q@%B">%Y'/3F@"M
MJMG>V]E>7/AVUTQ-7F*G?=(523!&=Y0;C\N<4_1-.GL+65[V6.6_NI3/=21*
M0A<@ !0>=JJJJ,_W<]Z5O$.B+8P7S:Q8+:7!Q#.;E DA]%;.#^%6GO[..X@M
MWNX%GG!,,;2 -(!U*C.3^% #H+2VM3*;>WBA,TAEE,:!=[GJS8ZGCJ:6XMX+
MN%H;B&.:)OO)(H93]0:?++'#$\LKK'&BEF=C@*!U)/85GKXAT5X9IEU>P,4&
M#*_VE,1YSC<<\9P<9]* +-OIUE9P-!;6=O!"_P!Z.*)55OJ *@_L'1Q 8/[)
ML?)+;C']G3:3ZXQC-2G5-/%Q;VYO[437*[X(_.7=*N,Y49RPQSQ3+C6M*M+Q
M+.YU*SAN7(589)U5R3T !.<GMZT %WHVE7\<$=YIMG<)!_J5F@5Q'_N@CC\*
MO 8&!TJE?ZQIFEE1J&HVEH6&5$\RID=,\FG7NJZ?IL"SWU];6L3?=>:54!XS
MP2?2@!-0TK3M6B6+4;"UO(U.56XA60 ^H# U-:V=M8VZV]G;PV\"_=CA0(H^
M@'%0R:MIL-I%=R:A:I;38\J9IE"29&?E.<'CGBFMK.EK917C:C:"UE.V.;SE
MV.>> V<'H>GH: '6VD:99W4EU:Z=:07$F=\L4*J[9ZY(&331HVE S$:99@SC
M$O[A?WG.?FXYY]:>-4T]M/\ [0%];&R_Y^!*OE]<?>SCKQ38-8TRZLY;NWU"
MTEMHB1),DRE$(ZACG Q[T -.AZ0T4<1TJQ,<1S&AMTPA]ACBN;T7PC)'XH\0
M:EK&G:9/#?W$<UL<^:\6U%3!#(,9V@\&NEL]:TO49S!9:E9W,PB68QPSJ["-
MAE6P#T(Q@]Z@UZ9XK:V$>M6^E.US$/,F56$HW#,0#$<MT!'//% %RYT^RO)(
M9+JSMYW@;?$TL88QMZJ2.#]*A?1-)D38^EV3)YAEVM;H1O/5NG4]S27>O:/8
M-.MYJME;M @>82W"J8U)P"V3P"?6K=O<07=O'<6TT<T$JAHY(V#*X/0@C@B@
M"C>Z8D4-S=Z38Z<FK^4P@FFBP-^. S*-VWUQVJ'0-/U& 3W^M26KZK=!!+]E
M#>5&B [43=R0"6;)[N:DU*9UU?2HDUJWLMTK;[215+W@V'Y5R<C!^;(STI;G
MQ+H5FLC76M:= (I!%(9+I%V.>0IR>#[4 :,T,5Q"T,\:2Q.,,CJ&5A[@U3.A
M:0T*0G2K$Q1DLB&W3:I/4@8X-4-6\8:+HVL:;I=Y?6\=Q?;F7?*%"(J%M[$\
M $@*/4GCH:T+S6]*T^X2WO=2L[::0@)'-.J,V>!@$]S0 ]=*TY;HW2V%J+@C
M:91"N\C&,9QGI3(=&TRV6$6VFV<7D,SPA(%41L>I7 X)[XIEYKVCZ<\J7VJV
M-L\2!Y%FN$0HI( )R>!D@?C3KK7-)LIXH+O5+*"67'EI+.JEL], GG/;UH S
M-!T_77O/[3\2OIQO8XF@@CT\/Y:(6!9LOR6;:GTV^YKHJHWNLZ7IK[+[4;2U
M;;NQ/,J''3/)Z50?Q?HR>*QX<-[ +[R?-96E P2P"ISU8Y)QUP/>@"^-$TI=
M^W3+(;Y1,V+=?FD'1SQRWOUI1H^F+>_;1IUF+K=N\\0+OSZ[L9SR:NT4 4AH
M^F"]^VC3K,76[=Y_D+OSZ[L9SR:AOM&BDM[V33DMK+5)X71+Y8%+HY& Q[G!
MP<9[5@^+=;U;2O$OAFQL;F%+?5;MK>820[F4!=V5.1@\$<YK3L?%VCW_ (EO
MM @OH'O+-8]X\Q<N[;R44=RH3)QTW>U ',6_@:ZO+(:=JOASPK"OEB-]0ME9
MYB,8W*K1@J_<,7.#SS7<?V/I9DFD.FV>^88E;R%S(/\ :..?QJ6_?R]/N'^U
M1VA$;8N),;8CCACGC@\\U2L]2MK/0K";4-:M+CS(D'VTLD:7+;<[U ..>3@=
MJ +]K:6UE"(;2WBMX@<A(D"+GZ"IJAM;JWO;9+BTGBG@?[DD3AE;G'!'!J:@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH *X;XF"$0^%Y) @=?$5EM9L9'SG.#7<U!<6
M5K=[?M-M#-M^[YD8;'TS0!P\%Y:6GQ<\0QW4ZQ-/I5KY2%L-)@RYVCJ<>W2L
M_P *S7^C:QX;TJ2>TUO0[FWD&D:C&-EQ;QK'G;(!PR[0JY'?&><5Z4;6W:59
M3!$9%4HKE!D*>P/I[5%;:;8V<KRVME;P2/P[11*I;ZD#F@"AXN6)_!NMB94*
M?89R=XX^X:\^U#3=+C_9X^UQVEH)GT"$-.(UW$[ >6Z_>)_$UZO-#%<1&*>)
M)8SU1U# _@:A_L^R-O\ 9_L=OY&=WE^4NW/KC&* .!U_4K/2/$_@W5;C4;2-
M%LIX_)N9UA4HR)ET=B%W [1@GD$XZ&N?UNPL;+X->,+JWOM.NFU"]>Z8V4RR
M)"'F0K%O'7 Y^I.*[G7?#VJS:Q;W>F1Z/<V,=MY']G:A$1'&=VXNC*#@G@$%
M?X:MZ-X6M;1[FYO-/TM)[D1J\%I;!85";L'D?,WSM\Q XP,#'(!BWL5I9_%[
MPTEJD,(DTJ[3$8"[E#1E1QVZG\ZY_06T^^^'5YI4NM+IMXFMRE9E*LUO,+LM
M$74]BP7@]:]373;!9$D6RMA(F-C")<KCI@XXIS6%FZ2HUI RS-NE!C!#GU/'
M)^M '+>"]0U6;5=<T[7+2T&IV30"6]L\B*Z5E.TX/W7 '(]QVQ2>-=2L+'6_
M#,5RL$=U+=2FUO+J0K#;,(CN+ $!F(;:H)')SGCGK+:TMK*$0VEO%!$#G9$@
M5<_04MQ:V]V@2Y@BF16#!9$# $=#SWH \*U"YL9OAG\0H3=PW,BZZTJL=N2&
MD@PX Z G.".O-=QJL45E\5=&33(H(9FT2[2-$ 4-AD*# [9S^M=S)IUC+O\
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M%_.TJZ(D0C]X-T>#GN.N*[<V-H8)(#:P&&1BSQF,;6).22.YS2-8V;3K.UI
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M+?6;/77UB]6QDC(#1;8X",D3*B+CYL8#<Y[<''=PVMO;;O(@BBWXW;$"[L#
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MPK>H'8^]$UA9W%S%<S6D$D\7^KE>,%D^A(R* /.[32]*G^+,5G<6D<T8\+1
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MH .O.  ==:>)M"OYS#::Q8SRB#[25CG4D1?W^OW?>IK#6]+U2>6"QO[>XFA
M,D<<@+*#T)'H>QZ&O)["!%_9\TV^TVV66>"*%KDVR*96B6=7E7./122#Z5K7
M4FA^)K?4-5\+ZM=:KKW]C7$$,D<@_=(RDJK@ 88MC /.>>QH [^#Q!H]S>FR
MAU.TDN0I?RUE&2HZD>H'?'2J[^,/#48B+:]IH$TIAC/VE,.XX(!SS@D"N(\.
M:AX3\3#PW+'J5U<ZK88,-AN"O:,%VR!U"C"  @YX/ &216#,U@WP<\?,IMSN
MU6]P05Y_?93_ .M0!Z];:_I%YJL^EVVIVDU_ ,RVT<RLZ '!R <\'KZ42Z_I
M$.H)82ZE:I=N_EK$TH!+XSM_WL=NM<9J<ME%\1/A\()+= UM>JH0@ J8DP..
MV>E<WH5UH.J^&1X<\2ZE>KK=K>,)M+#A)9+@2EU:/"[CN)#;LXY.3B@#T^Z\
M6^';$3FZUS3XA;NL<V^X4;'.<*>>#P>/:H-7\9:/HVHZ197%W"'U-CY;>8 J
MQA&;>3TP< #USQT-<C9G3G\8?$UG-L2+>W5BVWA?LQ##Z9'/TK*TZ_M;72/A
M+?75U%%:Q(\<D\C@(C&U90"3P#GC% 'L0(8 @Y!Y!%9&JW*)J^DP#78;&1IB
M3:,$+WB[3\@SR,'G(]*UU8.H89P1D9&*X;QS+!%XO\#>9)&K_P!IR8W$ X\E
MQ_,B@#JIM<TJWO!:3:A;I<&18A&T@!WMC:G^\<C Z\UH5Y5?W-UHNJ7>HZ1?
M6VK:1-K*)?:/< >?!<^:J[H6!R3N"N%(Z<UZK0!GWFNZ3I]Q]GO=3M+>?RVE
M\N695;8!DM@GH/6G66M:9J6F'4K+4+:>Q 8FXCE!08ZY/08[UR'B3[(WQ<\&
M)-Y)<6]\</C(.V/:?KP<?2N-OIG'A_QD]EB:UMO%B7-[##\Q:V'E-)P.HR,G
MZ'WH ]?M-=TF^:9;;4;:5H$\R55D&43LQ']WWZ52\->*],\56T\^G3HZQ321
M[=WS%58KN*]0#CC/:L#53%JWQ)\(7^C7$4YBAN7NY8'##[,R#:&([%\;<]P2
M.AJCX#\2:-H7@[4WU/4(;<6.I79N@Q):'=<,%W 9(R2,>OX&@#TJH+R^M=/M
M_/O+B."+(7?(P ))P /4D]!3X)HKF".>"19(I%#HZG(92,@@^F*Y/Q]J=CIH
MT'[;% #)J:""[NF(AM) CXD;!&>,@ D#)Y/% &[_ ,)'HO\ 9LNHG5;-;.%S
M'+,TRJJ..JL2>&]CS2VGB#1[[4I=-M-4M)[Z)=\EO',K.J^I .>X_.O'[Z_L
MF\-?%. ZA'<N[K*C-M!D!AC <  #!/0CK[]:ZC4)+2'QO\/%LWMD9K.\5 A
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MTYKJ:R_#<L<_AC2I(I%=#:1893D?<%:E !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
MR2*.:-HY45XV&&5AD$>XI]4;O6=.L+VULKN\BAN;L[;>)SAI3Z+ZT 61;0"-
M(Q#&(T^ZH487Z#M231 !I8H(7N /E+_+D^[8)'Y54MM>TN\GNX+:]BEEL_\
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MTOX5%G@W(E/EF$$9!<-@J".A/6L75/B3X7T[2[J\35;>Z>"U^U""!]SNIX7
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M0CT)K'AT#6KX1P:]<:-+;1LC'['8LDDA4@CEG(49 S@9]"* .&@UJSL_!GQ
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MOKQY8HR\@2\MY$55";1\S #;@<\#'3CUK:N -HP.G%(T:,RLR*67[I(Y'TH
M\IUN+^R'N+KP]JL5C>V6E01W>BZH0\=U;JAV+DG<' ++D$Y/7KD]_IOB"RGF
MT_39LVNJ7-@MY]A=3NC3@$$XQP3CUXK7:*-RI9%8J<@D9P:7:N[=@;L8SCG%
M "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJYRBR8V%N", ]01VJM<^//#%I>26DNJI]HCG2W>-(W<B1_NK\H/7CGIR/44
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M/GPQ3- [;&7#KU&& /<5H4 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MMMZA2%+=.A'K7M5% "(RN@="&5AD$'((]:6BB@ HHHH **** "BBB@ HHHH
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M&27GY%DQM)X('/)! KG-8MD\3>.?#5WI#Y&FQ73W%TBD"(21[$C)_O%CG;U
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MH53NZ'IG&#FO/+>*6Y^#$W@NXLY5\01QFR^QLARTGF964'&"G1M_0<\UT6G
M6?Q8N#/(S)%X?@MVN64A6D21BPW=,X()% '3)XKT671;+5XKT26=\ZQVK(C,
MTKDD!54#=NX/&.,'/0UE>(-?M]3\!^)+K2+ZX@N=/MK@.55HI89DC+8(89'8
M^X/!KB=$U"72_ /AV*2QD1!K$XN+EK(RR6*M+*RR*A4X)# !L$ -WJ:W8QZ-
M\3;;[/J(:Y61X#<02;I0]LJKR1RQ/1>OL* /2O#4LD_A;2)II&DEDLH6=W.2
MQ* DDGJ:U*Q_";!O"&C#D%;*%6!&"K! ""#T((QBMB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* .?U'PY/?>+]*UY;^.-=.CEC6 P%MXD"ALMN'/RC''YUT%%% !1110 4444
M <_JOAR?4?%6C:VM_'$-+$P2 P%O,\U0K9;<,< 8X_.N@HHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO(K?P[>64MY+?7,EA).LC0X\F/RHT\LD* &W8 4<G&3S6<WAF]\-^-+2^\/
M2>&];NHWOK51\MM,"&$J#L&Q@^Y^F #K?^$Y\/FYCMA=SF>6W-S'&+*<L\0_
MC V<K[UOPRI/#'-$VZ.10RMZ@C(->>WL3+\>M*F2)A;QZ*\)D"G8KER0N>@.
M.U>B*H50J@!0, #H* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH^&_'GAS1Y;R6]L=:2:$F5$$D,J $.I50"#NP01[CTH [FD) !)( '4FO+O
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M6X@N5C .QUR4(!&",8&2.<&M#X;:M?Z[\/\ 2M5U.Y-Q>7*,\CE%3D.P& H
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!1UG31K&BWNF-,T,=W"\#N@!8*P*G&>,X-<UIO@!M
M*\,6_AZUU^_33X<K@1Q;W1F+,A;;G!R0<8.*[.B@# U#PG8ZP)%U,FYC-_%?
MQJ5 \N2,* !Z@A<'/J?PI?\ ""P#4O$U\-0G$GB&%8;D;%Q&JH4&ST.TGKGF
MNLHH Q=*\/1Z1X3A\/PW4CPPVYMTF=1OVXQSC@FL_0O!7]@:)IVC6VL7;6%C
M*)%1D3=)AR^UF Z;CVQTKJJ* .27P%:V^EZII%A?W%II6IR/)/;1A24W\.L;
M$?*K>F#C)QBK.N^"]/UKP6?"B.]EIICCB @ W*B,K* 3GNHY.:Z2B@#F_$WA
M"'Q3X8CT*\O9HH5:-FEA50[%#D=<@=/2GW_AB34[+4;6[U:X:*]M'M"B1HJQ
MJ_WV  Y8^IS].M=#10!SNB^%FT:#2K:/5;F2UTZ(11Q&-%\P!"J[V R<!C@<
M#/-:>I:=)?-:217LUK):S><IC (?Y67:P(Y7YO8\#!%7Z* ,G1= MM%DU">$
MAKG4+@W-RX4*"^T+PHZ# ]SG)))-8NF> 8=*U7Q!J,&IW+3ZX/\ 20Z)M0_-
M@H,<8W'KFNPHH Q=0\,6.JS:1<WHWWFES+-;W  5@1P0?8CJ/IZ5!H?A2+0M
M;UO58KR6675Y5EF1U&U&4$#;CG&#WS70T4 <]X9\*1>%UU46UY+,=1O)+Z0R
MJ/DE?&<8Q\O X_6J6A^ K;0M%@TB*^EN+*.[:Z>.XC1O-)YVMQC:#AA[@5UU
M% ')1> K.TU[5]4L;J2T&JVPM[BUBC418 P' Q]X#//3D\4_1/!9T/1=-T>W
MUB[:PL9 ZQLB!I,,6"LP'3<<\8Z5U5% '-P^$(?.T9[Z]EOO['.ZT>5%$F[9
MLR[ #=P>@ YP3DBJNOV-W<>+-+U2+3=5G.EB3R3;&U\J3S%"MGS)5;H/0?C7
M744 <4L-^OC%O$?]@ZX9FLQ9&#=9;/+#EQ_RWSG)/.?PH$-^/&)\1_V#KGG&
MS%EY&ZRV>7OW_P#/?.[)ZY_"NUHH C@D>:WCD>&2!V4$Q2%2R'T.TD9^A(J2
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
)BB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>thackray-biocrystseparat009.jpg
<TEXT>
begin 644 thackray-biocrystseparat009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ7H<&JZEH^FVD7_$OT39)'=MNM[6%B[#RT/)=CG)W  !>>U '4>*M>O]$O\
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M ' H Y[0->O]2\4^)=*O([=8]+E@2%H0V6$D>_YB3UY X KHUD1G95=2R_>
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MQJ4.HZCHUE=7D.-DTL0+#'3/KCWJQJNNZ?HT=HUW<(IO+B.W@7<,R,[ #'L
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MH<F@&R^SM%?:M!93B5"6"2$Y*D$ 'CN#UKH9KJWMR@GGBB+G:@=PNX^@SUH
MH#PWHPEOI/[-MR]^NV[+)GSQC&'S][CCFH+;P?X<LVMFMM%LHGM598'2(!H]
MPP<'KG@<]:VZB>Y@C?8\\:MD+M+@')Z#\: ,K_A$?#_]F?V;_9-M]AW^9]FV
M?N]V<YV],YY^M/O_  OH>IW5O=7VEVUQ<6Z[(I9$RP7^Z3W'L<BM(W5N+D6Q
MGB$Y&X1;QN(]<=:Y[1]<U"[\=>(=%NA;_9;"*VDMS&A#$2!R=Q).3\HZ8H V
M=+TC3M%M?LNF64%I!DL4A0*"3U)]3[U3U31VFU>QUJSVB_LU>(AC@30OC=&3
MVY"L#ZCT)JSH[WPTB-M6N;.:Z4OYLMJ"L7#'&,DD8& >>H-6!?6K6C72W$3P
M*"3(K@KQ[B@#-N?"7AZ]O+F]NM%LI;F[C\N>1X@6=<8P3ZXXS4L7AK1;>Z@N
MH--MXIX(O)BDC7:8X_[JXZ#VK%\-:WKGB.'2=:MWT_\ LF\1WGM65A- ISY9
M5@2&/ # @>U=5/<06L?F7$T<,><;I&"C\S0!FIX7T*/3[NP72K7['>,7N("F
M4E8]68'J??KQ3;#PEX?TNZBNK+1[2*XA3RXY1&"ZK[,>:UC-$(UD,B!&QM;<
M,'/3!]ZH7DUW+/8/IUY8BV^T%;KS<L77!&U"#@-NQU]#0!8U'3K+5K"6QU"U
MBNK648DBE7<K<YZ?7FL^/PCX>A</%HUE&X@-L&2( ^6225R.QR<^N36HUW;)
M.('N(EF(R(RX#$=.E5H3?_VW=":XM&L/*C,$**1,K<[BQSC!XQQV- %8^%-"
M-I:VATNW^S6CB2WBV_+"PZ,H_A(]15&&VUK5M?5M7TZUM=-TVY>6S9+CS7N6
MVE4<C V85F.,DY(].>@6[MFD1%N(B\@)10XRP'7'K2RW-O Z)-/%&TAP@=P"
MQ]!GK0!+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %<-XRU*&R\:^$(-3=4TB>2
MX#F7_5&X"+Y6_/'=\9[X/:NYJIJ6EV&LV36>I6<%W;.03%/&'4D=#@]Z /-_
M%B:5H>FXTF0G3+OQ%;/K6V3=#&CG+KZ*I(3</1^>M:VI:>EO\6-%73X(Q!?Z
M=<IJD*J-CQ)M\MF7H3N;:">V1780Z-IEMI7]E0Z?:QZ?M*?95B41E3U&W&.:
M;9Z'I>GPR16EA;PI(H1PB#YE'0'U R<#M0!Y-X=\-:)-\#;O4Y=-MI+Z.PU)
M4G=-S( \N ">@&T$>AR>YJUJ-EIOA_P!X8U6&WBM8[U]/CU:\$>[=!L)!DSU
M7>4SGMQTXKTR+P]HL&FR:=#I-E'8RY\RV2!1&V>N5Q@U,NDZ<FF'3%L+86!3
M8;41+Y>WTVXQCVH X&\\/:3(VNRV?B9(Y]5LHXIC;HGD(=X6.1U7C+9V\GE=
MWI67J<]Q)H7C;2O$6AV=MK4>A&<W-G\UO=1HLHC< C*L&+<'GCVKTBT\+Z#8
MZ9-IEKHUC%8S',MNL"[)#_M#'/0=:S_$7AV-O!^M:=HVGQ"ZU"SDMAM(7)9"
MJ[F/\(ST[=A0!Q-YX?L+&V^'FL:+;I#J\U[:))-%]^X@>(F;>>K *"<GH*GT
MF.UUWP'XS;6TC_M**\O/M3R#YX"@)B(/4!5"E?I7;>&- M-+TG3RVF06U_#;
M+"Y4*2IP VTCH"1GC&>]7;CP_H]W?&^N-,M)+I@H:5H@6;;]W=ZX[9Z4 >:V
M%A_:GBGP&^O6B37MSH4QO!,G,I BQY@_BZYP>]9LUT-&\*:W:1?N-&7QG]EN
MU3Y4ALV9"ZC'W5)."/1B.]>PS:/IEQJ$>H3:?;27L0Q'</$ID0>@;&1447A_
M1H(+J"+2K)(;LDW,:P*%F)ZEQCYOQH Y"ZM=.A^,VBM;Q6Z&;1;A6\L !U#I
MMX'48SCVKCM0LK4?!OQO$((A';Z]=>2 HQ'BX4#;Z<<<5ZS9>$O#NG20R6>B
M:?!)""(W2W4,F>N#C(Z#\J?_ ,(OH'V.:S_L33_LLS^9+#]F39(_]YEQ@GW-
M '*R:;8Z1\7M"_L^VBMC=:9=BX,:X,VUHR"Y_B.23DY-<W;Z._B#PI_81%K=
MWBZZ\S:HTT3)(HG)9R"=Y.W,>W;@XZ[>:]2DT+3#<1W<>G6:WT";+>X:!2T7
M' !Z@>P(K@+/P)-/ +75_!/ARXO3GSM6\_\ US$Y,I01AMQ)SMR/0$#H >G0
MPQV\,<,,:QQ1J$1$& J@8  ["O&/$-S93^'K[4--:**$>)HSYMR^^YDG$Z*Q
M4\>6H ( ^8[?2O8[*V^Q6%O:^8\ODQ+'YDARS8 &2?4XK.E\)^'9Y+N270M.
M=[P@W+-;(3,00?FXYY //<4 <7:Z!H>M?%;Q1#?6-K=P26-G*(W4,C,?,!?'
M0G_:ZC/!YKE;+3(F\/>#;>[!EM8_$\UI9RNQW/:?O0J[NNTX_$8KOK;PJTWQ
M!U?4[_2(FTZXM8+>W<LA*^7NW< Y"MD<>W(J;QGX=GU:3PY;V>EQ3V.GWZ7$
M\1**GE*C)M53W^8<<#CK0!QNOZ?+X6\0^,%\)P?9+5O#@N)X+0;4BN/,9590
M.%;RU<\>F:Z+1[#P_?ZQX=UW3=<B:1(GBMH+..-/.C9,E) O.%QGGH?<UW%G
MIUGI\;I:6T<(D;=)M7ESC&6/<XP.:J:;X9T+1[B>XTW2+*TFN!B5X(%0N/0D
M#I[4 >:J?^+2?$3_ +".J?\ H9K?EFL9_$NAV86-M1CT-IMUXV;>*!B@9MG\
M;DKCJN%SD]!76+X:T)+.>S71[!;6X;?-"+==DC>K#&"?K1-X;T.X:S:;2+&0
MV7_'J7MU/D_[O''X4 >0Z:MK=?#3X>^<()RGB&.(E@&Q'YTX"\]%P ,>PKI)
M9-/U/QWXBT34KZTMH39VZV,<T4;)):F/Y_+W<</NSCT'IQW)\,Z$VFR:<=&L
M#922^<]N;=-C/G.XKC!/O1J?AG0M9%N-2T>QNQ;\0B:!6\L>@R.![=* (_"=
MI;V'A;3[.TOIKZV@C\N*YF(+2("0#D<$8Q@CJ,&N5BN=-U#XA^+M(\0M#DVL
M"6B7+  VK1GS-F?]LMN(]O3CT)55$"(H55&  , "LW5/#FB:Y+!+JNDV5[)
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MY^M37?AW1K^Z%S=Z7:33A/+\QX@6*_W2>Z^QXH \JLUN8_AYX$2XDDDC7Q/
MML\IRS0"601'Z;<8]L5KR"QU[Q1XRT37=2M[64LB1QW$:$_93"N&C9^F&WGC
MH3FO1+W1],U)8%OM/M;E8&#PB:)7$;#H5R.#]*KZEX9T+6;B"XU/2+*\F@XB
M>>!7*CT!(Z>U #O#L,=OX=T^"&[FO(8X$2.XG^_*H& Q]<C!S7$:%X<T:_\
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M%0JR2;1N;WR><]ZV:R?#>BIH&C1V$:1QH'=Q%$28XMS$[$SSM&<=O7 Z#6H
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MVY9G\J% BY8Y)P*\W\+Z%8.OC>ZM=,M9-1LM:N6L#Y0)AD$*%=@_A^8]OZ4
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M8+:)I'/<@#H/<] /6O-O$_A?Q&_@9KOS+ :I8W!UI2B/Y@G4ERH;.#QE!QT
MH ]2DD2&-I)75(U&69C@ >I-16]Y:W<1EMKF&:,$C?&X89'7D5P/BG6[?Q!X
M"\/Z]:74,=O)J%G=&WEE"K<8?F L> 0<]>,IS3K'0]/U7Q-XE\1RV^GR17=G
M'"D+&*:0%48,[%2P7.0, \A>>U '=PW]G<2>7!=P2OL\S:D@8[<XW8!Z9[TE
MIJ%E?AS9W=O<",[7\F0/M/H<'BO';6PLM,^!FEZY;62+<FWMTOKN&,-,UJ9D
M,JDD$D;1C!R,#'2MS5;?3I4U+Q!X;\037^MOH<\<*6C1%3&%)5F$:@Y#8"YY
MSQZT >C0ZA97%U+:P7EO+<1?ZR))59T^H!R*1M3L$9%>^ME9Y#$@,J@LXZJ.
M>3[5Y[H=OX6UX>%M4M=>DFN+9-EK:0F -ADQ)'(JH&V@ Y!],UR]QI.FK\&_
M&5PMG;B:WU.\\B0(-T6V?Y0A_A ]!0![;'>VLMU):QW,+W$0!DB60%T!]1U%
M-.H62WHLFO+<7;#(@,J^81Z[<YKA;ZPL]-^)W@MK&VAMWN+6^69HU"F4!$8;
MCU;G)R>_-<]H2Z+XD\&V\.M>(+BVU:TOS+<6T9A2Y2\64_=RA<EC@#KG..U
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MW3G3N+JWM$#W-Q%"I. 9'"@G\:XKQV'/BWP+Y&?M']JN>.OE^4V_\,5O^,-
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M/%.LLB* TH-KN^8]6Y&><\U0OO.T^'XKG2(S'*CP.%MQM(!@4R$8Z'!<Y]:
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M \IMIM#UFP\3Z%XIU^:QNAJ<[7-HS0H\B^9NA:/<A=OE"!<$G@ =JN"]T_\
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M3:!SGI^=3K>+-XCB,.O6K6QLC)_9RA&=_F4B<-G=MP0.F/F!KR32+ZT3X8^
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M717UK5K/^V;]9&$+.D;RXD=1M3C(PN.!VJ#1+RVM?BWXO@N)XXIKB"P,,;L
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M=(,94<\D9''O7 >&[KPMXDL_"S_VW<7&I6!3R--4Q)+;N%"R*R*@;8 #G/!
M[G%93VU@?A;\27$5N2-5OP&"CC#@J/P/2@#UR'6=+N-3ETR#4K22_A&Z2V29
M3(@]2H.1U'YTDNMZ5!J"6$NI6<=X[!4@:90[,1D +G.<=JX:^2TMO&WPW,"P
MQ[XKL93 W VX/X\\_6L#2;G0]8\,7/A_Q-KEU#JL%_(9],5HDFDG\XNC1?)O
M8L2I!!/7'2@#U2Z\1Z'8BX-WK&GP?9V59O-N47RRV=H;)X)P< ^AJIK'C#1M
M$N]+MKJ^MUDU)\0DR@*$VEO,)Z;>,9[DBN3T^TTZ7Q_\1/-@MF*VMH#N53@&
M!]WY\9K#TR\@M_#7PGO+JXCCMXY65YI' 5?W#@ D\#TH ]E5E=0RD,I&00<@
MBJ,FMZ5%?+8R:E9I=LP00-.H<L1D#&<YQVJYO\R#?$0=RY0GITXKQZTDAOO@
M)J=A?<ZU 9X[B%O]=]N\UF3CKN9BI'KF@#U.]U_1].DECOM5L;9XD\R19KA4
M*+D $@G@9(&?>KKSPQV[7#RQK"J[S(S *%ZYSTQ[UYM:Z=;7/Q9M;768+6YN
MCX63[0DJ*X>3SL,2#P>_X&O3%550(J@*!@ #@"@"E'K>E3:<^H1ZG9/8I]^Y
M6X4QK]6S@47>MZ5811R7FI6=O'(N]&EG50R^H)/(Y'->?6%C<:9XBO? *V[?
MV3<W U.W<+\B6A8M+#]/- 7']V4UIZ)="'XG^+K35F1))X;:2S\[ $ELJ$,%
MSV#EL^[4 =C)JFGQ26T<E]:H]UC[.K3*#+GIM&?F_"D&KZ:7ND&HVFZTP;D>
M<N8<]-_/R]#U]*\>M8WTOP?X2FNI/*TR'Q87M9)3A8[0F81DD]%.<@],$5KR
M:AIE[XN^((2YMIHY=&@*?,"LFV.7<5[, 2.1TH ](LM:TK49S!8ZE:7,PB68
MQPS*[!&&5; /0@C![YJ2ZU*QLI(X[N]MX))<^6LLJJ7P"3@$\X )/L*YSX<6
M.GQ> _#UW;6UNL[Z9 LDR(-[?*"06Z_>SQZUF>/8+&3QGX&-[' T;7TT;&4#
M!S"VU3GK\V./6@#K[;Q!HUYITFH6VK6,UE$2)+B.X1HT(ZY8' K.U?7M.NM(
MODT[Q3INGW,2(S7;/'*+<-@J64G'S '&?7-<%KFEVUM?_$J>QABCTUM"Q.J*
M!']K\N0\#IN"E2<<Y8>M3^+]/TN#X!S74%I:)))IEIF98UW.04QENIY)_,T
M>G7FHV6FQ+)?7D%NK' ::0(&..V:8^LZ7'81W[ZC:+9RX\NX,R^6^>F&S@YK
MDFO#;?&=!?.%M;K1MFFR,?D9Q)F55/\ >(VGZ 5Q&NVD</@?QH_[L:2_B"%K
M')&T?OHO-*'LN[<./1J /9[+4K'4EF:QO+>Z$,ABE,,H?8XZJ<'@CTJU5:SL
M;*Q1Q96L%NLC;W$,80,< 9..IP ,^U6: "BBB@ HHHH **** "BBB@ HHHH
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MK>G66G:CJ%[XIL[RS6]D N&>-$MQP1#N!PQ7U/)S6C::_H]_J<^FVFIVD]]
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M.F 1BG265I+$D4EK"\:?<1HP0OT':JLFOZ1%J"6$FI6J7;OY:Q-( 2^,[?\
M>QVZU3\3:]::7I=ZG]J06=\ENTD9<J2G!VD@\ $C'/!H VT1(T5(U5$48"J,
M "G5A>"[^ZU7P3HFH7LOFW5S912RR8 W,5!)P.!S6[0 4444 %%%% !1110
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MNO7*Q71\./;.\K<R3AHLJ#_$V<\#DUDN]A)X'^*LA>W9VU"[&[*DG$:;>?\
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M=Z=>W'PA#36\VRSE1MQ!PZVJC'U##'L1CJ*]@,4;2"0QH9 ,!BHR!Z9IHMH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 57O+ZUT^#SKN=(HRP4%C]YCT4#J2>P'-6
M*X7QK<2:;XT\'ZM=';HUO-<17,I^Y#))'MB=O09W#)X&[WH Z9/$>C2:?<7_
M /:=LMK;,4N))'">2PZAP<%3['!J.T\5Z!?ZC#I]KJUK+=S1>='"K_,ZXW9'
MX$''7%<%K:Q2:SX[UBTGB_LF3P]]GFE5AY<UUMDP >C$)M'_  ("H6N]/BL?
MA24N+9-KQYVNHP#;$-_X]P?>@#UB66."%YII%CB12SNYP% ZDGL*SK7Q'H]Y
M-<0PZA#YMO&)94<["B'^/#8^7_:Z>]8_Q*CO'\"WKV4,L[PR0S20P_?DB25&
M=1_P$&LWP]J/@_7M>@US2;VXOKRWM622YDFDVVT1Y*R;N 2>QYX)[4 6CXOT
MWP[X0L+V?6VUI;JZ^SPW84?OBTI4GY!@!<D9[[?4U#=>)S8_$>%;C6 FA2:*
M]WLD"JBR"9$!!QN.0>A)Z\5Q-G<VX^!FA3B5/)M-:CDG8'(B07K'+>@P0?H:
MZU]1TVZ^-.G3K<V[K_8$IC8L.IF4@C/JN2/4<]* .SMM<TJ[T=-6M[^WDT]Q
ME;A7&P\XQGUSQCKGBJX\5Z";.[NVU6VCAM&V7)E?RS"QY 8-@@GMD<]J\E@O
MUMO"AU")Y9=-T[Q=<SWHLVRT=N6D <!>=H+*W'IFMG7)_"M[X1\7ZUHEU)=R
M7.E/!/?23.4=@I\N,;N"_P!.1QGJ* /1]-\0:1K-Q<V^G:A;W4UKM\](GR8]
MPR,_7!_*JVH>,/#FE/<I?:U90O;;?.1I1NC+9P"!SDX/'7BG^%Q9MX:TR:S$
M)1K.%=\0&" H &1Z<URD5SIEK\9];:_EM8F;1[?8TY5<C<^[!/MC/TH [(Z]
MI7]F0:D+^![.X*B"5&W"4GH%Q]XGT'-0MXJT&/2IM3DU6UCLH9#%++(^S9(.
MJ,#R&_V>M>7Z9+;>&O#ND_:K>&VL+OQ%<S:;>7:D1V$!W^6^,C!89VYX^?)Z
M50U&_M!X+^)]JUZTLLEYYB-,H1I T<6UL8 YP<8 SC(H ])U7XC>'-.,<<6H
M0W4[7T-D\<+;O+9V )8CH N3[XQUK:M?$.DWNHG3K:_ADO!&)3 I^<(>C$=A
MR.:XWQU)86_ASPQJ,!@2QAUK3YI;B/&Q8E.-Q(XV@8&>U6/&DCZ5>:1XZTN"
M2Z^S8M;N*(?-<6LI &,]2K[6'U- ':6FH6E^TZVLZRF"0Q2A?X''53[U4U#Q
M%I&E2O'?7\4+1H))<Y/E(3@,Y'W%)!Y; X-.T'3Y--T>""<AKILS7+CHTSDL
MY'MN)Q[8KS?QAJ]E)=^/=,5DTZ\&EX*JFZ?4OW#E2,@_NUSM.T9ZDD8H ]&O
M/$FB:?<K;W>JV<,S1F81O* =@_BQZ>_>H/\ A+_#W]C+K']L6HTYI/+^T%\(
M'SC:3V/L:X*QU#3KOQ7\-7%Q ^W29P"Q&0WEQ =>^0P'T-7?"MAIOB6R\?Z+
M++%);W>LW (1@2 T<>''_ @2#ZB@#OKG5["S-NMQ<+&USGR58'+X&XX&.N.<
M52_X2[P__9L6I?VM;?8II/*CN-WR.^<;0>A.>*Y[P'-JNKNLVN0LEUHB/IA9
MNDTX;]Y*/4%%BP?]IZY^[\.W]W<^)O =LKPV<TO]KVER!\L0?+!%/8BX3/\
MN[NE 'H.NZI''I][;6M\;?4?L4ES#M4%P%&=V&!&,X'([UD>#/&%AJ&A>'[2
M^U>"36[NPBE>)G >1B@9N!QG'./3G%4='U*?5_ NI^)=6B^R3W&GF I+A=@C
M1@WTS*9/J M<S'=V$/@;X5[+BV1DU"TWX=05_<N'SZ?,1GW/- 'J-_XCT?2Y
MO*OM0A@8,JL7/RH6^Z&;HN>V2,U#J/B[P]I,\T-_K-E;RP1B26-Y1N120 2.
MV217G,-_H"7GB;PSXPN;V&YN=1GE2VWR!;V"1LQF,+]XXPN!S\HK8M1IP^,=
MM9R+""GAA8%@F<.RGSON$G.6V]?49H [*]\3:+IY7[7J4$2G:2Y;Y5#?=+-T
M7/;)&:U2RJA<L H&22>,5Y$E_H$&I^*?#?C"YO+::[OY98H-\@6\MY,>7L"_
M>( "X'/ 'T]3TZ*.TTFTA6-X(XH$41R/N9 % P3W([F@#$T_Q!I&GZ->:C=^
M*;>\LOMD@%U*Z*L9)XB4KPVWH.I-:=EXBT;4M3N--LM2MI[VW7=+#&X+*,XS
M[@'@XZ&O'K^]LG^#OCE5N8&W:[<;0'!R#<J5P/<#(]A7:W]W8+\7O#*V]Q;
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M9,DY[ D<^]5/%>H6?AWQ_IE_JLL]EH=S826\=W;EE2*X,@<[RO0. .>Y7V.
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M* "D(#*58 @\$'O2US_B/Q99^'+K2[:X25Y=0N1 FR)F"CDL20/0' ZGZ T
M;ZHJJ%50%'0 <"C ]!6;>^(=+T_BXN&#>5YS*D3NR1_WV"@E5X/)P.#Z5>MK
MF"]M8KFUFCF@E4/')&P974]"".HH EIJQH@(1%4$Y.!C)K(\5>(K;PIX;O-8
MNDDD2W0E412Q=NPXZ GN>!7.:WXDD@\7^#YX]3EM]*O/M?VJ&1 B-LA+ G<H
M;K[X/'% '=X&,8&#1@>@K E\2Z)JOAC4+ZVUQ+:TC62"6\4[&MGQSPPX89!
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M .X'7G@<UUS E2 2I(ZCJ* # ]!7))H'B2SU&_:TU;3+BRO+EKC%_9-)+#G
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M#HUE+9Z<6=X(Y6<L59B=V')8!CD@'L>W2MRBB@ HHHH **** "BBB@ HHHH
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MHVMU52&QCDC YR3Q31J,>F_!?PY*MA%<K$EE%<&2W,HM""NZ5D')*$9QZXH
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MUX6\0Z1J=G=ROI,:/-JEH45@80\499>-P(\W/7M]:ZKQ-K$EAX<>?371[RZ
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M*'B";6W6VM-6MK5[*YD;$0\I65XMYX#;F+ <9S7,3:9<Z/X0M-1G@FCT]?&
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M4?VR 2/)"9EMEWC,Q0<G9C(]\4 ;%AK^F:C)>1V]R1+98^TQS1M"\0(R"RN
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MPJ.K X.".N#6C>:M::%XQCU+6S?C1M3TNVBM[ZT>;9%+&7S&_E'/._(R/ZT
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MAQA#A21DC:00.I'%3S>,+>+QR/#9MKK*V9N7F%M(RY+JJX('W?O98\#@9ZT
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MKB-9(I%Z,I&0?RJ>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X/XA7$-KKW@J>?/E
M)JY+$*6Q^Y?GCL.N>W6N\KG_ !!X<GUK5=&O8[^.W&EW!N51H"_F,5*X)W#
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M5% 'A^E+=Z;X)\&ZI-8:A-9Z7=7B:A;VPD2>))7?;)M&&P.#]&K4\5KI-_\
M#GQ)>:%I5X/[0-LOG2Q3&:\9)!T5_G(5>^/7L*]<HH X#QY-);WOAOQ#';7E
MYI%I),MXMB7$B)(@"R *0V%(Y]C69KZZ5>_#GQ7>Z'I=V@U&W5!/-'+YUY(
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M,.60.1M/4#KWKI]#\2CQ2MLB:'?V=]%$RW,EW:-$+1BN"J,P^8EL<+VY..E
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MEMJ#I'#=+;2>3O?[J,^,*QZ8/([XJ_JOB;3M'%R9_M$BVJ"2Y-O T@@0\Y?
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M)!E5FC,;8[$J<$>N" :Y;Q]97JP:5K^E6KW.HZ/>+(L,?WIH9/W<J#ZJP/\
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M$Y+$D'U([XJ744N/^%?^ IA97K?V9?:?)>1+:R&6)4C*N2F-QP2.@H [F_\
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M=H%VF-2Q(R.Q.<D=B2*U: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ML.M 'H5%<Y=>-=,M=6GTDP:A+J,$"W#6T-H[N5)Q\N!ANAY!Q[U/;^+M'N]
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M7#WVH06@*+D(&<;L\]2N0!ZT ;.GZ=!IL#QPABTDAEED<Y:5SU9CZ]/8  #
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M.BU"P:5[68;HWDA>(LIY! < X/8XP:NT %%%% !1110 4444 %%%% !1110
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M:LUK>>))9T:*UF25(V"[)X\+GAE[?EV,.IZ7XDN?ASXLTII+W6(8Y(3IMQ/
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MO!/-%;.Z1>9&JIN8# R01_.EN(Y_^%QV=T+2[-JNC2V[7 MW,0D:5&"[\8Z
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M(X_#K7(Z/IFKV7AOPEJ@TR_)T75;N2\LVMG67RIGD D5",MM5@<#)Y->S44
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M/.+[,@$9VG.,^W7BN1M=-U6U\(Z/J']@WMW_ &5K5W<76FR6S+)+!*T@W(K
M;B X( KVBB@#F?"C:?>2W6HZ?X<DTJ.541I;FT$$TY&>J_>VJ,8)ZY..G.?X
M[CU*QU?PWXCL;"XU"#2KB47=K;+OE,<L>PNJ_P 17T'K]:[:B@#SKQ4NI>*?
M"_\ :.D:/=1&SO[:^CM[B+R9[P1-EAL/(&,8W8)*GC&,W;R(^)?&GAG6+2WO
M(K728[F:XDGM9(FS)&$6,!@"QZD@ XV^XKN** /&YK'4'^"FN::NE:E]NFOY
MFCM_L4N]@USO! V]-O.:ZW4_-N/B?X8O(K.]:UBL[I))OLD@2-GV;0QVX&=I
MZ].]=O37#%&",%8C@D9P?I0!X_HSG5/A-K>@VUE<SWUW=WMO"GV=]A9YGP^_
M&T*I.22>-OTST<=A<V'Q*T%1;W<UO::&]F]T+=S'YFY, OC R%)ZUTGA?PZO
MAC2WL([R2YB:>2<-(@#!G8LW3MDFMN@#QF235]1T_P -7=WH6M+J-GK\<U[;
MQVCI!;H#(,1H,*R\@[QNZG+#(%=/:B>+QYXRNY+"_6"XL+9(9/LDA61D60,%
M(&&(+#IU[9KOZ* /(HK2^C^'/@"T;3-2^TV.J6<EU$+*4M"L9.]F&W@#(^O:
MNBM/.A^)/B>\>ROA:RZ=;QQS?9)"LC)OW!3MY/S#IUKNZ* /'K:ROXOA=X'L
MGTO4A=V6JVDES#]BE+Q+'(6=B-O0 ]>_:K>M7@T[Q?XIC@M=82#4[>"*YEM]
M+>\0OY1&Y2A'EL$8#:P/(!QCKZM7,?\ "(W%MJ=Y=:9XDU2PBO9C//;HL,J;
MS@$J9$8KG XSCVH N^$Y=+?PO81:.9?L-M$+:-9D9)$V?+AU8 AACG(K:JO8
MV45A:B"(NPR69W;<SL3DL3W)-6* "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K$UWQ5
MIOAVZL+>^%R9+Z0QP^3 S@L 3C([G' &2?2MNN$^(-P+77_!4QCED":L<K$A
M=L>2^2 .3CK@<T :-C\0-$N[;5Y9Q=Z?)I">9>6][ 8Y8TQD-MYR#CC']15R
MS\5VEUJ;:=):7MK=BS%\D4L88R0YV[EV%LD$@8Z\CBN3UFRUF;6/$OBG0].=
MIAI$=A:0W$!5KEPY=W\M@"< @#(^8CTZMTM+F/XC:?K*Z/KGV*719()+B\C+
M2>9YJ,=RYRO /R@#/\(Q0!IM\3]/N-#FU33=(U>\A2VGN _V;9&/*)#*SDX4
M\9^GOQ5JS\;I%I'A^;5-/O8I]6\J*-PB;&E= W7?\H.3C/I6-X7TO4&^"M]H
MKV-S!J+6M]$()XC&2TC2E,9X.0R_G5^/1W\3?"FWTJXMKG3KN&SB6%KE/+>&
M>)5*N!U #KUXR >QH ZM=4C?6Y-*6&8S1P+.\F!L"L2%YSG)*MQCL:Q-0\4W
M-KX\L?#T>F7$D4UI)</,FSG#*HQE@<#<<_AC/-/\#?;KOP_'K6JQJFI:HJ7$
MJ+R$7:%11[;1NQZLU4=9@O;;XG:)JL>GW5S:'3Y[1G@3<(W9T8;N?E& >30!
MA>'O%%MX77QA)>QZI=V]MKLQ>2-6G^SQ>7%\S,Q^Z.>,DX'2NLU7QOI>E:C!
MI[07]U<W%LUU EK;-)YJJ 2$_O'![?CBN/\ L=\WA'XC6HTV_P#/U*\NI+-#
M:R S*\2(I''<J?IWK0M8KK_A-/!]R=/OA!;Z1);SR-:R!8I&$>%8D<?=/L*
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MVS$B1<Y1AV8%2-O)]!7-ZI(L'BRV\31^')]>\/ZEIL5N!!:"::U=&8K^[;D
MAR#Z$<]*LZI9R_:_!\MGX=EL+>'5&NI;:VM?]1&8W4-)Y8*AB2"0.F>^,T =
M-I_C/2[VWU:687&GMI)'VV.]CV-$I7<&P"<@CD8I]MXLLI=:ATFXMKNRNKBW
M:YMQ=(JB6-?O$$,<$9&0V#[5P^N:!JNN7_Q#MK.UN(I-0BLFLI9862.9H1EE
M#$8Z@+SUSZ5TEGK&H^,-*GL6T#4-(EDM9(KF:^BV"-V0KB,YR_S$'.,8'J10
M!?\ ^$TTU;O38Y8;N&VU1_+L;R1%$,[D94 @[AN'(W 9[5T=>8^$%8VVF:-J
M/@$V^KZ>8TEOI;*/[./+P/.27J6(&1CG<?3)KOM,U-]1DOD?3[RT^RW+0*UR
M@43  ?O$YY0YX/M0!Q^OO/H7Q3\/7SWEY_96JK)8R0&YD\F.YQNC;9G&6Y7&
M,<56\+W_ -A^+GB30I+Z^N+>6&.XL1<7$DB1E0/-C3<2."X/'3!':M[XC:'/
MKO@J\BL58ZC:E;RR*C+":([EQ[G!'XUSOB3PAK+Z/X:O=-;9KUM=,+J9!G:+
MK(N&'LK/N'H%H T99=-MO!6NZUK$NI2Z9?O*^R*:60I;_=39S\H8+OSQ]_TJ
MY?\ BR33O$'AO1K/3+N:WOX))1("I)1(P0HW-G(W*23^&<G$WCG3V_X5MJNE
MZ=:2RNUB;:V@@C+D_+M4 #M[UD:C#?1^(? NJQ:7?7$%K;7,$ZQPG?$[QH%W
M XVC*D9/ H I:7XBB\->(_',EQ#J=[!;7D4A6$-.88_(5F8ECPH))QGUP.*Z
M75-7T*YU3PNTYNY9+R7S=.DAWK&28R<N00"-N>#D^U<_#;W8F^(S'3[X#4!_
MHG^BR?OO]'$?R\<_-Q^O2H%M+Y=/^&B'3K_?IWE_;!]E?]QBW,9W<?WCC]>E
M '277Q"TNWEU:)++5;F32B/M:0VA)12N[=R1QCGG&>V:Z*UOX+_2X=1M"9[>
M>%9XB@Y=6&1C/J#WKA+>"Z35_B),VGWPCODC^RG[*_[[;;B,[>.?FX_7I72^
M!89K;P)H5K<P2P7%O8PPRQ2H4975 ",'W% &?X9\;?VMH-YJVHV4]E#%=2PI
MN"MG$IC5!M))<G QCDG S5W_ (333XKV]L;VUOK.]M+7[8UO+$'>2'.-Z>66
M# '@\Y'>N$30]<E\ ZCI4.CS'4-/UE[](;E0L-XHN?-"*3]X,OX9XK>LI[74
M]-O[NS\$7&DRK8RQ/)<:>L<[.PP(XPOS,,Y)/3I[X -6R^(.D7TNCA+?4(X-
M6 %K=2V^V)G*EA&6S][ /3(R",\5H>+O$ \+^%K[5O+$LD*!88C_ !R,0J+]
M"Q&?:N%^Q7Z^#/AW:G3;_P"T:=?6DEW&+60F%8XV5B>.Q(^O:N@^*UE/>?#^
M\DMT9WLY8;PHHY98Y%9O_'03^% '1VVFRPZ,;:6\F-U(F9[I" [.1RPR,#V
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M(C\C>< #=@G=NY [=: .GHKF6\;Z?%/I?G6MY#9:K*(;*^=4\F5V&4'#;AN
MX)49JS!XIM[J6+[/97DMK+=O:+=H$,?F*S*V1NW ;E(SMZ_49 +^LZ1:Z[I%
MSIEZ)/L]PNU_+<HPYR"".A! -9MCX7DMW07VOZMJ<,;!DANVBVY!R"Q1%+8(
M_B)'M6CJNK0:1%;M,KR27,ZV\$4>-TDC9( W$#H">2.E</\ $;45O_ UU<-;
MWEE-8ZG;1,DK;3DRQ$GY&(92K^] 'H]%8&G>++6_U^YT:2ROK*[AMQ=(+J,*
M)H=VW>N"3C/4, 1GI5:P\=:=J%QI*I:WD=OJY<6-U(J>7,5!/0,67(!(W 4
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MR1%&/E)E64%'W;L!B3P/0]*WK77-/M-)T2WL;:YE:\M5>RLT(,OE*BG+%FP
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MP3VK;6TM/!WAK5+_ $G2I5R'OFL!* %?:"RCDJ@XR0O'7&>*YFZ\,ZAH^A^
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M]0>7/_70U6GTO5_$G@O1O#5[I5Q9W=M-;"]F?;Y2)"P)=&!^;=MX Y&[G&*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'I]% %>P:1M/MS+ \$GEC=$Y!93CH<$C\C7/^.=&OM4TFUNM'1&U?3;N*[M
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MQDO$TB6XFO9H70*AE5\A0S D!G[#H/PKU"B@#$GUR[M_%UKH[:3(;*Y@9TU
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M8,ZZE!]GA$?VB'Y_+F5V8'?@+A>,G.>PZGU8D*"20 .I-!905!8#<<#GKWH
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MBV\R)9K66,$ C<=I4AN<'K].?1** *>E+<KIT1O((;>=LLT,)RL>22%SW(&
M3W.:N444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !7/>(_%2^';[2[4Z9=W;:C,8(C
M 4P'"EMO)SDX^GJ170UPGQ!EEAU_P5)# UPZZL2(D8 M^Y?."2!G'J10!9LO
MB C?VY;ZIHU[8:CI$/VF6S!69I8B.&C*\-GI[$U>L_%4LNOG1+O2VAO6T_\
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MHXPH.3@^O&9H6@ZKX4\5W%O8VT]WX?U%!/<2/+&&@NSP[A=P.U^I '!Z<<4
M:#>,V>VMM1M-)N+O2)[L6JW,!W2?>*>8(P/]7N'7.<<XQ7,6.HR^'?&GQ!FT
MW17O!$]K/)%"Z1*H%ON8Y/5CR< <G.<5=\(67B_PU8)X4;289;.VD9;;6/M*
M;?(+%AF/[Q< D8QC..<<FS;Z3J\6N>.KIM+F\K58XA9D2Q9D*0^6<_/\O///
M;\J -A/%8O8=%;2K"6Y;5[8W<)E)CCCC"JWSN V#\P &#SFLUOB-;#PSINM)
MI5W(EY?"P>-60F&3S#&<\_,,@XP#GCI61I^C>)K/3_"5C<Z.;O3;/3_LU[8_
M:8U G 4+(_S8D3 /'/7.,@51M_"WB6#P?9:4VBCSK7Q"+[$5S&081.9"1DCL
M0 .OJ!0!VNF^+?M&N:CI.I:;+IMQ9VRW@\R59!) 21NRN<$%2".?J:H/\0 E
MAHNHC1KF6RUJ80V1BF3S"S E-ZL55=P!(^8^^*2>TO(/B'J&OW=CY6D?V&+5
MYYY8P@99'D;<-Q(7#8SCUKE-&74M(T?2)=8\'ZH^FZ5_I<7EWT$D5L<$[U3(
MD(4,VU6)('N!0!V&N?$"STA=2DBBAN8],.+M3=I'+D*&81H?OD C/(YX!)!K
MJ+"^@U/3K:_M7WV]S$LT38QE6 (/Y&N'M[7Q7X7\2:Q%8:'#K&E:I=F]AF^U
MI";:1P ZN&R2N1D%0?QS@=W;+*EK$MPZO,$ D95P&;') [#- &'XD\4_\([>
M:5;'3+F[;4;C[/&T+* 'VD@')SDX^GJ155O&;Q1VUM=:?%8ZO+"\[V=[>QQK
M$@<J"9!D'=CC /?.,4WQCIVI7^K^&9["PDN8[#41=7#+)&NU-C+QN89/S9_"
MJGB&Q\0Z7XT@\2Z'IJ:M!-9"RO+$SK$X"N721&;@_>8$?Y !8TOQ];ZYINF3
MZ7I\\MS?7$MMY3MA('C4E_,D4, ,#@@'.1^#H/'MG)HLE[+;^1/'J9TIXI)0
M$%P&V_ZSIL[[L=.V>*J:S!XJO)-#GDTM9[(S2MJ.EP7**0I4"(,[%1( <EAT
M)/0@5F:3X=U:STC6]-U+PM;7=A>ZU+<-:I/&P>WD&04SM *D+C.T\< =0 =9
M<>)SING75QJE@]O+%=I9PPQ2"3[5(X39Y9(&<E\<XQM.>E-C\4/#XA30]2T]
MK>^GMVN+3RIA(ER%^\JL0N''&01C!SFN,?P%K2^'[FVTZ29(K#5;?4=%LK^<
M.R"(#=&S@G"DEMHR<<9ZFNFETV^UWQ9HFNW.F3V,>CP7#+#+)&TDLLJA=HVL
M1@ -R2,DCZT 48?B9YNAV>MMX?O(]+EN_LL\[RIF ^:8@=N<L,XSCIG@G!K5
MUOQ?)I3:PT6E2SP:/;K<7<KR>4&5@6Q%D$.0JDGD#D#.:Y'_ (1CQ#_PJ3_A
M'_[(D_M'[?Y^SSXMNS[5YV=V_'W>/K^=7?$>B^)-9NO$]M-HZWMM>V'EZ5)+
M<HL=JQB(92F3B0N?O '/ W 4 -UB]1?B;X<U?3-->\GN]'N&2./:CR@F,KN9
MB   3R3QVR>*9XG\16WBSX7>+8KG39+/4--B>.YL[G:[0R!=RL"."".0PJY;
MZ3KMGJGA+5Y-(:06&F265U;03QF2-F"8;YBJD?(<X/?O3-6\*:K=^'O&ES'9
M[M4\1!4CM%D0>4B1B--S$[<]2<$]<#.,T ;\OB2VTFSTJP#6YO9[,2HEQ<"%
M BA02S$''+   $GZ D6/"?BFT\6:9-=VT;126UR]K<1,P;9*G4!APPY!!'4&
MN=U33?$FGZKH?B/2-*6]EAL/L%]IDDZ1N4R&#(^2N0P]>1^G8:-)J,]D9]3M
M8[.:1MRVJ.'\E<  ,PX9N"3C@9QSC) 'ZQJUIH6D76IWTA2VMD+N0,D^@ [D
MG  ]37!ZQ+=7'Q3\!SWFD):2.;PK*)1(VW[.WR/@#!'7 R.3@UTOCWP_<^*/
M!E_I5E*L5W($DA9_N[T=7 /L2N/QK"GC\3:WXF\(ZI<>&WLO[-DN#>"2[B(!
M>$IE-K$E<GV/M0!;LO%.CZ?#XLU+^R&L&T^["WA)3=<2;%PQ() ^\HR3[GO6
MO)XF_L^TU&[U>T6VM;.WCN!<02^<DRN6 "':"6RH&,?Q"N?L=*UFUD\8RRZ"
M+E-2ODFAMYI8BMQ%M1'4_,0"55NO'3Z5DO\ #N]FTGQ%I.D_:M*TB]MHFM+*
M[F$@ANEDWDIM9MB':@//4GC % ':Q>([F/6([#4](FLXY;5KE+D/YD:!?O+(
MP ", <]2/>J$OCN.VTJQURYTZ2/0;R1$2\\P;XU<X21X\?*C$CD$D9&0*2Q?
MQ-XETJ?3M>T9-'CDMI(+F1;E)C,S(5_=A?NKSNR3G@#!Y-8G_"-Z[J?PX@\#
M:CIQB:,0VLNH+*AA:"-U.]1NW[BJ@8*CD]<4 =;:>)&N/&-[X<FL3!-;VZW2
M2M*")HV;:"HQG@C!ST/K59_&,,5E8RSPPPSW\DBVB2W(5'1.LA<CA2,$<$_,
MO'/%;QCX:U#4]2T;4M&E$%Y;R/:W$F<'[+*NV3'JRD*R^XJ/Q;HVKV]_H.M^
M&K*&ZET@2P/IS2"(302*H(5CP"NQ2,__ %J *K_%*RCT+4M0_LZ:673;Q+2Z
MA@E215+L%5U8'YE.X8P,^PJ]<>-;^PNK*/4O#=S90WE^+&*>6YC*@L,HS;<X
M#<COR,>E9_BJS\2^)?!%S!_8@@NY[BW:*R6XC8QK'*KLSOD+D[2,#.,#U..C
M\5Z7;:_X/U"SOF-JDD!D\QR,V[K\ROD$\J0#P>U %R'4WFU^YTQ+?,=O#'*\
MX?@%RV$QCKA2?H1ZU?=BJ,P0N0"0JXR?89XK \%VE]#X:M[K5B&U6^ NKQ@,
M?.R@!<=MJA5_X#70,2J,P4L0,A1C)]N: .*TSXAG4+-]2DT*\M=)@-R+J]EE
MCQ 8<Y!4'+9Q_#D9..><36WC^S?Q#IVDW,4,1U)':UDANTFPRC<4D"_<;'H6
M!Z9K,T;PGJ5W\-M;\-ZC;M87%Y+=-$[2(XQ([.A^0GID9%7]$G\7:K:+INNZ
M'#IH2(QW-ZETD@G^4KF-1RN3@_-T''4\ "ZCX]-GX>/B*'29+G13(L<<XG"R
M.&<(KA"/N%B.<YP<[:UX?$33>*;_ $ 6>+FUM4NDD,GR2*S%0.F0<J<\&O,=
M;A\2:/\ "&?P[JVD1QQ:<]M"FH)<J4GC%Q'L*H/F!QC(..YSVKM[NPUG3_B3
M)K-EI9OK.]TV.T9UG2/R)$D9LN&.=I#=5!/'2@">S\>V%WX7T[66A-NVH3O;
MP032JOSJS@[FZ  1L2?3L3@&K#\2M-\K6%N8XXKK2Y8(Y5CN%DB?SF"QNLO
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MBW,Z;UC0!6)8K@\X W#KSC*N?$VNS^,/"]I;V"6]KJ%E-=26]U*T4H957*N
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MZ*X0_$5V\(:/XEBTA38WMRMM<M)=;?LA,ACWDA#N0,.O'4<<\;FK>)6TJZU
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M^@"NFH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;X>USP_I^O:%9VL5W97T\\UC<M,%$'F]5E4\X4DD%<Y]J6]\)7UC;^"]/TN
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MLM+&TCE58+MP5! SR#STK9&C7]_XHA\1WEI%!+9V3V]K:B;<2[D%F9@, 84
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M!I/,Q*YR7<@8QD* !GC)/I531_"4UCXO&OVNFP:27M'COK6VGS'=S$J58
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M".!?MVJSWT7E2E\))C .0,$8JWXQT)_$?A6^TZ%Q'=,HDM9#QY<R$-&V>WS
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M7D4.GS$DJ-I/?!.?6K$/AV^6?Q+K#Q0_VEK$*016_F_+$B(54,^.I+$G XX
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MRC&X8  QC-=+9Z%K-AXZU36(VL9;/4K:W67<SJZ21!AA5P1M;=U)X]#75T4
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M&]N_LA@U2Y6XC$,C,R80)@Y4#HN<UKZW:3W^A7]G:^7YUQ;O"AE8JH+*1DD
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M/7C$>C>$GLO&,OB(VMCISS69@N(+&1F2XD+!O,;*J 1@@<$G<<GU +/Q"O\
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MP &)X8G"XY)H TKJVAO;.>UN$#P3QM'(A_B5A@C\C7#>(%"_&+P2J@!1:WP
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MV=%<JFO:IK=]K<&@FR1=*E^S9NHV?SYPH9E^5EV*-P&>><\<<X__  L&\NM
M\.>(;6"WATN_NUM+]9T9GM'+%,Y# ;=XVY([@^U 'H5%<QJ_B>;1UUJ^D2*7
M3]/6*)$5&$CW#X^7=D_+\\?(7^(_W>:UMK_B$^(H]/:P6ZM+BV=TO!8SVR6\
MJ\[)-^<J1T(QSQB@#L**\ZT7Q+XYU_PA%XALK/1 DEI+(ELPE,DDJN0%&#@
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MD#RNNX( K+@!<9//WL8XK-^$6[_A5^C[@ V9\@=CY\E ';,RHC.[!549))P
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M.<[0!@ D D@8[YHE\'WVIZKHU]J8L!>:9=><-1MRPGFC 8")AM'!R,G<<X/
MSQU6E:K9ZWI<&I:?-YUI<+NCD*,NX9QT8 CIW%7* (K@2FVD$(0RE2%#DA<^
MY -<#%X$U>'P+X?\/BYL3+I5[#<M,6<+(L;[P ,<$YQ[8[YX]#HH YJ#0M07
MX@S>(I&MA;2Z<ECY2NQ<;79]V<8/+8Q^/M4_C/0)O$_A2\TFWG2">4QO')(I
M*ADD5QD#L=N/QK>HH Y.70-9N?%VBZY<36+?8;::&5$WKO,NW)7@X"[1UZ^U
M9$GP^U"ZTC6[:6_AM;NZU@ZQ8W,&6-O-\NT$$#<!MZ]\GBO0Z* .9TZP\526
M-RVN7NFRW1@:&&*S1XX<GJ[ELDG@8   Y]>,2/P1K$7ACPGI*SV)DT*\BN6D
M+/B81A@% V_+D-UYQCO7H-9^F:YINLR7D>GW0G:SF\B?"D;'P#C)'/!'2@#0
M&<#/6N&3PCKFEZGKZZ/>V!TO6Y'N)(KI7WV\[KAV7;PP/!P<8_GV5M=P7BR-
M ^]8Y&B8X(&Y3AA[X.1]0:GH X"+P3K$6@^$-.-W8R/H-Q'.[X=!*$1D"CKV
M8_-[=*L^(?!]]XE22UOQ8,BW:SV>H L+FT0.&VK\O)X(SN Y'!QSVU% '$?\
M(MXCTCQ-J=[X=U/3X]/U:43W,%["[M!+@!GCVD9R .">U74\.:A%XZL];6>&
M2UM]-.GL)78ROEU8R$XQG*]._J*ZJB@#ASX7\3:1XDU&\\-ZKI\>G:I-]HN;
M>^@=S!*0 SQ[2,YP#@G'%7I?#.HQ>,M-URSOXF2'3CI]R+E"TCIO5]ZD$#<2
M._'.>>E=510!P;^ )M2TWQ9IVJ3PK!KMS]IC>W+%H& 4+U S@HI[>E:/_"/Z
MMJT^BOX@DLF&DS"Y4VS,?M,X0JKL"!L W$[1NYQSQSU=% ' GP5J[>%_%FD-
M/9!]=O)[A) [XA$H ((V\XV]>,Y[5JQ/X@LO$&B6"R6$FG?9/+O(45C*C*K8
ME#< *2J+@\Y8]<9'4T4 97B;3;C6?#&IZ7;-$DM[;26X>4G:F]2I/ YQGI6#
M<>%M6F_X1$B2R!T)@TN7;]\1$8_E^7C@YYSZ>]=G10!P.J>"-6U*?QBR7]O:
MC7H8(XGC+%HO*7;AN!D,,@XZ ]ZL6WA_6+/Q7:^)=1O])@@M]+:SN8H8F1(T
M#A\J2W ^7DG&!V[UVU-DC2:)XI45XW4JR,,A@>H([B@#A]'TW3-5^(M]XCTJ
M]2YL1;Q>9Y#AX7N\,H<$<;EB(!]G%=RRAU*L 5(P0>XJ&SLK73[5+6RMH;:W
M3[D4,815^@' JM:ZYIM[J]YI5O="2]LU5KB(*?D#9QSC'8]#0!RGAOPGXE\.
MQ+H<6LV;^'(9"T#&)_MBQEMWE;L[0.<;N3C.,<8M67AC5M!OM<71KBS:PU:=
M[L+<%@]K.XP[* "'4D [<KCIFNDTK5K+6]/6^T^8S6S,R!RC+DJQ5N& /4&K
MM '$P>!Y=,U'PC_9DD'V'P_%-&5E8B28R(%+<# .<M[DXXJG>_#V]U6T\307
M5Y!;MJM['?6LT!9FMY8PH7((&X?(,].IKJ5\5:*^JV^FB\_TFY9U@S$XCE9/
MOJDF-C$8.0#G@ULT <2OA[Q/?^)O#VLZI=Z2CZ6DZ2I;QR-YOF*H)&2,?=Z=
MO]K/&7??#_7I_#?B#P[;ZCIZ:=J%W)=02-&YE7?()"C=L YY&<^W6O2'=8T9
MW(55&23V%<^/'?A<^3C6;<^?_JNO[SC/R\<\>E &5?>%_$=KXI;Q#H&HZ<MS
M>6\<&HV]Y"_DR%,[9%VMD$ D8)Z=ZLZKX7U6YO?#FH6VI0/?Z5+,\KW,3%)1
M*A5R IR,9^5<],#-:'_":>'2MNRZI$PN+Q;&/:K,3.V,(0!P?F'7UK>H 8WF
M+$=@5Y O&X[03[G!Q^5>>KX#UA?AW;>&/M-B9H;T7/VC<^T@3^=C;CUXZ^_M
M7HM% '$7/AGQ-I_BF\UGPWJ.G11:H(S?6E_&\B)(JA?,C*D'. .#C./RFE\+
MZW%XKMM7M=5MYD_L_P"QS?;(F9D;>6:2, @ MG!' P!V %=C5:_O[72[&:]O
M9A#;0J7DD()"@=3Q0!P-AX#UVQT#PMIK7FGRG0KW[5N =/,4!P%Z'G#DY^G'
M<]%K.@W^H>,?#VLPO;+!I7G[XW9MTGFH$.,# QC/O[5NV-[;ZEI]M?VDGF6U
MS$LT3X(W(P!4X/(X(ZU%;ZM976JWNF0S%KNR$;7$>QAL#@E>2,'(!Z$T <DO
M@_5O[&\86)ELMWB"6:1&#OB$21B/!^7YL 9[9]JR=9@OCJ_A[0K:_P!%CU/2
MM.\QH[TR*K$XC5XW0J^<(^0. #SG@UZA5'4=%TK6%1=3TVSO53E1<P+)M^FX
M'% ')Z&=?DL9M,@BT")K&:-]UBSFVF1M_F1-D95^A)Y^^I/H=7PKX63P[=ZO
M=1Q6]JFHSI*+*U),,)5=I*Y Y8\G  Z#MFN@MK:"SMTM[6"."%!A(XD"JH]@
M.!4M '-^*M!OM;O-"EM'MD73=02]<2LP,FU67:, X^\>?;I5:V\.ZI;>(O%&
MIAK-DUB*%(DWL#&8T* L=O.=V>.F,<]:ZVB@##\'Z-<^'O">G:/=2122V<0A
M\R(G#@=#@CCZ5N444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6'XAU'4+"6P%L;6"
MTED87=[<,,0*%.T*NX%F9L*,9QZ&MRN:\1^']1U+7-#U;3;ZW@ETUY<PW432
M1R"10I; 8'<H!QSW- &%9?$"[D\-M+-! VIOK;:);?(T<<DF_"R,A.Y1MRQ7
M.>,<9X:(M43XS6Z7%W:RR'P_-Y,JVY4*?.CSN7><C/H1P<=LEK_#6_ETC4+9
M];C6Z.LG6;"X2WP89R<_.-V&')&!CKWK7L_#FO/XSL_$>I:AIV^&P>SD@MK=
M\,&<-D%GXY4<_ACO0!5T;Q7K&H>&[P7 L8_$-MJ3:<T"POY2R;P =I?<5V'?
MG(XSZ4WQ7XHUS08=9N ;"%+"V6>TC>,RO>X7=(=JONC4'Y<D<'DG%;$/A*&'
MQW<^)$G8+/;HKVV/E,Z@J)?KY;%/H36-JO@?5KZZ\5)!J]LEEK\ 1O-MR\L)
M$>P*K;@-G?IQDXY.: )KSQ+KDOBG1M+TY+".#4].DNP\Z.S1,NSK@C</GZ<9
M]15:P\<Z@-#F2^BM7U=-=.AQO&K+#))N&)"I)( 4DD9YQC(SQ=M/"NK0Z_H.
MISWMG+_9E@]FZK&R>9OVY8<G&-HXYSST[9\OPZN[O1M7M)M2C@NKG6#K-E=0
M(<VT_&T$'[P&.O&<F@#6OM<UOPU!K=]K,%M<Z79V@N+>YMQY;R/SF(H6;OC#
M=.>]1VFM^(AXDTZVELS=Z==(XN)DL9;?[&X&5Y<_.K<CH"#S[5*OAK5=:T._
ML?%>HVUP;NV:V"6$+11HIZO\Q)9\@'/08X')RGAO1/%-@UO!KFOVU]9V8Q"8
M+<QRSX& 96+$' [ <G!)]0#8\1ZW!X;\.7^LW*EXK.%I"BG!<]E_$X'XUS^H
M^)-9\//H-WJGV.>QU.YCM)U@B9&MI)!\A!+'<N>#D ]_:NDUW1K7Q#H5[I%Y
MN^SW<1B<KU&>A'N#@_A6!#X5U.]M-%L=<O;6XMM)GCG62%&#W3Q@B,N#PN."
M0,Y([#B@#-TF/4I/B]XB62[M7B6QM ZFV;F,M*0H_><'DY/(.>@KM-2DNK+1
M[J33;1+BZAA8V]MO$:NP'RKD\ =!6/8:!J%IXYU37GGMFM[Z"*#R5#!D$>[!
MST).X\8%7_%&C/XA\,:CI$=V]H]W T0F49*Y]NX[$>A- '.Z3XKU&Y\71:')
M<6-VL^F-=K/!"RI',KJK)G<0Z_-V.1C!-8?]N>*/$OPTU;5;W^RHK!M.U&*:
M*))/,+)YB*RDD@#Y<$'TSGG W[7PKKT?B32]<N-2TXRVE@]E);PVK)&5)5AM
M^8XY7D]AT'>I=#\'7-AX!OO"U[>Q.+E+F,7$,9&T3%R?E)[%SWYH PK#Q!XC
M\.:9X1GO8].FT*_6UL2D*N)[=G0!'+$X89ZC QG SUK3E\1ZW/+XZL5EM+>7
M1H8VM)DA+??A,F6!;D]!Z>QZ5;M?"E_<6>AV&L7-H]IHSQ2QBV1@;AXEQ&S;
MC\H'7:,Y('( P7VWA2[&L>*[JYNH?(UZ-(]L:G=#MB\H<GALCGMS0!SUKX@\
M0Z+X#\$S0R6%V^I2V5HWFQ.K!9(P>6WG+<'+8[]*W9=0\4V,EK;:I<Z3 KI*
MS7T43,'DW#RHDA+[RQ7).,],#UJB?!6N-X<\-:7)J=@[Z)=V\Z.('4.L*[54
MC<>2#RWY"M;4O#VJS>,[37[#4;:()9-9RP7$+2!07WEX\,,,< '/& * .1O?
M%&M^(/"7@C58)[>Q?4=8A@N8EA9U9E=\'[P.W='G;UY'/'/6#7]1M_B#'H-V
M;0V7]CO?-*D;*^]9$0]6("\DXZ^_%8UM\/=4M/"&CZ0FKVK7.D:F+ZVE:V;8
MP#NVUP&R2?,/(QT'UK</AR_?QQ;Z]-<VTL*:8VGR1>607W.'9^N!R,;>>.]
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M<[CTQV^M:_\ PC.HV/BI_$6G7=L]S=VJ6^H03(R1S,GW9%(R5(R1@YR.^>:
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MA=,EL[.WGO?-02NDLP)6(#./E"G)YSD 8ZT =917FD/C;7CX8L-2E:R-P_B
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M5R#M)&0#].] #LT5Y7H'B;4M#\#:GJ][=)?W,FK36L"21[-TS3^6I8@_='7
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M#!( ZY&?7I7;44 <Q'X7NH/&=OKL6H1F*#3/[.6"6(L[+O#[R^[DY4=JRG\
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M.1VP!Z5M:AX;OK_Q)X>U@ZA;H=(68-$+=CYQD0(<'?\ +@#CK7344 %<-8^
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M,X +L3DG X R>!V&!5JBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>!L,/-=-P^;Y<[.1@]>,5MP:EKB^)+7PG<ZI#+?&VEU"YOH;8(1 ) D:*A+
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M)B+A=_1AD_*,= /0UJ7OA:\O=6\.:@=3A5]%WG:+0D3%T,9_Y:?+\I]^?RH
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M#H>JVL=CKFI7$\;385E$$*[C*JAB S J "2 23C Q5/2K76%\?>.H;74(VU
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MYXAO;ZWU73H([];.RF27S# @DNI)!C:L:%6R,%BQQQ@=* .CHKRV/QEXCN?
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MN!CD >E5O^$%G&B>&M,75D":#<13Q.;7F4QJ54-\_3!.<?I79TW>AD,>Y=X
M)7/(![_H: .#OOAM->:=KNFIXAGBL-4O#?"+[,C-%*75SEB<LN5&!QCU-;8\
M,W/_  E]IX@;5!(\%BUD8WMQ\ZLP9F)##!RHZ#&*Z.B@# \,^'9?#[ZJSWRW
M(U&^DOF AV;'?&0/F.1\HQW]ZL^)M!@\3^'+W1KB:2&*Z4*9(\;E(8,#SQU
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M:OP_U-[#1K"Z\4RS6^CWD5S:G[&@D*QA@JNQ)#$ XS@=\@]1W2.DD:NC!D8
MJRG((/<4Z@#FX_#-U#XHU77(]2CWW]LEMY36V1&$SM.=_)^8YZ9]JRX_A_-%
MX3T30$U=?+TF[BN8YC:_,YC;<H(WXZGG'7VKMF=$QN8+N.!DXR?2JB:D'UJ7
M3/LEV#' LWV@Q8A;)(VA^[#&2/0B@#S#5[RWO/&>K//XPM-$N89$@CM=4T^*
M7<$4?/$9,$*S$D!2?7O@>B^&I]1N-$C?5)$FN-[A9D@,/G("=K["25R.<?\
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MK0 2JX8LJ[\_=!/H"0 ":L^'[/5;75-9>]U&XO+*:</:"XC"&+EMRKCDH!L
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M)SWQCJ,_1O$>NW?A_P"S:EJT,-WI^NR:9=W21?O;Q$&0(453^\;*\ = QXH
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M'2/,UR$,B[85"GYV*@G X&X\8JC/J^H:G\-/B%;ZA)-(=/>[MH3.$$@C\E6
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M5;+7[V*^&LW,4$L@B<!U2/:S90^@&!QCH!6CX?\ $-]XBTCP[!%>SPZD7?\
MM7Y8]Z>1\LJL-N!F0H!@ X;(Z4 =Y16-XKN=4M/#5W<:-;R7%['L*QQ %V3>
MN_8#P6V;L9[XZ]*XY/'4*^'-3U+2]4N+MA/;6BVM]$$GL9)) C!U('][<,D@
MD$9Q0!Z/+)Y43R;&?:"=J#)/L*S?#FOVOB?0;?6+*.:.WN"X19E <;7*'(!/
M=363I<7B:W\4YF>:30Y;<AUO9(C+'.#P4\L<J1U!Z'I7(^$-:N--^''A&PM
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M[J8XCG(^;&Y@IY )P,#KBNPHH X1/AE!'I<&FQZ]J:6EI?K?648\K_1W#E\
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M>S:C D;<$>A)K%DN-;G\(>.=0;Q)J:W&C:E=_9&1D7B)$958!<%>V.!R>,T
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MP3Q[YWKV#5+7XCV.DIX@U(VFJ6$\LZLR$HT;)@Q_+A,AL<#I[\@ ]!I"<*2
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MV@8'LP/G<,#R#7:5@R>)HYM8N=*TJSEU"ZM,?:F1E2* D9"LY/+8YPH..^*
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M23C&<X/ %;/AG19=0UOQD+B35[*WO=0)"^48DN(?+5<AG3(YW#*D']*ZF_\
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MRR+_  +C QU//3 IM]X,TR_UR?5GEO8IKFW%O=1P7#1QW"#.W>!R<9/0CTH
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MGG"UD)D4N,_P_*&V]..,5NW'@;3+BTA@:>[4QZ@-3:1'4-+<@Y$C?+CC X
MXZ5)=^#--O\ 4M0O;R6ZF?4+/[#<1LZA&AYXP """2<@YYH Y?1[^^M?&OAF
MV2YU&2SU#39S,]Y,S"Y=!&1*L;,3'G<>.#@XP,55M/\ D1?BE_U_ZG_Z(6NJ
MM/ .F6MYI-X;W5)KC2T:."2:[8DHP VMT! VC@8SWS4T7@JPATS6M/6[O3!K
M$DDMWEURS2##D';QD<<=.V* +OA7_D4-$_Z\(/\ T6M:]5-,L(]+TRVL(I))
M(K>-8HVD(+;5& "0!G@5;H **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L+6O$;:/K>B
M:<;%I4U2X: 3^8%$9",W3J>%]OK6[7"?$" W6O\ @R!9Y8"^J.OF1$!U'D2=
M"0<'WH [NBO(]4U75? >H>*K&TU*\O;*+28M0MVO93.]I(\IB(W-DD=7P<]/
MKGJ;#2-7MO$NFZE#J,<6FR1/'<6SZA+="Z)7<C)O "L,$Y'4?2@#LZ*;(VR-
MG"EMH)P.]>?>&TN/%7A#1O$YU^ZL[YY_M5Q(DK&(H'8- 8RP0+CY>F<C/)H
M]#HKS[27G\96_BN:>_O;6YL]2GL;3[/<O$+81*NUMJD DDECNSG..G%8FG:Q
MJWB6;X<W5UJ%[:-JMO=B\CMY3&LNR/AL#@$\G/;/&, @ ]<J.>>*VMY+B>18
MX8D+N[' 50,DG\*\TL#KBZ5XQT?2;V>YGT_5(TLUN[MO,:,B-VA$K'<,@LH.
M<C=U[UEZ[J5CK?PZ\9Q;-7LKVUMD:XTR_GDW6S@'!4[CNC;KCH<9QR* /88W
M66-9$.58!@?4&G5YOK5G/!KO@;3[35=3MK:\:=)T2\D.]1;ENK$G/H<\=L$"
MK.DVLVD_$P:"NJ:G=6*^'_-(N[MY"TGGE=^2>&V\9&* ._HKR32_$.I)X:T>
MT>\FD:_\07-B\]Q=.K>6K2E(_-Y922BKD<XR!CJ+>OW&O>!]&UV]_M*-;>Z:
M!;.W:Y>X:R9W6-Y \@R5^;< > <=J .SU'Q&VG^+-%T,V+.NJ"8K<^8 $\M-
MQ&WJ>WI6[7G>K:3#IOQ1\#M#/=N'2^5A/<O+DB$?-\Q."<\XZ\>E>B4 %%>2
MZ]J-Y;VDNJZ?JE]=O'X@CC-Z)FBA5#,J&W6/<0X4$J3@ G)R36P+&?5_B3XC
MTNXU?54L5L;:588+MXPC,9,[2I!7H. 1GOF@#T*L+3/$;:AXKUG0FL6@.FQP
MR><T@;S1)NQ@#IC;Z]^U<'X?\2ZCJFB_#[2KV]GSJ_VDW=RLA625;<':F\<@
ML=N2#DX//-;?A6RCL/BGXPABDF>,VUBRB:5I"N1)P"Q)Q[9XSZ4 =]15/5IA
M;:-?3M>+9".W=C=.NX0X4_.1WQUQ[5YYI5Y>V7C#PE%%<:B]IJ&G7'GO=SLQ
MO#&D;"7RBS>626)'(.&P0,4 =EXP\1-X4\+WFM"Q:\%JH9HED"<$@9R?KZ&M
MP'*@^HKQ;7)F\4_ ?4O$]W=W1O+H/+L2X<1QJ)MHB" [<!0 <C)//6NLO()[
M[XL#3)-3U&.PFT%IWMX;EHUW^<JY&T@J<=P0??DY .^JE-=7J:O:VT6G^;92
M1NTUWYRCR6&-J[.K;LGD=,5Y%,VI1_"_7]5_MW5C>Z%?W,-E+]K<86*; W@'
M]YD<'?GCIBNTU&YNU^*'AJ)+RY6WN["Z>6W$A\LLH3!V],_,>: .VJE<W5[%
MJ=C!!I_GVDWF?:+GSE7[/@97Y3RVX\<=*\FN1J#>"/&VJ'7=7%UI&K78LF%X
MX$8C*[00#\PQQALCT R<];JMY>#Q_P"!REY<)#>Q79GMUD(B<K &4E>AP2>M
M '<U#%=03SSPQ2J\ENP651_ 2 P!_ @_C7G":M=:;XIBL_$:ZC;FYU1CI^JV
M]R[VERK.=D#H&PAP0N".JY]2<^SG/AG3/B3K-B;@W5E?R^3YEQ)(H)BC^9E+
M$,03G)!.!CI0!Z[17$6FC:LNMZ7J5OJJP:=+$\=S&=2EN?M89<HZ;U 5P><K
MU'L*Y32KG4;#X8W7C!]:U6YU"R%['$DUR7B(\]D#.AR&*]03Z8Z "@#V*L+Q
M;XC;PMHPU'["UVGGQ0L%D";=[A 23GNPZ"L V6KZ5J-IK\%^@TY+64W-JVHR
MW7VW]V60IO4!6&"<CJ/I7+:XC:Q\'M.\175[=37UW<6EQ*1</Y9+W"?N_+SM
M"KD #'5<]<Y /9:I2W5ZFL6]M'I^^R>)WEO/.4>4X(VKLZG.3R.F*NUQFHS7
M4?Q:T>V2]N1:W&F7+O;B4^7N5D ;;TSR>: .SHKQ:Z.HK\/O%NL_V[J_VW2-
M6NA9M]L<!!'(H 8 _.,<8;(QT YS[-$YDA1SU9030 ^BN0U[_3/%L-@M[=SM
M]@=O[-MI6@"$N )Y)58$#@J!@G.2!P:Y?PWXEO\ 5-&^'VGZA?3_ /$WBN6N
M9Q(4DF,(^5-XP1G.20<G;[F@#U>BO/-=DNO"5K%9+KMQ+!JFMV\ ,KDR6,$N
M<J'))P2C ,>F[CI3_%CWG@;0O$6MZ=JEQ,&LU:WL+AVF$,@8(TJL[$X^=21T
MR/>@#T"BO/M?-SX:N_"FH:7?WMPM[J$-A=QS7+RK<1RJ?WF&) 8$;@5QQD=.
M*HZ+#<RW?BO4KK6-8F70]7EDM[=;M@KJD*MY;#^)3GIV[=3D [+Q9XC;POI4
M=_\ 86ND>XB@8"0($WN$!.<]SV%;M>.:Y&VK?";1O$-S?74U]=W5E<3$7#^6
M2\R93R\[0JYP !QM]<YVO&-Q,[>+7M-2OKBXL=-$D<=O,UO'IK+&[[BRM\[M
MPV-IX !P#0!Z317FD\]_J?B;P*DFJW\46IZ5/+=QP3F-798HSG Z'+MR.1G@
MBLZ'7[_1-!UBP_M&Y,,7BE-+CNYY3));VTAC+?.V2<!F )Z9'I0!ZY17%:[#
M<^$++7M<L-4N9472Y)(M-N)&F"RQC/FAG8G'*@@<=ZBT[3-8;4=#UJVU6..R
M9 +M9-0EN%O5=1M(5E"JV>05QUQTXH [JBD(R"#GGT.*\EOSJD%OXK\)PZGJ
M;:S]I2XT:7[=()&BE&54,6R539(#[#UH ];K,M=4F729+[6;1=,,;N&1IA(
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MB_M73Y'O!!,4$I^RA\D#C.2>>HSQ@@$ 'J586H>(VL/%VCZ$;%F74TF9;GS
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MX?,DDV*%WR-N9O<GN: ):*Y'7O\ 2_%MM8+>7<[&P=_[,MI6@"Y< 3R2JP(
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M* ,&/PE8*Z!YKN:VCNS>I;2R[HUFW%]PXW<,20N< ]J='X2TB/4M3O?)D?\
MM,'[5 \K&%R5VD^7G;DJ,$XK<J"YO+>T:!9Y51IY1%$#U=R"<#\ 3^% '/:#
MX"TCPY(6L)=0*HK+;QSW;RI:@\'RE8D*>V<$]NYJ[I/A73-'T2?1H4DFT^<R
M;X+A_,!WDEQSV))X]ZVZ* .9\/\ @31_#<P>R>^D1 5@ANKMY8[=3U$:L<+Q
MQGKCC/)JFWPR\/FPGTY6U"/399A.+*.\=88G#A_D4'Y1D=.W;%=E10 V-!'&
MJ*6(4  LQ8_B3R?J:RKGP[:77B&VUQY;A;VVB:&(J^%5&QN&W&#G Z^E:]%
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MY@.[=[YZ<=.*K2Z#IWA=K_Q#IFE7M]J+0HDD4=RSR3[> ?G;#, 3\QYQGUY
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MV,S3,&9!)*O)!^]A%^;KQUKU1?#>GIKMQK*?:%O[B$022"=\%!G "YP,$DC
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M(O)<*5;<H7YN%#$D <9YK2/AO3SKRZV?M']H+;?9!+]H?_59SMVYQUYSC.:
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MVKJ5GD@6=G#>9.@3KR% /\/;J:Z'5? /A_5];.KW%O/'>.H29[>YDA$ZCH)
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MR*H=TC7:0Q (ZE1GCWK;TK4[76M)M=3L9/,M;J)98FQC*D9Y]#[5PFI6NI^
M8?%.IVTME<:5J,KWB1S,XFCN7 4HJA2)-S;0!E>M3Z78ZCX6^%&CZ#&#_;-Q
M"+6-0P!223<[D'I\B[S_ , H Z#PQXNL/%4FJI9@@Z==M;,"?OC *R#_ &6Y
MQ]*Z"O+&$W@_XDZ/?MIJZ?I.KP)I$RK,'43(/W#<=\#9]*]3H **\OT[/BKP
M9XFU:\GFAU:WN[Q8IDE97LC%GRU7!^4 !21_%DYSFJD'VGQ1KG@DZK/>Q?VI
MH<\EY##<O&LC;8\$ $;<[L_+@]CQ0!ZW15>SM8M/T^"TB9S%;Q+&K2.6;"C
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MY/SMT7GIU_BH ]/HKRFRM+[QGX;O=476H-.U.WOYRUYM<RV7E2G"$;P OE@
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MS[65D!YV\'Z].,]!0 =:Y5/AQX5CMXH%TUA##<"YA3[3+B%\D_(-WR#).5&
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGE;1SC&S@COWKJKBW;Q=XO\ %6B7=S9H]HL,=M%<6[2/%&\0;S8\.N&WLWS
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M@?A0!TS-J?\ ;4:JEI_9?D,78LWG>;N& !TVXS[YJ[FN%N($_P"%V6O+_OM
MFWC><?ZZ,<<\<>E<%<:5:1?"77-857_M'3]7G:SN#(Q: K= #:<\<=?7OVH
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M/(*;W.20KLHY^@ H T-6UNY3Q!;>'],\A;^>TEO/-N49HT1&50"%())9O7@
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M"C><&T2V*32B9X_F\O>#G<$SM!SUP!GO5VZ\*Z'>ZG!J5QID#W<$8BCDP1A
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MXHC\\JI.%'/0#'3C@5TM<C+K^MZI?:O!X=CT]FTJZCMWBO W^D$JKOM=3\F
MV!E6R0: +^I>"/#.KZM%JFH:+:3WL8 $K+U Z;@.&Q[YJ[=:!IE[JEOJ=Q;%
M[VW!$,PD<-&",$+@\9'7'6M!71CA64G&< ]J$D23.QU;!P<'.#0!A:EX)\-:
MOK$>K:AHUK<7R8Q,Z\MCIN'1L>^:O'0M-;6QK)MO^)B(_*$_F-N"9SMZXVYY
MQTSS5\R(" 77).!SU/I2AU+%0P++U /(H S[/0M-L-2NM1MK;R[N[Q]HE\QB
M9<<#=D\X' ].U9J^ ?"BQF,:%9[//%P%V<*X.<@=ADG@<>U=$2%4D] ,UPUK
MXMUW5O"$OBK2+33KBT,<DL-BSL)65<]7&0&XSLV^V[O0!T;^&]*^T7]VEBC7
M-["8K@M(P$RX("MR>,' XX[4OAK0H/#>APZ9;*J0QL[JB9VIN<MM7/.!G SZ
M5IF14CWR,J+CDDX IV1C.1CKF@#.O] TS4[R*\N;8_:X5*)<12-%(%/5=R$$
MK[9Q4=WX9T:]L[2TGL(S;6;A[>)246)AT8!2.1V/45/JNLV&C:/<:K>SJEI
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MN+A!'-(F59U P%)'8#H.U0MX3T!M)BTIM(M&T^&02Q6S1@HCCNH[=3T]3ZT
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MH(0[81E?3J>GO77:Q)9P>/\ 2-")TZTTR33Y7M8IK8- ]QYB[@%!4;]IR/\
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M'EX"+P?</\/OCKWKLKZ2+5OB5JVAZG+8!!80-907UOYJR1MO\TH"P&<X![X
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M_P# A76*RNBNC!E89!!R"* (_M5O]I^S>?%Y^,^5O&['KCK1+<P0AS+/'&$
M+%W V@]"?2O&M3N+*?1M.U/3#'%;/XKC9);A]]U+)]HVN<\;%'("_,=N,XK>
ML="T;5/B1XU2ZL+6Y@>TLI-CH&0LR29?'3=_M=>3SR: /2&GB0@-*@+<@%AS
M3O,3S/+WKOZ[<\_E7D%EI<VH_!GPOX@MH5N-7T.)+RWW#+2)&2'BSZ% <#U
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MK8P^=>7,-O%G&^:0(N?3)J5'61%=&#(PRK*<@CU% %6[TK3[[3Q875C;S68
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M+Z*V,@5:GN(;6%IKB6.&)!EGD8*JCW)J'^TK#[/'<?;;;R)/N2>:NUOH<X-
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MTI]WH&C:A81V%YI5C<6<1!C@EMT9$^BD8'X4 >7ZGX>T&QT_PC9V$[:A9?\
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M0=$^#?BK1K@'[;9R7MF8\?-(\I/E8'4[O,7'KF@#L$\32:YX@BTG1;B*&/\
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M=\@'=@%R1VR*GU62X2XTX0:I;62FY E29 QN$P?W:9(PQ.#D9Z5R^D3VUO\
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M W$KD\C )X[#- $7]@Z/Y!@_LJQ\DMN,?V=-N?7&,9J\D:11K'&BHBC"JHP
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M4;9+/3+N*.*1PL*1HT:M@DGU;N:Z1M8TQ;**];4;06DQ"QSF==CD] &S@DT
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MJZ5IRW(N5L+47 7;YHA7=C&,9QG&.*H:QJ$4^@)=6'B&ST])FC,5^VR6-EW
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MZQIFEE1J&HVEH6&1Y\RID>O)Z4 8^C>$-.M(KAKO2=)1KEE=K6VMQY$948!
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M$VXM+AO0*0">,D9STI^F:W;Z5#=KK?BS2[M!();>=Y(HG6!\;/,P0I.20&
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M= 1NX/8&NNCMX8C(8X8T,AW/M4#<>F3ZU##IEA;VSV\-C;1P2'+Q)$H5CZD
M8- 'D-I%:6_PZ^&-Q$D,<K:O99D4 ,2P<-S[]#]*]<U=2VBWZJ"2;>0 #O\
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M7N*]6FTZQN;F.YGL[>6>+_5RR1*S)]"1D4Z2QM)IUGEM8))EQMD:,%ACI@T
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MP/0@^E>;26%UI7B[4/",$#G2/$3_ &Z-U'RP+D?:T/H&&W'H9:]-  & , 4
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M.W'SJ>.,FF7%AX9N["\NM(\07%L]_J4$B:P'62'[8H8K@'"L. &QP2P&<@X
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MIO.B6UM/%:-(^X;(8Q=R')/0#!'YT >O77B+1;)$>YU2TB1X_.5FE&/+_O\
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M]L#K_*@![V\,F-\,;;1@94' J2O.M<\=IJW@#Q'J?A^^DM;G3O-$3B,%F"$
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M(/&_A@V4]X-<LC!;R>7*WF?=;&<8Z] 3] 36D=6T\:;%J/VR$V<JJT<RME9
MWW=N.N>P'6@"[2;5#%MHW$8)QS6.?%OA]-,EU%]7M([2&0Q2222!=D@_@(/(
M;VQFI+;Q+HEY?W5C;:I:RW5JADGB20$HH."?H#P?0T :/D0^?Y_E)YVW;YFT
M;L>F?2@00K.TXBC$S#!D"C<1Z9KG]!\;:1KVF7.H17"Q003/&3)E3A7* X(_
MB(X'7D#K6Q8ZI9:D9A:3B1H&"RI@JT;$9 8$ @XP<'UH LR0Q2X\R-'QTW*#
MBE>*.50LB*X'.&&:H:CKNF:2^R]O$B?RS*5P6*QCJY !(4?WCQ3+CQ)HEJUH
ML^K649NT,EONF7]X@4L6'/*X!.>E &@+>$%"(8P8\["%'RYZX]*>RJZE74,I
MZ@C(K/TO7M*UJTEN]-OX+F"%RDCH_",.2#Z<<\URNI>*O/\ 'WA.RTO5R]G>
MO<?:+=4&V55A9D<,5R5R.H.#B@#N8XHXAB-%0'G"C%*% )( !)R>.M<G\2]1
MU#2/ 6HZCI=Z]I=6_EE715;(+JI'S ]B>G-:^G^*-"U74[C3;#5K2YO;?/FP
MQ2@LN#@\=\'@XZ4 :,%K;VH86\$408[F$:!<GU.*>L:(S,J*K,<L0,9/O6:_
MB/1X]0CL'U"!;F20Q(I. T@ZH&Z%O]G.?:JUWXS\-6/VG[1KEBGV9Q'-^]!V
M,><''?@Y].] &V8T*,A1=K9W#'!SUS2211R@"1%<#G##-5KC5;"UM(KJ6ZC\
MF;'E,IW>;D9&T#);CGC/%<]XH\<6.E>!+[Q!IEU;W16)Q;$-N5I!Q@X]#U'!
MXH ZKR8OD_=I\GW/E'R_3TIGV6WP1]GBP>HV"N+AD==>TV<>/7-I<NH33Y8H
MB]Q( 0P5L A3P2 .".HK9T_QCI>I>)=3T6&4"6P"!V;(#,0S,!GL !S[GTH
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M!C/'X<XZXJ+Q/KUIINE7\8U-;2]CMFE5U4.8N#M9@00H)&,MP>: -X *
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MNS+\K+MX''#'GGZ4 <?K,%L?%/C/6+)X1IQ\.&VNYE8>7)='>0,]"P3:#_O
M=Z@OT ^#WA+4-/A2:VLFTZ?45MU#,T$>&D4@<G#?,1[$UZRD:(@1$55'10,
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MWKC_  OJ7A/Q"FAPM;Z@^NZ849K.>:X!L9%&'9MQVA0 >O!X&,G%8=U/9O\
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MJZ-S<HTT@ +!9G4= !T Z"K<WBZQ7QFOAD><+@VIG:01-A2755 .,'JQ)Z#
MK(^$LT4G@6-$D5F2\NBR@\C,[D9^H(/XTR\NX=/^-4$MTQCCN=!\B%BI(>07
M&2HQW .3Z#F@"#PIXTM+*TU*'Q'K@:X76KJTADGP#L638F=H 4<8R0!G-=GJ
M6M:?I(_TR<J=AD*I&TC!!U8JH)"CN3Q7D%W<6DGPC\?JDL+23:Q=L@!&7W3
MH1ZY R/I6[J&MZ9HOCZZN_$%S=PZ5JMA;?8;^":58BT>_=&QC/4E]PSZGUH
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M5;-_H=AX@\4:!XQ-_$^H7CS6P62X\N]@D15"J(SAF &W&,]!VH ]9#"2,,C
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MKN(P3T  /- &[XSUV4^']$U70M586]SJ=I&7MRK+/$\@!!)!(_ COFM4>,+
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M8#2[I/E#=,X8?0'->HT4 >8^&=3\->('TA6T_4SKFG$-);W;W(%@ZKAV)<[
M." .^0,#G&K\+WB.DZRJ8#G6KR4C&"5:0E6]P1T-=S10!R_Q$L[^^\":G#ID
M+SW2B.584)#2A)%=E&.<E5(X]:QM U?PEKFIV^LV%OJ$EW8PN9KB]:X_T)2O
MS(3(2I8GC:,]">U>@T4 >4:?-'X9\8V_B(P*NB>)'?9&H):QD;:?-(["3:-_
M VG:">.='2M4TJP^*'C@ZA<01"2*QVF7&'7R3D#UZC@<FO1JYW2/#EUIOBS6
M];DU"&9-5\G,"VQ0Q^4I5<-O.<@\\4 >9V-C<^#=(\(ZAJ]IJ":/%]M2X6W:
M19+)9Y \3,$(;&!@CMG'6M+Q,FA2>";J[T2SG6WO]5M)6FG\TM=LLJ%W"R?-
MM"C[W?![ $^N44 >=ZG<VA^*TTS@3VQ\,RQN$/$A\T-L!'\17) ZXYK+T:'4
MK>Z31=#UG^V='NM,N%MGG4?:=*.P!$=QS@G PP!^7_9KUBB@#R;PG>>']7L=
M"T>^TO56\0Z6\.^QN'N=MM+%A3+DGRPH )'KG '-/T]YM,\06+^'=1-YIU[J
M;+=Z%=H&DLF9F+S1G[RJ#EN>#G@\BO5J* "O$KB<)\%?%.CM',M_'=W2M"T+
M [FN"R@<<DJ<\9XYKVVB@#S_ %2ZMV^)OA&:W=)(UL+M28R,?,(]BD]!G!P/
M:N075HKW3O!]W]GN;8VVO*9]-M[)UBL!B4;,!<ELD9))R2<  XKV^B@#A?"T
MXMOB)XQM)HYDFN;F">+,3;6C\A1NW8QC((Z]>*UOB P'P\\0H?O2:?/&B]V8
MH0 !W)-=)10!YC?3VQO/AFP="L+$N>T8^SE1N_N_-@<]^*I:GJ"VFJ?$VYCT
MZ/5 T=D4M7C+I,!&%<X'W@AY8#TQQ7K=% 'F.B7T,WQ:M;N.ZO;Z&ZT$QQW4
MEJR([B<,0H"@!0/_ *Y)J;2M)O=/\97?A183_8*W"ZU"_P#"BEB?(QVQ. X]
M@:]"NXIIK*>*WN#;SO&RQS! WEL1PV#P<'G!K-T#1KG2H99=1U-]3U*<*)KM
MH5BW*H.U51>% RQQSRQ/>@#8KS32KRPTR_\ '=GJL>)KR_>6&T>,[[N)H44"
M-<?O,D$<9KTNB@#QBUMI_ DOA>3Q.M^NFC118S7%I)+BUG\S?A_*.=I!"]^5
M'I7I'A&VTJ#2II=&L9K6RNKA[A3,9-TY8#,A$GS#)!Z]<9[UOT4 <-\0)8TU
MCP;N8#R]:25_]A/+D!8^@R0,^]4;&XMD\:?$621T5)+>U"NW1]L#*P![X) .
M._%>CT4 >+Z-J3^'+#P#KM]%.^D6^ER6%VZ1LYLY6V$,Z@9&=FWIQ6YXNGLK
MOP<FKZ7IK0Z?'K5K?32I;%&G59%,DY3 8CW(R0N>F#7IE% 'G-KK-E=_%R?4
M(FE^POX=15N6A<1MB=SG<1@#'<]<<5CZ48T_9KEMMNVX&FSPF';A_,);Y=O7
M<<CCOFO7J* /-?$\CQ>$/"6KVMO<76GZ=/#+>163,LBQ>2T98;2#\A;H/?WK
M+\10:;X@\(:YJG@^PO;R:5+<W-S(9]UTD<BL8E$O+84'./7'.2!Z]10!YG?>
M)-,U[Q[X%O\ 37FG@0WGF,MNY\HM" %;C@YP".W>O3*** /%;*WCU+X'IX12
M+=KSLT(L60K+#)YY8.RGE5 ^;<>,=^:ZSQG;ZCH.L:3XHT>#[5=[1I=U%G'G
M+(<1,?\ =E*_@QKOJP5T&_E\1OJ%_K4EU81R"6ST_P"SHBP/MVY+CE^K$ ]"
M<\X% &EI.GII6E6UBCE_)C"M(W5VZLQ]R<D^YKG_ (@Z9<7.@+JVG ?VIHLH
MO[4]-VP?/&?9DW#\JZRL'6]!O]9U"(?VW);Z.8C'=Z>ENA^T<Y_UA^901\I
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M$F5D [IT??TQDYKV2B@#S[3GCM?BY=FXN$8Q:!!"\[G 9UD<N,GOC!(]*I^
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M7KE% 'DHO-)TW7O$N@^+K?5,ZA>R3VHA-PT5[#(H 0+&<%AC:01Z5:MM4MO
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MA7RI9BV#DY'7C%07OCK6(=(\)^-O.:+P]=[8M6LQ&A$);*B0,5W;0W7GT]:
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@"CK.FC6-%O=,:9H8[N%X'= "P5@5.,\9P:YK3? #:5X8M_#UKK]
M^FGPY7 CBWNC,69"VW.#D@XP<5V=% &!J'A.QU@2+J9-S&;^*_C4J!Y<D84
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M^J6-U):#5;86]Q:Q1J(L 8#@8^\!GGIR>*?HG@LZ'HNFZ/;ZQ=M86,@=8V1
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>thackray-biocrystseparat010.jpg
<TEXT>
begin 644 thackray-biocrystseparat010.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5HTCU&QMKM(VWHL\0<*WJ >]-31M,CU$:BFGVJWP3R_M(B7S-O\ =W8SCVH
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MTV@C Q[4 <+J\&F>'O'.AZ0GV32-(N+:YDMP85\DW9=,\'Y0VS('U('6H_\
MA&Q9Z;':>&->MYKN'69+RV@O$!M7D,;%X%"=% 8L,9VD'N./0=3T73-:LA9:
MG86UY; @B*>,.H(Z$9Z&HV\/:,]A;6)TNT^RVIW6\0A4+"?5 /NGD\CGF@#R
M^Y\0(-+TL7=@N@VJ>(GMM8B.V2&.;RRRG/0QEV1LG@'Z5+XNT'2+7PEXWNK;
M44OI+JS2XF@C1/)AD485U"\*[ 'W.,UZ>VBZ8^F2::^GVSV,F=]NT0*/DY)(
M/4D\Y/>J\/A?0;?26TF+1K%=/9MS6P@7RV/J5Q@GZT <9-I=AIGQ#\$/96D,
M#WMG>I=,B_-< 11L-YZOSSDYJ;X=R:5I>G>([F9[*T$6MWZO*Y6/9&LO0DXP
MHROMR*[+^P-'^T6MQ_9=GYUH-MO)Y*[H1Z*<?+^%5[SPSI$]OJ*II.G>;J&/
MM+26RD3$'(+XP6QUY/7N.M &NCQS1*Z,KQNN593D,#W'J*\?U'0$-QXG^'D%
MK$O]J2KJ>FNT?RPH_,AXZ!7CP/\ ?4=*]7TO3X=)TFSTZWSY-K"D*9ZX4 #^
M53&V@-T+HPI]H5#&)=OS!202,^F0#^% '!^%]7A\0Z1_PD^HVS0?V9I[6LFV
M/:\4P&;C;]-J 8]&%<]ISVL.N?#:>V-M;64L5SY*%PTYA-NS9F?@$D@$C& V
M>37KD-I;V\+PPP1QQNSNR*H +,2S$CU)))^M9D'A+PY:K$MOH6FQ+#-Y\82U
M0;)/[PXX/O0!Q?@;PMH-_>>*);K2K2=K7Q%<B /&"(AL3A1T .3D=^/05@Z!
MI?AJQ^!D6MZE9OYAM);:2XMFVSE'G*A YZ G:.> ,^IKUNUT+2;$7 M-,M(!
M<DF?RH57S2>I; Y_&DAT#1[?2Y=,ATJRCL)01):I HC;/7*XQ0!PNG11?\+=
MN;.\&G".X\/();6W'[O_ %V%5L_?(!X.!P1Q7*Z5IEC;_";P1JT5M$NHKJMH
M!=8_> &X*E=W7;@GY>GM7K\/A?0+8PF#1=/C,,30QE+= 41NJCC@')S]31_P
MB^@?8HK+^Q=/^R0OYD<'V9-B-_>"XP#[T <OH-M8Q?%OQ>[0VZ2B&P:,E%!#
M,LFXCW/?'6M+QQ/8K_8-K=1O+<3ZI']DB,OEQ-*JL1YIP<J.N,9)"XK?_L?3
M?[334_[/M?M\<?E)<^4OF*G]T-C.*74])T[6K46NJ6-O>6X8.([B,.H8=#@]
MZ /'-02"3PI\4K69[2;RKCSD6% J*_DIN95R<'=U.>M=+)IMEI7Q \"36%K%
M;RW=K>)<21C#3@0HPWMU;GG)S7:-X7T!Q<!M%T]A<JBS@VR8D"C"AN.0 !@=
MJE_L#1S/:SG2[/S;0;;=_)7="/1#CY?PH \@GEM-:^ .OW^HI#)K!EG>^:0#
MS([@3$*#W&%V@#TP*]FCGCBTM9V;]TD(<LO/ &:S[GPCX<O+R>\N=#T^6YN!
MB:1[=2TGUXYK6A@AMX$@@B2*%!M6-%"JH] !TH \;M9[*-OAY>V+P6]C)?2F
M#S9 ]RT;1R%GEDR!R>JX.#C)-7M1LI-2C\>Z(5M[^ZO[L"WNFN(U$!,:;4;<
MP8>6?F^4'KQSD5Z#%X1\-P($BT'3443BX 6U0 2C.'Z=1DX/O7'2>#[NXU.]
M;6/!OA_69I[AY%U*2<1L4)^574QDC:N%X)Z>N30!%JWAC28O'G@C3)K&UDA-
MA>Q3(L05)MJ1GYE'!&2QQZFFK!IA\;:YX9O;FUL+6*QMXM/MYXD*M:["'$>_
MT?.<>@]..STKPEI6GVM@);&UGNK)2(9VB!:$$D[4+995&< 9Z 5;U;PYHNO-
M"VK:59WS0G,9N(5<K],CI[4 ><VSV>E^(O#>B3:V9-)&E2II]Y?(CK/*)<$9
M/RD^7M"GNO3[W/:>"=)L-%TFZLM-U![VU6\D96.W9$6P6CCV\;02>!T.1VK5
MU/0M)UFR2RU/3;6[MD(*131!E4C@8!Z?A5JTM+:PM8K6T@BM[>)=L<42!54>
M@ X% 'D7CB:QN]$^($UEY2O"T<=U-=MN<S(B[4A7C8HX(8DY;=@=ZV/$::B;
MN?6=,CT_7+8:7'#J>DW+8<Q N=\3\@$_."#UV^H&.VN/#.A7=Y<7EQHUA+<W
M,?E33/;J7D3&,,<9(QQ1)X8T*0H6TBR^2(0+B%1^Z'1..J_[/3VH ET&[M[_
M ,/:;=VB2);3VL4D2R#Y@A4$ ^^*\YM;<V%Y\3KG1[.%=1M2#9F*(;HV^RC[
MN!QSV'4UZJJJBA5 "@8  X JC9Z)I6GW4MU9Z;:6]Q,<RRQ0JK.?5B!D_C0!
MYKJD-L_PT\(:OH*H-42>R-I-']^1W(656/4YR^X'K@D]*Z/1_P#DKWBC_L'V
M7\Y*Z2U\/Z/8W9NK73+2&<LS[XX@"&;[Q'H3W(ZU(NBZ6E]-?+IUJ+N==LLX
MB4/(/1FQDB@#R#3KQ[;X9^$%EXTN?Q \6H$_=\LW$N _^P6VYSQV[UU]UIJ1
M?%NW@M((_L=_I$O]J6X4>6X5@(V9>FXY*YZX!]*ZV'0-'M]-ETV'2K*.QESY
MELD"B-\]<KC!J6PTK3]+1EL;.&W#XW&-<%L=,GJ<=O2@#QFXL+I/#5SX9L[2
M.74_!U\]_"\D>=]NA\R(?5U<KC_IFW?%=E-#:^+/"VJZ['<KI_\ ;"16]I=2
M19*Q!@$##NK2,V?56%=VMK D\LZ0QK+,%$CA1EP,XR>^,FH)-*T^72QI<EE;
MO8!%C%LT8,>U<8&T\8&!^5 '&>'+EIM6U[2/%&C65EJ'V&)KR>V?_1;NV_>*
M'YP5ZN"&YP/:NSTJ"PMM)M(-+$0L(XE6W\EMR>7CY<'N,=Z9#HNF6]O<6\=C
M (KE=DZ[ ?,7&,-GJ,$C![59M+6WL;2&TM(4@MX4"1Q1KA44<  >E $U%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 445!=WMK80^=>7,-O%D+OFD"+GTR: )Z*R[Z_EET8ZEHLL%X(U
M,JHC!DN%'50PZ$]CZ]:L:5J=KK6DVFIV,GF6MU$LL;=\$9Y]#ZB@"Y117%>/
M=?U[PLEEJMH;-M$$Z1ZB7MF>6WC8@>8,. 0.XQQQUH [6BN?UG4M1>ZTJST&
MYLS/=MYLKS1&5%MP.9!M9>Y4#GDMZ D:EWJ=CID<9U'4+6V+# ::58PQ'7&3
M0!<HJO)J%E%)#')=P))/_J5:0 R?[HSS^%+#>VEQ/+!!=0RS0G$L:2!F0_[0
M'3\: )Z*BN+F"T@:>YGCAA3[TDKA5'U)IEI?6=_ 9[.[@N802OF0R!UR.HR.
M* +%%9O]JVFH6UTNDZE937,2$Y1Q,(SVW*K _J*QO!OB<:CX'T75=:O;:*ZO
MHMQ+LL8=LGA0?PH ZNBJ-SK6E68F-UJ=E (2HE,LZKY9;.W=D\9P<9ZXJ>>\
MM;:U^TSW,,5O@'S9'"I@].3Q0!/15(:QIAL1?#4;3[&3@7'GKY9/INSBE_M;
M3?/B@_M"T\Z8!HH_.7<X/0J,\Y]J +E%<AX^\27&D>#-6U'0[ZT^VV!02 @2
ME,N%P1GY3R>N>G2NFOM1L=,A$U_>V]I$3@//*L:Y^I- %FBJ\E]:168O)+J!
M+4@-YS2 )@]#NZ8KF?"WB*ZUCQ;XGLGO;6[L;$VWV1[91MQ(C,V2"<G(QG/;
MH* .NHJE!K&F7,IB@U&TED&,I'.K$9XZ TL^K:;:WD=G<:A:174I CADF57?
M/3"DY- %RBD9E1&=V"JHR23@ 54AU;3KBVDN8=0M9+>+_62I,I5/J0<"@"Y1
M5.XU?3+6UCNKC4;2&WE&8Y9)U5'[\$G!ISZE8Q+ TE[;(+@@0EI5'FD]-O//
M4=* +5%5UO[-[B6W6[@::$;I(Q("R#U(ZC\:CMM6TV\G6"UU"TGE:/S1'%,K
M,4SC=@'IGC- %RBH);VT@N(K>:ZACGE_U<;R ,_T!Y-,74K%S<!+VV8VW^OQ
M*I\K_>Y^7H>OI0!:HJE#K&F7%U':P:C:2W$D0F2))U9VC(R& !R5([]*R_&'
MB"/1/#^I2V^I6-MJ4-I)/!'<,"7*J2 $W G.,?XT =#16+I>MPCPGI6J:M>V
M]N;BTADDEF=8U+L@8]< =ZT#J5@(()C>VPBN"!"_FKMD)Z!3GG/M0!:HK/.O
M:.+:.Y.K6/V>4D1R_:$VN0<'!S@X[U2OO&&AV&KZ=IDVHVPGOD:2/]\H C"Y
M#DYQ@\ >N>.E &[15.35]-AO5LI=1M([MB L#3*)"3T 7.>:+G5M-LC*+K4+
M2 PH'D$LRKL4G )R>!GN: +E%0&]M!9?;3=0BTV;_/\ ,&S;Z[NF/>N5T;Q-
M<:EX\UG3DU"SN=,M[*&>!X "%+,X;<P)R1M]OI0!V-%9&DWH@T2R;4]:LKV>
M1O+^V1[8XYW+$ *,D9Z# /45=L]2L=0,HLKVVN3"VR7R95?8WH<'@^QH M45
M276-,>X:!=1LVF7.Z,3J6&#@Y&<]>*M3316\+S3R)%%&I9W=@%4#J23T% #Z
M*\^\0>/A<^ +CQ!X8O[4M#<)&P91(VPW B!QGY<C+#(/':NWM]2L;NYGMK:]
MMII[<XFBBE5FC/HP!R/QH M453AU?3+F\:S@U&TENESNA2=6<8X.5!SQ5#1O
M%>CZ]?7]II][!-)93&%@L@)<A5)*CN 6QGID&@#;HJM=ZC8V!07E[;VQD.$\
MZ54W?3)YIS7EJMU':M<PBXD7<D1D&]AZ@=2* )Z*IQ:MIL]ZUE%J%K)=KG=
MDRF08ZY7.:4:KIQCGD%_:E+<XF83+B,_[1SQ^- %NBF0S17$*30R))$XW*Z,
M"K#U!'6JUWJ^FZ?*D5[J-I;2/@JDTRH6R<# )YYH N455NM3L+%MMW?6UN=A
MDQ+*J?*.K<GH/6HKC6])M(H);G4[*&.<!H7DN$42 ]"I)YZCIZT 7Z* <C(Z
M53FU?3;>\2SGU&TBNG("P/,JNQ/0!2<G- %RBN6FUC4HOB=:Z+YT/]G3:7+<
MA!%\XD5T7EL\CD],?C1X+UG4=6_X2%=3FAD:PU>:TC:*/RU$:JA'&3ZGJ30!
MU-%4[75],OC*+34;2X,(S((IU?8/4X/%1_V[I'V;[3_:MCY&[9YOVA-N[TSG
M&?:@#0HJN+^S,\, NX/.F7?%'Y@W2+URH[CW%1PZMIMS>O90:A:2W<8)>!)E
M9UQP<J#D4 7**X_XA^*3X>\*ZE/INIV,.K6\0D2&8J[D>R;@<XYS@].E=;$Q
M>%&/4J": 'T53?5]-COA8OJ-HMXQVBW,RB0G&<;<YZ50A\5Z//XGN- CO8#?
M6\:O(GF#[S$X0#NV!DCMD4 ;=%8_BN]O-,\):MJ%A)%'=6EI+.AECWKE%+8Q
MD>E&E:O&?"FF:IJEW!#YUI#+++*RQKN9 3UP!R: -BBJ@U33SIXU 7UM]B(R
M+CSE\LC./O9QUI8=2L+FR:\@O;:6U7.Z=)59!CKE@<<4 6J*Q=1\6:%INBW>
MK2ZG:O:VJYD:*97YYPHP?O'& .]:&G:A;:I8Q7=K-'+%(H.8W#@''(R.XH M
M45A?\)AHG_"17.B'4+9;JVA$LVZ95"DD_+R?O8!)'88]:O'7=(6!)SJMB(9&
M*I(;A-K$=0#G!- %^BH!>VANA:BYA-PR;Q$)!O*^N.N/>HK;5]-O;B6WM=0M
M)YXAF2.*969![@'(H N450&N:2TD$8U2R+W#%(%%PF96!P0HSR000<51;Q?H
MB^(YM#;4+9;N"$2RAI54)D\+R?O8R<=ACUH W:*IQZMILMI)=QZA:O;1_?F6
M92B_5LX%6HY(YHEEB=7C<!E=3D,#T(- #J*IW6K:;8SQP7>H6EO-)C9'+,J,
MV>!@$Y-23WUG:R)'<74$,CAF59) I8*,D@'J  2: +%%5K34+*_M!=V=Y;W%
ML<XFAE#IQU^8'%-L=4T_4_,^P7]K=^6</Y$RR;#Z'!XH MT5FZ_K4'A_1YM0
MG5I-A5(XE/S2R,0J(/<L0*I:@OB=[6WMM.FL8KN0,]Q=SQ,\473"(@(+$YZD
M] <]0* -^BN5\%Z_JNJC5M/UN"W34])NOLTLEMD13 J&5@#DC((R/_U4_P *
MZ[J.KZIXBM-02V0Z;?"WB\@'!4QJV23U/S>U '3T5BZ=K#G7KO0;XJ;V");F
M&11@3P,2N['9E8%2.G0C&<#99@JEF(  R2>U "T5QK^*I+CXBZ3I6GZE8W6F
M7-I<22K!M=E=-F,L"?[W3 _&NFCU?39KXV,6HVCW8SF!9E,@QU^7.>* +E%5
M+?5-/N_-^S7]K-Y7,GES*VSZX/%,?6=*CM8[I]2LUMY"0DK3J$8CJ <X- %Z
MBF0S17$*302I+$XRKHP96'J".M/H **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N-\7:
MA8VOBGPQ!*(8[^1[A[6ZN9"L,&(\.2H(WL0V ,CJ3D=^RJO=V%G?K&MY:07
MC8.@FC#[6]1D<'WH XCX5W4$EAXA@CNXIVCUV\;Y"/NE\A@!T!Y([5+\'UD7
MX:Z?NSY;37#0@_\ /,S/M_"NGOM+\VRN;:P6&S:\)^T3QH _(PS# Y?' )Z=
M><8-NQLK;3;"WL;.)8K:WC6**->BJ!@"@"Q4-U:P7UI-:742RV\R&.2-QD,I
M&"#^%34V2-)HVCD171AAE89!'N* /._@W!$GAB\<2O,\-]-9QR2/O98(F(C0
M'T )('^T:MZ)<;OBCXOLM5"^9);VK6:RCA[4(0X7/;>6W>YKL;33;#3]WV*R
MMK;=][R8E3/UP*2]TK3M2,9O["UNO+.4\^%7V_3(XH \=M$DL/"7A-[F3;IT
M'B[_ $.21N$M<RB,Y/1?0^A';%=?X>O[*X^+OBGR+F&3S+*S"['!WE?,W8]<
M=#CI7;75C:7MHUI=VL$]LP ,,L89"!T^4\46^GV5I(9+>T@A<HJ%HXPI*CH,
M@=!V% ',^/+ZPLXM"2\B5I9=5B%J\LICBBF 8AY".H&#A>YQTZCSO4-1>+3O
MB,+6\CO&%[:3SK:X'F0;8O/*J"?EV[@3D\=37M=W96FH6YM[VVAN8203'-&'
M4D=.#Q1'8VD,LLL5K!')* LCK& 7 & ">X X% ',VMYX3U?6(=6TJXM[O4/[
M.:)9;6;(CM\AL.H.%^;&,C.<^AQP?PRU,Z=;>&8=?6-K.\LPNB7/2.*4$B2-
M@>!(W9NX^48Y!];M]%TJSMYK>VTRS@@F.98XH%57/^T ,'\:0Z'I!@2 Z58F
M)&++&;=-JD]2!C@\4 <#9:7ID_CGXC":SM7"V]KPT:D+N@;<<=L]S65X;OI8
MC\+FOG_XEKZ?+'&['Y!=>6 @)]=H8+]3BO5!HNE*TA&F60,HVR$0+\X]#QS2
MG2-,:P:Q.G6ALV.3;F!?+)_W<8H X:UT&/5?&?CK3 H_L:^MH$G51\HNF0[B
MO8-MV$^Y4US7]J:F=&T3Q+/ RW'@Z;[%J9V$M,"WE3;?7"!)/3YO:O9;:UM[
M*!8+6WB@A7[L<2!5'T XI3:V[0RPM!$8IL^8A08?/7([YH \X\>0-#\&M<N[
MA/+N;[9=3!N"I>5-JGW50B?\!J?6-5M['XI26^L:NVF6USI48L)F\H1.0[^:
MFZ16 8Y0XXR .O%=]=65K?1>5>6T-Q'G.R:,.,^N#4-UH^F7UK':W>G6EQ;Q
MD%(I8%=%QZ C H \O@&D^'-=\$65M>S2^%_.O#!<W+J8S<$?)A@ -O+A..Y(
M[&GLVGSZY\5;>#4K>S6:S@9IXVSL_P!'?>^%Y.#UQS^->HW.G65[9_8[NSMY
M[7 'DRQ*R<=/E(Q65K7A[S] O[/0UL]-N[F-8Q*( %*C VMMP<%05XZ \=*
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M5IJ%LUM>VL-S V-T4T8=3CU!XJ+^R--VR+_9UIME54D'DKAU7A0>.0,# [4
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M!I(=&TNV1D@TVSB1HQ$52!5!0?P\#IR>/>@#QRSM[6X^$'P\\Z*)_P#B=6J
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M/+N>$C#V1CRV<=5SLQVR1CFL#4-$FEO?$_P]MXMD6J2#5;*8IE8$;F3V&)D
M _Z: ]J]0LM*T[32YL-/M;4R??\ (A5-WUP.:L^5'YWG>6OF[=N_'..N,^E
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M@  P> <8Z\^A111P1K'%&L<:]%08 _"JMMHVEV;W#VNFV<#7'^O,4"J9?][
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MJY:&U,V^6%&67<99"<Y)ZC  )QDXS7K]IHFDV#1M9Z796QCW;##;HFW=C=C
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MG-;WEU)%=P1%)&*B-V!SDX&5QP.W6NHN-;TJTO8[*XU*SANI&"I#).JNQ/0
M$YR>U>>ZWK?AV]USX=W6G7MD;=;IQ'LD4>7&8& 4C^'D*,'N,5F6-UH>J:+K
M?AOQ7KES;7ZZE.;C3\Q)).QF+Q-%E-[Y&P#:2> .F* /4KKQ#HME+)%=:O80
M21,JR++<(I0MG:"">"<''K@UHLRHC.[!549+$X %>=:5INF7?Q9\2P75I;3M
M_9UD3'.BN<Y<DD="<A<GZ5Z-0!Y_KGCZ&_\  GB#5?#.I6ZW6G"38Q"R%@A
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ME/4,A<>OI7#^(]1EU'X4:XVJZ?:6>H6FKQ03M;MF&6430EI(R>0"#S[@Y[T
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M;_5+#2XEDOKN*!6SMWMC=CDX'? J6TN[:_M(KJSN(KBWE7='+$X96'J".#0
M3VEM=;?M%O%-M^[YB!L?3-+-;07$8CFACDC!R%=00/P-0WVI6>G(C7=U'!YA
M*QASRQQG '4\<\5RG@GQ.U]I.O7^JZO!/:VFKSV\-VVQ$\E=FSD8!SGKW)H
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M*<,J%'D VLWW0?0GL#U[52D\7Z3%XO3PVUS&+PVYF;<X !+*JH/5CDG'M[T
M;]5WT^R<.'M+=A(^]\Q@[F]3QR?>EO+RWL+.:[NI5B@A4O([=% K)T+Q;I6N
M^'DUJ*ZABMBN]_,E \H$\;_[I(QQ0!J#3K)9$<6=N'3&QA$N5QTQQQ2BPLQ>
MF]%I +HC:9Q&-Y'INZXJ.PU;3]4,HL;R&=H6"RJC9:,GD!AU&?>H=?UVQ\-Z
M'=:MJ$FRWMT+$#JQ[*!W)H TJI_V3IN<_P!GVF?7R5_PKD-5\5RG6?"%S9:I
M"FEW\LJWB*49,+"S\N>F".>G2NLTS6M+UFT>[TS4+:[MT8H\D,@958=02.E
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MIH7Q.N1KVI3:98WVG0I8W656+*,_F1EB" ?F![=O:O2-JE@VT;@" <<@'_\
M4*9/;P7*!)X8Y4!R%D4,,^O- 'DT;Z1X7U_P7) TL'A0"\2VN+ECY:3O]UR3
MT##?M)[,<<&MWP7?Z?<_$?QR+.YMY!+)9R+Y3@AQY."PQU&>IKO988IXC%-$
MDD;=4=00?P-$<4<6?+C1,XSM&,X&!^@ H XGXP/$GPOU?S61<^3MW$#)\Y.E
M1:I?VEG\8-%N+BXBCAN-&GBA=FXE<RQD*O\ >)'8<UWCQI*,2(K@=F&:3RH_
MD_=K\GW./N_3TH H:5K^E:W)>1Z;>Q7+V4QM[A4SF-QU!S_/IQ7/^.]5L=-O
M/#@O$MXWEOSY%_=L1#:.(V^9L$ D@E0"<9.>U=)8Z7#975W=+@SW3 R,%"C
MS@ #ZD\Y))-6Y(HYEVRQJZYSAAD9H \*U&^LF\!?$VW-\D\C:CYJE]H9PRPX
M?  ')!P0.<<9KM-4EM(?B;X.2RDMD9M-O4C"$ $;8R@X[9SC\:] :"%MVZ*,
M[CELJ.3C&30+> ,&$,>1T.T<4 >%76M:?)^S]J&EWUS$FN6[E;VUF8"?S_M
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M"RK*5.QF&0#V)'<5B>']*U6V>2^U^]MKO4Y(UAW6T1CBCC4DX4$DY).2>,X
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M63W$/FP7EK%<1.<;&%R"RL#W !)'8<G@UU.L3?:/BE>V^EW4*WL_A.6*W*2
M?O3+E/QYS].: .X3Q'H[WL=FNH0^=*YCC&<+(XZJK=&88.0#D8-2)KFF22WL
M27D;2V(!NHQG="#D@L.HR 37EES-;ZY\%=*T/3V5/$$!M+:*TSB>"ZBD0.Q7
MJN '8D]B36Y%JEEHWQ.\6Q:C<+!+?65FUHC?>N-J2*VP=6(/8<T =#JGCK1=
M.71V6Z2=-5F"021DLFS!)?(XQP?J?QKHQ+&81-O CV[MQ.!CKFO%=*OK6W\
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M1&614'!?:%; 'J1B@#1P/04N*XCX?^(S/\.;+5M9U+SWEN)X_M$F,RG[0Z(
M%')("@ #TP*Z.R\2:/J%_)86^H0F]BSYEJ^4E3'/*-AAQSTH U  .@IJHBLS
M*JAF^\0.3]:R[?Q-H]UJ,-A%>J;B=6> ,C*LZCJ8V("N!_LDU#XN\2V_A+PW
M=ZO<QR2")<)&B$[G/"@XZ#.,DT 0^-O#L_B?PM>Z1:206\MWL#3R*3M"L&Z#
MKTQU[UO1JSQQM.D?FJ,G;R ?8D5Q&N>(FL_''A:1=4EAT>\AO6N(9$"(3&B[
M3RH;.6/!Z\8%=):^*=#O-%EU>#4H6L(7*23'*[&!P5((R&R0,8SR/6@#6"J
M %  Z#%&!Z"L<^*M(%IJ-P+B0_V<@>ZA\AQ+&",C,9 ;D=..:7PQK\/B7P_9
MZI"CQ^?$DC1LI&TL <9(YZ]1Q0!K%$9E9E4LOW21R/I0R(^-RJV#D9&<&J%M
MKNFW>KW.E070>^M0#/#L8&,'H3D8P>WKVIH\0:6;-[O[4!"DYMR2C F4':44
M8RS9!& "<@B@"?4=-AU*R:RFXMGXE10/G7NOL#T..<9J2_CNI=/N([&=+>[:
M-A#*Z;U1\<$KW /:J,?B;2);*\NUO!Y5D2+H-&P>#C/SH1N7CGD=.:>?$&E
MZ<#>)C4@#9M@[9LC<-IQC..<>E $6@Z5>:?%+/JEZE[J=SM\^=(O+3"C"JJY
M.%')Z]68]\#6:-'*ED5BIRI(S@^U-GGAM;>2XN)4BAB4O)([855 R22>@K-L
M_$NCWT[P0W@65(!<E)D:(F(_\M!O RO^T.* -5D5UVNH8>A&: H!)  R<GWK
M"L/&GAO5+J"VL=8MIYITDDB5"?F5"0QSC'!!_#GI5FT\2Z1?:@EA!> W,D9E
MB1T9/-0?Q1E@ Z^ZY% &FZ+(I5U#*>H(R*4*HSA0,G)XJO?ZA::9:FYO9UAB
MW*@+=69CA5 ')))  ')J"PUO3=22Z:VNE/V1MEPLBF-H3C/SJP!7CGD=* +S
M(CH4=593U!&12A0N< #/)P*X'5_%(G\<>$;;3-4N/LMY--YT'DE4G00LRNK,
MH+C..5)'2NLL/$.EZG%>265UYRV;F.XVQMF-QR5(QG</3K0!HO&DF-Z*V#D9
M&:'19%*NH93U##(-<_)J^F7VO:%Y&OO%)/'+)#8I@"\0IG<P(R H&X'C\:OG
MQ#I8O$M?M)\QYC;JPB<HTHSE ^-I88.1G(P?2@#3  & , 4$ ]1FLF^\3Z-I
MMQY-Y?+$1(L32%&\N-VQA7<#:I.1P2.H]:=JNLV%COMI[UX)S$9#Y,1D>).G
MF$!6"KGNPQQ0!IX&<XY]:7 SG%<G\,]3O-8^'NE:AJ%TUU=3"4R3-C+XE<#I
MQT K*3Q=!H/COQ3#K^ME-.MXK-K9)@/W9=9"P4(N2.!SR<#DT >@;1Z"C ]!
M60_BK0XUTYCJ,3+J6!9L@+B<^BD @GVJ]_:-J=3.G>:?M8B\XQ[#]S.,YQC&
M>* + C0.7"*'(P6QR:"BLP8J"PX!(Y%8/B'Q;9^'M2TFQG25IM1G,:E(F8(H
M4L22 >>,8Z\YZ U@6_BM-)\=>*$UG6)/[-@M[.2VCE3_ %>\2%@JJN3T!.03
M@<GB@#OMJA0H P.@QTI:H-K6G+IUO?BZ22VN0I@:(%S-D9&P+DL<9. #P#2Z
M7K&GZU:M<:=<I/&DAB? (9''564X*L/0@&@"Z$4  *!CIQTHP/05R.M>(+VY
M\:V?A#2)A;SO;->WUWL#M!"#M 0'(WLW<@@#G!J_/INM6EU8266L7%Q;BX47
M<%RD;%HSD$JP4$$$@GKP#C% !=:+JU_X@\RZU2$Z&C1RQV*6^',B<C=)GE=P
M#8QV Z9ST%9%YXGT;3YI([J^6,1.L<LA1C'$QQA7<#:A.1PQ'4>M+>^)M$TZ
M_%C=ZE!%=&(S>26RVP8YP/J,>N>* ,^R\.W<'CC5-<G>UDMKZ"&$0X)9/+W8
M;)&"3N/';WKIB >HKFV\?^%5T^.^;6K<6TCE-^&^4@X.X8RF#QE@*N:CXKT'
M2KDVU]JMM#.(3.8R^6V9 S@>I( ]<\9H UG1)%VNJLI[,,BAT212KHK*>Q&1
M63:^*]!OM#.M6VJ6\FG!MAF!X#9 VXZ[LD#;C)R/6E3Q1HK6U]<-?QPI88%V
M)U:)H,C(W*X!&1R..>U &JT:.FQD5EQC:1D4%$9-C*I3&-I'&*Q;/QAX?U#4
M+6PM=4AEN;J+S8$&?WB[=W!QC.#G;U'I5K3M?TS5OM?V"Y\\V;F.X"QMF-QU
M4C'WO;K0!HA5&<*!GKQ2XQ5:QO[;4K"*^LY?-MIEWQR $!E[$9[5B^'_ !CI
M_B"XU:. 21)87+P%Y8F0,$5"S$D #EB,'G S0!T*(D:[455'7"C%.(!ZBLJT
M\2:1?7L5G!> SS(9(5=&3SD'5HRP <>ZYJ_=74%E:R7-S*L4,8W.['@"@"7
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M^J26R:?KATVTPZW:);J[RJP &UR?D(YYP>OM6O;P16MM%;P((X8D"(B]%4#
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MS96)'S!(0"0>^UNOH:XVZFM7^#7C5(WB,DNKW+(JD;GS."A ZG(&1["O<**
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M-<EH7B'0M:\4>'+B^UVU74--M9+:"%()HO/ED558DR*N.%X3GD]>U9TKQ/\
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MS5Z1/,C9 [)N!&Y>H]Q7G'@/QM96OA338=;U.ZFO+B]GM_M$T<DBAC.ZHKR
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M,\T ;%%><_$;Q5"/"LCZ3J%]#,E[# EQ;(ZQNWG*KIY@&#QN'!QD$=1BO1J
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MR2&=_*4MEP",]2<G/>NB34[635IM+1I#=PQ+-(OE/M",2%.[&WDJW&<\'TH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH\$9^9-W;G KTBB@#S[Q9I>J1^"+6\ALYKJ]AU&'5+VUMV(DE ?<Z*1R2H(
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M(6<F8?+D8MGY>>.?ESQ7:Z?,B_%W6IV#K"VE6Z+(R,%+*SLPR1C(!!(KN:*
M/./!6C0:_P#"Z^T._CDC%Q<7:NLD95DW3.R. <>JL/I6E\/SJVHVKZGKT86^
MME.F*0<A_*8K)*#_ +;CG_KF*Z#7=-U'4[:"/3M:GTF1)@[RPPI(73!!7#@@
M=<Y]JN6%C#IMA!96X810H$7<<D^Y/<GJ3W)H J>)7">%]5)SS:2J !DDE2
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MJLNDSVB.[XW$L^1N.T #([]210!Z'J&H6NEV,EY>S"&WCQN8@GJ<  #DDD@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,X&<=* +_ASQ%'I-]X\U2[@U-K2SO8R\,A,DL"B$%N"Q^4')X)&.1Q7=?V[
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M$9D@M=N[RA@%R690HR0 21D],X->=O8Z@_@+X@68TR_^TZAJ5W):1&U<&9)
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M68O[$L<E &V219[@':P] Q'0"MO4]5MM*BB><LSSRB&"*,9>60YPJCUP"><
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MQAE/0UY_\3O$4-Y\.];>PCU!H86\D7]LVR(2*X5AD,&9<Y4G!7/?BO2V&Y2
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** (KB'[1;O%YLD6\8+1G# =\'M]>OI1:VL%E
M:Q6MM$L4$2A$C08"@=!4M% !117*ZQXHO;#QOH^A0:7/-#=Q33/*C1Y8( ,
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MSC.:TK#QA9W>J7VFW-G?:=<V=N+MEO(U'F0$D>8NUFXR",'!]J .BHKF=/\
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M]S2SOYDTK\M(V ,D_0  =   *M5S.L>-K/2-;.CG3=4N[[[(UVD=K;A_,52
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MGG-NRD,!_MAEC;VKT"L30/#%KX?\YX[S4+Z>7@SZA<M/(JY)" GHH)/'YYH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4O[4N+&5K4:$MH]S&HV&<2ER ,[L8/''M7,SZ%K<OPD\0Z,NCW7]HW=_/)#
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MTAS*!NB?)&P@CJ>"#UH U+CQYIL=SHD5K;7E\FM1/+9RVR*5<*FXCD@@]!R
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M2%\L;FVJ[+NW!"> V.XR #FK]OXEAN=>U31H[*Z^UZ?%',P.S;*K[MNP[O\
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M< @YR,\ $TRRU323XYUJ(Z:]IJ-M90O<WLI7;)%EMN"">!@\G!H ZAF5!EF
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M JX$B_*QY/R]NA^M9UKXZUMO#_B_5'T<%M)NKF.)#.FU!$B_*3U/\3' [X%
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M5MB=7"DX/3H<9Q3]8\8V^F27T<%N;M[",2W*B9(RH*[MJAC\S[<'''4<Y.*
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MW\Z,!"2!D<Y;D],?4BNGU+QU:6VNZ+H=C;M>:CJ\1N($+^6B1;2V]VP2.%.
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MSAL=J]I@B6W@CA0L5C4("S%C@#')/)/O0!G:[H%MX@MX(;FYOH%AE$H-G<O
MS<$8)4Y(YK1M[>&TMHK:WC6.&) D:*,!5 P /PKPS5/[(M_VAKNVU9[>'26L
M-[QROLCWF,<@?WOISFK_ ,./$NH>%_!7B#6?$LE__8-O<C^S/M08S2*21M7=
MR0?DQGC.[WH ]HHKDH/'MG#J&HV&M6YTVZL; :BZF3S%: ]2" /F!X(QUZ$U
M3T_XEVES+H+7FGRV5IK[.NGSM(&)8$ "11]PMD8P6Z\XH [FBO/G^)TCZKX@
MTNS\.7=U=Z(I>X"SHJ,@R203SG X&,FN/^+?B>S\4?"#2?$.DM)&)=0103\L
MD9VR!D)'NH]C@&@#W&BN7U?QG%8:Y+HEC9M?:A;V+W]P@D$:QQ+Q]X@Y8D\#
M\R*UM URS\2:#9ZQI[,UK=1[TW#!'."#[@@@_2@#2HKS+XV^,M0\)>$8(]*D
M,-[J$QA$Z_>C0#+%?1N@SVR>]7-;\$:=8?#>[6V0Q:K9V+3IJ2,1<F=$W;S)
M]XY(YYZ'% 'H-%>!7WQ"US6_V>KC40TBWZ3BQNKR)PAP&3YL=<LK ''O5;Q=
M:3:!H?AN33[*XM4UV[M&OH!= QS%%P$VC@!AACV.1GI0!]#9HKQ_2-)\/^'/
MC)IFFPVNK0:C+92W$2&\$ELBOO+*5QD8(8  XX!ZUT4OQ2L@4N[?3+FYTAM4
M_LLWL3 GS<?>"8Y3/&<Y/8=* .^HKBM5^(UGI\^M_9[*6[MM"\O^TID<+L+G
M&U ?OE1DGD8]2>*;K/Q*L=(\1Z3I(L+F\&JV_P!HM)K8AO,!!*C:<<D@ =N1
MDCF@#MZ*R?#>L7.NZ+'?W6DW>E3,[J;6[&'7#$9^AQFM:@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ KD/$6GZI_PG?AS6;'3VO+>VANK><)*B&,R!-K
M'<1E?E.<9/L:Z^B@#SA-'UK[%\08SH]P'U=I#9#S8OWFZ 1C^/Y>1GG'%)IV
MAZUHNL>&=?739IA#HB:1J%HKH9(=N&$B_-M8;@0<'.,'FO2.M% 'GS^'+AY/
M$NJWFA?;H]=NK=9=,=DW"WB0)N)+!0_5\9[#G/3*;P1KJ^'M6LM*EN!:6]Y:
MWFB6FIR[RK1'<\9.21&3@*">QSP<GU:B@#F?#5YJVHRB:^\,KH:1H0ZR21R/
M(YQ]W9T4<\G!/'%=%/"MQ;RPL2%D0H2.N",5)10!Y[X,7Q;HFEVGA6[T0;;$
M^2FK"=/)> 'A@F=V_;QMQUY)I6T[Q-!KWCR^TRP>"?4+> :9<2O&5>2.)E/&
MXD<GC<,>M>@T@8%BH(R.H]* /--+TC6%\8^'=8'ANXMXX[&:WO9+BZC>;S&V
M'>Y#$L/E..2?9152Y\.^()_A]XUTM=%N!>:IJEQ<6D9FA^>.1U()._ X!R#7
MJ])N 8+D9/(% '&:G9:I=^./".I1Z5<?9;&&Y6Z<R1?NC(BJHQOR>5.<9K-M
M](U-#XP^V^&7O;74]1BE2VEDA/GP8C1R/GX8!2PSCH.]>C4U)$DSL=6QP<'.
M* ..\$:'=^'[K5H4DO(_#Y\LV%M?2[W@(!\P*<DA/NX!/8_4I\,[*2#0=1U&
M12HUC5;G48E(Y$<C?(?Q50?QKK;NTAOK=K>X4M"_#IG <>A]0>X[]#Q4P 4
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MT\DB%6VLNT1[6);=MZX&,\^E>S@Y&1THH \,T6ZOK?XG_$I;'2I]0EEC$:I
MR AB"%SN(^7/4C)'I4.K?#+Q)!\%-*\-6E@;O5?[0^V7$:31JL0PPQN9@">5
MZ9YS7K&D^#=,T7Q#J&N6CW/VW4#FZ+R!ED].,<8]L5T- 'D>O^%]7M?BFOBJ
M'PTNNZ9J-FMO=6<C1>9 P"C.'.W^$<@XY;\?3=%M%L=)@MTT^VT]1DBUME 2
M+))P, #//)'&<U?IGFQB80^8GFE=P3<-Q'3./2@#C/BAX%_X3WPM]A@E2&_M
MY/.MG?[I;!!5O8@_F!5?5+WQ1J?@.;1T\.W4>N75H;25Y)8A A9=K2;PQR,9
M( !/08KO))8X8VDE=4C499F. ![FG4 >/ZY\-=0TOX)GPCHMLVH:C+,DTSHZ
M(K/O#,<N1P  !WX%6/'/AKQ!K6A^"X+#1IY)M-GAFND,T2^6$4 C)?!/';->
ML44 >::AH&MW/QSTGQ''I4W]DP:>;:6<RQ#:Y$G\.[=@;P.GK5#X=:/XN\!S
M:AX:?0_MNFR733VFHBY1452 #O&=W0 X )SGMS7K5% 'CMMX/U30OB)XAFN/
M"=OXAT?6YOM$4SM%^X<DDAA)T&6.< ]!C/2M/6_#&L2?%7PCJMIHX.EZ5:F&
M=X'C2.,E6 "(6!VC([=*]/HH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "N"\7:U+=^//#G@N%VCAO@]W?LIP6A0,5CSZ,RD'V&.YKO:\V\4Z?)
MI_QE\)>)'!^Q312:;+)VCD97,>?]XO@?2@#1NO'\5MXEU/P[IFFQW%QI4".\
M!N!%)*"N[$*;3OVKC/(Z\ U)X@^(":3JNK:;9Z?]KNM)T\ZC="68PJ8AR0AV
M-N;'K@>_7',?$3P)?^*-6GO=/TB6VUF">'^S]6M[B-$:,!-QF!;<"IWX(!/
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MVP^TQ;?+V,,YW=<MT]C7=:QX=UN]^-/ASQ-#IC_V996;0SN9HPRLZRC[N[)
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MGS:;?^)?$?A[4KW3)M-BTDRSNDTD;,\KIL"KL8_*,DDG&<#CDXY.^\->*?\
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M65U"@*<,#P6JI/X[E3PY)XGMM+%QH,4C!I5GQ,T2N4:58]N",@G!8$KSQTH
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M>11@Y)<]/3\QO:LLTFDW<5M#YTTD3(B;@N200,D]!5RB@#S,^$M>_P"%)_\
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M*1D$'TQ45GJ-EJ F-E=P7(AD,4IAD#[' !*G'0X(X]Z .7\6:1KMQJ&B^(M
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MO/(1M4U\,%@60;8E$7EQAF]>I)'K@9QD]9=:C96+P)=W<$#SR"*%99 ID<G
M50>I]A4[NL:,[L%102S,< #U- &1X3L[O3?">DZ=?0B*YLK2*VDPX96*(%)!
M'8X[XJC#H9U;Q#J%YK^C6LT(5(;$3!)@D8R6."/E9F8YQV5>>*Z&TO+:_M(K
MNSGBN+>5=T<L3!E<>H(ZU-0!PNE^'-0\/?$74+_2=-MXO#^H6\:SPQR*A6=,
M@2(@XQMX(X).32:%IGB'1_$_B?4CI,4L.JW$<L ^UJK*$3;\W!QGKQFN[HH
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MD#'O@=;1T&30!PFMZ#XAO?$VJR+;6=[87=@(+*2XG*_87VL'(3:<EMP.1@\
M9 JK!X7OKGPEHVA>(O#MKJ-G;6"02)#<*9894 571FVXR <X/'&,\UWEGJ%E
MJ*2/8W<%RD<AC=H9 X5QC*DCN,CBK- &+X2TR^T;PKI^G:E=M=7<$95Y6<L<
M9) W'K@$+GOBMJBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KE=;\4
M:EI_BNST&PTB*ZEO+66>&5[KRU!0J"&&TX'S=1D^U=57!>(9+F+XM^&GM;=9
MV&G7FZ,OL)7='T)XSTZX^M %:;XEWUKX6UV]N=#2/5=#N$@O;/[3\N'(".C;
M?F!W9P0.AK:D\4:K:7MOI]]I$$-]J-TT6G1+=;@\:IO>20A?EV@$$#.3@#CF
ML37?!&K:IX>\4F);4:MX@N(79&E(C@CBV!%+!22<(2<#JWH,G;\3:!J.J7F@
M:[IXA35=(F:06\LAV2QR+MD3<!P<=#CMTH (O%6H'5=6T)]-@.MV5L+RWB6<
MB*[B)P"K;<J=PVD$'G')I=*\73ZSX8T35;2S@-QJ<HC^SM.0(B-WF MMY*!&
MSP,D8[U/IVB7,OC&Y\3W\203M8I806Z/O*QAR[,QQC)8C@= O7GBOX=\)2Z)
MXEUB\,ZMITTS3V-N/^6+2A3-^;(,>F3ZT 1VOBFUMM<\7_;]/M[)-&B@EN+J
M-M[7"-&S GY0<@# '/6L'Q5>:EJ%SX%O;O3[:W@N-;MY$VREI8LHY"-Q@Y!R
M<' (QSUK1N?!E_JNI^-DO?)AL=?MX88)(Y"SQF.,KEEP.Y!X/:JD^A^,]1T[
MPS:WEGI:S:+J,$\LXO&Q<+&C+N \O*Y!'KS[4 :.K^/GM8=1N=-M(+R/3KAH
M)(/.83SE2!)Y:A2.#D#/4@]."=)/$LNKZG/INC6L4KV]K%<7+7;-&$\T$QQX
M )W$ D^@QUSBL:ST;QAX=UO5(-'72[K2-2NWO$DNI75[.20Y<;0/G7.2!D?4
M5-'H&OZ#XVO]8TI;;4;35H8$NTN9S"\<L2[%D!"D$$=1CK0 GPBR?AW:;HQ$
MWVJZS&#G:?M$G'X5GQ3:E:?$_P 7MHVGVUQ<FQLG(GF\I.!)U(4DD]N,>I'?
MH? &B:GX>\,+IVJ+;"9;B:53!(6!#R,_.0,'YL=ZBL]&U:T\<>(-9-O;O:W]
MM!# !.0^8PWWAMP =WJ>E $5KX_MK[0M O(8HX;G68FECCGDPD00#>2P&3@D
M 8'.1TYQGW/Q'O;3P[J6H/H8>?3[V.UD"S,(Y5=E59(F*_,#NZ<8QUJA9>"?
M$^D>&O"TNGO8#7- $T30R2L8+J&0_,N[ (/"D<=16MXDT7Q3XE\'3VEQ%I\5
M_<3P2+;K.WE0)'(K\OMRS'![ =/3) +LOBO4;&>*RU73[.ROKJ:7[*#=EXS
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M_M!\L*UQYW)V9SCCI6_J&AZGJ'CK2=7:WMQ8V]E/;3J9SOS+MZ#;@@;?4=:
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MV]S&UVQ+K$P#;#LZ]3DX^E;,?BG4XO%>D:=?:?;1V6LQ2M:/',6EC,:!\2#
M'*G^$G![GK0!UU%<#=?$&Z%BFK:=IIOK#[3Y1MX896N'C#E#*I"[>V=OIW!X
M$\WBSQ!/K7B32]/TFP,FCI#(LDUTVV171G[+G<< 8Z#GD\4 =O17G%]XMU;5
MF\!W>EB"WMM8D,DL4K,26$+-L)'\(/MDD#IW]&7=M&[&['..F: $DD2*-I)'
M5$4%F9C@ #N352QU?3-39EL-1M+LH,L()UDV_7!J[7F%XQ^&/C26\M[627P_
MXBDP8(%R8;_!VA1Z2=/KZ 4 >B0:KIUU=26MO?VLUS']^&.96=?J <BK=<TC
M6_@_PWJ>O:ML-TRM>:A)$.7<# 1?4* J+GT'<FJMWXKU'1I=$GUBRMDL=6G2
MVW0.Q>UE<916SPX/0L-N#V- '7T5QB^,;XZ1XMN39VWG^'Y94"[VVSJD0DST
MRI(..]177C/6#>^&[2PTFTEDURQDN8VEN641NL:N0V%^[\PY&2?0=: .XHJM
MI[WDFG6[ZA#%#>-&IFCB?>BOCD ]QFN:U[Q-K-CXKL]!TS2[2XDO+.:>&6:Y
M9 &3;PP"\#YNV<^W6@#KJIW&JZ?:7UM8W%[!%=W1(@@:0!Y, D[5ZG@&N6O/
M&.HJ+VVMK2V_M'3H(S=0D2R*\[1AS$C(O'!'S'UZ5G:MJ1UG6OASJ3V<UG)<
M7<SM;SJ5>(_9WRI! Z$4 >C45PVJ^.KN*'4KG2+!;U-.N&@:W\N4RW)0@2;"
MJE5(.0,YSCM4VM^+]0L+._OH;&&VL[2Q2ZC?4"8S=NRLQA0?PL N#G/+ 8[T
M =G17'3>-XGNM$MHY+6Q?5K 7L#WS$(Y.W$2D8^;YO7MP#GB>Y\4W,$FFZ=)
M!%;ZM<V(N[A75Y$M^@*X09;YB0.G"DYZ @'545@^$]>NO$&DR3WNFRV%U!</
M;R1NK!7*]'0L 2C @@X]1VJYKE_>Z=IWG:?8->W+RQQ+&#@*&8 NQ_NJ"2?I
M^- &E17#Q>/FCB\5B:&WO&T&&.<2V3DI.KHS8QSM(*D'D^OM6WH&L7&KLTRS
M6%YISPH\%Y9.2K,2=R$$G!&%[]^@Q0!NT5'/YWD2?9]GG;3L\S.W/;..<5YW
MX6\9:C#\/-.U;51#=7FI7IMK1$<J9)I)W4!B0=JCVSA5H ](HKF8O$=W9>+[
M7P[J\$ >_@>:RNK<D+(4^_&RG)! (.<D$>E=-0 5236--DOKBR2_MFNK9/,G
MB64%HE]6'\/XUR=]XWO]-NK%KVQM[>*[U4:>EG))BY\MG*+/Z%20#C'0CYJ?
M8@#XT:O@#G1;;/\ W]DH ZS3]2LM5M1=:?=PW5N691+"X=20<'!'!Y%6JXGX
M5@#P=( , :E>8'_;=ZZ'Q'KMOX:T"[U>Z5GCMU&(UZNS$*JCZL0/QH U:KWU
M_9Z9:/=W]U#:VT8R\LSA%7ZDUSMUXEU'1==TFQUFUM?(U9C##/;NV(9P,B-\
M_>!Y 88Y'W17)G4M9U7P#\1GU5[:1('U"W7R]WRF.(* H/\ #@9]<DF@#U.&
M:.X@CGA</%(H='7HRD9!%/K@M#\1ZI87/A/2KVPMDL-5L_+MY(YBTJ/'"'^<
M8Q@@'H3CUI+[X@72V+ZKIFFF_LH[HPFVBBE:>5%D\MI$(7;P02%[@=0>  =]
M17%'Q3XBN_%.KZ+IFCV,AT[[-)YDUVRAXY=Q/\'#8' Z<'D\ ]K0 54.JZ>N
MJ+IAO8/M[(9!;>8/,VCJVWKCGK7/7/B75;N+69O#^GPWBZ5.;=HI'(>ZE4 N
MB8X7&[ )SD@C ZFC>.9?BWX:F>%HG?1[IF1L;E.Z,X..XH [JJJ:C9/J4FFI
M=1->QQB5X PWJA) 8CTR*Y"X\;W]C>:3]NL;>W74=2^PK9/)BYC0LRI,>Q4E
M0<8X##DUHP:Y<R^.]5T9=,M%EM[".XBN/-.Z8,S *QV_* 0>/FZT =117FT/
MQ%UI_".D^*'T6T&GW5RL$\2W),PW2F,%,C:<''4C//2MVT\3ZI%XMN=#U?3[
M9&_L\ZA;M9RM(2BOM9&W*,MDC&.* .LHKE/"OBF?Q-%9WMLUA/8W$+/+]GD)
MDM)/EQ$X/4\MSA?N].:ZN@"-YXDFCA:11+)G8A/+8ZX'M4E<7X(U.36;37/$
MDB/-)->S0VZ+U$$)VHB_4AF^K&FV7C._/B'0]*U"TM(Y]7@ED-LDI\ZR=$#A
M)1WR,C.!R.AH [:D)"J68@ #))[5YS/\0-?30==UA-$L?(T2_FMKE&NV)D2,
MJ#Y?R=>2<G';@UTLWB&6\U]=$TE(3.MHMY/-/DK$C'"+M&"6;![C &><@4 :
M^GZG8:K"\VGWD%W$DAC:2!PZAAU&1QD5;KA/A89CH^NFXC2*8Z]>^8B-N56W
M\@' R,]\5TWB2^U'3/#]Y?Z79QWEU;QF46[N5\P 9(! /..GKTH U:*YNU\2
M2ZC:^'9M/%O/_:J>=)R0(X@FYF'T8JN#W8=*S)O&M]+X8N_%6G6,%QH]J\I\
MLN1--#&Q5Y%/0?=8A2.0.HS@ ';T5RUEXL?4/%MOI-O%"]G=Z/\ VI;7.3D@
MNJA2O_ LYS6-/\0M1A\)2ZRNDV\DD.K-ILD0G(Z3"+<N5Y)/8D?6@#T*BL[1
MY=8F@G.LVEI;3"9A$MK,9%:/C!)*CGJ.G:M&@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ KGM3T>]/BRPU^R\J9H+66TEMIG*#8[*V]" <,"@!!'(/48
MYZ&B@#@=2\ W%YX1\46%L]K;7FMW0NUC4DPQ./+P,XR=WEY)QU8\<5>NM%U^
M_P#%OAO6IX]-1=.BN%N(TN')S*%'R93G&WJ<9ST%=A10!S'A/0]2T?4/$$]^
M+3R]2U!KR+R)F<J"JKM;*CGY<\>M7_%>@1^*/"VHZ)+*8ENX2@D SL;.5..^
M"!Q6Q10!Y]+H7C+4W\,OJ,>CI+H]X)I98[F1OM $;)N V#:>>F3]1CFC?^"/
M%-UI.KV'FZ3+)<:HM_%>2RR>9,BRJZQN-OR;0, @L,#  ZUZ?10!PGC?3XM=
M&C6L&I1P:_!>+&K6S#>B.A$XQG*CR]QY[A?6NXAACMX(X(4"11J$15'"@#
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KG];U;4K+48[>W6TM;,V[2
MOJ%Y\T?F;@%A"AE.XY)SGMT-=!7*ZGH6M2>.+77+"XL7M5LC:M#=AR8&+[C+
M&!P21@$$KP!S0!0L_'\E_P"%_#&H1V:17>O7*VRJ[%HX6^;<QZ$_<.!QG(YH
M'B_6TO/%=FVGV$LF@0++YHF>,3;XS(OR[6QP"#\QY ['CGIM"U/0_"?AGP=-
M?:+)J(O'F@6?S$CD2,L^=X(97#.GW>>W(S6Q96VO&+6/#]SI^AI=:C9RR&YL
M[R63YR!&#,77=R&^4Y/"$=N "6U\9ZXF@V&LZE86*6VIPVJV4<#R/(9Y>NX!
M3\H&6XR<#')J0^.+[2YM8_M?39I+*RLQ=P7T-G+ DISM\DB3.'R1C!((.>,4
M^Z\&:A??#O2M#-Y#::MI2V[VMU"2Z"6$ *Q! .#@Y';/>I)/#OB'Q+X>U#3?
M%EWI\7VFV,")I8<H&)!\QB^"2"HP!@#GDYX %MO$NN?\)%9Z?)IAN;:\AD87
M$5G<0):RJ,A)&=2"K= P Y'W:Q%^(/B'_A";;Q6^EZ?]C6[,%U LKF1E\\PY
MC/0$<=>O/2NA\/V?C6$11Z_?:5-':J0C6@D5[IL$ REAA1SDA0<G'88.%_P@
MNN?\*P/A7S=/^TFZ\[S_ #7V;?M'G=-F<_P_K[4 ;EIXBU:#QL-"UBVL4BN+
M%[RWDMG8E-C!61]P&?O Y '3I68OCO4[FVTS5;#2Y;S3KV=5:WBLI_.CA8X$
MOF8V-Q@E<=_O'&:UKK0=2N_'>GZXZV8M(+"2TEB\YBY,A4DCY,8&W'OGM67X
M;\,^+O#T::$FJ:=)X>@<B"<H_P!L2+.?+_N>V[/ [=, $=QXP\2R?\)4+/3M
M+4Z"^299G82H(A)@8 ^8@]> ..O9M_X@U?4O$O@5].F@M[+5K::[\F5&8[A
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MN!&<?C7(V7@_4I?#^B^'M6FLSIVEM"2]N6+W0AQY892,(,A2<%LXQQFNWHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%8&MZU/;:[I&A69
M2.ZU'SI#,Z[A%'$H+$#(RQ+*!V')YQ@@&O=7MO9*CW,GEH[A Y!VACP,GH,G
MCGN0.XJQ6%I]KJU_I^J:;XDBMI87DDAAEBX\^W8<%U_A;D@_2L[X9:O<ZUX
MTVXO9#)=1;[:60]7,;E-Q]R%!/N: .NHHK&\4ZL=&T">>.1([F4K!;L_02.=
MJL?9<[C[*: -"RU"TU*%YK.=)HTE>%F0]'1BK#\"#5FO+? =Q8>&O'>I^%;&
M[\_3+^%=0L6+%B)  LR$GJ3@-]*U]:\87%KXHO=#-_;Z7="-#I@O(?W5\2N6
M_>$@ AOE R,'GYLX !W=%17-Q':6LUS,=L42&1SZ #)K@+KQAK<'@.#QP@MW
MLR%N)=.\OD6S-CA\_P"L ())&.HQWH [;4=6M-+$8N&D:67=Y4,,;222;1DX
M502<#^GK2Z1J]CKNEP:EILXGM)P2CA2N<$@@@X((((P?2N)U3[=<_%S0'MKZ
M)8GTNYDAW6Y;:I:+.?F&2>.>,>]=1XNENK/P9K-QIUP+6Y@LYI8Y0@;:54MP
M/7CK0!9U+7M.TFZL+:\G9);^806P$;,'<]!D# Z'J1TK2KR?4A?#PA\-6:>&
M>X;4[)HBR% H-L^ W))^O&?:MA?&6I:%+XN@UM[>];18(;F&2WB,/FB56PA!
M9L89<9R>#0!Z!17(6>J>)E\36$$MH]UI=S&XNIC:^1]DD RI7+'<K<C')'7-
M:/BO7WT'3[3R$1[V_O8;"U$F=@DD.-S8YP &.!UQCC.: +G]O:=_PD(T'SF_
MM$VYN1$8V \L$ G=C'5AWK2KST0ZA;_&BR%U=1W?_$AG,1$?EMGSH\@X.,9Z
M'W[]:+/Q=K$6O>'+.^EM)9-3EF@O;>",LEK(J,X5)02K$;<,"2>_% 'H6:*\
MQT;Q!J.BV7CO6=1O%O8[#5)8UB\K8681Q! #D[5Y Q@^N36_9:GXF7Q/8V\M
MH]UI5S$_VF<VOD&UD497&6.Y6Y&.2/6@#KZ*P/%?B!]!L[!8$1KO4;Z&PMO,
M!**\A^\P&"0 &.,C.,9&<U0.N:II?C:S\.W\T5Q#JEK++970BVM'+& 71U!P
MPP001@]N>M &GJ'BW1M+N?)NKEUQ.EM)*L+M'%*P!57<#"DY'4]QGJ*VZX#X
M;Q7K3>*6N;J*:(:_=*Z>1@LXV?,#N.!QTQ^-:GC+6]3\.R:7J$,ENNCM=I!J
M)DB+/$CG D#;@  Q .0>N: .KHKCM?\ %T^@P>(M6<1S:;I44<:1!,-)<MCY
M=^?N_/$.G5F]*35-<UGPUJN@C4I[>[LM5N5L93'"4:"=P2A3DY0D$$'D<'/:
M@#LJ*\]/B_6AX-\8ZEOM/M>AWUS! ?).R1(E5AN&[J=QY!_"IM0U_P 2S>)-
M'TG39].A74M+DNO,FMV8Q2*$YX;YAENG&/?&" =Y15-'O;?1P\ZI<W\=OEUA
M&U9) O(7.< GIFN4\'^*YO$TD9AU6U>5;9OMUC);F*>TN,K@;"<E!\XY]!\U
M '5:7JMIK%JUS9M(T2RO"2\;(=R,5;A@#U'6KM><V_CO58_ +ZQ=1VK7IU9M
M/\Q8RL,0\_RA(PSG '/7DXYK4M]6U\^/;SPZMU9R6T-@EXMQ):L7!<L@1MKJ
M/O+GIR,CWH [*BO++#QIXHE\(^'?$]S+IWV>]OH[6YM([=LLKS&/<'+<$<8&
M#TY)S6IXP\4ZUH,6N74<MI"+"))K*V\OSFN4P"[2!3F-<Y4'@<9R: ._S17
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M7.3E< #/4YZ#%-UCQ3XOT;PSXGO)+6)?[-5);&\N;8J+A&^\K('X93WZ'TH
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M#7%O')Y9D,3("=H;C<!D88<BM8'(R*\OU/Q#KEWX \=M]JM[:YTBZGM89;:
MK^Z2-#P"QPQW'G)QVK3U'Q-/X8L?#T.IWRVUA=PL)=36U)2)PJ>7&PR0H;+?
M,?[O;J #O:*H:+/<7.CVTUU/;7$SJ6,UK_JI!DX9>3P1@]35^@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *YCQ;X5N-=GTS4M,U'^SM8TN1GMK@Q^8A5QAT=<C*L /
MI73T4 8,1O="T>XO-4O/[1U&0<+#%Y:NV/DBC3)ZGU).223CHWP1X??PQX/T
M_2IG#W$2%YV7H978N^/;+$#V%;Y4$@D D=#CI2T %8]YI5[=^)-/U WD LK-
M7*VK0$L9&&W?OW8!"[@..CFMBB@#EO%GA6[U_4M$U"PU&&PNM)N3/'*]N92X
M(PR<.N%8=:B\0>$[[Q'9:GIM]>64VGWVPH)+8E[0A%5C&=V,Y!8=,$GKTK;T
M;7[#7A>FP>1A9W+6LWF1-&5D4 D88 _Q#M6G0!#]FB-G]E<&2+R_+(<YW+C'
M/K7&6W@*ZB\,-X3EU..;0/,^4&$_:/(W[_)+;L>V[&<<8SS7<T4 <W=^&[R?
MQMI^OPWUO'#9VLELML;<DLKD$G=N&/NC'%;&K:>FK:-?:;(Y1+NWD@9P,E0Z
ME<_K5RB@#ASX)U:72/#5E/K5J[:'=0W"N+(@2")"BKCS.,@DDY//0 <5/=>!
MO[1U?Q)<:A>1R66N6D=J\$<)5XA&&"L'+$$_,3T["NQHH Y3PYX?\1Z<T$6M
M>)%U*UM!M@5+7RGDXP#*VX[L ]!CGDDXJYXO\,+XJT>.U6[>SN[:XCN[2Z1=
MQAF0Y5L=QR1CWK?HH XL>$=;O/$4&LZGK5J)5TZ6PD2TM&3*N02RDN2&R <_
MIWJE9?#_ %BVMO#44GB"V/\ 8$I\@QV&W?&4*?-ES\^#UZ>H->@T4 <9_P (
M'YP\365UJ"R:1KLKSM L.V6.1D52=^2"!M! VCGOZV?#F@>(]/>!-;\1KJ5O
M:#; L=KY3R<;0TK;CN(!Z#'/)R:ZJB@#"\5^&H_%&DQVIN&M;FWN([NTN57<
M89D.5;'<=01Z&HX- N[C7;76]6N+:6\L[>2"U2")EC0OC>YR223M QV&>N<U
MT-% '.>%?#MYX>?5OM%]!=+J%_+?8C@,9C:3&5Y8Y Q3?&6JZ!#I5QHVLW$9
M?4;>1(K0'][<<8VH.[9(Q[UTM9%YK&DP>)--TJY4G4KE9&M28"1A5R^'Q@<8
MR <\B@#+MO!5M-\.5\*ZG))+YUMMNIMV7:8G<S@GN'Y&?04Z+PQJ%XVC+KVH
M6]Y'I,HGB,4!1IY54JDCY8XP&)P.IYS@8KJ 020",CK[4M ' WO@+4YK;Q/I
MUIK4$.F:[))<,C6I:6.61 K#=NQL^4'[N>V1UK1A\)ZA'XCT/57U2W<:99-9
MM&+0J9@VW+9WG:?E'8]ZZVL)?%^DOJ=I9+),?MDLD-O.(6,,LB9W('QC(VM[
M'!P30!KWD,EQ8W$$4IADDC9$D'5"1@'\.M<W;^%;F3Q)8:]J$]FVH65M) )K
M:W,9N2X S)\QX&#A<GD]>U=510!Y=K.DOX3\#?V+>ZY;1#4]5)%Y+:8@022&
M5UE#,1L(!7J,Y [DU?\ #,^J6NK+9VNI^&-1@N QF;3+4H\.$.QWVN01D!<'
M!YX/!KOY(HYHVCE17C8896&01[BF6UI;6<7E6MO%!'G.V) HS]!0!PT7P]OH
MO NE>&EUBW/]GW:7(N#:'Y]DOF!=OF<<G&<]*=J7@'4[X>)[>/7(H[/7E#2*
MUIOECDV!,!]^-G XQG' (ZUWM% ')'PEJ(UO1-6CUB(7-C9O97)-ID31L5.4
M&[Y""O&=WOGOG7O@+4YK7Q/IMKK4$.F:Y))<,C6I:6.610K#=NQL^4'[N>V1
MUKOJ* .2A\)ZA'XCT35GU2W<:;9-9M&+0J90VW+9WG:?E'8]Z@O/"&LVWBF\
MUCPYKT>GQZEL-[;7%KYZ%U&T2)\PPV ..A[UVE4]5U.UT;2[C4;UG6UMT,DK
M)&SE5 R3A03B@":TM_LEI%!YLDIC4 R2'+.>Y/N>M<E#X-U&VMM<TV#585TW
M6+J:YD;[.?/B\[_6*IW;3QT8CC/0UUEC>0ZAI]M>VY)AN(EEC)&#M8 CCZ&I
MZ .*U+P/>6^KV.J^%-5CTFXM[-+"2&:#SH9H$^X",@@KV.:L:MX2O]3L]%C;
M6$:XT_48]1FGFM]WGNN?E # (OS8 YP .O4Z$7B_29M4M+%))B;QI([:?R6\
MF9TSN57QC(P?8X.,UNT <M'X8OM,\2ZEJ^BWUO$FJ!&NK>XA9U$JC D0AAU'
M53U]12MX(L?^$ N/"BR,8IH75IV'S&5B7\SCOO.[\*ZBD) QD@9XH Y.3P):
MR7WAV[-S(9=)W>:QZW>[#DN?7S563ZYJ]?'6QXRTS['>QG2C&XO+,V^2.&(D
M\SM\P10O?D]CBY8Z_I^HZSJ.DVSRF[TX1FX5XF0+OR5P6 SPIY'%:= %'5M9
MTW0K+[9JM[#9VV\)YLS;5W'H,USO@+0;/3K/4K^T$GV;4KJ26V23HEON8HJC
MLI9G<#TDKK)H(;F,QSQ1RQD@[74,,CIP:K:GJUAH]NDU_<+"KN(XUP6:1CT5
M5&2Q]@": .3M? 5U9^'+SPK#J<?_  C]P[A%,)\^&%VR\2MNP1R0&(R >AJ_
M>^%;U/%=KK>BW]O9A+ :=-#-;F0>4'W*4PPPPR1SD>U:2>)]+:\MK222>WN+
MI]D$5S:R0F4X).W<HSP"3Z=ZV* .>\&^'+CPMHC:=/?+>#[1+,KB+81O<N0>
M3GD]<#Z4T^';P>.Y?$BWT&Q]/%BML8#D .7#%MWJ>F.E='10!Y[;_#S4[+2]
M*AMM<M_M6F:E+?Q.]F3$_F%RRLGF9.-YP01C]:W?#7AF\T+5M:O)]46[CU*X
M%SY8M_+*/L53SDY'R\#MW)KI:* .=\+>$[;PL-16"5I([JY>6)&'$$1)81+_
M +(9W/\ P(UCZ)X(UK09&TRS\1X\->:TD=H;;,\:$Y,2RYX7)/.,X/&#S7=4
M4 5M0LUU'3;JR=BB7$+PLR]0&!&1^=<O8^#;S^R-&T?5;^WN-.TEHFC6& HU
MP8A^[WY8@ $ D#J0.@X/8T4 <0O@S6]-U[4+G0?$:V6F:G.;FYM9;42M'*WW
MWB8G +>X(![&G7_@S5;;Q&VM>&=<33Y+F"."]ANK<W"3",81_O [P..O/\^U
MHH Y6?PI>2>(?#^J#55?^R4G#B: L]PTP =BP8!>F0 ,#ITJSX<\.W6B:CK=
MU/>PW"ZG=_:]B0%#&=JKC)8Y&%'I70U#=745E:2W,V_RHE+OL1G.!Z*H)/X"
M@#A_$_VD_%CPB+.6%)A9WQVS*2&&(^.""/K[=#4^I^ 9M1L-1D_M-(M7OKZ"
M]>X$.8LP[?+C*9Y0!>YY))]JZ#2Y='\165IKMK:PS+<()(9Y( 'QV/(R*UZ
M.2L?"VKVGB?4=<EUFWEEOK.."2(6950Z;L$?.2%^;H223_%VK+C^'%U;^%-
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M-/E"FUR6.!\V3UR0.G-='J&J6^FR6<<ZS,;N<6\?E1,X#$$Y; ^4<'D\5=H
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MGGH<UWM% ''S^$]4@\4IXATG5+6"[GMDMK^&>V9X9POW74!P58=.IXJ]X/\
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M(Y"\-@ULOF(N<^7YV<[,]L9QQFNLU35++1=-GU'4;A;>T@ :25LX49QV]R*
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M, M3A@S!RV[?QRHXQT_.I/"OAV;PY;7\,M\EW]KOI;W*P&/8TC;F7[S9&>E
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M4;3IPL0V(ZMEB%/5?*!<>OK3KW7M?U-M=CT!)O.TN8VL $43)/,L:N1(68$
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MN.JL,\C\:\KC_P"26_$G_L(ZK7I.CJS^&K!$D:-FLXP'4 E3L'(SD?G0!I
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M /NXZ9YZUI6VJZCXEUKQ!9:?J+:?'I4JVL;)$CF24IN9GW _*"0 !@\'GD8
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M<UP$6(;ED5T4$L<Y^\>./QKF/#EUK-CX!\6ZK'J\DUW:W>H,AN8D<%HF;!.
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M!B%)R, 'C!ZFQ_:'B?4_%GBK2+?6(;.&P@MI;=UM%=D,BN<<D@\J,D^G &:
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MH XR/P+,GAGQ!HK:LK)K5Q//)*+7!C,WWP!OY'IZ>]=+91?V3HL,5S.L@M(
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MK>:E#/I<:QRR6T<.'8H^Y8W?<1M# $C:"0 ,]<[MUX(OHO$MYJ^A>)+G24U
MJU];+;I,LC 8WIO^XV!UP:G'CBS6]LK2/1M987PCDMI8K/?')&Y \PE2=JC(
M)W8(!'%=3O3S/+W+OQG;GG'K0!SD?A62W\66VMV]^%6VTXZ<EN\)?*%@VXON
MR6RHY_\ UU6TSP?J&D6;16FN*LAU.742QM,JQD#[XV7?RN7R.01@5UU% '#W
M/PZ26%I;;4OLFHMJRZMYT-N/*$JILQY1/W2.O.<DG/:IE\!%Y?$QNM:N9X]?
MMQ#<+Y*+L81^7N! ].@_/-;B>(K-_%3^'0EP+U+3[86:/$9CW!>&/4Y/;T-:
MU ''W/@N]N](T*RFUS>^DW<-VLK6@_>-$,*N PPN.O4D]QTJW_PBUQ9>([_6
M='U%+234407D,MOYL;N@PLB@,I5L<'J#Z5TM% ''R> XH[7P_;6%]Y$6CW1N
MU\R'S&GE.[<7(8==[$X'4_A4DOAB]M=2\2:O;ZTUO/JT$<8:*SWM;F-2J,HW
M'<?F.1CGMBNLK!U#Q9::7I^KWUY9:C';Z6VV1C;']Z-H;='_ 'EYQG@9!H M
MZ$+^W\/6G]LSB2\2+]_*P"D^[ < XQG'&<UYYX"TE_$G@"ZTYM5A.F7%_="X
MABBS+L,[$H'W8 8?[).&.#TQZA;3I>6<-P@/ES1JZAAS@C/-2JBK]U0/H* .
M/O? KSZMK-S::S-:6FL6B6UU;) C8V(44HQ^Z-IY&/7D5FZRFE:;X0C^'M[>
MR:CJMSIP@M(?(*F3'R(V5!50I4$DG(VDFN^N9UM;:2=U=EC4L5C0LQQZ <FJ
M6@ZS:>(M$M-8LED%M=)OC\U0&QG'(Y]* ,S5?"":AX$;PK#>-!"\"P/.R>8[
M ?>;J/F)Y)/J:+KPQ=7>O:#JSZE$)-(25%C%L<2^8H5B?GXX Q[^M;$&I"?5
MKS3Q:7<9MEC8SR18BEW \(W\1&.?3(J[0!Q<OP^AOK?Q';:C?F:'7)EG?RHO
M+:"10H5D;<>FU3SW'X5:TSPQK-O9RQZIXHEU2;R6AMWDM$C6(,,%F53EWQQD
MGU]3GJJQ]5\2V&D3Z7%.)I/[3N$MK=X4W(68$C+= , G\* ,(> IU\.>'M'7
M5T":)=17,4AM>9#'G:&&_IR<X_2KC^$)AKFNZC;:Q-;KK$"I-$D2_)(L9C5U
M;K@ @X]0.>U=.[;$9L$[03A1DGZ55TO4!JFF6]\MK=6HF3=Y-U%Y<J>S+V-
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M7PGH!\+^&K/1?M7VI+12B2^7L)7.>1D\\UM444 %%%% !1110 4444 %%%%
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M40!,;]""#PRD<$=Z9%X9CDNK^]U&X^U7U]:BSDE1/+5(1N^1%R<<L222<GV
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MS%>-&D@#"9&Q\KJ",X(SD$=![Y +_A74$U30(KR+5TU6*220QW:*%W)O.T,
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M;BP9650,Y8]1WJPW@2QO/#][I.L7U_JIO%59;FZE'F *<ILV@!=IY&!UZYH
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M&"-QY.3S@G&,6D\"V5QH5[I>LW]_K O8Q%+/>2 NJ@Y4+M "X.#G&20,YP*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M SM)ZC/3VKF=0U2:_P#B/;^%S--!:)I;:A*89#&\S>8(U7<,$ <DX(R2.W!
M.NHKR36->UVQ\->/M,75+H7&@-&]I?#;YC1RH'5&)')4'&X8/3FO0]"TRYL5
MGN+G5KR_:[V2;+@KLA.WD1@ 8!]#F@!_B77$\-^'KS6);6:YBM8S(\<)4-@=
M_F(X_7VK0M9Q<VD-P%*B5%< ]LC-<U\2_P#DFGB/_KPD_E6?'JDU]XNT?PN9
MI;>T&B#4)3"YC>9MRQJFX8( ^9C@@GCMU .ZHKRJ?Q=J^B2Z_H,MX\C6FJV5
MG;:C* SQ0W6#EB1AF09P3ZC.>_57MA?Z(VK7D/B3[/8OIS>5'?DRBWG7/[[>
MQ)VX(RO3^5 '5$X4D DCL.]8WAOQ%%XDMKZ:.TFMC9WLMD\<Q4MOC(#'Y21U
M]S7*:)J=_!X[T>P6XU%[&]TF260WKD^=(C)B558EH\[C\OR]?NC%:'PW_P"/
M?Q/_ -C'?_\ H8H [6BLSQ%<26GAO49XK^'3Y([=REW.N4A..&([X_SFN)L=
M<O-*\9B!GU)]-.@2WSQWKEFEDC=?WBAB63()^4X_W10!U_BCQ''X7TM+^:SG
MN8VFCA/E%1L+L%!.2.,D= :VJ\>\0FYUKX3:;XBN]0N7NKRYL[B6-93Y.UYT
MQ&$Z +D<XW97DG)KI;@:C?\ Q1O]%;6[^'3VT>.Y$<#*A1C*RG:P7(X4<]??
M'% '>52>]N%UF*R&GS-;O TC7@9?+1@0 A&<Y.<].U>3MJFO1_"MO$K^(+][
M_2[PPQC*A)D2Z\K]Z,?.2O4^P]R>TNKR_3XLV>GKJ%P+&?2)IOL_R[%D61%#
M#CDX)ZYH [&J4E[<)K$%DNGS/;R1/(]V&79&P(PI&<Y.?3M7DUSJ.O0_#K7?
M$7_"1:BUYI.J3I NY0CJDX7$@"_,".,< =AUSVU[>WT/Q7TJQ6^F-C<:;<2M
M:\! ZL@#<#)/)ZDT =A4<<\4SRK'(KM$^R0 _=; .#[X(/XUYSHNNW*^)K+2
MO$,NIZ;K#7$Q4LY:SU&,J^T1'.U2 4., _+SDFLG34NM,\ >/K^QU2_ANK34
MM1\J3SMY_=MP3N!YX )Z^] 'L%-=UC1G=@J*,LQ. !ZUP$EO?V&B:??7'BJ_
M9M2EM/-A<!F<;26BMPH#*S\<Y) 4DGJ:P=5O;^\\'?$C3KJ>^2+3N;9)9]TL
M:M"'V,X)W+D]"3P<9- 'J%YJ,L*V#VEC->QW4R1L\+*!"C GS#DC*CCISS5^
MO/-7EO='T_P.++4[Q(KG4[:WGC9PPD1HV8@DC./E' .*L7.JS>&?B'<1ZG?7
M,FD:AI[W%FKN2(I8N98U'?*D,,^A H [NBN"N+O5;34/#WAUYI'N-0@N+NZ,
MEVT;%DV'RED + #>>F#A!SR<[?A.SUW3X[^UUN\AN4%P7LL3&66.%NBR,57)
M!!P>2?7B@#HJ*Q?%MS+:>%[Z6'5(],D"J%NW3?Y>6 X7J6(. !GDCK7-:/J>
MIP^.=8TN!;W[,-)BO+:VOYO,82EW7.XL2 V!P3QZ"@#OZ*\GL]3UG5=-\)O8
MZQJ"ZS=W7EZS"C F% &,I,;JRQ;&4 ?*,Y YS6G)/X@\5_\ "1#2;K[+<V%]
M)9V;B]:(0M&J\O&$(<,22=V>#@ 8R0#T6BO.U;6[_P"(-MI%WKMQ##-X>6YG
M2Q90@F\U58QMMR >Q/..F,UGZ1XHU,Z!H6F7.H2M->:Y/IDE\^/,,432$<]-
M[!57/7DGKS0!ZI17'WWAS6A9:[:V/B2Y0W"++I:LY:6UD5<,"[$ET9L<'IDX
M[55\.ZZ_BJW\/+;SW,$L$33ZFGFG<KIF/RG[\R;CSVC/K0!W5%%<%I=S>^,8
M_%$R:E=64]AJ,UA9""0HL)B5<.R]'+,22&R,8 Q0!WM%>2V7B+6O%!^'T_\
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M>!K*#5[+59M2U6[N[6W:U+W%P")HR0<. H'51TQGOFNCBN(9WF2*17:%_+D
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M:W<4B+,C*"HYV[3P<'*\U"G@'25.N"2XU"9-:B$5VDMP6!^386''#$#OG'8
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M_D QHL89]A7G:1R#[UTUYX(TG4-)O;&Z-S(][.MQ/=^9MG:5,;&#  #;M
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MN&N)RX8JH4''3H/Z# XH S]>9KCQ5;6*WUW*#8R.--LI&A?<7 $[RAEPHY4
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M6>0R22L>K,QY)_P ' %4M9\+:?K-];:BSW%IJ5L"L-[:2;)54]5/!#+[,"*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%4M5U!M+L7O3 TT$(WSA#\ZH.K ?Q8ZXZXSC)P#9@FBN8(Y
MX)%DBD4.CJ<AE(R"#Z8H DHHKE?%7C";PM?:;'-I?FV5_<+;"\^T!$A=CQYG
MRG ]^>E '545CZYK-SI3:?%:Z>+V>\G\A8A-L*\%BW(/R@ DGZ=<UKH6**7
M#8Y .0#]: %HHHH **P-7\12Z7XHT'2/L0DBU5Y4^T>;CRRD9?[N.<X'<5OT
M %%%% !1110 4444 %%075Y;V4:/<RK&LDJ0IG^)W8*H'U)%3T %%%-D+K$Q
MC0.X!VJ3@$^F>U #J*Y;1?%.H^(/ T>O:=HZ/>RNZI8O=!1\LQC/[PKCHI;I
M[5U- !116!HGB*75?$.O:3+9"W;29(4WB7?YHD3>#T&."..: -^BBB@ HHHH
M **** "BBB@ HHHH **** "BBJ5]<7\-Q9+9V*7,4LVVY=I@GDQX)W@8^;G
MQ[T 7:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBH+B\M[1[=)Y51[B
M3RH@>KO@M@?@I/X4 3T45!)>6\5Y!:/*HN)PS1Q]V"XW'Z#(_,4 3T52M+B_
MEO[Z*ZL4@M8G46LPF#F=2N6)7'RX/'O5V@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **I17%^VL7,$MBB6"1(T-T)@3(YSN4IC(QQSGG-7: "BBB@
MHK MO$4L_C>]\.R60C%O9I=K<>;N\P,Y7&W''W3W-:6EW%_<VKOJ-BEG,)75
M8TF$H*!B%;( ZC!QVH NT45@:UXBETCQ!H6F"R$L6JSO#Y_FX\HJC/\ =QSG
M'J* -^BBH);RWANX+6255GN-WE1]V"C+'Z#C\Q0!/16!X;\12Z[=ZU;S60M7
MTR]-H<2[]^$5MW08^]TK?H **@NKRWLEC:XE6,2RI"F?XG8X4#\:GH ****
M"BBB@ HHHH **@%Y;F_:Q$JFY6(2M&.H0D@$_4@_D:GH ***BNKF&RM)KJYD
M6*"%#)([' 50,DG\* ):*:CK)&LBG*L 0?8TZ@ HHHH **** "BBB@ HHHH
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MF$T@^99%+GA@ <D=1UK6L?"NCZ?X;/AZ*U+Z44:/[/-(T@VGJ,L2<<^O%5M
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M!$11@*H&  /3% 'D]Y=W:_!ZS\;6FH7#:Y''%>--YS%969P'B9,[2G)4+CC
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MV[!P>>>F<US7PZ\*1Q>!M$M]6M[U)[,B1K*Y9@B3!B0VT\''!'50>0,B@"U
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !65JOAW3-:N[.YOHI9);*3S;<I<21B-_[V%8#/UK5HH
MR+SPSIE[J2:B\<\5ZL7D&XM[B2)WCZ[6*D;AGUZ=JCN_"6B7EMIUM+:,L&G2
M++:1PSR1")UZ,-K#)Y/)]3ZUMT4 96I^'-*UB[LKJ^MC+/9%C XE="H8 ,#M
M(W*0!D'(-5U\'Z*L>J1BWGV:KDWH^UR_OLC!S\W'''&..*W:* *VGV%OI>GP
M6%HK);6Z".)&=G*J!@#+$G@5AMX \,MX@?6_[- O9)!+)ME<1R.#D,T8.TG/
M.2.O/6NEHH RI/#FF2P:I#)#*\>J9^UAIY#Y@*[<#YOE&.,+CBN1\0>%TAUC
MP;9:=87[:7IMQ*\K132,8$,15,.6W<-C@'@#TKT.B@#'?POI,NG7UC+!))%J
M'_'VS3OYD_&W#/G<1CC&<8XI;CPQH]YX<_L"ZLQ<:8(Q&(9I&?"CIAB=W&!@
MYR*UZ* .=LO WA^PTBXTN"SD^SW!0RLUS(TC;#E/WA;< I&0 1C\:L2>%=)G
MANH[B&:<W2(DLLEQ(9"J-N10^[< #D\$<DGJ:VJ* ,A?#6F[+L.D\KW<(@FE
MDN)&D:,9P@?.0/F/0CJ?6LV\2[\.6%CH7ASP_+=VLD3Q)))<@Q6F  N_>2Q7
MGH,\# KJ:* *.C:5;Z'HMEI=J,06D*Q)QC.!C/U/7\:BU3P_INLW-E<7T4DD
MME+YUN5GD38_3=A6 )P2.?6M.B@#&7PKI"7>IW2PSK/J:A;QQ=2_O0!@?Q<8
M' QCBKFDZ59Z)ID.G:?&T5I NV*-I&?:/0%B3BKM% &'+X0T26]U&\:T=9M1
M39=%+B10_P NW. P ;;QN !QD9Y-,/@S0S9Z9:?9I_(TMUDLT^US?N6484CY
MN<#@9[5OT4 8C>$M%>YU6X>VE:35HO)O2;F0B9-I4#&[ P"0,8QGBK-CH5C8
M78NXUFDN!%Y"RW$[RLL><[06)P,@$^N!G.!6E10!GW^B6.I7MG=W2S--9N7@
M*7$B!&(()PK $X)'(/!(J/7O#VE^)M..GZO;M<6A8,8A*Z D'(SM(SS6I10!
MYSXI\/K-X@M#>>'-3U/2[:S\FVN-/OF%Q&Y;+B0F1688"XY/?/48T-*\%6=W
MH]]I^I6VI+I%V8RFG7NH/(Z%<DDLKG )V_+N(^7/4D#MJ* ,C6/#&D:_HRZ5
MJMI]JM%(91)(Q=6'1@^=P/OG-0V_@[0;?0+C1!IZRV%S_KTF=I&E/'+,Q+$C
M P<\8&,8K=HH YS3? OA_2=+N].M+258+N/RIBUS*SM'_<#EMP7D\ @<U*_@
MW1'M-,M&MY_(TME>S07<P\EE&%(^;G X&<\5O44 9,?AK2H]6O=3%N[75[&(
MKEI)G=9$&0%*$E<<GC'<U1T3P%X<\.W$D^EV+0.P95S/(PB#=?+!8A,_[.*Z
M2B@#G/\ A!?#W]A/HGV2;^S7E\YH/MDV"^[=G._/WN>O7FKLGAK29=:M]8DM
MF:_@A$"3&9^4!W ,,X?!Y&X'!YK6HH S](T6PT*TDM=.A,44DSSLI=GR[G+'
M+$]ZT*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/! .2"<#C-=-7 ?%>WCT_P"%MXNGPQV[6TUL]JD*!0K^>F-H'3DG\Z[\=.:
M"N0\9^+-1\)SZ=.=/MI=(N;A+>XO'F9?LI8X#.H4Y7WS_.NOJGJNF6FM:5=:
M;?Q"6UN8S'(A[@_R/<'L: *&NZM?V,^FVVF6MM=W5Y,4,<LI0)&!EI,@'A>/
MQ91U-5[SQ++_ ,)%'X<TRWBN=4$ N+EW<K#;1YP"Q )+$]%';DD"N?\ A)'-
M-H$]S>W4EW<VMQ)ID,LN,K!"V%7ZGJ3U/&>@IGA^-],^-OBR*\RK:I:6US9L
MW_+1(UV.![@GI^- '0'Q+<:7XAL=&UV"",ZAN%E=V['RY'49,;*>4;'(Y(/J
M#Q4>B>)M0U/QGKV@S6=M%'I @+SI*S&7S4++A2!C&.>36+\2X'U37?!6EV?S
M7HUF.].WJD,0)=CZ#D?4\5-X:/D_&+QU')\KW$.GS1 _Q(L3*2/8'B@#I9=3
MOT\5P:4L%N;66V>X\XNV\;612NW&/X\YSVJAXU\37OA>TT^XM;."Z6[O8K,K
M)*4*M(2 V0#D"K3L)/'T(0@F#3)/,Q_#OE3;GZ^6_P"1KG?BXI?0=$19&C9M
M=LP'7&5^8\C((S]0: -?QKXFO_">A0:C%9V]VS3Q0/&TK1@%VV@@X/&371F;
MR+1IKMXT$:%Y6!^50!DGGM7F_P 5-.NK;PC#)+K5_=(-1M1Y4R0!3^]']R-3
M^M=5XM>XO(;70K..*:>_?,T<DA1?LR$&7)"L0&RJ=#_K* '>"_%D'C#1I;Z*
M![>2&YEMY8).&C*MQD>I4J?QJI)XIU&V^(MMX8NK&VCMKNV>XMKOSFS+M/S1
M[=OW@.>N,5@V4E[X8^+1-_;6]K9>*(<*L$YE07<(ZY*+@LAZ8Y-:GQ/TVY?P
M_!K^G)G4] G%_ !U=%_UJ?0IGZX% &[J>J:A;:]I>G65M;S+=B1YFDE*M#&F
M,L  <\LHQQRPK(L/$^MZCXLU[0H-/T\-I'D;II+AP)!*A<8 0XQCFK?A2\C\
M0O<>)X@WV:\5(;+>,$0IG)QV)<O]0JUS>AV4]Y\7/'ODZE=V6T:?G[.L1W9@
M/7>C=/;'6@#N]*N-1GCN!J5I#;S13%%\F0NDB;5(8$@'N1C'4&LJX\2S77B6
M?P_HEO%<7=I&LE[<3.5BM@WW%X!+.1SC@8[]JOZ% -/LSI;WK7ES;$M+*_+G
M>S,"Q  W$<D#\L$5QG@/.F_$7QSIEZ=E[<W:7T ;K+ P."OJ%Z'T- '66VI:
MM'X@ATS4+&#R9;:29;R"0E6960;"A&5.&)ZGI]<5O%7C*T\+7NC6]S&7&H70
MA=QTA0_+YC'L-[(.?4^E= T\2W$<#./.=2RIWP,9/TY'/N*\^U71M0\:Z;X@
M:.RL9;34D^RV<TUVR-''$3M<*(V',FYP<\C;Z4 =SJUU/8Z3=W=M'')+!$TH
M21BH;:"<9&<=*X<_$?4;/P58>+]1T6W&D7'EF;[/=LTL"NVT-M* -R1P".M7
M/#.OR^(?A;<3WF1J-K;36=\C=5GC4JV?<\-^-<!9VTL/@/P5=:]/+>>#6CC6
M^M@ @MY-W[N1RHR\0/!!/!P>>E 'J'C/Q1=>&=,LKZTM(+M+F[BMMLDI3'F'
M ;(!X]JO)=>(([ZT2XL+!K660I,\%PY>(;20V"@!&0!U[US'Q<Q+X4TSRY-H
M?5[/:Z8.,OP1G(KHETV33-9@U.\UV[N81"UJ(KD1@;Y)(]I41HO.5QSGK]:
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MI;3C?^;]LDV;1)LV_P"KSG/-=3I%Q>W6FQRZC:):W>YUDB1RZC:Y4$,0"00
M1P.#7'/_ ,E_A_[%AO\ TI%=VTT22I$TB"1P2B%AEL=<#O0!SOCOQ+<^$/"U
MQKEO:17:V[()(I)"A(9U08(![M5EKKQ)%=6RR:=I[V\DFR5X;ART0(.&VE!D
M9P#SWKG?C3_R2?6.<?-;_P#H^.NEL=$N;361?3:S>WR?9VA\NY\L!"64Y78B
M^G.<]J *'A'Q-?>([K6X[FRM[9-,OY+#,<I<R,F,MR!@8(]:N1:GJ<WB+4=,
M%O:+%:P13)*9&)?S#( "N.,>6><GK7._#<^5JWCBU?Y9E\033%#U".JE3]"
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M?906J2$LXA0*78]R1R3[GFL^/P;H,,]Q/%8F.:X??,Z3R*TC>K$-R?<UNT4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %<YXN>>ZM(-#LUC>YU)RCH\
MA0?9UYE)(!(!&$R >9!71U1DT?3Y=4CU-[5&OHUV)/SN5>X!]/:@#@'>^\+?
M%:SU"^M[6UL/$D0L91;SM(HN8QF)CE%P2N4 YKH]6TBQU[Q+>:7J,"SVESI(
M21#Z>:>1Z$'D'L16QJN@:3KGD_VI8078A;?&)EW!&]0.Q]Z>FC:?'J U!+91
M=B,1";<2VP?PYST]J /.-$N=7T7QCH7@O6_-N39W$L^G:B1Q<VPMY5PQ_OH6
M4'\/J=CP]_R6;QG_ ->EC_Z U=Q+:6\\\$\L*/+;L6B<CE"05.#VR"166_A'
MP_)>S7KZ5;M=38\V8CYW^IZF@#D-3QKOQQT'^SCYB:#:3OJ$R<JAE4JD9/\
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M:OHWC'0_!FM^9<M9SRSZ?J)'%S;""50&/]]25!_#ZG7\._\ )9/&O_7K8?\
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M(%T_.[[,H(CSG/W>G7GZUJ"",0>1L#1;=I5OFR/0YZT 9/A#_D2=!_[!UO\
M^BUKF_@[_P B"O\ U_77_HYJ[=+.WCL4LHX@ELD8C2-/E"J!@ 8[8%5M*T33
M-#@:#2[**TA8[C'"-JY]<=,T <3\)(GTNU\1:#=_)J%GJ\TDBMU>.3!23W#
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>=+#YJQDH8V0D%N.-P.*Z.\U&RTZ-9+Z\M[5&.U6GE5 3Z DU8!! (.0>A%
M'&Z=I^KVWCKQ#JT^ER?9KVSMXH3'-&=SQA]PY8'!+<$@=.<5S6G>%_%6B>&O
M"-[9:='+JVA)/;W.GRW"*+B*4C.QP2 1M4C.._X^KDA022 !R2>U5_[1L?LJ
M77VRW^SN0JR^:NQB3@ '.#SQ0!4T2?5KNW>YU6QCT]W($=HLHE:,#NSC@DGL
M,@ #GDU-K.E6^N:+>Z5=@_9[N%H7QU 88R/<=:O44 <7X7;Q'X;T>VT+4M$G
MU 62""WO[*:'9+$O"EED=65@, ]1QUH\3Z%K6H2:'K=JD,NI:3>FX^QK)M5X
MF78\:N<#=MY!.!G/05VE% '%S:-?:CXFN_$DFGS0-'I+:?;6CR1F61F;<S$A
MBH'W0/F_O=.*Q1X;UU/ ?@W2O[*D-WI-_:3W2B:+ 2(Y8@[L'/;]<5Z=10!P
MU[INI#QQK.L/82)I\NA_9%F,B??5G<_*&SC#8Z=:P=!TN^\5?"7PUH1T^2"V
M=+5Y[MY$*>5&P?Y &+;FV@8(&,GG@9]0O+6.^LYK64N(Y5*-L8J<'K@CD57T
M;2+30=*@TRP$BVD"[8D>0N57TR><4 ><>*/#7BG6]/\ %EC-I,5[/<R[M,O)
M+I L<'RD1(IY1N#D\ YY/ KHUL-8D^(]CK<NE.EJFD/:2%)XVVR-(K@=02 %
MP3CKZCFNSHH XOPEX>N4T+7],US3S%#J.H7<VQI$8/#,Q('RDX.#S2_#?2[N
MST#[1J%V+R9C]FMY\?>M82RPGWR-SY[[ZWM=\.:7XEMX(-5@>:."43(%E>/Y
M@".=I&1@GBM*..*W@2*)%CBC4*JJ,*J@< #L* 'UY-K?AOQ7JFEZO!<Z-%>:
MA_::7%M>O=H ]NLRLL<8/*85<$':#R<DFO5;>X@NX5FMIHYHFR \;!E.#@\C
MW!%)]I@^U?9?/C^T;-_E;QOVYQG'7&2.: . L+R\M_BUK[C3);EWTNS,B6\J
M91LR<9<J".O/Z5CZKHMWX:TWPIYD*S7UUXK^W301.,!Y%E8HI.!P,#)P"1VK
MT+3]&TG^WKS7;*=Y;V;_ $>X=;DNOR$_(5S@%23QU%2ZQX>L-<GLIKWSR]C,
M+BW\N9D"2#(#8!Y."1SZT <W?Z%J.IZYK&OG3Y(I'T9M+M+5I(_,D+,79V(;
M:HR5 YSP3Z"HYM#U>3X+#PZ-/<:I_9:V/DF6/&\(%W;MV-O&?7VKO>U!.!DT
M <'K7A[^W;&PLM6\-3W,,-DGE7%M/$EQ:7 X.UBXX("G()&0,@]L]=$\9Z%-
MH&N0Q1Z[J$.G?V?J=L]P(WD7=O5U=N"P/!)Z_CQZ/;W,%W;I<6TT<T+C*21,
M&5A[$<&I: . U_2?$]^^@^)(;&#^T]+NWF_LL3KS#(FQD$API?'.>G)&3C)M
M:+9:W)\1-0UR[T@V=C=Z?# OFW"-(K(SD@JA(S\W8X]^P[6B@ KS;3?#FO:1
MX(U;P4FG_:(I1<06.H>:@B$4Q8YD!;>&7><@*<X&#7I-% '"7OAZ_LM<\$+I
M]C+=6&A1R132^9&I*F#REP&8$GN?ZUW=%% ''Z]9:Y/XRLI5TY-3T+[(R&W>
MX6-(KG?D22*?OC;@# 8@Y(%<OIWA?Q+:^$/".ES:/^^TC61=S^7<QD&(-*<C
M)')\P8'L<XKUBB@#DM+TW48?B1KFJS6+QV-Y:V\,4QD0Y:/?G(#9 .X8X[=J
MH^%O#SV'C/6Q'.KZ/9W#2V4 '^IGG56E'X#ICH)6KJKZUTWQ'I-WI\SI<VDN
M89A#*1@CJ-RG((HTRSTK0X(-'L/*@"J72#S,NPS\S')W-R>2<]: -&N#U_2?
M$%_XEU-'TV+4=+GL!'8-)<*D=I+AM[,AY+'(PP!QC'&37>44 >5Z;X=\4:*/
M"&LQ:2L]SIFF_P!EWVGK<IO,>%PZ,2$SN7.,],<^C=0\'>(M=@\9JUG'82:E
M<VMY8-).KY>)4PK!<XR5P?0],CD^K4UW2*-I)&5$4%F9C@ #J2: .!FA\3:U
MXK\)ZO/X<-DNG?:1=K)>1-@R1A<KM)R,]._'(%6/#OAZ_.G>+]/U.SDM(M7O
M[J:*3S$?]U*@4?=8X88)Q^M=K#-%<0I-!(DL4BAD=&#*P/0@CJ*?0!PWA-O&
MEI:V6A:KHUK#'8A(FU5+I72>-, ;8\;@S  '. ,D^U48O"M])XGT[6[/29=%
MU07>=4FAG3[/>0?-G**Q)9N",J,$G)X!KT>D9E12S,% ZDG% 'G*>%;Z7Q/I
MVMV>DRZ+JHO,ZE<0SI]GO+<9SN16)9FXZJ""3D\ UZ/3$ECDSLD5L==ISBA)
MHI#A)$8^BL#0!PLUCXF\.>.=6U/2=)35]-UD1/(GVI(7MIHT"9.[JI '3)]O
M6S>Z7K<_CCPOJ<MIYT5C;W27<T3H%5Y0F H)#$#:1G&<8ZUVE10W,%PTJPSQ
MR-$VR0(X)1L9P<=#@CB@#S9M$\66^F^)/L%C)%+?:ZM\L8NHT>>U.P/&KAOD
M8A#SQP>N:?!X>UNWUCQ1<0>'H;:TU32HX8(HKF,%)%60;2.!NRX).<=>2:]+
MHH \X;0-;_X1_P !6@TJ0S:+/;R7@\Z+"B.)HSM.[GDY'M5"\M=3N]9\2_8/
M#=QJ.D:A<>3<&PU*&*.XV*$?<)/F#9W*Q0@'&.H)/JU<V? NA+?37<$=[:M/
M(99HK6_GABD<]2R(X4D]^.: .>O$UJ6_T7Q=X:T?SO)MI=.O-'GE2%U02=$;
M)7*NA'7!'3K6IJEEJ.NZ/!!KOAF"]M;F8FXT])D9[9-ORL')4%]W4J1@,0"<
M<];!!%;0)!!&D<4:A41!@*!T %24 <SX&T?4-"T6>RO9KAX1=2-91W,HDEAM
M^-B,P)!(P3U. 0,\5TW6BLO4K#2O%.CW.GW+K=6<C;)1!,1AD8'&Y#D$$#C-
M ',>!_#TFEZWK""=9=+L+F2#2XP/]2LFV65?<!L*/3:PJKI>@:[H7AO7/"T6
MG&[@N'N/L%Z)D$:I-DXE!;<"I8YVJ<CI76Z?=^']+MTTNQO;"%+=A%Y"W"EE
M9CP#DYW$D]>23ZUL4 >?'PSJ?AO7/"]UI5@VJ6VGZ6^F3*LR1.OW"LGS$ C*
MG('(ST-:?@/2M6TF+7$U6TC@-UJ]Q=Q&.8.&1VR#QTZ=^?85UU10W,%P9!!/
M'*8G\N0(X;8V =IQT."./>@"MK4<TVAW\-O"TTTENZ)&I +$J0.20._K7!_\
M(]K@\*> [#^RI#<:->6TUX/.BP%CC9&VG=SDL"/Z5Z510!Y/XB\->*]8TOQ)
M:3Z/%>7DM\LMA>R7: "V61&6*-3RA 4@YV@\G)-=3XOT'5M8M]&U/2O+M=<L
M+E64EMP6.0;)5SQD!3N]]G%=4]S!'/%!)/&DTN?+C9P&? R<#O@5+0!QOBSP
M[J(TW0[CPS'$][H4ZR06TS[5GCV&-H]W8E6X)K9T&[UJ_1[G5M+32A@+':>>
MLSY[LS+QZ  >Y/7 V:* "O,;#PMKC_#4>!KK3C S,T,U_P"=&T/E-*7+( V\
MMM. "HYZG%>G5%<7,%I%YMS/'#'N"[I'"C). ,GN2<4 <*UCXG\+>+M3N='T
M:+6-(U4QRE/M:P/:RJBQG.[[RD*.F3_6UJ.DZ\/%_AO6H[6&\-O:W%O=A)1&
ML32;"",\E05(X!..U=K10!QNI^$[FZ\>1ZC"8_[)O;58]5B;_EJT+AH>.^=Q
M![;5([TWP;X0NM&TS4=/U&7?"#)9V!!R4L]S,F3_ 'OG(/LJ^E=I10!P'A&+
MQII%C9^&KW2+4V]B%@36%NE*O O"XB^]OVC'/&>?8QZ/:>,/#%[?Z-::-;:A
MID]W+<6>H-=+&+=96+E9$/S-M+$_+U]NW?37,%N8Q//'$9'"1AW"[V/0#/4^
MU2T <=8:=JEI\0]7U:6PEDLY[""WBE62+,CQEB?EW#&=W']*G^'.E:AH?@:P
MTO4[4V]W;F0.N]7!S(S @J3V85U5% '-?$#3+[6O NJZ7IMN9[N[A\J--ZJ
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M(N[>)=_W<YVXXSUSVQS0!4T[QCIFG^$=;UO^QAI\5GJ,T$MM"5+33^8$+$@
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M!6B:+?QMQSD,,<@>M95AX>UN#X?^*-(DT_%[J4]ZUNHF0KB?=M).>,9Y_3-
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MV12[=,DL2<9P, 9J.]\/:U/I/@JW2SB\S1;B":Z!G&"(XC&0GJ3G(SBN]HH
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M%] L]K<(8Y8VZ,IZB@#C_#WA];;Q]KMW;W&_2XY1-%;@?+%=RH/.(]]H4_\
M;5JDTO1=:\,:IX@33[6&^L=5NWO[=FF"&":0#>K@CE,@$%<GKQ74Z7I5AHNG
M1:?IMK%:VD0PD48P!Z_4^]7* /.AX(U'P[:>##HL<-_)H'G)-%++Y/G"9"'9
M3@XPQ)QZ57NO"7B6YTGQQ;/;6)DUYPUN4N#A#Y:J=V5Z#'7J?[HS7IM% %33
M%F32[5+B(13)$JN@;< 0,'![BN$\0>%_$FIWGBN(06-U#J=H8;"ZGG(:U4Q[
M6C";3C+<Y!&<Y.<8KT:B@#SR#P]XETCQ!I7B&TM+2YE.EIINH6/VG;M"'*NC
ME<$CH00/;/6L^3P+XDNM'U7(L;;41XA_MW3\3LZ%QC"/\HP, \^_05ZG10!P
MT>G^);SQQIGB&ZTFTMH;?3YK:6$7N]]S,K<87!^[ZCZCI4>A^#KY_AE?^%-7
M5+>6X^T@2Q2>8H$LC.I[="PR/:N]HH Y'PXWC=E@M->MM.@2U7$EY;SF1KL@
M8&$*C9DX))/L ,\9FF>$;T>*=+U\:=#I&H)&XU9[68&*^)0@ (.OSG=E@",=
M^H]!HH \^TSPC>_\)3I.O'3H=(U&-7&KR6LP,5]E"  @ZG>0V6 (QWX-;/C_
M $?4->\,'3M-BCDG:Y@E)DDV*!'(KGGGKMQ7444 <7J/AZ^U7QT=0GM0NES:
M++ILQ\T>8&D<,2!Z #'7K6;'X2UR[\ 1>!]1B@^SQ^7;MJ*2C:]LCAAA/O!R
MJA<'@=<GI7HU% ''-X<U%?'.K7:PV[Z3JNGQ6LKF8K)#LW@@+@[LA^#D8_G5
M\*6'C;1[6T\/7L>G/I]CMCCU1)CYDD"_=7RMO#;0%))P.O)Z]W10!YBOA7Q/
MI?ASQ-X6L[2TO-/U 73V5V]SY;1B8'*.NTY().".#GG%=[H-M=67A_3[2]2)
M;F"W2*01.77*J!P2!Z>E:-% 'E2^$?%SZ7I<5S::;/J%CK4=_/>O=MOOE5V(
M)^3Y %8#'.,8 KJ=(T;5]-\>:]J#16KZ=J@MY/-$I#HT<6PKLQSDX.<]*ZRB
M@#E_&VC:CJT&BS:9'#+<:;JL-\8II/+$BJ&4@-@X/S9Z=J@M-+UB'XA7FNSV
M<1MIM,BM (Y@3YB,SG@X^4[L ]?4"NOHH \LLO!?B?3?"N@/9"T37=#N[B9(
MI)<PW,4SN63<!D':PYQU'XUWNA2:W<127.MV]M9R/@1V<$OFB,#.27P,DYZ
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MD;(_,D=)/K@8!_W?6N8EM)A\,OB3:1VLHDN=<E>VA6,[I4,D>TH,<C /(]*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5\0:C!J=RT^N#_20Z)M0_-@H,<8W'KFNPHH Q=0\,6.JS:1<WHWWFES+-;W
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
:*** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>thackray-biocrystseparat011.jpg
<TEXT>
begin 644 thackray-biocrystseparat011.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU'3&F\CY"S- <L2N#D^O6MK0]+L+'XA>+])M+2&#3I;"TE:UB4+'O(D!(4<
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M<WX6\+Z+<_#K5-2GL8Y+RW?4TAE8DF-=\@VCGIWQZDGJ: /7A)&S!0ZDD;@
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MX.V@#Z%CO8'LENVEC2(J&+,XPN?4U(;B$(KF:,(XRK;AAA[5XUXPN8M(\:^
M=.MUL;/16+R%#&%MS<%0%+JN!D%E(]-V:Q/B;X>?P]\*KJSEU*"^ UX30K%'
MM%H)$9C$O)P!G./]J@#Z CN(99)(XYHW>,X=58$J?<=JXOP;X[E\0:OXFL-1
MAM;0:->"T659"!*=SKGYNGW.GO7)7=G!H?Q]\+0Z##';QWFFM]LC@&%E3$A#
MOCJ<@')Y) KBY]-LKO3OC!=7%M'+/;:AF!W&3&3/)DKZ'MGKCB@#Z9HKG/ $
MTEQ\//#LLKL\C:=!N9CDD[!UKHZ "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'J'.SYL^]1'PGXH:VBMCX5^'QMXG+QQ&.7:C'&2!Y> 3@<^U %.["C]IVP(
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M=(E"ACCJ?4\#D^E85GX+UC6? 6H^';:.*_O9?$+3G6/,1H6"@*SDD[B00P(
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MW5N+<7!GB$! (D+C:0>G/2N'CNXF^,4-K,8C9'1F_LW&#&9!+B8+VWX SCG
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M\@EPP<^PR-W/H:YWP1XGEUGP[;W&L75HE_/=7$*(F(Q)Y<K*-JDDG@#N:R_
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MC=(X49],FN'\,"SA^*/C5&$"3-+9>4IP&.;?)V_D>GO74^(]$M_$?AV_T>Y
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M[4\Q>I56(R#QD@<5T/BF'2O"_B?PT$$.CZ1=7$[7%Q#$BQBZ\M1$S[E*YQO
M)[\^] 'H<-W;7-J+F"XBEMR"1*CAD('?(XIEOJ-C>6[W%M>6\\"9#212JRKC
MKD@X%>5:[#I7A[3)[O3=7N;G3+G7;:;5Y4\IX8 0=Q 5=OWO*+ @]1ZU>UK2
M?#\VG>+M3M-7.J7%UH<IN$5H7@&Q"8Y&"*,/UVDGH#Z4 >CQZC92SK!'>6[S
M-&)5C652Q0]& ST]Z=:WEK?1F2TN8;B,,5+1.' (ZC([UY5<Z/I@L_AC*+*
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MLQ:EI&FM-=6[:A-90W$L*N PW("3MZ@9-7Y=0LH+J.UFO+>.XE_U<3RJ'?Z
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MCY5U_P ?"?V&^)><_,/.^;GUJ6W\/:_9S+-;2>%H)4B$"O%HLBL(P<A 1/\
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MI=2MM+LH;Z;/F7,<"K(^>N6 R:5M#TAM6&JMI=D=1 P+LP+YH'3[^,]*OT4
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MT33K-;:;_60B!0C_ %7&#^-+::3IM@RM9Z?:6S*GEJ8850A,D[1@=,DG'N:
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHUKID-O/9V]A"EW=-(0$D"+^[0 '<V.O("\#KP*FH_$*:&RFU/3K!+ZS@NC
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M5URH).#T(Z_E6A_PE4^EV_AZPU"2QM[K4H&:.XGF;RCL5,*20,NV_I['KP"
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M2\B4/) L@+HIX!9>H_&K5>=W+ZA#\8=3_LBTMIKI]"@/^D2F.,?OI.6(!)_
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M1+>W"-)% 6^9U7&X@>V10!QVF>%+O1M=U/7M*L++2VGT]HS8+.3!-<YW+(P
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M-K*,I+$P96[=1[U9H X"7PYXDN;#PA'-!IJRZ+<QRS*ERY#*D1CPIV<DY)[
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M&XM-14'RY1L)8;"Q(9<=R0<@^Q36_"_B+Q#H4$USJ%E:Z_:7D=[9B ,UM$Z
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M_;YH/W<_Q;,=/XLUHZ!X?U&QU[Q+=:@EFUIJ\RRHL4S,R@1B,A@4 Y SP?\
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MM+V%9K>4;9(W^ZP]".X]JL44 06=G;Z?:1VEI$L-O$H6.->B@= /0>U3T44
M%4;[1=+U.YM;B_T^VNIK1B]N\T0<Q,<<KGIT'Y"KU% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45RZ>(-0U7Q
M%JVE:.+%#I)C2=KHL6D=UW@ +C:N"/F.><\<<V+?4=>U+PI+=6]I8V6LB66,
M0W4C/ A29D.64 D%5)! '44 =!12;@.I .* 0RA@00>010 M%(KJXRK!AZ@Y
MH5U8D*P)!P<'I0 M%(&4G 8$^F::SED?R2C2*" ">,^AQ0 ^BN<\$:_=^)/#
M$>I7T4$5PT\\3)#G: DK(,9.>BUT>: "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#@-?
M\'V/B?6[O5M!U2?1O$VGN+>2[MSPYV*RK*G\2[67_P"N!BN:\0:OJ'B+X'Z[
M+KD,0U+3KLVDDL/$<KQS(I=?8Y(_/Z5Z;<^&-&NKN:[DL$6ZG(\Z>)FCDDP
M &92"1@ 8/%23^'-&N=&31YM-MVTU,8M=F(^#D?*.#SS]>: .0UG2;#4/C'I
M\5W;K-%-HLYEC<DI)B6, ,O0CV/%<M!?KHOA;["SF'0X_&4MC<#.$BM=[$(?
M1-VT'M@D=Z]9.@:6=1BU VBF\AC\J.<LV]4_N@YSCVJ./POH<5A>6*Z9;_9+
MUB]S"R[EE8]68'J3Z]>!0!QWC"VL/#&B>)=4T&62"\N+6![B"V/[N*(.$:4*
MN-K%"W.03MXZ&K>G^'=*E\0:;J]MJ=AY5U:O +;3K;RH[R(KD%\.V=O8^^.]
M=1I/AO1="T^2PTS3+:VM9<^9&B<29&#NSUXXYJOI7@[P[H1N3I6D6MFUR-LK
M0KM+#TSU ]AQ0!Y7H]A:Z3\#8/%%K PU9+5H7O%9BZP-<XD P>@7)XY')!!)
M-=QI.AZ=%XGTW7+'5;%!<6K1+;Z;;"..[CQN#-AFSMXPWOCN*ZG3]$TS2].;
M3K&QAALF!!MU7]W@]1MZ8.3GZU4T?PCX?\/FX;2-)MK)KD8E:%=K,/3/4#V%
M 'GVB>&$\5?!R6S1(_MT5Y>364C '9,MQ(5Z]CC!]C71>$M1MO&EY:^(C9K$
MNGVGV95>/!BN6P9EY_N!54'_ &FK6NK*Y\,Z;##X2T"UG$EQ^]@:Y^SHBG)+
M]#WQD 9.>]7](TE=-T064@BEED\R2X(7:LLLC%I#CL"S'\* -"WN(+N!9[::
M.:)ONR1L&4_0BI*Q_#7A^U\-:3]AM(XXHC*\OE1 A$W'[JY[#CGN<GO6Q0 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4<4$4)<Q1HAD8NY5<;F/<^IH X_QYI6JZKJ'AEM.TZ2YCT_58KVX<2QKA%#
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\)?]"WI7_@(G^% '0T5SW_"">$O^A;TK_P !$_PH_P"$$\)?]"WI7_@(G^%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BN(\3>,M=\-Z+>ZQ+H-FUE!=>1&K7S++(IE\M7V^40
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M ***0YP<<GMF@!:*YWPCX@NO$$6KF\MH;>2PU.:Q"Q.6!$>WG) SG)["NBH
M**Q?$?B2W\.V]MOB>YO+V=;:SM8R TTA[9/  ZECT'Y50U?Q'JGAJQ&J:S86
MK::K*+F2SF9WM@2!N*E1O4$C)&"!S@T =316'K/B!+!](M[3RY;C5KCR;9SR
M@&QG+G'4!5Z \DCD=:RHO$/B!M43P_/9V$&M-%/<K+N9X'A1E5&V@A@6+XQG
MC:3SP* .QHK&\.W/B&ZMYI/$.GV5E)N7RHK:<RG&/FW' '7.,=JV: "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ]PXFXQ\P: @\<?3BJ^A>&-0\,RRRZ/X4\.VLDHPS+JL[$#.<#= =HSS@8%
M&-X>TM?$'ASPWXG37K2WO(Y(9KB[AM3Y\\A^62"1_,^8,QVXQZ8 &!5SP=X=
MT[4/$GB6YNUN)I-.U]GM=]S)^Z81)S][GKWR.!5FS\(75AKKZU:>#_#46H.Q
M<RKJD^ QZL%\C:#R>0,\FKVFZ5K^D7-U<6.@:+%+=OYD['6;AO,?^\=T)Y]Z
M .SHKGOM7C'_ *!&A_\ @TE_^1Z/M7C'_H$:'_X-)?\ Y'H Z&BN>^U>,?\
MH$:'_P"#27_Y'K>B,AA0S*BRE1O5&W*&[@$@9'O@4 /HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]#6;\&M%UCPGX.UBQUG2;RWN9+AIHT";_,4HJX!7(SD=Z /.-"UIS\'M0O\
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M>LDW6[CY&F7KY9/8]QZ'ZFMW6([J];1=&-I?)9L4EN[J!1B,H 43/7EPI/!
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M==B+4!$;1O*_UVV 1G'I\WKCUZ5D_P!E:JO@3P'8?V7>&ZTS4+.6\B$?,21
MASZ'J.F<T >CZMJ(TG2KG4&M;BY6W0R-%;A3(5')P"0#QVS6=%XJM;C0])U6
M"TNI8M4:-;>)/+W_ #@D$_/C@ DX)P ?2MWJ/8^M<#X.T"YTWQ-JE@SH^BZ1
M<.VFH/\ EFTZJ[(?38&('M*: -R]\8VMK#J-S#8WMY9Z;(T=Y<6ZH5C90"^
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M/TFUEU":UNWTJ"X^SSW\80QQMOV$XW;BH?Y20IY]:S;4)#\:-1>/>ROH$4I
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MSF/,T9)7Y6#E0=PP02/RK,\*^-GU7P;9ZWJ5E-#)=R%((U*'SF:1@J)AL\
M$MMZ$],FLW1;"]C^)4.JQ:#J-O87&C?9FGNY%:02"7<3(=Y.<<#J>G '3$M?
M#OB%?ACH=B-"9]1\/7RW#6=RR;+U09 RIR1C:^03CF@#T32/$]MJFLWVCO;7
M%GJ5DJR203[3NC;[KJ58@CMUR#UK<KD-'OI18WNJVO@R;3?)MVVVSQ11W-RX
MYVJ%) 7C'/4GH,<]39SO<V5O/+ ]O)+&KM#)C=&2,E3CC(Z4 34444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!F:GX?TW6)4EO8I7=%VJ4N)(^/HK"J/_"$:!_S[7'_@;/\ _%UT-% '
M/?\ "$:!_P ^UQ_X&S__ !='_"$:!_S[7'_@;/\ _%UT-% '/?\ "$:!_P ^
MUQ_X&S__ !='_"$:!_S[7'_@;/\ _%UT-% '(0?#7P]#?S7;_P!H7!=MT<<U
M_*4@XP=@W C/N35[_A"- _Y]KC_P-G_^+KH:* .>_P"$(T#_ )]KC_P-G_\
MBZ/^$(T#_GVN/_ V?_XNNAHH Y[_ (0C0/\ GVN/_ V?_P"+H_X0C0/^?:X_
M\#9__BZZ&B@#GO\ A"- _P"?:X_\#9__ (NC_A"- _Y]KC_P-G_^+KH:* .7
MO? &A7EG+;J+ZW+C E@OY@Z>X)8C]*+3X?>';.W6)+>Z<CEI'O9BSGNS'?R3
M7444 <]_PA&@?\^UQ_X&S_\ Q='_  A&@?\ /M<?^!L__P 770T4 <]_PA&@
M?\^UQ_X&S_\ Q='_  A&@?\ /M<?^!L__P 770T4 <]_PA&@?\^UQ_X&S_\
MQ='_  A&@?\ /M<?^!L__P 770T4 <]_PA&@?\^UQ_X&S_\ Q='_  A&@?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MR[OF*^HP>G/(![%17D%SXA\0W'C[P[X5U=9_,_LDW%Y#87(A-Q<88$[PR_*
MI; /7UQ7>>!X?$-MX6M[;Q.ZR:G"S(THD#ETS\I8COC@_3- &S/J-I;7UI93
M3*MS=EA!'W?:NYC] ._N/6K5>,Z[IR7G[26F6TES>K')I32?NKJ2,J<2#"E2
M"H^49 P#SZU4F\1:MKB?$O4Y-1O;630G\K3HX+AXUAV,_)4$!BVP9W ]2.E
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M\K9#?Q ]![UWW_"4ZKXC\?\ @O0[J2>TLKS1UU*[BMY&A,TC1,=I92&VJ5Z
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0O;2->N2,G.WT"Y[+CJ?6KK_  ]TE]:UG5OM-\+O6+=K:[(D7#1D 8 V\8
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M[<MG)1<8!Y/)SU/J<YZ_"7P\OAZ]T(3:A]@O;D74Z&9<M(.^=N1T'Y"N[HH
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MM<K+:R.\;!U#2=0K$CAQU% &[HGCJ'Q!X=TK6+"PD=-1NC;)"95#QD;LENW
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M@S2='G=7FM8 LC*<C>>6Q[9)K>H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **9'+'*F^.1'
M7^\K BN!T'Q[J_BG6)_[&T:&72K74FL;F22<+(B 9\[GJ,_P@$^_H >@T5D^
M(/$>G>&[2">_F"FXG2W@C!^:1V8  #\<GT K"UGQM/I/Q&T/PP+**6#5(V<7
M'F$-'M#9&,8/W?7O0!TFLZ-8Z_IKV&H1-) S*_RN4964AE8$$$$$ U67P[;/
M<VT][<W=^UK)YMN+F0%8WP0&PH ) )P3G&:LZG>W$&B7=YID"7MS'"[00B0
M2N <+N[9/%0Z%J-[=^';.^UJT33;V5 9K<R B-L],^_!Q[XH U:*0$$9!!'M
M7&V/C6XN?BGJ'@V6QB6.VL_M2W2R'+ [, KCC[_KVH W_$7A[3_%.B3Z1JD;
MO:3[2P1RK J0001[@5;L+&'3K-+6#?L3)W.Q9F).2Q)Y))))^M3"6,R&,.ID
M R5SR!]*R['Q)INI:_J6CVDRRW&G)&;EE(*JS[L)GU 7)],B@#7HK)T+Q'IW
MB-;Z339A-#:736IE4Y5V55)*^H^;&?:M-)8Y"P216*'#8.<'WH ?133)&H!+
MJ 3M&3U/I3J "BBO/SX^U(?%8>"?[/M<&+SOM?FM]W9NQLQU[=: /0*BN;:&
M\M9K6XC$D$R-'(AZ,I&"/R-2D@#)I-R\?,.?>@#GD\&Z>NF)I4ES?3:4B+&M
ME+/F/8.BDXW,O &"Q&.#70@   # '0"@LHSE@,>](CI*@>-U=3T93D&@!U%<
M3XF\=3:!XO\ #>CQ6EO=6^LSF'SA*0T14J#Q@@_>'ITKLVEC1E5W56<X4$X)
M/M0 ^BDW#.,C/I3#<0B,2&:,(QP&W#!/IF@"2BLC7?$FF^'H;1KV90]Y<QVM
MO&"-TCNP7@>@SDGL!6I)-'%'YDDB(G]YF % #Z*3<NT'<,'H<T@DC:0QAU+@
M9*@\@?2@!U%8GBS77\/>&]0U.!(9IK2!I_(D?;O5>N,<_I2^$==?Q-X3T[6G
M@6W:\B\PQ*VX+R1C/?I0!M45D2^)-.C\3P>'A,'U"6![AHU/^K12!EO3)/'T
M-8/A?QS+KGBOQ+HMW:06RZ-*L8G64D2[BPR00,=!W/6@#M:*1F55+,0% R23
MP*C-S +9KDSQB!5+-+O&T =23TQ0!1U?0;+6I+.:X\U+BRD,MM/#(4>)B"I(
M/0Y!((((I+70K:WU%=1FEGN[Y(S$D]PX)1"02%  49P,D#)P*/#^OV7B;2$U
M33G+VLDDB1L?X@CLFX>QVY'L:J:IJNMVOBC2+"QT9;K3+G?]LO#*%-O@<<?Y
MS0!OT5Y]J/CW5I_%^K>'?#>CPWUWI<,4LJSS"/SBY7*J20%VJV<G.2,8KH_%
M^N7/AOPI?:U!;Q3M9Q>:T,C%0P[@$=/RH WJ*YSP+XCN?%OA.SUVXMHK;[6&
M*0QN6VA79>20,_=STKH7ECC95=U4L<*"<9/M0 ZBN?U+5M;M_%6D6%CHZW6E
M7*N;N]\X#R,#CCOV^N:W3-$LHB,B"0C(0L,D?2@ FC\Z"2(.T>]2N],97/<9
MR*P_"?A#3?!FFR:?I+7 M7D,OES.'PQ !(.,\X'Y5O;AG&1GZTD<B2KNC=77
M.,J<C- #J*R?$?B/3O"^DMJ&HS!$W".- ?FE<G 51W/\AD]JPO$OC:?P_P"-
M?#FA+913P:RY3SO,(:(@@'C&#U% '9T55O+J1-,N;BQC2ZGCB=HHA( )' .%
MW=!D\50\-ZIJ-_X:M;_7K!-+O7!\ZW,@(3YB!S[C!QVS0!LT4@8,,@@CVJMJ
M>HVVDZ7=:C>/LMK6)II&]%49- %JBL'P9XGM_&/A6RUNW41^>I$D6<^6X.&7
M\Q^1%;;31+(L;2(';E5+#)^@H ?12;AG&1D^]()8RK,'4A20Q!Z8ZYH =134
M=)$#QLK(>0RG(-(DL<BEDD1E!P2IR : 'T4PRQAE4R(&?[H+<M]*59(W9E5U
M9DX8 Y(^M #J*9YL?F^5O7S,9V9YQZXH:6-%9G=55>22< 4 /HK*\0^(=.\,
M:%<:OJ4ZQVT*9'/,A[*OJ3VK3C<2QJXZ, : '45Q>@>.9=4\<>(?#MW:06Z:
M0%(N1*<2;NF01QU]:[,D 9)&.N: %HK/U;6+72- O=8E/FVUI \[>602P4$X
M'OQ7-^"_%6N^)X[;4;G2+:WT:[LS<1W*3@M')O*^4RGD_*,[L =J .THIB2Q
MRQB2-U=#T93D?G2F1!MRZC<<#)ZGTH =13#+&)1$77S",A<\X]<4\G R: "B
MF&6-2H:1 7.%!8<GVH$L;.R*ZET^\H/(^M #Z*3<I_B'YT9RORD>U "UA7'A
M'2;GQ2GB*2.;[>L*PG$I".JMO7<O0X8 CW ]*RO OC6X\6WFOVMQ8Q6SZ3>&
MUW1R%A)@L">0,?=KKTFBE9ECD1RAPP5@<'WH ?13!-$9#&)$+KU4,,C\*R].
M\2:=JNN:GI-G,)9M-$0N&4Y57?=\F?4;.?3..N: ->BD) !). .I-<7+XYGB
M^*5EX1^R026]Y:&Z2[24Y  ?C;C!Y0\Y[T =K13&FB658VD02-]U2PR?H*=N
M7.,C/IF@!:*0$'H0<4V26.%-\LBHO]YC@4 /HK%\6>(X/"GA:_UR>)IH[6,,
M(U."[$A5&>V21S5'PCK>O:W']JU+2[>WT^>UM[FTN89L^9YB!F0KDD;2<9.,
MXZ4 =113'ECC95=U4N<*"<9/M3MP!QD9],T +147VF#RA+YT?EDXW[AC/UJ0
ML <$@4 +149D\R.3[.\;.N5'.0&]#BN2^&_C:7QWX>N=3FL4LVANWMO+20N#
MM53G) _O?I0!V-%,CFBE4M'(CJ#@E6!%.WKC.X8^M "T4TNHSEAP,GFF_:(=
MB/YT>QSA6W##'V]: )**:\B1(7D=40=68X I=ZX!W#!Z'/6@ 8$J0"02.H[5
MS_ACP;IOA*2^;39+H_;I3-.LT@8-)_>Z<']*WUD1W9%=2R_> /(^M96E>)-.
MUK4M3LK"83-ITBQ3.I!7>025![X[^_':@#7HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS#X\
M7M_9_#Z-+-Y(X;F]C@NW0X(B(8D$]@2%!_+O7I]5[ZPM-3LI;*^MHKFUF7;)
M%*H96'N#0!Y;#$+'X_2:+I]M&ND7>B@WUHB#RB " S+TS]U?H<5#\![*UB@\
M43QVT*2KJLD*R*@#", $*#_=SVZ5Z;I_A[2M*>=[.T$<MPH268NS2,H& "Y)
M; '09X[4FD>'-(T S?V5816GGMNE$60';U(SR?>@#S/XXV=M-?\ @QY;>)R^
MJI$[.@.Y"5RI]O:J_C/2M-?XT>!M,2U@73_L\J?9XE"Q[1ORN!QC/!'0\@UZ
MQK&A:7X@M%M=6L8+R!7$BI*N=K#H1Z&J\OA70IM0M+]],@-U9J$MI0"#"HZ!
M<=!]* /%O"\:)\/OBKIZHOV2UGN3!#CY8\*^-H[?=7\J=%I>N7OPP\":AH'V
M>[O=-BN+DZ7<*'%TF[:S!3PQ4-C'7Y^.:]B@\&>';:VO;:'2H(X;[_CZ1<@3
M]_GYYZGKZTJ^#] 2UM;:/3DBBM-_V81.R&'?C=L((*YP,X_K0!F_#+5++6/
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/#:F)"I94^5BV2>=P8<8^[GOQSNI>,;V?XB)X-T9;6.XCLVN[FYNHVD5>FU
MJLO/().>AZ4 =G--%;PO--(D44:EG=V"JH'4DGH*I:;KFE:RTRZ;J-M=M#M\
MQ89 Q3<,J2!V(Y![UX[XO\;7'C;X":EJD$<=I)'<);7\/+?,)(_N-D<'<IY!
MX)'O7IG@;2H+3PW87S6MFFH7=G!]HGMXMAE54 3<2220N!U]: .E9U12S,%
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MKJ<$C/8\$?6N)T[6/$5_\?M7TPW=I]FTZQ4)$T3%1$[0NV,,/WAR!N.1QTH
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M[ILJ6D0AC-FKEI@!@,Y8#! '0#D\Y['JJ* ..T'P%;Z'X^U[Q)%(/+U((T<
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MBJHY8GT )JA!XS\.W+7:PZK"SV:-)<QX(>%5.&+J1E<9YR.*\Z\9ZSHWB >
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MEP"2""I7G'4<\BJWAGX?:?X>\13ZW;VMI9R2VOV46UDK"/&X,68L?F;@#@#
M'>NSHH 0 #H *:(HUD:0(H=A@L!R?QI]% #3%&9!(44R 8#8Y ^M+M7.<#\J
M6B@!-B_W1^5->*.5-DB*Z?W6&13Z* $*@]0.*-JYS@9^E+10 FU<DX&3UXZT
M*JHH50%4#  & *6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6;K]Y+9:+<26Q
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M>"T^R)/]GE"E=NT,5QG/MF@"#PAKS:-\,/!EM FZZU%1!$?*:0( KNS;5Y;
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M:)P#CH02*P[:Y^'EYKS:'!8:4VJ(2&M?[-PZXZY!3@>]<1\3KB;2?C5X)O\
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MW=B>Z+J58A'(C*]>>N3_ ': /:[>XBN[:*Y@</#*@D1QT92,@_E3V8(C,<X
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ME<;^OH$,9QZO[8H WZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1410J*,!5& !7-:%<7>MW^HRZUIQLY=-U("SC>0.5!@4;@PX.?,?\\=JZ>@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *PO&&@3>*/"][HL-Y':"[3RWE>$R;1D'@;ASQ6[10!PNC>#?$>@>$+?P_IW
MB.PC%O&\<5VVELTJAF+$C]]C//IV'%;<.@WUK?Z/+!?P?9M.M#:M&]NS/*"$
MR=V_@_NQV/4UOT4 <UI7@ZTT&]\07VEE(KO6)Q,[21[EC.WI@$9&XNW4?>]J
MQO 7P\O? F@ZAI<&LP78NI#*LCV978Q4+R!)R,#VKOJ* .+^&_@2?X?Z/<Z8
M=4COX)IS<!A;&)E8JJX^^01A:@^(?P^N?'<FF;-7BL4L)3*@-J92S''4[QQQ
MZ5W=% ',WVB>(=3GL!=:Y9)9V]U%<S0VU@R-/L8,%+-*V!D ].U4[CP*;3QK
M)XLT"\2SOKF,Q7MO-$7AN1QSP05;@'(STZ<G/944 <=;>!C=>-4\6:]>)>7]
MO%Y5E!#$4AMEYYP22S<GDXZ].!BUX\\*3^-/#$^AQW\=E%.R-)(T!E;Y6##
MW+W KIZ* ,?PUI%QH'AJQTB6ZBN&L[=((Y5B*;@HP"5W'GCUKDM$^'.J:%XO
MUOQ#;ZY92R:N6\V";3F**"V[ Q*/IS7HM% ')-X7UFZTG7[>_P!<@N+O5HS
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MPDE69[:!(3(J;0VT 9QDXZ>M<I\2? $_Q!TVTL!JL=A!;S>=G[,969MI']\
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M"R@[3ZCT-24 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%]975Z[);K-&K*Q5&<_.C,HX4\$Y]J6;Q);?VE<:=8VUUJ5W;8^T):!,0YY
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ KEO'EFFK>'Y-'GAU5[>]!25M.A61P 0<'=P,_XUU-% '*Z?XADL;"
M"U;1?$$_E($$CV:@L ,#."!629!:ZO=ZII&E>(=/GO2&NHQ8H\4S#@.5+</C
MN",]P:] HH X73+F+3+B]OAHOB.XU.] $U[-9H7('W5 ! 51V 'UR>:HZ%:V
MFBZ1J.E2Z/XDU"RU":6:>.ZLH^6D^^/E(X->D44 <)X:O'\-Z7'IJ6'BF]M8
M1M@%U:(6B7LH8$$@=!G-1:Z;?6=0M-4BT?Q-8:M9@K!>VUJF\*>J,&)#J?0C
MZ8KT"B@#BK/5KI)8YM1L/$=])%S&IL$C13TW;5/)^I/L!5-7^Q:I>:AHVE^(
M=/DOF\RZA%@DD,DG3S-I;*N1U((![@FO0:* .%TRYATM[VZCT7Q'-J5\0;B^
MFLT,CX&%  ( 4#HH&/QR:HSV5A?>$D\-ZGH?B2^LXW1U>2S17^5MPY4@>HZ=
M":](HH \\UD+K&NZ1JIT[Q-;R:2SO;116,>S++M;=DDGCCJ*(\)XU?Q1_9_B
M<W3VHLS";*/R_*#;L=<YSWS7H=% '%:]J3ZY8K:'2_$EK$)4D?R;)#YFU@P4
M[B?E) R.XXI-?U!/$7AZ[T>ZT3Q"D-U%Y4LB62;L'J1DD _AQ7;44 >=1F9-
M*TJP,'BIUTV1)(I7L8B[[!A0Y[C!]B?6K?B2:P\5:,VF:GX:UYX]P=)%M &C
M<=&4[N#_ $)%=U10!S<OBF1XF5-!UZ-B.'%FIQ^!:L/PFZ>$M*;3K?2_$UU
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M (^&LDOQISZ@%7R%N"/N$[MV.@W!=N3UJGXF\:V!.N:#91:C<7ME9-+<S6/
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M2/4'ZXXKCKC1O$/_  I0^#?^$:U8ZK::CEMML3&R%RP97Z,.<<9Z9Z5]'44
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M;=LS+)"J(1QQD@]<8[T =I=>*;.&]M[*TM[G4+J>T-ZD5L$SY((&[+LHY+
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M!>HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ KC?BO_ ,DM\0_]>W_LPKLJR/$WA^'Q1H5QH]U=7%O;7*[93;[0S#(.
M,LIQTH \[^(,6N/\-K8Z@MI+H"+;OJ26FY;EH@5/R%OEZXS]*Z'5]7N-.U_P
MSKD6H7!\-ZEMMIH3@)&\BYAD/&0"?E.3CD5H7O@>'5=,BTO5=:U2]TY-H:U8
MQ1K*%Q@.8XU8C@<9%5O%LMGJUO-X(CTR[DDNX$572V800INQO\S[H*!=P'J
M.] %JUMM0U_1]6GM]9NK-;^=A8S(%8P1*0H901SO*LW/9QC&*Z=%*HJLQ8@
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M -^X?_CE'_"3W/\ T*^N_P#?N'_XY0!T-%<]_P )/<_]"OKO_?N'_P".4?\
M"3W/_0KZ[_W[A_\ CE '0T5SW_"3W/\ T*^N_P#?N'_XY1_PD]S_ -"OKO\
MW[A_^.4 =#17/?\ "3W/_0KZ[_W[A_\ CE'_  D]S_T*^N_]^X?_ (Y0!T-%
M<]_PD]S_ -"OKO\ W[A_^.4?\)/<_P#0KZ[_ -^X?_CE '0T5SW_  D]S_T*
M^N_]^X?_ (Y1_P )/<_]"OKO_?N'_P".4 =#17/?\)/<_P#0KZ[_ -^X?_CE
M'_"3W/\ T*^N_P#?N'_XY0!T-%<]_P )/<_]"OKO_?N'_P".4?\ "3W/_0KZ
M[_W[A_\ CE '0T5SW_"3W/\ T*^N_P#?N'_XY1_PD]S_ -"OKO\ W[A_^.4
M=#17/?\ "3W/_0KZ[_W[A_\ CE'_  D]S_T*^N_]^X?_ (Y0!T-%<]_PD]S_
M -"OKO\ W[A_^.4?\)/<_P#0KZ[_ -^X?_CE '0T4V-B\:N59"P!VMU'L:=0
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !7+_$"TGN/"-X]I?W=C>1A?(GMKAX
MRC%@,D*0&'/0UU%8/C)G_P"$9N8XK>XGD<H%C@A:1CAU)X4'L* ,?PEXDN-=
ML[[P[X@5K7Q%IR[+M(I#&95_AFC9<':W'3H3[BK&A:Y!IGA?PQ!.]Y>ZEJ=I
M&\49D,DLS"(/(VZ1L #KR0.>*A\:^&+G68K7Q!X??[-XBT]2]J[J5\]/XH9
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MW3+R#Q%)JOAJ/5;#4Y-3"7MA) YL[V/S-K3$D;%.P;MP.<C&,D9]0H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_'*/^$,TW_G]UW_P=W?_ ,<KH:* .>_X0S3?^?W7?_!W=_\ QRC_ (0S3?\
MG]UW_P '=W_\<KH:* .>_P"$,TW_ )_==_\ !W=__'*/^$,TW_G]UW_P=W?_
M ,<KH:* .>_X0S3?^?W7?_!W=_\ QRC_ (0S3?\ G]UW_P '=W_\<KH:* .>
M_P"$,TW_ )_==_\ !W=__'*/^$,TW_G]UW_P=W?_ ,<KH:* .>_X0S3?^?W7
M?_!W=_\ QRC_ (0S3?\ G]UW_P '=W_\<KH:* .>_P"$,TW_ )_==_\ !W=_
M_'*/^$,TW_G]UW_P=W?_ ,<KH:* .>_X0S3?^?W7?_!W=_\ QRC_ (0S3?\
MG]UW_P '=W_\<KH:* .>_P"$,TW_ )_==_\ !W=__'*/^$,TW_G]UW_P=W?_
M ,<KH:* .>_X0S3?^?W7?_!W=_\ QRC_ (0S3?\ G]UW_P '=W_\<KH:* .>
M_P"$,TW_ )_==_\ !W=__'*/^$,TW_G]UW_P=W?_ ,<KH:* .>_X0S3?^?W7
M?_!W=_\ QRC_ (0S3?\ G]UW_P '=W_\<KH:* .>_P"$,TW_ )_==_\ !W=_
M_'*/^$,TW_G]UW_P=W?_ ,<KH:* .>_X0S3?^?W7?_!W=_\ QRC_ (0S3?\
MG]UW_P '=W_\<KH:* .>_P"$,TW_ )_==_\ !W=__'*/^$,TW_G]UW_P=W?_
M ,<KH:* .>_X0S3?^?W7?_!W=_\ QRC_ (0S3?\ G]UW_P '=W_\<KH:* &Q
MH(XU0%B%  +,2?Q)Y-.HHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'P,99NY]ZLT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M *%.X_\  V#_ .*KH:* .>_MK7_^A3N/_ V#_P"*H_MK7_\ H4[C_P #8/\
MXJNAHH Y[^VM?_Z%.X_\#8/_ (JC^VM?_P"A3N/_  -@_P#BJZ&B@#GO[:U_
M_H4[C_P-@_\ BJ/[:U__ *%.X_\  V#_ .*KH:* .>_MK7_^A3N/_ V#_P"*
MH_MK7_\ H4[C_P #8/\ XJNAHH Y[^VM?_Z%.X_\#8/_ (JC^VM?_P"A3N/_
M  -@_P#BJZ&B@#GO[:U__H4[C_P-@_\ BJ/[:U__ *%.X_\  V#_ .*KH:*
M.>_MK7_^A3N/_ V#_P"*H_MK7_\ H4[C_P #8/\ XJNAHH Y[^VM?_Z%.X_\
M#8/_ (JC^VM?_P"A3N/_  -@_P#BJZ&B@!L;,T:LZ;&(!*DYP?2G444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5@>+?%-OX3TVVNIU0M=7<=G%YDGEQJ[D_,[8.U0 23@]*
MWZYCQS#I5[I-KINM:=+>:=?7(AE,<;,8/D=A)\O*@%0-W;//% %M=<N+1[QM
M7M(X+2VMA<_;+>1I4=>=W 7(( R>O!'-/L/%.D:H+0V<\TB7:%[=S:RJDH R
M=K%0#P,XS7EVCZ'?>&X/%VD:9JMQJGA0Z-*UL\IW^7<,& B1APQQDG;ZKQFM
M[X9SC3?#^BVU[<S33SVL4<=M)#@V919"^X[1M&#U;DYQZ4 =98^./#FHW$,%
MMJ2EYYFMXO,B>-7E7[R!F4 L/3.:V'OK6/4(K!YT%W+&\L<1/S,BE0Q_ LOY
MUY1\._"<&KV+7>JR72+INO7%];VI41J7R-DC9&XCN.0/K3O&)U&/4]*^(&GV
MYF^P7IA\J)V:66T;Y&7R]O7[S]<C?STX /0[SQ9HUCJLNESW,@O8;?[4\*6T
MKD19QO\ E4_+GC-7[/4['4-,CU*TNHIK*1/,6=&RA7N<UY5XDCUG4/BG?W7A
MN98[B3POY5O/)%F-Y/.W>7D\!BO(ST[C%:OA9[&;X=Z-X<TZPFMC.K0W5G?,
M\;H 2TP9MO\ &20,#D,<8P< '>/K6GKI=OJ0G,EI<A#"\4;2&3?]W 4$G.?2
MJ%AXRT+5)-EE=2S'SWM\BUE $J*69,E<;@ 3CK7+_"J2[TRQU'PGJ:-YFBW+
M+:SL"4D@8DJ5<@9VY(/ID"D^$R?9M(\1FZC,1_MVZG3S5*_(P7#C/8\\_6@#
MJK;QEX?N]!;7(=2C.FA]GVAD90S9QM (!8YXP >>*M0:_IMQ>2V:3.+N*(3M
M;R0NDIC_ +P1@&89XX!YXZUXCHFBZH?AMX/NA9W+QZ/K_P!KOK01-Y@B\TG?
MLQDX'.,=#7=ZE%)K7Q<\/ZMIK[M.TFSG:]O%_P!4=ZD+'NZ$YY(["@#J]/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI4MQ!<K& =CKDH0",$8P,D<X-:'PVU:_UWX?Z5JNIW)N+RY1GD<HJ<AV P%
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M<8!Y/I6S110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MVD7-Z-]YI<RS6]P %8$<$'V(ZCZ>E0:'X4BT+6];U6*\EEEU>599D=1M1E!
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
EBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Oct. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-23186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BIOCRYST PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">62-1413174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">4505 Emperor Blvd., Suite 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Durham<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">27703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">859-1302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BCRX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210,543,224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000882796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 84,078<span></span>
</td>
<td class="nump">$ 104,713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">579<span></span>
</td>
<td class="nump">210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">128,795<span></span>
</td>
<td class="nump">216,137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Trade receivables</a></td>
<td class="nump">91,325<span></span>
</td>
<td class="nump">79,069<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">5,232<span></span>
</td>
<td class="nump">8,087<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">16,502<span></span>
</td>
<td class="nump">13,752<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">355,684<span></span>
</td>
<td class="nump">421,968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Long-term inventory, net</a></td>
<td class="nump">23,390<span></span>
</td>
<td class="nump">23,187<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">8,396<span></span>
</td>
<td class="nump">7,777<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">39,669<span></span>
</td>
<td class="nump">20,323<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RightOfUseAssetsNoncurrent', window );">Right of use assets</a></td>
<td class="nump">10,840<span></span>
</td>
<td class="nump">12,008<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">4,387<span></span>
</td>
<td class="nump">5,157<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">446,424<span></span>
</td>
<td class="nump">490,420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">5,567<span></span>
</td>
<td class="nump">11,644<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">118,778<span></span>
</td>
<td class="nump">113,292<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">348<span></span>
</td>
<td class="nump">937<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities</a></td>
<td class="nump">1,435<span></span>
</td>
<td class="nump">1,835<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyFinancingLiabilitiesCurrent', window );">Royalty financing obligations</a></td>
<td class="nump">37,686<span></span>
</td>
<td class="nump">32,676<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">190,237<span></span>
</td>
<td class="nump">160,384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">8,425<span></span>
</td>
<td class="nump">7,924<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities</a></td>
<td class="nump">1,742<span></span>
</td>
<td class="nump">2,124<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyFinancingLiabilitiesNoncurrent', window );">Royalty financing obligations</a></td>
<td class="nump">439,107<span></span>
</td>
<td class="nump">481,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Secured term loan</a></td>
<td class="nump">194,366<span></span>
</td>
<td class="nump">314,869<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">834,313<span></span>
</td>
<td class="nump">966,354<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.01 par value; shares authorized - 5,000; no shares issued and outstanding at September&#160;30, 2025 and December&#160;31, 2024</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value; shares authorized - 450,000; shares issued and outstanding &#8211; 210,522 at September&#160;30, 2025 and 208,543 at December&#160;31, 2024</a></td>
<td class="nump">2,105<span></span>
</td>
<td class="nump">2,085<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,360,890<span></span>
</td>
<td class="nump">1,291,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">1,140<span></span>
</td>
<td class="nump">921<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,752,024)<span></span>
</td>
<td class="num">(1,770,040)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; deficit</a></td>
<td class="num">(387,889)<span></span>
</td>
<td class="num">(475,934)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; deficit</a></td>
<td class="nump">446,424<span></span>
</td>
<td class="nump">490,420<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember', window );">Disposal Group, Held-for-Sale, Not Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current assets held for sale</a></td>
<td class="nump">29,173<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent', window );">Non-current assets held for sale</a></td>
<td class="nump">4,058<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current liabilities held for sale</a></td>
<td class="nump">26,423<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent', window );">Non-current liabilities held for sale</a></td>
<td class="nump">$ 436<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RightOfUseAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right-Of-Use-Assets, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RightOfUseAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyFinancingLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Financing Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyFinancingLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyFinancingLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations for future royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyFinancingLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value (in usd per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in usd per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">450,000,000<span></span>
</td>
<td class="nump">450,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued (in shares)</a></td>
<td class="nump">210,522,000<span></span>
</td>
<td class="nump">208,543,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding (in shares)</a></td>
<td class="nump">210,522,000<span></span>
</td>
<td class="nump">208,543,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Loss) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 159,395<span></span>
</td>
<td class="nump">$ 117,085<span></span>
</td>
<td class="nump">$ 468,282<span></span>
</td>
<td class="nump">$ 319,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of product sales</a></td>
<td class="nump">2,187<span></span>
</td>
<td class="nump">3,211<span></span>
</td>
<td class="nump">9,553<span></span>
</td>
<td class="nump">6,175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">44,603<span></span>
</td>
<td class="nump">41,081<span></span>
</td>
<td class="nump">125,259<span></span>
</td>
<td class="nump">125,197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">83,014<span></span>
</td>
<td class="nump">65,101<span></span>
</td>
<td class="nump">252,866<span></span>
</td>
<td class="nump">185,841<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">129,804<span></span>
</td>
<td class="nump">109,393<span></span>
</td>
<td class="nump">387,678<span></span>
</td>
<td class="nump">317,213<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive (loss) income</a></td>
<td class="num">(506)<span></span>
</td>
<td class="nump">1,736<span></span>
</td>
<td class="nump">219<span></span>
</td>
<td class="nump">956<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net comprehensive income (loss)</a></td>
<td class="nump">12,393<span></span>
</td>
<td class="num">(12,297)<span></span>
</td>
<td class="nump">18,235<span></span>
</td>
<td class="num">(61,130)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">29,591<span></span>
</td>
<td class="nump">7,692<span></span>
</td>
<td class="nump">80,604<span></span>
</td>
<td class="nump">1,965<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest income</a></td>
<td class="nump">2,238<span></span>
</td>
<td class="nump">3,591<span></span>
</td>
<td class="nump">7,778<span></span>
</td>
<td class="nump">11,176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(19,661)<span></span>
</td>
<td class="num">(24,828)<span></span>
</td>
<td class="num">(64,737)<span></span>
</td>
<td class="num">(74,067)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments', window );">Foreign currency gains (losses), net</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">98<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="num">(37)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="num">(2,740)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,911)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other income</a></td>
<td class="nump">2,667<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,667<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense, net</a></td>
<td class="num">(17,461)<span></span>
</td>
<td class="num">(21,139)<span></span>
</td>
<td class="num">(61,230)<span></span>
</td>
<td class="num">(62,928)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income taxes</a></td>
<td class="nump">12,130<span></span>
</td>
<td class="num">(13,447)<span></span>
</td>
<td class="nump">19,374<span></span>
</td>
<td class="num">(60,963)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="num">(769)<span></span>
</td>
<td class="nump">586<span></span>
</td>
<td class="nump">1,358<span></span>
</td>
<td class="nump">1,123<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 12,899<span></span>
</td>
<td class="num">$ (14,033)<span></span>
</td>
<td class="nump">$ 18,016<span></span>
</td>
<td class="num">$ (62,086)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per common share (in usd per share)</a></td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="num">$ (0.07)<span></span>
</td>
<td class="nump">$ 0.09<span></span>
</td>
<td class="num">$ (0.30)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, basic (in shares)</a></td>
<td class="nump">210,176<span></span>
</td>
<td class="nump">206,905<span></span>
</td>
<td class="nump">209,531<span></span>
</td>
<td class="nump">206,466<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per common share (in usd per share)</a></td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="num">$ (0.07)<span></span>
</td>
<td class="nump">$ 0.08<span></span>
</td>
<td class="num">$ (0.30)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, diluted (in shares)</a></td>
<td class="nump">219,885<span></span>
</td>
<td class="nump">206,905<span></span>
</td>
<td class="nump">218,349<span></span>
</td>
<td class="nump">206,466<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other Comprehensive Income (Loss), Net of Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="num">$ (523)<span></span>
</td>
<td class="nump">$ 563<span></span>
</td>
<td class="nump">$ 545<span></span>
</td>
<td class="nump">$ 170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gain (loss) on available for sale investments</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 1,173<span></span>
</td>
<td class="num">$ (326)<span></span>
</td>
<td class="nump">$ 786<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4CC<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CC<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 18,016<span></span>
</td>
<td class="num">$ (62,086)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">995<span></span>
</td>
<td class="nump">937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory obsolescence</a></td>
<td class="nump">1,056<span></span>
</td>
<td class="nump">1,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">61,273<span></span>
</td>
<td class="nump">44,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_PaymentsForPaidInKindInterest', window );">Payment of Pharmakon PIK Interest</a></td>
<td class="num">(9,153)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_NonCashInterestExpenseOnRoyaltyFinancingLiabilities', window );">Non-cash interest expense on royalty financing obligations</a></td>
<td class="nump">39,839<span></span>
</td>
<td class="nump">42,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_NonCashInterestExpenseOnSecuredTermLoanAndSecuredTermLoanAndAmortizationOfDebtIssuanceCosts', window );">Non-cash interest expense on secured term loan and amortization of debt issuance costs</a></td>
<td class="nump">1,387<span></span>
</td>
<td class="nump">11,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_AmortizationOfPremiumDiscountOnInvestments', window );">Amortization of discount on investments, net</a></td>
<td class="num">(3,240)<span></span>
</td>
<td class="num">(8,713)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">6,911<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfOtherAssets', window );">Gain on sale of non-financial asset</a></td>
<td class="num">(550)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Increase in receivables</a></td>
<td class="num">(21,312)<span></span>
</td>
<td class="num">(15,402)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Increase in inventory</a></td>
<td class="num">(1,124)<span></span>
</td>
<td class="num">(2,001)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">(Increase) decrease in prepaid expenses and other assets</a></td>
<td class="num">(5,890)<span></span>
</td>
<td class="nump">1,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_IncreaseDecreaseInRoyaltyFinancingLiabilities', window );">Decrease in royalty financing obligations</a></td>
<td class="num">(55,240)<span></span>
</td>
<td class="num">(54,308)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Increase (decrease) in accounts payable and accrued expenses</a></td>
<td class="nump">22,441<span></span>
</td>
<td class="num">(5,625)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="nump">55,409<span></span>
</td>
<td class="num">(46,807)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Acquisitions of property and equipment</a></td>
<td class="num">(1,666)<span></span>
</td>
<td class="num">(449)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of investments</a></td>
<td class="num">(136,737)<span></span>
</td>
<td class="num">(227,235)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Sales and maturities of investments</a></td>
<td class="nump">207,647<span></span>
</td>
<td class="nump">262,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities', window );">Sale of non-financial asset</a></td>
<td class="nump">550<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">69,794<span></span>
</td>
<td class="nump">34,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Net proceeds from common stock issued under stock-based compensation plans</a></td>
<td class="nump">8,458<span></span>
</td>
<td class="nump">4,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_ProceedsFromIssuanceOfCommonStockIssuedForServices', window );">Common stock issued to directors in lieu of cash retainer</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of Pharmakon term loan principal</a></td>
<td class="num">(115,847)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Prepayment premium and fees on Pharmakon term loan</a></td>
<td class="num">(3,802)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RepaymentOfRoyaltyFinancingLiabilitiesPrincipal', window );">Principal payments on royalty financing obligations</a></td>
<td class="num">(16,406)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Withholding taxes paid on stock-based awards</a></td>
<td class="num">(2,845)<span></span>
</td>
<td class="num">(4,451)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Principal payments on finance lease liabilities</a></td>
<td class="num">(1,565)<span></span>
</td>
<td class="num">(1,348)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(131,971)<span></span>
</td>
<td class="num">(1,740)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rates on cash, cash equivalents and restricted cash</a></td>
<td class="nump">1,342<span></span>
</td>
<td class="nump">368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations', window );">Net decrease in cash, and cash equivalents, and restricted cash</a></td>
<td class="num">(5,426)<span></span>
</td>
<td class="num">(13,383)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperationsLessAssetsHeldForSale', window );">Less: cash and cash equivalents classified within current assets held for sale</a></td>
<td class="num">(14,840)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperationsExcludingAssetsHeldForSale', window );">Net decrease in cash, and cash equivalents, and restricted cash</a></td>
<td class="num">(20,266)<span></span>
</td>
<td class="num">(13,383)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 112,447<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentContinuingOperationExcludingAssetsHeldForSale', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">86,057<span></span>
</td>
<td class="nump">99,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">84,078<span></span>
</td>
<td class="nump">96,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">579<span></span>
</td>
<td class="nump">813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RestrictedCashAndCashEquivalentsIncludedInOtherAssetsNonCurrent', window );">Restricted cash in other assets</a></td>
<td class="nump">1,400<span></span>
</td>
<td class="nump">1,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentContinuingOperationExcludingAssetsHeldForSale', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">86,057<span></span>
</td>
<td class="nump">99,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Cash Flow Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">22,789<span></span>
</td>
<td class="nump">20,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for taxes</a></td>
<td class="nump">2,220<span></span>
</td>
<td class="nump">1,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_WithholdingTaxesAccrued', window );">Taxes withheld on stock-based awards included in accrued expenses</a></td>
<td class="nump">$ 151<span></span>
</td>
<td class="nump">$ 245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AmortizationOfPremiumDiscountOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to the discount and premium on investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AmortizationOfPremiumDiscountOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentContinuingOperationExcludingAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation, Excluding Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentContinuingOperationExcludingAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperationsExcludingAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect, Continuing Operations, Excluding Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperationsExcludingAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperationsLessAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect, Continuing Operations, Less Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperationsLessAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_IncreaseDecreaseInRoyaltyFinancingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Royalty Financing Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_IncreaseDecreaseInRoyaltyFinancingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_NonCashInterestExpenseOnRoyaltyFinancingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of non-cash interest expense on royalty financing obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_NonCashInterestExpenseOnRoyaltyFinancingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_NonCashInterestExpenseOnSecuredTermLoanAndSecuredTermLoanAndAmortizationOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Interest Expense On Secured Term Loan And Secured Term Loan And Amortization Of Debt Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_NonCashInterestExpenseOnSecuredTermLoanAndSecuredTermLoanAndAmortizationOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PaymentsForPaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For Paid-In-Kind Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PaymentsForPaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ProceedsFromIssuanceOfCommonStockIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issuance Of Common Stock, Issued For Services</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ProceedsFromIssuanceOfCommonStockIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RepaymentOfRoyaltyFinancingLiabilitiesPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayment Of Royalty Financing Liabilities, Principal</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RepaymentOfRoyaltyFinancingLiabilitiesPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RestrictedCashAndCashEquivalentsIncludedInOtherAssetsNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restricted Cash and Cash Equivalents, Included In Other Assets, Non-Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RestrictedCashAndCashEquivalentsIncludedInOtherAssetsNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_WithholdingTaxesAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Withholding Taxes Accrued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_WithholdingTaxesAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalent, and cash and cash equivalent restricted to withdrawal or usage, including effect from exchange rate change; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtExtinguishmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtExtinguishmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the sale of other assets recognized in investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Deficit - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding, beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">205,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="num">$ (455,528)<span></span>
</td>
<td class="nump">$ 2,058<span></span>
</td>
<td class="nump">$ 1,222,236<span></span>
</td>
<td class="nump">$ 1,337<span></span>
</td>
<td class="num">$ (1,681,159)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(35,379)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35,379)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(566)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(566)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">552<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted stock units</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Shares withheld for taxes for vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Shares withheld for taxes for vesting of restricted stock units</a></td>
<td class="num">(38)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(38)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Employee stock purchase plan sales, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Employee stock purchase plan sales</a></td>
<td class="nump">1,129<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">1,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of shares to directors in lieu of cash retainer (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of shares to directors in lieu of cash retainer</a></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">13,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding, ending balance (in shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2024</a></td>
<td class="num">(476,167)<span></span>
</td>
<td class="nump">$ 2,063<span></span>
</td>
<td class="nump">1,237,537<span></span>
</td>
<td class="nump">771<span></span>
</td>
<td class="num">(1,716,538)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding, beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">205,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="num">(455,528)<span></span>
</td>
<td class="nump">$ 2,058<span></span>
</td>
<td class="nump">1,222,236<span></span>
</td>
<td class="nump">1,337<span></span>
</td>
<td class="num">(1,681,159)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(62,086)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding, ending balance (in shares) at Sep. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">207,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2024</a></td>
<td class="num">(468,563)<span></span>
</td>
<td class="nump">$ 2,071<span></span>
</td>
<td class="nump">1,270,318<span></span>
</td>
<td class="nump">2,293<span></span>
</td>
<td class="num">(1,743,245)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding, beginning balance (in shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2024</a></td>
<td class="num">(476,167)<span></span>
</td>
<td class="nump">$ 2,063<span></span>
</td>
<td class="nump">1,237,537<span></span>
</td>
<td class="nump">771<span></span>
</td>
<td class="num">(1,716,538)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(12,674)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,674)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(214)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(214)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">264<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted stock units</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of shares to directors in lieu of cash retainer (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of shares to directors in lieu of cash retainer</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">13,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding, ending balance (in shares) at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2024</a></td>
<td class="num">(475,606)<span></span>
</td>
<td class="nump">$ 2,066<span></span>
</td>
<td class="nump">1,250,983<span></span>
</td>
<td class="nump">557<span></span>
</td>
<td class="num">(1,729,212)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(14,033)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,033)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">1,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">1,362<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">1,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted stock units</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Employee stock purchase plan sales, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Employee stock purchase plan sales</a></td>
<td class="nump">723<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of shares to directors in lieu of cash retainer (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of shares to directors in lieu of cash retainer</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">17,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding, ending balance (in shares) at Sep. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">207,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2024</a></td>
<td class="num">$ (468,563)<span></span>
</td>
<td class="nump">$ 2,071<span></span>
</td>
<td class="nump">1,270,318<span></span>
</td>
<td class="nump">2,293<span></span>
</td>
<td class="num">(1,743,245)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding, beginning balance (in shares) at Dec. 31, 2024</a></td>
<td class="nump">208,543<span></span>
</td>
<td class="nump">208,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2024</a></td>
<td class="num">$ (475,934)<span></span>
</td>
<td class="nump">$ 2,085<span></span>
</td>
<td class="nump">1,291,100<span></span>
</td>
<td class="nump">921<span></span>
</td>
<td class="num">(1,770,040)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">1,229<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">1,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted stock units</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Shares withheld for taxes for vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Shares withheld for taxes for vesting of restricted stock units</a></td>
<td class="num">(56)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(56)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Employee stock purchase plan sales, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Employee stock purchase plan sales</a></td>
<td class="nump">1,217<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">1,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of shares to directors in lieu of cash retainer (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of shares to directors in lieu of cash retainer</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">21,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding, ending balance (in shares) at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2025</a></td>
<td class="num">$ (451,927)<span></span>
</td>
<td class="nump">$ 2,092<span></span>
</td>
<td class="nump">1,314,857<span></span>
</td>
<td class="nump">1,132<span></span>
</td>
<td class="num">(1,770,008)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding, beginning balance (in shares) at Dec. 31, 2024</a></td>
<td class="nump">208,543<span></span>
</td>
<td class="nump">208,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2024</a></td>
<td class="num">$ (475,934)<span></span>
</td>
<td class="nump">$ 2,085<span></span>
</td>
<td class="nump">1,291,100<span></span>
</td>
<td class="nump">921<span></span>
</td>
<td class="num">(1,770,040)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">18,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">$ 219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding, ending balance (in shares) at Sep. 30, 2025</a></td>
<td class="nump">210,522<span></span>
</td>
<td class="nump">210,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2025</a></td>
<td class="num">$ (387,889)<span></span>
</td>
<td class="nump">$ 2,105<span></span>
</td>
<td class="nump">1,360,890<span></span>
</td>
<td class="nump">1,140<span></span>
</td>
<td class="num">(1,752,024)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding, beginning balance (in shares) at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2025</a></td>
<td class="num">(451,927)<span></span>
</td>
<td class="nump">$ 2,092<span></span>
</td>
<td class="nump">1,314,857<span></span>
</td>
<td class="nump">1,132<span></span>
</td>
<td class="num">(1,770,008)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">5,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,085<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">3,421<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">3,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted stock units</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of shares to directors in lieu of cash retainer (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of shares to directors in lieu of cash retainer</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">21,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding, ending balance (in shares) at Jun. 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2025</a></td>
<td class="num">(421,594)<span></span>
</td>
<td class="nump">$ 2,099<span></span>
</td>
<td class="nump">1,339,584<span></span>
</td>
<td class="nump">1,646<span></span>
</td>
<td class="num">(1,764,923)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">12,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,899<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(506)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(506)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">1,566<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">1,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted stock units</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Employee stock purchase plan sales, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Employee stock purchase plan sales</a></td>
<td class="nump">1,081<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">1,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of shares to directors in lieu of cash retainer (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of shares to directors in lieu of cash retainer</a></td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 18,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding, ending balance (in shares) at Sep. 30, 2025</a></td>
<td class="nump">210,522<span></span>
</td>
<td class="nump">210,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2025</a></td>
<td class="num">$ (387,889)<span></span>
</td>
<td class="nump">$ 2,105<span></span>
</td>
<td class="nump">$ 1,360,890<span></span>
</td>
<td class="nump">$ 1,140<span></span>
</td>
<td class="num">$ (1,752,024)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies and Concentrations of Risk<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies and Concentrations of Risk</a></td>
<td class="text">Significant Accounting Policies and Concentrations of Risk<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Company</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">BioCryst Pharmaceuticals, Inc. (the &#8220;Company&#8221;) is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (&#8220;HAE&#8221;) and other rare diseases, driven by the Company&#8217;s deep commitment to improving the lives of people living with these conditions. The Company has built a robust commercial infrastructure to support the launch and continued success of ORLADEYO&#174;, an oral, once-daily therapy discovered and developed internally for the prevention of HAE attacks. The Company&#8217;s business strategy includes leveraging this established commercial platform to successfully commercialize a pipeline of potential first-in-class or best-in-class oral small-molecule and injectable protein therapeutics targeting a range of rare diseases. These programs are being pursued through both internal discovery efforts and strategic business development. By utilizing its existing commercial capabilities and focusing on rare disease markets, the Company believes that it can more effectively optimize its costs and strategically allocate resources to support long-term, sustainable growth. The Company was founded in 1986 and incorporated in Delaware in 1991, and its headquarters is located in Durham, North Carolina.  </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s marketed products include oral, once-daily ORLADEYO&#174; for the prevention of HAE attacks and RAPIVAB&#174; (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. ORLADEYO has received regulatory approval in the United States and other global markets. The Company is commercializing ORLADEYO in each of these territories directly or through other parties. In addition to its approval in the United States, peramivir injection has received regulatory approvals in Canada (RAPIVAB), Australia (RAPIVAB), Japan (RAPIACTA), Taiwan (RAPIACTA) and Korea (PERAMIFLU). </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Based on the Company&#8217;s expectations for revenue and operating expenses, the Company believes its financial resources available at September&#160;30, 2025 will be sufficient to fund its operations for at least the next 12 months. The Company may, in the future, issue securities, including common stock, preferred stock, depositary shares, purchase contracts, warrants, debt securities and units, through private placement transactions or registered public offerings. The Company&#8217;s future liquidity needs, and ability to address those needs, will largely be determined by the success of its products and product candidates; the timing, scope and magnitude of its research and development and commercial expenses; and key developments and regulatory events and its decisions in the future.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany transactions and balances among the consolidated entities have been eliminated from the condensed consolidated financial statements. The Company operates and manages its business as one reportable and operating segment (see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 13&#8212;Segment Information</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) for interim financial reporting and the instructions to Form 10-Q and do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Such financial statements reflect all adjustments that are, in management&#8217;s opinion, necessary to present fairly, in all material respects, the Company&#8217;s condensed consolidated financial position, results of operations, and cash flows. There were no adjustments other than normal recurring adjustments. Certain prior year amounts have been reclassified to conform to the current year presentation. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements should be read in conjunction with the financial statements for the fiscal year ended December&#160;31, 2024 and the notes thereto included in the Company&#8217;s 2024 Annual Report on Form 10-K as filed with the SEC on February 25, 2025. Interim operating results are not necessarily indicative of operating results for the full fiscal year. The condensed consolidated balance sheet as of December&#160;31, 2024 was derived from the audited consolidated financial statements included in the Company&#8217;s most recent Annual Report on Form 10-K.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. Significant estimates in the Company&#8217;s condensed consolidated financial statements have been made relative to the calculation of net product sales, royalty financing obligations, inventory reserves, certain accruals, primarily related to the Company&#8217;s research and development expenses, the valuation of stock options and the valuation allowance for deferred tax assets resulting from net operating losses. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets Held for Sale</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies its long-lived assets to be sold as held for sale when the six criteria in ASC 360, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, Plant and Equipment</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> are met. This generally occurs when an agreement to sell exists, or when management has committed to a plan to sell the assets within one year. Assets and liabilities to be disposed of together as a group in a single transaction (&#8220;disposal groups&#8221;) are classified as held for sale if their carrying amounts are principally expected to be recovered through a sale transaction rather than through continuing use.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The long-lived assets included in a disposal group are reported at the lower of their carrying value or fair value less cost to sell, beginning in the period the held for sale criteria are met. Prior to disposal, losses are recognized for any initial or subsequent write-down to fair value less cost to sell. Any gains or losses not previously recognized that result from the sale of a disposal group shall be recognized at the date of sale. Upon designation as an asset held for sale, the Company stops recording depreciation and amortization expense on long-lived assets. The Company assesses the fair value of a long-lived asset less any costs to sell at each reporting period and until the asset is no longer classified as held for sale.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded the following revenues for the three and nine months ended September&#160;30, 2025 and 2024 (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">157,735&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">116,066&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">463,952&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">313,325&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Collaborative and other revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,660&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,853&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">159,395</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">117,085</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">468,282</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">319,178</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, the Company recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, Topic 606 includes provisions within a five-step model that includes (i) identifying the contract with a customer, (ii) identifying the performance obligations in the contract, (iii) determining the transaction price, (iv) allocating the transaction price to the performance obligations, and (v) recognizing revenue when, or as, an entity satisfies a performance obligation.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, the Company identifies the goods or services promised within each contract, assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Sales, Net</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s principal sources of product sales are sales of ORLADEYO, which the Company began shipping to patients in December 2020, and sales of peramivir (RAPIVAB/RAPIACTA/PERAMIFLU) to the Company&#8217;s licensing partners and to the U.S. Department of Health and Human Services (&#8220;HHS&#8221;). In the United States, the Company generally ships ORLADEYO directly to patients through a single specialty pharmacy, which is considered its customer. Outside the United States, the Company sells ORLADEYO to specialty distributors and to hospitals and pharmacies, which collectively are considered its customers.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue for sales when the customer obtains control of the product, which generally occurs upon delivery. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue from sales of ORLADEYO is recorded at net selling price (transaction price), which includes reserves for variable consideration such as (i) estimated government rebates, such as Medicaid and Medicare Part D reimbursements, and estimated managed care rebates, (ii) estimated chargebacks, (iii) estimated costs of co-payment assistance programs and (iv) product returns. These reserves, representing the Company&#8217;s best estimates of the amount of consideration to which it is entitled based on the terms of the applicable contracts and statutory requirements, are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable if no payments are required of the Company or a current liability if a payment is required of the Company. Actual amounts of consideration may differ from the Company&#8217;s estimates. If actual results vary from estimates, these estimates are adjusted, which would affect net product revenue and earnings in the period such variances become known.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government and Managed Care Rebates</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The Company contracts with government agencies and managed care organizations or, collectively, third-party payors, so that ORLADEYO will be eligible for purchase by, or partial or full reimbursement from, such third-party payors. The Company estimates the rebates it will provide to third-party payors and deducts these estimated amounts from total gross product revenues at the time the revenues are recognized, resulting in a reduction of product revenue and the establishment of a current liability. The Company estimates the rebates that it will provide to third-party payors based upon (i) the Company&#8217;s contracts with these third-party payors, (ii) the government mandated discounts applicable to government-funded programs, and (iii) product distribution information obtained from the Company&#8217;s specialty pharmacy regarding payor mix.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chargebacks</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Chargebacks are discounts that occur when certain contracted customers, pharmacy benefit managers, insurance companies, and government programs purchase directly from the Company&#8217;s specialty pharmacy. These customers purchase the Company&#8217;s product under contracts negotiated between them and the Company&#8217;s specialty pharmacy. The specialty pharmacy, in turn, charges back to the Company the difference between the price that the specialty pharmacy paid and the negotiated price paid by the contracted customers, which may be higher or lower than the specialty pharmacy&#8217;s purchase price with the Company. The Company estimates chargebacks and adjusts gross product revenues and establishes a current liability at the time revenues are recognized.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Co-payment assistance and patient assistance programs</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. Based upon the terms of the program and co-payment assistance utilization reports received from the specialty pharmacy, the Company estimates the co-payment assistance amounts, which are recorded in the same period in which the related revenue is recognized, resulting in a reduction of product revenue and establishment of a current liability. The Company also offers a patient assistance program that provides free drug product, for a limited period of time, to allow a patient&#8217;s insurance coverage to be established. Based on patient assistance program utilization reports provided by the specialty pharmacy, the Company records gross revenue of the product provided and a full reduction of the revenue amount for the free drug discount.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product returns</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The Company does not provide contractual return rights to its customers, except in instances where the product is damaged or defective. Non-acceptance by the patient of shipped drug product by the specialty pharmacy is reflected as a reversal of sales in the period in which the sales were originally recorded. Reserves for estimated non-acceptances by patients are recorded as a reduction of revenue in the period that the related revenue is recognized, as well as a reduction to accounts receivable. Estimates of non-acceptance are based on quantitative information provided by the specialty pharmacy.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Revenues</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has collaboration and license agreements with a number of third parties. The Company&#8217;s primary sources of revenue from these collaborative and other research and development arrangements are license, service and royalty revenues.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from license fees, royalty payments, milestone payments, and research and development fees are recognized as revenue when the earnings process is complete and the Company has no further continuing performance obligations or the Company has completed the performance obligations under the terms of the agreement.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Arrangements that involve the delivery of more than one performance obligation are initially evaluated as to whether the intellectual property licenses granted by the Company represent distinct performance obligations. If they are determined to be distinct, the value of the intellectual property licenses would be recognized up front while the research and development service fees would be recognized as the performance obligations are satisfied. For performance obligations </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">based on services performed, the Company measures progress using an input method based on the effort it expends or costs it incurs toward the satisfaction of the performance obligation in relation to the total estimated effort or costs. Variable consideration is assessed at each reporting period as to whether it is not subject to significant future reversal and, therefore, should be included in the transaction price at the inception of the contract. If a contract includes a fixed or minimum amount of research and development support, this also would be included in the transaction price. Changes to collaborations, such as the extensions of the research term or increasing the number of targets or technology covered under an existing agreement, are assessed for whether they represent a modification or should be accounted for as a new contract. For contracts with multiple performance obligations, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the products or services. If a standalone selling price is not directly observable, then the Company estimates the standalone selling price using either an adjusted market assessment approach or an expected cost plus margin approach, representing the amount that the Company believes the market is willing to pay for the product or service. Analyzing the arrangement to identify performance obligations requires the use of judgment, and each may be an obligation to deliver services, a right or license to use an asset, or another performance obligation. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under certain of the Company&#8217;s license agreements, the Company receives royalty payments based upon its licensees&#8217; net sales of covered products. Royalties are recognized at the later of when (i) the subsequent sale or usage occurs, or (ii) the performance obligation to which some or all of the sales-based or usage-based royalty has been satisfied.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally considers cash equivalents to be all cash held in commercial checking accounts, money market accounts, or investments in debt instruments and certificates of deposit with maturities of three months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Total restricted cash was $1,979 and $1,610 as of September&#160;30, 2025 and December&#160;31, 2024, respectively, and primarily consisted of $1,400 as of September&#160;30, 2025 and December&#160;31, 2024, for a letter of credit the Company is required to maintain associated with its Birmingham lease. The letter of credit associated with the Birmingham lease of $1,400 is reflected within other assets on the Condensed Consolidated Balance Sheets as of September&#160;30, 2025 and December&#160;31, 2024.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests in high credit quality investments in accordance with its investment policy. The objectives of the Company&#8217;s investment policy are to eliminate or greatly minimize the probability of a loss of principal value, maintain sufficient liquidity to meet cash flow requirements, and earn a competitive level of return. The Company places its excess cash with high credit quality financial institutions to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that may consist of U.S. Treasury obligations, U.S government agency securities, money market funds, certificates of deposits and corporate notes and bonds. The Company&#8217;s investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of two years and requires an average portfolio maturity of no more than 12 months. Some of the securities in which the Company invests may have market risk. This means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, the Company does not believe it has a material exposure to interest rate risk arising from its investments. The Company has not realized any significant losses from its investments.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies all of its investments as available-for-sale. Available-for-sale investments are reported at fair value at each balance sheet date, and include any unrealized holding gains and losses in accumulated other comprehensive income, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company reviews its investments for other than temporary declines in fair value below cost basis at the end of each reporting period and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Factors considered to determine whether an unrealized loss is temporary include whether a decline in fair value below the amortized cost basis is due to credit-related factors or non-credit-related factors, the financial condition and near-term prospects of the Company, and the Company&#8217;s intent and ability to hold the investment to allow for an anticipated recovery in fair value. A credit-related impairment is recognized as an allowance on the balance sheet with a corresponding adjustment to earnings. Any impairment that is not credit-related is recognized in </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">other comprehensive income, net of applicable taxes unless deemed other than temporary. Realized gains and losses are reflected in interest and other income in the Condensed Consolidated Statements of Comprehensive Income (Loss) and are determined using the specific identification method with transactions recorded on a settlement date basis. Investments with original maturities at date of purchase beyond three months and which mature at or less than 12 months from the balance sheet date are classified as current. Investments with a maturity beyond 12 months from the balance sheet date are classified as long-term.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities recorded at fair value on a recurring basis on the Condensed Consolidated Balance Sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Assets measured at fair value on a recurring basis include investments (See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 4&#8212;Investments</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). There were no liabilities measured at fair value on a recurring basis as of September&#160;30, 2025 and December&#160;31, 2024. The carrying amounts reflected in the Condensed Consolidated Balance Sheets for cash and cash equivalents, trade receivables, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trade Receivables</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company&#8217;s trade receivables arise from product sales and primarily represent amounts due from its specialty pharmacy customer in the United States and other third-party distributors, hospitals and pharmacies globally and have standard payment terms that generally require payment within 30 to 90 days.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Receivables from collaborations are recorded for amounts due to the Company related to royalty receivables from the Company&#8217;s partners, including Shionogi &amp; Co., Ltd., Green Cross, and Torii (See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 12&#8212;Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides reserves against trade receivables for estimated losses that may result from a customer&#8217;s inability to pay. Receivables are evaluated to determine if any reserve or allowance should be recorded based on consideration of the current economic environment, expectations of future economic conditions, specific circumstances and the Company&#8217;s own historical collection experience. Amounts determined to be uncollectible are charged or written-off against the reserve.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s inventory primarily relates to ORLADEYO and also includes peramivir.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company values its inventory at the lower of cost or estimated net realizable value. The Company determines the cost of its inventory on a first-in, first-out (FIFO) basis. Raw materials and work-in-process include all inventory costs prior to packaging and labeling, including raw material, active product ingredient, and the drug product. Finished goods include packaged and labeled products. The Company classifies inventory as long-term when consumption or sale of the inventory is not expected to occur within 12 months from the balance sheet date.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s inventory is subject to expiration dating. At each reporting date, the Company evaluates the carrying value of its inventory and provides valuation reserves for any estimated excess, obsolete, short-dated or unmarketable inventory. In addition, the Company may experience spoilage of its raw materials and supplies. The Company&#8217;s determination that a valuation reserve might be required, in addition to the quantification of such reserve, requires it to utilize significant judgment. Additionally, the Company&#8217;s inventory is subject to strict quality control and monitoring that is performed throughout the manufacturing process, including release of work-in-process to finished goods. In the event that certain batches or units of product do not meet quality specifications, the Company will record a write-down of any potential unmarketable inventory to its estimated net realizable value and record the expense as cost of product in the Condensed Consolidated Statements of Comprehensive Income (Loss).</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prior to obtaining initial regulatory approval for an investigational product candidate, the Company expenses costs relating to production of pre-launch inventory as research and development expense in its Condensed Consolidated </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Statements of Comprehensive Income (Loss) in the period incurred. After regulatory approval has been received, the Company capitalizes inventory costs.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Computer equipment and office equipment are depreciated over a life of three years. Laboratory equipment, software, and furniture and fixtures are depreciated over a life of five years. Leasehold improvements are amortized over their estimated useful lives or the expected lease term, whichever is less. Construction in progress reflects amounts incurred for construction or improvements of property and equipment that have not been placed in service.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically reviews its property and equipment for impairment when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values. Property and equipment to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into contractual agreements with third-party vendors who provide research and development, manufacturing, distribution, and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing, and services are completed over an extended period of time. The Company records liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel to identify services that have been performed on its behalf and estimating the actual work completed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of actual cost. The majority of service providers invoice the Company monthly in arrears for services performed. The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances, which can include assumptions such as expected patient enrollment, site activation and estimated project duration. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued expenses include (i) fees paid to clinical research organizations (&#8220;CROs&#8221;) in connection with preclinical and toxicology studies and clinical trials; (ii) fees paid to investigative sites in connection with clinical trials; (iii) fees paid to contract manufacturers in connection with the production of the Company&#8217;s raw materials, drug substance, drug products, and product candidates; and (iv) professional fees.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company bases its expenses related to clinical trials on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on the Company&#8217;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. The Company accrues costs for clinical trial activities based upon estimates of the actual work completed in accordance with agreements established with third-party vendors. If the Company underestimates or overestimates the level of these costs, actual expenses could differ from such estimates. As of September&#160;30, 2025 and December&#160;31, 2024, the carrying value of accrued expenses approximates their fair value due to their short-term settlement.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Product Sales</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product sales includes the cost of producing inventory that is related to product revenue during the respective period, including freight. Cost of product sales may also include costs related to excess or obsolete inventory adjustment charges.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of costs associated with research activities as well as those with the Company&#8217;s product development efforts, conducting preclinical trials, clinical trials and manufacturing activities. Research and development expenses are expensed as incurred. Most of the Company&#8217;s clinical and preclinical studies are performed by third-party CROs. Costs for studies performed by CROs are accrued based upon estimates of the actual work completed in accordance with the third-party agreements. Advance payments for goods or services that will be used or rendered for </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of costs associated with research activities as well as those associated with product development efforts, conducting pre-clinical trials, clinical trials and manufacturing activities. Direct expenses consist of compensation for research and development personnel and costs of outside parties to conduct laboratory studies, develop manufacturing processes and manufacture the product candidate, conduct and manage clinical trials, as well as other costs related to the Company&#8217;s clinical and preclinical studies. Additionally, direct expenses consist of those costs necessary to discontinue and close out a development program, including termination fees and other commitments. Indirect expenses consist of lab supplies and services, facility expenses, depreciation of development equipment and an allocation of its general and administrative overhead costs that support the Company&#8217;s research and development efforts.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses are comprised of compensation and benefits and related costs associated with sales and marketing, finance, human resources, legal, information technology, quality, safety and regulatory activities related to marketed products, and other general and administrative personnel. Additionally, selling, general and administrative expenses are comprised of market research, marketing, advertising and legal expenses, including patent costs, licenses and other administrative costs.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All patent related costs are expensed to selling, general and administrative expenses when incurred as recoverability of such expenditures is uncertain.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases certain assets under operating and finance leases, which consist of real estate leases, laboratory equipment leases and office equipment leases as of September&#160;30, 2025. The Company determines whether a contract is, or contains, a lease at inception. The Company accounts for lease obligations in accordance with ASU 2016-02: </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases (Topic 842)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, which requires a lessee to recognize a right-of-use asset and a lease liability on its balance sheet for most leases. The Company elected the practical expedient that exempts leases with an initial lease term of twelve months or less, as well as the practical expedient that allows companies to select, by class of underlying asset, not to separate lease and non-lease components. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s operating leases provide for renewal options, which can vary by lease. The right-of-use asset and lease liabilities on the Company&#8217;s Condensed Consolidated Balance Sheets represent payments over the lease term, which include renewal options for certain real estate leases that the Company is likely to exercise. Certain operating leases include rent escalation provisions, which the Company recognizes as expense on a straight-line basis. Lease expense for leases with an initial term of twelve months or less was not material.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The discount rate used to determine the Company&#8217;s right-of-use asset and lease liability is the Company&#8217;s incremental borrowing rate on a collateralized basis over a similar term and amount in a similar economic environment, as generally an implicit rate in the lease is not readily determinable. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not made any residual value guarantees related to its leases; therefore, the Company has no corresponding liability recorded on its Condensed Consolidated Balance Sheets.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in the Company&#8217;s Condensed Consolidated Statements of Comprehensive Income (Loss) based on their fair values. Stock-based compensation cost is estimated at the grant date based on the fair value of the award and is recognized as expense on a straight-line basis over the requisite service period of the award. Determining the appropriate fair value model and the related assumptions for the model requires judgment, including estimating the stock price volatility and the expected term. The Company utilizes the Black-Scholes option-pricing model to value its stock option awards and recognize compensation expense on a straight-line basis over the requisite service period. The Company reduces stock-based compensation expense for estimated forfeitures. The estimation of share-based payment awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from the Company&#8217;s current estimates, such amounts will be recorded as a cumulative adjustment in the period estimates are revised. Actual results, and future changes in estimates, may differ substantially from the Company&#8217;s current estimates.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense, Deferred Financing Costs and Royalty Financing Obligations</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense primarily relates to the royalty financing obligations (see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7&#8212;Royalty Financing Obligations</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and the term loan borrowings under the Pharmakon Loan Agreement (see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8&#8212;Deb</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">t&#8221;) during the nine months ended September&#160;30, 2025 and 2024. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Costs directly associated with the borrowings were capitalized and netted against the corresponding debt liabilities on the Condensed Consolidated Balance Sheets. These costs are amortized to interest expense over the terms of the corresponding borrowings using the effective interest rate method. When utilizing the effective interest method, in periods in which payment-in-kind (&#8220;PIK&#8221;) interest was designated and added to the outstanding principal balance of the borrowing, the amortization of the deferred debt fees and issuance costs was accretive.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The royalty financing obligations are eligible to be repaid based on royalties from net sales of ORLADEYO. Interest expense is accrued using the effective interest rate method over the estimated period each of the related liabilities will be paid. This requires the Company to estimate the total amount of future royalty payments to be generated from product sales over the life of the agreement. The Company imputes interest on the carrying value of each of the royalty financing obligations and records interest expense using an imputed effective interest rate. The Company reassesses the expected royalty payments each reporting period and accounts for any changes through an adjustment to the effective interest rate on a prospective basis. The assumptions used in determining the expected repayment term of the debt and amortization period of the issuance costs require that the Company make estimates that could impact the carrying value of each of the liabilities, as well as the periods over which associated issuance costs will be amortized. A significant increase or decrease in forecasted net sales could materially impact each of the liability balances, interest expense and the time periods for repayment.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The liability method is used in the Company&#8217;s accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Significant management judgment is required in determining the Company&#8217;s provision for income taxes, deferred tax assets and liabilities and any valuation allowance recorded against net deferred tax assets. The Company has recorded a valuation allowance against substantially all potential tax assets, due to uncertainties in its ability to utilize deferred tax assets, primarily consisting of certain net operating losses carried forward, before they expire. The valuation allowance is based on estimates of future earnings in each of the jurisdictions in which the Company operates and the period over which its deferred tax assets will be recoverable.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertain tax positions in accordance with U.S. GAAP. Uncertain tax positions are recorded based upon certain recognition and measurement criteria. The Company re-evaluates uncertain tax positions and considers various factors, including, but not limited to, changes in tax law and the measurement of tax positions taken or expected to be taken in tax returns. The Company adjusts the amount of the liability to reflect any subsequent changes in the relevant facts and circumstances surrounding the uncertain tax positions. The Company recognizes interest and penalties related to income tax matters in income tax expense.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in fiscal year 2021, the Company began accruing for U.S. state taxes and foreign income taxes as a result of increased nexus in both U.S. state and foreign jurisdictions where historically the Company had no presence and where no net operating losses had historically been established.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, starting in 2022, amendments to Section 174 of the Internal Revenue Code of 1986, as amended (&#8220;IRC&#8221;), no longer permit an immediate deduction for research and development expenditures conducted on foreign soil in the tax year that such costs are incurred. Instead, these IRC Section 174 development costs must now be capitalized and amortized over a 15-year period. The new amortization period begins with the midpoint of any taxable year that IRC Section 174 costs are first incurred, regardless of whether the expenditures were made prior to or after July 1, and runs until the midpoint of year sixteen.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Certain countries in which the Company has operations have adopted legislation influenced by the Organization for Economic Cooperation and Development (&#8220;OECD&#8221;) Pillar Two rules, including a minimum tax rate of 15%. It is uncertain whether the U.S. will enact legislation to adopt the Pillar Two framework. While the Company is currently not within the scope of the rules, it is continuing to review and evaluate additional guidance released by the OECD, along with the pending legislative adoption by additional individual countries where the Company operates. </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">On July 4, 2025, the One Big Beautiful Bill Act (&#8220;OBBBA&#8221;) was signed into law, making permanent certain provisions of the Tax Cuts and Jobs Act, including permanent 100% bonus depreciation, expensing of domestic research costs, and amendments to the business interest expense limitation. In accordance with ASC Topic 740, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Income Taxes,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> the Company has recognized the effects of the new tax law in the period of enactment. As the Company maintains a full valuation allowance on its U.S. federal deferred tax assets, the legislation does not have a material impact on its condensed consolidated financial statements for the three months ended September 30, 2025.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency of each of the Company&#8217;s foreign subsidiaries is primarily the local currency of the country in which the subsidiary operates. The Company&#8217;s asset and liability accounts are translated at the current exchange rate as of the balance sheet date. Revenue and expense accounts are translated at the average exchange rate over the period. Adjustments resulting from the translation of the financial statements of the Company&#8217;s foreign subsidiaries into U.S. dollars are accumulated as a separate component of stockholders&#8217; equity within accumulated other comprehensive income. Gains or losses resulting from transactions denominated in foreign currencies are included in foreign currency losses, net, within the Condensed Consolidated Statement of Comprehensive Income (Loss).</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Income (Loss) Per Share</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income (loss) per share is based upon the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share is based upon the weighted average number of common shares outstanding and potentially dilutive common shares during the period as determined by using the treasury stock method. Potential common equivalent shares are excluded if their effect is anti-dilutive.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive income is comprised of cumulative foreign currency translation adjustments and unrealized gains and losses on available-for-sale investments and is disclosed as a separate component of stockholders&#8217; equity. Realized gain and loss amounts on available-for-sale investments are reclassified from accumulated other comprehensive income and recorded as interest and other income on the Condensed Consolidated Statements of Comprehensive Income (Loss). There were no realized gains or losses reclassified out of accumulated other comprehensive income for the three and nine months ended September&#160;30, 2025 and 2024.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Customers and Other Risks</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Significant Customers</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s primary sources of revenue and cash flow are the sales of ORLADEYO in the United States.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ORLADEYO is generally distributed through an arrangement with a single specialty pharmacy in the United States. The specialty pharmacy subsequently sells ORLADEYO to its customers (pharmacy benefit managers, insurance companies, government programs and group purchasing organizations) and dispenses product to patients. RAPIVAB is also generally distributed through the same specialty pharmacy in the United States. The specialty pharmacy&#8217;s inability or unwillingness to continue these distribution activities could adversely impact the Company&#8217;s business, results of operations and financial condition. Revenue where the specialty pharmacy is considered the customer was approximately 88% and 86% of total net revenues for the three and nine months ended September&#160;30, 2025, respectively. Revenue where the specialty pharmacy is considered the customer was approximately 88% of total net revenues for both the three and nine months ended September&#160;30, 2024.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is distributing ORLADEYO in other global markets directly or through other parties.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks from Third-Party Manufacturing and Distribution Concentration</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company relies on a single source manufacturer for active pharmaceutical ingredient and finished drug product manufacturing of product candidates in development and on a single specialty pharmacy for distribution of approved drug product in the United States. Delays or disruption in the manufacture or distribution of any product could adversely impact the future procurement stockpiling of the Company&#8217;s commercial product, commercial revenue and product candidates.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Further, the Company&#8217;s drug development activities are performed by a limited group of third-party vendors. If any of these vendors were unable to perform its services, this could significantly impact the Company&#8217;s ability to complete its drug development activities.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Risk</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents and investments are financial instruments that potentially subject the Company to concentration of risk to the extent recorded on the Condensed Consolidated Balance Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances may exceed the amount of insurance provided on such deposits. The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio of investments with an average maturity of approximately 12 months or less.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s receivables from sales of ORLADEYO are primarily due from one customer, resulting in a concentration of credit risk. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There have been no new accounting pronouncements adopted by the Company during the nine months ended September 30, 2025.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company expects adoption of this ASU will result in additional disclosures but does not expect it will have a material effect on the Company&#8217;s consolidated balance sheet, statement of comprehensive income (loss), or statement of cash flows.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which requires public entities, on an annual and interim basis, to provide disaggregated disclosure of certain income statement expenses into specified categories within the footnotes to the financial statements. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The Company is evaluating the impact of adopting ASU 2024-03.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In September 2025, the FASB issued ASU 2025-06, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software, which clarifies and modernizes the accounting for costs related to internal-use software, eliminating references to project stages and clarifying the threshold entities apply to begin capitalizing costs. ASU 2025-06 is effective for fiscal years beginning after December 15, 2027, and interim periods within those annual reporting periods, with early adoption permitted. The Company is evaluating the impact of adopting ASU 2025-06 but does not expect it will have a material effect on its consolidated balance sheet, statement of comprehensive income (loss), or statement of cash flows.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not expect any other recently issued accounting standards to have a material impact to its financial statements or disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Assets and Liabilities Held For Sale<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Assets and Liabilities Held For Sale</a></td>
<td class="text">Assets and Liabilities Held for Sale<div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On June 27, 2025, the Company entered into a definitive agreement (the &#8220;Stock Purchase Agreement&#8221;) with BioCryst Ireland Limited (&#8220;BioCryst Ireland&#8221;), a wholly owned subsidiary that operates the European ORLADEYO business, and Neopharmed Gentili S.p.A. (&#8220;Neopharmed&#8221;). On October 1, 2025 (the &#8220;Closing&#8221;), under the terms of the Stock Purchase Agreement, the Company sold to Neopharmed all of its equity interests in BioCryst Ireland, which, together with its subsidiaries, holds certain assets, rights, and employees related to our European ORLADEYO business (the &#8220;European ORLADEYO Business&#8221;). At the Closing, the Company received cash proceeds of $250,000, plus customary purchase price adjustments as set forth in the Stock Purchase Agreement. In addition, Neopharmed has agreed to pay the Company up to $14,000 if certain revenue milestones are achieved prior to December 31, 2032. Concurrent with the Closing, Neopharmed also paid a $15,000 royalty release fee to RPI 2019 Intermediate Finance Trust.  In connection </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">with the sale, the Company entered into several agreements with Neopharmed, including an Amended and Restated IP Licence Agreement, a Supply Agreement, a Global Brand and Support Agreement, a Transition Services Agreement, and a Trademark License Agreement (each as defined in</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Note 16&#8212;Subsequent Events&#8221;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On October 8, 2025, the Company used a portion of the proceeds from the sale of the European ORLADEYO business to pay off in full the outstanding principal balance and terminate the Pharmakon Loan Agreement (as defined in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8&#8212;Debt&#8221;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">). See </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Note 16&#8212;Subsequent Events&#8221;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2025, the Company concluded that the criteria under ASC 360-10-45-9 for classification as held for sale were met for BioCryst Ireland. Accordingly, the assets and liabilities of BioCryst Ireland are classified as a disposal group held for sale in the Company&#8217;s Condensed Consolidated Balance Sheet. The disposal group is not considered a discontinued operation under ASC 205-20, as it does not represent a strategic shift that will have a major effect on the Company&#8217;s operations or financial results. Therefore, the results of operations for BioCryst Ireland are included in income from continuing operations for all periods presented.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">No impairment loss was recognized in connection with the classification of the disposal group as held for sale, as the estimated fair value less costs to sell exceeded its carrying value.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the assets and liabilities of BioCryst Ireland that are classified as held for sale on the unaudited Condensed Consolidated Balance Sheet as of September&#160;30, 2025 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14,840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10,285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Inventory, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,902&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Current assets held for sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">29,173&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Non-current assets held for sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4,058&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total assets held for sale</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">33,231&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,714&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">24,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities held for sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">26,423&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Non-current liabilities held for sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">436&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities held for sale</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">26,859&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205-20/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue</a></td>
<td class="text">Revenue<div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded the following revenues for the three and nine months ended September&#160;30, 2025 and 2024 (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">ORLADEYO:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">141,557&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">103,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">402,054&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">278,987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outside of U.S.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">17,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13,207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">48,103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">34,487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total ORLADEYO</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">159,077&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">116,319&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">450,157&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">313,474&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">766&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">18,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,704&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">159,395&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">117,085&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">468,282&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">319,178&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ORLADEYO revenues represent total revenues from product sales, collaborative revenues, and royalties. Other revenues primarily relate to the Company&#8217;s product sales and royalties for peramivir.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">No individual country outside of the U.S. exceeded 10% of total revenues for the three and nine months ended September&#160;30, 2025 and 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock', window );">Investments</a></td>
<td class="text">Investments<div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. Fair value is determined based on observable and unobservable inputs. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect certain market assumptions. As a basis for considering such assumptions, U.S. GAAP establishes a three-tier value hierarchy, which prioritizes the inputs used to develop the assumptions and for measuring fair value as follows: (Level 1) observable inputs such as quoted prices in active markets for identical assets; (Level 2) inputs other than the quoted prices in active markets that are observable either directly or indirectly; and (Level 3) unobservable inputs for which there is little or no market data, which requires the Company to develop its own assumptions. This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments that are measured at fair value on a recurring basis consist of fixed income investments. These valuations are based on observable direct and indirect inputs, primarily quoted prices of similar, but not identical, instruments in active markets or quoted prices for identical or similar instruments in markets that are not active. These fair values are obtained from independent pricing services. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Assets measured at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.475%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Price in Active Markets (Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable Inputs (Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable Inputs&#160;(Level&#160;3)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Obligations of U.S. Government and its agencies</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">168,464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">168,464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">168,464&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">168,464&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.475%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Price in Active Markets (Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable Inputs (Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable Inputs&#160;(Level&#160;3)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Obligations of U.S. Government and its agencies</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">236,460&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">236,460&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">236,460&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">236,460&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2025, the Company had seven securities with a total estimated fair value of $69,245 in an unrealized loss position. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. The Company does not have an intent to sell these investments, and it is more likely than not that the investments will be held until recovery of their amortized cost basis. As such, no allowance was recognized.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the fair value of the Company&#8217;s investments by type (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:f-584">Accrued<br/>Interest</span></span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Obligations of U.S. Government and its agencies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">167,149&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,203&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">168,464&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">167,149&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,203&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">168,464&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:f-595">Accrued<br/>Interest</span></span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Obligations of U.S. Government and its agencies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">234,902&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">451&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">236,460&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">234,902&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,121&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">451&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">236,460&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the scheduled maturity for the Company&#8217;s investments at September&#160;30, 2025 and December&#160;31, 2024 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">128,795&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">216,137&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through two years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">39,669&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">20,323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">168,464&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">236,460&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade Receivables<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_TradeReceivablesTextBlock', window );">Trade Receivables</a></td>
<td class="text">Trade Receivables<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Receivables from product sales are recorded for amounts due to the Company related to sales of ORLADEYO and peramivir. At September&#160;30, 2025 and December&#160;31, 2024, receivables, net of reserves, related to sales of ORLADEYO were $88,034 and $76,282, respectively. At September&#160;30, 2025 and December&#160;31, 2024, receivables related to sales of peramivir were $153 and $564, respectively. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2025, there was $10,285 of accounts receivable, net of reserves, included in current assets held for sale. See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2&#8212;Assets and Liabilities Held for Sale</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; for further details. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaborative and Other Revenue</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> At September&#160;30, 2025 and December&#160;31, 2024 receivables from the Company&#8217;s royalty partners were $3,138 and $2,223, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_TradeReceivablesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for trade receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_TradeReceivablesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text">Inventory<div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2025 and December&#160;31, 2024, the Company&#8217;s inventory primarily related to ORLADEYO. The Company&#8217;s inventories consisted of the following (in thousands):  </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9,324&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10,006&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14,982&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">16,152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">30,283&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">33,923&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Reserves</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,661)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,649)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">28,622&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">31,274&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2025, there was $2,146 of inventory, net in current assets held for sale and $705 of inventory, net in non-current assets held for sale. See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2&#8212;Assets and Liabilities Held for Sale</span>&#8221; for further details.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty Financing Obligations<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvanceRoyaltiesAbstract', window );"><strong>Advance Royalties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyFinancingLiabilitiesTextBlock', window );">Royalty Financing Obligations</a></td>
<td class="text">Royalty Financing Obligations<div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;7, 2020, the Company and RPI 2019 Intermediate Finance Trust (&#8220;RPI&#8221;) entered into a Purchase and Sale Agreement (the &#8220;2020 RPI Royalty Purchase Agreement&#8221;), pursuant to which the Company sold to RPI the right to receive certain royalty payments from the Company for a purchase price of $125,000 in cash (the &#8220;2020 RPI Royalty Sale&#8221;). Under the 2020 RPI Royalty Purchase Agreement, RPI is entitled to receive tiered, sales-based royalties on net product sales of ORLADEYO in the United States and certain key European markets (collectively, the &#8220;Key Territories&#8221;), and other markets where the Company sells ORLADEYO directly or through distributors (collectively, the &#8220;Direct Sales&#8221;) in an amount equal to: (i) 8.75% of aggregate annual net sales of ORLADEYO for annual net sales up to $350,000 and (ii) 2.75% of annual net sales for annual net sales between $350,000 and $550,000. No royalty payments are payable on annual Direct Sales over $550,000.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2020 RPI Royalty Purchase Agreement, RPI is also entitled to receive a tiered revenue share on ORLADEYO sublicense revenue or net sales by licensees outside of the Key Territories (the &#8220;Other Markets&#8221;) equal to: (i) 20% of the proceeds received by the Company for upfront license fees and development milestones for ORLADEYO in the Other Markets, (ii) 20% of proceeds received on annual net sales of up to $150,000 in the Other Markets, and (iii) 10% of proceeds received by the Company on annual net sales between $150,000 and $230,000 in the Other Markets. No royalty payments are payable on annual net sales above $230,000 in the Other Markets.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;19, 2021, the Company and RPI entered into (i) a Purchase and Sale Agreement (the &#8220;2021 RPI Royalty Purchase Agreement&#8221; and together with the 2020 RPI Royalty Purchase Agreement, the &#8220;RPI Royalty Purchase Agreements&#8221;), pursuant to which the Company sold to RPI the right to receive certain royalty payments from the Company for a purchase price of $150,000 in cash, and (ii) a Purchase and Sale Agreement with OCM IP Healthcare Holdings Limited, an affiliate of OMERS Capital Markets (&#8220;OMERS&#8221;) (the &#8220;OMERS Royalty Purchase Agreement&#8221; and collectively with the RPI Royalty Purchase Agreements, the &#8220;Royalty Purchase Agreements&#8221;), pursuant to which the Company sold to OMERS the right to receive certain royalty payments from the Company for a purchase price of an additional $150,000 in cash.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2021 RPI Royalty Purchase Agreement, RPI is entitled to receive tiered, sales-based royalties on Direct Sales in an amount equal to: (i) 0.75% of aggregate annual net sales of ORLADEYO for annual net sales up to $350,000 and (ii) 1.75% of annual net sales of ORLADEYO for annual net sales between $350,000 and $550,000. No royalty payments are payable on Direct Sales over $550,000. RPI is also entitled to receive a tiered revenue share on ORLADEYO sublicense revenue or net sales by licensees in the Other Markets in an amount equal to (i) 3.0% of proceeds received by the Company on annual net sales of up to $150,000 in the Other Markets and (ii) 2.0% of proceeds received by the Company on annual net sales between $150,000 and $230,000 in the Other Markets. No royalty payments are payable on annual net sales above $230,000 in the Other Markets.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> The royalties payable under the 2021 RPI Royalty Purchase Agreement are in addition to the royalties payable to RPI under the 2020 RPI Royalty Purchase Agreement.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the OMERS Royalty Purchase Agreement, for the calendar quarter beginning October 1, 2023, OMERS was entitled to receive tiered, sales-based royalties on Direct Sales in an amount equal to: (i) 7.5% of aggregate annual net sales of ORLADEYO for annual net sales up to $350,000 and (ii) 6.0% of annual net sales of ORLADEYO for annual net sales between $350,000 and $550,000 (with no royalty payments payable on annual Direct Sales over $550,000). Commencing with the calendar quarter beginning January 1, 2024, OMERS is entitled to receive tiered, sales-based royalties on Direct Sales in an amount equal to: (i) 10.0% of aggregate annual net sales of ORLADEYO for annual net sales up to $350,000 and (ii) 3.0% of annual net sales of ORLADEYO for annual net sales between $350,000 and $550,000 (with no royalty payments payable on annual Direct Sales over $550,000).</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the OMERS Royalty Purchase Agreement, OMERS is also entitled to receive a tiered revenue share on ORLADEYO sublicense revenue or net sales by licensees in the Other Markets in an amount equal to: (i) 20.0% of the proceeds received by the Company for upfront license fees and development milestones for ORLADEYO in the Other Markets, (ii) 20.0% of proceeds received by the Company on annual net sales of up to $150,000 in the Other Markets, and (iii) 10.0% of proceeds received by the Company on annual net sales between $150,000 and $230,000 in the Other Markets. No royalty payments are payable on annual net sales above $230,000 in the Other Markets. OMERS is also entitled to receive profit share amounts of up to 10% from certain other permitted sales in certain other markets.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2020 RPI Royalty Purchase Agreement, the Company is required to make royalty payments of amounts owed to RPI each calendar quarter following the first commercial sale of ORLADEYO in any country. Under the 2021 RPI Royalty Purchase Agreement, the Company is required to make payments to RPI in respect of net sales or sublicense revenue in each calendar quarter from and after October 1, 2021. Under the OMERS Royalty Purchase Agreement, the Company is required to make payments to OMERS in respect of net sales or sublicense revenue in each calendar quarter from and after October 1, 2023. OMERS will no longer be entitled to receive any payments on the date in which aggregate payments actually received by OMERS equals 155.0% of the $150,000 purchase price.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The transactions contemplated by each of the Royalty Purchase Agreements are referred to herein as the &#8220;Royalty Sales&#8221;.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the Royalty Purchase Agreements, the Company has agreed to specified affirmative and negative covenants, including covenants regarding periodic reporting of information by the Company to RPI and OMERS, third-party audits of royalties paid under the Royalty Purchase Agreements, and restrictions on the ability of the Company or any of its subsidiaries to incur indebtedness other than certain royalty sales and as was permitted to be incurred under the terms of the Athyrium Credit Agreement (as defined in Note 8 herein) through its payoff and termination on April 17, 2023 or, subsequent to that date, the Pharmakon Loan Agreement (as defined in Note 8 herein), as applicable. See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8&#8212;Debt</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; for further details on the Athyrium Credit Agreement and the Pharmakon Loan Agreement. The restrictions under the Royalty Purchase Agreements on the ability of the Company or any of its subsidiaries to incur indebtedness are eliminated after the achievement of certain specified milestones in the Royalty Purchase Agreements. In addition, in connection with the Stock Purchase Agreement (as defined in </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2&#8212;Assets and Liabilities Held for Sale&#8221;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">), RPI and OMERS provided their written consent of the consummation of the sale of the Company&#8217;s European ORLADEYO Business. See </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Note 16&#8212;Subsequent Events&#8221;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information on the sale of the Company&#8217;s European ORLADEYO Business.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The cash consideration obtained pursuant to the Royalty Purchase Agreements is recorded in &#8220;Royalty financing obligations&#8221; on the Company&#8217;s Condensed Consolidated Balance Sheets. The fair value for the royalty financing obligations at the time of the transactions was based on the Company&#8217;s estimates of future royalties expected to be paid to the counterparty over the life of the arrangement. The Company subsequently records the obligations at their carrying value using the effective interest method. As of September&#160;30, 2025 and December&#160;31, 2024, the carrying value of the royalty financing obligations under the Royalty Purchase Agreements approximated fair value and was measured based on the Company&#8217;s current estimates of future payments to RPI and OMERS over the lives of the agreements, which are considered Level 3 inputs. The Company utilizes the prospective method to account for subsequent changes in the estimated future royalties to be paid by the Company to the counterparty over the life of the arrangement. Under the prospective method, a new effective interest rate is determined based on the revised estimate of remaining cash flows. The new rate is the discount rate that equates the present value of the revised estimate of remaining cash flows with the carrying amount of the debt, and it will be used to recognize interest expense for the remaining periods. The Company periodically assesses the amount and timing of expected royalty payments using internal projections of future net product sales, which are based on key assumptions, including paid patients and price. To the extent such payments are greater or less than the Company&#8217;s initial estimates or the timing of such payments is materially different than its original estimates, the Company </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">will prospectively adjust the amortization of the royalty financing obligations and the effective interest rate. On a quarterly basis, the Company assesses the projected royalty payments relative to the projected interest accretion for the next twelve months to determine if the royalty liability balance is reduced relative to the current outstanding liability. In such case of excess payments relative to interest accretion for the next twelve months, the excess payments are considered to be a short-term liability and classified within current liabilities on the Company&#8217;s Condensed Consolidated Balance Sheets.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2025, there were no significant changes to the amount and timing of expected royalties under the Royalty Purchase Agreements based on the Company&#8217;s latest forecasts related to ORLADEYO sales. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the royalty financing obligations activity for the three and nine months ended September&#160;30, 2025 (in thousands) as well as the effective interest rate as of September&#160;30, 2025: </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2020 RPI<br/>Royalty<br/>Agreement</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2021 RPI<br/>Royalty<br/>Agreement</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">OMERS<br/>Royalty<br/>Agreement</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">180,413&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">181,140&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">152,176&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">513,729&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense on royalty financing obligations</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9,756&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,758&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13,514&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenues payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(11,818)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,021)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(13,486)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(26,325)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of March 31, 2025</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">178,351&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">180,119&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">142,448&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">500,918&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense on royalty financing obligations</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9,804&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,598&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13,402&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenues payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(13,798)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,193)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(15,746)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(30,737)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2025</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">174,357&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">178,926&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">130,300&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">483,583&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense on royalty financing obligations</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9,610&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,313&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">12,923&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenues payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(8,258)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,195)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(9,260)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(19,713)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of September 30, 2025</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">175,709&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">176,731&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">124,353&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">476,793&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Effective interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for interest on the royalty financing obligations was $18,319 and $55,240 for the three and nine months ended September&#160;30, 2025, respectively. Cash paid for interest on the royalty financing obligations was $21,239 and $54,308 for the three and nine months ended September&#160;30, 2024, respectively.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Concurrent with entering into the 2021 RPI Royalty Purchase Agreement, the Company and RPI entered into a Common Stock Purchase Agreement pursuant to which the Company sold common stock to RPI for a premium of $4,269. This premium has been deferred and is being amortized through interest expense using the effective interest method over the term of the applicable arrangement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyFinancingLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty monetization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyFinancingLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvanceRoyaltiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvanceRoyaltiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">Debt<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pharmakon Loan Agreement</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On April 17, 2023, the Company entered into a $450,000 Loan Agreement (the &#8220;Pharmakon Loan Agreement&#8221;) with BioPharma Credit Investments V (Master) LP and BPCR Limited Partnership, as lenders, and BioPharma Credit PLC, as collateral agent for the lenders. Certain of the Company&#8217;s wholly-owned subsidiaries were guarantors to the Pharmakon Loan Agreement. The Pharmakon Loan Agreement provided for an initial term loan in the principal amount of $300,000 (the &#8220;Tranche A Loan&#8221;) funded on April 17, 2023 (the &#8220;Tranche A Closing Date&#8221;). The Company used a portion of the proceeds from the Tranche A Loan to repay the $241,787 of outstanding indebtedness (principal and interest due as of April 17, 2023) under the then-existing credit facility with Athyrium Opportunities III Co-Invest 1 LP (the &#8220;Athyrium Credit Agreement&#8221;) and to pay associated transaction costs and fees, and used the remaining net proceeds of $25,805 for other general corporate purposes.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmakon Loan Agreement also provided for three additional term loan tranches, at the Company&#8217;s option, in principal amounts of $50,000 each (each a &#8220;Subsequent Tranche Loan&#8221; and, collectively with the Tranche A Loan, the </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Pharmakon Term Loans&#8221; and each, a &#8220;Pharmakon Term Loan&#8221;), which could have been requested on or prior to September 30, 2024. The Company chose not to request any Subsequent Tranche Loans and the options have since expired. The maturity date of the Pharmakon Loan Agreement was April 17, 2028 (the &#8220;Maturity Date&#8221;), the fifth anniversary of the Tranche A Closing Date.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmakon Loan Agreement provided for quarterly interest-only payments until the Maturity Date, with the unpaid principal amount of the outstanding Pharmakon Term Loans due and payable on the Maturity Date. During the first 18 months following the Tranche A Closing Date, the Company had the option to make a portion of the applicable interest payment on the Tranche A Loan in-kind (a &#8220;Pharmakon PIK Interest Payment&#8221;) by capitalizing as principal up to 50% of the amount of interest accrued on the Tranche A Loan during the applicable interest period. The Pharmakon Term Loans bore interest at a rate equal to the three-month Secured Overnight Financing Rate (&#8220;SOFR&#8221;), which could be no less than 1.75%, plus 7.00%, per annum or, for each interest period in which a Pharmakon PIK Interest Payment was made, with respect to the Tranche A Loan, SOFR plus 7.25%, per annum.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Tranche A Loan accrued interest at an effective interest rate of 12.28% and 13.34% for the three months ended September&#160;30, 2025 and 2024, respectively.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company was required to make a mandatory prepayment of the Pharmakon Term Loans (i) upon the occurrence of a change of control and (ii) prior to any repayment of any convertible debt that the Company may have issued in the future, subject to certain exceptions. The Company could make voluntary prepayments in whole or in part, in minimum $25,000 increments. Prepayments were subject to a prepayment premium equal to, (i) with respect to any prepayment made prior to the second anniversary of the applicable Pharmakon Term Loan borrowing date, the sum of (1) 3.00% of the principal amount of the Pharmakon Term Loan being prepaid plus (2) the aggregate amount of all interest that would have accrued on the principal amount of the Pharmakon Term Loan being prepaid from the date of prepayment through and including the second anniversary of the date of the borrowing of such Pharmakon Term Loan; (ii) with respect to any prepayment made on or after the second anniversary and prior to the third anniversary of the applicable Pharmakon Term Loan borrowing date, 3.00% of the principal amount of the Pharmakon Term Loan being prepaid; (iii) with respect to any prepayment made on or after the third anniversary and prior to the fourth anniversary of the applicable Pharmakon Term Loan, 2.00% of the principal amount of the Pharmakon Term Loan being prepaid; and (iv) with respect to any prepayment made on or after the fourth anniversary of the applicable Pharmakon Term Loan borrowing date and before the Maturity Date, 1.00% of the principal amount of the Pharmakon Term Loan being prepaid. In addition, if the Company had requested any Subsequent Tranche Loans, certain funding fees would have been required to be paid.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmakon Loan Agreement also contained representations and warranties and affirmative and negative covenants customary for financings of this type, as well as customary events of default. Certain of the customary negative covenants limited the ability of the Company and certain of its subsidiaries to, among other things, dispose of assets, engage in mergers, acquisitions, and similar transactions, incur additional indebtedness, grant liens, make investments, pay dividends or make distributions or certain other restricted payments in respect of equity, prepay other indebtedness, enter into restrictive agreements, undertake fundamental changes or amend certain material contracts, among other customary covenants, in each case subject to certain exceptions.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A failure to comply with the covenants in the Pharmakon Loan Agreement, or an occurrence of any other event of default, could have permitted the lenders under the Pharmakon Loan Agreement to declare the borrowings thereunder, together with accrued interest and fees, and any applicable prepayment premium, to be immediately due and payable.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s obligations under the Pharmakon Loan Agreement were secured by a security interest in, subject to certain exceptions, substantially all of the Company&#8217;s assets.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On April 18, 2025, as allowable under the Pharmakon Loan Agreement, the Company made a $75,000 partial prepayment on the outstanding principal amount under the Pharmakon Term Loan. In conjunction with the partial prepayment, the Company incurred a $2,250 prepayment premium and paid $424 of interest accrued through the payment date. Additionally, unamortized deferred financing costs of $1,921 associated with the Pharmakon Term Loan were written-off at the time of repayment. Collectively, the prepayment and unamortized deferred financing costs totaled $4,171 and are reflected as a one-time loss on extinguishment of debt on the Condensed Consolidated Statements of Comprehensive Income (Loss) for the nine months ended September 30, 2025.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On July 24, 2025, as allowable under the Pharmakon Loan Agreement, the Company made a $50,000 partial prepayment on the outstanding principal amount under the Pharmakon Term Loan. In conjunction with the partial prepayment, the Company incurred a $1,500 prepayment premium and fees of $52 and paid $376 of interest accrued through the payment date. Additionally, unamortized deferred financing costs of $1,188 associated with the Pharmakon </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Term Loan were written-off at the time of repayment. Collectively, the prepayment and unamortized deferred financing costs totaled $2,740 and are reflected as a one-time loss on extinguishment of debt on the Condensed Consolidated Statements of Comprehensive Income (Loss) for the three and nine months ended September 30, 2025.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2025, borrowings, including Pharmakon PIK Interest Payments, totaled $198,704 under the Pharmakon Loan Agreement. Interest expense on the Tranche A Loan for the three and nine months ended September&#160;30, 2025 was $6,110 and $22,789, respectively, all of which was paid at the end of the quarterly period. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2024, borrowings, including the Pharmakon PIK Interest Payments, totaled $323,704 under the Pharmakon Loan Agreement. Interest expense on the Tranche A Loan for the three and nine months ended September&#160;30, 2024 was $10,201 and $30,283, respectively. As allowable under the Pharmakon Loan Agreement, the Company designated and accounted for 50% of the quarterly interest payments for each of the three months ended March&#160;31, 2024 and June&#160;30, 2024 as a Pharmakon PIK Interest Payment and the total amount of $10,041 was added to the outstanding principal balance of the borrowing. The remaining 50% of the total quarterly interest payments for the three months ended March&#160;31, 2024 and June&#160;30, 2024 and the full quarterly interest payment for the three months ended September 30, 2024 totaling $20,242 was paid at the end of each quarterly period. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the debt approximated its carrying value based on prevailing interest rates as of the balance sheet date and was considered as Level 2 in the fair value hierarchy.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Debt fees and issuance costs incurred with the Tranche A Loan under the Pharmakon Loan Agreement totaled $11,147 and were deferred and amortized as interest expense on an effective interest rate method over the term of the Tranche A Loan. Deferred financing amortization of $384 and $1,387 was recognized for the three and nine months ended September&#160;30, 2025, respectively. Deferred financing amortization of $511 and $1,061 was recognized for the three and nine months ended September&#160;30, 2024, respectively.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> In connection with the Stock Purchase Agreement (as defined in </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2&#8212;Assets and Liabilities Held for Sale&#8221;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">), Pharmakon provided its written consent of the consummation of the sale of the Company&#8217;s European ORLADEYO Business. On October 8, 2025, the Company used a portion of the proceeds from the sale of the European ORLADEYO Business to pay off in full the outstanding principal balance and terminate the Pharmakon Loan Agreement. See </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Note 16&#8212;Subsequent Events&#8221;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Obligations<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Lease Obligations</a></td>
<td class="text">Lease Obligations <div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases certain assets under operating leases, which primarily consist of real estate leases, and finance leases, which generally consist of laboratory equipment leases and office equipment leases, as of September&#160;30, 2025. The Company&#8217;s real estate agreements expire at various times between 2026 through 2033 and include renewal options that range from <span style="-sec-ix-hidden:f-764">three</span> to five years in length.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Lease expense under operating and finance leases was as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">526&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">569&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,596&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,741&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Finance lease expense:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Amortization of right-of-use assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">455&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,278&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total finance lease expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">631&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">536&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,907&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,509&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other supplemental information related to leases was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9.7 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9.0 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2.5 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2.6 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the presentation in the Condensed Consolidated Balance Sheets of the Company&#8217;s operating leases (in thousands): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Balance Sheet Location</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-793"><span style="-sec-ix-hidden:f-794">Right of use assets</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">7,725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">8,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Operating lease liabilities &#8211; current liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">348&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">937&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Operating lease liabilities &#8211; long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">8,425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">7,924&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">8,773&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">8,861&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the presentation in the Condensed Consolidated Balance Sheets of the Company&#8217;s finance leases (in thousands): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Balance Sheet Location</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-803"><span style="-sec-ix-hidden:f-804">Right of use assets</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Current finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Finance lease liabilities &#8211; current liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,435&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,835&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Non-current finance lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Finance lease liabilities &#8211; long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,177&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,959&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease assets are recorded net of accumulated amortization of $2,314 and $6,065 as of September&#160;30, 2025 and December&#160;31, 2024, respectively. Finance lease assets are recorded net of accumulated amortization of $4,519 and $4,059 as of September&#160;30, 2025 and December&#160;31, 2024, respectively.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of September&#160;30, 2025 are as follows (in thousands): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Finance Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2025 (remaining)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">119&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">496&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,153&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,050&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">486&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">9,024&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">14,802&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,578&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(6,029)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(401)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">8,773&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,177&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases was as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows for finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows for operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets obtained in exchange for operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease assets obtained in exchange for finance lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">870&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash increase to operating lease assets due to remeasurement of operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">786&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders<span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> Equity</span><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shares Reserved for Future Issuance of Common Stock</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company had reserved shares of common stock for issuance as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Shares reserved for exercises of outstanding stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">41,522&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">44,240&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Shares reserved for vesting of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9,744&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Shares reserved for future issuance under the Stock Incentive Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">13,721&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,065&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Shares reserved for future issuance under the Inducement Equity Incentive Plan </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,699&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Shares reserved for future issuance under the Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,674&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,042&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total shares reserved for future issuance</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">71,169&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">62,158&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2025, the Company had three stock-based employee compensation plans: the Amended and Restated Stock Incentive Plan (&#8220;Incentive Plan&#8221;), the Amended and Restated Inducement Equity Incentive Plan (&#8220;Inducement Plan&#8221;) and the Amended and Restated Employee Stock Purchase Plan (&#8220;ESPP&#8221;). The Incentive Plan was most recently amended and restated on April 21, 2025 and approved by the Company&#8217;s stockholders on June 12, 2025. The Inducement Plan was most recently amended and restated by the Company&#8217;s Board of Directors on October 26, 2023. The ESPP was most recently amended and restated by the Company&#8217;s Board of Directors on July 7, 2023.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded the following stock-based compensation expense (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Incentive Plan</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16,232</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14,794</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">54,841</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">37,294</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Inducement Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,179</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,234</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,852</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,241</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">233</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">221</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">623</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">539</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation costs</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">18,644</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">17,249</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">61,316</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">44,074</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized stock-based compensation costs</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(43)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation costs included in operating expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">18,601</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">17,249</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">61,273</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">44,074</span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Incentive Plan</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity under the Incentive Plan:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Shares<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">39,082&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7.96&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(897)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5.36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled or Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,924)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">36,799&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7.94&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6.10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">28,966&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2025</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">23,314&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7.92&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4.74</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">23,388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restricted stock unit activity under the Incentive Plan:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Shares <br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9,289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7.73&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9.17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(270)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(667)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at September 30, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8,745&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7.60&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For restricted stock unit awards granted under the Incentive Plan, the fair value of the awards is determined based on the market value of the Company&#8217;s shares on the grant date. The weighted average grant date fair value of these awards granted during the first nine months of 2025 and 2024 was $9.17 and $5.80, respectively. The fair value of the restricted stock unit awards is amortized to expense over the vesting periods using a straight-line expense attribution method.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inducement Equity Incentive Plan</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity under the Inducement Plan:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Shares<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,158&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.44&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.07&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(252)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5.65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled or Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(279)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,723&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.41&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6.20</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6,940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2025</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,519&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.18&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5.60</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6,324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restricted stock unit activity under the Inducement Plan:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Shares<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">823&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.53&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(197)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at September 30, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.39&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For restricted stock unit awards granted under the Inducement Plan, the fair value of the awards is determined based on the market value of the Company&#8217;s shares on the grant date. The weighted average grant date fair value of these awards granted during the first nine months of 2025 and 2024 was $8.47 and $6.25, respectively. The fair value of the restricted stock unit awards is amortized to expense over the vesting periods using a straight-line expense attribution method.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors under the Incentive and Inducement Plans</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For stock option awards granted under the Incentive Plan and the Inducement Plan, the fair value is estimated on the date of grant using a Black-Scholes option pricing model and the assumptions noted below. The fair value of the stock option awards is amortized to expense over the vesting periods using a straight-line expense attribution method. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Incentive Plan</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the key assumptions used by the Company to value the stock option awards granted under the Incentive Plan during the nine months ended September 30, 2025 and 2024. </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Expected Life in Years</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">5.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Expected Volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">79.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">83.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Expected Dividend Yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Risk-Free Interest Rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Weighted average grant date fair value per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4.56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inducement Equity Incentive Plan</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the key assumptions used by the Company to value the stock option awards granted under the Inducement Plan during the nine months ended September 30, 2025 and 2024.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Expected Life in Years</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">5.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Expected Volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">80.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">83.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Expected Dividend Yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Risk-Free Interest Rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Weighted average grant date fair value per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5.89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4.43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative and Other Relationships</a></td>
<td class="text">Collaborative and Other Relationships<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ORLADEYO</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Torii Pharmaceutical Co., Ltd</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(&#8220;Torii&#8221;)</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;5, 2019, the Company entered into a Commercialization and License Agreement with Torii (the &#8220;Original Torii Agreement&#8221;), granting Torii the exclusive right to commercialize ORLADEYO for the prevention of HAE attacks in Japan. Under the Original Torii Agreement, the Company received an upfront, non-refundable payment of $22,000. The Company received an additional milestone payment of $15,000 in the second quarter of 2021 upon receipt from the Japanese National Health Insurance System of a reimbursement price approval for ORLADEYO. In addition, the Company was entitled to receive tiered royalty payments, ranging from 20% to 40% of annual net sales of ORLADEYO in Japan during each calendar year. Torii&#8217;s royalty payment obligations were subject to customary reductions in certain circumstances, but could not be reduced by more than 50% of the amount that otherwise would have been payable to the Company in the applicable calendar quarter. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company identified performance obligations under the Original Torii Agreement related to (i) the license to develop and commercialize ORLADEYO, (ii) regulatory approval support, and (iii) reimbursement pricing approval support. These were each determined to be distinct from the other performance obligations. The Company allocated the $22,000 upfront consideration to the identified performance obligations using estimation approaches to determine the standalone selling prices under ASC Topic 606. Specifically, in determining the value related to the license, a valuation approach utilizing risk adjusted discounted cash flow projections was used, and an expected cost plus margin approach was utilized for the other performance obligations. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;30, 2023, the Company entered into an Amended and Restated Commercialization and License Agreement with Torii (as amended, the &#8220;Torii Agreement&#8221;). Under the Torii Agreement, the Company is entitled to receive tiered royalty payments, ranging from 20% to 80% of annual net sales of ORLADEYO in Japan during each calendar year. The Company is now responsible for all commercial promotion activities to support ORLADEYO sales in Japan, and Torii is responsible for HAE disease awareness activities in Japan. The Company will receive a 20% royalty on annual Japanese sales below a prespecified threshold and an 80% royalty on annual Japanese sales above the prespecified threshold.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Torii&#8217;s updated royalty payment obligations commenced on November&#160;30, 2023 and expire upon the later of (i) the tenth anniversary of the date of first commercial sale of ORLADEYO in Japan, (ii) the expiration of the Company&#8217;s patents covering ORLADEYO, and (iii) the expiration of regulatory exclusivity for ORLADEYO in Japan. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the Torii Agreement represented a contract modification to be accounted for as if it were part of the Original Torii Agreement under ASC Topic 606. As the performance obligations under the Original Torii Agreement had been fully satisfied, the Company was not required to adjust revenue previously recognized. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Peramivir Injection (RAPIVAB, RAPIACTA, PERAMIFLU)</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Department of Health and Human Services (&#8220;HHS&#8221;)</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In September 2024, the HHS awarded the Company up to a $69,388 contract for the procurement of up to 95.6 thousand doses over a five-year period of RAPIVAB (peramivir injection) for the treatment of influenza. The contract, awarded by the HHS Office of the Administration for Strategic Preparedness and Response (&#8220;ASPR&#8221;), supplied the Center for the Strategic National Stockpile, the nation&#8217;s largest supply of life-saving pharmaceuticals and medical supplies for use in a public health emergency. The contract was structured with a 12-month base ordering period and four optional 12-month ordering periods, which the government could exercise on an annual basis. ASPR executed the first ordering period for $13,878. The Company delivered no doses of peramivir under this contract and recorded no revenue for the three months ended September 30, 2025. The Company delivered 16.8 thousand doses of peramivir under this contract and recorded revenue of $12,206 for the nine months ended September 30, 2025. There were no doses delivered and no revenue recorded for the three and nine months ended September 30, 2024.  On May 15, 2025, ASPR notified the Company of its intent to not exercise any additional optional ordering periods available under the agreement.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shionogi &amp; Co., Ltd. (&#8220;Shionogi&#8221;)</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In February 2007, the Company entered into an exclusive license agreement with Shionogi to develop and commercialize peramivir in Japan for the treatment of seasonal and potentially life-threatening human influenza. Under the terms of the agreement, Shionogi obtained rights to injectable formulations of peramivir in Japan. In October 2008, the Company and Shionogi amended the license agreement to expand the territory covered by the agreement to include Taiwan. Shionogi has commercially launched peramivir under the commercial name RAPIACTA in Japan and Taiwan. The Company developed peramivir under a license from UAB and owes sublicense payments to UAB on any future milestone payments and/or royalties received by the Company from Shionogi. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Green Cross Corporation</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(&#8220;Green Cross&#8221;)</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In June 2006, the Company entered into an agreement with Green Cross to develop and commercialize peramivir in Korea. Under the terms of the agreement, Green Cross is responsible for all development, regulatory, and commercialization costs in Korea and the Company is entitled to share in profits resulting from the sale of peramivir in Korea, including the sale of peramivir to the Korean government for stockpiling purposes. Furthermore, Green Cross will pay the Company a premium over its cost to supply peramivir for development and any future marketing of peramivir products in Korea.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Collaborations and Relationships</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clearside Biomedical, Inc. (&#8220;Clearside&#8221;)</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;3, 2023, the Company announced that it entered into a license agreement (the &#8220;Clearside Agreement&#8221;) with Clearside, enabling the Company to develop its investigational plasma kallikrein inhibitor, avoralstat, with Clearside&#8217;s SCS Microinjector&#174; to deliver avoralstat to the back of the eye through the suprachoroidal space to treat patients with diabetic macular edema. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the Clearside Agreement, Clearside received a $5,000 upfront license fee from the Company, which was recognized in research and development expenses during the year ended December 31, 2023. Clearside is eligible to receive up to an additional $30,000 in clinical and regulatory milestone payments, and up to a total of $47,500 in three post-approval sales-based milestone payments as annual global net sales progress to $2,000,000. The Company will pay Clearside tiered mid-single digit royalties on annual global net product sales, at three tiers, including a top tier of &gt;$1,500,000.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text">Segment Information<div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as one reportable and operating segment, centered around its commercialized product, ORLADEYO, and its pipeline with the goal of developing first-in-class or best-in-class oral small-molecule and injectable protein therapeutics to target difficult-to-treat rare diseases. The determination of a single segment is consistent with the consolidated financial information regularly provided to the Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;). The Chief Executive Officer, as the CODM, uses consolidated, single-segment financial information for purposes of evaluating performance, making operating decisions, allocating resources, and planning and forecasting for future periods.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> The CODM assesses performance and decides how to allocate resources based on consolidated net income (loss). This measure is used to monitor budget versus actual results to evaluate the performance of the segment. The CODM uses consolidated cash, cash equivalents and investments as the measure of segment assets. As of September&#160;30, 2025 the Company&#8217;s cash, cash equivalents, and investments were $267,382, of which $14,840 was considered held for sale (see </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2 - Assets Held for Sale&#8221;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">). As of December&#160;31, 2024 the Company&#8217;s cash, cash equivalents, and investments were $341,173.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table illustrates information about segment revenues, significant segment expenses, and segment net income (loss) for the three and nine months ended September 30, 2025 and 2024 (in thousands):</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">159,395&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">117,085&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">468,282&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">319,178&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Less</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">9,553&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6,175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Berotralstat</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,575&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9,214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10,504&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">BCX17725</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">7,574&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13,346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,591&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Avoralstat</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,960&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Factor D Program</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">454&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Research, discovery and preclinical programs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">5,457&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11,641&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8,325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and related personnel costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">13,313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 25pt 0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">14,257&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">38,025&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">42,630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 25pt 0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">8,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">24,374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">20,923&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other non-program specific and indirect costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">7,329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 25pt 0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">7,580&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">20,621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">23,965&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">83,014&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">65,101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">252,866&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">185,841&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(2,238)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(3,591)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(7,778)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(11,176)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">19,661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">24,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">64,737&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">74,067&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency (gains) losses, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(98)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,740&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6,911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,667)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,667)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(769)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">586&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Segment net income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">12,899</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">(14,033)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">18,016</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">(62,086)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Reconciliation of segment profit or loss:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments and reconciling items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated net income (loss)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">12,899</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">(14,033)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">18,016</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">(62,086)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">1 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">The significant expense categories and amounts align with the segment-level information that is regularly provided to the CODM.</span></div></td></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">All material long-lived assets of the Company reside in the U.S. For geographic information about the Company&#8217;s product revenues, see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Note 3&#8212;Revenue</span>&#8221;.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Abbreviated New Drug Application</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In January 2025, the Company received a Paragraph IV notice of certification (the &#8220;Notice Letter&#8221;) from Annora Pharma Private Limited (&#8220;Annora&#8221;) advising that Annora has submitted an Abbreviated New Drug Application (&#8220;ANDA&#8221;) to the FDA seeking approval to manufacture, use or sell a generic version of ORLADEYO in the United States prior to the expiration of three patents listed in the FDA&#8217;s Orange Book: U.S. Patent Nos. 10,662,160; 11,117,867; and 11,618,733 (the &#8220;Challenged Patents&#8221;). The Notice Letter alleges that the Challenged Patents, which expire in 2039, are invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of the generic product described in </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Annora&#8217;s ANDA. The Notice Letter does not challenge the following six ORLADEYO Orange Book patents that expire in 2035:  U.S. Patent Nos. 10,125,102; 10,329,260; 10,689,346; 11,230,530; 11,708,333; and 12,116,346. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On March 10, 2025, the Company &#64257;led a patent infringement lawsuit in the United States District Court for the District of Delaware against Annora, Hetero Labs Limited, Hetero USA, Inc., and Camber Pharmaceuticals, Inc. (collectively, the &#8220;Defendants&#8221;), asserting infringement of the Challenged Patents arising from Annora&#8217;s ANDA filing with the FDA. The Company is seeking, among other remedies, equitable relief enjoining the Defendants from infringing the Challenged Patents, as well as an order that the e&#64256;ective date of any FDA approval of the ANDA would be a date no earlier than the expiration of the Challenged Patents (including any regulatory extensions). While the Company intends to vigorously defend its intellectual property rights protecting ORLADEYO, this matter is in the early stages of litigation and no assessment can be made as to the likely outcome of this matter or whether it will be material to the Company. Accordingly, an estimate of the potential loss, or range of loss, if any, to the Company relating to this matter is not possible at this time.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Income (Loss) Per Share</a></td>
<td class="text">Net Income (Loss) Per Share<div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net income (loss) per share for the three and nine months ended September&#160;30, 2025 and 2024 were calculated as follows (in thousands, except per share amounts):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">12,899&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(14,033)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">18,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(62,086)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding: basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">210,176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">206,905&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">209,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">206,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per common share: basic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">0.06&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(0.07)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">0.09&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(0.30)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stock options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,023&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock unit awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable under the employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive potential common shares</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9,709&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8,818&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding: diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">219,885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">206,905&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">218,349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">206,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per common share: diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">0.06&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(0.07)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">0.08&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(0.30)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s potentially dilutive securities include outstanding stock options, unvested restricted stock units and shares issuable under the employee stock purchase plan for the three and nine months ended September&#160;30, 2025 and 2024. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2025, the dilutive effect of outstanding stock options, restricted stock unit awards, and shares issuable under the employee stock purchase plan was calculated using the treasury method, whereby all such awards are assumed to be exercised at the beginning of the period. The hypothetical proceeds from such exercises, including the average unrecognized stock compensation expense for outstanding stock options, restricted stock units and shares issuable under the employee stock purchase plan, were assumed to be used to purchase outstanding common stock at the average price during the period. The net share impact of dilutive securities was added to the weighted average basic common shares outstanding to calculate weighted average diluted shares outstanding.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2024, during which the Company recorded a net loss, all potentially dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share, and thus they are considered &#8220;anti-dilutive.&#8221;  For this period, the weighted average number </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of shares of common stock outstanding used to calculate both basic and diluted net loss per share of common stock is the same.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes potential shares of common stock that were excluded from the computation of diluted net income (loss) per share attributable to common stockholders as they were anti-dilutive:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.113%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21,818&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">38,559&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock unit awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,882&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">22,191&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">44,441&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Event</a></td>
<td class="text">Subsequent Events<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Neopharmed Gentili S.p.A. Stock Purchase Agreement</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On October 1, 2025, under the terms of the Stock Purchase Agreement, the Company sold to Neopharmed all of its equity interests in BioCryst Ireland, which, together with its subsidiaries, holds certain assets, rights, and employees related to the Company&#8217;s European ORLADEYO Business. At the Closing, the Company received cash proceeds of </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$250,000</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, plus customary purchase price adjustments as set forth in the Stock Purchase Agreement. In addition, Neopharmed has agreed to pay the Company up to </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$14,000</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> if certain revenue milestones are achieved prior to December 31, 2032. In connection with the Closing, Neopharmed also paid a </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$15,000</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> royalty release fee to RPI 2019 Intermediate Finance Trust.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Concurrent with the Closing of the transactions contemplated by the Stock Purchase Agreement, on October 1, 2025, the Company and BioCryst Ireland amended and restated their existing intellectual property licence agreement pursuant to which the Company will continue to grant to BioCryst Ireland certain rights with respect to ORLADEYO in the territory (the &#8220;Amended and Restated IP Licence Agreement&#8221;). The terms of the Amended and Restated IP Licence Agreement may also extend to the pediatric line extension of ORLADEYO, subject to certain regulatory approvals. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Closing, on October 1, 2025, the Company entered into a supply agreement with BioCryst Ireland, pursuant to which the Company will be the exclusive supplier of ORLADEYO products to BioCryst Ireland for commercialization in the territory (the &#8220;Supply Agreement&#8221;). Additionally, in connection with the Closing, on October 1, 2025, the Company entered into a global brand and support agreement with BioCryst Ireland, which provides for coordination of brand and regulatory activities between the Company and BioCryst Ireland regarding ORLADEYO products (the &#8220;Global Brand and Support Agreement&#8221;). In connection with the Closing, on October 1, 2025, the Company entered into a mutual transition services agreement with BioCryst Ireland, pursuant to which the Company and BioCryst Ireland will provide each other with certain transition services for the periods of time and for the compensation set forth under the agreement, on customary commercial terms (the &#8220;Transition Services Agreement&#8221;).</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Lastly, in connection with the Closing, on October 1, 2025, the Company entered into a trademark license agreement with BioCryst Ireland, pursuant to which the Company granted to BioCryst Ireland a non-exclusive transitionary license to use the &#8220;BioCryst&#8221; name, solely to develop, manufacture and commercialize ORLADEYO products in the territory for a limited period of time, and an exclusive license to use the ORLADEYO product name to commercialize ORLADEYO products for such uses for the term of the Amended and Restated IP Licence Agreement, in each case subject to the terms and conditions set forth therein (the &#8220;Trademark License Agreement&#8221;).</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pharmakon Loan Agreement</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On October 8, 2025, the Company used a portion of the proceeds from the sale of the European ORLADEYO Business to pay off in full the outstanding principal balance of $198,704 and terminate the Pharmakon Loan Agreement. In conjunction with the repayment the Company incurred a $5,961 prepayment premium and paid $485 of interest accrued through the payment date.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Astria Therapeutics, Inc. Agreement and Plan of Merger</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On October 14, 2025, the Company, Axel Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (&#8220;Merger Sub&#8221;), and Astria Therapeutics, Inc., a Delaware corporation (&#8220;Astria&#8221;), entered into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;).  Pursuant to the Merger Agreement, and subject to the </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">satisfaction or waiver of the conditions specified therein, at the Effective Time (as defined below), Merger Sub will merge with and into Astria, with Astria surviving as a wholly owned subsidiary of the Company (the &#8220;Merger&#8221;). </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms and conditions of the Merger Agreement, at the effective time of the Merger (the &#8220;Effective Time&#8221;), each share of Astria common stock, par value $0.001 per share, issued and outstanding immediately prior to the Effective Time will be, subject to certain exceptions, converted into the right to receive (i) 0.59 of a share of the Company&#8217;s common stock (and, if applicable, cash in lieu of fractional shares), and (ii) $8.55 in cash, without interest, subject to certain adjustments and applicable withholding taxes. Holders of Astria&#8217;s Series X Convertible Preferred Stock, warrants, and certain options will also be entitled to certain consideration, as further set forth in the Merger Agreement. The Merger is subject to the approval of Astria&#8217;s stockholders, as well as customary regulatory approvals. In connection with entering into the Merger Agreement, certain stockholders of Astria entered into voting and support agreements with the Company, pursuant to which each such stockholder has agreed, among other things, to vote its, his or her shares of Astria common stock in favor of the adoption of the Merger Agreement and approval of the transactions contemplated thereby and, subject to certain exceptions, not to transfer such shares of Astria common stock prior to the earlier of the Effective Time and the termination of the Merger Agreement, without the prior written consent of the Company.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Commitments</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the transactions contemplated by the Merger Agreement, on October 14, 2025, the Company entered into a debt commitment letter (the &#8220;Commitment Letter&#8221;) with certain affiliates of Blackstone, Inc. (&#8220;Blackstone&#8221;), pursuant to which Blackstone agreed to provide a $550,000 senior secured credit facility consisting of (i) a committed initial term loan in an aggregate principal amount of $350,000 (the &#8220;Initial Term Loan&#8221;), (ii) a committed delayed draw term loan facility in an aggregate principal amount not exceeding $50,000 (the loans thereunder, the &#8220;Committed Delayed Draw Term Loans&#8221;), and (iii) an uncommitted delayed draw term loan facility in an aggregate principal amount not exceeding $150,000. The Initial Term Loan and any Committed Delayed Draw Term Loans funded on the closing date of the Merger will be used for the purpose of, among other things, funding the consideration for the transactions contemplated by the Merger Agreement and paying for related fees and expenses. The commitments with respect to the Initial Term Loan and any Committed Delayed Draw Term Loans funded on the closing date of the Merger are subject to customary conditions for acquisition financings, including the execution and delivery of definitive documentation with respect to the senior secured credit facility in accordance with the terms set forth in the Commitment Letter and the consummation of the Merger.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2025 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2025, two of the directors and officers of the Company adopted, modified or terminated the &#8220;Rule 10b5-1 trading arrangements&#8221; (as such term is defined in Item 408(a) of Regulation S-K) as set forth in the table below.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.242%"><tr><td style="width:1.0%"></td><td style="width:28.212%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.167%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.167%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.289%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.225%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Name (Title)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Action</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Date of Action</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Duration of Trading Arrangement</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Number of Securities</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Alane P. Barnes,</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chief Legal Officer and Secretary</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Modification</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">August 13, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Until December 20, 2027, or such earlier date upon which all transactions are completed or the plan is terminated</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A. Machelle Sanders, </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Member of the Board of Directors</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Adoption</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">August 14, 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Until December&#160;31, 2025, or such earlier date upon which all transactions are completed or the plan is terminated</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></div></td></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1) This trading plan was originally adopted on December 1, 2022 (the &#8220;2022 Barnes Plan&#8221;) and provided for the sale of up to (i) 24,710 shares of common stock and (ii) 137,897 shares of common stock underlying stock options through December 29, 2025. The 2022 Barnes Plan was amended on May 15, 2024 to cancel all open orders under the 2022 Barnes Plan and to provide for the sale of up to 119,897 shares of common stock underlying stock options expiring in 2024 and 2025 (the &#8220;2024 Barnes Plan&#8221;). The 2024 Barnes Plan was amended on August 13, 2025 (the &#8220;2025 Barnes Plan&#8221;) to cancel all open orders under the 2024 Barnes Plan and to provide for the sale of up to (i) 123,100 shares of common stock underlying restricted stock units, net of shares withheld to cover taxes, (ii) 19,770 shares of common stock, and (iii) 347,501 shares of common stock underlying stock options expiring in 2025 through 2027, pursuant to the terms of the 2025 Barnes Plan.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2) This trading plan (the &#8220;Sanders Plan&#8221;) provides for the sale of up to 9,600 shares of common stock, pursuant to the terms of the Sanders Plan.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=bcrx_A.MachelleSandersMember', window );">A. Machelle Sanders [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">A. Machelle Sanders<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Member of the Board of Directors<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">August 14, 2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">December&#160;31, 2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">139 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">9,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrSecuritiesAggAvailAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrSecuritiesAggAvailAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=bcrx_A.MachelleSandersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=bcrx_A.MachelleSandersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies and Concentrations of Risk (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_DescriptionOfCompanyPolicyTextBlock', window );">The Company</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Company</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">BioCryst Pharmaceuticals, Inc. (the &#8220;Company&#8221;) is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (&#8220;HAE&#8221;) and other rare diseases, driven by the Company&#8217;s deep commitment to improving the lives of people living with these conditions. The Company has built a robust commercial infrastructure to support the launch and continued success of ORLADEYO&#174;, an oral, once-daily therapy discovered and developed internally for the prevention of HAE attacks. The Company&#8217;s business strategy includes leveraging this established commercial platform to successfully commercialize a pipeline of potential first-in-class or best-in-class oral small-molecule and injectable protein therapeutics targeting a range of rare diseases. These programs are being pursued through both internal discovery efforts and strategic business development. By utilizing its existing commercial capabilities and focusing on rare disease markets, the Company believes that it can more effectively optimize its costs and strategically allocate resources to support long-term, sustainable growth. The Company was founded in 1986 and incorporated in Delaware in 1991, and its headquarters is located in Durham, North Carolina.  </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s marketed products include oral, once-daily ORLADEYO&#174; for the prevention of HAE attacks and RAPIVAB&#174; (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. ORLADEYO has received regulatory approval in the United States and other global markets. The Company is commercializing ORLADEYO in each of these territories directly or through other parties. In addition to its approval in the United States, peramivir injection has received regulatory approvals in Canada (RAPIVAB), Australia (RAPIVAB), Japan (RAPIACTA), Taiwan (RAPIACTA) and Korea (PERAMIFLU). </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Based on the Company&#8217;s expectations for revenue and operating expenses, the Company believes its financial resources available at September&#160;30, 2025 will be sufficient to fund its operations for at least the next 12 months. The Company may, in the future, issue securities, including common stock, preferred stock, depositary shares, purchase contracts, warrants, debt securities and units, through private placement transactions or registered public offerings. The Company&#8217;s future liquidity needs, and ability to address those needs, will largely be determined by the success of its products and product candidates; the timing, scope and magnitude of its research and development and commercial expenses; and key developments and regulatory events and its decisions in the future.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany transactions and balances among the consolidated entities have been eliminated from the condensed consolidated financial statements. The Company operates and manages its business as one reportable and operating segment (see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 13&#8212;Segment Information</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) for interim financial reporting and the instructions to Form 10-Q and do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Such financial statements reflect all adjustments that are, in management&#8217;s opinion, necessary to present fairly, in all material respects, the Company&#8217;s condensed consolidated financial position, results of operations, and cash flows. There were no adjustments other than normal recurring adjustments. Certain prior year amounts have been reclassified to conform to the current year presentation. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements should be read in conjunction with the financial statements for the fiscal year ended December&#160;31, 2024 and the notes thereto included in the Company&#8217;s 2024 Annual Report on Form 10-K as filed with the SEC on February 25, 2025. Interim operating results are not necessarily indicative of operating results for the full fiscal year. The condensed consolidated balance sheet as of December&#160;31, 2024 was derived from the audited consolidated financial statements included in the Company&#8217;s most recent Annual Report on Form 10-K.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. Significant estimates in the Company&#8217;s condensed consolidated financial statements have been made relative to the calculation of net product sales, royalty financing obligations, inventory reserves, certain accruals, primarily related to the Company&#8217;s research and development expenses, the valuation of stock options and the valuation allowance for deferred tax assets resulting from net operating losses. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_AssetsHeldForSalePolicyTextBlock', window );">Assets Held For Sale</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets Held for Sale</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies its long-lived assets to be sold as held for sale when the six criteria in ASC 360, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, Plant and Equipment</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> are met. This generally occurs when an agreement to sell exists, or when management has committed to a plan to sell the assets within one year. Assets and liabilities to be disposed of together as a group in a single transaction (&#8220;disposal groups&#8221;) are classified as held for sale if their carrying amounts are principally expected to be recovered through a sale transaction rather than through continuing use.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The long-lived assets included in a disposal group are reported at the lower of their carrying value or fair value less cost to sell, beginning in the period the held for sale criteria are met. Prior to disposal, losses are recognized for any initial or subsequent write-down to fair value less cost to sell. Any gains or losses not previously recognized that result from the sale of a disposal group shall be recognized at the date of sale. Upon designation as an asset held for sale, the Company stops recording depreciation and amortization expense on long-lived assets. The Company assesses the fair value of a long-lived asset less any costs to sell at each reporting period and until the asset is no longer classified as held for sale.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded the following revenues for the three and nine months ended September&#160;30, 2025 and 2024 (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">157,735&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">116,066&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">463,952&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">313,325&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Collaborative and other revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,660&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,853&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">159,395</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">117,085</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">468,282</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">319,178</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, the Company recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, Topic 606 includes provisions within a five-step model that includes (i) identifying the contract with a customer, (ii) identifying the performance obligations in the contract, (iii) determining the transaction price, (iv) allocating the transaction price to the performance obligations, and (v) recognizing revenue when, or as, an entity satisfies a performance obligation.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, the Company identifies the goods or services promised within each contract, assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Sales, Net</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s principal sources of product sales are sales of ORLADEYO, which the Company began shipping to patients in December 2020, and sales of peramivir (RAPIVAB/RAPIACTA/PERAMIFLU) to the Company&#8217;s licensing partners and to the U.S. Department of Health and Human Services (&#8220;HHS&#8221;). In the United States, the Company generally ships ORLADEYO directly to patients through a single specialty pharmacy, which is considered its customer. Outside the United States, the Company sells ORLADEYO to specialty distributors and to hospitals and pharmacies, which collectively are considered its customers.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue for sales when the customer obtains control of the product, which generally occurs upon delivery. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue from sales of ORLADEYO is recorded at net selling price (transaction price), which includes reserves for variable consideration such as (i) estimated government rebates, such as Medicaid and Medicare Part D reimbursements, and estimated managed care rebates, (ii) estimated chargebacks, (iii) estimated costs of co-payment assistance programs and (iv) product returns. These reserves, representing the Company&#8217;s best estimates of the amount of consideration to which it is entitled based on the terms of the applicable contracts and statutory requirements, are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable if no payments are required of the Company or a current liability if a payment is required of the Company. Actual amounts of consideration may differ from the Company&#8217;s estimates. If actual results vary from estimates, these estimates are adjusted, which would affect net product revenue and earnings in the period such variances become known.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government and Managed Care Rebates</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The Company contracts with government agencies and managed care organizations or, collectively, third-party payors, so that ORLADEYO will be eligible for purchase by, or partial or full reimbursement from, such third-party payors. The Company estimates the rebates it will provide to third-party payors and deducts these estimated amounts from total gross product revenues at the time the revenues are recognized, resulting in a reduction of product revenue and the establishment of a current liability. The Company estimates the rebates that it will provide to third-party payors based upon (i) the Company&#8217;s contracts with these third-party payors, (ii) the government mandated discounts applicable to government-funded programs, and (iii) product distribution information obtained from the Company&#8217;s specialty pharmacy regarding payor mix.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chargebacks</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Chargebacks are discounts that occur when certain contracted customers, pharmacy benefit managers, insurance companies, and government programs purchase directly from the Company&#8217;s specialty pharmacy. These customers purchase the Company&#8217;s product under contracts negotiated between them and the Company&#8217;s specialty pharmacy. The specialty pharmacy, in turn, charges back to the Company the difference between the price that the specialty pharmacy paid and the negotiated price paid by the contracted customers, which may be higher or lower than the specialty pharmacy&#8217;s purchase price with the Company. The Company estimates chargebacks and adjusts gross product revenues and establishes a current liability at the time revenues are recognized.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Co-payment assistance and patient assistance programs</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. Based upon the terms of the program and co-payment assistance utilization reports received from the specialty pharmacy, the Company estimates the co-payment assistance amounts, which are recorded in the same period in which the related revenue is recognized, resulting in a reduction of product revenue and establishment of a current liability. The Company also offers a patient assistance program that provides free drug product, for a limited period of time, to allow a patient&#8217;s insurance coverage to be established. Based on patient assistance program utilization reports provided by the specialty pharmacy, the Company records gross revenue of the product provided and a full reduction of the revenue amount for the free drug discount.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product returns</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The Company does not provide contractual return rights to its customers, except in instances where the product is damaged or defective. Non-acceptance by the patient of shipped drug product by the specialty pharmacy is reflected as a reversal of sales in the period in which the sales were originally recorded. Reserves for estimated non-acceptances by patients are recorded as a reduction of revenue in the period that the related revenue is recognized, as well as a reduction to accounts receivable. Estimates of non-acceptance are based on quantitative information provided by the specialty pharmacy.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Revenues</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has collaboration and license agreements with a number of third parties. The Company&#8217;s primary sources of revenue from these collaborative and other research and development arrangements are license, service and royalty revenues.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from license fees, royalty payments, milestone payments, and research and development fees are recognized as revenue when the earnings process is complete and the Company has no further continuing performance obligations or the Company has completed the performance obligations under the terms of the agreement.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Arrangements that involve the delivery of more than one performance obligation are initially evaluated as to whether the intellectual property licenses granted by the Company represent distinct performance obligations. If they are determined to be distinct, the value of the intellectual property licenses would be recognized up front while the research and development service fees would be recognized as the performance obligations are satisfied. For performance obligations </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">based on services performed, the Company measures progress using an input method based on the effort it expends or costs it incurs toward the satisfaction of the performance obligation in relation to the total estimated effort or costs. Variable consideration is assessed at each reporting period as to whether it is not subject to significant future reversal and, therefore, should be included in the transaction price at the inception of the contract. If a contract includes a fixed or minimum amount of research and development support, this also would be included in the transaction price. Changes to collaborations, such as the extensions of the research term or increasing the number of targets or technology covered under an existing agreement, are assessed for whether they represent a modification or should be accounted for as a new contract. For contracts with multiple performance obligations, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the products or services. If a standalone selling price is not directly observable, then the Company estimates the standalone selling price using either an adjusted market assessment approach or an expected cost plus margin approach, representing the amount that the Company believes the market is willing to pay for the product or service. Analyzing the arrangement to identify performance obligations requires the use of judgment, and each may be an obligation to deliver services, a right or license to use an asset, or another performance obligation. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under certain of the Company&#8217;s license agreements, the Company receives royalty payments based upon its licensees&#8217; net sales of covered products. Royalties are recognized at the later of when (i) the subsequent sale or usage occurs, or (ii) the performance obligation to which some or all of the sales-based or usage-based royalty has been satisfied.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally considers cash equivalents to be all cash held in commercial checking accounts, money market accounts, or investments in debt instruments and certificates of deposit with maturities of three months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Total restricted cash was $1,979 and $1,610 as of September&#160;30, 2025 and December&#160;31, 2024, respectively, and primarily consisted of $1,400 as of September&#160;30, 2025 and December&#160;31, 2024, for a letter of credit the Company is required to maintain associated with its Birmingham lease. The letter of credit associated with the Birmingham lease of $1,400 is reflected within other assets on the Condensed Consolidated Balance Sheets as of September&#160;30, 2025 and December&#160;31, 2024.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests in high credit quality investments in accordance with its investment policy. The objectives of the Company&#8217;s investment policy are to eliminate or greatly minimize the probability of a loss of principal value, maintain sufficient liquidity to meet cash flow requirements, and earn a competitive level of return. The Company places its excess cash with high credit quality financial institutions to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that may consist of U.S. Treasury obligations, U.S government agency securities, money market funds, certificates of deposits and corporate notes and bonds. The Company&#8217;s investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of two years and requires an average portfolio maturity of no more than 12 months. Some of the securities in which the Company invests may have market risk. This means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, the Company does not believe it has a material exposure to interest rate risk arising from its investments. The Company has not realized any significant losses from its investments.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies all of its investments as available-for-sale. Available-for-sale investments are reported at fair value at each balance sheet date, and include any unrealized holding gains and losses in accumulated other comprehensive income, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company reviews its investments for other than temporary declines in fair value below cost basis at the end of each reporting period and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Factors considered to determine whether an unrealized loss is temporary include whether a decline in fair value below the amortized cost basis is due to credit-related factors or non-credit-related factors, the financial condition and near-term prospects of the Company, and the Company&#8217;s intent and ability to hold the investment to allow for an anticipated recovery in fair value. A credit-related impairment is recognized as an allowance on the balance sheet with a corresponding adjustment to earnings. Any impairment that is not credit-related is recognized in </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">other comprehensive income, net of applicable taxes unless deemed other than temporary. Realized gains and losses are reflected in interest and other income in the Condensed Consolidated Statements of Comprehensive Income (Loss) and are determined using the specific identification method with transactions recorded on a settlement date basis. Investments with original maturities at date of purchase beyond three months and which mature at or less than 12 months from the balance sheet date are classified as current. Investments with a maturity beyond 12 months from the balance sheet date are classified as long-term.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities recorded at fair value on a recurring basis on the Condensed Consolidated Balance Sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Assets measured at fair value on a recurring basis include investments (See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 4&#8212;Investments</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). There were no liabilities measured at fair value on a recurring basis as of September&#160;30, 2025 and December&#160;31, 2024. The carrying amounts reflected in the Condensed Consolidated Balance Sheets for cash and cash equivalents, trade receivables, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Trade Receivables</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trade Receivables</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company&#8217;s trade receivables arise from product sales and primarily represent amounts due from its specialty pharmacy customer in the United States and other third-party distributors, hospitals and pharmacies globally and have standard payment terms that generally require payment within 30 to 90 days.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Receivables from collaborations are recorded for amounts due to the Company related to royalty receivables from the Company&#8217;s partners, including Shionogi &amp; Co., Ltd., Green Cross, and Torii (See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 12&#8212;Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides reserves against trade receivables for estimated losses that may result from a customer&#8217;s inability to pay. Receivables are evaluated to determine if any reserve or allowance should be recorded based on consideration of the current economic environment, expectations of future economic conditions, specific circumstances and the Company&#8217;s own historical collection experience. Amounts determined to be uncollectible are charged or written-off against the reserve.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s inventory primarily relates to ORLADEYO and also includes peramivir.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company values its inventory at the lower of cost or estimated net realizable value. The Company determines the cost of its inventory on a first-in, first-out (FIFO) basis. Raw materials and work-in-process include all inventory costs prior to packaging and labeling, including raw material, active product ingredient, and the drug product. Finished goods include packaged and labeled products. The Company classifies inventory as long-term when consumption or sale of the inventory is not expected to occur within 12 months from the balance sheet date.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s inventory is subject to expiration dating. At each reporting date, the Company evaluates the carrying value of its inventory and provides valuation reserves for any estimated excess, obsolete, short-dated or unmarketable inventory. In addition, the Company may experience spoilage of its raw materials and supplies. The Company&#8217;s determination that a valuation reserve might be required, in addition to the quantification of such reserve, requires it to utilize significant judgment. Additionally, the Company&#8217;s inventory is subject to strict quality control and monitoring that is performed throughout the manufacturing process, including release of work-in-process to finished goods. In the event that certain batches or units of product do not meet quality specifications, the Company will record a write-down of any potential unmarketable inventory to its estimated net realizable value and record the expense as cost of product in the Condensed Consolidated Statements of Comprehensive Income (Loss).</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prior to obtaining initial regulatory approval for an investigational product candidate, the Company expenses costs relating to production of pre-launch inventory as research and development expense in its Condensed Consolidated </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Statements of Comprehensive Income (Loss) in the period incurred. After regulatory approval has been received, the Company capitalizes inventory costs.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Computer equipment and office equipment are depreciated over a life of three years. Laboratory equipment, software, and furniture and fixtures are depreciated over a life of five years. Leasehold improvements are amortized over their estimated useful lives or the expected lease term, whichever is less. Construction in progress reflects amounts incurred for construction or improvements of property and equipment that have not been placed in service.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically reviews its property and equipment for impairment when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values. Property and equipment to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_AccruedExpensesPolicyTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into contractual agreements with third-party vendors who provide research and development, manufacturing, distribution, and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing, and services are completed over an extended period of time. The Company records liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel to identify services that have been performed on its behalf and estimating the actual work completed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of actual cost. The majority of service providers invoice the Company monthly in arrears for services performed. The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances, which can include assumptions such as expected patient enrollment, site activation and estimated project duration. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued expenses include (i) fees paid to clinical research organizations (&#8220;CROs&#8221;) in connection with preclinical and toxicology studies and clinical trials; (ii) fees paid to investigative sites in connection with clinical trials; (iii) fees paid to contract manufacturers in connection with the production of the Company&#8217;s raw materials, drug substance, drug products, and product candidates; and (iv) professional fees.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company bases its expenses related to clinical trials on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on the Company&#8217;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. The Company accrues costs for clinical trial activities based upon estimates of the actual work completed in accordance with agreements established with third-party vendors. If the Company underestimates or overestimates the level of these costs, actual expenses could differ from such estimates. As of September&#160;30, 2025 and December&#160;31, 2024, the carrying value of accrued expenses approximates their fair value due to their short-term settlement.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Product Sales</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Product Sales</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product sales includes the cost of producing inventory that is related to product revenue during the respective period, including freight. Cost of product sales may also include costs related to excess or obsolete inventory adjustment charges.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of costs associated with research activities as well as those with the Company&#8217;s product development efforts, conducting preclinical trials, clinical trials and manufacturing activities. Research and development expenses are expensed as incurred. Most of the Company&#8217;s clinical and preclinical studies are performed by third-party CROs. Costs for studies performed by CROs are accrued based upon estimates of the actual work completed in accordance with the third-party agreements. Advance payments for goods or services that will be used or rendered for </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of costs associated with research activities as well as those associated with product development efforts, conducting pre-clinical trials, clinical trials and manufacturing activities. Direct expenses consist of compensation for research and development personnel and costs of outside parties to conduct laboratory studies, develop manufacturing processes and manufacture the product candidate, conduct and manage clinical trials, as well as other costs related to the Company&#8217;s clinical and preclinical studies. Additionally, direct expenses consist of those costs necessary to discontinue and close out a development program, including termination fees and other commitments. Indirect expenses consist of lab supplies and services, facility expenses, depreciation of development equipment and an allocation of its general and administrative overhead costs that support the Company&#8217;s research and development efforts.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">Selling, General and Administrative Expenses</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses are comprised of compensation and benefits and related costs associated with sales and marketing, finance, human resources, legal, information technology, quality, safety and regulatory activities related to marketed products, and other general and administrative personnel. Additionally, selling, general and administrative expenses are comprised of market research, marketing, advertising and legal expenses, including patent costs, licenses and other administrative costs.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All patent related costs are expensed to selling, general and administrative expenses when incurred as recoverability of such expenditures is uncertain.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases certain assets under operating and finance leases, which consist of real estate leases, laboratory equipment leases and office equipment leases as of September&#160;30, 2025. The Company determines whether a contract is, or contains, a lease at inception. The Company accounts for lease obligations in accordance with ASU 2016-02: </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases (Topic 842)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, which requires a lessee to recognize a right-of-use asset and a lease liability on its balance sheet for most leases. The Company elected the practical expedient that exempts leases with an initial lease term of twelve months or less, as well as the practical expedient that allows companies to select, by class of underlying asset, not to separate lease and non-lease components. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s operating leases provide for renewal options, which can vary by lease. The right-of-use asset and lease liabilities on the Company&#8217;s Condensed Consolidated Balance Sheets represent payments over the lease term, which include renewal options for certain real estate leases that the Company is likely to exercise. Certain operating leases include rent escalation provisions, which the Company recognizes as expense on a straight-line basis. Lease expense for leases with an initial term of twelve months or less was not material.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The discount rate used to determine the Company&#8217;s right-of-use asset and lease liability is the Company&#8217;s incremental borrowing rate on a collateralized basis over a similar term and amount in a similar economic environment, as generally an implicit rate in the lease is not readily determinable. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not made any residual value guarantees related to its leases; therefore, the Company has no corresponding liability recorded on its Condensed Consolidated Balance Sheets.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in the Company&#8217;s Condensed Consolidated Statements of Comprehensive Income (Loss) based on their fair values. Stock-based compensation cost is estimated at the grant date based on the fair value of the award and is recognized as expense on a straight-line basis over the requisite service period of the award. Determining the appropriate fair value model and the related assumptions for the model requires judgment, including estimating the stock price volatility and the expected term. The Company utilizes the Black-Scholes option-pricing model to value its stock option awards and recognize compensation expense on a straight-line basis over the requisite service period. The Company reduces stock-based compensation expense for estimated forfeitures. The estimation of share-based payment awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from the Company&#8217;s current estimates, such amounts will be recorded as a cumulative adjustment in the period estimates are revised. Actual results, and future changes in estimates, may differ substantially from the Company&#8217;s current estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_InterestExpenseDeferredFinancingCostsAndRoyaltyFinancingLiabilitiesPolicyTextBlock', window );">Interest Expense, Deferred Financing Costs and Royalty Financing Obligations</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense, Deferred Financing Costs and Royalty Financing Obligations</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense primarily relates to the royalty financing obligations (see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7&#8212;Royalty Financing Obligations</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and the term loan borrowings under the Pharmakon Loan Agreement (see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8&#8212;Deb</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">t&#8221;) during the nine months ended September&#160;30, 2025 and 2024. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Costs directly associated with the borrowings were capitalized and netted against the corresponding debt liabilities on the Condensed Consolidated Balance Sheets. These costs are amortized to interest expense over the terms of the corresponding borrowings using the effective interest rate method. When utilizing the effective interest method, in periods in which payment-in-kind (&#8220;PIK&#8221;) interest was designated and added to the outstanding principal balance of the borrowing, the amortization of the deferred debt fees and issuance costs was accretive.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The royalty financing obligations are eligible to be repaid based on royalties from net sales of ORLADEYO. Interest expense is accrued using the effective interest rate method over the estimated period each of the related liabilities will be paid. This requires the Company to estimate the total amount of future royalty payments to be generated from product sales over the life of the agreement. The Company imputes interest on the carrying value of each of the royalty financing obligations and records interest expense using an imputed effective interest rate. The Company reassesses the expected royalty payments each reporting period and accounts for any changes through an adjustment to the effective interest rate on a prospective basis. The assumptions used in determining the expected repayment term of the debt and amortization period of the issuance costs require that the Company make estimates that could impact the carrying value of each of the liabilities, as well as the periods over which associated issuance costs will be amortized. A significant increase or decrease in forecasted net sales could materially impact each of the liability balances, interest expense and the time periods for repayment.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The liability method is used in the Company&#8217;s accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Significant management judgment is required in determining the Company&#8217;s provision for income taxes, deferred tax assets and liabilities and any valuation allowance recorded against net deferred tax assets. The Company has recorded a valuation allowance against substantially all potential tax assets, due to uncertainties in its ability to utilize deferred tax assets, primarily consisting of certain net operating losses carried forward, before they expire. The valuation allowance is based on estimates of future earnings in each of the jurisdictions in which the Company operates and the period over which its deferred tax assets will be recoverable.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertain tax positions in accordance with U.S. GAAP. Uncertain tax positions are recorded based upon certain recognition and measurement criteria. The Company re-evaluates uncertain tax positions and considers various factors, including, but not limited to, changes in tax law and the measurement of tax positions taken or expected to be taken in tax returns. The Company adjusts the amount of the liability to reflect any subsequent changes in the relevant facts and circumstances surrounding the uncertain tax positions. The Company recognizes interest and penalties related to income tax matters in income tax expense.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in fiscal year 2021, the Company began accruing for U.S. state taxes and foreign income taxes as a result of increased nexus in both U.S. state and foreign jurisdictions where historically the Company had no presence and where no net operating losses had historically been established.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, starting in 2022, amendments to Section 174 of the Internal Revenue Code of 1986, as amended (&#8220;IRC&#8221;), no longer permit an immediate deduction for research and development expenditures conducted on foreign soil in the tax year that such costs are incurred. Instead, these IRC Section 174 development costs must now be capitalized and amortized over a 15-year period. The new amortization period begins with the midpoint of any taxable year that IRC Section 174 costs are first incurred, regardless of whether the expenditures were made prior to or after July 1, and runs until the midpoint of year sixteen.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Certain countries in which the Company has operations have adopted legislation influenced by the Organization for Economic Cooperation and Development (&#8220;OECD&#8221;) Pillar Two rules, including a minimum tax rate of 15%. It is uncertain whether the U.S. will enact legislation to adopt the Pillar Two framework. While the Company is currently not within the scope of the rules, it is continuing to review and evaluate additional guidance released by the OECD, along with the pending legislative adoption by additional individual countries where the Company operates. </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">On July 4, 2025, the One Big Beautiful Bill Act (&#8220;OBBBA&#8221;) was signed into law, making permanent certain provisions of the Tax Cuts and Jobs Act, including permanent 100% bonus depreciation, expensing of domestic research costs, and amendments to the business interest expense limitation. In accordance with ASC Topic 740, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Income Taxes,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> the Company has recognized the effects of the new tax law in the period of enactment. As the Company maintains a full valuation allowance on its U.S. federal deferred tax assets, the legislation does not have a material impact on its condensed consolidated financial statements for the three months ended September 30, 2025.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency of each of the Company&#8217;s foreign subsidiaries is primarily the local currency of the country in which the subsidiary operates. The Company&#8217;s asset and liability accounts are translated at the current exchange rate as of the balance sheet date. Revenue and expense accounts are translated at the average exchange rate over the period. Adjustments resulting from the translation of the financial statements of the Company&#8217;s foreign subsidiaries into U.S. dollars are accumulated as a separate component of stockholders&#8217; equity within accumulated other comprehensive income. Gains or losses resulting from transactions denominated in foreign currencies are included in foreign currency losses, net, within the Condensed Consolidated Statement of Comprehensive Income (Loss).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Income (Loss) Per Share</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Income (Loss) Per Share</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income (loss) per share is based upon the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share is based upon the weighted average number of common shares outstanding and potentially dilutive common shares during the period as determined by using the treasury stock method. Potential common equivalent shares are excluded if their effect is anti-dilutive.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Accumulated Other Comprehensive Income</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive income is comprised of cumulative foreign currency translation adjustments and unrealized gains and losses on available-for-sale investments and is disclosed as a separate component of stockholders&#8217; equity. Realized gain and loss amounts on available-for-sale investments are reclassified from accumulated other comprehensive income and recorded as interest and other income on the Condensed Consolidated Statements of Comprehensive Income (Loss). There were no realized gains or losses reclassified out of accumulated other comprehensive income for the three and nine months ended September&#160;30, 2025 and 2024.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_ConcentrationOfMarketRiskPolicyTextBlock', window );">Significant Customers and Other Risks</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Customers and Other Risks</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Significant Customers</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s primary sources of revenue and cash flow are the sales of ORLADEYO in the United States.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ORLADEYO is generally distributed through an arrangement with a single specialty pharmacy in the United States. The specialty pharmacy subsequently sells ORLADEYO to its customers (pharmacy benefit managers, insurance companies, government programs and group purchasing organizations) and dispenses product to patients. RAPIVAB is also generally distributed through the same specialty pharmacy in the United States. The specialty pharmacy&#8217;s inability or unwillingness to continue these distribution activities could adversely impact the Company&#8217;s business, results of operations and financial condition. Revenue where the specialty pharmacy is considered the customer was approximately 88% and 86% of total net revenues for the three and nine months ended September&#160;30, 2025, respectively. Revenue where the specialty pharmacy is considered the customer was approximately 88% of total net revenues for both the three and nine months ended September&#160;30, 2024.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is distributing ORLADEYO in other global markets directly or through other parties.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks from Third-Party Manufacturing and Distribution Concentration</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company relies on a single source manufacturer for active pharmaceutical ingredient and finished drug product manufacturing of product candidates in development and on a single specialty pharmacy for distribution of approved drug product in the United States. Delays or disruption in the manufacture or distribution of any product could adversely impact the future procurement stockpiling of the Company&#8217;s commercial product, commercial revenue and product candidates.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Further, the Company&#8217;s drug development activities are performed by a limited group of third-party vendors. If any of these vendors were unable to perform its services, this could significantly impact the Company&#8217;s ability to complete its drug development activities.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Risk</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents and investments are financial instruments that potentially subject the Company to concentration of risk to the extent recorded on the Condensed Consolidated Balance Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances may exceed the amount of insurance provided on such deposits. The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio of investments with an average maturity of approximately 12 months or less.</span></div>The Company&#8217;s receivables from sales of ORLADEYO are primarily due from one customer, resulting in a concentration of credit risk.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements And New Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There have been no new accounting pronouncements adopted by the Company during the nine months ended September 30, 2025.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company expects adoption of this ASU will result in additional disclosures but does not expect it will have a material effect on the Company&#8217;s consolidated balance sheet, statement of comprehensive income (loss), or statement of cash flows.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which requires public entities, on an annual and interim basis, to provide disaggregated disclosure of certain income statement expenses into specified categories within the footnotes to the financial statements. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The Company is evaluating the impact of adopting ASU 2024-03.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In September 2025, the FASB issued ASU 2025-06, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software, which clarifies and modernizes the accounting for costs related to internal-use software, eliminating references to project stages and clarifying the threshold entities apply to begin capitalizing costs. ASU 2025-06 is effective for fiscal years beginning after December 15, 2027, and interim periods within those annual reporting periods, with early adoption permitted. The Company is evaluating the impact of adopting ASU 2025-06 but does not expect it will have a material effect on its consolidated balance sheet, statement of comprehensive income (loss), or statement of cash flows.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not expect any other recently issued accounting standards to have a material impact to its financial statements or disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AccruedExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents accrued expenses policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AccruedExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AssetsHeldForSalePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AssetsHeldForSalePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ConcentrationOfMarketRiskPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents concentration of market risk policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ConcentrationOfMarketRiskPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DescriptionOfCompanyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of company policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DescriptionOfCompanyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_InterestExpenseDeferredFinancingCostsAndRoyaltyFinancingLiabilitiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for interest expense and royalty financing obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_InterestExpenseDeferredFinancingCostsAndRoyaltyFinancingLiabilitiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 705<br> -Publisher FASB<br> -URI https://asc.fasb.org/705/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 12<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-4<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies and Concentrations of Risk (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Summary of Revenues</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded the following revenues for the three and nine months ended September&#160;30, 2025 and 2024 (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">157,735&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">116,066&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">463,952&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">313,325&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Collaborative and other revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,660&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,853&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">159,395</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">117,085</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">468,282</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">319,178</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded the following revenues for the three and nine months ended September&#160;30, 2025 and 2024 (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">ORLADEYO:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">141,557&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">103,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">402,054&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">278,987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outside of U.S.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">17,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13,207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">48,103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">34,487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total ORLADEYO</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">159,077&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">116,319&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">450,157&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">313,474&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">766&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">18,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,704&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">159,395&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">117,085&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">468,282&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">319,178&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Assets and Liabilities Held For Sale (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Disposal Groups, Including Discontinued Operations</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the assets and liabilities of BioCryst Ireland that are classified as held for sale on the unaudited Condensed Consolidated Balance Sheet as of September&#160;30, 2025 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14,840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10,285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Inventory, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,902&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Current assets held for sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">29,173&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Non-current assets held for sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4,058&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total assets held for sale</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">33,231&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,714&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">24,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities held for sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">26,423&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Non-current liabilities held for sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">436&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities held for sale</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">26,859&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-3A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4A<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4B<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5D<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3A<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Summary of Revenues</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded the following revenues for the three and nine months ended September&#160;30, 2025 and 2024 (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">157,735&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">116,066&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">463,952&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">313,325&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Collaborative and other revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,660&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,853&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">159,395</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">117,085</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">468,282</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">319,178</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded the following revenues for the three and nine months ended September&#160;30, 2025 and 2024 (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">ORLADEYO:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">141,557&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">103,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">402,054&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">278,987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outside of U.S.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">17,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13,207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">48,103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">34,487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total ORLADEYO</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">159,077&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">116,319&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">450,157&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">313,474&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">766&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">18,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,704&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">159,395&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">117,085&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">468,282&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">319,178&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Assets measured at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.475%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Price in Active Markets (Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable Inputs (Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable Inputs&#160;(Level&#160;3)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Obligations of U.S. Government and its agencies</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">168,464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">168,464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">168,464&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">168,464&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.475%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Price in Active Markets (Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable Inputs (Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable Inputs&#160;(Level&#160;3)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Obligations of U.S. Government and its agencies</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">236,460&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">236,460&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">236,460&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">236,460&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Fair Value of the Company's Investments by Type</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the fair value of the Company&#8217;s investments by type (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:f-584">Accrued<br/>Interest</span></span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Obligations of U.S. Government and its agencies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">167,149&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,203&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">168,464&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">167,149&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,203&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">168,464&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:f-595">Accrued<br/>Interest</span></span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Obligations of U.S. Government and its agencies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">234,902&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">451&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">236,460&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">234,902&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,121&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">451&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">236,460&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesTextBlock', window );">Schedule of the Maturity of Investments</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the scheduled maturity for the Company&#8217;s investments at September&#160;30, 2025 and December&#160;31, 2024 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">128,795&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">216,137&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through two years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">39,669&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">20,323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">168,464&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">236,460&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5B<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5A<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5B<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5B<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5B<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Summary of Inventories</a></td>
<td class="text">The Company&#8217;s inventories consisted of the following (in thousands):  <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9,324&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10,006&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14,982&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">16,152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">30,283&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">33,923&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Reserves</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,661)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,649)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">28,622&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">31,274&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty Financing Obligations (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvanceRoyaltiesAbstract', window );"><strong>Advance Royalties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyFinancingLiabilitiesTableTextBlock', window );">Schedule of Royalty Financing Obligations</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the royalty financing obligations activity for the three and nine months ended September&#160;30, 2025 (in thousands) as well as the effective interest rate as of September&#160;30, 2025: </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2020 RPI<br/>Royalty<br/>Agreement</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2021 RPI<br/>Royalty<br/>Agreement</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">OMERS<br/>Royalty<br/>Agreement</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">180,413&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">181,140&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">152,176&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">513,729&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense on royalty financing obligations</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9,756&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,758&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13,514&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenues payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(11,818)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,021)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(13,486)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(26,325)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of March 31, 2025</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">178,351&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">180,119&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">142,448&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">500,918&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense on royalty financing obligations</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9,804&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,598&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13,402&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenues payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(13,798)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,193)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(15,746)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(30,737)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2025</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">174,357&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">178,926&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">130,300&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">483,583&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense on royalty financing obligations</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9,610&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,313&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">12,923&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenues payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(8,258)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,195)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(9,260)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(19,713)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of September 30, 2025</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">175,709&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">176,731&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">124,353&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">476,793&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Effective interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyFinancingLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for royalty financing obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyFinancingLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvanceRoyaltiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvanceRoyaltiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Obligations (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Aggregate Lease Expense Under Operating Leases</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Lease expense under operating and finance leases was as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">526&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">569&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,596&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,741&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Finance lease expense:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Amortization of right-of-use assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">455&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,278&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total finance lease expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">631&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">536&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,907&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,509&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases was as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows for finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows for operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets obtained in exchange for operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease assets obtained in exchange for finance lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">870&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash increase to operating lease assets due to remeasurement of operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">786&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_OtherSupplementalInformationRelatedToLeasesTableTextBlock', window );">Other Supplemental Information Related to Leases</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other supplemental information related to leases was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9.7 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9.0 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2.5 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2.6 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock', window );">Balance Sheets of the Company's Operating Leases</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the presentation in the Condensed Consolidated Balance Sheets of the Company&#8217;s operating leases (in thousands): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Balance Sheet Location</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-793"><span style="-sec-ix-hidden:f-794">Right of use assets</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">7,725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">8,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Operating lease liabilities &#8211; current liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">348&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">937&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Operating lease liabilities &#8211; long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">8,425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">7,924&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">8,773&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">8,861&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the presentation in the Condensed Consolidated Balance Sheets of the Company&#8217;s finance leases (in thousands): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Balance Sheet Location</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-803"><span style="-sec-ix-hidden:f-804">Right of use assets</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Current finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Finance lease liabilities &#8211; current liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,435&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,835&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Non-current finance lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Finance lease liabilities &#8211; long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,177&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,959&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Maturities of Operating Lease Liabilities</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of September&#160;30, 2025 are as follows (in thousands): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Finance Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2025 (remaining)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">119&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">496&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,153&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,050&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">486&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">9,024&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">14,802&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,578&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(6,029)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(401)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">8,773&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,177&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the assets and liabilities of the lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_OtherSupplementalInformationRelatedToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Supplemental Information Related to Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_OtherSupplementalInformationRelatedToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Schedule of Stock by Class</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company had reserved shares of common stock for issuance as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Shares reserved for exercises of outstanding stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">41,522&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">44,240&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Shares reserved for vesting of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9,744&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Shares reserved for future issuance under the Stock Incentive Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">13,721&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,065&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Shares reserved for future issuance under the Inducement Equity Incentive Plan </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,699&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Shares reserved for future issuance under the Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4,674&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,042&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total shares reserved for future issuance</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">71,169&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">62,158&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-5<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481142/505-10-45-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-10<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded the following stock-based compensation expense (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Incentive Plan</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16,232</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14,794</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">54,841</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">37,294</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Inducement Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,179</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2,234</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5,852</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6,241</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">233</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">221</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">623</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">539</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation costs</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">18,644</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">17,249</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">61,316</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">44,074</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized stock-based compensation costs</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(43)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation costs included in operating expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">18,601</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">17,249</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">61,273</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">44,074</span></td></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity under the Incentive Plan:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Shares<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">39,082&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7.96&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(897)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5.36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled or Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,924)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">36,799&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7.94&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6.10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">28,966&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2025</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">23,314&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7.92&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4.74</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">23,388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity under the Inducement Plan:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Shares<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,158&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.44&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.07&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(252)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5.65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled or Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(279)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,723&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.41&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6.20</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6,940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2025</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,519&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.18&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5.60</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6,324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restricted stock unit activity under the Incentive Plan:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Shares <br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9,289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7.73&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9.17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(270)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(667)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at September 30, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8,745&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7.60&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restricted stock unit activity under the Inducement Plan:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Shares<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">823&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.53&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(197)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at September 30, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.39&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors Under the Plans</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Incentive Plan</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the key assumptions used by the Company to value the stock option awards granted under the Incentive Plan during the nine months ended September 30, 2025 and 2024. </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Expected Life in Years</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">5.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Expected Volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">79.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">83.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Expected Dividend Yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Risk-Free Interest Rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Weighted average grant date fair value per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4.56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inducement Equity Incentive Plan</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the key assumptions used by the Company to value the stock option awards granted under the Inducement Plan during the nine months ended September 30, 2025 and 2024.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Expected Life in Years</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">5.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Expected Volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">80.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">83.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Expected Dividend Yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Risk-Free Interest Rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Weighted average grant date fair value per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5.89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4.43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information, by Segment</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table illustrates information about segment revenues, significant segment expenses, and segment net income (loss) for the three and nine months ended September 30, 2025 and 2024 (in thousands):</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">159,395&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">117,085&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">468,282&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">319,178&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Less</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">9,553&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6,175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Berotralstat</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,575&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9,214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10,504&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">BCX17725</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">7,574&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13,346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,591&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Avoralstat</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,960&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Factor D Program</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">454&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Research, discovery and preclinical programs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">5,457&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11,641&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8,325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and related personnel costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">13,313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 25pt 0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">14,257&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">38,025&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">42,630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 25pt 0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">8,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">24,374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">20,923&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other non-program specific and indirect costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">7,329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 25pt 0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">7,580&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">20,621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">23,965&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">83,014&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">65,101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">252,866&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">185,841&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(2,238)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(3,591)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(7,778)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(11,176)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">19,661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">24,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">64,737&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">74,067&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency (gains) losses, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(98)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,740&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6,911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,667)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,667)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(769)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">586&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Segment net income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">12,899</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">(14,033)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">18,016</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">(62,086)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Reconciliation of segment profit or loss:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments and reconciling items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated net income (loss)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">12,899</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">(14,033)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">18,016</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">(62,086)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">1 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">The significant expense categories and amounts align with the segment-level information that is regularly provided to the CODM.</span></div></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock', window );">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net income (loss) per share for the three and nine months ended September&#160;30, 2025 and 2024 were calculated as follows (in thousands, except per share amounts):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">12,899&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(14,033)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">18,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(62,086)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding: basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">210,176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">206,905&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">209,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">206,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per common share: basic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">0.06&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(0.07)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">0.09&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(0.30)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stock options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,023&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock unit awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable under the employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive potential common shares</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9,709&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8,818&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding: diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">219,885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">206,905&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">218,349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">206,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per common share: diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">0.06&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(0.07)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">0.08&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(0.30)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes potential shares of common stock that were excluded from the computation of diluted net income (loss) per share attributable to common stockholders as they were anti-dilutive:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.113%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21,818&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">38,559&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock unit awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,882&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">22,191&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">44,441&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effect of income (loss) on basic earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies and Concentrations of Risk (Details)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($) </div>
<div>segment </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems', window );"><strong>Significant Accounting Policies and Concentration of Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Birmingham lease restricted cash</a></td>
<td class="nump">$ 1,979,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,979,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,610,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_LongTermInvestmentMaturityMinimum', window );">Long-term investment maturity, minimum (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,191<span></span>
</td>
<td class="nump">44,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax', window );">Reclassification from accumulated other comprehensive income, current period, before tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue Benchmark | Product Concentration Risk | ORLADEYO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems', window );"><strong>Significant Accounting Policies and Concentration of Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue percentage</a></td>
<td class="nump">88.00%<span></span>
</td>
<td class="nump">88.00%<span></span>
</td>
<td class="nump">86.00%<span></span>
</td>
<td class="nump">88.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems', window );"><strong>Significant Accounting Policies and Concentration of Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember', window );">Laboratory Equipment, Office Equipment and Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems', window );"><strong>Significant Accounting Policies and Concentration of Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems', window );"><strong>Significant Accounting Policies and Concentration of Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems', window );"><strong>Significant Accounting Policies and Concentration of Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_MaturityPeriodOfHighQualityMarketableSecurities', window );">Maturity period of high quality marketable securities (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities', window );">Average maturity period of high quality marketable securities (in months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_MaturityPeriodOfShortTermInvestment', window );">Maturity period of short term investment (in months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_CollateralForCreditMember', window );">Collateral for Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems', window );"><strong>Significant Accounting Policies and Concentration of Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Birmingham lease restricted cash</a></td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Average maturity period of high quality marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_LongTermInvestmentMaturityMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents long term investment maturity minimum.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_LongTermInvestmentMaturityMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MaturityPeriodOfHighQualityMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents maturity period of high quality marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MaturityPeriodOfHighQualityMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MaturityPeriodOfShortTermInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maturity period of short term investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MaturityPeriodOfShortTermInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Significant Accounting Policies and Concentrations of Risk</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bcrx_ORLADEYOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bcrx_ORLADEYOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_CollateralForCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_CollateralForCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies and Concentrations of Risk - Summary of Revenues (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems', window );"><strong>Significant Accounting Policies and Concentration of Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 159,395<span></span>
</td>
<td class="nump">$ 117,085<span></span>
</td>
<td class="nump">$ 468,282<span></span>
</td>
<td class="nump">$ 319,178<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems', window );"><strong>Significant Accounting Policies and Concentration of Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="nump">157,735<span></span>
</td>
<td class="nump">116,066<span></span>
</td>
<td class="nump">463,952<span></span>
</td>
<td class="nump">313,325<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bcrx_CollaborativeAndOtherResearchAndDevelopmentMember', window );">Collaborative and other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems', window );"><strong>Significant Accounting Policies and Concentration of Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 1,660<span></span>
</td>
<td class="nump">$ 1,019<span></span>
</td>
<td class="nump">$ 4,330<span></span>
</td>
<td class="nump">$ 5,853<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Significant Accounting Policies and Concentrations of Risk</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bcrx_CollaborativeAndOtherResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bcrx_CollaborativeAndOtherResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Assets and Liabilities Held For Sale (Details) - Disposal Group, Held-for-Sale, Not Discontinued Operations - BioCryst Ireland - Forecast<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Oct. 01, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Upfront consideration to be received</a></td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsideration', window );">Contingent consideration to be received</a></td>
<td class="nump">14,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_DisposalGroupIncludingDiscontinuedOperationConsiderationRoyaltyReleaseFee', window );">Royalty release fee</a></td>
<td class="nump">$ 15,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DisposalGroupIncludingDiscontinuedOperationConsiderationRoyaltyReleaseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Consideration, Royalty Release Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DisposalGroupIncludingDiscontinuedOperationConsiderationRoyaltyReleaseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bcrx_BioCrystIrelandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bcrx_BioCrystIrelandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Assets and Liabilities Held For Sale - Schedule of Assets Held For Sale (Details) - Disposal Group, Held-for-Sale, Not Discontinued Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current assets held for sale</a></td>
<td class="nump">$ 29,173<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent', window );">Non-current assets held for sale</a></td>
<td class="nump">4,058<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current liabilities held for sale</a></td>
<td class="nump">26,423<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent', window );">Non-current liabilities held for sale</a></td>
<td class="nump">436<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember', window );">BioCryst Ireland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">14,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet', window );">Trade receivables</a></td>
<td class="nump">10,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent', window );">Inventory, net</a></td>
<td class="nump">2,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current assets held for sale</a></td>
<td class="nump">29,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent', window );">Non-current assets held for sale</a></td>
<td class="nump">4,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Total assets held for sale</a></td>
<td class="nump">33,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">24,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="nump">338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current liabilities held for sale</a></td>
<td class="nump">26,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent', window );">Non-current liabilities held for sale</a></td>
<td class="nump">436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation', window );">Total liabilities held for sale</a></td>
<td class="nump">$ 26,859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bcrx_BioCrystIrelandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bcrx_BioCrystIrelandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 159,395<span></span>
</td>
<td class="nump">$ 117,085<span></span>
</td>
<td class="nump">$ 468,282<span></span>
</td>
<td class="nump">$ 319,178<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="nump">157,735<span></span>
</td>
<td class="nump">116,066<span></span>
</td>
<td class="nump">463,952<span></span>
</td>
<td class="nump">313,325<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="nump">141,557<span></span>
</td>
<td class="nump">103,112<span></span>
</td>
<td class="nump">402,054<span></span>
</td>
<td class="nump">278,987<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net | Outside of U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="nump">17,520<span></span>
</td>
<td class="nump">13,207<span></span>
</td>
<td class="nump">48,103<span></span>
</td>
<td class="nump">34,487<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bcrx_ORLADEYOMember', window );">ORLADEYO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="nump">159,077<span></span>
</td>
<td class="nump">116,319<span></span>
</td>
<td class="nump">450,157<span></span>
</td>
<td class="nump">313,474<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bcrx_OtherIncomeFromContractWithCustomerMember', window );">Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 318<span></span>
</td>
<td class="nump">$ 766<span></span>
</td>
<td class="nump">$ 18,125<span></span>
</td>
<td class="nump">$ 5,704<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeographicDistributionAxis=us-gaap_GeographicDistributionDomesticMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeographicDistributionAxis=us-gaap_GeographicDistributionDomesticMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeographicDistributionAxis=us-gaap_GeographicDistributionForeignMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeographicDistributionAxis=us-gaap_GeographicDistributionForeignMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bcrx_ORLADEYOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bcrx_ORLADEYOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bcrx_OtherIncomeFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bcrx_OtherIncomeFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Fair Value, Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 168,464<span></span>
</td>
<td class="nump">$ 236,460<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Obligations of U.S. Government and its agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">168,464<span></span>
</td>
<td class="nump">236,460<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Price in Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Price in Active Markets (Level 1) | Obligations of U.S. Government and its agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">168,464<span></span>
</td>
<td class="nump">236,460<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Obligations of U.S. Government and its agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">168,464<span></span>
</td>
<td class="nump">236,460<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs&#160;(Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs&#160;(Level&#160;3) | Obligations of U.S. Government and its agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($) </div>
<div>security</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of securities | security</a></td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair value of securities | $</a></td>
<td class="nump">$ 69,245<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments- Fair Value of the Company's Investments by Type (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">$ 167,149<span></span>
</td>
<td class="nump">$ 234,902<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss', window );">Accrued Interest</a></td>
<td class="nump">1,203<span></span>
</td>
<td class="nump">1,121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">138<span></span>
</td>
<td class="nump">451<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(26)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 168,464<span></span>
</td>
<td class="nump">$ 236,460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList', window );">Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Short-term investments<span></span>
</td>
<td class="text">Short-term investments<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Obligations of U.S. Government and its agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">$ 167,149<span></span>
</td>
<td class="nump">$ 234,902<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss', window );">Accrued Interest</a></td>
<td class="nump">1,203<span></span>
</td>
<td class="nump">1,121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">138<span></span>
</td>
<td class="nump">451<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(26)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 168,464<span></span>
</td>
<td class="nump">$ 236,460<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-3A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-3B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes accrued interest, after allowance for credit loss, on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Schedule of Maturity of Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Maturing in one year or less</a></td>
<td class="nump">$ 128,795<span></span>
</td>
<td class="nump">$ 216,137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterOneYearAndBeforeTwoYears', window );">Maturing after one year through two years</a></td>
<td class="nump">39,669<span></span>
</td>
<td class="nump">20,323<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 168,464<span></span>
</td>
<td class="nump">$ 236,460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList', window );">Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Short-term investments<span></span>
</td>
<td class="text">Short-term investments<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterOneYearAndBeforeTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt securities maturing after one year through two years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterOneYearAndBeforeTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes accrued interest, after allowance for credit loss, on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Trade Receivables (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember', window );">Disposal Group, Held-for-Sale, Not Discontinued Operations | BioCryst Ireland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet', window );">Trade receivables</a></td>
<td class="nump">$ 10,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_RoyaltyReceivablesFromPartnersMember', window );">Royalty Receivables from Partners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">3,138<span></span>
</td>
<td class="nump">$ 2,223<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bcrx_ORLADEYOMember', window );">ORLADEYO | Trade Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable, after allowance for credit loss, total</a></td>
<td class="nump">88,034<span></span>
</td>
<td class="nump">76,282<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bcrx_PeramivirMember', window );">Peramivir | Trade Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable, after allowance for credit loss, total</a></td>
<td class="nump">$ 153<span></span>
</td>
<td class="nump">$ 564<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 40<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481628/310-20-40-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479196/954-310-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bcrx_BioCrystIrelandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bcrx_BioCrystIrelandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_RoyaltyReceivablesFromPartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_RoyaltyReceivablesFromPartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bcrx_ORLADEYOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bcrx_ORLADEYOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_TradeAccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_TradeAccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bcrx_PeramivirMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bcrx_PeramivirMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory - Summary of Inventories (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 9,324<span></span>
</td>
<td class="nump">$ 10,006<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work-in-process</a></td>
<td class="nump">14,982<span></span>
</td>
<td class="nump">16,152<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">5,977<span></span>
</td>
<td class="nump">7,765<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total inventory</a></td>
<td class="nump">30,283<span></span>
</td>
<td class="nump">33,923<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Reserves</a></td>
<td class="num">(1,661)<span></span>
</td>
<td class="num">(2,649)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_InventoryIncludingNoncurrentPortion', window );">Total inventory, net</a></td>
<td class="nump">$ 28,622<span></span>
</td>
<td class="nump">$ 31,274<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_InventoryIncludingNoncurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory, Including Noncurrent Portion</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_InventoryIncludingNoncurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details) - Disposal Group, Held-for-Sale, Not Discontinued Operations - BioCryst Ireland<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent', window );">Inventory, net</a></td>
<td class="nump">$ 2,146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryNoncurrent', window );">Inventory, net, noncurrent</a></td>
<td class="nump">$ 705<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as inventory attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bcrx_BioCrystIrelandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bcrx_BioCrystIrelandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty Financing Obligations (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 19, 2021</div></th>
<th class="th"><div>Dec. 07, 2020</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationsLineItems', window );"><strong>Royalty Monetizations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_InterestPaidRoyaltyFinancingLiabilities', window );">Interest paid, royalty financing obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,319<span></span>
</td>
<td class="nump">$ 21,239<span></span>
</td>
<td class="nump">$ 55,240<span></span>
</td>
<td class="nump">$ 54,308<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_RPI2019IntermediateFinanceTrustMember', window );">RPI 2019 Intermediate Finance Trust</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationsLineItems', window );"><strong>Royalty Monetizations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_SharesIssuedCommonStockPremium', window );">Shares issued, common stock, premium</a></td>
<td class="nump">$ 4,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_RPI2019IntermediateFinanceTrustMember', window );">RPI 2019 Intermediate Finance Trust | ORLADEYO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationsLineItems', window );"><strong>Royalty Monetizations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets', window );">Royalty purchase agreement, royalties, percentage of sublicense revenue in other markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_RPI2019IntermediateFinanceTrustMember', window );">RPI 2019 Intermediate Finance Trust | ORLADEYO | Annual Net Sales Under $350,000</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationsLineItems', window );"><strong>Royalty Monetizations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories', window );">Royalty purchase agreement, royalties, percentage of annual net sales in key territories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_RPI2019IntermediateFinanceTrustMember', window );">RPI 2019 Intermediate Finance Trust | ORLADEYO | Annual Net Sales Between $350,000 and $550,000</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationsLineItems', window );"><strong>Royalty Monetizations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories', window );">Royalty purchase agreement, royalties, percentage of annual net sales in key territories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_RPI2019IntermediateFinanceTrustMember', window );">RPI 2019 Intermediate Finance Trust | ORLADEYO | Annual Net Sales Over $550,000</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationsLineItems', window );"><strong>Royalty Monetizations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories', window );">Royalty purchase agreement, royalties, percentage of annual net sales in key territories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_RPI2019IntermediateFinanceTrustMember', window );">RPI 2019 Intermediate Finance Trust | ORLADEYO | Annual Net Sales Under $150,000</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationsLineItems', window );"><strong>Royalty Monetizations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets', window );">Royalty purchase agreement, royalties, percentage of annual net sales in other markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_RPI2019IntermediateFinanceTrustMember', window );">RPI 2019 Intermediate Finance Trust | ORLADEYO | Annual Net Sales Between $150,000 and $230,000</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationsLineItems', window );"><strong>Royalty Monetizations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets', window );">Royalty purchase agreement, royalties, percentage of annual net sales in other markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_RPI2019IntermediateFinanceTrustMember', window );">RPI 2019 Intermediate Finance Trust | ORLADEYO | Annual Net Sales Over $230,000</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationsLineItems', window );"><strong>Royalty Monetizations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets', window );">Royalty purchase agreement, royalties, percentage of annual net sales in other markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_RPI2019IntermediateFinanceTrustMember', window );">RPI 2019 Intermediate Finance Trust | Future Royalties Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationsLineItems', window );"><strong>Royalty Monetizations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_RPI2021And2020IntermediateFinanceTrustMember', window );">RPI 2021 and 2020 Intermediate Finance Trust | Future Royalties Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationsLineItems', window );"><strong>Royalty Monetizations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_The2021RPIRoyaltyPurchaseAgreementMember', window );">The 2021 RPI Royalty Purchase Agreement | Annual Net Sales Under $350,000</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationsLineItems', window );"><strong>Royalty Monetizations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories', window );">Royalty purchase agreement, royalties, percentage of annual net sales in key territories</a></td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_The2021RPIRoyaltyPurchaseAgreementMember', window );">The 2021 RPI Royalty Purchase Agreement | Annual Net Sales Between $350,000 and $550,000</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationsLineItems', window );"><strong>Royalty Monetizations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories', window );">Royalty purchase agreement, royalties, percentage of annual net sales in key territories</a></td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_The2021RPIRoyaltyPurchaseAgreementMember', window );">The 2021 RPI Royalty Purchase Agreement | Annual Net Sales Over $550,000</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationsLineItems', window );"><strong>Royalty Monetizations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets', window );">Royalty purchase agreement, royalties, percentage of annual net sales in other markets</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_The2021RPIRoyaltyPurchaseAgreementMember', window );">The 2021 RPI Royalty Purchase Agreement | Annual Net Sales Under $150,000</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationsLineItems', window );"><strong>Royalty Monetizations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets', window );">Royalty purchase agreement, royalties, percentage of sublicense revenue in other markets</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_The2021RPIRoyaltyPurchaseAgreementMember', window );">The 2021 RPI Royalty Purchase Agreement | Annual Net Sales Between $150,000 and $230,000</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationsLineItems', window );"><strong>Royalty Monetizations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets', window );">Royalty purchase agreement, royalties, percentage of sublicense revenue in other markets</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_OMERSCapitalMarketsMember', window );">OMERS Capital Markets | ORLADEYO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationsLineItems', window );"><strong>Royalty Monetizations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets', window );">Royalty purchase agreement, royalties, percentage of sublicense revenue in other markets</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets', window );">Royalty purchase agreement, royalties, percentage of annual net sales in other markets</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice', window );">Royalty purchase agreement, royalties, percentage of purchase price</a></td>
<td class="nump">155.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount', window );">Royalty purchase agreement, royalties, purchase price, amount</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_OMERSCapitalMarketsMember', window );">OMERS Capital Markets | ORLADEYO | Annual Net Sales Under $350,000</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationsLineItems', window );"><strong>Royalty Monetizations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales', window );">Royalty purchase agreement, royalties, percentage of annual net sales</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales', window );">Royalty purchase agreement, royalties, percentage of annual net sales, based on reduction in sales</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_OMERSCapitalMarketsMember', window );">OMERS Capital Markets | ORLADEYO | Annual Net Sales Between $350,000 and $550,000</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationsLineItems', window );"><strong>Royalty Monetizations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales', window );">Royalty purchase agreement, royalties, percentage of annual net sales</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales', window );">Royalty purchase agreement, royalties, percentage of annual net sales, based on reduction in sales</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_OMERSCapitalMarketsMember', window );">OMERS Capital Markets | ORLADEYO | Annual Net Sales Over $550,000</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationsLineItems', window );"><strong>Royalty Monetizations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales', window );">Royalty purchase agreement, royalties, percentage of annual net sales</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales', window );">Royalty purchase agreement, royalties, percentage of annual net sales, based on reduction in sales</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_OMERSCapitalMarketsMember', window );">OMERS Capital Markets | ORLADEYO | Annual Net Sales Under $150,000</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationsLineItems', window );"><strong>Royalty Monetizations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets', window );">Royalty purchase agreement, royalties, percentage of sublicense revenue in other markets</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_OMERSCapitalMarketsMember', window );">OMERS Capital Markets | ORLADEYO | Annual Net Sales Between $150,000 and $230,000</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationsLineItems', window );"><strong>Royalty Monetizations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets', window );">Royalty purchase agreement, royalties, percentage of sublicense revenue in other markets</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_OMERSCapitalMarketsMember', window );">OMERS Capital Markets | ORLADEYO | Annual Net Sales Over $230,000</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationsLineItems', window );"><strong>Royalty Monetizations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets', window );">Royalty purchase agreement, royalties, percentage of sublicense revenue in other markets</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_InterestPaidRoyaltyFinancingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest Paid, Royalty Financing Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_InterestPaidRoyaltyFinancingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyMonetizationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Monetizations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyMonetizationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of annual net sales for royalties to be paid under the royalty purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>he percentage of annual net sales of royalties to be paid under the royalty purchase agreement if sales are less than specified.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of net sales in key territories for royalties to be paid under the royalty purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of annual net sales in other markets of royalties to be paid under the royalty purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of the purchase price under the royalty purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of sublicense revenue in other markets of royalties to be paid under the royalty purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the purchase price under the royalty purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_SharesIssuedCommonStockPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Information on the amount of the common stock premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_SharesIssuedCommonStockPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bcrx_RPI2019IntermediateFinanceTrustMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bcrx_RPI2019IntermediateFinanceTrustMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bcrx_ORLADEYOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bcrx_ORLADEYOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AnnualNetSalesRangeAxis=bcrx_AnnualNetSalesUnder350000Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AnnualNetSalesRangeAxis=bcrx_AnnualNetSalesUnder350000Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AnnualNetSalesRangeAxis=bcrx_AnnualNetSalesBetween350000And550000Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AnnualNetSalesRangeAxis=bcrx_AnnualNetSalesBetween350000And550000Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AnnualNetSalesRangeAxis=bcrx_AnnualNetSalesOver550000Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AnnualNetSalesRangeAxis=bcrx_AnnualNetSalesOver550000Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AnnualNetSalesRangeAxis=bcrx_AnnualNetSalesUnder150000Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AnnualNetSalesRangeAxis=bcrx_AnnualNetSalesUnder150000Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AnnualNetSalesRangeAxis=bcrx_AnnualNetSalesBetween150000And230000Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AnnualNetSalesRangeAxis=bcrx_AnnualNetSalesBetween150000And230000Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AnnualNetSalesRangeAxis=bcrx_AnnualNetSalesOver230000Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AnnualNetSalesRangeAxis=bcrx_AnnualNetSalesOver230000Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bcrx_FutureRoyaltiesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bcrx_FutureRoyaltiesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bcrx_RPI2021And2020IntermediateFinanceTrustMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bcrx_RPI2021And2020IntermediateFinanceTrustMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bcrx_The2021RPIRoyaltyPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bcrx_The2021RPIRoyaltyPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bcrx_OMERSCapitalMarketsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bcrx_OMERSCapitalMarketsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty Financing Obligations - Schedule of Royalty Financing Obligations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMontizationsRollForward', window );"><strong>Royalty Montizations [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyFinancingLiabilities', window );">Balance</a></td>
<td class="nump">$ 483,583<span></span>
</td>
<td class="nump">$ 500,918<span></span>
</td>
<td class="nump">$ 513,729<span></span>
</td>
<td class="nump">$ 513,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_NonCashInterestExpenseOnRoyaltyFinancingLiabilities', window );">Non-cash interest expense on royalty financing obligations</a></td>
<td class="nump">12,923<span></span>
</td>
<td class="nump">13,402<span></span>
</td>
<td class="nump">13,514<span></span>
</td>
<td class="nump">39,839<span></span>
</td>
<td class="nump">$ 42,469<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyRevenuesPayable', window );">Royalty revenues payable</a></td>
<td class="num">(19,713)<span></span>
</td>
<td class="num">(30,737)<span></span>
</td>
<td class="num">(26,325)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyFinancingLiabilities', window );">Balance</a></td>
<td class="nump">476,793<span></span>
</td>
<td class="nump">483,583<span></span>
</td>
<td class="nump">500,918<span></span>
</td>
<td class="nump">476,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_TwentyTwentyRPIRoyaltyAgreementMember', window );">2020 RPI Royalty Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMontizationsRollForward', window );"><strong>Royalty Montizations [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyFinancingLiabilities', window );">Balance</a></td>
<td class="nump">174,357<span></span>
</td>
<td class="nump">178,351<span></span>
</td>
<td class="nump">180,413<span></span>
</td>
<td class="nump">180,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_NonCashInterestExpenseOnRoyaltyFinancingLiabilities', window );">Non-cash interest expense on royalty financing obligations</a></td>
<td class="nump">9,610<span></span>
</td>
<td class="nump">9,804<span></span>
</td>
<td class="nump">9,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyRevenuesPayable', window );">Royalty revenues payable</a></td>
<td class="num">(8,258)<span></span>
</td>
<td class="num">(13,798)<span></span>
</td>
<td class="num">(11,818)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyFinancingLiabilities', window );">Balance</a></td>
<td class="nump">$ 175,709<span></span>
</td>
<td class="nump">174,357<span></span>
</td>
<td class="nump">178,351<span></span>
</td>
<td class="nump">$ 175,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">21.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_TwentyTwentyOneRPIRoyaltyAgreementMember', window );">2021 RPI Royalty Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMontizationsRollForward', window );"><strong>Royalty Montizations [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyFinancingLiabilities', window );">Balance</a></td>
<td class="nump">$ 178,926<span></span>
</td>
<td class="nump">180,119<span></span>
</td>
<td class="nump">181,140<span></span>
</td>
<td class="nump">$ 181,140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_NonCashInterestExpenseOnRoyaltyFinancingLiabilities', window );">Non-cash interest expense on royalty financing obligations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyRevenuesPayable', window );">Royalty revenues payable</a></td>
<td class="num">(2,195)<span></span>
</td>
<td class="num">(1,193)<span></span>
</td>
<td class="num">(1,021)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyFinancingLiabilities', window );">Balance</a></td>
<td class="nump">$ 176,731<span></span>
</td>
<td class="nump">178,926<span></span>
</td>
<td class="nump">180,119<span></span>
</td>
<td class="nump">$ 176,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_OMERSRoyaltyAgreementMember', window );">OMERS Royalty Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMontizationsRollForward', window );"><strong>Royalty Montizations [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyFinancingLiabilities', window );">Balance</a></td>
<td class="nump">$ 130,300<span></span>
</td>
<td class="nump">142,448<span></span>
</td>
<td class="nump">152,176<span></span>
</td>
<td class="nump">$ 152,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_NonCashInterestExpenseOnRoyaltyFinancingLiabilities', window );">Non-cash interest expense on royalty financing obligations</a></td>
<td class="nump">3,313<span></span>
</td>
<td class="nump">3,598<span></span>
</td>
<td class="nump">3,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyRevenuesPayable', window );">Royalty revenues payable</a></td>
<td class="num">(9,260)<span></span>
</td>
<td class="num">(15,746)<span></span>
</td>
<td class="num">(13,486)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyFinancingLiabilities', window );">Balance</a></td>
<td class="nump">$ 124,353<span></span>
</td>
<td class="nump">$ 130,300<span></span>
</td>
<td class="nump">$ 142,448<span></span>
</td>
<td class="nump">$ 124,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">10.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_NonCashInterestExpenseOnRoyaltyFinancingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of non-cash interest expense on royalty financing obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_NonCashInterestExpenseOnRoyaltyFinancingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyFinancingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Financing Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyFinancingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyMontizationsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Montizations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyMontizationsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyRevenuesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents royalties revenues payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyRevenuesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bcrx_TwentyTwentyRPIRoyaltyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bcrx_TwentyTwentyRPIRoyaltyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bcrx_TwentyTwentyOneRPIRoyaltyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bcrx_TwentyTwentyOneRPIRoyaltyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bcrx_OMERSRoyaltyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bcrx_OMERSRoyaltyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 24, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 18, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 17, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Prepayment premium and fees on Pharmakon term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,802<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,740<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,911<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=bcrx_PharmakonAdvisorsLPMember', window );">Pharmakon Advisors, LP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_DebtInstrumentCapitalizedInterestRate', window );">Debt instrument capitalized interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_DebtInstrumentVariableRateFloor', window );">Debt Instrument, SOFR floor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=bcrx_PharmakonAdvisorsLPMember', window );">Pharmakon Advisors, LP | PIK Interest Payment is Made</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=bcrx_PharmakonAdvisorsLPMember', window );">Pharmakon Advisors, LP | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Debt instrument, periodic payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments', window );">Debt instrument, prepayment fee, percentage of principal voluntary payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Prepayment premium and fees on Pharmakon term loan</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_DebtInstrumentPrepaymentPremium', window );">Prepayment premium</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">2,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseLongTermDebt', window );">Interest expense</a></td>
<td class="nump">376<span></span>
</td>
<td class="nump">424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_UnamortizedDeferredFinancingCosts', window );">Unamortized deferred financing costs</a></td>
<td class="nump">1,188<span></span>
</td>
<td class="nump">$ 1,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Debt fees</a></td>
<td class="nump">52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_DeferredDebtPrepaymentAndDebtIssuanceCostsWriteoff', window );">Prepayment and debt issuance costs writeoff</a></td>
<td class="nump">$ 2,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=bcrx_PharmakonAdvisorsLPMember', window );">Pharmakon Advisors, LP | Line of Credit | Between the Second and Third Anniversaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments', window );">Debt instrument, prepayment fee, percentage of principal voluntary payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=bcrx_PharmakonAdvisorsLPMember', window );">Pharmakon Advisors, LP | Line of Credit | After Fourth Anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments', window );">Debt instrument, prepayment fee, percentage of principal voluntary payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=bcrx_PharmakonAdvisorsLPMember', window );">Pharmakon Advisors, LP | Line of Credit | After Third Anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments', window );">Debt instrument, prepayment fee, percentage of principal voluntary payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=bcrx_AthyriumMember', window );">Athyrium | Senior Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Repayments of lines of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 241,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_TermLoanTrancheAMember', window );">Term Loan Tranche A | Pharmakon Advisors, LP | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.28%<span></span>
</td>
<td class="nump">13.34%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.28%<span></span>
</td>
<td class="nump">13.34%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense, debt, total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,110<span></span>
</td>
<td class="nump">$ 10,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,789<span></span>
</td>
<td class="nump">$ 30,283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentInterest', window );">Periodic payment, interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,242<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">198,704<span></span>
</td>
<td class="nump">323,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">198,704<span></span>
</td>
<td class="nump">323,704<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Debt instrument, unamortized discount (premium) and debt issuance costs, net, total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 384<span></span>
</td>
<td class="nump">$ 511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,387<span></span>
</td>
<td class="nump">$ 1,061<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_TermLoanTrancheAMember', window );">Term Loan Tranche A | Pharmakon Advisors, LP | Line of Credit | PIK Interest Payment is Made</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_PercentOfInterestPayment', window );">Percent of interest payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50<span></span>
</td>
<td class="nump">0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_LoanAgreementMember', window );">Loan Agreement | Pharmakon Advisors, LP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_TermLoanTrancheBMember', window );">Term Loan Tranche B | Pharmakon Advisors, LP | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_TermLoanTrancheCMember', window );">Term Loan Tranche C | Pharmakon Advisors, LP | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_TermLoanTrancheDMember', window );">Term Loan Tranche D | Pharmakon Advisors, LP | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DebtInstrumentCapitalizedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Capitalized Interest Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DebtInstrumentCapitalizedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of principal paid voluntarily for prepayment fee of the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DebtInstrumentPrepaymentPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Premium</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DebtInstrumentPrepaymentPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DebtInstrumentVariableRateFloor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Variable Rate floor</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DebtInstrumentVariableRateFloor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DeferredDebtPrepaymentAndDebtIssuanceCostsWriteoff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Debt, Prepayment And Debt Issuance Costs, Writeoff</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DeferredDebtPrepaymentAndDebtIssuanceCostsWriteoff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PercentOfInterestPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percent of Interest Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PercentOfInterestPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_UnamortizedDeferredFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unamortized Deferred Financing Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_UnamortizedDeferredFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments including both interest and principal payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of interest paid or due on all long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph b<br> -Subparagraph (1)<br> -Publisher SEC<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtExtinguishmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtExtinguishmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=bcrx_PharmakonAdvisorsLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=bcrx_PharmakonAdvisorsLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DebtCovenantTermsAxis=bcrx_PikInterestPaymentIsMadeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DebtCovenantTermsAxis=bcrx_PikInterestPaymentIsMadeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DebtCovenantTermsAxis=bcrx_BetweenTheSecondAndThirdAnniversariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DebtCovenantTermsAxis=bcrx_BetweenTheSecondAndThirdAnniversariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DebtCovenantTermsAxis=bcrx_AfterFourthAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DebtCovenantTermsAxis=bcrx_AfterFourthAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DebtCovenantTermsAxis=bcrx_AfterThirdAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DebtCovenantTermsAxis=bcrx_AfterThirdAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=bcrx_AthyriumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=bcrx_AthyriumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=bcrx_SeniorCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=bcrx_SeniorCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bcrx_TermLoanTrancheAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bcrx_TermLoanTrancheAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bcrx_LoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bcrx_LoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bcrx_TermLoanTrancheBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bcrx_TermLoanTrancheBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bcrx_TermLoanTrancheCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bcrx_TermLoanTrancheCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bcrx_TermLoanTrancheDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bcrx_TermLoanTrancheDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Lease Obligations (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_OperatingLeaseRightOfUseAssetAccumulatedAmortization', window );">Operating lease, right-of-use asset, accumulated amortization</a></td>
<td class="nump">$ 2,314<span></span>
</td>
<td class="nump">$ 6,065<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization', window );">Finance lease, right-of-use asset, accumulated amortization</a></td>
<td class="nump">$ 4,519<span></span>
</td>
<td class="nump">$ 4,059<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, operating lease, term of contract (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, operating lease, term of contract (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_OperatingLeaseRightOfUseAssetAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated amortization on lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_OperatingLeaseRightOfUseAssetAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated amortization of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Obligations - Aggregate Lease Expense Under Operating Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="nump">$ 526<span></span>
</td>
<td class="nump">$ 569<span></span>
</td>
<td class="nump">$ 1,596<span></span>
</td>
<td class="nump">$ 1,741<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of right-of-use assets</a></td>
<td class="nump">547<span></span>
</td>
<td class="nump">455<span></span>
</td>
<td class="nump">1,639<span></span>
</td>
<td class="nump">1,278<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">81<span></span>
</td>
<td class="nump">268<span></span>
</td>
<td class="nump">231<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_FinancingLeaseExpense', window );">Total finance lease expense</a></td>
<td class="nump">$ 631<span></span>
</td>
<td class="nump">$ 536<span></span>
</td>
<td class="nump">$ 1,907<span></span>
</td>
<td class="nump">$ 1,509<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_FinancingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financing Lease, Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_FinancingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Lease Obligations - Other Supplemental Information Related to Leases (Details)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (in years)</a></td>
<td class="text">9 years 8 months 12 days<span></span>
</td>
<td class="text">9 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases</a></td>
<td class="nump">10.71%<span></span>
</td>
<td class="nump">10.91%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (in years)</a></td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance leases</a></td>
<td class="nump">9.63%<span></span>
</td>
<td class="nump">8.66%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Lease Obligations - Balance Sheets of the Company's Operating Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_OperatingLeaseAssets', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Right of use assets<span></span>
</td>
<td class="text">Right of use assets<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets, net</a></td>
<td class="nump">$ 7,725<span></span>
</td>
<td class="nump">$ 8,061<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityAbstract', window );"><strong>Operating Lease, Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">348<span></span>
</td>
<td class="nump">937<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">8,425<span></span>
</td>
<td class="nump">7,924<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 8,773<span></span>
</td>
<td class="nump">$ 8,861<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_OperatingLeaseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Information on operating lease right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_OperatingLeaseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Lease Obligations - Balance Sheets of the Company's Finance Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Right of use assets<span></span>
</td>
<td class="text">Right of use assets<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease assets, net</a></td>
<td class="nump">$ 3,115<span></span>
</td>
<td class="nump">$ 3,947<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities</a></td>
<td class="nump">1,435<span></span>
</td>
<td class="nump">1,835<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities</a></td>
<td class="nump">1,742<span></span>
</td>
<td class="nump">2,124<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total</a></td>
<td class="nump">$ 3,177<span></span>
</td>
<td class="nump">$ 3,959<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Lease Obligations - Maturities of Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2025 (remaining)</a></td>
<td class="nump">$ 119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2026</a></td>
<td class="nump">1,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2027</a></td>
<td class="nump">1,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2028</a></td>
<td class="nump">1,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2029</a></td>
<td class="nump">1,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">9,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">14,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(6,029)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">8,773<span></span>
</td>
<td class="nump">$ 8,861<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2025 (remaining)</a></td>
<td class="nump">496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2026</a></td>
<td class="nump">1,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2027</a></td>
<td class="nump">1,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2028</a></td>
<td class="nump">486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2029</a></td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_FinanceLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">3,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(401)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total</a></td>
<td class="nump">$ 3,177<span></span>
</td>
<td class="nump">$ 3,959<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_FinanceLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Liability, to be Paid, After Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_FinanceLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Obligations - Supplemental Cash Flows (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Operating cash flows for finance leases</a></td>
<td class="nump">$ 268<span></span>
</td>
<td class="nump">$ 231<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows for operating leases</a></td>
<td class="nump">1,347<span></span>
</td>
<td class="nump">1,731<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease assets obtained in exchange for operating lease liabilities</a></td>
<td class="nump">366<span></span>
</td>
<td class="nump">261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Finance lease assets obtained in exchange for finance lease liabilities</a></td>
<td class="nump">870<span></span>
</td>
<td class="nump">828<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_NonCashIncreaseInOperatingLeaseAssetsDueToRemeasurementOfOperatingLeaseLiabilities', window );">Non-cash increase to operating lease assets due to remeasurement of operating lease liabilities</a></td>
<td class="nump">$ 786<span></span>
</td>
<td class="nump">$ 365<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_NonCashIncreaseInOperatingLeaseAssetsDueToRemeasurementOfOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-cash Increase In Operating Lease Assets Due To Remeasurement Of Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_NonCashIncreaseInOperatingLeaseAssetsDueToRemeasurementOfOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Shares Reserved for Future Issuance (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Equity Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares reserved for future issuance</a></td>
<td class="nump">71,169<span></span>
</td>
<td class="nump">62,158<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Equity Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares reserved for future issuance</a></td>
<td class="nump">41,522<span></span>
</td>
<td class="nump">44,240<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock unit awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Equity Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares reserved for future issuance</a></td>
<td class="nump">9,744<span></span>
</td>
<td class="nump">10,112<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Equity Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares reserved for future issuance</a></td>
<td class="nump">13,721<span></span>
</td>
<td class="nump">1,065<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_InducementPlanMember', window );">Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Equity Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares reserved for future issuance</a></td>
<td class="nump">1,508<span></span>
</td>
<td class="nump">1,699<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_EmployeeStockPurchasePlanMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Equity Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares reserved for future issuance</a></td>
<td class="nump">4,674<span></span>
</td>
<td class="nump">5,042<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcrx_IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcrx_InducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcrx_InducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcrx_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcrx_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Details Textual)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>plan </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_ShareBasedPaymentArrangementNumberOfPlans', window );">Number of plans | plan</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan | Unvested restricted stock unit awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Restricted stock units, grants in period, weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 9.17<span></span>
</td>
<td class="nump">$ 5.80<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_InducementPlanMember', window );">Inducement Plan | Unvested restricted stock unit awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Restricted stock units, grants in period, weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 8.47<span></span>
</td>
<td class="nump">$ 6.25<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ShareBasedPaymentArrangementNumberOfPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Payment Arrangement, Number of Plans</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ShareBasedPaymentArrangementNumberOfPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcrx_IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcrx_InducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcrx_InducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Share-Based Compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1', window );">Total stock-based compensation costs</a></td>
<td class="nump">$ 18,644<span></span>
</td>
<td class="nump">$ 17,249<span></span>
</td>
<td class="nump">$ 61,316<span></span>
</td>
<td class="nump">$ 44,074<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized stock-based compensation costs</a></td>
<td class="num">(43)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(43)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation costs included in operating expenses</a></td>
<td class="nump">18,601<span></span>
</td>
<td class="nump">17,249<span></span>
</td>
<td class="nump">61,273<span></span>
</td>
<td class="nump">44,074<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1', window );">Total stock-based compensation costs</a></td>
<td class="nump">16,232<span></span>
</td>
<td class="nump">14,794<span></span>
</td>
<td class="nump">54,841<span></span>
</td>
<td class="nump">37,294<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_InducementPlanMember', window );">Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1', window );">Total stock-based compensation costs</a></td>
<td class="nump">2,179<span></span>
</td>
<td class="nump">2,234<span></span>
</td>
<td class="nump">5,852<span></span>
</td>
<td class="nump">6,241<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_EmployeeStockPurchasePlanMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1', window );">Total stock-based compensation costs</a></td>
<td class="nump">$ 233<span></span>
</td>
<td class="nump">$ 221<span></span>
</td>
<td class="nump">$ 623<span></span>
</td>
<td class="nump">$ 539<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost expensed and capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcrx_IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcrx_InducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcrx_InducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcrx_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcrx_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Option Activity (Details) - Employee Stock Option - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, beginning balance (in shares)</a></td>
<td class="nump">39,082<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, grants in period, gross (in shares)</a></td>
<td class="nump">538<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares)</a></td>
<td class="num">(897)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options cancelled or forfeited (in shares)</a></td>
<td class="num">(1,924)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending balance (in shares)</a></td>
<td class="nump">36,799<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable (in shares)</a></td>
<td class="nump">23,314<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, beginning balance (in usd per share)</a></td>
<td class="nump">$ 7.96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price of stock option awards granted (in usd per share)</a></td>
<td class="nump">9.31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price of stock option awards exercised (in usd per share)</a></td>
<td class="nump">5.36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price of stock option awards cancelled (in usd per share)</a></td>
<td class="nump">9.99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, ending balance (in usd per share)</a></td>
<td class="nump">7.94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, stock option awards, exercisable (in dollars per share)</a></td>
<td class="nump">$ 7.92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Weighted average remaining contractual life</a></td>
<td class="nump">$ 3,290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options, exercises in period, intrinsic value</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, aggregate intrinsic value</a></td>
<td class="nump">$ 28,966<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options, exercisable, weighted average remaining contractual term (year)</a></td>
<td class="text">4 years 8 months 26 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Stock option awards vested and exercisable, aggregate intrinsic value</a></td>
<td class="nump">$ 23,388<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, beginning balance (in shares)</a></td>
<td class="nump">5,158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, grants in period, gross (in shares)</a></td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares)</a></td>
<td class="num">(252)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options cancelled or forfeited (in shares)</a></td>
<td class="num">(279)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending balance (in shares)</a></td>
<td class="nump">4,723<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable (in shares)</a></td>
<td class="nump">3,519<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, beginning balance (in usd per share)</a></td>
<td class="nump">$ 8.44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price of stock option awards granted (in usd per share)</a></td>
<td class="nump">8.07<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price of stock option awards exercised (in usd per share)</a></td>
<td class="nump">5.65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price of stock option awards cancelled (in usd per share)</a></td>
<td class="nump">11.31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, ending balance (in usd per share)</a></td>
<td class="nump">8.41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, stock option awards, exercisable (in dollars per share)</a></td>
<td class="nump">$ 8.18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Weighted average remaining contractual life</a></td>
<td class="nump">$ 994<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options, exercises in period, intrinsic value</a></td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, aggregate intrinsic value</a></td>
<td class="nump">$ 6,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options, exercisable, weighted average remaining contractual term (year)</a></td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Stock option awards vested and exercisable, aggregate intrinsic value</a></td>
<td class="nump">$ 6,324<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcrx_IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcrx_InducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcrx_InducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Restricted Stock Unit Activity (Details) - Unvested restricted stock unit awards - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested RSU beginning balance (in shares)</a></td>
<td class="nump">9,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Issued RSU (in shares)</a></td>
<td class="nump">393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested RSU (in shares)</a></td>
<td class="num">(270)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited RSU (in shares)</a></td>
<td class="num">(667)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested RSU ending balance (in shares)</a></td>
<td class="nump">8,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested RSU weighted average grant date fair value beginning balance (in dollars per share)</a></td>
<td class="nump">$ 7.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Restricted stock units, grants in period, weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">9.17<span></span>
</td>
<td class="nump">$ 5.80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Restricted stock units, vested in period, weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">8.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Restricted stock units, forfeited in period, weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">7.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested RSU weighted average grant date fair value ending balance (in dollars per share)</a></td>
<td class="nump">$ 7.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested RSU beginning balance (in shares)</a></td>
<td class="nump">823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Issued RSU (in shares)</a></td>
<td class="nump">472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested RSU (in shares)</a></td>
<td class="num">(197)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited RSU (in shares)</a></td>
<td class="num">(99)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested RSU ending balance (in shares)</a></td>
<td class="nump">999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested RSU weighted average grant date fair value beginning balance (in dollars per share)</a></td>
<td class="nump">$ 8.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Restricted stock units, grants in period, weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">8.47<span></span>
</td>
<td class="nump">$ 6.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Restricted stock units, vested in period, weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">9.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Restricted stock units, forfeited in period, weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">8.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested RSU weighted average grant date fair value ending balance (in dollars per share)</a></td>
<td class="nump">$ 8.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcrx_IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcrx_InducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcrx_InducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors Under the Plans (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life in years</a></td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected Life in Years</a></td>
<td class="nump">79.00%<span></span>
</td>
<td class="nump">83.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected Volatility</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Expected Dividend Yield</a></td>
<td class="nump">4.10%<span></span>
</td>
<td class="nump">4.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value stock option awards (in dollars per share)</a></td>
<td class="nump">$ 6.64<span></span>
</td>
<td class="nump">$ 4.56<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_InducementPlanMember', window );">Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life in years</a></td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected Life in Years</a></td>
<td class="nump">80.90%<span></span>
</td>
<td class="nump">83.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected Volatility</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Expected Dividend Yield</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value stock option awards (in dollars per share)</a></td>
<td class="nump">$ 5.89<span></span>
</td>
<td class="nump">$ 4.43<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcrx_IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcrx_InducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcrx_InducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 03, 2023 </div>
<div>USD ($) </div>
<div>payment</div>
</th>
<th class="th">
<div>Nov. 05, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>period </div>
<div>dose</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($) </div>
<div>dose</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>dose</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($) </div>
<div>dose</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>dose</div>
</th>
<th class="th"><div>Nov. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Collaborative and Other Relationships [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 159,395<span></span>
</td>
<td class="nump">$ 117,085<span></span>
</td>
<td class="nump">$ 468,282<span></span>
</td>
<td class="nump">$ 319,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_ToriiPharmaceuticalCoMember', window );">Torii Pharmaceutical Co.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Collaborative and Other Relationships [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeMilestone', window );">Potential milestone payments receivable if regulatory approval before specified date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_MaximumCustomaryReductionOnRoyaltyRate', window );">Maximum customary reduction on royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_ToriiPharmaceuticalCoMember', window );">Torii Pharmaceutical Co. | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Collaborative and Other Relationships [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyRateIfMaintainsSakigakeDesignation', window );">Royalty rate if maintains sakigake designation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyRate', window );">Royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_ToriiPharmaceuticalCoMember', window );">Torii Pharmaceutical Co. | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Collaborative and Other Relationships [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyRateIfMaintainsSakigakeDesignation', window );">Royalty rate if maintains sakigake designation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyRate', window );">Royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_ClearsideBiomedicalIncMember', window );">Clearside Biomedical, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Collaborative and Other Relationships [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_LicenseAgreementUpfrontPayment', window );">Upfront payment</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_LicenseAgreementNumberOfMilestonePayments', window );">Number of milestone payments | payment</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_LicenseAgreementRoyaltyPaymentNumberOfTiers', window );">Number of royalties tiers | payment</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_ClearsideBiomedicalIncMember', window );">Clearside Biomedical, Inc. | Annual Net Sales Of $2 Million</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Collaborative and Other Relationships [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_LicenseAgreementAnnualGlobalNetSales', window );">Annual global net sales</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_ClearsideBiomedicalIncMember', window );">Clearside Biomedical, Inc. | Annual Net Sales Greater Than $1.5 Million</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Collaborative and Other Relationships [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_LicenseAgreementAnnualGlobalNetSales', window );">Annual global net sales</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_ClearsideBiomedicalIncMember', window );">Clearside Biomedical, Inc. | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Collaborative and Other Relationships [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_PotentialMilestonePaymentsPayable', window );">Potential milestone payment</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_PotentialMilestonePaymentsPayableIfRegulatoryApprovalBeforeMilestone', window );">Potential payment if milestone reached</a></td>
<td class="nump">$ 47,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_HHSOfficeOfTheAdministrationForStrategicPreparednessAndResponseMember', window );">HHS Office of the Administration for Strategic Preparedness and Response</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Collaborative and Other Relationships [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_CollaborativeAgreementContractValue', window );">Contract value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_ContractTerm', window );">Contract term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_HHSOfficeOfTheAdministrationForStrategicPreparednessAndResponseMember', window );">HHS Office of the Administration for Strategic Preparedness and Response | RAPIVAB</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Collaborative and Other Relationships [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses', window );">Number of doses permitted to be procured | dose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_ContractTerm', window );">Contract term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_NumberOfOptionalOrderingPeriods', window );">Number of optional ordering periods | period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Proceeds from collaborators</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_NumberOfProductDeliveredDoses', window );">Doses delivered | dose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,800<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_CollaborativeAgreementContractValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement Contract Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_CollaborativeAgreementContractValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ContractTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ContractTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_LicenseAgreementAnnualGlobalNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Annual Global Net Sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_LicenseAgreementAnnualGlobalNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_LicenseAgreementNumberOfMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Number of Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_LicenseAgreementNumberOfMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_LicenseAgreementRoyaltyPaymentNumberOfTiers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Royalty Payment, Number of Tiers</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_LicenseAgreementRoyaltyPaymentNumberOfTiers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_LicenseAgreementUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_LicenseAgreementUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MaximumCustomaryReductionOnRoyaltyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum percentage of customary reductions allowed on royalty rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MaximumCustomaryReductionOnRoyaltyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Number Of Products Permitted To Be Obtained, Doses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_NumberOfOptionalOrderingPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Optional Ordering Periods</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_NumberOfOptionalOrderingPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_NumberOfProductDeliveredDoses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Product Delivered, Doses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_NumberOfProductDeliveredDoses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PotentialMilestonePaymentsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential Milestone Payments Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PotentialMilestonePaymentsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PotentialMilestonePaymentsPayableIfRegulatoryApprovalBeforeMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential Milestone Payments Payable If Regulatory Approval Before Milestone</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PotentialMilestonePaymentsPayableIfRegulatoryApprovalBeforeMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of potential milestone payments receivable if regulatory approval is granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyRateIfMaintainsSakigakeDesignation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percent of net sales that the company will receive if berotralstat maintains its Sakigake designation during the PMDA review.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyRateIfMaintainsSakigakeDesignation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bcrx_ToriiPharmaceuticalCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bcrx_ToriiPharmaceuticalCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bcrx_ClearsideBiomedicalIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bcrx_ClearsideBiomedicalIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AnnualNetSalesRangeAxis=bcrx_AnnualNetSalesOf2MillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AnnualNetSalesRangeAxis=bcrx_AnnualNetSalesOf2MillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AnnualNetSalesRangeAxis=bcrx_AnnualNetSalesGreaterThan15MillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AnnualNetSalesRangeAxis=bcrx_AnnualNetSalesGreaterThan15MillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bcrx_HHSOfficeOfTheAdministrationForStrategicPreparednessAndResponseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bcrx_HHSOfficeOfTheAdministrationForStrategicPreparednessAndResponseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bcrx_RAPIVABMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bcrx_RAPIVABMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_CashCashEquivalentsShortAndLongTermInvestments', window );">Cash, cash equivalents, and investments | $</a></td>
<td class="nump">$ 267,382<span></span>
</td>
<td class="nump">$ 341,173<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember', window );">Disposal Group, Held-for-Sale, Not Discontinued Operations | BioCryst Ireland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents', window );">Cash and cash equivalents | $</a></td>
<td class="nump">$ 14,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_CashCashEquivalentsShortAndLongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Short and Long-Term Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_CashCashEquivalentsShortAndLongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bcrx_BioCrystIrelandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bcrx_BioCrystIrelandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Segment Reporting Information by Segment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 159,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 117,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 468,282<span></span>
</td>
<td class="nump">$ 319,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract', window );"><strong>Segment Reconciliation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of product sales</a></td>
<td class="nump">2,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,553<span></span>
</td>
<td class="nump">6,175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">44,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,259<span></span>
</td>
<td class="nump">125,197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">83,014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">252,866<span></span>
</td>
<td class="nump">185,841<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="nump">19,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,737<span></span>
</td>
<td class="nump">74,067<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">2,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,911<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other income</a></td>
<td class="nump">2,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,667<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="num">(769)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,358<span></span>
</td>
<td class="nump">1,123<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">12,899<span></span>
</td>
<td class="nump">$ 5,085<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
<td class="num">(14,033)<span></span>
</td>
<td class="num">$ (12,674)<span></span>
</td>
<td class="num">$ (35,379)<span></span>
</td>
<td class="nump">18,016<span></span>
</td>
<td class="num">(62,086)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bcrx_ReportableSegmentMember', window );">Reportable Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="nump">159,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">468,282<span></span>
</td>
<td class="nump">319,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract', window );"><strong>Segment Reconciliation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of product sales</a></td>
<td class="nump">2,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,553<span></span>
</td>
<td class="nump">6,175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">83,014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">252,866<span></span>
</td>
<td class="nump">185,841<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Interest income</a></td>
<td class="num">(2,238)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,591)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,778)<span></span>
</td>
<td class="num">(11,176)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="nump">19,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,737<span></span>
</td>
<td class="nump">74,067<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency (gains) losses, net</a></td>
<td class="num">(35)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(98)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">2,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,911<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other income</a></td>
<td class="nump">2,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,667<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="num">(769)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,358<span></span>
</td>
<td class="nump">1,123<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">12,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,033)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,016<span></span>
</td>
<td class="num">(62,086)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_SegmentReportingAdjustmentsAndReconcilingItemsAmount', window );">Adjustments and reconciling items</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bcrx_ReportableSegmentMember', window );">Reportable Segment | Berotralstat</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract', window );"><strong>Segment Reconciliation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">2,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,214<span></span>
</td>
<td class="nump">10,504<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bcrx_ReportableSegmentMember', window );">Reportable Segment | BCX17725</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract', window );"><strong>Segment Reconciliation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">7,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,346<span></span>
</td>
<td class="nump">6,591<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bcrx_ReportableSegmentMember', window );">Reportable Segment | Avoralstat</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract', window );"><strong>Segment Reconciliation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,584<span></span>
</td>
<td class="nump">4,960<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bcrx_ReportableSegmentMember', window );">Reportable Segment | Factor D Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract', window );"><strong>Segment Reconciliation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">454<span></span>
</td>
<td class="nump">7,299<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bcrx_ReportableSegmentMember', window );">Reportable Segment | Research, discovery and preclinical programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract', window );"><strong>Segment Reconciliation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">5,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,641<span></span>
</td>
<td class="nump">8,325<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bcrx_ReportableSegmentMember', window );">Reportable Segment | Compensation and related personnel costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract', window );"><strong>Segment Reconciliation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">13,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,025<span></span>
</td>
<td class="nump">42,630<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bcrx_ReportableSegmentMember', window );">Reportable Segment | Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract', window );"><strong>Segment Reconciliation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">6,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,374<span></span>
</td>
<td class="nump">20,923<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bcrx_ReportableSegmentMember', window );">Reportable Segment | Other non-program specific and indirect costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract', window );"><strong>Segment Reconciliation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 7,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,621<span></span>
</td>
<td class="nump">$ 23,965<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_SegmentReportingAdjustmentsAndReconcilingItemsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Segment Reporting, Adjustments and Reconciling Items, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_SegmentReportingAdjustmentsAndReconcilingItemsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479255/942-310-S50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.H.2.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478116/942-310-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 39<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477346/946-830-45-39<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bcrx_ReportableSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bcrx_ReportableSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bcrx_BerotralstatMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bcrx_BerotralstatMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bcrx_BCX17725Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bcrx_BCX17725Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bcrx_AvoralstatMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bcrx_AvoralstatMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bcrx_FactorDProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bcrx_FactorDProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bcrx_ResearchDiscoveryAndPreclinicalProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bcrx_ResearchDiscoveryAndPreclinicalProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bcrx_CompensationAndRelatedPersonnelCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bcrx_CompensationAndRelatedPersonnelCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bcrx_StockBasedCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bcrx_StockBasedCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bcrx_OtherExpenses1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bcrx_OtherExpenses1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share - Schedule of Earnings Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 12,899<span></span>
</td>
<td class="nump">$ 5,085<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
<td class="num">$ (14,033)<span></span>
</td>
<td class="num">$ (12,674)<span></span>
</td>
<td class="num">$ (35,379)<span></span>
</td>
<td class="nump">$ 18,016<span></span>
</td>
<td class="num">$ (62,086)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, basic (in shares)</a></td>
<td class="nump">210,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209,531<span></span>
</td>
<td class="nump">206,466<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per common share, basic (in usd per share)</a></td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.07)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.09<span></span>
</td>
<td class="num">$ (0.30)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock options to purchase common stock (in shares)</a></td>
<td class="nump">5,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,261<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements', window );">Unvested restricted stock unit awards (in shares)</a></td>
<td class="nump">4,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,532<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_IncrementalCommonSharesAttributableToDilutiveEffectOfSharePurchasePlans', window );">Shares issuable under the employee stock purchase plan</a></td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive potential common shares (in shares)</a></td>
<td class="nump">9,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,818<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, diluted (in shares)</a></td>
<td class="nump">219,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">218,349<span></span>
</td>
<td class="nump">206,466<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per common share, diluted (in usd per share)</a></td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.07)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.08<span></span>
</td>
<td class="num">$ (0.30)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_IncrementalCommonSharesAttributableToDilutiveEffectOfSharePurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Incremental Common Shares Attributable To Dilutive Effect Of Share Purchase Plans</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_IncrementalCommonSharesAttributableToDilutiveEffectOfSharePurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of equity unit purchase agreements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480454/718-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-28A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount (in shares)</a></td>
<td class="nump">22,191<span></span>
</td>
<td class="nump">44,441<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount (in shares)</a></td>
<td class="nump">21,818<span></span>
</td>
<td class="nump">38,559<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock unit awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount (in shares)</a></td>
<td class="nump">373<span></span>
</td>
<td class="nump">5,882<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 14, 2025 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Oct. 08, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 24, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 18, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 01, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Prepayment premium and fees on Pharmakon term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,802<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=bcrx_PharmakonAdvisorsLPMember', window );">Pharmakon Advisors, LP | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Prepayment premium and fees on Pharmakon term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_DebtInstrumentPrepaymentPremium', window );">Prepayment premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">2,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseLongTermDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 376<span></span>
</td>
<td class="nump">$ 424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember', window );">Disposal Group, Held-for-Sale, Not Discontinued Operations | BioCryst Ireland | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Upfront consideration to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsideration', window );">Contingent consideration to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_DisposalGroupIncludingDiscontinuedOperationConsiderationRoyaltyReleaseFee', window );">Royalty release fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Astria</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_CommonStockConversionRatio', window );">Conversion ratio</a></td>
<td class="nump">0.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Price per share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 8.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Pharmakon Advisors, LP | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Prepayment premium and fees on Pharmakon term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 198,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_DebtInstrumentPrepaymentPremium', window );">Prepayment premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseLongTermDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Blackstone | Line of Credit | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">$ 550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="nump">350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum aggregate principal amount</a></td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Blackstone | Line of Credit | Unsecured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum aggregate principal amount</a></td>
<td class="nump">$ 150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_CommonStockConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Conversion Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_CommonStockConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DebtInstrumentPrepaymentPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Premium</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DebtInstrumentPrepaymentPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DisposalGroupIncludingDiscontinuedOperationConsiderationRoyaltyReleaseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Consideration, Royalty Release Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DisposalGroupIncludingDiscontinuedOperationConsiderationRoyaltyReleaseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share price of saleable stock paid or offered to be paid by acquirer in business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479299/805-40-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-42<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of interest paid or due on all long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph b<br> -Subparagraph (1)<br> -Publisher SEC<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtExtinguishmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtExtinguishmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=bcrx_PharmakonAdvisorsLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=bcrx_PharmakonAdvisorsLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bcrx_BioCrystIrelandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bcrx_BioCrystIrelandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bcrx_AstriaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bcrx_AstriaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=bcrx_BlackstoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=bcrx_BlackstoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>305</ContextCount>
  <ElementCount>385</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>83</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>9952151 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952152 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952153 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952154 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952155 - Statement - Condensed Consolidated Statements of Stockholders' Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/CondensedConsolidatedStatementsofStockholdersDeficit</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Deficit</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952156 - Disclosure - Significant Accounting Policies and Concentrations of Risk</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRisk</Role>
      <ShortName>Significant Accounting Policies and Concentrations of Risk</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - Assets and Liabilities Held For Sale</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSale</Role>
      <ShortName>Assets and Liabilities Held For Sale</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - Trade Receivables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/TradeReceivables</Role>
      <ShortName>Trade Receivables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - Royalty Financing Obligations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/RoyaltyFinancingObligations</Role>
      <ShortName>Royalty Financing Obligations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - Lease Obligations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/LeaseObligations</Role>
      <ShortName>Lease Obligations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/StockbasedCompensation</Role>
      <ShortName>Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - Collaborative and Other Relationships</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/CollaborativeandOtherRelationships</Role>
      <ShortName>Collaborative and Other Relationships</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952168 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9952169 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9952170 - Disclosure - Net Income (Loss) Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/NetIncomeLossPerShare</Role>
      <ShortName>Net Income (Loss) Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9952171 - Disclosure - Subsequent Event</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/SubsequentEvent</Role>
      <ShortName>Subsequent Event</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - Significant Accounting Policies and Concentrations of Risk (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskPolicies</Role>
      <ShortName>Significant Accounting Policies and Concentrations of Risk (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRisk</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - Significant Accounting Policies and Concentrations of Risk (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskTables</Role>
      <ShortName>Significant Accounting Policies and Concentrations of Risk (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRisk</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - Assets and Liabilities Held For Sale (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleTables</Role>
      <ShortName>Assets and Liabilities Held For Sale (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSale</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/RevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biocryst.com/role/Revenue</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/InvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biocryst.com/role/Investments</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biocryst.com/role/Inventory</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - Royalty Financing Obligations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/RoyaltyFinancingObligationsTables</Role>
      <ShortName>Royalty Financing Obligations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biocryst.com/role/RoyaltyFinancingObligations</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - Lease Obligations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/LeaseObligationsTables</Role>
      <ShortName>Lease Obligations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biocryst.com/role/LeaseObligations</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biocryst.com/role/StockholdersEquity</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/StockbasedCompensationTables</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biocryst.com/role/StockbasedCompensation</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biocryst.com/role/SegmentInformation</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - Net Income (Loss) Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/NetIncomeLossPerShareTables</Role>
      <ShortName>Net Income (Loss) Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biocryst.com/role/NetIncomeLossPerShare</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - Significant Accounting Policies and Concentrations of Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails</Role>
      <ShortName>Significant Accounting Policies and Concentrations of Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - Significant Accounting Policies and Concentrations of Risk - Summary of Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskSummaryofRevenuesDetails</Role>
      <ShortName>Significant Accounting Policies and Concentrations of Risk - Summary of Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - Assets and Liabilities Held For Sale (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleDetails</Role>
      <ShortName>Assets and Liabilities Held For Sale (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - Assets and Liabilities Held For Sale - Schedule of Assets Held For Sale (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleScheduleofAssetsHeldForSaleDetails</Role>
      <ShortName>Assets and Liabilities Held For Sale - Schedule of Assets Held For Sale (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/RevenueDetails</Role>
      <ShortName>Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/role/RevenueTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - Investments - Fair Value, Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/InvestmentsFairValueRecurringBasisDetails</Role>
      <ShortName>Investments - Fair Value, Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - Investments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/InvestmentsNarrativeDetails</Role>
      <ShortName>Investments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - Investments- Fair Value of the Company's Investments by Type (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/InvestmentsFairValueoftheCompanysInvestmentsbyTypeDetails</Role>
      <ShortName>Investments- Fair Value of the Company's Investments by Type (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - Investments - Schedule of Maturity of Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/InvestmentsScheduleofMaturityofInvestmentsDetails</Role>
      <ShortName>Investments - Schedule of Maturity of Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9955532 - Disclosure - Trade Receivables (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/TradeReceivablesDetailsTextual</Role>
      <ShortName>Trade Receivables (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/role/TradeReceivables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9955533 - Disclosure - Inventory - Summary of Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/InventorySummaryofInventoriesDetails</Role>
      <ShortName>Inventory - Summary of Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9955534 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/role/InventoryTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9955535 - Disclosure - Royalty Financing Obligations (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/RoyaltyFinancingObligationsDetailsTextual</Role>
      <ShortName>Royalty Financing Obligations (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/role/RoyaltyFinancingObligationsTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9955536 - Disclosure - Royalty Financing Obligations - Schedule of Royalty Financing Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/RoyaltyFinancingObligationsScheduleofRoyaltyFinancingObligationsDetails</Role>
      <ShortName>Royalty Financing Obligations - Schedule of Royalty Financing Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9955537 - Disclosure - Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/DebtDetails</Role>
      <ShortName>Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/role/Debt</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9955538 - Disclosure - Lease Obligations (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/LeaseObligationsDetailsTextual</Role>
      <ShortName>Lease Obligations (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/role/LeaseObligationsTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9955539 - Disclosure - Lease Obligations - Aggregate Lease Expense Under Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/LeaseObligationsAggregateLeaseExpenseUnderOperatingLeasesDetails</Role>
      <ShortName>Lease Obligations - Aggregate Lease Expense Under Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9955540 - Disclosure - Lease Obligations - Other Supplemental Information Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/LeaseObligationsOtherSupplementalInformationRelatedtoLeasesDetails</Role>
      <ShortName>Lease Obligations - Other Supplemental Information Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9955541 - Disclosure - Lease Obligations - Balance Sheets of the Company's Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/LeaseObligationsBalanceSheetsoftheCompanysOperatingLeasesDetails</Role>
      <ShortName>Lease Obligations - Balance Sheets of the Company's Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9955542 - Disclosure - Lease Obligations - Balance Sheets of the Company's Finance Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/LeaseObligationsBalanceSheetsoftheCompanysFinanceLeasesDetails</Role>
      <ShortName>Lease Obligations - Balance Sheets of the Company's Finance Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9955543 - Disclosure - Lease Obligations - Maturities of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/LeaseObligationsMaturitiesofLeaseLiabilitiesDetails</Role>
      <ShortName>Lease Obligations - Maturities of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9955544 - Disclosure - Lease Obligations - Supplemental Cash Flows (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/LeaseObligationsSupplementalCashFlowsDetails</Role>
      <ShortName>Lease Obligations - Supplemental Cash Flows (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9955545 - Disclosure - Stockholders' Equity - Shares Reserved for Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/StockholdersEquitySharesReservedforFutureIssuanceDetails</Role>
      <ShortName>Stockholders' Equity - Shares Reserved for Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9955546 - Disclosure - Stock-based Compensation (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/StockbasedCompensationDetailsTextual</Role>
      <ShortName>Stock-based Compensation (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/role/StockbasedCompensationTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9955547 - Disclosure - Stock-based Compensation - Share-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/StockbasedCompensationShareBasedCompensationDetails</Role>
      <ShortName>Stock-based Compensation - Share-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9955548 - Disclosure - Stock-based Compensation - Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/StockbasedCompensationOptionActivityDetails</Role>
      <ShortName>Stock-based Compensation - Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9955549 - Disclosure - Stock-based Compensation - Restricted Stock Unit Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails</Role>
      <ShortName>Stock-based Compensation - Restricted Stock Unit Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9955550 - Disclosure - Stock-based Compensation - Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors Under the Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/StockbasedCompensationWeightedAverageAssumptionsforStockOptionAwardsGrantedtoEmployeesandDirectorsUnderthePlansDetails</Role>
      <ShortName>Stock-based Compensation - Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors Under the Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9955551 - Disclosure - Collaborative and Other Relationships (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails</Role>
      <ShortName>Collaborative and Other Relationships (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/role/CollaborativeandOtherRelationships</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9955552 - Disclosure - Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/SegmentInformationDetails</Role>
      <ShortName>Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/role/SegmentInformationTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9955553 - Disclosure - Segment Information - Segment Reporting Information by Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/SegmentInformationSegmentReportingInformationbySegmentDetails</Role>
      <ShortName>Segment Information - Segment Reporting Information by Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9955554 - Disclosure - Net Income (Loss) Per Share - Schedule of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/NetIncomeLossPerShareScheduleofEarningsPerShareDetails</Role>
      <ShortName>Net Income (Loss) Per Share - Schedule of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/role/NetIncomeLossPerShareTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9955555 - Disclosure - Net Income (Loss) Per Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/NetIncomeLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails</Role>
      <ShortName>Net Income (Loss) Per Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/role/NetIncomeLossPerShareTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="bcrx-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9955556 - Disclosure - Subsequent Event (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/SubsequentEventDetails</Role>
      <ShortName>Subsequent Event (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/role/SubsequentEvent</ParentRole>
      <Position>69</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="bcrx-20250930.htm">bcrx-20250930.htm</File>
    <File>bcrx-20250930.xsd</File>
    <File>bcrx-20250930_cal.xml</File>
    <File>bcrx-20250930_def.xml</File>
    <File>bcrx-20250930_lab.xml</File>
    <File>bcrx-20250930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="925">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="11">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>100
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "bcrx-20250930.htm": {
   "nsprefix": "bcrx",
   "nsuri": "http://www.biocryst.com/20250930",
   "dts": {
    "inline": {
     "local": [
      "bcrx-20250930.htm"
     ]
    },
    "schema": {
     "local": [
      "bcrx-20250930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "bcrx-20250930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "bcrx-20250930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "bcrx-20250930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bcrx-20250930_pre.xml"
     ]
    }
   },
   "keyStandard": 309,
   "keyCustom": 76,
   "axisStandard": 27,
   "axisCustom": 2,
   "memberStandard": 26,
   "memberCustom": 55,
   "hidden": {
    "total": 13,
    "http://xbrl.sec.gov/dei/2025": 5,
    "http://fasb.org/us-gaap/2025": 7,
    "http://xbrl.sec.gov/ecd/2025": 1
   },
   "contextCount": 305,
   "entityCount": 1,
   "segmentCount": 83,
   "elementCount": 701,
   "unitCount": 10,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 925,
    "http://xbrl.sec.gov/dei/2025": 29,
    "http://xbrl.sec.gov/ecd/2025": 11
   },
   "report": {
    "R1": {
     "role": "http://www.biocryst.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets",
     "longName": "9952151 - Statement - Condensed Consolidated Balance Sheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:ShortTermInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "longName": "9952152 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.biocryst.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss",
     "longName": "9952153 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss)",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income (Loss)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:CostsAndExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows",
     "longName": "9952154 - Statement - Condensed Consolidated Statements of Cash Flows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.biocryst.com/role/CondensedConsolidatedStatementsofStockholdersDeficit",
     "longName": "9952155 - Statement - Condensed Consolidated Statements of Stockholders' Deficit",
     "shortName": "Condensed Consolidated Statements of Stockholders' Deficit",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-44",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-48",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRisk",
     "longName": "9952156 - Disclosure - Significant Accounting Policies and Concentrations of Risk",
     "shortName": "Significant Accounting Policies and Concentrations of Risk",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSale",
     "longName": "9952157 - Disclosure - Assets and Liabilities Held For Sale",
     "shortName": "Assets and Liabilities Held For Sale",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.biocryst.com/role/Revenue",
     "longName": "9952158 - Disclosure - Revenue",
     "shortName": "Revenue",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.biocryst.com/role/Investments",
     "longName": "9952159 - Disclosure - Investments",
     "shortName": "Investments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.biocryst.com/role/TradeReceivables",
     "longName": "9952160 - Disclosure - Trade Receivables",
     "shortName": "Trade Receivables",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "bcrx:TradeReceivablesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "bcrx:TradeReceivablesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.biocryst.com/role/Inventory",
     "longName": "9952161 - Disclosure - Inventory",
     "shortName": "Inventory",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.biocryst.com/role/RoyaltyFinancingObligations",
     "longName": "9952162 - Disclosure - Royalty Financing Obligations",
     "shortName": "Royalty Financing Obligations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "bcrx:RoyaltyFinancingLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "bcrx:RoyaltyFinancingLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.biocryst.com/role/Debt",
     "longName": "9952163 - Disclosure - Debt",
     "shortName": "Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.biocryst.com/role/LeaseObligations",
     "longName": "9952164 - Disclosure - Lease Obligations",
     "shortName": "Lease Obligations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.biocryst.com/role/StockholdersEquity",
     "longName": "9952165 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.biocryst.com/role/StockbasedCompensation",
     "longName": "9952166 - Disclosure - Stock-based Compensation",
     "shortName": "Stock-based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.biocryst.com/role/CollaborativeandOtherRelationships",
     "longName": "9952167 - Disclosure - Collaborative and Other Relationships",
     "shortName": "Collaborative and Other Relationships",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.biocryst.com/role/SegmentInformation",
     "longName": "9952168 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.biocryst.com/role/CommitmentsandContingencies",
     "longName": "9952169 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.biocryst.com/role/NetIncomeLossPerShare",
     "longName": "9952170 - Disclosure - Net Income (Loss) Per Share",
     "shortName": "Net Income (Loss) Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.biocryst.com/role/SubsequentEvent",
     "longName": "9952171 - Disclosure - Subsequent Event",
     "shortName": "Subsequent Event",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-7",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskPolicies",
     "longName": "9955511 - Disclosure - Significant Accounting Policies and Concentrations of Risk (Policies)",
     "shortName": "Significant Accounting Policies and Concentrations of Risk (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "bcrx:DescriptionOfCompanyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "bcrx:DescriptionOfCompanyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskTables",
     "longName": "9955512 - Disclosure - Significant Accounting Policies and Concentrations of Risk (Tables)",
     "shortName": "Significant Accounting Policies and Concentrations of Risk (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R26": {
     "role": "http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleTables",
     "longName": "9955513 - Disclosure - Assets and Liabilities Held For Sale (Tables)",
     "shortName": "Assets and Liabilities Held For Sale (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.biocryst.com/role/RevenueTables",
     "longName": "9955514 - Disclosure - Revenue (Tables)",
     "shortName": "Revenue (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R28": {
     "role": "http://www.biocryst.com/role/InvestmentsTables",
     "longName": "9955515 - Disclosure - Investments (Tables)",
     "shortName": "Investments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.biocryst.com/role/InventoryTables",
     "longName": "9955516 - Disclosure - Inventory (Tables)",
     "shortName": "Inventory (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.biocryst.com/role/RoyaltyFinancingObligationsTables",
     "longName": "9955517 - Disclosure - Royalty Financing Obligations (Tables)",
     "shortName": "Royalty Financing Obligations (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "bcrx:RoyaltyFinancingLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "bcrx:RoyaltyFinancingLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.biocryst.com/role/LeaseObligationsTables",
     "longName": "9955518 - Disclosure - Lease Obligations (Tables)",
     "shortName": "Lease Obligations (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.biocryst.com/role/StockholdersEquityTables",
     "longName": "9955519 - Disclosure - Stockholders' Equity (Tables)",
     "shortName": "Stockholders' Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.biocryst.com/role/StockbasedCompensationTables",
     "longName": "9955520 - Disclosure - Stock-based Compensation (Tables)",
     "shortName": "Stock-based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.biocryst.com/role/SegmentInformationTables",
     "longName": "9955521 - Disclosure - Segment Information (Tables)",
     "shortName": "Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.biocryst.com/role/NetIncomeLossPerShareTables",
     "longName": "9955522 - Disclosure - Net Income (Loss) Per Share (Tables)",
     "shortName": "Net Income (Loss) Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails",
     "longName": "9955523 - Disclosure - Significant Accounting Policies and Concentrations of Risk (Details)",
     "shortName": "Significant Accounting Policies and Concentrations of Risk (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:NumberOfOperatingSegments",
       "span",
       "div",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:RestrictedCashAndCashEquivalentsNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskSummaryofRevenuesDetails",
     "longName": "9955524 - Disclosure - Significant Accounting Policies and Concentrations of Risk - Summary of Revenues (Details)",
     "shortName": "Significant Accounting Policies and Concentrations of Risk - Summary of Revenues (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-80",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleDetails",
     "longName": "9955525 - Disclosure - Assets and Liabilities Held For Sale (Details)",
     "shortName": "Assets and Liabilities Held For Sale (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-94",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R39": {
     "role": "http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleScheduleofAssetsHeldForSaleDetails",
     "longName": "9955526 - Disclosure - Assets and Liabilities Held For Sale - Schedule of Assets Held For Sale (Details)",
     "shortName": "Assets and Liabilities Held For Sale - Schedule of Assets Held For Sale (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-95",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.biocryst.com/role/RevenueDetails",
     "longName": "9955527 - Disclosure - Revenue (Details)",
     "shortName": "Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-96",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.biocryst.com/role/InvestmentsFairValueRecurringBasisDetails",
     "longName": "9955528 - Disclosure - Investments - Fair Value, Recurring Basis (Details)",
     "shortName": "Investments - Fair Value, Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-116",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.biocryst.com/role/InvestmentsNarrativeDetails",
     "longName": "9955529 - Disclosure - Investments - Narrative (Details)",
     "shortName": "Investments - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "unitRef": "security",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "unitRef": "security",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.biocryst.com/role/InvestmentsFairValueoftheCompanysInvestmentsbyTypeDetails",
     "longName": "9955530 - Disclosure - Investments- Fair Value of the Company's Investments by Type (Details)",
     "shortName": "Investments- Fair Value of the Company's Investments by Type (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.biocryst.com/role/InvestmentsScheduleofMaturityofInvestmentsDetails",
     "longName": "9955531 - Disclosure - Investments - Schedule of Maturity of Investments (Details)",
     "shortName": "Investments - Schedule of Maturity of Investments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:HeldToMaturitySecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:HeldToMaturitySecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.biocryst.com/role/TradeReceivablesDetailsTextual",
     "longName": "9955532 - Disclosure - Trade Receivables (Details Textual)",
     "shortName": "Trade Receivables (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-95",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-130",
      "name": "us-gaap:ReceivablesNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.biocryst.com/role/InventorySummaryofInventoriesDetails",
     "longName": "9955533 - Disclosure - Inventory - Summary of Inventories (Details)",
     "shortName": "Inventory - Summary of Inventories (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.biocryst.com/role/InventoryDetails",
     "longName": "9955534 - Disclosure - Inventory (Details)",
     "shortName": "Inventory (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-95",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-95",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.biocryst.com/role/RoyaltyFinancingObligationsDetailsTextual",
     "longName": "9955535 - Disclosure - Royalty Financing Obligations (Details Textual)",
     "shortName": "Royalty Financing Obligations (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "bcrx:InterestPaidRoyaltyFinancingLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-7",
      "name": "bcrx:InterestPaidRoyaltyFinancingLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.biocryst.com/role/RoyaltyFinancingObligationsScheduleofRoyaltyFinancingObligationsDetails",
     "longName": "9955536 - Disclosure - Royalty Financing Obligations - Schedule of Royalty Financing Obligations (Details)",
     "shortName": "Royalty Financing Obligations - Schedule of Royalty Financing Obligations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-35",
      "name": "bcrx:RoyaltyFinancingLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bcrx:RoyaltyFinancingLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-27",
      "name": "bcrx:NonCashInterestExpenseOnRoyaltyFinancingLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bcrx:RoyaltyFinancingLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.biocryst.com/role/DebtDetails",
     "longName": "9955537 - Disclosure - Debt (Details)",
     "shortName": "Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PaymentsOfDebtExtinguishmentCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-187",
      "name": "bcrx:DebtInstrumentCapitalizedInterestRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.biocryst.com/role/LeaseObligationsDetailsTextual",
     "longName": "9955538 - Disclosure - Lease Obligations (Details Textual)",
     "shortName": "Lease Obligations (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "bcrx:OperatingLeaseRightOfUseAssetAccumulatedAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "bcrx:OperatingLeaseRightOfUseAssetAccumulatedAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.biocryst.com/role/LeaseObligationsAggregateLeaseExpenseUnderOperatingLeasesDetails",
     "longName": "9955539 - Disclosure - Lease Obligations - Aggregate Lease Expense Under Operating Leases (Details)",
     "shortName": "Lease Obligations - Aggregate Lease Expense Under Operating Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.biocryst.com/role/LeaseObligationsOtherSupplementalInformationRelatedtoLeasesDetails",
     "longName": "9955540 - Disclosure - Lease Obligations - Other Supplemental Information Related to Leases (Details)",
     "shortName": "Lease Obligations - Other Supplemental Information Related to Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bcrx:OtherSupplementalInformationRelatedToLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bcrx:OtherSupplementalInformationRelatedToLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.biocryst.com/role/LeaseObligationsBalanceSheetsoftheCompanysOperatingLeasesDetails",
     "longName": "9955541 - Disclosure - Lease Obligations - Balance Sheets of the Company's Operating Leases (Details)",
     "shortName": "Lease Obligations - Balance Sheets of the Company's Operating Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bcrx:LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bcrx:LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.biocryst.com/role/LeaseObligationsBalanceSheetsoftheCompanysFinanceLeasesDetails",
     "longName": "9955542 - Disclosure - Lease Obligations - Balance Sheets of the Company's Finance Leases (Details)",
     "shortName": "Lease Obligations - Balance Sheets of the Company's Finance Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:FinanceLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bcrx:LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:FinanceLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bcrx:LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.biocryst.com/role/LeaseObligationsMaturitiesofLeaseLiabilitiesDetails",
     "longName": "9955543 - Disclosure - Lease Obligations - Maturities of Lease Liabilities (Details)",
     "shortName": "Lease Obligations - Maturities of Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.biocryst.com/role/LeaseObligationsSupplementalCashFlowsDetails",
     "longName": "9955544 - Disclosure - Lease Obligations - Supplemental Cash Flows (Details)",
     "shortName": "Lease Obligations - Supplemental Cash Flows (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FinanceLeaseInterestPaymentOnLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FinanceLeaseInterestPaymentOnLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.biocryst.com/role/StockholdersEquitySharesReservedforFutureIssuanceDetails",
     "longName": "9955545 - Disclosure - Stockholders' Equity - Shares Reserved for Future Issuance (Details)",
     "shortName": "Stockholders' Equity - Shares Reserved for Future Issuance (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual",
     "longName": "9955546 - Disclosure - Stock-based Compensation (Details Textual)",
     "shortName": "Stock-based Compensation (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "bcrx:ShareBasedPaymentArrangementNumberOfPlans",
      "unitRef": "plan",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "bcrx:ShareBasedPaymentArrangementNumberOfPlans",
      "unitRef": "plan",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.biocryst.com/role/StockbasedCompensationShareBasedCompensationDetails",
     "longName": "9955547 - Disclosure - Stock-based Compensation - Share-Based Compensation (Details)",
     "shortName": "Stock-based Compensation - Share-Based Compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.biocryst.com/role/StockbasedCompensationOptionActivityDetails",
     "longName": "9955548 - Disclosure - Stock-based Compensation - Option Activity (Details)",
     "shortName": "Stock-based Compensation - Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-229",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-229",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.biocryst.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails",
     "longName": "9955549 - Disclosure - Stock-based Compensation - Restricted Stock Unit Activity (Details)",
     "shortName": "Stock-based Compensation - Restricted Stock Unit Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-232",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-232",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.biocryst.com/role/StockbasedCompensationWeightedAverageAssumptionsforStockOptionAwardsGrantedtoEmployeesandDirectorsUnderthePlansDetails",
     "longName": "9955550 - Disclosure - Stock-based Compensation - Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors Under the Plans (Details)",
     "shortName": "Stock-based Compensation - Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors Under the Plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-219",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-219",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails",
     "longName": "9955551 - Disclosure - Collaborative and Other Relationships (Details)",
     "shortName": "Collaborative and Other Relationships (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-243",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.biocryst.com/role/SegmentInformationDetails",
     "longName": "9955552 - Disclosure - Segment Information (Details)",
     "shortName": "Segment Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:NumberOfOperatingSegments",
       "span",
       "div",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "bcrx:CashCashEquivalentsShortAndLongTermInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.biocryst.com/role/SegmentInformationSegmentReportingInformationbySegmentDetails",
     "longName": "9955553 - Disclosure - Segment Information - Segment Reporting Information by Segment (Details)",
     "shortName": "Segment Information - Segment Reporting Information by Segment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-259",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.biocryst.com/role/NetIncomeLossPerShareScheduleofEarningsPerShareDetails",
     "longName": "9955554 - Disclosure - Net Income (Loss) Per Share - Schedule of Earnings Per Share (Details)",
     "shortName": "Net Income (Loss) Per Share - Schedule of Earnings Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.biocryst.com/role/NetIncomeLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails",
     "longName": "9955555 - Disclosure - Net Income (Loss) Per Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "shortName": "Net Income (Loss) Per Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-295",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.biocryst.com/role/SubsequentEventDetails",
     "longName": "9955556 - Disclosure - Subsequent Event (Details)",
     "shortName": "Subsequent Event (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PaymentsOfDebtExtinguishmentCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-300",
      "name": "bcrx:CommonStockConversionRatio",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcrx-20250930.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "bcrx_A.MachelleSandersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "A.MachelleSandersMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "A. Machelle Sanders [Member]",
        "documentation": "A. Machelle Sanders"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "presentation": [
      "http://www.biocryst.com/role/TradeReceivablesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r286",
      "r1151"
     ]
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "presentation": [
      "http://www.biocryst.com/role/TradeReceivablesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivable Type [Axis]",
        "label": "Receivable Type [Axis]",
        "documentation": "Information by type of receivable."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r77"
     ]
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis",
     "presentation": [
      "http://www.biocryst.com/role/TradeReceivablesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Entity of Counterparty, Type [Axis]",
        "label": "Legal Entity of Counterparty, Type [Axis]",
        "documentation": "Information by legal entity of counterparty. A counterparty is the other party that participates in a financial transaction."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r77"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r937"
     ]
    },
    "us-gaap_AccountsReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableNet",
     "crdr": "debit",
     "presentation": [
      "http://www.biocryst.com/role/TradeReceivablesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable, after allowance for credit loss, total",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business."
       }
      }
     },
     "auth_ref": [
      "r801",
      "r854",
      "r950",
      "r1286",
      "r1287"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade receivables",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1149"
     ]
    },
    "bcrx_AccruedExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "AccruedExpensesPolicyTextBlock",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Expenses",
        "label": "Accrued Expenses [Policy Text Block]",
        "documentation": "Represents accrued expenses policy."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive income",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r81",
      "r175",
      "r728",
      "r767",
      "r768",
      "r1254"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r12",
      "r20",
      "r603",
      "r606",
      "r671",
      "r763",
      "r764",
      "r1074",
      "r1075",
      "r1076",
      "r1132",
      "r1133",
      "r1134",
      "r1135"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r994"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r937",
      "r1318"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r781",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1255",
      "r1321"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Shares withheld for taxes for vesting of restricted stock units",
        "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1233"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdvanceRoyaltiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdvanceRoyaltiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Advance Royalties [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_AfterFourthAnniversaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "AfterFourthAnniversaryMember",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "After Fourth Anniversary",
        "label": "After Fourth Anniversary [Member]",
        "documentation": "Represents after the fourth anniversary."
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_AfterThirdAnniversaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "AfterThirdAnniversaryMember",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "After Third Anniversary",
        "label": "After Third Anniversary [Member]",
        "documentation": "After Third Anniversary"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1040"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r966",
      "r976",
      "r986",
      "r1018"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r969",
      "r979",
      "r989",
      "r1021"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1041"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r1014"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r970",
      "r980",
      "r990",
      "r1014",
      "r1022",
      "r1026",
      "r1034"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r1032"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total stock-based compensation costs included in operating expenses",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r504",
      "r510",
      "r519"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.biocryst.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmortizationOfFinancingCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of debt issuance costs",
        "label": "Amortization of Debt Issuance Costs",
        "documentation": "Amount of amortization expense attributable to debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r409",
      "r1123",
      "r1269"
     ]
    },
    "bcrx_AmortizationOfPremiumDiscountOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "AmortizationOfPremiumDiscountOnInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of discount on investments, net",
        "label": "Amortization Of Premium/Discount On Investments",
        "documentation": "Amount of amortization expense attributable to the discount and premium on investments."
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_AnnualNetSalesBetween150000And230000Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "AnnualNetSalesBetween150000And230000Member",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyFinancingObligationsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual Net Sales Between $150,000 and $230,000",
        "label": "Annual Net Sales Between $150,000 and $230,000 [Member]",
        "documentation": "Represents annual net sales between $150,000 and $230,000."
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_AnnualNetSalesBetween350000And550000Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "AnnualNetSalesBetween350000And550000Member",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyFinancingObligationsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual Net Sales Between $350,000 and $550,000",
        "label": "Annual Net Sales Between $350,000 and $550,000 [Member]",
        "documentation": "Represents annual net sales between $350,000 and $550,000."
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_AnnualNetSalesGreaterThan15MillionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "AnnualNetSalesGreaterThan15MillionMember",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual Net Sales Greater Than $1.5 Million",
        "label": "Annual Net Sales Greater Than $1.5 Million [Member]",
        "documentation": "Annual Net Sales Greater Than $1.5 Million"
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_AnnualNetSalesOf2MillionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "AnnualNetSalesOf2MillionMember",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual Net Sales Of $2 Million",
        "label": "Annual Net Sales Of $2 Million [Member]",
        "documentation": "Annual Net Sales Of $2 Million"
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_AnnualNetSalesOver230000Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "AnnualNetSalesOver230000Member",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyFinancingObligationsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual Net Sales Over $230,000",
        "label": "Annual Net Sales Over $230,000 [Member]",
        "documentation": "Represents annual net sales over $230,000."
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_AnnualNetSalesOver550000Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "AnnualNetSalesOver550000Member",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyFinancingObligationsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual Net Sales Over $550,000",
        "label": "Annual Net Sales Over $550,000 [Member]",
        "documentation": "Represents annual net sales over $550,000."
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_AnnualNetSalesRangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "AnnualNetSalesRangeAxis",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails",
      "http://www.biocryst.com/role/RoyaltyFinancingObligationsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual Net Sales Range [Axis]",
        "label": "Annual Net Sales Range [Axis]",
        "documentation": "Annual Net Sales Range"
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_AnnualNetSalesRangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "AnnualNetSalesRangeDomain",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails",
      "http://www.biocryst.com/role/RoyaltyFinancingObligationsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual Net Sales Range [Domain]",
        "label": "Annual Net Sales Range [Domain]",
        "documentation": "Annual Net Sales Range"
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_AnnualNetSalesUnder150000Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "AnnualNetSalesUnder150000Member",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyFinancingObligationsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual Net Sales Under $150,000",
        "label": "Annual Net Sales Under $150,000 [Member]",
        "documentation": "Represents annual net sales under $150,000."
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_AnnualNetSalesUnder350000Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "AnnualNetSalesUnder350000Member",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyFinancingObligationsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual Net Sales Under $350,000",
        "label": "Annual Net Sales Under $350,000 [Member]",
        "documentation": "Represents annual net sales under $350,000."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.biocryst.com/role/NetIncomeLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails",
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share, amount (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r240"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleDetails",
      "http://www.biocryst.com/role/NetIncomeLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails",
      "http://www.biocryst.com/role/StockholdersEquitySharesReservedforFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r240"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.biocryst.com/role/NetIncomeLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r240"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleDetails",
      "http://www.biocryst.com/role/NetIncomeLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails",
      "http://www.biocryst.com/role/StockholdersEquitySharesReservedforFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r240"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r125",
      "r173",
      "r205",
      "r207",
      "r208",
      "r245",
      "r256",
      "r274",
      "r278",
      "r323",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r597",
      "r599",
      "r633",
      "r714",
      "r715",
      "r725",
      "r806",
      "r884",
      "r885",
      "r900",
      "r937",
      "r944",
      "r945",
      "r957",
      "r1201",
      "r1202",
      "r1275"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleScheduleofAssetsHeldForSaleDetails",
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r178",
      "r205",
      "r207",
      "r208",
      "r323",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r597",
      "r599",
      "r633",
      "r937",
      "r1201",
      "r1202",
      "r1275"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleScheduleofAssetsHeldForSaleDetails",
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_AssetsHeldForSalePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "AssetsHeldForSalePolicyTextBlock",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets Held For Sale",
        "label": "Assets Held For Sale [Policy Text Block]",
        "documentation": "Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation",
     "crdr": "debit",
     "calculation": {
      "http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleScheduleofAssetsHeldForSaleDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleScheduleofAssetsHeldForSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets held for sale",
        "label": "Disposal Group, Including Discontinued Operation, Assets",
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r47",
      "r53",
      "r101",
      "r165",
      "r166"
     ]
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleScheduleofAssetsHeldForSaleDetails": {
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleScheduleofAssetsHeldForSaleDetails",
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets held for sale",
        "totalLabel": "Current assets held for sale",
        "label": "Disposal Group, Including Discontinued Operation, Assets, Current",
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r47",
      "r53",
      "r99",
      "r101",
      "r165",
      "r166"
     ]
    },
    "bcrx_AstriaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "AstriaMember",
     "presentation": [
      "http://www.biocryst.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Astria",
        "label": "Astria [Member]",
        "documentation": "Astria"
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_AthyriumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "AthyriumMember",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Athyrium",
        "label": "Athyrium [Member]",
        "documentation": "Represents Athyrium Opportunities III Co-Invest 1 LP (\u201cAthyrium\u201d)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://www.biocryst.com/role/InvestmentsFairValueoftheCompanysInvestmentsbyTypeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Unrealized Gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r296"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://www.biocryst.com/role/InvestmentsFairValueoftheCompanysInvestmentsbyTypeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gross Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r297"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.biocryst.com/role/InvestmentsScheduleofMaturityofInvestmentsDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/InvestmentsScheduleofMaturityofInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturing in one year or less",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r721"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.biocryst.com/role/InvestmentsScheduleofMaturityofInvestmentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/InvestmentsFairValueRecurringBasisDetails",
      "http://www.biocryst.com/role/InvestmentsFairValueoftheCompanysInvestmentsbyTypeDetails",
      "http://www.biocryst.com/role/InvestmentsScheduleofMaturityofInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated Fair Value",
        "totalLabel": "Estimated Fair Value",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r294",
      "r331",
      "r618",
      "r627",
      "r628",
      "r629",
      "r630",
      "r711",
      "r860",
      "r925",
      "r927",
      "r934",
      "r1152",
      "r1259",
      "r1260",
      "r1261"
     ]
    },
    "bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "AverageMaturityPeriodOfHighQualityMarketableSecurities",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average maturity period of high quality marketable securities (in months)",
        "label": "Average Maturity Period Of High Quality Marketable Securities",
        "documentation": "Average maturity period of high quality marketable securities."
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_AvoralstatMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "AvoralstatMember",
     "presentation": [
      "http://www.biocryst.com/role/SegmentInformationSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Avoralstat",
        "label": "Avoralstat [Member]",
        "documentation": "Avoralstat"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r1029"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r1030"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1025"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1025"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1025"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1025"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1025"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1025"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual",
      "http://www.biocryst.com/role/StockbasedCompensationOptionActivityDetails",
      "http://www.biocryst.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails",
      "http://www.biocryst.com/role/StockholdersEquitySharesReservedforFutureIssuanceDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r474",
      "r475",
      "r476",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r1028"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1027"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r1026"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1026"
     ]
    },
    "bcrx_BCX17725Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "BCX17725Member",
     "presentation": [
      "http://www.biocryst.com/role/SegmentInformationSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BCX17725",
        "label": "BCX17725 [Member]",
        "documentation": "BCX17725"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r1125"
     ]
    },
    "bcrx_BerotralstatMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "BerotralstatMember",
     "presentation": [
      "http://www.biocryst.com/role/SegmentInformationSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Berotralstat",
        "label": "Berotralstat [Member]",
        "documentation": "Berotralstat"
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_BetweenTheSecondAndThirdAnniversariesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "BetweenTheSecondAndThirdAnniversariesMember",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Between the Second and Third Anniversaries",
        "label": "Between the Second and Third Anniversaries [Member]",
        "documentation": "Represents between the second and third anniversaries."
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_BioCrystIrelandMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "BioCrystIrelandMember",
     "presentation": [
      "http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleDetails",
      "http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleScheduleofAssetsHeldForSaleDetails",
      "http://www.biocryst.com/role/InventoryDetails",
      "http://www.biocryst.com/role/SegmentInformationDetails",
      "http://www.biocryst.com/role/SubsequentEventDetails",
      "http://www.biocryst.com/role/TradeReceivablesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BioCryst Ireland",
        "label": "BioCryst Ireland [Member]",
        "documentation": "BioCryst Ireland"
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_BlackstoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "BlackstoneMember",
     "presentation": [
      "http://www.biocryst.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Blackstone",
        "label": "Blackstone [Member]",
        "documentation": "Blackstone"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.biocryst.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination [Domain]",
        "label": "Business Combination [Domain]",
        "documentation": "Business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r770",
      "r915",
      "r916",
      "r1238",
      "r1241",
      "r1242"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.biocryst.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination [Axis]",
        "label": "Business Combination [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r770",
      "r915",
      "r916",
      "r1238",
      "r1241",
      "r1242"
     ]
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionSharePrice",
     "presentation": [
      "http://www.biocryst.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Price per share (in usd per share)",
        "label": "Business Combination, Price Per Share",
        "documentation": "Per share price of saleable stock paid or offered to be paid by acquirer in business combination."
       }
      }
     },
     "auth_ref": [
      "r923",
      "r1239",
      "r1240",
      "r1243",
      "r1244"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentContinuingOperationExcludingAssetsHeldForSale",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalent",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r170",
      "r862"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Cash",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r112"
     ]
    },
    "bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentContinuingOperationExcludingAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentContinuingOperationExcludingAssetsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "totalLabel": "Total cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation, Excluding Assets Held For Sale",
        "documentation": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation, Excluding Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperationsExcludingAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperationsExcludingAssetsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net decrease in cash, and cash equivalents, and restricted cash",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect, Continuing Operations, Excluding Assets Held For Sale",
        "documentation": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect, Continuing Operations, Excluding Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperationsLessAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperationsLessAssetsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: cash and cash equivalents classified within current assets held for sale",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect, Continuing Operations, Less Assets Held For Sale",
        "documentation": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect, Continuing Operations, Less Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r91",
      "r202"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation [Abstract]",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net decrease in cash, and cash equivalents, and restricted cash",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect, Continuing Operation",
        "documentation": "Amount of increase (decrease) in cash, cash equivalent, and cash and cash equivalent restricted to withdrawal or usage, including effect from exchange rate change; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r1122",
      "r1267"
     ]
    },
    "bcrx_CashCashEquivalentsShortAndLongTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "CashCashEquivalentsShortAndLongTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.biocryst.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, cash equivalents, and investments",
        "label": "Cash, Cash Equivalents, Short and Long-Term Investments",
        "documentation": "Cash, Cash Equivalents, Short and Long-Term Investments"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1005"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1002"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r1000"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.biocryst.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_ClearsideBiomedicalIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "ClearsideBiomedicalIncMember",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clearside Biomedical, Inc.",
        "label": "Clearside Biomedical, Inc. [Member]",
        "documentation": "Clearside Biomedical, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r1006"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1006"
     ]
    },
    "bcrx_CollaborativeAgreementContractValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "CollaborativeAgreementContractValue",
     "crdr": "debit",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract value",
        "label": "Collaborative Agreement Contract Value",
        "documentation": "Collaborative Agreement Contract Value"
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_CollaborativeAndOtherResearchAndDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "CollaborativeAndOtherResearchAndDevelopmentMember",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskSummaryofRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative and other revenues",
        "label": "Collaborative and Other Research and Development [Member]",
        "documentation": "Information pertaining to Collaborative and other research and development."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationships"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative and Other Relationships",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r595",
      "r596"
     ]
    },
    "bcrx_CollateralForCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "CollateralForCreditMember",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collateral for Credit",
        "label": "Collateral for Credit [Member]",
        "documentation": "Restricted cash and cash equivalents required to maintain as collateral for a letter of credit."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.biocryst.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r370",
      "r371",
      "r856",
      "r1191",
      "r1196"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.biocryst.com/role/StockholdersEquitySharesReservedforFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total shares reserved for future issuance",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "bcrx_CommonStockConversionRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "CommonStockConversionRatio",
     "presentation": [
      "http://www.biocryst.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion ratio",
        "label": "Common Stock, Conversion Ratio",
        "documentation": "Common Stock, Conversion Ratio"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r947",
      "r948",
      "r949",
      "r951",
      "r952",
      "r953",
      "r954",
      "r1132",
      "r1133",
      "r1135",
      "r1255",
      "r1317",
      "r1321"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock par value (in usd per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r793"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares, issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares, outstanding (in shares)",
        "periodStartLabel": "Common stock, shares outstanding, beginning balance (in shares)",
        "periodEndLabel": "Common stock, shares outstanding, ending balance (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r70",
      "r793",
      "r812",
      "r1321",
      "r1322"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.01 par value; shares authorized - 450,000; shares issued and outstanding \u2013 210,522 at September\u00a030, 2025 and 208,543 at December\u00a031, 2024",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r420",
      "r426",
      "r727",
      "r937"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1011"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1010"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1012"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "bcrx_CompensationAndRelatedPersonnelCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "CompensationAndRelatedPersonnelCostsMember",
     "presentation": [
      "http://www.biocryst.com/role/SegmentInformationSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation and related personnel costs",
        "label": "Compensation And Related Personnel Costs [Member]",
        "documentation": "Compensation And Related Personnel Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net comprehensive income (loss)",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r184",
      "r186",
      "r191",
      "r712",
      "r737",
      "r738"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer Equipment",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_ConcentrationOfMarketRiskPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "ConcentrationOfMarketRiskPolicyTextBlock",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Customers and Other Risks",
        "label": "Concentration of Market Risk [Policy Text Block]",
        "documentation": "Represents concentration of market risk policy."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Domain]",
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r284",
      "r771",
      "r772",
      "r855",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Axis]",
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r284",
      "r771",
      "r772",
      "r855",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Axis]",
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r284",
      "r771",
      "r772",
      "r855",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue percentage",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r284",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Domain]",
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r284",
      "r771",
      "r772",
      "r855",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143"
     ]
    },
    "bcrx_ContractTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "ContractTerm",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract term",
        "label": "Contract Term",
        "documentation": "Contract Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.biocryst.com/role/SegmentInformationSegmentReportingInformationbySegmentDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.biocryst.com/role/SegmentInformationSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of product sales",
        "label": "Cost of Product and Service Sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r84",
      "r710",
      "r868",
      "r872",
      "r924",
      "r1116"
     ]
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostOfSalesPolicyTextBlock",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of Product Sales",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered."
       }
      }
     },
     "auth_ref": [
      "r1050"
     ]
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Costs and Expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostsAndExpensesAbstract",
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expenses:",
        "label": "Costs and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails",
      "http://www.biocryst.com/role/RoyaltyFinancingObligationsDetailsTextual",
      "http://www.biocryst.com/role/RoyaltyFinancingObligationsScheduleofRoyaltyFinancingObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r205",
      "r210",
      "r211",
      "r391",
      "r431",
      "r672",
      "r692",
      "r724",
      "r864",
      "r865",
      "r866",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1250",
      "r1251",
      "r1252",
      "r1253"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails",
      "http://www.biocryst.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Axis]",
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r377",
      "r1199"
     ]
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails",
      "http://www.biocryst.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Domain]",
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r377",
      "r1199"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.biocryst.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_DebtCovenantTermsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "DebtCovenantTermsAxis",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Covenant Terms [Axis]",
        "label": "Debt Covenant Terms [Axis]",
        "documentation": "Debt Covenant Terms"
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_DebtCovenantTermsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "DebtCovenantTermsDomain",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Covenant Terms [Domain]",
        "label": "Debt Covenant Terms [Domain]",
        "documentation": "Debt Covenant Terms"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.biocryst.com/role/Debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r205",
      "r206",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r376",
      "r377",
      "r387",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r403",
      "r410",
      "r411",
      "r413",
      "r601",
      "r649"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r60",
      "r61",
      "r114",
      "r115",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r394",
      "r399",
      "r400",
      "r401",
      "r402",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r935",
      "r1126",
      "r1127",
      "r1128",
      "r1131",
      "r1192",
      "r1193",
      "r1194",
      "r1268",
      "r1270",
      "r1284"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, basis spread on variable rate",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_DebtInstrumentCapitalizedInterestRate": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "DebtInstrumentCapitalizedInterestRate",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument capitalized interest rate",
        "label": "Debt Instrument Capitalized Interest Rate",
        "documentation": "Debt Instrument Capitalized Interest Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails",
      "http://www.biocryst.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, face amount",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r388",
      "r649",
      "r650",
      "r896",
      "r897",
      "r935"
     ]
    },
    "us-gaap_DebtInstrumentFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value",
        "label": "Debt Instrument, Fair Value Disclosure",
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r628",
      "r629",
      "r630",
      "r631",
      "r896",
      "r897",
      "r1258",
      "r1259",
      "r1260",
      "r1261",
      "r1262"
     ]
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentFeeAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt fees",
        "label": "Debt Instrument, Fee Amount",
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails",
      "http://www.biocryst.com/role/RoyaltyFinancingObligationsScheduleofRoyaltyFinancingObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective interest rate",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r415",
      "r649",
      "r650",
      "r935"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r394",
      "r399",
      "r400",
      "r401",
      "r402",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r412",
      "r601",
      "r718",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r935",
      "r1126",
      "r1127",
      "r1128",
      "r1131",
      "r1268",
      "r1270"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r394",
      "r399",
      "r400",
      "r401",
      "r402",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r935",
      "r1126",
      "r1127",
      "r1128",
      "r1131",
      "r1192",
      "r1193",
      "r1194",
      "r1268",
      "r1270",
      "r1284"
     ]
    },
    "us-gaap_DebtInstrumentPeriodicPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentPeriodicPayment",
     "crdr": "debit",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, periodic payment",
        "label": "Debt Instrument, Periodic Payment",
        "documentation": "Amount of the required periodic payments including both interest and principal payments."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r45"
     ]
    },
    "us-gaap_DebtInstrumentPeriodicPaymentInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentPeriodicPaymentInterest",
     "crdr": "debit",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Periodic payment, interest",
        "label": "Debt Instrument, Periodic Payment, Interest",
        "documentation": "Amount of the required periodic payments applied to interest."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, prepayment fee, percentage of principal voluntary payments",
        "label": "Debt Instrument Prepayment Fee Percentage of Principal Voluntary Payments",
        "documentation": "The percentage of principal paid voluntarily for prepayment fee of the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_DebtInstrumentPrepaymentPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "DebtInstrumentPrepaymentPremium",
     "crdr": "credit",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails",
      "http://www.biocryst.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayment premium",
        "label": "Debt Instrument, Prepayment Premium",
        "documentation": "Debt Instrument, Prepayment Premium"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Debt, Type [Axis]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r39",
      "r42",
      "r44",
      "r106",
      "r107",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r394",
      "r399",
      "r400",
      "r401",
      "r402",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r412",
      "r601",
      "r718",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r935",
      "r1126",
      "r1127",
      "r1128",
      "r1131",
      "r1268",
      "r1270"
     ]
    },
    "us-gaap_DebtInstrumentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentTerm",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, term",
        "label": "Debt Instrument, Term",
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, unamortized discount (premium) and debt issuance costs, net, total",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r414",
      "r648",
      "r649",
      "r650",
      "r896",
      "r897",
      "r935"
     ]
    },
    "bcrx_DebtInstrumentVariableRateFloor": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "DebtInstrumentVariableRateFloor",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, SOFR floor",
        "label": "Debt Instrument, Variable Rate floor",
        "documentation": "Debt Instrument, Variable Rate floor"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.biocryst.com/role/InvestmentsFairValueoftheCompanysInvestmentsbyTypeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Interest",
        "label": "Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss",
        "documentation": "Amount, after allowance for credit loss, of accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r299",
      "r331",
      "r332",
      "r333"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.biocryst.com/role/InvestmentsFairValueoftheCompanysInvestmentsbyTypeDetails",
      "http://www.biocryst.com/role/InvestmentsScheduleofMaturityofInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Statement of Financial Position [Extensible Enumeration]",
        "label": "Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes accrued interest, after allowance for credit loss, on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.biocryst.com/role/InvestmentsFairValueoftheCompanysInvestmentsbyTypeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss",
        "documentation": "Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r1188"
     ]
    },
    "bcrx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterOneYearAndBeforeTwoYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterOneYearAndBeforeTwoYears",
     "crdr": "debit",
     "calculation": {
      "http://www.biocryst.com/role/InvestmentsScheduleofMaturityofInvestmentsDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/InvestmentsScheduleofMaturityofInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturing after one year through two years",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date After One Year and Before Two Years",
        "documentation": "Amount of investment in debt securities maturing after one year through two years."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://www.biocryst.com/role/InvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of the Company's Investments by Type",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164",
      "r1183"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "crdr": "debit",
     "presentation": [
      "http://www.biocryst.com/role/InvestmentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of securities",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r335",
      "r893"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "presentation": [
      "http://www.biocryst.com/role/InvestmentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of securities",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions",
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r336"
     ]
    },
    "bcrx_DeferredDebtPrepaymentAndDebtIssuanceCostsWriteoff": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "DeferredDebtPrepaymentAndDebtIssuanceCostsWriteoff",
     "crdr": "debit",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayment and debt issuance costs writeoff",
        "label": "Deferred Debt, Prepayment And Debt Issuance Costs, Writeoff",
        "documentation": "Deferred Debt, Prepayment And Debt Issuance Costs, Writeoff"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r194",
      "r245",
      "r261",
      "r278",
      "r867",
      "r884",
      "r885"
     ]
    },
    "bcrx_DescriptionOfCompanyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "DescriptionOfCompanyPolicyTextBlock",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "The Company",
        "label": "Description of Company [Policy Text Block]",
        "documentation": "The description of company policy."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DilutiveSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DilutiveSecuritiesAbstract",
     "presentation": [
      "http://www.biocryst.com/role/NetIncomeLossPerShareScheduleofEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of dilutive securities:",
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.biocryst.com/role/RevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Line Items]",
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r453",
      "r454",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.biocryst.com/role/RevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Table]",
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r453",
      "r454",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://www.biocryst.com/role/RevenueTables",
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Revenues",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r1204"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r468",
      "r473",
      "r506",
      "r507",
      "r508",
      "r918"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award",
        "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]",
        "documentation": "Tabular disclosure of share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1205"
     ]
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupClassificationAxis",
     "presentation": [
      "http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleDetails",
      "http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleScheduleofAssetsHeldForSaleDetails",
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.biocryst.com/role/InventoryDetails",
      "http://www.biocryst.com/role/SegmentInformationDetails",
      "http://www.biocryst.com/role/SubsequentEventDetails",
      "http://www.biocryst.com/role/TradeReceivablesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Classification [Axis]",
        "label": "Disposal Group Classification [Axis]",
        "documentation": "Information by disposal group classification."
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupClassificationDomain",
     "presentation": [
      "http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleDetails",
      "http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleScheduleofAssetsHeldForSaleDetails",
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.biocryst.com/role/InventoryDetails",
      "http://www.biocryst.com/role/SegmentInformationDetails",
      "http://www.biocryst.com/role/SubsequentEventDetails",
      "http://www.biocryst.com/role/TradeReceivablesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Classification [Domain]",
        "label": "Disposal Group Classification [Domain]",
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupHeldforsaleNotDiscontinuedOperationsMember",
     "presentation": [
      "http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleDetails",
      "http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleScheduleofAssetsHeldForSaleDetails",
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.biocryst.com/role/InventoryDetails",
      "http://www.biocryst.com/role/SegmentInformationDetails",
      "http://www.biocryst.com/role/SubsequentEventDetails",
      "http://www.biocryst.com/role/TradeReceivablesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group, Held-for-Sale, Not Discontinued Operations",
        "label": "Disposal Group, Held-for-Sale, Not Discontinued Operations [Member]",
        "documentation": "Disposal group that is classified as held-for-sale. Excludes disposals classified as discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r15",
      "r165"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet",
     "crdr": "debit",
     "calculation": {
      "http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleScheduleofAssetsHeldForSaleDetails": {
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleScheduleofAssetsHeldForSaleDetails",
      "http://www.biocryst.com/role/TradeReceivablesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade receivables",
        "label": "Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net",
        "documentation": "Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r47",
      "r53",
      "r101"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleScheduleofAssetsHeldForSaleDetails": {
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleScheduleofAssetsHeldForSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Disposal Group, Including Discontinued Operation, Accounts Payable, Current",
        "documentation": "Amount classified as accounts payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r47",
      "r53",
      "r99",
      "r101"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleScheduleofAssetsHeldForSaleDetails": {
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleScheduleofAssetsHeldForSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Disposal Group, Including Discontinued Operation, Accrued Liabilities, Current",
        "documentation": "Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r47",
      "r53",
      "r99",
      "r101"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleScheduleofAssetsHeldForSaleDetails": {
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleScheduleofAssetsHeldForSaleDetails",
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current assets held for sale",
        "label": "Disposal Group, Including Discontinued Operation, Assets, Noncurrent",
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r2",
      "r47",
      "r53",
      "r101",
      "r165",
      "r166"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleScheduleofAssetsHeldForSaleDetails": {
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleScheduleofAssetsHeldForSaleDetails",
      "http://www.biocryst.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents",
        "documentation": "Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r47",
      "r53",
      "r101"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration",
     "crdr": "debit",
     "presentation": [
      "http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleDetails",
      "http://www.biocryst.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront consideration to be received",
        "label": "Disposal Group, Including Discontinued Operation, Consideration",
        "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation."
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_DisposalGroupIncludingDiscontinuedOperationConsiderationRoyaltyReleaseFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsiderationRoyaltyReleaseFee",
     "crdr": "credit",
     "presentation": [
      "http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleDetails",
      "http://www.biocryst.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty release fee",
        "label": "Disposal Group, Including Discontinued Operation, Consideration, Royalty Release Fee",
        "documentation": "Disposal Group, Including Discontinued Operation, Consideration, Royalty Release Fee"
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_DisposalGroupIncludingDiscontinuedOperationContingentConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "DisposalGroupIncludingDiscontinuedOperationContingentConsideration",
     "crdr": "debit",
     "presentation": [
      "http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleDetails",
      "http://www.biocryst.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration to be received",
        "label": "Disposal Group, Including Discontinued Operation, Contingent Consideration",
        "documentation": "Disposal Group, Including Discontinued Operation, Contingent Consideration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupIncludingDiscontinuedOperationInventoryCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleScheduleofAssetsHeldForSaleDetails": {
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleScheduleofAssetsHeldForSaleDetails",
      "http://www.biocryst.com/role/InventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory, net",
        "label": "Disposal Group, Including Discontinued Operation, Inventory, Current",
        "documentation": "Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r47",
      "r53",
      "r99",
      "r101"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupIncludingDiscontinuedOperationInventoryNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.biocryst.com/role/InventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory, net, noncurrent",
        "label": "Disposal Group, Including Discontinued Operation, Inventory, Noncurrent",
        "documentation": "Amount classified as inventory attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r2",
      "r47",
      "r53",
      "r101"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleScheduleofAssetsHeldForSaleDetails": {
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleScheduleofAssetsHeldForSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current liabilities",
        "label": "Disposal Group, Including Discontinued Operation, Other Liabilities, Current",
        "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r47",
      "r53",
      "r99",
      "r101"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleScheduleofAssetsHeldForSaleDetails": {
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleScheduleofAssetsHeldForSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current",
        "documentation": "Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r47",
      "r53",
      "r99",
      "r101"
     ]
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "presentation": [
      "http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSale"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets and Liabilities Held For Sale",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r98"
     ]
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "presentation": [
      "http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleDetails",
      "http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleScheduleofAssetsHeldForSaleDetails",
      "http://www.biocryst.com/role/InventoryDetails",
      "http://www.biocryst.com/role/SegmentInformationDetails",
      "http://www.biocryst.com/role/SubsequentEventDetails",
      "http://www.biocryst.com/role/TradeReceivablesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Name [Domain]",
        "label": "Disposal Group Name [Domain]",
        "documentation": "Name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r361",
      "r362",
      "r915",
      "r916"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.biocryst.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.biocryst.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.biocryst.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.biocryst.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r961"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.biocryst.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r993"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.biocryst.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1004"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.biocryst.com/role/NetIncomeLossPerShareScheduleofEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic net loss per common share (in usd per share)",
        "verboseLabel": "Net income (loss) per common share, basic (in usd per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r192",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r230",
      "r232",
      "r237",
      "r238",
      "r239",
      "r244",
      "r418",
      "r509",
      "r538",
      "r594",
      "r615",
      "r616",
      "r713",
      "r739",
      "r876"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.biocryst.com/role/NetIncomeLossPerShareScheduleofEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted net loss per common share (in usd per share)",
        "verboseLabel": "Net income (loss) per common share, diluted (in usd per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r192",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r232",
      "r237",
      "r238",
      "r239",
      "r244",
      "r418",
      "r509",
      "r538",
      "r594",
      "r615",
      "r616",
      "r713",
      "r739",
      "r876"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Income (Loss) Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r241"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.biocryst.com/role/NetIncomeLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Income (Loss) Per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r240",
      "r242",
      "r243"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows_1": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rates on cash, cash equivalents and restricted cash",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r640"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized stock-based compensation costs",
        "label": "Share-Based Payment Arrangement, Amount Capitalized",
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleDetails",
      "http://www.biocryst.com/role/NetIncomeLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails",
      "http://www.biocryst.com/role/StockbasedCompensationOptionActivityDetails",
      "http://www.biocryst.com/role/StockholdersEquitySharesReservedforFutureIssuanceDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Option",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222",
      "r1223",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1231",
      "r1232"
     ]
    },
    "bcrx_EmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "EmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationShareBasedCompensationDetails",
      "http://www.biocryst.com/role/StockholdersEquitySharesReservedforFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ESPP",
        "label": "Employee Stock Purchase Plan [Member]",
        "documentation": "Employee stock purchase plan, (ESPP)."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.biocryst.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.biocryst.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.biocryst.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.biocryst.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.biocryst.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r959"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.biocryst.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.biocryst.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.biocryst.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r959"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.biocryst.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.biocryst.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r959"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.biocryst.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.biocryst.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1043"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.biocryst.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r959"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.biocryst.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r959"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.biocryst.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r959"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.biocryst.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r959"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r998"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1039"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r1039"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1039"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r159",
      "r160",
      "r161",
      "r188",
      "r189",
      "r190",
      "r212",
      "r213",
      "r214",
      "r216",
      "r223",
      "r225",
      "r227",
      "r246",
      "r324",
      "r325",
      "r359",
      "r417",
      "r443",
      "r509",
      "r532",
      "r533",
      "r535",
      "r536",
      "r537",
      "r539",
      "r593",
      "r594",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r614",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r651",
      "r653",
      "r671",
      "r735",
      "r763",
      "r764",
      "r765",
      "r781",
      "r833"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1008"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r966",
      "r976",
      "r986",
      "r1018"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r963",
      "r973",
      "r983",
      "r1015"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1014"
     ]
    },
    "bcrx_FactorDProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "FactorDProgramMember",
     "presentation": [
      "http://www.biocryst.com/role/SegmentInformationSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Factor D Program",
        "label": "Factor D Program [Member]",
        "documentation": "Factor D Program"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.biocryst.com/role/InvestmentsFairValueRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r617",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r628",
      "r679",
      "r680",
      "r681",
      "r860",
      "r896",
      "r897",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r925",
      "r927",
      "r934"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.biocryst.com/role/InvestmentsFairValueRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Quoted Price in Active Markets (Level 1)",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r457",
      "r462",
      "r463",
      "r619",
      "r624",
      "r628",
      "r679",
      "r860",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r925",
      "r934"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.biocryst.com/role/InvestmentsFairValueRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Other Observable Inputs (Level 2)",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r457",
      "r462",
      "r463",
      "r465",
      "r619",
      "r620",
      "r624",
      "r628",
      "r680",
      "r860",
      "r896",
      "r897",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r925",
      "r934"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.biocryst.com/role/InvestmentsFairValueRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Unobservable Inputs\u00a0(Level\u00a03)",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r619",
      "r620",
      "r621",
      "r622",
      "r624",
      "r628",
      "r681",
      "r860",
      "r896",
      "r897",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r925",
      "r927",
      "r934"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.biocryst.com/role/InvestmentsFairValueRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r617",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r628",
      "r679",
      "r680",
      "r681",
      "r860",
      "r896",
      "r897",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r925",
      "r927",
      "r934"
     ]
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.biocryst.com/role/LeaseObligationsAggregateLeaseExpenseUnderOperatingLeasesDetails": {
       "parentTag": "bcrx_FinancingLeaseExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsAggregateLeaseExpenseUnderOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest on lease liabilities",
        "label": "Finance Lease, Interest Expense",
        "documentation": "Amount of interest expense on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r657",
      "r663",
      "r936"
     ]
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsSupplementalCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating cash flows for finance leases",
        "label": "Finance Lease, Interest Payment on Liability",
        "documentation": "Amount of interest paid on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r659",
      "r664"
     ]
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsMaturitiesofLeaseLiabilitiesDetails",
      "http://www.biocryst.com/role/LeaseObligationsOtherSupplementalInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]",
        "label": "Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/LeaseObligationsMaturitiesofLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.biocryst.com/role/LeaseObligationsBalanceSheetsoftheCompanysFinanceLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsBalanceSheetsoftheCompanysFinanceLeasesDetails",
      "http://www.biocryst.com/role/LeaseObligationsMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Total",
        "label": "Finance Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r655",
      "r668"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/LeaseObligationsBalanceSheetsoftheCompanysFinanceLeasesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.biocryst.com/role/LeaseObligationsBalanceSheetsoftheCompanysFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease liabilities",
        "label": "Finance Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/LeaseObligationsBalanceSheetsoftheCompanysFinanceLeasesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.biocryst.com/role/LeaseObligationsBalanceSheetsoftheCompanysFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease liabilities",
        "label": "Finance Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/LeaseObligationsMaturitiesofLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.biocryst.com/role/LeaseObligationsMaturitiesofLeaseLiabilitiesDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease payments",
        "label": "Finance Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r668",
      "r1127",
      "r1131",
      "r1284"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/LeaseObligationsMaturitiesofLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r668",
      "r1127",
      "r1131",
      "r1284"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/LeaseObligationsMaturitiesofLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r668",
      "r1127",
      "r1131",
      "r1284"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/LeaseObligationsMaturitiesofLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r668",
      "r1127",
      "r1131",
      "r1284"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/LeaseObligationsMaturitiesofLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r668",
      "r1127",
      "r1131",
      "r1284"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/LeaseObligationsMaturitiesofLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025 (remaining)",
        "label": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r1274"
     ]
    },
    "bcrx_FinanceLeaseLiabilityToBePaidAfterYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "FinanceLeaseLiabilityToBePaidAfterYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/LeaseObligationsMaturitiesofLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Finance Lease, Liability, to be Paid, After Year Four",
        "documentation": "Finance Lease, Liability, to be Paid, After Year Four"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/LeaseObligationsMaturitiesofLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less imputed interest",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r668"
     ]
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Principal payments on finance lease liabilities",
        "label": "Finance Lease, Principal Payments",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r658",
      "r664"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsBalanceSheetsoftheCompanysFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease assets, net",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseRightOfUseAssetAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease, right-of-use asset, accumulated amortization",
        "label": "Finance Lease, Right-of-Use Asset, Accumulated Amortization",
        "documentation": "Amount of accumulated amortization of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r1047",
      "r1049"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.biocryst.com/role/LeaseObligationsAggregateLeaseExpenseUnderOperatingLeasesDetails": {
       "parentTag": "bcrx_FinancingLeaseExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsAggregateLeaseExpenseUnderOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of right-of-use assets",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r657",
      "r663",
      "r936"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsBalanceSheetsoftheCompanysFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsOtherSupplementalInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance leases",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for finance lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r667",
      "r936"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsOtherSupplementalInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining lease term (in years)",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r666",
      "r936"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.biocryst.com/role/InvestmentsFairValueRecurringBasisDetails",
      "http://www.biocryst.com/role/InvestmentsFairValueoftheCompanysInvestmentsbyTypeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r334",
      "r337",
      "r338",
      "r412",
      "r441",
      "r601",
      "r612",
      "r626",
      "r632",
      "r634",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r723",
      "r736",
      "r893",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r938",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1256",
      "r1259",
      "r1260",
      "r1261",
      "r1262",
      "r1263",
      "r1264",
      "r1265"
     ]
    },
    "bcrx_FinancingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "FinancingLeaseExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.biocryst.com/role/LeaseObligationsAggregateLeaseExpenseUnderOperatingLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsAggregateLeaseExpenseUnderOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total finance lease expense",
        "label": "Financing Lease, Expense",
        "documentation": "Financing Lease, Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/SegmentInformationSegmentReportingInformationbySegmentDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/SegmentInformationSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Foreign currency (gains) losses, net",
        "label": "Gain (Loss), Foreign Currency Transaction, before Tax",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r636",
      "r637",
      "r638",
      "r639",
      "r830"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Currency",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r635"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r970",
      "r980",
      "r990",
      "r1022"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r970",
      "r980",
      "r990",
      "r1022"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r970",
      "r980",
      "r990",
      "r1022"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r970",
      "r980",
      "r990",
      "r1022"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r970",
      "r980",
      "r990",
      "r1022"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and Fixtures",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_FutureRoyaltiesPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "FutureRoyaltiesPayableMember",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyFinancingObligationsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future Royalties Payable",
        "label": "Future Royalties Payable [Member]",
        "documentation": "Represents future royalties payable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency gains (losses), net",
        "label": "Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments",
        "documentation": "Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments."
       }
      }
     },
     "auth_ref": [
      "r1248",
      "r1249"
     ]
    },
    "us-gaap_GainLossOnSaleOfOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainLossOnSaleOfOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gain on sale of non-financial asset",
        "label": "Gain (Loss) on Disposition of Other Assets",
        "documentation": "Amount of gain (loss) on sale or disposal of other assets."
       }
      }
     },
     "auth_ref": [
      "r1123"
     ]
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      },
      "http://www.biocryst.com/role/SegmentInformationSegmentReportingInformationbySegmentDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.biocryst.com/role/DebtDetails",
      "http://www.biocryst.com/role/SegmentInformationSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on extinguishment of debt",
        "negatedTerseLabel": "Loss on extinguishment of debt",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r35",
      "r36"
     ]
    },
    "us-gaap_GeographicDistributionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeographicDistributionAxis",
     "presentation": [
      "http://www.biocryst.com/role/RevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographic Distribution [Axis]",
        "label": "Geographic Distribution [Axis]",
        "documentation": "Information by geographic distribution of business activity identified as either domestic or foreign. Excludes names of countries, states and provinces, and cities."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r714",
      "r715",
      "r716",
      "r717",
      "r890",
      "r891",
      "r892"
     ]
    },
    "us-gaap_GeographicDistributionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeographicDistributionDomain",
     "presentation": [
      "http://www.biocryst.com/role/RevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographic Distribution [Domain]",
        "label": "Geographic Distribution [Domain]",
        "documentation": "Allocation of business activity identified as domestic or foreign. Excludes names of countries, states and provinces, and cities."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r714",
      "r715",
      "r716",
      "r717",
      "r891",
      "r892"
     ]
    },
    "us-gaap_GeographicDistributionDomesticMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeographicDistributionDomesticMember",
     "presentation": [
      "http://www.biocryst.com/role/RevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S.",
        "label": "Geographic Distribution, Domestic [Member]",
        "documentation": "Allocation of business activity identified as domestic."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r891"
     ]
    },
    "us-gaap_GeographicDistributionForeignMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeographicDistributionForeignMember",
     "presentation": [
      "http://www.biocryst.com/role/RevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outside of U.S.",
        "label": "Geographic Distribution, Foreign [Member]",
        "documentation": "Allocation of business activity identified as foreign."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r714",
      "r715",
      "r716",
      "r717",
      "r892"
     ]
    },
    "bcrx_HHSOfficeOfTheAdministrationForStrategicPreparednessAndResponseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "HHSOfficeOfTheAdministrationForStrategicPreparednessAndResponseMember",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "HHS Office of the Administration for Strategic Preparedness and Response",
        "label": "HHS Office of the Administration for Strategic Preparedness and Response [Member]",
        "documentation": "HHS Office of the Administration for Strategic Preparedness and Response"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_HeldToMaturitySecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "HeldToMaturitySecuritiesTextBlock",
     "presentation": [
      "http://www.biocryst.com/role/InvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of the Maturity of Investments",
        "label": "Debt Securities, Held-to-Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of information about investment in debt security measured at amortized cost (held-to-maturity)."
       }
      }
     },
     "auth_ref": [
      "r1165",
      "r1166",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182"
     ]
    },
    "bcrx_IncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "IncentivePlanMember",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual",
      "http://www.biocryst.com/role/StockbasedCompensationOptionActivityDetails",
      "http://www.biocryst.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails",
      "http://www.biocryst.com/role/StockbasedCompensationShareBasedCompensationDetails",
      "http://www.biocryst.com/role/StockbasedCompensationWeightedAverageAssumptionsforStockOptionAwardsGrantedtoEmployeesandDirectorsUnderthePlansDetails",
      "http://www.biocryst.com/role/StockholdersEquitySharesReservedforFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incentive Plan",
        "label": "Incentive Plan [Member]",
        "documentation": "Represents Incentive Plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income (loss) before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r119",
      "r124",
      "r714",
      "r716",
      "r733",
      "r869",
      "r871",
      "r872",
      "r879",
      "r884",
      "r1138",
      "r1145",
      "r1146",
      "r1147",
      "r1148"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "presentation": [
      "http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleDetails",
      "http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleScheduleofAssetsHeldForSaleDetails",
      "http://www.biocryst.com/role/InventoryDetails",
      "http://www.biocryst.com/role/SegmentInformationDetails",
      "http://www.biocryst.com/role/SubsequentEventDetails",
      "http://www.biocryst.com/role/TradeReceivablesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Name [Axis]",
        "label": "Disposal Group Name [Axis]",
        "documentation": "Information by name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r361",
      "r362",
      "r915",
      "r916"
     ]
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "presentation": [
      "http://www.biocryst.com/role/InventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r361",
      "r362"
     ]
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "presentation": [
      "http://www.biocryst.com/role/InventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r15",
      "r18",
      "r47",
      "r48",
      "r49",
      "r50",
      "r51",
      "r52",
      "r54",
      "r55",
      "r56",
      "r102",
      "r361",
      "r362"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.biocryst.com/role/SegmentInformationSegmentReportingInformationbySegmentDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.biocryst.com/role/SegmentInformationSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Expense (Benefit)",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r136",
      "r205",
      "r226",
      "r227",
      "r245",
      "r264",
      "r278",
      "r526",
      "r527",
      "r534",
      "r742",
      "r869",
      "r871",
      "r872",
      "r919"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r524",
      "r525",
      "r528",
      "r529",
      "r530",
      "r531",
      "r777"
     ]
    },
    "us-gaap_IncomeTaxesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for taxes",
        "label": "Income Taxes Paid",
        "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r94",
      "r1124",
      "r1236",
      "r1237"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Increase (decrease) in accounts payable and accrued expenses",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Increase in inventory",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "(Increase) decrease in prepaid expenses and other assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInReceivables",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Increase in receivables",
        "label": "Increase (Decrease) in Receivables",
        "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "bcrx_IncreaseDecreaseInRoyaltyFinancingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "IncreaseDecreaseInRoyaltyFinancingLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Decrease in royalty financing obligations",
        "label": "Increase (Decrease) In Royalty Financing Liabilities",
        "documentation": "Increase (Decrease) In Royalty Financing Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_IncrementalCommonSharesAttributableToDilutiveEffectOfSharePurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "IncrementalCommonSharesAttributableToDilutiveEffectOfSharePurchasePlans",
     "calculation": {
      "http://www.biocryst.com/role/NetIncomeLossPerShareScheduleofEarningsPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/NetIncomeLossPerShareScheduleofEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issuable under the employee stock purchase plan",
        "label": "Incremental Common Shares Attributable To Dilutive Effect Of Share Purchase Plans",
        "documentation": "Incremental Common Shares Attributable To Dilutive Effect Of Share Purchase Plans"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements",
     "calculation": {
      "http://www.biocryst.com/role/NetIncomeLossPerShareScheduleofEarningsPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/NetIncomeLossPerShareScheduleofEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unvested restricted stock unit awards (in shares)",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Equity Unit Purchase Agreements",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of equity unit purchase agreements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r234",
      "r239"
     ]
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "calculation": {
      "http://www.biocryst.com/role/NetIncomeLossPerShareScheduleofEarningsPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/NetIncomeLossPerShareScheduleofEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options to purchase common stock (in shares)",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r234",
      "r235",
      "r239",
      "r472"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r970",
      "r980",
      "r990",
      "r1014",
      "r1022",
      "r1026",
      "r1034"
     ]
    },
    "bcrx_InducementPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "InducementPlanMember",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual",
      "http://www.biocryst.com/role/StockbasedCompensationOptionActivityDetails",
      "http://www.biocryst.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails",
      "http://www.biocryst.com/role/StockbasedCompensationShareBasedCompensationDetails",
      "http://www.biocryst.com/role/StockbasedCompensationWeightedAverageAssumptionsforStockOptionAwardsGrantedtoEmployeesandDirectorsUnderthePlansDetails",
      "http://www.biocryst.com/role/StockholdersEquitySharesReservedforFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inducement Plan",
        "label": "Inducement Plan [Member]",
        "documentation": "Related to the Inducement Plan."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1032"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r962",
      "r1038"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r962",
      "r1038"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r962",
      "r1038"
     ]
    },
    "us-gaap_InterestAndOtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestAndOtherIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Interest and Other Income",
        "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense, debt, total",
        "label": "Interest Expense, Debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r407",
      "r416",
      "r898",
      "r899",
      "r1320"
     ]
    },
    "bcrx_InterestExpenseDeferredFinancingCostsAndRoyaltyFinancingLiabilitiesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "InterestExpenseDeferredFinancingCostsAndRoyaltyFinancingLiabilitiesPolicyTextBlock",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Expense, Deferred Financing Costs and Royalty Financing Obligations",
        "label": "Interest Expense, Deferred Financing Costs, and Royalty Financing Liabilities [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for interest expense and royalty financing obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpenseLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseLongTermDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails",
      "http://www.biocryst.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense",
        "label": "Interest Expense, Long-Term Debt",
        "documentation": "Aggregate amount of interest paid or due on all long-term debt."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r139",
      "r141"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 3.0
      },
      "http://www.biocryst.com/role/SegmentInformationSegmentReportingInformationbySegmentDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.biocryst.com/role/SegmentInformationSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "terseLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r869",
      "r872",
      "r1078"
     ]
    },
    "us-gaap_InterestIncomeOperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestIncomeOperating",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/SegmentInformationSegmentReportingInformationbySegmentDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/SegmentInformationSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest income",
        "label": "Interest Income, Operating",
        "documentation": "Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r719",
      "r720",
      "r814",
      "r845",
      "r847",
      "r884",
      "r955",
      "r956",
      "r1077",
      "r1323"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for interest",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activity",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r200",
      "r201"
     ]
    },
    "bcrx_InterestPaidRoyaltyFinancingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "InterestPaidRoyaltyFinancingLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyFinancingObligationsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest paid, royalty financing obligations",
        "label": "Interest Paid, Royalty Financing Liabilities",
        "documentation": "Interest Paid, Royalty Financing Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://www.biocryst.com/role/Inventory"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory",
        "label": "Inventory Disclosure [Text Block]",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "us-gaap_InventoryFinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryFinishedGoods",
     "crdr": "debit",
     "calculation": {
      "http://www.biocryst.com/role/InventorySummaryofInventoriesDetails": {
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/InventorySummaryofInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finished goods",
        "label": "Inventory, Finished Goods, Gross",
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1059"
     ]
    },
    "us-gaap_InventoryGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryGross",
     "crdr": "debit",
     "calculation": {
      "http://www.biocryst.com/role/InventorySummaryofInventoriesDetails": {
       "parentTag": "bcrx_InventoryIncludingNoncurrentPortion",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/InventorySummaryofInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total inventory",
        "label": "Inventory, Gross",
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r1062"
     ]
    },
    "bcrx_InventoryIncludingNoncurrentPortion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "InventoryIncludingNoncurrentPortion",
     "crdr": "debit",
     "calculation": {
      "http://www.biocryst.com/role/InventorySummaryofInventoriesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/InventorySummaryofInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total inventory, net",
        "label": "Inventory, Including Noncurrent Portion",
        "documentation": "Inventory, Including Noncurrent Portion"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory, net",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r863",
      "r937"
     ]
    },
    "us-gaap_InventoryNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term inventory, net",
        "label": "Inventory, Noncurrent",
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle."
       }
      }
     },
     "auth_ref": [
      "r1058"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r169",
      "r176",
      "r339",
      "r340",
      "r342",
      "r709",
      "r873"
     ]
    },
    "us-gaap_InventoryRawMaterials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryRawMaterials",
     "crdr": "debit",
     "calculation": {
      "http://www.biocryst.com/role/InventorySummaryofInventoriesDetails": {
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/InventorySummaryofInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Raw materials",
        "label": "Inventory, Raw Materials, Gross",
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1061"
     ]
    },
    "us-gaap_InventoryValuationReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryValuationReserves",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/InventorySummaryofInventoriesDetails": {
       "parentTag": "bcrx_InventoryIncludingNoncurrentPortion",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/InventorySummaryofInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Reserves",
        "label": "Inventory Valuation Reserves",
        "documentation": "Amount of valuation reserve for inventory."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r1062"
     ]
    },
    "us-gaap_InventoryWorkInProcess": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryWorkInProcess",
     "crdr": "debit",
     "calculation": {
      "http://www.biocryst.com/role/InventorySummaryofInventoriesDetails": {
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/InventorySummaryofInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Work-in-process",
        "label": "Inventory, Work in Process, Gross",
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1060"
     ]
    },
    "us-gaap_InventoryWriteDown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryWriteDown",
     "crdr": "debit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory obsolescence",
        "label": "Inventory Write-down",
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels."
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentPolicyTextBlock",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Investment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment in financial asset."
       }
      }
     },
     "auth_ref": [
      "r740",
      "r773",
      "r774",
      "r775",
      "r776",
      "r839",
      "r840"
     ]
    },
    "us-gaap_InvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsAllOtherInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentsAllOtherInvestmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, All Other Investments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentsAndOtherNoncurrentAssetsTextBlock",
     "presentation": [
      "http://www.biocryst.com/role/Investments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Investments and Other Noncurrent Assets [Text Block]",
        "documentation": "The entire disclosure for investments and other noncurrent assets."
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "LaboratoryEquipmentOfficeEquipmentAndSoftwareMember",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Laboratory Equipment, Office Equipment and Software",
        "label": "Laboratory Equipment, Office Equipment and Software [Member]",
        "documentation": "Information pertaining to laboratory equipment, office equipment and software."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Lease Expense Under Operating Leases",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1273"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LegalEntityTypeOfCounterpartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LegalEntityTypeOfCounterpartyDomain",
     "presentation": [
      "http://www.biocryst.com/role/TradeReceivablesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Entity Type of Counterparty [Domain]",
        "label": "Legal Entity Type of Counterparty [Domain]",
        "documentation": "Nature of the other party participating in a financial transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Line Items]",
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r662",
      "r670"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Table]",
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r662",
      "r670"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r661"
     ]
    },
    "bcrx_LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheets of the Company's Operating Leases",
        "label": "Lessee, Operating Lease, Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the assets and liabilities of the lessee's operating lease."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturities of Operating Lease Liabilities",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1274"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/LeaseObligationsMaturitiesofLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.biocryst.com/role/LeaseObligationsMaturitiesofLeaseLiabilitiesDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r668",
      "r1127",
      "r1131",
      "r1284"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/LeaseObligationsMaturitiesofLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r668",
      "r1127",
      "r1131",
      "r1284"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/LeaseObligationsMaturitiesofLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r668",
      "r1127",
      "r1131",
      "r1284"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/LeaseObligationsMaturitiesofLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r668",
      "r1127",
      "r1131",
      "r1284"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/LeaseObligationsMaturitiesofLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r668",
      "r1127",
      "r1131",
      "r1284"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/LeaseObligationsMaturitiesofLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025 (remaining)",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r1274"
     ]
    },
    "bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/LeaseObligationsMaturitiesofLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee Operating Lease Liability To Be Paid After Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/LeaseObligationsMaturitiesofLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r668"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, operating lease, term of contract (in years)",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1272"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Obligations",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r60",
      "r61",
      "r62",
      "r65",
      "r66",
      "r67",
      "r68",
      "r205",
      "r207",
      "r208",
      "r323",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r598",
      "r599",
      "r600",
      "r633",
      "r792",
      "r878",
      "r900",
      "r957",
      "r1201",
      "r1275",
      "r1276"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 deficit",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r116",
      "r730",
      "r937",
      "r944",
      "r945",
      "r1126",
      "r1130",
      "r1187",
      "r1266"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleScheduleofAssetsHeldForSaleDetails",
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and Stockholders\u2019 Deficit",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r168",
      "r205",
      "r207",
      "r208",
      "r323",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r598",
      "r599",
      "r600",
      "r633",
      "r937",
      "r1201",
      "r1275",
      "r1276"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleScheduleofAssetsHeldForSaleDetails",
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleScheduleofAssetsHeldForSaleDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleScheduleofAssetsHeldForSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities held for sale",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities",
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r47",
      "r53",
      "r101",
      "r165",
      "r166"
     ]
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleScheduleofAssetsHeldForSaleDetails": {
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleScheduleofAssetsHeldForSaleDetails",
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities held for sale",
        "totalLabel": "Current liabilities held for sale",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current",
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r47",
      "r53",
      "r99",
      "r101",
      "r165",
      "r166"
     ]
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleScheduleofAssetsHeldForSaleDetails": {
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleScheduleofAssetsHeldForSaleDetails",
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current liabilities held for sale",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent",
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r2",
      "r47",
      "r53",
      "r101",
      "r165",
      "r166"
     ]
    },
    "bcrx_LicenseAgreementAnnualGlobalNetSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "LicenseAgreementAnnualGlobalNetSales",
     "crdr": "credit",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual global net sales",
        "label": "License Agreement, Annual Global Net Sales",
        "documentation": "License Agreement, Annual Global Net Sales"
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_LicenseAgreementNumberOfMilestonePayments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "LicenseAgreementNumberOfMilestonePayments",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of milestone payments",
        "label": "License Agreement, Number of Milestone Payments",
        "documentation": "License Agreement, Number of Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_LicenseAgreementRoyaltyPaymentNumberOfTiers": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "LicenseAgreementRoyaltyPaymentNumberOfTiers",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of royalties tiers",
        "label": "License Agreement, Royalty Payment, Number of Tiers",
        "documentation": "License Agreement, Royalty Payment, Number of Tiers"
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_LicenseAgreementUpfrontPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "LicenseAgreementUpfrontPayment",
     "crdr": "credit",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront payment",
        "label": "License Agreement, Upfront Payment",
        "documentation": "License Agreement, Upfront Payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityAxis",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails",
      "http://www.biocryst.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lender Name [Axis]",
        "label": "Lender Name [Axis]",
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r64",
      "r1126",
      "r1128",
      "r1199",
      "r1200"
     ]
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityLenderDomain",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails",
      "http://www.biocryst.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit Facility, Lender [Domain]",
        "label": "Line of Credit Facility, Lender [Domain]",
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r64",
      "r1126",
      "r1128",
      "r1199",
      "r1200"
     ]
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.biocryst.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum aggregate principal amount",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r64"
     ]
    },
    "us-gaap_LineOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditMember",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails",
      "http://www.biocryst.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit",
        "label": "Line of Credit [Member]",
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars."
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_LoanAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "LoanAgreementMember",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan Agreement",
        "label": "Loan Agreement [Member]",
        "documentation": "Loan Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.biocryst.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Secured term loan",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "bcrx_LongTermInvestmentMaturityMinimum": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "LongTermInvestmentMaturityMinimum",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term investment maturity, minimum (in years)",
        "label": "Long term Investment Maturity Minimum",
        "documentation": "Represents long term investment maturity minimum."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term investments",
        "label": "Long-Term Investments",
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle)."
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails",
      "http://www.biocryst.com/role/RoyaltyFinancingObligationsDetailsTextual",
      "http://www.biocryst.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r1192",
      "r1193",
      "r1194"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails",
      "http://www.biocryst.com/role/RoyaltyFinancingObligationsDetailsTextual",
      "http://www.biocryst.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r34",
      "r1192",
      "r1193",
      "r1194"
     ]
    },
    "us-gaap_MarketableSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesLineItems",
     "presentation": [
      "http://www.biocryst.com/role/InvestmentsFairValueRecurringBasisDetails",
      "http://www.biocryst.com/role/InvestmentsFairValueoftheCompanysInvestmentsbyTypeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities [Line Items]",
        "label": "Marketable Securities [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesTable",
     "presentation": [
      "http://www.biocryst.com/role/InvestmentsFairValueRecurringBasisDetails",
      "http://www.biocryst.com/role/InvestmentsFairValueoftheCompanysInvestmentsbyTypeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities [Table]",
        "label": "Marketable Securities [Table]",
        "documentation": "Disclosure of information about investment in marketable security."
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_MaturityPeriodOfHighQualityMarketableSecurities": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "MaturityPeriodOfHighQualityMarketableSecurities",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity period of high quality marketable securities (in years)",
        "label": "Maturity Period Of High Quality Marketable Securities",
        "documentation": "Represents maturity period of high quality marketable securities."
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_MaturityPeriodOfShortTermInvestment": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "MaturityPeriodOfShortTermInvestment",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity period of short term investment (in months)",
        "label": "Maturity Period Of Short Term Investment",
        "documentation": "Maturity period of short term investment."
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_MaximumCustomaryReductionOnRoyaltyRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "MaximumCustomaryReductionOnRoyaltyRate",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum customary reduction on royalty rate",
        "label": "Maximum Customary Reduction On Royalty Rate",
        "documentation": "The maximum percentage of customary reductions allowed on royalty rate."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails",
      "http://www.biocryst.com/role/LeaseObligationsDetailsTextual",
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r251",
      "r372",
      "r373",
      "r374",
      "r375",
      "r466",
      "r499",
      "r500",
      "r501",
      "r520",
      "r622",
      "r708",
      "r761",
      "r762",
      "r769",
      "r784",
      "r785",
      "r838",
      "r841",
      "r842",
      "r843",
      "r844",
      "r850",
      "r851",
      "r852",
      "r853",
      "r857",
      "r858",
      "r889",
      "r901",
      "r917",
      "r920",
      "r921",
      "r922",
      "r927",
      "r928",
      "r932",
      "r933",
      "r940",
      "r1203",
      "r1277",
      "r1278",
      "r1279",
      "r1280",
      "r1281",
      "r1282"
     ]
    },
    "bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "MaximumNumberOfProductsPermittedToBeObtainedDoses",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of doses permitted to be procured",
        "label": "Maximum Number Of Products Permitted To Be Obtained, Doses",
        "documentation": "Maximum Number Of Products Permitted To Be Obtained, Doses"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1006"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1006"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails",
      "http://www.biocryst.com/role/LeaseObligationsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r251",
      "r372",
      "r373",
      "r374",
      "r375",
      "r466",
      "r499",
      "r500",
      "r501",
      "r520",
      "r622",
      "r708",
      "r761",
      "r762",
      "r769",
      "r784",
      "r785",
      "r838",
      "r841",
      "r842",
      "r843",
      "r844",
      "r850",
      "r851",
      "r852",
      "r853",
      "r857",
      "r858",
      "r889",
      "r901",
      "r917",
      "r920",
      "r921",
      "r922",
      "r927",
      "r928",
      "r932",
      "r940",
      "r1203",
      "r1277",
      "r1278",
      "r1279",
      "r1280",
      "r1281",
      "r1282"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1025"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1033"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows_1": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r199"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows_1": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by investing activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r199"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows_1": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r92",
      "r95"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.biocryst.com/role/SegmentInformationSegmentReportingInformationbySegmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofStockholdersDeficit",
      "http://www.biocryst.com/role/NetIncomeLossPerShareScheduleofEarningsPerShareDetails",
      "http://www.biocryst.com/role/SegmentInformationSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income (loss)",
        "terseLabel": "Net income (loss)",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r95",
      "r120",
      "r161",
      "r166",
      "r182",
      "r185",
      "r190",
      "r205",
      "r207",
      "r208",
      "r209",
      "r215",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r226",
      "r227",
      "r236",
      "r323",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r418",
      "r421",
      "r423",
      "r427",
      "r509",
      "r538",
      "r594",
      "r616",
      "r633",
      "r734",
      "r813",
      "r831",
      "r832",
      "r869",
      "r871",
      "r872",
      "r956",
      "r1201"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract",
     "presentation": [
      "http://www.biocryst.com/role/NetIncomeLossPerShareScheduleofEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Numerator:",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Adopted Accounting Pronouncements And New Accounting Pronouncements Not Yet Adopted",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_NonCashIncreaseInOperatingLeaseAssetsDueToRemeasurementOfOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "NonCashIncreaseInOperatingLeaseAssetsDueToRemeasurementOfOperatingLeaseLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsSupplementalCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash increase to operating lease assets due to remeasurement of operating lease liabilities",
        "label": "Non-cash Increase In Operating Lease Assets Due To Remeasurement Of Operating Lease Liabilities",
        "documentation": "Non-cash Increase In Operating Lease Assets Due To Remeasurement Of Operating Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_NonCashInterestExpenseOnRoyaltyFinancingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "NonCashInterestExpenseOnRoyaltyFinancingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.biocryst.com/role/RoyaltyFinancingObligationsScheduleofRoyaltyFinancingObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash interest expense on royalty financing obligations",
        "label": "Non-Cash Interest Expense On Royalty Financing Liabilities",
        "documentation": "Amount of non-cash interest expense on royalty financing obligation."
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_NonCashInterestExpenseOnSecuredTermLoanAndSecuredTermLoanAndAmortizationOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "NonCashInterestExpenseOnSecuredTermLoanAndSecuredTermLoanAndAmortizationOfDebtIssuanceCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash interest expense on secured term loan and amortization of debt issuance costs",
        "label": "Non-Cash Interest Expense On Secured Term Loan And Secured Term Loan And Amortization Of Debt Issuance Costs",
        "documentation": "Non-Cash Interest Expense On Secured Term Loan And Secured Term Loan And Amortization Of Debt Issuance Costs"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1006"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r970",
      "r980",
      "r990",
      "r1014",
      "r1022"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r1014"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1033"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1033"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other expense, net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.biocryst.com/role/SegmentInformationDetails",
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r885",
      "r1144"
     ]
    },
    "bcrx_NumberOfOptionalOrderingPeriods": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "NumberOfOptionalOrderingPeriods",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of optional ordering periods",
        "label": "Number of Optional Ordering Periods",
        "documentation": "Number of Optional Ordering Periods"
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_NumberOfProductDeliveredDoses": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "NumberOfProductDeliveredDoses",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Doses delivered",
        "label": "Number Of Product Delivered, Doses",
        "documentation": "Number Of Product Delivered, Doses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.biocryst.com/role/SegmentInformationDetails",
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r880",
      "r888",
      "r1144"
     ]
    },
    "bcrx_OMERSCapitalMarketsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "OMERSCapitalMarketsMember",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyFinancingObligationsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OMERS Capital Markets",
        "label": "OMERS Capital Markets [Member]",
        "documentation": "Information on the rights of OMERS Capital Markets to receive certain royalty payments under the OMERS Royalty Purchase Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_OMERSRoyaltyAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "OMERSRoyaltyAgreementMember",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyFinancingObligationsScheduleofRoyaltyFinancingObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OMERS Royalty Agreement",
        "label": "OMERS Royalty Agreement [Member]",
        "documentation": "Information on OMERS Royalty Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_ORLADEYOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "ORLADEYOMember",
     "presentation": [
      "http://www.biocryst.com/role/RevenueDetails",
      "http://www.biocryst.com/role/RoyaltyFinancingObligationsDetailsTextual",
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails",
      "http://www.biocryst.com/role/TradeReceivablesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ORLADEYO",
        "label": "ORLADEYO [Member]",
        "documentation": "Represents ORLADEYO."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r869",
      "r872",
      "r879",
      "r1138",
      "r1145",
      "r1146",
      "r1147",
      "r1148"
     ]
    },
    "bcrx_OperatingLeaseAssets": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "OperatingLeaseAssets",
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsBalanceSheetsoftheCompanysOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets:",
        "label": "Assets:",
        "documentation": "Information on operating lease right-of-use assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsAggregateLeaseExpenseUnderOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease expense",
        "label": "Operating Lease, Expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r1271"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsMaturitiesofLeaseLiabilitiesDetails",
      "http://www.biocryst.com/role/LeaseObligationsOtherSupplementalInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/LeaseObligationsMaturitiesofLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.biocryst.com/role/LeaseObligationsBalanceSheetsoftheCompanysOperatingLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsBalanceSheetsoftheCompanysOperatingLeasesDetails",
      "http://www.biocryst.com/role/LeaseObligationsMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Total",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityAbstract",
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsBalanceSheetsoftheCompanysOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease, Liability [Abstract]",
        "label": "Operating Lease, Liability [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/LeaseObligationsBalanceSheetsoftheCompanysOperatingLeasesDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.biocryst.com/role/LeaseObligationsBalanceSheetsoftheCompanysOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.biocryst.com/role/LeaseObligationsBalanceSheetsoftheCompanysOperatingLeasesDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.biocryst.com/role/LeaseObligationsBalanceSheetsoftheCompanysOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsSupplementalCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating cash flows for operating leases",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r660",
      "r664"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsBalanceSheetsoftheCompanysOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease assets, net",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "bcrx_OperatingLeaseRightOfUseAssetAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "OperatingLeaseRightOfUseAssetAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, right-of-use asset, accumulated amortization",
        "label": "Operating Lease Right of use Asset Accumulated Amortization",
        "documentation": "Amount of accumulated amortization on lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsBalanceSheetsoftheCompanysOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsOtherSupplementalInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating leases",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r667",
      "r936"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsOtherSupplementalInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining lease term (in years)",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r666",
      "r936"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation adjustment",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r12",
      "r111"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain (loss) on available for sale investments",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r180",
      "r181",
      "r735"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other comprehensive (loss) income",
        "terseLabel": "Other comprehensive income (loss)",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r12",
      "r111",
      "r183",
      "r186",
      "r223"
     ]
    },
    "bcrx_OtherExpenses1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "OtherExpenses1Member",
     "presentation": [
      "http://www.biocryst.com/role/SegmentInformationSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-program specific and indirect costs",
        "label": "Other Expenses 1 [Member]",
        "documentation": "Other Expenses 1"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.biocryst.com/role/SegmentInformationSegmentReportingInformationbySegmentDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.biocryst.com/role/SegmentInformationSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income",
        "label": "Other Income",
        "documentation": "Amount of revenue and income classified as other."
       }
      }
     },
     "auth_ref": [
      "r741",
      "r815",
      "r846",
      "r847",
      "r848",
      "r944",
      "r945"
     ]
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherIncomeAndExpensesAbstract",
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense):",
        "label": "Other Income and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_OtherIncomeFromContractWithCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "OtherIncomeFromContractWithCustomerMember",
     "presentation": [
      "http://www.biocryst.com/role/RevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other revenues",
        "label": "Other Income From Contract With Customer [Member]",
        "documentation": "Other Income From Contract With Customer"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r1006"
     ]
    },
    "bcrx_OtherSupplementalInformationRelatedToLeasesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "OtherSupplementalInformationRelatedToLeasesTableTextBlock",
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Supplemental Information Related to Leases",
        "label": "Other Supplemental Information Related to Leases [Table Text Block]",
        "documentation": "Other Supplemental Information Related to Leases"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r968",
      "r978",
      "r988",
      "r1020"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r971",
      "r981",
      "r991",
      "r1023"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r971",
      "r981",
      "r991",
      "r1023"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r995"
     ]
    },
    "bcrx_PaymentsForPaidInKindInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "PaymentsForPaidInKindInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payment of Pharmakon PIK Interest",
        "label": "Payments For Paid-In-Kind Interest",
        "documentation": "Payments For Paid-In-Kind Interest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfDebtExtinguishmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfDebtExtinguishmentCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.biocryst.com/role/DebtDetails",
      "http://www.biocryst.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Prepayment premium and fees on Pharmakon term loan",
        "terseLabel": "Prepayment premium and fees on Pharmakon term loan",
        "label": "Payment for Debt Extinguishment or Debt Prepayment Cost",
        "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Withholding taxes paid on stock-based awards",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of investments",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r195",
      "r291"
     ]
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireProductiveAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Acquisitions of property and equipment",
        "label": "Payments to Acquire Productive Assets",
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r1245",
      "r1246",
      "r1247"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1005"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1005"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r1014"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "bcrx_PeramivirMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "PeramivirMember",
     "presentation": [
      "http://www.biocryst.com/role/TradeReceivablesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peramivir",
        "label": "Peramivir [Member]",
        "documentation": "Peramivir"
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_PercentOfInterestPayment": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "PercentOfInterestPayment",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percent of interest payment",
        "label": "Percent of Interest Payment",
        "documentation": "Percent of Interest Payment"
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_PharmakonAdvisorsLPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "PharmakonAdvisorsLPMember",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails",
      "http://www.biocryst.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pharmakon Advisors, LP",
        "label": "Pharmakon Advisors, LP [Member]",
        "documentation": "Pharmakon Advisors, LP"
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_PikInterestPaymentIsMadeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "PikInterestPaymentIsMadeMember",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PIK Interest Payment is Made",
        "label": "PIK Interest Payment is Made [Member]",
        "documentation": "Represents PIK interest payment is made."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual",
      "http://www.biocryst.com/role/StockbasedCompensationOptionActivityDetails",
      "http://www.biocryst.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails",
      "http://www.biocryst.com/role/StockbasedCompensationShareBasedCompensationDetails",
      "http://www.biocryst.com/role/StockbasedCompensationWeightedAverageAssumptionsforStockOptionAwardsGrantedtoEmployeesandDirectorsUnderthePlansDetails",
      "http://www.biocryst.com/role/StockholdersEquitySharesReservedforFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222",
      "r1223",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1231",
      "r1232"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual",
      "http://www.biocryst.com/role/StockbasedCompensationOptionActivityDetails",
      "http://www.biocryst.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails",
      "http://www.biocryst.com/role/StockbasedCompensationShareBasedCompensationDetails",
      "http://www.biocryst.com/role/StockbasedCompensationWeightedAverageAssumptionsforStockOptionAwardsGrantedtoEmployeesandDirectorsUnderthePlansDetails",
      "http://www.biocryst.com/role/StockholdersEquitySharesReservedforFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222",
      "r1223",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1231",
      "r1232"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r998"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1042"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "bcrx_PotentialMilestonePaymentsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "PotentialMilestonePaymentsPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential milestone payment",
        "label": "Potential Milestone Payments Payable",
        "documentation": "Potential Milestone Payments Payable"
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_PotentialMilestonePaymentsPayableIfRegulatoryApprovalBeforeMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "PotentialMilestonePaymentsPayableIfRegulatoryApprovalBeforeMilestone",
     "crdr": "credit",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential payment if milestone reached",
        "label": "Potential Milestone Payments Payable If Regulatory Approval Before Milestone",
        "documentation": "Potential Milestone Payments Payable If Regulatory Approval Before Milestone"
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeMilestone",
     "crdr": "debit",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential milestone payments receivable if regulatory approval before specified date",
        "label": "Potential Milestone Payments Receivable If Regulatory Approval Before Milestone",
        "documentation": "The amount of potential milestone payments receivable if regulatory approval is granted."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock par value (in usd per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r429"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r793"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r429"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r793",
      "r812",
      "r1321",
      "r1322"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, $0.01 par value; shares authorized - 5,000; no shares issued and outstanding at September\u00a030, 2025 and December\u00a031, 2024",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r420",
      "r425",
      "r726",
      "r937"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1064"
     ]
    },
    "us-gaap_ProceedsFromCollaborators": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromCollaborators",
     "crdr": "debit",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from collaborators",
        "label": "Proceeds from Collaborators",
        "documentation": "Cash received from collaborators during the current period."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "bcrx_ProceedsFromIssuanceOfCommonStockIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "ProceedsFromIssuanceOfCommonStockIssuedForServices",
     "crdr": "debit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued to directors in lieu of cash retainer",
        "label": "Proceeds From Issuance Of Common Stock, Issued For Services",
        "documentation": "Proceeds From Issuance Of Common Stock, Issued For Services"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyFinancingObligationsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of debt",
        "label": "Proceeds from Issuance of Debt",
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt."
       }
      }
     },
     "auth_ref": [
      "r1121"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails",
      "http://www.biocryst.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of long-term debt",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r778"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "crdr": "debit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from common stock issued under stock-based compensation plans",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r14"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales and maturities of investments",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r196",
      "r1153"
     ]
    },
    "us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleOfOtherAssetsInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of non-financial asset",
        "label": "Proceeds from Sale of Other Assets, Investing Activities",
        "documentation": "Amount of cash inflow from the sale of other assets recognized in investing activities."
       }
      }
     },
     "auth_ref": [
      "r1046"
     ]
    },
    "us-gaap_ProductConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProductConcentrationRiskMember",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product Concentration Risk",
        "label": "Product Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence."
       }
      }
     },
     "auth_ref": [
      "r1141"
     ]
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProductMember",
     "presentation": [
      "http://www.biocryst.com/role/RevenueDetails",
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskSummaryofRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product sales, net",
        "label": "Product [Member]",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r868",
      "r872",
      "r902",
      "r903"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails",
      "http://www.biocryst.com/role/RevenueDetails",
      "http://www.biocryst.com/role/RoyaltyFinancingObligationsDetailsTextual",
      "http://www.biocryst.com/role/SegmentInformationSegmentReportingInformationbySegmentDetails",
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails",
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskSummaryofRevenuesDetails",
      "http://www.biocryst.com/role/TradeReceivablesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r281",
      "r710",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r861",
      "r868",
      "r871",
      "r872",
      "r902",
      "r903",
      "r939",
      "r940",
      "r941",
      "r943",
      "r946",
      "r1048",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1197",
      "r1198",
      "r1288",
      "r1289",
      "r1290",
      "r1291",
      "r1292",
      "r1293",
      "r1294",
      "r1295",
      "r1296",
      "r1297",
      "r1298",
      "r1299",
      "r1300",
      "r1301",
      "r1302",
      "r1303",
      "r1304",
      "r1305",
      "r1306",
      "r1307",
      "r1308",
      "r1309",
      "r1310",
      "r1311",
      "r1312",
      "r1313",
      "r1314",
      "r1315",
      "r1316"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails",
      "http://www.biocryst.com/role/RevenueDetails",
      "http://www.biocryst.com/role/RoyaltyFinancingObligationsDetailsTextual",
      "http://www.biocryst.com/role/SegmentInformationSegmentReportingInformationbySegmentDetails",
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails",
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskSummaryofRevenuesDetails",
      "http://www.biocryst.com/role/TradeReceivablesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r281",
      "r710",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r861",
      "r868",
      "r871",
      "r872",
      "r902",
      "r903",
      "r939",
      "r940",
      "r941",
      "r943",
      "r946",
      "r1048",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1197",
      "r1198",
      "r1288",
      "r1289",
      "r1290",
      "r1291",
      "r1292",
      "r1293",
      "r1294",
      "r1295",
      "r1296",
      "r1297",
      "r1298",
      "r1299",
      "r1300",
      "r1301",
      "r1302",
      "r1303",
      "r1304",
      "r1305",
      "r1306",
      "r1307",
      "r1308",
      "r1309",
      "r1310",
      "r1311",
      "r1312",
      "r1313",
      "r1314",
      "r1315",
      "r1316"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r669"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleDetails",
      "http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleScheduleofAssetsHeldForSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r669"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r669",
      "r722",
      "r732",
      "r937"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r134",
      "r135",
      "r731"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r669"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment, useful life (in years)",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r995"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r995"
     ]
    },
    "bcrx_RAPIVABMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "RAPIVABMember",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RAPIVAB",
        "label": "RAPIVAB [Member]",
        "documentation": "Represents RAPIVAB product."
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_RPI2019IntermediateFinanceTrustMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "RPI2019IntermediateFinanceTrustMember",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyFinancingObligationsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RPI 2019 Intermediate Finance Trust",
        "label": "RPI 2019 Intermediate Finance Trust [Member]",
        "documentation": "Represents RPI 2019 Intermediate Finance Trust (RPI).."
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_RPI2021And2020IntermediateFinanceTrustMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "RPI2021And2020IntermediateFinanceTrustMember",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyFinancingObligationsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RPI 2021 and 2020 Intermediate Finance Trust",
        "label": "RPI 2021 and 2020 Intermediate Finance Trust [Member]",
        "documentation": "Represents RPI 2021 and 2020 Intermediate Finance Trust (RPI)."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails",
      "http://www.biocryst.com/role/LeaseObligationsDetailsTextual",
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r251",
      "r372",
      "r373",
      "r374",
      "r375",
      "r456",
      "r466",
      "r499",
      "r500",
      "r501",
      "r508",
      "r520",
      "r622",
      "r682",
      "r691",
      "r708",
      "r761",
      "r762",
      "r769",
      "r784",
      "r785",
      "r838",
      "r841",
      "r842",
      "r843",
      "r844",
      "r850",
      "r851",
      "r852",
      "r853",
      "r857",
      "r858",
      "r889",
      "r901",
      "r917",
      "r920",
      "r921",
      "r922",
      "r927",
      "r928",
      "r932",
      "r933",
      "r940",
      "r949",
      "r1195",
      "r1203",
      "r1260",
      "r1278",
      "r1279",
      "r1280",
      "r1281",
      "r1282"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails",
      "http://www.biocryst.com/role/LeaseObligationsDetailsTextual",
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r251",
      "r372",
      "r373",
      "r374",
      "r375",
      "r456",
      "r466",
      "r499",
      "r500",
      "r501",
      "r508",
      "r520",
      "r622",
      "r682",
      "r691",
      "r708",
      "r761",
      "r762",
      "r769",
      "r784",
      "r785",
      "r838",
      "r841",
      "r842",
      "r843",
      "r844",
      "r850",
      "r851",
      "r852",
      "r853",
      "r857",
      "r858",
      "r889",
      "r901",
      "r917",
      "r920",
      "r921",
      "r922",
      "r927",
      "r928",
      "r932",
      "r933",
      "r940",
      "r949",
      "r1195",
      "r1203",
      "r1260",
      "r1278",
      "r1279",
      "r1280",
      "r1281",
      "r1282"
     ]
    },
    "us-gaap_ReceivableTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReceivableTypeDomain",
     "presentation": [
      "http://www.biocryst.com/role/TradeReceivablesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivable [Domain]",
        "label": "Receivable [Domain]",
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r77"
     ]
    },
    "us-gaap_ReceivablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReceivablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReceivablesNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.biocryst.com/role/TradeReceivablesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivables",
        "label": "Receivables, Net, Current",
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value."
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReceivablesPolicyTextBlock",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade Receivables",
        "label": "Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r288",
      "r289",
      "r290",
      "r1150"
     ]
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification from accumulated other comprehensive income, current period, before tax",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax",
        "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r189",
      "r641",
      "r645",
      "r646",
      "r735",
      "r1074"
     ]
    },
    "us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReconciliationFromSegmentTotalsToConsolidatedAbstract",
     "presentation": [
      "http://www.biocryst.com/role/SegmentInformationSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reconciliation [Abstract]",
        "label": "Segment Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r963",
      "r973",
      "r983",
      "r1015"
     ]
    },
    "bcrx_RepaymentOfRoyaltyFinancingLiabilitiesPrincipal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "RepaymentOfRoyaltyFinancingLiabilitiesPrincipal",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Principal payments on royalty financing obligations",
        "label": "Repayment Of Royalty Financing Liabilities, Principal",
        "documentation": "Repayment Of Royalty Financing Liabilities, Principal"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfLinesOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repayments of lines of credit",
        "label": "Repayments of Lines of Credit",
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r1126",
      "r1128"
     ]
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfLongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repayment of Pharmakon term loan principal",
        "label": "Repayments of Long-Term Debt",
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r779"
     ]
    },
    "bcrx_ReportableSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "ReportableSegmentMember",
     "presentation": [
      "http://www.biocryst.com/role/SegmentInformationSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reportable Segment",
        "label": "Reportable Segment [Member]",
        "documentation": "Reportable Segment"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails",
      "http://www.biocryst.com/role/RoyaltyFinancingObligationsDetailsTextual",
      "http://www.biocryst.com/role/RoyaltyFinancingObligationsScheduleofRoyaltyFinancingObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r205",
      "r210",
      "r211",
      "r391",
      "r431",
      "r672",
      "r692",
      "r724",
      "r864",
      "r865",
      "r866",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1250",
      "r1251",
      "r1252",
      "r1253"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative and Other Relationships [Line Items]",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r523",
      "r1235"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.biocryst.com/role/SegmentInformationSegmentReportingInformationbySegmentDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.biocryst.com/role/SegmentInformationSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r522",
      "r859",
      "r869",
      "r870",
      "r884",
      "r1283"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Expenses",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r521"
     ]
    },
    "bcrx_ResearchDiscoveryAndPreclinicalProgramsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "ResearchDiscoveryAndPreclinicalProgramsMember",
     "presentation": [
      "http://www.biocryst.com/role/SegmentInformationSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research, discovery and preclinical programs",
        "label": "Research, Discovery And Preclinical Programs [Member]",
        "documentation": "Research, Discovery And Preclinical Programs"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r964",
      "r974",
      "r984",
      "r1016"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r965",
      "r975",
      "r985",
      "r1017"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r972",
      "r982",
      "r992",
      "r1024"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentContinuingOperationExcludingAssetsHeldForSale",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash and Cash Equivalent, Current",
        "documentation": "Amount of cash and cash equivalent restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r170",
      "r202"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Cash and Cash Equivalents [Axis]",
        "label": "Restricted Cash and Cash Equivalents [Axis]",
        "documentation": "Information by category of cash or cash equivalent items which are restricted as to withdrawal or usage."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Domain]",
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "bcrx_RestrictedCashAndCashEquivalentsIncludedInOtherAssetsNonCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "RestrictedCashAndCashEquivalentsIncludedInOtherAssetsNonCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "bcrx_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentContinuingOperationExcludingAssetsHeldForSale",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash in other assets",
        "label": "Restricted Cash and Cash Equivalents, Included In Other Assets, Non-Current",
        "documentation": "Restricted Cash and Cash Equivalents, Included In Other Assets, Non-Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Birmingham lease restricted cash",
        "label": "Restricted Cash and Cash Equivalent, Noncurrent",
        "documentation": "Amount of cash and cash equivalent restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r130",
      "r202"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.biocryst.com/role/NetIncomeLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails",
      "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual",
      "http://www.biocryst.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails",
      "http://www.biocryst.com/role/StockholdersEquitySharesReservedforFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unvested restricted stock unit awards",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222",
      "r1223",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1231",
      "r1232"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r108",
      "r729",
      "r766",
      "r768",
      "r780",
      "r794",
      "r937"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r160",
      "r161",
      "r212",
      "r213",
      "r214",
      "r216",
      "r223",
      "r225",
      "r227",
      "r324",
      "r325",
      "r359",
      "r417",
      "r509",
      "r532",
      "r533",
      "r535",
      "r536",
      "r537",
      "r539",
      "r593",
      "r594",
      "r602",
      "r604",
      "r605",
      "r607",
      "r614",
      "r651",
      "r653",
      "r763",
      "r765",
      "r781",
      "r1321"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.biocryst.com/role/SegmentInformationSegmentReportingInformationbySegmentDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails",
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.biocryst.com/role/RevenueDetails",
      "http://www.biocryst.com/role/SegmentInformationSegmentReportingInformationbySegmentDetails",
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskSummaryofRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r123",
      "r245",
      "r257",
      "r258",
      "r272",
      "r278",
      "r281",
      "r283",
      "r284",
      "r452",
      "r453",
      "r454",
      "r710"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://www.biocryst.com/role/Revenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r454",
      "r455"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues",
        "label": "Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsSupplementalCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease assets obtained in exchange for finance lease liabilities",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r665",
      "r936"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsSupplementalCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease assets obtained in exchange for operating lease liabilities",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r665",
      "r936"
     ]
    },
    "bcrx_RightOfUseAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "RightOfUseAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right of use assets",
        "label": "Right-Of-Use-Assets, Noncurrent",
        "documentation": "Right-Of-Use-Assets, Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_RoyaltiesMonetizationsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "RoyaltiesMonetizationsTable",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyFinancingObligationsDetailsTextual",
      "http://www.biocryst.com/role/RoyaltyFinancingObligationsScheduleofRoyaltyFinancingObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalties Monetizations [Table]",
        "label": "Royalties Monetizations [Table]",
        "documentation": "Royalties Monetizations"
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_RoyaltyFinancingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "RoyaltyFinancingLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyFinancingObligationsScheduleofRoyaltyFinancingObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Royalty Financing Liabilities",
        "documentation": "Royalty Financing Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_RoyaltyFinancingLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "RoyaltyFinancingLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty financing obligations",
        "label": "Royalty Financing Liabilities, Current",
        "documentation": "Royalty Financing Liabilities, Current"
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_RoyaltyFinancingLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "RoyaltyFinancingLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty financing obligations",
        "label": "Royalty Financing Liabilities, Noncurrent",
        "documentation": "Carrying amount as of the balance sheet date of obligations for future royalties."
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_RoyaltyFinancingLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "RoyaltyFinancingLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyFinancingObligationsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Royalty Financing Obligations",
        "label": "Royalty Financing Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure for royalty financing obligations."
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_RoyaltyFinancingLiabilitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "RoyaltyFinancingLiabilitiesTextBlock",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyFinancingObligations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty Financing Obligations",
        "label": "Royalty Financing Liabilities [Text Block]",
        "documentation": "Royalty monetization."
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_RoyaltyMonetizationsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "RoyaltyMonetizationsLineItems",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyFinancingObligationsDetailsTextual",
      "http://www.biocryst.com/role/RoyaltyFinancingObligationsScheduleofRoyaltyFinancingObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty Monetizations [Line Items]",
        "label": "Royalty Monetizations [Line Items]",
        "documentation": "Royalty Monetizations"
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_RoyaltyMontizationsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "RoyaltyMontizationsRollForward",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyFinancingObligationsScheduleofRoyaltyFinancingObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty Montizations [Roll Forward]",
        "label": "Royalty Montizations [Roll Forward]",
        "documentation": "Royalty Montizations"
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyFinancingObligationsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty purchase agreement, royalties, percentage of annual net sales",
        "label": "Royalty Purchase Agreement Royalties Percentage Of Annual Net Sales",
        "documentation": "The percentage of annual net sales for royalties to be paid under the royalty purchase agreement."
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyFinancingObligationsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty purchase agreement, royalties, percentage of annual net sales, based on reduction in sales",
        "label": "Royalty Purchase Agreement Royalties Percentage Of Annual Net Sales Based On Reduction In Sales",
        "documentation": "he percentage of annual net sales of royalties to be paid under the royalty purchase agreement if sales are less than specified."
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyFinancingObligationsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty purchase agreement, royalties, percentage of annual net sales in key territories",
        "label": "Royalty Purchase Agreement Royalties Percentage Of Annual Net Sales In Key Territories",
        "documentation": "The percentage of net sales in key territories for royalties to be paid under the royalty purchase agreement."
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyFinancingObligationsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty purchase agreement, royalties, percentage of annual net sales in other markets",
        "label": "Royalty Purchase Agreement Royalties Percentage Of Annual Net Sales In Other Markets",
        "documentation": "The percentage of annual net sales in other markets of royalties to be paid under the royalty purchase agreement."
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyFinancingObligationsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty purchase agreement, royalties, percentage of purchase price",
        "label": "Royalty Purchase Agreement Royalties Percentage Of Purchase Price",
        "documentation": "The percentage of the purchase price under the royalty purchase agreement."
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyFinancingObligationsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty purchase agreement, royalties, percentage of sublicense revenue in other markets",
        "label": "Royalty Purchase Agreement Royalties Percentage of Sublicense Revenue In Other Markets",
        "documentation": "The percentage of sublicense revenue in other markets of royalties to be paid under the royalty purchase agreement."
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyFinancingObligationsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty purchase agreement, royalties, purchase price, amount",
        "label": "Royalty Purchase Agreement Royalties Purchase Price Amount",
        "documentation": "The amount of the purchase price under the royalty purchase agreement."
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_RoyaltyRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "RoyaltyRate",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty rate",
        "label": "Royalty Rate",
        "documentation": "Royalty Rate"
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_RoyaltyRateIfMaintainsSakigakeDesignation": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "RoyaltyRateIfMaintainsSakigakeDesignation",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty rate if maintains sakigake designation",
        "label": "Royalty Rate If Maintains Sakigake Designation",
        "documentation": "The percent of net sales that the company will receive if berotralstat maintains its Sakigake designation during the PMDA review."
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_RoyaltyReceivablesFromPartnersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "RoyaltyReceivablesFromPartnersMember",
     "presentation": [
      "http://www.biocryst.com/role/TradeReceivablesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty Receivables from Partners",
        "label": "Royalty Receivables from Partners [Member]",
        "documentation": "Information related to royalty receivables from partners."
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_RoyaltyRevenuesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "RoyaltyRevenuesPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyFinancingObligationsScheduleofRoyaltyFinancingObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty revenues payable",
        "label": "Royalty Revenues Payable",
        "documentation": "Represents royalties revenues payable."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1033"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1033"
     ]
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Benchmark",
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r1140",
      "r1141"
     ]
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleDetails",
      "http://www.biocryst.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forecast",
        "label": "Forecast [Member]"
       }
      }
     },
     "auth_ref": [
      "r467"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleDetails",
      "http://www.biocryst.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Domain]",
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r162",
      "r163",
      "r228",
      "r467",
      "r1044"
     ]
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "presentation": [
      "http://www.biocryst.com/role/TradeReceivablesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade Receivables [Table]",
        "label": "Accounts and Financing Receivables [Table]",
        "documentation": "Disclosure of information about accounts and financing receivables. Includes, but is not limited to, amount of receivable and allowance for credit loss."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r77",
      "r286",
      "r1151"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.biocryst.com/role/NetIncomeLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r240"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.biocryst.com/role/NetIncomeLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "presentation": [
      "http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Groups, Including Discontinued Operations",
        "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]",
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r15",
      "r18",
      "r47",
      "r48",
      "r49",
      "r50",
      "r51",
      "r52",
      "r54",
      "r55",
      "r56",
      "r102",
      "r1189",
      "r1190"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTextBlock",
     "presentation": [
      "http://www.biocryst.com/role/NetIncomeLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method",
        "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table Text Block]",
        "documentation": "Tabular disclosure of the effect of income (loss) on basic earnings per share."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r30",
      "r1136"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.biocryst.com/role/InvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1257",
      "r1258"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.biocryst.com/role/InventoryTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Inventories",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r78",
      "r79",
      "r80"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleDetails",
      "http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleScheduleofAssetsHeldForSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r669"
     ]
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
        "label": "Research and Development, Contract to Perform for Others [Table]",
        "documentation": "Disclosure of information about research and development arrangement accounted for as contract to perform research and development for others. Includes, but is not limited to, royalty arrangement, purchase provision, license agreement, and commitment to provide additional funding."
       }
      }
     },
     "auth_ref": [
      "r523",
      "r1235"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.biocryst.com/role/SegmentInformationDetails",
      "http://www.biocryst.com/role/SegmentInformationSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r33"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.biocryst.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r33"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual",
      "http://www.biocryst.com/role/StockbasedCompensationOptionActivityDetails",
      "http://www.biocryst.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails",
      "http://www.biocryst.com/role/StockbasedCompensationShareBasedCompensationDetails",
      "http://www.biocryst.com/role/StockbasedCompensationWeightedAverageAssumptionsforStockOptionAwardsGrantedtoEmployeesandDirectorsUnderthePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r469",
      "r471",
      "r474",
      "r475",
      "r476",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r508"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors Under the Plans",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity",
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r1217"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockByClassTextBlock",
     "presentation": [
      "http://www.biocryst.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock by Class",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r37",
      "r38",
      "r39",
      "r40",
      "r41",
      "r42",
      "r69",
      "r70",
      "r106",
      "r107",
      "r108"
     ]
    },
    "us-gaap_SecuredDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SecuredDebtMember",
     "presentation": [
      "http://www.biocryst.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Secured Debt",
        "label": "Secured Debt [Member]",
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.biocryst.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r958"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.biocryst.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r960"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.biocryst.com/role/SegmentInformationSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Domain]",
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r125",
      "r245",
      "r253",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r278",
      "r279",
      "r280",
      "r284",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r358",
      "r368",
      "r369",
      "r586",
      "r589",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r881",
      "r884",
      "r885",
      "r894",
      "r942",
      "r1288",
      "r1289",
      "r1290",
      "r1291",
      "r1292",
      "r1293",
      "r1294",
      "r1295",
      "r1296",
      "r1297",
      "r1298",
      "r1299",
      "r1300",
      "r1301",
      "r1302",
      "r1303",
      "r1304",
      "r1305",
      "r1306",
      "r1307",
      "r1308",
      "r1309",
      "r1310",
      "r1311",
      "r1312",
      "r1313",
      "r1314",
      "r1315",
      "r1316"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_SegmentReportingAdjustmentsAndReconcilingItemsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "SegmentReportingAdjustmentsAndReconcilingItemsAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.biocryst.com/role/SegmentInformationSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments and reconciling items",
        "label": "Segment Reporting, Adjustments and Reconciling Items, Amount",
        "documentation": "Segment Reporting, Adjustments and Reconciling Items, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.biocryst.com/role/SegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r245",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r268",
      "r270",
      "r271",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r284",
      "r880",
      "r882",
      "r883",
      "r884",
      "r886",
      "r887",
      "r888"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.biocryst.com/role/SegmentInformationDetails",
      "http://www.biocryst.com/role/SegmentInformationSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting Information [Line Items]",
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.biocryst.com/role/SegmentInformationSegmentReportingInformationbySegmentDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.biocryst.com/role/SegmentInformationSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative",
        "label": "Selling, General and Administrative Expense",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r868",
      "r869",
      "r870",
      "r872",
      "r1116"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, General and Administrative Expenses",
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption."
       }
      }
     },
     "auth_ref": [
      "r1234"
     ]
    },
    "bcrx_SeniorCreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "SeniorCreditFacilityMember",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior Credit Facility",
        "label": "Senior Credit Facility [Member]",
        "documentation": "Represents senior credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Forfeited RSU (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r491"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock units, forfeited in period, weighted average grant date fair value (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r491"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued RSU (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r489"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual",
      "http://www.biocryst.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock units, grants in period, weighted average grant date fair value (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r489"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Unvested RSU beginning balance (in shares)",
        "periodEndLabel": "Unvested RSU ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r486",
      "r487"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Nonvested RSU weighted average grant date fair value beginning balance (in dollars per share)",
        "periodEndLabel": "Nonvested RSU weighted average grant date fair value ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r486",
      "r487"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Vested RSU (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r490"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock units, vested in period, weighted average grant date fair value (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r490"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationWeightedAverageAssumptionsforStockOptionAwardsGrantedtoEmployeesandDirectorsUnderthePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected Volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r500"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationWeightedAverageAssumptionsforStockOptionAwardsGrantedtoEmployeesandDirectorsUnderthePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected Life in Years",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r499"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationWeightedAverageAssumptionsforStockOptionAwardsGrantedtoEmployeesandDirectorsUnderthePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected Dividend Yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r501"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual",
      "http://www.biocryst.com/role/StockbasedCompensationOptionActivityDetails",
      "http://www.biocryst.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails",
      "http://www.biocryst.com/role/StockbasedCompensationShareBasedCompensationDetails",
      "http://www.biocryst.com/role/StockbasedCompensationWeightedAverageAssumptionsforStockOptionAwardsGrantedtoEmployeesandDirectorsUnderthePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r469",
      "r471",
      "r474",
      "r475",
      "r476",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r508"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, stock option awards, exercisable (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual life",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r493"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Options cancelled or forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r1212"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price of stock option awards cancelled (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r1212"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationOptionActivityDetails",
      "http://www.biocryst.com/role/StockbasedCompensationWeightedAverageAssumptionsforStockOptionAwardsGrantedtoEmployeesandDirectorsUnderthePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Options, grants in period, gross (in shares)",
        "terseLabel": "Performance-based stock options issued in period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r482"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationWeightedAverageAssumptionsforStockOptionAwardsGrantedtoEmployeesandDirectorsUnderthePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant date fair value stock option awards (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r492"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options outstanding, aggregate intrinsic value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Options outstanding, beginning balance (in shares)",
        "periodEndLabel": "Options outstanding, ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r478",
      "r479"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price, beginning balance (in usd per share)",
        "periodEndLabel": "Weighted average exercise price, ending balance (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r478",
      "r479"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual",
      "http://www.biocryst.com/role/StockbasedCompensationOptionActivityDetails",
      "http://www.biocryst.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails",
      "http://www.biocryst.com/role/StockholdersEquitySharesReservedforFutureIssuanceDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r474",
      "r475",
      "r476",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price of stock option awards exercised (in usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r483"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price of stock option awards granted (in usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r482"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r468",
      "r477",
      "r496",
      "r497",
      "r498",
      "r499",
      "r502",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518"
     ]
    },
    "bcrx_ShareBasedPaymentArrangementNumberOfPlans": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "ShareBasedPaymentArrangementNumberOfPlans",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of plans",
        "label": "Share-Based Payment Arrangement, Number of Plans",
        "documentation": "Share-Based Payment Arrangement, Number of Plans"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1",
     "crdr": "debit",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total stock-based compensation costs",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount",
        "documentation": "Amount of cost expensed and capitalized for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationWeightedAverageAssumptionsforStockOptionAwardsGrantedtoEmployeesandDirectorsUnderthePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected life in years",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r498"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock option awards vested and exercisable, aggregate intrinsic value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, exercisable, weighted average remaining contractual term (year)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, exercises in period, intrinsic value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "bcrx_SharesIssuedCommonStockPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "SharesIssuedCommonStockPremium",
     "crdr": "credit",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyFinancingObligationsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued, common stock, premium",
        "label": "Shares Issued Common Stock Premium",
        "documentation": "Information on the amount of the common stock premium."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Shares withheld for taxes for vesting of restricted stock units (in shares)",
        "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation",
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1233"
     ]
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term investments",
        "label": "Short-Term Investments",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r118",
      "r1063"
     ]
    },
    "bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails",
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskSummaryofRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Accounting Policies and Concentration of Risk [Line Items]",
        "label": "Significant Accounting Policies and Concentrations of Risk [Line Items]",
        "documentation": "Significant Accounting Policies and Concentrations of Risk"
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "SignificantAccountingPoliciesAndConcentrationsOfRiskTable",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails",
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskSummaryofRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Accounting Policies and Concentrations of Risk [Table]",
        "label": "Significant Accounting Policies and Concentrations of Risk [Table]",
        "documentation": "Significant Accounting Policies and Concentrations of Risk"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRisk"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Accounting Policies and Concentrations of Risk",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r204"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.biocryst.com/role/SegmentInformationSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Axis]",
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r125",
      "r164",
      "r245",
      "r253",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r278",
      "r279",
      "r280",
      "r284",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r358",
      "r360",
      "r368",
      "r369",
      "r586",
      "r589",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r881",
      "r884",
      "r885",
      "r894",
      "r942",
      "r1288",
      "r1289",
      "r1290",
      "r1291",
      "r1292",
      "r1293",
      "r1294",
      "r1295",
      "r1296",
      "r1297",
      "r1298",
      "r1299",
      "r1300",
      "r1301",
      "r1302",
      "r1303",
      "r1304",
      "r1305",
      "r1306",
      "r1307",
      "r1308",
      "r1309",
      "r1310",
      "r1311",
      "r1312",
      "r1313",
      "r1314",
      "r1315",
      "r1316"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r70",
      "r74",
      "r75",
      "r159",
      "r160",
      "r161",
      "r188",
      "r189",
      "r190",
      "r212",
      "r213",
      "r214",
      "r216",
      "r223",
      "r225",
      "r227",
      "r246",
      "r324",
      "r325",
      "r359",
      "r417",
      "r443",
      "r509",
      "r532",
      "r533",
      "r535",
      "r536",
      "r537",
      "r539",
      "r593",
      "r594",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r614",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r651",
      "r653",
      "r671",
      "r735",
      "r763",
      "r764",
      "r765",
      "r781",
      "r833"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r213",
      "r214",
      "r246",
      "r419",
      "r420",
      "r422",
      "r424",
      "r653",
      "r710",
      "r773",
      "r782",
      "r783",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r793",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r802",
      "r803",
      "r804",
      "r805",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r833",
      "r871",
      "r872",
      "r950",
      "r1319"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.biocryst.com/role/AssetsandLiabilitiesHeldForSaleDetails",
      "http://www.biocryst.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Axis]",
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r162",
      "r163",
      "r228",
      "r467",
      "r1044",
      "r1045"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r213",
      "r214",
      "r246",
      "r285",
      "r419",
      "r420",
      "r422",
      "r424",
      "r653",
      "r710",
      "r773",
      "r782",
      "r783",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r793",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r802",
      "r803",
      "r804",
      "r805",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r833",
      "r871",
      "r872",
      "r950",
      "r1319"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r967",
      "r977",
      "r987",
      "r1019"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222",
      "r1223",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1231",
      "r1232"
     ]
    },
    "bcrx_StockBasedCompensationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "StockBasedCompensationMember",
     "presentation": [
      "http://www.biocryst.com/role/SegmentInformationSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Stock-Based Compensation [Member]",
        "documentation": "Stock-Based Compensation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee stock purchase plan sales, net (in shares)",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r69",
      "r70",
      "r108"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares to directors in lieu of cash retainer (in shares)",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting of restricted stock units (in shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r108"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofStockholdersDeficit",
      "http://www.biocryst.com/role/StockbasedCompensationOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options, net (in shares)",
        "negatedLabel": "Options exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r69",
      "r70",
      "r108",
      "r483"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee stock purchase plan sales",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r69",
      "r70",
      "r108"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares to directors in lieu of cash retainer",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting of restricted stock units",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r69",
      "r70",
      "r108"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r70",
      "r74",
      "r75",
      "r108"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 deficit",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r74",
      "r75",
      "r96",
      "r795",
      "r812",
      "r834",
      "r835",
      "r937",
      "r957",
      "r1126",
      "r1129",
      "r1130",
      "r1187",
      "r1266",
      "r1321"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 deficit:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.biocryst.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r428",
      "r430",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r442",
      "r443",
      "r601",
      "r613",
      "r836",
      "r837",
      "r849"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.biocryst.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Line Items]",
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r647",
      "r674"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.biocryst.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r647",
      "r674"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.biocryst.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Table]",
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r647",
      "r674"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.biocryst.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r647",
      "r674"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.biocryst.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r647",
      "r674"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.biocryst.com/role/SubsequentEvent"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r673",
      "r675"
     ]
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "presentation": [
      "http://www.biocryst.com/role/StockholdersEquitySharesReservedforFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Disclosure [Table]",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]",
        "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group by type of sale. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockLineItems",
     "presentation": [
      "http://www.biocryst.com/role/StockholdersEquitySharesReservedforFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Disclosure [Line Items]",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental Cash Flow Information [Abstract]",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1013"
     ]
    },
    "bcrx_TermLoanTrancheAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "TermLoanTrancheAMember",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term Loan Tranche A",
        "label": "Term Loan Tranche A [Member]",
        "documentation": "Term Loan Tranche A"
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_TermLoanTrancheBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "TermLoanTrancheBMember",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term Loan Tranche B",
        "label": "Term Loan Tranche B [Member]",
        "documentation": "Term Loan Tranche B"
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_TermLoanTrancheCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "TermLoanTrancheCMember",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term Loan Tranche C",
        "label": "Term Loan Tranche C [Member]",
        "documentation": "Term Loan Tranche C"
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_TermLoanTrancheDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "TermLoanTrancheDMember",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term Loan Tranche D",
        "label": "Term Loan Tranche D [Member]",
        "documentation": "Term Loan Tranche D"
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_The2021RPIRoyaltyPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "The2021RPIRoyaltyPurchaseAgreementMember",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyFinancingObligationsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "The 2021 RPI Royalty Purchase Agreement",
        "label": "The 2021 RPI Royalty Purchase Agreement [Member]",
        "documentation": "Represents the 2021 RPI Royalty Purchase Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_ToriiPharmaceuticalCoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "ToriiPharmaceuticalCoMember",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Torii Pharmaceutical Co.",
        "label": "Torii Pharmaceutical Co. [Member]",
        "documentation": "Information related to Torii Pharmaceutical Co., Ltd."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1005"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1012"
     ]
    },
    "us-gaap_TradeAccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TradeAccountsReceivableMember",
     "presentation": [
      "http://www.biocryst.com/role/TradeReceivablesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade Accounts Receivable",
        "label": "Trade Accounts Receivable [Member]",
        "documentation": "Amount due from customers or clients for goods or services that have been delivered or sold in the normal course of business."
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_TradeReceivablesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "TradeReceivablesTextBlock",
     "presentation": [
      "http://www.biocryst.com/role/TradeReceivables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade Receivables",
        "label": "Trade Receivables [Text Block]",
        "documentation": "The entire disclosure for trade receivables."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1032"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r1034"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.biocryst.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.biocryst.com/role/InvestmentsFairValueRecurringBasisDetails",
      "http://www.biocryst.com/role/InvestmentsFairValueoftheCompanysInvestmentsbyTypeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r412",
      "r441",
      "r601",
      "r612",
      "r626",
      "r632",
      "r634",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r723",
      "r736",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r938",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1256",
      "r1259",
      "r1260",
      "r1261",
      "r1262",
      "r1263",
      "r1264",
      "r1265"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r1035"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r1036"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r1036"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1034"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r1034"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r1037"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r1035"
     ]
    },
    "bcrx_TwentyTwentyOneRPIRoyaltyAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "TwentyTwentyOneRPIRoyaltyAgreementMember",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyFinancingObligationsScheduleofRoyaltyFinancingObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2021 RPI Royalty Agreement",
        "label": "2021 RPI Royalty Agreement [Member]",
        "documentation": "Information on 2021 RPI Royalty Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_TwentyTwentyRPIRoyaltyAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "TwentyTwentyRPIRoyaltyAgreementMember",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyFinancingObligationsScheduleofRoyaltyFinancingObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2020 RPI Royalty Agreement",
        "label": "2020 RPI Royalty Agreement [Member]",
        "documentation": "Information on 2020 RPI Royalty agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "presentation": [
      "http://www.biocryst.com/role/InvestmentsFairValueRecurringBasisDetails",
      "http://www.biocryst.com/role/InvestmentsFairValueoftheCompanysInvestmentsbyTypeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Obligations of U.S. Government and its agencies",
        "label": "US Government Agencies Debt Securities [Member]",
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)."
       }
      }
     },
     "auth_ref": [
      "r874",
      "r875",
      "r910",
      "r912",
      "r1285"
     ]
    },
    "bcrx_UnamortizedDeferredFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "UnamortizedDeferredFinancingCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unamortized deferred financing costs",
        "label": "Unamortized Deferred Financing Costs",
        "documentation": "Unamortized Deferred Financing Costs"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r1031"
     ]
    },
    "us-gaap_UnsecuredDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnsecuredDebtMember",
     "presentation": [
      "http://www.biocryst.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unsecured Debt",
        "label": "Unsecured Debt [Member]",
        "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r133",
      "r247",
      "r249",
      "r250",
      "r251",
      "r714",
      "r716",
      "r877"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1001"
     ]
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "calculation": {
      "http://www.biocryst.com/role/NetIncomeLossPerShareScheduleofEarningsPerShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biocryst.com/role/NetIncomeLossPerShareScheduleofEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Dilutive potential common shares (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation."
       }
      }
     },
     "auth_ref": [
      "r1137"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.biocryst.com/role/NetIncomeLossPerShareScheduleofEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average shares outstanding, diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r239"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.biocryst.com/role/NetIncomeLossPerShareScheduleofEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average shares outstanding, basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r239"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "presentation": [
      "http://www.biocryst.com/role/NetIncomeLossPerShareScheduleofEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Denominator:",
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "bcrx_WithholdingTaxesAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biocryst.com/20250930",
     "localname": "WithholdingTaxesAccrued",
     "crdr": "debit",
     "presentation": [
      "http://www.biocryst.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Taxes withheld on stock-based awards included in accrued expenses",
        "label": "Withholding Taxes Accrued",
        "documentation": "Withholding Taxes Accrued"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r999"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-10"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-11"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205-20/tableOfContent"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3A"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4A"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5D"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-9"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/808/tableOfContent"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Subparagraph": "(Instruction 5)",
   "Publisher": "SEC"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(4)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(5)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(1)(i)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(1)(ii)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Subparagraph": "(Instruction 5)",
   "Publisher": "SEC"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "a",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "a",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "a",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "a",
   "Subparagraph": "(4)",
   "Publisher": "SEC"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "a",
   "Subparagraph": "(5)",
   "Publisher": "SEC"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "c",
   "Publisher": "SEC"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481003/205-10-S50-2"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SAB Topic 1.B.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-7"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2A"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-3A"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-3B"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-4"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-7"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-3"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-4"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-5"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-2"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479255/942-310-S50-4"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.H.2.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478116/942-310-S99-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "805",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478072/944-805-50-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "12",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479196/954-310-45-1"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-12"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-12"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-12"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479299/805-40-55-10"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "39",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477346/946-830-45-39"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "705",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/705/tableOfContent"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(r)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(s)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(t)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(u)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "40",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481628/310-20-40-7"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1205": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1206": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1207": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1208": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1209": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1210": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1211": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1212": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1213": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1214": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1215": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1216": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1217": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1218": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1219": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1220": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1221": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1222": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1223": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1224": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1225": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1226": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1227": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1228": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1229": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1230": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1231": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1232": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1233": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4"
  },
  "r1234": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1"
  },
  "r1235": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r1236": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r1237": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r1238": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1239": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r1240": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-42"
  },
  "r1241": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r1242": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r1243": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r1244": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r1245": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1"
  },
  "r1246": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1"
  },
  "r1247": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2"
  },
  "r1248": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r1249": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CC"
  },
  "r1250": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r1251": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1252": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1253": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1254": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r1255": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1256": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1257": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1258": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1259": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1260": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1261": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1262": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1263": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1264": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r1265": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1266": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1267": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1268": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1269": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r1270": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1271": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r1272": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1273": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1274": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1275": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1276": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1277": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1278": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1279": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1280": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1281": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1282": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1283": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1284": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r1285": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r1286": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1287": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1288": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1289": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1290": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1291": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1292": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1293": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1294": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1295": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1296": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1297": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1298": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1299": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1300": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1301": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1302": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1303": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1304": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1305": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1306": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1307": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1308": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1309": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1310": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1311": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1312": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1313": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1314": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1315": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1316": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1317": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1318": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1319": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1320": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1321": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1322": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1323": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>101
<FILENAME>0001628280-25-048785-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-25-048785-xbrl.zip
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MB7$+,-#>;>?'X]W3W6U/:=_?*+?_[/S>OO_M5NETOW^_Z_7NNO<BC_X/X@\
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M8*BHIF2R)=1L@#\R*O?OU7F6#2OVC8ZB'.WFDC6KI>N:MH\JWHIO!8@.G H
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M%B#7P7Y+.? S1Q]L:4(P2GRP1*0VB\P<\G9E%NVE%-<6=PBOQ4I?Q7'Q2)/
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M9HN&ULTB^'6NS/T(HS5ECMU.NYUV.U_@=AN\6%OG7GMP<-IIKW_?61*P'-4
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M_0_P/CSX[?/WL]\OOOSVQT]'3>*,CY[4.,KN?:S@@PN %6*D52+X)=\.(1X
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M1;J(J[)K\-?D_'SG&[4@/[W?H):"(Y3:F4B5DK!#,V\1B_?J'W0OS[R']WY
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MR$BNQ"55(<U)E4$P_2.9:M%M(3^=M.#2?6A4(,"@4SZ*;*E.%L"!]"/C['*
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MZC$D'+_8*)TR \XK-D0+^[RXB[?:307,+/G8-3?&&]\A7GBL:\UP.PPQE,I
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MZD<CI&&"&H9D81WD1I>MH A]F+,5S(Z4)I HIZD3,&<LTBSU,O^)<M*[*<S
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M[N-.\QZZN_6)5!<*KPI-;'\*!;.'XBX$2MUY@?).?+DCP;#W_OKRM3N;.4%
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M.JBEY'L"N]R%4.Z7F"]FX4.N>5VXC%9L=&9KBC_[*'^6[NZ9C)KP+F8W@UW
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MW>%YOE!1O65@R\#;,? C]</[4@.&K9VI 9:++1>_=2Y^I&QX#]?PL&VO8<O
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M"#,"'F3'&: '#\9+:-6C$"9-^,_4IP!Q_%U$M_<0 ]H+1L*Y]V(:X3; !W*
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MV\F.IC0\..V76$#Y8VF0@*JF(!>E#YS^O1=OMMTGCW6!]>-%"+3V"ZB4BXM
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MS!]EMYTKH&X75.OT*H@Q=2)$OY3SPAW=UY\VCK$&ZN.L=Q\%(IU-$)\[7;#
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M14-R 2A+L-8%ES7.<U<Z*@S6]8D[%!E5-%YE56L"!NOJR0^U?@U@H,M:KY@
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M]#HWI;@B A(!D>-BM^P:SX]MD;H'-.[5.* =DJI4ZD3458LW[+^14JV]7N7
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M0#J^74;O 72\X[F/-U@XM7?;V'/+'CN2;@1TFHFTJ.DQCM%CU/</H+2GU;@
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MS(MC">H_7,L.3* 7T/G]+Q,^>CO'?]5F')5JH-1B6MOV^9;"3#XO8)4*WVI
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M.LB :'!YK=NYP57#.5&V=TX^QI<!\2W/G9OQ5HH.R0"3F?:^S6E/9%H _[*
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M 3O7SX'WP(C&WSO/DI%YF9^\#&AWN_!M1U)YJF2?_FPL%KZ'AO?#<Q9)<7%
MP \D+G; 1_PC<D%>JOP)R7)R6]]V/14O?.,9OH6 ?V?#]T./O_8.?L(T3W5
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MGVQ87 (@XZC@&%2 (\$O<1B=3NJ@<(K0E"I8[((/?./B/YS!OV:>8R72[Y@
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MQT_&(KC2;L3L:<H%L';XJ6GDX*V *.>^./@43+@#P0>O!=H"GVN)S>&I2(
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M%A9PTO "Y 8*JH2X7WAM(DX0+' X<X,DD1TD&&<4L0I" \TBV(@#.O\Q#MK
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M0(RHD-$P5SG<^/@S]1V1($CI(F,& <R>VXC420K*+2CR45U6;H5)DDV*"-,
M7$, []/93GI;!/;"C89V<.TM)O1B1$A[97>(U2NB%),QL=H;1TE*,;(BFB_H
MJL]O*0/#82%:8<['J()*LFS8C@JF=40&5A!YXS$O,@C>POJ,-#P;A@QWVW2A
M;8<R2!4U%N&%@C.(]0*C-"EOE+N+V)VGPC G3Y5F@N#N1>"7*T3!/)DK*C3$
MQ39<^9,$;#@0Z;TXC4I*SHZ4_PLT>&8PI[U9GJJX3I4 B3#$1OXU;&>E.#AE
M$)0!R-!4<<89)"2;TFL]4:&@(1$7Y-,BFG$=^4@1$!US20ZZE]HPZ,4UR[]
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M9TN5O@V&@,K^$W% Q\2EDT\Z.^*@/-XGG(Y3P<'^_GGPC^%O0_@*+-,LB<-
M#QD3SR,DH/<M%7AIGCD4*[\/W@^"OYNHLBG&LR,BAE50ZX1%E( [AD]:"T+K
M@5Q&[J)<1EDT!A--AO4L#"YJC+?"O>C^\K\CW-BG6IW ;SY$R5WC5[@&_P3_
M KYI#MJF\CUW0_,D^2(@!2D[WZ+S\)8JI/0<"$<ZF20QF@9D9B *NY(LR?T)
M(1! I *P>3TY1!N7V-N8<HLUJAP&6'8$1EZ$EG,HM6VR<[PYQ,Z.J26BZNE@
M]"(&B])P#7B9>D+A".(U-HC7T.<0S#J2>K!8:32B^-"M6@M$P'F9*$9.*TWK
M[8Z)B 6KA(SI=.&!X,=BX6HT\A@%5?<R7&%> @Y</@>/*LWG/8/5,^%[(>LG
M3+EE+FLLL/-NV$C&"& \.;2;Z'1C;(]I[,(];%,2.K*T^?B'>B[."V'7F5T=
M"]7LBCEX'V+L<!Z+>"?;/(W71^;0O3Q;1:6)BD[J/]E5(DW-SB1><??I/<9.
M(NZ4CI8@W!S :6-G7*U(4$7;08+"^P:Y:9_E?%=OETY"HG>6%")9<DK<]^I:
M!4]BF7JCK+KQ<;#W\$0G%N?JBZG*8@T'(-PCZ\J=9O]*FMW2 E! 801"*8%F
M3#D7.?=$P$(-*9?"(ASB$^P71<YJIB1MC*A*)3O-L1,YS?HH,)B#8C8&KT1_
M&R<5%0\3+"2/8Q"]I! B&7R O@XD:C"N[;@9?2@U/TRDX^JN;/PS&<?<>N%>
MNT]R5+0-FZ=@+DH*EE!4Q2R@,9&:U3B,Q8'Q[TDK&*J0*Y)2XSX159,I!-&P
MUIFI"/."DSIE[;#(:UUYCA\M%&LF>.V,*M51[L8:&HUQ28,!TOC/0?"R-K$B
MQ"FPJK%6747E[WE9$A&J10L:+:I+ZS4O%'$]"S^1 V-%?(Q<]80?EDN98\EY
MP32C%'XD['QH@/11DE(I('^9&\F*M'FTEK&&:#O0U6B,?+RX*A$9+VK\^46B
M1S\]%AJCS^G A*N+ "W;5_&F0TH,8J:[0&:U>7BYZ,=N)7%13Q'V8Y@Q"6:>
MY0BP&_/Q08P:!K?W[O("));01AR.1\;UP^/]1GH$,?/T#\F]70X=X .<_CLA
M0<=(0$*V!)J:=.@0;TZ5)X11*UL0> H%.UH)@^&@!-"6QI[BS.;-3:O@HH+W
M224@LVNH@GKJ"IRN5%-+RZ9;[,$%@]@3A3]1>",G>C053*,Y#8^*)VT@A5.)
M#EZN_S[HV>W-E?7UX%,/(?&/B1J$H_#?-8B*AOH^DAU&!_!.\5VJ^Q9(G0$%
MR5X38"<;,Y[^PC&+<K])V>N7%R:SIKO0O8[@J'\H\(!Q8L86(9G=[HP6=N7P
M8<5^ Q7 ;:G[U<>=OE@-9:O5(!W0(J-+V(O&:A?V7]DOI5:\0ZX<(U9=/6QA
M7:1HS\0I>_JKAN<P"!1&>-)_/G\H"-+)#H+T_4*0MNZF60%DLMZ<MLS"TBJ?
M2TP)<J2UH$0L6)?YA;-L'34R[SU DR2S"8]^S0U'?0)OFJVBNBDN9U\@L9P.
M-8S%CH)9;TYZCDV\"%JK/B(2V)!.2+".[B(W/#!2BQS--;X%OB-;ZS>5S[&7
M(BS.WQ%RG2;!^\%\<#$(/EB>X6][.![3&+N@\I5;A-(Q])R,\#%E"/Z[SE1P
M<.J(;8/ 7[I&U$5,8F(;^'J]P.E#U_I#K69QW=U^@S=2,F2X^QL?< C!T?6_
MQ4H;7684VV:7TO[.U) QF\X=11U,=^ UVO)Q=*57B$)B@[<M]_)B&F6P'9VO
M!Y&U;?[L(VTKJK>MELI^<P2FD[8K8=_!',PR]+X=H"T%$XI2"LZ4HC35<12,
M*Q/3,_?7(2W9TST=6Z9,R<KD'44WT2PC1:VQ\TII>S:4)1'14!LFB6DCLW>^
M4.UD1[M!K&'+\7I4]?:1=3K02T-4W;>:M#$U@!ISER33JA;6X)%\DR<'Q_N#
M?<RWI(XVVA2=$<)U4KO-@8P&X!B<UW"I@PF\3QX;?!:.1-IF/;H?,+R_GN,/
MC[5#PZ/-W2!L_J6/F2Z:=G)WE-3B1-_8]OPQ)!>'I&L.#QYI93N[2GDGUE-5
M9<Z]?Z/@R?#8;DE0Y(LHK1!\F1+QU411C.G=]15,;G@>4'=?Z3$G=-,*3  0
MW"5YR^_N^@=?1^.+F^M\?S<JL4#[KY>\=7^)33YNW_>1TV.^T#WF/;XSO(12
M+,.KA55%89%L*CWHK?'1[NAS)WT"W?I,"M3@/UHC,2>'+J968P2W<EJNVB*A
MM*A[$UTXTWFGIW-US6WLXZXV]D1UX]W;*S^#DH)T%$#2T"&0K(WEWB%2#/JC
M9ARPL=Z./F+=W=Y^G&-QGP;J$>RF>8QDT M',CLMW:X65'>FL:6DRV*X<#&9
M2H^4KFQ&$ V6I4N:B6FH!;)IRBZ817+O8A0_%);J+UT S?59:"N[U<&O;TEX
M&4RR@"=!]=$F8VF?ZDJK31^/5'6'<$B!\;06IC!TS:V%O/\*ZM-L= ;]19C5
MI+!(C7(C TR/))A)^3S)Z)P-B8N&_1/;4&Y-<7VLN\9@F,F$_0%UCV[PI_^&
M_A1HCDB^J<TYZVY$GLYWF]<8KB32; \51]@"%?(F*JN'.TFP<U@;4GP4,)GZ
M3-G1Z8DN31$%69[M65UCI06W4K\7*4%*Y8)[](,TL 4;7X7H5_IUT*$#<5(M
M3E_5H<Y:%RSG&[67+\@($5@IP\X<9=DQY.9+:+!+Z!K,6/#5A$&H2Q?GC9V>
MUKVM22;HB,9H+Y4K-'&V9Z[BUMK?44#N&DWYZ".< ^JM99;INPM0]X7:-LY[
MS"5!>^ &TF<1=;^D7"'9WTJ 68\9)MGD*(G6"VY7\U;+07N%]AV#P6,MKA-\
M/'/D@&@XD!NE<)D^3,S,9"R0:4K_==.VIC],^%C\NQ+5RB<3)N1*TR6R S:U
MAL,_&9Z?#4Y-T(/PN-*162T7JTW;DX?R+K_IC-;-OG+/[0\.X;QT*/9[5UYC
MM@YVEYL@/A2*_I$Q/^W6T"TS-UNZ#EY\I=GST\\F77Q2J?[6^WK$BXRY&>S3
M>8?Q3S=)HZL\^C) 3_UWP@/];K2]V]K[1OU$_J8- 5T[-GO5T=E4"#5]BQ']
MLG(B36JQMWJ$>6FM>UTK$AF#!.A$5F2H^_ TFKL_C4IN%(I!/@3MPD3MY-G7
MG.'/O-J,UH71\'1"V0->E;(&1Y-Z8\!#EZYR:W?MNFQ1(<G[%<QYO_6KN[N5
M7T_%KKC_<2_?Y>V;E4KR+LH;%#OXLNR$BXFFTBE!<3X!(VI_B.X4?P79!*B-
M!9\+>P,E,XF7$Y.AI W<^_W'1GJ=[I!>WR_2Z]')IAHJ6L+#G=%[[&&N*49!
MZ\!E4.DKEJHBB0&%** H[1T\39X%^X/C<Z;0,VJC54?QE.)*R433ZH^PSI12
MYD2[K6HJ))'&X\A-@D\J;<OV9\&3L\'Q,87$X%M\3X"",?""SMEXV60,\9B7
MT_<15$"EQ=$G+)W\!]7,EU;MF0+W]\CV7@;_QEW'):&JE6L0&U445,%/:A&N
M:@R1"1Y!CR'GY>15IR#OB&R7I$HYF*8_Z'4PIVH[S??<RH(WM3\G@.2W/@<O
MA5AUC6Y[9K0[-SQQK\+/!F*[$SH=46Z_C+7[EM*3==_KW#.>37>;5[HFK17\
ME]P:,E*V@Y5\A=74)L"\Q@$"='>3YS<BA2/B31*J4+W1%UO9<QF2RX4(.WW3
M1N/<8[WL;##O;LCR/"E96R-B+KOWO&*Q%I%AP<,F2F*.RT?O7<78^R"QUE]#
M:^AZ3>TC+IFC/9W"G(N698%%>BSE2RLPEFO+S7+*I-4TB)+M4-]/T> :F(<G
MWT&>HM,SZTE:W L%Z!"B5BICK$:5VUHO5575,&OM1@1OZ*^^=V=NALDD21,J
M7\+Z!"2&)82+^-0&.6C^8![35C?V0R[02/)I4?#DV TU@C+/\#R4R.J(L#'J
M/HBED<QA2[< @Q9@8'B]1DZ)JT;X4O(@S2-I_@'OG6).LE+M,"%&>@Z]$;C+
M=24/_( /Q#"/=03HUG5?/E;(QPO_6T1WS@C,T.\="BHH5%B*;MTG[4'A\TK6
M>62?A4%K9W$@+V4@+W$@9N0&IZ=M!AQ^QN0Y7VD&0W<*? FW%E1R2XO@WO$C
MK>68.^.0]RU8FK$0P3N'1"?X*:!JLK!U,<^)6K#[?L.GZQ:4GJWA%!.M>49U
M?QTJ[E6:1E\3(#@X3/OE1XM)?^!DM-;2+6Q.]:TVK]%ZQ\UX&R^?LI7Q7W4B
M*?>)OF@:E#B([P!%XO0;L(4%%(5)F.$CCVOBX; ZN3'S>[02'@PBF8],SR,;
MH6B9IRT=;(P'E+M:$WA[R_+Y)=2G&]EGM[/!!VHY["S0W<7$5#5*Q;X].JM\
MZVB;N-)>>]U=[ED.-,TK*D$6-ALJPP'E>SXX,O>'NV1/AL/3P=#\:;+&RXY8
MB\,9*PCZB1+=>'EDB"C@;C\Z&)R9%[G?,NFAC-J6T9?=L\L84\*V6_X7_5S_
M4;=Y6G,HCVE5VIU83-$UCLTT(Y8R:5U*K7N1-)Y.N&N#@/ F?F.[D!!.MKQ)
MYJOQ:6R0J%WF)1E!&K7!B[>.3!S3XJ!PT (_.1@<>%FS)X?V%V%@Z4O2!0O3
M6-DUC3M'@X]M2X'W1:2TR,@)1UJ6XI;N5]3(:,XPB?_J\_DL_;)-F_Z!>$?2
M-+_C^ [&:^CB*> AI1"<];#;6-8:CUR<"N<D#1*[W8QO:"7S@EA1Z'Q:&A/^
M&&[4E$MYHO+^%[=P=4*W@A5-="SSNH3OEL]^6:=YKRR"#I-CLXX](M^:E^H7
M_8_GXZ0$DV_Q2Y+1HM*7GOLD.1A4IB!8'*42-Z<-YS_;>/-@GV/.50'_-]9O
MEC\/X$\_MW]_.AR<'W;_:7\P[/Q]WZ.&!X/]L^ZO]#VJ__='^R</-ZC#I8_Z
MF=:+UPRV!??W__QT^)-- HQ1(G_9#X:PK3_['SMO?>Q@_@D_^+R5Y&AN(>_>
M-[63]OFDHNKYE57/J[;J,1)>C;]L;>S'1/CI;,PK1!O"W8:3?+XUJ^9R7]#*
M?.Y,?XBE.EI'B-H!->PH.9DLFW&J)BV=^/7GV[KZ:+XO',JCIHC<-\75MGL_
MV/ E>/*5YNW.ES)AFS+A@_#X])B;8'Z=J>.?UEJ"?HURW_%R-=).7K]7>3T_
M/MHT>5W[7I!$R[;<"\+!U&LV'*PWU<Y3M5%2=@I:<5TIZ][3KZ;[&J_KM,:^
MNWT9AL.U3_\#[<MW;OMU4#2M<\H[)KL-TG2VO_]Y=\D&6#C?[[X<A,/]S[SC
M=S?YTI5E#O+@97#-4<D?YT8_7-?)V5WGW^0Z/S_<7>=?867?2:8@I(K/G!+[
M3(2L#,F@;L_PXUSXQ^'1\>GNPM^X?3D,#_?/=Q?^5UC92Y=#@_E'&%DU5T6)
M6,N4$XT_CB$P!&$;/M*ELS,&EFW,47BPMG;>60.K+"U5F>R-HE)82K5&^'%N
M_I/P^&#GZF_>OIR%QX>/M"_?^<W_EA#<R*W40B!QY;0@CGZPZ_\T/#Q8U]3<
MW?[?).-RMJXBV*S+G]Y[N@D*H0<N)6#D>R"$GYE5%83?(:S#.*\1+TB9U:U+
MLW>OW>>FV;]L53;@L'8OQ]%1>+)_^.VK<?:E^?SG)_^_:$,V&\JR.X$_T@D<
MAOMGP]T)7/5Z_YG@Z#\Z5\S9CBOFA^&*V8!2FN /K!^ERN=9E&3,:5($"@F@
ML#B,"%BR94:I- K/J-L.>;%[HX5Q:$=1F92#P.EQC-1GV/80W5PLM'?X(E<J
MW#%-CK%+]$>NR>U_=>CW,^<>V9F:)#!?&$PR3Y5)L@V"%PJV)]/55KIM8:-D
MBE6K+5^\P^$$:9Y1^6^:YEC,T^W5(\\^K:8L6F'7EW_#U (RF@_4"5IJD;"L
M6,VC0I-L*>39L!7)3EMM8O1/8*PE_+.DUMFC_%8-@G?W+NU-=(N-717R_,=I
M5)9,"K=6B:7FE<>QCJB^F&8"XT]*7*@$_H)55+;T\IY1;5-EVOU+K$LPN93U
MZ&AP\EF5K,?,I_KD:/A I;"-(D539EJYM7:_K+P58A'LH7U*="C>YNP-SQYC
M=XA"XN3YMS?)X.W^B@R/!L>X D].G")GMSK7]%2]KWS84J=K-B4#'LAM93I1
M/TEOPXXFKO"<&Q6EU<V"RI%!L2!Q$],_<!/$Y[N=?^"=/W .KKNAQ1JPD+9T
M8"%Q62732)C6L''X&+L4"SD:_GI/96"[D+C8IAB-MFK(%@57*??N2N:*+A7]
MVN>:[#LE8F)DB!@M=KKAX27$$NBXQ>)E3ZI07S)MJ2#J,O#Q4LT) \;6O4^I
MYVA9-0C/"E4EA713 O\O)O(0YH3?1U;X#L%H:BSD\RN2&(6-:<KJ#*PQI,(=
ME[H-Q4[=/+0P#1U: U>8FG!35V1( 5%C+ M.H=8$>\3^9@C>Z7OP+!2!Y_BI
MW>X]\.[M#\X[=R]>$3ODJ(2H@M,WJD77^S04O;:X?BQ8">,8N;*^.Z,\K9'.
M#:PCR;EZ"5B?](K\P[Q_L>RMVDV']9BD?B\;$Q)".CS,GBRA*]$[02M<3%]=
M,A,2,D(C*1[= :KDYCD9$:&DX((6S#):5O68B''DB0T+EOI%E*6PC;F-@439
MT/-B))Y&]BU-QRKOD>]$4]5HU.W3GS)UFJ;O\ P?\[6FS27C;O9#:TJ(LZ#5
M36[\]TSAK) '#/L>&;VJK$[%Y:/CZ*PSJU:/%,SAYS2<;'HZAOX,"5R7# QV
M0_>+$Y83Z?D56DXPRY,R5K@,B3$<O!/T5YW,#5<<CP--5M03]T=T)L@K5JX2
MF+B-J(5;G'-?-KF?LIH\6B;<88,8=:+>,>],"D596:%L-&:A*8V;YO4@>!-A
M (B_U+:^=4=%HOV9Y22CV&=*F%;Y:^;3SL4JP:)49=/JQC16T[S\ON":H=_
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M;M.9*?SWIFV-@8P9/-N+&IPYN#\?::WU;9E/)A1BK\'Y[I<=@5]PY^3S,P<
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M>_A72BML:?/P%?7IP7YX</+9YMPW[]_]#7)DNT/PPQV"+[.%-[N)_;?%C/:
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M=(RG1WV:&ZP?)ZIZXSIQ-#?51KL->0 -2<&V)J!@#MZGA@Z4X/<D&MC0P!/
M)B9CJLCQ/)_=X?GZ5@R7'H O(ENCLB+'ZXPS?0P)=U'[O&.[;7BP(P/'I!,+
M8VX1K,JO*:O5P+VXV0\*.?>"L!J/<(^E%PC?[?+#[K+'D .;52(8P2^K9E/1
MV: .7,_G@WIV&_BUCRG%[4!;,JRK9Q]\'*5DS1#H1=^.YO,43AWMZU-IQO[;
MRPOI,OY,BKAVF_G%H3^L Z\2@Y$W'C>I/($Q[I;Y(<X,H318<Y5D1-SFZ:V0
M69GT>1<H8;?Z7PJ2AP7?,W#OV$":!)P%KI,U++  RN:'6INQJPMY"&/[7K3P
MKC+D051.6]-$5(T[)S>&"G:[BI<EF*-K?#$,RU72/EZQ_70"K'*A1:O*&G_0
M%<#T U59C^F?MLZ:$J]<8LTEU-L$#.D!.8V4M74P^QPEI8<=U@@28LZ8S5-5
MJ0>U>'E]I3*W5.JC'85^=1.69?<Y#ZKHHV)+ *O/":-N H(^LE!'>N6A'!TL
M!\&%G:O&DN%0$% -:V,Q,7<W*B,8E*+0E1X4)O8QCI\)2%6@&@9G[>&N[O+B
MHU_RZA;U^ *,K^(KP ZP\?U5\%AB)7GQ:UB529XF.4=\UJL TD0(@^!7! OB
M::6"EC1=<*7&LCD:]"JCBI3%A&<U<B"%-N$>.@$J6X# (*V.+'MG[52O?_W<
MJ(A0/YPA8)5FO'4>5ZC;1-V57GF6T,-Y%(].HMK[MIW^<T<SX=@L+I&5BM5F
M2TLT+&1.K&*4.WC>2F4N!!E%1'2G+8U>KKH5.*Q?BL!?5U*PP*@QW\&24C5E
M!F"+*$;J)DHG+)-NJJL-_VO#+ISXB8:LVC*5%-_$&R9*+!K#TQ*Z)=!,TEZZ
M7M!Q1 RK9EJ#X+U2@3AQ7^^&7),V[UU2?@Q>,]).>E[@K\K@'64H6?>A8GDA
M>RX?>FV*37"!WAB8)WWY4>Y_L3Z&O&7?RSJW/_02 P,O&Y?B95.#RM>O)GCC
M34 4Z9R1'G#UO$.I5[@WBE-F%A!T>"IZE8JPQNX=9=@N0-O6F;Z/OLH5'E 5
MF[!9V9/UR.(&*WH-RQ5<787!5:5FP?""*T$2U')&)TSJ@E+PB.2J344#:4K:
M8X>?IQ.Z+]=<5WU;,OX_/]V/ 1GNG_STN"1)W2QVEXA$Q[OA@LF9<=ZOX,Z;
MX99OE]U+;#<&_J&H%C?)ZU+S3M/EA81"5(&"3C;C-=B <H)](!E<?W!Q<6VJ
M,9#QG6M^V<]@$"'Z&MXAPJHK1*831QUU:""YLN6!,+Y*\PE=2F:Z:X#BTW@5
MUW_6XZD%=T=E6<_FG&<8">6>% S@Y&@Y4+%0L4=4YJ@>%D&:?$0K$@2=/A A
MAZTJB*%H-H]B8ZK%H'D6."*LX^$;6H^VDV0<+$4[ &*E'",(@_#(G1N0H\Z*
MM?AU?(3IH?KG3+29_L1QKB-=U@DJ !0^/1W+!0JT9Y3#FF4@[KS#]%VNZ!S+
MZ,RR*:>.,DZ*N)YQ7!G&^$+%45TJK4ZRB"N:^*?^P5/-M3?X$(VXFE,_E*CE
M@O)Q@K4=AJ^H;#Y4Z<.JY\%?6V=SN92X<U>-!>:6HUNK:IL4Q$V2<@V2>Z*Z
M)!,%@4JD)G5*I7<E2.F(3_VF63:_@2L1#,7>>.],S%'GUV9B9*MDB%;5^4G8
M3C1R'O\21QG#R9!BN#1*]-)5HM;L?6^4J#4 ]/W?N/Z]2FU2C![K5Z\$$!D"
M\B@8%8754LDX6.0UD?62<)!:,*70=!ZY[C$1[E,>A'<#Z*-$*H$;4O/+BF7:
MWIQSG@1,JB[5DHNH\\;9H:81-7V\0TU_OZCI#62*?B=4$N]@03#B 2NR11?G
MM5,Z[=PJ[U'I$9'X93XFE>4ERB_>7YI$^8=\GL3!R?Z)9E7!5?B/*6G&!X\5
M?(3U(%6[HLG#8<M9@O? -,_'Y($BUV<2"\<S<1V@E8E6::;Y)R1_-DD59].4
M,4>E6ENCA2G2!;.I%D+_H:U2^F7*-[[Z).7+3.Z"5;*MP8"E"G=#?"-W3(*V
M&]7/$S,&=KDQ2Z";8Y7,]L!EJ-*/-P*E?:M NM0<;H.Q2GDJYAM/DV<&CV<3
M(%P5)C!VLR8A?+KCXU*DQC6&3M\H Y#FI]&WX>LZT*R_[E0BX^R0+^=I<OL,
M4SIY+$&2KH]I-H*>UW-D]>GM,R,<G(=F\<!P1\@T/?A!O65('%].Z+KN>>XV
MF:<7ML /-US-.=L%Y\4@,'$!V^? '!$1(A61#Z#W$<WZLL0U))^'_NJ=*N=A
MR+,[IMJKF%EA;*)!))_D$:VCGHVD(GM[P(D26,ZXQ[W4(R0D[:66)DN7+.PB
M&.CM?C&'Q/HE#)^JY66\H5T&>K2OQ.'>(V5GB&WIMDBHWU)44=,#:5HD)QTE
M;8W0\*5_.9DG&W@!C3S%8=\D\[F$8>>PE]KZ?ZEB[JQQL'^PSV)K'H:>ZBRY
M38I!("3!O\/]B_TX*G&9E3!LH#%/ 5?]?C@)(,@5ATK,^S1) ]A2,)14,F-$
M#2*E00L]<+H%^-Y18^%P8]V,R<(*_] SHA+YJLTX$(-H7H+'$YS1&@,7NI08
M3B8%)R5PR\-(W(  I=?A],!DHD+U#6N[W/DN0T(WKR^M/M"3D[!NR:HQ3[46
M$DG4:V6%(8]C,'R8$4'S(&T5O1EVL#0+@]&CUA$+R$E&'B9,J%74R 5E3UB]
M0(,^;2GI9T:\M57"_.M2:X,A5S+:?9.+HX!LP6A'UJ,Z+]2(Q5]_\E<U!I,R
M&9-,\P\@N>3IO_2+YL5ZL(_ED!HRXE#D4QY,YI#]$!AUQ50A2UBIC1WGCSIW
M&^=[NKF2Y0ATV&?(;$$#2"NT0E5UD7'HLE1F;3"K3$3UF0D,C(CUVCCU(H[V
MBNRQ64$]X+2,A6JBG99 2S^*(]JR&0[[ ,8#ZE;6.O2#IW8PI>'F+G30%E$Q
M]F,Z=V)[U)&227'%\+YE,P"71X><.AI!8FXKRQU*H\)!K,!7F+\B,CR8.D:Y
MH*28_AY+M/NM 78DJPTY7=E>6LR>N4%68@/4^P+WQJ09ER6*3_JH$WOET*S=
M3QQ_-/ZSQE8$/J.3A'RD:Y)(C>4:Q,5&6+$)[<#IS\=\+NAT40)_I C"\#'+
M[S;-S%W3P'%(GNBHR^&]Q 5\QX?WD:*39,SZ_E57<P9&,C@J)R_ 7)'<*DIM
MZ-W H=<.">264A!ESM:O4<T:0@,WSS0ALAZL/M;D4B,FLY9N7,PXGJ8-,A$4
M45&H[5?2Y+2XRC&FQ29BM(195XF-D&SPYM?%.R#I]45_;$X:IRRP!5TP+;#%
M;4/<RT""L<P==Z.</Q3.]3X._69+D=4FKBWI'B+R['4F4(.B.I1'_RKH(.L*
M2\$ZDPP%O-\D"R@*5U<8D_/4WG>ZE=BQ,Y(UP\ *D4@C[0@MI:/+80SVLWN(
M96.*(.]&PJ?J=3$F([?Y(^^(UVXD]$-&[;6-66$39/32 KGCDD_;K6\N[<7_
M:'K%&0.)NMUH$CLR/=F$U3E7+5"H8[2Y'MI=&H'9.DDJT4-,VU76A70,[NLO
M8RK8C5XQ/L\2D="VC8V^F:^[4#;IB6 .@JGE!IM%57>*[?.9(67K>5&G@X57
M(YA9H5AQ> 3CCT)X2Y 7NLXIW>N\RXTR5)U/YG:)6H$X(^9OTE\%<-F](7S/
M"QX'^P&AXX%,;7>4/(ZRGA=3 N_TN;.4_$;2'G5#6<>N]!!#/)H9O3J6;6/-
MB=%A0+E:N$<#;_F1[[3BR5EFO[[+N'\TY7"M8PUW-X+1<*"1]EB3V4'-JD1%
ML*7 6^JA<5$<#<EIUU(,@A?V"FOY$;(@@AWK6DF/"I_RG=JRUY=+M]0S3ZQ[
M^W8_7PP*%ZAAW%:QDLMH9DSE)'/B^]HYT=:!N+R?:UBL;%1$:9DS+2=Y)WUB
MQMI([ LTF93BXD,3ER!L.'?]0D7$4\2M(:)=S$EC)MN^Q*@2]P9 (OVITMD-
M"Y'2.X_>??\8N_;7[:*]9'=YGT0WZ87T0R_V4:3,M"7K;(1C&FH'63/MVP73
M=^@NQTTY[I-=CON'R7%OY*5[[4?$'M.''^=4YZ.].&VZ<4P'1^?PBGL!\9":
M/,XQ(T?$8!Q[ <-<\$%:@V'>+)I1!(#Z'4W8V1\$O^79GL/J*KI2JUJD:\6D
M!KIZCL[O5ZE\>U%BF\-J$>G%HN0J& [ ^7$C[S*4V+BB( 58"YET,N:[=!"\
M<T.YUJ'/O%D0V-0D1+S+6$;DJ&YS[7J#,B;X/;>ST[O3?2Y>>NT(XL#BEO'-
M_J#]X.9?B&=(*BX=<5WB^V^UK4H>7K;ZS[VE++  4K81W^TP^4F3"NX.H%H-
M]2*I-A,\H"U'XEH]<+"H38:3E?2R)1RS:7?P8^QP/T^Y6Z\1$0E[S(U\=9*=
M6$:DG8!VMS;,OUI>3..NDE[\B:(DATQ+1_&[FA6$FHRJ>_WP00WGTX41F+R>
M"9/KSFF4;I6R%ZDUE?:WIOC#Z5_0AX,!O7=G)(V?-EX*G+&X<#_Y8KK=;-'.
M7KBR*] C+D+@.B+;#(:PJA3/H*WMQEPP\6*"$>IT8?J!C*43LT:DX*.[2\!%
MMDKP'D!=LU*N2YM),UB5?C3*%>T&9[V=HEGV@RS4!<=@RAQ6&! G<D:>D-9S
M/!$PJCL"F@MLI5O(M2H@8>]Z6%0N%3H&3&@X2_ :4P$]'S5WG@4,\2=U[9B*
M2K?72U!S=U(T>.9U!7^O;O)&FI$;NI'S_HG:!E!E&*9,$:Y$/="K_(Z:T-SH
M@4:>-]>'TLD,-ZN&_G#^P-HB\F[]QD'PK^Z,<U(*](E3VX1[8M]5CC_:(;XD
M)F3(H:7H]%-R =E2WFU,+NJ;A5]5,";4\#=Z*R4Y;L(3;:R3&$ &ZJ571ANG
MG'CT,&&<;D>0X"<V-!&8-ZMG3M*X7^*X/C9D="(%)^Y6'BP%K*GHF6H+G0O8
M2=A7FHZUU%E>[PA0GPHJJ"?J+5/^;J]H#&IR Q^'<I="%WBZA%3?DH-'3O\R
MS+7JS4;3U=$M"T=?1(BJM%!5!(N8'1.#4A?CXSHC$93=CM=Y*ZTSP]#1/%T"
M:W3L6@_4QC"\[D-@CEI225TB%3@3W#9%=>M!- 8"Q&W_I?1MWGR$&H#K2^7/
ME<44E%P_@ @A0A\YWDT#Z4IBV3<:?8!,'L&^E4Y*UHKX]3Z)]9!TKT!PKR33
M3;,,VG"VN9 ) %<T%Q&9LX.$&H);L_)=:S[8@&,XP N=]K,%(TJ_,&%> X-
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M9&SG,!A3OXAP\YH'PY"-..7TY3Q/4N'DHGK7UEE!UR,U83=]+.6:HGJ2]@S
MM4%KQ6$M(]"''HAV#CF..W%X&\@;D8>$UHRJ27\*?4-GD:W+$*8YKOKV%?%4
M\"]X.R7;-:*<,O)YEB#I -E]7,UB_&U=/( *ANW*#EHE3QTH; A-2]M4.-A
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M*4-+X-BO3=+F!I_(-D6^WE=Y_'&/2P0O'9=KB_3;A>X!+P@7"T.WW@KAB^D
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M8#,T[ Q^H0O%Q&W-&NZBI@RG =TLRB1&<%(4XS9K>EVG)P?U&T]FHQK4YLQ
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M^'B4N):T<*1#&%EYYMVB1##)$?O-W.VNF,1/TO'#C:. "BMO)FNX <V!<HD
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MG7']-YPI3U_^]_-G9X^^ ;%J7458J&2LJ!S*G'12,)LN(/ZN )9?GP"6OQN
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MH^\QZ#PU0);SKB7-Q?\=BW]U<YE70MK2<A_R$"8]W32D_7PNT";I[&VQ/":
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M>,QCNU&#EGC[5N$-BG)O[;[=%1O+R9/%T\7H'Q-.P:8K^2'A% I?_O^ZL*G
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MN(G.NC/P8<ZNRX7+ZJ1LQ>'I?^C1! ,DYR>L4#1KSRPX&CT&J_10JOT#5EK
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M,OV%42\W/-L2!*F+=*L8R'O[\@H##\]U?IVQ.-S%]3_H^4MRL5Z\W9;,KML
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MM9(,H4.!VFL*9J#HFS6C.1V8Q]^$*Q*!40@[28M4BE_.\^N!F,A(G&WRMXP
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M0<),TW!<DN">3+KKCU5N?"IE1#$_[A01)+4EQD!^8#JG&UK:M\ZRV#/7.>!
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M9.T0.A1E^2+&O)#\;)B@K,<J@EGMJL@G=TPVY:DSWIRA9I.=DL!K.ORV8>:
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M-^I,.+_;$*)5@M;,V$\5\"IIV"\BI6\BO!2YCGFFPM^M#YC=Z5-#[WVGC#R
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M5A4&"T5M/7@U).,*T'D?([\$06T*[^[F5@MUE94)OS N/K\DQ66.!#4M]'4
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MT@Y]:^IUB>)/U9+_RFUK0>)G_?@S1.M.;(X.+,U?!;.:8L<.-5E,38! C V
MLC-6AK+!4MF=AZK!@267'"J V))VB[2Z7K]Y=>7IM',\LDNKT!,QU><++3N)
MJEB"-)Y8<?:']E6EIQJ%Q"85GFZH];ED>X"7K7U?B.9FTZE^]E)QH<:;CAJ1
M-'XWL:6J26!;Q7->/M8 \2(3IR>J;CJ%"+I6W:1Y-LK@M5"& #<H9Q]Y 9,O
M0#9([ ^"GA0Z-%RI"7"EK6I+["J/)G8YF02WX<K6KD)5BEW2)-[3\3:W#0"Q
M2I3&%;86 /0L8[<3'K,7_,I; 1]Z\U7?M<!Y@A:F\=0^>D=]F R=\[-VZ:R[
M6(U)60[X+$N3L:0ZD'2!#/8E[[+HAK-0%M9+>_S79GF]9-H.V1?.J7C=C91_
MQ3-C<=-P="9K&NK+;UZ=6T1V1/A5@Q&122P!>N5?JW9R0D:\9CH&^*34TJ1T
MP$!&I!]$7CMU8[$_YR1%?5RO/7[T7DP^*9NP \4A0Z%0.=42PXNP=F@8I9%'
ME(:%_?<T@D@0Z.W@=,\</89<CS;[_LPZ(#KN0WY5VN7^;I6W9@BNKR,1^SN$
MJ@Z5Z$G@>)H+<?5.)=/DR"C=Q10O R<M=5B6VDKB/]'FU#0 :L-D$8EX3=A,
M<RZ^>NA&3H)Z@=+*&=R9/D P.6G6CT/<B%_:R0M-8,?<TR%QWN)(49F%<@R&
MMRK )E$H,:53O2<(BF&EEJU)J;\+AIFF+SBTXIR8I$T*Y= -8[UHYP2GDYO.
MY">("1%B])X.16)DY<+5GBO1CDQ0K((;2J65&T.M6596A!='M:D8GD*TF>("
M$42"M%#8LL&E".\8_-5]6U_KC1KG%>1KA_WAX3.@EH:(WKL4LTZ:>KL%0_,3
MX\W%(_%AA3I@]!WOD,I!]'<C PRN .8<W- $*%X+F1D]Y!/;N4?RJ5/66;2^
M,>$?.9S9)7->/PUC1_4J44-,S .I$R;Q)8X7K@H9"</S2RM=2$%+K&TOE&NC
MW!C4--*._8P*P=IV9S#+D%6!*F>IS$!C80J/Y*@L0?$018WQ,]KBUA\:]F8*
MLV0/%ZYF5D K#R1]["ZU$M,@*2@Z7VBKX>4@M:6O '[B'-+5.>]&ASLU#J-Y
MO,^)WC<9_DD!P9E2$*B9+4^=1"1D9JLR:-KIEY!YU,8,)5NE]W:59]=.]LV5
M)#'G9EGS#%Z*>Q*F$K-K6V/@$7.J)Z+#,P=-7J-^P&8"K2O.#*S\%&B=8&XH
M?V5JV,93IX85WQ(6]HKZD9&GGT*!,)CI2Q^,J1JUT$^2D?75/C2:U$^3[!HJ
MTHO/4<' \IPW8D@>-]4ER6^'<H?9ICBK&SA@+4E#/T\H0@OR\RE\#FV"TD2D
MO'!(VE!*5^/PB9:1FD:]X$9E<7 F.DYREH)%7(:^X-QIV$<KL3CL.K91LBW%
MR3$I".XB'?\6YN"V2'MCD5\)P;:";$'6 =C>J<IN/8#&W#""*9S'U8Y[L&LO
M49Z?ZRLYW^@""H)+Z0O:->&H-ROB$2[D@X@9=GE6,]4==_?N:D 0<$ OE^GJ
M()XAB1L;NIH1 X1_3CE<D^C6R\:Z=TX=_DH?_7H E 4.B%R\B*2D\\MKM\#'
M".@Q6L(Q4]<P5Y&?Y^>E*HIB4GE6G1\3QDD[DWK[KNFT^J%*ND?[DNZ^I/M=
MLPD-!\@/"6RTA(><#4D9 86@0>4V^0Q<=9]"7_83FL)5N/X@(\YV4?*:9==@
MUEYP5*6]GT4&3'!$LQ(X95FZ8>$9&?<T4GUJEX($R',Z4^FE;&N=)(Q3LAH4
MVNG,4@M.%05261OESA:$6OM%H@:UMN^$&UQ3:%*T#&23$TTNDX[?DX*#& (V
M^:0LD7.M.&$1V_/'?T\#6ZLC>^L=-)RBE3?NI,8,ZYV1!%G-9)DB7=5]\+J;
MUE(+-[E[$V=8O+":M #QM)^M1]]*RD-&P:*S&M%^<3\Y?=I@#-!H;C*)D!!/
M:>]6;W1J<;%P:RYSJG'9V .GBI,[UFNV3X7%T,PL'XDBP,*_Q1%,)#.\3:F#
M8>#,QETF@[<AF?X&^R" 50  @EC*O:9L05>JH"8:;%G!4R@)FP&U$99EUP0>
ME:I07S> VR^#CL[7QYG,JYN<R_EE1R[%+6T^6,9)5DM2N_2S-B1C%(-BSA)0
M[V7:,:GZXD+S$%DM<-$"\S9E,/RYZ@7MT\^ ;XY*KS &TF^!WB\G'8UNNRFW
M00V7I.ABFF94#]:;-%'7E&(@R']7(R/O-CI?+(1%WY32MAB9NP*AW]:,'X8.
M&\S=!6\K!X_BX#W+H8V$WJ+,LI3?0(\YA.Y0(T119=,@S_T*!/]-:-VR@I!)
MU;AXS=:SZ<(&\S57JM3G6U*41L8R6B:3=.7 JV+:I#PZ2L5$0#)45S!JD.H[
M9%<O^"W+%0Q"*--]YY><LBFR:0E9,"_3Q@!AV(HE<=RFB@6"9-:?P4!+2-9'
M"%&RTR<[JUK/,9&VT+LBU7N)%CIJB94WG:E>814R,&E"%R0>7RX(F7X:,-7V
M *B] Q8G\HXGDQ PWU= @)6 %NL-0W*/H;N]G40=^LX5(JJ9#1W6A,PH*)*W
M"*&)!=I$M'^1$*>)/AAAC[:VM5KQ).HVY;,L$HNKLQMVS.2XVA PSP)$>?1M
ME@1KRPRY&DS4[%A"U&0;VH^@U[E\"-J+4@345E7\0QC7#Z>LY5X5N]0\GF+E
M=&6Z%=(546%4-8^.M'[:YEH/1F!Y9])5-_-01RX,S#SN9OU\B^RS<T)%81XX
M@W+4T81Q/+^4H^I*DH*WTPT;;5S3DTA(5.FDN98!K!OA+8'HM"@]JG?:65Y_
M&=O4G43JO<5E\U84!Q"[]Y6O<L\RI[=TPO[I085-%5<:3"FYQ<;3]E4";XNQ
MI+8AXNW[7\]?O?[OM\'+>W6J'E(N]BM'S7;^;C9NP0-U:0-P #M>R7!O6Q/\
M[U!]&G*;.W/>@?7Y59S0?U4ITA\&'_1(/WRS.\PY/#;:S0M+OG,AR7?>V-0$
M]G)9U=MFH[R@1WFV;4+*=.YV^%XWFA);C:26!?.W7,T954,XBU6-&,]HO+A
MPT8H!$AV!R ZT.C]\!.R!FW+=G9]$Y _T1XRG&QCA<Y),-/OK #9 :;>Z^"H
M7]$V?A"JW0X-]=>:"^--K06@VBVW1"1+!>-, 8 [P % D&.E6HKJ=A^PTIR.
MCJTYW5TC;/UAQ'"8J*EV,GF]RPT+BR&G+ZE*G8,)1XA4SG*BT<;/XT00!F)H
M9TQ W/9M%JJD3V/X\S+)+G(=OP:74 M"VT4M&2B'%#J)6,2&% 8<8B%M"HD!
M\1Z(D*>&IEPE6 ?7JW!"J&A&L)(BO)(/=^/0P-=_5Y04 +SJ.RH,$D")80*+
MJZQ;27GM.-8VL.@BKXON>?N)B^$^1X;-P!=E$6ZRETV-L]DI9.S/-(LK3E*6
MN-]<8A*S2LI"XRR.R[G&'/[H303!;:O@IY/-]:L,E-[W:-:>=Q;&'YU7U4!Q
MLNXQKU5],QUH9 OE1.%YLDGA Z8M3;-K8^8W=+)N=910!-;V)!PJ4\XCHR.?
M>NTL0RAGJ8 S1F];Y#PTN"2[X\U#V^?4V_E"08L^);!>HRC%@E^HI[T"JBB5
M(J8G2%\^AY0?IT3UC9&L(+)G*M:^C#/QCTH[&9@T;;+M_,.;"LQTL9VE-]CX
M8?T:%GR 4_8 HFS/3'1-NZB004H31CRW4Y Z6YIB>X@8;8C6A1="TWG3O&SX
M>M=0?;#S;PX$*$+,&5I#A'5B# 07H6]>-[NE-5CKRAZ&.^)/HRYBLSJT.B?6
M:5DWVIP'9>WK/> ! 0_'>\###P-XV(:*V5]9\*==RX<<#(%\O@&%)TE171^6
M:/#)VEK=EFG$L%#P2%.BXS(6I*O$26W;AA&F)=W;SA",I5G9<6290EQ+(_YX
M\?ZM;"\HPL#K??!RY? ID?R,C'22]ZB02]\IE(45@^*U(9>&3T/<T'D*O38F
M,3081G!BO5AF1&_@> B8:XDK%8YN2;:FR78!KMNU+T"_F?"K%F%MRCOZS6ZY
M1G=I$5PVT-LW8@^Z-J99,!OO/G_SY8IK(.1=Z*"-6=MJ51T!;R"/7]Z/@]UZ
MJVV-:9]7'\G(ZQ\PFR9H\;4SLUS28R"LV9:Q% .IS6/<?&O1K,1U'D[MA%@
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M:AIS5<X M0^[ 8)4V_ 9UISX-AXT@581FMF=V:]=,A"USB#*VDY7(0\M+WQ
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M"!QX.?F,P%3+O>==KZ[W#A0HW&G9.B]\I/'Z"-WS%3A(KNEB[N11L9JCD,6
M\L(D?0C;$UG78<6G*V,3&NN,_(ESW-@7WLIA$X-9PY8=A(J0CG)(S^LNV5H^
MN=H%,4T;&9]7EJK(50K7GGIAZ\F&F@B<1(&_^;)3O+V9D 2(JRO6O9D9BEL]
M'Y8,"2[BB+.1JPN!>][Q*:FZ-C]*&]GH%J0TP.'^:>DG39]?"Y]4!PB6DE*4
MP, 7\,;)?EL,+N>\NTW+M:T/,P+/')^.)TH/B[D/T^([\0B>:CS::O<0&VP+
M/9:M@V*\X?:E6+OEA:FQFS&, U+18GIX YG5AP=LNY1F@2K'T!^H7ZK$]>*$
M=V1:6TRQX$,*N;60HA[9GRBMGJ$]]^=ODD"RD(I8LRR%7DTL<H5R-W#5WJY'
M;%QV[;2>K\(*9!1O6XPE13\.V]T Q[:V)C07D9]4L4MNEPSQ/V7;NPT<2:9*
MJ4]45*4H$O$5L"@"T5+.MMO*%?E$P7RY,;#5?S8,9[C?K5EA9"!9J[R<:HN5
M^>S3R$)E^,+];G(\])=57E1$F>3:S^7Z)V_SQD7)WFV=6<GX^"2A2%Z"6?G8
M&B*$Z5AJ@)Y(2">J@JFB6%>C3L3<@F#6ZXHB KO+$!E,OJU[.=L)"!Q_=3%%
M3*@3^ 7F<2$:G)DKC2B&84=K+X(NQ?""HIK/S1NQ ;??[@6OM0WG W62N8]3
M+M(]75A#R& O(&'[6VLUZ-V;TOU3_/1X15;!'/M<A)(VHGAFROQ=@^G(VKQ.
M:\K+\.U%KJV6-Y5K&FVCI$CBX)!S;D1$9R,_O^/7&Q@^4>WMA7(@;!*W_&^P
M7FBV<)P1;1,CP&<]Q-]/$@OE3MN$V4$=V]KH;7P+#-6 6EM[ ]O&R=(4,X2Q
M?Y=G)*KZ&X"F\FW@84E05L"F^@Q<2414?,HY2V?G3S0SR?FK<8UX[4:&T,!:
M:A3KO,:"+]R%!@8;GQ7R=>W2T=9F9,FK0=6Q)*:$:(HY^4@RO)ID@^1-<8EV
M;4JRO(&JIX,CTF8(\)>*"&%KDJ$FNT2)'K =GPA][6;+^J=0KC; ,/3V&TTU
M=(ZBS5T9B1?KL\E71++8'*7?/F=6"@E9X1)0D++I8\H(Z^%'PCZR=5R2,4^
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MA*5PZHOZ>G]FB7X"@.VPR(JE#88&49O&IMSH/%OH5S#"!>ZZ^X/NKI+65#/
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M"8*BH#(T*8SD1H,MT/A33HEGDN%9E=FS-X/ZG(I<(+A+?E?+H&!%KC$R["*
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MIJO&YX2X>/M?EZ\.!F?V"\_6K:KFH@HE&6LQJ\I)=KU :']AM1);$& U*A-
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M1#W797$0T6 Z%,9R11!$ D3(%=IQV4V!S(B&7TUAWHJW%N9W&*;0T/59&'-
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M4V74,/<% 2:^S!^2:A9:. I!;XY;FGE;\6L1,)\A6JT>#H'?S0@W3NN4$^O
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M&RFZBLHZJ5J[3?? V#[9?H;C4[QT<:>DH'\,YT=O2"/TA.E5A7,M9J;_\J)
M)SJ**IV'4.KY;UT;UQ"!H*0@+9.\1-&Z 'T#F+TR65ORYVYNOENM-4R^WLHR
M1Y^E<%E \(G\:,P2 C(/R6O/.:T[T;4V"H]O6.XYRFC-C*T$WBX3-!E/;@[L
M:@M "Y\Y2Z!#(;\G"$9\)$R&.6UB,(4U[X_W()CM ^J+</ZRJ<K%EP^BXMDH
MLE Q5/7E3$.,RH$OE@1OI.2\-<7O1]*G%; -(^Y&UEMKH!GG?PO#<9V^A^-;
MCL];G [/%OM@OX]G\^GBCL'9'Y/Y6YS1IVHYR<'LWS%_64CFZ@.#*(JR*DB(
MV6=RQ)@!CQC!!Q;1Z]I6H'458>,A],E![H9_^]1YP[S@Q21:"N2ZI :B.*Y$
M%.!Y=1J28[6;=X&LR0QIU %+5VO9/7#6W#_O.#_8Z8JVK3*:+FNSRG$DEK_[
M5H&<#F='E:^'I?: 'AB/.5F.8"LVY3S1UQ5R.+1!EC%R[5N;]"=!]>DX17=+
M3SN]M$TQ+<VP<U$&E C)5KYBM! H:@<,##EYI='SYA'R>M[/KDY&=$.!367=
M>$>IFRVRJ(/)SCI@)BI0/'AP'DDZB1<3=8J:MW9_=K9%VB8!Y;)D$IVHE@"K
MA!PXDR.8X@13S!AR=W>=@-IOD-$7/CYXJ\Z&VMM%7.Y1*ZT92,-%W9'F%#PA
M!^:+*48&XW/KFLD5X_+]Q@U]I50;3>[YB$B8'?TZFGSMZ%#(U;?OYAC(_8-I
M=?"#OOU65]8['<)OOG#MDQ\H&)UD8LFTWMST%B_^ODH2O_N6CL+X"WZDP;PK
M!=/\/IH/N(NU1,&!C*'>[9$R.*<*"&181 H&FY_WV_^HMVK;=1?^RNB;@'^/
ML]E%$YI_QU%>[DH/K$A&R8*@90T+"BNU7T<!:S2C2#(XR<53DZ^_P^N3.[)_
M^JXU:6\T2NNE<M?B;IO6>_N6 WWJ^U;>36$HIR.WM3%"TN1!*IXA6N4@2^NL
M#2*IVY7;/9W(#X^Q3Y[@_Y_->V?QWJ?T/6-[9&@YV-IG+H!4B=2%VD)@I#@,
M67L>3;ES$7/[";H6XIU?+L2<+=XJ".AJ R&VV)N6P+**)3EZIWE?\@XN%^K:
MG>@O:;>^M&@-_>_XWA&>I=%<&T">S65;JRPA1I$#*FM)%!U$.TT(V;5%?#Z$
M;*_K1@V=GY@H%^85R>S>[%E[=;.3"<EPPR AES1Q?(0H,4'AB7D5LDE*K619
MM@32AP/-_6?CSE7>\D1?A?EA.CD;$K;7YW_.*L*+;NA5/FD^/+OH3!.*\E9R
M17Z<H=!,.L)7JJN*+%HL4BO?^ES(ZNBV;C8;SA=IOL^3@T0JFR(],Y_6KU_V
M$1]DH6WB5D *]; G\Q9<J>3P6I-36W3"UL-_$M2:SDOGQZFZH-*=#K5--=7N
M]H[;L!X^+++8N[=*EYAC ",,>48)D4R2X)"5PVQ83D&V+K%>$V*OJFCW1:Z&
M6FQY40P]*"_VJRHF,C5_#_,*Z_RP/ QXX)PS(B4%1B>:%YYPABPD^.R$,3Q(
MFUI[O!M"[8/7L6OF[4"IG3'PL%QS:>Z33/0Q64FBP&B0YDDQY'LS!]:2D'@6
M+*76Q^'7Q=BK@K+]<*ZI&KMV47\=CL,XW<3'2JZ9Q@BL!GMDZBUXX1&RU9F6
M:>5T\[NL5T?7<M+]/IN=TO>3QCX=A2G._ASG1:$8V:[J!XWSXN778;&=?5S+
M!A:TJ_=;S:XRNXLNEH<G%YEGIR/2_S3(8!VHJ!T$9Q0XH1BOM6J8.KA@K+L!
M]2&OUS&#'YO.^R5(FQS*_>.Y=E-!?1$7@?NRI>% .8',Y@)<ZQI#%P3O4H*D
M,G(DY5F[6MID_6?W(6^W(\+M0CL-FTV>+)WZPW)YV=O"=R_!"6Z2AF1,)32%
MB4&PO+A!W:&5,MK6=W ]A*5?QQYVLUHUT4OS\/VBLOYFM?WBQ.7 :"NM,!:T
MBK'>4IQIK(I0IBP%YXZ7YCW?GP2UIL_Z0_"FK:9:9?N77#XL'R?G830_OQKU
MM=[>'Z9#>NDDC :+JW6BSY +%E#6D1\M)(V?L:AUO=/@=HN=![/[:SUXS1,3
MSYHOG2NF^=KS$1=77WR>? [?ZF'_VF">@%8+>J^S1N&84J'NKI+=)+'8D.HY
M0H2B7?*!IR!"5SG$=;&N>='DLV;>3O7:C(47H\?WM?CG:D)<#F' '"JFR&$3
MS 90/M/$T"&"4"8(FX-34C2FVJ. UKQT\H?@4SL-=9V;N3H.<VWDF9F8"BVH
M4MI8K]&NN:,*U]M@M#%81.L;NE9'U[8QJK9"^MK!2+I:Q9=D505/0%-7R5!D
M+*;U9.EM8^:.&/)XG^9U%-#NQE\\F6(:+H1"/X]PV0CKX+@VN_J_%TL[=];G
M4D]XEZ#(-ZWI>LT9Z."20YDBIM8G9E?!]0R2%ZT9TUQ=#0_=GM&*/IF>_V-*
MDGH[^3H>V(#.(5JP7/J+F-@96UL[R8A<"^.Q]>)Y%\4SV)5K39(M5='N7HS[
M'47DF+..1,I0;V_1BSO.70(:DA*HG"JF]0'AS=W[/6^>M:9& Y4T2I,O/4"*
M)RXN;OV/X3A?'4$542EFL/90K-T4@]80DPR0K&!*%*TBWCK4]U!&_+''/(?$
M0BL"-!9Z&Q+4.D(:\ZWF,H?C1[(> T-Q9JIA9O)UZU@%#BZJ>EF+]%(H995W
M*U%C@X>OF0]X]GSI6C_=LFA1;X*YINC?3\)X<8G8[5>N^TT7N=G+7:&+K&QF
MNEY@F$ KI,BW-D5V,0N(PA<FE2>7?3NV-0"Y9E;AAV7EKO7=AKTW$7V8XO'P
M]/CM<)8FI^/YX;)ZYB)9$B1Q2M.*S$*5F*Z=!*U)((LJ+G/RYX)9B8RK/W,5
M;KD?B%L=:6.';<^8]@)U/3#BZ]W3.2Q<.5\O<RA&2I=EE(V]ZR9MS_P/XFAU
MHZF6O;%NG9C]B F'9[5.<S;0R09M-?E\6 ^R)YO *9&AUJ9'FZ5'U[J9QJ.
M5LH)LA^,.>U4U"%K+G,,=;#)1Q<$N7PBQ% ;0Q<(,M;LI:E')M%(SCMGS35
M*[%FWR=,NF?-IBKJD#5D4$\H\'R+!:?DF"U=M\LVR<N3, &3YL$IR)H54$5+
M")FDP"7'D&N]5?.RZ\V0KL2S?1\VZ9YGS97:QK&^9QE])&SEV@I!DP-DCG7S
M!6N7;C++UIN(/"B6;E]+^H!OO=9C5V+0OFOHFCK8W6FEPV7K("W\_]F'<%Z-
M\,!*SRV7"3(N;ETS"#XD";%>2*Q\%(5U;_!N@5J)2C]8-KNMICIHN7_G?,I
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M"Z/?II/3DRNZ+^H0%OS&?$7O09*I>!\YR.)K'0)C$'S,8(74TEN#QK0.*C>
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M/84&4_K]FI OD0<K(@9:&J/DN?9B<N E"Y $MRQE1.9;)Y);X.Y3(/!\J-N
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M5=E?9JXXKX K7T#QY,D;-#0Y#"\ET/^%:;UH/8ZH#Y:M)3MN+U@-]=',PCV
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MU3H"N0+&LXY,;2O6 7S%#[,I;2V+BP_C0$2>Y.K5?JT>3;5UA G"A\)!9&U
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M1&L=L""-%$IZ+P;K=/]NH.[].9%9+1T#:5,D8SM*\)&+>OF=Y^BXU*I]0.M
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MV]%!)%\(5-0V9V.*,NT+G/L@?)$<:Z&M%>3:.O/PV"OQ$*T+GHOB/$C4 91
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M[$%Z*CZ@_XV;3Z>IE6G9.(G7'J3D@'F!!:R0M']%P9AO':!]!,[+MDDV4LH
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MV2]?^JAA:)[4*&&9SNA+_&VZH+^J88S1Y!SSU;WBZ>2FT;)BQAL;:FR8U5&
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M@-03OGR9X9>K23I7C_P>,=,1DU-&0,[U3I.*#D(J$C &+8M%8=( S=<?Q=3
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M3&0;5^2 =+][9G=?A\K"%IDX,*D$;0,N@0NNIH*%<[:PFEC<+8?_8NNN]#G
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M#L,]Q+QS+V$_E7?N(ZF=Y)W)M D^\ PY)#I25)VU$)&,'/)"HZBQ%-NU9.
M\\Y;Z&Y+6>WZ)G:)WCNM)+#ER!IF&42&#D10*#CM,4P]Z=@^BYO8&ZNTI02'
M2AX_<.\?.BSQOI%X^\?KR#I^(KT012?:9+BAD\8[#CYH#R85'8RK4:?6@\W:
MH7^6$;VM7,7]*'Z D/C-&X:S;Z.$:^0Z7G[0LLOA1TS3+Y,ZF_,RZ+B<N'AU
MDZ5^]]59G==YPIG$8'T!I>OH]Z@LN.0MT/>3<K1@:5K7V0^TE!='[D.@Q! E
M8)>(,:]>T-4,^Y,H'1<2ZT6KP.L5YPBN& :R1(/%(1K>O'-T)V0OCH<#*&R'
MTR >G Z7*9M7B;R+T>*B>2YC]<</EL/HL)K#R5WH+*VSM?8&#9(3X&CG8=Z
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M/PF*LK60XJ&(0QY*BFZ[O;0/<OD 9"9R@<A)WC*@]V1Z1IZ;O_.U9^,9[P.
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M^G!&YW)P6D/"6L.NR>IPQ>1J%=$?N^B*'TRD\/?A]>%$J3!:1O:D=G3W<"?
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M_/KJ4]/_@R5Z5[5V+]5>(?"R<#V,W]>/DH]^6;D^/Q/2QZ"9 5/*:H13M"F
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M L(X3!)^^HJX((_W1<ZCR]?^R@-99A<SG+_\<8/7^<\JB?5\+C=K5K%VGBO
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MA"Q1&SZT8^4^=HY?V'=XD$Z'"98>GK'74W:M_6$7^GJJ_]]&VW%: @P&#)U
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M!GF Y:J'8KG^P7*[$40LC-+$IP1K=1:=@KF);4]'$6RB[$8/N*9_''H6Z[5
M-K-J&\+R]08]VAVC8,7"!6C[IY1BM;I2C6?<'31."9BK>%V7K,T;B#L!J <1
MME/0.#<-Y N_4\[OSVUMY;RXVTHMDDQT7VX6(9X7<T]X&?3"P(<HBD*8T2"
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ML<HI7Z0I#U"*"?32(.F230@5& 8X\R,:)2@)J;Y=L.9C:B/2,;:I $I6K%V
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M5&NK/#&?$QNH+7J@5H\0MLVL -WN+T059V;F::JGIF?0OH-G86@"QWK==0R
M+9;<6<*)T7)D.Z?B<E9K.S'4^_9Y:G(V6]NRD2]T3I:_YDNYV"P+WK_OJZ8;
M5Y*)NZ>E>F=?+A\?J_*9++M(J_4="^+3,/:I)RUV+&TW1BK57B"(PBSP(BJR
M%&L5H7?&T=3;Y!6+F]V/  \KXJ#B1!WEF6P373P%G6WUS-@:;K[7L*Z)K:SO
MNE$0N!)@PR)8\0@Z)C<WS@V^R4Y^YH=@F84PQ\,P] DX!&[8<^""T(S^!8>X
M['HA7 YL,3E]E)-DL>7?O2R*)[+\\[+,R/(3;U0EV7KA\]B+>2)@RE4%JM"+
M( GB%+)4))1&G'M^I#WYZ%"<>'+I2(*[EB8H>-/&PFJN]_5ATY@M7(-A-AOT
MU#>'8'+5W4'3<=#6&_TR!30&MMPU1':VV@%49I;81.Q!2ZLUT'R6U$2N'4MI
M=*.%)?R2RVV JO@GA^Z:XJGR6N4R5TUB+@NY,9#"%4V?"2$W#GG]1Q?HEI!
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M(8M$ !%)J"J^D$#! YQ0(5*$,A.E/4)C8FU=4[1P.1U#1$]'SY333#EW19S
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MOIOQH*6RN%/9 TZTU7=-#O3,U6V(>G]>(%8,@C);YG==JQ&3"&A#V#5.TZ9
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MFK,PL?*VCD.Q++_60#TM4*Y#)LB:E3^93;T6,.M-RM."9^&?77&BC@)_5,R
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MAI'3LSO.\# S+&= 86QDM$1T9$6&:<UJ)K3$WK<#>C=91*:\>?M??I($45^
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M]N5W12YR2HJF+WEPG=6\ZEH#==R 'UM^0&!Z[#P H.89LQM8# ^4UQO(BQZ
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M10)R+OS0\Y- 1,(@3G6<HI:JGAVFNFH/IMIAW)/J@?PA=>WFZC_!E5%RJ@:
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MMI(\WSY5E5PW++!(HL3S&4R1QR$2O@>)YW.5P$&0YWMR#V?4L4"#YL0ZVW,
M>,="%WM1MCYIVC'0!V689G*,@ZFGUHXA,G1W]>CTU%MPMO.P+T#/@LM\#6UY
MG:5JC%.<.4M#&X+#! W]6V?V%74G.IMZ[G7+VNT]*?I#T$]E\=QV4_Y<+I=R
MS:%N6G@!XVD0!-"/<"(7!G)C0((HEO\@QBE%*0Z,LL7F97_JB-/SW1;].=N6
M7+V"-U*R50C"!5@+)W]]4I.-VM?TE:]_5P*#7F+#9-.9WZ:)75F3OR.S>[7F
M>SWF<WN=]91>VP-FQ_P_AC/LK ?CS"]V'A<NF@6M3G64[ZVK&)\_\QLNE;QH
MR!U?H,!/!)'384"0G!.3U(<X]3#TXL3/8NHE/-)J/F)%?>I#D17%=<EC4 UY
MRQW J3<I3 :2F4T_:$FTXJ0]5+@ &_PVW$S5JT@3A$DZ&(W1?L6^1IJP#'<[
MTAW$S-XPGB_>%XVT;Y>,R>'KF[)NR/+_R1_?EHPO8AXC:3LB*.2&'B*FUMEI
M&$,)"<%!F@J>Q3J&99C,U!:D)0QZRJK(@*(-)'&@J.M9DA&@ADV&._'-;(.M
MY-IF0$^P@: V.4"GZO*7C8:/##N+*NN)MM)9S:O-@W@_2Y67&J\LP#LN7_Z'
MOG'D.W40KQF=.S3&Q+JW11KLT ;OM"?Q41B&E<\E J8.<2OAC6)/=22S"BH=
M''BV:%$=\;;#0+6NM\YC[HNW=?6X5SN(S[P]X'DK%;YN-Q#9U@:B-LRL.X_(
M/)Z#M4=@RVDP13Z<&RS<9?6>P\S<Z;X.@#N2!^QB5,M:]:2^5_^IO?@S6:J1
ME:I7N0I.45]<%FSW@ZTK%SA@8<;#4-4(1Q"%",.4J2HK-.,B%#3@D=$IU5G<
M3#SC*FH77=[KAN@%V+ #NBO4R<W>ASLWO"WE<J9X:@NW=#F3I6;O3C?/3,]>
MSO8DS,SEJSP$\_+F+L!S5?_\+%[F+9#N K:#"NI.!K6NOE ^\"^KA=-ZR<*%
M'V?,CV <!C%$L2I.A:C\,^.(Q0A1[!NE*)^@,[%![(L!K,E:=W,\!9.>I7(@
MO)D-LI';IF;!D%3N"A0<I3)W-8(A48^4'AB\_!Q5O27?^@/]-[S@(F\6:>)C
MGT<)%*D(Y#)'=7"E:0PI3H@(J<C"T&B%<X+./*HJR:X#3'[L*1MV-SF%DXFN
MGB6]E:Z:"6ZIK"?%<JJLAU1>05E/BGI<64]?;I$1NBFII@J/].,N.$-([D0\
MZ*<$0SF%IE)/?0PC$C*"HHREJHBXRF >UM/3)(Q4=$U(^TWMLJM%WVQSV1;+
MZ4/E#!(=CX,SK)QN1#;3RZURC5U;T?>.1#7(Y3Q;9+L<3F/1S3(W!Z4:S-@\
M?N=\F9J#G.]D: Y?Z2(PX VI\_K+8\4)NR[^0JI<%653)X3^(L8HB3G.8.(%
M""*/A3#UPPAZ+,A2'!'DQ49Q<KJ$)UXBM,?=^=9Q=Z8X 77+BJH3\=PS<W:4
MP "VFK[<"1 S,U\'L0$M$^#+&JP5'XX3$$TEGR0@8(#L*\8"C(,Q' :@<;_%
M8F457-#;J'=<\*KB;&W 6N>N\D"<+A=[T"@YXHA&1-H?5<8512&"!",/!F&"
M/(X]*G"H7<_:/7^3[V3Z()R>XPNPXGFK!'3+=><#=%0L>X+GJ+$H>]VG8[K3
MTGTP%R>>S$[A[K.Z14_PM S6E:_[U.P6I9LS*!5/3&C; %X]E*X3=5OH:1TF
MR+=R5*K^,8KU8RS7"N:JN/AT@ ZNAR<@.]]B>CK,=E;B$Y*QSJWK6-CJF=J5
M!5S@," H91[$7/Z#!";JL)+!C OA4QYZ-#7*?#]-:N(Y<$UXKYUQWE6ZM.Y<
M/("=WL+<#2)F\\X&C)W&Q7W93Z?9<B.RN4N2.T5H[MRX$8&/I,2-W6'1I:BH
MBTOVM_K+,WU;-X8-BX[<.[5N2C/8)OZLJVC+;2&OGG/*V]6/06.C8X(/ZZ$+
MF0VU;T1<U[V0!H2S:XMT;,#Y.B0-B+/3+&GH.C.5JJM&]19C3[2=E_MG5;\K
M'TA>+,(@$RF/,*2I\FU1HMJ&Q#&,0A[P,$ZX"(2.\@U2F7QV;.FVJ]/5J_A[
M1UES#S&,T; *.I/<=!:T$%I;];2$&IK^Y !;4Y_\:Z.%PV//HHI:XJWT4>]B
MN\7KNE#4FY?UK_^1\TH.=/_RD3]+Z56K6(*#,(E( A/$,X@8I9!$40!##S&?
M(IZBV*C GQ[9B=5VJZK;FG;[.G^Z_(M5=UU-,/56MNXA,CPO.P,=XZ6NF;".
MEKV:1&== IL!L;\<-KS;PKM\)+;MRWU9J7ZA'\OB[I97#U=M!FV[,%O$-(QH
M&%"84?D/2K,4DIBF4-J,)/S_N'O7YLAM9&WPKR!BW]AC1P@G>+^<_23WQ=.Q
M=DNKECTQX0\*W"CQN$1JR"JY-;]^ 9!5Q;JQD"B0W3,3$VVUFD1F/B 2B41>
M.$U9%!GM[A:T)U8>7= G4U&>8LM/YV@LMUP 7(A : V<N=,!!E,E1T-H6W5N
MELQHQ!0[6/&#/LV!'<"U.AV&=FY3UUC"_*)V:(SZ/(%#SN?/M)-UQU=I.<1E
MJ86U:#_7RSNEE1JAFFF]BF9PK6"1:#@^XL2*=IAYQR4GNE]$T_&"ULS891^>
M0>J\YV,:D&#*=2<S4>$CN4!W>_B8M:6USE8TD_WBW,4S9+Y))J.9Z*?R&@W?
MMCO;W32/I.J[[KZKJ[9>E+PKE%+Q6_E%K?>>FZ*_)"&+38PS--G1":WI%LF0
M/9V*LV50[YE#%M5UY(;);<Q].TG0O5/<')V+W/ TZ[')*8S[IRJW@]MG+'<)
M9()OTL>4-TC^PTO=DL7/3;UZL4E1!HPZ873;@)%M>EP74+/F!77,3):?; &$
MPX1D"/79,Y MH#F6<FPSC.76I\IZ=9D DD0?*K!='7GL)RS(<IRFNE])%.,\
M3"/,LCP)J9_F$0&EV(R3F]A [FKVE5W:R0]]I,R/P+["9P S- *<P0#<W34"
M?>*-4AEKTM-LV492NMJ+QXG-N\D:"7ZP>YJ]!3_SJL(%UVRY(HO%F^J:]'O[
MKOXBNN:!OPJB(LO IU[(F%,[&'>*>O8\=2T47]O_UC4_2?6&UMRAGCWSDS (
MO_-GX:F@ [H:[5";X'QL@X?5"1E$:+8SLHWXPU.RU?L6%QKW?TDK_:W[\Z82
M=[>?^L#!Z\=&:!.^CX/A<4Y3+^6JYV."(S]D..=)@#W?B[RBB(N8&,7R@:A.
MK&/D=^0C27P3&KTA#_"]&R-H<&,Q!2XP!7(:DO.!19=\7>8W$E-@9'<7\:DJ
MZN:Y=YI4Z#1TKL*RH:*/7CP8#S;?E0-4OIW+!O#+-KUQY<'MN7PMU\VJ?9+S
M7)VALE358*)%@DE8>#A-*(OS5'7WHL9*<6_PJ8.VUM0@35WWQ#?0:!<(!5-<
M&T(V>FI?,$A_6GL!+3O2GITX8./9XP*,MYK=>V?&YK+'N=UM)WOB&7@]X7>J
M"FHC2%=!V.>>H'F(I;DCS2 1I#CCA&.?A(P7122\R,AKLC_PU <I73=7T@*6
M"-Z1?7RE7R(1\'QC)@RHZN\QSJWJ_.X,-%MEWV/L#VOY'OUWN+M!]P^X?W[\
M6_W7K]5+^:YJN?P[U,$P/LK$*T$31_?E<UD]7B') OKULS37U)U&*4$8R5V!
MHG'>7> ."-@".HO!!*X ,UFM#O]GAI[MN&\FXO" ;_B&;4Y>S83@[4?)Y+MZ
M(?^I;M0$M0]!P(67^2'FS".JE@;!-".JV!9GN8@9+3*C7/:SE*8V7WNZ2,T#
M8D/*T!2\4U"9.?V=   T=7=D?V<DNT7VW1FYG"7?G:(S<^[=&7$/4^_.O6"Q
MQRX6]PWA4C4/"E*WL R\L3&FWE\7"]33'E;4-ER09P$PV%0=R0[<4D^([3@3
MST0XNSUT;.#Y=E #\7;V3Y/GX4OPPS^EM?Q7P]MK_K\?*[!]>^+UB1=>W\E.
MFQ3M,#-4=2.OEU4-Z4]Q"H'SR\^!\+"59R#W!.;L&3&MUN"I,6=;?F>$&JZ\
M<X_"%YVNQ*BSUY_JA7SE;EG]WMX*T>B@&/ B-!QNXD79E9<<L('NQ'+55.CW
M%BEFNG@N\W5I"M+Y=3H!/K!U:P;-!$L7*+G54C:E,=O2!@H]7.K05RVN5'ZK
MR'/=+,M_"7Z\ELU#5 19G 8<9RRAJC%[BFD2%MA/291Z.?,CS_R2Y2RYB;7"
M@#[BZSHJVU).3+$ N+@XC]ZX.G"/"4P3#.$X5;W,*1R FQVGL-C=]5P$#^P:
MR%C:T8NA\Z/,=U5D+-'.Y9'Y6W:NN6O&FI7@@W)<?>_Z!R*\(A4DP'G>E;GU
M<9Z0%"=)EC#!HCB.4XAK[B2EJ=T '=UUT3J@/^XT/F;^."=2 QT O< #FE>H
MI^K.(7=6,$<.N=-T9G7(G15WWR%W_@4+Z^17\K5\7CUWC=]OBG49DEO5CF^Y
M%/R^_DG<T"4I*ZDN:OFQ/X1%02,_3C O\@Q'+/1PEM( <Y%F>4[#C MN;*V
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M1B@E$*4*9V%BU:D+C!:+^J\^R+I<<X+(AA5@B1D+F,V4X[3@ >T_A=N:$W6
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MIJ[1E]<5__#/5?G2^</NY8@Z84G0, UBN;8I26,<Y;%<Y81DV(M%6)!4)$2
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M/-NQ[%1?GY=?/?ZB_"1KK\BP %P84N(7@N$B\96>XRG.N#PYQ83GC"6,B)1
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M*4^+'Q?DT33<9F2(B174KY]O/PTW7<V!KIFQLRT#@LS/07+>7'&$!DQ/08!
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M'30')HSE,'8ZZ5X:YFTA5^]UQ3O+IZP>!^?D0>SLO:30'O^GOEIEY <I"8H
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M7WAIXADMR#,T)EZ,.XKU">X*_)OW5\\'S[@ +XK\?X!2A8N5 &\WC^NB:KX
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M#U2EUN=B_9(S#BA^SE7=:55@>5T4ZS_4Y:8*BEAO-U66Q(K7%WK*/4U5BA3
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MR+R]0&?J@(H=5? LR<)\U=XTF:W;2RCIK5H'LINMV8[85?L**?;' ;&-%^R
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M,X]BR(E 2<8I\9E6;3L-6A/KE/_:KI4[HMX-I8UP357]9_ K+OXI(00_5:P
MW]!:Z,-.SU9PA(B9(MKW U69^XJNNNFM )B@L*6&B([,A#Y*LQH)&B(?FP@Z
MKU@N\'7!\X=5':%(7U7MNA)3I9U_QOE*!21_X%)A\WO\8Y&E62((9I!&C,BC
M04BDZ< 2R 7RD! BXVR7D:ZYY/6I:WWPA_GG9DJ@X070AAGPTX/DH?P+4(D0
M*IYVQ0UO>TVPU50(CO&RJW\K2>T2&EK46I9 AZ<K0"IN5+J#0XUACH$K#6)
M>5Z-8@[)B8:Q&,+Z5OGU3GY:C\I&>2AX=2NPNRJ29U'5?@$_\%MQO5IM\?(W
MOOF&EZI$1Y4VT6S*"Y1$TNR@" 9<'F:0EZ80ASB%GA]$:9B$*--K;>F6K5EN
MK%_!<\,HP"VG5Z!H>:V"5!IN5;(1KOA5Z@N4BF-EX=19=T\UT\97O2[F3^,
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M,>T<;7[9]:=/!$EC$G&8^ID'$9<K//68!Z.,IDG($B07NE%4I0;1J4.Y:A;
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ME)?/ZQ(O?Y;[]_/-BBZW*F]95=%=KS;Y:LO9;5LGM@W*#.,TBW""89R)4-4
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M"YJ7RJ*J7?>+A*&8HB2$(E8NO4 >X;$?(!B&.(TQ#3R1:74$G8S#R2.0*K*
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MC(&"5B]G:>I;^$M]&H\[XA'G:V+/TVL69G8JW29@/E?Q"+.W]@*_S'O=/#Z
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M+(VQ#3/'B$H2(JE%GH4Y)KE0+E[ZB;%G\:4?MO1@"K@+@IO:>8H&4[8O#O*
M%>L$YR.IT^[(LRK1"9$.5>?4(Y-7%=GHZU<C1Y?CGI(LCR*.6*0B1-*(F:5.
MQ"@BU)#+H\2L?A.5$3G!SL1KXLYJ42CC_!8;PI,5$#F%N9M*SX<DS K 2X3L
MP/YU&/$IRX'T #5__8]3S+S7@A\]P%U0X:-O5#]K>&U(R*/:RO;V]^>5;;BR
MB)@6L<YR6\$X023.,T1UGB"9Y$2DDH:I L7-#1&<V*+MDM\K_6TY"'Y?\P!L
M9#"(H9O]&A,9F(6Z$!2P 7*5="03,TAN5B/B*ORAF7!^S\\0W)8K^2SL68(P
M5F5M;NZ6U;_:N_"8"RE#J8V?8V-H8\Q0+A5!*2-Y8O;W,I&@ZFG]Y"8V BWQ
M8(]Z8,G#%'\ ,S>U'P\)F-*?!V$XL@*L\6Y"CJ3O \1FU78WP0]UW?$MWQ.#
M0MWH#Z62R_H3$TT&ZZ_LS^7C\^-/J[)<_6&\CP_LR7Q3ORX(HSP7DB"=I@P1
M%E/$C>*C&"M!>2K#6(#T'D)\8BO0D@W8_7W9)+,&3^6R$,LGXZHS0%Z+%ZZN
MIQ33H 4]QBB:$A5K/H*.D:N@0W##2] Q,^9Q!QR"T<Y# *1G/C"!@W)\HN(Q
M!CS$_[:HBFOYS^JV++^]B ]5W2Z.CNEN9UZ?VD%01=5479;_?*[J=73_;;FT
MUWFJ?%FV_0W<T][.@=!O!4:2'^@6.(D^HHO@(*57DL.Y,6?+<!@0:C>]8>A1
M;Y=>*"6K3X8M>_5W7<A?6=V$>=_HZQ>V?+!E0=M[P>V68L'3*,]UQE D,N/K
M"T)0KA*,.)%$<J(3IAC0U_?A8V(=M\36<3J/:V8,2;O*+8L7U?[PP;L!+[B=
MMPE3@PC>/S0,!?97WX0Y-&!V3%DHFY8PN^<)&SZ17I5HG-"(D0 :;^_AQ<7<
MFY)+H#JQ6[EH.+A3\6M=/C1M6V_T]U)>E^4VC]71KS@_PN2[CO6];]NOV&C)
MB5Q"=\^B!XEAYV(<$&!FPTG^D5-\W63U\C)ZAIW-T1@6;=?7<'C:,_>^-E-K
M9^_+)HF7:ZE2'!$4)O:R-,($<1IG*$Y#E8493SAS*I![GL343D)'T"VYUQ47
MMR7_,FEA:@D4%)Y=?U:6L=+JCPG,FT]_5L"C1/KS3\)7PKOG!Q5BGH2V+HU<
M/=5*?GI@]Z[+X)G7)]8J2S6P9%&X9_5;#MQ7OW/2#R]](P@.4[ !F8/?+?F1
MUKH!X;P6NG-CSK;*#0BUN\0-/>JWOK51N/NQM]5U_8&5Y:MQ8/[!'I[5(L(9
MUI@39'?)B(2)0#2F$L4Z$9&*B9 QJ!"A$]6)];4)@K>;N\,T%]A"Z :@V]HX
M.BPP;=X@<I ?,-Z""1)PI#74C>:LRRH(AL.5%O;R?.&$78\3FB8RC"A%,2'"
MV(J<(4J)[4*IDC"G621AE^H7\#*Q!=D/))P^>-"ML<[,N,%,S$5A@Z/UFQD1
MHC<,&)RUG<V(D(T1*GA9&YRJK!<?[%VX*I]86;_:>*.FNFF<Y"(1(4&9,F:+
MI'&(J-8<2<(IR37/TC!RL5WG"$SMTNR0;,/<^@NBNJ'2;V_&D!7HIT#%=#8,
M0[+T:;MY=T?3S5];+3\[["RJ.R14IX^#SXU2O7)[7J0%8:G$$F&SBT $2X)H
MQ#02)-,XSY@B47Q!\<K93M,.2CE><JAV#BK'H[41   >L'G)?FD5R\E.V\Z1
M><L:EL,G;T//>QX,K!X?5\4WVSF]BY9E)$^C7*!,$HH(38V^:D)0'&<\(=B6
M,P.=>Q]1F'QUM/2"AB!PCW^$A>-^_A()H6OB5K@)0EW/2C+6)OUH_'DWY.?$
M.]I\GWW0<W'T[4]NM_[UZ^>BJLNF;D1U4_]0Y?<?K&@[E_]#5;627>?R!4Y5
MEG.1(A7C')$DR1&+661#7G&<4>/W1GG7<N4[8,V=B7\GQ=EOXO(=;B'6-(.[
M;[\%_[4L@LIR7OTW< V?:T8=?8+W-$%^/H9E#S7\!;LR[%TX\-=@][FN#54C
MR56PEB78$29HI EJ(T[0RG,5M--O9OZVOV85W(&9>1;&<HCF8GM>!VOFR3AR
MV.:F[YE$>3;&R4; [83Z92SD6":93:"*K5](4:XBC106(<-1&B?<J;@TE/#$
M[F+72%$&G]BR#)IC=6 *I2N"+(Z9Y'F.0DX,@FFF$8VE0&D6QB*3,N6)@)2X
MF 1!>/V+&1%T6PRGP 5X_CUG\"A4W+$R4UW)SINA"@3C*%,5^CZ\=/_'HF[L
MNUB53ZOU@7<35M,<RI6O'U92+?(\(IK3$*7,MDZD.D,\R112*DSB).&8XLRU
MDK\#O:EM;,-!L,?"5= P85 +6D8"RXE[M7\7&/OMQ03@P,S$&+B &@0 I/7J
M%^ R_FSM P#"[G83@+P&CWG[NBJ^JE4%2R3;>VEB736TT->/-X[A,<<B]:O<
M1=+ E*L39.1TKY/<>T6E[8\T6RS:20%V(]!./W!Y>_&=,ECM=J?Z^5E=<[//
M8:)>I#H+$\TP$IB830;C,:)1G"$6Y3*/LD1AG/BV&.\G/;%&'331WG1>O@KJ
M5<!5<,N6\BKXM*QL9X/_5ZS<YB']WK$(O&$"P.[F4D\#)DRAI\7QHB[E;I!,
MT*E\@/";=2MW Z2O8[GC"#[M?5:O[*%^O3-K^L(8F CSC".>98GQLQE#7&N%
M*(^D8"Q)C#%R;]ZS'7ABD])2"HQ[ JG2O2MYO]Y?(@],JSM1[OQ%@?2Z\1/)
MLY.-BVC 3C7'_/?WH=EY?L8N,\=<[O>0.?&]?]3)4BY9^6HWZS>ZN;+[L@FH
MB$(9:IY&B"0B-^J=Q2BG]CI,$BEYE%*C[-#8D_/DIMY%KZ\W;,3<PZIZ+M6%
M(2@]N+DY!>.A 3,96[I7Z]SME>YNQ%T \8I+&99SQ.B4'F*SQZ@,"WXJ4L7A
M+8^5^R=5_Z%4\?V'/99;%?*ZD-]_+$OS_\7RQ2@4*XVWT.Y#24)U')E-1)3;
MVH]I$MGKB@0Q;0R 4BDE0CBO[ #"$QN!EI.@_M%4.S2\-*D<#3?!'CN Q12"
MJX/?,!%:,"/A#I1/,SX(8@#W9"+D?!OQ/9EOFVMTO@-FM06S;L!DN\S]STB.
MC@<2O8X09+SY'"4/*?<<*9_W_1RM_U/+^Q^UDM=F6':OOC[;,7^V)3V5;*ZQ
MJYOGNJK-K\(V[MC47UJ$QN;&2DO$F;!FF&?KE$(L(YUS3G%JNVNXWWEZ\C'Q
M%>C/70':IU5MJ-D2$6(=J;<.+O*/,_+%W<V#FP%-F-7N& I:CH(U2XV'MT9R
MAR';(;1A]6JGXM=X;M^%X(SD#_IR,:NC>"%4AQ[DI<.=,W&[OPWCD/[K[W_K
M/C'_X:Q2?__;?P!02P,$%     @ 5X!D6Y;TMQ&2OP  YO,( !4   !B8W)X
M+3(P,C4P.3,P7W!R92YX;6SLO6F76TF.'OQ]?D6][:\ONF)?YLR,CTJJZM&Q
M6I(EM=OV%YY8$!+=3%)#,E7*^?5&D+DG,Y-)QLT;JN.>&BD7ZEXL3R  ! +X
ME__Z_63VTS=<KJ:+^;_^B?^9_>DGG*=%GLX__^N?_O;I-W!_^J__]D__]"__
M'\#__.7#FY]>+=+I"<[7/[U<8EAC_NGWZ?K+3^LO^-/?%\M_3+^%G][/PKHL
MEB< _[;Y9R\77\^6T\]?UC\))O3%QRY^N_QG'Z2).2%P;CBH5!*X(BP@2QJS
MD,%G^_]__F=?OV(>08DB017Z*ABIH'B9%2+CQJG-0V?3^3_^N?X1PPI_(O;F
MJ\VW__JG+^OUUW_^^>???__]S]_C<O;GQ?+SSX(Q^?/%I_]T_O'O=S[_N]Q\
MFGOO?][\]O*CJ^FN#])C^<__\Z]O/J8O>!)@.E^MPSS5%ZRF_[S:_/#-(H7U
M1NJ/TO73O9^HW\'%QZ#^"+@ R?_\?97_]&__]--/6W$L%S/\@.6G^O??/KR^
M\<HX7:3EV6K]Y[0X^;E^X.>7"P($D;KYI^NSK_BO?UI-3[[.\.)G7Y98_O5/
M,2V_0]4I\Y+5%_Z7[3_\^>J]7Y>X(K!L^'Q#/SC_]_4M3Z<!OZ]QGG'+U\4;
M9HMTXT.S*M7%Y;^<A8BSS4\G&:>3S5-?Q-5Z&=)Z$EP.5A)L@N 95(@*? D.
M+"'1:V:38^8FRY7D%=&\4<(*TY\_+[[]3 _^N8JA?K&1QT86=UZWE<MA=%^L
MND_TV8D,AHL@$;(U$90+!CP1#!QSP(1!19F/(OOZVVY2?5V?+Y;II\4RXY+,
MQL7KPC+=T>U-P)Y_XN>O84D/@O1E.KLDMBP7)RUTM5XTD-Q6+43NGWXBK@LN
MEYC?;+5R+W,;SM9D3''SR18:_^^G84E/G)U]P*^+Y7H2K1!"DQR$<20'5C@X
M'26X@%B<*2*&-LJ_]>*]<"#ZQ\$Q\NP$$N]Q.5WD7^?Y%6W $Y.DU%I[4%S0
MOB@C@Q!\ ($^)Y&3LI8W <2-U^X%!]D_' Z792=@^+0,\]6T"OX<T-S;R+,+
MY =8<I:*+1!XBE"8CL9;:T2(;7:'6V_>"Q*J?T@<)=&14?'K?#U=G_TVG>';
MTY.(RXF.05L6'7A$4W<\\II3RH J&BQ)DGD31Z'A]AOW0H'N%P5'2; +[7_
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M1P%@,;0V.H#8!R3)3-,:\W[LJ1)#O5 $GI4"RC@'P46$Y%-(R=DDRD/G68>
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M)-8KG0(-1"P%7*)U1^$D/;_U9,HG$;@?+/\0YU;#*:X#5%YSP3\M[JD[WRS
M>-L#_X DY=5TC>>L;Z7R =/B\WSSE&UGK&2C3Q1-0O9"@#+60F#6U]2S)?]=
M<ZY:Y[:&YFD_[/\ACL"Z@D<'R^7A@J]">TXF-B+67'4T#IRNC;6T4EX6GBWO
MKPSO#W$.UDPMG;3KW5$#AI')F!D'&[BJ<Y 5\6,E\,RT"L[0:ADDGGIZ%1[_
MXYQ7':Z"ID!JW!GCXY1,<)FF,%^_2&EQ6GNA?7Z_F$W3%%>T:%XNYHG><S['
M8U$^3%?_N,G7?ITQ#GI/D\X8QW/8J#/&W;=?MD!@*D53:*O#HA&4+1ZBL@K0
M)$EN(].I>5GM_=0<;; >$O@G$N8O].E_3))W&8/V8&O-@0I)09#,@>2.R1*Y
M<J9U5^;]*!NW9+T12NZ8L/9*Z;79S[9I(ZWL:^/<K_?)/,!Z/?;()H;J270W
MLDFOIJNT[7^)^6I<TXMYIE]\7:S"["_+Q>G7*PC&)-GF&H[5OL[1I6 V&)[
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MZ;H]R!K7]6T.A7VA=J!>.H#:]NP!EY>LG-OKHE'ZVF,]1B1[':P#)[2'PIG
M0#Z]]*VK-^XAI5-(':KR'5.$CI7_V+$V/6&QK!\XN^3B7:%] "^_)<%]7)3U
M[R3R<_Z<,=D$5<B-"';;>M4)S\ 6QA2+!H6ZU<7@OFNS3W_YN,>-0R'J6531
M@<7Z[70YGZYK'Z=Y_FWZO7YUD;V0V1FM%1+]KG;;M=5I%04$N9X\B*1*8(V-
MUOW4C%L^.[3=:J2%#O!TPRNM+NDO9[_@/'TY"<M_;#P&%JVM4W4AV<2V5\VC
MT?2',IQEP5.4OOE6^#!-X]RW'M');ZJD+D%WP<WYVF3(A$):D9A*HD7$&:U-
M5" -2Q1U%YUMZV8XC]$TKB/6%@&/PNL(=70 K]I)=W7>D?XM7OB4ED6VF72?
M#3I0:(@)+1(0#UZ(6%L5M#9D.PGI#4C'Z/IVV=?1@N\ /3N6VF7X3+;;RA0B
M>8><6)$4G/C:E=D*B25$(L>W3GH]0,Y>2&H^E+&O?? @U?2(LFN>*?KL<D1B
MQ48)2D0+Y*MJ2,*B=P6==H.[7+TDM9JI_#$H'2C_#J!$P4X^3>L[')V;7_3%
M:,L4H',*5*ZCF-/F IY6WF%6SK;N6O(P19T!ZE#%W\V.MM+"R$=_YYR\6W[$
MY;=IVJXU4WLW1^-!NQK6,DWT\Q2 H\ZF<,9":G'HN^O=>^'%_ &VN2;"[P,\
M53CG'*S.%Y?4&95@%J)U]5:?9A!TL$ L&)=*B6F_D4'[(>@N >.=)Q^OT[L
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M:WS=]FY,2!P51RC6D)N!7(#7,D&UX XC4]&WKJ2\GYIQ$Y[#:/]^B!VCB@Y
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M/N;\G!G[P.=.X[2WE_>A+)M<VC5B>_5L_C$3;$N5S\A1&@:<<=*H(D3"L,W
M0]!!F"*,XL. ,'3):?SCL3 R"J,[T"/_P,6G9?CZ>9;((%LO9_'RIK.3--(8
MF2LE.=:'(W3M(1H(.F;4GLG 6K>M>'PWTX8)FQNKC=G?+9"VYXZ)K*6(&H39
MT%(0'&8%K Z[2[JV46C],.>I_4SK^;22^2 H[2& GL&$J_4L;6_:R+53*4N0
MSM4NFCJ"3Z+.40I88E86=>O)Y4/VU2.X]D'!4'CM*Y)N85;GF\P^7<_"5@&=
MW+1BX4R#<DR L^1NYI*SU3QDHUJW,1NPK6G5X9%!MK] .L#8(Z;#VYNZ8ATQ
M.64$Y%S[%*KH(*0B 6/0LE@4)HTPP/?)/4V;VAK-V&HJB@Z@]4SP_29'5U]
MT/_SQ_#WN99:%2(*+/DZ1")Y)EZB@,2(@PPQTI?C)FT>VF:7H>D]<;(XKM!Z
MG810GWROUO5)Q>KW,%O^,UQ<TM^N]0U$["]A-5L=D&D=_N%-DK![TM(H/WMK
M]9O\FI+)"J=(Z5KDH 2G:S$S#C;0?4F*,LO[$TX:-%O]:1N'7FA_A.6_B'%T
MSW^HW-P4'FS'BC%4UBL/,M;YIE)E<#X3N9S9H W9F*%U+.+1S4S=)/,PZ=^_
MC]KPO -M>',2?_E^\\O_,\,E;>KS][=TZUY<98[HTA2%?&J?ZP0DS4I]JB]
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M([)-(O.P#Q!^G;+=W=& L \7.W NWL[F>%9>T\*S]>\AU1#O]ZLR3\$RLT4
MZAQ)Q3DRH)F6D G.M4L"BZYUW.*QO?1D41SND#;A>*?(>5NCA,OMR4J^UEJ6
M B75#!)G'GPMHU/(H^5>>%7<$1!T>T\3CR9J(OD!<-I;#%-KIG>?P_)+^!>)
M(W^;K1;+U=MWVVM5,\Z-U!IJ9S90N3:@K7,$M8G<._+'C!MFKCZZ1'_8V%^,
MB^8\G1H9K]:?OR]GEU^NRRV-Y3;4<Y)J&_,@&3@N'3"G2/G6:5XXK);U[N=.
MJVG&P\ !W.M!TSPTYB\'XH4(&0(96J $"B#(:I!<9R=#8LJHUMIEW[F91_)S
M&]@FAW*Z0[1<=RM6Y*BCE1"\KL^O38)0/)'"D_*"\:#T?^S(S)TD/&QDYB[L
M[@$TMZ[>[26I5"F)L4*.8?%TV28!9(T)X#F5VIS)F-P<,#_MHB^P["/;)\S5
M/1C= 50>LM^]8\D7\OFEJUV/&+$F&@Y&&8_!B1!":T]G3R_Y2(&VPS71@5SN
M#B?7;X\(YR:9"$@&&*C",WB1)1A,J2A?O+V??FN,E!YTT*&R?1(J>S!Z:M_F
M \YGB^5=,K9W(QT5GHR.P$Q]5F;(2'=>*?#!&U>""66@V_OX&CUA81_A+=IS
M<FI U,OT]>(;S@-=I:1_5U>#S;-CRI*!)C,YZ:IH4?M/62ADNJ%$+Y,8YO,^
M^/$]A>?W5Q^-V-<= *X/AF?>&#3UP2H#I6T=DE+GF0N-.B>3&1_V^.Z1!29\
M6-5 :$]B8 \.3HV"=[-__6@N]GU3%+WZ(^3KX?,Q69UEJ#TX:OB."0;1Z&J+
M%^.RS-GD82_MGEZG)TSL(\3%.!R=&AS;"5L?/^,'3(MY?C7/'S_/EO3?^>P;
M+1'J\(CKF6W1>1V%@6)KRQ9.7IN+DJPKM!BR$T7$88^B=EATPB=US6$S%J^G
MQM"K0A_T^^)RN?[\@Y1K@TG&6 QF!BXC&6$2.40;-22>71!92>^'M1Q]:I4)
MW],U1TDS;G8!BWL _WY3\&253"&3&5T0E ]8.UXD,J,9$H$QEX%E8T\L,N%S
MNG% T8"7'00T[MKH;V\Z(D1B0>0>0>=*1E((G@D$84NT5V.V6F=B'MG*-*,$
MCO-R83]^=P<;\LJO^RD'*TV29-MS47MT)9\AF!S QD F/I?2QS(J;G[LI:>R
M]3T%_21X]N1Z!^AY>(1?34Q\W"8FR$<,NL3$P8LZSR<I!8Z1 8;"<2V8Q\AM
M8QP]OZN>:M;:(*JQ)#K UGO\>N4$KH@.XM'J.C%U;GT* >E4",T]J!P18D)2
MU-Q8J>C\L-!:I3VZF9XJ#-H@J0W?.P#0/8U/Q^#<*A<98YIL.MR4UD2(*#@=
M@1BTDD)PUOHR^GD7/:4"QU!G.W-Z:H_J[O9?AZ^S=;B8_2_FVUT.SG,=89*S
M RFC(-="!' A"^ \<,NC8\X,:U4R:+F> OZ'@60D%O<%FG^&Y:RZ%)6,WR\6
MBR5=EE84I5T=LTF796$<HG,9BG7*L&021[X'7'Y:J">OJCE0#F-K=SKHE[":
MK3[07D(^F]^FC9]K8T3@P8*/01'#1*7+") U]<G1A&#';43Q^-ZF&:UV/'W5
M2"K=H>W9'CV6"><MJ6@6<QUF2/Y 00-1"IVUDZ'(<2-#+?HH-9^A=CS<M91/
M=^![MVD0-DO;1-YYH-M9LMI#1BE=57L=25 ,:(F(9!%BR>.&D^YM:)JI:<<#
MUR'\[\NT>K>\=DA_1[PS9' YFZ?9UW#QS\7%)7UO^7U+[.H\Z&2T31&T$+4-
ML"S@:QL ,@YR<2&)X(<7XQRTE8E&JAW)/AM;-AU<:^]N@B&5]-_^7L_FGRYG
MJ\]7+>Q71%"BPZ0WR</"1,T^T=%*)==^ U*K:(7 UO7%SVYJ&.Q.*F;>5A"]
MWG'7,\XQ%&5*21!$I063J?7\!9)WVD@E.4_FH!MLE^'Q_"1"X<WYVL'M<Z]!
M])UXOA"DNVN:6TO'2*4[(L61/VP3G0(FL\L9&]\[3VQG&)!.*A+>BOE3WS5_
MS<.7Q7)=PVV_;I>_Z1Q\=7-:]%)DRX!9Z4&IXL%CB<0EE9,E!@H<-KOHV:6&
MP>0DHM\C\+:#&^<?839?O5VL5K@ZF]_5LE>:]]SP8EQM.QXT)^7*:@A.A-J6
M7G-5T L?6\<-GMW4,%B=1+Q\'$'LCBQ_A:PY?@IKS!_'JCC!Z]*'.L;91%YI
M(/6LF MDQ]D"(7-;ZW0"JI$+3G"G>I.3B*FW9/K4:NSZ?JVT_##L7LTWW[BN
M>=C<N?^SG*UQ4<IY=$'91(8>XUP3>8J#S^@AA2!DR&BC'58/N?O:PT!T$F'S
M8W"_ \UWS]S;7+',&ZYD3( LI]J$Q4'4JH QPF4=A-&R]:R!![8Q#$LG%0H_
ME-E37T;;8-=9N?=BY5PRZST9=I!3#N1@.@T^&5+/.?E SB7*,FR8[&,K# /#
M282NVW&R@^OCR?C[-6WG/##,@DOPD=2L"K[VU_<.C)4EV?J5CYOG?61CPRHB
M3R)./9Y ND/9[V&V_&>XN,3S9)3G14>P=:ZI2BE L,*376?(+]!8>WB,7*Z]
MW<HP))U4Z+D%T[O#SNW(Q6R5JCNP#9(^9-3]B70AB^0DN@(H(UW((4@(Q@K
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MBQ]=-WZTTN R&!E)8%A")F6O&#C!"J"0W++BN%6]5>L^2=")ZK(^3E [J+R
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M=A!TR, B7<.1R7IB!F'IZ76&@>F%!M@;BF!J-#V>*Z#_;E+!R97H,['%.%Y
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M:V*-847V,RTB!'="I$4< U8"B_KSN>>\+7W3IG7HNZIGJC@2. .(ZL*?#4G
ME;" 2+?'PM1"%P"'9MX^A7Z\E(BCZ+!)OV#8I$"TU?JQ/,-$*,^X/W2DRO<*
MTJ@ '%$.BIP;Q!!!1(:^A7ZE0&0BA0-V^YG; "O'WKV^.<I9'4\['76!% 0"
M$>PK.7'?^%(#R%EN5%$4-NO7-'+'!Y)8MH;@50<V7AHUQE_7TU8&(Z,H<HMW
ME@.,L@(PI J@(6%,PSQ71:^+_:F*UB=U]3YDJ0EB^328LZ4PM\"2*<G]QMA
M@#/) 2,V [D4*-,40YL'I$_RU>F/PK17=?IC#!Q[@3DU3>VV!+/6(;!RCTY5
M08J<@0Q9IS[C$'##G4$*I9"DK*"RWY/GM[*C0S\6K3J<Z:(C?_:_65$@LK[P
M-K# F3: Y(5/E,_]F;[B@!-N;48YLH3U0_V5W'A-^:9 ?+C)8J-]\E"_IJJD
M4"IB&#"(^QO!S)?E0Q3HW'F]3!6$\)ZMM#8DQVOX/ 'BH\P6&_-/0KF??G!F
MN6G$4TM1:(W('54U0<X45/F,*RZ "X>,D%A@PE0OW+=)CW,M,!'VH\T7&__U
MP\[%O<6#:1Z=<2X:H]Q?+I68K0;6/JU=5"N(,=#*A4"XX&Y7I'@&H!:9I890
MB?LEE1WUV3AE>"=BS'0&CTVEL_KNWE3M$AC?P'XF.J,OG/"ZJLSLK&Z[]; 8
MRZC.J7;[<^7K*B)?F(Q0P$7NEDN);:;Z/=3O_\TX=7@G(M%$IH[-H,NN5G^=
MBM;HEP-</^"P@AI&L6.!S[8D5 #&C-N265X8:#,B\G[M&O=])4[5W(E8$LR<
ML7FQ*"3P\;L?@FFSM6M4+I;"C *K% 98<?^Z30N@W HK%;:B8/U\R#;I<2K@
M3L2#T>9+YQ)D?SJ'91(I0PM 5.9[F;(""%Z@13I'9B7"4&V<>/],7@Y_]Q8:
MJ038-Z3'5<:H),:%_8(2[1,@?2,-BD!N+)*V@)0S&IB,/USSLO!<"="<[!C@
MDN"FJBM5SLJ%V?Q(UU.Y[L2LO:K=P-MZ5FH?(CXE=Q#!*?%E>"!U0\.90$#D
M_J:+<)T98[-,AF?G $5_@/SI<?R<&KP$&.JW(^?VE[K6+Z.:RWJFKSF2;D]K
M%"BD"T4PUA P9')0<*V9+=RHBM!YK;NUB=W(<7(JU)/@D@##MI<G6X6\UTR[
M<)8HY":H/X\UQM_JYQ!0Y#;'."M8)L+[NCT*Q>Z\^-X\"X=. E2[-#/WHYM?
M3&4:,5N\<[XKJ]*;R7<Y6H_*[:",R@4$2%"W6>/6K0=N2P6,%KDN"J)S&YIS
M_32+W6KQO<DW 5X)L/!SY629MEL^P7]Z?74-%<R4YLSWA'2Q*S,62$I]0U)9
M:&A$84QHVNU0)7:KQ??F60A$CB<67Q*K,C=^(%?!^;6:'E_KJGX:D>30%KG2
MP##,W8B8KZ1C-6"Y(;3(>:%)Z S4/>K$[M$8BV=CD4G B7VJ&U/>5&=S]^U*
M/5XUHFK%HB7I+Z*LOM1MNRR0[C?E.L>%408!KMSD<1&#!BX\E4!;K8@U.E/!
MBPP>H5[L)H_O3<*ID!OK (/0T@^A]6,P[7GU\;N?6?.RO?4&/;<?C.RN"\TQ
MU=3Z[A+^>)0+P*7PO;\SI+"PC&[FQ8PFXT&E8O=[?&\*AD4IG95W<5FS#"*N
MA9%::VZ 7=2RYH8#SE4&."$685E(@T.?CKSX?.PND._-J*&63V E76KMO.TJ
M*CAUNQU;=M=806L656>X^P5#F0/!H 6*$9EC""7D+'BHME65V%TAWS],&X](
M L3Z:E8;&N]IKZF G*@,@D)RMY0CHH'4, ,9-01J_RA&!B_4\U*!'Z "QIC+
M@.'&'LX4S_\ B3N;;XCUO^:K6AV+]*35[',V\T8ZN:OG57>MLX)9F%& !+)N
M*G#I<]LL@-*MSU REME^V>1#OOX#%*<80J7W02/58A2O)M"%:2YO'1KK_(?:
M?A1-Y4;]]),152@&?BE(^8D0HPQ4=V+S6T]+IR0:X8*XV)LY F.4&Q<_40&(
M--RR+$>.48%7BEVZ!%T"3QZ<+7V*C \9[N[J:I%C=UO/G+]H/Y2S^<OX(;>V
ML"C3 !7&;4 8Y$ @*8#A0F(E-6<PM!$&*QOW[C,(C_8NIY,!EUR09C(F#$'2
M[7.=#\<:0L"Q,OY237.$!:'!2T4='Z1-QJ1W GUOY'8, @G0YW],>7/K+?%@
M&G%CUB7]%A.Q/9]W;2>J96FKA<&>JSDOPX>U_;302$)G-62(\MT$W999:0**
M+/>/\@DKM G,NS":Q[V.G\3U18#T!R+RJ6A+=6TPQ#*'V&^]E:\AF ,)C73S
M73%39(44P4.4HQ2,ZT=C,&@@B8^',P&N;D[[Y2 @LJ3(M-OS$^/V_"+'0!:&
M@H(B(YD23-C0:_=61>*ZQ 2X-QZ>P1QS@Y9UL,*CSD+E@[DT:MZ476F>K2.Q
M80)A K3ET)\N^ LZ[8\82&Z1@1+9T&\E=FL3]V O ;X% BH!Q^;BX&91H4O,
M5C'WPHPG7=>4<MXMH_'UG#)ZU</U12?9]CI#N84%1\ 2/V*!%."%-<#F1"BK
M,LWST)'D>*UC=\0(PY^WMQCO">:/0E]?Q+=[_+TJNXMYHV[%B];$[36!.<DU
M=9&'L19@3AE@;M,'K(8N=(=:&39!2ZUQ2L==[V.2-QB4L=_(]AKMVM(?K36J
M6RUQZX%?S$357HO<"DRT -BBS!>OR( HW,!ECCF7A3(9[M?</)!"<4.#P-2,
MAE0"GG5KE+4*J=Z$6L]75M="%)DRU "E%04X\\63"C<=E80"Z2S#&,+WV*<?
M5C7NG>)$7O0]8(MX?7U@#[!KH&YXV$"N-=!2NV!?"#<\H0TH-!+"%V;1>>C"
MZD>J&)>-">RIIH0T 7_ZYIYW.:[K0BCW-6V!F^9NLN>^5J7%+N"66%!D=&XV
MTRJ"GR&M5(F;FI\  T- %/ <Z3VR+4ZJKM1O5J*/W_T[>Z/MXAW^W?U\^?7I
M4S("J3-=WL84]IHZN0,SF&>Y04!#X:8$LAI(R350!2Q80; H2.BN&E,E=SP7
M1]D/Q*?70)R_ 6)9-X4S5"C?+<-HWT\H*PC@5FD "P(UM#[PP8$M$W8$B::!
M',.XW:U(WAWB!**$D6,^?=PN8%$5FV@."U,P8*'V&:K4;2N@(K[C'\JM)#1#
MH1\"3CB<5#JDO#]+ZS0ID^SL>=E16B%AI20@(X8#MW_0@"F$@&%6"D:%P3+T
M2[!#.L7E<3+DZ47J@4@FP,R/+B2N'XU99+2=W[\H[(BAX1ES V',F0HC3H#P
MGJ# DC.32:J"=U/>J4R*7!R*^>;>+@@ "3#IFW%!5JG\D8@?BK\*:;]=_KX>
M#$<9I50!N>A6(+B;<X7(0&XSC)";<P2&/N?:JU#<FZI)&14.B 18-7(=^/+T
M"H:C0G(D$"BL+\RBM+. 9120 KH%P+),I!9D?CFJ[N<[-$+ZT2/*863X\2?!
MZF46L6XU*=PJ(HE$?CUA@!F6 YA9@G&>.[<2>D$/HGB*B__4G M+_ $$2/5I
MWN5<MN;ON:_[]F#&-8#>+BE,9^<>6H9JV?SZ4\\7#M!(;2D2(,\) 5BZWW'M
M'*V0D'%+)-4Z>.6X';J,/EU]+7=56UI2;I3.@1%8 ES(# @-%4 8Y9P)Q# +
M7J1[BQZ1CWM"H/_FI'.LN1-8,C?'X/[98N]?Y%19006PF.< <U\WP5 "3"&E
MS(6O$AF\D_=V59(BS@",#Y!FB,'3Y,UJ2T8-MC:W%A34:K]^YT!J1D"NJ<I(
M5G!19-,S)X6SN2!0'Z;/ +NG1Z#5KILC[;ROQ4!EV.UZF(1 4O='33EF.%>8
M%A.[G10.T@*!O)\Z RR> &T^E.U]W8K9+TT]OS^;B;8M;:F6R/BYQ0BGABGF
MO#*TOA>@\@:20'#IANF+@&:A"71 I<BG$J'7KY  I,VGU92#F? 3I  D0QA@
M;060PDI <@V1U$1A$SK'X*!2L1^_!*1 ?WH-P",U@OUJ9MK6C?NC^5IWBY:$
M55=6<Z-7!8SK:MU'3E-,M)N)H, " HP+"R0Q FA#%1>,,9&'/H4:J&JR9!Q"
MF'UTG B]!$BZS).[=*@M'DJ<BIFHE+F\-:9;5'#7I1^<F#TG;;:GCZ]LTSZU
M]MENEZ5C@(8BJ3+ H.^-"+4!3/F"H3G*N M\M<*A+[?>9V21"^6%7N,3I$,"
MD^2H ;ZXHRP4A)3K#&2\R "6D@(AW9K(!$4H(XOS[BD]>7]5XWKR%%FW;SF8
MB *Q'S:>EO69/Z7_W!@'@%XM:")WZR9&!<@Q0V[CF6/ J/L=0Q1:BKC6<N-4
M9\<SQ:WB$PHAID*U#FKB!-RAO[$[MV?NPV7W2?@"E]WC8H)9;*TR/O8AD+KP
M7SJ+P P"D2,DBH(K$KS0SRY=(E<=#;TN!S%YHM3YXB_YFM7,8APJBWQCC8Q(
M_V"' %%(GP9!94$HY@:&OK,ZI%-<%Q4&^1YT&@Q#[&7KXE8T=^(O!X=^*%NW
M2_MRL?:K&"K*E0#(^6M_W$Z!-(:!G&:04T.<HX6]EJZ=GTB/&\-AK(/;-#8S
M3F="_=5V=656RALI<LH+!7R\Y^SA+,.=]P7:[<JY5)A*WH\0FY+C'O5.QX-1
M%DQAO:FK&R?MSK<I>;J%RR3.-<DH(%99%V[Y8R&.W&I,<B&9-M*0T =LV_2(
M^V@W?(@RUM0)TF4U?5Q4+MSZ2H#,?(\22[4OZ "!9=P@E4&4Z]#% K=K$GFY
M&8WP <H,,'<*I'GA?5=>4C+I)DPF@36< PR-V]!)6@!E2,$$T\SHX![FC19I
MD64(MGNBU@&&3H JI_/6C:%M3]3?\[(MG^[-?,T+Z#NW&1?"NU751?6,604(
M1V[[3Z',<A*8+SM4B=M?+_BB%,+@B?+&_[8QZWG%K,QS?X2D+?=]DQ #$A$.
MW)3"-A.X<"9\!P:]4BJN PH"?0\Z#<<A]O;HQ+^"$BM/2A1FD&4YR'U6$69"
M VEI!C0UC!AH,K9YZ[QC:_12:GH,&(%6'<)T"3B3+6=)>:9,46 W IMK@+&1
M@''F[5! HWU1;QWZ>G;@D>UD?36#+STCS9P<45931B)K",P9H(6?,I CP"!R
M8\ *$9VC@A2AVP-OTR.N9QF+[5ZJ##!T F19/+HRVH?[:[>(*2R(VQ1J3(4;
M@+" V2P#E#"CI']E08*7Z-E4(B6:#,%U,Y%WE)$38,GO5?MF"#G*(=%4 :M(
ML;S(\&X7(&,%L4H4"(?.DMBB1MP3W.!,&6OHB%QIF^[Z*1?D4IE*-&6]\+&0
M8,QS1(%&OABO*/P <@AR+HSR#8.+?JWIW1=>L,3]Z9DA.S\>MT=SL.@DC'%C
MLV.EMR/YO5&E+1W-5P$]S3$O<@PRKMPJ7!@!.%%N<Y<39RIBM3:]2A@?8L@N
M!>*L-X% K4-;.!&:?*H;HT2[=H-8*<F,E#Y2HP O&M4CR8&5A<%"(8BS7G4N
M>G+D]=<C$B0,I%M(,L*^"80D&Z[URU,Y I(CPA5WRZ^F/J)7',B"8J SBK@S
MDL P='.47;K$[>D^]4O8829/@#JOT@?W9P_ZMO>E7OWA&F,KD"40%$RZ2(Q:
MX8U'_;4%H=9F.1+A6T(-TS6I]Y #F;(OEW<JV&(?[AXW2-^\W-EW8[@&Y]#B
M'% )<X -S0%3QCERK:#*.>)8;RR4.XZ$Q^N2U%/*<2R,@<Z/1<;G07ZK'\6L
M>_QF9D:TYI,QUUDF"S<%-7![5C<%!3. "4)!3C&4,B\R6_2[I@BF4E(O@-Z=
MFJ&P2F U7_54:\^M/S/Y^-W/NGG9WMXMIE[;M=<L-Y1EU/@\??_&%67 OR($
MN5;"%#@7>?!6) >52BK1/<SZ'!:(Z+[/C>%SU7;-W.M_T9C[Y?#<[^[*^=VU
MBYP)0DP"BG+B'W]((%$F?1:5YM0B*&C>SZ/M_U!2Z88A_%1 NR;@?3Y73I9I
M'=WO3>5DUM7-U2I]ZEH8)8UPT:8QSH=B6T"W08?"EZ6C A%B1/!"PWO422I%
M*(S'"67\V+YFU>7.%[5U:_.#$^H79H_-M<VT08:Z7;I2;C&6A@%!N 2:<TLY
MH5(6_5+?=W\CJ0O\ !XFD#43<"Y;,F&6;0Z;4IGK/+.$,&<;2S#RYW\*2"5S
M8 M6( ZQY<&[S.Q5**FKEC .)AP ";#I]<K[2:AU^50DD<"Z<,%87K@MJ8#4
M6<@Y36DM=IL!(A -7H)IARY)G9@&.K8*8?8$Z'/1U,H8W?JBO)_;=N[?^I_;
M5VNNT9#:S!0 %<;X:RL,!*;.QSK3$4YRB(-W=SJL5;^34/A#<2HP%@FPZ\N6
MMW"_B>_EW?SNM&Z:^A^WF3P3]^XGW>.UU! 2Z+:0FB,W-HP+P"&"P.T3B$(<
M%SD,G7IRC'[]&/=C';Y/AD_\>MP+V:U1_WE3/_R747HI_N0?T>BK\FYUB+:L
M7_):Z6WEN%\1[:70)<>4?J;6]B\<6:9[L/(CJW2[3UTOOW*W^,03RP:;8[?$
M@:[EI<#?JOO2"[URPSYU/_PKB)IOI4:Y=3N(Q7HR][)(Q,7@E7ZFNZUU8+PV
M9$:YG1J&UG9K)(+5A?MLU]Q5^M-,W 1!ZK7$*%<U@W#::HE$4/(S_JQJ=1,.
MI@V14>XT!GN_M[9(!*A?ZW^>]0OK 7>(CG+', BX_;:)#.#3FEK>&?VI;GSO
MFC_$;/1TVR<WRJG^4=#UL$H*$Z\]<V&RN:J?U/7Y<@%GWP'Y40[ACY^"_:R4
M+)X3P1CGZ#L0>HF ]KG2Y4.IYV*V>+<Q!J@-47$W9?MM7A\R0.RI-)L]Z[6N
M'SYJ$FT3& VA'3:O^QD@@7/3Y?Q?EZ8*>^;Y6G;<S7*O6;37* F M>S@+5JC
M?0QDJG9EOT94-XM'0.WIX_/?6>53+0;S/*)*7\Q$]:($=%C,)U$Q;I_+K638
M?-HP(3()$&]W__&P[$FTS_FDZ/9M>YX0'1:ZG=R[SZMRF01<WMQV[>7)M\M)
M:''X>W'?";PC/7J;/G;<MVW1=8&0'V'X3=1:<)3LC_';J V[I #=[Y5N9H\W
MSSV53^ZZ\;AME1HGO^)XU/:9) 7(/GYOU#*1;C1.SZ+BI"(<#\Z;P:> R"]N
M!>@^B,Y\$F7SAYC- T"S168OC!*XA]QMCLA@O9[9C[_]U2VH='9;W5RH<6[O
M@.A>T,6]FNQGG%33<#XVB_N"B5)PWDH/DGYS0.D J3??C*H?3/-X;M]\ZPT9
M!O&^UP=&3-F5U/5GQA_.;Q48[5SQ&'Q>3M9]9HGL9+^9=EVKQJ\!HP_IM\F+
MAM=>N]>]C/#_^OIDDNBD+R@_+TY^7IP<A<W7NOIJZA"@O)84[Z)QGZWK P-/
M:%TQOO5 62V; ;O_&6R!>2,XFE,;&AGT,5-LEW=STZT&-?JTZ;6H: F@0]':
M;HK(^*P5JL3LL2W;,+E-.X5&2P8=&7OO-$]D]"Z[ORX:==Y<M<W'MBOOQ/)J
M*5R6?*\/1,L4'8KJ,6:+C/#YO',^OO)U>P*ZTMU2HZ6.#L7RH('260"_UMV?
MYFFE-J'2N/M\(%HF:8#%\J#9(B/\R0FM*[,>:8@+T1TBHV64#D5QOVG2PNW#
MW%S5JZHQ;IR5K1NU"*W'.MMCOA/MLCL0PGV,F"#L?Y3U;&'F<_MK?6?.?"V&
MYO&+^&<*[/=^+-[%>4@&]+%G@C1P(_Y[+F:E+=5*^ROQ_=14QI;=Z&2)01^,
M=U4?D@Y][9H6)9P;FXEJI?#GN_M&J,X-0"[J'(2)W89],5YN0"!2'&?9='9@
M(4.\/6+C)1 $V(2E&>MM43#P/GI3;"\0DSKK.FRCA&X%:M.Z?>$WL^@!^70;
M&,0I'_&97B G=?1UO U3S0*Z>)@J ^BUY"#9/WN4#9#Y<R$>_V@O3.-V6W>^
M[%?HQ)\^\D?,:V><\;D^3T*B7;@>@<++&;DY^M@70M^-FG?E@SES;N*F;AY'
MIXYLEQ@/IDU[UST''_L@>3;;5*\T@9)(=@N.EWVU%XKZ.+M$AN["U %P>I82
M,Z?DL*WK/0./G^3C5/H:!(Y-6?'>0A\)R@XC_,Q5?,^5YF=^XL_\Q..PT?^Z
MJA?[\;'3X[6D:&E4^V;'UL'&!F V>U(KS-38%!=O6=]J[KK/V&.#<G/3+5XM
M56WUAW"3]W)^=[<\MVJ[ZDK./M7-R?U,SOYL0F!V]-=B1FJ[$*L#F"\!V+W.
M;HCMY8,Z>VK).Q;=K4)C1G8]0=QGC-B;G] X#<9HFHEVR/IU/U,D@M)%TP0'
M:E-FO/DT *L=!HE]2O=W]WCR3Z-;KV( J+;)BU=AN9?;VV."5,"9.!PYYCOQ
MSO'VP+0-S1\F!GDUL(_?U>S&15#?[IM.OQU"Z!G:[W/Q'FD>B?G1%HP,_9_-
MQTI_\N4NSNW3('YI*J_XV4.C_VS\7;JN;DXJ_7OUT'8Z  $&?S2-J7\<OG4X
M8T?FBM]>?:Y6^F]JNCD>%VS\V818SX=_-0VG,9@MH\T=F2Y_N '>?.BV\MV-
MP_WXB?8!:'+\UZ(%A6'H,=B\Z7B1D_;<KH9Q;A<,?AI&8'8,_FBT9Y[!?<@@
M8\=.8UXKOM2WTF_7S:7C^S33B[&=U95N/S3N-Z&8$TB%: ]+P_ H+!"16?7A
M0>OVO#GO;IN/3L/V0I]73Z/YVOG__T_[S<Z4']95-_,&\HT]0E$JQ/>C/6X-
MPZ> $,1NBF.$SXL;?97Y4DZT16??1>:6@<8^Z%UI&R97^JVT>-D6X](O4WMV
M<E9?FIE1G=$K#HU^<;)=8KS[_V%X[;5+[/0RIXI^RL4ZM[943NZG*LQ<.RP]
MG@L<AF5O>\7VF<8TOS3U_-[WU0Z(Z#ZYT6+?H7[TL(UB>]1;7[M?/RD:"L5]
M<J-%G$.]ZV$;19^+]57=B5F(YWN;LJ)521D\Y[;:(CY")ZJ;B]GL\4*4.A!0
MVT1&JX<R'*\]EHF=4^6OW)V&BUUC(->X2V:T,B<#@3M@F]AAYSJA_^3A)IAO
MW"DT7H62H5'F ?,DA-Y"LQ<>(B2(VV3'*R\2 ,L]QDK!E3ZI&MRA[I0<KS#(
M&+]ZR%#1\WSF9??H6YLL3>FV-W>+%FX?2NN4,6ZTH= ]\E/QZH0,A'N8*6-O
M&S?<S!_M8A%9-'^[K6?.RM^Z4#O)XSX5K\3(X+.[(:9,#O^OIOM<J?HNT!EZ
MKP_$JS02#.O=9DL.X3>'S%,AO>=#O1!/ZNQH@!DC([_%_?B1KPZ_PH#>]QN]
M\$[I].E(XR4WR<^[6]-,/+^W?Z,7U"D=7!UIO-BS6LCY3#1?RK8+>-6]6VHO
M.%,ZSCIHH-@ OO4L8T]"=HCLE:V0TF'6?M-$/_E?.__P !Z2W0O)E(ZR>AHK
M^K*Y$<*-Q7&KP%[@I722L<\LL4N=^I79CR@08-OD]<(KI9.'/49)X:PX2'NL
MEX)Z 932<<$V,T1?S>K1.7=K&;WP2&DSOS'X-/*%1\-Q;.(C2FF_G6"^8UW]
M(L3]2K$/IE5-N3C/#Y3P>%A\+Q!3VDGW-UGT=4F77B\QPQ ]/(\NU#WF(>F]
MD$UI4]W;8+&7M:JM3BO;^;<HP1)9=\CLE5R>TO;Z@'&B7T4_/R,*=^>\768O
MZ%+:3Q\P3JIE[#]7;>F,>=6(10O#IO$)N+X\_\:#H9$U[?=\)DB!^[[#"%#M
M_LVGWM!B8-78G6+''&4^B3OU+5'&U[G?*C!B2=5#6+PZO-QCC-A'SD^JC7Z4
MN"$J&C9[K;T5E82>*9[,9EM\29BZJ[L%)X#5GA*L!PWRLX1WK#GTLYSWSW+>
MO;&1JOE^??*?OPEU:V8S<RE<0+2]ZI/_FPL((,_A H:]_S9FM>'=AJ[[CWHP
M*+/1)XQ=,[LRS5U[;J\:[>9[F-W5'K'1?-IQ,=MAPT2/W+Q6(5HROI84[6'\
ML3'UEN&G LE5V8W>[KP2%>V%^T!07AD@,BK?YC.304DR'V7J^KXS^M-,W(R"
M9Y?,:*_7C\/I@$GB7Z],@=D>L=&>JQ\'VV'#).$ %WKYURVB"^$$7XF+]E1]
MB"/<9HB$G.%5<U=U87WA"Y'1'JD/=X5O#9*6)PP$V&ZIT=ZGC_*#R<&VWC T
M=^6RVWL@3[@I,=Z3]"'><(<]DL#JX_?[L@D)U8; > _.AR"UW1I) /5AOE0L
M $1/HN(]'Q\"SJ8%DH#ETJAY4W:E:4]N;DX>1#D;_7!AC]QX#\"' +;7-C_&
M]?Q%/2N5&\!%4ZL)K^=??6:"Z_G=PPA^/?_R4V\X$N">?KO\49=8*_'ZI>A0
M>^_#TA.YRM^+V^N;KY[VBGXYN4W/KW6W4C7,>7__KR1R_#\2YSWVF]ZCKW[@
M?Y&B-?_]'_\'4$L#!!0    ( %> 9%NC02:P;"H  ,WO   <    8F-R>"TR
M,#(U,#DS,'@Q,'AQ>&5X,3 T+FAT;>U]6W/;2);F^_Z*7-=LM;0!L41*LGRI
M=H0LT39W9,DCTN6IIXDDD"2S# )L7"2S?_V>2V8B 8*27.VR2+5[)EP4">0]
MS_4[Y_PZ*^;QJU]G2D:O_M>O_WMO3YRE83E722'"3,E"1:+,=3(5GR*5?Q9[
M>^:ITW2QS/1T5HC>?N](?$JSS_I:\N^%+F+URK;SZR_\]Z^_4">_CM-H^>K7
M2%\+'?W]B>YUG\J).IP<'AU-#L/)1/:B7J]WV'T^B;J]R:'ZG^X3>!4>YW?R
M8AFKOS^9ZV1OIK#_%\>]1?'R1D?%[$5W?___/*D]5Z@OQ9Z,]31Y0:.%7R<I
MS,W\'*9QFKWX:9_^]Q)_V9O(N8Z7+_XVTG.5BPMU(Z[2N4S^%N0JTQ-^)M?_
M5- 9]$M_WIB!0!.Q3I0=6+>'H^E_F>FQ+D1WOW/XZR_XO)W.ZJ1D-H5YC=.B
M2.?P.K3OC3^$M539MYQ [QX3X!%$*DPS6>@T>5$FD<KPJ2>O3B\OAA_/1X.+
MM^+D[56__[Y_,:I/\=Z3^Z/,"SU9_I6S.VS=GI]_ZC[=?[GZ[VBF<V$G\UU7
M_/9U_<[+(W:*F1(___2LU]M_>3+-E,(K37]W7^X*6*.9RM1X*>AP K'029$*
M^%LFD1BKXD:I1+Q3,?P[FLGP<R:78L<T=YHF>1D7TFL/WWJMT]-LF1?BPTQF
M<QFJLM"AC/- #)*P P-*IPH&E8D;7<R$+G)Q,IGH6 .M@F=,V[:1JF5QIF)Y
M(S,EX"@OS&D.N)$4&@AAO60A#H_VCT1_OE!9FHG7:1FK:YE%@1B6NE! Z_8#
M<59F,SD/Q$6:P;NG,DMAW:3H'1_O'] ,\IF,8YB]4).)"@M]K83,H1,Q5(M"
MS<<P]F[ =--?WKY[^@SF8D?>$9]PB)G*%_"K@-55FJ:_D%FQ=!-V:V#>$W,E
M$YA10ENCBZ6 ^:395";ZGS1U6(:D@*'#V*>!^P-V<$R/TC6'K^?SZE%>K+P,
M9]QY1X@W\"A.85'"FN:*9EG@U8G41">:.C(C-(W4QT?OICF\F=-V1#K#64*K
M.N'/ 3>)C]W B&#^U3.A+'-%/_)WV)MY&@Z]G-)AI2U9P!Z%FL<GD_I"0$.\
M1' :9GRTL(7T)E%9/M,+?.<Z+9 )YBHL,Y@5GC18)YJ2Y+&D^.*-SE7G3Y+
MAZ'O3UY]$@,Q$A>B+X;P?WWX_.[GGXZ>O7PLE'Q YS?7<)ZE?T*@FVNZ]9G"
ML\XGOZ))>-(L%0GH!;@,"Y7DW A2.3B34D?XT7L-&JE>PZ-'I[$L2AF+19;.
M-=X2_%Y::LHT%$C(!/8?AE6("5(6[A0O&IY;? 0ZHI>0FDS@LJ8W^5?OU$)&
M$9SDO5A-8.&>M>X=?P47$ ;W8@\?^OZ[V>T\"/.MK\]SNSSM\L](9?,'XLM
M>DE"<2P9:#/P'*37*@F!>"5T>NHLA8X=TBR=E H(K.%/HES@&>:SFJ7E= :\
M,F0^=6 850 ,(08B+92$R2.%A+G#D47] &A_7IH;,S14N-MSG* :HL_L<.TJ
M%B<>XQ'N;<$1'AHB^'#'&*0IY*QX-/!,!#XM)6J7X[F:R\\*:6"NX@D0;)FG
MB1S'(&9>2QW#)X4/H8R4)D20=?*/4F=(."= <X&H)AK9_!?@WW@=2 YP@F:F
MIB#CV5$ 1P=N83G%C$BRX11X18C/PW@*N 'PS3@MX>[--,A$WL!G0*$_)^D-
MR%-3)79"E*SH'L9+)NOF%MCE]VZ"UPK+D9D":;4P$@Y,V>-+GK0)K.4:6!PU
M;EO%*RY#V/9((DVX83G2K!T2@+S(2KJON9C"X(BKX>P\'M8VHB0%FE& N/E/
M10(F7/,L8I$0NR2VI3)@8G/JU_!;-RH<!ZX:/9?AOMR 3%4HYM-(*+S-62]-
MK9(!^TW&)^R@<[0AHLG(G[X3-UC$;M!(7 *01<O"$U!:MI$.*ER7O#H+PR(-
M/Z..A,(L4/P/,0BZ/LFM_U33N? IU] @B<J01].'6P2;>FNC[F&O56ZTIJCA
M._5V:C<!O[#7 (2:Y]Q$*!>ZD'C0(C-=$/A!4(/3@X>0E Q2.IO+R =U)J_Y
M1J"R 2<CKZ0K>U"IWUTGJ64*?E4^$<(Q=8]? N?CM4 =,L)=#!5,),*[3W>)
M6E/S19PNYXTS7-?RN)D3:L9M@N'>AC7#-00:!?.KT\9U!X'N?D[7V-PUN5B
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M3S$5BW=!<G8GF5\EYDA'X'*GUTR=6P9E'(:58H>J&,?$-I0Y4"G@UF?K&J*
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MC15?#?[R1T/)#$E"J!JI+P&95QH-/CJ"LRT>_7,X@TFN'A]UV1;5:3#QO:A
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M\VH'@+;/.P'D<$TGNU^3H>?QF*O;K^733:#?=YBKKZSO>I!0K,C#Y;#PL1M
M0B@S%9Y90F:L]RNM2<&X0.6P$!ZB 6F/RCEBIY%3T226\9)#F/0.2$&T,3D8
M*2U3TS*66>42G&%NBH O-ZQ*HHQKC!.![7 $(0)PO(1!E" R3!><XWD7+MXN
M3:I.MTT6-&<Z8>G.B(J8O8MA<CL:WJX6(1<3&>J8\CYS CH8&HA.%$!614_
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M?K<Q?^36"<(BG:V37\VY*H)++&4J$=2EQ,=YO3<B\?U=UYL (QH/]N'Q2UN
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M)KI(,_CYAQL2$WS^<$/^-8?_5&8I?"N=^LW992RU=3'[<!RM1FI)M$E_O9)
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MT:'*OMH(VV((^VH-[VZ^_>^$67K^YS!+OXS3: G_F17S^-7_!U!+ P04
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M   <    8F-R>"TR,#(U,#DS,'@Q,'AQ>&5X,S$R+FAT;>5:77/;-A9][Z]
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MUN\7X]%>8+QFZ56([\QS:TC?G2%W!CPVR40)PC&WNN!4"KC%'B =2^#F1C1
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M/ MZ**GHI;)(RL[RP.!'^9BCMY5"R%,N@@W'_ WTBA63C*6KX-.<953"$;V
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MN;3C4X]TJ>=UNKY//+_-//J75T-19"]DE%XE;+^6\LR)F;$?]%JY'EQQJN/
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M/RWR ^[=^2S>\#;MF^5_ %!+ P04    " !7@&1;G^^ J1@L  ",D0  '
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MG]S+-64;*SVV!:"Q2LPO5L)>!RB%N_.:#8!14'%"P7Y@<!*'+%2\C<BLW2W
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MQR,9,@*] MPAK#6W;%MZ)X8424TF+"O]H!+CR 8?[=?=#F]#9@N-XF;!D>/
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M=@Z98$66VT7A\OEEID/0_:M-S#0,$7=8=2"AP]*=5^V>YAVSR;G*.U-PC]-
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M+3(P,C4P.3,P+GAS9%!+ 0(4 Q0    ( %> 9%O^3-[>KR4  ,Y[ 0 5
M          "  4NB @!B8W)X+3(P,C4P.3,P7V-A;"YX;6Q02P$"% ,4
M" !7@&1;(0 PS -U  ",4P4 %0              @ $MR ( 8F-R>"TR,#(U
M,#DS,%]D968N>&UL4$L! A0#%     @ 5X!D6T_>](#J.0$ =5 , !4
M         ( !8ST# &)C<G@M,C R-3 Y,S!?;&%B+GAM;%!+ 0(4 Q0    (
M %> 9%N6]+<1DK\  .;S"  5              "  8!W! !B8W)X+3(P,C4P
M.3,P7W!R92YX;6Q02P$"% ,4    " !7@&1;HT$FL&PJ  #-[P  '
M        @ %%-P4 8F-R>"TR,#(U,#DS,'@Q,'AQ>&5X,3 T+FAT;5!+ 0(4
M Q0    ( %> 9%MN""A5^0<  &@I   <              "  >MA!0!B8W)X
M+3(P,C4P.3,P>#$P>'%X97@S,3$N:'1M4$L! A0#%     @ 5X!D6S$(H/GQ
M!P  22D  !P              ( !'FH% &)C<G@M,C R-3 Y,S!X,3!X<7AE
M>#,Q,BYH=&U02P$"% ,4    " !7@&1;9=.CP_ $  !,%P  '
M    @ %)<@4 8F-R>"TR,#(U,#DS,'@Q,'AQ>&5X,S(Q+FAT;5!+ 0(4 Q0
M   ( %> 9%L+X?EPX00  & 6   <              "  7-W!0!B8W)X+3(P
M,C4P.3,P>#$P>'%X97@S,C(N:'1M4$L! A0#%     @ 5X!D6Y_O@*D8+
MC)$  !P              ( !CGP% '1H86-K<F%Y+6)I;V-R>7-T<V5P87)A
;="YH=&U02P4&      P # !& P  X*@%

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>bcrx-20250930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:bcrx="http://www.biocryst.com/20250930"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="bcrx-20250930.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">bcrx:CollateralForCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">bcrx:CollateralForCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bcrx:LaboratoryEquipmentOfficeEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bcrx:BioCrystIrelandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-01</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bcrx:BioCrystIrelandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionDomesticMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionDomesticMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionDomesticMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionDomesticMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:OtherIncomeFromContractWithCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:OtherIncomeFromContractWithCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:OtherIncomeFromContractWithCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:OtherIncomeFromContractWithCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:PeramivirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:PeramivirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:RoyaltyReceivablesFromPartnersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:RoyaltyReceivablesFromPartnersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcrx:FutureRoyaltiesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesUnder350000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesBetween350000And550000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesOver550000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesUnder150000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesBetween150000And230000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesOver230000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2021And2020IntermediateFinanceTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcrx:FutureRoyaltiesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:The2021RPIRoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesUnder350000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:The2021RPIRoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesBetween350000And550000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:The2021RPIRoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesOver550000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:The2021RPIRoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesUnder150000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:The2021RPIRoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesBetween150000And230000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesUnder350000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesBetween350000And550000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesOver550000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesUnder350000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesBetween350000And550000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesOver550000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesUnder150000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesBetween150000And230000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesOver230000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyRPIRoyaltyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyOneRPIRoyaltyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSRoyaltyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyRPIRoyaltyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyOneRPIRoyaltyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSRoyaltyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyRPIRoyaltyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyOneRPIRoyaltyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSRoyaltyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyRPIRoyaltyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyOneRPIRoyaltyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSRoyaltyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyRPIRoyaltyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyOneRPIRoyaltyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSRoyaltyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyRPIRoyaltyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyOneRPIRoyaltyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSRoyaltyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyRPIRoyaltyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyOneRPIRoyaltyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSRoyaltyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:PharmakonAdvisorsLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-17</instant>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:TermLoanTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:PharmakonAdvisorsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bcrx:SeniorCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-17</startDate>
            <endDate>2023-04-17</endDate>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:PharmakonAdvisorsLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-17</startDate>
            <endDate>2023-04-17</endDate>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:TermLoanTrancheCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:PharmakonAdvisorsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-17</instant>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:TermLoanTrancheDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:PharmakonAdvisorsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-17</instant>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:TermLoanTrancheBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:PharmakonAdvisorsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-17</instant>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:TermLoanTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:PharmakonAdvisorsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-17</startDate>
            <endDate>2023-04-17</endDate>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:PharmakonAdvisorsLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-17</startDate>
            <endDate>2023-04-17</endDate>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:PharmakonAdvisorsLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-17</instant>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:PharmakonAdvisorsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcrx:DebtCovenantTermsAxis">bcrx:PikInterestPaymentIsMadeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-17</startDate>
            <endDate>2023-04-17</endDate>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:TermLoanTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:PharmakonAdvisorsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:TermLoanTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:PharmakonAdvisorsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:PharmakonAdvisorsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:PharmakonAdvisorsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcrx:DebtCovenantTermsAxis">bcrx:BetweenTheSecondAndThirdAnniversariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:PharmakonAdvisorsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcrx:DebtCovenantTermsAxis">bcrx:AfterThirdAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:PharmakonAdvisorsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcrx:DebtCovenantTermsAxis">bcrx:AfterFourthAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:PharmakonAdvisorsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-18</startDate>
            <endDate>2025-04-18</endDate>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:PharmakonAdvisorsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-24</startDate>
            <endDate>2025-07-24</endDate>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:PharmakonAdvisorsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-24</instant>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:TermLoanTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:PharmakonAdvisorsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:TermLoanTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:PharmakonAdvisorsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:TermLoanTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:PharmakonAdvisorsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:TermLoanTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:PharmakonAdvisorsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcrx:DebtCovenantTermsAxis">bcrx:PikInterestPaymentIsMadeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:TermLoanTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:PharmakonAdvisorsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcrx:DebtCovenantTermsAxis">bcrx:PikInterestPaymentIsMadeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:TermLoanTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:PharmakonAdvisorsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-05</startDate>
            <endDate>2019-11-05</endDate>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-05</instant>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-05</instant>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-05</instant>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:HHSOfficeOfTheAdministrationForStrategicPreparednessAndResponseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:HHSOfficeOfTheAdministrationForStrategicPreparednessAndResponseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:RAPIVABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:HHSOfficeOfTheAdministrationForStrategicPreparednessAndResponseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:RAPIVABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:HHSOfficeOfTheAdministrationForStrategicPreparednessAndResponseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:RAPIVABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:HHSOfficeOfTheAdministrationForStrategicPreparednessAndResponseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:RAPIVABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:HHSOfficeOfTheAdministrationForStrategicPreparednessAndResponseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:RAPIVABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ClearsideBiomedicalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-03</startDate>
            <endDate>2023-11-03</endDate>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ClearsideBiomedicalIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-03</startDate>
            <endDate>2023-11-03</endDate>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ClearsideBiomedicalIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesOf2MillionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-03</startDate>
            <endDate>2023-11-03</endDate>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ClearsideBiomedicalIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesGreaterThan15MillionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-03</startDate>
            <endDate>2023-11-03</endDate>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:BerotralstatMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:BerotralstatMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:BerotralstatMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:BerotralstatMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:BCX17725Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:BCX17725Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:BCX17725Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:BCX17725Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:AvoralstatMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:AvoralstatMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:AvoralstatMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:AvoralstatMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:FactorDProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:FactorDProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:FactorDProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:FactorDProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ResearchDiscoveryAndPreclinicalProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ResearchDiscoveryAndPreclinicalProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ResearchDiscoveryAndPreclinicalProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ResearchDiscoveryAndPreclinicalProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CompensationAndRelatedPersonnelCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CompensationAndRelatedPersonnelCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CompensationAndRelatedPersonnelCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CompensationAndRelatedPersonnelCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:StockBasedCompensationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:StockBasedCompensationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:StockBasedCompensationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:StockBasedCompensationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:OtherExpenses1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:OtherExpenses1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:OtherExpenses1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:OtherExpenses1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcrx:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:PharmakonAdvisorsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-08</startDate>
            <endDate>2025-10-08</endDate>
        </period>
    </context>
    <context id="c-300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bcrx:AstriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-14</instant>
        </period>
    </context>
    <context id="c-301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:BlackstoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-14</instant>
        </period>
    </context>
    <context id="c-302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:BlackstoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-14</startDate>
            <endDate>2025-10-14</endDate>
        </period>
    </context>
    <context id="c-303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:BlackstoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-14</instant>
        </period>
    </context>
    <context id="c-304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">bcrx:A.MachelleSandersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">bcrx:A.MachelleSandersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>bcrx:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="security">
        <measure>bcrx:security</measure>
    </unit>
    <unit id="plan">
        <measure>bcrx:plan</measure>
    </unit>
    <unit id="dose">
        <measure>bcrx:dose</measure>
    </unit>
    <unit id="period">
        <measure>bcrx:period</measure>
    </unit>
    <unit id="payment">
        <measure>bcrx:payment</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-25">0000882796</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-26">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-27">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-28">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-29">false</dei:AmendmentFlag>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList contextRef="c-3" id="f-584">http://fasb.org/us-gaap/2025#ShortTermInvestments</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList contextRef="c-4" id="f-595">http://fasb.org/us-gaap/2025#ShortTermInvestments</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-205" id="f-764">P3Y0M0D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList contextRef="c-3" id="f-793">http://www.biocryst.com/20250930#RightOfUseAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList contextRef="c-4" id="f-794">http://www.biocryst.com/20250930#RightOfUseAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList contextRef="c-3" id="f-803">http://www.biocryst.com/20250930#RightOfUseAssetsNoncurrent</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList contextRef="c-4" id="f-804">http://www.biocryst.com/20250930#RightOfUseAssetsNoncurrent</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <ecd:TrdArrDuration contextRef="c-304" id="f-1156">P139D</ecd:TrdArrDuration>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2025-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">000-23186</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">BIOCRYST PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">62-1413174</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">4505 Emperor Blvd., Suite 200</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-10">Durham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-11">NC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-12">27703</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-13">919</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-14">859-1302</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-15">Common Stock, par value $0.01</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-16">BCRX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-17">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-18">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-19">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-20">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-21">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-22">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c-1" id="f-23">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-24" unitRef="shares">210543224</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-30" unitRef="usd">84078000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-31" unitRef="usd">104713000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-32" unitRef="usd">579000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-33" unitRef="usd">210000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments contextRef="c-3" decimals="-3" id="f-34" unitRef="usd">128795000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments contextRef="c-4" decimals="-3" id="f-35" unitRef="usd">216137000</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-3" decimals="-3" id="f-36" unitRef="usd">91325000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-4" decimals="-3" id="f-37" unitRef="usd">79069000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c-3" decimals="-3" id="f-38" unitRef="usd">5232000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-4" decimals="-3" id="f-39" unitRef="usd">8087000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-3" decimals="-3" id="f-40" unitRef="usd">16502000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-41" unitRef="usd">13752000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="c-5" decimals="-3" id="f-42" unitRef="usd">29173000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="c-6" decimals="-3" id="f-43" unitRef="usd">0</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsCurrent contextRef="c-3" decimals="-3" id="f-44" unitRef="usd">355684000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-45" unitRef="usd">421968000</us-gaap:AssetsCurrent>
    <us-gaap:InventoryNoncurrent contextRef="c-3" decimals="-3" id="f-46" unitRef="usd">23390000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent contextRef="c-4" decimals="-3" id="f-47" unitRef="usd">23187000</us-gaap:InventoryNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-3" id="f-48" unitRef="usd">8396000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-49" unitRef="usd">7777000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:LongTermInvestments contextRef="c-3" decimals="-3" id="f-50" unitRef="usd">39669000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments contextRef="c-4" decimals="-3" id="f-51" unitRef="usd">20323000</us-gaap:LongTermInvestments>
    <bcrx:RightOfUseAssetsNoncurrent contextRef="c-3" decimals="-3" id="f-52" unitRef="usd">10840000</bcrx:RightOfUseAssetsNoncurrent>
    <bcrx:RightOfUseAssetsNoncurrent contextRef="c-4" decimals="-3" id="f-53" unitRef="usd">12008000</bcrx:RightOfUseAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-3" decimals="-3" id="f-54" unitRef="usd">4387000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-4" decimals="-3" id="f-55" unitRef="usd">5157000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent contextRef="c-5" decimals="-3" id="f-56" unitRef="usd">4058000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent contextRef="c-6" decimals="-3" id="f-57" unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-3" decimals="-3" id="f-58" unitRef="usd">446424000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-59" unitRef="usd">490420000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-3" decimals="-3" id="f-60" unitRef="usd">5567000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-3" id="f-61" unitRef="usd">11644000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-62" unitRef="usd">118778000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-63" unitRef="usd">113292000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="-3" id="f-64" unitRef="usd">348000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-65" unitRef="usd">937000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c-3" decimals="-3" id="f-66" unitRef="usd">1435000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-67" unitRef="usd">1835000</us-gaap:FinanceLeaseLiabilityCurrent>
    <bcrx:RoyaltyFinancingLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-68" unitRef="usd">37686000</bcrx:RoyaltyFinancingLiabilitiesCurrent>
    <bcrx:RoyaltyFinancingLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-69" unitRef="usd">32676000</bcrx:RoyaltyFinancingLiabilitiesCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="c-5" decimals="-3" id="f-70" unitRef="usd">26423000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="c-6" decimals="-3" id="f-71" unitRef="usd">0</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-72" unitRef="usd">190237000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-73" unitRef="usd">160384000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-74" unitRef="usd">8425000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-75" unitRef="usd">7924000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-76" unitRef="usd">1742000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-77" unitRef="usd">2124000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <bcrx:RoyaltyFinancingLiabilitiesNoncurrent contextRef="c-3" decimals="-3" id="f-78" unitRef="usd">439107000</bcrx:RoyaltyFinancingLiabilitiesNoncurrent>
    <bcrx:RoyaltyFinancingLiabilitiesNoncurrent contextRef="c-4" decimals="-3" id="f-79" unitRef="usd">481053000</bcrx:RoyaltyFinancingLiabilitiesNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-3" decimals="-3" id="f-80" unitRef="usd">194366000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-4" decimals="-3" id="f-81" unitRef="usd">314869000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent contextRef="c-5" decimals="-3" id="f-82" unitRef="usd">436000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent contextRef="c-6" decimals="-3" id="f-83" unitRef="usd">0</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent>
    <us-gaap:Liabilities contextRef="c-3" decimals="-3" id="f-84" unitRef="usd">834313000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-85" unitRef="usd">966354000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-86"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-87"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-88" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-89" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-90" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-91" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="c-4" decimals="INF" id="f-92" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="c-3" decimals="INF" id="f-93" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue contextRef="c-3" decimals="-3" id="f-94" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-4" decimals="-3" id="f-95" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-96"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-97"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="-3" id="f-98" unitRef="shares">450000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="-3" id="f-99" unitRef="shares">450000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-3" decimals="-3" id="f-100" unitRef="shares">210522000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-3" decimals="-3" id="f-101" unitRef="shares">210522000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="-3" id="f-102" unitRef="shares">208543000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="-3" id="f-103" unitRef="shares">208543000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue contextRef="c-3" decimals="-3" id="f-104" unitRef="usd">2105000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-3" id="f-105" unitRef="usd">2085000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-3" decimals="-3" id="f-106" unitRef="usd">1360890000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-4" decimals="-3" id="f-107" unitRef="usd">1291100000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-3" decimals="-3" id="f-108" unitRef="usd">1140000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="-3" id="f-109" unitRef="usd">921000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-3" id="f-110" unitRef="usd">-1752024000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-111" unitRef="usd">-1770040000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-112" unitRef="usd">-387889000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-113" unitRef="usd">-475934000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-3" decimals="-3" id="f-114" unitRef="usd">446424000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-115" unitRef="usd">490420000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-7" decimals="-3" id="f-116" unitRef="usd">159395000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-8" decimals="-3" id="f-117" unitRef="usd">117085000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-1" decimals="-3" id="f-118" unitRef="usd">468282000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-9" decimals="-3" id="f-119" unitRef="usd">319178000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-7" decimals="-3" id="f-120" unitRef="usd">2187000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-8" decimals="-3" id="f-121" unitRef="usd">3211000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-1" decimals="-3" id="f-122" unitRef="usd">9553000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-9" decimals="-3" id="f-123" unitRef="usd">6175000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-7" decimals="-3" id="f-124" unitRef="usd">44603000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-8" decimals="-3" id="f-125" unitRef="usd">41081000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-126" unitRef="usd">125259000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-9" decimals="-3" id="f-127" unitRef="usd">125197000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-7" decimals="-3" id="f-128" unitRef="usd">83014000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-8" decimals="-3" id="f-129" unitRef="usd">65101000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-130" unitRef="usd">252866000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-9" decimals="-3" id="f-131" unitRef="usd">185841000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses contextRef="c-7" decimals="-3" id="f-132" unitRef="usd">129804000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-8" decimals="-3" id="f-133" unitRef="usd">109393000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-1" decimals="-3" id="f-134" unitRef="usd">387678000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-9" decimals="-3" id="f-135" unitRef="usd">317213000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-7" decimals="-3" id="f-136" unitRef="usd">29591000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-8" decimals="-3" id="f-137" unitRef="usd">7692000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-138" unitRef="usd">80604000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-9" decimals="-3" id="f-139" unitRef="usd">1965000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestAndOtherIncome contextRef="c-7" decimals="-3" id="f-140" unitRef="usd">2238000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome contextRef="c-8" decimals="-3" id="f-141" unitRef="usd">3591000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome contextRef="c-1" decimals="-3" id="f-142" unitRef="usd">7778000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome contextRef="c-9" decimals="-3" id="f-143" unitRef="usd">11176000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestExpenseNonoperating contextRef="c-7" decimals="-3" id="f-144" unitRef="usd">19661000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-8" decimals="-3" id="f-145" unitRef="usd">24828000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-1" decimals="-3" id="f-146" unitRef="usd">64737000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-9" decimals="-3" id="f-147" unitRef="usd">74067000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="c-7" decimals="-3" id="f-148" unitRef="usd">35000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="c-8" decimals="-3" id="f-149" unitRef="usd">98000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="c-1" decimals="-3" id="f-150" unitRef="usd">-27000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="c-9" decimals="-3" id="f-151" unitRef="usd">-37000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-7" decimals="-3" id="f-152" unitRef="usd">-2740000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-8" decimals="-3" id="f-153" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-1" decimals="-3" id="f-154" unitRef="usd">-6911000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-9" decimals="-3" id="f-155" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherIncome contextRef="c-7" decimals="-3" id="f-156" unitRef="usd">2667000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-8" decimals="-3" id="f-157" unitRef="usd">0</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-1" decimals="-3" id="f-158" unitRef="usd">2667000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-9" decimals="-3" id="f-159" unitRef="usd">0</us-gaap:OtherIncome>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-7" decimals="-3" id="f-160" unitRef="usd">-17461000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-8" decimals="-3" id="f-161" unitRef="usd">-21139000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-162" unitRef="usd">-61230000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-9" decimals="-3" id="f-163" unitRef="usd">-62928000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-7" decimals="-3" id="f-164" unitRef="usd">12130000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-8" decimals="-3" id="f-165" unitRef="usd">-13447000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-166" unitRef="usd">19374000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-9" decimals="-3" id="f-167" unitRef="usd">-60963000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-7" decimals="-3" id="f-168" unitRef="usd">-769000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-8" decimals="-3" id="f-169" unitRef="usd">586000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-170" unitRef="usd">1358000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-9" decimals="-3" id="f-171" unitRef="usd">1123000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-172" unitRef="usd">12899000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-8" decimals="-3" id="f-173" unitRef="usd">-14033000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-174" unitRef="usd">18016000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-9" decimals="-3" id="f-175" unitRef="usd">-62086000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-7" decimals="-3" id="f-176" unitRef="usd">-523000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-8" decimals="-3" id="f-177" unitRef="usd">563000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-178" unitRef="usd">545000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-9" decimals="-3" id="f-179" unitRef="usd">170000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-7" decimals="-3" id="f-180" unitRef="usd">17000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-8" decimals="-3" id="f-181" unitRef="usd">1173000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-1" decimals="-3" id="f-182" unitRef="usd">-326000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-9" decimals="-3" id="f-183" unitRef="usd">786000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-7" decimals="-3" id="f-184" unitRef="usd">-506000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-8" decimals="-3" id="f-185" unitRef="usd">1736000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-186" unitRef="usd">219000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-9" decimals="-3" id="f-187" unitRef="usd">956000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-7" decimals="-3" id="f-188" unitRef="usd">12393000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-8" decimals="-3" id="f-189" unitRef="usd">-12297000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-190" unitRef="usd">18235000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-9" decimals="-3" id="f-191" unitRef="usd">-61130000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-7"
      decimals="2"
      id="f-192"
      unitRef="usdPerShare">0.06</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-8"
      decimals="2"
      id="f-193"
      unitRef="usdPerShare">-0.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-194"
      unitRef="usdPerShare">0.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-9"
      decimals="2"
      id="f-195"
      unitRef="usdPerShare">-0.30</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-7" decimals="-3" id="f-196" unitRef="shares">210176000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-8" decimals="-3" id="f-197" unitRef="shares">206905000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-198" unitRef="shares">209531000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-9" decimals="-3" id="f-199" unitRef="shares">206466000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-7"
      decimals="2"
      id="f-200"
      unitRef="usdPerShare">0.06</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-8"
      decimals="2"
      id="f-201"
      unitRef="usdPerShare">-0.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-202"
      unitRef="usdPerShare">0.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-9"
      decimals="2"
      id="f-203"
      unitRef="usdPerShare">-0.30</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-7" decimals="-3" id="f-204" unitRef="shares">219885000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-8" decimals="-3" id="f-205" unitRef="shares">206905000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-206" unitRef="shares">218349000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-9" decimals="-3" id="f-207" unitRef="shares">206466000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-208" unitRef="usd">18016000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-9" decimals="-3" id="f-209" unitRef="usd">-62086000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-3" id="f-210" unitRef="usd">995000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-9" decimals="-3" id="f-211" unitRef="usd">937000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:InventoryWriteDown contextRef="c-1" decimals="-3" id="f-212" unitRef="usd">1056000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown contextRef="c-9" decimals="-3" id="f-213" unitRef="usd">1361000</us-gaap:InventoryWriteDown>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-214" unitRef="usd">61273000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-9" decimals="-3" id="f-215" unitRef="usd">44074000</us-gaap:ShareBasedCompensation>
    <bcrx:PaymentsForPaidInKindInterest contextRef="c-1" decimals="-3" id="f-216" unitRef="usd">9153000</bcrx:PaymentsForPaidInKindInterest>
    <bcrx:PaymentsForPaidInKindInterest contextRef="c-9" decimals="-3" id="f-217" unitRef="usd">0</bcrx:PaymentsForPaidInKindInterest>
    <bcrx:NonCashInterestExpenseOnRoyaltyFinancingLiabilities contextRef="c-1" decimals="-3" id="f-218" unitRef="usd">39839000</bcrx:NonCashInterestExpenseOnRoyaltyFinancingLiabilities>
    <bcrx:NonCashInterestExpenseOnRoyaltyFinancingLiabilities contextRef="c-9" decimals="-3" id="f-219" unitRef="usd">42469000</bcrx:NonCashInterestExpenseOnRoyaltyFinancingLiabilities>
    <bcrx:NonCashInterestExpenseOnSecuredTermLoanAndSecuredTermLoanAndAmortizationOfDebtIssuanceCosts contextRef="c-1" decimals="-3" id="f-220" unitRef="usd">1387000</bcrx:NonCashInterestExpenseOnSecuredTermLoanAndSecuredTermLoanAndAmortizationOfDebtIssuanceCosts>
    <bcrx:NonCashInterestExpenseOnSecuredTermLoanAndSecuredTermLoanAndAmortizationOfDebtIssuanceCosts contextRef="c-9" decimals="-3" id="f-221" unitRef="usd">11102000</bcrx:NonCashInterestExpenseOnSecuredTermLoanAndSecuredTermLoanAndAmortizationOfDebtIssuanceCosts>
    <bcrx:AmortizationOfPremiumDiscountOnInvestments contextRef="c-1" decimals="-3" id="f-222" unitRef="usd">-3240000</bcrx:AmortizationOfPremiumDiscountOnInvestments>
    <bcrx:AmortizationOfPremiumDiscountOnInvestments contextRef="c-9" decimals="-3" id="f-223" unitRef="usd">-8713000</bcrx:AmortizationOfPremiumDiscountOnInvestments>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-1" decimals="-3" id="f-224" unitRef="usd">-6911000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-9" decimals="-3" id="f-225" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainLossOnSaleOfOtherAssets contextRef="c-1" decimals="-3" id="f-226" unitRef="usd">550000</us-gaap:GainLossOnSaleOfOtherAssets>
    <us-gaap:GainLossOnSaleOfOtherAssets contextRef="c-9" decimals="-3" id="f-227" unitRef="usd">0</us-gaap:GainLossOnSaleOfOtherAssets>
    <us-gaap:IncreaseDecreaseInReceivables contextRef="c-1" decimals="-3" id="f-228" unitRef="usd">21312000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables contextRef="c-9" decimals="-3" id="f-229" unitRef="usd">15402000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-1" decimals="-3" id="f-230" unitRef="usd">1124000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-9" decimals="-3" id="f-231" unitRef="usd">2001000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-232" unitRef="usd">5890000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-9" decimals="-3" id="f-233" unitRef="usd">-1385000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <bcrx:IncreaseDecreaseInRoyaltyFinancingLiabilities contextRef="c-1" decimals="-3" id="f-234" unitRef="usd">55240000</bcrx:IncreaseDecreaseInRoyaltyFinancingLiabilities>
    <bcrx:IncreaseDecreaseInRoyaltyFinancingLiabilities contextRef="c-9" decimals="-3" id="f-235" unitRef="usd">54308000</bcrx:IncreaseDecreaseInRoyaltyFinancingLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-236" unitRef="usd">22441000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-9" decimals="-3" id="f-237" unitRef="usd">-5625000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-238" unitRef="usd">55409000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-9" decimals="-3" id="f-239" unitRef="usd">-46807000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireProductiveAssets contextRef="c-1" decimals="-3" id="f-240" unitRef="usd">1666000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets contextRef="c-9" decimals="-3" id="f-241" unitRef="usd">449000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-1" decimals="-3" id="f-242" unitRef="usd">136737000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-9" decimals="-3" id="f-243" unitRef="usd">227235000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="c-1" decimals="-3" id="f-244" unitRef="usd">207647000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="c-9" decimals="-3" id="f-245" unitRef="usd">262480000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleOfOtherAssetsInvestingActivities contextRef="c-1" decimals="-3" id="f-246" unitRef="usd">550000</us-gaap:ProceedsFromSaleOfOtherAssetsInvestingActivities>
    <us-gaap:ProceedsFromSaleOfOtherAssetsInvestingActivities contextRef="c-9" decimals="-3" id="f-247" unitRef="usd">0</us-gaap:ProceedsFromSaleOfOtherAssetsInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-248" unitRef="usd">69794000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-9" decimals="-3" id="f-249" unitRef="usd">34796000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-1" decimals="-3" id="f-250" unitRef="usd">8458000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-9" decimals="-3" id="f-251" unitRef="usd">4030000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <bcrx:ProceedsFromIssuanceOfCommonStockIssuedForServices contextRef="c-1" decimals="-3" id="f-252" unitRef="usd">36000</bcrx:ProceedsFromIssuanceOfCommonStockIssuedForServices>
    <bcrx:ProceedsFromIssuanceOfCommonStockIssuedForServices contextRef="c-9" decimals="-3" id="f-253" unitRef="usd">29000</bcrx:ProceedsFromIssuanceOfCommonStockIssuedForServices>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-1" decimals="-3" id="f-254" unitRef="usd">115847000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-9" decimals="-3" id="f-255" unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts contextRef="c-1" decimals="-3" id="f-256" unitRef="usd">3802000</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts contextRef="c-9" decimals="-3" id="f-257" unitRef="usd">0</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <bcrx:RepaymentOfRoyaltyFinancingLiabilitiesPrincipal contextRef="c-1" decimals="-3" id="f-258" unitRef="usd">16406000</bcrx:RepaymentOfRoyaltyFinancingLiabilitiesPrincipal>
    <bcrx:RepaymentOfRoyaltyFinancingLiabilitiesPrincipal contextRef="c-9" decimals="-3" id="f-259" unitRef="usd">0</bcrx:RepaymentOfRoyaltyFinancingLiabilitiesPrincipal>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-1" decimals="-3" id="f-260" unitRef="usd">2845000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-9" decimals="-3" id="f-261" unitRef="usd">4451000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-1" decimals="-3" id="f-262" unitRef="usd">1565000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-9" decimals="-3" id="f-263" unitRef="usd">1348000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-264" unitRef="usd">-131971000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-9" decimals="-3" id="f-265" unitRef="usd">-1740000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-1" decimals="-3" id="f-266" unitRef="usd">1342000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-9" decimals="-3" id="f-267" unitRef="usd">368000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations contextRef="c-1" decimals="-3" id="f-268" unitRef="usd">-5426000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations contextRef="c-9" decimals="-3" id="f-269" unitRef="usd">-13383000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations>
    <bcrx:CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperationsLessAssetsHeldForSale contextRef="c-1" decimals="-3" id="f-270" unitRef="usd">14840000</bcrx:CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperationsLessAssetsHeldForSale>
    <bcrx:CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperationsLessAssetsHeldForSale contextRef="c-9" decimals="-3" id="f-271" unitRef="usd">0</bcrx:CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperationsLessAssetsHeldForSale>
    <bcrx:CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperationsExcludingAssetsHeldForSale contextRef="c-1" decimals="-3" id="f-272" unitRef="usd">-20266000</bcrx:CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperationsExcludingAssetsHeldForSale>
    <bcrx:CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperationsExcludingAssetsHeldForSale contextRef="c-9" decimals="-3" id="f-273" unitRef="usd">-13383000</bcrx:CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperationsExcludingAssetsHeldForSale>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-274" unitRef="usd">106323000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-10" decimals="-3" id="f-275" unitRef="usd">112447000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <bcrx:CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentContinuingOperationExcludingAssetsHeldForSale contextRef="c-3" decimals="-3" id="f-276" unitRef="usd">86057000</bcrx:CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentContinuingOperationExcludingAssetsHeldForSale>
    <bcrx:CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentContinuingOperationExcludingAssetsHeldForSale contextRef="c-11" decimals="-3" id="f-277" unitRef="usd">99064000</bcrx:CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentContinuingOperationExcludingAssetsHeldForSale>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-278" unitRef="usd">84078000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-11" decimals="-3" id="f-279" unitRef="usd">96841000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-280" unitRef="usd">579000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c-11" decimals="-3" id="f-281" unitRef="usd">813000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <bcrx:RestrictedCashAndCashEquivalentsIncludedInOtherAssetsNonCurrent contextRef="c-3" decimals="-3" id="f-282" unitRef="usd">1400000</bcrx:RestrictedCashAndCashEquivalentsIncludedInOtherAssetsNonCurrent>
    <bcrx:RestrictedCashAndCashEquivalentsIncludedInOtherAssetsNonCurrent contextRef="c-11" decimals="-3" id="f-283" unitRef="usd">1410000</bcrx:RestrictedCashAndCashEquivalentsIncludedInOtherAssetsNonCurrent>
    <bcrx:CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentContinuingOperationExcludingAssetsHeldForSale contextRef="c-3" decimals="-3" id="f-284" unitRef="usd">86057000</bcrx:CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentContinuingOperationExcludingAssetsHeldForSale>
    <bcrx:CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentContinuingOperationExcludingAssetsHeldForSale contextRef="c-11" decimals="-3" id="f-285" unitRef="usd">99064000</bcrx:CashCashEquivalentRestrictedCashAndRestrictedCashEquivalentContinuingOperationExcludingAssetsHeldForSale>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="-3" id="f-286" unitRef="usd">22789000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-9" decimals="-3" id="f-287" unitRef="usd">20242000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid contextRef="c-1" decimals="-3" id="f-288" unitRef="usd">2220000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="c-9" decimals="-3" id="f-289" unitRef="usd">1225000</us-gaap:IncomeTaxesPaid>
    <bcrx:WithholdingTaxesAccrued contextRef="c-1" decimals="-3" id="f-290" unitRef="usd">151000</bcrx:WithholdingTaxesAccrued>
    <bcrx:WithholdingTaxesAccrued contextRef="c-9" decimals="-3" id="f-291" unitRef="usd">245000</bcrx:WithholdingTaxesAccrued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-12" decimals="-3" id="f-292" unitRef="shares">208543000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-12" decimals="-3" id="f-293" unitRef="usd">2085000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-13" decimals="-3" id="f-294" unitRef="usd">1291100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-14" decimals="-3" id="f-295" unitRef="usd">921000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-15" decimals="-3" id="f-296" unitRef="usd">-1770040000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-297" unitRef="usd">-475934000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-16" decimals="-3" id="f-298" unitRef="usd">32000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-17" decimals="-3" id="f-299" unitRef="usd">32000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-18" decimals="-3" id="f-300" unitRef="usd">211000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-17" decimals="-3" id="f-301" unitRef="usd">211000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-19" decimals="-3" id="f-302" unitRef="shares">286000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-19" decimals="-3" id="f-303" unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-20" decimals="-3" id="f-304" unitRef="usd">1226000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-17" decimals="-3" id="f-305" unitRef="usd">1229000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="c-19" decimals="-3" id="f-306" unitRef="shares">184000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-19" decimals="-3" id="f-307" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-20" decimals="-3" id="f-308" unitRef="usd">-2000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-17" decimals="-3" id="f-309" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation contextRef="c-19" decimals="-3" id="f-310" unitRef="shares">8000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-20" decimals="-3" id="f-311" unitRef="usd">56000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-17" decimals="-3" id="f-312" unitRef="usd">56000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="c-19" decimals="-3" id="f-313" unitRef="shares">202000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-19" decimals="-3" id="f-314" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-20" decimals="-3" id="f-315" unitRef="usd">1215000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-17" decimals="-3" id="f-316" unitRef="usd">1217000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="c-19" decimals="-3" id="f-317" unitRef="shares">1000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c-20" decimals="-3" id="f-318" unitRef="usd">6000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c-17" decimals="-3" id="f-319" unitRef="usd">6000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-20" decimals="-3" id="f-320" unitRef="usd">21368000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-17" decimals="-3" id="f-321" unitRef="usd">21368000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-21" decimals="-3" id="f-322" unitRef="shares">209208000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-21" decimals="-3" id="f-323" unitRef="usd">2092000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-22" decimals="-3" id="f-324" unitRef="usd">1314857000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-23" decimals="-3" id="f-325" unitRef="usd">1132000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-24" decimals="-3" id="f-326" unitRef="usd">-1770008000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-25" decimals="-3" id="f-327" unitRef="usd">-451927000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-26" decimals="-3" id="f-328" unitRef="usd">5085000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-27" decimals="-3" id="f-329" unitRef="usd">5085000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-28" decimals="-3" id="f-330" unitRef="usd">514000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-27" decimals="-3" id="f-331" unitRef="usd">514000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-29" decimals="-3" id="f-332" unitRef="shares">560000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-29" decimals="-3" id="f-333" unitRef="usd">6000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-30" decimals="-3" id="f-334" unitRef="usd">3415000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-27" decimals="-3" id="f-335" unitRef="usd">3421000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="c-29" decimals="-3" id="f-336" unitRef="shares">136000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-29" decimals="-3" id="f-337" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-30" decimals="-3" id="f-338" unitRef="usd">-1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-27" decimals="-3" id="f-339" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="c-29" decimals="-3" id="f-340" unitRef="shares">1000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c-30" decimals="-3" id="f-341" unitRef="usd">9000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c-27" decimals="-3" id="f-342" unitRef="usd">9000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-30" decimals="-3" id="f-343" unitRef="usd">21304000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-27" decimals="-3" id="f-344" unitRef="usd">21304000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-31" decimals="-3" id="f-345" unitRef="shares">209905000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-31" decimals="-3" id="f-346" unitRef="usd">2099000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-32" decimals="-3" id="f-347" unitRef="usd">1339584000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-33" decimals="-3" id="f-348" unitRef="usd">1646000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-34" decimals="-3" id="f-349" unitRef="usd">-1764923000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-35" decimals="-3" id="f-350" unitRef="usd">-421594000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-36" decimals="-3" id="f-351" unitRef="usd">12899000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-352" unitRef="usd">12899000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-37" decimals="-3" id="f-353" unitRef="usd">-506000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-7" decimals="-3" id="f-354" unitRef="usd">-506000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-38" decimals="-3" id="f-355" unitRef="shares">300000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-38" decimals="-3" id="f-356" unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-39" decimals="-3" id="f-357" unitRef="usd">1563000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-7" decimals="-3" id="f-358" unitRef="usd">1566000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="c-38" decimals="-3" id="f-359" unitRef="shares">147000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-38" decimals="-3" id="f-360" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-39" decimals="-3" id="f-361" unitRef="usd">-1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-7" decimals="-3" id="f-362" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="c-38" decimals="-3" id="f-363" unitRef="shares">167000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-38" decimals="-3" id="f-364" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-39" decimals="-3" id="f-365" unitRef="usd">1079000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-7" decimals="-3" id="f-366" unitRef="usd">1081000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="c-38" decimals="-3" id="f-367" unitRef="shares">3000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c-39" decimals="-3" id="f-368" unitRef="usd">21000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c-7" decimals="-3" id="f-369" unitRef="usd">21000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-39" decimals="-3" id="f-370" unitRef="usd">18644000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-7" decimals="-3" id="f-371" unitRef="usd">18644000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-40" decimals="-3" id="f-372" unitRef="shares">210522000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-40" decimals="-3" id="f-373" unitRef="usd">2105000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-41" decimals="-3" id="f-374" unitRef="usd">1360890000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-42" decimals="-3" id="f-375" unitRef="usd">1140000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-43" decimals="-3" id="f-376" unitRef="usd">-1752024000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-377" unitRef="usd">-387889000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-44" decimals="-3" id="f-378" unitRef="shares">205771000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-44" decimals="-3" id="f-379" unitRef="usd">2058000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-45" decimals="-3" id="f-380" unitRef="usd">1222236000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-46" decimals="-3" id="f-381" unitRef="usd">1337000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-47" decimals="-3" id="f-382" unitRef="usd">-1681159000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-10" decimals="-3" id="f-383" unitRef="usd">-455528000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-48" decimals="-3" id="f-384" unitRef="usd">-35379000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-49" decimals="-3" id="f-385" unitRef="usd">-35379000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-50" decimals="-3" id="f-386" unitRef="usd">-566000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-49" decimals="-3" id="f-387" unitRef="usd">-566000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-51" decimals="-3" id="f-388" unitRef="shares">176000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-51" decimals="-3" id="f-389" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-52" decimals="-3" id="f-390" unitRef="usd">550000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-49" decimals="-3" id="f-391" unitRef="usd">552000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="c-51" decimals="-3" id="f-392" unitRef="shares">155000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-51" decimals="-3" id="f-393" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-52" decimals="-3" id="f-394" unitRef="usd">-1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-49" decimals="-3" id="f-395" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation contextRef="c-51" decimals="-3" id="f-396" unitRef="shares">8000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-52" decimals="-3" id="f-397" unitRef="usd">38000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-49" decimals="-3" id="f-398" unitRef="usd">38000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="c-51" decimals="-3" id="f-399" unitRef="shares">251000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-51" decimals="-3" id="f-400" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-52" decimals="-3" id="f-401" unitRef="usd">1127000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-49" decimals="-3" id="f-402" unitRef="usd">1129000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="c-51" decimals="-3" id="f-403" unitRef="shares">2000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c-52" decimals="-3" id="f-404" unitRef="usd">11000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c-49" decimals="-3" id="f-405" unitRef="usd">11000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-52" decimals="-3" id="f-406" unitRef="usd">13652000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-49" decimals="-3" id="f-407" unitRef="usd">13652000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-53" decimals="-3" id="f-408" unitRef="shares">206347000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-53" decimals="-3" id="f-409" unitRef="usd">2063000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-54" decimals="-3" id="f-410" unitRef="usd">1237537000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-55" decimals="-3" id="f-411" unitRef="usd">771000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-56" decimals="-3" id="f-412" unitRef="usd">-1716538000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-57" decimals="-3" id="f-413" unitRef="usd">-476167000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-58" decimals="-3" id="f-414" unitRef="usd">-12674000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-59" decimals="-3" id="f-415" unitRef="usd">-12674000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-60" decimals="-3" id="f-416" unitRef="usd">-214000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-59" decimals="-3" id="f-417" unitRef="usd">-214000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-61" decimals="-3" id="f-418" unitRef="shares">80000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-61" decimals="-3" id="f-419" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-62" decimals="-3" id="f-420" unitRef="usd">263000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-59" decimals="-3" id="f-421" unitRef="usd">264000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="c-61" decimals="-3" id="f-422" unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-61" decimals="-3" id="f-423" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-62" decimals="-3" id="f-424" unitRef="usd">-2000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-59" decimals="-3" id="f-425" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="c-61" decimals="-3" id="f-426" unitRef="shares">2000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c-62" decimals="-3" id="f-427" unitRef="usd">12000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c-59" decimals="-3" id="f-428" unitRef="usd">12000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-62" decimals="-3" id="f-429" unitRef="usd">13173000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-59" decimals="-3" id="f-430" unitRef="usd">13173000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-63" decimals="-3" id="f-431" unitRef="shares">206629000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-63" decimals="-3" id="f-432" unitRef="usd">2066000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-64" decimals="-3" id="f-433" unitRef="usd">1250983000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-65" decimals="-3" id="f-434" unitRef="usd">557000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-66" decimals="-3" id="f-435" unitRef="usd">-1729212000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-67" decimals="-3" id="f-436" unitRef="usd">-475606000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-68" decimals="-3" id="f-437" unitRef="usd">-14033000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-8" decimals="-3" id="f-438" unitRef="usd">-14033000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-69" decimals="-3" id="f-439" unitRef="usd">1736000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-8" decimals="-3" id="f-440" unitRef="usd">1736000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-70" decimals="-3" id="f-441" unitRef="shares">262000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-70" decimals="-3" id="f-442" unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-71" decimals="-3" id="f-443" unitRef="usd">1359000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-8" decimals="-3" id="f-444" unitRef="usd">1362000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="c-70" decimals="-3" id="f-445" unitRef="shares">66000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-70" decimals="-3" id="f-446" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-71" decimals="-3" id="f-447" unitRef="usd">-1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-8" decimals="-3" id="f-448" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="c-70" decimals="-3" id="f-449" unitRef="shares">161000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-70" decimals="-3" id="f-450" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-71" decimals="-3" id="f-451" unitRef="usd">722000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-8" decimals="-3" id="f-452" unitRef="usd">723000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="c-70" decimals="-3" id="f-453" unitRef="shares">1000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c-71" decimals="-3" id="f-454" unitRef="usd">6000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c-8" decimals="-3" id="f-455" unitRef="usd">6000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-71" decimals="-3" id="f-456" unitRef="usd">17249000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-8" decimals="-3" id="f-457" unitRef="usd">17249000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-72" decimals="-3" id="f-458" unitRef="shares">207119000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-72" decimals="-3" id="f-459" unitRef="usd">2071000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-73" decimals="-3" id="f-460" unitRef="usd">1270318000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-74" decimals="-3" id="f-461" unitRef="usd">2293000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-75" decimals="-3" id="f-462" unitRef="usd">-1743245000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-11" decimals="-3" id="f-463" unitRef="usd">-468563000</us-gaap:StockholdersEquity>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-464">Significant Accounting Policies and Concentrations of Risk&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;The Company&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;BioCryst Pharmaceuticals, Inc. (the &#x201c;Company&#x201d;) is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (&#x201c;HAE&#x201d;) and other rare diseases, driven by the Company&#x2019;s deep commitment to improving the lives of people living with these conditions. The Company has built a robust commercial infrastructure to support the launch and continued success of ORLADEYO&#xae;, an oral, once-daily therapy discovered and developed internally for the prevention of HAE attacks. The Company&#x2019;s business strategy includes leveraging this established commercial platform to successfully commercialize a pipeline of potential first-in-class or best-in-class oral small-molecule and injectable protein therapeutics targeting a range of rare diseases. These programs are being pursued through both internal discovery efforts and strategic business development. By utilizing its existing commercial capabilities and focusing on rare disease markets, the Company believes that it can more effectively optimize its costs and strategically allocate resources to support long-term, sustainable growth. The Company was founded in 1986 and incorporated in Delaware in 1991, and its headquarters is located in Durham, North Carolina.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s marketed products include oral, once-daily ORLADEYO&#xae; for the prevention of HAE attacks and RAPIVAB&#xae; (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. ORLADEYO has received regulatory approval in the United States and other global markets. The Company is commercializing ORLADEYO in each of these territories directly or through other parties. In addition to its approval in the United States, peramivir injection has received regulatory approvals in Canada (RAPIVAB), Australia (RAPIVAB), Japan (RAPIACTA), Taiwan (RAPIACTA) and Korea (PERAMIFLU). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on the Company&#x2019;s expectations for revenue and operating expenses, the Company believes its financial resources available at September&#160;30, 2025 will be sufficient to fund its operations for at least the next 12 months. The Company may, in the future, issue securities, including common stock, preferred stock, depositary shares, purchase contracts, warrants, debt securities and units, through private placement transactions or registered public offerings. The Company&#x2019;s future liquidity needs, and ability to address those needs, will largely be determined by the success of its products and product candidates; the timing, scope and magnitude of its research and development and commercial expenses; and key developments and regulatory events and its decisions in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The condensed consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany transactions and balances among the consolidated entities have been eliminated from the condensed consolidated financial statements. The Company operates and manages its business as one reportable and operating segment (see &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 13&#x2014;Segment Information&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;) for interim financial reporting and the instructions to Form 10-Q and do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Such financial statements reflect all adjustments that are, in management&#x2019;s opinion, necessary to present fairly, in all material respects, the Company&#x2019;s condensed consolidated financial position, results of operations, and cash flows. There were no adjustments other than normal recurring adjustments. Certain prior year amounts have been reclassified to conform to the current year presentation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These financial statements should be read in conjunction with the financial statements for the fiscal year ended December&#160;31, 2024 and the notes thereto included in the Company&#x2019;s 2024 Annual Report on Form 10-K as filed with the SEC on February 25, 2025. Interim operating results are not necessarily indicative of operating results for the full fiscal year. The condensed consolidated balance sheet as of December&#160;31, 2024 was derived from the audited consolidated financial statements included in the Company&#x2019;s most recent Annual Report on Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. Significant estimates in the Company&#x2019;s condensed consolidated financial statements have been made relative to the calculation of net product sales, royalty financing obligations, inventory reserves, certain accruals, primarily related to the Company&#x2019;s research and development expenses, the valuation of stock options and the valuation allowance for deferred tax assets resulting from net operating losses. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assets Held for Sale&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies its long-lived assets to be sold as held for sale when the six criteria in ASC 360, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; are met. This generally occurs when an agreement to sell exists, or when management has committed to a plan to sell the assets within one year. Assets and liabilities to be disposed of together as a group in a single transaction (&#x201c;disposal groups&#x201d;) are classified as held for sale if their carrying amounts are principally expected to be recovered through a sale transaction rather than through continuing use.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The long-lived assets included in a disposal group are reported at the lower of their carrying value or fair value less cost to sell, beginning in the period the held for sale criteria are met. Prior to disposal, losses are recognized for any initial or subsequent write-down to fair value less cost to sell. Any gains or losses not previously recognized that result from the sale of a disposal group shall be recognized at the date of sale. Upon designation as an asset held for sale, the Company stops recording depreciation and amortization expense on long-lived assets. The Company assesses the fair value of a long-lived asset less any costs to sell at each reporting period and until the asset is no longer classified as held for sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded the following revenues for the three and nine months ended September&#160;30, 2025 and 2024 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product sales, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;463,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaborative and other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;159,395&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;117,085&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;468,282&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;319,178&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, the Company recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, Topic 606 includes provisions within a five-step model that includes (i) identifying the contract with a customer, (ii) identifying the performance obligations in the contract, (iii) determining the transaction price, (iv) allocating the transaction price to the performance obligations, and (v) recognizing revenue when, or as, an entity satisfies a performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At contract inception, the Company identifies the goods or services promised within each contract, assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Sales, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s principal sources of product sales are sales of ORLADEYO, which the Company began shipping to patients in December 2020, and sales of peramivir (RAPIVAB/RAPIACTA/PERAMIFLU) to the Company&#x2019;s licensing partners and to the U.S. Department of Health and Human Services (&#x201c;HHS&#x201d;). In the United States, the Company generally ships ORLADEYO directly to patients through a single specialty pharmacy, which is considered its customer. Outside the United States, the Company sells ORLADEYO to specialty distributors and to hospitals and pharmacies, which collectively are considered its customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue for sales when the customer obtains control of the product, which generally occurs upon delivery. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net revenue from sales of ORLADEYO is recorded at net selling price (transaction price), which includes reserves for variable consideration such as (i) estimated government rebates, such as Medicaid and Medicare Part D reimbursements, and estimated managed care rebates, (ii) estimated chargebacks, (iii) estimated costs of co-payment assistance programs and (iv) product returns. These reserves, representing the Company&#x2019;s best estimates of the amount of consideration to which it is entitled based on the terms of the applicable contracts and statutory requirements, are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable if no payments are required of the Company or a current liability if a payment is required of the Company. Actual amounts of consideration may differ from the Company&#x2019;s estimates. If actual results vary from estimates, these estimates are adjusted, which would affect net product revenue and earnings in the period such variances become known.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Government and Managed Care Rebates&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company contracts with government agencies and managed care organizations or, collectively, third-party payors, so that ORLADEYO will be eligible for purchase by, or partial or full reimbursement from, such third-party payors. The Company estimates the rebates it will provide to third-party payors and deducts these estimated amounts from total gross product revenues at the time the revenues are recognized, resulting in a reduction of product revenue and the establishment of a current liability. The Company estimates the rebates that it will provide to third-party payors based upon (i) the Company&#x2019;s contracts with these third-party payors, (ii) the government mandated discounts applicable to government-funded programs, and (iii) product distribution information obtained from the Company&#x2019;s specialty pharmacy regarding payor mix.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Chargebacks&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Chargebacks are discounts that occur when certain contracted customers, pharmacy benefit managers, insurance companies, and government programs purchase directly from the Company&#x2019;s specialty pharmacy. These customers purchase the Company&#x2019;s product under contracts negotiated between them and the Company&#x2019;s specialty pharmacy. The specialty pharmacy, in turn, charges back to the Company the difference between the price that the specialty pharmacy paid and the negotiated price paid by the contracted customers, which may be higher or lower than the specialty pharmacy&#x2019;s purchase price with the Company. The Company estimates chargebacks and adjusts gross product revenues and establishes a current liability at the time revenues are recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Co-payment assistance and patient assistance programs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. Based upon the terms of the program and co-payment assistance utilization reports received from the specialty pharmacy, the Company estimates the co-payment assistance amounts, which are recorded in the same period in which the related revenue is recognized, resulting in a reduction of product revenue and establishment of a current liability. The Company also offers a patient assistance program that provides free drug product, for a limited period of time, to allow a patient&#x2019;s insurance coverage to be established. Based on patient assistance program utilization reports provided by the specialty pharmacy, the Company records gross revenue of the product provided and a full reduction of the revenue amount for the free drug discount.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product returns&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company does not provide contractual return rights to its customers, except in instances where the product is damaged or defective. Non-acceptance by the patient of shipped drug product by the specialty pharmacy is reflected as a reversal of sales in the period in which the sales were originally recorded. Reserves for estimated non-acceptances by patients are recorded as a reduction of revenue in the period that the related revenue is recognized, as well as a reduction to accounts receivable. Estimates of non-acceptance are based on quantitative information provided by the specialty pharmacy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative and Other Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has collaboration and license agreements with a number of third parties. The Company&#x2019;s primary sources of revenue from these collaborative and other research and development arrangements are license, service and royalty revenues.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from license fees, royalty payments, milestone payments, and research and development fees are recognized as revenue when the earnings process is complete and the Company has no further continuing performance obligations or the Company has completed the performance obligations under the terms of the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Arrangements that involve the delivery of more than one performance obligation are initially evaluated as to whether the intellectual property licenses granted by the Company represent distinct performance obligations. If they are determined to be distinct, the value of the intellectual property licenses would be recognized up front while the research and development service fees would be recognized as the performance obligations are satisfied. For performance obligations &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;based on services performed, the Company measures progress using an input method based on the effort it expends or costs it incurs toward the satisfaction of the performance obligation in relation to the total estimated effort or costs. Variable consideration is assessed at each reporting period as to whether it is not subject to significant future reversal and, therefore, should be included in the transaction price at the inception of the contract. If a contract includes a fixed or minimum amount of research and development support, this also would be included in the transaction price. Changes to collaborations, such as the extensions of the research term or increasing the number of targets or technology covered under an existing agreement, are assessed for whether they represent a modification or should be accounted for as a new contract. For contracts with multiple performance obligations, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the products or services. If a standalone selling price is not directly observable, then the Company estimates the standalone selling price using either an adjusted market assessment approach or an expected cost plus margin approach, representing the amount that the Company believes the market is willing to pay for the product or service. Analyzing the arrangement to identify performance obligations requires the use of judgment, and each may be an obligation to deliver services, a right or license to use an asset, or another performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under certain of the Company&#x2019;s license agreements, the Company receives royalty payments based upon its licensees&#x2019; net sales of covered products. Royalties are recognized at the later of when (i) the subsequent sale or usage occurs, or (ii) the performance obligation to which some or all of the sales-based or usage-based royalty has been satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generally considers cash equivalents to be all cash held in commercial checking accounts, money market accounts, or investments in debt instruments and certificates of deposit with maturities of three months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Total restricted cash was $1,979 and $1,610 as of September&#160;30, 2025 and December&#160;31, 2024, respectively, and primarily consisted of $1,400 as of September&#160;30, 2025 and December&#160;31, 2024, for a letter of credit the Company is required to maintain associated with its Birmingham lease. The letter of credit associated with the Birmingham lease of $1,400 is reflected within other assets on the Condensed Consolidated Balance Sheets as of September&#160;30, 2025 and December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company invests in high credit quality investments in accordance with its investment policy. The objectives of the Company&#x2019;s investment policy are to eliminate or greatly minimize the probability of a loss of principal value, maintain sufficient liquidity to meet cash flow requirements, and earn a competitive level of return. The Company places its excess cash with high credit quality financial institutions to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that may consist of U.S. Treasury obligations, U.S government agency securities, money market funds, certificates of deposits and corporate notes and bonds. The Company&#x2019;s investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of two years and requires an average portfolio maturity of no more than 12 months. Some of the securities in which the Company invests may have market risk. This means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, the Company does not believe it has a material exposure to interest rate risk arising from its investments. The Company has not realized any significant losses from its investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies all of its investments as available-for-sale. Available-for-sale investments are reported at fair value at each balance sheet date, and include any unrealized holding gains and losses in accumulated other comprehensive income, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company reviews its investments for other than temporary declines in fair value below cost basis at the end of each reporting period and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Factors considered to determine whether an unrealized loss is temporary include whether a decline in fair value below the amortized cost basis is due to credit-related factors or non-credit-related factors, the financial condition and near-term prospects of the Company, and the Company&#x2019;s intent and ability to hold the investment to allow for an anticipated recovery in fair value. A credit-related impairment is recognized as an allowance on the balance sheet with a corresponding adjustment to earnings. Any impairment that is not credit-related is recognized in &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;other comprehensive income, net of applicable taxes unless deemed other than temporary. Realized gains and losses are reflected in interest and other income in the Condensed Consolidated Statements of Comprehensive Income (Loss) and are determined using the specific identification method with transactions recorded on a settlement date basis. Investments with original maturities at date of purchase beyond three months and which mature at or less than 12 months from the balance sheet date are classified as current. Investments with a maturity beyond 12 months from the balance sheet date are classified as long-term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities recorded at fair value on a recurring basis on the Condensed Consolidated Balance Sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets measured at fair value on a recurring basis include investments (See &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 4&#x2014;Investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;). There were no liabilities measured at fair value on a recurring basis as of September&#160;30, 2025 and December&#160;31, 2024. The carrying amounts reflected in the Condensed Consolidated Balance Sheets for cash and cash equivalents, trade receivables, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Trade Receivables&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The majority of the Company&#x2019;s trade receivables arise from product sales and primarily represent amounts due from its specialty pharmacy customer in the United States and other third-party distributors, hospitals and pharmacies globally and have standard payment terms that generally require payment within 30 to 90 days.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Receivables from collaborations are recorded for amounts due to the Company related to royalty receivables from the Company&#x2019;s partners, including Shionogi &amp;amp; Co., Ltd., Green Cross, and Torii (See &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 12&#x2014;Collaborative and Other Relationships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides reserves against trade receivables for estimated losses that may result from a customer&#x2019;s inability to pay. Receivables are evaluated to determine if any reserve or allowance should be recorded based on consideration of the current economic environment, expectations of future economic conditions, specific circumstances and the Company&#x2019;s own historical collection experience. Amounts determined to be uncollectible are charged or written-off against the reserve.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s inventory primarily relates to ORLADEYO and also includes peramivir.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company values its inventory at the lower of cost or estimated net realizable value. The Company determines the cost of its inventory on a first-in, first-out (FIFO) basis. Raw materials and work-in-process include all inventory costs prior to packaging and labeling, including raw material, active product ingredient, and the drug product. Finished goods include packaged and labeled products. The Company classifies inventory as long-term when consumption or sale of the inventory is not expected to occur within 12 months from the balance sheet date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s inventory is subject to expiration dating. At each reporting date, the Company evaluates the carrying value of its inventory and provides valuation reserves for any estimated excess, obsolete, short-dated or unmarketable inventory. In addition, the Company may experience spoilage of its raw materials and supplies. The Company&#x2019;s determination that a valuation reserve might be required, in addition to the quantification of such reserve, requires it to utilize significant judgment. Additionally, the Company&#x2019;s inventory is subject to strict quality control and monitoring that is performed throughout the manufacturing process, including release of work-in-process to finished goods. In the event that certain batches or units of product do not meet quality specifications, the Company will record a write-down of any potential unmarketable inventory to its estimated net realizable value and record the expense as cost of product in the Condensed Consolidated Statements of Comprehensive Income (Loss).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to obtaining initial regulatory approval for an investigational product candidate, the Company expenses costs relating to production of pre-launch inventory as research and development expense in its Condensed Consolidated &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Statements of Comprehensive Income (Loss) in the period incurred. After regulatory approval has been received, the Company capitalizes inventory costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Computer equipment and office equipment are depreciated over a life of three years. Laboratory equipment, software, and furniture and fixtures are depreciated over a life of five years. Leasehold improvements are amortized over their estimated useful lives or the expected lease term, whichever is less. Construction in progress reflects amounts incurred for construction or improvements of property and equipment that have not been placed in service.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company periodically reviews its property and equipment for impairment when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values. Property and equipment to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into contractual agreements with third-party vendors who provide research and development, manufacturing, distribution, and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing, and services are completed over an extended period of time. The Company records liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel to identify services that have been performed on its behalf and estimating the actual work completed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of actual cost. The majority of service providers invoice the Company monthly in arrears for services performed. The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances, which can include assumptions such as expected patient enrollment, site activation and estimated project duration. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued expenses include (i) fees paid to clinical research organizations (&#x201c;CROs&#x201d;) in connection with preclinical and toxicology studies and clinical trials; (ii) fees paid to investigative sites in connection with clinical trials; (iii) fees paid to contract manufacturers in connection with the production of the Company&#x2019;s raw materials, drug substance, drug products, and product candidates; and (iv) professional fees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company bases its expenses related to clinical trials on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on the Company&#x2019;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. The Company accrues costs for clinical trial activities based upon estimates of the actual work completed in accordance with agreements established with third-party vendors. If the Company underestimates or overestimates the level of these costs, actual expenses could differ from such estimates. As of September&#160;30, 2025 and December&#160;31, 2024, the carrying value of accrued expenses approximates their fair value due to their short-term settlement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of product sales includes the cost of producing inventory that is related to product revenue during the respective period, including freight. Cost of product sales may also include costs related to excess or obsolete inventory adjustment charges.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses consist of costs associated with research activities as well as those with the Company&#x2019;s product development efforts, conducting preclinical trials, clinical trials and manufacturing activities. Research and development expenses are expensed as incurred. Most of the Company&#x2019;s clinical and preclinical studies are performed by third-party CROs. Costs for studies performed by CROs are accrued based upon estimates of the actual work completed in accordance with the third-party agreements. Advance payments for goods or services that will be used or rendered for &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses consist of costs associated with research activities as well as those associated with product development efforts, conducting pre-clinical trials, clinical trials and manufacturing activities. Direct expenses consist of compensation for research and development personnel and costs of outside parties to conduct laboratory studies, develop manufacturing processes and manufacture the product candidate, conduct and manage clinical trials, as well as other costs related to the Company&#x2019;s clinical and preclinical studies. Additionally, direct expenses consist of those costs necessary to discontinue and close out a development program, including termination fees and other commitments. Indirect expenses consist of lab supplies and services, facility expenses, depreciation of development equipment and an allocation of its general and administrative overhead costs that support the Company&#x2019;s research and development efforts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Selling, General and Administrative Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling, general and administrative expenses are comprised of compensation and benefits and related costs associated with sales and marketing, finance, human resources, legal, information technology, quality, safety and regulatory activities related to marketed products, and other general and administrative personnel. Additionally, selling, general and administrative expenses are comprised of market research, marketing, advertising and legal expenses, including patent costs, licenses and other administrative costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All patent related costs are expensed to selling, general and administrative expenses when incurred as recoverability of such expenditures is uncertain.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases certain assets under operating and finance leases, which consist of real estate leases, laboratory equipment leases and office equipment leases as of September&#160;30, 2025. The Company determines whether a contract is, or contains, a lease at inception. The Company accounts for lease obligations in accordance with ASU 2016-02: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases (Topic 842)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which requires a lessee to recognize a right-of-use asset and a lease liability on its balance sheet for most leases. The Company elected the practical expedient that exempts leases with an initial lease term of twelve months or less, as well as the practical expedient that allows companies to select, by class of underlying asset, not to separate lease and non-lease components. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of the Company&#x2019;s operating leases provide for renewal options, which can vary by lease. The right-of-use asset and lease liabilities on the Company&#x2019;s Condensed Consolidated Balance Sheets represent payments over the lease term, which include renewal options for certain real estate leases that the Company is likely to exercise. Certain operating leases include rent escalation provisions, which the Company recognizes as expense on a straight-line basis. Lease expense for leases with an initial term of twelve months or less was not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The discount rate used to determine the Company&#x2019;s right-of-use asset and lease liability is the Company&#x2019;s incremental borrowing rate on a collateralized basis over a similar term and amount in a similar economic environment, as generally an implicit rate in the lease is not readily determinable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has not made any residual value guarantees related to its leases; therefore, the Company has no corresponding liability recorded on its Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in the Company&#x2019;s Condensed Consolidated Statements of Comprehensive Income (Loss) based on their fair values. Stock-based compensation cost is estimated at the grant date based on the fair value of the award and is recognized as expense on a straight-line basis over the requisite service period of the award. Determining the appropriate fair value model and the related assumptions for the model requires judgment, including estimating the stock price volatility and the expected term. The Company utilizes the Black-Scholes option-pricing model to value its stock option awards and recognize compensation expense on a straight-line basis over the requisite service period. The Company reduces stock-based compensation expense for estimated forfeitures. The estimation of share-based payment awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from the Company&#x2019;s current estimates, such amounts will be recorded as a cumulative adjustment in the period estimates are revised. Actual results, and future changes in estimates, may differ substantially from the Company&#x2019;s current estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Interest Expense, Deferred Financing Costs and Royalty Financing Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense primarily relates to the royalty financing obligations (see &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 7&#x2014;Royalty Financing Obligations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;) and the term loan borrowings under the Pharmakon Loan Agreement (see &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 8&#x2014;Deb&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;t&#x201d;) during the nine months ended September&#160;30, 2025 and 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs directly associated with the borrowings were capitalized and netted against the corresponding debt liabilities on the Condensed Consolidated Balance Sheets. These costs are amortized to interest expense over the terms of the corresponding borrowings using the effective interest rate method. When utilizing the effective interest method, in periods in which payment-in-kind (&#x201c;PIK&#x201d;) interest was designated and added to the outstanding principal balance of the borrowing, the amortization of the deferred debt fees and issuance costs was accretive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The royalty financing obligations are eligible to be repaid based on royalties from net sales of ORLADEYO. Interest expense is accrued using the effective interest rate method over the estimated period each of the related liabilities will be paid. This requires the Company to estimate the total amount of future royalty payments to be generated from product sales over the life of the agreement. The Company imputes interest on the carrying value of each of the royalty financing obligations and records interest expense using an imputed effective interest rate. The Company reassesses the expected royalty payments each reporting period and accounts for any changes through an adjustment to the effective interest rate on a prospective basis. The assumptions used in determining the expected repayment term of the debt and amortization period of the issuance costs require that the Company make estimates that could impact the carrying value of each of the liabilities, as well as the periods over which associated issuance costs will be amortized. A significant increase or decrease in forecasted net sales could materially impact each of the liability balances, interest expense and the time periods for repayment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The liability method is used in the Company&#x2019;s accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant management judgment is required in determining the Company&#x2019;s provision for income taxes, deferred tax assets and liabilities and any valuation allowance recorded against net deferred tax assets. The Company has recorded a valuation allowance against substantially all potential tax assets, due to uncertainties in its ability to utilize deferred tax assets, primarily consisting of certain net operating losses carried forward, before they expire. The valuation allowance is based on estimates of future earnings in each of the jurisdictions in which the Company operates and the period over which its deferred tax assets will be recoverable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for uncertain tax positions in accordance with U.S. GAAP. Uncertain tax positions are recorded based upon certain recognition and measurement criteria. The Company re-evaluates uncertain tax positions and considers various factors, including, but not limited to, changes in tax law and the measurement of tax positions taken or expected to be taken in tax returns. The Company adjusts the amount of the liability to reflect any subsequent changes in the relevant facts and circumstances surrounding the uncertain tax positions. The Company recognizes interest and penalties related to income tax matters in income tax expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in fiscal year 2021, the Company began accruing for U.S. state taxes and foreign income taxes as a result of increased nexus in both U.S. state and foreign jurisdictions where historically the Company had no presence and where no net operating losses had historically been established.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, starting in 2022, amendments to Section 174 of the Internal Revenue Code of 1986, as amended (&#x201c;IRC&#x201d;), no longer permit an immediate deduction for research and development expenditures conducted on foreign soil in the tax year that such costs are incurred. Instead, these IRC Section 174 development costs must now be capitalized and amortized over a 15-year period. The new amortization period begins with the midpoint of any taxable year that IRC Section 174 costs are first incurred, regardless of whether the expenditures were made prior to or after July 1, and runs until the midpoint of year sixteen.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain countries in which the Company has operations have adopted legislation influenced by the Organization for Economic Cooperation and Development (&#x201c;OECD&#x201d;) Pillar Two rules, including a minimum tax rate of 15%. It is uncertain whether the U.S. will enact legislation to adopt the Pillar Two framework. While the Company is currently not within the scope of the rules, it is continuing to review and evaluate additional guidance released by the OECD, along with the pending legislative adoption by additional individual countries where the Company operates. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On July 4, 2025, the One Big Beautiful Bill Act (&#x201c;OBBBA&#x201d;) was signed into law, making permanent certain provisions of the Tax Cuts and Jobs Act, including permanent 100% bonus depreciation, expensing of domestic research costs, and amendments to the business interest expense limitation. In accordance with ASC Topic 740, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Income Taxes,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt; the Company has recognized the effects of the new tax law in the period of enactment. As the Company maintains a full valuation allowance on its U.S. federal deferred tax assets, the legislation does not have a material impact on its condensed consolidated financial statements for the three months ended September 30, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional currency of each of the Company&#x2019;s foreign subsidiaries is primarily the local currency of the country in which the subsidiary operates. The Company&#x2019;s asset and liability accounts are translated at the current exchange rate as of the balance sheet date. Revenue and expense accounts are translated at the average exchange rate over the period. Adjustments resulting from the translation of the financial statements of the Company&#x2019;s foreign subsidiaries into U.S. dollars are accumulated as a separate component of stockholders&#x2019; equity within accumulated other comprehensive income. Gains or losses resulting from transactions denominated in foreign currencies are included in foreign currency losses, net, within the Condensed Consolidated Statement of Comprehensive Income (Loss).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Income (Loss) Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net income (loss) per share is based upon the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share is based upon the weighted average number of common shares outstanding and potentially dilutive common shares during the period as determined by using the treasury stock method. Potential common equivalent shares are excluded if their effect is anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accumulated Other Comprehensive Income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accumulated other comprehensive income is comprised of cumulative foreign currency translation adjustments and unrealized gains and losses on available-for-sale investments and is disclosed as a separate component of stockholders&#x2019; equity. Realized gain and loss amounts on available-for-sale investments are reclassified from accumulated other comprehensive income and recorded as interest and other income on the Condensed Consolidated Statements of Comprehensive Income (Loss). There were no realized gains or losses reclassified out of accumulated other comprehensive income for the three and nine months ended September&#160;30, 2025 and 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Significant Customers and Other Risks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Significant Customers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s primary sources of revenue and cash flow are the sales of ORLADEYO in the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ORLADEYO is generally distributed through an arrangement with a single specialty pharmacy in the United States. The specialty pharmacy subsequently sells ORLADEYO to its customers (pharmacy benefit managers, insurance companies, government programs and group purchasing organizations) and dispenses product to patients. RAPIVAB is also generally distributed through the same specialty pharmacy in the United States. The specialty pharmacy&#x2019;s inability or unwillingness to continue these distribution activities could adversely impact the Company&#x2019;s business, results of operations and financial condition. Revenue where the specialty pharmacy is considered the customer was approximately 88% and 86% of total net revenues for the three and nine months ended September&#160;30, 2025, respectively. Revenue where the specialty pharmacy is considered the customer was approximately 88% of total net revenues for both the three and nine months ended September&#160;30, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is distributing ORLADEYO in other global markets directly or through other parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risks from Third-Party Manufacturing and Distribution Concentration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company relies on a single source manufacturer for active pharmaceutical ingredient and finished drug product manufacturing of product candidates in development and on a single specialty pharmacy for distribution of approved drug product in the United States. Delays or disruption in the manufacture or distribution of any product could adversely impact the future procurement stockpiling of the Company&#x2019;s commercial product, commercial revenue and product candidates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Further, the Company&#x2019;s drug development activities are performed by a limited group of third-party vendors. If any of these vendors were unable to perform its services, this could significantly impact the Company&#x2019;s ability to complete its drug development activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents and investments are financial instruments that potentially subject the Company to concentration of risk to the extent recorded on the Condensed Consolidated Balance Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances may exceed the amount of insurance provided on such deposits. The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio of investments with an average maturity of approximately 12 months or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s receivables from sales of ORLADEYO are primarily due from one customer, resulting in a concentration of credit risk. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no new accounting pronouncements adopted by the Company during the nine months ended September 30, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;New Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company expects adoption of this ASU will result in additional disclosures but does not expect it will have a material effect on the Company&#x2019;s consolidated balance sheet, statement of comprehensive income (loss), or statement of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which requires public entities, on an annual and interim basis, to provide disaggregated disclosure of certain income statement expenses into specified categories within the footnotes to the financial statements. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The Company is evaluating the impact of adopting ASU 2024-03.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2025, the FASB issued ASU 2025-06, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software, which clarifies and modernizes the accounting for costs related to internal-use software, eliminating references to project stages and clarifying the threshold entities apply to begin capitalizing costs. ASU 2025-06 is effective for fiscal years beginning after December 15, 2027, and interim periods within those annual reporting periods, with early adoption permitted. The Company is evaluating the impact of adopting ASU 2025-06 but does not expect it will have a material effect on its consolidated balance sheet, statement of comprehensive income (loss), or statement of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not expect any other recently issued accounting standards to have a material impact to its financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <bcrx:DescriptionOfCompanyPolicyTextBlock contextRef="c-1" id="f-465">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;The Company&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;BioCryst Pharmaceuticals, Inc. (the &#x201c;Company&#x201d;) is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (&#x201c;HAE&#x201d;) and other rare diseases, driven by the Company&#x2019;s deep commitment to improving the lives of people living with these conditions. The Company has built a robust commercial infrastructure to support the launch and continued success of ORLADEYO&#xae;, an oral, once-daily therapy discovered and developed internally for the prevention of HAE attacks. The Company&#x2019;s business strategy includes leveraging this established commercial platform to successfully commercialize a pipeline of potential first-in-class or best-in-class oral small-molecule and injectable protein therapeutics targeting a range of rare diseases. These programs are being pursued through both internal discovery efforts and strategic business development. By utilizing its existing commercial capabilities and focusing on rare disease markets, the Company believes that it can more effectively optimize its costs and strategically allocate resources to support long-term, sustainable growth. The Company was founded in 1986 and incorporated in Delaware in 1991, and its headquarters is located in Durham, North Carolina.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s marketed products include oral, once-daily ORLADEYO&#xae; for the prevention of HAE attacks and RAPIVAB&#xae; (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. ORLADEYO has received regulatory approval in the United States and other global markets. The Company is commercializing ORLADEYO in each of these territories directly or through other parties. In addition to its approval in the United States, peramivir injection has received regulatory approvals in Canada (RAPIVAB), Australia (RAPIVAB), Japan (RAPIACTA), Taiwan (RAPIACTA) and Korea (PERAMIFLU). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on the Company&#x2019;s expectations for revenue and operating expenses, the Company believes its financial resources available at September&#160;30, 2025 will be sufficient to fund its operations for at least the next 12 months. The Company may, in the future, issue securities, including common stock, preferred stock, depositary shares, purchase contracts, warrants, debt securities and units, through private placement transactions or registered public offerings. The Company&#x2019;s future liquidity needs, and ability to address those needs, will largely be determined by the success of its products and product candidates; the timing, scope and magnitude of its research and development and commercial expenses; and key developments and regulatory events and its decisions in the future.&lt;/span&gt;&lt;/div&gt;</bcrx:DescriptionOfCompanyPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-466">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The condensed consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany transactions and balances among the consolidated entities have been eliminated from the condensed consolidated financial statements. The Company operates and manages its business as one reportable and operating segment (see &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 13&#x2014;Segment Information&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;) for interim financial reporting and the instructions to Form 10-Q and do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Such financial statements reflect all adjustments that are, in management&#x2019;s opinion, necessary to present fairly, in all material respects, the Company&#x2019;s condensed consolidated financial position, results of operations, and cash flows. There were no adjustments other than normal recurring adjustments. Certain prior year amounts have been reclassified to conform to the current year presentation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These financial statements should be read in conjunction with the financial statements for the fiscal year ended December&#160;31, 2024 and the notes thereto included in the Company&#x2019;s 2024 Annual Report on Form 10-K as filed with the SEC on February 25, 2025. Interim operating results are not necessarily indicative of operating results for the full fiscal year. The condensed consolidated balance sheet as of December&#160;31, 2024 was derived from the audited consolidated financial statements included in the Company&#x2019;s most recent Annual Report on Form 10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-467"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-468"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-469">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. Significant estimates in the Company&#x2019;s condensed consolidated financial statements have been made relative to the calculation of net product sales, royalty financing obligations, inventory reserves, certain accruals, primarily related to the Company&#x2019;s research and development expenses, the valuation of stock options and the valuation allowance for deferred tax assets resulting from net operating losses. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <bcrx:AssetsHeldForSalePolicyTextBlock contextRef="c-1" id="f-470">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assets Held for Sale&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies its long-lived assets to be sold as held for sale when the six criteria in ASC 360, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; are met. This generally occurs when an agreement to sell exists, or when management has committed to a plan to sell the assets within one year. Assets and liabilities to be disposed of together as a group in a single transaction (&#x201c;disposal groups&#x201d;) are classified as held for sale if their carrying amounts are principally expected to be recovered through a sale transaction rather than through continuing use.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The long-lived assets included in a disposal group are reported at the lower of their carrying value or fair value less cost to sell, beginning in the period the held for sale criteria are met. Prior to disposal, losses are recognized for any initial or subsequent write-down to fair value less cost to sell. Any gains or losses not previously recognized that result from the sale of a disposal group shall be recognized at the date of sale. Upon designation as an asset held for sale, the Company stops recording depreciation and amortization expense on long-lived assets. The Company assesses the fair value of a long-lived asset less any costs to sell at each reporting period and until the asset is no longer classified as held for sale.&lt;/span&gt;&lt;/div&gt;</bcrx:AssetsHeldForSalePolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c-1" id="f-471">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded the following revenues for the three and nine months ended September&#160;30, 2025 and 2024 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product sales, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;463,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaborative and other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;159,395&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;117,085&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;468,282&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;319,178&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, the Company recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, Topic 606 includes provisions within a five-step model that includes (i) identifying the contract with a customer, (ii) identifying the performance obligations in the contract, (iii) determining the transaction price, (iv) allocating the transaction price to the performance obligations, and (v) recognizing revenue when, or as, an entity satisfies a performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At contract inception, the Company identifies the goods or services promised within each contract, assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Sales, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s principal sources of product sales are sales of ORLADEYO, which the Company began shipping to patients in December 2020, and sales of peramivir (RAPIVAB/RAPIACTA/PERAMIFLU) to the Company&#x2019;s licensing partners and to the U.S. Department of Health and Human Services (&#x201c;HHS&#x201d;). In the United States, the Company generally ships ORLADEYO directly to patients through a single specialty pharmacy, which is considered its customer. Outside the United States, the Company sells ORLADEYO to specialty distributors and to hospitals and pharmacies, which collectively are considered its customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue for sales when the customer obtains control of the product, which generally occurs upon delivery. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net revenue from sales of ORLADEYO is recorded at net selling price (transaction price), which includes reserves for variable consideration such as (i) estimated government rebates, such as Medicaid and Medicare Part D reimbursements, and estimated managed care rebates, (ii) estimated chargebacks, (iii) estimated costs of co-payment assistance programs and (iv) product returns. These reserves, representing the Company&#x2019;s best estimates of the amount of consideration to which it is entitled based on the terms of the applicable contracts and statutory requirements, are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable if no payments are required of the Company or a current liability if a payment is required of the Company. Actual amounts of consideration may differ from the Company&#x2019;s estimates. If actual results vary from estimates, these estimates are adjusted, which would affect net product revenue and earnings in the period such variances become known.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Government and Managed Care Rebates&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company contracts with government agencies and managed care organizations or, collectively, third-party payors, so that ORLADEYO will be eligible for purchase by, or partial or full reimbursement from, such third-party payors. The Company estimates the rebates it will provide to third-party payors and deducts these estimated amounts from total gross product revenues at the time the revenues are recognized, resulting in a reduction of product revenue and the establishment of a current liability. The Company estimates the rebates that it will provide to third-party payors based upon (i) the Company&#x2019;s contracts with these third-party payors, (ii) the government mandated discounts applicable to government-funded programs, and (iii) product distribution information obtained from the Company&#x2019;s specialty pharmacy regarding payor mix.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Chargebacks&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Chargebacks are discounts that occur when certain contracted customers, pharmacy benefit managers, insurance companies, and government programs purchase directly from the Company&#x2019;s specialty pharmacy. These customers purchase the Company&#x2019;s product under contracts negotiated between them and the Company&#x2019;s specialty pharmacy. The specialty pharmacy, in turn, charges back to the Company the difference between the price that the specialty pharmacy paid and the negotiated price paid by the contracted customers, which may be higher or lower than the specialty pharmacy&#x2019;s purchase price with the Company. The Company estimates chargebacks and adjusts gross product revenues and establishes a current liability at the time revenues are recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Co-payment assistance and patient assistance programs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. Based upon the terms of the program and co-payment assistance utilization reports received from the specialty pharmacy, the Company estimates the co-payment assistance amounts, which are recorded in the same period in which the related revenue is recognized, resulting in a reduction of product revenue and establishment of a current liability. The Company also offers a patient assistance program that provides free drug product, for a limited period of time, to allow a patient&#x2019;s insurance coverage to be established. Based on patient assistance program utilization reports provided by the specialty pharmacy, the Company records gross revenue of the product provided and a full reduction of the revenue amount for the free drug discount.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product returns&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company does not provide contractual return rights to its customers, except in instances where the product is damaged or defective. Non-acceptance by the patient of shipped drug product by the specialty pharmacy is reflected as a reversal of sales in the period in which the sales were originally recorded. Reserves for estimated non-acceptances by patients are recorded as a reduction of revenue in the period that the related revenue is recognized, as well as a reduction to accounts receivable. Estimates of non-acceptance are based on quantitative information provided by the specialty pharmacy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative and Other Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has collaboration and license agreements with a number of third parties. The Company&#x2019;s primary sources of revenue from these collaborative and other research and development arrangements are license, service and royalty revenues.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from license fees, royalty payments, milestone payments, and research and development fees are recognized as revenue when the earnings process is complete and the Company has no further continuing performance obligations or the Company has completed the performance obligations under the terms of the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Arrangements that involve the delivery of more than one performance obligation are initially evaluated as to whether the intellectual property licenses granted by the Company represent distinct performance obligations. If they are determined to be distinct, the value of the intellectual property licenses would be recognized up front while the research and development service fees would be recognized as the performance obligations are satisfied. For performance obligations &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;based on services performed, the Company measures progress using an input method based on the effort it expends or costs it incurs toward the satisfaction of the performance obligation in relation to the total estimated effort or costs. Variable consideration is assessed at each reporting period as to whether it is not subject to significant future reversal and, therefore, should be included in the transaction price at the inception of the contract. If a contract includes a fixed or minimum amount of research and development support, this also would be included in the transaction price. Changes to collaborations, such as the extensions of the research term or increasing the number of targets or technology covered under an existing agreement, are assessed for whether they represent a modification or should be accounted for as a new contract. For contracts with multiple performance obligations, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the products or services. If a standalone selling price is not directly observable, then the Company estimates the standalone selling price using either an adjusted market assessment approach or an expected cost plus margin approach, representing the amount that the Company believes the market is willing to pay for the product or service. Analyzing the arrangement to identify performance obligations requires the use of judgment, and each may be an obligation to deliver services, a right or license to use an asset, or another performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under certain of the Company&#x2019;s license agreements, the Company receives royalty payments based upon its licensees&#x2019; net sales of covered products. Royalties are recognized at the later of when (i) the subsequent sale or usage occurs, or (ii) the performance obligation to which some or all of the sales-based or usage-based royalty has been satisfied.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="c-1" id="f-472">&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded the following revenues for the three and nine months ended September&#160;30, 2025 and 2024 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product sales, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;463,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaborative and other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;159,395&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;117,085&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;468,282&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;319,178&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded the following revenues for the three and nine months ended September&#160;30, 2025 and 2024 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ORLADEYO:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outside of U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total ORLADEYO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-76" decimals="-3" id="f-473" unitRef="usd">157735000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-77" decimals="-3" id="f-474" unitRef="usd">116066000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-78" decimals="-3" id="f-475" unitRef="usd">463952000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-79" decimals="-3" id="f-476" unitRef="usd">313325000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-80" decimals="-3" id="f-477" unitRef="usd">1660000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-81" decimals="-3" id="f-478" unitRef="usd">1019000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-82" decimals="-3" id="f-479" unitRef="usd">4330000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-83" decimals="-3" id="f-480" unitRef="usd">5853000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-7" decimals="-3" id="f-481" unitRef="usd">159395000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-8" decimals="-3" id="f-482" unitRef="usd">117085000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-1" decimals="-3" id="f-483" unitRef="usd">468282000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-9" decimals="-3" id="f-484" unitRef="usd">319178000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c-1" id="f-485">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generally considers cash equivalents to be all cash held in commercial checking accounts, money market accounts, or investments in debt instruments and certificates of deposit with maturities of three months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="c-1" id="f-486">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Total restricted cash was $1,979 and $1,610 as of September&#160;30, 2025 and December&#160;31, 2024, respectively, and primarily consisted of $1,400 as of September&#160;30, 2025 and December&#160;31, 2024, for a letter of credit the Company is required to maintain associated with its Birmingham lease. The letter of credit associated with the Birmingham lease of $1,400 is reflected within other assets on the Condensed Consolidated Balance Sheets as of September&#160;30, 2025 and December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c-3" decimals="-3" id="f-487" unitRef="usd">1979000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c-4" decimals="-3" id="f-488" unitRef="usd">1610000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c-84" decimals="-3" id="f-489" unitRef="usd">1400000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c-85" decimals="-3" id="f-490" unitRef="usd">1400000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c-84" decimals="-3" id="f-491" unitRef="usd">1400000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c-85" decimals="-3" id="f-492" unitRef="usd">1400000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:InvestmentPolicyTextBlock contextRef="c-1" id="f-493">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company invests in high credit quality investments in accordance with its investment policy. The objectives of the Company&#x2019;s investment policy are to eliminate or greatly minimize the probability of a loss of principal value, maintain sufficient liquidity to meet cash flow requirements, and earn a competitive level of return. The Company places its excess cash with high credit quality financial institutions to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that may consist of U.S. Treasury obligations, U.S government agency securities, money market funds, certificates of deposits and corporate notes and bonds. The Company&#x2019;s investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of two years and requires an average portfolio maturity of no more than 12 months. Some of the securities in which the Company invests may have market risk. This means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, the Company does not believe it has a material exposure to interest rate risk arising from its investments. The Company has not realized any significant losses from its investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies all of its investments as available-for-sale. Available-for-sale investments are reported at fair value at each balance sheet date, and include any unrealized holding gains and losses in accumulated other comprehensive income, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company reviews its investments for other than temporary declines in fair value below cost basis at the end of each reporting period and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Factors considered to determine whether an unrealized loss is temporary include whether a decline in fair value below the amortized cost basis is due to credit-related factors or non-credit-related factors, the financial condition and near-term prospects of the Company, and the Company&#x2019;s intent and ability to hold the investment to allow for an anticipated recovery in fair value. A credit-related impairment is recognized as an allowance on the balance sheet with a corresponding adjustment to earnings. Any impairment that is not credit-related is recognized in &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;other comprehensive income, net of applicable taxes unless deemed other than temporary. Realized gains and losses are reflected in interest and other income in the Condensed Consolidated Statements of Comprehensive Income (Loss) and are determined using the specific identification method with transactions recorded on a settlement date basis. Investments with original maturities at date of purchase beyond three months and which mature at or less than 12 months from the balance sheet date are classified as current. Investments with a maturity beyond 12 months from the balance sheet date are classified as long-term.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
    <bcrx:MaturityPeriodOfHighQualityMarketableSecurities contextRef="c-86" id="f-494">P2Y</bcrx:MaturityPeriodOfHighQualityMarketableSecurities>
    <bcrx:AverageMaturityPeriodOfHighQualityMarketableSecurities contextRef="c-86" id="f-495">P12M</bcrx:AverageMaturityPeriodOfHighQualityMarketableSecurities>
    <bcrx:MaturityPeriodOfShortTermInvestment contextRef="c-86" id="f-496">P12M</bcrx:MaturityPeriodOfShortTermInvestment>
    <bcrx:LongTermInvestmentMaturityMinimum contextRef="c-1" id="f-497">P12M</bcrx:LongTermInvestmentMaturityMinimum>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c-1" id="f-498">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities recorded at fair value on a recurring basis on the Condensed Consolidated Balance Sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets measured at fair value on a recurring basis include investments (See &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 4&#x2014;Investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;). There were no liabilities measured at fair value on a recurring basis as of September&#160;30, 2025 and December&#160;31, 2024. The carrying amounts reflected in the Condensed Consolidated Balance Sheets for cash and cash equivalents, trade receivables, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ReceivablesPolicyTextBlock contextRef="c-1" id="f-499">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Trade Receivables&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The majority of the Company&#x2019;s trade receivables arise from product sales and primarily represent amounts due from its specialty pharmacy customer in the United States and other third-party distributors, hospitals and pharmacies globally and have standard payment terms that generally require payment within 30 to 90 days.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Receivables from collaborations are recorded for amounts due to the Company related to royalty receivables from the Company&#x2019;s partners, including Shionogi &amp;amp; Co., Ltd., Green Cross, and Torii (See &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 12&#x2014;Collaborative and Other Relationships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides reserves against trade receivables for estimated losses that may result from a customer&#x2019;s inability to pay. Receivables are evaluated to determine if any reserve or allowance should be recorded based on consideration of the current economic environment, expectations of future economic conditions, specific circumstances and the Company&#x2019;s own historical collection experience. Amounts determined to be uncollectible are charged or written-off against the reserve.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock contextRef="c-1" id="f-500">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s inventory primarily relates to ORLADEYO and also includes peramivir.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company values its inventory at the lower of cost or estimated net realizable value. The Company determines the cost of its inventory on a first-in, first-out (FIFO) basis. Raw materials and work-in-process include all inventory costs prior to packaging and labeling, including raw material, active product ingredient, and the drug product. Finished goods include packaged and labeled products. The Company classifies inventory as long-term when consumption or sale of the inventory is not expected to occur within 12 months from the balance sheet date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s inventory is subject to expiration dating. At each reporting date, the Company evaluates the carrying value of its inventory and provides valuation reserves for any estimated excess, obsolete, short-dated or unmarketable inventory. In addition, the Company may experience spoilage of its raw materials and supplies. The Company&#x2019;s determination that a valuation reserve might be required, in addition to the quantification of such reserve, requires it to utilize significant judgment. Additionally, the Company&#x2019;s inventory is subject to strict quality control and monitoring that is performed throughout the manufacturing process, including release of work-in-process to finished goods. In the event that certain batches or units of product do not meet quality specifications, the Company will record a write-down of any potential unmarketable inventory to its estimated net realizable value and record the expense as cost of product in the Condensed Consolidated Statements of Comprehensive Income (Loss).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to obtaining initial regulatory approval for an investigational product candidate, the Company expenses costs relating to production of pre-launch inventory as research and development expense in its Condensed Consolidated &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Statements of Comprehensive Income (Loss) in the period incurred. After regulatory approval has been received, the Company capitalizes inventory costs.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-501">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Computer equipment and office equipment are depreciated over a life of three years. Laboratory equipment, software, and furniture and fixtures are depreciated over a life of five years. Leasehold improvements are amortized over their estimated useful lives or the expected lease term, whichever is less. Construction in progress reflects amounts incurred for construction or improvements of property and equipment that have not been placed in service.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company periodically reviews its property and equipment for impairment when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values. Property and equipment to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-87" id="f-502">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-88" id="f-503">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-89" id="f-504">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <bcrx:AccruedExpensesPolicyTextBlock contextRef="c-1" id="f-505">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into contractual agreements with third-party vendors who provide research and development, manufacturing, distribution, and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing, and services are completed over an extended period of time. The Company records liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel to identify services that have been performed on its behalf and estimating the actual work completed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of actual cost. The majority of service providers invoice the Company monthly in arrears for services performed. The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances, which can include assumptions such as expected patient enrollment, site activation and estimated project duration. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued expenses include (i) fees paid to clinical research organizations (&#x201c;CROs&#x201d;) in connection with preclinical and toxicology studies and clinical trials; (ii) fees paid to investigative sites in connection with clinical trials; (iii) fees paid to contract manufacturers in connection with the production of the Company&#x2019;s raw materials, drug substance, drug products, and product candidates; and (iv) professional fees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company bases its expenses related to clinical trials on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on the Company&#x2019;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. The Company accrues costs for clinical trial activities based upon estimates of the actual work completed in accordance with agreements established with third-party vendors. If the Company underestimates or overestimates the level of these costs, actual expenses could differ from such estimates. As of September&#160;30, 2025 and December&#160;31, 2024, the carrying value of accrued expenses approximates their fair value due to their short-term settlement.&lt;/span&gt;&lt;/div&gt;</bcrx:AccruedExpensesPolicyTextBlock>
    <us-gaap:CostOfSalesPolicyTextBlock contextRef="c-1" id="f-506">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of product sales includes the cost of producing inventory that is related to product revenue during the respective period, including freight. Cost of product sales may also include costs related to excess or obsolete inventory adjustment charges.&lt;/span&gt;&lt;/div&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-507">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses consist of costs associated with research activities as well as those with the Company&#x2019;s product development efforts, conducting preclinical trials, clinical trials and manufacturing activities. Research and development expenses are expensed as incurred. Most of the Company&#x2019;s clinical and preclinical studies are performed by third-party CROs. Costs for studies performed by CROs are accrued based upon estimates of the actual work completed in accordance with the third-party agreements. Advance payments for goods or services that will be used or rendered for &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses consist of costs associated with research activities as well as those associated with product development efforts, conducting pre-clinical trials, clinical trials and manufacturing activities. Direct expenses consist of compensation for research and development personnel and costs of outside parties to conduct laboratory studies, develop manufacturing processes and manufacture the product candidate, conduct and manage clinical trials, as well as other costs related to the Company&#x2019;s clinical and preclinical studies. Additionally, direct expenses consist of those costs necessary to discontinue and close out a development program, including termination fees and other commitments. Indirect expenses consist of lab supplies and services, facility expenses, depreciation of development equipment and an allocation of its general and administrative overhead costs that support the Company&#x2019;s research and development efforts.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock contextRef="c-1" id="f-508">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Selling, General and Administrative Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling, general and administrative expenses are comprised of compensation and benefits and related costs associated with sales and marketing, finance, human resources, legal, information technology, quality, safety and regulatory activities related to marketed products, and other general and administrative personnel. Additionally, selling, general and administrative expenses are comprised of market research, marketing, advertising and legal expenses, including patent costs, licenses and other administrative costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All patent related costs are expensed to selling, general and administrative expenses when incurred as recoverability of such expenditures is uncertain.&lt;/span&gt;&lt;/div&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-509">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases certain assets under operating and finance leases, which consist of real estate leases, laboratory equipment leases and office equipment leases as of September&#160;30, 2025. The Company determines whether a contract is, or contains, a lease at inception. The Company accounts for lease obligations in accordance with ASU 2016-02: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases (Topic 842)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which requires a lessee to recognize a right-of-use asset and a lease liability on its balance sheet for most leases. The Company elected the practical expedient that exempts leases with an initial lease term of twelve months or less, as well as the practical expedient that allows companies to select, by class of underlying asset, not to separate lease and non-lease components. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of the Company&#x2019;s operating leases provide for renewal options, which can vary by lease. The right-of-use asset and lease liabilities on the Company&#x2019;s Condensed Consolidated Balance Sheets represent payments over the lease term, which include renewal options for certain real estate leases that the Company is likely to exercise. Certain operating leases include rent escalation provisions, which the Company recognizes as expense on a straight-line basis. Lease expense for leases with an initial term of twelve months or less was not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The discount rate used to determine the Company&#x2019;s right-of-use asset and lease liability is the Company&#x2019;s incremental borrowing rate on a collateralized basis over a similar term and amount in a similar economic environment, as generally an implicit rate in the lease is not readily determinable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has not made any residual value guarantees related to its leases; therefore, the Company has no corresponding liability recorded on its Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-510">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in the Company&#x2019;s Condensed Consolidated Statements of Comprehensive Income (Loss) based on their fair values. Stock-based compensation cost is estimated at the grant date based on the fair value of the award and is recognized as expense on a straight-line basis over the requisite service period of the award. Determining the appropriate fair value model and the related assumptions for the model requires judgment, including estimating the stock price volatility and the expected term. The Company utilizes the Black-Scholes option-pricing model to value its stock option awards and recognize compensation expense on a straight-line basis over the requisite service period. The Company reduces stock-based compensation expense for estimated forfeitures. The estimation of share-based payment awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from the Company&#x2019;s current estimates, such amounts will be recorded as a cumulative adjustment in the period estimates are revised. Actual results, and future changes in estimates, may differ substantially from the Company&#x2019;s current estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <bcrx:InterestExpenseDeferredFinancingCostsAndRoyaltyFinancingLiabilitiesPolicyTextBlock contextRef="c-1" id="f-511">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Interest Expense, Deferred Financing Costs and Royalty Financing Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense primarily relates to the royalty financing obligations (see &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 7&#x2014;Royalty Financing Obligations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;) and the term loan borrowings under the Pharmakon Loan Agreement (see &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 8&#x2014;Deb&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;t&#x201d;) during the nine months ended September&#160;30, 2025 and 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs directly associated with the borrowings were capitalized and netted against the corresponding debt liabilities on the Condensed Consolidated Balance Sheets. These costs are amortized to interest expense over the terms of the corresponding borrowings using the effective interest rate method. When utilizing the effective interest method, in periods in which payment-in-kind (&#x201c;PIK&#x201d;) interest was designated and added to the outstanding principal balance of the borrowing, the amortization of the deferred debt fees and issuance costs was accretive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The royalty financing obligations are eligible to be repaid based on royalties from net sales of ORLADEYO. Interest expense is accrued using the effective interest rate method over the estimated period each of the related liabilities will be paid. This requires the Company to estimate the total amount of future royalty payments to be generated from product sales over the life of the agreement. The Company imputes interest on the carrying value of each of the royalty financing obligations and records interest expense using an imputed effective interest rate. The Company reassesses the expected royalty payments each reporting period and accounts for any changes through an adjustment to the effective interest rate on a prospective basis. The assumptions used in determining the expected repayment term of the debt and amortization period of the issuance costs require that the Company make estimates that could impact the carrying value of each of the liabilities, as well as the periods over which associated issuance costs will be amortized. A significant increase or decrease in forecasted net sales could materially impact each of the liability balances, interest expense and the time periods for repayment.&lt;/span&gt;&lt;/div&gt;</bcrx:InterestExpenseDeferredFinancingCostsAndRoyaltyFinancingLiabilitiesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-512">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The liability method is used in the Company&#x2019;s accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant management judgment is required in determining the Company&#x2019;s provision for income taxes, deferred tax assets and liabilities and any valuation allowance recorded against net deferred tax assets. The Company has recorded a valuation allowance against substantially all potential tax assets, due to uncertainties in its ability to utilize deferred tax assets, primarily consisting of certain net operating losses carried forward, before they expire. The valuation allowance is based on estimates of future earnings in each of the jurisdictions in which the Company operates and the period over which its deferred tax assets will be recoverable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for uncertain tax positions in accordance with U.S. GAAP. Uncertain tax positions are recorded based upon certain recognition and measurement criteria. The Company re-evaluates uncertain tax positions and considers various factors, including, but not limited to, changes in tax law and the measurement of tax positions taken or expected to be taken in tax returns. The Company adjusts the amount of the liability to reflect any subsequent changes in the relevant facts and circumstances surrounding the uncertain tax positions. The Company recognizes interest and penalties related to income tax matters in income tax expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in fiscal year 2021, the Company began accruing for U.S. state taxes and foreign income taxes as a result of increased nexus in both U.S. state and foreign jurisdictions where historically the Company had no presence and where no net operating losses had historically been established.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, starting in 2022, amendments to Section 174 of the Internal Revenue Code of 1986, as amended (&#x201c;IRC&#x201d;), no longer permit an immediate deduction for research and development expenditures conducted on foreign soil in the tax year that such costs are incurred. Instead, these IRC Section 174 development costs must now be capitalized and amortized over a 15-year period. The new amortization period begins with the midpoint of any taxable year that IRC Section 174 costs are first incurred, regardless of whether the expenditures were made prior to or after July 1, and runs until the midpoint of year sixteen.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain countries in which the Company has operations have adopted legislation influenced by the Organization for Economic Cooperation and Development (&#x201c;OECD&#x201d;) Pillar Two rules, including a minimum tax rate of 15%. It is uncertain whether the U.S. will enact legislation to adopt the Pillar Two framework. While the Company is currently not within the scope of the rules, it is continuing to review and evaluate additional guidance released by the OECD, along with the pending legislative adoption by additional individual countries where the Company operates. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On July 4, 2025, the One Big Beautiful Bill Act (&#x201c;OBBBA&#x201d;) was signed into law, making permanent certain provisions of the Tax Cuts and Jobs Act, including permanent 100% bonus depreciation, expensing of domestic research costs, and amendments to the business interest expense limitation. In accordance with ASC Topic 740, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Income Taxes,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt; the Company has recognized the effects of the new tax law in the period of enactment. As the Company maintains a full valuation allowance on its U.S. federal deferred tax assets, the legislation does not have a material impact on its condensed consolidated financial statements for the three months ended September 30, 2025.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c-1" id="f-513">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional currency of each of the Company&#x2019;s foreign subsidiaries is primarily the local currency of the country in which the subsidiary operates. The Company&#x2019;s asset and liability accounts are translated at the current exchange rate as of the balance sheet date. Revenue and expense accounts are translated at the average exchange rate over the period. Adjustments resulting from the translation of the financial statements of the Company&#x2019;s foreign subsidiaries into U.S. dollars are accumulated as a separate component of stockholders&#x2019; equity within accumulated other comprehensive income. Gains or losses resulting from transactions denominated in foreign currencies are included in foreign currency losses, net, within the Condensed Consolidated Statement of Comprehensive Income (Loss).&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-514">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Income (Loss) Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net income (loss) per share is based upon the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share is based upon the weighted average number of common shares outstanding and potentially dilutive common shares during the period as determined by using the treasury stock method. Potential common equivalent shares are excluded if their effect is anti-dilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="c-1" id="f-515">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accumulated Other Comprehensive Income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accumulated other comprehensive income is comprised of cumulative foreign currency translation adjustments and unrealized gains and losses on available-for-sale investments and is disclosed as a separate component of stockholders&#x2019; equity. Realized gain and loss amounts on available-for-sale investments are reclassified from accumulated other comprehensive income and recorded as interest and other income on the Condensed Consolidated Statements of Comprehensive Income (Loss). There were no realized gains or losses reclassified out of accumulated other comprehensive income for the three and nine months ended September&#160;30, 2025 and 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax contextRef="c-1" decimals="0" id="f-516" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax contextRef="c-9" decimals="0" id="f-517" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <bcrx:ConcentrationOfMarketRiskPolicyTextBlock contextRef="c-1" id="f-518">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Significant Customers and Other Risks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Significant Customers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s primary sources of revenue and cash flow are the sales of ORLADEYO in the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ORLADEYO is generally distributed through an arrangement with a single specialty pharmacy in the United States. The specialty pharmacy subsequently sells ORLADEYO to its customers (pharmacy benefit managers, insurance companies, government programs and group purchasing organizations) and dispenses product to patients. RAPIVAB is also generally distributed through the same specialty pharmacy in the United States. The specialty pharmacy&#x2019;s inability or unwillingness to continue these distribution activities could adversely impact the Company&#x2019;s business, results of operations and financial condition. Revenue where the specialty pharmacy is considered the customer was approximately 88% and 86% of total net revenues for the three and nine months ended September&#160;30, 2025, respectively. Revenue where the specialty pharmacy is considered the customer was approximately 88% of total net revenues for both the three and nine months ended September&#160;30, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is distributing ORLADEYO in other global markets directly or through other parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risks from Third-Party Manufacturing and Distribution Concentration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company relies on a single source manufacturer for active pharmaceutical ingredient and finished drug product manufacturing of product candidates in development and on a single specialty pharmacy for distribution of approved drug product in the United States. Delays or disruption in the manufacture or distribution of any product could adversely impact the future procurement stockpiling of the Company&#x2019;s commercial product, commercial revenue and product candidates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Further, the Company&#x2019;s drug development activities are performed by a limited group of third-party vendors. If any of these vendors were unable to perform its services, this could significantly impact the Company&#x2019;s ability to complete its drug development activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents and investments are financial instruments that potentially subject the Company to concentration of risk to the extent recorded on the Condensed Consolidated Balance Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances may exceed the amount of insurance provided on such deposits. The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio of investments with an average maturity of approximately 12 months or less.&lt;/span&gt;&lt;/div&gt;The Company&#x2019;s receivables from sales of ORLADEYO are primarily due from one customer, resulting in a concentration of credit risk.</bcrx:ConcentrationOfMarketRiskPolicyTextBlock>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-90" decimals="2" id="f-519" unitRef="number">0.88</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-91" decimals="2" id="f-520" unitRef="number">0.86</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-92" decimals="2" id="f-521" unitRef="number">0.88</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-93" decimals="2" id="f-522" unitRef="number">0.88</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-523">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no new accounting pronouncements adopted by the Company during the nine months ended September 30, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;New Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company expects adoption of this ASU will result in additional disclosures but does not expect it will have a material effect on the Company&#x2019;s consolidated balance sheet, statement of comprehensive income (loss), or statement of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which requires public entities, on an annual and interim basis, to provide disaggregated disclosure of certain income statement expenses into specified categories within the footnotes to the financial statements. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The Company is evaluating the impact of adopting ASU 2024-03.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2025, the FASB issued ASU 2025-06, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software, which clarifies and modernizes the accounting for costs related to internal-use software, eliminating references to project stages and clarifying the threshold entities apply to begin capitalizing costs. ASU 2025-06 is effective for fiscal years beginning after December 15, 2027, and interim periods within those annual reporting periods, with early adoption permitted. The Company is evaluating the impact of adopting ASU 2025-06 but does not expect it will have a material effect on its consolidated balance sheet, statement of comprehensive income (loss), or statement of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not expect any other recently issued accounting standards to have a material impact to its financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="c-1" id="f-524">Assets and Liabilities Held for Sale&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 27, 2025, the Company entered into a definitive agreement (the &#x201c;Stock Purchase Agreement&#x201d;) with BioCryst Ireland Limited (&#x201c;BioCryst Ireland&#x201d;), a wholly owned subsidiary that operates the European ORLADEYO business, and Neopharmed Gentili S.p.A. (&#x201c;Neopharmed&#x201d;). On October 1, 2025 (the &#x201c;Closing&#x201d;), under the terms of the Stock Purchase Agreement, the Company sold to Neopharmed all of its equity interests in BioCryst Ireland, which, together with its subsidiaries, holds certain assets, rights, and employees related to our European ORLADEYO business (the &#x201c;European ORLADEYO Business&#x201d;). At the Closing, the Company received cash proceeds of $250,000, plus customary purchase price adjustments as set forth in the Stock Purchase Agreement. In addition, Neopharmed has agreed to pay the Company up to $14,000 if certain revenue milestones are achieved prior to December 31, 2032. Concurrent with the Closing, Neopharmed also paid a $15,000 royalty release fee to RPI 2019 Intermediate Finance Trust.  In connection &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;with the sale, the Company entered into several agreements with Neopharmed, including an Amended and Restated IP Licence Agreement, a Supply Agreement, a Global Brand and Support Agreement, a Transition Services Agreement, and a Trademark License Agreement (each as defined in&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;Note 16&#x2014;Subsequent Events&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 8, 2025, the Company used a portion of the proceeds from the sale of the European ORLADEYO business to pay off in full the outstanding principal balance and terminate the Pharmakon Loan Agreement (as defined in &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 8&#x2014;Debt&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;Note 16&#x2014;Subsequent Events&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2025, the Company concluded that the criteria under ASC 360-10-45-9 for classification as held for sale were met for BioCryst Ireland. Accordingly, the assets and liabilities of BioCryst Ireland are classified as a disposal group held for sale in the Company&#x2019;s Condensed Consolidated Balance Sheet. The disposal group is not considered a discontinued operation under ASC 205-20, as it does not represent a strategic shift that will have a major effect on the Company&#x2019;s operations or financial results. Therefore, the results of operations for BioCryst Ireland are included in income from continuing operations for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No impairment loss was recognized in connection with the classification of the disposal group as held for sale, as the estimated fair value less costs to sell exceeded its carrying value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the assets and liabilities of BioCryst Ireland that are classified as held for sale on the unaudited Condensed Consolidated Balance Sheet as of September&#160;30, 2025 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets held for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current assets held for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets held for sale&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;33,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities held for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current liabilities held for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities held for sale&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;26,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration contextRef="c-94" decimals="-3" id="f-525" unitRef="usd">250000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <bcrx:DisposalGroupIncludingDiscontinuedOperationContingentConsideration contextRef="c-94" decimals="-3" id="f-526" unitRef="usd">14000000</bcrx:DisposalGroupIncludingDiscontinuedOperationContingentConsideration>
    <bcrx:DisposalGroupIncludingDiscontinuedOperationConsiderationRoyaltyReleaseFee contextRef="c-94" decimals="-3" id="f-527" unitRef="usd">15000000</bcrx:DisposalGroupIncludingDiscontinuedOperationConsiderationRoyaltyReleaseFee>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock contextRef="c-1" id="f-528">&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the assets and liabilities of BioCryst Ireland that are classified as held for sale on the unaudited Condensed Consolidated Balance Sheet as of September&#160;30, 2025 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets held for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current assets held for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets held for sale&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;33,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities held for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current liabilities held for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities held for sale&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;26,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents contextRef="c-95" decimals="-3" id="f-529" unitRef="usd">14840000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet contextRef="c-95" decimals="-3" id="f-530" unitRef="usd">10285000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent contextRef="c-95" decimals="-3" id="f-531" unitRef="usd">2146000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent contextRef="c-95" decimals="-3" id="f-532" unitRef="usd">1902000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="c-95" decimals="-3" id="f-533" unitRef="usd">29173000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent contextRef="c-95" decimals="-3" id="f-534" unitRef="usd">4058000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation contextRef="c-95" decimals="-3" id="f-535" unitRef="usd">33231000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent contextRef="c-95" decimals="-3" id="f-536" unitRef="usd">1714000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent contextRef="c-95" decimals="-3" id="f-537" unitRef="usd">24371000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities contextRef="c-95" decimals="-3" id="f-538" unitRef="usd">338000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="c-95" decimals="-3" id="f-539" unitRef="usd">26423000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent contextRef="c-95" decimals="-3" id="f-540" unitRef="usd">436000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation contextRef="c-95" decimals="-3" id="f-541" unitRef="usd">26859000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="c-1" id="f-542">Revenue&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded the following revenues for the three and nine months ended September&#160;30, 2025 and 2024 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ORLADEYO:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outside of U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total ORLADEYO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ORLADEYO revenues represent total revenues from product sales, collaborative revenues, and royalties. Other revenues primarily relate to the Company&#x2019;s product sales and royalties for peramivir.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No individual country outside of the U.S. exceeded 10% of total revenues for the three and nine months ended September&#160;30, 2025 and 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-96" decimals="-3" id="f-543" unitRef="usd">141557000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-97" decimals="-3" id="f-544" unitRef="usd">103112000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-98" decimals="-3" id="f-545" unitRef="usd">402054000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-99" decimals="-3" id="f-546" unitRef="usd">278987000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-100" decimals="-3" id="f-547" unitRef="usd">17520000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-101" decimals="-3" id="f-548" unitRef="usd">13207000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-102" decimals="-3" id="f-549" unitRef="usd">48103000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-103" decimals="-3" id="f-550" unitRef="usd">34487000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-104" decimals="-3" id="f-551" unitRef="usd">159077000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-105" decimals="-3" id="f-552" unitRef="usd">116319000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-106" decimals="-3" id="f-553" unitRef="usd">450157000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-107" decimals="-3" id="f-554" unitRef="usd">313474000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-108" decimals="-3" id="f-555" unitRef="usd">318000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-109" decimals="-3" id="f-556" unitRef="usd">766000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-110" decimals="-3" id="f-557" unitRef="usd">18125000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-111" decimals="-3" id="f-558" unitRef="usd">5704000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-7" decimals="-3" id="f-559" unitRef="usd">159395000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-8" decimals="-3" id="f-560" unitRef="usd">117085000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-1" decimals="-3" id="f-561" unitRef="usd">468282000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-9" decimals="-3" id="f-562" unitRef="usd">319178000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock contextRef="c-1" id="f-563">Investments&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. Fair value is determined based on observable and unobservable inputs. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect certain market assumptions. As a basis for considering such assumptions, U.S. GAAP establishes a three-tier value hierarchy, which prioritizes the inputs used to develop the assumptions and for measuring fair value as follows: (Level 1) observable inputs such as quoted prices in active markets for identical assets; (Level 2) inputs other than the quoted prices in active markets that are observable either directly or indirectly; and (Level 3) unobservable inputs for which there is little or no market data, which requires the Company to develop its own assumptions. This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial instruments that are measured at fair value on a recurring basis consist of fixed income investments. These valuations are based on observable direct and indirect inputs, primarily quoted prices of similar, but not identical, instruments in active markets or quoted prices for identical or similar instruments in markets that are not active. These fair values are obtained from independent pricing services. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets measured at fair value on a recurring basis were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:36.475%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.054%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Quoted Price in Active Markets (Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs (Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&#160;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Obligations of U.S. Government and its agencies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:36.475%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.054%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Quoted Price in Active Markets (Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs (Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&#160;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Obligations of U.S. Government and its agencies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2025, the Company had seven securities with a total estimated fair value of $69,245 in an unrealized loss position. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. The Company does not have an intent to sell these investments, and it is more likely than not that the investments will be held until recovery of their amortized cost basis. As such, no allowance was recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the fair value of the Company&#x2019;s investments by type (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.086%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-584"&gt;Accrued&lt;br/&gt;Interest&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Obligations of U.S. Government and its agencies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.086%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-595"&gt;Accrued&lt;br/&gt;Interest&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Obligations of U.S. Government and its agencies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the scheduled maturity for the Company&#x2019;s investments at September&#160;30, 2025 and December&#160;31, 2024 (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing after one year through two years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c-1" id="f-564">&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets measured at fair value on a recurring basis were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:36.475%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.054%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Quoted Price in Active Markets (Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs (Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&#160;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Obligations of U.S. Government and its agencies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:36.475%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.054%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Quoted Price in Active Markets (Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs (Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&#160;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Obligations of U.S. Government and its agencies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-112" decimals="-3" id="f-565" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-113" decimals="-3" id="f-566" unitRef="usd">168464000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-114" decimals="-3" id="f-567" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-115" decimals="-3" id="f-568" unitRef="usd">168464000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-116" decimals="-3" id="f-569" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-117" decimals="-3" id="f-570" unitRef="usd">168464000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-118" decimals="-3" id="f-571" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-3" decimals="-3" id="f-572" unitRef="usd">168464000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-119" decimals="-3" id="f-573" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-120" decimals="-3" id="f-574" unitRef="usd">236460000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-121" decimals="-3" id="f-575" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-122" decimals="-3" id="f-576" unitRef="usd">236460000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-123" decimals="-3" id="f-577" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-124" decimals="-3" id="f-578" unitRef="usd">236460000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-125" decimals="-3" id="f-579" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-4" decimals="-3" id="f-580" unitRef="usd">236460000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="c-3"
      decimals="INF"
      id="f-581"
      unitRef="security">7</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-3" decimals="-3" id="f-582" unitRef="usd">69245000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock contextRef="c-1" id="f-583">&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the fair value of the Company&#x2019;s investments by type (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.086%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-584"&gt;Accrued&lt;br/&gt;Interest&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Obligations of U.S. Government and its agencies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.086%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-595"&gt;Accrued&lt;br/&gt;Interest&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Obligations of U.S. Government and its agencies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-115" decimals="-3" id="f-585" unitRef="usd">167149000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss contextRef="c-115" decimals="-3" id="f-586" unitRef="usd">1203000</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-115" decimals="-3" id="f-587" unitRef="usd">138000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-115" decimals="-3" id="f-588" unitRef="usd">26000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-115" decimals="-3" id="f-589" unitRef="usd">168464000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-3" decimals="-3" id="f-590" unitRef="usd">167149000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss contextRef="c-3" decimals="-3" id="f-591" unitRef="usd">1203000</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-3" decimals="-3" id="f-592" unitRef="usd">138000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-3" decimals="-3" id="f-593" unitRef="usd">26000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-3" decimals="-3" id="f-594" unitRef="usd">168464000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-122" decimals="-3" id="f-596" unitRef="usd">234902000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss contextRef="c-122" decimals="-3" id="f-597" unitRef="usd">1121000</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-122" decimals="-3" id="f-598" unitRef="usd">451000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-122" decimals="-3" id="f-599" unitRef="usd">14000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-122" decimals="-3" id="f-600" unitRef="usd">236460000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-4" decimals="-3" id="f-601" unitRef="usd">234902000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss contextRef="c-4" decimals="-3" id="f-602" unitRef="usd">1121000</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-4" decimals="-3" id="f-603" unitRef="usd">451000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-4" decimals="-3" id="f-604" unitRef="usd">14000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-4" decimals="-3" id="f-605" unitRef="usd">236460000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:HeldToMaturitySecuritiesTextBlock contextRef="c-1" id="f-606">&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the scheduled maturity for the Company&#x2019;s investments at September&#160;30, 2025 and December&#160;31, 2024 (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing after one year through two years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:HeldToMaturitySecuritiesTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="c-3" decimals="-3" id="f-607" unitRef="usd">128795000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="c-4" decimals="-3" id="f-608" unitRef="usd">216137000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <bcrx:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterOneYearAndBeforeTwoYears contextRef="c-3" decimals="-3" id="f-609" unitRef="usd">39669000</bcrx:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterOneYearAndBeforeTwoYears>
    <bcrx:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterOneYearAndBeforeTwoYears contextRef="c-4" decimals="-3" id="f-610" unitRef="usd">20323000</bcrx:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterOneYearAndBeforeTwoYears>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-3" decimals="-3" id="f-611" unitRef="usd">168464000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-4" decimals="-3" id="f-612" unitRef="usd">236460000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <bcrx:TradeReceivablesTextBlock contextRef="c-1" id="f-613">Trade Receivables&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Receivables from product sales are recorded for amounts due to the Company related to sales of ORLADEYO and peramivir. At September&#160;30, 2025 and December&#160;31, 2024, receivables, net of reserves, related to sales of ORLADEYO were $88,034 and $76,282, respectively. At September&#160;30, 2025 and December&#160;31, 2024, receivables related to sales of peramivir were $153 and $564, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September&#160;30, 2025, there was $10,285 of accounts receivable, net of reserves, included in current assets held for sale. See &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2&#x2014;Assets and Liabilities Held for Sale&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d; for further details. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaborative and Other Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; At September&#160;30, 2025 and December&#160;31, 2024 receivables from the Company&#x2019;s royalty partners were $3,138 and $2,223, respectively.&lt;/span&gt;&lt;/div&gt;</bcrx:TradeReceivablesTextBlock>
    <us-gaap:AccountsReceivableNet contextRef="c-126" decimals="-3" id="f-614" unitRef="usd">88034000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet contextRef="c-127" decimals="-3" id="f-615" unitRef="usd">76282000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet contextRef="c-128" decimals="-3" id="f-616" unitRef="usd">153000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet contextRef="c-129" decimals="-3" id="f-617" unitRef="usd">564000</us-gaap:AccountsReceivableNet>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet contextRef="c-95" decimals="-3" id="f-618" unitRef="usd">10285000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet>
    <us-gaap:ReceivablesNetCurrent contextRef="c-130" decimals="-3" id="f-619" unitRef="usd">3138000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent contextRef="c-131" decimals="-3" id="f-620" unitRef="usd">2223000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:InventoryDisclosureTextBlock contextRef="c-1" id="f-621">Inventory&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September&#160;30, 2025 and December&#160;31, 2024, the Company&#x2019;s inventory primarily related to ORLADEYO. The Company&#x2019;s inventories consisted of the following (in thousands):  &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,661)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,649)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2025, there was $2,146 of inventory, net in current assets held for sale and $705 of inventory, net in non-current assets held for sale. See &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2&#x2014;Assets and Liabilities Held for Sale&lt;/span&gt;&#x201d; for further details.</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c-1" id="f-622">The Company&#x2019;s inventories consisted of the following (in thousands):  &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,661)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,649)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials contextRef="c-3" decimals="-3" id="f-623" unitRef="usd">9324000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials contextRef="c-4" decimals="-3" id="f-624" unitRef="usd">10006000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess contextRef="c-3" decimals="-3" id="f-625" unitRef="usd">14982000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess contextRef="c-4" decimals="-3" id="f-626" unitRef="usd">16152000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods contextRef="c-3" decimals="-3" id="f-627" unitRef="usd">5977000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods contextRef="c-4" decimals="-3" id="f-628" unitRef="usd">7765000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryGross contextRef="c-3" decimals="-3" id="f-629" unitRef="usd">30283000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross contextRef="c-4" decimals="-3" id="f-630" unitRef="usd">33923000</us-gaap:InventoryGross>
    <us-gaap:InventoryValuationReserves contextRef="c-3" decimals="-3" id="f-631" unitRef="usd">1661000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves contextRef="c-4" decimals="-3" id="f-632" unitRef="usd">2649000</us-gaap:InventoryValuationReserves>
    <bcrx:InventoryIncludingNoncurrentPortion contextRef="c-3" decimals="-3" id="f-633" unitRef="usd">28622000</bcrx:InventoryIncludingNoncurrentPortion>
    <bcrx:InventoryIncludingNoncurrentPortion contextRef="c-4" decimals="-3" id="f-634" unitRef="usd">31274000</bcrx:InventoryIncludingNoncurrentPortion>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent contextRef="c-95" decimals="-3" id="f-635" unitRef="usd">2146000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryNoncurrent contextRef="c-95" decimals="-3" id="f-636" unitRef="usd">705000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryNoncurrent>
    <bcrx:RoyaltyFinancingLiabilitiesTextBlock contextRef="c-1" id="f-637">Royalty Financing Obligations&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;7, 2020, the Company and RPI 2019 Intermediate Finance Trust (&#x201c;RPI&#x201d;) entered into a Purchase and Sale Agreement (the &#x201c;2020 RPI Royalty Purchase Agreement&#x201d;), pursuant to which the Company sold to RPI the right to receive certain royalty payments from the Company for a purchase price of $125,000 in cash (the &#x201c;2020 RPI Royalty Sale&#x201d;). Under the 2020 RPI Royalty Purchase Agreement, RPI is entitled to receive tiered, sales-based royalties on net product sales of ORLADEYO in the United States and certain key European markets (collectively, the &#x201c;Key Territories&#x201d;), and other markets where the Company sells ORLADEYO directly or through distributors (collectively, the &#x201c;Direct Sales&#x201d;) in an amount equal to: (i) 8.75% of aggregate annual net sales of ORLADEYO for annual net sales up to $350,000 and (ii) 2.75% of annual net sales for annual net sales between $350,000 and $550,000. No royalty payments are payable on annual Direct Sales over $550,000.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the 2020 RPI Royalty Purchase Agreement, RPI is also entitled to receive a tiered revenue share on ORLADEYO sublicense revenue or net sales by licensees outside of the Key Territories (the &#x201c;Other Markets&#x201d;) equal to: (i) 20% of the proceeds received by the Company for upfront license fees and development milestones for ORLADEYO in the Other Markets, (ii) 20% of proceeds received on annual net sales of up to $150,000 in the Other Markets, and (iii) 10% of proceeds received by the Company on annual net sales between $150,000 and $230,000 in the Other Markets. No royalty payments are payable on annual net sales above $230,000 in the Other Markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November&#160;19, 2021, the Company and RPI entered into (i) a Purchase and Sale Agreement (the &#x201c;2021 RPI Royalty Purchase Agreement&#x201d; and together with the 2020 RPI Royalty Purchase Agreement, the &#x201c;RPI Royalty Purchase Agreements&#x201d;), pursuant to which the Company sold to RPI the right to receive certain royalty payments from the Company for a purchase price of $150,000 in cash, and (ii) a Purchase and Sale Agreement with OCM IP Healthcare Holdings Limited, an affiliate of OMERS Capital Markets (&#x201c;OMERS&#x201d;) (the &#x201c;OMERS Royalty Purchase Agreement&#x201d; and collectively with the RPI Royalty Purchase Agreements, the &#x201c;Royalty Purchase Agreements&#x201d;), pursuant to which the Company sold to OMERS the right to receive certain royalty payments from the Company for a purchase price of an additional $150,000 in cash.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the 2021 RPI Royalty Purchase Agreement, RPI is entitled to receive tiered, sales-based royalties on Direct Sales in an amount equal to: (i) 0.75% of aggregate annual net sales of ORLADEYO for annual net sales up to $350,000 and (ii) 1.75% of annual net sales of ORLADEYO for annual net sales between $350,000 and $550,000. No royalty payments are payable on Direct Sales over $550,000. RPI is also entitled to receive a tiered revenue share on ORLADEYO sublicense revenue or net sales by licensees in the Other Markets in an amount equal to (i) 3.0% of proceeds received by the Company on annual net sales of up to $150,000 in the Other Markets and (ii) 2.0% of proceeds received by the Company on annual net sales between $150,000 and $230,000 in the Other Markets. No royalty payments are payable on annual net sales above $230,000 in the Other Markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The royalties payable under the 2021 RPI Royalty Purchase Agreement are in addition to the royalties payable to RPI under the 2020 RPI Royalty Purchase Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the OMERS Royalty Purchase Agreement, for the calendar quarter beginning October 1, 2023, OMERS was entitled to receive tiered, sales-based royalties on Direct Sales in an amount equal to: (i) 7.5% of aggregate annual net sales of ORLADEYO for annual net sales up to $350,000 and (ii) 6.0% of annual net sales of ORLADEYO for annual net sales between $350,000 and $550,000 (with no royalty payments payable on annual Direct Sales over $550,000). Commencing with the calendar quarter beginning January 1, 2024, OMERS is entitled to receive tiered, sales-based royalties on Direct Sales in an amount equal to: (i) 10.0% of aggregate annual net sales of ORLADEYO for annual net sales up to $350,000 and (ii) 3.0% of annual net sales of ORLADEYO for annual net sales between $350,000 and $550,000 (with no royalty payments payable on annual Direct Sales over $550,000).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the OMERS Royalty Purchase Agreement, OMERS is also entitled to receive a tiered revenue share on ORLADEYO sublicense revenue or net sales by licensees in the Other Markets in an amount equal to: (i) 20.0% of the proceeds received by the Company for upfront license fees and development milestones for ORLADEYO in the Other Markets, (ii) 20.0% of proceeds received by the Company on annual net sales of up to $150,000 in the Other Markets, and (iii) 10.0% of proceeds received by the Company on annual net sales between $150,000 and $230,000 in the Other Markets. No royalty payments are payable on annual net sales above $230,000 in the Other Markets. OMERS is also entitled to receive profit share amounts of up to 10% from certain other permitted sales in certain other markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the 2020 RPI Royalty Purchase Agreement, the Company is required to make royalty payments of amounts owed to RPI each calendar quarter following the first commercial sale of ORLADEYO in any country. Under the 2021 RPI Royalty Purchase Agreement, the Company is required to make payments to RPI in respect of net sales or sublicense revenue in each calendar quarter from and after October 1, 2021. Under the OMERS Royalty Purchase Agreement, the Company is required to make payments to OMERS in respect of net sales or sublicense revenue in each calendar quarter from and after October 1, 2023. OMERS will no longer be entitled to receive any payments on the date in which aggregate payments actually received by OMERS equals 155.0% of the $150,000 purchase price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The transactions contemplated by each of the Royalty Purchase Agreements are referred to herein as the &#x201c;Royalty Sales&#x201d;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Royalty Purchase Agreements, the Company has agreed to specified affirmative and negative covenants, including covenants regarding periodic reporting of information by the Company to RPI and OMERS, third-party audits of royalties paid under the Royalty Purchase Agreements, and restrictions on the ability of the Company or any of its subsidiaries to incur indebtedness other than certain royalty sales and as was permitted to be incurred under the terms of the Athyrium Credit Agreement (as defined in Note 8 herein) through its payoff and termination on April 17, 2023 or, subsequent to that date, the Pharmakon Loan Agreement (as defined in Note 8 herein), as applicable. See &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 8&#x2014;Debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d; for further details on the Athyrium Credit Agreement and the Pharmakon Loan Agreement. The restrictions under the Royalty Purchase Agreements on the ability of the Company or any of its subsidiaries to incur indebtedness are eliminated after the achievement of certain specified milestones in the Royalty Purchase Agreements. In addition, in connection with the Stock Purchase Agreement (as defined in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2&#x2014;Assets and Liabilities Held for Sale&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), RPI and OMERS provided their written consent of the consummation of the sale of the Company&#x2019;s European ORLADEYO Business. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;Note 16&#x2014;Subsequent Events&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for additional information on the sale of the Company&#x2019;s European ORLADEYO Business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The cash consideration obtained pursuant to the Royalty Purchase Agreements is recorded in &#x201c;Royalty financing obligations&#x201d; on the Company&#x2019;s Condensed Consolidated Balance Sheets. The fair value for the royalty financing obligations at the time of the transactions was based on the Company&#x2019;s estimates of future royalties expected to be paid to the counterparty over the life of the arrangement. The Company subsequently records the obligations at their carrying value using the effective interest method. As of September&#160;30, 2025 and December&#160;31, 2024, the carrying value of the royalty financing obligations under the Royalty Purchase Agreements approximated fair value and was measured based on the Company&#x2019;s current estimates of future payments to RPI and OMERS over the lives of the agreements, which are considered Level 3 inputs. The Company utilizes the prospective method to account for subsequent changes in the estimated future royalties to be paid by the Company to the counterparty over the life of the arrangement. Under the prospective method, a new effective interest rate is determined based on the revised estimate of remaining cash flows. The new rate is the discount rate that equates the present value of the revised estimate of remaining cash flows with the carrying amount of the debt, and it will be used to recognize interest expense for the remaining periods. The Company periodically assesses the amount and timing of expected royalty payments using internal projections of future net product sales, which are based on key assumptions, including paid patients and price. To the extent such payments are greater or less than the Company&#x2019;s initial estimates or the timing of such payments is materially different than its original estimates, the Company &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;will prospectively adjust the amortization of the royalty financing obligations and the effective interest rate. On a quarterly basis, the Company assesses the projected royalty payments relative to the projected interest accretion for the next twelve months to determine if the royalty liability balance is reduced relative to the current outstanding liability. In such case of excess payments relative to interest accretion for the next twelve months, the excess payments are considered to be a short-term liability and classified within current liabilities on the Company&#x2019;s Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended September 30, 2025, there were no significant changes to the amount and timing of expected royalties under the Royalty Purchase Agreements based on the Company&#x2019;s latest forecasts related to ORLADEYO sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the royalty financing obligations activity for the three and nine months ended September&#160;30, 2025 (in thousands) as well as the effective interest rate as of September&#160;30, 2025: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2020 RPI&lt;br/&gt;Royalty&lt;br/&gt;Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021 RPI&lt;br/&gt;Royalty&lt;br/&gt;Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;OMERS&lt;br/&gt;Royalty&lt;br/&gt;Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;513,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash interest expense on royalty financing obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty revenues payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,818)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,021)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,486)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,325)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash interest expense on royalty financing obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty revenues payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,798)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,746)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,737)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;483,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash interest expense on royalty financing obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty revenues payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,258)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,195)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,260)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,713)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;476,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for interest on the royalty financing obligations was $18,319 and $55,240 for the three and nine months ended September&#160;30, 2025, respectively. Cash paid for interest on the royalty financing obligations was $21,239 and $54,308 for the three and nine months ended September&#160;30, 2024, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Concurrent with entering into the 2021 RPI Royalty Purchase Agreement, the Company and RPI entered into a Common Stock Purchase Agreement pursuant to which the Company sold common stock to RPI for a premium of $4,269. This premium has been deferred and is being amortized through interest expense using the effective interest method over the term of the applicable arrangement.&lt;/span&gt;&lt;/div&gt;</bcrx:RoyaltyFinancingLiabilitiesTextBlock>
    <us-gaap:ProceedsFromIssuanceOfDebt contextRef="c-132" decimals="-6" id="f-638" unitRef="usd">125000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories contextRef="c-133" decimals="4" id="f-639" unitRef="number">0.0875</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories contextRef="c-134" decimals="4" id="f-640" unitRef="number">0.0275</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories
      contextRef="c-135"
      decimals="INF"
      id="f-641"
      unitRef="number">0</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets contextRef="c-136" decimals="2" id="f-642" unitRef="number">0.20</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets contextRef="c-137" decimals="1" id="f-643" unitRef="number">0.20</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets contextRef="c-138" decimals="2" id="f-644" unitRef="number">0.10</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets
      contextRef="c-139"
      decimals="INF"
      id="f-645"
      unitRef="number">0</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets>
    <us-gaap:ProceedsFromIssuanceOfDebt contextRef="c-140" decimals="-6" id="f-646" unitRef="usd">150000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount contextRef="c-141" decimals="-3" id="f-647" unitRef="usd">150000000</bcrx:RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories contextRef="c-142" decimals="4" id="f-648" unitRef="number">0.0075</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories contextRef="c-143" decimals="4" id="f-649" unitRef="number">0.0175</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets
      contextRef="c-144"
      decimals="INF"
      id="f-650"
      unitRef="number">0</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets contextRef="c-145" decimals="2" id="f-651" unitRef="number">0.030</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets contextRef="c-146" decimals="2" id="f-652" unitRef="number">0.020</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales contextRef="c-147" decimals="3" id="f-653" unitRef="number">0.075</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales contextRef="c-148" decimals="2" id="f-654" unitRef="number">0.060</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales
      contextRef="c-149"
      decimals="INF"
      id="f-655"
      unitRef="number">0</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales contextRef="c-150" decimals="3" id="f-656" unitRef="number">0.100</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales contextRef="c-151" decimals="2" id="f-657" unitRef="number">0.030</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales
      contextRef="c-152"
      decimals="INF"
      id="f-658"
      unitRef="number">0</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets contextRef="c-153" decimals="1" id="f-659" unitRef="number">0.200</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets contextRef="c-154" decimals="1" id="f-660" unitRef="number">0.200</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets contextRef="c-155" decimals="1" id="f-661" unitRef="number">0.100</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets
      contextRef="c-156"
      decimals="INF"
      id="f-662"
      unitRef="number">0</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets contextRef="c-153" decimals="1" id="f-663" unitRef="number">0.10</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice contextRef="c-153" decimals="3" id="f-664" unitRef="number">1.550</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount contextRef="c-141" decimals="-3" id="f-665" unitRef="usd">150000000</bcrx:RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount>
    <bcrx:RoyaltyFinancingLiabilitiesTableTextBlock contextRef="c-1" id="f-666">&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the royalty financing obligations activity for the three and nine months ended September&#160;30, 2025 (in thousands) as well as the effective interest rate as of September&#160;30, 2025: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2020 RPI&lt;br/&gt;Royalty&lt;br/&gt;Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021 RPI&lt;br/&gt;Royalty&lt;br/&gt;Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;OMERS&lt;br/&gt;Royalty&lt;br/&gt;Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;513,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash interest expense on royalty financing obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty revenues payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,818)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,021)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,486)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,325)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash interest expense on royalty financing obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty revenues payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,798)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,746)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,737)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;483,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash interest expense on royalty financing obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty revenues payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,258)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,195)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,260)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,713)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;476,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bcrx:RoyaltyFinancingLiabilitiesTableTextBlock>
    <bcrx:RoyaltyFinancingLiabilities contextRef="c-157" decimals="-3" id="f-667" unitRef="usd">180413000</bcrx:RoyaltyFinancingLiabilities>
    <bcrx:RoyaltyFinancingLiabilities contextRef="c-158" decimals="-3" id="f-668" unitRef="usd">181140000</bcrx:RoyaltyFinancingLiabilities>
    <bcrx:RoyaltyFinancingLiabilities contextRef="c-159" decimals="-3" id="f-669" unitRef="usd">152176000</bcrx:RoyaltyFinancingLiabilities>
    <bcrx:RoyaltyFinancingLiabilities contextRef="c-4" decimals="-3" id="f-670" unitRef="usd">513729000</bcrx:RoyaltyFinancingLiabilities>
    <bcrx:NonCashInterestExpenseOnRoyaltyFinancingLiabilities contextRef="c-160" decimals="-3" id="f-671" unitRef="usd">9756000</bcrx:NonCashInterestExpenseOnRoyaltyFinancingLiabilities>
    <bcrx:NonCashInterestExpenseOnRoyaltyFinancingLiabilities contextRef="c-161" decimals="-3" id="f-672" unitRef="usd">0</bcrx:NonCashInterestExpenseOnRoyaltyFinancingLiabilities>
    <bcrx:NonCashInterestExpenseOnRoyaltyFinancingLiabilities contextRef="c-162" decimals="-3" id="f-673" unitRef="usd">3758000</bcrx:NonCashInterestExpenseOnRoyaltyFinancingLiabilities>
    <bcrx:NonCashInterestExpenseOnRoyaltyFinancingLiabilities contextRef="c-17" decimals="-3" id="f-674" unitRef="usd">13514000</bcrx:NonCashInterestExpenseOnRoyaltyFinancingLiabilities>
    <bcrx:RoyaltyRevenuesPayable contextRef="c-160" decimals="-3" id="f-675" unitRef="usd">-11818000</bcrx:RoyaltyRevenuesPayable>
    <bcrx:RoyaltyRevenuesPayable contextRef="c-161" decimals="-3" id="f-676" unitRef="usd">-1021000</bcrx:RoyaltyRevenuesPayable>
    <bcrx:RoyaltyRevenuesPayable contextRef="c-162" decimals="-3" id="f-677" unitRef="usd">-13486000</bcrx:RoyaltyRevenuesPayable>
    <bcrx:RoyaltyRevenuesPayable contextRef="c-17" decimals="-3" id="f-678" unitRef="usd">-26325000</bcrx:RoyaltyRevenuesPayable>
    <bcrx:RoyaltyFinancingLiabilities contextRef="c-163" decimals="-3" id="f-679" unitRef="usd">178351000</bcrx:RoyaltyFinancingLiabilities>
    <bcrx:RoyaltyFinancingLiabilities contextRef="c-164" decimals="-3" id="f-680" unitRef="usd">180119000</bcrx:RoyaltyFinancingLiabilities>
    <bcrx:RoyaltyFinancingLiabilities contextRef="c-165" decimals="-3" id="f-681" unitRef="usd">142448000</bcrx:RoyaltyFinancingLiabilities>
    <bcrx:RoyaltyFinancingLiabilities contextRef="c-25" decimals="-3" id="f-682" unitRef="usd">500918000</bcrx:RoyaltyFinancingLiabilities>
    <bcrx:NonCashInterestExpenseOnRoyaltyFinancingLiabilities contextRef="c-166" decimals="-3" id="f-683" unitRef="usd">9804000</bcrx:NonCashInterestExpenseOnRoyaltyFinancingLiabilities>
    <bcrx:NonCashInterestExpenseOnRoyaltyFinancingLiabilities contextRef="c-167" decimals="-3" id="f-684" unitRef="usd">0</bcrx:NonCashInterestExpenseOnRoyaltyFinancingLiabilities>
    <bcrx:NonCashInterestExpenseOnRoyaltyFinancingLiabilities contextRef="c-168" decimals="-3" id="f-685" unitRef="usd">3598000</bcrx:NonCashInterestExpenseOnRoyaltyFinancingLiabilities>
    <bcrx:NonCashInterestExpenseOnRoyaltyFinancingLiabilities contextRef="c-27" decimals="-3" id="f-686" unitRef="usd">13402000</bcrx:NonCashInterestExpenseOnRoyaltyFinancingLiabilities>
    <bcrx:RoyaltyRevenuesPayable contextRef="c-166" decimals="-3" id="f-687" unitRef="usd">-13798000</bcrx:RoyaltyRevenuesPayable>
    <bcrx:RoyaltyRevenuesPayable contextRef="c-167" decimals="-3" id="f-688" unitRef="usd">-1193000</bcrx:RoyaltyRevenuesPayable>
    <bcrx:RoyaltyRevenuesPayable contextRef="c-168" decimals="-3" id="f-689" unitRef="usd">-15746000</bcrx:RoyaltyRevenuesPayable>
    <bcrx:RoyaltyRevenuesPayable contextRef="c-27" decimals="-3" id="f-690" unitRef="usd">-30737000</bcrx:RoyaltyRevenuesPayable>
    <bcrx:RoyaltyFinancingLiabilities contextRef="c-169" decimals="-3" id="f-691" unitRef="usd">174357000</bcrx:RoyaltyFinancingLiabilities>
    <bcrx:RoyaltyFinancingLiabilities contextRef="c-170" decimals="-3" id="f-692" unitRef="usd">178926000</bcrx:RoyaltyFinancingLiabilities>
    <bcrx:RoyaltyFinancingLiabilities contextRef="c-171" decimals="-3" id="f-693" unitRef="usd">130300000</bcrx:RoyaltyFinancingLiabilities>
    <bcrx:RoyaltyFinancingLiabilities contextRef="c-35" decimals="-3" id="f-694" unitRef="usd">483583000</bcrx:RoyaltyFinancingLiabilities>
    <bcrx:NonCashInterestExpenseOnRoyaltyFinancingLiabilities contextRef="c-172" decimals="-3" id="f-695" unitRef="usd">9610000</bcrx:NonCashInterestExpenseOnRoyaltyFinancingLiabilities>
    <bcrx:NonCashInterestExpenseOnRoyaltyFinancingLiabilities contextRef="c-173" decimals="-3" id="f-696" unitRef="usd">0</bcrx:NonCashInterestExpenseOnRoyaltyFinancingLiabilities>
    <bcrx:NonCashInterestExpenseOnRoyaltyFinancingLiabilities contextRef="c-174" decimals="-3" id="f-697" unitRef="usd">3313000</bcrx:NonCashInterestExpenseOnRoyaltyFinancingLiabilities>
    <bcrx:NonCashInterestExpenseOnRoyaltyFinancingLiabilities contextRef="c-7" decimals="-3" id="f-698" unitRef="usd">12923000</bcrx:NonCashInterestExpenseOnRoyaltyFinancingLiabilities>
    <bcrx:RoyaltyRevenuesPayable contextRef="c-172" decimals="-3" id="f-699" unitRef="usd">-8258000</bcrx:RoyaltyRevenuesPayable>
    <bcrx:RoyaltyRevenuesPayable contextRef="c-173" decimals="-3" id="f-700" unitRef="usd">-2195000</bcrx:RoyaltyRevenuesPayable>
    <bcrx:RoyaltyRevenuesPayable contextRef="c-174" decimals="-3" id="f-701" unitRef="usd">-9260000</bcrx:RoyaltyRevenuesPayable>
    <bcrx:RoyaltyRevenuesPayable contextRef="c-7" decimals="-3" id="f-702" unitRef="usd">-19713000</bcrx:RoyaltyRevenuesPayable>
    <bcrx:RoyaltyFinancingLiabilities contextRef="c-175" decimals="-3" id="f-703" unitRef="usd">175709000</bcrx:RoyaltyFinancingLiabilities>
    <bcrx:RoyaltyFinancingLiabilities contextRef="c-176" decimals="-3" id="f-704" unitRef="usd">176731000</bcrx:RoyaltyFinancingLiabilities>
    <bcrx:RoyaltyFinancingLiabilities contextRef="c-177" decimals="-3" id="f-705" unitRef="usd">124353000</bcrx:RoyaltyFinancingLiabilities>
    <bcrx:RoyaltyFinancingLiabilities contextRef="c-3" decimals="-3" id="f-706" unitRef="usd">476793000</bcrx:RoyaltyFinancingLiabilities>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-175" decimals="3" id="f-707" unitRef="number">0.216</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-176" decimals="3" id="f-708" unitRef="number">0</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-177" decimals="3" id="f-709" unitRef="number">0.101</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <bcrx:InterestPaidRoyaltyFinancingLiabilities contextRef="c-7" decimals="-3" id="f-710" unitRef="usd">18319000</bcrx:InterestPaidRoyaltyFinancingLiabilities>
    <bcrx:InterestPaidRoyaltyFinancingLiabilities contextRef="c-1" decimals="-3" id="f-711" unitRef="usd">55240000</bcrx:InterestPaidRoyaltyFinancingLiabilities>
    <bcrx:InterestPaidRoyaltyFinancingLiabilities contextRef="c-8" decimals="-3" id="f-712" unitRef="usd">21239000</bcrx:InterestPaidRoyaltyFinancingLiabilities>
    <bcrx:InterestPaidRoyaltyFinancingLiabilities contextRef="c-9" decimals="-3" id="f-713" unitRef="usd">54308000</bcrx:InterestPaidRoyaltyFinancingLiabilities>
    <bcrx:SharesIssuedCommonStockPremium contextRef="c-178" decimals="-3" id="f-714" unitRef="usd">4269000</bcrx:SharesIssuedCommonStockPremium>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-715">Debt&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Pharmakon Loan Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 17, 2023, the Company entered into a $450,000 Loan Agreement (the &#x201c;Pharmakon Loan Agreement&#x201d;) with BioPharma Credit Investments V (Master) LP and BPCR Limited Partnership, as lenders, and BioPharma Credit PLC, as collateral agent for the lenders. Certain of the Company&#x2019;s wholly-owned subsidiaries were guarantors to the Pharmakon Loan Agreement. The Pharmakon Loan Agreement provided for an initial term loan in the principal amount of $300,000 (the &#x201c;Tranche A Loan&#x201d;) funded on April 17, 2023 (the &#x201c;Tranche A Closing Date&#x201d;). The Company used a portion of the proceeds from the Tranche A Loan to repay the $241,787 of outstanding indebtedness (principal and interest due as of April 17, 2023) under the then-existing credit facility with Athyrium Opportunities III Co-Invest 1 LP (the &#x201c;Athyrium Credit Agreement&#x201d;) and to pay associated transaction costs and fees, and used the remaining net proceeds of $25,805 for other general corporate purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Pharmakon Loan Agreement also provided for three additional term loan tranches, at the Company&#x2019;s option, in principal amounts of $50,000 each (each a &#x201c;Subsequent Tranche Loan&#x201d; and, collectively with the Tranche A Loan, the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201c;Pharmakon Term Loans&#x201d; and each, a &#x201c;Pharmakon Term Loan&#x201d;), which could have been requested on or prior to September 30, 2024. The Company chose not to request any Subsequent Tranche Loans and the options have since expired. The maturity date of the Pharmakon Loan Agreement was April 17, 2028 (the &#x201c;Maturity Date&#x201d;), the fifth anniversary of the Tranche A Closing Date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Pharmakon Loan Agreement provided for quarterly interest-only payments until the Maturity Date, with the unpaid principal amount of the outstanding Pharmakon Term Loans due and payable on the Maturity Date. During the first 18 months following the Tranche A Closing Date, the Company had the option to make a portion of the applicable interest payment on the Tranche A Loan in-kind (a &#x201c;Pharmakon PIK Interest Payment&#x201d;) by capitalizing as principal up to 50% of the amount of interest accrued on the Tranche A Loan during the applicable interest period. The Pharmakon Term Loans bore interest at a rate equal to the three-month Secured Overnight Financing Rate (&#x201c;SOFR&#x201d;), which could be no less than 1.75%, plus 7.00%, per annum or, for each interest period in which a Pharmakon PIK Interest Payment was made, with respect to the Tranche A Loan, SOFR plus 7.25%, per annum.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Tranche A Loan accrued interest at an effective interest rate of 12.28% and 13.34% for the three months ended September&#160;30, 2025 and 2024, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company was required to make a mandatory prepayment of the Pharmakon Term Loans (i) upon the occurrence of a change of control and (ii) prior to any repayment of any convertible debt that the Company may have issued in the future, subject to certain exceptions. The Company could make voluntary prepayments in whole or in part, in minimum $25,000 increments. Prepayments were subject to a prepayment premium equal to, (i) with respect to any prepayment made prior to the second anniversary of the applicable Pharmakon Term Loan borrowing date, the sum of (1) 3.00% of the principal amount of the Pharmakon Term Loan being prepaid plus (2) the aggregate amount of all interest that would have accrued on the principal amount of the Pharmakon Term Loan being prepaid from the date of prepayment through and including the second anniversary of the date of the borrowing of such Pharmakon Term Loan; (ii) with respect to any prepayment made on or after the second anniversary and prior to the third anniversary of the applicable Pharmakon Term Loan borrowing date, 3.00% of the principal amount of the Pharmakon Term Loan being prepaid; (iii) with respect to any prepayment made on or after the third anniversary and prior to the fourth anniversary of the applicable Pharmakon Term Loan, 2.00% of the principal amount of the Pharmakon Term Loan being prepaid; and (iv) with respect to any prepayment made on or after the fourth anniversary of the applicable Pharmakon Term Loan borrowing date and before the Maturity Date, 1.00% of the principal amount of the Pharmakon Term Loan being prepaid. In addition, if the Company had requested any Subsequent Tranche Loans, certain funding fees would have been required to be paid.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Pharmakon Loan Agreement also contained representations and warranties and affirmative and negative covenants customary for financings of this type, as well as customary events of default. Certain of the customary negative covenants limited the ability of the Company and certain of its subsidiaries to, among other things, dispose of assets, engage in mergers, acquisitions, and similar transactions, incur additional indebtedness, grant liens, make investments, pay dividends or make distributions or certain other restricted payments in respect of equity, prepay other indebtedness, enter into restrictive agreements, undertake fundamental changes or amend certain material contracts, among other customary covenants, in each case subject to certain exceptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A failure to comply with the covenants in the Pharmakon Loan Agreement, or an occurrence of any other event of default, could have permitted the lenders under the Pharmakon Loan Agreement to declare the borrowings thereunder, together with accrued interest and fees, and any applicable prepayment premium, to be immediately due and payable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s obligations under the Pharmakon Loan Agreement were secured by a security interest in, subject to certain exceptions, substantially all of the Company&#x2019;s assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 18, 2025, as allowable under the Pharmakon Loan Agreement, the Company made a $75,000 partial prepayment on the outstanding principal amount under the Pharmakon Term Loan. In conjunction with the partial prepayment, the Company incurred a $2,250 prepayment premium and paid $424 of interest accrued through the payment date. Additionally, unamortized deferred financing costs of $1,921 associated with the Pharmakon Term Loan were written-off at the time of repayment. Collectively, the prepayment and unamortized deferred financing costs totaled $4,171 and are reflected as a one-time loss on extinguishment of debt on the Condensed Consolidated Statements of Comprehensive Income (Loss) for the nine months ended September 30, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 24, 2025, as allowable under the Pharmakon Loan Agreement, the Company made a $50,000 partial prepayment on the outstanding principal amount under the Pharmakon Term Loan. In conjunction with the partial prepayment, the Company incurred a $1,500 prepayment premium and fees of $52 and paid $376 of interest accrued through the payment date. Additionally, unamortized deferred financing costs of $1,188 associated with the Pharmakon &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Term Loan were written-off at the time of repayment. Collectively, the prepayment and unamortized deferred financing costs totaled $2,740 and are reflected as a one-time loss on extinguishment of debt on the Condensed Consolidated Statements of Comprehensive Income (Loss) for the three and nine months ended September 30, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2025, borrowings, including Pharmakon PIK Interest Payments, totaled $198,704 under the Pharmakon Loan Agreement. Interest expense on the Tranche A Loan for the three and nine months ended September&#160;30, 2025 was $6,110 and $22,789, respectively, all of which was paid at the end of the quarterly period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2024, borrowings, including the Pharmakon PIK Interest Payments, totaled $323,704 under the Pharmakon Loan Agreement. Interest expense on the Tranche A Loan for the three and nine months ended September&#160;30, 2024 was $10,201 and $30,283, respectively. As allowable under the Pharmakon Loan Agreement, the Company designated and accounted for 50% of the quarterly interest payments for each of the three months ended March&#160;31, 2024 and June&#160;30, 2024 as a Pharmakon PIK Interest Payment and the total amount of $10,041 was added to the outstanding principal balance of the borrowing. The remaining 50% of the total quarterly interest payments for the three months ended March&#160;31, 2024 and June&#160;30, 2024 and the full quarterly interest payment for the three months ended September 30, 2024 totaling $20,242 was paid at the end of each quarterly period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the debt approximated its carrying value based on prevailing interest rates as of the balance sheet date and was considered as Level 2 in the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt fees and issuance costs incurred with the Tranche A Loan under the Pharmakon Loan Agreement totaled $11,147 and were deferred and amortized as interest expense on an effective interest rate method over the term of the Tranche A Loan. Deferred financing amortization of $384 and $1,387 was recognized for the three and nine months ended September&#160;30, 2025, respectively. Deferred financing amortization of $511 and $1,061 was recognized for the three and nine months ended September&#160;30, 2024, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In connection with the Stock Purchase Agreement (as defined in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2&#x2014;Assets and Liabilities Held for Sale&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), Pharmakon provided its written consent of the consummation of the sale of the Company&#x2019;s European ORLADEYO Business. On October 8, 2025, the Company used a portion of the proceeds from the sale of the European ORLADEYO Business to pay off in full the outstanding principal balance and terminate the Pharmakon Loan Agreement. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;Note 16&#x2014;Subsequent Events&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-179" decimals="-3" id="f-716" unitRef="usd">450000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-180" decimals="-3" id="f-717" unitRef="usd">300000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLinesOfCredit contextRef="c-181" decimals="-3" id="f-718" unitRef="usd">241787000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-182" decimals="-3" id="f-719" unitRef="usd">25805000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-183" decimals="-3" id="f-720" unitRef="usd">50000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-184" decimals="-3" id="f-721" unitRef="usd">50000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-185" decimals="-3" id="f-722" unitRef="usd">50000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm contextRef="c-186" id="f-723">P18M</us-gaap:DebtInstrumentTerm>
    <bcrx:DebtInstrumentCapitalizedInterestRate contextRef="c-187" decimals="2" id="f-724" unitRef="number">0.50</bcrx:DebtInstrumentCapitalizedInterestRate>
    <bcrx:DebtInstrumentVariableRateFloor contextRef="c-188" decimals="4" id="f-725" unitRef="number">0.0175</bcrx:DebtInstrumentVariableRateFloor>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="c-187" decimals="4" id="f-726" unitRef="number">0.0700</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="c-189" decimals="4" id="f-727" unitRef="number">0.0725</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-190" decimals="4" id="f-728" unitRef="number">0.1228</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-191" decimals="4" id="f-729" unitRef="number">0.1334</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentPeriodicPayment contextRef="c-192" decimals="-3" id="f-730" unitRef="usd">25000000</us-gaap:DebtInstrumentPeriodicPayment>
    <bcrx:DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments contextRef="c-192" decimals="4" id="f-731" unitRef="number">0.0300</bcrx:DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments>
    <bcrx:DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments contextRef="c-193" decimals="4" id="f-732" unitRef="number">0.0300</bcrx:DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments>
    <bcrx:DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments contextRef="c-194" decimals="4" id="f-733" unitRef="number">0.0200</bcrx:DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments>
    <bcrx:DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments contextRef="c-195" decimals="4" id="f-734" unitRef="number">0.0100</bcrx:DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts contextRef="c-196" decimals="-3" id="f-735" unitRef="usd">75000000</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <bcrx:DebtInstrumentPrepaymentPremium contextRef="c-196" decimals="-3" id="f-736" unitRef="usd">2250000</bcrx:DebtInstrumentPrepaymentPremium>
    <us-gaap:InterestExpenseLongTermDebt contextRef="c-196" decimals="-3" id="f-737" unitRef="usd">424000</us-gaap:InterestExpenseLongTermDebt>
    <bcrx:UnamortizedDeferredFinancingCosts contextRef="c-196" decimals="-3" id="f-738" unitRef="usd">1921000</bcrx:UnamortizedDeferredFinancingCosts>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-192" decimals="-3" id="f-739" unitRef="usd">-4171000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts contextRef="c-197" decimals="-3" id="f-740" unitRef="usd">50000000</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <bcrx:DebtInstrumentPrepaymentPremium contextRef="c-197" decimals="-3" id="f-741" unitRef="usd">1500000</bcrx:DebtInstrumentPrepaymentPremium>
    <us-gaap:DebtInstrumentFeeAmount contextRef="c-198" decimals="-3" id="f-742" unitRef="usd">52000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:InterestExpenseLongTermDebt contextRef="c-197" decimals="-3" id="f-743" unitRef="usd">376000</us-gaap:InterestExpenseLongTermDebt>
    <bcrx:UnamortizedDeferredFinancingCosts contextRef="c-197" decimals="-3" id="f-744" unitRef="usd">1188000</bcrx:UnamortizedDeferredFinancingCosts>
    <bcrx:DeferredDebtPrepaymentAndDebtIssuanceCostsWriteoff contextRef="c-197" decimals="-3" id="f-745" unitRef="usd">2740000</bcrx:DeferredDebtPrepaymentAndDebtIssuanceCostsWriteoff>
    <us-gaap:DebtInstrumentFairValue contextRef="c-190" decimals="-3" id="f-746" unitRef="usd">198704000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:InterestExpenseDebt contextRef="c-199" decimals="-3" id="f-747" unitRef="usd">6110000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-180" decimals="-3" id="f-748" unitRef="usd">22789000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentFairValue contextRef="c-191" decimals="-3" id="f-749" unitRef="usd">323704000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:InterestExpenseDebt contextRef="c-200" decimals="-3" id="f-750" unitRef="usd">10201000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-201" decimals="-3" id="f-751" unitRef="usd">30283000</us-gaap:InterestExpenseDebt>
    <bcrx:PercentOfInterestPayment contextRef="c-202" decimals="2" id="f-752" unitRef="number">0.50</bcrx:PercentOfInterestPayment>
    <bcrx:PercentOfInterestPayment contextRef="c-203" decimals="2" id="f-753" unitRef="number">0.50</bcrx:PercentOfInterestPayment>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest contextRef="c-204" decimals="-3" id="f-754" unitRef="usd">10041000</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <bcrx:PercentOfInterestPayment contextRef="c-203" decimals="2" id="f-755" unitRef="number">0.50</bcrx:PercentOfInterestPayment>
    <bcrx:PercentOfInterestPayment contextRef="c-202" decimals="2" id="f-756" unitRef="number">0.50</bcrx:PercentOfInterestPayment>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest contextRef="c-201" decimals="-3" id="f-757" unitRef="usd">20242000</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet contextRef="c-190" decimals="-3" id="f-758" unitRef="usd">11147000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-199" decimals="-3" id="f-759" unitRef="usd">384000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-180" decimals="-3" id="f-760" unitRef="usd">1387000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-200" decimals="-3" id="f-761" unitRef="usd">511000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-201" decimals="-3" id="f-762" unitRef="usd">1061000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-763">Lease Obligations &lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases certain assets under operating leases, which primarily consist of real estate leases, and finance leases, which generally consist of laboratory equipment leases and office equipment leases, as of September&#160;30, 2025. The Company&#x2019;s real estate agreements expire at various times between 2026 through 2033 and include renewal options that range from &lt;span style="-sec-ix-hidden:f-764"&gt;three&lt;/span&gt; to five years in length.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease expense under operating and finance leases was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Finance lease expense:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Amortization of right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total finance lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other supplemental information related to leases was as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.7 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the presentation in the Condensed Consolidated Balance Sheets of the Company&#x2019;s operating leases (in thousands): &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.596%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-793"&gt;&lt;span style="-sec-ix-hidden:f-794"&gt;Right of use assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Operating lease liabilities &#x2013; current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Operating lease liabilities &#x2013; long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the presentation in the Condensed Consolidated Balance Sheets of the Company&#x2019;s finance leases (in thousands): &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.596%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-803"&gt;&lt;span style="-sec-ix-hidden:f-804"&gt;Right of use assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Finance lease liabilities &#x2013; current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Finance lease liabilities &#x2013; long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease assets are recorded net of accumulated amortization of $2,314 and $6,065 as of September&#160;30, 2025 and December&#160;31, 2024, respectively. Finance lease assets are recorded net of accumulated amortization of $4,519 and $4,059 as of September&#160;30, 2025 and December&#160;31, 2024, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of lease liabilities as of September&#160;30, 2025 are as follows (in thousands): &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2025 (remaining)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;14,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(6,029)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(401)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information related to leases was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows for finance leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows for operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease assets obtained in exchange for operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease assets obtained in exchange for finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash increase to operating lease assets due to remeasurement of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-206" id="f-765">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LeaseCostTableTextBlock contextRef="c-1" id="f-766">&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease expense under operating and finance leases was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Finance lease expense:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Amortization of right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total finance lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information related to leases was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows for finance leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows for operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease assets obtained in exchange for operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease assets obtained in exchange for finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash increase to operating lease assets due to remeasurement of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseExpense contextRef="c-7" decimals="-3" id="f-767" unitRef="usd">526000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c-8" decimals="-3" id="f-768" unitRef="usd">569000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c-1" decimals="-3" id="f-769" unitRef="usd">1596000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c-9" decimals="-3" id="f-770" unitRef="usd">1741000</us-gaap:OperatingLeaseExpense>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c-7" decimals="-3" id="f-771" unitRef="usd">547000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c-8" decimals="-3" id="f-772" unitRef="usd">455000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c-1" decimals="-3" id="f-773" unitRef="usd">1639000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c-9" decimals="-3" id="f-774" unitRef="usd">1278000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c-7" decimals="-3" id="f-775" unitRef="usd">84000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c-8" decimals="-3" id="f-776" unitRef="usd">81000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c-1" decimals="-3" id="f-777" unitRef="usd">268000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c-9" decimals="-3" id="f-778" unitRef="usd">231000</us-gaap:FinanceLeaseInterestExpense>
    <bcrx:FinancingLeaseExpense contextRef="c-7" decimals="-3" id="f-779" unitRef="usd">631000</bcrx:FinancingLeaseExpense>
    <bcrx:FinancingLeaseExpense contextRef="c-8" decimals="-3" id="f-780" unitRef="usd">536000</bcrx:FinancingLeaseExpense>
    <bcrx:FinancingLeaseExpense contextRef="c-1" decimals="-3" id="f-781" unitRef="usd">1907000</bcrx:FinancingLeaseExpense>
    <bcrx:FinancingLeaseExpense contextRef="c-9" decimals="-3" id="f-782" unitRef="usd">1509000</bcrx:FinancingLeaseExpense>
    <bcrx:OtherSupplementalInformationRelatedToLeasesTableTextBlock contextRef="c-1" id="f-783">&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other supplemental information related to leases was as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.7 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bcrx:OtherSupplementalInformationRelatedToLeasesTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-3" id="f-784">P9Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-4" id="f-785">P9Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-3" id="f-786">P2Y6M</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-4" id="f-787">P2Y7M6D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-3" decimals="4" id="f-788" unitRef="number">0.1071</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-4" decimals="4" id="f-789" unitRef="number">0.1091</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent contextRef="c-3" decimals="4" id="f-790" unitRef="number">0.0963</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent contextRef="c-4" decimals="4" id="f-791" unitRef="number">0.0866</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <bcrx:LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock contextRef="c-1" id="f-792">&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the presentation in the Condensed Consolidated Balance Sheets of the Company&#x2019;s operating leases (in thousands): &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.596%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-793"&gt;&lt;span style="-sec-ix-hidden:f-794"&gt;Right of use assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Operating lease liabilities &#x2013; current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Operating lease liabilities &#x2013; long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the presentation in the Condensed Consolidated Balance Sheets of the Company&#x2019;s finance leases (in thousands): &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.596%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-803"&gt;&lt;span style="-sec-ix-hidden:f-804"&gt;Right of use assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Finance lease liabilities &#x2013; current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Finance lease liabilities &#x2013; long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bcrx:LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-3" decimals="-3" id="f-795" unitRef="usd">7725000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-796" unitRef="usd">8061000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="-3" id="f-797" unitRef="usd">348000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-798" unitRef="usd">937000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-799" unitRef="usd">8425000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-800" unitRef="usd">7924000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability contextRef="c-3" decimals="-3" id="f-801" unitRef="usd">8773000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability contextRef="c-4" decimals="-3" id="f-802" unitRef="usd">8861000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="c-3" decimals="-3" id="f-805" unitRef="usd">3115000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-806" unitRef="usd">3947000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c-3" decimals="-3" id="f-807" unitRef="usd">1435000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-808" unitRef="usd">1835000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-809" unitRef="usd">1742000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-810" unitRef="usd">2124000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiability contextRef="c-3" decimals="-3" id="f-811" unitRef="usd">3177000</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiability contextRef="c-4" decimals="-3" id="f-812" unitRef="usd">3959000</us-gaap:FinanceLeaseLiability>
    <bcrx:OperatingLeaseRightOfUseAssetAccumulatedAmortization contextRef="c-3" decimals="-3" id="f-813" unitRef="usd">2314000</bcrx:OperatingLeaseRightOfUseAssetAccumulatedAmortization>
    <bcrx:OperatingLeaseRightOfUseAssetAccumulatedAmortization contextRef="c-4" decimals="-3" id="f-814" unitRef="usd">6065000</bcrx:OperatingLeaseRightOfUseAssetAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization contextRef="c-3" decimals="-3" id="f-815" unitRef="usd">4519000</us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization contextRef="c-4" decimals="-3" id="f-816" unitRef="usd">4059000</us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-817">&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of lease liabilities as of September&#160;30, 2025 are as follows (in thousands): &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2025 (remaining)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;14,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(6,029)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(401)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="c-3" decimals="-3" id="f-818" unitRef="usd">119000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="c-3" decimals="-3" id="f-819" unitRef="usd">496000</us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-3" decimals="-3" id="f-820" unitRef="usd">1153000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-3" decimals="-3" id="f-821" unitRef="usd">1520000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-3" decimals="-3" id="f-822" unitRef="usd">1462000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo contextRef="c-3" decimals="-3" id="f-823" unitRef="usd">1050000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-3" decimals="-3" id="f-824" unitRef="usd">1506000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree contextRef="c-3" decimals="-3" id="f-825" unitRef="usd">486000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-3" decimals="-3" id="f-826" unitRef="usd">1538000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour contextRef="c-3" decimals="-3" id="f-827" unitRef="usd">26000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <bcrx:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour contextRef="c-3" decimals="-3" id="f-828" unitRef="usd">9024000</bcrx:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
    <bcrx:FinanceLeaseLiabilityToBePaidAfterYearFour contextRef="c-3" decimals="-3" id="f-829" unitRef="usd">0</bcrx:FinanceLeaseLiabilityToBePaidAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-3" decimals="-3" id="f-830" unitRef="usd">14802000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue contextRef="c-3" decimals="-3" id="f-831" unitRef="usd">3578000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-3" decimals="-3" id="f-832" unitRef="usd">6029000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount contextRef="c-3" decimals="-3" id="f-833" unitRef="usd">401000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-3" decimals="-3" id="f-834" unitRef="usd">8773000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability contextRef="c-3" decimals="-3" id="f-835" unitRef="usd">3177000</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability contextRef="c-1" decimals="-3" id="f-836" unitRef="usd">268000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability contextRef="c-9" decimals="-3" id="f-837" unitRef="usd">231000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:OperatingLeasePayments contextRef="c-1" decimals="-3" id="f-838" unitRef="usd">1347000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-9" decimals="-3" id="f-839" unitRef="usd">1731000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-840" unitRef="usd">366000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-9" decimals="-3" id="f-841" unitRef="usd">261000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability contextRef="c-1" decimals="-3" id="f-842" unitRef="usd">870000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability contextRef="c-9" decimals="-3" id="f-843" unitRef="usd">828000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <bcrx:NonCashIncreaseInOperatingLeaseAssetsDueToRemeasurementOfOperatingLeaseLiabilities contextRef="c-1" decimals="-3" id="f-844" unitRef="usd">786000</bcrx:NonCashIncreaseInOperatingLeaseAssetsDueToRemeasurementOfOperatingLeaseLiabilities>
    <bcrx:NonCashIncreaseInOperatingLeaseAssetsDueToRemeasurementOfOperatingLeaseLiabilities contextRef="c-9" decimals="-3" id="f-845" unitRef="usd">365000</bcrx:NonCashIncreaseInOperatingLeaseAssetsDueToRemeasurementOfOperatingLeaseLiabilities>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-846">Stockholders&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt; Equity&lt;/span&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Shares Reserved for Future Issuance of Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had reserved shares of common stock for issuance as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares reserved for exercises of outstanding stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;41,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;44,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares reserved for vesting of restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares reserved for future issuance under the Stock Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares reserved for future issuance under the Inducement Equity Incentive Plan &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares reserved for future issuance under the Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total shares reserved for future issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ScheduleOfStockByClassTextBlock contextRef="c-1" id="f-847">&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had reserved shares of common stock for issuance as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares reserved for exercises of outstanding stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;41,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;44,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares reserved for vesting of restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares reserved for future issuance under the Stock Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares reserved for future issuance under the Inducement Equity Incentive Plan &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares reserved for future issuance under the Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total shares reserved for future issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-207"
      decimals="-3"
      id="f-848"
      unitRef="shares">41522000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-208"
      decimals="-3"
      id="f-849"
      unitRef="shares">44240000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-209"
      decimals="-3"
      id="f-850"
      unitRef="shares">9744000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-210"
      decimals="-3"
      id="f-851"
      unitRef="shares">10112000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-211"
      decimals="-3"
      id="f-852"
      unitRef="shares">13721000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-212"
      decimals="-3"
      id="f-853"
      unitRef="shares">1065000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-213"
      decimals="-3"
      id="f-854"
      unitRef="shares">1508000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-214"
      decimals="-3"
      id="f-855"
      unitRef="shares">1699000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-215"
      decimals="-3"
      id="f-856"
      unitRef="shares">4674000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-216"
      decimals="-3"
      id="f-857"
      unitRef="shares">5042000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c-3" decimals="-3" id="f-858" unitRef="shares">71169000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c-4" decimals="-3" id="f-859" unitRef="shares">62158000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-860">Stock-Based Compensation&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2025, the Company had three stock-based employee compensation plans: the Amended and Restated Stock Incentive Plan (&#x201c;Incentive Plan&#x201d;), the Amended and Restated Inducement Equity Incentive Plan (&#x201c;Inducement Plan&#x201d;) and the Amended and Restated Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;). The Incentive Plan was most recently amended and restated on April 21, 2025 and approved by the Company&#x2019;s stockholders on June 12, 2025. The Inducement Plan was most recently amended and restated by the Company&#x2019;s Board of Directors on October 26, 2023. The ESPP was most recently amended and restated by the Company&#x2019;s Board of Directors on July 7, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded the following stock-based compensation expense (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16,232&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,794&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;54,841&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37,294&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inducement Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,179&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,234&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,852&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,241&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;233&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;221&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;623&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;539&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,644&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,249&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,316&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,074&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized stock-based compensation costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation costs included in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,601&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,249&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,273&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,074&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity under the Incentive Plan:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Term&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(897)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled or Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,924)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;28,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.74&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;23,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes restricted stock unit activity under the Incentive Plan:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares &lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(270)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(667)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For restricted stock unit awards granted under the Incentive Plan, the fair value of the awards is determined based on the market value of the Company&#x2019;s shares on the grant date. The weighted average grant date fair value of these awards granted during the first nine months of 2025 and 2024 was $9.17 and $5.80, respectively. The fair value of the restricted stock unit awards is amortized to expense over the vesting periods using a straight-line expense attribution method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inducement Equity Incentive Plan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity under the Inducement Plan:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Term&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(252)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled or Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(279)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.60&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes restricted stock unit activity under the Inducement Plan:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(197)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For restricted stock unit awards granted under the Inducement Plan, the fair value of the awards is determined based on the market value of the Company&#x2019;s shares on the grant date. The weighted average grant date fair value of these awards granted during the first nine months of 2025 and 2024 was $8.47 and $6.25, respectively. The fair value of the restricted stock unit awards is amortized to expense over the vesting periods using a straight-line expense attribution method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors under the Incentive and Inducement Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For stock option awards granted under the Incentive Plan and the Inducement Plan, the fair value is estimated on the date of grant using a Black-Scholes option pricing model and the assumptions noted below. The fair value of the stock option awards is amortized to expense over the vesting periods using a straight-line expense attribution method. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Incentive Plan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the key assumptions used by the Company to value the stock option awards granted under the Incentive Plan during the nine months ended September 30, 2025 and 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected Life in Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;79.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;83.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected Dividend Yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Risk-Free Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Weighted average grant date fair value per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Inducement Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the key assumptions used by the Company to value the stock option awards granted under the Inducement Plan during the nine months ended September 30, 2025 and 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected Life in Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;80.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;83.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected Dividend Yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Risk-Free Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Weighted average grant date fair value per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <bcrx:ShareBasedPaymentArrangementNumberOfPlans contextRef="c-3" decimals="INF" id="f-861" unitRef="plan">3</bcrx:ShareBasedPaymentArrangementNumberOfPlans>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="c-1" id="f-862">&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded the following stock-based compensation expense (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16,232&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,794&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;54,841&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37,294&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inducement Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,179&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,234&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,852&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,241&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;233&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;221&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;623&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;539&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,644&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,249&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,316&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,074&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized stock-based compensation costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation costs included in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,601&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,249&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,273&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,074&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity under the Incentive Plan:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Term&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(897)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled or Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,924)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;28,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.74&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;23,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity under the Inducement Plan:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Term&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(252)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled or Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(279)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.60&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1 contextRef="c-217" decimals="-3" id="f-863" unitRef="usd">16232000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1 contextRef="c-218" decimals="-3" id="f-864" unitRef="usd">14794000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1 contextRef="c-219" decimals="-3" id="f-865" unitRef="usd">54841000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1 contextRef="c-220" decimals="-3" id="f-866" unitRef="usd">37294000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1 contextRef="c-221" decimals="-3" id="f-867" unitRef="usd">2179000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1 contextRef="c-222" decimals="-3" id="f-868" unitRef="usd">2234000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1 contextRef="c-223" decimals="-3" id="f-869" unitRef="usd">5852000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1 contextRef="c-224" decimals="-3" id="f-870" unitRef="usd">6241000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1 contextRef="c-225" decimals="-3" id="f-871" unitRef="usd">233000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1 contextRef="c-226" decimals="-3" id="f-872" unitRef="usd">221000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1 contextRef="c-227" decimals="-3" id="f-873" unitRef="usd">623000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1 contextRef="c-228" decimals="-3" id="f-874" unitRef="usd">539000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1 contextRef="c-7" decimals="-3" id="f-875" unitRef="usd">18644000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1 contextRef="c-8" decimals="-3" id="f-876" unitRef="usd">17249000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1 contextRef="c-1" decimals="-3" id="f-877" unitRef="usd">61316000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1 contextRef="c-9" decimals="-3" id="f-878" unitRef="usd">44074000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="c-7" decimals="-3" id="f-879" unitRef="usd">-43000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="c-8" decimals="-3" id="f-880" unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="c-1" decimals="-3" id="f-881" unitRef="usd">-43000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="c-9" decimals="-3" id="f-882" unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-7" decimals="-3" id="f-883" unitRef="usd">18601000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-8" decimals="-3" id="f-884" unitRef="usd">17249000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-885" unitRef="usd">61273000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-9" decimals="-3" id="f-886" unitRef="usd">44074000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-229"
      decimals="-3"
      id="f-887"
      unitRef="shares">39082000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-229"
      decimals="2"
      id="f-888"
      unitRef="usdPerShare">7.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-230"
      decimals="-3"
      id="f-889"
      unitRef="shares">538000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-230"
      decimals="2"
      id="f-890"
      unitRef="usdPerShare">9.31</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-230"
      decimals="-3"
      id="f-891"
      unitRef="shares">897000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-230"
      decimals="2"
      id="f-892"
      unitRef="usdPerShare">5.36</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-230" decimals="-3" id="f-893" unitRef="usd">3290000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="c-230"
      decimals="-3"
      id="f-894"
      unitRef="shares">1924000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-230"
      decimals="2"
      id="f-895"
      unitRef="usdPerShare">9.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-231"
      decimals="-3"
      id="f-896"
      unitRef="shares">36799000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-231"
      decimals="2"
      id="f-897"
      unitRef="usdPerShare">7.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-230" id="f-898">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-231" decimals="-3" id="f-899" unitRef="usd">28966000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c-231"
      decimals="-3"
      id="f-900"
      unitRef="shares">23314000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-231"
      decimals="2"
      id="f-901"
      unitRef="usdPerShare">7.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-230" id="f-902">P4Y8M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-231" decimals="-3" id="f-903" unitRef="usd">23388000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock contextRef="c-1" id="f-904">&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes restricted stock unit activity under the Incentive Plan:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares &lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(270)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(667)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes restricted stock unit activity under the Inducement Plan:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(197)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-232"
      decimals="-3"
      id="f-905"
      unitRef="shares">9289000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-232"
      decimals="2"
      id="f-906"
      unitRef="usdPerShare">7.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-233"
      decimals="-3"
      id="f-907"
      unitRef="shares">393000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-233"
      decimals="2"
      id="f-908"
      unitRef="usdPerShare">9.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-233"
      decimals="-3"
      id="f-909"
      unitRef="shares">270000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-233"
      decimals="2"
      id="f-910"
      unitRef="usdPerShare">8.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-233"
      decimals="-3"
      id="f-911"
      unitRef="shares">667000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-233"
      decimals="2"
      id="f-912"
      unitRef="usdPerShare">7.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-234"
      decimals="-3"
      id="f-913"
      unitRef="shares">8745000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-234"
      decimals="2"
      id="f-914"
      unitRef="usdPerShare">7.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-233"
      decimals="2"
      id="f-915"
      unitRef="usdPerShare">9.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-235"
      decimals="2"
      id="f-916"
      unitRef="usdPerShare">5.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-236"
      decimals="-3"
      id="f-917"
      unitRef="shares">5158000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-236"
      decimals="2"
      id="f-918"
      unitRef="usdPerShare">8.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-237"
      decimals="-3"
      id="f-919"
      unitRef="shares">96000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-237"
      decimals="2"
      id="f-920"
      unitRef="usdPerShare">8.07</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-237"
      decimals="-3"
      id="f-921"
      unitRef="shares">252000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-237"
      decimals="2"
      id="f-922"
      unitRef="usdPerShare">5.65</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-237" decimals="-3" id="f-923" unitRef="usd">994000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="c-237"
      decimals="-3"
      id="f-924"
      unitRef="shares">279000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-237"
      decimals="2"
      id="f-925"
      unitRef="usdPerShare">11.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-238"
      decimals="-3"
      id="f-926"
      unitRef="shares">4723000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-238"
      decimals="2"
      id="f-927"
      unitRef="usdPerShare">8.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-237" id="f-928">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-238" decimals="-3" id="f-929" unitRef="usd">6940000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c-238"
      decimals="-3"
      id="f-930"
      unitRef="shares">3519000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-238"
      decimals="2"
      id="f-931"
      unitRef="usdPerShare">8.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-237" id="f-932">P5Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-238" decimals="-3" id="f-933" unitRef="usd">6324000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-239"
      decimals="-3"
      id="f-934"
      unitRef="shares">823000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-239"
      decimals="2"
      id="f-935"
      unitRef="usdPerShare">8.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-240"
      decimals="-3"
      id="f-936"
      unitRef="shares">472000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-240"
      decimals="2"
      id="f-937"
      unitRef="usdPerShare">8.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-240"
      decimals="-3"
      id="f-938"
      unitRef="shares">197000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-240"
      decimals="2"
      id="f-939"
      unitRef="usdPerShare">9.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-240"
      decimals="-3"
      id="f-940"
      unitRef="shares">99000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-240"
      decimals="2"
      id="f-941"
      unitRef="usdPerShare">8.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-241"
      decimals="-3"
      id="f-942"
      unitRef="shares">999000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-241"
      decimals="2"
      id="f-943"
      unitRef="usdPerShare">8.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-240"
      decimals="2"
      id="f-944"
      unitRef="usdPerShare">8.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-242"
      decimals="2"
      id="f-945"
      unitRef="usdPerShare">6.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-946">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Incentive Plan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the key assumptions used by the Company to value the stock option awards granted under the Incentive Plan during the nine months ended September 30, 2025 and 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected Life in Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;79.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;83.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected Dividend Yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Risk-Free Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Weighted average grant date fair value per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Inducement Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the key assumptions used by the Company to value the stock option awards granted under the Inducement Plan during the nine months ended September 30, 2025 and 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected Life in Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;80.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;83.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected Dividend Yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Risk-Free Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Weighted average grant date fair value per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-219" id="f-947">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-220" id="f-948">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-219" decimals="3" id="f-949" unitRef="number">0.790</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-220" decimals="3" id="f-950" unitRef="number">0.837</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-219" decimals="3" id="f-951" unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-220" decimals="3" id="f-952" unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-219" decimals="3" id="f-953" unitRef="number">0.041</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-220" decimals="3" id="f-954" unitRef="number">0.043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-219"
      decimals="2"
      id="f-955"
      unitRef="usdPerShare">6.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-220"
      decimals="2"
      id="f-956"
      unitRef="usdPerShare">4.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-223" id="f-957">P6Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-224" id="f-958">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-223" decimals="3" id="f-959" unitRef="number">0.809</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-224" decimals="3" id="f-960" unitRef="number">0.834</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-223" decimals="3" id="f-961" unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-224" decimals="3" id="f-962" unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-223" decimals="3" id="f-963" unitRef="number">0.040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-224" decimals="3" id="f-964" unitRef="number">0.042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-223"
      decimals="2"
      id="f-965"
      unitRef="usdPerShare">5.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-224"
      decimals="2"
      id="f-966"
      unitRef="usdPerShare">4.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c-1" id="f-967">Collaborative and Other Relationships&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ORLADEYO&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Torii Pharmaceutical Co., Ltd&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(&#x201c;Torii&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November&#160;5, 2019, the Company entered into a Commercialization and License Agreement with Torii (the &#x201c;Original Torii Agreement&#x201d;), granting Torii the exclusive right to commercialize ORLADEYO for the prevention of HAE attacks in Japan. Under the Original Torii Agreement, the Company received an upfront, non-refundable payment of $22,000. The Company received an additional milestone payment of $15,000 in the second quarter of 2021 upon receipt from the Japanese National Health Insurance System of a reimbursement price approval for ORLADEYO. In addition, the Company was entitled to receive tiered royalty payments, ranging from 20% to 40% of annual net sales of ORLADEYO in Japan during each calendar year. Torii&#x2019;s royalty payment obligations were subject to customary reductions in certain circumstances, but could not be reduced by more than 50% of the amount that otherwise would have been payable to the Company in the applicable calendar quarter. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company identified performance obligations under the Original Torii Agreement related to (i) the license to develop and commercialize ORLADEYO, (ii) regulatory approval support, and (iii) reimbursement pricing approval support. These were each determined to be distinct from the other performance obligations. The Company allocated the $22,000 upfront consideration to the identified performance obligations using estimation approaches to determine the standalone selling prices under ASC Topic 606. Specifically, in determining the value related to the license, a valuation approach utilizing risk adjusted discounted cash flow projections was used, and an expected cost plus margin approach was utilized for the other performance obligations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November&#160;30, 2023, the Company entered into an Amended and Restated Commercialization and License Agreement with Torii (as amended, the &#x201c;Torii Agreement&#x201d;). Under the Torii Agreement, the Company is entitled to receive tiered royalty payments, ranging from 20% to 80% of annual net sales of ORLADEYO in Japan during each calendar year. The Company is now responsible for all commercial promotion activities to support ORLADEYO sales in Japan, and Torii is responsible for HAE disease awareness activities in Japan. The Company will receive a 20% royalty on annual Japanese sales below a prespecified threshold and an 80% royalty on annual Japanese sales above the prespecified threshold.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Torii&#x2019;s updated royalty payment obligations commenced on November&#160;30, 2023 and expire upon the later of (i) the tenth anniversary of the date of first commercial sale of ORLADEYO in Japan, (ii) the expiration of the Company&#x2019;s patents covering ORLADEYO, and (iii) the expiration of regulatory exclusivity for ORLADEYO in Japan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that the Torii Agreement represented a contract modification to be accounted for as if it were part of the Original Torii Agreement under ASC Topic 606. As the performance obligations under the Original Torii Agreement had been fully satisfied, the Company was not required to adjust revenue previously recognized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Peramivir Injection (RAPIVAB, RAPIACTA, PERAMIFLU)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;U.S. Department of Health and Human Services (&#x201c;HHS&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2024, the HHS awarded the Company up to a $69,388 contract for the procurement of up to 95.6 thousand doses over a five-year period of RAPIVAB (peramivir injection) for the treatment of influenza. The contract, awarded by the HHS Office of the Administration for Strategic Preparedness and Response (&#x201c;ASPR&#x201d;), supplied the Center for the Strategic National Stockpile, the nation&#x2019;s largest supply of life-saving pharmaceuticals and medical supplies for use in a public health emergency. The contract was structured with a 12-month base ordering period and four optional 12-month ordering periods, which the government could exercise on an annual basis. ASPR executed the first ordering period for $13,878. The Company delivered no doses of peramivir under this contract and recorded no revenue for the three months ended September 30, 2025. The Company delivered 16.8 thousand doses of peramivir under this contract and recorded revenue of $12,206 for the nine months ended September 30, 2025. There were no doses delivered and no revenue recorded for the three and nine months ended September 30, 2024.  On May 15, 2025, ASPR notified the Company of its intent to not exercise any additional optional ordering periods available under the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Shionogi &amp;amp; Co., Ltd. (&#x201c;Shionogi&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2007, the Company entered into an exclusive license agreement with Shionogi to develop and commercialize peramivir in Japan for the treatment of seasonal and potentially life-threatening human influenza. Under the terms of the agreement, Shionogi obtained rights to injectable formulations of peramivir in Japan. In October 2008, the Company and Shionogi amended the license agreement to expand the territory covered by the agreement to include Taiwan. Shionogi has commercially launched peramivir under the commercial name RAPIACTA in Japan and Taiwan. The Company developed peramivir under a license from UAB and owes sublicense payments to UAB on any future milestone payments and/or royalties received by the Company from Shionogi. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Green Cross Corporation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(&#x201c;Green Cross&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2006, the Company entered into an agreement with Green Cross to develop and commercialize peramivir in Korea. Under the terms of the agreement, Green Cross is responsible for all development, regulatory, and commercialization costs in Korea and the Company is entitled to share in profits resulting from the sale of peramivir in Korea, including the sale of peramivir to the Korean government for stockpiling purposes. Furthermore, Green Cross will pay the Company a premium over its cost to supply peramivir for development and any future marketing of peramivir products in Korea.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Collaborations and Relationships&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Clearside Biomedical, Inc. (&#x201c;Clearside&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November&#160;3, 2023, the Company announced that it entered into a license agreement (the &#x201c;Clearside Agreement&#x201d;) with Clearside, enabling the Company to develop its investigational plasma kallikrein inhibitor, avoralstat, with Clearside&#x2019;s SCS Microinjector&#xae; to deliver avoralstat to the back of the eye through the suprachoroidal space to treat patients with diabetic macular edema. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Clearside Agreement, Clearside received a $5,000 upfront license fee from the Company, which was recognized in research and development expenses during the year ended December 31, 2023. Clearside is eligible to receive up to an additional $30,000 in clinical and regulatory milestone payments, and up to a total of $47,500 in three post-approval sales-based milestone payments as annual global net sales progress to $2,000,000. The Company will pay Clearside tiered mid-single digit royalties on annual global net product sales, at three tiers, including a top tier of &amp;gt;$1,500,000.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-243" decimals="-6" id="f-968" unitRef="usd">22000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <bcrx:PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeMilestone contextRef="c-244" decimals="-6" id="f-969" unitRef="usd">15000000</bcrx:PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeMilestone>
    <bcrx:RoyaltyRateIfMaintainsSakigakeDesignation contextRef="c-245" decimals="2" id="f-970" unitRef="number">0.20</bcrx:RoyaltyRateIfMaintainsSakigakeDesignation>
    <bcrx:RoyaltyRateIfMaintainsSakigakeDesignation contextRef="c-246" decimals="2" id="f-971" unitRef="number">0.40</bcrx:RoyaltyRateIfMaintainsSakigakeDesignation>
    <bcrx:MaximumCustomaryReductionOnRoyaltyRate contextRef="c-244" decimals="2" id="f-972" unitRef="number">0.50</bcrx:MaximumCustomaryReductionOnRoyaltyRate>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-243" decimals="-6" id="f-973" unitRef="usd">22000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <bcrx:RoyaltyRate contextRef="c-247" decimals="2" id="f-974" unitRef="number">0.20</bcrx:RoyaltyRate>
    <bcrx:RoyaltyRate contextRef="c-248" decimals="2" id="f-975" unitRef="number">0.80</bcrx:RoyaltyRate>
    <bcrx:RoyaltyRate contextRef="c-247" decimals="2" id="f-976" unitRef="number">0.20</bcrx:RoyaltyRate>
    <bcrx:RoyaltyRate contextRef="c-248" decimals="2" id="f-977" unitRef="number">0.80</bcrx:RoyaltyRate>
    <bcrx:CollaborativeAgreementContractValue contextRef="c-249" decimals="-3" id="f-978" unitRef="usd">69388000</bcrx:CollaborativeAgreementContractValue>
    <bcrx:MaximumNumberOfProductsPermittedToBeObtainedDoses contextRef="c-250" decimals="-2" id="f-979" unitRef="dose">95600</bcrx:MaximumNumberOfProductsPermittedToBeObtainedDoses>
    <bcrx:ContractTerm contextRef="c-249" id="f-980">P5Y</bcrx:ContractTerm>
    <bcrx:ContractTerm contextRef="c-250" id="f-981">P12M</bcrx:ContractTerm>
    <bcrx:NumberOfOptionalOrderingPeriods
      contextRef="c-250"
      decimals="INF"
      id="f-982"
      unitRef="period">4</bcrx:NumberOfOptionalOrderingPeriods>
    <bcrx:ContractTerm contextRef="c-250" id="f-983">P12M</bcrx:ContractTerm>
    <us-gaap:ProceedsFromCollaborators contextRef="c-250" decimals="-3" id="f-984" unitRef="usd">13878000</us-gaap:ProceedsFromCollaborators>
    <bcrx:NumberOfProductDeliveredDoses contextRef="c-251" decimals="INF" id="f-985" unitRef="dose">0</bcrx:NumberOfProductDeliveredDoses>
    <bcrx:NumberOfProductDeliveredDoses contextRef="c-251" decimals="INF" id="f-986" unitRef="dose">0</bcrx:NumberOfProductDeliveredDoses>
    <bcrx:NumberOfProductDeliveredDoses contextRef="c-252" decimals="INF" id="f-987" unitRef="dose">16800</bcrx:NumberOfProductDeliveredDoses>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-252" decimals="-3" id="f-988" unitRef="usd">12206000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <bcrx:NumberOfProductDeliveredDoses contextRef="c-253" decimals="INF" id="f-989" unitRef="dose">0</bcrx:NumberOfProductDeliveredDoses>
    <bcrx:NumberOfProductDeliveredDoses contextRef="c-254" decimals="INF" id="f-990" unitRef="dose">0</bcrx:NumberOfProductDeliveredDoses>
    <bcrx:NumberOfProductDeliveredDoses contextRef="c-253" decimals="INF" id="f-991" unitRef="dose">0</bcrx:NumberOfProductDeliveredDoses>
    <bcrx:NumberOfProductDeliveredDoses contextRef="c-254" decimals="INF" id="f-992" unitRef="dose">0</bcrx:NumberOfProductDeliveredDoses>
    <bcrx:LicenseAgreementUpfrontPayment contextRef="c-255" decimals="-3" id="f-993" unitRef="usd">5000000</bcrx:LicenseAgreementUpfrontPayment>
    <bcrx:PotentialMilestonePaymentsPayable contextRef="c-256" decimals="-3" id="f-994" unitRef="usd">30000000</bcrx:PotentialMilestonePaymentsPayable>
    <bcrx:PotentialMilestonePaymentsPayableIfRegulatoryApprovalBeforeMilestone contextRef="c-256" decimals="-3" id="f-995" unitRef="usd">47500000</bcrx:PotentialMilestonePaymentsPayableIfRegulatoryApprovalBeforeMilestone>
    <bcrx:LicenseAgreementNumberOfMilestonePayments
      contextRef="c-255"
      decimals="0"
      id="f-996"
      unitRef="payment">3</bcrx:LicenseAgreementNumberOfMilestonePayments>
    <bcrx:LicenseAgreementAnnualGlobalNetSales contextRef="c-257" decimals="-6" id="f-997" unitRef="usd">2000000000</bcrx:LicenseAgreementAnnualGlobalNetSales>
    <bcrx:LicenseAgreementRoyaltyPaymentNumberOfTiers
      contextRef="c-255"
      decimals="0"
      id="f-998"
      unitRef="payment">3</bcrx:LicenseAgreementRoyaltyPaymentNumberOfTiers>
    <bcrx:LicenseAgreementAnnualGlobalNetSales contextRef="c-258" decimals="-6" id="f-999" unitRef="usd">1500000000</bcrx:LicenseAgreementAnnualGlobalNetSales>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-1000">Segment Information&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates as one reportable and operating segment, centered around its commercialized product, ORLADEYO, and its pipeline with the goal of developing first-in-class or best-in-class oral small-molecule and injectable protein therapeutics to target difficult-to-treat rare diseases. The determination of a single segment is consistent with the consolidated financial information regularly provided to the Company&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;). The Chief Executive Officer, as the CODM, uses consolidated, single-segment financial information for purposes of evaluating performance, making operating decisions, allocating resources, and planning and forecasting for future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The CODM assesses performance and decides how to allocate resources based on consolidated net income (loss). This measure is used to monitor budget versus actual results to evaluate the performance of the segment. The CODM uses consolidated cash, cash equivalents and investments as the measure of segment assets. As of September&#160;30, 2025 the Company&#x2019;s cash, cash equivalents, and investments were $267,382, of which $14,840 was considered held for sale (see &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2 - Assets Held for Sale&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). As of December&#160;31, 2024 the Company&#x2019;s cash, cash equivalents, and investments were $341,173.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table illustrates information about segment revenues, significant segment expenses, and segment net income (loss) for the three and nine months ended September 30, 2025 and 2024 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;159,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;117,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;468,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;319,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Less&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Berotralstat&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;BCX17725&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Avoralstat&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Factor D Program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research, discovery and preclinical programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation and related personnel costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;13,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 25pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;14,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;38,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;42,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 25pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;24,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-program specific and indirect costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 25pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;23,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;83,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;65,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;252,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;185,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2,238)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(3,591)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(7,778)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(11,176)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;19,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;24,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;64,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;74,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency (gains) losses, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(98)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on extinguishment of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,667)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,667)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax (benefit) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(769)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Segment net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;12,899&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;(14,033)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;18,016&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;(62,086)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Reconciliation of segment profit or loss:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments and reconciling items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;12,899&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;(14,033)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;18,016&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;(62,086)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;1 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;The significant expense categories and amounts align with the segment-level information that is regularly provided to the CODM.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;All material long-lived assets of the Company reside in the U.S. For geographic information about the Company&#x2019;s product revenues, see &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Note 3&#x2014;Revenue&lt;/span&gt;&#x201d;.</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-1001"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-1002"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <bcrx:CashCashEquivalentsShortAndLongTermInvestments contextRef="c-3" decimals="-3" id="f-1003" unitRef="usd">267382000</bcrx:CashCashEquivalentsShortAndLongTermInvestments>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents contextRef="c-95" decimals="-3" id="f-1004" unitRef="usd">14840000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents>
    <bcrx:CashCashEquivalentsShortAndLongTermInvestments contextRef="c-4" decimals="-3" id="f-1005" unitRef="usd">341173000</bcrx:CashCashEquivalentsShortAndLongTermInvestments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c-1" id="f-1006">&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table illustrates information about segment revenues, significant segment expenses, and segment net income (loss) for the three and nine months ended September 30, 2025 and 2024 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;159,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;117,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;468,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;319,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Less&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Berotralstat&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;BCX17725&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Avoralstat&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Factor D Program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research, discovery and preclinical programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation and related personnel costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;13,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 25pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;14,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;38,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;42,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 25pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;24,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-program specific and indirect costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 25pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;23,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;83,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;65,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;252,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;185,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2,238)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(3,591)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(7,778)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(11,176)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;19,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;24,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;64,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;74,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency (gains) losses, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(98)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on extinguishment of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,667)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,667)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax (benefit) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(769)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Segment net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;12,899&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;(14,033)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;18,016&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;(62,086)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Reconciliation of segment profit or loss:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments and reconciling items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;12,899&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;(14,033)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;18,016&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;(62,086)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;1 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;The significant expense categories and amounts align with the segment-level information that is regularly provided to the CODM.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-259" decimals="-3" id="f-1007" unitRef="usd">159395000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-260" decimals="-3" id="f-1008" unitRef="usd">117085000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-261" decimals="-3" id="f-1009" unitRef="usd">468282000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-262" decimals="-3" id="f-1010" unitRef="usd">319178000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-259" decimals="-3" id="f-1011" unitRef="usd">2187000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-260" decimals="-3" id="f-1012" unitRef="usd">3211000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-261" decimals="-3" id="f-1013" unitRef="usd">9553000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-262" decimals="-3" id="f-1014" unitRef="usd">6175000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-263" decimals="-3" id="f-1015" unitRef="usd">2575000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-264" decimals="-3" id="f-1016" unitRef="usd">2954000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-265" decimals="-3" id="f-1017" unitRef="usd">9214000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-266" decimals="-3" id="f-1018" unitRef="usd">10504000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-267" decimals="-3" id="f-1019" unitRef="usd">7574000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-268" decimals="-3" id="f-1020" unitRef="usd">1154000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-269" decimals="-3" id="f-1021" unitRef="usd">13346000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-270" decimals="-3" id="f-1022" unitRef="usd">6591000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-271" decimals="-3" id="f-1023" unitRef="usd">1800000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-272" decimals="-3" id="f-1024" unitRef="usd">2104000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-273" decimals="-3" id="f-1025" unitRef="usd">7584000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-274" decimals="-3" id="f-1026" unitRef="usd">4960000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-275" decimals="-3" id="f-1027" unitRef="usd">35000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-276" decimals="-3" id="f-1028" unitRef="usd">1193000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-277" decimals="-3" id="f-1029" unitRef="usd">454000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-278" decimals="-3" id="f-1030" unitRef="usd">7299000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-279" decimals="-3" id="f-1031" unitRef="usd">5457000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-280" decimals="-3" id="f-1032" unitRef="usd">3309000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-281" decimals="-3" id="f-1033" unitRef="usd">11641000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-282" decimals="-3" id="f-1034" unitRef="usd">8325000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-283" decimals="-3" id="f-1035" unitRef="usd">13313000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-284" decimals="-3" id="f-1036" unitRef="usd">14257000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-285" decimals="-3" id="f-1037" unitRef="usd">38025000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-286" decimals="-3" id="f-1038" unitRef="usd">42630000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-287" decimals="-3" id="f-1039" unitRef="usd">6520000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-288" decimals="-3" id="f-1040" unitRef="usd">8530000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-289" decimals="-3" id="f-1041" unitRef="usd">24374000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-290" decimals="-3" id="f-1042" unitRef="usd">20923000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-291" decimals="-3" id="f-1043" unitRef="usd">7329000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-292" decimals="-3" id="f-1044" unitRef="usd">7580000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-293" decimals="-3" id="f-1045" unitRef="usd">20621000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-294" decimals="-3" id="f-1046" unitRef="usd">23965000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-259" decimals="-3" id="f-1047" unitRef="usd">83014000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-260" decimals="-3" id="f-1048" unitRef="usd">65101000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-261" decimals="-3" id="f-1049" unitRef="usd">252866000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-262" decimals="-3" id="f-1050" unitRef="usd">185841000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:InterestIncomeOperating contextRef="c-259" decimals="-3" id="f-1051" unitRef="usd">2238000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating contextRef="c-260" decimals="-3" id="f-1052" unitRef="usd">3591000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating contextRef="c-261" decimals="-3" id="f-1053" unitRef="usd">7778000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating contextRef="c-262" decimals="-3" id="f-1054" unitRef="usd">11176000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-259" decimals="-3" id="f-1055" unitRef="usd">19661000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-260" decimals="-3" id="f-1056" unitRef="usd">24828000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-261" decimals="-3" id="f-1057" unitRef="usd">64737000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-262" decimals="-3" id="f-1058" unitRef="usd">74067000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c-259" decimals="-3" id="f-1059" unitRef="usd">35000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c-260" decimals="-3" id="f-1060" unitRef="usd">98000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c-261" decimals="-3" id="f-1061" unitRef="usd">-27000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c-262" decimals="-3" id="f-1062" unitRef="usd">-37000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-259" decimals="-3" id="f-1063" unitRef="usd">-2740000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-260" decimals="-3" id="f-1064" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-261" decimals="-3" id="f-1065" unitRef="usd">-6911000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-262" decimals="-3" id="f-1066" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherIncome contextRef="c-259" decimals="-3" id="f-1067" unitRef="usd">2667000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-260" decimals="-3" id="f-1068" unitRef="usd">0</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-261" decimals="-3" id="f-1069" unitRef="usd">2667000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-262" decimals="-3" id="f-1070" unitRef="usd">0</us-gaap:OtherIncome>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-259" decimals="-3" id="f-1071" unitRef="usd">-769000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-260" decimals="-3" id="f-1072" unitRef="usd">586000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-261" decimals="-3" id="f-1073" unitRef="usd">1358000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-262" decimals="-3" id="f-1074" unitRef="usd">1123000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-259" decimals="-3" id="f-1075" unitRef="usd">12899000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-260" decimals="-3" id="f-1076" unitRef="usd">-14033000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-261" decimals="-3" id="f-1077" unitRef="usd">18016000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-262" decimals="-3" id="f-1078" unitRef="usd">-62086000</us-gaap:NetIncomeLoss>
    <bcrx:SegmentReportingAdjustmentsAndReconcilingItemsAmount contextRef="c-259" decimals="-3" id="f-1079" unitRef="usd">0</bcrx:SegmentReportingAdjustmentsAndReconcilingItemsAmount>
    <bcrx:SegmentReportingAdjustmentsAndReconcilingItemsAmount contextRef="c-260" decimals="-3" id="f-1080" unitRef="usd">0</bcrx:SegmentReportingAdjustmentsAndReconcilingItemsAmount>
    <bcrx:SegmentReportingAdjustmentsAndReconcilingItemsAmount contextRef="c-261" decimals="-3" id="f-1081" unitRef="usd">0</bcrx:SegmentReportingAdjustmentsAndReconcilingItemsAmount>
    <bcrx:SegmentReportingAdjustmentsAndReconcilingItemsAmount contextRef="c-262" decimals="-3" id="f-1082" unitRef="usd">0</bcrx:SegmentReportingAdjustmentsAndReconcilingItemsAmount>
    <us-gaap:NetIncomeLoss contextRef="c-259" decimals="-3" id="f-1083" unitRef="usd">12899000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-260" decimals="-3" id="f-1084" unitRef="usd">-14033000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-261" decimals="-3" id="f-1085" unitRef="usd">18016000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-262" decimals="-3" id="f-1086" unitRef="usd">-62086000</us-gaap:NetIncomeLoss>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-1087">Commitments and Contingencies&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Abbreviated New Drug Application&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2025, the Company received a Paragraph IV notice of certification (the &#x201c;Notice Letter&#x201d;) from Annora Pharma Private Limited (&#x201c;Annora&#x201d;) advising that Annora has submitted an Abbreviated New Drug Application (&#x201c;ANDA&#x201d;) to the FDA seeking approval to manufacture, use or sell a generic version of ORLADEYO in the United States prior to the expiration of three patents listed in the FDA&#x2019;s Orange Book: U.S. Patent Nos. 10,662,160; 11,117,867; and 11,618,733 (the &#x201c;Challenged Patents&#x201d;). The Notice Letter alleges that the Challenged Patents, which expire in 2039, are invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of the generic product described in &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Annora&#x2019;s ANDA. The Notice Letter does not challenge the following six ORLADEYO Orange Book patents that expire in 2035:  U.S. Patent Nos. 10,125,102; 10,329,260; 10,689,346; 11,230,530; 11,708,333; and 12,116,346. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 10, 2025, the Company &#xfb01;led a patent infringement lawsuit in the United States District Court for the District of Delaware against Annora, Hetero Labs Limited, Hetero USA, Inc., and Camber Pharmaceuticals, Inc. (collectively, the &#x201c;Defendants&#x201d;), asserting infringement of the Challenged Patents arising from Annora&#x2019;s ANDA filing with the FDA. The Company is seeking, among other remedies, equitable relief enjoining the Defendants from infringing the Challenged Patents, as well as an order that the e&#xfb00;ective date of any FDA approval of the ANDA would be a date no earlier than the expiration of the Challenged Patents (including any regulatory extensions). While the Company intends to vigorously defend its intellectual property rights protecting ORLADEYO, this matter is in the early stages of litigation and no assessment can be made as to the likely outcome of this matter or whether it will be material to the Company. Accordingly, an estimate of the potential loss, or range of loss, if any, to the Company relating to this matter is not possible at this time.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-1088">Net Income (Loss) Per Share&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted net income (loss) per share for the three and nine months ended September&#160;30, 2025 and 2024 were calculated as follows (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,033)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62,086)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares of common stock outstanding: basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) per common share: basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.07)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock unit awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares issuable under the employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive potential common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares of common stock outstanding: diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) per common share: diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.07)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s potentially dilutive securities include outstanding stock options, unvested restricted stock units and shares issuable under the employee stock purchase plan for the three and nine months ended September&#160;30, 2025 and 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and nine months ended September 30, 2025, the dilutive effect of outstanding stock options, restricted stock unit awards, and shares issuable under the employee stock purchase plan was calculated using the treasury method, whereby all such awards are assumed to be exercised at the beginning of the period. The hypothetical proceeds from such exercises, including the average unrecognized stock compensation expense for outstanding stock options, restricted stock units and shares issuable under the employee stock purchase plan, were assumed to be used to purchase outstanding common stock at the average price during the period. The net share impact of dilutive securities was added to the weighted average basic common shares outstanding to calculate weighted average diluted shares outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and nine months ended September 30, 2024, during which the Company recorded a net loss, all potentially dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share, and thus they are considered &#x201c;anti-dilutive.&#x201d;  For this period, the weighted average number &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of shares of common stock outstanding used to calculate both basic and diluted net loss per share of common stock is the same.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes potential shares of common stock that were excluded from the computation of diluted net income (loss) per share attributable to common stockholders as they were anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.113%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock unit awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock contextRef="c-1" id="f-1089">&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted net income (loss) per share for the three and nine months ended September&#160;30, 2025 and 2024 were calculated as follows (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,033)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62,086)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares of common stock outstanding: basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) per common share: basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.07)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock unit awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares issuable under the employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive potential common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares of common stock outstanding: diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) per common share: diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.07)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-1090" unitRef="usd">12899000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-8" decimals="-3" id="f-1091" unitRef="usd">-14033000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-1092" unitRef="usd">18016000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-9" decimals="-3" id="f-1093" unitRef="usd">-62086000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-7" decimals="-3" id="f-1094" unitRef="shares">210176000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-8" decimals="-3" id="f-1095" unitRef="shares">206905000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-1096" unitRef="shares">209531000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-9" decimals="-3" id="f-1097" unitRef="shares">206466000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-7"
      decimals="2"
      id="f-1098"
      unitRef="usdPerShare">0.06</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-8"
      decimals="2"
      id="f-1099"
      unitRef="usdPerShare">-0.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-1100"
      unitRef="usdPerShare">0.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-9"
      decimals="2"
      id="f-1101"
      unitRef="usdPerShare">-0.30</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-7" decimals="-3" id="f-1102" unitRef="shares">5023000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-8" decimals="-3" id="f-1103" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-1" decimals="-3" id="f-1104" unitRef="shares">5261000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-9" decimals="-3" id="f-1105" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements contextRef="c-7" decimals="-3" id="f-1106" unitRef="shares">4663000</us-gaap:IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements>
    <us-gaap:IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements contextRef="c-8" decimals="-3" id="f-1107" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements>
    <us-gaap:IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements contextRef="c-1" decimals="-3" id="f-1108" unitRef="shares">3532000</us-gaap:IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements>
    <us-gaap:IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements contextRef="c-9" decimals="-3" id="f-1109" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements>
    <bcrx:IncrementalCommonSharesAttributableToDilutiveEffectOfSharePurchasePlans contextRef="c-7" decimals="-3" id="f-1110" unitRef="shares">23000</bcrx:IncrementalCommonSharesAttributableToDilutiveEffectOfSharePurchasePlans>
    <bcrx:IncrementalCommonSharesAttributableToDilutiveEffectOfSharePurchasePlans contextRef="c-8" decimals="-3" id="f-1111" unitRef="shares">0</bcrx:IncrementalCommonSharesAttributableToDilutiveEffectOfSharePurchasePlans>
    <bcrx:IncrementalCommonSharesAttributableToDilutiveEffectOfSharePurchasePlans contextRef="c-1" decimals="-3" id="f-1112" unitRef="shares">25000</bcrx:IncrementalCommonSharesAttributableToDilutiveEffectOfSharePurchasePlans>
    <bcrx:IncrementalCommonSharesAttributableToDilutiveEffectOfSharePurchasePlans contextRef="c-9" decimals="-3" id="f-1113" unitRef="shares">0</bcrx:IncrementalCommonSharesAttributableToDilutiveEffectOfSharePurchasePlans>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="c-7" decimals="-3" id="f-1114" unitRef="shares">9709000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="c-8" decimals="-3" id="f-1115" unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="c-1" decimals="-3" id="f-1116" unitRef="shares">8818000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="c-9" decimals="-3" id="f-1117" unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-7" decimals="-3" id="f-1118" unitRef="shares">219885000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-8" decimals="-3" id="f-1119" unitRef="shares">206905000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-1120" unitRef="shares">218349000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-9" decimals="-3" id="f-1121" unitRef="shares">206466000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-7"
      decimals="2"
      id="f-1122"
      unitRef="usdPerShare">0.06</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-8"
      decimals="2"
      id="f-1123"
      unitRef="usdPerShare">-0.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-1124"
      unitRef="usdPerShare">0.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-9"
      decimals="2"
      id="f-1125"
      unitRef="usdPerShare">-0.30</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-1126">&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes potential shares of common stock that were excluded from the computation of diluted net income (loss) per share attributable to common stockholders as they were anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.113%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock unit awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-295"
      decimals="-3"
      id="f-1127"
      unitRef="shares">21818000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-296"
      decimals="-3"
      id="f-1128"
      unitRef="shares">38559000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-297"
      decimals="-3"
      id="f-1129"
      unitRef="shares">373000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-298"
      decimals="-3"
      id="f-1130"
      unitRef="shares">5882000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="-3" id="f-1131" unitRef="shares">22191000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-9" decimals="-3" id="f-1132" unitRef="shares">44441000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SubsequentEventsTextBlock contextRef="c-1" id="f-1133">Subsequent Events&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Neopharmed Gentili S.p.A. Stock Purchase Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 1, 2025, under the terms of the Stock Purchase Agreement, the Company sold to Neopharmed all of its equity interests in BioCryst Ireland, which, together with its subsidiaries, holds certain assets, rights, and employees related to the Company&#x2019;s European ORLADEYO Business. At the Closing, the Company received cash proceeds of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$250,000&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, plus customary purchase price adjustments as set forth in the Stock Purchase Agreement. In addition, Neopharmed has agreed to pay the Company up to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$14,000&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; if certain revenue milestones are achieved prior to December 31, 2032. In connection with the Closing, Neopharmed also paid a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$15,000&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; royalty release fee to RPI 2019 Intermediate Finance Trust.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Concurrent with the Closing of the transactions contemplated by the Stock Purchase Agreement, on October 1, 2025, the Company and BioCryst Ireland amended and restated their existing intellectual property licence agreement pursuant to which the Company will continue to grant to BioCryst Ireland certain rights with respect to ORLADEYO in the territory (the &#x201c;Amended and Restated IP Licence Agreement&#x201d;). The terms of the Amended and Restated IP Licence Agreement may also extend to the pediatric line extension of ORLADEYO, subject to certain regulatory approvals. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Closing, on October 1, 2025, the Company entered into a supply agreement with BioCryst Ireland, pursuant to which the Company will be the exclusive supplier of ORLADEYO products to BioCryst Ireland for commercialization in the territory (the &#x201c;Supply Agreement&#x201d;). Additionally, in connection with the Closing, on October 1, 2025, the Company entered into a global brand and support agreement with BioCryst Ireland, which provides for coordination of brand and regulatory activities between the Company and BioCryst Ireland regarding ORLADEYO products (the &#x201c;Global Brand and Support Agreement&#x201d;). In connection with the Closing, on October 1, 2025, the Company entered into a mutual transition services agreement with BioCryst Ireland, pursuant to which the Company and BioCryst Ireland will provide each other with certain transition services for the periods of time and for the compensation set forth under the agreement, on customary commercial terms (the &#x201c;Transition Services Agreement&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lastly, in connection with the Closing, on October 1, 2025, the Company entered into a trademark license agreement with BioCryst Ireland, pursuant to which the Company granted to BioCryst Ireland a non-exclusive transitionary license to use the &#x201c;BioCryst&#x201d; name, solely to develop, manufacture and commercialize ORLADEYO products in the territory for a limited period of time, and an exclusive license to use the ORLADEYO product name to commercialize ORLADEYO products for such uses for the term of the Amended and Restated IP Licence Agreement, in each case subject to the terms and conditions set forth therein (the &#x201c;Trademark License Agreement&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Pharmakon Loan Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 8, 2025, the Company used a portion of the proceeds from the sale of the European ORLADEYO Business to pay off in full the outstanding principal balance of $198,704 and terminate the Pharmakon Loan Agreement. In conjunction with the repayment the Company incurred a $5,961 prepayment premium and paid $485 of interest accrued through the payment date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Astria Therapeutics, Inc. Agreement and Plan of Merger&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 14, 2025, the Company, Axel Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (&#x201c;Merger Sub&#x201d;), and Astria Therapeutics, Inc., a Delaware corporation (&#x201c;Astria&#x201d;), entered into an Agreement and Plan of Merger (the &#x201c;Merger Agreement&#x201d;).  Pursuant to the Merger Agreement, and subject to the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;satisfaction or waiver of the conditions specified therein, at the Effective Time (as defined below), Merger Sub will merge with and into Astria, with Astria surviving as a wholly owned subsidiary of the Company (the &#x201c;Merger&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subject to the terms and conditions of the Merger Agreement, at the effective time of the Merger (the &#x201c;Effective Time&#x201d;), each share of Astria common stock, par value $0.001 per share, issued and outstanding immediately prior to the Effective Time will be, subject to certain exceptions, converted into the right to receive (i) 0.59 of a share of the Company&#x2019;s common stock (and, if applicable, cash in lieu of fractional shares), and (ii) $8.55 in cash, without interest, subject to certain adjustments and applicable withholding taxes. Holders of Astria&#x2019;s Series X Convertible Preferred Stock, warrants, and certain options will also be entitled to certain consideration, as further set forth in the Merger Agreement. The Merger is subject to the approval of Astria&#x2019;s stockholders, as well as customary regulatory approvals. In connection with entering into the Merger Agreement, certain stockholders of Astria entered into voting and support agreements with the Company, pursuant to which each such stockholder has agreed, among other things, to vote its, his or her shares of Astria common stock in favor of the adoption of the Merger Agreement and approval of the transactions contemplated thereby and, subject to certain exceptions, not to transfer such shares of Astria common stock prior to the earlier of the Effective Time and the termination of the Merger Agreement, without the prior written consent of the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financing Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the transactions contemplated by the Merger Agreement, on October 14, 2025, the Company entered into a debt commitment letter (the &#x201c;Commitment Letter&#x201d;) with certain affiliates of Blackstone, Inc. (&#x201c;Blackstone&#x201d;), pursuant to which Blackstone agreed to provide a $550,000 senior secured credit facility consisting of (i) a committed initial term loan in an aggregate principal amount of $350,000 (the &#x201c;Initial Term Loan&#x201d;), (ii) a committed delayed draw term loan facility in an aggregate principal amount not exceeding $50,000 (the loans thereunder, the &#x201c;Committed Delayed Draw Term Loans&#x201d;), and (iii) an uncommitted delayed draw term loan facility in an aggregate principal amount not exceeding $150,000. The Initial Term Loan and any Committed Delayed Draw Term Loans funded on the closing date of the Merger will be used for the purpose of, among other things, funding the consideration for the transactions contemplated by the Merger Agreement and paying for related fees and expenses. The commitments with respect to the Initial Term Loan and any Committed Delayed Draw Term Loans funded on the closing date of the Merger are subject to customary conditions for acquisition financings, including the execution and delivery of definitive documentation with respect to the senior secured credit facility in accordance with the terms set forth in the Commitment Letter and the consummation of the Merger.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration contextRef="c-94" decimals="-3" id="f-1134" unitRef="usd">250000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <bcrx:DisposalGroupIncludingDiscontinuedOperationContingentConsideration contextRef="c-94" decimals="-3" id="f-1135" unitRef="usd">14000000</bcrx:DisposalGroupIncludingDiscontinuedOperationContingentConsideration>
    <bcrx:DisposalGroupIncludingDiscontinuedOperationConsiderationRoyaltyReleaseFee contextRef="c-94" decimals="-3" id="f-1136" unitRef="usd">15000000</bcrx:DisposalGroupIncludingDiscontinuedOperationConsiderationRoyaltyReleaseFee>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts contextRef="c-299" decimals="-3" id="f-1137" unitRef="usd">198704000</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <bcrx:DebtInstrumentPrepaymentPremium contextRef="c-299" decimals="-3" id="f-1138" unitRef="usd">5961000</bcrx:DebtInstrumentPrepaymentPremium>
    <us-gaap:InterestExpenseLongTermDebt contextRef="c-299" decimals="-3" id="f-1139" unitRef="usd">485000</us-gaap:InterestExpenseLongTermDebt>
    <bcrx:CommonStockConversionRatio
      contextRef="c-300"
      decimals="4"
      id="f-1140"
      unitRef="number">0.59</bcrx:CommonStockConversionRatio>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="c-300"
      decimals="2"
      id="f-1141"
      unitRef="usdPerShare">8.55</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-301" decimals="-3" id="f-1142" unitRef="usd">550000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-302" decimals="-3" id="f-1143" unitRef="usd">350000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-301" decimals="-3" id="f-1144" unitRef="usd">50000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-303" decimals="-3" id="f-1145" unitRef="usd">150000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="c-7" id="f-1146">&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended September 30, 2025, two of the directors and officers of the Company adopted, modified or terminated the &#x201c;Rule 10b5-1 trading arrangements&#x201d; (as such term is defined in Item 408(a) of Regulation S-K) as set forth in the table below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.242%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.212%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.410%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.167%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.410%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.167%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.410%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.289%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.410%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.225%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Name (Title)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Action&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Date of Action&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Duration of Trading Arrangement&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate Number of Securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Alane P. Barnes,&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Chief Legal Officer and Secretary&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Modification&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;August 13, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Until December 20, 2027, or such earlier date upon which all transactions are completed or the plan is terminated&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A. Machelle Sanders, &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Member of the Board of Directors&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adoption&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;August 14, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Until December&#160;31, 2025, or such earlier date upon which all transactions are completed or the plan is terminated&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) This trading plan was originally adopted on December 1, 2022 (the &#x201c;2022 Barnes Plan&#x201d;) and provided for the sale of up to (i) 24,710 shares of common stock and (ii) 137,897 shares of common stock underlying stock options through December 29, 2025. The 2022 Barnes Plan was amended on May 15, 2024 to cancel all open orders under the 2022 Barnes Plan and to provide for the sale of up to 119,897 shares of common stock underlying stock options expiring in 2024 and 2025 (the &#x201c;2024 Barnes Plan&#x201d;). The 2024 Barnes Plan was amended on August 13, 2025 (the &#x201c;2025 Barnes Plan&#x201d;) to cancel all open orders under the 2024 Barnes Plan and to provide for the sale of up to (i) 123,100 shares of common stock underlying restricted stock units, net of shares withheld to cover taxes, (ii) 19,770 shares of common stock, and (iii) 347,501 shares of common stock underlying stock options expiring in 2025 through 2027, pursuant to the terms of the 2025 Barnes Plan.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2) This trading plan (the &#x201c;Sanders Plan&#x201d;) provides for the sale of up to 9,600 shares of common stock, pursuant to the terms of the Sanders Plan.&lt;/span&gt;&lt;/div&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-7" id="f-1147">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-7" id="f-1148">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-7" id="f-1149">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:TrdArrIndName contextRef="c-304" id="f-1150">A. Machelle Sanders</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-304" id="f-1151">Member of the Board of Directors</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-304" id="f-1152">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate contextRef="c-304" id="f-1153">August 14, 2025</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrExpirationDate contextRef="c-304" id="f-1154">December&#160;31, 2025</ecd:TrdArrExpirationDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-305"
      decimals="INF"
      id="f-1155"
      unitRef="shares">9600</ecd:TrdArrSecuritiesAggAvailAmt>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
